<!DOCTYPE html>
<html>
<head><meta charset="utf-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0">

<title>Vrticki</title><script src="https://cdnjs.cloudflare.com/ajax/libs/require.js/2.1.10/require.min.js"></script>




<style type="text/css">
    pre { line-height: 125%; }
td.linenos pre { color: #000000; background-color: #f0f0f0; padding-left: 5px; padding-right: 5px; }
span.linenos { color: #000000; background-color: #f0f0f0; padding-left: 5px; padding-right: 5px; }
td.linenos pre.special { color: #000000; background-color: #ffffc0; padding-left: 5px; padding-right: 5px; }
span.linenos.special { color: #000000; background-color: #ffffc0; padding-left: 5px; padding-right: 5px; }
.highlight .hll { background-color: var(--jp-cell-editor-active-background) }
.highlight { background: var(--jp-cell-editor-background); color: var(--jp-mirror-editor-variable-color) }
.highlight .c { color: var(--jp-mirror-editor-comment-color); font-style: italic } /* Comment */
.highlight .err { color: var(--jp-mirror-editor-error-color) } /* Error */
.highlight .k { color: var(--jp-mirror-editor-keyword-color); font-weight: bold } /* Keyword */
.highlight .o { color: var(--jp-mirror-editor-operator-color); font-weight: bold } /* Operator */
.highlight .p { color: var(--jp-mirror-editor-punctuation-color) } /* Punctuation */
.highlight .ch { color: var(--jp-mirror-editor-comment-color); font-style: italic } /* Comment.Hashbang */
.highlight .cm { color: var(--jp-mirror-editor-comment-color); font-style: italic } /* Comment.Multiline */
.highlight .cp { color: var(--jp-mirror-editor-comment-color); font-style: italic } /* Comment.Preproc */
.highlight .cpf { color: var(--jp-mirror-editor-comment-color); font-style: italic } /* Comment.PreprocFile */
.highlight .c1 { color: var(--jp-mirror-editor-comment-color); font-style: italic } /* Comment.Single */
.highlight .cs { color: var(--jp-mirror-editor-comment-color); font-style: italic } /* Comment.Special */
.highlight .kc { color: var(--jp-mirror-editor-keyword-color); font-weight: bold } /* Keyword.Constant */
.highlight .kd { color: var(--jp-mirror-editor-keyword-color); font-weight: bold } /* Keyword.Declaration */
.highlight .kn { color: var(--jp-mirror-editor-keyword-color); font-weight: bold } /* Keyword.Namespace */
.highlight .kp { color: var(--jp-mirror-editor-keyword-color); font-weight: bold } /* Keyword.Pseudo */
.highlight .kr { color: var(--jp-mirror-editor-keyword-color); font-weight: bold } /* Keyword.Reserved */
.highlight .kt { color: var(--jp-mirror-editor-keyword-color); font-weight: bold } /* Keyword.Type */
.highlight .m { color: var(--jp-mirror-editor-number-color) } /* Literal.Number */
.highlight .s { color: var(--jp-mirror-editor-string-color) } /* Literal.String */
.highlight .ow { color: var(--jp-mirror-editor-operator-color); font-weight: bold } /* Operator.Word */
.highlight .w { color: var(--jp-mirror-editor-variable-color) } /* Text.Whitespace */
.highlight .mb { color: var(--jp-mirror-editor-number-color) } /* Literal.Number.Bin */
.highlight .mf { color: var(--jp-mirror-editor-number-color) } /* Literal.Number.Float */
.highlight .mh { color: var(--jp-mirror-editor-number-color) } /* Literal.Number.Hex */
.highlight .mi { color: var(--jp-mirror-editor-number-color) } /* Literal.Number.Integer */
.highlight .mo { color: var(--jp-mirror-editor-number-color) } /* Literal.Number.Oct */
.highlight .sa { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Affix */
.highlight .sb { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Backtick */
.highlight .sc { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Char */
.highlight .dl { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Delimiter */
.highlight .sd { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Doc */
.highlight .s2 { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Double */
.highlight .se { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Escape */
.highlight .sh { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Heredoc */
.highlight .si { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Interpol */
.highlight .sx { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Other */
.highlight .sr { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Regex */
.highlight .s1 { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Single */
.highlight .ss { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Symbol */
.highlight .il { color: var(--jp-mirror-editor-number-color) } /* Literal.Number.Integer.Long */
  </style>



<style type="text/css">
/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*
 * Mozilla scrollbar styling
 */

/* use standard opaque scrollbars for most nodes */
[data-jp-theme-scrollbars='true'] {
  scrollbar-color: rgb(var(--jp-scrollbar-thumb-color))
    var(--jp-scrollbar-background-color);
}

/* for code nodes, use a transparent style of scrollbar. These selectors
 * will match lower in the tree, and so will override the above */
[data-jp-theme-scrollbars='true'] .CodeMirror-hscrollbar,
[data-jp-theme-scrollbars='true'] .CodeMirror-vscrollbar {
  scrollbar-color: rgba(var(--jp-scrollbar-thumb-color), 0.5) transparent;
}

/*
 * Webkit scrollbar styling
 */

/* use standard opaque scrollbars for most nodes */

[data-jp-theme-scrollbars='true'] ::-webkit-scrollbar,
[data-jp-theme-scrollbars='true'] ::-webkit-scrollbar-corner {
  background: var(--jp-scrollbar-background-color);
}

[data-jp-theme-scrollbars='true'] ::-webkit-scrollbar-thumb {
  background: rgb(var(--jp-scrollbar-thumb-color));
  border: var(--jp-scrollbar-thumb-margin) solid transparent;
  background-clip: content-box;
  border-radius: var(--jp-scrollbar-thumb-radius);
}

[data-jp-theme-scrollbars='true'] ::-webkit-scrollbar-track:horizontal {
  border-left: var(--jp-scrollbar-endpad) solid
    var(--jp-scrollbar-background-color);
  border-right: var(--jp-scrollbar-endpad) solid
    var(--jp-scrollbar-background-color);
}

[data-jp-theme-scrollbars='true'] ::-webkit-scrollbar-track:vertical {
  border-top: var(--jp-scrollbar-endpad) solid
    var(--jp-scrollbar-background-color);
  border-bottom: var(--jp-scrollbar-endpad) solid
    var(--jp-scrollbar-background-color);
}

/* for code nodes, use a transparent style of scrollbar */

[data-jp-theme-scrollbars='true'] .CodeMirror-hscrollbar::-webkit-scrollbar,
[data-jp-theme-scrollbars='true'] .CodeMirror-vscrollbar::-webkit-scrollbar,
[data-jp-theme-scrollbars='true']
  .CodeMirror-hscrollbar::-webkit-scrollbar-corner,
[data-jp-theme-scrollbars='true']
  .CodeMirror-vscrollbar::-webkit-scrollbar-corner {
  background-color: transparent;
}

[data-jp-theme-scrollbars='true']
  .CodeMirror-hscrollbar::-webkit-scrollbar-thumb,
[data-jp-theme-scrollbars='true']
  .CodeMirror-vscrollbar::-webkit-scrollbar-thumb {
  background: rgba(var(--jp-scrollbar-thumb-color), 0.5);
  border: var(--jp-scrollbar-thumb-margin) solid transparent;
  background-clip: content-box;
  border-radius: var(--jp-scrollbar-thumb-radius);
}

[data-jp-theme-scrollbars='true']
  .CodeMirror-hscrollbar::-webkit-scrollbar-track:horizontal {
  border-left: var(--jp-scrollbar-endpad) solid transparent;
  border-right: var(--jp-scrollbar-endpad) solid transparent;
}

[data-jp-theme-scrollbars='true']
  .CodeMirror-vscrollbar::-webkit-scrollbar-track:vertical {
  border-top: var(--jp-scrollbar-endpad) solid transparent;
  border-bottom: var(--jp-scrollbar-endpad) solid transparent;
}

/*
 * Phosphor
 */

.lm-ScrollBar[data-orientation='horizontal'] {
  min-height: 16px;
  max-height: 16px;
  min-width: 45px;
  border-top: 1px solid #a0a0a0;
}

.lm-ScrollBar[data-orientation='vertical'] {
  min-width: 16px;
  max-width: 16px;
  min-height: 45px;
  border-left: 1px solid #a0a0a0;
}

.lm-ScrollBar-button {
  background-color: #f0f0f0;
  background-position: center center;
  min-height: 15px;
  max-height: 15px;
  min-width: 15px;
  max-width: 15px;
}

.lm-ScrollBar-button:hover {
  background-color: #dadada;
}

.lm-ScrollBar-button.lm-mod-active {
  background-color: #cdcdcd;
}

.lm-ScrollBar-track {
  background: #f0f0f0;
}

.lm-ScrollBar-thumb {
  background: #cdcdcd;
}

.lm-ScrollBar-thumb:hover {
  background: #bababa;
}

.lm-ScrollBar-thumb.lm-mod-active {
  background: #a0a0a0;
}

.lm-ScrollBar[data-orientation='horizontal'] .lm-ScrollBar-thumb {
  height: 100%;
  min-width: 15px;
  border-left: 1px solid #a0a0a0;
  border-right: 1px solid #a0a0a0;
}

.lm-ScrollBar[data-orientation='vertical'] .lm-ScrollBar-thumb {
  width: 100%;
  min-height: 15px;
  border-top: 1px solid #a0a0a0;
  border-bottom: 1px solid #a0a0a0;
}

.lm-ScrollBar[data-orientation='horizontal']
  .lm-ScrollBar-button[data-action='decrement'] {
  background-image: var(--jp-icon-caret-left);
  background-size: 17px;
}

.lm-ScrollBar[data-orientation='horizontal']
  .lm-ScrollBar-button[data-action='increment'] {
  background-image: var(--jp-icon-caret-right);
  background-size: 17px;
}

.lm-ScrollBar[data-orientation='vertical']
  .lm-ScrollBar-button[data-action='decrement'] {
  background-image: var(--jp-icon-caret-up);
  background-size: 17px;
}

.lm-ScrollBar[data-orientation='vertical']
  .lm-ScrollBar-button[data-action='increment'] {
  background-image: var(--jp-icon-caret-down);
  background-size: 17px;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/


/* <DEPRECATED> */ .p-Widget, /* </DEPRECATED> */
.lm-Widget {
  box-sizing: border-box;
  position: relative;
  overflow: hidden;
  cursor: default;
}


/* <DEPRECATED> */ .p-Widget.p-mod-hidden, /* </DEPRECATED> */
.lm-Widget.lm-mod-hidden {
  display: none !important;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/


/* <DEPRECATED> */ .p-CommandPalette, /* </DEPRECATED> */
.lm-CommandPalette {
  display: flex;
  flex-direction: column;
  -webkit-user-select: none;
  -moz-user-select: none;
  -ms-user-select: none;
  user-select: none;
}


/* <DEPRECATED> */ .p-CommandPalette-search, /* </DEPRECATED> */
.lm-CommandPalette-search {
  flex: 0 0 auto;
}


/* <DEPRECATED> */ .p-CommandPalette-content, /* </DEPRECATED> */
.lm-CommandPalette-content {
  flex: 1 1 auto;
  margin: 0;
  padding: 0;
  min-height: 0;
  overflow: auto;
  list-style-type: none;
}


/* <DEPRECATED> */ .p-CommandPalette-header, /* </DEPRECATED> */
.lm-CommandPalette-header {
  overflow: hidden;
  white-space: nowrap;
  text-overflow: ellipsis;
}


/* <DEPRECATED> */ .p-CommandPalette-item, /* </DEPRECATED> */
.lm-CommandPalette-item {
  display: flex;
  flex-direction: row;
}


/* <DEPRECATED> */ .p-CommandPalette-itemIcon, /* </DEPRECATED> */
.lm-CommandPalette-itemIcon {
  flex: 0 0 auto;
}


/* <DEPRECATED> */ .p-CommandPalette-itemContent, /* </DEPRECATED> */
.lm-CommandPalette-itemContent {
  flex: 1 1 auto;
  overflow: hidden;
}


/* <DEPRECATED> */ .p-CommandPalette-itemShortcut, /* </DEPRECATED> */
.lm-CommandPalette-itemShortcut {
  flex: 0 0 auto;
}


/* <DEPRECATED> */ .p-CommandPalette-itemLabel, /* </DEPRECATED> */
.lm-CommandPalette-itemLabel {
  overflow: hidden;
  white-space: nowrap;
  text-overflow: ellipsis;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/


/* <DEPRECATED> */ .p-DockPanel, /* </DEPRECATED> */
.lm-DockPanel {
  z-index: 0;
}


/* <DEPRECATED> */ .p-DockPanel-widget, /* </DEPRECATED> */
.lm-DockPanel-widget {
  z-index: 0;
}


/* <DEPRECATED> */ .p-DockPanel-tabBar, /* </DEPRECATED> */
.lm-DockPanel-tabBar {
  z-index: 1;
}


/* <DEPRECATED> */ .p-DockPanel-handle, /* </DEPRECATED> */
.lm-DockPanel-handle {
  z-index: 2;
}


/* <DEPRECATED> */ .p-DockPanel-handle.p-mod-hidden, /* </DEPRECATED> */
.lm-DockPanel-handle.lm-mod-hidden {
  display: none !important;
}


/* <DEPRECATED> */ .p-DockPanel-handle:after, /* </DEPRECATED> */
.lm-DockPanel-handle:after {
  position: absolute;
  top: 0;
  left: 0;
  width: 100%;
  height: 100%;
  content: '';
}


/* <DEPRECATED> */
.p-DockPanel-handle[data-orientation='horizontal'],
/* </DEPRECATED> */
.lm-DockPanel-handle[data-orientation='horizontal'] {
  cursor: ew-resize;
}


/* <DEPRECATED> */
.p-DockPanel-handle[data-orientation='vertical'],
/* </DEPRECATED> */
.lm-DockPanel-handle[data-orientation='vertical'] {
  cursor: ns-resize;
}


/* <DEPRECATED> */
.p-DockPanel-handle[data-orientation='horizontal']:after,
/* </DEPRECATED> */
.lm-DockPanel-handle[data-orientation='horizontal']:after {
  left: 50%;
  min-width: 8px;
  transform: translateX(-50%);
}


/* <DEPRECATED> */
.p-DockPanel-handle[data-orientation='vertical']:after,
/* </DEPRECATED> */
.lm-DockPanel-handle[data-orientation='vertical']:after {
  top: 50%;
  min-height: 8px;
  transform: translateY(-50%);
}


/* <DEPRECATED> */ .p-DockPanel-overlay, /* </DEPRECATED> */
.lm-DockPanel-overlay {
  z-index: 3;
  box-sizing: border-box;
  pointer-events: none;
}


/* <DEPRECATED> */ .p-DockPanel-overlay.p-mod-hidden, /* </DEPRECATED> */
.lm-DockPanel-overlay.lm-mod-hidden {
  display: none !important;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/


/* <DEPRECATED> */ .p-Menu, /* </DEPRECATED> */
.lm-Menu {
  z-index: 10000;
  position: absolute;
  white-space: nowrap;
  overflow-x: hidden;
  overflow-y: auto;
  outline: none;
  -webkit-user-select: none;
  -moz-user-select: none;
  -ms-user-select: none;
  user-select: none;
}


/* <DEPRECATED> */ .p-Menu-content, /* </DEPRECATED> */
.lm-Menu-content {
  margin: 0;
  padding: 0;
  display: table;
  list-style-type: none;
}


/* <DEPRECATED> */ .p-Menu-item, /* </DEPRECATED> */
.lm-Menu-item {
  display: table-row;
}


/* <DEPRECATED> */
.p-Menu-item.p-mod-hidden,
.p-Menu-item.p-mod-collapsed,
/* </DEPRECATED> */
.lm-Menu-item.lm-mod-hidden,
.lm-Menu-item.lm-mod-collapsed {
  display: none !important;
}


/* <DEPRECATED> */
.p-Menu-itemIcon,
.p-Menu-itemSubmenuIcon,
/* </DEPRECATED> */
.lm-Menu-itemIcon,
.lm-Menu-itemSubmenuIcon {
  display: table-cell;
  text-align: center;
}


/* <DEPRECATED> */ .p-Menu-itemLabel, /* </DEPRECATED> */
.lm-Menu-itemLabel {
  display: table-cell;
  text-align: left;
}


/* <DEPRECATED> */ .p-Menu-itemShortcut, /* </DEPRECATED> */
.lm-Menu-itemShortcut {
  display: table-cell;
  text-align: right;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/


/* <DEPRECATED> */ .p-MenuBar, /* </DEPRECATED> */
.lm-MenuBar {
  outline: none;
  -webkit-user-select: none;
  -moz-user-select: none;
  -ms-user-select: none;
  user-select: none;
}


/* <DEPRECATED> */ .p-MenuBar-content, /* </DEPRECATED> */
.lm-MenuBar-content {
  margin: 0;
  padding: 0;
  display: flex;
  flex-direction: row;
  list-style-type: none;
}


/* <DEPRECATED> */ .p--MenuBar-item, /* </DEPRECATED> */
.lm-MenuBar-item {
  box-sizing: border-box;
}


/* <DEPRECATED> */
.p-MenuBar-itemIcon,
.p-MenuBar-itemLabel,
/* </DEPRECATED> */
.lm-MenuBar-itemIcon,
.lm-MenuBar-itemLabel {
  display: inline-block;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/


/* <DEPRECATED> */ .p-ScrollBar, /* </DEPRECATED> */
.lm-ScrollBar {
  display: flex;
  -webkit-user-select: none;
  -moz-user-select: none;
  -ms-user-select: none;
  user-select: none;
}


/* <DEPRECATED> */
.p-ScrollBar[data-orientation='horizontal'],
/* </DEPRECATED> */
.lm-ScrollBar[data-orientation='horizontal'] {
  flex-direction: row;
}


/* <DEPRECATED> */
.p-ScrollBar[data-orientation='vertical'],
/* </DEPRECATED> */
.lm-ScrollBar[data-orientation='vertical'] {
  flex-direction: column;
}


/* <DEPRECATED> */ .p-ScrollBar-button, /* </DEPRECATED> */
.lm-ScrollBar-button {
  box-sizing: border-box;
  flex: 0 0 auto;
}


/* <DEPRECATED> */ .p-ScrollBar-track, /* </DEPRECATED> */
.lm-ScrollBar-track {
  box-sizing: border-box;
  position: relative;
  overflow: hidden;
  flex: 1 1 auto;
}


/* <DEPRECATED> */ .p-ScrollBar-thumb, /* </DEPRECATED> */
.lm-ScrollBar-thumb {
  box-sizing: border-box;
  position: absolute;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/


/* <DEPRECATED> */ .p-SplitPanel-child, /* </DEPRECATED> */
.lm-SplitPanel-child {
  z-index: 0;
}


/* <DEPRECATED> */ .p-SplitPanel-handle, /* </DEPRECATED> */
.lm-SplitPanel-handle {
  z-index: 1;
}


/* <DEPRECATED> */ .p-SplitPanel-handle.p-mod-hidden, /* </DEPRECATED> */
.lm-SplitPanel-handle.lm-mod-hidden {
  display: none !important;
}


/* <DEPRECATED> */ .p-SplitPanel-handle:after, /* </DEPRECATED> */
.lm-SplitPanel-handle:after {
  position: absolute;
  top: 0;
  left: 0;
  width: 100%;
  height: 100%;
  content: '';
}


/* <DEPRECATED> */
.p-SplitPanel[data-orientation='horizontal'] > .p-SplitPanel-handle,
/* </DEPRECATED> */
.lm-SplitPanel[data-orientation='horizontal'] > .lm-SplitPanel-handle {
  cursor: ew-resize;
}


/* <DEPRECATED> */
.p-SplitPanel[data-orientation='vertical'] > .p-SplitPanel-handle,
/* </DEPRECATED> */
.lm-SplitPanel[data-orientation='vertical'] > .lm-SplitPanel-handle {
  cursor: ns-resize;
}


/* <DEPRECATED> */
.p-SplitPanel[data-orientation='horizontal'] > .p-SplitPanel-handle:after,
/* </DEPRECATED> */
.lm-SplitPanel[data-orientation='horizontal'] > .lm-SplitPanel-handle:after {
  left: 50%;
  min-width: 8px;
  transform: translateX(-50%);
}


/* <DEPRECATED> */
.p-SplitPanel[data-orientation='vertical'] > .p-SplitPanel-handle:after,
/* </DEPRECATED> */
.lm-SplitPanel[data-orientation='vertical'] > .lm-SplitPanel-handle:after {
  top: 50%;
  min-height: 8px;
  transform: translateY(-50%);
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/


/* <DEPRECATED> */ .p-TabBar, /* </DEPRECATED> */
.lm-TabBar {
  display: flex;
  -webkit-user-select: none;
  -moz-user-select: none;
  -ms-user-select: none;
  user-select: none;
}


/* <DEPRECATED> */ .p-TabBar[data-orientation='horizontal'], /* </DEPRECATED> */
.lm-TabBar[data-orientation='horizontal'] {
  flex-direction: row;
}


/* <DEPRECATED> */ .p-TabBar[data-orientation='vertical'], /* </DEPRECATED> */
.lm-TabBar[data-orientation='vertical'] {
  flex-direction: column;
}


/* <DEPRECATED> */ .p-TabBar-content, /* </DEPRECATED> */
.lm-TabBar-content {
  margin: 0;
  padding: 0;
  display: flex;
  flex: 1 1 auto;
  list-style-type: none;
}


/* <DEPRECATED> */
.p-TabBar[data-orientation='horizontal'] > .p-TabBar-content,
/* </DEPRECATED> */
.lm-TabBar[data-orientation='horizontal'] > .lm-TabBar-content {
  flex-direction: row;
}


/* <DEPRECATED> */
.p-TabBar[data-orientation='vertical'] > .p-TabBar-content,
/* </DEPRECATED> */
.lm-TabBar[data-orientation='vertical'] > .lm-TabBar-content {
  flex-direction: column;
}


/* <DEPRECATED> */ .p-TabBar-tab, /* </DEPRECATED> */
.lm-TabBar-tab {
  display: flex;
  flex-direction: row;
  box-sizing: border-box;
  overflow: hidden;
}


/* <DEPRECATED> */
.p-TabBar-tabIcon,
.p-TabBar-tabCloseIcon,
/* </DEPRECATED> */
.lm-TabBar-tabIcon,
.lm-TabBar-tabCloseIcon {
  flex: 0 0 auto;
}


/* <DEPRECATED> */ .p-TabBar-tabLabel, /* </DEPRECATED> */
.lm-TabBar-tabLabel {
  flex: 1 1 auto;
  overflow: hidden;
  white-space: nowrap;
}


/* <DEPRECATED> */ .p-TabBar-tab.p-mod-hidden, /* </DEPRECATED> */
.lm-TabBar-tab.lm-mod-hidden {
  display: none !important;
}


/* <DEPRECATED> */ .p-TabBar.p-mod-dragging .p-TabBar-tab, /* </DEPRECATED> */
.lm-TabBar.lm-mod-dragging .lm-TabBar-tab {
  position: relative;
}


/* <DEPRECATED> */
.p-TabBar.p-mod-dragging[data-orientation='horizontal'] .p-TabBar-tab,
/* </DEPRECATED> */
.lm-TabBar.lm-mod-dragging[data-orientation='horizontal'] .lm-TabBar-tab {
  left: 0;
  transition: left 150ms ease;
}


/* <DEPRECATED> */
.p-TabBar.p-mod-dragging[data-orientation='vertical'] .p-TabBar-tab,
/* </DEPRECATED> */
.lm-TabBar.lm-mod-dragging[data-orientation='vertical'] .lm-TabBar-tab {
  top: 0;
  transition: top 150ms ease;
}


/* <DEPRECATED> */
.p-TabBar.p-mod-dragging .p-TabBar-tab.p-mod-dragging
/* </DEPRECATED> */
.lm-TabBar.lm-mod-dragging .lm-TabBar-tab.lm-mod-dragging {
  transition: none;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/


/* <DEPRECATED> */ .p-TabPanel-tabBar, /* </DEPRECATED> */
.lm-TabPanel-tabBar {
  z-index: 1;
}


/* <DEPRECATED> */ .p-TabPanel-stackedPanel, /* </DEPRECATED> */
.lm-TabPanel-stackedPanel {
  z-index: 0;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/

@charset "UTF-8";
/*!

Copyright 2015-present Palantir Technologies, Inc. All rights reserved.
Licensed under the Apache License, Version 2.0.

*/
html{
  -webkit-box-sizing:border-box;
          box-sizing:border-box; }

*,
*::before,
*::after{
  -webkit-box-sizing:inherit;
          box-sizing:inherit; }

body{
  text-transform:none;
  line-height:1.28581;
  letter-spacing:0;
  font-size:14px;
  font-weight:400;
  color:#182026;
  font-family:-apple-system, "BlinkMacSystemFont", "Segoe UI", "Roboto", "Oxygen", "Ubuntu", "Cantarell", "Open Sans", "Helvetica Neue", "Icons16", sans-serif; }

p{
  margin-top:0;
  margin-bottom:10px; }

small{
  font-size:12px; }

strong{
  font-weight:600; }

::-moz-selection{
  background:rgba(125, 188, 255, 0.6); }

::selection{
  background:rgba(125, 188, 255, 0.6); }
.bp3-heading{
  color:#182026;
  font-weight:600;
  margin:0 0 10px;
  padding:0; }
  .bp3-dark .bp3-heading{
    color:#f5f8fa; }

h1.bp3-heading, .bp3-running-text h1{
  line-height:40px;
  font-size:36px; }

h2.bp3-heading, .bp3-running-text h2{
  line-height:32px;
  font-size:28px; }

h3.bp3-heading, .bp3-running-text h3{
  line-height:25px;
  font-size:22px; }

h4.bp3-heading, .bp3-running-text h4{
  line-height:21px;
  font-size:18px; }

h5.bp3-heading, .bp3-running-text h5{
  line-height:19px;
  font-size:16px; }

h6.bp3-heading, .bp3-running-text h6{
  line-height:16px;
  font-size:14px; }
.bp3-ui-text{
  text-transform:none;
  line-height:1.28581;
  letter-spacing:0;
  font-size:14px;
  font-weight:400; }

.bp3-monospace-text{
  text-transform:none;
  font-family:monospace; }

.bp3-text-muted{
  color:#5c7080; }
  .bp3-dark .bp3-text-muted{
    color:#a7b6c2; }

.bp3-text-disabled{
  color:rgba(92, 112, 128, 0.6); }
  .bp3-dark .bp3-text-disabled{
    color:rgba(167, 182, 194, 0.6); }

.bp3-text-overflow-ellipsis{
  overflow:hidden;
  text-overflow:ellipsis;
  white-space:nowrap;
  word-wrap:normal; }
.bp3-running-text{
  line-height:1.5;
  font-size:14px; }
  .bp3-running-text h1{
    color:#182026;
    font-weight:600;
    margin-top:40px;
    margin-bottom:20px; }
    .bp3-dark .bp3-running-text h1{
      color:#f5f8fa; }
  .bp3-running-text h2{
    color:#182026;
    font-weight:600;
    margin-top:40px;
    margin-bottom:20px; }
    .bp3-dark .bp3-running-text h2{
      color:#f5f8fa; }
  .bp3-running-text h3{
    color:#182026;
    font-weight:600;
    margin-top:40px;
    margin-bottom:20px; }
    .bp3-dark .bp3-running-text h3{
      color:#f5f8fa; }
  .bp3-running-text h4{
    color:#182026;
    font-weight:600;
    margin-top:40px;
    margin-bottom:20px; }
    .bp3-dark .bp3-running-text h4{
      color:#f5f8fa; }
  .bp3-running-text h5{
    color:#182026;
    font-weight:600;
    margin-top:40px;
    margin-bottom:20px; }
    .bp3-dark .bp3-running-text h5{
      color:#f5f8fa; }
  .bp3-running-text h6{
    color:#182026;
    font-weight:600;
    margin-top:40px;
    margin-bottom:20px; }
    .bp3-dark .bp3-running-text h6{
      color:#f5f8fa; }
  .bp3-running-text hr{
    margin:20px 0;
    border:none;
    border-bottom:1px solid rgba(16, 22, 26, 0.15); }
    .bp3-dark .bp3-running-text hr{
      border-color:rgba(255, 255, 255, 0.15); }
  .bp3-running-text p{
    margin:0 0 10px;
    padding:0; }

.bp3-text-large{
  font-size:16px; }

.bp3-text-small{
  font-size:12px; }
a{
  text-decoration:none;
  color:#106ba3; }
  a:hover{
    cursor:pointer;
    text-decoration:underline;
    color:#106ba3; }
  a .bp3-icon, a .bp3-icon-standard, a .bp3-icon-large{
    color:inherit; }
  a code,
  .bp3-dark a code{
    color:inherit; }
  .bp3-dark a,
  .bp3-dark a:hover{
    color:#48aff0; }
    .bp3-dark a .bp3-icon, .bp3-dark a .bp3-icon-standard, .bp3-dark a .bp3-icon-large,
    .bp3-dark a:hover .bp3-icon,
    .bp3-dark a:hover .bp3-icon-standard,
    .bp3-dark a:hover .bp3-icon-large{
      color:inherit; }
.bp3-running-text code, .bp3-code{
  text-transform:none;
  font-family:monospace;
  border-radius:3px;
  -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2);
          box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2);
  background:rgba(255, 255, 255, 0.7);
  padding:2px 5px;
  color:#5c7080;
  font-size:smaller; }
  .bp3-dark .bp3-running-text code, .bp3-running-text .bp3-dark code, .bp3-dark .bp3-code{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4);
    background:rgba(16, 22, 26, 0.3);
    color:#a7b6c2; }
  .bp3-running-text a > code, a > .bp3-code{
    color:#137cbd; }
    .bp3-dark .bp3-running-text a > code, .bp3-running-text .bp3-dark a > code, .bp3-dark a > .bp3-code{
      color:inherit; }

.bp3-running-text pre, .bp3-code-block{
  text-transform:none;
  font-family:monospace;
  display:block;
  margin:10px 0;
  border-radius:3px;
  -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.15);
          box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.15);
  background:rgba(255, 255, 255, 0.7);
  padding:13px 15px 12px;
  line-height:1.4;
  color:#182026;
  font-size:13px;
  word-break:break-all;
  word-wrap:break-word; }
  .bp3-dark .bp3-running-text pre, .bp3-running-text .bp3-dark pre, .bp3-dark .bp3-code-block{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4);
    background:rgba(16, 22, 26, 0.3);
    color:#f5f8fa; }
  .bp3-running-text pre > code, .bp3-code-block > code{
    -webkit-box-shadow:none;
            box-shadow:none;
    background:none;
    padding:0;
    color:inherit;
    font-size:inherit; }

.bp3-running-text kbd, .bp3-key{
  display:-webkit-inline-box;
  display:-ms-inline-flexbox;
  display:inline-flex;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center;
  -webkit-box-pack:center;
      -ms-flex-pack:center;
          justify-content:center;
  border-radius:3px;
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.2);
  background:#ffffff;
  min-width:24px;
  height:24px;
  padding:3px 6px;
  vertical-align:middle;
  line-height:24px;
  color:#5c7080;
  font-family:inherit;
  font-size:12px; }
  .bp3-running-text kbd .bp3-icon, .bp3-key .bp3-icon, .bp3-running-text kbd .bp3-icon-standard, .bp3-key .bp3-icon-standard, .bp3-running-text kbd .bp3-icon-large, .bp3-key .bp3-icon-large{
    margin-right:5px; }
  .bp3-dark .bp3-running-text kbd, .bp3-running-text .bp3-dark kbd, .bp3-dark .bp3-key{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.4);
    background:#394b59;
    color:#a7b6c2; }
.bp3-running-text blockquote, .bp3-blockquote{
  margin:0 0 10px;
  border-left:solid 4px rgba(167, 182, 194, 0.5);
  padding:0 20px; }
  .bp3-dark .bp3-running-text blockquote, .bp3-running-text .bp3-dark blockquote, .bp3-dark .bp3-blockquote{
    border-color:rgba(115, 134, 148, 0.5); }
.bp3-running-text ul,
.bp3-running-text ol, .bp3-list{
  margin:10px 0;
  padding-left:30px; }
  .bp3-running-text ul li:not(:last-child), .bp3-running-text ol li:not(:last-child), .bp3-list li:not(:last-child){
    margin-bottom:5px; }
  .bp3-running-text ul ol, .bp3-running-text ol ol, .bp3-list ol,
  .bp3-running-text ul ul,
  .bp3-running-text ol ul,
  .bp3-list ul{
    margin-top:5px; }

.bp3-list-unstyled{
  margin:0;
  padding:0;
  list-style:none; }
  .bp3-list-unstyled li{
    padding:0; }
.bp3-rtl{
  text-align:right; }

.bp3-dark{
  color:#f5f8fa; }

:focus{
  outline:rgba(19, 124, 189, 0.6) auto 2px;
  outline-offset:2px;
  -moz-outline-radius:6px; }

.bp3-focus-disabled :focus{
  outline:none !important; }
  .bp3-focus-disabled :focus ~ .bp3-control-indicator{
    outline:none !important; }

.bp3-alert{
  max-width:400px;
  padding:20px; }

.bp3-alert-body{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex; }
  .bp3-alert-body .bp3-icon{
    margin-top:0;
    margin-right:20px;
    font-size:40px; }

.bp3-alert-footer{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-orient:horizontal;
  -webkit-box-direction:reverse;
      -ms-flex-direction:row-reverse;
          flex-direction:row-reverse;
  margin-top:10px; }
  .bp3-alert-footer .bp3-button{
    margin-left:10px; }
.bp3-breadcrumbs{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -ms-flex-wrap:wrap;
      flex-wrap:wrap;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center;
  margin:0;
  cursor:default;
  height:30px;
  padding:0;
  list-style:none; }
  .bp3-breadcrumbs > li{
    display:-webkit-box;
    display:-ms-flexbox;
    display:flex;
    -webkit-box-align:center;
        -ms-flex-align:center;
            align-items:center; }
    .bp3-breadcrumbs > li::after{
      display:block;
      margin:0 5px;
      background:url("data:image/svg+xml,%3csvg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 16 16'%3e%3cpath fill-rule='evenodd' clip-rule='evenodd' d='M10.71 7.29l-4-4a1.003 1.003 0 0 0-1.42 1.42L8.59 8 5.3 11.29c-.19.18-.3.43-.3.71a1.003 1.003 0 0 0 1.71.71l4-4c.18-.18.29-.43.29-.71 0-.28-.11-.53-.29-.71z' fill='%235C7080'/%3e%3c/svg%3e");
      width:16px;
      height:16px;
      content:""; }
    .bp3-breadcrumbs > li:last-of-type::after{
      display:none; }

.bp3-breadcrumb,
.bp3-breadcrumb-current,
.bp3-breadcrumbs-collapsed{
  display:-webkit-inline-box;
  display:-ms-inline-flexbox;
  display:inline-flex;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center;
  font-size:16px; }

.bp3-breadcrumb,
.bp3-breadcrumbs-collapsed{
  color:#5c7080; }

.bp3-breadcrumb:hover{
  text-decoration:none; }

.bp3-breadcrumb.bp3-disabled{
  cursor:not-allowed;
  color:rgba(92, 112, 128, 0.6); }

.bp3-breadcrumb .bp3-icon{
  margin-right:5px; }

.bp3-breadcrumb-current{
  color:inherit;
  font-weight:600; }
  .bp3-breadcrumb-current .bp3-input{
    vertical-align:baseline;
    font-size:inherit;
    font-weight:inherit; }

.bp3-breadcrumbs-collapsed{
  margin-right:2px;
  border:none;
  border-radius:3px;
  background:#ced9e0;
  cursor:pointer;
  padding:1px 5px;
  vertical-align:text-bottom; }
  .bp3-breadcrumbs-collapsed::before{
    display:block;
    background:url("data:image/svg+xml,%3csvg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 16 16'%3e%3cg fill='%235C7080'%3e%3ccircle cx='2' cy='8.03' r='2'/%3e%3ccircle cx='14' cy='8.03' r='2'/%3e%3ccircle cx='8' cy='8.03' r='2'/%3e%3c/g%3e%3c/svg%3e") center no-repeat;
    width:16px;
    height:16px;
    content:""; }
  .bp3-breadcrumbs-collapsed:hover{
    background:#bfccd6;
    text-decoration:none;
    color:#182026; }

.bp3-dark .bp3-breadcrumb,
.bp3-dark .bp3-breadcrumbs-collapsed{
  color:#a7b6c2; }

.bp3-dark .bp3-breadcrumbs > li::after{
  color:#a7b6c2; }

.bp3-dark .bp3-breadcrumb.bp3-disabled{
  color:rgba(167, 182, 194, 0.6); }

.bp3-dark .bp3-breadcrumb-current{
  color:#f5f8fa; }

.bp3-dark .bp3-breadcrumbs-collapsed{
  background:rgba(16, 22, 26, 0.4); }
  .bp3-dark .bp3-breadcrumbs-collapsed:hover{
    background:rgba(16, 22, 26, 0.6);
    color:#f5f8fa; }
.bp3-button{
  display:-webkit-inline-box;
  display:-ms-inline-flexbox;
  display:inline-flex;
  -webkit-box-orient:horizontal;
  -webkit-box-direction:normal;
      -ms-flex-direction:row;
          flex-direction:row;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center;
  -webkit-box-pack:center;
      -ms-flex-pack:center;
          justify-content:center;
  border:none;
  border-radius:3px;
  cursor:pointer;
  padding:5px 10px;
  vertical-align:middle;
  text-align:left;
  font-size:14px;
  min-width:30px;
  min-height:30px; }
  .bp3-button > *{
    -webkit-box-flex:0;
        -ms-flex-positive:0;
            flex-grow:0;
    -ms-flex-negative:0;
        flex-shrink:0; }
  .bp3-button > .bp3-fill{
    -webkit-box-flex:1;
        -ms-flex-positive:1;
            flex-grow:1;
    -ms-flex-negative:1;
        flex-shrink:1; }
  .bp3-button::before,
  .bp3-button > *{
    margin-right:7px; }
  .bp3-button:empty::before,
  .bp3-button > :last-child{
    margin-right:0; }
  .bp3-button:empty{
    padding:0 !important; }
  .bp3-button:disabled, .bp3-button.bp3-disabled{
    cursor:not-allowed; }
  .bp3-button.bp3-fill{
    display:-webkit-box;
    display:-ms-flexbox;
    display:flex;
    width:100%; }
  .bp3-button.bp3-align-right,
  .bp3-align-right .bp3-button{
    text-align:right; }
  .bp3-button.bp3-align-left,
  .bp3-align-left .bp3-button{
    text-align:left; }
  .bp3-button:not([class*="bp3-intent-"]){
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
    background-color:#f5f8fa;
    background-image:-webkit-gradient(linear, left top, left bottom, from(rgba(255, 255, 255, 0.8)), to(rgba(255, 255, 255, 0)));
    background-image:linear-gradient(to bottom, rgba(255, 255, 255, 0.8), rgba(255, 255, 255, 0));
    color:#182026; }
    .bp3-button:not([class*="bp3-intent-"]):hover{
      -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
              box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
      background-clip:padding-box;
      background-color:#ebf1f5; }
    .bp3-button:not([class*="bp3-intent-"]):active, .bp3-button:not([class*="bp3-intent-"]).bp3-active{
      -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 1px 2px rgba(16, 22, 26, 0.2);
              box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 1px 2px rgba(16, 22, 26, 0.2);
      background-color:#d8e1e8;
      background-image:none; }
    .bp3-button:not([class*="bp3-intent-"]):disabled, .bp3-button:not([class*="bp3-intent-"]).bp3-disabled{
      outline:none;
      -webkit-box-shadow:none;
              box-shadow:none;
      background-color:rgba(206, 217, 224, 0.5);
      background-image:none;
      cursor:not-allowed;
      color:rgba(92, 112, 128, 0.6); }
      .bp3-button:not([class*="bp3-intent-"]):disabled.bp3-active, .bp3-button:not([class*="bp3-intent-"]):disabled.bp3-active:hover, .bp3-button:not([class*="bp3-intent-"]).bp3-disabled.bp3-active, .bp3-button:not([class*="bp3-intent-"]).bp3-disabled.bp3-active:hover{
        background:rgba(206, 217, 224, 0.7); }
  .bp3-button.bp3-intent-primary{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
    background-color:#137cbd;
    background-image:-webkit-gradient(linear, left top, left bottom, from(rgba(255, 255, 255, 0.1)), to(rgba(255, 255, 255, 0)));
    background-image:linear-gradient(to bottom, rgba(255, 255, 255, 0.1), rgba(255, 255, 255, 0));
    color:#ffffff; }
    .bp3-button.bp3-intent-primary:hover, .bp3-button.bp3-intent-primary:active, .bp3-button.bp3-intent-primary.bp3-active{
      color:#ffffff; }
    .bp3-button.bp3-intent-primary:hover{
      -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
              box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
      background-color:#106ba3; }
    .bp3-button.bp3-intent-primary:active, .bp3-button.bp3-intent-primary.bp3-active{
      -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
              box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
      background-color:#0e5a8a;
      background-image:none; }
    .bp3-button.bp3-intent-primary:disabled, .bp3-button.bp3-intent-primary.bp3-disabled{
      border-color:transparent;
      -webkit-box-shadow:none;
              box-shadow:none;
      background-color:rgba(19, 124, 189, 0.5);
      background-image:none;
      color:rgba(255, 255, 255, 0.6); }
  .bp3-button.bp3-intent-success{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
    background-color:#0f9960;
    background-image:-webkit-gradient(linear, left top, left bottom, from(rgba(255, 255, 255, 0.1)), to(rgba(255, 255, 255, 0)));
    background-image:linear-gradient(to bottom, rgba(255, 255, 255, 0.1), rgba(255, 255, 255, 0));
    color:#ffffff; }
    .bp3-button.bp3-intent-success:hover, .bp3-button.bp3-intent-success:active, .bp3-button.bp3-intent-success.bp3-active{
      color:#ffffff; }
    .bp3-button.bp3-intent-success:hover{
      -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
              box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
      background-color:#0d8050; }
    .bp3-button.bp3-intent-success:active, .bp3-button.bp3-intent-success.bp3-active{
      -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
              box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
      background-color:#0a6640;
      background-image:none; }
    .bp3-button.bp3-intent-success:disabled, .bp3-button.bp3-intent-success.bp3-disabled{
      border-color:transparent;
      -webkit-box-shadow:none;
              box-shadow:none;
      background-color:rgba(15, 153, 96, 0.5);
      background-image:none;
      color:rgba(255, 255, 255, 0.6); }
  .bp3-button.bp3-intent-warning{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
    background-color:#d9822b;
    background-image:-webkit-gradient(linear, left top, left bottom, from(rgba(255, 255, 255, 0.1)), to(rgba(255, 255, 255, 0)));
    background-image:linear-gradient(to bottom, rgba(255, 255, 255, 0.1), rgba(255, 255, 255, 0));
    color:#ffffff; }
    .bp3-button.bp3-intent-warning:hover, .bp3-button.bp3-intent-warning:active, .bp3-button.bp3-intent-warning.bp3-active{
      color:#ffffff; }
    .bp3-button.bp3-intent-warning:hover{
      -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
              box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
      background-color:#bf7326; }
    .bp3-button.bp3-intent-warning:active, .bp3-button.bp3-intent-warning.bp3-active{
      -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
              box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
      background-color:#a66321;
      background-image:none; }
    .bp3-button.bp3-intent-warning:disabled, .bp3-button.bp3-intent-warning.bp3-disabled{
      border-color:transparent;
      -webkit-box-shadow:none;
              box-shadow:none;
      background-color:rgba(217, 130, 43, 0.5);
      background-image:none;
      color:rgba(255, 255, 255, 0.6); }
  .bp3-button.bp3-intent-danger{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
    background-color:#db3737;
    background-image:-webkit-gradient(linear, left top, left bottom, from(rgba(255, 255, 255, 0.1)), to(rgba(255, 255, 255, 0)));
    background-image:linear-gradient(to bottom, rgba(255, 255, 255, 0.1), rgba(255, 255, 255, 0));
    color:#ffffff; }
    .bp3-button.bp3-intent-danger:hover, .bp3-button.bp3-intent-danger:active, .bp3-button.bp3-intent-danger.bp3-active{
      color:#ffffff; }
    .bp3-button.bp3-intent-danger:hover{
      -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
              box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
      background-color:#c23030; }
    .bp3-button.bp3-intent-danger:active, .bp3-button.bp3-intent-danger.bp3-active{
      -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
              box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
      background-color:#a82a2a;
      background-image:none; }
    .bp3-button.bp3-intent-danger:disabled, .bp3-button.bp3-intent-danger.bp3-disabled{
      border-color:transparent;
      -webkit-box-shadow:none;
              box-shadow:none;
      background-color:rgba(219, 55, 55, 0.5);
      background-image:none;
      color:rgba(255, 255, 255, 0.6); }
  .bp3-button[class*="bp3-intent-"] .bp3-button-spinner .bp3-spinner-head{
    stroke:#ffffff; }
  .bp3-button.bp3-large,
  .bp3-large .bp3-button{
    min-width:40px;
    min-height:40px;
    padding:5px 15px;
    font-size:16px; }
    .bp3-button.bp3-large::before,
    .bp3-button.bp3-large > *,
    .bp3-large .bp3-button::before,
    .bp3-large .bp3-button > *{
      margin-right:10px; }
    .bp3-button.bp3-large:empty::before,
    .bp3-button.bp3-large > :last-child,
    .bp3-large .bp3-button:empty::before,
    .bp3-large .bp3-button > :last-child{
      margin-right:0; }
  .bp3-button.bp3-small,
  .bp3-small .bp3-button{
    min-width:24px;
    min-height:24px;
    padding:0 7px; }
  .bp3-button.bp3-loading{
    position:relative; }
    .bp3-button.bp3-loading[class*="bp3-icon-"]::before{
      visibility:hidden; }
    .bp3-button.bp3-loading .bp3-button-spinner{
      position:absolute;
      margin:0; }
    .bp3-button.bp3-loading > :not(.bp3-button-spinner){
      visibility:hidden; }
  .bp3-button[class*="bp3-icon-"]::before{
    line-height:1;
    font-family:"Icons16", sans-serif;
    font-size:16px;
    font-weight:400;
    font-style:normal;
    -moz-osx-font-smoothing:grayscale;
    -webkit-font-smoothing:antialiased;
    color:#5c7080; }
  .bp3-button .bp3-icon, .bp3-button .bp3-icon-standard, .bp3-button .bp3-icon-large{
    color:#5c7080; }
    .bp3-button .bp3-icon.bp3-align-right, .bp3-button .bp3-icon-standard.bp3-align-right, .bp3-button .bp3-icon-large.bp3-align-right{
      margin-left:7px; }
  .bp3-button .bp3-icon:first-child:last-child,
  .bp3-button .bp3-spinner + .bp3-icon:last-child{
    margin:0 -7px; }
  .bp3-dark .bp3-button:not([class*="bp3-intent-"]){
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
    background-color:#394b59;
    background-image:-webkit-gradient(linear, left top, left bottom, from(rgba(255, 255, 255, 0.05)), to(rgba(255, 255, 255, 0)));
    background-image:linear-gradient(to bottom, rgba(255, 255, 255, 0.05), rgba(255, 255, 255, 0));
    color:#f5f8fa; }
    .bp3-dark .bp3-button:not([class*="bp3-intent-"]):hover, .bp3-dark .bp3-button:not([class*="bp3-intent-"]):active, .bp3-dark .bp3-button:not([class*="bp3-intent-"]).bp3-active{
      color:#f5f8fa; }
    .bp3-dark .bp3-button:not([class*="bp3-intent-"]):hover{
      -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
      background-color:#30404d; }
    .bp3-dark .bp3-button:not([class*="bp3-intent-"]):active, .bp3-dark .bp3-button:not([class*="bp3-intent-"]).bp3-active{
      -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.6), inset 0 1px 2px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px rgba(16, 22, 26, 0.6), inset 0 1px 2px rgba(16, 22, 26, 0.2);
      background-color:#202b33;
      background-image:none; }
    .bp3-dark .bp3-button:not([class*="bp3-intent-"]):disabled, .bp3-dark .bp3-button:not([class*="bp3-intent-"]).bp3-disabled{
      -webkit-box-shadow:none;
              box-shadow:none;
      background-color:rgba(57, 75, 89, 0.5);
      background-image:none;
      color:rgba(167, 182, 194, 0.6); }
      .bp3-dark .bp3-button:not([class*="bp3-intent-"]):disabled.bp3-active, .bp3-dark .bp3-button:not([class*="bp3-intent-"]).bp3-disabled.bp3-active{
        background:rgba(57, 75, 89, 0.7); }
    .bp3-dark .bp3-button:not([class*="bp3-intent-"]) .bp3-button-spinner .bp3-spinner-head{
      background:rgba(16, 22, 26, 0.5);
      stroke:#8a9ba8; }
    .bp3-dark .bp3-button:not([class*="bp3-intent-"])[class*="bp3-icon-"]::before{
      color:#a7b6c2; }
    .bp3-dark .bp3-button:not([class*="bp3-intent-"]) .bp3-icon, .bp3-dark .bp3-button:not([class*="bp3-intent-"]) .bp3-icon-standard, .bp3-dark .bp3-button:not([class*="bp3-intent-"]) .bp3-icon-large{
      color:#a7b6c2; }
  .bp3-dark .bp3-button[class*="bp3-intent-"]{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4); }
    .bp3-dark .bp3-button[class*="bp3-intent-"]:hover{
      -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4); }
    .bp3-dark .bp3-button[class*="bp3-intent-"]:active, .bp3-dark .bp3-button[class*="bp3-intent-"].bp3-active{
      -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2); }
    .bp3-dark .bp3-button[class*="bp3-intent-"]:disabled, .bp3-dark .bp3-button[class*="bp3-intent-"].bp3-disabled{
      -webkit-box-shadow:none;
              box-shadow:none;
      background-image:none;
      color:rgba(255, 255, 255, 0.3); }
    .bp3-dark .bp3-button[class*="bp3-intent-"] .bp3-button-spinner .bp3-spinner-head{
      stroke:#8a9ba8; }
  .bp3-button:disabled::before,
  .bp3-button:disabled .bp3-icon, .bp3-button:disabled .bp3-icon-standard, .bp3-button:disabled .bp3-icon-large, .bp3-button.bp3-disabled::before,
  .bp3-button.bp3-disabled .bp3-icon, .bp3-button.bp3-disabled .bp3-icon-standard, .bp3-button.bp3-disabled .bp3-icon-large, .bp3-button[class*="bp3-intent-"]::before,
  .bp3-button[class*="bp3-intent-"] .bp3-icon, .bp3-button[class*="bp3-intent-"] .bp3-icon-standard, .bp3-button[class*="bp3-intent-"] .bp3-icon-large{
    color:inherit !important; }
  .bp3-button.bp3-minimal{
    -webkit-box-shadow:none;
            box-shadow:none;
    background:none; }
    .bp3-button.bp3-minimal:hover{
      -webkit-box-shadow:none;
              box-shadow:none;
      background:rgba(167, 182, 194, 0.3);
      text-decoration:none;
      color:#182026; }
    .bp3-button.bp3-minimal:active, .bp3-button.bp3-minimal.bp3-active{
      -webkit-box-shadow:none;
              box-shadow:none;
      background:rgba(115, 134, 148, 0.3);
      color:#182026; }
    .bp3-button.bp3-minimal:disabled, .bp3-button.bp3-minimal:disabled:hover, .bp3-button.bp3-minimal.bp3-disabled, .bp3-button.bp3-minimal.bp3-disabled:hover{
      background:none;
      cursor:not-allowed;
      color:rgba(92, 112, 128, 0.6); }
      .bp3-button.bp3-minimal:disabled.bp3-active, .bp3-button.bp3-minimal:disabled:hover.bp3-active, .bp3-button.bp3-minimal.bp3-disabled.bp3-active, .bp3-button.bp3-minimal.bp3-disabled:hover.bp3-active{
        background:rgba(115, 134, 148, 0.3); }
    .bp3-dark .bp3-button.bp3-minimal{
      -webkit-box-shadow:none;
              box-shadow:none;
      background:none;
      color:inherit; }
      .bp3-dark .bp3-button.bp3-minimal:hover, .bp3-dark .bp3-button.bp3-minimal:active, .bp3-dark .bp3-button.bp3-minimal.bp3-active{
        -webkit-box-shadow:none;
                box-shadow:none;
        background:none; }
      .bp3-dark .bp3-button.bp3-minimal:hover{
        background:rgba(138, 155, 168, 0.15); }
      .bp3-dark .bp3-button.bp3-minimal:active, .bp3-dark .bp3-button.bp3-minimal.bp3-active{
        background:rgba(138, 155, 168, 0.3);
        color:#f5f8fa; }
      .bp3-dark .bp3-button.bp3-minimal:disabled, .bp3-dark .bp3-button.bp3-minimal:disabled:hover, .bp3-dark .bp3-button.bp3-minimal.bp3-disabled, .bp3-dark .bp3-button.bp3-minimal.bp3-disabled:hover{
        background:none;
        cursor:not-allowed;
        color:rgba(167, 182, 194, 0.6); }
        .bp3-dark .bp3-button.bp3-minimal:disabled.bp3-active, .bp3-dark .bp3-button.bp3-minimal:disabled:hover.bp3-active, .bp3-dark .bp3-button.bp3-minimal.bp3-disabled.bp3-active, .bp3-dark .bp3-button.bp3-minimal.bp3-disabled:hover.bp3-active{
          background:rgba(138, 155, 168, 0.3); }
    .bp3-button.bp3-minimal.bp3-intent-primary{
      color:#106ba3; }
      .bp3-button.bp3-minimal.bp3-intent-primary:hover, .bp3-button.bp3-minimal.bp3-intent-primary:active, .bp3-button.bp3-minimal.bp3-intent-primary.bp3-active{
        -webkit-box-shadow:none;
                box-shadow:none;
        background:none;
        color:#106ba3; }
      .bp3-button.bp3-minimal.bp3-intent-primary:hover{
        background:rgba(19, 124, 189, 0.15);
        color:#106ba3; }
      .bp3-button.bp3-minimal.bp3-intent-primary:active, .bp3-button.bp3-minimal.bp3-intent-primary.bp3-active{
        background:rgba(19, 124, 189, 0.3);
        color:#106ba3; }
      .bp3-button.bp3-minimal.bp3-intent-primary:disabled, .bp3-button.bp3-minimal.bp3-intent-primary.bp3-disabled{
        background:none;
        color:rgba(16, 107, 163, 0.5); }
        .bp3-button.bp3-minimal.bp3-intent-primary:disabled.bp3-active, .bp3-button.bp3-minimal.bp3-intent-primary.bp3-disabled.bp3-active{
          background:rgba(19, 124, 189, 0.3); }
      .bp3-button.bp3-minimal.bp3-intent-primary .bp3-button-spinner .bp3-spinner-head{
        stroke:#106ba3; }
      .bp3-dark .bp3-button.bp3-minimal.bp3-intent-primary{
        color:#48aff0; }
        .bp3-dark .bp3-button.bp3-minimal.bp3-intent-primary:hover{
          background:rgba(19, 124, 189, 0.2);
          color:#48aff0; }
        .bp3-dark .bp3-button.bp3-minimal.bp3-intent-primary:active, .bp3-dark .bp3-button.bp3-minimal.bp3-intent-primary.bp3-active{
          background:rgba(19, 124, 189, 0.3);
          color:#48aff0; }
        .bp3-dark .bp3-button.bp3-minimal.bp3-intent-primary:disabled, .bp3-dark .bp3-button.bp3-minimal.bp3-intent-primary.bp3-disabled{
          background:none;
          color:rgba(72, 175, 240, 0.5); }
          .bp3-dark .bp3-button.bp3-minimal.bp3-intent-primary:disabled.bp3-active, .bp3-dark .bp3-button.bp3-minimal.bp3-intent-primary.bp3-disabled.bp3-active{
            background:rgba(19, 124, 189, 0.3); }
    .bp3-button.bp3-minimal.bp3-intent-success{
      color:#0d8050; }
      .bp3-button.bp3-minimal.bp3-intent-success:hover, .bp3-button.bp3-minimal.bp3-intent-success:active, .bp3-button.bp3-minimal.bp3-intent-success.bp3-active{
        -webkit-box-shadow:none;
                box-shadow:none;
        background:none;
        color:#0d8050; }
      .bp3-button.bp3-minimal.bp3-intent-success:hover{
        background:rgba(15, 153, 96, 0.15);
        color:#0d8050; }
      .bp3-button.bp3-minimal.bp3-intent-success:active, .bp3-button.bp3-minimal.bp3-intent-success.bp3-active{
        background:rgba(15, 153, 96, 0.3);
        color:#0d8050; }
      .bp3-button.bp3-minimal.bp3-intent-success:disabled, .bp3-button.bp3-minimal.bp3-intent-success.bp3-disabled{
        background:none;
        color:rgba(13, 128, 80, 0.5); }
        .bp3-button.bp3-minimal.bp3-intent-success:disabled.bp3-active, .bp3-button.bp3-minimal.bp3-intent-success.bp3-disabled.bp3-active{
          background:rgba(15, 153, 96, 0.3); }
      .bp3-button.bp3-minimal.bp3-intent-success .bp3-button-spinner .bp3-spinner-head{
        stroke:#0d8050; }
      .bp3-dark .bp3-button.bp3-minimal.bp3-intent-success{
        color:#3dcc91; }
        .bp3-dark .bp3-button.bp3-minimal.bp3-intent-success:hover{
          background:rgba(15, 153, 96, 0.2);
          color:#3dcc91; }
        .bp3-dark .bp3-button.bp3-minimal.bp3-intent-success:active, .bp3-dark .bp3-button.bp3-minimal.bp3-intent-success.bp3-active{
          background:rgba(15, 153, 96, 0.3);
          color:#3dcc91; }
        .bp3-dark .bp3-button.bp3-minimal.bp3-intent-success:disabled, .bp3-dark .bp3-button.bp3-minimal.bp3-intent-success.bp3-disabled{
          background:none;
          color:rgba(61, 204, 145, 0.5); }
          .bp3-dark .bp3-button.bp3-minimal.bp3-intent-success:disabled.bp3-active, .bp3-dark .bp3-button.bp3-minimal.bp3-intent-success.bp3-disabled.bp3-active{
            background:rgba(15, 153, 96, 0.3); }
    .bp3-button.bp3-minimal.bp3-intent-warning{
      color:#bf7326; }
      .bp3-button.bp3-minimal.bp3-intent-warning:hover, .bp3-button.bp3-minimal.bp3-intent-warning:active, .bp3-button.bp3-minimal.bp3-intent-warning.bp3-active{
        -webkit-box-shadow:none;
                box-shadow:none;
        background:none;
        color:#bf7326; }
      .bp3-button.bp3-minimal.bp3-intent-warning:hover{
        background:rgba(217, 130, 43, 0.15);
        color:#bf7326; }
      .bp3-button.bp3-minimal.bp3-intent-warning:active, .bp3-button.bp3-minimal.bp3-intent-warning.bp3-active{
        background:rgba(217, 130, 43, 0.3);
        color:#bf7326; }
      .bp3-button.bp3-minimal.bp3-intent-warning:disabled, .bp3-button.bp3-minimal.bp3-intent-warning.bp3-disabled{
        background:none;
        color:rgba(191, 115, 38, 0.5); }
        .bp3-button.bp3-minimal.bp3-intent-warning:disabled.bp3-active, .bp3-button.bp3-minimal.bp3-intent-warning.bp3-disabled.bp3-active{
          background:rgba(217, 130, 43, 0.3); }
      .bp3-button.bp3-minimal.bp3-intent-warning .bp3-button-spinner .bp3-spinner-head{
        stroke:#bf7326; }
      .bp3-dark .bp3-button.bp3-minimal.bp3-intent-warning{
        color:#ffb366; }
        .bp3-dark .bp3-button.bp3-minimal.bp3-intent-warning:hover{
          background:rgba(217, 130, 43, 0.2);
          color:#ffb366; }
        .bp3-dark .bp3-button.bp3-minimal.bp3-intent-warning:active, .bp3-dark .bp3-button.bp3-minimal.bp3-intent-warning.bp3-active{
          background:rgba(217, 130, 43, 0.3);
          color:#ffb366; }
        .bp3-dark .bp3-button.bp3-minimal.bp3-intent-warning:disabled, .bp3-dark .bp3-button.bp3-minimal.bp3-intent-warning.bp3-disabled{
          background:none;
          color:rgba(255, 179, 102, 0.5); }
          .bp3-dark .bp3-button.bp3-minimal.bp3-intent-warning:disabled.bp3-active, .bp3-dark .bp3-button.bp3-minimal.bp3-intent-warning.bp3-disabled.bp3-active{
            background:rgba(217, 130, 43, 0.3); }
    .bp3-button.bp3-minimal.bp3-intent-danger{
      color:#c23030; }
      .bp3-button.bp3-minimal.bp3-intent-danger:hover, .bp3-button.bp3-minimal.bp3-intent-danger:active, .bp3-button.bp3-minimal.bp3-intent-danger.bp3-active{
        -webkit-box-shadow:none;
                box-shadow:none;
        background:none;
        color:#c23030; }
      .bp3-button.bp3-minimal.bp3-intent-danger:hover{
        background:rgba(219, 55, 55, 0.15);
        color:#c23030; }
      .bp3-button.bp3-minimal.bp3-intent-danger:active, .bp3-button.bp3-minimal.bp3-intent-danger.bp3-active{
        background:rgba(219, 55, 55, 0.3);
        color:#c23030; }
      .bp3-button.bp3-minimal.bp3-intent-danger:disabled, .bp3-button.bp3-minimal.bp3-intent-danger.bp3-disabled{
        background:none;
        color:rgba(194, 48, 48, 0.5); }
        .bp3-button.bp3-minimal.bp3-intent-danger:disabled.bp3-active, .bp3-button.bp3-minimal.bp3-intent-danger.bp3-disabled.bp3-active{
          background:rgba(219, 55, 55, 0.3); }
      .bp3-button.bp3-minimal.bp3-intent-danger .bp3-button-spinner .bp3-spinner-head{
        stroke:#c23030; }
      .bp3-dark .bp3-button.bp3-minimal.bp3-intent-danger{
        color:#ff7373; }
        .bp3-dark .bp3-button.bp3-minimal.bp3-intent-danger:hover{
          background:rgba(219, 55, 55, 0.2);
          color:#ff7373; }
        .bp3-dark .bp3-button.bp3-minimal.bp3-intent-danger:active, .bp3-dark .bp3-button.bp3-minimal.bp3-intent-danger.bp3-active{
          background:rgba(219, 55, 55, 0.3);
          color:#ff7373; }
        .bp3-dark .bp3-button.bp3-minimal.bp3-intent-danger:disabled, .bp3-dark .bp3-button.bp3-minimal.bp3-intent-danger.bp3-disabled{
          background:none;
          color:rgba(255, 115, 115, 0.5); }
          .bp3-dark .bp3-button.bp3-minimal.bp3-intent-danger:disabled.bp3-active, .bp3-dark .bp3-button.bp3-minimal.bp3-intent-danger.bp3-disabled.bp3-active{
            background:rgba(219, 55, 55, 0.3); }

a.bp3-button{
  text-align:center;
  text-decoration:none;
  -webkit-transition:none;
  transition:none; }
  a.bp3-button, a.bp3-button:hover, a.bp3-button:active{
    color:#182026; }
  a.bp3-button.bp3-disabled{
    color:rgba(92, 112, 128, 0.6); }

.bp3-button-text{
  -webkit-box-flex:0;
      -ms-flex:0 1 auto;
          flex:0 1 auto; }

.bp3-button.bp3-align-left .bp3-button-text, .bp3-button.bp3-align-right .bp3-button-text,
.bp3-button-group.bp3-align-left .bp3-button-text,
.bp3-button-group.bp3-align-right .bp3-button-text{
  -webkit-box-flex:1;
      -ms-flex:1 1 auto;
          flex:1 1 auto; }
.bp3-button-group{
  display:-webkit-inline-box;
  display:-ms-inline-flexbox;
  display:inline-flex; }
  .bp3-button-group .bp3-button{
    -webkit-box-flex:0;
        -ms-flex:0 0 auto;
            flex:0 0 auto;
    position:relative;
    z-index:4; }
    .bp3-button-group .bp3-button:focus{
      z-index:5; }
    .bp3-button-group .bp3-button:hover{
      z-index:6; }
    .bp3-button-group .bp3-button:active, .bp3-button-group .bp3-button.bp3-active{
      z-index:7; }
    .bp3-button-group .bp3-button:disabled, .bp3-button-group .bp3-button.bp3-disabled{
      z-index:3; }
    .bp3-button-group .bp3-button[class*="bp3-intent-"]{
      z-index:9; }
      .bp3-button-group .bp3-button[class*="bp3-intent-"]:focus{
        z-index:10; }
      .bp3-button-group .bp3-button[class*="bp3-intent-"]:hover{
        z-index:11; }
      .bp3-button-group .bp3-button[class*="bp3-intent-"]:active, .bp3-button-group .bp3-button[class*="bp3-intent-"].bp3-active{
        z-index:12; }
      .bp3-button-group .bp3-button[class*="bp3-intent-"]:disabled, .bp3-button-group .bp3-button[class*="bp3-intent-"].bp3-disabled{
        z-index:8; }
  .bp3-button-group:not(.bp3-minimal) > .bp3-popover-wrapper:not(:first-child) .bp3-button,
  .bp3-button-group:not(.bp3-minimal) > .bp3-button:not(:first-child){
    border-top-left-radius:0;
    border-bottom-left-radius:0; }
  .bp3-button-group:not(.bp3-minimal) > .bp3-popover-wrapper:not(:last-child) .bp3-button,
  .bp3-button-group:not(.bp3-minimal) > .bp3-button:not(:last-child){
    margin-right:-1px;
    border-top-right-radius:0;
    border-bottom-right-radius:0; }
  .bp3-button-group.bp3-minimal .bp3-button{
    -webkit-box-shadow:none;
            box-shadow:none;
    background:none; }
    .bp3-button-group.bp3-minimal .bp3-button:hover{
      -webkit-box-shadow:none;
              box-shadow:none;
      background:rgba(167, 182, 194, 0.3);
      text-decoration:none;
      color:#182026; }
    .bp3-button-group.bp3-minimal .bp3-button:active, .bp3-button-group.bp3-minimal .bp3-button.bp3-active{
      -webkit-box-shadow:none;
              box-shadow:none;
      background:rgba(115, 134, 148, 0.3);
      color:#182026; }
    .bp3-button-group.bp3-minimal .bp3-button:disabled, .bp3-button-group.bp3-minimal .bp3-button:disabled:hover, .bp3-button-group.bp3-minimal .bp3-button.bp3-disabled, .bp3-button-group.bp3-minimal .bp3-button.bp3-disabled:hover{
      background:none;
      cursor:not-allowed;
      color:rgba(92, 112, 128, 0.6); }
      .bp3-button-group.bp3-minimal .bp3-button:disabled.bp3-active, .bp3-button-group.bp3-minimal .bp3-button:disabled:hover.bp3-active, .bp3-button-group.bp3-minimal .bp3-button.bp3-disabled.bp3-active, .bp3-button-group.bp3-minimal .bp3-button.bp3-disabled:hover.bp3-active{
        background:rgba(115, 134, 148, 0.3); }
    .bp3-dark .bp3-button-group.bp3-minimal .bp3-button{
      -webkit-box-shadow:none;
              box-shadow:none;
      background:none;
      color:inherit; }
      .bp3-dark .bp3-button-group.bp3-minimal .bp3-button:hover, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button:active, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-active{
        -webkit-box-shadow:none;
                box-shadow:none;
        background:none; }
      .bp3-dark .bp3-button-group.bp3-minimal .bp3-button:hover{
        background:rgba(138, 155, 168, 0.15); }
      .bp3-dark .bp3-button-group.bp3-minimal .bp3-button:active, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-active{
        background:rgba(138, 155, 168, 0.3);
        color:#f5f8fa; }
      .bp3-dark .bp3-button-group.bp3-minimal .bp3-button:disabled, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button:disabled:hover, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-disabled, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-disabled:hover{
        background:none;
        cursor:not-allowed;
        color:rgba(167, 182, 194, 0.6); }
        .bp3-dark .bp3-button-group.bp3-minimal .bp3-button:disabled.bp3-active, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button:disabled:hover.bp3-active, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-disabled.bp3-active, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-disabled:hover.bp3-active{
          background:rgba(138, 155, 168, 0.3); }
    .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary{
      color:#106ba3; }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary:hover, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary:active, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary.bp3-active{
        -webkit-box-shadow:none;
                box-shadow:none;
        background:none;
        color:#106ba3; }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary:hover{
        background:rgba(19, 124, 189, 0.15);
        color:#106ba3; }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary:active, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary.bp3-active{
        background:rgba(19, 124, 189, 0.3);
        color:#106ba3; }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary:disabled, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary.bp3-disabled{
        background:none;
        color:rgba(16, 107, 163, 0.5); }
        .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary:disabled.bp3-active, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary.bp3-disabled.bp3-active{
          background:rgba(19, 124, 189, 0.3); }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary .bp3-button-spinner .bp3-spinner-head{
        stroke:#106ba3; }
      .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary{
        color:#48aff0; }
        .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary:hover{
          background:rgba(19, 124, 189, 0.2);
          color:#48aff0; }
        .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary:active, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary.bp3-active{
          background:rgba(19, 124, 189, 0.3);
          color:#48aff0; }
        .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary:disabled, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary.bp3-disabled{
          background:none;
          color:rgba(72, 175, 240, 0.5); }
          .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary:disabled.bp3-active, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary.bp3-disabled.bp3-active{
            background:rgba(19, 124, 189, 0.3); }
    .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success{
      color:#0d8050; }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success:hover, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success:active, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success.bp3-active{
        -webkit-box-shadow:none;
                box-shadow:none;
        background:none;
        color:#0d8050; }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success:hover{
        background:rgba(15, 153, 96, 0.15);
        color:#0d8050; }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success:active, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success.bp3-active{
        background:rgba(15, 153, 96, 0.3);
        color:#0d8050; }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success:disabled, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success.bp3-disabled{
        background:none;
        color:rgba(13, 128, 80, 0.5); }
        .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success:disabled.bp3-active, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success.bp3-disabled.bp3-active{
          background:rgba(15, 153, 96, 0.3); }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success .bp3-button-spinner .bp3-spinner-head{
        stroke:#0d8050; }
      .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success{
        color:#3dcc91; }
        .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success:hover{
          background:rgba(15, 153, 96, 0.2);
          color:#3dcc91; }
        .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success:active, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success.bp3-active{
          background:rgba(15, 153, 96, 0.3);
          color:#3dcc91; }
        .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success:disabled, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success.bp3-disabled{
          background:none;
          color:rgba(61, 204, 145, 0.5); }
          .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success:disabled.bp3-active, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success.bp3-disabled.bp3-active{
            background:rgba(15, 153, 96, 0.3); }
    .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning{
      color:#bf7326; }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning:hover, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning:active, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning.bp3-active{
        -webkit-box-shadow:none;
                box-shadow:none;
        background:none;
        color:#bf7326; }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning:hover{
        background:rgba(217, 130, 43, 0.15);
        color:#bf7326; }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning:active, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning.bp3-active{
        background:rgba(217, 130, 43, 0.3);
        color:#bf7326; }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning:disabled, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning.bp3-disabled{
        background:none;
        color:rgba(191, 115, 38, 0.5); }
        .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning:disabled.bp3-active, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning.bp3-disabled.bp3-active{
          background:rgba(217, 130, 43, 0.3); }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning .bp3-button-spinner .bp3-spinner-head{
        stroke:#bf7326; }
      .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning{
        color:#ffb366; }
        .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning:hover{
          background:rgba(217, 130, 43, 0.2);
          color:#ffb366; }
        .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning:active, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning.bp3-active{
          background:rgba(217, 130, 43, 0.3);
          color:#ffb366; }
        .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning:disabled, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning.bp3-disabled{
          background:none;
          color:rgba(255, 179, 102, 0.5); }
          .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning:disabled.bp3-active, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning.bp3-disabled.bp3-active{
            background:rgba(217, 130, 43, 0.3); }
    .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger{
      color:#c23030; }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger:hover, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger:active, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger.bp3-active{
        -webkit-box-shadow:none;
                box-shadow:none;
        background:none;
        color:#c23030; }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger:hover{
        background:rgba(219, 55, 55, 0.15);
        color:#c23030; }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger:active, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger.bp3-active{
        background:rgba(219, 55, 55, 0.3);
        color:#c23030; }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger:disabled, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger.bp3-disabled{
        background:none;
        color:rgba(194, 48, 48, 0.5); }
        .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger:disabled.bp3-active, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger.bp3-disabled.bp3-active{
          background:rgba(219, 55, 55, 0.3); }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger .bp3-button-spinner .bp3-spinner-head{
        stroke:#c23030; }
      .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger{
        color:#ff7373; }
        .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger:hover{
          background:rgba(219, 55, 55, 0.2);
          color:#ff7373; }
        .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger:active, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger.bp3-active{
          background:rgba(219, 55, 55, 0.3);
          color:#ff7373; }
        .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger:disabled, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger.bp3-disabled{
          background:none;
          color:rgba(255, 115, 115, 0.5); }
          .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger:disabled.bp3-active, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger.bp3-disabled.bp3-active{
            background:rgba(219, 55, 55, 0.3); }
  .bp3-button-group .bp3-popover-wrapper,
  .bp3-button-group .bp3-popover-target{
    display:-webkit-box;
    display:-ms-flexbox;
    display:flex;
    -webkit-box-flex:1;
        -ms-flex:1 1 auto;
            flex:1 1 auto; }
  .bp3-button-group.bp3-fill{
    display:-webkit-box;
    display:-ms-flexbox;
    display:flex;
    width:100%; }
  .bp3-button-group .bp3-button.bp3-fill,
  .bp3-button-group.bp3-fill .bp3-button:not(.bp3-fixed){
    -webkit-box-flex:1;
        -ms-flex:1 1 auto;
            flex:1 1 auto; }
  .bp3-button-group.bp3-vertical{
    -webkit-box-orient:vertical;
    -webkit-box-direction:normal;
        -ms-flex-direction:column;
            flex-direction:column;
    -webkit-box-align:stretch;
        -ms-flex-align:stretch;
            align-items:stretch;
    vertical-align:top; }
    .bp3-button-group.bp3-vertical.bp3-fill{
      width:unset;
      height:100%; }
    .bp3-button-group.bp3-vertical .bp3-button{
      margin-right:0 !important;
      width:100%; }
    .bp3-button-group.bp3-vertical:not(.bp3-minimal) > .bp3-popover-wrapper:first-child .bp3-button,
    .bp3-button-group.bp3-vertical:not(.bp3-minimal) > .bp3-button:first-child{
      border-radius:3px 3px 0 0; }
    .bp3-button-group.bp3-vertical:not(.bp3-minimal) > .bp3-popover-wrapper:last-child .bp3-button,
    .bp3-button-group.bp3-vertical:not(.bp3-minimal) > .bp3-button:last-child{
      border-radius:0 0 3px 3px; }
    .bp3-button-group.bp3-vertical:not(.bp3-minimal) > .bp3-popover-wrapper:not(:last-child) .bp3-button,
    .bp3-button-group.bp3-vertical:not(.bp3-minimal) > .bp3-button:not(:last-child){
      margin-bottom:-1px; }
  .bp3-button-group.bp3-align-left .bp3-button{
    text-align:left; }
  .bp3-dark .bp3-button-group:not(.bp3-minimal) > .bp3-popover-wrapper:not(:last-child) .bp3-button,
  .bp3-dark .bp3-button-group:not(.bp3-minimal) > .bp3-button:not(:last-child){
    margin-right:1px; }
  .bp3-dark .bp3-button-group.bp3-vertical > .bp3-popover-wrapper:not(:last-child) .bp3-button,
  .bp3-dark .bp3-button-group.bp3-vertical > .bp3-button:not(:last-child){
    margin-bottom:1px; }
.bp3-callout{
  line-height:1.5;
  font-size:14px;
  position:relative;
  border-radius:3px;
  background-color:rgba(138, 155, 168, 0.15);
  width:100%;
  padding:10px 12px 9px; }
  .bp3-callout[class*="bp3-icon-"]{
    padding-left:40px; }
    .bp3-callout[class*="bp3-icon-"]::before{
      line-height:1;
      font-family:"Icons20", sans-serif;
      font-size:20px;
      font-weight:400;
      font-style:normal;
      -moz-osx-font-smoothing:grayscale;
      -webkit-font-smoothing:antialiased;
      position:absolute;
      top:10px;
      left:10px;
      color:#5c7080; }
  .bp3-callout.bp3-callout-icon{
    padding-left:40px; }
    .bp3-callout.bp3-callout-icon > .bp3-icon:first-child{
      position:absolute;
      top:10px;
      left:10px;
      color:#5c7080; }
  .bp3-callout .bp3-heading{
    margin-top:0;
    margin-bottom:5px;
    line-height:20px; }
    .bp3-callout .bp3-heading:last-child{
      margin-bottom:0; }
  .bp3-dark .bp3-callout{
    background-color:rgba(138, 155, 168, 0.2); }
    .bp3-dark .bp3-callout[class*="bp3-icon-"]::before{
      color:#a7b6c2; }
  .bp3-callout.bp3-intent-primary{
    background-color:rgba(19, 124, 189, 0.15); }
    .bp3-callout.bp3-intent-primary[class*="bp3-icon-"]::before,
    .bp3-callout.bp3-intent-primary > .bp3-icon:first-child,
    .bp3-callout.bp3-intent-primary .bp3-heading{
      color:#106ba3; }
    .bp3-dark .bp3-callout.bp3-intent-primary{
      background-color:rgba(19, 124, 189, 0.25); }
      .bp3-dark .bp3-callout.bp3-intent-primary[class*="bp3-icon-"]::before,
      .bp3-dark .bp3-callout.bp3-intent-primary > .bp3-icon:first-child,
      .bp3-dark .bp3-callout.bp3-intent-primary .bp3-heading{
        color:#48aff0; }
  .bp3-callout.bp3-intent-success{
    background-color:rgba(15, 153, 96, 0.15); }
    .bp3-callout.bp3-intent-success[class*="bp3-icon-"]::before,
    .bp3-callout.bp3-intent-success > .bp3-icon:first-child,
    .bp3-callout.bp3-intent-success .bp3-heading{
      color:#0d8050; }
    .bp3-dark .bp3-callout.bp3-intent-success{
      background-color:rgba(15, 153, 96, 0.25); }
      .bp3-dark .bp3-callout.bp3-intent-success[class*="bp3-icon-"]::before,
      .bp3-dark .bp3-callout.bp3-intent-success > .bp3-icon:first-child,
      .bp3-dark .bp3-callout.bp3-intent-success .bp3-heading{
        color:#3dcc91; }
  .bp3-callout.bp3-intent-warning{
    background-color:rgba(217, 130, 43, 0.15); }
    .bp3-callout.bp3-intent-warning[class*="bp3-icon-"]::before,
    .bp3-callout.bp3-intent-warning > .bp3-icon:first-child,
    .bp3-callout.bp3-intent-warning .bp3-heading{
      color:#bf7326; }
    .bp3-dark .bp3-callout.bp3-intent-warning{
      background-color:rgba(217, 130, 43, 0.25); }
      .bp3-dark .bp3-callout.bp3-intent-warning[class*="bp3-icon-"]::before,
      .bp3-dark .bp3-callout.bp3-intent-warning > .bp3-icon:first-child,
      .bp3-dark .bp3-callout.bp3-intent-warning .bp3-heading{
        color:#ffb366; }
  .bp3-callout.bp3-intent-danger{
    background-color:rgba(219, 55, 55, 0.15); }
    .bp3-callout.bp3-intent-danger[class*="bp3-icon-"]::before,
    .bp3-callout.bp3-intent-danger > .bp3-icon:first-child,
    .bp3-callout.bp3-intent-danger .bp3-heading{
      color:#c23030; }
    .bp3-dark .bp3-callout.bp3-intent-danger{
      background-color:rgba(219, 55, 55, 0.25); }
      .bp3-dark .bp3-callout.bp3-intent-danger[class*="bp3-icon-"]::before,
      .bp3-dark .bp3-callout.bp3-intent-danger > .bp3-icon:first-child,
      .bp3-dark .bp3-callout.bp3-intent-danger .bp3-heading{
        color:#ff7373; }
  .bp3-running-text .bp3-callout{
    margin:20px 0; }
.bp3-card{
  border-radius:3px;
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.15), 0 0 0 rgba(16, 22, 26, 0), 0 0 0 rgba(16, 22, 26, 0);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.15), 0 0 0 rgba(16, 22, 26, 0), 0 0 0 rgba(16, 22, 26, 0);
  background-color:#ffffff;
  padding:20px;
  -webkit-transition:-webkit-transform 200ms cubic-bezier(0.4, 1, 0.75, 0.9), -webkit-box-shadow 200ms cubic-bezier(0.4, 1, 0.75, 0.9);
  transition:-webkit-transform 200ms cubic-bezier(0.4, 1, 0.75, 0.9), -webkit-box-shadow 200ms cubic-bezier(0.4, 1, 0.75, 0.9);
  transition:transform 200ms cubic-bezier(0.4, 1, 0.75, 0.9), box-shadow 200ms cubic-bezier(0.4, 1, 0.75, 0.9);
  transition:transform 200ms cubic-bezier(0.4, 1, 0.75, 0.9), box-shadow 200ms cubic-bezier(0.4, 1, 0.75, 0.9), -webkit-transform 200ms cubic-bezier(0.4, 1, 0.75, 0.9), -webkit-box-shadow 200ms cubic-bezier(0.4, 1, 0.75, 0.9); }
  .bp3-card.bp3-dark,
  .bp3-dark .bp3-card{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4), 0 0 0 rgba(16, 22, 26, 0), 0 0 0 rgba(16, 22, 26, 0);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4), 0 0 0 rgba(16, 22, 26, 0), 0 0 0 rgba(16, 22, 26, 0);
    background-color:#30404d; }

.bp3-elevation-0{
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.15), 0 0 0 rgba(16, 22, 26, 0), 0 0 0 rgba(16, 22, 26, 0);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.15), 0 0 0 rgba(16, 22, 26, 0), 0 0 0 rgba(16, 22, 26, 0); }
  .bp3-elevation-0.bp3-dark,
  .bp3-dark .bp3-elevation-0{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4), 0 0 0 rgba(16, 22, 26, 0), 0 0 0 rgba(16, 22, 26, 0);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4), 0 0 0 rgba(16, 22, 26, 0), 0 0 0 rgba(16, 22, 26, 0); }

.bp3-elevation-1{
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.2); }
  .bp3-elevation-1.bp3-dark,
  .bp3-dark .bp3-elevation-1{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.4); }

.bp3-elevation-2{
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 1px 1px rgba(16, 22, 26, 0.2), 0 2px 6px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 1px 1px rgba(16, 22, 26, 0.2), 0 2px 6px rgba(16, 22, 26, 0.2); }
  .bp3-elevation-2.bp3-dark,
  .bp3-dark .bp3-elevation-2{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 1px 1px rgba(16, 22, 26, 0.4), 0 2px 6px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 1px 1px rgba(16, 22, 26, 0.4), 0 2px 6px rgba(16, 22, 26, 0.4); }

.bp3-elevation-3{
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 2px 4px rgba(16, 22, 26, 0.2), 0 8px 24px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 2px 4px rgba(16, 22, 26, 0.2), 0 8px 24px rgba(16, 22, 26, 0.2); }
  .bp3-elevation-3.bp3-dark,
  .bp3-dark .bp3-elevation-3{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 2px 4px rgba(16, 22, 26, 0.4), 0 8px 24px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 2px 4px rgba(16, 22, 26, 0.4), 0 8px 24px rgba(16, 22, 26, 0.4); }

.bp3-elevation-4{
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 4px 8px rgba(16, 22, 26, 0.2), 0 18px 46px 6px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 4px 8px rgba(16, 22, 26, 0.2), 0 18px 46px 6px rgba(16, 22, 26, 0.2); }
  .bp3-elevation-4.bp3-dark,
  .bp3-dark .bp3-elevation-4{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 4px 8px rgba(16, 22, 26, 0.4), 0 18px 46px 6px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 4px 8px rgba(16, 22, 26, 0.4), 0 18px 46px 6px rgba(16, 22, 26, 0.4); }

.bp3-card.bp3-interactive:hover{
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 2px 4px rgba(16, 22, 26, 0.2), 0 8px 24px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 2px 4px rgba(16, 22, 26, 0.2), 0 8px 24px rgba(16, 22, 26, 0.2);
  cursor:pointer; }
  .bp3-card.bp3-interactive:hover.bp3-dark,
  .bp3-dark .bp3-card.bp3-interactive:hover{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 2px 4px rgba(16, 22, 26, 0.4), 0 8px 24px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 2px 4px rgba(16, 22, 26, 0.4), 0 8px 24px rgba(16, 22, 26, 0.4); }

.bp3-card.bp3-interactive:active{
  opacity:0.9;
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.2);
  -webkit-transition-duration:0;
          transition-duration:0; }
  .bp3-card.bp3-interactive:active.bp3-dark,
  .bp3-dark .bp3-card.bp3-interactive:active{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.4); }

.bp3-collapse{
  height:0;
  overflow-y:hidden;
  -webkit-transition:height 200ms cubic-bezier(0.4, 1, 0.75, 0.9);
  transition:height 200ms cubic-bezier(0.4, 1, 0.75, 0.9); }
  .bp3-collapse .bp3-collapse-body{
    -webkit-transition:-webkit-transform 200ms cubic-bezier(0.4, 1, 0.75, 0.9);
    transition:-webkit-transform 200ms cubic-bezier(0.4, 1, 0.75, 0.9);
    transition:transform 200ms cubic-bezier(0.4, 1, 0.75, 0.9);
    transition:transform 200ms cubic-bezier(0.4, 1, 0.75, 0.9), -webkit-transform 200ms cubic-bezier(0.4, 1, 0.75, 0.9); }
    .bp3-collapse .bp3-collapse-body[aria-hidden="true"]{
      display:none; }

.bp3-context-menu .bp3-popover-target{
  display:block; }

.bp3-context-menu-popover-target{
  position:fixed; }

.bp3-divider{
  margin:5px;
  border-right:1px solid rgba(16, 22, 26, 0.15);
  border-bottom:1px solid rgba(16, 22, 26, 0.15); }
  .bp3-dark .bp3-divider{
    border-color:rgba(16, 22, 26, 0.4); }
.bp3-dialog-container{
  opacity:1;
  -webkit-transform:scale(1);
          transform:scale(1);
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center;
  -webkit-box-pack:center;
      -ms-flex-pack:center;
          justify-content:center;
  width:100%;
  min-height:100%;
  pointer-events:none;
  -webkit-user-select:none;
     -moz-user-select:none;
      -ms-user-select:none;
          user-select:none; }
  .bp3-dialog-container.bp3-overlay-enter > .bp3-dialog, .bp3-dialog-container.bp3-overlay-appear > .bp3-dialog{
    opacity:0;
    -webkit-transform:scale(0.5);
            transform:scale(0.5); }
  .bp3-dialog-container.bp3-overlay-enter-active > .bp3-dialog, .bp3-dialog-container.bp3-overlay-appear-active > .bp3-dialog{
    opacity:1;
    -webkit-transform:scale(1);
            transform:scale(1);
    -webkit-transition-property:opacity, -webkit-transform;
    transition-property:opacity, -webkit-transform;
    transition-property:opacity, transform;
    transition-property:opacity, transform, -webkit-transform;
    -webkit-transition-duration:300ms;
            transition-duration:300ms;
    -webkit-transition-timing-function:cubic-bezier(0.54, 1.12, 0.38, 1.11);
            transition-timing-function:cubic-bezier(0.54, 1.12, 0.38, 1.11);
    -webkit-transition-delay:0;
            transition-delay:0; }
  .bp3-dialog-container.bp3-overlay-exit > .bp3-dialog{
    opacity:1;
    -webkit-transform:scale(1);
            transform:scale(1); }
  .bp3-dialog-container.bp3-overlay-exit-active > .bp3-dialog{
    opacity:0;
    -webkit-transform:scale(0.5);
            transform:scale(0.5);
    -webkit-transition-property:opacity, -webkit-transform;
    transition-property:opacity, -webkit-transform;
    transition-property:opacity, transform;
    transition-property:opacity, transform, -webkit-transform;
    -webkit-transition-duration:300ms;
            transition-duration:300ms;
    -webkit-transition-timing-function:cubic-bezier(0.54, 1.12, 0.38, 1.11);
            transition-timing-function:cubic-bezier(0.54, 1.12, 0.38, 1.11);
    -webkit-transition-delay:0;
            transition-delay:0; }

.bp3-dialog{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-orient:vertical;
  -webkit-box-direction:normal;
      -ms-flex-direction:column;
          flex-direction:column;
  margin:30px 0;
  border-radius:6px;
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 4px 8px rgba(16, 22, 26, 0.2), 0 18px 46px 6px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 4px 8px rgba(16, 22, 26, 0.2), 0 18px 46px 6px rgba(16, 22, 26, 0.2);
  background:#ebf1f5;
  width:500px;
  padding-bottom:20px;
  pointer-events:all;
  -webkit-user-select:text;
     -moz-user-select:text;
      -ms-user-select:text;
          user-select:text; }
  .bp3-dialog:focus{
    outline:0; }
  .bp3-dialog.bp3-dark,
  .bp3-dark .bp3-dialog{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 4px 8px rgba(16, 22, 26, 0.4), 0 18px 46px 6px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 4px 8px rgba(16, 22, 26, 0.4), 0 18px 46px 6px rgba(16, 22, 26, 0.4);
    background:#293742;
    color:#f5f8fa; }

.bp3-dialog-header{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-flex:0;
      -ms-flex:0 0 auto;
          flex:0 0 auto;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center;
  border-radius:6px 6px 0 0;
  -webkit-box-shadow:0 1px 0 rgba(16, 22, 26, 0.15);
          box-shadow:0 1px 0 rgba(16, 22, 26, 0.15);
  background:#ffffff;
  min-height:40px;
  padding-right:5px;
  padding-left:20px; }
  .bp3-dialog-header .bp3-icon-large,
  .bp3-dialog-header .bp3-icon{
    -webkit-box-flex:0;
        -ms-flex:0 0 auto;
            flex:0 0 auto;
    margin-right:10px;
    color:#5c7080; }
  .bp3-dialog-header .bp3-heading{
    overflow:hidden;
    text-overflow:ellipsis;
    white-space:nowrap;
    word-wrap:normal;
    -webkit-box-flex:1;
        -ms-flex:1 1 auto;
            flex:1 1 auto;
    margin:0;
    line-height:inherit; }
    .bp3-dialog-header .bp3-heading:last-child{
      margin-right:20px; }
  .bp3-dark .bp3-dialog-header{
    -webkit-box-shadow:0 1px 0 rgba(16, 22, 26, 0.4);
            box-shadow:0 1px 0 rgba(16, 22, 26, 0.4);
    background:#30404d; }
    .bp3-dark .bp3-dialog-header .bp3-icon-large,
    .bp3-dark .bp3-dialog-header .bp3-icon{
      color:#a7b6c2; }

.bp3-dialog-body{
  -webkit-box-flex:1;
      -ms-flex:1 1 auto;
          flex:1 1 auto;
  margin:20px;
  line-height:18px; }

.bp3-dialog-footer{
  -webkit-box-flex:0;
      -ms-flex:0 0 auto;
          flex:0 0 auto;
  margin:0 20px; }

.bp3-dialog-footer-actions{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-pack:end;
      -ms-flex-pack:end;
          justify-content:flex-end; }
  .bp3-dialog-footer-actions .bp3-button{
    margin-left:10px; }
.bp3-drawer{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-orient:vertical;
  -webkit-box-direction:normal;
      -ms-flex-direction:column;
          flex-direction:column;
  margin:0;
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 4px 8px rgba(16, 22, 26, 0.2), 0 18px 46px 6px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 4px 8px rgba(16, 22, 26, 0.2), 0 18px 46px 6px rgba(16, 22, 26, 0.2);
  background:#ffffff;
  padding:0; }
  .bp3-drawer:focus{
    outline:0; }
  .bp3-drawer.bp3-position-top{
    top:0;
    right:0;
    left:0;
    height:50%; }
    .bp3-drawer.bp3-position-top.bp3-overlay-enter, .bp3-drawer.bp3-position-top.bp3-overlay-appear{
      -webkit-transform:translateY(-100%);
              transform:translateY(-100%); }
    .bp3-drawer.bp3-position-top.bp3-overlay-enter-active, .bp3-drawer.bp3-position-top.bp3-overlay-appear-active{
      -webkit-transform:translateY(0);
              transform:translateY(0);
      -webkit-transition-property:-webkit-transform;
      transition-property:-webkit-transform;
      transition-property:transform;
      transition-property:transform, -webkit-transform;
      -webkit-transition-duration:200ms;
              transition-duration:200ms;
      -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
              transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
      -webkit-transition-delay:0;
              transition-delay:0; }
    .bp3-drawer.bp3-position-top.bp3-overlay-exit{
      -webkit-transform:translateY(0);
              transform:translateY(0); }
    .bp3-drawer.bp3-position-top.bp3-overlay-exit-active{
      -webkit-transform:translateY(-100%);
              transform:translateY(-100%);
      -webkit-transition-property:-webkit-transform;
      transition-property:-webkit-transform;
      transition-property:transform;
      transition-property:transform, -webkit-transform;
      -webkit-transition-duration:100ms;
              transition-duration:100ms;
      -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
              transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
      -webkit-transition-delay:0;
              transition-delay:0; }
  .bp3-drawer.bp3-position-bottom{
    right:0;
    bottom:0;
    left:0;
    height:50%; }
    .bp3-drawer.bp3-position-bottom.bp3-overlay-enter, .bp3-drawer.bp3-position-bottom.bp3-overlay-appear{
      -webkit-transform:translateY(100%);
              transform:translateY(100%); }
    .bp3-drawer.bp3-position-bottom.bp3-overlay-enter-active, .bp3-drawer.bp3-position-bottom.bp3-overlay-appear-active{
      -webkit-transform:translateY(0);
              transform:translateY(0);
      -webkit-transition-property:-webkit-transform;
      transition-property:-webkit-transform;
      transition-property:transform;
      transition-property:transform, -webkit-transform;
      -webkit-transition-duration:200ms;
              transition-duration:200ms;
      -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
              transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
      -webkit-transition-delay:0;
              transition-delay:0; }
    .bp3-drawer.bp3-position-bottom.bp3-overlay-exit{
      -webkit-transform:translateY(0);
              transform:translateY(0); }
    .bp3-drawer.bp3-position-bottom.bp3-overlay-exit-active{
      -webkit-transform:translateY(100%);
              transform:translateY(100%);
      -webkit-transition-property:-webkit-transform;
      transition-property:-webkit-transform;
      transition-property:transform;
      transition-property:transform, -webkit-transform;
      -webkit-transition-duration:100ms;
              transition-duration:100ms;
      -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
              transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
      -webkit-transition-delay:0;
              transition-delay:0; }
  .bp3-drawer.bp3-position-left{
    top:0;
    bottom:0;
    left:0;
    width:50%; }
    .bp3-drawer.bp3-position-left.bp3-overlay-enter, .bp3-drawer.bp3-position-left.bp3-overlay-appear{
      -webkit-transform:translateX(-100%);
              transform:translateX(-100%); }
    .bp3-drawer.bp3-position-left.bp3-overlay-enter-active, .bp3-drawer.bp3-position-left.bp3-overlay-appear-active{
      -webkit-transform:translateX(0);
              transform:translateX(0);
      -webkit-transition-property:-webkit-transform;
      transition-property:-webkit-transform;
      transition-property:transform;
      transition-property:transform, -webkit-transform;
      -webkit-transition-duration:200ms;
              transition-duration:200ms;
      -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
              transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
      -webkit-transition-delay:0;
              transition-delay:0; }
    .bp3-drawer.bp3-position-left.bp3-overlay-exit{
      -webkit-transform:translateX(0);
              transform:translateX(0); }
    .bp3-drawer.bp3-position-left.bp3-overlay-exit-active{
      -webkit-transform:translateX(-100%);
              transform:translateX(-100%);
      -webkit-transition-property:-webkit-transform;
      transition-property:-webkit-transform;
      transition-property:transform;
      transition-property:transform, -webkit-transform;
      -webkit-transition-duration:100ms;
              transition-duration:100ms;
      -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
              transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
      -webkit-transition-delay:0;
              transition-delay:0; }
  .bp3-drawer.bp3-position-right{
    top:0;
    right:0;
    bottom:0;
    width:50%; }
    .bp3-drawer.bp3-position-right.bp3-overlay-enter, .bp3-drawer.bp3-position-right.bp3-overlay-appear{
      -webkit-transform:translateX(100%);
              transform:translateX(100%); }
    .bp3-drawer.bp3-position-right.bp3-overlay-enter-active, .bp3-drawer.bp3-position-right.bp3-overlay-appear-active{
      -webkit-transform:translateX(0);
              transform:translateX(0);
      -webkit-transition-property:-webkit-transform;
      transition-property:-webkit-transform;
      transition-property:transform;
      transition-property:transform, -webkit-transform;
      -webkit-transition-duration:200ms;
              transition-duration:200ms;
      -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
              transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
      -webkit-transition-delay:0;
              transition-delay:0; }
    .bp3-drawer.bp3-position-right.bp3-overlay-exit{
      -webkit-transform:translateX(0);
              transform:translateX(0); }
    .bp3-drawer.bp3-position-right.bp3-overlay-exit-active{
      -webkit-transform:translateX(100%);
              transform:translateX(100%);
      -webkit-transition-property:-webkit-transform;
      transition-property:-webkit-transform;
      transition-property:transform;
      transition-property:transform, -webkit-transform;
      -webkit-transition-duration:100ms;
              transition-duration:100ms;
      -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
              transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
      -webkit-transition-delay:0;
              transition-delay:0; }
  .bp3-drawer:not(.bp3-position-top):not(.bp3-position-bottom):not(.bp3-position-left):not(
  .bp3-position-right):not(.bp3-vertical){
    top:0;
    right:0;
    bottom:0;
    width:50%; }
    .bp3-drawer:not(.bp3-position-top):not(.bp3-position-bottom):not(.bp3-position-left):not(
    .bp3-position-right):not(.bp3-vertical).bp3-overlay-enter, .bp3-drawer:not(.bp3-position-top):not(.bp3-position-bottom):not(.bp3-position-left):not(
    .bp3-position-right):not(.bp3-vertical).bp3-overlay-appear{
      -webkit-transform:translateX(100%);
              transform:translateX(100%); }
    .bp3-drawer:not(.bp3-position-top):not(.bp3-position-bottom):not(.bp3-position-left):not(
    .bp3-position-right):not(.bp3-vertical).bp3-overlay-enter-active, .bp3-drawer:not(.bp3-position-top):not(.bp3-position-bottom):not(.bp3-position-left):not(
    .bp3-position-right):not(.bp3-vertical).bp3-overlay-appear-active{
      -webkit-transform:translateX(0);
              transform:translateX(0);
      -webkit-transition-property:-webkit-transform;
      transition-property:-webkit-transform;
      transition-property:transform;
      transition-property:transform, -webkit-transform;
      -webkit-transition-duration:200ms;
              transition-duration:200ms;
      -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
              transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
      -webkit-transition-delay:0;
              transition-delay:0; }
    .bp3-drawer:not(.bp3-position-top):not(.bp3-position-bottom):not(.bp3-position-left):not(
    .bp3-position-right):not(.bp3-vertical).bp3-overlay-exit{
      -webkit-transform:translateX(0);
              transform:translateX(0); }
    .bp3-drawer:not(.bp3-position-top):not(.bp3-position-bottom):not(.bp3-position-left):not(
    .bp3-position-right):not(.bp3-vertical).bp3-overlay-exit-active{
      -webkit-transform:translateX(100%);
              transform:translateX(100%);
      -webkit-transition-property:-webkit-transform;
      transition-property:-webkit-transform;
      transition-property:transform;
      transition-property:transform, -webkit-transform;
      -webkit-transition-duration:100ms;
              transition-duration:100ms;
      -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
              transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
      -webkit-transition-delay:0;
              transition-delay:0; }
  .bp3-drawer:not(.bp3-position-top):not(.bp3-position-bottom):not(.bp3-position-left):not(
  .bp3-position-right).bp3-vertical{
    right:0;
    bottom:0;
    left:0;
    height:50%; }
    .bp3-drawer:not(.bp3-position-top):not(.bp3-position-bottom):not(.bp3-position-left):not(
    .bp3-position-right).bp3-vertical.bp3-overlay-enter, .bp3-drawer:not(.bp3-position-top):not(.bp3-position-bottom):not(.bp3-position-left):not(
    .bp3-position-right).bp3-vertical.bp3-overlay-appear{
      -webkit-transform:translateY(100%);
              transform:translateY(100%); }
    .bp3-drawer:not(.bp3-position-top):not(.bp3-position-bottom):not(.bp3-position-left):not(
    .bp3-position-right).bp3-vertical.bp3-overlay-enter-active, .bp3-drawer:not(.bp3-position-top):not(.bp3-position-bottom):not(.bp3-position-left):not(
    .bp3-position-right).bp3-vertical.bp3-overlay-appear-active{
      -webkit-transform:translateY(0);
              transform:translateY(0);
      -webkit-transition-property:-webkit-transform;
      transition-property:-webkit-transform;
      transition-property:transform;
      transition-property:transform, -webkit-transform;
      -webkit-transition-duration:200ms;
              transition-duration:200ms;
      -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
              transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
      -webkit-transition-delay:0;
              transition-delay:0; }
    .bp3-drawer:not(.bp3-position-top):not(.bp3-position-bottom):not(.bp3-position-left):not(
    .bp3-position-right).bp3-vertical.bp3-overlay-exit{
      -webkit-transform:translateY(0);
              transform:translateY(0); }
    .bp3-drawer:not(.bp3-position-top):not(.bp3-position-bottom):not(.bp3-position-left):not(
    .bp3-position-right).bp3-vertical.bp3-overlay-exit-active{
      -webkit-transform:translateY(100%);
              transform:translateY(100%);
      -webkit-transition-property:-webkit-transform;
      transition-property:-webkit-transform;
      transition-property:transform;
      transition-property:transform, -webkit-transform;
      -webkit-transition-duration:100ms;
              transition-duration:100ms;
      -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
              transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
      -webkit-transition-delay:0;
              transition-delay:0; }
  .bp3-drawer.bp3-dark,
  .bp3-dark .bp3-drawer{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 4px 8px rgba(16, 22, 26, 0.4), 0 18px 46px 6px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 4px 8px rgba(16, 22, 26, 0.4), 0 18px 46px 6px rgba(16, 22, 26, 0.4);
    background:#30404d;
    color:#f5f8fa; }

.bp3-drawer-header{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-flex:0;
      -ms-flex:0 0 auto;
          flex:0 0 auto;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center;
  position:relative;
  border-radius:0;
  -webkit-box-shadow:0 1px 0 rgba(16, 22, 26, 0.15);
          box-shadow:0 1px 0 rgba(16, 22, 26, 0.15);
  min-height:40px;
  padding:5px;
  padding-left:20px; }
  .bp3-drawer-header .bp3-icon-large,
  .bp3-drawer-header .bp3-icon{
    -webkit-box-flex:0;
        -ms-flex:0 0 auto;
            flex:0 0 auto;
    margin-right:10px;
    color:#5c7080; }
  .bp3-drawer-header .bp3-heading{
    overflow:hidden;
    text-overflow:ellipsis;
    white-space:nowrap;
    word-wrap:normal;
    -webkit-box-flex:1;
        -ms-flex:1 1 auto;
            flex:1 1 auto;
    margin:0;
    line-height:inherit; }
    .bp3-drawer-header .bp3-heading:last-child{
      margin-right:20px; }
  .bp3-dark .bp3-drawer-header{
    -webkit-box-shadow:0 1px 0 rgba(16, 22, 26, 0.4);
            box-shadow:0 1px 0 rgba(16, 22, 26, 0.4); }
    .bp3-dark .bp3-drawer-header .bp3-icon-large,
    .bp3-dark .bp3-drawer-header .bp3-icon{
      color:#a7b6c2; }

.bp3-drawer-body{
  -webkit-box-flex:1;
      -ms-flex:1 1 auto;
          flex:1 1 auto;
  overflow:auto;
  line-height:18px; }

.bp3-drawer-footer{
  -webkit-box-flex:0;
      -ms-flex:0 0 auto;
          flex:0 0 auto;
  position:relative;
  -webkit-box-shadow:inset 0 1px 0 rgba(16, 22, 26, 0.15);
          box-shadow:inset 0 1px 0 rgba(16, 22, 26, 0.15);
  padding:10px 20px; }
  .bp3-dark .bp3-drawer-footer{
    -webkit-box-shadow:inset 0 1px 0 rgba(16, 22, 26, 0.4);
            box-shadow:inset 0 1px 0 rgba(16, 22, 26, 0.4); }
.bp3-editable-text{
  display:inline-block;
  position:relative;
  cursor:text;
  max-width:100%;
  vertical-align:top;
  white-space:nowrap; }
  .bp3-editable-text::before{
    position:absolute;
    top:-3px;
    right:-3px;
    bottom:-3px;
    left:-3px;
    border-radius:3px;
    content:"";
    -webkit-transition:background-color 100ms cubic-bezier(0.4, 1, 0.75, 0.9), -webkit-box-shadow 100ms cubic-bezier(0.4, 1, 0.75, 0.9);
    transition:background-color 100ms cubic-bezier(0.4, 1, 0.75, 0.9), -webkit-box-shadow 100ms cubic-bezier(0.4, 1, 0.75, 0.9);
    transition:background-color 100ms cubic-bezier(0.4, 1, 0.75, 0.9), box-shadow 100ms cubic-bezier(0.4, 1, 0.75, 0.9);
    transition:background-color 100ms cubic-bezier(0.4, 1, 0.75, 0.9), box-shadow 100ms cubic-bezier(0.4, 1, 0.75, 0.9), -webkit-box-shadow 100ms cubic-bezier(0.4, 1, 0.75, 0.9); }
  .bp3-editable-text:hover::before{
    -webkit-box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px rgba(16, 22, 26, 0.15);
            box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px rgba(16, 22, 26, 0.15); }
  .bp3-editable-text.bp3-editable-text-editing::before{
    -webkit-box-shadow:0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
    background-color:#ffffff; }
  .bp3-editable-text.bp3-disabled::before{
    -webkit-box-shadow:none;
            box-shadow:none; }
  .bp3-editable-text.bp3-intent-primary .bp3-editable-text-input,
  .bp3-editable-text.bp3-intent-primary .bp3-editable-text-content{
    color:#137cbd; }
  .bp3-editable-text.bp3-intent-primary:hover::before{
    -webkit-box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px rgba(19, 124, 189, 0.4);
            box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px rgba(19, 124, 189, 0.4); }
  .bp3-editable-text.bp3-intent-primary.bp3-editable-text-editing::before{
    -webkit-box-shadow:0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
  .bp3-editable-text.bp3-intent-success .bp3-editable-text-input,
  .bp3-editable-text.bp3-intent-success .bp3-editable-text-content{
    color:#0f9960; }
  .bp3-editable-text.bp3-intent-success:hover::before{
    -webkit-box-shadow:0 0 0 0 rgba(15, 153, 96, 0), 0 0 0 0 rgba(15, 153, 96, 0), inset 0 0 0 1px rgba(15, 153, 96, 0.4);
            box-shadow:0 0 0 0 rgba(15, 153, 96, 0), 0 0 0 0 rgba(15, 153, 96, 0), inset 0 0 0 1px rgba(15, 153, 96, 0.4); }
  .bp3-editable-text.bp3-intent-success.bp3-editable-text-editing::before{
    -webkit-box-shadow:0 0 0 1px #0f9960, 0 0 0 3px rgba(15, 153, 96, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 1px #0f9960, 0 0 0 3px rgba(15, 153, 96, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
  .bp3-editable-text.bp3-intent-warning .bp3-editable-text-input,
  .bp3-editable-text.bp3-intent-warning .bp3-editable-text-content{
    color:#d9822b; }
  .bp3-editable-text.bp3-intent-warning:hover::before{
    -webkit-box-shadow:0 0 0 0 rgba(217, 130, 43, 0), 0 0 0 0 rgba(217, 130, 43, 0), inset 0 0 0 1px rgba(217, 130, 43, 0.4);
            box-shadow:0 0 0 0 rgba(217, 130, 43, 0), 0 0 0 0 rgba(217, 130, 43, 0), inset 0 0 0 1px rgba(217, 130, 43, 0.4); }
  .bp3-editable-text.bp3-intent-warning.bp3-editable-text-editing::before{
    -webkit-box-shadow:0 0 0 1px #d9822b, 0 0 0 3px rgba(217, 130, 43, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 1px #d9822b, 0 0 0 3px rgba(217, 130, 43, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
  .bp3-editable-text.bp3-intent-danger .bp3-editable-text-input,
  .bp3-editable-text.bp3-intent-danger .bp3-editable-text-content{
    color:#db3737; }
  .bp3-editable-text.bp3-intent-danger:hover::before{
    -webkit-box-shadow:0 0 0 0 rgba(219, 55, 55, 0), 0 0 0 0 rgba(219, 55, 55, 0), inset 0 0 0 1px rgba(219, 55, 55, 0.4);
            box-shadow:0 0 0 0 rgba(219, 55, 55, 0), 0 0 0 0 rgba(219, 55, 55, 0), inset 0 0 0 1px rgba(219, 55, 55, 0.4); }
  .bp3-editable-text.bp3-intent-danger.bp3-editable-text-editing::before{
    -webkit-box-shadow:0 0 0 1px #db3737, 0 0 0 3px rgba(219, 55, 55, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 1px #db3737, 0 0 0 3px rgba(219, 55, 55, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
  .bp3-dark .bp3-editable-text:hover::before{
    -webkit-box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px rgba(255, 255, 255, 0.15);
            box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px rgba(255, 255, 255, 0.15); }
  .bp3-dark .bp3-editable-text.bp3-editable-text-editing::before{
    -webkit-box-shadow:0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
    background-color:rgba(16, 22, 26, 0.3); }
  .bp3-dark .bp3-editable-text.bp3-disabled::before{
    -webkit-box-shadow:none;
            box-shadow:none; }
  .bp3-dark .bp3-editable-text.bp3-intent-primary .bp3-editable-text-content{
    color:#48aff0; }
  .bp3-dark .bp3-editable-text.bp3-intent-primary:hover::before{
    -webkit-box-shadow:0 0 0 0 rgba(72, 175, 240, 0), 0 0 0 0 rgba(72, 175, 240, 0), inset 0 0 0 1px rgba(72, 175, 240, 0.4);
            box-shadow:0 0 0 0 rgba(72, 175, 240, 0), 0 0 0 0 rgba(72, 175, 240, 0), inset 0 0 0 1px rgba(72, 175, 240, 0.4); }
  .bp3-dark .bp3-editable-text.bp3-intent-primary.bp3-editable-text-editing::before{
    -webkit-box-shadow:0 0 0 1px #48aff0, 0 0 0 3px rgba(72, 175, 240, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px #48aff0, 0 0 0 3px rgba(72, 175, 240, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
  .bp3-dark .bp3-editable-text.bp3-intent-success .bp3-editable-text-content{
    color:#3dcc91; }
  .bp3-dark .bp3-editable-text.bp3-intent-success:hover::before{
    -webkit-box-shadow:0 0 0 0 rgba(61, 204, 145, 0), 0 0 0 0 rgba(61, 204, 145, 0), inset 0 0 0 1px rgba(61, 204, 145, 0.4);
            box-shadow:0 0 0 0 rgba(61, 204, 145, 0), 0 0 0 0 rgba(61, 204, 145, 0), inset 0 0 0 1px rgba(61, 204, 145, 0.4); }
  .bp3-dark .bp3-editable-text.bp3-intent-success.bp3-editable-text-editing::before{
    -webkit-box-shadow:0 0 0 1px #3dcc91, 0 0 0 3px rgba(61, 204, 145, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px #3dcc91, 0 0 0 3px rgba(61, 204, 145, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
  .bp3-dark .bp3-editable-text.bp3-intent-warning .bp3-editable-text-content{
    color:#ffb366; }
  .bp3-dark .bp3-editable-text.bp3-intent-warning:hover::before{
    -webkit-box-shadow:0 0 0 0 rgba(255, 179, 102, 0), 0 0 0 0 rgba(255, 179, 102, 0), inset 0 0 0 1px rgba(255, 179, 102, 0.4);
            box-shadow:0 0 0 0 rgba(255, 179, 102, 0), 0 0 0 0 rgba(255, 179, 102, 0), inset 0 0 0 1px rgba(255, 179, 102, 0.4); }
  .bp3-dark .bp3-editable-text.bp3-intent-warning.bp3-editable-text-editing::before{
    -webkit-box-shadow:0 0 0 1px #ffb366, 0 0 0 3px rgba(255, 179, 102, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px #ffb366, 0 0 0 3px rgba(255, 179, 102, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
  .bp3-dark .bp3-editable-text.bp3-intent-danger .bp3-editable-text-content{
    color:#ff7373; }
  .bp3-dark .bp3-editable-text.bp3-intent-danger:hover::before{
    -webkit-box-shadow:0 0 0 0 rgba(255, 115, 115, 0), 0 0 0 0 rgba(255, 115, 115, 0), inset 0 0 0 1px rgba(255, 115, 115, 0.4);
            box-shadow:0 0 0 0 rgba(255, 115, 115, 0), 0 0 0 0 rgba(255, 115, 115, 0), inset 0 0 0 1px rgba(255, 115, 115, 0.4); }
  .bp3-dark .bp3-editable-text.bp3-intent-danger.bp3-editable-text-editing::before{
    -webkit-box-shadow:0 0 0 1px #ff7373, 0 0 0 3px rgba(255, 115, 115, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px #ff7373, 0 0 0 3px rgba(255, 115, 115, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }

.bp3-editable-text-input,
.bp3-editable-text-content{
  display:inherit;
  position:relative;
  min-width:inherit;
  max-width:inherit;
  vertical-align:top;
  text-transform:inherit;
  letter-spacing:inherit;
  color:inherit;
  font:inherit;
  resize:none; }

.bp3-editable-text-input{
  border:none;
  -webkit-box-shadow:none;
          box-shadow:none;
  background:none;
  width:100%;
  padding:0;
  white-space:pre-wrap; }
  .bp3-editable-text-input::-webkit-input-placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-editable-text-input::-moz-placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-editable-text-input:-ms-input-placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-editable-text-input::-ms-input-placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-editable-text-input::placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-editable-text-input:focus{
    outline:none; }
  .bp3-editable-text-input::-ms-clear{
    display:none; }

.bp3-editable-text-content{
  overflow:hidden;
  padding-right:2px;
  text-overflow:ellipsis;
  white-space:pre; }
  .bp3-editable-text-editing > .bp3-editable-text-content{
    position:absolute;
    left:0;
    visibility:hidden; }
  .bp3-editable-text-placeholder > .bp3-editable-text-content{
    color:rgba(92, 112, 128, 0.6); }
    .bp3-dark .bp3-editable-text-placeholder > .bp3-editable-text-content{
      color:rgba(167, 182, 194, 0.6); }

.bp3-editable-text.bp3-multiline{
  display:block; }
  .bp3-editable-text.bp3-multiline .bp3-editable-text-content{
    overflow:auto;
    white-space:pre-wrap;
    word-wrap:break-word; }
.bp3-control-group{
  -webkit-transform:translateZ(0);
          transform:translateZ(0);
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-orient:horizontal;
  -webkit-box-direction:normal;
      -ms-flex-direction:row;
          flex-direction:row;
  -webkit-box-align:stretch;
      -ms-flex-align:stretch;
          align-items:stretch; }
  .bp3-control-group > *{
    -webkit-box-flex:0;
        -ms-flex-positive:0;
            flex-grow:0;
    -ms-flex-negative:0;
        flex-shrink:0; }
  .bp3-control-group > .bp3-fill{
    -webkit-box-flex:1;
        -ms-flex-positive:1;
            flex-grow:1;
    -ms-flex-negative:1;
        flex-shrink:1; }
  .bp3-control-group .bp3-button,
  .bp3-control-group .bp3-html-select,
  .bp3-control-group .bp3-input,
  .bp3-control-group .bp3-select{
    position:relative; }
  .bp3-control-group .bp3-input{
    z-index:2;
    border-radius:inherit; }
    .bp3-control-group .bp3-input:focus{
      z-index:14;
      border-radius:3px; }
    .bp3-control-group .bp3-input[class*="bp3-intent"]{
      z-index:13; }
      .bp3-control-group .bp3-input[class*="bp3-intent"]:focus{
        z-index:15; }
    .bp3-control-group .bp3-input[readonly], .bp3-control-group .bp3-input:disabled, .bp3-control-group .bp3-input.bp3-disabled{
      z-index:1; }
  .bp3-control-group .bp3-input-group[class*="bp3-intent"] .bp3-input{
    z-index:13; }
    .bp3-control-group .bp3-input-group[class*="bp3-intent"] .bp3-input:focus{
      z-index:15; }
  .bp3-control-group .bp3-button,
  .bp3-control-group .bp3-html-select select,
  .bp3-control-group .bp3-select select{
    -webkit-transform:translateZ(0);
            transform:translateZ(0);
    z-index:4;
    border-radius:inherit; }
    .bp3-control-group .bp3-button:focus,
    .bp3-control-group .bp3-html-select select:focus,
    .bp3-control-group .bp3-select select:focus{
      z-index:5; }
    .bp3-control-group .bp3-button:hover,
    .bp3-control-group .bp3-html-select select:hover,
    .bp3-control-group .bp3-select select:hover{
      z-index:6; }
    .bp3-control-group .bp3-button:active,
    .bp3-control-group .bp3-html-select select:active,
    .bp3-control-group .bp3-select select:active{
      z-index:7; }
    .bp3-control-group .bp3-button[readonly], .bp3-control-group .bp3-button:disabled, .bp3-control-group .bp3-button.bp3-disabled,
    .bp3-control-group .bp3-html-select select[readonly],
    .bp3-control-group .bp3-html-select select:disabled,
    .bp3-control-group .bp3-html-select select.bp3-disabled,
    .bp3-control-group .bp3-select select[readonly],
    .bp3-control-group .bp3-select select:disabled,
    .bp3-control-group .bp3-select select.bp3-disabled{
      z-index:3; }
    .bp3-control-group .bp3-button[class*="bp3-intent"],
    .bp3-control-group .bp3-html-select select[class*="bp3-intent"],
    .bp3-control-group .bp3-select select[class*="bp3-intent"]{
      z-index:9; }
      .bp3-control-group .bp3-button[class*="bp3-intent"]:focus,
      .bp3-control-group .bp3-html-select select[class*="bp3-intent"]:focus,
      .bp3-control-group .bp3-select select[class*="bp3-intent"]:focus{
        z-index:10; }
      .bp3-control-group .bp3-button[class*="bp3-intent"]:hover,
      .bp3-control-group .bp3-html-select select[class*="bp3-intent"]:hover,
      .bp3-control-group .bp3-select select[class*="bp3-intent"]:hover{
        z-index:11; }
      .bp3-control-group .bp3-button[class*="bp3-intent"]:active,
      .bp3-control-group .bp3-html-select select[class*="bp3-intent"]:active,
      .bp3-control-group .bp3-select select[class*="bp3-intent"]:active{
        z-index:12; }
      .bp3-control-group .bp3-button[class*="bp3-intent"][readonly], .bp3-control-group .bp3-button[class*="bp3-intent"]:disabled, .bp3-control-group .bp3-button[class*="bp3-intent"].bp3-disabled,
      .bp3-control-group .bp3-html-select select[class*="bp3-intent"][readonly],
      .bp3-control-group .bp3-html-select select[class*="bp3-intent"]:disabled,
      .bp3-control-group .bp3-html-select select[class*="bp3-intent"].bp3-disabled,
      .bp3-control-group .bp3-select select[class*="bp3-intent"][readonly],
      .bp3-control-group .bp3-select select[class*="bp3-intent"]:disabled,
      .bp3-control-group .bp3-select select[class*="bp3-intent"].bp3-disabled{
        z-index:8; }
  .bp3-control-group .bp3-input-group > .bp3-icon,
  .bp3-control-group .bp3-input-group > .bp3-button,
  .bp3-control-group .bp3-input-group > .bp3-input-action{
    z-index:16; }
  .bp3-control-group .bp3-select::after,
  .bp3-control-group .bp3-html-select::after,
  .bp3-control-group .bp3-select > .bp3-icon,
  .bp3-control-group .bp3-html-select > .bp3-icon{
    z-index:17; }
  .bp3-control-group:not(.bp3-vertical) > *{
    margin-right:-1px; }
  .bp3-dark .bp3-control-group:not(.bp3-vertical) > *{
    margin-right:0; }
  .bp3-dark .bp3-control-group:not(.bp3-vertical) > .bp3-button + .bp3-button{
    margin-left:1px; }
  .bp3-control-group .bp3-popover-wrapper,
  .bp3-control-group .bp3-popover-target{
    border-radius:inherit; }
  .bp3-control-group > :first-child{
    border-radius:3px 0 0 3px; }
  .bp3-control-group > :last-child{
    margin-right:0;
    border-radius:0 3px 3px 0; }
  .bp3-control-group > :only-child{
    margin-right:0;
    border-radius:3px; }
  .bp3-control-group .bp3-input-group .bp3-button{
    border-radius:3px; }
  .bp3-control-group > .bp3-fill{
    -webkit-box-flex:1;
        -ms-flex:1 1 auto;
            flex:1 1 auto; }
  .bp3-control-group.bp3-fill > *:not(.bp3-fixed){
    -webkit-box-flex:1;
        -ms-flex:1 1 auto;
            flex:1 1 auto; }
  .bp3-control-group.bp3-vertical{
    -webkit-box-orient:vertical;
    -webkit-box-direction:normal;
        -ms-flex-direction:column;
            flex-direction:column; }
    .bp3-control-group.bp3-vertical > *{
      margin-top:-1px; }
    .bp3-control-group.bp3-vertical > :first-child{
      margin-top:0;
      border-radius:3px 3px 0 0; }
    .bp3-control-group.bp3-vertical > :last-child{
      border-radius:0 0 3px 3px; }
.bp3-control{
  display:block;
  position:relative;
  margin-bottom:10px;
  cursor:pointer;
  text-transform:none; }
  .bp3-control input:checked ~ .bp3-control-indicator{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
    background-color:#137cbd;
    background-image:-webkit-gradient(linear, left top, left bottom, from(rgba(255, 255, 255, 0.1)), to(rgba(255, 255, 255, 0)));
    background-image:linear-gradient(to bottom, rgba(255, 255, 255, 0.1), rgba(255, 255, 255, 0));
    color:#ffffff; }
  .bp3-control:hover input:checked ~ .bp3-control-indicator{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
    background-color:#106ba3; }
  .bp3-control input:not(:disabled):active:checked ~ .bp3-control-indicator{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
    background:#0e5a8a; }
  .bp3-control input:disabled:checked ~ .bp3-control-indicator{
    -webkit-box-shadow:none;
            box-shadow:none;
    background:rgba(19, 124, 189, 0.5); }
  .bp3-dark .bp3-control input:checked ~ .bp3-control-indicator{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4); }
  .bp3-dark .bp3-control:hover input:checked ~ .bp3-control-indicator{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
    background-color:#106ba3; }
  .bp3-dark .bp3-control input:not(:disabled):active:checked ~ .bp3-control-indicator{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
    background-color:#0e5a8a; }
  .bp3-dark .bp3-control input:disabled:checked ~ .bp3-control-indicator{
    -webkit-box-shadow:none;
            box-shadow:none;
    background:rgba(14, 90, 138, 0.5); }
  .bp3-control:not(.bp3-align-right){
    padding-left:26px; }
    .bp3-control:not(.bp3-align-right) .bp3-control-indicator{
      margin-left:-26px; }
  .bp3-control.bp3-align-right{
    padding-right:26px; }
    .bp3-control.bp3-align-right .bp3-control-indicator{
      margin-right:-26px; }
  .bp3-control.bp3-disabled{
    cursor:not-allowed;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-control.bp3-inline{
    display:inline-block;
    margin-right:20px; }
  .bp3-control input{
    position:absolute;
    top:0;
    left:0;
    opacity:0;
    z-index:-1; }
  .bp3-control .bp3-control-indicator{
    display:inline-block;
    position:relative;
    margin-top:-3px;
    margin-right:10px;
    border:none;
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
    background-clip:padding-box;
    background-color:#f5f8fa;
    background-image:-webkit-gradient(linear, left top, left bottom, from(rgba(255, 255, 255, 0.8)), to(rgba(255, 255, 255, 0)));
    background-image:linear-gradient(to bottom, rgba(255, 255, 255, 0.8), rgba(255, 255, 255, 0));
    cursor:pointer;
    width:1em;
    height:1em;
    vertical-align:middle;
    font-size:16px;
    -webkit-user-select:none;
       -moz-user-select:none;
        -ms-user-select:none;
            user-select:none; }
    .bp3-control .bp3-control-indicator::before{
      display:block;
      width:1em;
      height:1em;
      content:""; }
  .bp3-control:hover .bp3-control-indicator{
    background-color:#ebf1f5; }
  .bp3-control input:not(:disabled):active ~ .bp3-control-indicator{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 1px 2px rgba(16, 22, 26, 0.2);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 1px 2px rgba(16, 22, 26, 0.2);
    background:#d8e1e8; }
  .bp3-control input:disabled ~ .bp3-control-indicator{
    -webkit-box-shadow:none;
            box-shadow:none;
    background:rgba(206, 217, 224, 0.5);
    cursor:not-allowed; }
  .bp3-control input:focus ~ .bp3-control-indicator{
    outline:rgba(19, 124, 189, 0.6) auto 2px;
    outline-offset:2px;
    -moz-outline-radius:6px; }
  .bp3-control.bp3-align-right .bp3-control-indicator{
    float:right;
    margin-top:1px;
    margin-left:10px; }
  .bp3-control.bp3-large{
    font-size:16px; }
    .bp3-control.bp3-large:not(.bp3-align-right){
      padding-left:30px; }
      .bp3-control.bp3-large:not(.bp3-align-right) .bp3-control-indicator{
        margin-left:-30px; }
    .bp3-control.bp3-large.bp3-align-right{
      padding-right:30px; }
      .bp3-control.bp3-large.bp3-align-right .bp3-control-indicator{
        margin-right:-30px; }
    .bp3-control.bp3-large .bp3-control-indicator{
      font-size:20px; }
    .bp3-control.bp3-large.bp3-align-right .bp3-control-indicator{
      margin-top:0; }
  .bp3-control.bp3-checkbox input:indeterminate ~ .bp3-control-indicator{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
    background-color:#137cbd;
    background-image:-webkit-gradient(linear, left top, left bottom, from(rgba(255, 255, 255, 0.1)), to(rgba(255, 255, 255, 0)));
    background-image:linear-gradient(to bottom, rgba(255, 255, 255, 0.1), rgba(255, 255, 255, 0));
    color:#ffffff; }
  .bp3-control.bp3-checkbox:hover input:indeterminate ~ .bp3-control-indicator{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
    background-color:#106ba3; }
  .bp3-control.bp3-checkbox input:not(:disabled):active:indeterminate ~ .bp3-control-indicator{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
    background:#0e5a8a; }
  .bp3-control.bp3-checkbox input:disabled:indeterminate ~ .bp3-control-indicator{
    -webkit-box-shadow:none;
            box-shadow:none;
    background:rgba(19, 124, 189, 0.5); }
  .bp3-dark .bp3-control.bp3-checkbox input:indeterminate ~ .bp3-control-indicator{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4); }
  .bp3-dark .bp3-control.bp3-checkbox:hover input:indeterminate ~ .bp3-control-indicator{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
    background-color:#106ba3; }
  .bp3-dark .bp3-control.bp3-checkbox input:not(:disabled):active:indeterminate ~ .bp3-control-indicator{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
    background-color:#0e5a8a; }
  .bp3-dark .bp3-control.bp3-checkbox input:disabled:indeterminate ~ .bp3-control-indicator{
    -webkit-box-shadow:none;
            box-shadow:none;
    background:rgba(14, 90, 138, 0.5); }
  .bp3-control.bp3-checkbox .bp3-control-indicator{
    border-radius:3px; }
  .bp3-control.bp3-checkbox input:checked ~ .bp3-control-indicator::before{
    background-image:url("data:image/svg+xml,%3csvg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 16 16'%3e%3cpath fill-rule='evenodd' clip-rule='evenodd' d='M12 5c-.28 0-.53.11-.71.29L7 9.59l-2.29-2.3a1.003 1.003 0 0 0-1.42 1.42l3 3c.18.18.43.29.71.29s.53-.11.71-.29l5-5A1.003 1.003 0 0 0 12 5z' fill='white'/%3e%3c/svg%3e"); }
  .bp3-control.bp3-checkbox input:indeterminate ~ .bp3-control-indicator::before{
    background-image:url("data:image/svg+xml,%3csvg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 16 16'%3e%3cpath fill-rule='evenodd' clip-rule='evenodd' d='M11 7H5c-.55 0-1 .45-1 1s.45 1 1 1h6c.55 0 1-.45 1-1s-.45-1-1-1z' fill='white'/%3e%3c/svg%3e"); }
  .bp3-control.bp3-radio .bp3-control-indicator{
    border-radius:50%; }
  .bp3-control.bp3-radio input:checked ~ .bp3-control-indicator::before{
    background-image:radial-gradient(#ffffff, #ffffff 28%, transparent 32%); }
  .bp3-control.bp3-radio input:checked:disabled ~ .bp3-control-indicator::before{
    opacity:0.5; }
  .bp3-control.bp3-radio input:focus ~ .bp3-control-indicator{
    -moz-outline-radius:16px; }
  .bp3-control.bp3-switch input ~ .bp3-control-indicator{
    background:rgba(167, 182, 194, 0.5); }
  .bp3-control.bp3-switch:hover input ~ .bp3-control-indicator{
    background:rgba(115, 134, 148, 0.5); }
  .bp3-control.bp3-switch input:not(:disabled):active ~ .bp3-control-indicator{
    background:rgba(92, 112, 128, 0.5); }
  .bp3-control.bp3-switch input:disabled ~ .bp3-control-indicator{
    background:rgba(206, 217, 224, 0.5); }
    .bp3-control.bp3-switch input:disabled ~ .bp3-control-indicator::before{
      background:rgba(255, 255, 255, 0.8); }
  .bp3-control.bp3-switch input:checked ~ .bp3-control-indicator{
    background:#137cbd; }
  .bp3-control.bp3-switch:hover input:checked ~ .bp3-control-indicator{
    background:#106ba3; }
  .bp3-control.bp3-switch input:checked:not(:disabled):active ~ .bp3-control-indicator{
    background:#0e5a8a; }
  .bp3-control.bp3-switch input:checked:disabled ~ .bp3-control-indicator{
    background:rgba(19, 124, 189, 0.5); }
    .bp3-control.bp3-switch input:checked:disabled ~ .bp3-control-indicator::before{
      background:rgba(255, 255, 255, 0.8); }
  .bp3-control.bp3-switch:not(.bp3-align-right){
    padding-left:38px; }
    .bp3-control.bp3-switch:not(.bp3-align-right) .bp3-control-indicator{
      margin-left:-38px; }
  .bp3-control.bp3-switch.bp3-align-right{
    padding-right:38px; }
    .bp3-control.bp3-switch.bp3-align-right .bp3-control-indicator{
      margin-right:-38px; }
  .bp3-control.bp3-switch .bp3-control-indicator{
    border:none;
    border-radius:1.75em;
    -webkit-box-shadow:none !important;
            box-shadow:none !important;
    width:auto;
    min-width:1.75em;
    -webkit-transition:background-color 100ms cubic-bezier(0.4, 1, 0.75, 0.9);
    transition:background-color 100ms cubic-bezier(0.4, 1, 0.75, 0.9); }
    .bp3-control.bp3-switch .bp3-control-indicator::before{
      position:absolute;
      left:0;
      margin:2px;
      border-radius:50%;
      -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 1px 1px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 1px 1px rgba(16, 22, 26, 0.2);
      background:#ffffff;
      width:calc(1em - 4px);
      height:calc(1em - 4px);
      -webkit-transition:left 100ms cubic-bezier(0.4, 1, 0.75, 0.9);
      transition:left 100ms cubic-bezier(0.4, 1, 0.75, 0.9); }
  .bp3-control.bp3-switch input:checked ~ .bp3-control-indicator::before{
    left:calc(100% - 1em); }
  .bp3-control.bp3-switch.bp3-large:not(.bp3-align-right){
    padding-left:45px; }
    .bp3-control.bp3-switch.bp3-large:not(.bp3-align-right) .bp3-control-indicator{
      margin-left:-45px; }
  .bp3-control.bp3-switch.bp3-large.bp3-align-right{
    padding-right:45px; }
    .bp3-control.bp3-switch.bp3-large.bp3-align-right .bp3-control-indicator{
      margin-right:-45px; }
  .bp3-dark .bp3-control.bp3-switch input ~ .bp3-control-indicator{
    background:rgba(16, 22, 26, 0.5); }
  .bp3-dark .bp3-control.bp3-switch:hover input ~ .bp3-control-indicator{
    background:rgba(16, 22, 26, 0.7); }
  .bp3-dark .bp3-control.bp3-switch input:not(:disabled):active ~ .bp3-control-indicator{
    background:rgba(16, 22, 26, 0.9); }
  .bp3-dark .bp3-control.bp3-switch input:disabled ~ .bp3-control-indicator{
    background:rgba(57, 75, 89, 0.5); }
    .bp3-dark .bp3-control.bp3-switch input:disabled ~ .bp3-control-indicator::before{
      background:rgba(16, 22, 26, 0.4); }
  .bp3-dark .bp3-control.bp3-switch input:checked ~ .bp3-control-indicator{
    background:#137cbd; }
  .bp3-dark .bp3-control.bp3-switch:hover input:checked ~ .bp3-control-indicator{
    background:#106ba3; }
  .bp3-dark .bp3-control.bp3-switch input:checked:not(:disabled):active ~ .bp3-control-indicator{
    background:#0e5a8a; }
  .bp3-dark .bp3-control.bp3-switch input:checked:disabled ~ .bp3-control-indicator{
    background:rgba(14, 90, 138, 0.5); }
    .bp3-dark .bp3-control.bp3-switch input:checked:disabled ~ .bp3-control-indicator::before{
      background:rgba(16, 22, 26, 0.4); }
  .bp3-dark .bp3-control.bp3-switch .bp3-control-indicator::before{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
    background:#394b59; }
  .bp3-dark .bp3-control.bp3-switch input:checked ~ .bp3-control-indicator::before{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4); }
  .bp3-control.bp3-switch .bp3-switch-inner-text{
    text-align:center;
    font-size:0.7em; }
  .bp3-control.bp3-switch .bp3-control-indicator-child:first-child{
    visibility:hidden;
    margin-right:1.2em;
    margin-left:0.5em;
    line-height:0; }
  .bp3-control.bp3-switch .bp3-control-indicator-child:last-child{
    visibility:visible;
    margin-right:0.5em;
    margin-left:1.2em;
    line-height:1em; }
  .bp3-control.bp3-switch input:checked ~ .bp3-control-indicator .bp3-control-indicator-child:first-child{
    visibility:visible;
    line-height:1em; }
  .bp3-control.bp3-switch input:checked ~ .bp3-control-indicator .bp3-control-indicator-child:last-child{
    visibility:hidden;
    line-height:0; }
  .bp3-dark .bp3-control{
    color:#f5f8fa; }
    .bp3-dark .bp3-control.bp3-disabled{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-control .bp3-control-indicator{
      -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
      background-color:#394b59;
      background-image:-webkit-gradient(linear, left top, left bottom, from(rgba(255, 255, 255, 0.05)), to(rgba(255, 255, 255, 0)));
      background-image:linear-gradient(to bottom, rgba(255, 255, 255, 0.05), rgba(255, 255, 255, 0)); }
    .bp3-dark .bp3-control:hover .bp3-control-indicator{
      background-color:#30404d; }
    .bp3-dark .bp3-control input:not(:disabled):active ~ .bp3-control-indicator{
      -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.6), inset 0 1px 2px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px rgba(16, 22, 26, 0.6), inset 0 1px 2px rgba(16, 22, 26, 0.2);
      background:#202b33; }
    .bp3-dark .bp3-control input:disabled ~ .bp3-control-indicator{
      -webkit-box-shadow:none;
              box-shadow:none;
      background:rgba(57, 75, 89, 0.5);
      cursor:not-allowed; }
    .bp3-dark .bp3-control.bp3-checkbox input:disabled:checked ~ .bp3-control-indicator, .bp3-dark .bp3-control.bp3-checkbox input:disabled:indeterminate ~ .bp3-control-indicator{
      color:rgba(167, 182, 194, 0.6); }
.bp3-file-input{
  display:inline-block;
  position:relative;
  cursor:pointer;
  height:30px; }
  .bp3-file-input input{
    opacity:0;
    margin:0;
    min-width:200px; }
    .bp3-file-input input:disabled + .bp3-file-upload-input,
    .bp3-file-input input.bp3-disabled + .bp3-file-upload-input{
      -webkit-box-shadow:none;
              box-shadow:none;
      background:rgba(206, 217, 224, 0.5);
      cursor:not-allowed;
      color:rgba(92, 112, 128, 0.6);
      resize:none; }
      .bp3-file-input input:disabled + .bp3-file-upload-input::after,
      .bp3-file-input input.bp3-disabled + .bp3-file-upload-input::after{
        outline:none;
        -webkit-box-shadow:none;
                box-shadow:none;
        background-color:rgba(206, 217, 224, 0.5);
        background-image:none;
        cursor:not-allowed;
        color:rgba(92, 112, 128, 0.6); }
        .bp3-file-input input:disabled + .bp3-file-upload-input::after.bp3-active, .bp3-file-input input:disabled + .bp3-file-upload-input::after.bp3-active:hover,
        .bp3-file-input input.bp3-disabled + .bp3-file-upload-input::after.bp3-active,
        .bp3-file-input input.bp3-disabled + .bp3-file-upload-input::after.bp3-active:hover{
          background:rgba(206, 217, 224, 0.7); }
      .bp3-dark .bp3-file-input input:disabled + .bp3-file-upload-input, .bp3-dark
      .bp3-file-input input.bp3-disabled + .bp3-file-upload-input{
        -webkit-box-shadow:none;
                box-shadow:none;
        background:rgba(57, 75, 89, 0.5);
        color:rgba(167, 182, 194, 0.6); }
        .bp3-dark .bp3-file-input input:disabled + .bp3-file-upload-input::after, .bp3-dark
        .bp3-file-input input.bp3-disabled + .bp3-file-upload-input::after{
          -webkit-box-shadow:none;
                  box-shadow:none;
          background-color:rgba(57, 75, 89, 0.5);
          background-image:none;
          color:rgba(167, 182, 194, 0.6); }
          .bp3-dark .bp3-file-input input:disabled + .bp3-file-upload-input::after.bp3-active, .bp3-dark
          .bp3-file-input input.bp3-disabled + .bp3-file-upload-input::after.bp3-active{
            background:rgba(57, 75, 89, 0.7); }
  .bp3-file-input.bp3-file-input-has-selection .bp3-file-upload-input{
    color:#182026; }
  .bp3-dark .bp3-file-input.bp3-file-input-has-selection .bp3-file-upload-input{
    color:#f5f8fa; }
  .bp3-file-input.bp3-fill{
    width:100%; }
  .bp3-file-input.bp3-large,
  .bp3-large .bp3-file-input{
    height:40px; }
  .bp3-file-input .bp3-file-upload-input-custom-text::after{
    content:attr(bp3-button-text); }

.bp3-file-upload-input{
  outline:none;
  border:none;
  border-radius:3px;
  -webkit-box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2);
  background:#ffffff;
  height:30px;
  padding:0 10px;
  vertical-align:middle;
  line-height:30px;
  color:#182026;
  font-size:14px;
  font-weight:400;
  -webkit-transition:-webkit-box-shadow 100ms cubic-bezier(0.4, 1, 0.75, 0.9);
  transition:-webkit-box-shadow 100ms cubic-bezier(0.4, 1, 0.75, 0.9);
  transition:box-shadow 100ms cubic-bezier(0.4, 1, 0.75, 0.9);
  transition:box-shadow 100ms cubic-bezier(0.4, 1, 0.75, 0.9), -webkit-box-shadow 100ms cubic-bezier(0.4, 1, 0.75, 0.9);
  -webkit-appearance:none;
     -moz-appearance:none;
          appearance:none;
  overflow:hidden;
  text-overflow:ellipsis;
  white-space:nowrap;
  word-wrap:normal;
  position:absolute;
  top:0;
  right:0;
  left:0;
  padding-right:80px;
  color:rgba(92, 112, 128, 0.6);
  -webkit-user-select:none;
     -moz-user-select:none;
      -ms-user-select:none;
          user-select:none; }
  .bp3-file-upload-input::-webkit-input-placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-file-upload-input::-moz-placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-file-upload-input:-ms-input-placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-file-upload-input::-ms-input-placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-file-upload-input::placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-file-upload-input:focus, .bp3-file-upload-input.bp3-active{
    -webkit-box-shadow:0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
  .bp3-file-upload-input[type="search"], .bp3-file-upload-input.bp3-round{
    border-radius:30px;
    -webkit-box-sizing:border-box;
            box-sizing:border-box;
    padding-left:10px; }
  .bp3-file-upload-input[readonly]{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.15);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.15); }
  .bp3-file-upload-input:disabled, .bp3-file-upload-input.bp3-disabled{
    -webkit-box-shadow:none;
            box-shadow:none;
    background:rgba(206, 217, 224, 0.5);
    cursor:not-allowed;
    color:rgba(92, 112, 128, 0.6);
    resize:none; }
  .bp3-file-upload-input::after{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
    background-color:#f5f8fa;
    background-image:-webkit-gradient(linear, left top, left bottom, from(rgba(255, 255, 255, 0.8)), to(rgba(255, 255, 255, 0)));
    background-image:linear-gradient(to bottom, rgba(255, 255, 255, 0.8), rgba(255, 255, 255, 0));
    color:#182026;
    min-width:24px;
    min-height:24px;
    overflow:hidden;
    text-overflow:ellipsis;
    white-space:nowrap;
    word-wrap:normal;
    position:absolute;
    top:0;
    right:0;
    margin:3px;
    border-radius:3px;
    width:70px;
    text-align:center;
    line-height:24px;
    content:"Browse"; }
    .bp3-file-upload-input::after:hover{
      -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
              box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
      background-clip:padding-box;
      background-color:#ebf1f5; }
    .bp3-file-upload-input::after:active, .bp3-file-upload-input::after.bp3-active{
      -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 1px 2px rgba(16, 22, 26, 0.2);
              box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 1px 2px rgba(16, 22, 26, 0.2);
      background-color:#d8e1e8;
      background-image:none; }
    .bp3-file-upload-input::after:disabled, .bp3-file-upload-input::after.bp3-disabled{
      outline:none;
      -webkit-box-shadow:none;
              box-shadow:none;
      background-color:rgba(206, 217, 224, 0.5);
      background-image:none;
      cursor:not-allowed;
      color:rgba(92, 112, 128, 0.6); }
      .bp3-file-upload-input::after:disabled.bp3-active, .bp3-file-upload-input::after:disabled.bp3-active:hover, .bp3-file-upload-input::after.bp3-disabled.bp3-active, .bp3-file-upload-input::after.bp3-disabled.bp3-active:hover{
        background:rgba(206, 217, 224, 0.7); }
  .bp3-file-upload-input:hover::after{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
    background-clip:padding-box;
    background-color:#ebf1f5; }
  .bp3-file-upload-input:active::after{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 1px 2px rgba(16, 22, 26, 0.2);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 1px 2px rgba(16, 22, 26, 0.2);
    background-color:#d8e1e8;
    background-image:none; }
  .bp3-large .bp3-file-upload-input{
    height:40px;
    line-height:40px;
    font-size:16px;
    padding-right:95px; }
    .bp3-large .bp3-file-upload-input[type="search"], .bp3-large .bp3-file-upload-input.bp3-round{
      padding:0 15px; }
    .bp3-large .bp3-file-upload-input::after{
      min-width:30px;
      min-height:30px;
      margin:5px;
      width:85px;
      line-height:30px; }
  .bp3-dark .bp3-file-upload-input{
    -webkit-box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
    background:rgba(16, 22, 26, 0.3);
    color:#f5f8fa;
    color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-file-upload-input::-webkit-input-placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-file-upload-input::-moz-placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-file-upload-input:-ms-input-placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-file-upload-input::-ms-input-placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-file-upload-input::placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-file-upload-input:focus{
      -webkit-box-shadow:0 0 0 1px #137cbd, 0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 1px #137cbd, 0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
    .bp3-dark .bp3-file-upload-input[readonly]{
      -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4);
              box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4); }
    .bp3-dark .bp3-file-upload-input:disabled, .bp3-dark .bp3-file-upload-input.bp3-disabled{
      -webkit-box-shadow:none;
              box-shadow:none;
      background:rgba(57, 75, 89, 0.5);
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-file-upload-input::after{
      -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
      background-color:#394b59;
      background-image:-webkit-gradient(linear, left top, left bottom, from(rgba(255, 255, 255, 0.05)), to(rgba(255, 255, 255, 0)));
      background-image:linear-gradient(to bottom, rgba(255, 255, 255, 0.05), rgba(255, 255, 255, 0));
      color:#f5f8fa; }
      .bp3-dark .bp3-file-upload-input::after:hover, .bp3-dark .bp3-file-upload-input::after:active, .bp3-dark .bp3-file-upload-input::after.bp3-active{
        color:#f5f8fa; }
      .bp3-dark .bp3-file-upload-input::after:hover{
        -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
                box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
        background-color:#30404d; }
      .bp3-dark .bp3-file-upload-input::after:active, .bp3-dark .bp3-file-upload-input::after.bp3-active{
        -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.6), inset 0 1px 2px rgba(16, 22, 26, 0.2);
                box-shadow:0 0 0 1px rgba(16, 22, 26, 0.6), inset 0 1px 2px rgba(16, 22, 26, 0.2);
        background-color:#202b33;
        background-image:none; }
      .bp3-dark .bp3-file-upload-input::after:disabled, .bp3-dark .bp3-file-upload-input::after.bp3-disabled{
        -webkit-box-shadow:none;
                box-shadow:none;
        background-color:rgba(57, 75, 89, 0.5);
        background-image:none;
        color:rgba(167, 182, 194, 0.6); }
        .bp3-dark .bp3-file-upload-input::after:disabled.bp3-active, .bp3-dark .bp3-file-upload-input::after.bp3-disabled.bp3-active{
          background:rgba(57, 75, 89, 0.7); }
      .bp3-dark .bp3-file-upload-input::after .bp3-button-spinner .bp3-spinner-head{
        background:rgba(16, 22, 26, 0.5);
        stroke:#8a9ba8; }
    .bp3-dark .bp3-file-upload-input:hover::after{
      -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
      background-color:#30404d; }
    .bp3-dark .bp3-file-upload-input:active::after{
      -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.6), inset 0 1px 2px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px rgba(16, 22, 26, 0.6), inset 0 1px 2px rgba(16, 22, 26, 0.2);
      background-color:#202b33;
      background-image:none; }

.bp3-file-upload-input::after{
  -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
          box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1); }
.bp3-form-group{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-orient:vertical;
  -webkit-box-direction:normal;
      -ms-flex-direction:column;
          flex-direction:column;
  margin:0 0 15px; }
  .bp3-form-group label.bp3-label{
    margin-bottom:5px; }
  .bp3-form-group .bp3-control{
    margin-top:7px; }
  .bp3-form-group .bp3-form-helper-text{
    margin-top:5px;
    color:#5c7080;
    font-size:12px; }
  .bp3-form-group.bp3-intent-primary .bp3-form-helper-text{
    color:#106ba3; }
  .bp3-form-group.bp3-intent-success .bp3-form-helper-text{
    color:#0d8050; }
  .bp3-form-group.bp3-intent-warning .bp3-form-helper-text{
    color:#bf7326; }
  .bp3-form-group.bp3-intent-danger .bp3-form-helper-text{
    color:#c23030; }
  .bp3-form-group.bp3-inline{
    -webkit-box-orient:horizontal;
    -webkit-box-direction:normal;
        -ms-flex-direction:row;
            flex-direction:row;
    -webkit-box-align:start;
        -ms-flex-align:start;
            align-items:flex-start; }
    .bp3-form-group.bp3-inline.bp3-large label.bp3-label{
      margin:0 10px 0 0;
      line-height:40px; }
    .bp3-form-group.bp3-inline label.bp3-label{
      margin:0 10px 0 0;
      line-height:30px; }
  .bp3-form-group.bp3-disabled .bp3-label,
  .bp3-form-group.bp3-disabled .bp3-text-muted,
  .bp3-form-group.bp3-disabled .bp3-form-helper-text{
    color:rgba(92, 112, 128, 0.6) !important; }
  .bp3-dark .bp3-form-group.bp3-intent-primary .bp3-form-helper-text{
    color:#48aff0; }
  .bp3-dark .bp3-form-group.bp3-intent-success .bp3-form-helper-text{
    color:#3dcc91; }
  .bp3-dark .bp3-form-group.bp3-intent-warning .bp3-form-helper-text{
    color:#ffb366; }
  .bp3-dark .bp3-form-group.bp3-intent-danger .bp3-form-helper-text{
    color:#ff7373; }
  .bp3-dark .bp3-form-group .bp3-form-helper-text{
    color:#a7b6c2; }
  .bp3-dark .bp3-form-group.bp3-disabled .bp3-label,
  .bp3-dark .bp3-form-group.bp3-disabled .bp3-text-muted,
  .bp3-dark .bp3-form-group.bp3-disabled .bp3-form-helper-text{
    color:rgba(167, 182, 194, 0.6) !important; }
.bp3-input-group{
  display:block;
  position:relative; }
  .bp3-input-group .bp3-input{
    position:relative;
    width:100%; }
    .bp3-input-group .bp3-input:not(:first-child){
      padding-left:30px; }
    .bp3-input-group .bp3-input:not(:last-child){
      padding-right:30px; }
  .bp3-input-group .bp3-input-action,
  .bp3-input-group > .bp3-button,
  .bp3-input-group > .bp3-icon{
    position:absolute;
    top:0; }
    .bp3-input-group .bp3-input-action:first-child,
    .bp3-input-group > .bp3-button:first-child,
    .bp3-input-group > .bp3-icon:first-child{
      left:0; }
    .bp3-input-group .bp3-input-action:last-child,
    .bp3-input-group > .bp3-button:last-child,
    .bp3-input-group > .bp3-icon:last-child{
      right:0; }
  .bp3-input-group .bp3-button{
    min-width:24px;
    min-height:24px;
    margin:3px;
    padding:0 7px; }
    .bp3-input-group .bp3-button:empty{
      padding:0; }
  .bp3-input-group > .bp3-icon{
    z-index:1;
    color:#5c7080; }
    .bp3-input-group > .bp3-icon:empty{
      line-height:1;
      font-family:"Icons16", sans-serif;
      font-size:16px;
      font-weight:400;
      font-style:normal;
      -moz-osx-font-smoothing:grayscale;
      -webkit-font-smoothing:antialiased; }
  .bp3-input-group > .bp3-icon,
  .bp3-input-group .bp3-input-action > .bp3-spinner{
    margin:7px; }
  .bp3-input-group .bp3-tag{
    margin:5px; }
  .bp3-input-group .bp3-input:not(:focus) + .bp3-button.bp3-minimal:not(:hover):not(:focus),
  .bp3-input-group .bp3-input:not(:focus) + .bp3-input-action .bp3-button.bp3-minimal:not(:hover):not(:focus){
    color:#5c7080; }
    .bp3-dark .bp3-input-group .bp3-input:not(:focus) + .bp3-button.bp3-minimal:not(:hover):not(:focus), .bp3-dark
    .bp3-input-group .bp3-input:not(:focus) + .bp3-input-action .bp3-button.bp3-minimal:not(:hover):not(:focus){
      color:#a7b6c2; }
    .bp3-input-group .bp3-input:not(:focus) + .bp3-button.bp3-minimal:not(:hover):not(:focus) .bp3-icon, .bp3-input-group .bp3-input:not(:focus) + .bp3-button.bp3-minimal:not(:hover):not(:focus) .bp3-icon-standard, .bp3-input-group .bp3-input:not(:focus) + .bp3-button.bp3-minimal:not(:hover):not(:focus) .bp3-icon-large,
    .bp3-input-group .bp3-input:not(:focus) + .bp3-input-action .bp3-button.bp3-minimal:not(:hover):not(:focus) .bp3-icon,
    .bp3-input-group .bp3-input:not(:focus) + .bp3-input-action .bp3-button.bp3-minimal:not(:hover):not(:focus) .bp3-icon-standard,
    .bp3-input-group .bp3-input:not(:focus) + .bp3-input-action .bp3-button.bp3-minimal:not(:hover):not(:focus) .bp3-icon-large{
      color:#5c7080; }
  .bp3-input-group .bp3-input:not(:focus) + .bp3-button.bp3-minimal:disabled,
  .bp3-input-group .bp3-input:not(:focus) + .bp3-input-action .bp3-button.bp3-minimal:disabled{
    color:rgba(92, 112, 128, 0.6) !important; }
    .bp3-input-group .bp3-input:not(:focus) + .bp3-button.bp3-minimal:disabled .bp3-icon, .bp3-input-group .bp3-input:not(:focus) + .bp3-button.bp3-minimal:disabled .bp3-icon-standard, .bp3-input-group .bp3-input:not(:focus) + .bp3-button.bp3-minimal:disabled .bp3-icon-large,
    .bp3-input-group .bp3-input:not(:focus) + .bp3-input-action .bp3-button.bp3-minimal:disabled .bp3-icon,
    .bp3-input-group .bp3-input:not(:focus) + .bp3-input-action .bp3-button.bp3-minimal:disabled .bp3-icon-standard,
    .bp3-input-group .bp3-input:not(:focus) + .bp3-input-action .bp3-button.bp3-minimal:disabled .bp3-icon-large{
      color:rgba(92, 112, 128, 0.6) !important; }
  .bp3-input-group.bp3-disabled{
    cursor:not-allowed; }
    .bp3-input-group.bp3-disabled .bp3-icon{
      color:rgba(92, 112, 128, 0.6); }
  .bp3-input-group.bp3-large .bp3-button{
    min-width:30px;
    min-height:30px;
    margin:5px; }
  .bp3-input-group.bp3-large > .bp3-icon,
  .bp3-input-group.bp3-large .bp3-input-action > .bp3-spinner{
    margin:12px; }
  .bp3-input-group.bp3-large .bp3-input{
    height:40px;
    line-height:40px;
    font-size:16px; }
    .bp3-input-group.bp3-large .bp3-input[type="search"], .bp3-input-group.bp3-large .bp3-input.bp3-round{
      padding:0 15px; }
    .bp3-input-group.bp3-large .bp3-input:not(:first-child){
      padding-left:40px; }
    .bp3-input-group.bp3-large .bp3-input:not(:last-child){
      padding-right:40px; }
  .bp3-input-group.bp3-small .bp3-button{
    min-width:20px;
    min-height:20px;
    margin:2px; }
  .bp3-input-group.bp3-small .bp3-tag{
    min-width:20px;
    min-height:20px;
    margin:2px; }
  .bp3-input-group.bp3-small > .bp3-icon,
  .bp3-input-group.bp3-small .bp3-input-action > .bp3-spinner{
    margin:4px; }
  .bp3-input-group.bp3-small .bp3-input{
    height:24px;
    padding-right:8px;
    padding-left:8px;
    line-height:24px;
    font-size:12px; }
    .bp3-input-group.bp3-small .bp3-input[type="search"], .bp3-input-group.bp3-small .bp3-input.bp3-round{
      padding:0 12px; }
    .bp3-input-group.bp3-small .bp3-input:not(:first-child){
      padding-left:24px; }
    .bp3-input-group.bp3-small .bp3-input:not(:last-child){
      padding-right:24px; }
  .bp3-input-group.bp3-fill{
    -webkit-box-flex:1;
        -ms-flex:1 1 auto;
            flex:1 1 auto;
    width:100%; }
  .bp3-input-group.bp3-round .bp3-button,
  .bp3-input-group.bp3-round .bp3-input,
  .bp3-input-group.bp3-round .bp3-tag{
    border-radius:30px; }
  .bp3-dark .bp3-input-group .bp3-icon{
    color:#a7b6c2; }
  .bp3-dark .bp3-input-group.bp3-disabled .bp3-icon{
    color:rgba(167, 182, 194, 0.6); }
  .bp3-input-group.bp3-intent-primary .bp3-input{
    -webkit-box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px #137cbd, inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px #137cbd, inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-input-group.bp3-intent-primary .bp3-input:focus{
      -webkit-box-shadow:0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-input-group.bp3-intent-primary .bp3-input[readonly]{
      -webkit-box-shadow:inset 0 0 0 1px #137cbd;
              box-shadow:inset 0 0 0 1px #137cbd; }
    .bp3-input-group.bp3-intent-primary .bp3-input:disabled, .bp3-input-group.bp3-intent-primary .bp3-input.bp3-disabled{
      -webkit-box-shadow:none;
              box-shadow:none; }
  .bp3-input-group.bp3-intent-primary > .bp3-icon{
    color:#106ba3; }
    .bp3-dark .bp3-input-group.bp3-intent-primary > .bp3-icon{
      color:#48aff0; }
  .bp3-input-group.bp3-intent-success .bp3-input{
    -webkit-box-shadow:0 0 0 0 rgba(15, 153, 96, 0), 0 0 0 0 rgba(15, 153, 96, 0), inset 0 0 0 1px #0f9960, inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 0 rgba(15, 153, 96, 0), 0 0 0 0 rgba(15, 153, 96, 0), inset 0 0 0 1px #0f9960, inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-input-group.bp3-intent-success .bp3-input:focus{
      -webkit-box-shadow:0 0 0 1px #0f9960, 0 0 0 3px rgba(15, 153, 96, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px #0f9960, 0 0 0 3px rgba(15, 153, 96, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-input-group.bp3-intent-success .bp3-input[readonly]{
      -webkit-box-shadow:inset 0 0 0 1px #0f9960;
              box-shadow:inset 0 0 0 1px #0f9960; }
    .bp3-input-group.bp3-intent-success .bp3-input:disabled, .bp3-input-group.bp3-intent-success .bp3-input.bp3-disabled{
      -webkit-box-shadow:none;
              box-shadow:none; }
  .bp3-input-group.bp3-intent-success > .bp3-icon{
    color:#0d8050; }
    .bp3-dark .bp3-input-group.bp3-intent-success > .bp3-icon{
      color:#3dcc91; }
  .bp3-input-group.bp3-intent-warning .bp3-input{
    -webkit-box-shadow:0 0 0 0 rgba(217, 130, 43, 0), 0 0 0 0 rgba(217, 130, 43, 0), inset 0 0 0 1px #d9822b, inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 0 rgba(217, 130, 43, 0), 0 0 0 0 rgba(217, 130, 43, 0), inset 0 0 0 1px #d9822b, inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-input-group.bp3-intent-warning .bp3-input:focus{
      -webkit-box-shadow:0 0 0 1px #d9822b, 0 0 0 3px rgba(217, 130, 43, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px #d9822b, 0 0 0 3px rgba(217, 130, 43, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-input-group.bp3-intent-warning .bp3-input[readonly]{
      -webkit-box-shadow:inset 0 0 0 1px #d9822b;
              box-shadow:inset 0 0 0 1px #d9822b; }
    .bp3-input-group.bp3-intent-warning .bp3-input:disabled, .bp3-input-group.bp3-intent-warning .bp3-input.bp3-disabled{
      -webkit-box-shadow:none;
              box-shadow:none; }
  .bp3-input-group.bp3-intent-warning > .bp3-icon{
    color:#bf7326; }
    .bp3-dark .bp3-input-group.bp3-intent-warning > .bp3-icon{
      color:#ffb366; }
  .bp3-input-group.bp3-intent-danger .bp3-input{
    -webkit-box-shadow:0 0 0 0 rgba(219, 55, 55, 0), 0 0 0 0 rgba(219, 55, 55, 0), inset 0 0 0 1px #db3737, inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 0 rgba(219, 55, 55, 0), 0 0 0 0 rgba(219, 55, 55, 0), inset 0 0 0 1px #db3737, inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-input-group.bp3-intent-danger .bp3-input:focus{
      -webkit-box-shadow:0 0 0 1px #db3737, 0 0 0 3px rgba(219, 55, 55, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px #db3737, 0 0 0 3px rgba(219, 55, 55, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-input-group.bp3-intent-danger .bp3-input[readonly]{
      -webkit-box-shadow:inset 0 0 0 1px #db3737;
              box-shadow:inset 0 0 0 1px #db3737; }
    .bp3-input-group.bp3-intent-danger .bp3-input:disabled, .bp3-input-group.bp3-intent-danger .bp3-input.bp3-disabled{
      -webkit-box-shadow:none;
              box-shadow:none; }
  .bp3-input-group.bp3-intent-danger > .bp3-icon{
    color:#c23030; }
    .bp3-dark .bp3-input-group.bp3-intent-danger > .bp3-icon{
      color:#ff7373; }
.bp3-input{
  outline:none;
  border:none;
  border-radius:3px;
  -webkit-box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2);
  background:#ffffff;
  height:30px;
  padding:0 10px;
  vertical-align:middle;
  line-height:30px;
  color:#182026;
  font-size:14px;
  font-weight:400;
  -webkit-transition:-webkit-box-shadow 100ms cubic-bezier(0.4, 1, 0.75, 0.9);
  transition:-webkit-box-shadow 100ms cubic-bezier(0.4, 1, 0.75, 0.9);
  transition:box-shadow 100ms cubic-bezier(0.4, 1, 0.75, 0.9);
  transition:box-shadow 100ms cubic-bezier(0.4, 1, 0.75, 0.9), -webkit-box-shadow 100ms cubic-bezier(0.4, 1, 0.75, 0.9);
  -webkit-appearance:none;
     -moz-appearance:none;
          appearance:none; }
  .bp3-input::-webkit-input-placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-input::-moz-placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-input:-ms-input-placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-input::-ms-input-placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-input::placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-input:focus, .bp3-input.bp3-active{
    -webkit-box-shadow:0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
  .bp3-input[type="search"], .bp3-input.bp3-round{
    border-radius:30px;
    -webkit-box-sizing:border-box;
            box-sizing:border-box;
    padding-left:10px; }
  .bp3-input[readonly]{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.15);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.15); }
  .bp3-input:disabled, .bp3-input.bp3-disabled{
    -webkit-box-shadow:none;
            box-shadow:none;
    background:rgba(206, 217, 224, 0.5);
    cursor:not-allowed;
    color:rgba(92, 112, 128, 0.6);
    resize:none; }
  .bp3-input.bp3-large{
    height:40px;
    line-height:40px;
    font-size:16px; }
    .bp3-input.bp3-large[type="search"], .bp3-input.bp3-large.bp3-round{
      padding:0 15px; }
  .bp3-input.bp3-small{
    height:24px;
    padding-right:8px;
    padding-left:8px;
    line-height:24px;
    font-size:12px; }
    .bp3-input.bp3-small[type="search"], .bp3-input.bp3-small.bp3-round{
      padding:0 12px; }
  .bp3-input.bp3-fill{
    -webkit-box-flex:1;
        -ms-flex:1 1 auto;
            flex:1 1 auto;
    width:100%; }
  .bp3-dark .bp3-input{
    -webkit-box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
    background:rgba(16, 22, 26, 0.3);
    color:#f5f8fa; }
    .bp3-dark .bp3-input::-webkit-input-placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-input::-moz-placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-input:-ms-input-placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-input::-ms-input-placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-input::placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-input:focus{
      -webkit-box-shadow:0 0 0 1px #137cbd, 0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 1px #137cbd, 0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
    .bp3-dark .bp3-input[readonly]{
      -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4);
              box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4); }
    .bp3-dark .bp3-input:disabled, .bp3-dark .bp3-input.bp3-disabled{
      -webkit-box-shadow:none;
              box-shadow:none;
      background:rgba(57, 75, 89, 0.5);
      color:rgba(167, 182, 194, 0.6); }
  .bp3-input.bp3-intent-primary{
    -webkit-box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px #137cbd, inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px #137cbd, inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-input.bp3-intent-primary:focus{
      -webkit-box-shadow:0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-input.bp3-intent-primary[readonly]{
      -webkit-box-shadow:inset 0 0 0 1px #137cbd;
              box-shadow:inset 0 0 0 1px #137cbd; }
    .bp3-input.bp3-intent-primary:disabled, .bp3-input.bp3-intent-primary.bp3-disabled{
      -webkit-box-shadow:none;
              box-shadow:none; }
    .bp3-dark .bp3-input.bp3-intent-primary{
      -webkit-box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px #137cbd, inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px #137cbd, inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
      .bp3-dark .bp3-input.bp3-intent-primary:focus{
        -webkit-box-shadow:0 0 0 1px #137cbd, 0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
                box-shadow:0 0 0 1px #137cbd, 0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
      .bp3-dark .bp3-input.bp3-intent-primary[readonly]{
        -webkit-box-shadow:inset 0 0 0 1px #137cbd;
                box-shadow:inset 0 0 0 1px #137cbd; }
      .bp3-dark .bp3-input.bp3-intent-primary:disabled, .bp3-dark .bp3-input.bp3-intent-primary.bp3-disabled{
        -webkit-box-shadow:none;
                box-shadow:none; }
  .bp3-input.bp3-intent-success{
    -webkit-box-shadow:0 0 0 0 rgba(15, 153, 96, 0), 0 0 0 0 rgba(15, 153, 96, 0), inset 0 0 0 1px #0f9960, inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 0 rgba(15, 153, 96, 0), 0 0 0 0 rgba(15, 153, 96, 0), inset 0 0 0 1px #0f9960, inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-input.bp3-intent-success:focus{
      -webkit-box-shadow:0 0 0 1px #0f9960, 0 0 0 3px rgba(15, 153, 96, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px #0f9960, 0 0 0 3px rgba(15, 153, 96, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-input.bp3-intent-success[readonly]{
      -webkit-box-shadow:inset 0 0 0 1px #0f9960;
              box-shadow:inset 0 0 0 1px #0f9960; }
    .bp3-input.bp3-intent-success:disabled, .bp3-input.bp3-intent-success.bp3-disabled{
      -webkit-box-shadow:none;
              box-shadow:none; }
    .bp3-dark .bp3-input.bp3-intent-success{
      -webkit-box-shadow:0 0 0 0 rgba(15, 153, 96, 0), 0 0 0 0 rgba(15, 153, 96, 0), 0 0 0 0 rgba(15, 153, 96, 0), inset 0 0 0 1px #0f9960, inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 0 rgba(15, 153, 96, 0), 0 0 0 0 rgba(15, 153, 96, 0), 0 0 0 0 rgba(15, 153, 96, 0), inset 0 0 0 1px #0f9960, inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
      .bp3-dark .bp3-input.bp3-intent-success:focus{
        -webkit-box-shadow:0 0 0 1px #0f9960, 0 0 0 1px #0f9960, 0 0 0 3px rgba(15, 153, 96, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
                box-shadow:0 0 0 1px #0f9960, 0 0 0 1px #0f9960, 0 0 0 3px rgba(15, 153, 96, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
      .bp3-dark .bp3-input.bp3-intent-success[readonly]{
        -webkit-box-shadow:inset 0 0 0 1px #0f9960;
                box-shadow:inset 0 0 0 1px #0f9960; }
      .bp3-dark .bp3-input.bp3-intent-success:disabled, .bp3-dark .bp3-input.bp3-intent-success.bp3-disabled{
        -webkit-box-shadow:none;
                box-shadow:none; }
  .bp3-input.bp3-intent-warning{
    -webkit-box-shadow:0 0 0 0 rgba(217, 130, 43, 0), 0 0 0 0 rgba(217, 130, 43, 0), inset 0 0 0 1px #d9822b, inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 0 rgba(217, 130, 43, 0), 0 0 0 0 rgba(217, 130, 43, 0), inset 0 0 0 1px #d9822b, inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-input.bp3-intent-warning:focus{
      -webkit-box-shadow:0 0 0 1px #d9822b, 0 0 0 3px rgba(217, 130, 43, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px #d9822b, 0 0 0 3px rgba(217, 130, 43, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-input.bp3-intent-warning[readonly]{
      -webkit-box-shadow:inset 0 0 0 1px #d9822b;
              box-shadow:inset 0 0 0 1px #d9822b; }
    .bp3-input.bp3-intent-warning:disabled, .bp3-input.bp3-intent-warning.bp3-disabled{
      -webkit-box-shadow:none;
              box-shadow:none; }
    .bp3-dark .bp3-input.bp3-intent-warning{
      -webkit-box-shadow:0 0 0 0 rgba(217, 130, 43, 0), 0 0 0 0 rgba(217, 130, 43, 0), 0 0 0 0 rgba(217, 130, 43, 0), inset 0 0 0 1px #d9822b, inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 0 rgba(217, 130, 43, 0), 0 0 0 0 rgba(217, 130, 43, 0), 0 0 0 0 rgba(217, 130, 43, 0), inset 0 0 0 1px #d9822b, inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
      .bp3-dark .bp3-input.bp3-intent-warning:focus{
        -webkit-box-shadow:0 0 0 1px #d9822b, 0 0 0 1px #d9822b, 0 0 0 3px rgba(217, 130, 43, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
                box-shadow:0 0 0 1px #d9822b, 0 0 0 1px #d9822b, 0 0 0 3px rgba(217, 130, 43, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
      .bp3-dark .bp3-input.bp3-intent-warning[readonly]{
        -webkit-box-shadow:inset 0 0 0 1px #d9822b;
                box-shadow:inset 0 0 0 1px #d9822b; }
      .bp3-dark .bp3-input.bp3-intent-warning:disabled, .bp3-dark .bp3-input.bp3-intent-warning.bp3-disabled{
        -webkit-box-shadow:none;
                box-shadow:none; }
  .bp3-input.bp3-intent-danger{
    -webkit-box-shadow:0 0 0 0 rgba(219, 55, 55, 0), 0 0 0 0 rgba(219, 55, 55, 0), inset 0 0 0 1px #db3737, inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 0 rgba(219, 55, 55, 0), 0 0 0 0 rgba(219, 55, 55, 0), inset 0 0 0 1px #db3737, inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-input.bp3-intent-danger:focus{
      -webkit-box-shadow:0 0 0 1px #db3737, 0 0 0 3px rgba(219, 55, 55, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px #db3737, 0 0 0 3px rgba(219, 55, 55, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-input.bp3-intent-danger[readonly]{
      -webkit-box-shadow:inset 0 0 0 1px #db3737;
              box-shadow:inset 0 0 0 1px #db3737; }
    .bp3-input.bp3-intent-danger:disabled, .bp3-input.bp3-intent-danger.bp3-disabled{
      -webkit-box-shadow:none;
              box-shadow:none; }
    .bp3-dark .bp3-input.bp3-intent-danger{
      -webkit-box-shadow:0 0 0 0 rgba(219, 55, 55, 0), 0 0 0 0 rgba(219, 55, 55, 0), 0 0 0 0 rgba(219, 55, 55, 0), inset 0 0 0 1px #db3737, inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 0 rgba(219, 55, 55, 0), 0 0 0 0 rgba(219, 55, 55, 0), 0 0 0 0 rgba(219, 55, 55, 0), inset 0 0 0 1px #db3737, inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
      .bp3-dark .bp3-input.bp3-intent-danger:focus{
        -webkit-box-shadow:0 0 0 1px #db3737, 0 0 0 1px #db3737, 0 0 0 3px rgba(219, 55, 55, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
                box-shadow:0 0 0 1px #db3737, 0 0 0 1px #db3737, 0 0 0 3px rgba(219, 55, 55, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
      .bp3-dark .bp3-input.bp3-intent-danger[readonly]{
        -webkit-box-shadow:inset 0 0 0 1px #db3737;
                box-shadow:inset 0 0 0 1px #db3737; }
      .bp3-dark .bp3-input.bp3-intent-danger:disabled, .bp3-dark .bp3-input.bp3-intent-danger.bp3-disabled{
        -webkit-box-shadow:none;
                box-shadow:none; }
  .bp3-input::-ms-clear{
    display:none; }
textarea.bp3-input{
  max-width:100%;
  padding:10px; }
  textarea.bp3-input, textarea.bp3-input.bp3-large, textarea.bp3-input.bp3-small{
    height:auto;
    line-height:inherit; }
  textarea.bp3-input.bp3-small{
    padding:8px; }
  .bp3-dark textarea.bp3-input{
    -webkit-box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
    background:rgba(16, 22, 26, 0.3);
    color:#f5f8fa; }
    .bp3-dark textarea.bp3-input::-webkit-input-placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark textarea.bp3-input::-moz-placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark textarea.bp3-input:-ms-input-placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark textarea.bp3-input::-ms-input-placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark textarea.bp3-input::placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark textarea.bp3-input:focus{
      -webkit-box-shadow:0 0 0 1px #137cbd, 0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 1px #137cbd, 0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
    .bp3-dark textarea.bp3-input[readonly]{
      -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4);
              box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4); }
    .bp3-dark textarea.bp3-input:disabled, .bp3-dark textarea.bp3-input.bp3-disabled{
      -webkit-box-shadow:none;
              box-shadow:none;
      background:rgba(57, 75, 89, 0.5);
      color:rgba(167, 182, 194, 0.6); }
label.bp3-label{
  display:block;
  margin-top:0;
  margin-bottom:15px; }
  label.bp3-label .bp3-html-select,
  label.bp3-label .bp3-input,
  label.bp3-label .bp3-select,
  label.bp3-label .bp3-slider,
  label.bp3-label .bp3-popover-wrapper{
    display:block;
    margin-top:5px;
    text-transform:none; }
  label.bp3-label .bp3-button-group{
    margin-top:5px; }
  label.bp3-label .bp3-select select,
  label.bp3-label .bp3-html-select select{
    width:100%;
    vertical-align:top;
    font-weight:400; }
  label.bp3-label.bp3-disabled,
  label.bp3-label.bp3-disabled .bp3-text-muted{
    color:rgba(92, 112, 128, 0.6); }
  label.bp3-label.bp3-inline{
    line-height:30px; }
    label.bp3-label.bp3-inline .bp3-html-select,
    label.bp3-label.bp3-inline .bp3-input,
    label.bp3-label.bp3-inline .bp3-input-group,
    label.bp3-label.bp3-inline .bp3-select,
    label.bp3-label.bp3-inline .bp3-popover-wrapper{
      display:inline-block;
      margin:0 0 0 5px;
      vertical-align:top; }
    label.bp3-label.bp3-inline .bp3-button-group{
      margin:0 0 0 5px; }
    label.bp3-label.bp3-inline .bp3-input-group .bp3-input{
      margin-left:0; }
    label.bp3-label.bp3-inline.bp3-large{
      line-height:40px; }
  label.bp3-label:not(.bp3-inline) .bp3-popover-target{
    display:block; }
  .bp3-dark label.bp3-label{
    color:#f5f8fa; }
    .bp3-dark label.bp3-label.bp3-disabled,
    .bp3-dark label.bp3-label.bp3-disabled .bp3-text-muted{
      color:rgba(167, 182, 194, 0.6); }
.bp3-numeric-input .bp3-button-group.bp3-vertical > .bp3-button{
  -webkit-box-flex:1;
      -ms-flex:1 1 14px;
          flex:1 1 14px;
  width:30px;
  min-height:0;
  padding:0; }
  .bp3-numeric-input .bp3-button-group.bp3-vertical > .bp3-button:first-child{
    border-radius:0 3px 0 0; }
  .bp3-numeric-input .bp3-button-group.bp3-vertical > .bp3-button:last-child{
    border-radius:0 0 3px 0; }

.bp3-numeric-input .bp3-button-group.bp3-vertical:first-child > .bp3-button:first-child{
  border-radius:3px 0 0 0; }

.bp3-numeric-input .bp3-button-group.bp3-vertical:first-child > .bp3-button:last-child{
  border-radius:0 0 0 3px; }

.bp3-numeric-input.bp3-large .bp3-button-group.bp3-vertical > .bp3-button{
  width:40px; }

form{
  display:block; }
.bp3-html-select select,
.bp3-select select{
  display:-webkit-inline-box;
  display:-ms-inline-flexbox;
  display:inline-flex;
  -webkit-box-orient:horizontal;
  -webkit-box-direction:normal;
      -ms-flex-direction:row;
          flex-direction:row;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center;
  -webkit-box-pack:center;
      -ms-flex-pack:center;
          justify-content:center;
  border:none;
  border-radius:3px;
  cursor:pointer;
  padding:5px 10px;
  vertical-align:middle;
  text-align:left;
  font-size:14px;
  -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
          box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
  background-color:#f5f8fa;
  background-image:-webkit-gradient(linear, left top, left bottom, from(rgba(255, 255, 255, 0.8)), to(rgba(255, 255, 255, 0)));
  background-image:linear-gradient(to bottom, rgba(255, 255, 255, 0.8), rgba(255, 255, 255, 0));
  color:#182026;
  border-radius:3px;
  width:100%;
  height:30px;
  padding:0 25px 0 10px;
  -moz-appearance:none;
  -webkit-appearance:none; }
  .bp3-html-select select > *, .bp3-select select > *{
    -webkit-box-flex:0;
        -ms-flex-positive:0;
            flex-grow:0;
    -ms-flex-negative:0;
        flex-shrink:0; }
  .bp3-html-select select > .bp3-fill, .bp3-select select > .bp3-fill{
    -webkit-box-flex:1;
        -ms-flex-positive:1;
            flex-grow:1;
    -ms-flex-negative:1;
        flex-shrink:1; }
  .bp3-html-select select::before,
  .bp3-select select::before, .bp3-html-select select > *, .bp3-select select > *{
    margin-right:7px; }
  .bp3-html-select select:empty::before,
  .bp3-select select:empty::before,
  .bp3-html-select select > :last-child,
  .bp3-select select > :last-child{
    margin-right:0; }
  .bp3-html-select select:hover,
  .bp3-select select:hover{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
    background-clip:padding-box;
    background-color:#ebf1f5; }
  .bp3-html-select select:active,
  .bp3-select select:active, .bp3-html-select select.bp3-active,
  .bp3-select select.bp3-active{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 1px 2px rgba(16, 22, 26, 0.2);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 1px 2px rgba(16, 22, 26, 0.2);
    background-color:#d8e1e8;
    background-image:none; }
  .bp3-html-select select:disabled,
  .bp3-select select:disabled, .bp3-html-select select.bp3-disabled,
  .bp3-select select.bp3-disabled{
    outline:none;
    -webkit-box-shadow:none;
            box-shadow:none;
    background-color:rgba(206, 217, 224, 0.5);
    background-image:none;
    cursor:not-allowed;
    color:rgba(92, 112, 128, 0.6); }
    .bp3-html-select select:disabled.bp3-active,
    .bp3-select select:disabled.bp3-active, .bp3-html-select select:disabled.bp3-active:hover,
    .bp3-select select:disabled.bp3-active:hover, .bp3-html-select select.bp3-disabled.bp3-active,
    .bp3-select select.bp3-disabled.bp3-active, .bp3-html-select select.bp3-disabled.bp3-active:hover,
    .bp3-select select.bp3-disabled.bp3-active:hover{
      background:rgba(206, 217, 224, 0.7); }

.bp3-html-select.bp3-minimal select,
.bp3-select.bp3-minimal select{
  -webkit-box-shadow:none;
          box-shadow:none;
  background:none; }
  .bp3-html-select.bp3-minimal select:hover,
  .bp3-select.bp3-minimal select:hover{
    -webkit-box-shadow:none;
            box-shadow:none;
    background:rgba(167, 182, 194, 0.3);
    text-decoration:none;
    color:#182026; }
  .bp3-html-select.bp3-minimal select:active,
  .bp3-select.bp3-minimal select:active, .bp3-html-select.bp3-minimal select.bp3-active,
  .bp3-select.bp3-minimal select.bp3-active{
    -webkit-box-shadow:none;
            box-shadow:none;
    background:rgba(115, 134, 148, 0.3);
    color:#182026; }
  .bp3-html-select.bp3-minimal select:disabled,
  .bp3-select.bp3-minimal select:disabled, .bp3-html-select.bp3-minimal select:disabled:hover,
  .bp3-select.bp3-minimal select:disabled:hover, .bp3-html-select.bp3-minimal select.bp3-disabled,
  .bp3-select.bp3-minimal select.bp3-disabled, .bp3-html-select.bp3-minimal select.bp3-disabled:hover,
  .bp3-select.bp3-minimal select.bp3-disabled:hover{
    background:none;
    cursor:not-allowed;
    color:rgba(92, 112, 128, 0.6); }
    .bp3-html-select.bp3-minimal select:disabled.bp3-active,
    .bp3-select.bp3-minimal select:disabled.bp3-active, .bp3-html-select.bp3-minimal select:disabled:hover.bp3-active,
    .bp3-select.bp3-minimal select:disabled:hover.bp3-active, .bp3-html-select.bp3-minimal select.bp3-disabled.bp3-active,
    .bp3-select.bp3-minimal select.bp3-disabled.bp3-active, .bp3-html-select.bp3-minimal select.bp3-disabled:hover.bp3-active,
    .bp3-select.bp3-minimal select.bp3-disabled:hover.bp3-active{
      background:rgba(115, 134, 148, 0.3); }
  .bp3-dark .bp3-html-select.bp3-minimal select, .bp3-html-select.bp3-minimal .bp3-dark select,
  .bp3-dark .bp3-select.bp3-minimal select, .bp3-select.bp3-minimal .bp3-dark select{
    -webkit-box-shadow:none;
            box-shadow:none;
    background:none;
    color:inherit; }
    .bp3-dark .bp3-html-select.bp3-minimal select:hover, .bp3-html-select.bp3-minimal .bp3-dark select:hover,
    .bp3-dark .bp3-select.bp3-minimal select:hover, .bp3-select.bp3-minimal .bp3-dark select:hover, .bp3-dark .bp3-html-select.bp3-minimal select:active, .bp3-html-select.bp3-minimal .bp3-dark select:active,
    .bp3-dark .bp3-select.bp3-minimal select:active, .bp3-select.bp3-minimal .bp3-dark select:active, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-active,
    .bp3-dark .bp3-select.bp3-minimal select.bp3-active, .bp3-select.bp3-minimal .bp3-dark select.bp3-active{
      -webkit-box-shadow:none;
              box-shadow:none;
      background:none; }
    .bp3-dark .bp3-html-select.bp3-minimal select:hover, .bp3-html-select.bp3-minimal .bp3-dark select:hover,
    .bp3-dark .bp3-select.bp3-minimal select:hover, .bp3-select.bp3-minimal .bp3-dark select:hover{
      background:rgba(138, 155, 168, 0.15); }
    .bp3-dark .bp3-html-select.bp3-minimal select:active, .bp3-html-select.bp3-minimal .bp3-dark select:active,
    .bp3-dark .bp3-select.bp3-minimal select:active, .bp3-select.bp3-minimal .bp3-dark select:active, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-active,
    .bp3-dark .bp3-select.bp3-minimal select.bp3-active, .bp3-select.bp3-minimal .bp3-dark select.bp3-active{
      background:rgba(138, 155, 168, 0.3);
      color:#f5f8fa; }
    .bp3-dark .bp3-html-select.bp3-minimal select:disabled, .bp3-html-select.bp3-minimal .bp3-dark select:disabled,
    .bp3-dark .bp3-select.bp3-minimal select:disabled, .bp3-select.bp3-minimal .bp3-dark select:disabled, .bp3-dark .bp3-html-select.bp3-minimal select:disabled:hover, .bp3-html-select.bp3-minimal .bp3-dark select:disabled:hover,
    .bp3-dark .bp3-select.bp3-minimal select:disabled:hover, .bp3-select.bp3-minimal .bp3-dark select:disabled:hover, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-disabled, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-disabled,
    .bp3-dark .bp3-select.bp3-minimal select.bp3-disabled, .bp3-select.bp3-minimal .bp3-dark select.bp3-disabled, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-disabled:hover, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-disabled:hover,
    .bp3-dark .bp3-select.bp3-minimal select.bp3-disabled:hover, .bp3-select.bp3-minimal .bp3-dark select.bp3-disabled:hover{
      background:none;
      cursor:not-allowed;
      color:rgba(167, 182, 194, 0.6); }
      .bp3-dark .bp3-html-select.bp3-minimal select:disabled.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select:disabled.bp3-active,
      .bp3-dark .bp3-select.bp3-minimal select:disabled.bp3-active, .bp3-select.bp3-minimal .bp3-dark select:disabled.bp3-active, .bp3-dark .bp3-html-select.bp3-minimal select:disabled:hover.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select:disabled:hover.bp3-active,
      .bp3-dark .bp3-select.bp3-minimal select:disabled:hover.bp3-active, .bp3-select.bp3-minimal .bp3-dark select:disabled:hover.bp3-active, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-disabled.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-disabled.bp3-active,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-disabled.bp3-active, .bp3-select.bp3-minimal .bp3-dark select.bp3-disabled.bp3-active, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-disabled:hover.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-disabled:hover.bp3-active,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-disabled:hover.bp3-active, .bp3-select.bp3-minimal .bp3-dark select.bp3-disabled:hover.bp3-active{
        background:rgba(138, 155, 168, 0.3); }
  .bp3-html-select.bp3-minimal select.bp3-intent-primary,
  .bp3-select.bp3-minimal select.bp3-intent-primary{
    color:#106ba3; }
    .bp3-html-select.bp3-minimal select.bp3-intent-primary:hover,
    .bp3-select.bp3-minimal select.bp3-intent-primary:hover, .bp3-html-select.bp3-minimal select.bp3-intent-primary:active,
    .bp3-select.bp3-minimal select.bp3-intent-primary:active, .bp3-html-select.bp3-minimal select.bp3-intent-primary.bp3-active,
    .bp3-select.bp3-minimal select.bp3-intent-primary.bp3-active{
      -webkit-box-shadow:none;
              box-shadow:none;
      background:none;
      color:#106ba3; }
    .bp3-html-select.bp3-minimal select.bp3-intent-primary:hover,
    .bp3-select.bp3-minimal select.bp3-intent-primary:hover{
      background:rgba(19, 124, 189, 0.15);
      color:#106ba3; }
    .bp3-html-select.bp3-minimal select.bp3-intent-primary:active,
    .bp3-select.bp3-minimal select.bp3-intent-primary:active, .bp3-html-select.bp3-minimal select.bp3-intent-primary.bp3-active,
    .bp3-select.bp3-minimal select.bp3-intent-primary.bp3-active{
      background:rgba(19, 124, 189, 0.3);
      color:#106ba3; }
    .bp3-html-select.bp3-minimal select.bp3-intent-primary:disabled,
    .bp3-select.bp3-minimal select.bp3-intent-primary:disabled, .bp3-html-select.bp3-minimal select.bp3-intent-primary.bp3-disabled,
    .bp3-select.bp3-minimal select.bp3-intent-primary.bp3-disabled{
      background:none;
      color:rgba(16, 107, 163, 0.5); }
      .bp3-html-select.bp3-minimal select.bp3-intent-primary:disabled.bp3-active,
      .bp3-select.bp3-minimal select.bp3-intent-primary:disabled.bp3-active, .bp3-html-select.bp3-minimal select.bp3-intent-primary.bp3-disabled.bp3-active,
      .bp3-select.bp3-minimal select.bp3-intent-primary.bp3-disabled.bp3-active{
        background:rgba(19, 124, 189, 0.3); }
    .bp3-html-select.bp3-minimal select.bp3-intent-primary .bp3-button-spinner .bp3-spinner-head, .bp3-select.bp3-minimal select.bp3-intent-primary .bp3-button-spinner .bp3-spinner-head{
      stroke:#106ba3; }
    .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-primary, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-primary,
    .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-primary, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-primary{
      color:#48aff0; }
      .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-primary:hover, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-primary:hover,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-primary:hover, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-primary:hover{
        background:rgba(19, 124, 189, 0.2);
        color:#48aff0; }
      .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-primary:active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-primary:active,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-primary:active, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-primary:active, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-primary.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-primary.bp3-active,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-primary.bp3-active, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-primary.bp3-active{
        background:rgba(19, 124, 189, 0.3);
        color:#48aff0; }
      .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-primary:disabled, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-primary:disabled,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-primary:disabled, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-primary:disabled, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-primary.bp3-disabled, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-primary.bp3-disabled,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-primary.bp3-disabled, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-primary.bp3-disabled{
        background:none;
        color:rgba(72, 175, 240, 0.5); }
        .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-primary:disabled.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-primary:disabled.bp3-active,
        .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-primary:disabled.bp3-active, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-primary:disabled.bp3-active, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-primary.bp3-disabled.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-primary.bp3-disabled.bp3-active,
        .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-primary.bp3-disabled.bp3-active, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-primary.bp3-disabled.bp3-active{
          background:rgba(19, 124, 189, 0.3); }
  .bp3-html-select.bp3-minimal select.bp3-intent-success,
  .bp3-select.bp3-minimal select.bp3-intent-success{
    color:#0d8050; }
    .bp3-html-select.bp3-minimal select.bp3-intent-success:hover,
    .bp3-select.bp3-minimal select.bp3-intent-success:hover, .bp3-html-select.bp3-minimal select.bp3-intent-success:active,
    .bp3-select.bp3-minimal select.bp3-intent-success:active, .bp3-html-select.bp3-minimal select.bp3-intent-success.bp3-active,
    .bp3-select.bp3-minimal select.bp3-intent-success.bp3-active{
      -webkit-box-shadow:none;
              box-shadow:none;
      background:none;
      color:#0d8050; }
    .bp3-html-select.bp3-minimal select.bp3-intent-success:hover,
    .bp3-select.bp3-minimal select.bp3-intent-success:hover{
      background:rgba(15, 153, 96, 0.15);
      color:#0d8050; }
    .bp3-html-select.bp3-minimal select.bp3-intent-success:active,
    .bp3-select.bp3-minimal select.bp3-intent-success:active, .bp3-html-select.bp3-minimal select.bp3-intent-success.bp3-active,
    .bp3-select.bp3-minimal select.bp3-intent-success.bp3-active{
      background:rgba(15, 153, 96, 0.3);
      color:#0d8050; }
    .bp3-html-select.bp3-minimal select.bp3-intent-success:disabled,
    .bp3-select.bp3-minimal select.bp3-intent-success:disabled, .bp3-html-select.bp3-minimal select.bp3-intent-success.bp3-disabled,
    .bp3-select.bp3-minimal select.bp3-intent-success.bp3-disabled{
      background:none;
      color:rgba(13, 128, 80, 0.5); }
      .bp3-html-select.bp3-minimal select.bp3-intent-success:disabled.bp3-active,
      .bp3-select.bp3-minimal select.bp3-intent-success:disabled.bp3-active, .bp3-html-select.bp3-minimal select.bp3-intent-success.bp3-disabled.bp3-active,
      .bp3-select.bp3-minimal select.bp3-intent-success.bp3-disabled.bp3-active{
        background:rgba(15, 153, 96, 0.3); }
    .bp3-html-select.bp3-minimal select.bp3-intent-success .bp3-button-spinner .bp3-spinner-head, .bp3-select.bp3-minimal select.bp3-intent-success .bp3-button-spinner .bp3-spinner-head{
      stroke:#0d8050; }
    .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-success, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-success,
    .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-success, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-success{
      color:#3dcc91; }
      .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-success:hover, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-success:hover,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-success:hover, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-success:hover{
        background:rgba(15, 153, 96, 0.2);
        color:#3dcc91; }
      .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-success:active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-success:active,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-success:active, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-success:active, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-success.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-success.bp3-active,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-success.bp3-active, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-success.bp3-active{
        background:rgba(15, 153, 96, 0.3);
        color:#3dcc91; }
      .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-success:disabled, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-success:disabled,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-success:disabled, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-success:disabled, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-success.bp3-disabled, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-success.bp3-disabled,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-success.bp3-disabled, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-success.bp3-disabled{
        background:none;
        color:rgba(61, 204, 145, 0.5); }
        .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-success:disabled.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-success:disabled.bp3-active,
        .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-success:disabled.bp3-active, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-success:disabled.bp3-active, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-success.bp3-disabled.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-success.bp3-disabled.bp3-active,
        .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-success.bp3-disabled.bp3-active, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-success.bp3-disabled.bp3-active{
          background:rgba(15, 153, 96, 0.3); }
  .bp3-html-select.bp3-minimal select.bp3-intent-warning,
  .bp3-select.bp3-minimal select.bp3-intent-warning{
    color:#bf7326; }
    .bp3-html-select.bp3-minimal select.bp3-intent-warning:hover,
    .bp3-select.bp3-minimal select.bp3-intent-warning:hover, .bp3-html-select.bp3-minimal select.bp3-intent-warning:active,
    .bp3-select.bp3-minimal select.bp3-intent-warning:active, .bp3-html-select.bp3-minimal select.bp3-intent-warning.bp3-active,
    .bp3-select.bp3-minimal select.bp3-intent-warning.bp3-active{
      -webkit-box-shadow:none;
              box-shadow:none;
      background:none;
      color:#bf7326; }
    .bp3-html-select.bp3-minimal select.bp3-intent-warning:hover,
    .bp3-select.bp3-minimal select.bp3-intent-warning:hover{
      background:rgba(217, 130, 43, 0.15);
      color:#bf7326; }
    .bp3-html-select.bp3-minimal select.bp3-intent-warning:active,
    .bp3-select.bp3-minimal select.bp3-intent-warning:active, .bp3-html-select.bp3-minimal select.bp3-intent-warning.bp3-active,
    .bp3-select.bp3-minimal select.bp3-intent-warning.bp3-active{
      background:rgba(217, 130, 43, 0.3);
      color:#bf7326; }
    .bp3-html-select.bp3-minimal select.bp3-intent-warning:disabled,
    .bp3-select.bp3-minimal select.bp3-intent-warning:disabled, .bp3-html-select.bp3-minimal select.bp3-intent-warning.bp3-disabled,
    .bp3-select.bp3-minimal select.bp3-intent-warning.bp3-disabled{
      background:none;
      color:rgba(191, 115, 38, 0.5); }
      .bp3-html-select.bp3-minimal select.bp3-intent-warning:disabled.bp3-active,
      .bp3-select.bp3-minimal select.bp3-intent-warning:disabled.bp3-active, .bp3-html-select.bp3-minimal select.bp3-intent-warning.bp3-disabled.bp3-active,
      .bp3-select.bp3-minimal select.bp3-intent-warning.bp3-disabled.bp3-active{
        background:rgba(217, 130, 43, 0.3); }
    .bp3-html-select.bp3-minimal select.bp3-intent-warning .bp3-button-spinner .bp3-spinner-head, .bp3-select.bp3-minimal select.bp3-intent-warning .bp3-button-spinner .bp3-spinner-head{
      stroke:#bf7326; }
    .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-warning, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-warning,
    .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-warning, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-warning{
      color:#ffb366; }
      .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-warning:hover, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-warning:hover,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-warning:hover, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-warning:hover{
        background:rgba(217, 130, 43, 0.2);
        color:#ffb366; }
      .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-warning:active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-warning:active,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-warning:active, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-warning:active, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-warning.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-warning.bp3-active,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-warning.bp3-active, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-warning.bp3-active{
        background:rgba(217, 130, 43, 0.3);
        color:#ffb366; }
      .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-warning:disabled, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-warning:disabled,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-warning:disabled, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-warning:disabled, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-warning.bp3-disabled, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-warning.bp3-disabled,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-warning.bp3-disabled, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-warning.bp3-disabled{
        background:none;
        color:rgba(255, 179, 102, 0.5); }
        .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-warning:disabled.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-warning:disabled.bp3-active,
        .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-warning:disabled.bp3-active, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-warning:disabled.bp3-active, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-warning.bp3-disabled.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-warning.bp3-disabled.bp3-active,
        .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-warning.bp3-disabled.bp3-active, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-warning.bp3-disabled.bp3-active{
          background:rgba(217, 130, 43, 0.3); }
  .bp3-html-select.bp3-minimal select.bp3-intent-danger,
  .bp3-select.bp3-minimal select.bp3-intent-danger{
    color:#c23030; }
    .bp3-html-select.bp3-minimal select.bp3-intent-danger:hover,
    .bp3-select.bp3-minimal select.bp3-intent-danger:hover, .bp3-html-select.bp3-minimal select.bp3-intent-danger:active,
    .bp3-select.bp3-minimal select.bp3-intent-danger:active, .bp3-html-select.bp3-minimal select.bp3-intent-danger.bp3-active,
    .bp3-select.bp3-minimal select.bp3-intent-danger.bp3-active{
      -webkit-box-shadow:none;
              box-shadow:none;
      background:none;
      color:#c23030; }
    .bp3-html-select.bp3-minimal select.bp3-intent-danger:hover,
    .bp3-select.bp3-minimal select.bp3-intent-danger:hover{
      background:rgba(219, 55, 55, 0.15);
      color:#c23030; }
    .bp3-html-select.bp3-minimal select.bp3-intent-danger:active,
    .bp3-select.bp3-minimal select.bp3-intent-danger:active, .bp3-html-select.bp3-minimal select.bp3-intent-danger.bp3-active,
    .bp3-select.bp3-minimal select.bp3-intent-danger.bp3-active{
      background:rgba(219, 55, 55, 0.3);
      color:#c23030; }
    .bp3-html-select.bp3-minimal select.bp3-intent-danger:disabled,
    .bp3-select.bp3-minimal select.bp3-intent-danger:disabled, .bp3-html-select.bp3-minimal select.bp3-intent-danger.bp3-disabled,
    .bp3-select.bp3-minimal select.bp3-intent-danger.bp3-disabled{
      background:none;
      color:rgba(194, 48, 48, 0.5); }
      .bp3-html-select.bp3-minimal select.bp3-intent-danger:disabled.bp3-active,
      .bp3-select.bp3-minimal select.bp3-intent-danger:disabled.bp3-active, .bp3-html-select.bp3-minimal select.bp3-intent-danger.bp3-disabled.bp3-active,
      .bp3-select.bp3-minimal select.bp3-intent-danger.bp3-disabled.bp3-active{
        background:rgba(219, 55, 55, 0.3); }
    .bp3-html-select.bp3-minimal select.bp3-intent-danger .bp3-button-spinner .bp3-spinner-head, .bp3-select.bp3-minimal select.bp3-intent-danger .bp3-button-spinner .bp3-spinner-head{
      stroke:#c23030; }
    .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-danger, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-danger,
    .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-danger, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-danger{
      color:#ff7373; }
      .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-danger:hover, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-danger:hover,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-danger:hover, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-danger:hover{
        background:rgba(219, 55, 55, 0.2);
        color:#ff7373; }
      .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-danger:active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-danger:active,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-danger:active, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-danger:active, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-danger.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-danger.bp3-active,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-danger.bp3-active, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-danger.bp3-active{
        background:rgba(219, 55, 55, 0.3);
        color:#ff7373; }
      .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-danger:disabled, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-danger:disabled,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-danger:disabled, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-danger:disabled, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-danger.bp3-disabled, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-danger.bp3-disabled,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-danger.bp3-disabled, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-danger.bp3-disabled{
        background:none;
        color:rgba(255, 115, 115, 0.5); }
        .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-danger:disabled.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-danger:disabled.bp3-active,
        .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-danger:disabled.bp3-active, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-danger:disabled.bp3-active, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-danger.bp3-disabled.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-danger.bp3-disabled.bp3-active,
        .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-danger.bp3-disabled.bp3-active, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-danger.bp3-disabled.bp3-active{
          background:rgba(219, 55, 55, 0.3); }

.bp3-html-select.bp3-large select,
.bp3-select.bp3-large select{
  height:40px;
  padding-right:35px;
  font-size:16px; }

.bp3-dark .bp3-html-select select, .bp3-dark .bp3-select select{
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
  background-color:#394b59;
  background-image:-webkit-gradient(linear, left top, left bottom, from(rgba(255, 255, 255, 0.05)), to(rgba(255, 255, 255, 0)));
  background-image:linear-gradient(to bottom, rgba(255, 255, 255, 0.05), rgba(255, 255, 255, 0));
  color:#f5f8fa; }
  .bp3-dark .bp3-html-select select:hover, .bp3-dark .bp3-select select:hover, .bp3-dark .bp3-html-select select:active, .bp3-dark .bp3-select select:active, .bp3-dark .bp3-html-select select.bp3-active, .bp3-dark .bp3-select select.bp3-active{
    color:#f5f8fa; }
  .bp3-dark .bp3-html-select select:hover, .bp3-dark .bp3-select select:hover{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
    background-color:#30404d; }
  .bp3-dark .bp3-html-select select:active, .bp3-dark .bp3-select select:active, .bp3-dark .bp3-html-select select.bp3-active, .bp3-dark .bp3-select select.bp3-active{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.6), inset 0 1px 2px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.6), inset 0 1px 2px rgba(16, 22, 26, 0.2);
    background-color:#202b33;
    background-image:none; }
  .bp3-dark .bp3-html-select select:disabled, .bp3-dark .bp3-select select:disabled, .bp3-dark .bp3-html-select select.bp3-disabled, .bp3-dark .bp3-select select.bp3-disabled{
    -webkit-box-shadow:none;
            box-shadow:none;
    background-color:rgba(57, 75, 89, 0.5);
    background-image:none;
    color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-html-select select:disabled.bp3-active, .bp3-dark .bp3-select select:disabled.bp3-active, .bp3-dark .bp3-html-select select.bp3-disabled.bp3-active, .bp3-dark .bp3-select select.bp3-disabled.bp3-active{
      background:rgba(57, 75, 89, 0.7); }
  .bp3-dark .bp3-html-select select .bp3-button-spinner .bp3-spinner-head, .bp3-dark .bp3-select select .bp3-button-spinner .bp3-spinner-head{
    background:rgba(16, 22, 26, 0.5);
    stroke:#8a9ba8; }

.bp3-html-select select:disabled,
.bp3-select select:disabled{
  -webkit-box-shadow:none;
          box-shadow:none;
  background-color:rgba(206, 217, 224, 0.5);
  cursor:not-allowed;
  color:rgba(92, 112, 128, 0.6); }

.bp3-html-select .bp3-icon,
.bp3-select .bp3-icon, .bp3-select::after{
  position:absolute;
  top:7px;
  right:7px;
  color:#5c7080;
  pointer-events:none; }
  .bp3-html-select .bp3-disabled.bp3-icon,
  .bp3-select .bp3-disabled.bp3-icon, .bp3-disabled.bp3-select::after{
    color:rgba(92, 112, 128, 0.6); }
.bp3-html-select,
.bp3-select{
  display:inline-block;
  position:relative;
  vertical-align:middle;
  letter-spacing:normal; }
  .bp3-html-select select::-ms-expand,
  .bp3-select select::-ms-expand{
    display:none; }
  .bp3-html-select .bp3-icon,
  .bp3-select .bp3-icon{
    color:#5c7080; }
    .bp3-html-select .bp3-icon:hover,
    .bp3-select .bp3-icon:hover{
      color:#182026; }
    .bp3-dark .bp3-html-select .bp3-icon, .bp3-dark
    .bp3-select .bp3-icon{
      color:#a7b6c2; }
      .bp3-dark .bp3-html-select .bp3-icon:hover, .bp3-dark
      .bp3-select .bp3-icon:hover{
        color:#f5f8fa; }
  .bp3-html-select.bp3-large::after,
  .bp3-html-select.bp3-large .bp3-icon,
  .bp3-select.bp3-large::after,
  .bp3-select.bp3-large .bp3-icon{
    top:12px;
    right:12px; }
  .bp3-html-select.bp3-fill,
  .bp3-html-select.bp3-fill select,
  .bp3-select.bp3-fill,
  .bp3-select.bp3-fill select{
    width:100%; }
  .bp3-dark .bp3-html-select option, .bp3-dark
  .bp3-select option{
    background-color:#30404d;
    color:#f5f8fa; }
  .bp3-dark .bp3-html-select::after, .bp3-dark
  .bp3-select::after{
    color:#a7b6c2; }

.bp3-select::after{
  line-height:1;
  font-family:"Icons16", sans-serif;
  font-size:16px;
  font-weight:400;
  font-style:normal;
  -moz-osx-font-smoothing:grayscale;
  -webkit-font-smoothing:antialiased;
  content:""; }
.bp3-running-text table, table.bp3-html-table{
  border-spacing:0;
  font-size:14px; }
  .bp3-running-text table th, table.bp3-html-table th,
  .bp3-running-text table td,
  table.bp3-html-table td{
    padding:11px;
    vertical-align:top;
    text-align:left; }
  .bp3-running-text table th, table.bp3-html-table th{
    color:#182026;
    font-weight:600; }
  
  .bp3-running-text table td,
  table.bp3-html-table td{
    color:#182026; }
  .bp3-running-text table tbody tr:first-child th, table.bp3-html-table tbody tr:first-child th,
  .bp3-running-text table tbody tr:first-child td,
  table.bp3-html-table tbody tr:first-child td{
    -webkit-box-shadow:inset 0 1px 0 0 rgba(16, 22, 26, 0.15);
            box-shadow:inset 0 1px 0 0 rgba(16, 22, 26, 0.15); }
  .bp3-dark .bp3-running-text table th, .bp3-running-text .bp3-dark table th, .bp3-dark table.bp3-html-table th{
    color:#f5f8fa; }
  .bp3-dark .bp3-running-text table td, .bp3-running-text .bp3-dark table td, .bp3-dark table.bp3-html-table td{
    color:#f5f8fa; }
  .bp3-dark .bp3-running-text table tbody tr:first-child th, .bp3-running-text .bp3-dark table tbody tr:first-child th, .bp3-dark table.bp3-html-table tbody tr:first-child th,
  .bp3-dark .bp3-running-text table tbody tr:first-child td,
  .bp3-running-text .bp3-dark table tbody tr:first-child td,
  .bp3-dark table.bp3-html-table tbody tr:first-child td{
    -webkit-box-shadow:inset 0 1px 0 0 rgba(255, 255, 255, 0.15);
            box-shadow:inset 0 1px 0 0 rgba(255, 255, 255, 0.15); }

table.bp3-html-table.bp3-html-table-condensed th,
table.bp3-html-table.bp3-html-table-condensed td, table.bp3-html-table.bp3-small th,
table.bp3-html-table.bp3-small td{
  padding-top:6px;
  padding-bottom:6px; }

table.bp3-html-table.bp3-html-table-striped tbody tr:nth-child(odd) td{
  background:rgba(191, 204, 214, 0.15); }

table.bp3-html-table.bp3-html-table-bordered th:not(:first-child){
  -webkit-box-shadow:inset 1px 0 0 0 rgba(16, 22, 26, 0.15);
          box-shadow:inset 1px 0 0 0 rgba(16, 22, 26, 0.15); }

table.bp3-html-table.bp3-html-table-bordered tbody tr td{
  -webkit-box-shadow:inset 0 1px 0 0 rgba(16, 22, 26, 0.15);
          box-shadow:inset 0 1px 0 0 rgba(16, 22, 26, 0.15); }
  table.bp3-html-table.bp3-html-table-bordered tbody tr td:not(:first-child){
    -webkit-box-shadow:inset 1px 1px 0 0 rgba(16, 22, 26, 0.15);
            box-shadow:inset 1px 1px 0 0 rgba(16, 22, 26, 0.15); }

table.bp3-html-table.bp3-html-table-bordered.bp3-html-table-striped tbody tr:not(:first-child) td{
  -webkit-box-shadow:none;
          box-shadow:none; }
  table.bp3-html-table.bp3-html-table-bordered.bp3-html-table-striped tbody tr:not(:first-child) td:not(:first-child){
    -webkit-box-shadow:inset 1px 0 0 0 rgba(16, 22, 26, 0.15);
            box-shadow:inset 1px 0 0 0 rgba(16, 22, 26, 0.15); }

table.bp3-html-table.bp3-interactive tbody tr:hover td{
  background-color:rgba(191, 204, 214, 0.3);
  cursor:pointer; }

table.bp3-html-table.bp3-interactive tbody tr:active td{
  background-color:rgba(191, 204, 214, 0.4); }

.bp3-dark table.bp3-html-table.bp3-html-table-striped tbody tr:nth-child(odd) td{
  background:rgba(92, 112, 128, 0.15); }

.bp3-dark table.bp3-html-table.bp3-html-table-bordered th:not(:first-child){
  -webkit-box-shadow:inset 1px 0 0 0 rgba(255, 255, 255, 0.15);
          box-shadow:inset 1px 0 0 0 rgba(255, 255, 255, 0.15); }

.bp3-dark table.bp3-html-table.bp3-html-table-bordered tbody tr td{
  -webkit-box-shadow:inset 0 1px 0 0 rgba(255, 255, 255, 0.15);
          box-shadow:inset 0 1px 0 0 rgba(255, 255, 255, 0.15); }
  .bp3-dark table.bp3-html-table.bp3-html-table-bordered tbody tr td:not(:first-child){
    -webkit-box-shadow:inset 1px 1px 0 0 rgba(255, 255, 255, 0.15);
            box-shadow:inset 1px 1px 0 0 rgba(255, 255, 255, 0.15); }

.bp3-dark table.bp3-html-table.bp3-html-table-bordered.bp3-html-table-striped tbody tr:not(:first-child) td{
  -webkit-box-shadow:inset 1px 0 0 0 rgba(255, 255, 255, 0.15);
          box-shadow:inset 1px 0 0 0 rgba(255, 255, 255, 0.15); }
  .bp3-dark table.bp3-html-table.bp3-html-table-bordered.bp3-html-table-striped tbody tr:not(:first-child) td:first-child{
    -webkit-box-shadow:none;
            box-shadow:none; }

.bp3-dark table.bp3-html-table.bp3-interactive tbody tr:hover td{
  background-color:rgba(92, 112, 128, 0.3);
  cursor:pointer; }

.bp3-dark table.bp3-html-table.bp3-interactive tbody tr:active td{
  background-color:rgba(92, 112, 128, 0.4); }

.bp3-key-combo{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-orient:horizontal;
  -webkit-box-direction:normal;
      -ms-flex-direction:row;
          flex-direction:row;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center; }
  .bp3-key-combo > *{
    -webkit-box-flex:0;
        -ms-flex-positive:0;
            flex-grow:0;
    -ms-flex-negative:0;
        flex-shrink:0; }
  .bp3-key-combo > .bp3-fill{
    -webkit-box-flex:1;
        -ms-flex-positive:1;
            flex-grow:1;
    -ms-flex-negative:1;
        flex-shrink:1; }
  .bp3-key-combo::before,
  .bp3-key-combo > *{
    margin-right:5px; }
  .bp3-key-combo:empty::before,
  .bp3-key-combo > :last-child{
    margin-right:0; }

.bp3-hotkey-dialog{
  top:40px;
  padding-bottom:0; }
  .bp3-hotkey-dialog .bp3-dialog-body{
    margin:0;
    padding:0; }
  .bp3-hotkey-dialog .bp3-hotkey-label{
    -webkit-box-flex:1;
        -ms-flex-positive:1;
            flex-grow:1; }

.bp3-hotkey-column{
  margin:auto;
  max-height:80vh;
  overflow-y:auto;
  padding:30px; }
  .bp3-hotkey-column .bp3-heading{
    margin-bottom:20px; }
    .bp3-hotkey-column .bp3-heading:not(:first-child){
      margin-top:40px; }

.bp3-hotkey{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center;
  -webkit-box-pack:justify;
      -ms-flex-pack:justify;
          justify-content:space-between;
  margin-right:0;
  margin-left:0; }
  .bp3-hotkey:not(:last-child){
    margin-bottom:10px; }
.bp3-icon{
  display:inline-block;
  -webkit-box-flex:0;
      -ms-flex:0 0 auto;
          flex:0 0 auto;
  vertical-align:text-bottom; }
  .bp3-icon:not(:empty)::before{
    content:"" !important;
    content:unset !important; }
  .bp3-icon > svg{
    display:block; }
    .bp3-icon > svg:not([fill]){
      fill:currentColor; }

.bp3-icon.bp3-intent-primary, .bp3-icon-standard.bp3-intent-primary, .bp3-icon-large.bp3-intent-primary{
  color:#106ba3; }
  .bp3-dark .bp3-icon.bp3-intent-primary, .bp3-dark .bp3-icon-standard.bp3-intent-primary, .bp3-dark .bp3-icon-large.bp3-intent-primary{
    color:#48aff0; }

.bp3-icon.bp3-intent-success, .bp3-icon-standard.bp3-intent-success, .bp3-icon-large.bp3-intent-success{
  color:#0d8050; }
  .bp3-dark .bp3-icon.bp3-intent-success, .bp3-dark .bp3-icon-standard.bp3-intent-success, .bp3-dark .bp3-icon-large.bp3-intent-success{
    color:#3dcc91; }

.bp3-icon.bp3-intent-warning, .bp3-icon-standard.bp3-intent-warning, .bp3-icon-large.bp3-intent-warning{
  color:#bf7326; }
  .bp3-dark .bp3-icon.bp3-intent-warning, .bp3-dark .bp3-icon-standard.bp3-intent-warning, .bp3-dark .bp3-icon-large.bp3-intent-warning{
    color:#ffb366; }

.bp3-icon.bp3-intent-danger, .bp3-icon-standard.bp3-intent-danger, .bp3-icon-large.bp3-intent-danger{
  color:#c23030; }
  .bp3-dark .bp3-icon.bp3-intent-danger, .bp3-dark .bp3-icon-standard.bp3-intent-danger, .bp3-dark .bp3-icon-large.bp3-intent-danger{
    color:#ff7373; }

span.bp3-icon-standard{
  line-height:1;
  font-family:"Icons16", sans-serif;
  font-size:16px;
  font-weight:400;
  font-style:normal;
  -moz-osx-font-smoothing:grayscale;
  -webkit-font-smoothing:antialiased;
  display:inline-block; }

span.bp3-icon-large{
  line-height:1;
  font-family:"Icons20", sans-serif;
  font-size:20px;
  font-weight:400;
  font-style:normal;
  -moz-osx-font-smoothing:grayscale;
  -webkit-font-smoothing:antialiased;
  display:inline-block; }

span.bp3-icon:empty{
  line-height:1;
  font-family:"Icons20";
  font-size:inherit;
  font-weight:400;
  font-style:normal; }
  span.bp3-icon:empty::before{
    -moz-osx-font-smoothing:grayscale;
    -webkit-font-smoothing:antialiased; }

.bp3-icon-add::before{
  content:""; }

.bp3-icon-add-column-left::before{
  content:""; }

.bp3-icon-add-column-right::before{
  content:""; }

.bp3-icon-add-row-bottom::before{
  content:""; }

.bp3-icon-add-row-top::before{
  content:""; }

.bp3-icon-add-to-artifact::before{
  content:""; }

.bp3-icon-add-to-folder::before{
  content:""; }

.bp3-icon-airplane::before{
  content:""; }

.bp3-icon-align-center::before{
  content:""; }

.bp3-icon-align-justify::before{
  content:""; }

.bp3-icon-align-left::before{
  content:""; }

.bp3-icon-align-right::before{
  content:""; }

.bp3-icon-alignment-bottom::before{
  content:""; }

.bp3-icon-alignment-horizontal-center::before{
  content:""; }

.bp3-icon-alignment-left::before{
  content:""; }

.bp3-icon-alignment-right::before{
  content:""; }

.bp3-icon-alignment-top::before{
  content:""; }

.bp3-icon-alignment-vertical-center::before{
  content:""; }

.bp3-icon-annotation::before{
  content:""; }

.bp3-icon-application::before{
  content:""; }

.bp3-icon-applications::before{
  content:""; }

.bp3-icon-archive::before{
  content:""; }

.bp3-icon-arrow-bottom-left::before{
  content:""; }

.bp3-icon-arrow-bottom-right::before{
  content:""; }

.bp3-icon-arrow-down::before{
  content:""; }

.bp3-icon-arrow-left::before{
  content:""; }

.bp3-icon-arrow-right::before{
  content:""; }

.bp3-icon-arrow-top-left::before{
  content:""; }

.bp3-icon-arrow-top-right::before{
  content:""; }

.bp3-icon-arrow-up::before{
  content:""; }

.bp3-icon-arrows-horizontal::before{
  content:""; }

.bp3-icon-arrows-vertical::before{
  content:""; }

.bp3-icon-asterisk::before{
  content:"*"; }

.bp3-icon-automatic-updates::before{
  content:""; }

.bp3-icon-badge::before{
  content:""; }

.bp3-icon-ban-circle::before{
  content:""; }

.bp3-icon-bank-account::before{
  content:""; }

.bp3-icon-barcode::before{
  content:""; }

.bp3-icon-blank::before{
  content:""; }

.bp3-icon-blocked-person::before{
  content:""; }

.bp3-icon-bold::before{
  content:""; }

.bp3-icon-book::before{
  content:""; }

.bp3-icon-bookmark::before{
  content:""; }

.bp3-icon-box::before{
  content:""; }

.bp3-icon-briefcase::before{
  content:""; }

.bp3-icon-bring-data::before{
  content:""; }

.bp3-icon-build::before{
  content:""; }

.bp3-icon-calculator::before{
  content:""; }

.bp3-icon-calendar::before{
  content:""; }

.bp3-icon-camera::before{
  content:""; }

.bp3-icon-caret-down::before{
  content:""; }

.bp3-icon-caret-left::before{
  content:""; }

.bp3-icon-caret-right::before{
  content:""; }

.bp3-icon-caret-up::before{
  content:""; }

.bp3-icon-cell-tower::before{
  content:""; }

.bp3-icon-changes::before{
  content:""; }

.bp3-icon-chart::before{
  content:""; }

.bp3-icon-chat::before{
  content:""; }

.bp3-icon-chevron-backward::before{
  content:""; }

.bp3-icon-chevron-down::before{
  content:""; }

.bp3-icon-chevron-forward::before{
  content:""; }

.bp3-icon-chevron-left::before{
  content:""; }

.bp3-icon-chevron-right::before{
  content:""; }

.bp3-icon-chevron-up::before{
  content:""; }

.bp3-icon-circle::before{
  content:""; }

.bp3-icon-circle-arrow-down::before{
  content:""; }

.bp3-icon-circle-arrow-left::before{
  content:""; }

.bp3-icon-circle-arrow-right::before{
  content:""; }

.bp3-icon-circle-arrow-up::before{
  content:""; }

.bp3-icon-citation::before{
  content:""; }

.bp3-icon-clean::before{
  content:""; }

.bp3-icon-clipboard::before{
  content:""; }

.bp3-icon-cloud::before{
  content:""; }

.bp3-icon-cloud-download::before{
  content:""; }

.bp3-icon-cloud-upload::before{
  content:""; }

.bp3-icon-code::before{
  content:""; }

.bp3-icon-code-block::before{
  content:""; }

.bp3-icon-cog::before{
  content:""; }

.bp3-icon-collapse-all::before{
  content:""; }

.bp3-icon-column-layout::before{
  content:""; }

.bp3-icon-comment::before{
  content:""; }

.bp3-icon-comparison::before{
  content:""; }

.bp3-icon-compass::before{
  content:""; }

.bp3-icon-compressed::before{
  content:""; }

.bp3-icon-confirm::before{
  content:""; }

.bp3-icon-console::before{
  content:""; }

.bp3-icon-contrast::before{
  content:""; }

.bp3-icon-control::before{
  content:""; }

.bp3-icon-credit-card::before{
  content:""; }

.bp3-icon-cross::before{
  content:""; }

.bp3-icon-crown::before{
  content:""; }

.bp3-icon-cube::before{
  content:""; }

.bp3-icon-cube-add::before{
  content:""; }

.bp3-icon-cube-remove::before{
  content:""; }

.bp3-icon-curved-range-chart::before{
  content:""; }

.bp3-icon-cut::before{
  content:""; }

.bp3-icon-dashboard::before{
  content:""; }

.bp3-icon-data-lineage::before{
  content:""; }

.bp3-icon-database::before{
  content:""; }

.bp3-icon-delete::before{
  content:""; }

.bp3-icon-delta::before{
  content:""; }

.bp3-icon-derive-column::before{
  content:""; }

.bp3-icon-desktop::before{
  content:""; }

.bp3-icon-diagram-tree::before{
  content:""; }

.bp3-icon-direction-left::before{
  content:""; }

.bp3-icon-direction-right::before{
  content:""; }

.bp3-icon-disable::before{
  content:""; }

.bp3-icon-document::before{
  content:""; }

.bp3-icon-document-open::before{
  content:""; }

.bp3-icon-document-share::before{
  content:""; }

.bp3-icon-dollar::before{
  content:"$"; }

.bp3-icon-dot::before{
  content:""; }

.bp3-icon-double-caret-horizontal::before{
  content:""; }

.bp3-icon-double-caret-vertical::before{
  content:""; }

.bp3-icon-double-chevron-down::before{
  content:""; }

.bp3-icon-double-chevron-left::before{
  content:""; }

.bp3-icon-double-chevron-right::before{
  content:""; }

.bp3-icon-double-chevron-up::before{
  content:""; }

.bp3-icon-doughnut-chart::before{
  content:""; }

.bp3-icon-download::before{
  content:""; }

.bp3-icon-drag-handle-horizontal::before{
  content:""; }

.bp3-icon-drag-handle-vertical::before{
  content:""; }

.bp3-icon-draw::before{
  content:""; }

.bp3-icon-drive-time::before{
  content:""; }

.bp3-icon-duplicate::before{
  content:""; }

.bp3-icon-edit::before{
  content:""; }

.bp3-icon-eject::before{
  content:""; }

.bp3-icon-endorsed::before{
  content:""; }

.bp3-icon-envelope::before{
  content:""; }

.bp3-icon-equals::before{
  content:""; }

.bp3-icon-eraser::before{
  content:""; }

.bp3-icon-error::before{
  content:""; }

.bp3-icon-euro::before{
  content:""; }

.bp3-icon-exchange::before{
  content:""; }

.bp3-icon-exclude-row::before{
  content:""; }

.bp3-icon-expand-all::before{
  content:""; }

.bp3-icon-export::before{
  content:""; }

.bp3-icon-eye-off::before{
  content:""; }

.bp3-icon-eye-on::before{
  content:""; }

.bp3-icon-eye-open::before{
  content:""; }

.bp3-icon-fast-backward::before{
  content:""; }

.bp3-icon-fast-forward::before{
  content:""; }

.bp3-icon-feed::before{
  content:""; }

.bp3-icon-feed-subscribed::before{
  content:""; }

.bp3-icon-film::before{
  content:""; }

.bp3-icon-filter::before{
  content:""; }

.bp3-icon-filter-keep::before{
  content:""; }

.bp3-icon-filter-list::before{
  content:""; }

.bp3-icon-filter-open::before{
  content:""; }

.bp3-icon-filter-remove::before{
  content:""; }

.bp3-icon-flag::before{
  content:""; }

.bp3-icon-flame::before{
  content:""; }

.bp3-icon-flash::before{
  content:""; }

.bp3-icon-floppy-disk::before{
  content:""; }

.bp3-icon-flow-branch::before{
  content:""; }

.bp3-icon-flow-end::before{
  content:""; }

.bp3-icon-flow-linear::before{
  content:""; }

.bp3-icon-flow-review::before{
  content:""; }

.bp3-icon-flow-review-branch::before{
  content:""; }

.bp3-icon-flows::before{
  content:""; }

.bp3-icon-folder-close::before{
  content:""; }

.bp3-icon-folder-new::before{
  content:""; }

.bp3-icon-folder-open::before{
  content:""; }

.bp3-icon-folder-shared::before{
  content:""; }

.bp3-icon-folder-shared-open::before{
  content:""; }

.bp3-icon-follower::before{
  content:""; }

.bp3-icon-following::before{
  content:""; }

.bp3-icon-font::before{
  content:""; }

.bp3-icon-fork::before{
  content:""; }

.bp3-icon-form::before{
  content:""; }

.bp3-icon-full-circle::before{
  content:""; }

.bp3-icon-full-stacked-chart::before{
  content:""; }

.bp3-icon-fullscreen::before{
  content:""; }

.bp3-icon-function::before{
  content:""; }

.bp3-icon-gantt-chart::before{
  content:""; }

.bp3-icon-geolocation::before{
  content:""; }

.bp3-icon-geosearch::before{
  content:""; }

.bp3-icon-git-branch::before{
  content:""; }

.bp3-icon-git-commit::before{
  content:""; }

.bp3-icon-git-merge::before{
  content:""; }

.bp3-icon-git-new-branch::before{
  content:""; }

.bp3-icon-git-pull::before{
  content:""; }

.bp3-icon-git-push::before{
  content:""; }

.bp3-icon-git-repo::before{
  content:""; }

.bp3-icon-glass::before{
  content:""; }

.bp3-icon-globe::before{
  content:""; }

.bp3-icon-globe-network::before{
  content:""; }

.bp3-icon-graph::before{
  content:""; }

.bp3-icon-graph-remove::before{
  content:""; }

.bp3-icon-greater-than::before{
  content:""; }

.bp3-icon-greater-than-or-equal-to::before{
  content:""; }

.bp3-icon-grid::before{
  content:""; }

.bp3-icon-grid-view::before{
  content:""; }

.bp3-icon-group-objects::before{
  content:""; }

.bp3-icon-grouped-bar-chart::before{
  content:""; }

.bp3-icon-hand::before{
  content:""; }

.bp3-icon-hand-down::before{
  content:""; }

.bp3-icon-hand-left::before{
  content:""; }

.bp3-icon-hand-right::before{
  content:""; }

.bp3-icon-hand-up::before{
  content:""; }

.bp3-icon-header::before{
  content:""; }

.bp3-icon-header-one::before{
  content:""; }

.bp3-icon-header-two::before{
  content:""; }

.bp3-icon-headset::before{
  content:""; }

.bp3-icon-heart::before{
  content:""; }

.bp3-icon-heart-broken::before{
  content:""; }

.bp3-icon-heat-grid::before{
  content:""; }

.bp3-icon-heatmap::before{
  content:""; }

.bp3-icon-help::before{
  content:"?"; }

.bp3-icon-helper-management::before{
  content:""; }

.bp3-icon-highlight::before{
  content:""; }

.bp3-icon-history::before{
  content:""; }

.bp3-icon-home::before{
  content:""; }

.bp3-icon-horizontal-bar-chart::before{
  content:""; }

.bp3-icon-horizontal-bar-chart-asc::before{
  content:""; }

.bp3-icon-horizontal-bar-chart-desc::before{
  content:""; }

.bp3-icon-horizontal-distribution::before{
  content:""; }

.bp3-icon-id-number::before{
  content:""; }

.bp3-icon-image-rotate-left::before{
  content:""; }

.bp3-icon-image-rotate-right::before{
  content:""; }

.bp3-icon-import::before{
  content:""; }

.bp3-icon-inbox::before{
  content:""; }

.bp3-icon-inbox-filtered::before{
  content:""; }

.bp3-icon-inbox-geo::before{
  content:""; }

.bp3-icon-inbox-search::before{
  content:""; }

.bp3-icon-inbox-update::before{
  content:""; }

.bp3-icon-info-sign::before{
  content:""; }

.bp3-icon-inheritance::before{
  content:""; }

.bp3-icon-inner-join::before{
  content:""; }

.bp3-icon-insert::before{
  content:""; }

.bp3-icon-intersection::before{
  content:""; }

.bp3-icon-ip-address::before{
  content:""; }

.bp3-icon-issue::before{
  content:""; }

.bp3-icon-issue-closed::before{
  content:""; }

.bp3-icon-issue-new::before{
  content:""; }

.bp3-icon-italic::before{
  content:""; }

.bp3-icon-join-table::before{
  content:""; }

.bp3-icon-key::before{
  content:""; }

.bp3-icon-key-backspace::before{
  content:""; }

.bp3-icon-key-command::before{
  content:""; }

.bp3-icon-key-control::before{
  content:""; }

.bp3-icon-key-delete::before{
  content:""; }

.bp3-icon-key-enter::before{
  content:""; }

.bp3-icon-key-escape::before{
  content:""; }

.bp3-icon-key-option::before{
  content:""; }

.bp3-icon-key-shift::before{
  content:""; }

.bp3-icon-key-tab::before{
  content:""; }

.bp3-icon-known-vehicle::before{
  content:""; }

.bp3-icon-label::before{
  content:""; }

.bp3-icon-layer::before{
  content:""; }

.bp3-icon-layers::before{
  content:""; }

.bp3-icon-layout::before{
  content:""; }

.bp3-icon-layout-auto::before{
  content:""; }

.bp3-icon-layout-balloon::before{
  content:""; }

.bp3-icon-layout-circle::before{
  content:""; }

.bp3-icon-layout-grid::before{
  content:""; }

.bp3-icon-layout-group-by::before{
  content:""; }

.bp3-icon-layout-hierarchy::before{
  content:""; }

.bp3-icon-layout-linear::before{
  content:""; }

.bp3-icon-layout-skew-grid::before{
  content:""; }

.bp3-icon-layout-sorted-clusters::before{
  content:""; }

.bp3-icon-learning::before{
  content:""; }

.bp3-icon-left-join::before{
  content:""; }

.bp3-icon-less-than::before{
  content:""; }

.bp3-icon-less-than-or-equal-to::before{
  content:""; }

.bp3-icon-lifesaver::before{
  content:""; }

.bp3-icon-lightbulb::before{
  content:""; }

.bp3-icon-link::before{
  content:""; }

.bp3-icon-list::before{
  content:""; }

.bp3-icon-list-columns::before{
  content:""; }

.bp3-icon-list-detail-view::before{
  content:""; }

.bp3-icon-locate::before{
  content:""; }

.bp3-icon-lock::before{
  content:""; }

.bp3-icon-log-in::before{
  content:""; }

.bp3-icon-log-out::before{
  content:""; }

.bp3-icon-manual::before{
  content:""; }

.bp3-icon-manually-entered-data::before{
  content:""; }

.bp3-icon-map::before{
  content:""; }

.bp3-icon-map-create::before{
  content:""; }

.bp3-icon-map-marker::before{
  content:""; }

.bp3-icon-maximize::before{
  content:""; }

.bp3-icon-media::before{
  content:""; }

.bp3-icon-menu::before{
  content:""; }

.bp3-icon-menu-closed::before{
  content:""; }

.bp3-icon-menu-open::before{
  content:""; }

.bp3-icon-merge-columns::before{
  content:""; }

.bp3-icon-merge-links::before{
  content:""; }

.bp3-icon-minimize::before{
  content:""; }

.bp3-icon-minus::before{
  content:""; }

.bp3-icon-mobile-phone::before{
  content:""; }

.bp3-icon-mobile-video::before{
  content:""; }

.bp3-icon-moon::before{
  content:""; }

.bp3-icon-more::before{
  content:""; }

.bp3-icon-mountain::before{
  content:""; }

.bp3-icon-move::before{
  content:""; }

.bp3-icon-mugshot::before{
  content:""; }

.bp3-icon-multi-select::before{
  content:""; }

.bp3-icon-music::before{
  content:""; }

.bp3-icon-new-drawing::before{
  content:""; }

.bp3-icon-new-grid-item::before{
  content:""; }

.bp3-icon-new-layer::before{
  content:""; }

.bp3-icon-new-layers::before{
  content:""; }

.bp3-icon-new-link::before{
  content:""; }

.bp3-icon-new-object::before{
  content:""; }

.bp3-icon-new-person::before{
  content:""; }

.bp3-icon-new-prescription::before{
  content:""; }

.bp3-icon-new-text-box::before{
  content:""; }

.bp3-icon-ninja::before{
  content:""; }

.bp3-icon-not-equal-to::before{
  content:""; }

.bp3-icon-notifications::before{
  content:""; }

.bp3-icon-notifications-updated::before{
  content:""; }

.bp3-icon-numbered-list::before{
  content:""; }

.bp3-icon-numerical::before{
  content:""; }

.bp3-icon-office::before{
  content:""; }

.bp3-icon-offline::before{
  content:""; }

.bp3-icon-oil-field::before{
  content:""; }

.bp3-icon-one-column::before{
  content:""; }

.bp3-icon-outdated::before{
  content:""; }

.bp3-icon-page-layout::before{
  content:""; }

.bp3-icon-panel-stats::before{
  content:""; }

.bp3-icon-panel-table::before{
  content:""; }

.bp3-icon-paperclip::before{
  content:""; }

.bp3-icon-paragraph::before{
  content:""; }

.bp3-icon-path::before{
  content:""; }

.bp3-icon-path-search::before{
  content:""; }

.bp3-icon-pause::before{
  content:""; }

.bp3-icon-people::before{
  content:""; }

.bp3-icon-percentage::before{
  content:""; }

.bp3-icon-person::before{
  content:""; }

.bp3-icon-phone::before{
  content:""; }

.bp3-icon-pie-chart::before{
  content:""; }

.bp3-icon-pin::before{
  content:""; }

.bp3-icon-pivot::before{
  content:""; }

.bp3-icon-pivot-table::before{
  content:""; }

.bp3-icon-play::before{
  content:""; }

.bp3-icon-plus::before{
  content:"+"; }

.bp3-icon-polygon-filter::before{
  content:""; }

.bp3-icon-power::before{
  content:""; }

.bp3-icon-predictive-analysis::before{
  content:""; }

.bp3-icon-prescription::before{
  content:""; }

.bp3-icon-presentation::before{
  content:""; }

.bp3-icon-print::before{
  content:""; }

.bp3-icon-projects::before{
  content:""; }

.bp3-icon-properties::before{
  content:""; }

.bp3-icon-property::before{
  content:""; }

.bp3-icon-publish-function::before{
  content:""; }

.bp3-icon-pulse::before{
  content:""; }

.bp3-icon-random::before{
  content:""; }

.bp3-icon-record::before{
  content:""; }

.bp3-icon-redo::before{
  content:""; }

.bp3-icon-refresh::before{
  content:""; }

.bp3-icon-regression-chart::before{
  content:""; }

.bp3-icon-remove::before{
  content:""; }

.bp3-icon-remove-column::before{
  content:""; }

.bp3-icon-remove-column-left::before{
  content:""; }

.bp3-icon-remove-column-right::before{
  content:""; }

.bp3-icon-remove-row-bottom::before{
  content:""; }

.bp3-icon-remove-row-top::before{
  content:""; }

.bp3-icon-repeat::before{
  content:""; }

.bp3-icon-reset::before{
  content:""; }

.bp3-icon-resolve::before{
  content:""; }

.bp3-icon-rig::before{
  content:""; }

.bp3-icon-right-join::before{
  content:""; }

.bp3-icon-ring::before{
  content:""; }

.bp3-icon-rotate-document::before{
  content:""; }

.bp3-icon-rotate-page::before{
  content:""; }

.bp3-icon-satellite::before{
  content:""; }

.bp3-icon-saved::before{
  content:""; }

.bp3-icon-scatter-plot::before{
  content:""; }

.bp3-icon-search::before{
  content:""; }

.bp3-icon-search-around::before{
  content:""; }

.bp3-icon-search-template::before{
  content:""; }

.bp3-icon-search-text::before{
  content:""; }

.bp3-icon-segmented-control::before{
  content:""; }

.bp3-icon-select::before{
  content:""; }

.bp3-icon-selection::before{
  content:""; }

.bp3-icon-send-to::before{
  content:""; }

.bp3-icon-send-to-graph::before{
  content:""; }

.bp3-icon-send-to-map::before{
  content:""; }

.bp3-icon-series-add::before{
  content:""; }

.bp3-icon-series-configuration::before{
  content:""; }

.bp3-icon-series-derived::before{
  content:""; }

.bp3-icon-series-filtered::before{
  content:""; }

.bp3-icon-series-search::before{
  content:""; }

.bp3-icon-settings::before{
  content:""; }

.bp3-icon-share::before{
  content:""; }

.bp3-icon-shield::before{
  content:""; }

.bp3-icon-shop::before{
  content:""; }

.bp3-icon-shopping-cart::before{
  content:""; }

.bp3-icon-signal-search::before{
  content:""; }

.bp3-icon-sim-card::before{
  content:""; }

.bp3-icon-slash::before{
  content:""; }

.bp3-icon-small-cross::before{
  content:""; }

.bp3-icon-small-minus::before{
  content:""; }

.bp3-icon-small-plus::before{
  content:""; }

.bp3-icon-small-tick::before{
  content:""; }

.bp3-icon-snowflake::before{
  content:""; }

.bp3-icon-social-media::before{
  content:""; }

.bp3-icon-sort::before{
  content:""; }

.bp3-icon-sort-alphabetical::before{
  content:""; }

.bp3-icon-sort-alphabetical-desc::before{
  content:""; }

.bp3-icon-sort-asc::before{
  content:""; }

.bp3-icon-sort-desc::before{
  content:""; }

.bp3-icon-sort-numerical::before{
  content:""; }

.bp3-icon-sort-numerical-desc::before{
  content:""; }

.bp3-icon-split-columns::before{
  content:""; }

.bp3-icon-square::before{
  content:""; }

.bp3-icon-stacked-chart::before{
  content:""; }

.bp3-icon-star::before{
  content:""; }

.bp3-icon-star-empty::before{
  content:""; }

.bp3-icon-step-backward::before{
  content:""; }

.bp3-icon-step-chart::before{
  content:""; }

.bp3-icon-step-forward::before{
  content:""; }

.bp3-icon-stop::before{
  content:""; }

.bp3-icon-stopwatch::before{
  content:""; }

.bp3-icon-strikethrough::before{
  content:""; }

.bp3-icon-style::before{
  content:""; }

.bp3-icon-swap-horizontal::before{
  content:""; }

.bp3-icon-swap-vertical::before{
  content:""; }

.bp3-icon-symbol-circle::before{
  content:""; }

.bp3-icon-symbol-cross::before{
  content:""; }

.bp3-icon-symbol-diamond::before{
  content:""; }

.bp3-icon-symbol-square::before{
  content:""; }

.bp3-icon-symbol-triangle-down::before{
  content:""; }

.bp3-icon-symbol-triangle-up::before{
  content:""; }

.bp3-icon-tag::before{
  content:""; }

.bp3-icon-take-action::before{
  content:""; }

.bp3-icon-taxi::before{
  content:""; }

.bp3-icon-text-highlight::before{
  content:""; }

.bp3-icon-th::before{
  content:""; }

.bp3-icon-th-derived::before{
  content:""; }

.bp3-icon-th-disconnect::before{
  content:""; }

.bp3-icon-th-filtered::before{
  content:""; }

.bp3-icon-th-list::before{
  content:""; }

.bp3-icon-thumbs-down::before{
  content:""; }

.bp3-icon-thumbs-up::before{
  content:""; }

.bp3-icon-tick::before{
  content:""; }

.bp3-icon-tick-circle::before{
  content:""; }

.bp3-icon-time::before{
  content:""; }

.bp3-icon-timeline-area-chart::before{
  content:""; }

.bp3-icon-timeline-bar-chart::before{
  content:""; }

.bp3-icon-timeline-events::before{
  content:""; }

.bp3-icon-timeline-line-chart::before{
  content:""; }

.bp3-icon-tint::before{
  content:""; }

.bp3-icon-torch::before{
  content:""; }

.bp3-icon-tractor::before{
  content:""; }

.bp3-icon-train::before{
  content:""; }

.bp3-icon-translate::before{
  content:""; }

.bp3-icon-trash::before{
  content:""; }

.bp3-icon-tree::before{
  content:""; }

.bp3-icon-trending-down::before{
  content:""; }

.bp3-icon-trending-up::before{
  content:""; }

.bp3-icon-truck::before{
  content:""; }

.bp3-icon-two-columns::before{
  content:""; }

.bp3-icon-unarchive::before{
  content:""; }

.bp3-icon-underline::before{
  content:""; }

.bp3-icon-undo::before{
  content:""; }

.bp3-icon-ungroup-objects::before{
  content:""; }

.bp3-icon-unknown-vehicle::before{
  content:""; }

.bp3-icon-unlock::before{
  content:""; }

.bp3-icon-unpin::before{
  content:""; }

.bp3-icon-unresolve::before{
  content:""; }

.bp3-icon-updated::before{
  content:""; }

.bp3-icon-upload::before{
  content:""; }

.bp3-icon-user::before{
  content:""; }

.bp3-icon-variable::before{
  content:""; }

.bp3-icon-vertical-bar-chart-asc::before{
  content:""; }

.bp3-icon-vertical-bar-chart-desc::before{
  content:""; }

.bp3-icon-vertical-distribution::before{
  content:""; }

.bp3-icon-video::before{
  content:""; }

.bp3-icon-volume-down::before{
  content:""; }

.bp3-icon-volume-off::before{
  content:""; }

.bp3-icon-volume-up::before{
  content:""; }

.bp3-icon-walk::before{
  content:""; }

.bp3-icon-warning-sign::before{
  content:""; }

.bp3-icon-waterfall-chart::before{
  content:""; }

.bp3-icon-widget::before{
  content:""; }

.bp3-icon-widget-button::before{
  content:""; }

.bp3-icon-widget-footer::before{
  content:""; }

.bp3-icon-widget-header::before{
  content:""; }

.bp3-icon-wrench::before{
  content:""; }

.bp3-icon-zoom-in::before{
  content:""; }

.bp3-icon-zoom-out::before{
  content:""; }

.bp3-icon-zoom-to-fit::before{
  content:""; }
.bp3-submenu > .bp3-popover-wrapper{
  display:block; }

.bp3-submenu .bp3-popover-target{
  display:block; }

.bp3-submenu.bp3-popover{
  -webkit-box-shadow:none;
          box-shadow:none;
  padding:0 5px; }
  .bp3-submenu.bp3-popover > .bp3-popover-content{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 2px 4px rgba(16, 22, 26, 0.2), 0 8px 24px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 2px 4px rgba(16, 22, 26, 0.2), 0 8px 24px rgba(16, 22, 26, 0.2); }
  .bp3-dark .bp3-submenu.bp3-popover, .bp3-submenu.bp3-popover.bp3-dark{
    -webkit-box-shadow:none;
            box-shadow:none; }
    .bp3-dark .bp3-submenu.bp3-popover > .bp3-popover-content, .bp3-submenu.bp3-popover.bp3-dark > .bp3-popover-content{
      -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 2px 4px rgba(16, 22, 26, 0.4), 0 8px 24px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 2px 4px rgba(16, 22, 26, 0.4), 0 8px 24px rgba(16, 22, 26, 0.4); }
.bp3-menu{
  margin:0;
  border-radius:3px;
  background:#ffffff;
  min-width:180px;
  padding:5px;
  list-style:none;
  text-align:left;
  color:#182026; }

.bp3-menu-divider{
  display:block;
  margin:5px;
  border-top:1px solid rgba(16, 22, 26, 0.15); }
  .bp3-dark .bp3-menu-divider{
    border-top-color:rgba(255, 255, 255, 0.15); }

.bp3-menu-item{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-orient:horizontal;
  -webkit-box-direction:normal;
      -ms-flex-direction:row;
          flex-direction:row;
  -webkit-box-align:start;
      -ms-flex-align:start;
          align-items:flex-start;
  border-radius:2px;
  padding:5px 7px;
  text-decoration:none;
  line-height:20px;
  color:inherit;
  -webkit-user-select:none;
     -moz-user-select:none;
      -ms-user-select:none;
          user-select:none; }
  .bp3-menu-item > *{
    -webkit-box-flex:0;
        -ms-flex-positive:0;
            flex-grow:0;
    -ms-flex-negative:0;
        flex-shrink:0; }
  .bp3-menu-item > .bp3-fill{
    -webkit-box-flex:1;
        -ms-flex-positive:1;
            flex-grow:1;
    -ms-flex-negative:1;
        flex-shrink:1; }
  .bp3-menu-item::before,
  .bp3-menu-item > *{
    margin-right:7px; }
  .bp3-menu-item:empty::before,
  .bp3-menu-item > :last-child{
    margin-right:0; }
  .bp3-menu-item > .bp3-fill{
    word-break:break-word; }
  .bp3-menu-item:hover, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-menu-item{
    background-color:rgba(167, 182, 194, 0.3);
    cursor:pointer;
    text-decoration:none; }
  .bp3-menu-item.bp3-disabled{
    background-color:inherit;
    cursor:not-allowed;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-dark .bp3-menu-item{
    color:inherit; }
    .bp3-dark .bp3-menu-item:hover, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-menu-item, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-menu-item{
      background-color:rgba(138, 155, 168, 0.15);
      color:inherit; }
    .bp3-dark .bp3-menu-item.bp3-disabled{
      background-color:inherit;
      color:rgba(167, 182, 194, 0.6); }
  .bp3-menu-item.bp3-intent-primary{
    color:#106ba3; }
    .bp3-menu-item.bp3-intent-primary .bp3-icon{
      color:inherit; }
    .bp3-menu-item.bp3-intent-primary::before, .bp3-menu-item.bp3-intent-primary::after,
    .bp3-menu-item.bp3-intent-primary .bp3-menu-item-label{
      color:#106ba3; }
    .bp3-menu-item.bp3-intent-primary:hover, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-primary.bp3-menu-item, .bp3-menu-item.bp3-intent-primary.bp3-active{
      background-color:#137cbd; }
    .bp3-menu-item.bp3-intent-primary:active{
      background-color:#106ba3; }
    .bp3-menu-item.bp3-intent-primary:hover, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-primary.bp3-menu-item, .bp3-menu-item.bp3-intent-primary:hover::before, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-primary.bp3-menu-item::before, .bp3-menu-item.bp3-intent-primary:hover::after, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-primary.bp3-menu-item::after,
    .bp3-menu-item.bp3-intent-primary:hover .bp3-menu-item-label,
    .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-primary.bp3-menu-item .bp3-menu-item-label, .bp3-menu-item.bp3-intent-primary:active, .bp3-menu-item.bp3-intent-primary:active::before, .bp3-menu-item.bp3-intent-primary:active::after,
    .bp3-menu-item.bp3-intent-primary:active .bp3-menu-item-label, .bp3-menu-item.bp3-intent-primary.bp3-active, .bp3-menu-item.bp3-intent-primary.bp3-active::before, .bp3-menu-item.bp3-intent-primary.bp3-active::after,
    .bp3-menu-item.bp3-intent-primary.bp3-active .bp3-menu-item-label{
      color:#ffffff; }
  .bp3-menu-item.bp3-intent-success{
    color:#0d8050; }
    .bp3-menu-item.bp3-intent-success .bp3-icon{
      color:inherit; }
    .bp3-menu-item.bp3-intent-success::before, .bp3-menu-item.bp3-intent-success::after,
    .bp3-menu-item.bp3-intent-success .bp3-menu-item-label{
      color:#0d8050; }
    .bp3-menu-item.bp3-intent-success:hover, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-success.bp3-menu-item, .bp3-menu-item.bp3-intent-success.bp3-active{
      background-color:#0f9960; }
    .bp3-menu-item.bp3-intent-success:active{
      background-color:#0d8050; }
    .bp3-menu-item.bp3-intent-success:hover, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-success.bp3-menu-item, .bp3-menu-item.bp3-intent-success:hover::before, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-success.bp3-menu-item::before, .bp3-menu-item.bp3-intent-success:hover::after, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-success.bp3-menu-item::after,
    .bp3-menu-item.bp3-intent-success:hover .bp3-menu-item-label,
    .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-success.bp3-menu-item .bp3-menu-item-label, .bp3-menu-item.bp3-intent-success:active, .bp3-menu-item.bp3-intent-success:active::before, .bp3-menu-item.bp3-intent-success:active::after,
    .bp3-menu-item.bp3-intent-success:active .bp3-menu-item-label, .bp3-menu-item.bp3-intent-success.bp3-active, .bp3-menu-item.bp3-intent-success.bp3-active::before, .bp3-menu-item.bp3-intent-success.bp3-active::after,
    .bp3-menu-item.bp3-intent-success.bp3-active .bp3-menu-item-label{
      color:#ffffff; }
  .bp3-menu-item.bp3-intent-warning{
    color:#bf7326; }
    .bp3-menu-item.bp3-intent-warning .bp3-icon{
      color:inherit; }
    .bp3-menu-item.bp3-intent-warning::before, .bp3-menu-item.bp3-intent-warning::after,
    .bp3-menu-item.bp3-intent-warning .bp3-menu-item-label{
      color:#bf7326; }
    .bp3-menu-item.bp3-intent-warning:hover, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-warning.bp3-menu-item, .bp3-menu-item.bp3-intent-warning.bp3-active{
      background-color:#d9822b; }
    .bp3-menu-item.bp3-intent-warning:active{
      background-color:#bf7326; }
    .bp3-menu-item.bp3-intent-warning:hover, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-warning.bp3-menu-item, .bp3-menu-item.bp3-intent-warning:hover::before, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-warning.bp3-menu-item::before, .bp3-menu-item.bp3-intent-warning:hover::after, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-warning.bp3-menu-item::after,
    .bp3-menu-item.bp3-intent-warning:hover .bp3-menu-item-label,
    .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-warning.bp3-menu-item .bp3-menu-item-label, .bp3-menu-item.bp3-intent-warning:active, .bp3-menu-item.bp3-intent-warning:active::before, .bp3-menu-item.bp3-intent-warning:active::after,
    .bp3-menu-item.bp3-intent-warning:active .bp3-menu-item-label, .bp3-menu-item.bp3-intent-warning.bp3-active, .bp3-menu-item.bp3-intent-warning.bp3-active::before, .bp3-menu-item.bp3-intent-warning.bp3-active::after,
    .bp3-menu-item.bp3-intent-warning.bp3-active .bp3-menu-item-label{
      color:#ffffff; }
  .bp3-menu-item.bp3-intent-danger{
    color:#c23030; }
    .bp3-menu-item.bp3-intent-danger .bp3-icon{
      color:inherit; }
    .bp3-menu-item.bp3-intent-danger::before, .bp3-menu-item.bp3-intent-danger::after,
    .bp3-menu-item.bp3-intent-danger .bp3-menu-item-label{
      color:#c23030; }
    .bp3-menu-item.bp3-intent-danger:hover, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-danger.bp3-menu-item, .bp3-menu-item.bp3-intent-danger.bp3-active{
      background-color:#db3737; }
    .bp3-menu-item.bp3-intent-danger:active{
      background-color:#c23030; }
    .bp3-menu-item.bp3-intent-danger:hover, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-danger.bp3-menu-item, .bp3-menu-item.bp3-intent-danger:hover::before, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-danger.bp3-menu-item::before, .bp3-menu-item.bp3-intent-danger:hover::after, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-danger.bp3-menu-item::after,
    .bp3-menu-item.bp3-intent-danger:hover .bp3-menu-item-label,
    .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-danger.bp3-menu-item .bp3-menu-item-label, .bp3-menu-item.bp3-intent-danger:active, .bp3-menu-item.bp3-intent-danger:active::before, .bp3-menu-item.bp3-intent-danger:active::after,
    .bp3-menu-item.bp3-intent-danger:active .bp3-menu-item-label, .bp3-menu-item.bp3-intent-danger.bp3-active, .bp3-menu-item.bp3-intent-danger.bp3-active::before, .bp3-menu-item.bp3-intent-danger.bp3-active::after,
    .bp3-menu-item.bp3-intent-danger.bp3-active .bp3-menu-item-label{
      color:#ffffff; }
  .bp3-menu-item::before{
    line-height:1;
    font-family:"Icons16", sans-serif;
    font-size:16px;
    font-weight:400;
    font-style:normal;
    -moz-osx-font-smoothing:grayscale;
    -webkit-font-smoothing:antialiased;
    margin-right:7px; }
  .bp3-menu-item::before,
  .bp3-menu-item > .bp3-icon{
    margin-top:2px;
    color:#5c7080; }
  .bp3-menu-item .bp3-menu-item-label{
    color:#5c7080; }
  .bp3-menu-item:hover, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-menu-item{
    color:inherit; }
  .bp3-menu-item.bp3-active, .bp3-menu-item:active{
    background-color:rgba(115, 134, 148, 0.3); }
  .bp3-menu-item.bp3-disabled{
    outline:none !important;
    background-color:inherit !important;
    cursor:not-allowed !important;
    color:rgba(92, 112, 128, 0.6) !important; }
    .bp3-menu-item.bp3-disabled::before,
    .bp3-menu-item.bp3-disabled > .bp3-icon,
    .bp3-menu-item.bp3-disabled .bp3-menu-item-label{
      color:rgba(92, 112, 128, 0.6) !important; }
  .bp3-large .bp3-menu-item{
    padding:9px 7px;
    line-height:22px;
    font-size:16px; }
    .bp3-large .bp3-menu-item .bp3-icon{
      margin-top:3px; }
    .bp3-large .bp3-menu-item::before{
      line-height:1;
      font-family:"Icons20", sans-serif;
      font-size:20px;
      font-weight:400;
      font-style:normal;
      -moz-osx-font-smoothing:grayscale;
      -webkit-font-smoothing:antialiased;
      margin-top:1px;
      margin-right:10px; }

button.bp3-menu-item{
  border:none;
  background:none;
  width:100%;
  text-align:left; }
.bp3-menu-header{
  display:block;
  margin:5px;
  border-top:1px solid rgba(16, 22, 26, 0.15);
  cursor:default;
  padding-left:2px; }
  .bp3-dark .bp3-menu-header{
    border-top-color:rgba(255, 255, 255, 0.15); }
  .bp3-menu-header:first-of-type{
    border-top:none; }
  .bp3-menu-header > h6{
    color:#182026;
    font-weight:600;
    overflow:hidden;
    text-overflow:ellipsis;
    white-space:nowrap;
    word-wrap:normal;
    margin:0;
    padding:10px 7px 0 1px;
    line-height:17px; }
    .bp3-dark .bp3-menu-header > h6{
      color:#f5f8fa; }
  .bp3-menu-header:first-of-type > h6{
    padding-top:0; }
  .bp3-large .bp3-menu-header > h6{
    padding-top:15px;
    padding-bottom:5px;
    font-size:18px; }
  .bp3-large .bp3-menu-header:first-of-type > h6{
    padding-top:0; }

.bp3-dark .bp3-menu{
  background:#30404d;
  color:#f5f8fa; }

.bp3-dark .bp3-menu-item.bp3-intent-primary{
  color:#48aff0; }
  .bp3-dark .bp3-menu-item.bp3-intent-primary .bp3-icon{
    color:inherit; }
  .bp3-dark .bp3-menu-item.bp3-intent-primary::before, .bp3-dark .bp3-menu-item.bp3-intent-primary::after,
  .bp3-dark .bp3-menu-item.bp3-intent-primary .bp3-menu-item-label{
    color:#48aff0; }
  .bp3-dark .bp3-menu-item.bp3-intent-primary:hover, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-primary.bp3-menu-item, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-primary.bp3-menu-item, .bp3-dark .bp3-menu-item.bp3-intent-primary.bp3-active{
    background-color:#137cbd; }
  .bp3-dark .bp3-menu-item.bp3-intent-primary:active{
    background-color:#106ba3; }
  .bp3-dark .bp3-menu-item.bp3-intent-primary:hover, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-primary.bp3-menu-item, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-primary.bp3-menu-item, .bp3-dark .bp3-menu-item.bp3-intent-primary:hover::before, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-primary.bp3-menu-item::before, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-primary.bp3-menu-item::before, .bp3-dark .bp3-menu-item.bp3-intent-primary:hover::after, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-primary.bp3-menu-item::after, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-primary.bp3-menu-item::after,
  .bp3-dark .bp3-menu-item.bp3-intent-primary:hover .bp3-menu-item-label,
  .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-primary.bp3-menu-item .bp3-menu-item-label,
  .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-primary.bp3-menu-item .bp3-menu-item-label, .bp3-dark .bp3-menu-item.bp3-intent-primary:active, .bp3-dark .bp3-menu-item.bp3-intent-primary:active::before, .bp3-dark .bp3-menu-item.bp3-intent-primary:active::after,
  .bp3-dark .bp3-menu-item.bp3-intent-primary:active .bp3-menu-item-label, .bp3-dark .bp3-menu-item.bp3-intent-primary.bp3-active, .bp3-dark .bp3-menu-item.bp3-intent-primary.bp3-active::before, .bp3-dark .bp3-menu-item.bp3-intent-primary.bp3-active::after,
  .bp3-dark .bp3-menu-item.bp3-intent-primary.bp3-active .bp3-menu-item-label{
    color:#ffffff; }

.bp3-dark .bp3-menu-item.bp3-intent-success{
  color:#3dcc91; }
  .bp3-dark .bp3-menu-item.bp3-intent-success .bp3-icon{
    color:inherit; }
  .bp3-dark .bp3-menu-item.bp3-intent-success::before, .bp3-dark .bp3-menu-item.bp3-intent-success::after,
  .bp3-dark .bp3-menu-item.bp3-intent-success .bp3-menu-item-label{
    color:#3dcc91; }
  .bp3-dark .bp3-menu-item.bp3-intent-success:hover, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-success.bp3-menu-item, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-success.bp3-menu-item, .bp3-dark .bp3-menu-item.bp3-intent-success.bp3-active{
    background-color:#0f9960; }
  .bp3-dark .bp3-menu-item.bp3-intent-success:active{
    background-color:#0d8050; }
  .bp3-dark .bp3-menu-item.bp3-intent-success:hover, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-success.bp3-menu-item, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-success.bp3-menu-item, .bp3-dark .bp3-menu-item.bp3-intent-success:hover::before, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-success.bp3-menu-item::before, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-success.bp3-menu-item::before, .bp3-dark .bp3-menu-item.bp3-intent-success:hover::after, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-success.bp3-menu-item::after, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-success.bp3-menu-item::after,
  .bp3-dark .bp3-menu-item.bp3-intent-success:hover .bp3-menu-item-label,
  .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-success.bp3-menu-item .bp3-menu-item-label,
  .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-success.bp3-menu-item .bp3-menu-item-label, .bp3-dark .bp3-menu-item.bp3-intent-success:active, .bp3-dark .bp3-menu-item.bp3-intent-success:active::before, .bp3-dark .bp3-menu-item.bp3-intent-success:active::after,
  .bp3-dark .bp3-menu-item.bp3-intent-success:active .bp3-menu-item-label, .bp3-dark .bp3-menu-item.bp3-intent-success.bp3-active, .bp3-dark .bp3-menu-item.bp3-intent-success.bp3-active::before, .bp3-dark .bp3-menu-item.bp3-intent-success.bp3-active::after,
  .bp3-dark .bp3-menu-item.bp3-intent-success.bp3-active .bp3-menu-item-label{
    color:#ffffff; }

.bp3-dark .bp3-menu-item.bp3-intent-warning{
  color:#ffb366; }
  .bp3-dark .bp3-menu-item.bp3-intent-warning .bp3-icon{
    color:inherit; }
  .bp3-dark .bp3-menu-item.bp3-intent-warning::before, .bp3-dark .bp3-menu-item.bp3-intent-warning::after,
  .bp3-dark .bp3-menu-item.bp3-intent-warning .bp3-menu-item-label{
    color:#ffb366; }
  .bp3-dark .bp3-menu-item.bp3-intent-warning:hover, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-warning.bp3-menu-item, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-warning.bp3-menu-item, .bp3-dark .bp3-menu-item.bp3-intent-warning.bp3-active{
    background-color:#d9822b; }
  .bp3-dark .bp3-menu-item.bp3-intent-warning:active{
    background-color:#bf7326; }
  .bp3-dark .bp3-menu-item.bp3-intent-warning:hover, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-warning.bp3-menu-item, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-warning.bp3-menu-item, .bp3-dark .bp3-menu-item.bp3-intent-warning:hover::before, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-warning.bp3-menu-item::before, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-warning.bp3-menu-item::before, .bp3-dark .bp3-menu-item.bp3-intent-warning:hover::after, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-warning.bp3-menu-item::after, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-warning.bp3-menu-item::after,
  .bp3-dark .bp3-menu-item.bp3-intent-warning:hover .bp3-menu-item-label,
  .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-warning.bp3-menu-item .bp3-menu-item-label,
  .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-warning.bp3-menu-item .bp3-menu-item-label, .bp3-dark .bp3-menu-item.bp3-intent-warning:active, .bp3-dark .bp3-menu-item.bp3-intent-warning:active::before, .bp3-dark .bp3-menu-item.bp3-intent-warning:active::after,
  .bp3-dark .bp3-menu-item.bp3-intent-warning:active .bp3-menu-item-label, .bp3-dark .bp3-menu-item.bp3-intent-warning.bp3-active, .bp3-dark .bp3-menu-item.bp3-intent-warning.bp3-active::before, .bp3-dark .bp3-menu-item.bp3-intent-warning.bp3-active::after,
  .bp3-dark .bp3-menu-item.bp3-intent-warning.bp3-active .bp3-menu-item-label{
    color:#ffffff; }

.bp3-dark .bp3-menu-item.bp3-intent-danger{
  color:#ff7373; }
  .bp3-dark .bp3-menu-item.bp3-intent-danger .bp3-icon{
    color:inherit; }
  .bp3-dark .bp3-menu-item.bp3-intent-danger::before, .bp3-dark .bp3-menu-item.bp3-intent-danger::after,
  .bp3-dark .bp3-menu-item.bp3-intent-danger .bp3-menu-item-label{
    color:#ff7373; }
  .bp3-dark .bp3-menu-item.bp3-intent-danger:hover, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-danger.bp3-menu-item, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-danger.bp3-menu-item, .bp3-dark .bp3-menu-item.bp3-intent-danger.bp3-active{
    background-color:#db3737; }
  .bp3-dark .bp3-menu-item.bp3-intent-danger:active{
    background-color:#c23030; }
  .bp3-dark .bp3-menu-item.bp3-intent-danger:hover, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-danger.bp3-menu-item, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-danger.bp3-menu-item, .bp3-dark .bp3-menu-item.bp3-intent-danger:hover::before, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-danger.bp3-menu-item::before, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-danger.bp3-menu-item::before, .bp3-dark .bp3-menu-item.bp3-intent-danger:hover::after, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-danger.bp3-menu-item::after, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-danger.bp3-menu-item::after,
  .bp3-dark .bp3-menu-item.bp3-intent-danger:hover .bp3-menu-item-label,
  .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-danger.bp3-menu-item .bp3-menu-item-label,
  .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-danger.bp3-menu-item .bp3-menu-item-label, .bp3-dark .bp3-menu-item.bp3-intent-danger:active, .bp3-dark .bp3-menu-item.bp3-intent-danger:active::before, .bp3-dark .bp3-menu-item.bp3-intent-danger:active::after,
  .bp3-dark .bp3-menu-item.bp3-intent-danger:active .bp3-menu-item-label, .bp3-dark .bp3-menu-item.bp3-intent-danger.bp3-active, .bp3-dark .bp3-menu-item.bp3-intent-danger.bp3-active::before, .bp3-dark .bp3-menu-item.bp3-intent-danger.bp3-active::after,
  .bp3-dark .bp3-menu-item.bp3-intent-danger.bp3-active .bp3-menu-item-label{
    color:#ffffff; }

.bp3-dark .bp3-menu-item::before,
.bp3-dark .bp3-menu-item > .bp3-icon{
  color:#a7b6c2; }

.bp3-dark .bp3-menu-item .bp3-menu-item-label{
  color:#a7b6c2; }

.bp3-dark .bp3-menu-item.bp3-active, .bp3-dark .bp3-menu-item:active{
  background-color:rgba(138, 155, 168, 0.3); }

.bp3-dark .bp3-menu-item.bp3-disabled{
  color:rgba(167, 182, 194, 0.6) !important; }
  .bp3-dark .bp3-menu-item.bp3-disabled::before,
  .bp3-dark .bp3-menu-item.bp3-disabled > .bp3-icon,
  .bp3-dark .bp3-menu-item.bp3-disabled .bp3-menu-item-label{
    color:rgba(167, 182, 194, 0.6) !important; }

.bp3-dark .bp3-menu-divider,
.bp3-dark .bp3-menu-header{
  border-color:rgba(255, 255, 255, 0.15); }

.bp3-dark .bp3-menu-header > h6{
  color:#f5f8fa; }

.bp3-label .bp3-menu{
  margin-top:5px; }
.bp3-navbar{
  position:relative;
  z-index:10;
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.2);
  background-color:#ffffff;
  width:100%;
  height:50px;
  padding:0 15px; }
  .bp3-navbar.bp3-dark,
  .bp3-dark .bp3-navbar{
    background-color:#394b59; }
  .bp3-navbar.bp3-dark{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.4);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.4); }
  .bp3-dark .bp3-navbar{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.4); }
  .bp3-navbar.bp3-fixed-top{
    position:fixed;
    top:0;
    right:0;
    left:0; }

.bp3-navbar-heading{
  margin-right:15px;
  font-size:16px; }

.bp3-navbar-group{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center;
  height:50px; }
  .bp3-navbar-group.bp3-align-left{
    float:left; }
  .bp3-navbar-group.bp3-align-right{
    float:right; }

.bp3-navbar-divider{
  margin:0 10px;
  border-left:1px solid rgba(16, 22, 26, 0.15);
  height:20px; }
  .bp3-dark .bp3-navbar-divider{
    border-left-color:rgba(255, 255, 255, 0.15); }
.bp3-non-ideal-state{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-orient:vertical;
  -webkit-box-direction:normal;
      -ms-flex-direction:column;
          flex-direction:column;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center;
  -webkit-box-pack:center;
      -ms-flex-pack:center;
          justify-content:center;
  width:100%;
  height:100%;
  text-align:center; }
  .bp3-non-ideal-state > *{
    -webkit-box-flex:0;
        -ms-flex-positive:0;
            flex-grow:0;
    -ms-flex-negative:0;
        flex-shrink:0; }
  .bp3-non-ideal-state > .bp3-fill{
    -webkit-box-flex:1;
        -ms-flex-positive:1;
            flex-grow:1;
    -ms-flex-negative:1;
        flex-shrink:1; }
  .bp3-non-ideal-state::before,
  .bp3-non-ideal-state > *{
    margin-bottom:20px; }
  .bp3-non-ideal-state:empty::before,
  .bp3-non-ideal-state > :last-child{
    margin-bottom:0; }
  .bp3-non-ideal-state > *{
    max-width:400px; }

.bp3-non-ideal-state-visual{
  color:rgba(92, 112, 128, 0.6);
  font-size:60px; }
  .bp3-dark .bp3-non-ideal-state-visual{
    color:rgba(167, 182, 194, 0.6); }

.bp3-overflow-list{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -ms-flex-wrap:nowrap;
      flex-wrap:nowrap;
  min-width:0; }

.bp3-overflow-list-spacer{
  -ms-flex-negative:1;
      flex-shrink:1;
  width:1px; }

body.bp3-overlay-open{
  overflow:hidden; }

.bp3-overlay{
  position:static;
  top:0;
  right:0;
  bottom:0;
  left:0;
  z-index:20; }
  .bp3-overlay:not(.bp3-overlay-open){
    pointer-events:none; }
  .bp3-overlay.bp3-overlay-container{
    position:fixed;
    overflow:hidden; }
    .bp3-overlay.bp3-overlay-container.bp3-overlay-inline{
      position:absolute; }
  .bp3-overlay.bp3-overlay-scroll-container{
    position:fixed;
    overflow:auto; }
    .bp3-overlay.bp3-overlay-scroll-container.bp3-overlay-inline{
      position:absolute; }
  .bp3-overlay.bp3-overlay-inline{
    display:inline;
    overflow:visible; }

.bp3-overlay-content{
  position:fixed;
  z-index:20; }
  .bp3-overlay-inline .bp3-overlay-content,
  .bp3-overlay-scroll-container .bp3-overlay-content{
    position:absolute; }

.bp3-overlay-backdrop{
  position:fixed;
  top:0;
  right:0;
  bottom:0;
  left:0;
  opacity:1;
  z-index:20;
  background-color:rgba(16, 22, 26, 0.7);
  overflow:auto;
  -webkit-user-select:none;
     -moz-user-select:none;
      -ms-user-select:none;
          user-select:none; }
  .bp3-overlay-backdrop.bp3-overlay-enter, .bp3-overlay-backdrop.bp3-overlay-appear{
    opacity:0; }
  .bp3-overlay-backdrop.bp3-overlay-enter-active, .bp3-overlay-backdrop.bp3-overlay-appear-active{
    opacity:1;
    -webkit-transition-property:opacity;
    transition-property:opacity;
    -webkit-transition-duration:200ms;
            transition-duration:200ms;
    -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
            transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
    -webkit-transition-delay:0;
            transition-delay:0; }
  .bp3-overlay-backdrop.bp3-overlay-exit{
    opacity:1; }
  .bp3-overlay-backdrop.bp3-overlay-exit-active{
    opacity:0;
    -webkit-transition-property:opacity;
    transition-property:opacity;
    -webkit-transition-duration:200ms;
            transition-duration:200ms;
    -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
            transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
    -webkit-transition-delay:0;
            transition-delay:0; }
  .bp3-overlay-backdrop:focus{
    outline:none; }
  .bp3-overlay-inline .bp3-overlay-backdrop{
    position:absolute; }
.bp3-panel-stack{
  position:relative;
  overflow:hidden; }

.bp3-panel-stack-header{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -ms-flex-negative:0;
      flex-shrink:0;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center;
  z-index:1;
  -webkit-box-shadow:0 1px rgba(16, 22, 26, 0.15);
          box-shadow:0 1px rgba(16, 22, 26, 0.15);
  height:30px; }
  .bp3-dark .bp3-panel-stack-header{
    -webkit-box-shadow:0 1px rgba(255, 255, 255, 0.15);
            box-shadow:0 1px rgba(255, 255, 255, 0.15); }
  .bp3-panel-stack-header > span{
    display:-webkit-box;
    display:-ms-flexbox;
    display:flex;
    -webkit-box-flex:1;
        -ms-flex:1;
            flex:1;
    -webkit-box-align:stretch;
        -ms-flex-align:stretch;
            align-items:stretch; }
  .bp3-panel-stack-header .bp3-heading{
    margin:0 5px; }

.bp3-button.bp3-panel-stack-header-back{
  margin-left:5px;
  padding-left:0;
  white-space:nowrap; }
  .bp3-button.bp3-panel-stack-header-back .bp3-icon{
    margin:0 2px; }

.bp3-panel-stack-view{
  position:absolute;
  top:0;
  right:0;
  bottom:0;
  left:0;
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-orient:vertical;
  -webkit-box-direction:normal;
      -ms-flex-direction:column;
          flex-direction:column;
  margin-right:-1px;
  border-right:1px solid rgba(16, 22, 26, 0.15);
  background-color:#ffffff;
  overflow-y:auto; }
  .bp3-dark .bp3-panel-stack-view{
    background-color:#30404d; }

.bp3-panel-stack-push .bp3-panel-stack-enter, .bp3-panel-stack-push .bp3-panel-stack-appear{
  -webkit-transform:translateX(100%);
          transform:translateX(100%);
  opacity:0; }

.bp3-panel-stack-push .bp3-panel-stack-enter-active, .bp3-panel-stack-push .bp3-panel-stack-appear-active{
  -webkit-transform:translate(0%);
          transform:translate(0%);
  opacity:1;
  -webkit-transition-property:opacity, -webkit-transform;
  transition-property:opacity, -webkit-transform;
  transition-property:transform, opacity;
  transition-property:transform, opacity, -webkit-transform;
  -webkit-transition-duration:400ms;
          transition-duration:400ms;
  -webkit-transition-timing-function:ease;
          transition-timing-function:ease;
  -webkit-transition-delay:0;
          transition-delay:0; }

.bp3-panel-stack-push .bp3-panel-stack-exit{
  -webkit-transform:translate(0%);
          transform:translate(0%);
  opacity:1; }

.bp3-panel-stack-push .bp3-panel-stack-exit-active{
  -webkit-transform:translateX(-50%);
          transform:translateX(-50%);
  opacity:0;
  -webkit-transition-property:opacity, -webkit-transform;
  transition-property:opacity, -webkit-transform;
  transition-property:transform, opacity;
  transition-property:transform, opacity, -webkit-transform;
  -webkit-transition-duration:400ms;
          transition-duration:400ms;
  -webkit-transition-timing-function:ease;
          transition-timing-function:ease;
  -webkit-transition-delay:0;
          transition-delay:0; }

.bp3-panel-stack-pop .bp3-panel-stack-enter, .bp3-panel-stack-pop .bp3-panel-stack-appear{
  -webkit-transform:translateX(-50%);
          transform:translateX(-50%);
  opacity:0; }

.bp3-panel-stack-pop .bp3-panel-stack-enter-active, .bp3-panel-stack-pop .bp3-panel-stack-appear-active{
  -webkit-transform:translate(0%);
          transform:translate(0%);
  opacity:1;
  -webkit-transition-property:opacity, -webkit-transform;
  transition-property:opacity, -webkit-transform;
  transition-property:transform, opacity;
  transition-property:transform, opacity, -webkit-transform;
  -webkit-transition-duration:400ms;
          transition-duration:400ms;
  -webkit-transition-timing-function:ease;
          transition-timing-function:ease;
  -webkit-transition-delay:0;
          transition-delay:0; }

.bp3-panel-stack-pop .bp3-panel-stack-exit{
  -webkit-transform:translate(0%);
          transform:translate(0%);
  opacity:1; }

.bp3-panel-stack-pop .bp3-panel-stack-exit-active{
  -webkit-transform:translateX(100%);
          transform:translateX(100%);
  opacity:0;
  -webkit-transition-property:opacity, -webkit-transform;
  transition-property:opacity, -webkit-transform;
  transition-property:transform, opacity;
  transition-property:transform, opacity, -webkit-transform;
  -webkit-transition-duration:400ms;
          transition-duration:400ms;
  -webkit-transition-timing-function:ease;
          transition-timing-function:ease;
  -webkit-transition-delay:0;
          transition-delay:0; }
.bp3-popover{
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 2px 4px rgba(16, 22, 26, 0.2), 0 8px 24px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 2px 4px rgba(16, 22, 26, 0.2), 0 8px 24px rgba(16, 22, 26, 0.2);
  -webkit-transform:scale(1);
          transform:scale(1);
  display:inline-block;
  z-index:20;
  border-radius:3px; }
  .bp3-popover .bp3-popover-arrow{
    position:absolute;
    width:30px;
    height:30px; }
    .bp3-popover .bp3-popover-arrow::before{
      margin:5px;
      width:20px;
      height:20px; }
  .bp3-tether-element-attached-bottom.bp3-tether-target-attached-top > .bp3-popover{
    margin-top:-17px;
    margin-bottom:17px; }
    .bp3-tether-element-attached-bottom.bp3-tether-target-attached-top > .bp3-popover > .bp3-popover-arrow{
      bottom:-11px; }
      .bp3-tether-element-attached-bottom.bp3-tether-target-attached-top > .bp3-popover > .bp3-popover-arrow svg{
        -webkit-transform:rotate(-90deg);
                transform:rotate(-90deg); }
  .bp3-tether-element-attached-left.bp3-tether-target-attached-right > .bp3-popover{
    margin-left:17px; }
    .bp3-tether-element-attached-left.bp3-tether-target-attached-right > .bp3-popover > .bp3-popover-arrow{
      left:-11px; }
      .bp3-tether-element-attached-left.bp3-tether-target-attached-right > .bp3-popover > .bp3-popover-arrow svg{
        -webkit-transform:rotate(0);
                transform:rotate(0); }
  .bp3-tether-element-attached-top.bp3-tether-target-attached-bottom > .bp3-popover{
    margin-top:17px; }
    .bp3-tether-element-attached-top.bp3-tether-target-attached-bottom > .bp3-popover > .bp3-popover-arrow{
      top:-11px; }
      .bp3-tether-element-attached-top.bp3-tether-target-attached-bottom > .bp3-popover > .bp3-popover-arrow svg{
        -webkit-transform:rotate(90deg);
                transform:rotate(90deg); }
  .bp3-tether-element-attached-right.bp3-tether-target-attached-left > .bp3-popover{
    margin-right:17px;
    margin-left:-17px; }
    .bp3-tether-element-attached-right.bp3-tether-target-attached-left > .bp3-popover > .bp3-popover-arrow{
      right:-11px; }
      .bp3-tether-element-attached-right.bp3-tether-target-attached-left > .bp3-popover > .bp3-popover-arrow svg{
        -webkit-transform:rotate(180deg);
                transform:rotate(180deg); }
  .bp3-tether-element-attached-middle > .bp3-popover > .bp3-popover-arrow{
    top:50%;
    -webkit-transform:translateY(-50%);
            transform:translateY(-50%); }
  .bp3-tether-element-attached-center > .bp3-popover > .bp3-popover-arrow{
    right:50%;
    -webkit-transform:translateX(50%);
            transform:translateX(50%); }
  .bp3-tether-element-attached-top.bp3-tether-target-attached-top > .bp3-popover > .bp3-popover-arrow{
    top:-0.3934px; }
  .bp3-tether-element-attached-right.bp3-tether-target-attached-right > .bp3-popover > .bp3-popover-arrow{
    right:-0.3934px; }
  .bp3-tether-element-attached-left.bp3-tether-target-attached-left > .bp3-popover > .bp3-popover-arrow{
    left:-0.3934px; }
  .bp3-tether-element-attached-bottom.bp3-tether-target-attached-bottom > .bp3-popover > .bp3-popover-arrow{
    bottom:-0.3934px; }
  .bp3-tether-element-attached-top.bp3-tether-element-attached-left > .bp3-popover{
    -webkit-transform-origin:top left;
            transform-origin:top left; }
  .bp3-tether-element-attached-top.bp3-tether-element-attached-center > .bp3-popover{
    -webkit-transform-origin:top center;
            transform-origin:top center; }
  .bp3-tether-element-attached-top.bp3-tether-element-attached-right > .bp3-popover{
    -webkit-transform-origin:top right;
            transform-origin:top right; }
  .bp3-tether-element-attached-middle.bp3-tether-element-attached-left > .bp3-popover{
    -webkit-transform-origin:center left;
            transform-origin:center left; }
  .bp3-tether-element-attached-middle.bp3-tether-element-attached-center > .bp3-popover{
    -webkit-transform-origin:center center;
            transform-origin:center center; }
  .bp3-tether-element-attached-middle.bp3-tether-element-attached-right > .bp3-popover{
    -webkit-transform-origin:center right;
            transform-origin:center right; }
  .bp3-tether-element-attached-bottom.bp3-tether-element-attached-left > .bp3-popover{
    -webkit-transform-origin:bottom left;
            transform-origin:bottom left; }
  .bp3-tether-element-attached-bottom.bp3-tether-element-attached-center > .bp3-popover{
    -webkit-transform-origin:bottom center;
            transform-origin:bottom center; }
  .bp3-tether-element-attached-bottom.bp3-tether-element-attached-right > .bp3-popover{
    -webkit-transform-origin:bottom right;
            transform-origin:bottom right; }
  .bp3-popover .bp3-popover-content{
    background:#ffffff;
    color:inherit; }
  .bp3-popover .bp3-popover-arrow::before{
    -webkit-box-shadow:1px 1px 6px rgba(16, 22, 26, 0.2);
            box-shadow:1px 1px 6px rgba(16, 22, 26, 0.2); }
  .bp3-popover .bp3-popover-arrow-border{
    fill:#10161a;
    fill-opacity:0.1; }
  .bp3-popover .bp3-popover-arrow-fill{
    fill:#ffffff; }
  .bp3-popover-enter > .bp3-popover, .bp3-popover-appear > .bp3-popover{
    -webkit-transform:scale(0.3);
            transform:scale(0.3); }
  .bp3-popover-enter-active > .bp3-popover, .bp3-popover-appear-active > .bp3-popover{
    -webkit-transform:scale(1);
            transform:scale(1);
    -webkit-transition-property:-webkit-transform;
    transition-property:-webkit-transform;
    transition-property:transform;
    transition-property:transform, -webkit-transform;
    -webkit-transition-duration:300ms;
            transition-duration:300ms;
    -webkit-transition-timing-function:cubic-bezier(0.54, 1.12, 0.38, 1.11);
            transition-timing-function:cubic-bezier(0.54, 1.12, 0.38, 1.11);
    -webkit-transition-delay:0;
            transition-delay:0; }
  .bp3-popover-exit > .bp3-popover{
    -webkit-transform:scale(1);
            transform:scale(1); }
  .bp3-popover-exit-active > .bp3-popover{
    -webkit-transform:scale(0.3);
            transform:scale(0.3);
    -webkit-transition-property:-webkit-transform;
    transition-property:-webkit-transform;
    transition-property:transform;
    transition-property:transform, -webkit-transform;
    -webkit-transition-duration:300ms;
            transition-duration:300ms;
    -webkit-transition-timing-function:cubic-bezier(0.54, 1.12, 0.38, 1.11);
            transition-timing-function:cubic-bezier(0.54, 1.12, 0.38, 1.11);
    -webkit-transition-delay:0;
            transition-delay:0; }
  .bp3-popover .bp3-popover-content{
    position:relative;
    border-radius:3px; }
  .bp3-popover.bp3-popover-content-sizing .bp3-popover-content{
    max-width:350px;
    padding:20px; }
  .bp3-popover-target + .bp3-overlay .bp3-popover.bp3-popover-content-sizing{
    width:350px; }
  .bp3-popover.bp3-minimal{
    margin:0 !important; }
    .bp3-popover.bp3-minimal .bp3-popover-arrow{
      display:none; }
    .bp3-popover.bp3-minimal.bp3-popover{
      -webkit-transform:scale(1);
              transform:scale(1); }
      .bp3-popover-enter > .bp3-popover.bp3-minimal.bp3-popover, .bp3-popover-appear > .bp3-popover.bp3-minimal.bp3-popover{
        -webkit-transform:scale(1);
                transform:scale(1); }
      .bp3-popover-enter-active > .bp3-popover.bp3-minimal.bp3-popover, .bp3-popover-appear-active > .bp3-popover.bp3-minimal.bp3-popover{
        -webkit-transform:scale(1);
                transform:scale(1);
        -webkit-transition-property:-webkit-transform;
        transition-property:-webkit-transform;
        transition-property:transform;
        transition-property:transform, -webkit-transform;
        -webkit-transition-duration:100ms;
                transition-duration:100ms;
        -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
                transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
        -webkit-transition-delay:0;
                transition-delay:0; }
      .bp3-popover-exit > .bp3-popover.bp3-minimal.bp3-popover{
        -webkit-transform:scale(1);
                transform:scale(1); }
      .bp3-popover-exit-active > .bp3-popover.bp3-minimal.bp3-popover{
        -webkit-transform:scale(1);
                transform:scale(1);
        -webkit-transition-property:-webkit-transform;
        transition-property:-webkit-transform;
        transition-property:transform;
        transition-property:transform, -webkit-transform;
        -webkit-transition-duration:100ms;
                transition-duration:100ms;
        -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
                transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
        -webkit-transition-delay:0;
                transition-delay:0; }
  .bp3-popover.bp3-dark,
  .bp3-dark .bp3-popover{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 2px 4px rgba(16, 22, 26, 0.4), 0 8px 24px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 2px 4px rgba(16, 22, 26, 0.4), 0 8px 24px rgba(16, 22, 26, 0.4); }
    .bp3-popover.bp3-dark .bp3-popover-content,
    .bp3-dark .bp3-popover .bp3-popover-content{
      background:#30404d;
      color:inherit; }
    .bp3-popover.bp3-dark .bp3-popover-arrow::before,
    .bp3-dark .bp3-popover .bp3-popover-arrow::before{
      -webkit-box-shadow:1px 1px 6px rgba(16, 22, 26, 0.4);
              box-shadow:1px 1px 6px rgba(16, 22, 26, 0.4); }
    .bp3-popover.bp3-dark .bp3-popover-arrow-border,
    .bp3-dark .bp3-popover .bp3-popover-arrow-border{
      fill:#10161a;
      fill-opacity:0.2; }
    .bp3-popover.bp3-dark .bp3-popover-arrow-fill,
    .bp3-dark .bp3-popover .bp3-popover-arrow-fill{
      fill:#30404d; }

.bp3-popover-arrow::before{
  display:block;
  position:absolute;
  -webkit-transform:rotate(45deg);
          transform:rotate(45deg);
  border-radius:2px;
  content:""; }

.bp3-tether-pinned .bp3-popover-arrow{
  display:none; }

.bp3-popover-backdrop{
  background:rgba(255, 255, 255, 0); }

.bp3-transition-container{
  opacity:1;
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  z-index:20; }
  .bp3-transition-container.bp3-popover-enter, .bp3-transition-container.bp3-popover-appear{
    opacity:0; }
  .bp3-transition-container.bp3-popover-enter-active, .bp3-transition-container.bp3-popover-appear-active{
    opacity:1;
    -webkit-transition-property:opacity;
    transition-property:opacity;
    -webkit-transition-duration:100ms;
            transition-duration:100ms;
    -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
            transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
    -webkit-transition-delay:0;
            transition-delay:0; }
  .bp3-transition-container.bp3-popover-exit{
    opacity:1; }
  .bp3-transition-container.bp3-popover-exit-active{
    opacity:0;
    -webkit-transition-property:opacity;
    transition-property:opacity;
    -webkit-transition-duration:100ms;
            transition-duration:100ms;
    -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
            transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
    -webkit-transition-delay:0;
            transition-delay:0; }
  .bp3-transition-container:focus{
    outline:none; }
  .bp3-transition-container.bp3-popover-leave .bp3-popover-content{
    pointer-events:none; }
  .bp3-transition-container[data-x-out-of-boundaries]{
    display:none; }

span.bp3-popover-target{
  display:inline-block; }

.bp3-popover-wrapper.bp3-fill{
  width:100%; }

.bp3-portal{
  position:absolute;
  top:0;
  right:0;
  left:0; }
@-webkit-keyframes linear-progress-bar-stripes{
  from{
    background-position:0 0; }
  to{
    background-position:30px 0; } }
@keyframes linear-progress-bar-stripes{
  from{
    background-position:0 0; }
  to{
    background-position:30px 0; } }

.bp3-progress-bar{
  display:block;
  position:relative;
  border-radius:40px;
  background:rgba(92, 112, 128, 0.2);
  width:100%;
  height:8px;
  overflow:hidden; }
  .bp3-progress-bar .bp3-progress-meter{
    position:absolute;
    border-radius:40px;
    background:linear-gradient(-45deg, rgba(255, 255, 255, 0.2) 25%, transparent 25%, transparent 50%, rgba(255, 255, 255, 0.2) 50%, rgba(255, 255, 255, 0.2) 75%, transparent 75%);
    background-color:rgba(92, 112, 128, 0.8);
    background-size:30px 30px;
    width:100%;
    height:100%;
    -webkit-transition:width 200ms cubic-bezier(0.4, 1, 0.75, 0.9);
    transition:width 200ms cubic-bezier(0.4, 1, 0.75, 0.9); }
  .bp3-progress-bar:not(.bp3-no-animation):not(.bp3-no-stripes) .bp3-progress-meter{
    animation:linear-progress-bar-stripes 300ms linear infinite reverse; }
  .bp3-progress-bar.bp3-no-stripes .bp3-progress-meter{
    background-image:none; }

.bp3-dark .bp3-progress-bar{
  background:rgba(16, 22, 26, 0.5); }
  .bp3-dark .bp3-progress-bar .bp3-progress-meter{
    background-color:#8a9ba8; }

.bp3-progress-bar.bp3-intent-primary .bp3-progress-meter{
  background-color:#137cbd; }

.bp3-progress-bar.bp3-intent-success .bp3-progress-meter{
  background-color:#0f9960; }

.bp3-progress-bar.bp3-intent-warning .bp3-progress-meter{
  background-color:#d9822b; }

.bp3-progress-bar.bp3-intent-danger .bp3-progress-meter{
  background-color:#db3737; }
@-webkit-keyframes skeleton-glow{
  from{
    border-color:rgba(206, 217, 224, 0.2);
    background:rgba(206, 217, 224, 0.2); }
  to{
    border-color:rgba(92, 112, 128, 0.2);
    background:rgba(92, 112, 128, 0.2); } }
@keyframes skeleton-glow{
  from{
    border-color:rgba(206, 217, 224, 0.2);
    background:rgba(206, 217, 224, 0.2); }
  to{
    border-color:rgba(92, 112, 128, 0.2);
    background:rgba(92, 112, 128, 0.2); } }
.bp3-skeleton{
  border-color:rgba(206, 217, 224, 0.2) !important;
  border-radius:2px;
  -webkit-box-shadow:none !important;
          box-shadow:none !important;
  background:rgba(206, 217, 224, 0.2);
  background-clip:padding-box !important;
  cursor:default;
  color:transparent !important;
  -webkit-animation:1000ms linear infinite alternate skeleton-glow;
          animation:1000ms linear infinite alternate skeleton-glow;
  pointer-events:none;
  -webkit-user-select:none;
     -moz-user-select:none;
      -ms-user-select:none;
          user-select:none; }
  .bp3-skeleton::before, .bp3-skeleton::after,
  .bp3-skeleton *{
    visibility:hidden !important; }
.bp3-slider{
  width:100%;
  min-width:150px;
  height:40px;
  position:relative;
  outline:none;
  cursor:default;
  -webkit-user-select:none;
     -moz-user-select:none;
      -ms-user-select:none;
          user-select:none; }
  .bp3-slider:hover{
    cursor:pointer; }
  .bp3-slider:active{
    cursor:-webkit-grabbing;
    cursor:grabbing; }
  .bp3-slider.bp3-disabled{
    opacity:0.5;
    cursor:not-allowed; }
  .bp3-slider.bp3-slider-unlabeled{
    height:16px; }

.bp3-slider-track,
.bp3-slider-progress{
  top:5px;
  right:0;
  left:0;
  height:6px;
  position:absolute; }

.bp3-slider-track{
  border-radius:3px;
  overflow:hidden; }

.bp3-slider-progress{
  background:rgba(92, 112, 128, 0.2); }
  .bp3-dark .bp3-slider-progress{
    background:rgba(16, 22, 26, 0.5); }
  .bp3-slider-progress.bp3-intent-primary{
    background-color:#137cbd; }
  .bp3-slider-progress.bp3-intent-success{
    background-color:#0f9960; }
  .bp3-slider-progress.bp3-intent-warning{
    background-color:#d9822b; }
  .bp3-slider-progress.bp3-intent-danger{
    background-color:#db3737; }

.bp3-slider-handle{
  -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
          box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
  background-color:#f5f8fa;
  background-image:-webkit-gradient(linear, left top, left bottom, from(rgba(255, 255, 255, 0.8)), to(rgba(255, 255, 255, 0)));
  background-image:linear-gradient(to bottom, rgba(255, 255, 255, 0.8), rgba(255, 255, 255, 0));
  color:#182026;
  position:absolute;
  top:0;
  left:0;
  border-radius:3px;
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 1px 1px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 1px 1px rgba(16, 22, 26, 0.2);
  cursor:pointer;
  width:16px;
  height:16px; }
  .bp3-slider-handle:hover{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
    background-clip:padding-box;
    background-color:#ebf1f5; }
  .bp3-slider-handle:active, .bp3-slider-handle.bp3-active{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 1px 2px rgba(16, 22, 26, 0.2);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 1px 2px rgba(16, 22, 26, 0.2);
    background-color:#d8e1e8;
    background-image:none; }
  .bp3-slider-handle:disabled, .bp3-slider-handle.bp3-disabled{
    outline:none;
    -webkit-box-shadow:none;
            box-shadow:none;
    background-color:rgba(206, 217, 224, 0.5);
    background-image:none;
    cursor:not-allowed;
    color:rgba(92, 112, 128, 0.6); }
    .bp3-slider-handle:disabled.bp3-active, .bp3-slider-handle:disabled.bp3-active:hover, .bp3-slider-handle.bp3-disabled.bp3-active, .bp3-slider-handle.bp3-disabled.bp3-active:hover{
      background:rgba(206, 217, 224, 0.7); }
  .bp3-slider-handle:focus{
    z-index:1; }
  .bp3-slider-handle:hover{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
    background-clip:padding-box;
    background-color:#ebf1f5;
    z-index:2;
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 1px 1px rgba(16, 22, 26, 0.2);
    cursor:-webkit-grab;
    cursor:grab; }
  .bp3-slider-handle.bp3-active{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 1px 2px rgba(16, 22, 26, 0.2);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 1px 2px rgba(16, 22, 26, 0.2);
    background-color:#d8e1e8;
    background-image:none;
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 1px 1px rgba(16, 22, 26, 0.1);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 1px 1px rgba(16, 22, 26, 0.1);
    cursor:-webkit-grabbing;
    cursor:grabbing; }
  .bp3-disabled .bp3-slider-handle{
    -webkit-box-shadow:none;
            box-shadow:none;
    background:#bfccd6;
    pointer-events:none; }
  .bp3-dark .bp3-slider-handle{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
    background-color:#394b59;
    background-image:-webkit-gradient(linear, left top, left bottom, from(rgba(255, 255, 255, 0.05)), to(rgba(255, 255, 255, 0)));
    background-image:linear-gradient(to bottom, rgba(255, 255, 255, 0.05), rgba(255, 255, 255, 0));
    color:#f5f8fa; }
    .bp3-dark .bp3-slider-handle:hover, .bp3-dark .bp3-slider-handle:active, .bp3-dark .bp3-slider-handle.bp3-active{
      color:#f5f8fa; }
    .bp3-dark .bp3-slider-handle:hover{
      -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
      background-color:#30404d; }
    .bp3-dark .bp3-slider-handle:active, .bp3-dark .bp3-slider-handle.bp3-active{
      -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.6), inset 0 1px 2px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px rgba(16, 22, 26, 0.6), inset 0 1px 2px rgba(16, 22, 26, 0.2);
      background-color:#202b33;
      background-image:none; }
    .bp3-dark .bp3-slider-handle:disabled, .bp3-dark .bp3-slider-handle.bp3-disabled{
      -webkit-box-shadow:none;
              box-shadow:none;
      background-color:rgba(57, 75, 89, 0.5);
      background-image:none;
      color:rgba(167, 182, 194, 0.6); }
      .bp3-dark .bp3-slider-handle:disabled.bp3-active, .bp3-dark .bp3-slider-handle.bp3-disabled.bp3-active{
        background:rgba(57, 75, 89, 0.7); }
    .bp3-dark .bp3-slider-handle .bp3-button-spinner .bp3-spinner-head{
      background:rgba(16, 22, 26, 0.5);
      stroke:#8a9ba8; }
    .bp3-dark .bp3-slider-handle, .bp3-dark .bp3-slider-handle:hover{
      background-color:#394b59; }
    .bp3-dark .bp3-slider-handle.bp3-active{
      background-color:#293742; }
  .bp3-dark .bp3-disabled .bp3-slider-handle{
    border-color:#5c7080;
    -webkit-box-shadow:none;
            box-shadow:none;
    background:#5c7080; }
  .bp3-slider-handle .bp3-slider-label{
    margin-left:8px;
    border-radius:3px;
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 2px 4px rgba(16, 22, 26, 0.2), 0 8px 24px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 2px 4px rgba(16, 22, 26, 0.2), 0 8px 24px rgba(16, 22, 26, 0.2);
    background:#394b59;
    color:#f5f8fa; }
    .bp3-dark .bp3-slider-handle .bp3-slider-label{
      -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 2px 4px rgba(16, 22, 26, 0.4), 0 8px 24px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 2px 4px rgba(16, 22, 26, 0.4), 0 8px 24px rgba(16, 22, 26, 0.4);
      background:#e1e8ed;
      color:#394b59; }
    .bp3-disabled .bp3-slider-handle .bp3-slider-label{
      -webkit-box-shadow:none;
              box-shadow:none; }
  .bp3-slider-handle.bp3-start, .bp3-slider-handle.bp3-end{
    width:8px; }
  .bp3-slider-handle.bp3-start{
    border-top-right-radius:0;
    border-bottom-right-radius:0; }
  .bp3-slider-handle.bp3-end{
    margin-left:8px;
    border-top-left-radius:0;
    border-bottom-left-radius:0; }
    .bp3-slider-handle.bp3-end .bp3-slider-label{
      margin-left:0; }

.bp3-slider-label{
  -webkit-transform:translate(-50%, 20px);
          transform:translate(-50%, 20px);
  display:inline-block;
  position:absolute;
  padding:2px 5px;
  vertical-align:top;
  line-height:1;
  font-size:12px; }

.bp3-slider.bp3-vertical{
  width:40px;
  min-width:40px;
  height:150px; }
  .bp3-slider.bp3-vertical .bp3-slider-track,
  .bp3-slider.bp3-vertical .bp3-slider-progress{
    top:0;
    bottom:0;
    left:5px;
    width:6px;
    height:auto; }
  .bp3-slider.bp3-vertical .bp3-slider-progress{
    top:auto; }
  .bp3-slider.bp3-vertical .bp3-slider-label{
    -webkit-transform:translate(20px, 50%);
            transform:translate(20px, 50%); }
  .bp3-slider.bp3-vertical .bp3-slider-handle{
    top:auto; }
    .bp3-slider.bp3-vertical .bp3-slider-handle .bp3-slider-label{
      margin-top:-8px;
      margin-left:0; }
    .bp3-slider.bp3-vertical .bp3-slider-handle.bp3-end, .bp3-slider.bp3-vertical .bp3-slider-handle.bp3-start{
      margin-left:0;
      width:16px;
      height:8px; }
    .bp3-slider.bp3-vertical .bp3-slider-handle.bp3-start{
      border-top-left-radius:0;
      border-bottom-right-radius:3px; }
      .bp3-slider.bp3-vertical .bp3-slider-handle.bp3-start .bp3-slider-label{
        -webkit-transform:translate(20px);
                transform:translate(20px); }
    .bp3-slider.bp3-vertical .bp3-slider-handle.bp3-end{
      margin-bottom:8px;
      border-top-left-radius:3px;
      border-bottom-left-radius:0;
      border-bottom-right-radius:0; }

@-webkit-keyframes pt-spinner-animation{
  from{
    -webkit-transform:rotate(0deg);
            transform:rotate(0deg); }
  to{
    -webkit-transform:rotate(360deg);
            transform:rotate(360deg); } }

@keyframes pt-spinner-animation{
  from{
    -webkit-transform:rotate(0deg);
            transform:rotate(0deg); }
  to{
    -webkit-transform:rotate(360deg);
            transform:rotate(360deg); } }

.bp3-spinner{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center;
  -webkit-box-pack:center;
      -ms-flex-pack:center;
          justify-content:center;
  overflow:visible;
  vertical-align:middle; }
  .bp3-spinner svg{
    display:block; }
  .bp3-spinner path{
    fill-opacity:0; }
  .bp3-spinner .bp3-spinner-head{
    -webkit-transform-origin:center;
            transform-origin:center;
    -webkit-transition:stroke-dashoffset 200ms cubic-bezier(0.4, 1, 0.75, 0.9);
    transition:stroke-dashoffset 200ms cubic-bezier(0.4, 1, 0.75, 0.9);
    stroke:rgba(92, 112, 128, 0.8);
    stroke-linecap:round; }
  .bp3-spinner .bp3-spinner-track{
    stroke:rgba(92, 112, 128, 0.2); }

.bp3-spinner-animation{
  -webkit-animation:pt-spinner-animation 500ms linear infinite;
          animation:pt-spinner-animation 500ms linear infinite; }
  .bp3-no-spin > .bp3-spinner-animation{
    -webkit-animation:none;
            animation:none; }

.bp3-dark .bp3-spinner .bp3-spinner-head{
  stroke:#8a9ba8; }

.bp3-dark .bp3-spinner .bp3-spinner-track{
  stroke:rgba(16, 22, 26, 0.5); }

.bp3-spinner.bp3-intent-primary .bp3-spinner-head{
  stroke:#137cbd; }

.bp3-spinner.bp3-intent-success .bp3-spinner-head{
  stroke:#0f9960; }

.bp3-spinner.bp3-intent-warning .bp3-spinner-head{
  stroke:#d9822b; }

.bp3-spinner.bp3-intent-danger .bp3-spinner-head{
  stroke:#db3737; }
.bp3-tabs.bp3-vertical{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex; }
  .bp3-tabs.bp3-vertical > .bp3-tab-list{
    -webkit-box-orient:vertical;
    -webkit-box-direction:normal;
        -ms-flex-direction:column;
            flex-direction:column;
    -webkit-box-align:start;
        -ms-flex-align:start;
            align-items:flex-start; }
    .bp3-tabs.bp3-vertical > .bp3-tab-list .bp3-tab{
      border-radius:3px;
      width:100%;
      padding:0 10px; }
      .bp3-tabs.bp3-vertical > .bp3-tab-list .bp3-tab[aria-selected="true"]{
        -webkit-box-shadow:none;
                box-shadow:none;
        background-color:rgba(19, 124, 189, 0.2); }
    .bp3-tabs.bp3-vertical > .bp3-tab-list .bp3-tab-indicator-wrapper .bp3-tab-indicator{
      top:0;
      right:0;
      bottom:0;
      left:0;
      border-radius:3px;
      background-color:rgba(19, 124, 189, 0.2);
      height:auto; }
  .bp3-tabs.bp3-vertical > .bp3-tab-panel{
    margin-top:0;
    padding-left:20px; }

.bp3-tab-list{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-flex:0;
      -ms-flex:0 0 auto;
          flex:0 0 auto;
  -webkit-box-align:end;
      -ms-flex-align:end;
          align-items:flex-end;
  position:relative;
  margin:0;
  border:none;
  padding:0;
  list-style:none; }
  .bp3-tab-list > *:not(:last-child){
    margin-right:20px; }

.bp3-tab{
  overflow:hidden;
  text-overflow:ellipsis;
  white-space:nowrap;
  word-wrap:normal;
  -webkit-box-flex:0;
      -ms-flex:0 0 auto;
          flex:0 0 auto;
  position:relative;
  cursor:pointer;
  max-width:100%;
  vertical-align:top;
  line-height:30px;
  color:#182026;
  font-size:14px; }
  .bp3-tab a{
    display:block;
    text-decoration:none;
    color:inherit; }
  .bp3-tab-indicator-wrapper ~ .bp3-tab{
    -webkit-box-shadow:none !important;
            box-shadow:none !important;
    background-color:transparent !important; }
  .bp3-tab[aria-disabled="true"]{
    cursor:not-allowed;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-tab[aria-selected="true"]{
    border-radius:0;
    -webkit-box-shadow:inset 0 -3px 0 #106ba3;
            box-shadow:inset 0 -3px 0 #106ba3; }
  .bp3-tab[aria-selected="true"], .bp3-tab:not([aria-disabled="true"]):hover{
    color:#106ba3; }
  .bp3-tab:focus{
    -moz-outline-radius:0; }
  .bp3-large > .bp3-tab{
    line-height:40px;
    font-size:16px; }

.bp3-tab-panel{
  margin-top:20px; }
  .bp3-tab-panel[aria-hidden="true"]{
    display:none; }

.bp3-tab-indicator-wrapper{
  position:absolute;
  top:0;
  left:0;
  -webkit-transform:translateX(0), translateY(0);
          transform:translateX(0), translateY(0);
  -webkit-transition:height, width, -webkit-transform;
  transition:height, width, -webkit-transform;
  transition:height, transform, width;
  transition:height, transform, width, -webkit-transform;
  -webkit-transition-duration:200ms;
          transition-duration:200ms;
  -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
          transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
  pointer-events:none; }
  .bp3-tab-indicator-wrapper .bp3-tab-indicator{
    position:absolute;
    right:0;
    bottom:0;
    left:0;
    background-color:#106ba3;
    height:3px; }
  .bp3-tab-indicator-wrapper.bp3-no-animation{
    -webkit-transition:none;
    transition:none; }

.bp3-dark .bp3-tab{
  color:#f5f8fa; }
  .bp3-dark .bp3-tab[aria-disabled="true"]{
    color:rgba(167, 182, 194, 0.6); }
  .bp3-dark .bp3-tab[aria-selected="true"]{
    -webkit-box-shadow:inset 0 -3px 0 #48aff0;
            box-shadow:inset 0 -3px 0 #48aff0; }
  .bp3-dark .bp3-tab[aria-selected="true"], .bp3-dark .bp3-tab:not([aria-disabled="true"]):hover{
    color:#48aff0; }

.bp3-dark .bp3-tab-indicator{
  background-color:#48aff0; }

.bp3-flex-expander{
  -webkit-box-flex:1;
      -ms-flex:1 1;
          flex:1 1; }
.bp3-tag{
  display:-webkit-inline-box;
  display:-ms-inline-flexbox;
  display:inline-flex;
  -webkit-box-orient:horizontal;
  -webkit-box-direction:normal;
      -ms-flex-direction:row;
          flex-direction:row;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center;
  position:relative;
  border:none;
  border-radius:3px;
  -webkit-box-shadow:none;
          box-shadow:none;
  background-color:#5c7080;
  min-width:20px;
  max-width:100%;
  min-height:20px;
  padding:2px 6px;
  line-height:16px;
  color:#f5f8fa;
  font-size:12px; }
  .bp3-tag.bp3-interactive{
    cursor:pointer; }
    .bp3-tag.bp3-interactive:hover{
      background-color:rgba(92, 112, 128, 0.85); }
    .bp3-tag.bp3-interactive.bp3-active, .bp3-tag.bp3-interactive:active{
      background-color:rgba(92, 112, 128, 0.7); }
  .bp3-tag > *{
    -webkit-box-flex:0;
        -ms-flex-positive:0;
            flex-grow:0;
    -ms-flex-negative:0;
        flex-shrink:0; }
  .bp3-tag > .bp3-fill{
    -webkit-box-flex:1;
        -ms-flex-positive:1;
            flex-grow:1;
    -ms-flex-negative:1;
        flex-shrink:1; }
  .bp3-tag::before,
  .bp3-tag > *{
    margin-right:4px; }
  .bp3-tag:empty::before,
  .bp3-tag > :last-child{
    margin-right:0; }
  .bp3-tag:focus{
    outline:rgba(19, 124, 189, 0.6) auto 2px;
    outline-offset:0;
    -moz-outline-radius:6px; }
  .bp3-tag.bp3-round{
    border-radius:30px;
    padding-right:8px;
    padding-left:8px; }
  .bp3-dark .bp3-tag{
    background-color:#bfccd6;
    color:#182026; }
    .bp3-dark .bp3-tag.bp3-interactive{
      cursor:pointer; }
      .bp3-dark .bp3-tag.bp3-interactive:hover{
        background-color:rgba(191, 204, 214, 0.85); }
      .bp3-dark .bp3-tag.bp3-interactive.bp3-active, .bp3-dark .bp3-tag.bp3-interactive:active{
        background-color:rgba(191, 204, 214, 0.7); }
    .bp3-dark .bp3-tag > .bp3-icon, .bp3-dark .bp3-tag .bp3-icon-standard, .bp3-dark .bp3-tag .bp3-icon-large{
      fill:currentColor; }
  .bp3-tag > .bp3-icon, .bp3-tag .bp3-icon-standard, .bp3-tag .bp3-icon-large{
    fill:#ffffff; }
  .bp3-tag.bp3-large,
  .bp3-large .bp3-tag{
    min-width:30px;
    min-height:30px;
    padding:0 10px;
    line-height:20px;
    font-size:14px; }
    .bp3-tag.bp3-large::before,
    .bp3-tag.bp3-large > *,
    .bp3-large .bp3-tag::before,
    .bp3-large .bp3-tag > *{
      margin-right:7px; }
    .bp3-tag.bp3-large:empty::before,
    .bp3-tag.bp3-large > :last-child,
    .bp3-large .bp3-tag:empty::before,
    .bp3-large .bp3-tag > :last-child{
      margin-right:0; }
    .bp3-tag.bp3-large.bp3-round,
    .bp3-large .bp3-tag.bp3-round{
      padding-right:12px;
      padding-left:12px; }
  .bp3-tag.bp3-intent-primary{
    background:#137cbd;
    color:#ffffff; }
    .bp3-tag.bp3-intent-primary.bp3-interactive{
      cursor:pointer; }
      .bp3-tag.bp3-intent-primary.bp3-interactive:hover{
        background-color:rgba(19, 124, 189, 0.85); }
      .bp3-tag.bp3-intent-primary.bp3-interactive.bp3-active, .bp3-tag.bp3-intent-primary.bp3-interactive:active{
        background-color:rgba(19, 124, 189, 0.7); }
  .bp3-tag.bp3-intent-success{
    background:#0f9960;
    color:#ffffff; }
    .bp3-tag.bp3-intent-success.bp3-interactive{
      cursor:pointer; }
      .bp3-tag.bp3-intent-success.bp3-interactive:hover{
        background-color:rgba(15, 153, 96, 0.85); }
      .bp3-tag.bp3-intent-success.bp3-interactive.bp3-active, .bp3-tag.bp3-intent-success.bp3-interactive:active{
        background-color:rgba(15, 153, 96, 0.7); }
  .bp3-tag.bp3-intent-warning{
    background:#d9822b;
    color:#ffffff; }
    .bp3-tag.bp3-intent-warning.bp3-interactive{
      cursor:pointer; }
      .bp3-tag.bp3-intent-warning.bp3-interactive:hover{
        background-color:rgba(217, 130, 43, 0.85); }
      .bp3-tag.bp3-intent-warning.bp3-interactive.bp3-active, .bp3-tag.bp3-intent-warning.bp3-interactive:active{
        background-color:rgba(217, 130, 43, 0.7); }
  .bp3-tag.bp3-intent-danger{
    background:#db3737;
    color:#ffffff; }
    .bp3-tag.bp3-intent-danger.bp3-interactive{
      cursor:pointer; }
      .bp3-tag.bp3-intent-danger.bp3-interactive:hover{
        background-color:rgba(219, 55, 55, 0.85); }
      .bp3-tag.bp3-intent-danger.bp3-interactive.bp3-active, .bp3-tag.bp3-intent-danger.bp3-interactive:active{
        background-color:rgba(219, 55, 55, 0.7); }
  .bp3-tag.bp3-fill{
    display:-webkit-box;
    display:-ms-flexbox;
    display:flex;
    width:100%; }
  .bp3-tag.bp3-minimal > .bp3-icon, .bp3-tag.bp3-minimal .bp3-icon-standard, .bp3-tag.bp3-minimal .bp3-icon-large{
    fill:#5c7080; }
  .bp3-tag.bp3-minimal:not([class*="bp3-intent-"]){
    background-color:rgba(138, 155, 168, 0.2);
    color:#182026; }
    .bp3-tag.bp3-minimal:not([class*="bp3-intent-"]).bp3-interactive{
      cursor:pointer; }
      .bp3-tag.bp3-minimal:not([class*="bp3-intent-"]).bp3-interactive:hover{
        background-color:rgba(92, 112, 128, 0.3); }
      .bp3-tag.bp3-minimal:not([class*="bp3-intent-"]).bp3-interactive.bp3-active, .bp3-tag.bp3-minimal:not([class*="bp3-intent-"]).bp3-interactive:active{
        background-color:rgba(92, 112, 128, 0.4); }
    .bp3-dark .bp3-tag.bp3-minimal:not([class*="bp3-intent-"]){
      color:#f5f8fa; }
      .bp3-dark .bp3-tag.bp3-minimal:not([class*="bp3-intent-"]).bp3-interactive{
        cursor:pointer; }
        .bp3-dark .bp3-tag.bp3-minimal:not([class*="bp3-intent-"]).bp3-interactive:hover{
          background-color:rgba(191, 204, 214, 0.3); }
        .bp3-dark .bp3-tag.bp3-minimal:not([class*="bp3-intent-"]).bp3-interactive.bp3-active, .bp3-dark .bp3-tag.bp3-minimal:not([class*="bp3-intent-"]).bp3-interactive:active{
          background-color:rgba(191, 204, 214, 0.4); }
      .bp3-dark .bp3-tag.bp3-minimal:not([class*="bp3-intent-"]) > .bp3-icon, .bp3-dark .bp3-tag.bp3-minimal:not([class*="bp3-intent-"]) .bp3-icon-standard, .bp3-dark .bp3-tag.bp3-minimal:not([class*="bp3-intent-"]) .bp3-icon-large{
        fill:#a7b6c2; }
  .bp3-tag.bp3-minimal.bp3-intent-primary{
    background-color:rgba(19, 124, 189, 0.15);
    color:#106ba3; }
    .bp3-tag.bp3-minimal.bp3-intent-primary.bp3-interactive{
      cursor:pointer; }
      .bp3-tag.bp3-minimal.bp3-intent-primary.bp3-interactive:hover{
        background-color:rgba(19, 124, 189, 0.25); }
      .bp3-tag.bp3-minimal.bp3-intent-primary.bp3-interactive.bp3-active, .bp3-tag.bp3-minimal.bp3-intent-primary.bp3-interactive:active{
        background-color:rgba(19, 124, 189, 0.35); }
    .bp3-tag.bp3-minimal.bp3-intent-primary > .bp3-icon, .bp3-tag.bp3-minimal.bp3-intent-primary .bp3-icon-standard, .bp3-tag.bp3-minimal.bp3-intent-primary .bp3-icon-large{
      fill:#137cbd; }
    .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-primary{
      background-color:rgba(19, 124, 189, 0.25);
      color:#48aff0; }
      .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-primary.bp3-interactive{
        cursor:pointer; }
        .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-primary.bp3-interactive:hover{
          background-color:rgba(19, 124, 189, 0.35); }
        .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-primary.bp3-interactive.bp3-active, .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-primary.bp3-interactive:active{
          background-color:rgba(19, 124, 189, 0.45); }
  .bp3-tag.bp3-minimal.bp3-intent-success{
    background-color:rgba(15, 153, 96, 0.15);
    color:#0d8050; }
    .bp3-tag.bp3-minimal.bp3-intent-success.bp3-interactive{
      cursor:pointer; }
      .bp3-tag.bp3-minimal.bp3-intent-success.bp3-interactive:hover{
        background-color:rgba(15, 153, 96, 0.25); }
      .bp3-tag.bp3-minimal.bp3-intent-success.bp3-interactive.bp3-active, .bp3-tag.bp3-minimal.bp3-intent-success.bp3-interactive:active{
        background-color:rgba(15, 153, 96, 0.35); }
    .bp3-tag.bp3-minimal.bp3-intent-success > .bp3-icon, .bp3-tag.bp3-minimal.bp3-intent-success .bp3-icon-standard, .bp3-tag.bp3-minimal.bp3-intent-success .bp3-icon-large{
      fill:#0f9960; }
    .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-success{
      background-color:rgba(15, 153, 96, 0.25);
      color:#3dcc91; }
      .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-success.bp3-interactive{
        cursor:pointer; }
        .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-success.bp3-interactive:hover{
          background-color:rgba(15, 153, 96, 0.35); }
        .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-success.bp3-interactive.bp3-active, .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-success.bp3-interactive:active{
          background-color:rgba(15, 153, 96, 0.45); }
  .bp3-tag.bp3-minimal.bp3-intent-warning{
    background-color:rgba(217, 130, 43, 0.15);
    color:#bf7326; }
    .bp3-tag.bp3-minimal.bp3-intent-warning.bp3-interactive{
      cursor:pointer; }
      .bp3-tag.bp3-minimal.bp3-intent-warning.bp3-interactive:hover{
        background-color:rgba(217, 130, 43, 0.25); }
      .bp3-tag.bp3-minimal.bp3-intent-warning.bp3-interactive.bp3-active, .bp3-tag.bp3-minimal.bp3-intent-warning.bp3-interactive:active{
        background-color:rgba(217, 130, 43, 0.35); }
    .bp3-tag.bp3-minimal.bp3-intent-warning > .bp3-icon, .bp3-tag.bp3-minimal.bp3-intent-warning .bp3-icon-standard, .bp3-tag.bp3-minimal.bp3-intent-warning .bp3-icon-large{
      fill:#d9822b; }
    .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-warning{
      background-color:rgba(217, 130, 43, 0.25);
      color:#ffb366; }
      .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-warning.bp3-interactive{
        cursor:pointer; }
        .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-warning.bp3-interactive:hover{
          background-color:rgba(217, 130, 43, 0.35); }
        .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-warning.bp3-interactive.bp3-active, .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-warning.bp3-interactive:active{
          background-color:rgba(217, 130, 43, 0.45); }
  .bp3-tag.bp3-minimal.bp3-intent-danger{
    background-color:rgba(219, 55, 55, 0.15);
    color:#c23030; }
    .bp3-tag.bp3-minimal.bp3-intent-danger.bp3-interactive{
      cursor:pointer; }
      .bp3-tag.bp3-minimal.bp3-intent-danger.bp3-interactive:hover{
        background-color:rgba(219, 55, 55, 0.25); }
      .bp3-tag.bp3-minimal.bp3-intent-danger.bp3-interactive.bp3-active, .bp3-tag.bp3-minimal.bp3-intent-danger.bp3-interactive:active{
        background-color:rgba(219, 55, 55, 0.35); }
    .bp3-tag.bp3-minimal.bp3-intent-danger > .bp3-icon, .bp3-tag.bp3-minimal.bp3-intent-danger .bp3-icon-standard, .bp3-tag.bp3-minimal.bp3-intent-danger .bp3-icon-large{
      fill:#db3737; }
    .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-danger{
      background-color:rgba(219, 55, 55, 0.25);
      color:#ff7373; }
      .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-danger.bp3-interactive{
        cursor:pointer; }
        .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-danger.bp3-interactive:hover{
          background-color:rgba(219, 55, 55, 0.35); }
        .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-danger.bp3-interactive.bp3-active, .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-danger.bp3-interactive:active{
          background-color:rgba(219, 55, 55, 0.45); }

.bp3-tag-remove{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  opacity:0.5;
  margin-top:-2px;
  margin-right:-6px !important;
  margin-bottom:-2px;
  border:none;
  background:none;
  cursor:pointer;
  padding:2px;
  padding-left:0;
  color:inherit; }
  .bp3-tag-remove:hover{
    opacity:0.8;
    background:none;
    text-decoration:none; }
  .bp3-tag-remove:active{
    opacity:1; }
  .bp3-tag-remove:empty::before{
    line-height:1;
    font-family:"Icons16", sans-serif;
    font-size:16px;
    font-weight:400;
    font-style:normal;
    -moz-osx-font-smoothing:grayscale;
    -webkit-font-smoothing:antialiased;
    content:""; }
  .bp3-large .bp3-tag-remove{
    margin-right:-10px !important;
    padding:5px;
    padding-left:0; }
    .bp3-large .bp3-tag-remove:empty::before{
      line-height:1;
      font-family:"Icons20", sans-serif;
      font-size:20px;
      font-weight:400;
      font-style:normal; }
.bp3-tag-input{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-orient:horizontal;
  -webkit-box-direction:normal;
      -ms-flex-direction:row;
          flex-direction:row;
  -webkit-box-align:start;
      -ms-flex-align:start;
          align-items:flex-start;
  cursor:text;
  height:auto;
  min-height:30px;
  padding-right:0;
  padding-left:5px;
  line-height:inherit; }
  .bp3-tag-input > *{
    -webkit-box-flex:0;
        -ms-flex-positive:0;
            flex-grow:0;
    -ms-flex-negative:0;
        flex-shrink:0; }
  .bp3-tag-input > .bp3-tag-input-values{
    -webkit-box-flex:1;
        -ms-flex-positive:1;
            flex-grow:1;
    -ms-flex-negative:1;
        flex-shrink:1; }
  .bp3-tag-input .bp3-tag-input-icon{
    margin-top:7px;
    margin-right:7px;
    margin-left:2px;
    color:#5c7080; }
  .bp3-tag-input .bp3-tag-input-values{
    display:-webkit-box;
    display:-ms-flexbox;
    display:flex;
    -webkit-box-orient:horizontal;
    -webkit-box-direction:normal;
        -ms-flex-direction:row;
            flex-direction:row;
    -ms-flex-wrap:wrap;
        flex-wrap:wrap;
    -webkit-box-align:center;
        -ms-flex-align:center;
            align-items:center;
    -ms-flex-item-align:stretch;
        align-self:stretch;
    margin-top:5px;
    margin-right:7px;
    min-width:0; }
    .bp3-tag-input .bp3-tag-input-values > *{
      -webkit-box-flex:0;
          -ms-flex-positive:0;
              flex-grow:0;
      -ms-flex-negative:0;
          flex-shrink:0; }
    .bp3-tag-input .bp3-tag-input-values > .bp3-fill{
      -webkit-box-flex:1;
          -ms-flex-positive:1;
              flex-grow:1;
      -ms-flex-negative:1;
          flex-shrink:1; }
    .bp3-tag-input .bp3-tag-input-values::before,
    .bp3-tag-input .bp3-tag-input-values > *{
      margin-right:5px; }
    .bp3-tag-input .bp3-tag-input-values:empty::before,
    .bp3-tag-input .bp3-tag-input-values > :last-child{
      margin-right:0; }
    .bp3-tag-input .bp3-tag-input-values:first-child .bp3-input-ghost:first-child{
      padding-left:5px; }
    .bp3-tag-input .bp3-tag-input-values > *{
      margin-bottom:5px; }
  .bp3-tag-input .bp3-tag{
    overflow-wrap:break-word; }
    .bp3-tag-input .bp3-tag.bp3-active{
      outline:rgba(19, 124, 189, 0.6) auto 2px;
      outline-offset:0;
      -moz-outline-radius:6px; }
  .bp3-tag-input .bp3-input-ghost{
    -webkit-box-flex:1;
        -ms-flex:1 1 auto;
            flex:1 1 auto;
    width:80px;
    line-height:20px; }
    .bp3-tag-input .bp3-input-ghost:disabled, .bp3-tag-input .bp3-input-ghost.bp3-disabled{
      cursor:not-allowed; }
  .bp3-tag-input .bp3-button,
  .bp3-tag-input .bp3-spinner{
    margin:3px;
    margin-left:0; }
  .bp3-tag-input .bp3-button{
    min-width:24px;
    min-height:24px;
    padding:0 7px; }
  .bp3-tag-input.bp3-large{
    height:auto;
    min-height:40px; }
    .bp3-tag-input.bp3-large::before,
    .bp3-tag-input.bp3-large > *{
      margin-right:10px; }
    .bp3-tag-input.bp3-large:empty::before,
    .bp3-tag-input.bp3-large > :last-child{
      margin-right:0; }
    .bp3-tag-input.bp3-large .bp3-tag-input-icon{
      margin-top:10px;
      margin-left:5px; }
    .bp3-tag-input.bp3-large .bp3-input-ghost{
      line-height:30px; }
    .bp3-tag-input.bp3-large .bp3-button{
      min-width:30px;
      min-height:30px;
      padding:5px 10px;
      margin:5px;
      margin-left:0; }
    .bp3-tag-input.bp3-large .bp3-spinner{
      margin:8px;
      margin-left:0; }
  .bp3-tag-input.bp3-active{
    -webkit-box-shadow:0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
    background-color:#ffffff; }
    .bp3-tag-input.bp3-active.bp3-intent-primary{
      -webkit-box-shadow:0 0 0 1px #106ba3, 0 0 0 3px rgba(16, 107, 163, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px #106ba3, 0 0 0 3px rgba(16, 107, 163, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-tag-input.bp3-active.bp3-intent-success{
      -webkit-box-shadow:0 0 0 1px #0d8050, 0 0 0 3px rgba(13, 128, 80, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px #0d8050, 0 0 0 3px rgba(13, 128, 80, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-tag-input.bp3-active.bp3-intent-warning{
      -webkit-box-shadow:0 0 0 1px #bf7326, 0 0 0 3px rgba(191, 115, 38, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px #bf7326, 0 0 0 3px rgba(191, 115, 38, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-tag-input.bp3-active.bp3-intent-danger{
      -webkit-box-shadow:0 0 0 1px #c23030, 0 0 0 3px rgba(194, 48, 48, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px #c23030, 0 0 0 3px rgba(194, 48, 48, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
  .bp3-dark .bp3-tag-input .bp3-tag-input-icon, .bp3-tag-input.bp3-dark .bp3-tag-input-icon{
    color:#a7b6c2; }
  .bp3-dark .bp3-tag-input .bp3-input-ghost, .bp3-tag-input.bp3-dark .bp3-input-ghost{
    color:#f5f8fa; }
    .bp3-dark .bp3-tag-input .bp3-input-ghost::-webkit-input-placeholder, .bp3-tag-input.bp3-dark .bp3-input-ghost::-webkit-input-placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-tag-input .bp3-input-ghost::-moz-placeholder, .bp3-tag-input.bp3-dark .bp3-input-ghost::-moz-placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-tag-input .bp3-input-ghost:-ms-input-placeholder, .bp3-tag-input.bp3-dark .bp3-input-ghost:-ms-input-placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-tag-input .bp3-input-ghost::-ms-input-placeholder, .bp3-tag-input.bp3-dark .bp3-input-ghost::-ms-input-placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-tag-input .bp3-input-ghost::placeholder, .bp3-tag-input.bp3-dark .bp3-input-ghost::placeholder{
      color:rgba(167, 182, 194, 0.6); }
  .bp3-dark .bp3-tag-input.bp3-active, .bp3-tag-input.bp3-dark.bp3-active{
    -webkit-box-shadow:0 0 0 1px #137cbd, 0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px #137cbd, 0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
    background-color:rgba(16, 22, 26, 0.3); }
    .bp3-dark .bp3-tag-input.bp3-active.bp3-intent-primary, .bp3-tag-input.bp3-dark.bp3-active.bp3-intent-primary{
      -webkit-box-shadow:0 0 0 1px #106ba3, 0 0 0 3px rgba(16, 107, 163, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 1px #106ba3, 0 0 0 3px rgba(16, 107, 163, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
    .bp3-dark .bp3-tag-input.bp3-active.bp3-intent-success, .bp3-tag-input.bp3-dark.bp3-active.bp3-intent-success{
      -webkit-box-shadow:0 0 0 1px #0d8050, 0 0 0 3px rgba(13, 128, 80, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 1px #0d8050, 0 0 0 3px rgba(13, 128, 80, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
    .bp3-dark .bp3-tag-input.bp3-active.bp3-intent-warning, .bp3-tag-input.bp3-dark.bp3-active.bp3-intent-warning{
      -webkit-box-shadow:0 0 0 1px #bf7326, 0 0 0 3px rgba(191, 115, 38, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 1px #bf7326, 0 0 0 3px rgba(191, 115, 38, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
    .bp3-dark .bp3-tag-input.bp3-active.bp3-intent-danger, .bp3-tag-input.bp3-dark.bp3-active.bp3-intent-danger{
      -webkit-box-shadow:0 0 0 1px #c23030, 0 0 0 3px rgba(194, 48, 48, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 1px #c23030, 0 0 0 3px rgba(194, 48, 48, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }

.bp3-input-ghost{
  border:none;
  -webkit-box-shadow:none;
          box-shadow:none;
  background:none;
  padding:0; }
  .bp3-input-ghost::-webkit-input-placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-input-ghost::-moz-placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-input-ghost:-ms-input-placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-input-ghost::-ms-input-placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-input-ghost::placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-input-ghost:focus{
    outline:none !important; }
.bp3-toast{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-align:start;
      -ms-flex-align:start;
          align-items:flex-start;
  position:relative !important;
  margin:20px 0 0;
  border-radius:3px;
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 2px 4px rgba(16, 22, 26, 0.2), 0 8px 24px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 2px 4px rgba(16, 22, 26, 0.2), 0 8px 24px rgba(16, 22, 26, 0.2);
  background-color:#ffffff;
  min-width:300px;
  max-width:500px;
  pointer-events:all; }
  .bp3-toast.bp3-toast-enter, .bp3-toast.bp3-toast-appear{
    -webkit-transform:translateY(-40px);
            transform:translateY(-40px); }
  .bp3-toast.bp3-toast-enter-active, .bp3-toast.bp3-toast-appear-active{
    -webkit-transform:translateY(0);
            transform:translateY(0);
    -webkit-transition-property:-webkit-transform;
    transition-property:-webkit-transform;
    transition-property:transform;
    transition-property:transform, -webkit-transform;
    -webkit-transition-duration:300ms;
            transition-duration:300ms;
    -webkit-transition-timing-function:cubic-bezier(0.54, 1.12, 0.38, 1.11);
            transition-timing-function:cubic-bezier(0.54, 1.12, 0.38, 1.11);
    -webkit-transition-delay:0;
            transition-delay:0; }
  .bp3-toast.bp3-toast-enter ~ .bp3-toast, .bp3-toast.bp3-toast-appear ~ .bp3-toast{
    -webkit-transform:translateY(-40px);
            transform:translateY(-40px); }
  .bp3-toast.bp3-toast-enter-active ~ .bp3-toast, .bp3-toast.bp3-toast-appear-active ~ .bp3-toast{
    -webkit-transform:translateY(0);
            transform:translateY(0);
    -webkit-transition-property:-webkit-transform;
    transition-property:-webkit-transform;
    transition-property:transform;
    transition-property:transform, -webkit-transform;
    -webkit-transition-duration:300ms;
            transition-duration:300ms;
    -webkit-transition-timing-function:cubic-bezier(0.54, 1.12, 0.38, 1.11);
            transition-timing-function:cubic-bezier(0.54, 1.12, 0.38, 1.11);
    -webkit-transition-delay:0;
            transition-delay:0; }
  .bp3-toast.bp3-toast-exit{
    opacity:1;
    -webkit-filter:blur(0);
            filter:blur(0); }
  .bp3-toast.bp3-toast-exit-active{
    opacity:0;
    -webkit-filter:blur(10px);
            filter:blur(10px);
    -webkit-transition-property:opacity, -webkit-filter;
    transition-property:opacity, -webkit-filter;
    transition-property:opacity, filter;
    transition-property:opacity, filter, -webkit-filter;
    -webkit-transition-duration:300ms;
            transition-duration:300ms;
    -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
            transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
    -webkit-transition-delay:0;
            transition-delay:0; }
  .bp3-toast.bp3-toast-exit ~ .bp3-toast{
    -webkit-transform:translateY(0);
            transform:translateY(0); }
  .bp3-toast.bp3-toast-exit-active ~ .bp3-toast{
    -webkit-transform:translateY(-40px);
            transform:translateY(-40px);
    -webkit-transition-property:-webkit-transform;
    transition-property:-webkit-transform;
    transition-property:transform;
    transition-property:transform, -webkit-transform;
    -webkit-transition-duration:100ms;
            transition-duration:100ms;
    -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
            transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
    -webkit-transition-delay:50ms;
            transition-delay:50ms; }
  .bp3-toast .bp3-button-group{
    -webkit-box-flex:0;
        -ms-flex:0 0 auto;
            flex:0 0 auto;
    padding:5px;
    padding-left:0; }
  .bp3-toast > .bp3-icon{
    margin:12px;
    margin-right:0;
    color:#5c7080; }
  .bp3-toast.bp3-dark,
  .bp3-dark .bp3-toast{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 2px 4px rgba(16, 22, 26, 0.4), 0 8px 24px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 2px 4px rgba(16, 22, 26, 0.4), 0 8px 24px rgba(16, 22, 26, 0.4);
    background-color:#394b59; }
    .bp3-toast.bp3-dark > .bp3-icon,
    .bp3-dark .bp3-toast > .bp3-icon{
      color:#a7b6c2; }
  .bp3-toast[class*="bp3-intent-"] a{
    color:rgba(255, 255, 255, 0.7); }
    .bp3-toast[class*="bp3-intent-"] a:hover{
      color:#ffffff; }
  .bp3-toast[class*="bp3-intent-"] > .bp3-icon{
    color:#ffffff; }
  .bp3-toast[class*="bp3-intent-"] .bp3-button, .bp3-toast[class*="bp3-intent-"] .bp3-button::before,
  .bp3-toast[class*="bp3-intent-"] .bp3-button .bp3-icon, .bp3-toast[class*="bp3-intent-"] .bp3-button:active{
    color:rgba(255, 255, 255, 0.7) !important; }
  .bp3-toast[class*="bp3-intent-"] .bp3-button:focus{
    outline-color:rgba(255, 255, 255, 0.5); }
  .bp3-toast[class*="bp3-intent-"] .bp3-button:hover{
    background-color:rgba(255, 255, 255, 0.15) !important;
    color:#ffffff !important; }
  .bp3-toast[class*="bp3-intent-"] .bp3-button:active{
    background-color:rgba(255, 255, 255, 0.3) !important;
    color:#ffffff !important; }
  .bp3-toast[class*="bp3-intent-"] .bp3-button::after{
    background:rgba(255, 255, 255, 0.3) !important; }
  .bp3-toast.bp3-intent-primary{
    background-color:#137cbd;
    color:#ffffff; }
  .bp3-toast.bp3-intent-success{
    background-color:#0f9960;
    color:#ffffff; }
  .bp3-toast.bp3-intent-warning{
    background-color:#d9822b;
    color:#ffffff; }
  .bp3-toast.bp3-intent-danger{
    background-color:#db3737;
    color:#ffffff; }

.bp3-toast-message{
  -webkit-box-flex:1;
      -ms-flex:1 1 auto;
          flex:1 1 auto;
  padding:11px;
  word-break:break-word; }

.bp3-toast-container{
  display:-webkit-box !important;
  display:-ms-flexbox !important;
  display:flex !important;
  -webkit-box-orient:vertical;
  -webkit-box-direction:normal;
      -ms-flex-direction:column;
          flex-direction:column;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center;
  position:fixed;
  right:0;
  left:0;
  z-index:40;
  overflow:hidden;
  padding:0 20px 20px;
  pointer-events:none; }
  .bp3-toast-container.bp3-toast-container-top{
    top:0;
    bottom:auto; }
  .bp3-toast-container.bp3-toast-container-bottom{
    -webkit-box-orient:vertical;
    -webkit-box-direction:reverse;
        -ms-flex-direction:column-reverse;
            flex-direction:column-reverse;
    top:auto;
    bottom:0; }
  .bp3-toast-container.bp3-toast-container-left{
    -webkit-box-align:start;
        -ms-flex-align:start;
            align-items:flex-start; }
  .bp3-toast-container.bp3-toast-container-right{
    -webkit-box-align:end;
        -ms-flex-align:end;
            align-items:flex-end; }

.bp3-toast-container-bottom .bp3-toast.bp3-toast-enter:not(.bp3-toast-enter-active),
.bp3-toast-container-bottom .bp3-toast.bp3-toast-enter:not(.bp3-toast-enter-active) ~ .bp3-toast, .bp3-toast-container-bottom .bp3-toast.bp3-toast-appear:not(.bp3-toast-appear-active),
.bp3-toast-container-bottom .bp3-toast.bp3-toast-appear:not(.bp3-toast-appear-active) ~ .bp3-toast,
.bp3-toast-container-bottom .bp3-toast.bp3-toast-leave-active ~ .bp3-toast{
  -webkit-transform:translateY(60px);
          transform:translateY(60px); }
.bp3-tooltip{
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 2px 4px rgba(16, 22, 26, 0.2), 0 8px 24px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 2px 4px rgba(16, 22, 26, 0.2), 0 8px 24px rgba(16, 22, 26, 0.2);
  -webkit-transform:scale(1);
          transform:scale(1); }
  .bp3-tooltip .bp3-popover-arrow{
    position:absolute;
    width:22px;
    height:22px; }
    .bp3-tooltip .bp3-popover-arrow::before{
      margin:4px;
      width:14px;
      height:14px; }
  .bp3-tether-element-attached-bottom.bp3-tether-target-attached-top > .bp3-tooltip{
    margin-top:-11px;
    margin-bottom:11px; }
    .bp3-tether-element-attached-bottom.bp3-tether-target-attached-top > .bp3-tooltip > .bp3-popover-arrow{
      bottom:-8px; }
      .bp3-tether-element-attached-bottom.bp3-tether-target-attached-top > .bp3-tooltip > .bp3-popover-arrow svg{
        -webkit-transform:rotate(-90deg);
                transform:rotate(-90deg); }
  .bp3-tether-element-attached-left.bp3-tether-target-attached-right > .bp3-tooltip{
    margin-left:11px; }
    .bp3-tether-element-attached-left.bp3-tether-target-attached-right > .bp3-tooltip > .bp3-popover-arrow{
      left:-8px; }
      .bp3-tether-element-attached-left.bp3-tether-target-attached-right > .bp3-tooltip > .bp3-popover-arrow svg{
        -webkit-transform:rotate(0);
                transform:rotate(0); }
  .bp3-tether-element-attached-top.bp3-tether-target-attached-bottom > .bp3-tooltip{
    margin-top:11px; }
    .bp3-tether-element-attached-top.bp3-tether-target-attached-bottom > .bp3-tooltip > .bp3-popover-arrow{
      top:-8px; }
      .bp3-tether-element-attached-top.bp3-tether-target-attached-bottom > .bp3-tooltip > .bp3-popover-arrow svg{
        -webkit-transform:rotate(90deg);
                transform:rotate(90deg); }
  .bp3-tether-element-attached-right.bp3-tether-target-attached-left > .bp3-tooltip{
    margin-right:11px;
    margin-left:-11px; }
    .bp3-tether-element-attached-right.bp3-tether-target-attached-left > .bp3-tooltip > .bp3-popover-arrow{
      right:-8px; }
      .bp3-tether-element-attached-right.bp3-tether-target-attached-left > .bp3-tooltip > .bp3-popover-arrow svg{
        -webkit-transform:rotate(180deg);
                transform:rotate(180deg); }
  .bp3-tether-element-attached-middle > .bp3-tooltip > .bp3-popover-arrow{
    top:50%;
    -webkit-transform:translateY(-50%);
            transform:translateY(-50%); }
  .bp3-tether-element-attached-center > .bp3-tooltip > .bp3-popover-arrow{
    right:50%;
    -webkit-transform:translateX(50%);
            transform:translateX(50%); }
  .bp3-tether-element-attached-top.bp3-tether-target-attached-top > .bp3-tooltip > .bp3-popover-arrow{
    top:-0.22183px; }
  .bp3-tether-element-attached-right.bp3-tether-target-attached-right > .bp3-tooltip > .bp3-popover-arrow{
    right:-0.22183px; }
  .bp3-tether-element-attached-left.bp3-tether-target-attached-left > .bp3-tooltip > .bp3-popover-arrow{
    left:-0.22183px; }
  .bp3-tether-element-attached-bottom.bp3-tether-target-attached-bottom > .bp3-tooltip > .bp3-popover-arrow{
    bottom:-0.22183px; }
  .bp3-tether-element-attached-top.bp3-tether-element-attached-left > .bp3-tooltip{
    -webkit-transform-origin:top left;
            transform-origin:top left; }
  .bp3-tether-element-attached-top.bp3-tether-element-attached-center > .bp3-tooltip{
    -webkit-transform-origin:top center;
            transform-origin:top center; }
  .bp3-tether-element-attached-top.bp3-tether-element-attached-right > .bp3-tooltip{
    -webkit-transform-origin:top right;
            transform-origin:top right; }
  .bp3-tether-element-attached-middle.bp3-tether-element-attached-left > .bp3-tooltip{
    -webkit-transform-origin:center left;
            transform-origin:center left; }
  .bp3-tether-element-attached-middle.bp3-tether-element-attached-center > .bp3-tooltip{
    -webkit-transform-origin:center center;
            transform-origin:center center; }
  .bp3-tether-element-attached-middle.bp3-tether-element-attached-right > .bp3-tooltip{
    -webkit-transform-origin:center right;
            transform-origin:center right; }
  .bp3-tether-element-attached-bottom.bp3-tether-element-attached-left > .bp3-tooltip{
    -webkit-transform-origin:bottom left;
            transform-origin:bottom left; }
  .bp3-tether-element-attached-bottom.bp3-tether-element-attached-center > .bp3-tooltip{
    -webkit-transform-origin:bottom center;
            transform-origin:bottom center; }
  .bp3-tether-element-attached-bottom.bp3-tether-element-attached-right > .bp3-tooltip{
    -webkit-transform-origin:bottom right;
            transform-origin:bottom right; }
  .bp3-tooltip .bp3-popover-content{
    background:#394b59;
    color:#f5f8fa; }
  .bp3-tooltip .bp3-popover-arrow::before{
    -webkit-box-shadow:1px 1px 6px rgba(16, 22, 26, 0.2);
            box-shadow:1px 1px 6px rgba(16, 22, 26, 0.2); }
  .bp3-tooltip .bp3-popover-arrow-border{
    fill:#10161a;
    fill-opacity:0.1; }
  .bp3-tooltip .bp3-popover-arrow-fill{
    fill:#394b59; }
  .bp3-popover-enter > .bp3-tooltip, .bp3-popover-appear > .bp3-tooltip{
    -webkit-transform:scale(0.8);
            transform:scale(0.8); }
  .bp3-popover-enter-active > .bp3-tooltip, .bp3-popover-appear-active > .bp3-tooltip{
    -webkit-transform:scale(1);
            transform:scale(1);
    -webkit-transition-property:-webkit-transform;
    transition-property:-webkit-transform;
    transition-property:transform;
    transition-property:transform, -webkit-transform;
    -webkit-transition-duration:100ms;
            transition-duration:100ms;
    -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
            transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
    -webkit-transition-delay:0;
            transition-delay:0; }
  .bp3-popover-exit > .bp3-tooltip{
    -webkit-transform:scale(1);
            transform:scale(1); }
  .bp3-popover-exit-active > .bp3-tooltip{
    -webkit-transform:scale(0.8);
            transform:scale(0.8);
    -webkit-transition-property:-webkit-transform;
    transition-property:-webkit-transform;
    transition-property:transform;
    transition-property:transform, -webkit-transform;
    -webkit-transition-duration:100ms;
            transition-duration:100ms;
    -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
            transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
    -webkit-transition-delay:0;
            transition-delay:0; }
  .bp3-tooltip .bp3-popover-content{
    padding:10px 12px; }
  .bp3-tooltip.bp3-dark,
  .bp3-dark .bp3-tooltip{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 2px 4px rgba(16, 22, 26, 0.4), 0 8px 24px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 2px 4px rgba(16, 22, 26, 0.4), 0 8px 24px rgba(16, 22, 26, 0.4); }
    .bp3-tooltip.bp3-dark .bp3-popover-content,
    .bp3-dark .bp3-tooltip .bp3-popover-content{
      background:#e1e8ed;
      color:#394b59; }
    .bp3-tooltip.bp3-dark .bp3-popover-arrow::before,
    .bp3-dark .bp3-tooltip .bp3-popover-arrow::before{
      -webkit-box-shadow:1px 1px 6px rgba(16, 22, 26, 0.4);
              box-shadow:1px 1px 6px rgba(16, 22, 26, 0.4); }
    .bp3-tooltip.bp3-dark .bp3-popover-arrow-border,
    .bp3-dark .bp3-tooltip .bp3-popover-arrow-border{
      fill:#10161a;
      fill-opacity:0.2; }
    .bp3-tooltip.bp3-dark .bp3-popover-arrow-fill,
    .bp3-dark .bp3-tooltip .bp3-popover-arrow-fill{
      fill:#e1e8ed; }
  .bp3-tooltip.bp3-intent-primary .bp3-popover-content{
    background:#137cbd;
    color:#ffffff; }
  .bp3-tooltip.bp3-intent-primary .bp3-popover-arrow-fill{
    fill:#137cbd; }
  .bp3-tooltip.bp3-intent-success .bp3-popover-content{
    background:#0f9960;
    color:#ffffff; }
  .bp3-tooltip.bp3-intent-success .bp3-popover-arrow-fill{
    fill:#0f9960; }
  .bp3-tooltip.bp3-intent-warning .bp3-popover-content{
    background:#d9822b;
    color:#ffffff; }
  .bp3-tooltip.bp3-intent-warning .bp3-popover-arrow-fill{
    fill:#d9822b; }
  .bp3-tooltip.bp3-intent-danger .bp3-popover-content{
    background:#db3737;
    color:#ffffff; }
  .bp3-tooltip.bp3-intent-danger .bp3-popover-arrow-fill{
    fill:#db3737; }

.bp3-tooltip-indicator{
  border-bottom:dotted 1px;
  cursor:help; }
.bp3-tree .bp3-icon, .bp3-tree .bp3-icon-standard, .bp3-tree .bp3-icon-large{
  color:#5c7080; }
  .bp3-tree .bp3-icon.bp3-intent-primary, .bp3-tree .bp3-icon-standard.bp3-intent-primary, .bp3-tree .bp3-icon-large.bp3-intent-primary{
    color:#137cbd; }
  .bp3-tree .bp3-icon.bp3-intent-success, .bp3-tree .bp3-icon-standard.bp3-intent-success, .bp3-tree .bp3-icon-large.bp3-intent-success{
    color:#0f9960; }
  .bp3-tree .bp3-icon.bp3-intent-warning, .bp3-tree .bp3-icon-standard.bp3-intent-warning, .bp3-tree .bp3-icon-large.bp3-intent-warning{
    color:#d9822b; }
  .bp3-tree .bp3-icon.bp3-intent-danger, .bp3-tree .bp3-icon-standard.bp3-intent-danger, .bp3-tree .bp3-icon-large.bp3-intent-danger{
    color:#db3737; }

.bp3-tree-node-list{
  margin:0;
  padding-left:0;
  list-style:none; }

.bp3-tree-root{
  position:relative;
  background-color:transparent;
  cursor:default;
  padding-left:0; }

.bp3-tree-node-content-0{
  padding-left:0px; }

.bp3-tree-node-content-1{
  padding-left:23px; }

.bp3-tree-node-content-2{
  padding-left:46px; }

.bp3-tree-node-content-3{
  padding-left:69px; }

.bp3-tree-node-content-4{
  padding-left:92px; }

.bp3-tree-node-content-5{
  padding-left:115px; }

.bp3-tree-node-content-6{
  padding-left:138px; }

.bp3-tree-node-content-7{
  padding-left:161px; }

.bp3-tree-node-content-8{
  padding-left:184px; }

.bp3-tree-node-content-9{
  padding-left:207px; }

.bp3-tree-node-content-10{
  padding-left:230px; }

.bp3-tree-node-content-11{
  padding-left:253px; }

.bp3-tree-node-content-12{
  padding-left:276px; }

.bp3-tree-node-content-13{
  padding-left:299px; }

.bp3-tree-node-content-14{
  padding-left:322px; }

.bp3-tree-node-content-15{
  padding-left:345px; }

.bp3-tree-node-content-16{
  padding-left:368px; }

.bp3-tree-node-content-17{
  padding-left:391px; }

.bp3-tree-node-content-18{
  padding-left:414px; }

.bp3-tree-node-content-19{
  padding-left:437px; }

.bp3-tree-node-content-20{
  padding-left:460px; }

.bp3-tree-node-content{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center;
  width:100%;
  height:30px;
  padding-right:5px; }
  .bp3-tree-node-content:hover{
    background-color:rgba(191, 204, 214, 0.4); }

.bp3-tree-node-caret,
.bp3-tree-node-caret-none{
  min-width:30px; }

.bp3-tree-node-caret{
  color:#5c7080;
  -webkit-transform:rotate(0deg);
          transform:rotate(0deg);
  cursor:pointer;
  padding:7px;
  -webkit-transition:-webkit-transform 200ms cubic-bezier(0.4, 1, 0.75, 0.9);
  transition:-webkit-transform 200ms cubic-bezier(0.4, 1, 0.75, 0.9);
  transition:transform 200ms cubic-bezier(0.4, 1, 0.75, 0.9);
  transition:transform 200ms cubic-bezier(0.4, 1, 0.75, 0.9), -webkit-transform 200ms cubic-bezier(0.4, 1, 0.75, 0.9); }
  .bp3-tree-node-caret:hover{
    color:#182026; }
  .bp3-dark .bp3-tree-node-caret{
    color:#a7b6c2; }
    .bp3-dark .bp3-tree-node-caret:hover{
      color:#f5f8fa; }
  .bp3-tree-node-caret.bp3-tree-node-caret-open{
    -webkit-transform:rotate(90deg);
            transform:rotate(90deg); }
  .bp3-tree-node-caret.bp3-icon-standard::before{
    content:""; }

.bp3-tree-node-icon{
  position:relative;
  margin-right:7px; }

.bp3-tree-node-label{
  overflow:hidden;
  text-overflow:ellipsis;
  white-space:nowrap;
  word-wrap:normal;
  -webkit-box-flex:1;
      -ms-flex:1 1 auto;
          flex:1 1 auto;
  position:relative;
  -webkit-user-select:none;
     -moz-user-select:none;
      -ms-user-select:none;
          user-select:none; }
  .bp3-tree-node-label span{
    display:inline; }

.bp3-tree-node-secondary-label{
  padding:0 5px;
  -webkit-user-select:none;
     -moz-user-select:none;
      -ms-user-select:none;
          user-select:none; }
  .bp3-tree-node-secondary-label .bp3-popover-wrapper,
  .bp3-tree-node-secondary-label .bp3-popover-target{
    display:-webkit-box;
    display:-ms-flexbox;
    display:flex;
    -webkit-box-align:center;
        -ms-flex-align:center;
            align-items:center; }

.bp3-tree-node.bp3-disabled .bp3-tree-node-content{
  background-color:inherit;
  cursor:not-allowed;
  color:rgba(92, 112, 128, 0.6); }

.bp3-tree-node.bp3-disabled .bp3-tree-node-caret,
.bp3-tree-node.bp3-disabled .bp3-tree-node-icon{
  cursor:not-allowed;
  color:rgba(92, 112, 128, 0.6); }

.bp3-tree-node.bp3-tree-node-selected > .bp3-tree-node-content{
  background-color:#137cbd; }
  .bp3-tree-node.bp3-tree-node-selected > .bp3-tree-node-content,
  .bp3-tree-node.bp3-tree-node-selected > .bp3-tree-node-content .bp3-icon, .bp3-tree-node.bp3-tree-node-selected > .bp3-tree-node-content .bp3-icon-standard, .bp3-tree-node.bp3-tree-node-selected > .bp3-tree-node-content .bp3-icon-large{
    color:#ffffff; }
  .bp3-tree-node.bp3-tree-node-selected > .bp3-tree-node-content .bp3-tree-node-caret::before{
    color:rgba(255, 255, 255, 0.7); }
  .bp3-tree-node.bp3-tree-node-selected > .bp3-tree-node-content .bp3-tree-node-caret:hover::before{
    color:#ffffff; }

.bp3-dark .bp3-tree-node-content:hover{
  background-color:rgba(92, 112, 128, 0.3); }

.bp3-dark .bp3-tree .bp3-icon, .bp3-dark .bp3-tree .bp3-icon-standard, .bp3-dark .bp3-tree .bp3-icon-large{
  color:#a7b6c2; }
  .bp3-dark .bp3-tree .bp3-icon.bp3-intent-primary, .bp3-dark .bp3-tree .bp3-icon-standard.bp3-intent-primary, .bp3-dark .bp3-tree .bp3-icon-large.bp3-intent-primary{
    color:#137cbd; }
  .bp3-dark .bp3-tree .bp3-icon.bp3-intent-success, .bp3-dark .bp3-tree .bp3-icon-standard.bp3-intent-success, .bp3-dark .bp3-tree .bp3-icon-large.bp3-intent-success{
    color:#0f9960; }
  .bp3-dark .bp3-tree .bp3-icon.bp3-intent-warning, .bp3-dark .bp3-tree .bp3-icon-standard.bp3-intent-warning, .bp3-dark .bp3-tree .bp3-icon-large.bp3-intent-warning{
    color:#d9822b; }
  .bp3-dark .bp3-tree .bp3-icon.bp3-intent-danger, .bp3-dark .bp3-tree .bp3-icon-standard.bp3-intent-danger, .bp3-dark .bp3-tree .bp3-icon-large.bp3-intent-danger{
    color:#db3737; }

.bp3-dark .bp3-tree-node.bp3-tree-node-selected > .bp3-tree-node-content{
  background-color:#137cbd; }
/*!

Copyright 2017-present Palantir Technologies, Inc. All rights reserved.
Licensed under the Apache License, Version 2.0.

*/
.bp3-omnibar{
  -webkit-filter:blur(0);
          filter:blur(0);
  opacity:1;
  top:20vh;
  left:calc(50% - 250px);
  z-index:21;
  border-radius:3px;
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 4px 8px rgba(16, 22, 26, 0.2), 0 18px 46px 6px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 4px 8px rgba(16, 22, 26, 0.2), 0 18px 46px 6px rgba(16, 22, 26, 0.2);
  background-color:#ffffff;
  width:500px; }
  .bp3-omnibar.bp3-overlay-enter, .bp3-omnibar.bp3-overlay-appear{
    -webkit-filter:blur(20px);
            filter:blur(20px);
    opacity:0.2; }
  .bp3-omnibar.bp3-overlay-enter-active, .bp3-omnibar.bp3-overlay-appear-active{
    -webkit-filter:blur(0);
            filter:blur(0);
    opacity:1;
    -webkit-transition-property:opacity, -webkit-filter;
    transition-property:opacity, -webkit-filter;
    transition-property:filter, opacity;
    transition-property:filter, opacity, -webkit-filter;
    -webkit-transition-duration:200ms;
            transition-duration:200ms;
    -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
            transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
    -webkit-transition-delay:0;
            transition-delay:0; }
  .bp3-omnibar.bp3-overlay-exit{
    -webkit-filter:blur(0);
            filter:blur(0);
    opacity:1; }
  .bp3-omnibar.bp3-overlay-exit-active{
    -webkit-filter:blur(20px);
            filter:blur(20px);
    opacity:0.2;
    -webkit-transition-property:opacity, -webkit-filter;
    transition-property:opacity, -webkit-filter;
    transition-property:filter, opacity;
    transition-property:filter, opacity, -webkit-filter;
    -webkit-transition-duration:200ms;
            transition-duration:200ms;
    -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
            transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
    -webkit-transition-delay:0;
            transition-delay:0; }
  .bp3-omnibar .bp3-input{
    border-radius:0;
    background-color:transparent; }
    .bp3-omnibar .bp3-input, .bp3-omnibar .bp3-input:focus{
      -webkit-box-shadow:none;
              box-shadow:none; }
  .bp3-omnibar .bp3-menu{
    border-radius:0;
    -webkit-box-shadow:inset 0 1px 0 rgba(16, 22, 26, 0.15);
            box-shadow:inset 0 1px 0 rgba(16, 22, 26, 0.15);
    background-color:transparent;
    max-height:calc(60vh - 40px);
    overflow:auto; }
    .bp3-omnibar .bp3-menu:empty{
      display:none; }
  .bp3-dark .bp3-omnibar, .bp3-omnibar.bp3-dark{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 4px 8px rgba(16, 22, 26, 0.4), 0 18px 46px 6px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 4px 8px rgba(16, 22, 26, 0.4), 0 18px 46px 6px rgba(16, 22, 26, 0.4);
    background-color:#30404d; }

.bp3-omnibar-overlay .bp3-overlay-backdrop{
  background-color:rgba(16, 22, 26, 0.2); }

.bp3-select-popover .bp3-popover-content{
  padding:5px; }

.bp3-select-popover .bp3-input-group{
  margin-bottom:0; }

.bp3-select-popover .bp3-menu{
  max-width:400px;
  max-height:300px;
  overflow:auto;
  padding:0; }
  .bp3-select-popover .bp3-menu:not(:first-child){
    padding-top:5px; }

.bp3-multi-select{
  min-width:150px; }

.bp3-multi-select-popover .bp3-menu{
  max-width:400px;
  max-height:300px;
  overflow:auto; }

.bp3-select-popover .bp3-popover-content{
  padding:5px; }

.bp3-select-popover .bp3-input-group{
  margin-bottom:0; }

.bp3-select-popover .bp3-menu{
  max-width:400px;
  max-height:300px;
  overflow:auto;
  padding:0; }
  .bp3-select-popover .bp3-menu:not(:first-child){
    padding-top:5px; }
/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/* This file was auto-generated by ensureUiComponents() in @jupyterlab/buildutils */

/**
 * (DEPRECATED) Support for consuming icons as CSS background images
 */

/* Icons urls */

:root {
  --jp-icon-add: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTE5IDEzaC02djZoLTJ2LTZINXYtMmg2VjVoMnY2aDZ2MnoiLz4KICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-bug: url(data:image/svg+xml;base64,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);
  --jp-icon-build: url(data:image/svg+xml;base64,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);
  --jp-icon-caret-down-empty-thin: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDIwIDIwIj4KCTxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSIgc2hhcGUtcmVuZGVyaW5nPSJnZW9tZXRyaWNQcmVjaXNpb24iPgoJCTxwb2x5Z29uIGNsYXNzPSJzdDEiIHBvaW50cz0iOS45LDEzLjYgMy42LDcuNCA0LjQsNi42IDkuOSwxMi4yIDE1LjQsNi43IDE2LjEsNy40ICIvPgoJPC9nPgo8L3N2Zz4K);
  --jp-icon-caret-down-empty: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDE4IDE4Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiIHNoYXBlLXJlbmRlcmluZz0iZ2VvbWV0cmljUHJlY2lzaW9uIj4KICAgIDxwYXRoIGQ9Ik01LjIsNS45TDksOS43bDMuOC0zLjhsMS4yLDEuMmwtNC45LDVsLTQuOS01TDUuMiw1Ljl6Ii8+CiAgPC9nPgo8L3N2Zz4K);
  --jp-icon-caret-down: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDE4IDE4Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiIHNoYXBlLXJlbmRlcmluZz0iZ2VvbWV0cmljUHJlY2lzaW9uIj4KICAgIDxwYXRoIGQ9Ik01LjIsNy41TDksMTEuMmwzLjgtMy44SDUuMnoiLz4KICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-caret-left: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDE4IDE4Ij4KCTxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSIgc2hhcGUtcmVuZGVyaW5nPSJnZW9tZXRyaWNQcmVjaXNpb24iPgoJCTxwYXRoIGQ9Ik0xMC44LDEyLjhMNy4xLDlsMy44LTMuOGwwLDcuNkgxMC44eiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-caret-right: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDE4IDE4Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiIHNoYXBlLXJlbmRlcmluZz0iZ2VvbWV0cmljUHJlY2lzaW9uIj4KICAgIDxwYXRoIGQ9Ik03LjIsNS4yTDEwLjksOWwtMy44LDMuOFY1LjJINy4yeiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-caret-up-empty-thin: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDIwIDIwIj4KCTxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSIgc2hhcGUtcmVuZGVyaW5nPSJnZW9tZXRyaWNQcmVjaXNpb24iPgoJCTxwb2x5Z29uIGNsYXNzPSJzdDEiIHBvaW50cz0iMTUuNCwxMy4zIDkuOSw3LjcgNC40LDEzLjIgMy42LDEyLjUgOS45LDYuMyAxNi4xLDEyLjYgIi8+Cgk8L2c+Cjwvc3ZnPgo=);
  --jp-icon-caret-up: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDE4IDE4Ij4KCTxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSIgc2hhcGUtcmVuZGVyaW5nPSJnZW9tZXRyaWNQcmVjaXNpb24iPgoJCTxwYXRoIGQ9Ik01LjIsMTAuNUw5LDYuOGwzLjgsMy44SDUuMnoiLz4KICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-case-sensitive: url(data:image/svg+xml;base64,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);
  --jp-icon-check: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTkgMTYuMTdMNC44MyAxMmwtMS40MiAxLjQxTDkgMTkgMjEgN2wtMS40MS0xLjQxeiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-circle-empty: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTEyIDJDNi40NyAyIDIgNi40NyAyIDEyczQuNDcgMTAgMTAgMTAgMTAtNC40NyAxMC0xMFMxNy41MyAyIDEyIDJ6bTAgMThjLTQuNDEgMC04LTMuNTktOC04czMuNTktOCA4LTggOCAzLjU5IDggOC0zLjU5IDgtOCA4eiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-circle: url(data:image/svg+xml;base64,PHN2ZyB2aWV3Qm94PSIwIDAgMTggMTgiIHdpZHRoPSIxNiIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPGNpcmNsZSBjeD0iOSIgY3k9IjkiIHI9IjgiLz4KICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-clear: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8bWFzayBpZD0iZG9udXRIb2xlIj4KICAgIDxyZWN0IHdpZHRoPSIyNCIgaGVpZ2h0PSIyNCIgZmlsbD0id2hpdGUiIC8+CiAgICA8Y2lyY2xlIGN4PSIxMiIgY3k9IjEyIiByPSI4IiBmaWxsPSJibGFjayIvPgogIDwvbWFzaz4KCiAgPGcgY2xhc3M9ImpwLWljb24zIiBmaWxsPSIjNjE2MTYxIj4KICAgIDxyZWN0IGhlaWdodD0iMTgiIHdpZHRoPSIyIiB4PSIxMSIgeT0iMyIgdHJhbnNmb3JtPSJyb3RhdGUoMzE1LCAxMiwgMTIpIi8+CiAgICA8Y2lyY2xlIGN4PSIxMiIgY3k9IjEyIiByPSIxMCIgbWFzaz0idXJsKCNkb251dEhvbGUpIi8+CiAgPC9nPgo8L3N2Zz4K);
  --jp-icon-close: url(data:image/svg+xml;base64,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);
  --jp-icon-console: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDIwMCAyMDAiPgogIDxnIGNsYXNzPSJqcC1pY29uLWJyYW5kMSBqcC1pY29uLXNlbGVjdGFibGUiIGZpbGw9IiMwMjg4RDEiPgogICAgPHBhdGggZD0iTTIwIDE5LjhoMTYwdjE1OS45SDIweiIvPgogIDwvZz4KICA8ZyBjbGFzcz0ianAtaWNvbi1zZWxlY3RhYmxlLWludmVyc2UiIGZpbGw9IiNmZmYiPgogICAgPHBhdGggZD0iTTEwNSAxMjcuM2g0MHYxMi44aC00MHpNNTEuMSA3N0w3NCA5OS45bC0yMy4zIDIzLjMgMTAuNSAxMC41IDIzLjMtMjMuM0w5NSA5OS45IDg0LjUgODkuNCA2MS42IDY2LjV6Ii8+CiAgPC9nPgo8L3N2Zz4K);
  --jp-icon-copy: url(data:image/svg+xml;base64,PHN2ZyB2aWV3Qm94PSIwIDAgMTggMTgiIHdpZHRoPSIxNiIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTExLjksMUgzLjJDMi40LDEsMS43LDEuNywxLjcsMi41djEwLjJoMS41VjIuNWg4LjdWMXogTTE0LjEsMy45aC04Yy0wLjgsMC0xLjUsMC43LTEuNSwxLjV2MTAuMmMwLDAuOCwwLjcsMS41LDEuNSwxLjVoOCBjMC44LDAsMS41LTAuNywxLjUtMS41VjUuNEMxNS41LDQuNiwxNC45LDMuOSwxNC4xLDMuOXogTTE0LjEsMTUuNWgtOFY1LjRoOFYxNS41eiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-cut: url(data:image/svg+xml;base64,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);
  --jp-icon-download: url(data:image/svg+xml;base64,PHN2ZyB2aWV3Qm94PSIwIDAgMjQgMjQiIHdpZHRoPSIxNiIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTE5IDloLTRWM0g5djZINWw3IDcgNy03ek01IDE4djJoMTR2LTJINXoiLz4KICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-edit: url(data:image/svg+xml;base64,PHN2ZyB2aWV3Qm94PSIwIDAgMjQgMjQiIHdpZHRoPSIxNiIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTMgMTcuMjVWMjFoMy43NUwxNy44MSA5Ljk0bC0zLjc1LTMuNzVMMyAxNy4yNXpNMjAuNzEgNy4wNGMuMzktLjM5LjM5LTEuMDIgMC0xLjQxbC0yLjM0LTIuMzRjLS4zOS0uMzktMS4wMi0uMzktMS40MSAwbC0xLjgzIDEuODMgMy43NSAzLjc1IDEuODMtMS44M3oiLz4KICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-ellipses: url(data:image/svg+xml;base64,PHN2ZyB2aWV3Qm94PSIwIDAgMjQgMjQiIHdpZHRoPSIxNiIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPGNpcmNsZSBjeD0iNSIgY3k9IjEyIiByPSIyIi8+CiAgICA8Y2lyY2xlIGN4PSIxMiIgY3k9IjEyIiByPSIyIi8+CiAgICA8Y2lyY2xlIGN4PSIxOSIgY3k9IjEyIiByPSIyIi8+CiAgPC9nPgo8L3N2Zz4K);
  --jp-icon-extension: url(data:image/svg+xml;base64,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);
  --jp-icon-fast-forward: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIyNCIgaGVpZ2h0PSIyNCIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICAgIDxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSI+CiAgICAgICAgPHBhdGggZD0iTTQgMThsOC41LTZMNCA2djEyem05LTEydjEybDguNS02TDEzIDZ6Ii8+CiAgICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-file-upload: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTkgMTZoNnYtNmg0bC03LTctNyA3aDR6bS00IDJoMTR2Mkg1eiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-file: url(data:image/svg+xml;base64,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);
  --jp-icon-filter-list: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTEwIDE4aDR2LTJoLTR2MnpNMyA2djJoMThWNkgzem0zIDdoMTJ2LTJINnYyeiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-folder: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8cGF0aCBjbGFzcz0ianAtaWNvbjMganAtaWNvbi1zZWxlY3RhYmxlIiBmaWxsPSIjNjE2MTYxIiBkPSJNMTAgNEg0Yy0xLjEgMC0xLjk5LjktMS45OSAyTDIgMThjMCAxLjEuOSAyIDIgMmgxNmMxLjEgMCAyLS45IDItMlY4YzAtMS4xLS45LTItMi0yaC04bC0yLTJ6Ii8+Cjwvc3ZnPgo=);
  --jp-icon-html5: url(data:image/svg+xml;base64,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);
  --jp-icon-image: url(data:image/svg+xml;base64,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);
  --jp-icon-inspector: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8cGF0aCBjbGFzcz0ianAtaWNvbjMganAtaWNvbi1zZWxlY3RhYmxlIiBmaWxsPSIjNjE2MTYxIiBkPSJNMjAgNEg0Yy0xLjEgMC0xLjk5LjktMS45OSAyTDIgMThjMCAxLjEuOSAyIDIgMmgxNmMxLjEgMCAyLS45IDItMlY2YzAtMS4xLS45LTItMi0yem0tNSAxNEg0di00aDExdjR6bTAtNUg0VjloMTF2NHptNSA1aC00VjloNHY5eiIvPgo8L3N2Zz4K);
  --jp-icon-json: url(data:image/svg+xml;base64,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);
  --jp-icon-jupyter-favicon: url(data:image/svg+xml;base64,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);
  --jp-icon-jupyter: url(data:image/svg+xml;base64,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);
  --jp-icon-jupyterlab-wordmark: url(data:image/svg+xml;base64,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);
  --jp-icon-kernel: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICAgIDxwYXRoIGNsYXNzPSJqcC1pY29uMiIgZmlsbD0iIzYxNjE2MSIgZD0iTTE1IDlIOXY2aDZWOXptLTIgNGgtMnYtMmgydjJ6bTgtMlY5aC0yVjdjMC0xLjEtLjktMi0yLTJoLTJWM2gtMnYyaC0yVjNIOXYySDdjLTEuMSAwLTIgLjktMiAydjJIM3YyaDJ2MkgzdjJoMnYyYzAgMS4xLjkgMiAyIDJoMnYyaDJ2LTJoMnYyaDJ2LTJoMmMxLjEgMCAyLS45IDItMnYtMmgydi0yaC0ydi0yaDJ6bS00IDZIN1Y3aDEwdjEweiIvPgo8L3N2Zz4K);
  --jp-icon-keyboard: url(data:image/svg+xml;base64,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);
  --jp-icon-launcher: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8cGF0aCBjbGFzcz0ianAtaWNvbjMganAtaWNvbi1zZWxlY3RhYmxlIiBmaWxsPSIjNjE2MTYxIiBkPSJNMTkgMTlINVY1aDdWM0g1YTIgMiAwIDAwLTIgMnYxNGEyIDIgMCAwMDIgMmgxNGMxLjEgMCAyLS45IDItMnYtN2gtMnY3ek0xNCAzdjJoMy41OWwtOS44MyA5LjgzIDEuNDEgMS40MUwxOSA2LjQxVjEwaDJWM2gtN3oiLz4KPC9zdmc+Cg==);
  --jp-icon-line-form: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICAgIDxwYXRoIGZpbGw9IndoaXRlIiBkPSJNNS44OCA0LjEyTDEzLjc2IDEybC03Ljg4IDcuODhMOCAyMmwxMC0xMEw4IDJ6Ii8+Cjwvc3ZnPgo=);
  --jp-icon-link: url(data:image/svg+xml;base64,PHN2ZyB2aWV3Qm94PSIwIDAgMjQgMjQiIHdpZHRoPSIxNiIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTMuOSAxMmMwLTEuNzEgMS4zOS0zLjEgMy4xLTMuMWg0VjdIN2MtMi43NiAwLTUgMi4yNC01IDVzMi4yNCA1IDUgNWg0di0xLjlIN2MtMS43MSAwLTMuMS0xLjM5LTMuMS0zLjF6TTggMTNoOHYtMkg4djJ6bTktNmgtNHYxLjloNGMxLjcxIDAgMy4xIDEuMzkgMy4xIDMuMXMtMS4zOSAzLjEtMy4xIDMuMWgtNFYxN2g0YzIuNzYgMCA1LTIuMjQgNS01cy0yLjI0LTUtNS01eiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-list: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICAgIDxwYXRoIGNsYXNzPSJqcC1pY29uMiBqcC1pY29uLXNlbGVjdGFibGUiIGZpbGw9IiM2MTYxNjEiIGQ9Ik0xOSA1djE0SDVWNWgxNG0xLjEtMkgzLjljLS41IDAtLjkuNC0uOS45djE2LjJjMCAuNC40LjkuOS45aDE2LjJjLjQgMCAuOS0uNS45LS45VjMuOWMwLS41LS41LS45LS45LS45ek0xMSA3aDZ2MmgtNlY3em0wIDRoNnYyaC02di0yem0wIDRoNnYyaC02ek03IDdoMnYySDd6bTAgNGgydjJIN3ptMCA0aDJ2Mkg3eiIvPgo8L3N2Zz4=);
  --jp-icon-listings-info: url(data:image/svg+xml;base64,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);
  --jp-icon-markdown: url(data:image/svg+xml;base64,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);
  --jp-icon-new-folder: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTIwIDZoLThsLTItMkg0Yy0xLjExIDAtMS45OS44OS0xLjk5IDJMMiAxOGMwIDEuMTEuODkgMiAyIDJoMTZjMS4xMSAwIDItLjg5IDItMlY4YzAtMS4xMS0uODktMi0yLTJ6bS0xIDhoLTN2M2gtMnYtM2gtM3YtMmgzVjloMnYzaDN2MnoiLz4KICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-not-trusted: url(data:image/svg+xml;base64,PHN2ZyBmaWxsPSJub25lIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI1IDI1Ij4KICAgIDxwYXRoIGNsYXNzPSJqcC1pY29uMiIgc3Ryb2tlPSIjMzMzMzMzIiBzdHJva2Utd2lkdGg9IjIiIHRyYW5zZm9ybT0idHJhbnNsYXRlKDMgMykiIGQ9Ik0xLjg2MDk0IDExLjQ0MDlDMC44MjY0NDggOC43NzAyNyAwLjg2Mzc3OSA2LjA1NzY0IDEuMjQ5MDcgNC4xOTkzMkMyLjQ4MjA2IDMuOTMzNDcgNC4wODA2OCAzLjQwMzQ3IDUuNjAxMDIgMi44NDQ5QzcuMjM1NDkgMi4yNDQ0IDguODU2NjYgMS41ODE1IDkuOTg3NiAxLjA5NTM5QzExLjA1OTcgMS41ODM0MSAxMi42MDk0IDIuMjQ0NCAxNC4yMTggMi44NDMzOUMxNS43NTAzIDMuNDEzOTQgMTcuMzk5NSAzLjk1MjU4IDE4Ljc1MzkgNC4yMTM4NUMxOS4xMzY0IDYuMDcxNzcgMTkuMTcwOSA4Ljc3NzIyIDE4LjEzOSAxMS40NDA5QzE3LjAzMDMgMTQuMzAzMiAxNC42NjY4IDE3LjE4NDQgOS45OTk5OSAxOC45MzU0QzUuMzMzMTkgMTcuMTg0NCAyLjk2OTY4IDE0LjMwMzIgMS44NjA5NCAxMS40NDA5WiIvPgogICAgPHBhdGggY2xhc3M9ImpwLWljb24yIiBzdHJva2U9IiMzMzMzMzMiIHN0cm9rZS13aWR0aD0iMiIgdHJhbnNmb3JtPSJ0cmFuc2xhdGUoOS4zMTU5MiA5LjMyMDMxKSIgZD0iTTcuMzY4NDIgMEwwIDcuMzY0NzkiLz4KICAgIDxwYXRoIGNsYXNzPSJqcC1pY29uMiIgc3Ryb2tlPSIjMzMzMzMzIiBzdHJva2Utd2lkdGg9IjIiIHRyYW5zZm9ybT0idHJhbnNsYXRlKDkuMzE1OTIgMTYuNjgzNikgc2NhbGUoMSAtMSkiIGQ9Ik03LjM2ODQyIDBMMCA3LjM2NDc5Ii8+Cjwvc3ZnPgo=);
  --jp-icon-notebook: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDIyIDIyIj4KICA8ZyBjbGFzcz0ianAtaWNvbi13YXJuMCBqcC1pY29uLXNlbGVjdGFibGUiIGZpbGw9IiNFRjZDMDAiPgogICAgPHBhdGggZD0iTTE4LjcgMy4zdjE1LjRIMy4zVjMuM2gxNS40bTEuNS0xLjVIMS44djE4LjNoMTguM2wuMS0xOC4zeiIvPgogICAgPHBhdGggZD0iTTE2LjUgMTYuNWwtNS40LTQuMy01LjYgNC4zdi0xMWgxMXoiLz4KICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-palette: url(data:image/svg+xml;base64,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);
  --jp-icon-paste: url(data:image/svg+xml;base64,PHN2ZyBoZWlnaHQ9IjI0IiB2aWV3Qm94PSIwIDAgMjQgMjQiIHdpZHRoPSIyNCIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICAgIDxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSI+CiAgICAgICAgPHBhdGggZD0iTTE5IDJoLTQuMThDMTQuNC44NCAxMy4zIDAgMTIgMGMtMS4zIDAtMi40Ljg0LTIuODIgMkg1Yy0xLjEgMC0yIC45LTIgMnYxNmMwIDEuMS45IDIgMiAyaDE0YzEuMSAwIDItLjkgMi0yVjRjMC0xLjEtLjktMi0yLTJ6bS03IDBjLjU1IDAgMSAuNDUgMSAxcy0uNDUgMS0xIDEtMS0uNDUtMS0xIC40NS0xIDEtMXptNyAxOEg1VjRoMnYzaDEwVjRoMnYxNnoiLz4KICAgIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-python: url(data:image/svg+xml;base64,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);
  --jp-icon-r-kernel: url(data:image/svg+xml;base64,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);
  --jp-icon-react: url(data:image/svg+xml;base64,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);
  --jp-icon-refresh: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDE4IDE4Ij4KICAgIDxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSI+CiAgICAgICAgPHBhdGggZD0iTTkgMTMuNWMtMi40OSAwLTQuNS0yLjAxLTQuNS00LjVTNi41MSA0LjUgOSA0LjVjMS4yNCAwIDIuMzYuNTIgMy4xNyAxLjMzTDEwIDhoNVYzbC0xLjc2IDEuNzZDMTIuMTUgMy42OCAxMC42NiAzIDkgMyA1LjY5IDMgMy4wMSA1LjY5IDMuMDEgOVM1LjY5IDE1IDkgMTVjMi45NyAwIDUuNDMtMi4xNiA1LjktNWgtMS41MmMtLjQ2IDItMi4yNCAzLjUtNC4zOCAzLjV6Ii8+CiAgICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-regex: url(data:image/svg+xml;base64,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);
  --jp-icon-run: url(data:image/svg+xml;base64,PHN2ZyBoZWlnaHQ9IjI0IiB2aWV3Qm94PSIwIDAgMjQgMjQiIHdpZHRoPSIyNCIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICAgIDxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSI+CiAgICAgICAgPHBhdGggZD0iTTggNXYxNGwxMS03eiIvPgogICAgPC9nPgo8L3N2Zz4K);
  --jp-icon-running: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDUxMiA1MTIiPgogIDxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSI+CiAgICA8cGF0aCBkPSJNMjU2IDhDMTE5IDggOCAxMTkgOCAyNTZzMTExIDI0OCAyNDggMjQ4IDI0OC0xMTEgMjQ4LTI0OFMzOTMgOCAyNTYgOHptOTYgMzI4YzAgOC44LTcuMiAxNi0xNiAxNkgxNzZjLTguOCAwLTE2LTcuMi0xNi0xNlYxNzZjMC04LjggNy4yLTE2IDE2LTE2aDE2MGM4LjggMCAxNiA3LjIgMTYgMTZ2MTYweiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-save: url(data:image/svg+xml;base64,PHN2ZyBoZWlnaHQ9IjI0IiB2aWV3Qm94PSIwIDAgMjQgMjQiIHdpZHRoPSIyNCIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICAgIDxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSI+CiAgICAgICAgPHBhdGggZD0iTTE3IDNINWMtMS4xMSAwLTIgLjktMiAydjE0YzAgMS4xLjg5IDIgMiAyaDE0YzEuMSAwIDItLjkgMi0yVjdsLTQtNHptLTUgMTZjLTEuNjYgMC0zLTEuMzQtMy0zczEuMzQtMyAzLTMgMyAxLjM0IDMgMy0xLjM0IDMtMyAzem0zLTEwSDVWNWgxMHY0eiIvPgogICAgPC9nPgo8L3N2Zz4K);
  --jp-icon-search: url(data:image/svg+xml;base64,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);
  --jp-icon-settings: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8cGF0aCBjbGFzcz0ianAtaWNvbjMganAtaWNvbi1zZWxlY3RhYmxlIiBmaWxsPSIjNjE2MTYxIiBkPSJNMTkuNDMgMTIuOThjLjA0LS4zMi4wNy0uNjQuMDctLjk4cy0uMDMtLjY2LS4wNy0uOThsMi4xMS0xLjY1Yy4xOS0uMTUuMjQtLjQyLjEyLS42NGwtMi0zLjQ2Yy0uMTItLjIyLS4zOS0uMy0uNjEtLjIybC0yLjQ5IDFjLS41Mi0uNC0xLjA4LS43My0xLjY5LS45OGwtLjM4LTIuNjVBLjQ4OC40ODggMCAwMDE0IDJoLTRjLS4yNSAwLS40Ni4xOC0uNDkuNDJsLS4zOCAyLjY1Yy0uNjEuMjUtMS4xNy41OS0xLjY5Ljk4bC0yLjQ5LTFjLS4yMy0uMDktLjQ5IDAtLjYxLjIybC0yIDMuNDZjLS4xMy4yMi0uMDcuNDkuMTIuNjRsMi4xMSAxLjY1Yy0uMDQuMzItLjA3LjY1LS4wNy45OHMuMDMuNjYuMDcuOThsLTIuMTEgMS42NWMtLjE5LjE1LS4yNC40Mi0uMTIuNjRsMiAzLjQ2Yy4xMi4yMi4zOS4zLjYxLjIybDIuNDktMWMuNTIuNCAxLjA4LjczIDEuNjkuOThsLjM4IDIuNjVjLjAzLjI0LjI0LjQyLjQ5LjQyaDRjLjI1IDAgLjQ2LS4xOC40OS0uNDJsLjM4LTIuNjVjLjYxLS4yNSAxLjE3LS41OSAxLjY5LS45OGwyLjQ5IDFjLjIzLjA5LjQ5IDAgLjYxLS4yMmwyLTMuNDZjLjEyLS4yMi4wNy0uNDktLjEyLS42NGwtMi4xMS0xLjY1ek0xMiAxNS41Yy0xLjkzIDAtMy41LTEuNTctMy41LTMuNXMxLjU3LTMuNSAzLjUtMy41IDMuNSAxLjU3IDMuNSAzLjUtMS41NyAzLjUtMy41IDMuNXoiLz4KPC9zdmc+Cg==);
  --jp-icon-spreadsheet: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDIyIDIyIj4KICA8cGF0aCBjbGFzcz0ianAtaWNvbi1jb250cmFzdDEganAtaWNvbi1zZWxlY3RhYmxlIiBmaWxsPSIjNENBRjUwIiBkPSJNMi4yIDIuMnYxNy42aDE3LjZWMi4ySDIuMnptMTUuNCA3LjdoLTUuNVY0LjRoNS41djUuNXpNOS45IDQuNHY1LjVINC40VjQuNGg1LjV6bS01LjUgNy43aDUuNXY1LjVINC40di01LjV6bTcuNyA1LjV2LTUuNWg1LjV2NS41aC01LjV6Ii8+Cjwvc3ZnPgo=);
  --jp-icon-stop: url(data:image/svg+xml;base64,PHN2ZyBoZWlnaHQ9IjI0IiB2aWV3Qm94PSIwIDAgMjQgMjQiIHdpZHRoPSIyNCIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICAgIDxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSI+CiAgICAgICAgPHBhdGggZD0iTTAgMGgyNHYyNEgweiIgZmlsbD0ibm9uZSIvPgogICAgICAgIDxwYXRoIGQ9Ik02IDZoMTJ2MTJINnoiLz4KICAgIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-tab: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTIxIDNIM2MtMS4xIDAtMiAuOS0yIDJ2MTRjMCAxLjEuOSAyIDIgMmgxOGMxLjEgMCAyLS45IDItMlY1YzAtMS4xLS45LTItMi0yem0wIDE2SDNWNWgxMHY0aDh2MTB6Ii8+CiAgPC9nPgo8L3N2Zz4K);
  --jp-icon-terminal: url(data:image/svg+xml;base64,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);
  --jp-icon-text-editor: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8cGF0aCBjbGFzcz0ianAtaWNvbjMganAtaWNvbi1zZWxlY3RhYmxlIiBmaWxsPSIjNjE2MTYxIiBkPSJNMTUgMTVIM3YyaDEydi0yem0wLThIM3YyaDEyVjd6TTMgMTNoMTh2LTJIM3Yyem0wIDhoMTh2LTJIM3Yyek0zIDN2MmgxOFYzSDN6Ii8+Cjwvc3ZnPgo=);
  --jp-icon-trusted: url(data:image/svg+xml;base64,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);
  --jp-icon-undo: url(data:image/svg+xml;base64,PHN2ZyB2aWV3Qm94PSIwIDAgMjQgMjQiIHdpZHRoPSIxNiIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTEyLjUgOGMtMi42NSAwLTUuMDUuOTktNi45IDIuNkwyIDd2OWg5bC0zLjYyLTMuNjJjMS4zOS0xLjE2IDMuMTYtMS44OCA1LjEyLTEuODggMy41NCAwIDYuNTUgMi4zMSA3LjYgNS41bDIuMzctLjc4QzIxLjA4IDExLjAzIDE3LjE1IDggMTIuNSA4eiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-vega: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDIyIDIyIj4KICA8ZyBjbGFzcz0ianAtaWNvbjEganAtaWNvbi1zZWxlY3RhYmxlIiBmaWxsPSIjMjEyMTIxIj4KICAgIDxwYXRoIGQ9Ik0xMC42IDUuNGwyLjItMy4ySDIuMnY3LjNsNC02LjZ6Ii8+CiAgICA8cGF0aCBkPSJNMTUuOCAyLjJsLTQuNCA2LjZMNyA2LjNsLTQuOCA4djUuNWgxNy42VjIuMmgtNHptLTcgMTUuNEg1LjV2LTQuNGgzLjN2NC40em00LjQgMEg5LjhWOS44aDMuNHY3Ljh6bTQuNCAwaC0zLjRWNi41aDMuNHYxMS4xeiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-yaml: url(data:image/svg+xml;base64,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);
}

/* Icon CSS class declarations */

.jp-AddIcon {
  background-image: var(--jp-icon-add);
}
.jp-BugIcon {
  background-image: var(--jp-icon-bug);
}
.jp-BuildIcon {
  background-image: var(--jp-icon-build);
}
.jp-CaretDownEmptyIcon {
  background-image: var(--jp-icon-caret-down-empty);
}
.jp-CaretDownEmptyThinIcon {
  background-image: var(--jp-icon-caret-down-empty-thin);
}
.jp-CaretDownIcon {
  background-image: var(--jp-icon-caret-down);
}
.jp-CaretLeftIcon {
  background-image: var(--jp-icon-caret-left);
}
.jp-CaretRightIcon {
  background-image: var(--jp-icon-caret-right);
}
.jp-CaretUpEmptyThinIcon {
  background-image: var(--jp-icon-caret-up-empty-thin);
}
.jp-CaretUpIcon {
  background-image: var(--jp-icon-caret-up);
}
.jp-CaseSensitiveIcon {
  background-image: var(--jp-icon-case-sensitive);
}
.jp-CheckIcon {
  background-image: var(--jp-icon-check);
}
.jp-CircleEmptyIcon {
  background-image: var(--jp-icon-circle-empty);
}
.jp-CircleIcon {
  background-image: var(--jp-icon-circle);
}
.jp-ClearIcon {
  background-image: var(--jp-icon-clear);
}
.jp-CloseIcon {
  background-image: var(--jp-icon-close);
}
.jp-ConsoleIcon {
  background-image: var(--jp-icon-console);
}
.jp-CopyIcon {
  background-image: var(--jp-icon-copy);
}
.jp-CutIcon {
  background-image: var(--jp-icon-cut);
}
.jp-DownloadIcon {
  background-image: var(--jp-icon-download);
}
.jp-EditIcon {
  background-image: var(--jp-icon-edit);
}
.jp-EllipsesIcon {
  background-image: var(--jp-icon-ellipses);
}
.jp-ExtensionIcon {
  background-image: var(--jp-icon-extension);
}
.jp-FastForwardIcon {
  background-image: var(--jp-icon-fast-forward);
}
.jp-FileIcon {
  background-image: var(--jp-icon-file);
}
.jp-FileUploadIcon {
  background-image: var(--jp-icon-file-upload);
}
.jp-FilterListIcon {
  background-image: var(--jp-icon-filter-list);
}
.jp-FolderIcon {
  background-image: var(--jp-icon-folder);
}
.jp-Html5Icon {
  background-image: var(--jp-icon-html5);
}
.jp-ImageIcon {
  background-image: var(--jp-icon-image);
}
.jp-InspectorIcon {
  background-image: var(--jp-icon-inspector);
}
.jp-JsonIcon {
  background-image: var(--jp-icon-json);
}
.jp-JupyterFaviconIcon {
  background-image: var(--jp-icon-jupyter-favicon);
}
.jp-JupyterIcon {
  background-image: var(--jp-icon-jupyter);
}
.jp-JupyterlabWordmarkIcon {
  background-image: var(--jp-icon-jupyterlab-wordmark);
}
.jp-KernelIcon {
  background-image: var(--jp-icon-kernel);
}
.jp-KeyboardIcon {
  background-image: var(--jp-icon-keyboard);
}
.jp-LauncherIcon {
  background-image: var(--jp-icon-launcher);
}
.jp-LineFormIcon {
  background-image: var(--jp-icon-line-form);
}
.jp-LinkIcon {
  background-image: var(--jp-icon-link);
}
.jp-ListIcon {
  background-image: var(--jp-icon-list);
}
.jp-ListingsInfoIcon {
  background-image: var(--jp-icon-listings-info);
}
.jp-MarkdownIcon {
  background-image: var(--jp-icon-markdown);
}
.jp-NewFolderIcon {
  background-image: var(--jp-icon-new-folder);
}
.jp-NotTrustedIcon {
  background-image: var(--jp-icon-not-trusted);
}
.jp-NotebookIcon {
  background-image: var(--jp-icon-notebook);
}
.jp-PaletteIcon {
  background-image: var(--jp-icon-palette);
}
.jp-PasteIcon {
  background-image: var(--jp-icon-paste);
}
.jp-PythonIcon {
  background-image: var(--jp-icon-python);
}
.jp-RKernelIcon {
  background-image: var(--jp-icon-r-kernel);
}
.jp-ReactIcon {
  background-image: var(--jp-icon-react);
}
.jp-RefreshIcon {
  background-image: var(--jp-icon-refresh);
}
.jp-RegexIcon {
  background-image: var(--jp-icon-regex);
}
.jp-RunIcon {
  background-image: var(--jp-icon-run);
}
.jp-RunningIcon {
  background-image: var(--jp-icon-running);
}
.jp-SaveIcon {
  background-image: var(--jp-icon-save);
}
.jp-SearchIcon {
  background-image: var(--jp-icon-search);
}
.jp-SettingsIcon {
  background-image: var(--jp-icon-settings);
}
.jp-SpreadsheetIcon {
  background-image: var(--jp-icon-spreadsheet);
}
.jp-StopIcon {
  background-image: var(--jp-icon-stop);
}
.jp-TabIcon {
  background-image: var(--jp-icon-tab);
}
.jp-TerminalIcon {
  background-image: var(--jp-icon-terminal);
}
.jp-TextEditorIcon {
  background-image: var(--jp-icon-text-editor);
}
.jp-TrustedIcon {
  background-image: var(--jp-icon-trusted);
}
.jp-UndoIcon {
  background-image: var(--jp-icon-undo);
}
.jp-VegaIcon {
  background-image: var(--jp-icon-vega);
}
.jp-YamlIcon {
  background-image: var(--jp-icon-yaml);
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/**
 * (DEPRECATED) Support for consuming icons as CSS background images
 */

:root {
  --jp-icon-search-white: url(data:image/svg+xml;base64,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);
}

.jp-Icon,
.jp-MaterialIcon {
  background-position: center;
  background-repeat: no-repeat;
  background-size: 16px;
  min-width: 16px;
  min-height: 16px;
}

.jp-Icon-cover {
  background-position: center;
  background-repeat: no-repeat;
  background-size: cover;
}

/**
 * (DEPRECATED) Support for specific CSS icon sizes
 */

.jp-Icon-16 {
  background-size: 16px;
  min-width: 16px;
  min-height: 16px;
}

.jp-Icon-18 {
  background-size: 18px;
  min-width: 18px;
  min-height: 18px;
}

.jp-Icon-20 {
  background-size: 20px;
  min-width: 20px;
  min-height: 20px;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/**
 * Support for icons as inline SVG HTMLElements
 */

/* recolor the primary elements of an icon */
.jp-icon0[fill] {
  fill: var(--jp-inverse-layout-color0);
}
.jp-icon1[fill] {
  fill: var(--jp-inverse-layout-color1);
}
.jp-icon2[fill] {
  fill: var(--jp-inverse-layout-color2);
}
.jp-icon3[fill] {
  fill: var(--jp-inverse-layout-color3);
}
.jp-icon4[fill] {
  fill: var(--jp-inverse-layout-color4);
}

.jp-icon0[stroke] {
  stroke: var(--jp-inverse-layout-color0);
}
.jp-icon1[stroke] {
  stroke: var(--jp-inverse-layout-color1);
}
.jp-icon2[stroke] {
  stroke: var(--jp-inverse-layout-color2);
}
.jp-icon3[stroke] {
  stroke: var(--jp-inverse-layout-color3);
}
.jp-icon4[stroke] {
  stroke: var(--jp-inverse-layout-color4);
}
/* recolor the accent elements of an icon */
.jp-icon-accent0[fill] {
  fill: var(--jp-layout-color0);
}
.jp-icon-accent1[fill] {
  fill: var(--jp-layout-color1);
}
.jp-icon-accent2[fill] {
  fill: var(--jp-layout-color2);
}
.jp-icon-accent3[fill] {
  fill: var(--jp-layout-color3);
}
.jp-icon-accent4[fill] {
  fill: var(--jp-layout-color4);
}

.jp-icon-accent0[stroke] {
  stroke: var(--jp-layout-color0);
}
.jp-icon-accent1[stroke] {
  stroke: var(--jp-layout-color1);
}
.jp-icon-accent2[stroke] {
  stroke: var(--jp-layout-color2);
}
.jp-icon-accent3[stroke] {
  stroke: var(--jp-layout-color3);
}
.jp-icon-accent4[stroke] {
  stroke: var(--jp-layout-color4);
}
/* set the color of an icon to transparent */
.jp-icon-none[fill] {
  fill: none;
}

.jp-icon-none[stroke] {
  stroke: none;
}
/* brand icon colors. Same for light and dark */
.jp-icon-brand0[fill] {
  fill: var(--jp-brand-color0);
}
.jp-icon-brand1[fill] {
  fill: var(--jp-brand-color1);
}
.jp-icon-brand2[fill] {
  fill: var(--jp-brand-color2);
}
.jp-icon-brand3[fill] {
  fill: var(--jp-brand-color3);
}
.jp-icon-brand4[fill] {
  fill: var(--jp-brand-color4);
}

.jp-icon-brand0[stroke] {
  stroke: var(--jp-brand-color0);
}
.jp-icon-brand1[stroke] {
  stroke: var(--jp-brand-color1);
}
.jp-icon-brand2[stroke] {
  stroke: var(--jp-brand-color2);
}
.jp-icon-brand3[stroke] {
  stroke: var(--jp-brand-color3);
}
.jp-icon-brand4[stroke] {
  stroke: var(--jp-brand-color4);
}
/* warn icon colors. Same for light and dark */
.jp-icon-warn0[fill] {
  fill: var(--jp-warn-color0);
}
.jp-icon-warn1[fill] {
  fill: var(--jp-warn-color1);
}
.jp-icon-warn2[fill] {
  fill: var(--jp-warn-color2);
}
.jp-icon-warn3[fill] {
  fill: var(--jp-warn-color3);
}

.jp-icon-warn0[stroke] {
  stroke: var(--jp-warn-color0);
}
.jp-icon-warn1[stroke] {
  stroke: var(--jp-warn-color1);
}
.jp-icon-warn2[stroke] {
  stroke: var(--jp-warn-color2);
}
.jp-icon-warn3[stroke] {
  stroke: var(--jp-warn-color3);
}
/* icon colors that contrast well with each other and most backgrounds */
.jp-icon-contrast0[fill] {
  fill: var(--jp-icon-contrast-color0);
}
.jp-icon-contrast1[fill] {
  fill: var(--jp-icon-contrast-color1);
}
.jp-icon-contrast2[fill] {
  fill: var(--jp-icon-contrast-color2);
}
.jp-icon-contrast3[fill] {
  fill: var(--jp-icon-contrast-color3);
}

.jp-icon-contrast0[stroke] {
  stroke: var(--jp-icon-contrast-color0);
}
.jp-icon-contrast1[stroke] {
  stroke: var(--jp-icon-contrast-color1);
}
.jp-icon-contrast2[stroke] {
  stroke: var(--jp-icon-contrast-color2);
}
.jp-icon-contrast3[stroke] {
  stroke: var(--jp-icon-contrast-color3);
}

/* CSS for icons in selected items in the settings editor */
#setting-editor .jp-PluginList .jp-mod-selected .jp-icon-selectable[fill] {
  fill: #fff;
}
#setting-editor
  .jp-PluginList
  .jp-mod-selected
  .jp-icon-selectable-inverse[fill] {
  fill: var(--jp-brand-color1);
}

/* CSS for icons in selected filebrowser listing items */
.jp-DirListing-item.jp-mod-selected .jp-icon-selectable[fill] {
  fill: #fff;
}
.jp-DirListing-item.jp-mod-selected .jp-icon-selectable-inverse[fill] {
  fill: var(--jp-brand-color1);
}

/* CSS for icons in selected tabs in the sidebar tab manager */
#tab-manager .lm-TabBar-tab.jp-mod-active .jp-icon-selectable[fill] {
  fill: #fff;
}

#tab-manager .lm-TabBar-tab.jp-mod-active .jp-icon-selectable-inverse[fill] {
  fill: var(--jp-brand-color1);
}
#tab-manager
  .lm-TabBar-tab.jp-mod-active
  .jp-icon-hover
  :hover
  .jp-icon-selectable[fill] {
  fill: var(--jp-brand-color1);
}

#tab-manager
  .lm-TabBar-tab.jp-mod-active
  .jp-icon-hover
  :hover
  .jp-icon-selectable-inverse[fill] {
  fill: #fff;
}

/**
 * TODO: come up with non css-hack solution for showing the busy icon on top
 *  of the close icon
 * CSS for complex behavior of close icon of tabs in the sidebar tab manager
 */
#tab-manager
  .lm-TabBar-tab.jp-mod-dirty
  > .lm-TabBar-tabCloseIcon
  > :not(:hover)
  > .jp-icon3[fill] {
  fill: none;
}
#tab-manager
  .lm-TabBar-tab.jp-mod-dirty
  > .lm-TabBar-tabCloseIcon
  > :not(:hover)
  > .jp-icon-busy[fill] {
  fill: var(--jp-inverse-layout-color3);
}

#tab-manager
  .lm-TabBar-tab.jp-mod-dirty.jp-mod-active
  > .lm-TabBar-tabCloseIcon
  > :not(:hover)
  > .jp-icon-busy[fill] {
  fill: #fff;
}

/**
* TODO: come up with non css-hack solution for showing the busy icon on top
*  of the close icon
* CSS for complex behavior of close icon of tabs in the main area tabbar
*/
.lm-DockPanel-tabBar
  .lm-TabBar-tab.lm-mod-closable.jp-mod-dirty
  > .lm-TabBar-tabCloseIcon
  > :not(:hover)
  > .jp-icon3[fill] {
  fill: none;
}
.lm-DockPanel-tabBar
  .lm-TabBar-tab.lm-mod-closable.jp-mod-dirty
  > .lm-TabBar-tabCloseIcon
  > :not(:hover)
  > .jp-icon-busy[fill] {
  fill: var(--jp-inverse-layout-color3);
}

/* CSS for icons in status bar */
#jp-main-statusbar .jp-mod-selected .jp-icon-selectable[fill] {
  fill: #fff;
}

#jp-main-statusbar .jp-mod-selected .jp-icon-selectable-inverse[fill] {
  fill: var(--jp-brand-color1);
}
/* special handling for splash icon CSS. While the theme CSS reloads during
   splash, the splash icon can loose theming. To prevent that, we set a
   default for its color variable */
:root {
  --jp-warn-color0: var(--md-orange-700);
}

/* not sure what to do with this one, used in filebrowser listing */
.jp-DragIcon {
  margin-right: 4px;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/**
 * Support for alt colors for icons as inline SVG HTMLElements
 */

/* alt recolor the primary elements of an icon */
.jp-icon-alt .jp-icon0[fill] {
  fill: var(--jp-layout-color0);
}
.jp-icon-alt .jp-icon1[fill] {
  fill: var(--jp-layout-color1);
}
.jp-icon-alt .jp-icon2[fill] {
  fill: var(--jp-layout-color2);
}
.jp-icon-alt .jp-icon3[fill] {
  fill: var(--jp-layout-color3);
}
.jp-icon-alt .jp-icon4[fill] {
  fill: var(--jp-layout-color4);
}

.jp-icon-alt .jp-icon0[stroke] {
  stroke: var(--jp-layout-color0);
}
.jp-icon-alt .jp-icon1[stroke] {
  stroke: var(--jp-layout-color1);
}
.jp-icon-alt .jp-icon2[stroke] {
  stroke: var(--jp-layout-color2);
}
.jp-icon-alt .jp-icon3[stroke] {
  stroke: var(--jp-layout-color3);
}
.jp-icon-alt .jp-icon4[stroke] {
  stroke: var(--jp-layout-color4);
}

/* alt recolor the accent elements of an icon */
.jp-icon-alt .jp-icon-accent0[fill] {
  fill: var(--jp-inverse-layout-color0);
}
.jp-icon-alt .jp-icon-accent1[fill] {
  fill: var(--jp-inverse-layout-color1);
}
.jp-icon-alt .jp-icon-accent2[fill] {
  fill: var(--jp-inverse-layout-color2);
}
.jp-icon-alt .jp-icon-accent3[fill] {
  fill: var(--jp-inverse-layout-color3);
}
.jp-icon-alt .jp-icon-accent4[fill] {
  fill: var(--jp-inverse-layout-color4);
}

.jp-icon-alt .jp-icon-accent0[stroke] {
  stroke: var(--jp-inverse-layout-color0);
}
.jp-icon-alt .jp-icon-accent1[stroke] {
  stroke: var(--jp-inverse-layout-color1);
}
.jp-icon-alt .jp-icon-accent2[stroke] {
  stroke: var(--jp-inverse-layout-color2);
}
.jp-icon-alt .jp-icon-accent3[stroke] {
  stroke: var(--jp-inverse-layout-color3);
}
.jp-icon-alt .jp-icon-accent4[stroke] {
  stroke: var(--jp-inverse-layout-color4);
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-icon-hoverShow:not(:hover) svg {
  display: none !important;
}

/**
 * Support for hover colors for icons as inline SVG HTMLElements
 */

/**
 * regular colors
 */

/* recolor the primary elements of an icon */
.jp-icon-hover :hover .jp-icon0-hover[fill] {
  fill: var(--jp-inverse-layout-color0);
}
.jp-icon-hover :hover .jp-icon1-hover[fill] {
  fill: var(--jp-inverse-layout-color1);
}
.jp-icon-hover :hover .jp-icon2-hover[fill] {
  fill: var(--jp-inverse-layout-color2);
}
.jp-icon-hover :hover .jp-icon3-hover[fill] {
  fill: var(--jp-inverse-layout-color3);
}
.jp-icon-hover :hover .jp-icon4-hover[fill] {
  fill: var(--jp-inverse-layout-color4);
}

.jp-icon-hover :hover .jp-icon0-hover[stroke] {
  stroke: var(--jp-inverse-layout-color0);
}
.jp-icon-hover :hover .jp-icon1-hover[stroke] {
  stroke: var(--jp-inverse-layout-color1);
}
.jp-icon-hover :hover .jp-icon2-hover[stroke] {
  stroke: var(--jp-inverse-layout-color2);
}
.jp-icon-hover :hover .jp-icon3-hover[stroke] {
  stroke: var(--jp-inverse-layout-color3);
}
.jp-icon-hover :hover .jp-icon4-hover[stroke] {
  stroke: var(--jp-inverse-layout-color4);
}

/* recolor the accent elements of an icon */
.jp-icon-hover :hover .jp-icon-accent0-hover[fill] {
  fill: var(--jp-layout-color0);
}
.jp-icon-hover :hover .jp-icon-accent1-hover[fill] {
  fill: var(--jp-layout-color1);
}
.jp-icon-hover :hover .jp-icon-accent2-hover[fill] {
  fill: var(--jp-layout-color2);
}
.jp-icon-hover :hover .jp-icon-accent3-hover[fill] {
  fill: var(--jp-layout-color3);
}
.jp-icon-hover :hover .jp-icon-accent4-hover[fill] {
  fill: var(--jp-layout-color4);
}

.jp-icon-hover :hover .jp-icon-accent0-hover[stroke] {
  stroke: var(--jp-layout-color0);
}
.jp-icon-hover :hover .jp-icon-accent1-hover[stroke] {
  stroke: var(--jp-layout-color1);
}
.jp-icon-hover :hover .jp-icon-accent2-hover[stroke] {
  stroke: var(--jp-layout-color2);
}
.jp-icon-hover :hover .jp-icon-accent3-hover[stroke] {
  stroke: var(--jp-layout-color3);
}
.jp-icon-hover :hover .jp-icon-accent4-hover[stroke] {
  stroke: var(--jp-layout-color4);
}

/* set the color of an icon to transparent */
.jp-icon-hover :hover .jp-icon-none-hover[fill] {
  fill: none;
}

.jp-icon-hover :hover .jp-icon-none-hover[stroke] {
  stroke: none;
}

/**
 * inverse colors
 */

/* inverse recolor the primary elements of an icon */
.jp-icon-hover.jp-icon-alt :hover .jp-icon0-hover[fill] {
  fill: var(--jp-layout-color0);
}
.jp-icon-hover.jp-icon-alt :hover .jp-icon1-hover[fill] {
  fill: var(--jp-layout-color1);
}
.jp-icon-hover.jp-icon-alt :hover .jp-icon2-hover[fill] {
  fill: var(--jp-layout-color2);
}
.jp-icon-hover.jp-icon-alt :hover .jp-icon3-hover[fill] {
  fill: var(--jp-layout-color3);
}
.jp-icon-hover.jp-icon-alt :hover .jp-icon4-hover[fill] {
  fill: var(--jp-layout-color4);
}

.jp-icon-hover.jp-icon-alt :hover .jp-icon0-hover[stroke] {
  stroke: var(--jp-layout-color0);
}
.jp-icon-hover.jp-icon-alt :hover .jp-icon1-hover[stroke] {
  stroke: var(--jp-layout-color1);
}
.jp-icon-hover.jp-icon-alt :hover .jp-icon2-hover[stroke] {
  stroke: var(--jp-layout-color2);
}
.jp-icon-hover.jp-icon-alt :hover .jp-icon3-hover[stroke] {
  stroke: var(--jp-layout-color3);
}
.jp-icon-hover.jp-icon-alt :hover .jp-icon4-hover[stroke] {
  stroke: var(--jp-layout-color4);
}

/* inverse recolor the accent elements of an icon */
.jp-icon-hover.jp-icon-alt :hover .jp-icon-accent0-hover[fill] {
  fill: var(--jp-inverse-layout-color0);
}
.jp-icon-hover.jp-icon-alt :hover .jp-icon-accent1-hover[fill] {
  fill: var(--jp-inverse-layout-color1);
}
.jp-icon-hover.jp-icon-alt :hover .jp-icon-accent2-hover[fill] {
  fill: var(--jp-inverse-layout-color2);
}
.jp-icon-hover.jp-icon-alt :hover .jp-icon-accent3-hover[fill] {
  fill: var(--jp-inverse-layout-color3);
}
.jp-icon-hover.jp-icon-alt :hover .jp-icon-accent4-hover[fill] {
  fill: var(--jp-inverse-layout-color4);
}

.jp-icon-hover.jp-icon-alt :hover .jp-icon-accent0-hover[stroke] {
  stroke: var(--jp-inverse-layout-color0);
}
.jp-icon-hover.jp-icon-alt :hover .jp-icon-accent1-hover[stroke] {
  stroke: var(--jp-inverse-layout-color1);
}
.jp-icon-hover.jp-icon-alt :hover .jp-icon-accent2-hover[stroke] {
  stroke: var(--jp-inverse-layout-color2);
}
.jp-icon-hover.jp-icon-alt :hover .jp-icon-accent3-hover[stroke] {
  stroke: var(--jp-inverse-layout-color3);
}
.jp-icon-hover.jp-icon-alt :hover .jp-icon-accent4-hover[stroke] {
  stroke: var(--jp-inverse-layout-color4);
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/* Sibling imports */

/* Override Blueprint's _reset.scss styles */
html {
  box-sizing: unset;
}

*,
*::before,
*::after {
  box-sizing: unset;
}

body {
  color: unset;
  font-family: var(--jp-ui-font-family);
}

p {
  margin-top: unset;
  margin-bottom: unset;
}

small {
  font-size: unset;
}

strong {
  font-weight: unset;
}

/* Override Blueprint's _typography.scss styles */
a {
  text-decoration: unset;
  color: unset;
}
a:hover {
  text-decoration: unset;
  color: unset;
}

/* Override Blueprint's _accessibility.scss styles */
:focus {
  outline: unset;
  outline-offset: unset;
  -moz-outline-radius: unset;
}

/* Styles for ui-components */
.jp-Button {
  border-radius: var(--jp-border-radius);
  padding: 0px 12px;
  font-size: var(--jp-ui-font-size1);
}

/* Use our own theme for hover styles */
button.jp-Button.bp3-button.bp3-minimal:hover {
  background-color: var(--jp-layout-color2);
}
.jp-Button.minimal {
  color: unset !important;
}

.jp-Button.jp-ToolbarButtonComponent {
  text-transform: none;
}

.jp-InputGroup input {
  box-sizing: border-box;
  border-radius: 0;
  background-color: transparent;
  color: var(--jp-ui-font-color0);
  box-shadow: inset 0 0 0 var(--jp-border-width) var(--jp-input-border-color);
}

.jp-InputGroup input:focus {
  box-shadow: inset 0 0 0 var(--jp-border-width)
      var(--jp-input-active-box-shadow-color),
    inset 0 0 0 3px var(--jp-input-active-box-shadow-color);
}

.jp-InputGroup input::placeholder,
input::placeholder {
  color: var(--jp-ui-font-color3);
}

.jp-BPIcon {
  display: inline-block;
  vertical-align: middle;
  margin: auto;
}

/* Stop blueprint futzing with our icon fills */
.bp3-icon.jp-BPIcon > svg:not([fill]) {
  fill: var(--jp-inverse-layout-color3);
}

.jp-InputGroupAction {
  padding: 6px;
}

.jp-HTMLSelect.jp-DefaultStyle select {
  background-color: initial;
  border: none;
  border-radius: 0;
  box-shadow: none;
  color: var(--jp-ui-font-color0);
  display: block;
  font-size: var(--jp-ui-font-size1);
  height: 24px;
  line-height: 14px;
  padding: 0 25px 0 10px;
  text-align: left;
  -moz-appearance: none;
  -webkit-appearance: none;
}

/* Use our own theme for hover and option styles */
.jp-HTMLSelect.jp-DefaultStyle select:hover,
.jp-HTMLSelect.jp-DefaultStyle select > option {
  background-color: var(--jp-layout-color2);
  color: var(--jp-ui-font-color0);
}
select {
  box-sizing: border-box;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/* This file was auto-generated by ensurePackage() in @jupyterlab/buildutils */

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-Collapse {
  display: flex;
  flex-direction: column;
  align-items: stretch;
  border-top: 1px solid var(--jp-border-color2);
  border-bottom: 1px solid var(--jp-border-color2);
}

.jp-Collapse-header {
  padding: 1px 12px;
  color: var(--jp-ui-font-color1);
  background-color: var(--jp-layout-color1);
  font-size: var(--jp-ui-font-size2);
}

.jp-Collapse-header:hover {
  background-color: var(--jp-layout-color2);
}

.jp-Collapse-contents {
  padding: 0px 12px 0px 12px;
  background-color: var(--jp-layout-color1);
  color: var(--jp-ui-font-color1);
  overflow: auto;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Variables
|----------------------------------------------------------------------------*/

:root {
  --jp-private-commandpalette-search-height: 28px;
}

/*-----------------------------------------------------------------------------
| Overall styles
|----------------------------------------------------------------------------*/

.lm-CommandPalette {
  padding-bottom: 0px;
  color: var(--jp-ui-font-color1);
  background: var(--jp-layout-color1);
  /* This is needed so that all font sizing of children done in ems is
   * relative to this base size */
  font-size: var(--jp-ui-font-size1);
}

/*-----------------------------------------------------------------------------
| Search
|----------------------------------------------------------------------------*/

.lm-CommandPalette-search {
  padding: 4px;
  background-color: var(--jp-layout-color1);
  z-index: 2;
}

.lm-CommandPalette-wrapper {
  overflow: overlay;
  padding: 0px 9px;
  background-color: var(--jp-input-active-background);
  height: 30px;
  box-shadow: inset 0 0 0 var(--jp-border-width) var(--jp-input-border-color);
}

.lm-CommandPalette.lm-mod-focused .lm-CommandPalette-wrapper {
  box-shadow: inset 0 0 0 1px var(--jp-input-active-box-shadow-color),
    inset 0 0 0 3px var(--jp-input-active-box-shadow-color);
}

.lm-CommandPalette-wrapper::after {
  content: ' ';
  color: white;
  background-color: var(--jp-brand-color1);
  position: absolute;
  top: 4px;
  right: 4px;
  height: 30px;
  width: 10px;
  padding: 0px 10px;
  background-image: var(--jp-icon-search-white);
  background-size: 20px;
  background-repeat: no-repeat;
  background-position: center;
}

.lm-CommandPalette-input {
  background: transparent;
  width: calc(100% - 18px);
  float: left;
  border: none;
  outline: none;
  font-size: var(--jp-ui-font-size1);
  color: var(--jp-ui-font-color0);
  line-height: var(--jp-private-commandpalette-search-height);
}

.lm-CommandPalette-input::-webkit-input-placeholder,
.lm-CommandPalette-input::-moz-placeholder,
.lm-CommandPalette-input:-ms-input-placeholder {
  color: var(--jp-ui-font-color3);
  font-size: var(--jp-ui-font-size1);
}

/*-----------------------------------------------------------------------------
| Results
|----------------------------------------------------------------------------*/

.lm-CommandPalette-header:first-child {
  margin-top: 0px;
}

.lm-CommandPalette-header {
  border-bottom: solid var(--jp-border-width) var(--jp-border-color2);
  color: var(--jp-ui-font-color1);
  cursor: pointer;
  display: flex;
  font-size: var(--jp-ui-font-size0);
  font-weight: 600;
  letter-spacing: 1px;
  margin-top: 8px;
  padding: 8px 0 8px 12px;
  text-transform: uppercase;
}

.lm-CommandPalette-header.lm-mod-active {
  background: var(--jp-layout-color2);
}

.lm-CommandPalette-header > mark {
  background-color: transparent;
  font-weight: bold;
  color: var(--jp-ui-font-color1);
}

.lm-CommandPalette-item {
  padding: 4px 12px 4px 4px;
  color: var(--jp-ui-font-color1);
  font-size: var(--jp-ui-font-size1);
  font-weight: 400;
  display: flex;
}

.lm-CommandPalette-item.lm-mod-disabled {
  color: var(--jp-ui-font-color3);
}

.lm-CommandPalette-item.lm-mod-active {
  background: var(--jp-layout-color3);
}

.lm-CommandPalette-item.lm-mod-active:hover:not(.lm-mod-disabled) {
  background: var(--jp-layout-color4);
}

.lm-CommandPalette-item:hover:not(.lm-mod-active):not(.lm-mod-disabled) {
  background: var(--jp-layout-color2);
}

.lm-CommandPalette-itemContent {
  overflow: hidden;
}

.lm-CommandPalette-itemLabel > mark {
  color: var(--jp-ui-font-color0);
  background-color: transparent;
  font-weight: bold;
}

.lm-CommandPalette-item.lm-mod-disabled mark {
  color: var(--jp-ui-font-color3);
}

.lm-CommandPalette-item .lm-CommandPalette-itemIcon {
  margin: 0 4px 0 0;
  position: relative;
  width: 16px;
  top: 2px;
  flex: 0 0 auto;
}

.lm-CommandPalette-item.lm-mod-disabled .lm-CommandPalette-itemIcon {
  opacity: 0.4;
}

.lm-CommandPalette-item .lm-CommandPalette-itemShortcut {
  flex: 0 0 auto;
}

.lm-CommandPalette-itemCaption {
  display: none;
}

.lm-CommandPalette-content {
  background-color: var(--jp-layout-color1);
}

.lm-CommandPalette-content:empty:after {
  content: 'No results';
  margin: auto;
  margin-top: 20px;
  width: 100px;
  display: block;
  font-size: var(--jp-ui-font-size2);
  font-family: var(--jp-ui-font-family);
  font-weight: lighter;
}

.lm-CommandPalette-emptyMessage {
  text-align: center;
  margin-top: 24px;
  line-height: 1.32;
  padding: 0px 8px;
  color: var(--jp-content-font-color3);
}

/*-----------------------------------------------------------------------------
| Copyright (c) 2014-2017, Jupyter Development Team.
|
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-Dialog {
  position: absolute;
  z-index: 10000;
  display: flex;
  flex-direction: column;
  align-items: center;
  justify-content: center;
  top: 0px;
  left: 0px;
  margin: 0;
  padding: 0;
  width: 100%;
  height: 100%;
  background: var(--jp-dialog-background);
}

.jp-Dialog-content {
  display: flex;
  flex-direction: column;
  margin-left: auto;
  margin-right: auto;
  background: var(--jp-layout-color1);
  padding: 24px;
  padding-bottom: 12px;
  min-width: 300px;
  min-height: 150px;
  max-width: 1000px;
  max-height: 500px;
  box-sizing: border-box;
  box-shadow: var(--jp-elevation-z20);
  word-wrap: break-word;
  border-radius: var(--jp-border-radius);
  /* This is needed so that all font sizing of children done in ems is
   * relative to this base size */
  font-size: var(--jp-ui-font-size1);
  color: var(--jp-ui-font-color1);
}

.jp-Dialog-button {
  overflow: visible;
}

button.jp-Dialog-button:focus {
  outline: 1px solid var(--jp-brand-color1);
  outline-offset: 4px;
  -moz-outline-radius: 0px;
}

button.jp-Dialog-button:focus::-moz-focus-inner {
  border: 0;
}

.jp-Dialog-header {
  flex: 0 0 auto;
  padding-bottom: 12px;
  font-size: var(--jp-ui-font-size3);
  font-weight: 400;
  color: var(--jp-ui-font-color0);
}

.jp-Dialog-body {
  display: flex;
  flex-direction: column;
  flex: 1 1 auto;
  font-size: var(--jp-ui-font-size1);
  background: var(--jp-layout-color1);
  overflow: auto;
}

.jp-Dialog-footer {
  display: flex;
  flex-direction: row;
  justify-content: flex-end;
  flex: 0 0 auto;
  margin-left: -12px;
  margin-right: -12px;
  padding: 12px;
}

.jp-Dialog-title {
  overflow: hidden;
  white-space: nowrap;
  text-overflow: ellipsis;
}

.jp-Dialog-body > .jp-select-wrapper {
  width: 100%;
}

.jp-Dialog-body > button {
  padding: 0px 16px;
}

.jp-Dialog-body > label {
  line-height: 1.4;
  color: var(--jp-ui-font-color0);
}

.jp-Dialog-button.jp-mod-styled:not(:last-child) {
  margin-right: 12px;
}

/*-----------------------------------------------------------------------------
| Copyright (c) 2014-2016, Jupyter Development Team.
|
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-HoverBox {
  position: fixed;
}

.jp-HoverBox.jp-mod-outofview {
  display: none;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-IFrame {
  width: 100%;
  height: 100%;
}

.jp-IFrame > iframe {
  border: none;
}

/*
When drag events occur, `p-mod-override-cursor` is added to the body.
Because iframes steal all cursor events, the following two rules are necessary
to suppress pointer events while resize drags are occurring. There may be a
better solution to this problem.
*/
body.lm-mod-override-cursor .jp-IFrame {
  position: relative;
}

body.lm-mod-override-cursor .jp-IFrame:before {
  content: '';
  position: absolute;
  top: 0;
  left: 0;
  right: 0;
  bottom: 0;
  background: transparent;
}

/*-----------------------------------------------------------------------------
| Copyright (c) 2014-2016, Jupyter Development Team.
|
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-MainAreaWidget > :focus {
  outline: none;
}

/**
 * google-material-color v1.2.6
 * https://github.com/danlevan/google-material-color
 */
:root {
  --md-red-50: #ffebee;
  --md-red-100: #ffcdd2;
  --md-red-200: #ef9a9a;
  --md-red-300: #e57373;
  --md-red-400: #ef5350;
  --md-red-500: #f44336;
  --md-red-600: #e53935;
  --md-red-700: #d32f2f;
  --md-red-800: #c62828;
  --md-red-900: #b71c1c;
  --md-red-A100: #ff8a80;
  --md-red-A200: #ff5252;
  --md-red-A400: #ff1744;
  --md-red-A700: #d50000;

  --md-pink-50: #fce4ec;
  --md-pink-100: #f8bbd0;
  --md-pink-200: #f48fb1;
  --md-pink-300: #f06292;
  --md-pink-400: #ec407a;
  --md-pink-500: #e91e63;
  --md-pink-600: #d81b60;
  --md-pink-700: #c2185b;
  --md-pink-800: #ad1457;
  --md-pink-900: #880e4f;
  --md-pink-A100: #ff80ab;
  --md-pink-A200: #ff4081;
  --md-pink-A400: #f50057;
  --md-pink-A700: #c51162;

  --md-purple-50: #f3e5f5;
  --md-purple-100: #e1bee7;
  --md-purple-200: #ce93d8;
  --md-purple-300: #ba68c8;
  --md-purple-400: #ab47bc;
  --md-purple-500: #9c27b0;
  --md-purple-600: #8e24aa;
  --md-purple-700: #7b1fa2;
  --md-purple-800: #6a1b9a;
  --md-purple-900: #4a148c;
  --md-purple-A100: #ea80fc;
  --md-purple-A200: #e040fb;
  --md-purple-A400: #d500f9;
  --md-purple-A700: #aa00ff;

  --md-deep-purple-50: #ede7f6;
  --md-deep-purple-100: #d1c4e9;
  --md-deep-purple-200: #b39ddb;
  --md-deep-purple-300: #9575cd;
  --md-deep-purple-400: #7e57c2;
  --md-deep-purple-500: #673ab7;
  --md-deep-purple-600: #5e35b1;
  --md-deep-purple-700: #512da8;
  --md-deep-purple-800: #4527a0;
  --md-deep-purple-900: #311b92;
  --md-deep-purple-A100: #b388ff;
  --md-deep-purple-A200: #7c4dff;
  --md-deep-purple-A400: #651fff;
  --md-deep-purple-A700: #6200ea;

  --md-indigo-50: #e8eaf6;
  --md-indigo-100: #c5cae9;
  --md-indigo-200: #9fa8da;
  --md-indigo-300: #7986cb;
  --md-indigo-400: #5c6bc0;
  --md-indigo-500: #3f51b5;
  --md-indigo-600: #3949ab;
  --md-indigo-700: #303f9f;
  --md-indigo-800: #283593;
  --md-indigo-900: #1a237e;
  --md-indigo-A100: #8c9eff;
  --md-indigo-A200: #536dfe;
  --md-indigo-A400: #3d5afe;
  --md-indigo-A700: #304ffe;

  --md-blue-50: #e3f2fd;
  --md-blue-100: #bbdefb;
  --md-blue-200: #90caf9;
  --md-blue-300: #64b5f6;
  --md-blue-400: #42a5f5;
  --md-blue-500: #2196f3;
  --md-blue-600: #1e88e5;
  --md-blue-700: #1976d2;
  --md-blue-800: #1565c0;
  --md-blue-900: #0d47a1;
  --md-blue-A100: #82b1ff;
  --md-blue-A200: #448aff;
  --md-blue-A400: #2979ff;
  --md-blue-A700: #2962ff;

  --md-light-blue-50: #e1f5fe;
  --md-light-blue-100: #b3e5fc;
  --md-light-blue-200: #81d4fa;
  --md-light-blue-300: #4fc3f7;
  --md-light-blue-400: #29b6f6;
  --md-light-blue-500: #03a9f4;
  --md-light-blue-600: #039be5;
  --md-light-blue-700: #0288d1;
  --md-light-blue-800: #0277bd;
  --md-light-blue-900: #01579b;
  --md-light-blue-A100: #80d8ff;
  --md-light-blue-A200: #40c4ff;
  --md-light-blue-A400: #00b0ff;
  --md-light-blue-A700: #0091ea;

  --md-cyan-50: #e0f7fa;
  --md-cyan-100: #b2ebf2;
  --md-cyan-200: #80deea;
  --md-cyan-300: #4dd0e1;
  --md-cyan-400: #26c6da;
  --md-cyan-500: #00bcd4;
  --md-cyan-600: #00acc1;
  --md-cyan-700: #0097a7;
  --md-cyan-800: #00838f;
  --md-cyan-900: #006064;
  --md-cyan-A100: #84ffff;
  --md-cyan-A200: #18ffff;
  --md-cyan-A400: #00e5ff;
  --md-cyan-A700: #00b8d4;

  --md-teal-50: #e0f2f1;
  --md-teal-100: #b2dfdb;
  --md-teal-200: #80cbc4;
  --md-teal-300: #4db6ac;
  --md-teal-400: #26a69a;
  --md-teal-500: #009688;
  --md-teal-600: #00897b;
  --md-teal-700: #00796b;
  --md-teal-800: #00695c;
  --md-teal-900: #004d40;
  --md-teal-A100: #a7ffeb;
  --md-teal-A200: #64ffda;
  --md-teal-A400: #1de9b6;
  --md-teal-A700: #00bfa5;

  --md-green-50: #e8f5e9;
  --md-green-100: #c8e6c9;
  --md-green-200: #a5d6a7;
  --md-green-300: #81c784;
  --md-green-400: #66bb6a;
  --md-green-500: #4caf50;
  --md-green-600: #43a047;
  --md-green-700: #388e3c;
  --md-green-800: #2e7d32;
  --md-green-900: #1b5e20;
  --md-green-A100: #b9f6ca;
  --md-green-A200: #69f0ae;
  --md-green-A400: #00e676;
  --md-green-A700: #00c853;

  --md-light-green-50: #f1f8e9;
  --md-light-green-100: #dcedc8;
  --md-light-green-200: #c5e1a5;
  --md-light-green-300: #aed581;
  --md-light-green-400: #9ccc65;
  --md-light-green-500: #8bc34a;
  --md-light-green-600: #7cb342;
  --md-light-green-700: #689f38;
  --md-light-green-800: #558b2f;
  --md-light-green-900: #33691e;
  --md-light-green-A100: #ccff90;
  --md-light-green-A200: #b2ff59;
  --md-light-green-A400: #76ff03;
  --md-light-green-A700: #64dd17;

  --md-lime-50: #f9fbe7;
  --md-lime-100: #f0f4c3;
  --md-lime-200: #e6ee9c;
  --md-lime-300: #dce775;
  --md-lime-400: #d4e157;
  --md-lime-500: #cddc39;
  --md-lime-600: #c0ca33;
  --md-lime-700: #afb42b;
  --md-lime-800: #9e9d24;
  --md-lime-900: #827717;
  --md-lime-A100: #f4ff81;
  --md-lime-A200: #eeff41;
  --md-lime-A400: #c6ff00;
  --md-lime-A700: #aeea00;

  --md-yellow-50: #fffde7;
  --md-yellow-100: #fff9c4;
  --md-yellow-200: #fff59d;
  --md-yellow-300: #fff176;
  --md-yellow-400: #ffee58;
  --md-yellow-500: #ffeb3b;
  --md-yellow-600: #fdd835;
  --md-yellow-700: #fbc02d;
  --md-yellow-800: #f9a825;
  --md-yellow-900: #f57f17;
  --md-yellow-A100: #ffff8d;
  --md-yellow-A200: #ffff00;
  --md-yellow-A400: #ffea00;
  --md-yellow-A700: #ffd600;

  --md-amber-50: #fff8e1;
  --md-amber-100: #ffecb3;
  --md-amber-200: #ffe082;
  --md-amber-300: #ffd54f;
  --md-amber-400: #ffca28;
  --md-amber-500: #ffc107;
  --md-amber-600: #ffb300;
  --md-amber-700: #ffa000;
  --md-amber-800: #ff8f00;
  --md-amber-900: #ff6f00;
  --md-amber-A100: #ffe57f;
  --md-amber-A200: #ffd740;
  --md-amber-A400: #ffc400;
  --md-amber-A700: #ffab00;

  --md-orange-50: #fff3e0;
  --md-orange-100: #ffe0b2;
  --md-orange-200: #ffcc80;
  --md-orange-300: #ffb74d;
  --md-orange-400: #ffa726;
  --md-orange-500: #ff9800;
  --md-orange-600: #fb8c00;
  --md-orange-700: #f57c00;
  --md-orange-800: #ef6c00;
  --md-orange-900: #e65100;
  --md-orange-A100: #ffd180;
  --md-orange-A200: #ffab40;
  --md-orange-A400: #ff9100;
  --md-orange-A700: #ff6d00;

  --md-deep-orange-50: #fbe9e7;
  --md-deep-orange-100: #ffccbc;
  --md-deep-orange-200: #ffab91;
  --md-deep-orange-300: #ff8a65;
  --md-deep-orange-400: #ff7043;
  --md-deep-orange-500: #ff5722;
  --md-deep-orange-600: #f4511e;
  --md-deep-orange-700: #e64a19;
  --md-deep-orange-800: #d84315;
  --md-deep-orange-900: #bf360c;
  --md-deep-orange-A100: #ff9e80;
  --md-deep-orange-A200: #ff6e40;
  --md-deep-orange-A400: #ff3d00;
  --md-deep-orange-A700: #dd2c00;

  --md-brown-50: #efebe9;
  --md-brown-100: #d7ccc8;
  --md-brown-200: #bcaaa4;
  --md-brown-300: #a1887f;
  --md-brown-400: #8d6e63;
  --md-brown-500: #795548;
  --md-brown-600: #6d4c41;
  --md-brown-700: #5d4037;
  --md-brown-800: #4e342e;
  --md-brown-900: #3e2723;

  --md-grey-50: #fafafa;
  --md-grey-100: #f5f5f5;
  --md-grey-200: #eeeeee;
  --md-grey-300: #e0e0e0;
  --md-grey-400: #bdbdbd;
  --md-grey-500: #9e9e9e;
  --md-grey-600: #757575;
  --md-grey-700: #616161;
  --md-grey-800: #424242;
  --md-grey-900: #212121;

  --md-blue-grey-50: #eceff1;
  --md-blue-grey-100: #cfd8dc;
  --md-blue-grey-200: #b0bec5;
  --md-blue-grey-300: #90a4ae;
  --md-blue-grey-400: #78909c;
  --md-blue-grey-500: #607d8b;
  --md-blue-grey-600: #546e7a;
  --md-blue-grey-700: #455a64;
  --md-blue-grey-800: #37474f;
  --md-blue-grey-900: #263238;
}

/*-----------------------------------------------------------------------------
| Copyright (c) 2017, Jupyter Development Team.
|
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-Spinner {
  position: absolute;
  display: flex;
  justify-content: center;
  align-items: center;
  z-index: 10;
  left: 0;
  top: 0;
  width: 100%;
  height: 100%;
  background: var(--jp-layout-color0);
  outline: none;
}

.jp-SpinnerContent {
  font-size: 10px;
  margin: 50px auto;
  text-indent: -9999em;
  width: 3em;
  height: 3em;
  border-radius: 50%;
  background: var(--jp-brand-color3);
  background: linear-gradient(
    to right,
    #f37626 10%,
    rgba(255, 255, 255, 0) 42%
  );
  position: relative;
  animation: load3 1s infinite linear, fadeIn 1s;
}

.jp-SpinnerContent:before {
  width: 50%;
  height: 50%;
  background: #f37626;
  border-radius: 100% 0 0 0;
  position: absolute;
  top: 0;
  left: 0;
  content: '';
}

.jp-SpinnerContent:after {
  background: var(--jp-layout-color0);
  width: 75%;
  height: 75%;
  border-radius: 50%;
  content: '';
  margin: auto;
  position: absolute;
  top: 0;
  left: 0;
  bottom: 0;
  right: 0;
}

@keyframes fadeIn {
  0% {
    opacity: 0;
  }
  100% {
    opacity: 1;
  }
}

@keyframes load3 {
  0% {
    transform: rotate(0deg);
  }
  100% {
    transform: rotate(360deg);
  }
}

/*-----------------------------------------------------------------------------
| Copyright (c) 2014-2017, Jupyter Development Team.
|
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

button.jp-mod-styled {
  font-size: var(--jp-ui-font-size1);
  color: var(--jp-ui-font-color0);
  border: none;
  box-sizing: border-box;
  text-align: center;
  line-height: 32px;
  height: 32px;
  padding: 0px 12px;
  letter-spacing: 0.8px;
  outline: none;
  appearance: none;
  -webkit-appearance: none;
  -moz-appearance: none;
}

input.jp-mod-styled {
  background: var(--jp-input-background);
  height: 28px;
  box-sizing: border-box;
  border: var(--jp-border-width) solid var(--jp-border-color1);
  padding-left: 7px;
  padding-right: 7px;
  font-size: var(--jp-ui-font-size2);
  color: var(--jp-ui-font-color0);
  outline: none;
  appearance: none;
  -webkit-appearance: none;
  -moz-appearance: none;
}

input.jp-mod-styled:focus {
  border: var(--jp-border-width) solid var(--md-blue-500);
  box-shadow: inset 0 0 4px var(--md-blue-300);
}

.jp-select-wrapper {
  display: flex;
  position: relative;
  flex-direction: column;
  padding: 1px;
  background-color: var(--jp-layout-color1);
  height: 28px;
  box-sizing: border-box;
  margin-bottom: 12px;
}

.jp-select-wrapper.jp-mod-focused select.jp-mod-styled {
  border: var(--jp-border-width) solid var(--jp-input-active-border-color);
  box-shadow: var(--jp-input-box-shadow);
  background-color: var(--jp-input-active-background);
}

select.jp-mod-styled:hover {
  background-color: var(--jp-layout-color1);
  cursor: pointer;
  color: var(--jp-ui-font-color0);
  background-color: var(--jp-input-hover-background);
  box-shadow: inset 0 0px 1px rgba(0, 0, 0, 0.5);
}

select.jp-mod-styled {
  flex: 1 1 auto;
  height: 32px;
  width: 100%;
  font-size: var(--jp-ui-font-size2);
  background: var(--jp-input-background);
  color: var(--jp-ui-font-color0);
  padding: 0 25px 0 8px;
  border: var(--jp-border-width) solid var(--jp-input-border-color);
  border-radius: 0px;
  outline: none;
  appearance: none;
  -webkit-appearance: none;
  -moz-appearance: none;
}

/*-----------------------------------------------------------------------------
| Copyright (c) 2014-2016, Jupyter Development Team.
|
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

:root {
  --jp-private-toolbar-height: calc(
    28px + var(--jp-border-width)
  ); /* leave 28px for content */
}

.jp-Toolbar {
  color: var(--jp-ui-font-color1);
  flex: 0 0 auto;
  display: flex;
  flex-direction: row;
  border-bottom: var(--jp-border-width) solid var(--jp-toolbar-border-color);
  box-shadow: var(--jp-toolbar-box-shadow);
  background: var(--jp-toolbar-background);
  min-height: var(--jp-toolbar-micro-height);
  padding: 2px;
  z-index: 1;
}

/* Toolbar items */

.jp-Toolbar > .jp-Toolbar-item.jp-Toolbar-spacer {
  flex-grow: 1;
  flex-shrink: 1;
}

.jp-Toolbar-item.jp-Toolbar-kernelStatus {
  display: inline-block;
  width: 32px;
  background-repeat: no-repeat;
  background-position: center;
  background-size: 16px;
}

.jp-Toolbar > .jp-Toolbar-item {
  flex: 0 0 auto;
  display: flex;
  padding-left: 1px;
  padding-right: 1px;
  font-size: var(--jp-ui-font-size1);
  line-height: var(--jp-private-toolbar-height);
  height: 100%;
}

/* Toolbar buttons */

/* This is the div we use to wrap the react component into a Widget */
div.jp-ToolbarButton {
  color: transparent;
  border: none;
  box-sizing: border-box;
  outline: none;
  appearance: none;
  -webkit-appearance: none;
  -moz-appearance: none;
  padding: 0px;
  margin: 0px;
}

button.jp-ToolbarButtonComponent {
  background: var(--jp-layout-color1);
  border: none;
  box-sizing: border-box;
  outline: none;
  appearance: none;
  -webkit-appearance: none;
  -moz-appearance: none;
  padding: 0px 6px;
  margin: 0px;
  height: 24px;
  border-radius: var(--jp-border-radius);
  display: flex;
  align-items: center;
  text-align: center;
  font-size: 14px;
  min-width: unset;
  min-height: unset;
}

button.jp-ToolbarButtonComponent:disabled {
  opacity: 0.4;
}

button.jp-ToolbarButtonComponent span {
  padding: 0px;
  flex: 0 0 auto;
}

button.jp-ToolbarButtonComponent .jp-ToolbarButtonComponent-label {
  font-size: var(--jp-ui-font-size1);
  line-height: 100%;
  padding-left: 2px;
  color: var(--jp-ui-font-color1);
}

/*-----------------------------------------------------------------------------
| Copyright (c) 2014-2017, Jupyter Development Team.
|
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/* This file was auto-generated by ensurePackage() in @jupyterlab/buildutils */

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/


/* <DEPRECATED> */ body.p-mod-override-cursor *, /* </DEPRECATED> */
body.lm-mod-override-cursor * {
  cursor: inherit !important;
}

/*-----------------------------------------------------------------------------
| Copyright (c) 2014-2016, Jupyter Development Team.
|
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-JSONEditor {
  display: flex;
  flex-direction: column;
  width: 100%;
}

.jp-JSONEditor-host {
  flex: 1 1 auto;
  border: var(--jp-border-width) solid var(--jp-input-border-color);
  border-radius: 0px;
  background: var(--jp-layout-color0);
  min-height: 50px;
  padding: 1px;
}

.jp-JSONEditor.jp-mod-error .jp-JSONEditor-host {
  border-color: red;
  outline-color: red;
}

.jp-JSONEditor-header {
  display: flex;
  flex: 1 0 auto;
  padding: 0 0 0 12px;
}

.jp-JSONEditor-header label {
  flex: 0 0 auto;
}

.jp-JSONEditor-commitButton {
  height: 16px;
  width: 16px;
  background-size: 18px;
  background-repeat: no-repeat;
  background-position: center;
}

.jp-JSONEditor-host.jp-mod-focused {
  background-color: var(--jp-input-active-background);
  border: 1px solid var(--jp-input-active-border-color);
  box-shadow: var(--jp-input-box-shadow);
}

.jp-Editor.jp-mod-dropTarget {
  border: var(--jp-border-width) solid var(--jp-input-active-border-color);
  box-shadow: var(--jp-input-box-shadow);
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/* This file was auto-generated by ensurePackage() in @jupyterlab/buildutils */

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/* BASICS */

.CodeMirror {
  /* Set height, width, borders, and global font properties here */
  font-family: monospace;
  height: 300px;
  color: black;
  direction: ltr;
}

/* PADDING */

.CodeMirror-lines {
  padding: 4px 0; /* Vertical padding around content */
}
.CodeMirror pre.CodeMirror-line,
.CodeMirror pre.CodeMirror-line-like {
  padding: 0 4px; /* Horizontal padding of content */
}

.CodeMirror-scrollbar-filler, .CodeMirror-gutter-filler {
  background-color: white; /* The little square between H and V scrollbars */
}

/* GUTTER */

.CodeMirror-gutters {
  border-right: 1px solid #ddd;
  background-color: #f7f7f7;
  white-space: nowrap;
}
.CodeMirror-linenumbers {}
.CodeMirror-linenumber {
  padding: 0 3px 0 5px;
  min-width: 20px;
  text-align: right;
  color: #999;
  white-space: nowrap;
}

.CodeMirror-guttermarker { color: black; }
.CodeMirror-guttermarker-subtle { color: #999; }

/* CURSOR */

.CodeMirror-cursor {
  border-left: 1px solid black;
  border-right: none;
  width: 0;
}
/* Shown when moving in bi-directional text */
.CodeMirror div.CodeMirror-secondarycursor {
  border-left: 1px solid silver;
}
.cm-fat-cursor .CodeMirror-cursor {
  width: auto;
  border: 0 !important;
  background: #7e7;
}
.cm-fat-cursor div.CodeMirror-cursors {
  z-index: 1;
}
.cm-fat-cursor-mark {
  background-color: rgba(20, 255, 20, 0.5);
  -webkit-animation: blink 1.06s steps(1) infinite;
  -moz-animation: blink 1.06s steps(1) infinite;
  animation: blink 1.06s steps(1) infinite;
}
.cm-animate-fat-cursor {
  width: auto;
  border: 0;
  -webkit-animation: blink 1.06s steps(1) infinite;
  -moz-animation: blink 1.06s steps(1) infinite;
  animation: blink 1.06s steps(1) infinite;
  background-color: #7e7;
}
@-moz-keyframes blink {
  0% {}
  50% { background-color: transparent; }
  100% {}
}
@-webkit-keyframes blink {
  0% {}
  50% { background-color: transparent; }
  100% {}
}
@keyframes blink {
  0% {}
  50% { background-color: transparent; }
  100% {}
}

/* Can style cursor different in overwrite (non-insert) mode */
.CodeMirror-overwrite .CodeMirror-cursor {}

.cm-tab { display: inline-block; text-decoration: inherit; }

.CodeMirror-rulers {
  position: absolute;
  left: 0; right: 0; top: -50px; bottom: 0;
  overflow: hidden;
}
.CodeMirror-ruler {
  border-left: 1px solid #ccc;
  top: 0; bottom: 0;
  position: absolute;
}

/* DEFAULT THEME */

.cm-s-default .cm-header {color: blue;}
.cm-s-default .cm-quote {color: #090;}
.cm-negative {color: #d44;}
.cm-positive {color: #292;}
.cm-header, .cm-strong {font-weight: bold;}
.cm-em {font-style: italic;}
.cm-link {text-decoration: underline;}
.cm-strikethrough {text-decoration: line-through;}

.cm-s-default .cm-keyword {color: #708;}
.cm-s-default .cm-atom {color: #219;}
.cm-s-default .cm-number {color: #164;}
.cm-s-default .cm-def {color: #00f;}
.cm-s-default .cm-variable,
.cm-s-default .cm-punctuation,
.cm-s-default .cm-property,
.cm-s-default .cm-operator {}
.cm-s-default .cm-variable-2 {color: #05a;}
.cm-s-default .cm-variable-3, .cm-s-default .cm-type {color: #085;}
.cm-s-default .cm-comment {color: #a50;}
.cm-s-default .cm-string {color: #a11;}
.cm-s-default .cm-string-2 {color: #f50;}
.cm-s-default .cm-meta {color: #555;}
.cm-s-default .cm-qualifier {color: #555;}
.cm-s-default .cm-builtin {color: #30a;}
.cm-s-default .cm-bracket {color: #997;}
.cm-s-default .cm-tag {color: #170;}
.cm-s-default .cm-attribute {color: #00c;}
.cm-s-default .cm-hr {color: #999;}
.cm-s-default .cm-link {color: #00c;}

.cm-s-default .cm-error {color: #f00;}
.cm-invalidchar {color: #f00;}

.CodeMirror-composing { border-bottom: 2px solid; }

/* Default styles for common addons */

div.CodeMirror span.CodeMirror-matchingbracket {color: #0b0;}
div.CodeMirror span.CodeMirror-nonmatchingbracket {color: #a22;}
.CodeMirror-matchingtag { background: rgba(255, 150, 0, .3); }
.CodeMirror-activeline-background {background: #e8f2ff;}

/* STOP */

/* The rest of this file contains styles related to the mechanics of
   the editor. You probably shouldn't touch them. */

.CodeMirror {
  position: relative;
  overflow: hidden;
  background: white;
}

.CodeMirror-scroll {
  overflow: scroll !important; /* Things will break if this is overridden */
  /* 30px is the magic margin used to hide the element's real scrollbars */
  /* See overflow: hidden in .CodeMirror */
  margin-bottom: -30px; margin-right: -30px;
  padding-bottom: 30px;
  height: 100%;
  outline: none; /* Prevent dragging from highlighting the element */
  position: relative;
}
.CodeMirror-sizer {
  position: relative;
  border-right: 30px solid transparent;
}

/* The fake, visible scrollbars. Used to force redraw during scrolling
   before actual scrolling happens, thus preventing shaking and
   flickering artifacts. */
.CodeMirror-vscrollbar, .CodeMirror-hscrollbar, .CodeMirror-scrollbar-filler, .CodeMirror-gutter-filler {
  position: absolute;
  z-index: 6;
  display: none;
}
.CodeMirror-vscrollbar {
  right: 0; top: 0;
  overflow-x: hidden;
  overflow-y: scroll;
}
.CodeMirror-hscrollbar {
  bottom: 0; left: 0;
  overflow-y: hidden;
  overflow-x: scroll;
}
.CodeMirror-scrollbar-filler {
  right: 0; bottom: 0;
}
.CodeMirror-gutter-filler {
  left: 0; bottom: 0;
}

.CodeMirror-gutters {
  position: absolute; left: 0; top: 0;
  min-height: 100%;
  z-index: 3;
}
.CodeMirror-gutter {
  white-space: normal;
  height: 100%;
  display: inline-block;
  vertical-align: top;
  margin-bottom: -30px;
}
.CodeMirror-gutter-wrapper {
  position: absolute;
  z-index: 4;
  background: none !important;
  border: none !important;
}
.CodeMirror-gutter-background {
  position: absolute;
  top: 0; bottom: 0;
  z-index: 4;
}
.CodeMirror-gutter-elt {
  position: absolute;
  cursor: default;
  z-index: 4;
}
.CodeMirror-gutter-wrapper ::selection { background-color: transparent }
.CodeMirror-gutter-wrapper ::-moz-selection { background-color: transparent }

.CodeMirror-lines {
  cursor: text;
  min-height: 1px; /* prevents collapsing before first draw */
}
.CodeMirror pre.CodeMirror-line,
.CodeMirror pre.CodeMirror-line-like {
  /* Reset some styles that the rest of the page might have set */
  -moz-border-radius: 0; -webkit-border-radius: 0; border-radius: 0;
  border-width: 0;
  background: transparent;
  font-family: inherit;
  font-size: inherit;
  margin: 0;
  white-space: pre;
  word-wrap: normal;
  line-height: inherit;
  color: inherit;
  z-index: 2;
  position: relative;
  overflow: visible;
  -webkit-tap-highlight-color: transparent;
  -webkit-font-variant-ligatures: contextual;
  font-variant-ligatures: contextual;
}
.CodeMirror-wrap pre.CodeMirror-line,
.CodeMirror-wrap pre.CodeMirror-line-like {
  word-wrap: break-word;
  white-space: pre-wrap;
  word-break: normal;
}

.CodeMirror-linebackground {
  position: absolute;
  left: 0; right: 0; top: 0; bottom: 0;
  z-index: 0;
}

.CodeMirror-linewidget {
  position: relative;
  z-index: 2;
  padding: 0.1px; /* Force widget margins to stay inside of the container */
}

.CodeMirror-widget {}

.CodeMirror-rtl pre { direction: rtl; }

.CodeMirror-code {
  outline: none;
}

/* Force content-box sizing for the elements where we expect it */
.CodeMirror-scroll,
.CodeMirror-sizer,
.CodeMirror-gutter,
.CodeMirror-gutters,
.CodeMirror-linenumber {
  -moz-box-sizing: content-box;
  box-sizing: content-box;
}

.CodeMirror-measure {
  position: absolute;
  width: 100%;
  height: 0;
  overflow: hidden;
  visibility: hidden;
}

.CodeMirror-cursor {
  position: absolute;
  pointer-events: none;
}
.CodeMirror-measure pre { position: static; }

div.CodeMirror-cursors {
  visibility: hidden;
  position: relative;
  z-index: 3;
}
div.CodeMirror-dragcursors {
  visibility: visible;
}

.CodeMirror-focused div.CodeMirror-cursors {
  visibility: visible;
}

.CodeMirror-selected { background: #d9d9d9; }
.CodeMirror-focused .CodeMirror-selected { background: #d7d4f0; }
.CodeMirror-crosshair { cursor: crosshair; }
.CodeMirror-line::selection, .CodeMirror-line > span::selection, .CodeMirror-line > span > span::selection { background: #d7d4f0; }
.CodeMirror-line::-moz-selection, .CodeMirror-line > span::-moz-selection, .CodeMirror-line > span > span::-moz-selection { background: #d7d4f0; }

.cm-searching {
  background-color: #ffa;
  background-color: rgba(255, 255, 0, .4);
}

/* Used to force a border model for a node */
.cm-force-border { padding-right: .1px; }

@media print {
  /* Hide the cursor when printing */
  .CodeMirror div.CodeMirror-cursors {
    visibility: hidden;
  }
}

/* See issue #2901 */
.cm-tab-wrap-hack:after { content: ''; }

/* Help users use markselection to safely style text background */
span.CodeMirror-selectedtext { background: none; }

.CodeMirror-dialog {
  position: absolute;
  left: 0; right: 0;
  background: inherit;
  z-index: 15;
  padding: .1em .8em;
  overflow: hidden;
  color: inherit;
}

.CodeMirror-dialog-top {
  border-bottom: 1px solid #eee;
  top: 0;
}

.CodeMirror-dialog-bottom {
  border-top: 1px solid #eee;
  bottom: 0;
}

.CodeMirror-dialog input {
  border: none;
  outline: none;
  background: transparent;
  width: 20em;
  color: inherit;
  font-family: monospace;
}

.CodeMirror-dialog button {
  font-size: 70%;
}

.CodeMirror-foldmarker {
  color: blue;
  text-shadow: #b9f 1px 1px 2px, #b9f -1px -1px 2px, #b9f 1px -1px 2px, #b9f -1px 1px 2px;
  font-family: arial;
  line-height: .3;
  cursor: pointer;
}
.CodeMirror-foldgutter {
  width: .7em;
}
.CodeMirror-foldgutter-open,
.CodeMirror-foldgutter-folded {
  cursor: pointer;
}
.CodeMirror-foldgutter-open:after {
  content: "\25BE";
}
.CodeMirror-foldgutter-folded:after {
  content: "\25B8";
}

/*
  Name:       material
  Author:     Mattia Astorino (http://github.com/equinusocio)
  Website:    https://material-theme.site/
*/

.cm-s-material.CodeMirror {
  background-color: #263238;
  color: #EEFFFF;
}

.cm-s-material .CodeMirror-gutters {
  background: #263238;
  color: #546E7A;
  border: none;
}

.cm-s-material .CodeMirror-guttermarker,
.cm-s-material .CodeMirror-guttermarker-subtle,
.cm-s-material .CodeMirror-linenumber {
  color: #546E7A;
}

.cm-s-material .CodeMirror-cursor {
  border-left: 1px solid #FFCC00;
}

.cm-s-material div.CodeMirror-selected {
  background: rgba(128, 203, 196, 0.2);
}

.cm-s-material.CodeMirror-focused div.CodeMirror-selected {
  background: rgba(128, 203, 196, 0.2);
}

.cm-s-material .CodeMirror-line::selection,
.cm-s-material .CodeMirror-line>span::selection,
.cm-s-material .CodeMirror-line>span>span::selection {
  background: rgba(128, 203, 196, 0.2);
}

.cm-s-material .CodeMirror-line::-moz-selection,
.cm-s-material .CodeMirror-line>span::-moz-selection,
.cm-s-material .CodeMirror-line>span>span::-moz-selection {
  background: rgba(128, 203, 196, 0.2);
}

.cm-s-material .CodeMirror-activeline-background {
  background: rgba(0, 0, 0, 0.5);
}

.cm-s-material .cm-keyword {
  color: #C792EA;
}

.cm-s-material .cm-operator {
  color: #89DDFF;
}

.cm-s-material .cm-variable-2 {
  color: #EEFFFF;
}

.cm-s-material .cm-variable-3,
.cm-s-material .cm-type {
  color: #f07178;
}

.cm-s-material .cm-builtin {
  color: #FFCB6B;
}

.cm-s-material .cm-atom {
  color: #F78C6C;
}

.cm-s-material .cm-number {
  color: #FF5370;
}

.cm-s-material .cm-def {
  color: #82AAFF;
}

.cm-s-material .cm-string {
  color: #C3E88D;
}

.cm-s-material .cm-string-2 {
  color: #f07178;
}

.cm-s-material .cm-comment {
  color: #546E7A;
}

.cm-s-material .cm-variable {
  color: #f07178;
}

.cm-s-material .cm-tag {
  color: #FF5370;
}

.cm-s-material .cm-meta {
  color: #FFCB6B;
}

.cm-s-material .cm-attribute {
  color: #C792EA;
}

.cm-s-material .cm-property {
  color: #C792EA;
}

.cm-s-material .cm-qualifier {
  color: #DECB6B;
}

.cm-s-material .cm-variable-3,
.cm-s-material .cm-type {
  color: #DECB6B;
}


.cm-s-material .cm-error {
  color: rgba(255, 255, 255, 1.0);
  background-color: #FF5370;
}

.cm-s-material .CodeMirror-matchingbracket {
  text-decoration: underline;
  color: white !important;
}
/**
 * "
 *  Using Zenburn color palette from the Emacs Zenburn Theme
 *  https://github.com/bbatsov/zenburn-emacs/blob/master/zenburn-theme.el
 *
 *  Also using parts of https://github.com/xavi/coderay-lighttable-theme
 * "
 * From: https://github.com/wisenomad/zenburn-lighttable-theme/blob/master/zenburn.css
 */

.cm-s-zenburn .CodeMirror-gutters { background: #3f3f3f !important; }
.cm-s-zenburn .CodeMirror-foldgutter-open, .CodeMirror-foldgutter-folded { color: #999; }
.cm-s-zenburn .CodeMirror-cursor { border-left: 1px solid white; }
.cm-s-zenburn { background-color: #3f3f3f; color: #dcdccc; }
.cm-s-zenburn span.cm-builtin { color: #dcdccc; font-weight: bold; }
.cm-s-zenburn span.cm-comment { color: #7f9f7f; }
.cm-s-zenburn span.cm-keyword { color: #f0dfaf; font-weight: bold; }
.cm-s-zenburn span.cm-atom { color: #bfebbf; }
.cm-s-zenburn span.cm-def { color: #dcdccc; }
.cm-s-zenburn span.cm-variable { color: #dfaf8f; }
.cm-s-zenburn span.cm-variable-2 { color: #dcdccc; }
.cm-s-zenburn span.cm-string { color: #cc9393; }
.cm-s-zenburn span.cm-string-2 { color: #cc9393; }
.cm-s-zenburn span.cm-number { color: #dcdccc; }
.cm-s-zenburn span.cm-tag { color: #93e0e3; }
.cm-s-zenburn span.cm-property { color: #dfaf8f; }
.cm-s-zenburn span.cm-attribute { color: #dfaf8f; }
.cm-s-zenburn span.cm-qualifier { color: #7cb8bb; }
.cm-s-zenburn span.cm-meta { color: #f0dfaf; }
.cm-s-zenburn span.cm-header { color: #f0efd0; }
.cm-s-zenburn span.cm-operator { color: #f0efd0; }
.cm-s-zenburn span.CodeMirror-matchingbracket { box-sizing: border-box; background: transparent; border-bottom: 1px solid; }
.cm-s-zenburn span.CodeMirror-nonmatchingbracket { border-bottom: 1px solid; background: none; }
.cm-s-zenburn .CodeMirror-activeline { background: #000000; }
.cm-s-zenburn .CodeMirror-activeline-background { background: #000000; }
.cm-s-zenburn div.CodeMirror-selected { background: #545454; }
.cm-s-zenburn .CodeMirror-focused div.CodeMirror-selected { background: #4f4f4f; }

.cm-s-abcdef.CodeMirror { background: #0f0f0f; color: #defdef; }
.cm-s-abcdef div.CodeMirror-selected { background: #515151; }
.cm-s-abcdef .CodeMirror-line::selection, .cm-s-abcdef .CodeMirror-line > span::selection, .cm-s-abcdef .CodeMirror-line > span > span::selection { background: rgba(56, 56, 56, 0.99); }
.cm-s-abcdef .CodeMirror-line::-moz-selection, .cm-s-abcdef .CodeMirror-line > span::-moz-selection, .cm-s-abcdef .CodeMirror-line > span > span::-moz-selection { background: rgba(56, 56, 56, 0.99); }
.cm-s-abcdef .CodeMirror-gutters { background: #555; border-right: 2px solid #314151; }
.cm-s-abcdef .CodeMirror-guttermarker { color: #222; }
.cm-s-abcdef .CodeMirror-guttermarker-subtle { color: azure; }
.cm-s-abcdef .CodeMirror-linenumber { color: #FFFFFF; }
.cm-s-abcdef .CodeMirror-cursor { border-left: 1px solid #00FF00; }

.cm-s-abcdef span.cm-keyword { color: darkgoldenrod; font-weight: bold; }
.cm-s-abcdef span.cm-atom { color: #77F; }
.cm-s-abcdef span.cm-number { color: violet; }
.cm-s-abcdef span.cm-def { color: #fffabc; }
.cm-s-abcdef span.cm-variable { color: #abcdef; }
.cm-s-abcdef span.cm-variable-2 { color: #cacbcc; }
.cm-s-abcdef span.cm-variable-3, .cm-s-abcdef span.cm-type { color: #def; }
.cm-s-abcdef span.cm-property { color: #fedcba; }
.cm-s-abcdef span.cm-operator { color: #ff0; }
.cm-s-abcdef span.cm-comment { color: #7a7b7c; font-style: italic;}
.cm-s-abcdef span.cm-string { color: #2b4; }
.cm-s-abcdef span.cm-meta { color: #C9F; }
.cm-s-abcdef span.cm-qualifier { color: #FFF700; }
.cm-s-abcdef span.cm-builtin { color: #30aabc; }
.cm-s-abcdef span.cm-bracket { color: #8a8a8a; }
.cm-s-abcdef span.cm-tag { color: #FFDD44; }
.cm-s-abcdef span.cm-attribute { color: #DDFF00; }
.cm-s-abcdef span.cm-error { color: #FF0000; }
.cm-s-abcdef span.cm-header { color: aquamarine; font-weight: bold; }
.cm-s-abcdef span.cm-link { color: blueviolet; }

.cm-s-abcdef .CodeMirror-activeline-background { background: #314151; }

/*

    Name:       Base16 Default Light
    Author:     Chris Kempson (http://chriskempson.com)

    CodeMirror template by Jan T. Sott (https://github.com/idleberg/base16-codemirror)
    Original Base16 color scheme by Chris Kempson (https://github.com/chriskempson/base16)

*/

.cm-s-base16-light.CodeMirror { background: #f5f5f5; color: #202020; }
.cm-s-base16-light div.CodeMirror-selected { background: #e0e0e0; }
.cm-s-base16-light .CodeMirror-line::selection, .cm-s-base16-light .CodeMirror-line > span::selection, .cm-s-base16-light .CodeMirror-line > span > span::selection { background: #e0e0e0; }
.cm-s-base16-light .CodeMirror-line::-moz-selection, .cm-s-base16-light .CodeMirror-line > span::-moz-selection, .cm-s-base16-light .CodeMirror-line > span > span::-moz-selection { background: #e0e0e0; }
.cm-s-base16-light .CodeMirror-gutters { background: #f5f5f5; border-right: 0px; }
.cm-s-base16-light .CodeMirror-guttermarker { color: #ac4142; }
.cm-s-base16-light .CodeMirror-guttermarker-subtle { color: #b0b0b0; }
.cm-s-base16-light .CodeMirror-linenumber { color: #b0b0b0; }
.cm-s-base16-light .CodeMirror-cursor { border-left: 1px solid #505050; }

.cm-s-base16-light span.cm-comment { color: #8f5536; }
.cm-s-base16-light span.cm-atom { color: #aa759f; }
.cm-s-base16-light span.cm-number { color: #aa759f; }

.cm-s-base16-light span.cm-property, .cm-s-base16-light span.cm-attribute { color: #90a959; }
.cm-s-base16-light span.cm-keyword { color: #ac4142; }
.cm-s-base16-light span.cm-string { color: #f4bf75; }

.cm-s-base16-light span.cm-variable { color: #90a959; }
.cm-s-base16-light span.cm-variable-2 { color: #6a9fb5; }
.cm-s-base16-light span.cm-def { color: #d28445; }
.cm-s-base16-light span.cm-bracket { color: #202020; }
.cm-s-base16-light span.cm-tag { color: #ac4142; }
.cm-s-base16-light span.cm-link { color: #aa759f; }
.cm-s-base16-light span.cm-error { background: #ac4142; color: #505050; }

.cm-s-base16-light .CodeMirror-activeline-background { background: #DDDCDC; }
.cm-s-base16-light .CodeMirror-matchingbracket { color: #f5f5f5 !important; background-color: #6A9FB5 !important}

/*

    Name:       Base16 Default Dark
    Author:     Chris Kempson (http://chriskempson.com)

    CodeMirror template by Jan T. Sott (https://github.com/idleberg/base16-codemirror)
    Original Base16 color scheme by Chris Kempson (https://github.com/chriskempson/base16)

*/

.cm-s-base16-dark.CodeMirror { background: #151515; color: #e0e0e0; }
.cm-s-base16-dark div.CodeMirror-selected { background: #303030; }
.cm-s-base16-dark .CodeMirror-line::selection, .cm-s-base16-dark .CodeMirror-line > span::selection, .cm-s-base16-dark .CodeMirror-line > span > span::selection { background: rgba(48, 48, 48, .99); }
.cm-s-base16-dark .CodeMirror-line::-moz-selection, .cm-s-base16-dark .CodeMirror-line > span::-moz-selection, .cm-s-base16-dark .CodeMirror-line > span > span::-moz-selection { background: rgba(48, 48, 48, .99); }
.cm-s-base16-dark .CodeMirror-gutters { background: #151515; border-right: 0px; }
.cm-s-base16-dark .CodeMirror-guttermarker { color: #ac4142; }
.cm-s-base16-dark .CodeMirror-guttermarker-subtle { color: #505050; }
.cm-s-base16-dark .CodeMirror-linenumber { color: #505050; }
.cm-s-base16-dark .CodeMirror-cursor { border-left: 1px solid #b0b0b0; }

.cm-s-base16-dark span.cm-comment { color: #8f5536; }
.cm-s-base16-dark span.cm-atom { color: #aa759f; }
.cm-s-base16-dark span.cm-number { color: #aa759f; }

.cm-s-base16-dark span.cm-property, .cm-s-base16-dark span.cm-attribute { color: #90a959; }
.cm-s-base16-dark span.cm-keyword { color: #ac4142; }
.cm-s-base16-dark span.cm-string { color: #f4bf75; }

.cm-s-base16-dark span.cm-variable { color: #90a959; }
.cm-s-base16-dark span.cm-variable-2 { color: #6a9fb5; }
.cm-s-base16-dark span.cm-def { color: #d28445; }
.cm-s-base16-dark span.cm-bracket { color: #e0e0e0; }
.cm-s-base16-dark span.cm-tag { color: #ac4142; }
.cm-s-base16-dark span.cm-link { color: #aa759f; }
.cm-s-base16-dark span.cm-error { background: #ac4142; color: #b0b0b0; }

.cm-s-base16-dark .CodeMirror-activeline-background { background: #202020; }
.cm-s-base16-dark .CodeMirror-matchingbracket { text-decoration: underline; color: white !important; }

/*

    Name:       dracula
    Author:     Michael Kaminsky (http://github.com/mkaminsky11)

    Original dracula color scheme by Zeno Rocha (https://github.com/zenorocha/dracula-theme)

*/


.cm-s-dracula.CodeMirror, .cm-s-dracula .CodeMirror-gutters {
  background-color: #282a36 !important;
  color: #f8f8f2 !important;
  border: none;
}
.cm-s-dracula .CodeMirror-gutters { color: #282a36; }
.cm-s-dracula .CodeMirror-cursor { border-left: solid thin #f8f8f0; }
.cm-s-dracula .CodeMirror-linenumber { color: #6D8A88; }
.cm-s-dracula .CodeMirror-selected { background: rgba(255, 255, 255, 0.10); }
.cm-s-dracula .CodeMirror-line::selection, .cm-s-dracula .CodeMirror-line > span::selection, .cm-s-dracula .CodeMirror-line > span > span::selection { background: rgba(255, 255, 255, 0.10); }
.cm-s-dracula .CodeMirror-line::-moz-selection, .cm-s-dracula .CodeMirror-line > span::-moz-selection, .cm-s-dracula .CodeMirror-line > span > span::-moz-selection { background: rgba(255, 255, 255, 0.10); }
.cm-s-dracula span.cm-comment { color: #6272a4; }
.cm-s-dracula span.cm-string, .cm-s-dracula span.cm-string-2 { color: #f1fa8c; }
.cm-s-dracula span.cm-number { color: #bd93f9; }
.cm-s-dracula span.cm-variable { color: #50fa7b; }
.cm-s-dracula span.cm-variable-2 { color: white; }
.cm-s-dracula span.cm-def { color: #50fa7b; }
.cm-s-dracula span.cm-operator { color: #ff79c6; }
.cm-s-dracula span.cm-keyword { color: #ff79c6; }
.cm-s-dracula span.cm-atom { color: #bd93f9; }
.cm-s-dracula span.cm-meta { color: #f8f8f2; }
.cm-s-dracula span.cm-tag { color: #ff79c6; }
.cm-s-dracula span.cm-attribute { color: #50fa7b; }
.cm-s-dracula span.cm-qualifier { color: #50fa7b; }
.cm-s-dracula span.cm-property { color: #66d9ef; }
.cm-s-dracula span.cm-builtin { color: #50fa7b; }
.cm-s-dracula span.cm-variable-3, .cm-s-dracula span.cm-type { color: #ffb86c; }

.cm-s-dracula .CodeMirror-activeline-background { background: rgba(255,255,255,0.1); }
.cm-s-dracula .CodeMirror-matchingbracket { text-decoration: underline; color: white !important; }

/*

    Name:       Hopscotch
    Author:     Jan T. Sott

    CodeMirror template by Jan T. Sott (https://github.com/idleberg/base16-codemirror)
    Original Base16 color scheme by Chris Kempson (https://github.com/chriskempson/base16)

*/

.cm-s-hopscotch.CodeMirror {background: #322931; color: #d5d3d5;}
.cm-s-hopscotch div.CodeMirror-selected {background: #433b42 !important;}
.cm-s-hopscotch .CodeMirror-gutters {background: #322931; border-right: 0px;}
.cm-s-hopscotch .CodeMirror-linenumber {color: #797379;}
.cm-s-hopscotch .CodeMirror-cursor {border-left: 1px solid #989498 !important;}

.cm-s-hopscotch span.cm-comment {color: #b33508;}
.cm-s-hopscotch span.cm-atom {color: #c85e7c;}
.cm-s-hopscotch span.cm-number {color: #c85e7c;}

.cm-s-hopscotch span.cm-property, .cm-s-hopscotch span.cm-attribute {color: #8fc13e;}
.cm-s-hopscotch span.cm-keyword {color: #dd464c;}
.cm-s-hopscotch span.cm-string {color: #fdcc59;}

.cm-s-hopscotch span.cm-variable {color: #8fc13e;}
.cm-s-hopscotch span.cm-variable-2 {color: #1290bf;}
.cm-s-hopscotch span.cm-def {color: #fd8b19;}
.cm-s-hopscotch span.cm-error {background: #dd464c; color: #989498;}
.cm-s-hopscotch span.cm-bracket {color: #d5d3d5;}
.cm-s-hopscotch span.cm-tag {color: #dd464c;}
.cm-s-hopscotch span.cm-link {color: #c85e7c;}

.cm-s-hopscotch .CodeMirror-matchingbracket { text-decoration: underline; color: white !important;}
.cm-s-hopscotch .CodeMirror-activeline-background { background: #302020; }

/****************************************************************/
/*   Based on mbonaci's Brackets mbo theme                      */
/*   https://github.com/mbonaci/global/blob/master/Mbo.tmTheme  */
/*   Create your own: http://tmtheme-editor.herokuapp.com       */
/****************************************************************/

.cm-s-mbo.CodeMirror { background: #2c2c2c; color: #ffffec; }
.cm-s-mbo div.CodeMirror-selected { background: #716C62; }
.cm-s-mbo .CodeMirror-line::selection, .cm-s-mbo .CodeMirror-line > span::selection, .cm-s-mbo .CodeMirror-line > span > span::selection { background: rgba(113, 108, 98, .99); }
.cm-s-mbo .CodeMirror-line::-moz-selection, .cm-s-mbo .CodeMirror-line > span::-moz-selection, .cm-s-mbo .CodeMirror-line > span > span::-moz-selection { background: rgba(113, 108, 98, .99); }
.cm-s-mbo .CodeMirror-gutters { background: #4e4e4e; border-right: 0px; }
.cm-s-mbo .CodeMirror-guttermarker { color: white; }
.cm-s-mbo .CodeMirror-guttermarker-subtle { color: grey; }
.cm-s-mbo .CodeMirror-linenumber { color: #dadada; }
.cm-s-mbo .CodeMirror-cursor { border-left: 1px solid #ffffec; }

.cm-s-mbo span.cm-comment { color: #95958a; }
.cm-s-mbo span.cm-atom { color: #00a8c6; }
.cm-s-mbo span.cm-number { color: #00a8c6; }

.cm-s-mbo span.cm-property, .cm-s-mbo span.cm-attribute { color: #9ddfe9; }
.cm-s-mbo span.cm-keyword { color: #ffb928; }
.cm-s-mbo span.cm-string { color: #ffcf6c; }
.cm-s-mbo span.cm-string.cm-property { color: #ffffec; }

.cm-s-mbo span.cm-variable { color: #ffffec; }
.cm-s-mbo span.cm-variable-2 { color: #00a8c6; }
.cm-s-mbo span.cm-def { color: #ffffec; }
.cm-s-mbo span.cm-bracket { color: #fffffc; font-weight: bold; }
.cm-s-mbo span.cm-tag { color: #9ddfe9; }
.cm-s-mbo span.cm-link { color: #f54b07; }
.cm-s-mbo span.cm-error { border-bottom: #636363; color: #ffffec; }
.cm-s-mbo span.cm-qualifier { color: #ffffec; }

.cm-s-mbo .CodeMirror-activeline-background { background: #494b41; }
.cm-s-mbo .CodeMirror-matchingbracket { color: #ffb928 !important; }
.cm-s-mbo .CodeMirror-matchingtag { background: rgba(255, 255, 255, .37); }

/*
  MDN-LIKE Theme - Mozilla
  Ported to CodeMirror by Peter Kroon <plakroon@gmail.com>
  Report bugs/issues here: https://github.com/codemirror/CodeMirror/issues
  GitHub: @peterkroon

  The mdn-like theme is inspired on the displayed code examples at: https://developer.mozilla.org/en-US/docs/Web/CSS/animation

*/
.cm-s-mdn-like.CodeMirror { color: #999; background-color: #fff; }
.cm-s-mdn-like div.CodeMirror-selected { background: #cfc; }
.cm-s-mdn-like .CodeMirror-line::selection, .cm-s-mdn-like .CodeMirror-line > span::selection, .cm-s-mdn-like .CodeMirror-line > span > span::selection { background: #cfc; }
.cm-s-mdn-like .CodeMirror-line::-moz-selection, .cm-s-mdn-like .CodeMirror-line > span::-moz-selection, .cm-s-mdn-like .CodeMirror-line > span > span::-moz-selection { background: #cfc; }

.cm-s-mdn-like .CodeMirror-gutters { background: #f8f8f8; border-left: 6px solid rgba(0,83,159,0.65); color: #333; }
.cm-s-mdn-like .CodeMirror-linenumber { color: #aaa; padding-left: 8px; }
.cm-s-mdn-like .CodeMirror-cursor { border-left: 2px solid #222; }

.cm-s-mdn-like .cm-keyword { color: #6262FF; }
.cm-s-mdn-like .cm-atom { color: #F90; }
.cm-s-mdn-like .cm-number { color:  #ca7841; }
.cm-s-mdn-like .cm-def { color: #8DA6CE; }
.cm-s-mdn-like span.cm-variable-2, .cm-s-mdn-like span.cm-tag { color: #690; }
.cm-s-mdn-like span.cm-variable-3, .cm-s-mdn-like span.cm-def, .cm-s-mdn-like span.cm-type { color: #07a; }

.cm-s-mdn-like .cm-variable { color: #07a; }
.cm-s-mdn-like .cm-property { color: #905; }
.cm-s-mdn-like .cm-qualifier { color: #690; }

.cm-s-mdn-like .cm-operator { color: #cda869; }
.cm-s-mdn-like .cm-comment { color:#777; font-weight:normal; }
.cm-s-mdn-like .cm-string { color:#07a; font-style:italic; }
.cm-s-mdn-like .cm-string-2 { color:#bd6b18; } /*?*/
.cm-s-mdn-like .cm-meta { color: #000; } /*?*/
.cm-s-mdn-like .cm-builtin { color: #9B7536; } /*?*/
.cm-s-mdn-like .cm-tag { color: #997643; }
.cm-s-mdn-like .cm-attribute { color: #d6bb6d; } /*?*/
.cm-s-mdn-like .cm-header { color: #FF6400; }
.cm-s-mdn-like .cm-hr { color: #AEAEAE; }
.cm-s-mdn-like .cm-link { color:#ad9361; font-style:italic; text-decoration:none; }
.cm-s-mdn-like .cm-error { border-bottom: 1px solid red; }

div.cm-s-mdn-like .CodeMirror-activeline-background { background: #efefff; }
div.cm-s-mdn-like span.CodeMirror-matchingbracket { outline:1px solid grey; color: inherit; }

.cm-s-mdn-like.CodeMirror { background-image: url(data:image/png;base64,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); }

/*

    Name:       seti
    Author:     Michael Kaminsky (http://github.com/mkaminsky11)

    Original seti color scheme by Jesse Weed (https://github.com/jesseweed/seti-syntax)

*/


.cm-s-seti.CodeMirror {
  background-color: #151718 !important;
  color: #CFD2D1 !important;
  border: none;
}
.cm-s-seti .CodeMirror-gutters {
  color: #404b53;
  background-color: #0E1112;
  border: none;
}
.cm-s-seti .CodeMirror-cursor { border-left: solid thin #f8f8f0; }
.cm-s-seti .CodeMirror-linenumber { color: #6D8A88; }
.cm-s-seti.CodeMirror-focused div.CodeMirror-selected { background: rgba(255, 255, 255, 0.10); }
.cm-s-seti .CodeMirror-line::selection, .cm-s-seti .CodeMirror-line > span::selection, .cm-s-seti .CodeMirror-line > span > span::selection { background: rgba(255, 255, 255, 0.10); }
.cm-s-seti .CodeMirror-line::-moz-selection, .cm-s-seti .CodeMirror-line > span::-moz-selection, .cm-s-seti .CodeMirror-line > span > span::-moz-selection { background: rgba(255, 255, 255, 0.10); }
.cm-s-seti span.cm-comment { color: #41535b; }
.cm-s-seti span.cm-string, .cm-s-seti span.cm-string-2 { color: #55b5db; }
.cm-s-seti span.cm-number { color: #cd3f45; }
.cm-s-seti span.cm-variable { color: #55b5db; }
.cm-s-seti span.cm-variable-2 { color: #a074c4; }
.cm-s-seti span.cm-def { color: #55b5db; }
.cm-s-seti span.cm-keyword { color: #ff79c6; }
.cm-s-seti span.cm-operator { color: #9fca56; }
.cm-s-seti span.cm-keyword { color: #e6cd69; }
.cm-s-seti span.cm-atom { color: #cd3f45; }
.cm-s-seti span.cm-meta { color: #55b5db; }
.cm-s-seti span.cm-tag { color: #55b5db; }
.cm-s-seti span.cm-attribute { color: #9fca56; }
.cm-s-seti span.cm-qualifier { color: #9fca56; }
.cm-s-seti span.cm-property { color: #a074c4; }
.cm-s-seti span.cm-variable-3, .cm-s-seti span.cm-type { color: #9fca56; }
.cm-s-seti span.cm-builtin { color: #9fca56; }
.cm-s-seti .CodeMirror-activeline-background { background: #101213; }
.cm-s-seti .CodeMirror-matchingbracket { text-decoration: underline; color: white !important; }

/*
Solarized theme for code-mirror
http://ethanschoonover.com/solarized
*/

/*
Solarized color palette
http://ethanschoonover.com/solarized/img/solarized-palette.png
*/

.solarized.base03 { color: #002b36; }
.solarized.base02 { color: #073642; }
.solarized.base01 { color: #586e75; }
.solarized.base00 { color: #657b83; }
.solarized.base0 { color: #839496; }
.solarized.base1 { color: #93a1a1; }
.solarized.base2 { color: #eee8d5; }
.solarized.base3  { color: #fdf6e3; }
.solarized.solar-yellow  { color: #b58900; }
.solarized.solar-orange  { color: #cb4b16; }
.solarized.solar-red { color: #dc322f; }
.solarized.solar-magenta { color: #d33682; }
.solarized.solar-violet  { color: #6c71c4; }
.solarized.solar-blue { color: #268bd2; }
.solarized.solar-cyan { color: #2aa198; }
.solarized.solar-green { color: #859900; }

/* Color scheme for code-mirror */

.cm-s-solarized {
  line-height: 1.45em;
  color-profile: sRGB;
  rendering-intent: auto;
}
.cm-s-solarized.cm-s-dark {
  color: #839496;
  background-color: #002b36;
  text-shadow: #002b36 0 1px;
}
.cm-s-solarized.cm-s-light {
  background-color: #fdf6e3;
  color: #657b83;
  text-shadow: #eee8d5 0 1px;
}

.cm-s-solarized .CodeMirror-widget {
  text-shadow: none;
}

.cm-s-solarized .cm-header { color: #586e75; }
.cm-s-solarized .cm-quote { color: #93a1a1; }

.cm-s-solarized .cm-keyword { color: #cb4b16; }
.cm-s-solarized .cm-atom { color: #d33682; }
.cm-s-solarized .cm-number { color: #d33682; }
.cm-s-solarized .cm-def { color: #2aa198; }

.cm-s-solarized .cm-variable { color: #839496; }
.cm-s-solarized .cm-variable-2 { color: #b58900; }
.cm-s-solarized .cm-variable-3, .cm-s-solarized .cm-type { color: #6c71c4; }

.cm-s-solarized .cm-property { color: #2aa198; }
.cm-s-solarized .cm-operator { color: #6c71c4; }

.cm-s-solarized .cm-comment { color: #586e75; font-style:italic; }

.cm-s-solarized .cm-string { color: #859900; }
.cm-s-solarized .cm-string-2 { color: #b58900; }

.cm-s-solarized .cm-meta { color: #859900; }
.cm-s-solarized .cm-qualifier { color: #b58900; }
.cm-s-solarized .cm-builtin { color: #d33682; }
.cm-s-solarized .cm-bracket { color: #cb4b16; }
.cm-s-solarized .CodeMirror-matchingbracket { color: #859900; }
.cm-s-solarized .CodeMirror-nonmatchingbracket { color: #dc322f; }
.cm-s-solarized .cm-tag { color: #93a1a1; }
.cm-s-solarized .cm-attribute { color: #2aa198; }
.cm-s-solarized .cm-hr {
  color: transparent;
  border-top: 1px solid #586e75;
  display: block;
}
.cm-s-solarized .cm-link { color: #93a1a1; cursor: pointer; }
.cm-s-solarized .cm-special { color: #6c71c4; }
.cm-s-solarized .cm-em {
  color: #999;
  text-decoration: underline;
  text-decoration-style: dotted;
}
.cm-s-solarized .cm-error,
.cm-s-solarized .cm-invalidchar {
  color: #586e75;
  border-bottom: 1px dotted #dc322f;
}

.cm-s-solarized.cm-s-dark div.CodeMirror-selected { background: #073642; }
.cm-s-solarized.cm-s-dark.CodeMirror ::selection { background: rgba(7, 54, 66, 0.99); }
.cm-s-solarized.cm-s-dark .CodeMirror-line::-moz-selection, .cm-s-dark .CodeMirror-line > span::-moz-selection, .cm-s-dark .CodeMirror-line > span > span::-moz-selection { background: rgba(7, 54, 66, 0.99); }

.cm-s-solarized.cm-s-light div.CodeMirror-selected { background: #eee8d5; }
.cm-s-solarized.cm-s-light .CodeMirror-line::selection, .cm-s-light .CodeMirror-line > span::selection, .cm-s-light .CodeMirror-line > span > span::selection { background: #eee8d5; }
.cm-s-solarized.cm-s-light .CodeMirror-line::-moz-selection, .cm-s-ligh .CodeMirror-line > span::-moz-selection, .cm-s-ligh .CodeMirror-line > span > span::-moz-selection { background: #eee8d5; }

/* Editor styling */



/* Little shadow on the view-port of the buffer view */
.cm-s-solarized.CodeMirror {
  -moz-box-shadow: inset 7px 0 12px -6px #000;
  -webkit-box-shadow: inset 7px 0 12px -6px #000;
  box-shadow: inset 7px 0 12px -6px #000;
}

/* Remove gutter border */
.cm-s-solarized .CodeMirror-gutters {
  border-right: 0;
}

/* Gutter colors and line number styling based of color scheme (dark / light) */

/* Dark */
.cm-s-solarized.cm-s-dark .CodeMirror-gutters {
  background-color: #073642;
}

.cm-s-solarized.cm-s-dark .CodeMirror-linenumber {
  color: #586e75;
  text-shadow: #021014 0 -1px;
}

/* Light */
.cm-s-solarized.cm-s-light .CodeMirror-gutters {
  background-color: #eee8d5;
}

.cm-s-solarized.cm-s-light .CodeMirror-linenumber {
  color: #839496;
}

/* Common */
.cm-s-solarized .CodeMirror-linenumber {
  padding: 0 5px;
}
.cm-s-solarized .CodeMirror-guttermarker-subtle { color: #586e75; }
.cm-s-solarized.cm-s-dark .CodeMirror-guttermarker { color: #ddd; }
.cm-s-solarized.cm-s-light .CodeMirror-guttermarker { color: #cb4b16; }

.cm-s-solarized .CodeMirror-gutter .CodeMirror-gutter-text {
  color: #586e75;
}

/* Cursor */
.cm-s-solarized .CodeMirror-cursor { border-left: 1px solid #819090; }

/* Fat cursor */
.cm-s-solarized.cm-s-light.cm-fat-cursor .CodeMirror-cursor { background: #77ee77; }
.cm-s-solarized.cm-s-light .cm-animate-fat-cursor { background-color: #77ee77; }
.cm-s-solarized.cm-s-dark.cm-fat-cursor .CodeMirror-cursor { background: #586e75; }
.cm-s-solarized.cm-s-dark .cm-animate-fat-cursor { background-color: #586e75; }

/* Active line */
.cm-s-solarized.cm-s-dark .CodeMirror-activeline-background {
  background: rgba(255, 255, 255, 0.06);
}
.cm-s-solarized.cm-s-light .CodeMirror-activeline-background {
  background: rgba(0, 0, 0, 0.06);
}

.cm-s-the-matrix.CodeMirror { background: #000000; color: #00FF00; }
.cm-s-the-matrix div.CodeMirror-selected { background: #2D2D2D; }
.cm-s-the-matrix .CodeMirror-line::selection, .cm-s-the-matrix .CodeMirror-line > span::selection, .cm-s-the-matrix .CodeMirror-line > span > span::selection { background: rgba(45, 45, 45, 0.99); }
.cm-s-the-matrix .CodeMirror-line::-moz-selection, .cm-s-the-matrix .CodeMirror-line > span::-moz-selection, .cm-s-the-matrix .CodeMirror-line > span > span::-moz-selection { background: rgba(45, 45, 45, 0.99); }
.cm-s-the-matrix .CodeMirror-gutters { background: #060; border-right: 2px solid #00FF00; }
.cm-s-the-matrix .CodeMirror-guttermarker { color: #0f0; }
.cm-s-the-matrix .CodeMirror-guttermarker-subtle { color: white; }
.cm-s-the-matrix .CodeMirror-linenumber { color: #FFFFFF; }
.cm-s-the-matrix .CodeMirror-cursor { border-left: 1px solid #00FF00; }

.cm-s-the-matrix span.cm-keyword { color: #008803; font-weight: bold; }
.cm-s-the-matrix span.cm-atom { color: #3FF; }
.cm-s-the-matrix span.cm-number { color: #FFB94F; }
.cm-s-the-matrix span.cm-def { color: #99C; }
.cm-s-the-matrix span.cm-variable { color: #F6C; }
.cm-s-the-matrix span.cm-variable-2 { color: #C6F; }
.cm-s-the-matrix span.cm-variable-3, .cm-s-the-matrix span.cm-type { color: #96F; }
.cm-s-the-matrix span.cm-property { color: #62FFA0; }
.cm-s-the-matrix span.cm-operator { color: #999; }
.cm-s-the-matrix span.cm-comment { color: #CCCCCC; }
.cm-s-the-matrix span.cm-string { color: #39C; }
.cm-s-the-matrix span.cm-meta { color: #C9F; }
.cm-s-the-matrix span.cm-qualifier { color: #FFF700; }
.cm-s-the-matrix span.cm-builtin { color: #30a; }
.cm-s-the-matrix span.cm-bracket { color: #cc7; }
.cm-s-the-matrix span.cm-tag { color: #FFBD40; }
.cm-s-the-matrix span.cm-attribute { color: #FFF700; }
.cm-s-the-matrix span.cm-error { color: #FF0000; }

.cm-s-the-matrix .CodeMirror-activeline-background { background: #040; }

/*
Copyright (C) 2011 by MarkLogic Corporation
Author: Mike Brevoort <mike@brevoort.com>

Permission is hereby granted, free of charge, to any person obtaining a copy
of this software and associated documentation files (the "Software"), to deal
in the Software without restriction, including without limitation the rights
to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
copies of the Software, and to permit persons to whom the Software is
furnished to do so, subject to the following conditions:

The above copyright notice and this permission notice shall be included in
all copies or substantial portions of the Software.

THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN
THE SOFTWARE.
*/
.cm-s-xq-light span.cm-keyword { line-height: 1em; font-weight: bold; color: #5A5CAD; }
.cm-s-xq-light span.cm-atom { color: #6C8CD5; }
.cm-s-xq-light span.cm-number { color: #164; }
.cm-s-xq-light span.cm-def { text-decoration:underline; }
.cm-s-xq-light span.cm-variable { color: black; }
.cm-s-xq-light span.cm-variable-2 { color:black; }
.cm-s-xq-light span.cm-variable-3, .cm-s-xq-light span.cm-type { color: black; }
.cm-s-xq-light span.cm-property {}
.cm-s-xq-light span.cm-operator {}
.cm-s-xq-light span.cm-comment { color: #0080FF; font-style: italic; }
.cm-s-xq-light span.cm-string { color: red; }
.cm-s-xq-light span.cm-meta { color: yellow; }
.cm-s-xq-light span.cm-qualifier { color: grey; }
.cm-s-xq-light span.cm-builtin { color: #7EA656; }
.cm-s-xq-light span.cm-bracket { color: #cc7; }
.cm-s-xq-light span.cm-tag { color: #3F7F7F; }
.cm-s-xq-light span.cm-attribute { color: #7F007F; }
.cm-s-xq-light span.cm-error { color: #f00; }

.cm-s-xq-light .CodeMirror-activeline-background { background: #e8f2ff; }
.cm-s-xq-light .CodeMirror-matchingbracket { outline:1px solid grey;color:black !important;background:yellow; }

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.CodeMirror {
  line-height: var(--jp-code-line-height);
  font-size: var(--jp-code-font-size);
  font-family: var(--jp-code-font-family);
  border: 0;
  border-radius: 0;
  height: auto;
  /* Changed to auto to autogrow */
}

.CodeMirror pre {
  padding: 0 var(--jp-code-padding);
}

.jp-CodeMirrorEditor[data-type='inline'] .CodeMirror-dialog {
  background-color: var(--jp-layout-color0);
  color: var(--jp-content-font-color1);
}

/* This causes https://github.com/jupyter/jupyterlab/issues/522 */
/* May not cause it not because we changed it! */
.CodeMirror-lines {
  padding: var(--jp-code-padding) 0;
}

.CodeMirror-linenumber {
  padding: 0 8px;
}

.jp-CodeMirrorEditor-static {
  margin: var(--jp-code-padding);
}

.jp-CodeMirrorEditor,
.jp-CodeMirrorEditor-static {
  cursor: text;
}

.jp-CodeMirrorEditor[data-type='inline'] .CodeMirror-cursor {
  border-left: var(--jp-code-cursor-width0) solid var(--jp-editor-cursor-color);
}

/* When zoomed out 67% and 33% on a screen of 1440 width x 900 height */
@media screen and (min-width: 2138px) and (max-width: 4319px) {
  .jp-CodeMirrorEditor[data-type='inline'] .CodeMirror-cursor {
    border-left: var(--jp-code-cursor-width1) solid
      var(--jp-editor-cursor-color);
  }
}

/* When zoomed out less than 33% */
@media screen and (min-width: 4320px) {
  .jp-CodeMirrorEditor[data-type='inline'] .CodeMirror-cursor {
    border-left: var(--jp-code-cursor-width2) solid
      var(--jp-editor-cursor-color);
  }
}

.CodeMirror.jp-mod-readOnly .CodeMirror-cursor {
  display: none;
}

.CodeMirror-gutters {
  border-right: 1px solid var(--jp-border-color2);
  background-color: var(--jp-layout-color0);
}

.jp-CollaboratorCursor {
  border-left: 5px solid transparent;
  border-right: 5px solid transparent;
  border-top: none;
  border-bottom: 3px solid;
  background-clip: content-box;
  margin-left: -5px;
  margin-right: -5px;
}

.CodeMirror-selectedtext.cm-searching {
  background-color: var(--jp-search-selected-match-background-color) !important;
  color: var(--jp-search-selected-match-color) !important;
}

.cm-searching {
  background-color: var(
    --jp-search-unselected-match-background-color
  ) !important;
  color: var(--jp-search-unselected-match-color) !important;
}

.CodeMirror-focused .CodeMirror-selected {
  background-color: var(--jp-editor-selected-focused-background);
}

.CodeMirror-selected {
  background-color: var(--jp-editor-selected-background);
}

.jp-CollaboratorCursor-hover {
  position: absolute;
  z-index: 1;
  transform: translateX(-50%);
  color: white;
  border-radius: 3px;
  padding-left: 4px;
  padding-right: 4px;
  padding-top: 1px;
  padding-bottom: 1px;
  text-align: center;
  font-size: var(--jp-ui-font-size1);
  white-space: nowrap;
}

.jp-CodeMirror-ruler {
  border-left: 1px dashed var(--jp-border-color2);
}

/**
 * Here is our jupyter theme for CodeMirror syntax highlighting
 * This is used in our marked.js syntax highlighting and CodeMirror itself
 * The string "jupyter" is set in ../codemirror/widget.DEFAULT_CODEMIRROR_THEME
 * This came from the classic notebook, which came form highlight.js/GitHub
 */

/**
 * CodeMirror themes are handling the background/color in this way. This works
 * fine for CodeMirror editors outside the notebook, but the notebook styles
 * these things differently.
 */
.CodeMirror.cm-s-jupyter {
  background: var(--jp-layout-color0);
  color: var(--jp-content-font-color1);
}

/* In the notebook, we want this styling to be handled by its container */
.jp-CodeConsole .CodeMirror.cm-s-jupyter,
.jp-Notebook .CodeMirror.cm-s-jupyter {
  background: transparent;
}

.cm-s-jupyter .CodeMirror-cursor {
  border-left: var(--jp-code-cursor-width0) solid var(--jp-editor-cursor-color);
}
.cm-s-jupyter span.cm-keyword {
  color: var(--jp-mirror-editor-keyword-color);
  font-weight: bold;
}
.cm-s-jupyter span.cm-atom {
  color: var(--jp-mirror-editor-atom-color);
}
.cm-s-jupyter span.cm-number {
  color: var(--jp-mirror-editor-number-color);
}
.cm-s-jupyter span.cm-def {
  color: var(--jp-mirror-editor-def-color);
}
.cm-s-jupyter span.cm-variable {
  color: var(--jp-mirror-editor-variable-color);
}
.cm-s-jupyter span.cm-variable-2 {
  color: var(--jp-mirror-editor-variable-2-color);
}
.cm-s-jupyter span.cm-variable-3 {
  color: var(--jp-mirror-editor-variable-3-color);
}
.cm-s-jupyter span.cm-punctuation {
  color: var(--jp-mirror-editor-punctuation-color);
}
.cm-s-jupyter span.cm-property {
  color: var(--jp-mirror-editor-property-color);
}
.cm-s-jupyter span.cm-operator {
  color: var(--jp-mirror-editor-operator-color);
  font-weight: bold;
}
.cm-s-jupyter span.cm-comment {
  color: var(--jp-mirror-editor-comment-color);
  font-style: italic;
}
.cm-s-jupyter span.cm-string {
  color: var(--jp-mirror-editor-string-color);
}
.cm-s-jupyter span.cm-string-2 {
  color: var(--jp-mirror-editor-string-2-color);
}
.cm-s-jupyter span.cm-meta {
  color: var(--jp-mirror-editor-meta-color);
}
.cm-s-jupyter span.cm-qualifier {
  color: var(--jp-mirror-editor-qualifier-color);
}
.cm-s-jupyter span.cm-builtin {
  color: var(--jp-mirror-editor-builtin-color);
}
.cm-s-jupyter span.cm-bracket {
  color: var(--jp-mirror-editor-bracket-color);
}
.cm-s-jupyter span.cm-tag {
  color: var(--jp-mirror-editor-tag-color);
}
.cm-s-jupyter span.cm-attribute {
  color: var(--jp-mirror-editor-attribute-color);
}
.cm-s-jupyter span.cm-header {
  color: var(--jp-mirror-editor-header-color);
}
.cm-s-jupyter span.cm-quote {
  color: var(--jp-mirror-editor-quote-color);
}
.cm-s-jupyter span.cm-link {
  color: var(--jp-mirror-editor-link-color);
}
.cm-s-jupyter span.cm-error {
  color: var(--jp-mirror-editor-error-color);
}
.cm-s-jupyter span.cm-hr {
  color: #999;
}

.cm-s-jupyter span.cm-tab {
  background: url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAADAAAAAMCAYAAAAkuj5RAAAAAXNSR0IArs4c6QAAAGFJREFUSMft1LsRQFAQheHPowAKoACx3IgEKtaEHujDjORSgWTH/ZOdnZOcM/sgk/kFFWY0qV8foQwS4MKBCS3qR6ixBJvElOobYAtivseIE120FaowJPN75GMu8j/LfMwNjh4HUpwg4LUAAAAASUVORK5CYII=);
  background-position: right;
  background-repeat: no-repeat;
}

.cm-s-jupyter .CodeMirror-activeline-background,
.cm-s-jupyter .CodeMirror-gutter {
  background-color: var(--jp-layout-color2);
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/* This file was auto-generated by ensurePackage() in @jupyterlab/buildutils */

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| RenderedText
|----------------------------------------------------------------------------*/

.jp-RenderedText {
  text-align: left;
  padding-left: var(--jp-code-padding);
  line-height: var(--jp-code-line-height);
  font-family: var(--jp-code-font-family);
}

.jp-RenderedText pre,
.jp-RenderedJavaScript pre,
.jp-RenderedHTMLCommon pre {
  color: var(--jp-content-font-color1);
  font-size: var(--jp-code-font-size);
  border: none;
  margin: 0px;
  padding: 0px;
  line-height: normal;
}

.jp-RenderedText pre a:link {
  text-decoration: none;
  color: var(--jp-content-link-color);
}
.jp-RenderedText pre a:hover {
  text-decoration: underline;
  color: var(--jp-content-link-color);
}
.jp-RenderedText pre a:visited {
  text-decoration: none;
  color: var(--jp-content-link-color);
}

/* console foregrounds and backgrounds */
.jp-RenderedText pre .ansi-black-fg {
  color: #3e424d;
}
.jp-RenderedText pre .ansi-red-fg {
  color: #e75c58;
}
.jp-RenderedText pre .ansi-green-fg {
  color: #00a250;
}
.jp-RenderedText pre .ansi-yellow-fg {
  color: #ddb62b;
}
.jp-RenderedText pre .ansi-blue-fg {
  color: #208ffb;
}
.jp-RenderedText pre .ansi-magenta-fg {
  color: #d160c4;
}
.jp-RenderedText pre .ansi-cyan-fg {
  color: #60c6c8;
}
.jp-RenderedText pre .ansi-white-fg {
  color: #c5c1b4;
}

.jp-RenderedText pre .ansi-black-bg {
  background-color: #3e424d;
}
.jp-RenderedText pre .ansi-red-bg {
  background-color: #e75c58;
}
.jp-RenderedText pre .ansi-green-bg {
  background-color: #00a250;
}
.jp-RenderedText pre .ansi-yellow-bg {
  background-color: #ddb62b;
}
.jp-RenderedText pre .ansi-blue-bg {
  background-color: #208ffb;
}
.jp-RenderedText pre .ansi-magenta-bg {
  background-color: #d160c4;
}
.jp-RenderedText pre .ansi-cyan-bg {
  background-color: #60c6c8;
}
.jp-RenderedText pre .ansi-white-bg {
  background-color: #c5c1b4;
}

.jp-RenderedText pre .ansi-black-intense-fg {
  color: #282c36;
}
.jp-RenderedText pre .ansi-red-intense-fg {
  color: #b22b31;
}
.jp-RenderedText pre .ansi-green-intense-fg {
  color: #007427;
}
.jp-RenderedText pre .ansi-yellow-intense-fg {
  color: #b27d12;
}
.jp-RenderedText pre .ansi-blue-intense-fg {
  color: #0065ca;
}
.jp-RenderedText pre .ansi-magenta-intense-fg {
  color: #a03196;
}
.jp-RenderedText pre .ansi-cyan-intense-fg {
  color: #258f8f;
}
.jp-RenderedText pre .ansi-white-intense-fg {
  color: #a1a6b2;
}

.jp-RenderedText pre .ansi-black-intense-bg {
  background-color: #282c36;
}
.jp-RenderedText pre .ansi-red-intense-bg {
  background-color: #b22b31;
}
.jp-RenderedText pre .ansi-green-intense-bg {
  background-color: #007427;
}
.jp-RenderedText pre .ansi-yellow-intense-bg {
  background-color: #b27d12;
}
.jp-RenderedText pre .ansi-blue-intense-bg {
  background-color: #0065ca;
}
.jp-RenderedText pre .ansi-magenta-intense-bg {
  background-color: #a03196;
}
.jp-RenderedText pre .ansi-cyan-intense-bg {
  background-color: #258f8f;
}
.jp-RenderedText pre .ansi-white-intense-bg {
  background-color: #a1a6b2;
}

.jp-RenderedText pre .ansi-default-inverse-fg {
  color: var(--jp-ui-inverse-font-color0);
}
.jp-RenderedText pre .ansi-default-inverse-bg {
  background-color: var(--jp-inverse-layout-color0);
}

.jp-RenderedText pre .ansi-bold {
  font-weight: bold;
}
.jp-RenderedText pre .ansi-underline {
  text-decoration: underline;
}

.jp-RenderedText[data-mime-type='application/vnd.jupyter.stderr'] {
  background: var(--jp-rendermime-error-background);
  padding-top: var(--jp-code-padding);
}

/*-----------------------------------------------------------------------------
| RenderedLatex
|----------------------------------------------------------------------------*/

.jp-RenderedLatex {
  color: var(--jp-content-font-color1);
  font-size: var(--jp-content-font-size1);
  line-height: var(--jp-content-line-height);
}

/* Left-justify outputs.*/
.jp-OutputArea-output.jp-RenderedLatex {
  padding: var(--jp-code-padding);
  text-align: left;
}

/*-----------------------------------------------------------------------------
| RenderedHTML
|----------------------------------------------------------------------------*/

.jp-RenderedHTMLCommon {
  color: var(--jp-content-font-color1);
  font-family: var(--jp-content-font-family);
  font-size: var(--jp-content-font-size1);
  line-height: var(--jp-content-line-height);
  /* Give a bit more R padding on Markdown text to keep line lengths reasonable */
  padding-right: 20px;
}

.jp-RenderedHTMLCommon em {
  font-style: italic;
}

.jp-RenderedHTMLCommon strong {
  font-weight: bold;
}

.jp-RenderedHTMLCommon u {
  text-decoration: underline;
}

.jp-RenderedHTMLCommon a:link {
  text-decoration: none;
  color: var(--jp-content-link-color);
}

.jp-RenderedHTMLCommon a:hover {
  text-decoration: underline;
  color: var(--jp-content-link-color);
}

.jp-RenderedHTMLCommon a:visited {
  text-decoration: none;
  color: var(--jp-content-link-color);
}

/* Headings */

.jp-RenderedHTMLCommon h1,
.jp-RenderedHTMLCommon h2,
.jp-RenderedHTMLCommon h3,
.jp-RenderedHTMLCommon h4,
.jp-RenderedHTMLCommon h5,
.jp-RenderedHTMLCommon h6 {
  line-height: var(--jp-content-heading-line-height);
  font-weight: var(--jp-content-heading-font-weight);
  font-style: normal;
  margin: var(--jp-content-heading-margin-top) 0
    var(--jp-content-heading-margin-bottom) 0;
}

.jp-RenderedHTMLCommon h1:first-child,
.jp-RenderedHTMLCommon h2:first-child,
.jp-RenderedHTMLCommon h3:first-child,
.jp-RenderedHTMLCommon h4:first-child,
.jp-RenderedHTMLCommon h5:first-child,
.jp-RenderedHTMLCommon h6:first-child {
  margin-top: calc(0.5 * var(--jp-content-heading-margin-top));
}

.jp-RenderedHTMLCommon h1:last-child,
.jp-RenderedHTMLCommon h2:last-child,
.jp-RenderedHTMLCommon h3:last-child,
.jp-RenderedHTMLCommon h4:last-child,
.jp-RenderedHTMLCommon h5:last-child,
.jp-RenderedHTMLCommon h6:last-child {
  margin-bottom: calc(0.5 * var(--jp-content-heading-margin-bottom));
}

.jp-RenderedHTMLCommon h1 {
  font-size: var(--jp-content-font-size5);
}

.jp-RenderedHTMLCommon h2 {
  font-size: var(--jp-content-font-size4);
}

.jp-RenderedHTMLCommon h3 {
  font-size: var(--jp-content-font-size3);
}

.jp-RenderedHTMLCommon h4 {
  font-size: var(--jp-content-font-size2);
}

.jp-RenderedHTMLCommon h5 {
  font-size: var(--jp-content-font-size1);
}

.jp-RenderedHTMLCommon h6 {
  font-size: var(--jp-content-font-size0);
}

/* Lists */

.jp-RenderedHTMLCommon ul:not(.list-inline),
.jp-RenderedHTMLCommon ol:not(.list-inline) {
  padding-left: 2em;
}

.jp-RenderedHTMLCommon ul {
  list-style: disc;
}

.jp-RenderedHTMLCommon ul ul {
  list-style: square;
}

.jp-RenderedHTMLCommon ul ul ul {
  list-style: circle;
}

.jp-RenderedHTMLCommon ol {
  list-style: decimal;
}

.jp-RenderedHTMLCommon ol ol {
  list-style: upper-alpha;
}

.jp-RenderedHTMLCommon ol ol ol {
  list-style: lower-alpha;
}

.jp-RenderedHTMLCommon ol ol ol ol {
  list-style: lower-roman;
}

.jp-RenderedHTMLCommon ol ol ol ol ol {
  list-style: decimal;
}

.jp-RenderedHTMLCommon ol,
.jp-RenderedHTMLCommon ul {
  margin-bottom: 1em;
}

.jp-RenderedHTMLCommon ul ul,
.jp-RenderedHTMLCommon ul ol,
.jp-RenderedHTMLCommon ol ul,
.jp-RenderedHTMLCommon ol ol {
  margin-bottom: 0em;
}

.jp-RenderedHTMLCommon hr {
  color: var(--jp-border-color2);
  background-color: var(--jp-border-color1);
  margin-top: 1em;
  margin-bottom: 1em;
}

.jp-RenderedHTMLCommon > pre {
  margin: 1.5em 2em;
}

.jp-RenderedHTMLCommon pre,
.jp-RenderedHTMLCommon code {
  border: 0;
  background-color: var(--jp-layout-color0);
  color: var(--jp-content-font-color1);
  font-family: var(--jp-code-font-family);
  font-size: inherit;
  line-height: var(--jp-code-line-height);
  padding: 0;
  white-space: pre-wrap;
}

.jp-RenderedHTMLCommon :not(pre) > code {
  background-color: var(--jp-layout-color2);
  padding: 1px 5px;
}

/* Tables */

.jp-RenderedHTMLCommon table {
  border-collapse: collapse;
  border-spacing: 0;
  border: none;
  color: var(--jp-ui-font-color1);
  font-size: 12px;
  table-layout: fixed;
  margin-left: auto;
  margin-right: auto;
}

.jp-RenderedHTMLCommon thead {
  border-bottom: var(--jp-border-width) solid var(--jp-border-color1);
  vertical-align: bottom;
}

.jp-RenderedHTMLCommon td,
.jp-RenderedHTMLCommon th,
.jp-RenderedHTMLCommon tr {
  vertical-align: middle;
  padding: 0.5em 0.5em;
  line-height: normal;
  white-space: normal;
  max-width: none;
  border: none;
}

.jp-RenderedMarkdown.jp-RenderedHTMLCommon td,
.jp-RenderedMarkdown.jp-RenderedHTMLCommon th {
  max-width: none;
}

:not(.jp-RenderedMarkdown).jp-RenderedHTMLCommon td,
:not(.jp-RenderedMarkdown).jp-RenderedHTMLCommon th,
:not(.jp-RenderedMarkdown).jp-RenderedHTMLCommon tr {
  text-align: right;
}

.jp-RenderedHTMLCommon th {
  font-weight: bold;
}

.jp-RenderedHTMLCommon tbody tr:nth-child(odd) {
  background: var(--jp-layout-color0);
}

.jp-RenderedHTMLCommon tbody tr:nth-child(even) {
  background: var(--jp-rendermime-table-row-background);
}

.jp-RenderedHTMLCommon tbody tr:hover {
  background: var(--jp-rendermime-table-row-hover-background);
}

.jp-RenderedHTMLCommon table {
  margin-bottom: 1em;
}

.jp-RenderedHTMLCommon p {
  text-align: left;
  margin: 0px;
}

.jp-RenderedHTMLCommon p {
  margin-bottom: 1em;
}

.jp-RenderedHTMLCommon img {
  -moz-force-broken-image-icon: 1;
}

/* Restrict to direct children as other images could be nested in other content. */
.jp-RenderedHTMLCommon > img {
  display: block;
  margin-left: 0;
  margin-right: 0;
  margin-bottom: 1em;
}

/* Change color behind transparent images if they need it... */
[data-jp-theme-light='false'] .jp-RenderedImage img.jp-needs-light-background {
  background-color: var(--jp-inverse-layout-color1);
}
[data-jp-theme-light='true'] .jp-RenderedImage img.jp-needs-dark-background {
  background-color: var(--jp-inverse-layout-color1);
}
/* ...or leave it untouched if they don't */
[data-jp-theme-light='false'] .jp-RenderedImage img.jp-needs-dark-background {
}
[data-jp-theme-light='true'] .jp-RenderedImage img.jp-needs-light-background {
}

.jp-RenderedHTMLCommon img,
.jp-RenderedImage img,
.jp-RenderedHTMLCommon svg,
.jp-RenderedSVG svg {
  max-width: 100%;
  height: auto;
}

.jp-RenderedHTMLCommon img.jp-mod-unconfined,
.jp-RenderedImage img.jp-mod-unconfined,
.jp-RenderedHTMLCommon svg.jp-mod-unconfined,
.jp-RenderedSVG svg.jp-mod-unconfined {
  max-width: none;
}

.jp-RenderedHTMLCommon .alert {
  padding: var(--jp-notebook-padding);
  border: var(--jp-border-width) solid transparent;
  border-radius: var(--jp-border-radius);
  margin-bottom: 1em;
}

.jp-RenderedHTMLCommon .alert-info {
  color: var(--jp-info-color0);
  background-color: var(--jp-info-color3);
  border-color: var(--jp-info-color2);
}
.jp-RenderedHTMLCommon .alert-info hr {
  border-color: var(--jp-info-color3);
}
.jp-RenderedHTMLCommon .alert-info > p:last-child,
.jp-RenderedHTMLCommon .alert-info > ul:last-child {
  margin-bottom: 0;
}

.jp-RenderedHTMLCommon .alert-warning {
  color: var(--jp-warn-color0);
  background-color: var(--jp-warn-color3);
  border-color: var(--jp-warn-color2);
}
.jp-RenderedHTMLCommon .alert-warning hr {
  border-color: var(--jp-warn-color3);
}
.jp-RenderedHTMLCommon .alert-warning > p:last-child,
.jp-RenderedHTMLCommon .alert-warning > ul:last-child {
  margin-bottom: 0;
}

.jp-RenderedHTMLCommon .alert-success {
  color: var(--jp-success-color0);
  background-color: var(--jp-success-color3);
  border-color: var(--jp-success-color2);
}
.jp-RenderedHTMLCommon .alert-success hr {
  border-color: var(--jp-success-color3);
}
.jp-RenderedHTMLCommon .alert-success > p:last-child,
.jp-RenderedHTMLCommon .alert-success > ul:last-child {
  margin-bottom: 0;
}

.jp-RenderedHTMLCommon .alert-danger {
  color: var(--jp-error-color0);
  background-color: var(--jp-error-color3);
  border-color: var(--jp-error-color2);
}
.jp-RenderedHTMLCommon .alert-danger hr {
  border-color: var(--jp-error-color3);
}
.jp-RenderedHTMLCommon .alert-danger > p:last-child,
.jp-RenderedHTMLCommon .alert-danger > ul:last-child {
  margin-bottom: 0;
}

.jp-RenderedHTMLCommon blockquote {
  margin: 1em 2em;
  padding: 0 1em;
  border-left: 5px solid var(--jp-border-color2);
}

a.jp-InternalAnchorLink {
  visibility: hidden;
  margin-left: 8px;
  color: var(--md-blue-800);
}

h1:hover .jp-InternalAnchorLink,
h2:hover .jp-InternalAnchorLink,
h3:hover .jp-InternalAnchorLink,
h4:hover .jp-InternalAnchorLink,
h5:hover .jp-InternalAnchorLink,
h6:hover .jp-InternalAnchorLink {
  visibility: visible;
}

.jp-RenderedHTMLCommon kbd {
  background-color: var(--jp-rendermime-table-row-background);
  border: 1px solid var(--jp-border-color0);
  border-bottom-color: var(--jp-border-color2);
  border-radius: 3px;
  box-shadow: inset 0 -1px 0 rgba(0, 0, 0, 0.25);
  display: inline-block;
  font-size: 0.8em;
  line-height: 1em;
  padding: 0.2em 0.5em;
}

/* Most direct children of .jp-RenderedHTMLCommon have a margin-bottom of 1.0.
 * At the bottom of cells this is a bit too much as there is also spacing
 * between cells. Going all the way to 0 gets too tight between markdown and
 * code cells.
 */
.jp-RenderedHTMLCommon > *:last-child {
  margin-bottom: 0.5em;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/* This file was auto-generated by ensurePackage() in @jupyterlab/buildutils */

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-MimeDocument {
  outline: none;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/* This file was auto-generated by ensurePackage() in @jupyterlab/buildutils */

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Variables
|----------------------------------------------------------------------------*/

:root {
  --jp-private-filebrowser-button-height: 28px;
  --jp-private-filebrowser-button-width: 48px;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-FileBrowser {
  display: flex;
  flex-direction: column;
  color: var(--jp-ui-font-color1);
  background: var(--jp-layout-color1);
  /* This is needed so that all font sizing of children done in ems is
   * relative to this base size */
  font-size: var(--jp-ui-font-size1);
}

.jp-FileBrowser-toolbar.jp-Toolbar {
  border-bottom: none;
  height: auto;
  margin: var(--jp-toolbar-header-margin);
  box-shadow: none;
}

.jp-BreadCrumbs {
  flex: 0 0 auto;
  margin: 4px 12px;
}

.jp-BreadCrumbs-item {
  margin: 0px 2px;
  padding: 0px 2px;
  border-radius: var(--jp-border-radius);
  cursor: pointer;
}

.jp-BreadCrumbs-item:hover {
  background-color: var(--jp-layout-color2);
}

.jp-BreadCrumbs-item:first-child {
  margin-left: 0px;
}

.jp-BreadCrumbs-item.jp-mod-dropTarget {
  background-color: var(--jp-brand-color2);
  opacity: 0.7;
}

/*-----------------------------------------------------------------------------
| Buttons
|----------------------------------------------------------------------------*/

.jp-FileBrowser-toolbar.jp-Toolbar {
  padding: 0px;
}

.jp-FileBrowser-toolbar.jp-Toolbar {
  justify-content: space-evenly;
}

.jp-FileBrowser-toolbar.jp-Toolbar .jp-Toolbar-item {
  flex: 1;
}

.jp-FileBrowser-toolbar.jp-Toolbar .jp-ToolbarButtonComponent {
  width: 100%;
}

/*-----------------------------------------------------------------------------
| DirListing
|----------------------------------------------------------------------------*/

.jp-DirListing {
  flex: 1 1 auto;
  display: flex;
  flex-direction: column;
  outline: 0;
}

.jp-DirListing-header {
  flex: 0 0 auto;
  display: flex;
  flex-direction: row;
  overflow: hidden;
  border-top: var(--jp-border-width) solid var(--jp-border-color2);
  border-bottom: var(--jp-border-width) solid var(--jp-border-color1);
  box-shadow: var(--jp-toolbar-box-shadow);
  z-index: 2;
}

.jp-DirListing-headerItem {
  padding: 4px 12px 2px 12px;
  font-weight: 500;
}

.jp-DirListing-headerItem:hover {
  background: var(--jp-layout-color2);
}

.jp-DirListing-headerItem.jp-id-name {
  flex: 1 0 84px;
}

.jp-DirListing-headerItem.jp-id-modified {
  flex: 0 0 112px;
  border-left: var(--jp-border-width) solid var(--jp-border-color2);
  text-align: right;
}

.jp-DirListing-narrow .jp-id-modified,
.jp-DirListing-narrow .jp-DirListing-itemModified {
  display: none;
}

.jp-DirListing-headerItem.jp-mod-selected {
  font-weight: 600;
}

/* increase specificity to override bundled default */
.jp-DirListing-content {
  flex: 1 1 auto;
  margin: 0;
  padding: 0;
  list-style-type: none;
  overflow: auto;
  background-color: var(--jp-layout-color1);
}

/* Style the directory listing content when a user drops a file to upload */
.jp-DirListing.jp-mod-native-drop .jp-DirListing-content {
  outline: 5px dashed rgba(128, 128, 128, 0.5);
  outline-offset: -10px;
  cursor: copy;
}

.jp-DirListing-item {
  display: flex;
  flex-direction: row;
  padding: 4px 12px;
  -webkit-user-select: none;
  -moz-user-select: none;
  -ms-user-select: none;
  user-select: none;
}

.jp-DirListing-item.jp-mod-selected {
  color: white;
  background: var(--jp-brand-color1);
}

.jp-DirListing-item.jp-mod-dropTarget {
  background: var(--jp-brand-color3);
}

.jp-DirListing-item:hover:not(.jp-mod-selected) {
  background: var(--jp-layout-color2);
}

.jp-DirListing-itemIcon {
  flex: 0 0 20px;
  margin-right: 4px;
}

.jp-DirListing-itemText {
  flex: 1 0 64px;
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;
  user-select: none;
}

.jp-DirListing-itemModified {
  flex: 0 0 125px;
  text-align: right;
}

.jp-DirListing-editor {
  flex: 1 0 64px;
  outline: none;
  border: none;
}

.jp-DirListing-item.jp-mod-running .jp-DirListing-itemIcon:before {
  color: limegreen;
  content: '\25CF';
  font-size: 8px;
  position: absolute;
  left: -8px;
}

.jp-DirListing-item.lm-mod-drag-image,
.jp-DirListing-item.jp-mod-selected.lm-mod-drag-image {
  font-size: var(--jp-ui-font-size1);
  padding-left: 4px;
  margin-left: 4px;
  width: 160px;
  background-color: var(--jp-ui-inverse-font-color2);
  box-shadow: var(--jp-elevation-z2);
  border-radius: 0px;
  color: var(--jp-ui-font-color1);
  transform: translateX(-40%) translateY(-58%);
}

.jp-DirListing-deadSpace {
  flex: 1 1 auto;
  margin: 0;
  padding: 0;
  list-style-type: none;
  overflow: auto;
  background-color: var(--jp-layout-color1);
}

.jp-Document {
  min-width: 120px;
  min-height: 120px;
  outline: none;
}

.jp-FileDialog.jp-mod-conflict input {
  color: red;
}

.jp-FileDialog .jp-new-name-title {
  margin-top: 12px;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/* This file was auto-generated by ensurePackage() in @jupyterlab/buildutils */

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Private CSS variables
|----------------------------------------------------------------------------*/

:root {
}

/*-----------------------------------------------------------------------------
| Main OutputArea
| OutputArea has a list of Outputs
|----------------------------------------------------------------------------*/

.jp-OutputArea {
  overflow-y: auto;
}

.jp-OutputArea-child {
  display: flex;
  flex-direction: row;
}

.jp-OutputPrompt {
  flex: 0 0 var(--jp-cell-prompt-width);
  color: var(--jp-cell-outprompt-font-color);
  font-family: var(--jp-cell-prompt-font-family);
  padding: var(--jp-code-padding);
  letter-spacing: var(--jp-cell-prompt-letter-spacing);
  line-height: var(--jp-code-line-height);
  font-size: var(--jp-code-font-size);
  border: var(--jp-border-width) solid transparent;
  opacity: var(--jp-cell-prompt-opacity);
  /* Right align prompt text, don't wrap to handle large prompt numbers */
  text-align: right;
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;
  /* Disable text selection */
  -webkit-user-select: none;
  -moz-user-select: none;
  -ms-user-select: none;
  user-select: none;
}

.jp-OutputArea-output {
  height: auto;
  overflow: auto;
  user-select: text;
  -moz-user-select: text;
  -webkit-user-select: text;
  -ms-user-select: text;
}

.jp-OutputArea-child .jp-OutputArea-output {
  flex-grow: 1;
  flex-shrink: 1;
}

/**
 * Isolated output.
 */
.jp-OutputArea-output.jp-mod-isolated {
  width: 100%;
  display: block;
}

/*
When drag events occur, `p-mod-override-cursor` is added to the body.
Because iframes steal all cursor events, the following two rules are necessary
to suppress pointer events while resize drags are occurring. There may be a
better solution to this problem.
*/
body.lm-mod-override-cursor .jp-OutputArea-output.jp-mod-isolated {
  position: relative;
}

body.lm-mod-override-cursor .jp-OutputArea-output.jp-mod-isolated:before {
  content: '';
  position: absolute;
  top: 0;
  left: 0;
  right: 0;
  bottom: 0;
  background: transparent;
}

/* pre */

.jp-OutputArea-output pre {
  border: none;
  margin: 0px;
  padding: 0px;
  overflow-x: auto;
  overflow-y: auto;
  word-break: break-all;
  word-wrap: break-word;
  white-space: pre-wrap;
}

/* tables */

.jp-OutputArea-output.jp-RenderedHTMLCommon table {
  margin-left: 0;
  margin-right: 0;
}

/* description lists */

.jp-OutputArea-output dl,
.jp-OutputArea-output dt,
.jp-OutputArea-output dd {
  display: block;
}

.jp-OutputArea-output dl {
  width: 100%;
  overflow: hidden;
  padding: 0;
  margin: 0;
}

.jp-OutputArea-output dt {
  font-weight: bold;
  float: left;
  width: 20%;
  padding: 0;
  margin: 0;
}

.jp-OutputArea-output dd {
  float: left;
  width: 80%;
  padding: 0;
  margin: 0;
}

/* Hide the gutter in case of
 *  - nested output areas (e.g. in the case of output widgets)
 *  - mirrored output areas
 */
.jp-OutputArea .jp-OutputArea .jp-OutputArea-prompt {
  display: none;
}

/*-----------------------------------------------------------------------------
| executeResult is added to any Output-result for the display of the object
| returned by a cell
|----------------------------------------------------------------------------*/

.jp-OutputArea-output.jp-OutputArea-executeResult {
  margin-left: 0px;
  flex: 1 1 auto;
}

.jp-OutputArea-executeResult.jp-RenderedText {
  padding-top: var(--jp-code-padding);
}

/*-----------------------------------------------------------------------------
| The Stdin output
|----------------------------------------------------------------------------*/

.jp-OutputArea-stdin {
  line-height: var(--jp-code-line-height);
  padding-top: var(--jp-code-padding);
  display: flex;
}

.jp-Stdin-prompt {
  color: var(--jp-content-font-color0);
  padding-right: var(--jp-code-padding);
  vertical-align: baseline;
  flex: 0 0 auto;
}

.jp-Stdin-input {
  font-family: var(--jp-code-font-family);
  font-size: inherit;
  color: inherit;
  background-color: inherit;
  width: 42%;
  min-width: 200px;
  /* make sure input baseline aligns with prompt */
  vertical-align: baseline;
  /* padding + margin = 0.5em between prompt and cursor */
  padding: 0em 0.25em;
  margin: 0em 0.25em;
  flex: 0 0 70%;
}

.jp-Stdin-input:focus {
  box-shadow: none;
}

/*-----------------------------------------------------------------------------
| Output Area View
|----------------------------------------------------------------------------*/

.jp-LinkedOutputView .jp-OutputArea {
  height: 100%;
  display: block;
}

.jp-LinkedOutputView .jp-OutputArea-output:only-child {
  height: 100%;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/* This file was auto-generated by ensurePackage() in @jupyterlab/buildutils */

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-Collapser {
  flex: 0 0 var(--jp-cell-collapser-width);
  padding: 0px;
  margin: 0px;
  border: none;
  outline: none;
  background: transparent;
  border-radius: var(--jp-border-radius);
  opacity: 1;
}

.jp-Collapser-child {
  display: block;
  width: 100%;
  box-sizing: border-box;
  /* height: 100% doesn't work because the height of its parent is computed from content */
  position: absolute;
  top: 0px;
  bottom: 0px;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Header/Footer
|----------------------------------------------------------------------------*/

/* Hidden by zero height by default */
.jp-CellHeader,
.jp-CellFooter {
  height: 0px;
  width: 100%;
  padding: 0px;
  margin: 0px;
  border: none;
  outline: none;
  background: transparent;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Input
|----------------------------------------------------------------------------*/

/* All input areas */
.jp-InputArea {
  display: flex;
  flex-direction: row;
}

.jp-InputArea-editor {
  flex: 1 1 auto;
}

.jp-InputArea-editor {
  /* This is the non-active, default styling */
  border: var(--jp-border-width) solid var(--jp-cell-editor-border-color);
  border-radius: 0px;
  background: var(--jp-cell-editor-background);
}

.jp-InputPrompt {
  flex: 0 0 var(--jp-cell-prompt-width);
  color: var(--jp-cell-inprompt-font-color);
  font-family: var(--jp-cell-prompt-font-family);
  padding: var(--jp-code-padding);
  letter-spacing: var(--jp-cell-prompt-letter-spacing);
  opacity: var(--jp-cell-prompt-opacity);
  line-height: var(--jp-code-line-height);
  font-size: var(--jp-code-font-size);
  border: var(--jp-border-width) solid transparent;
  opacity: var(--jp-cell-prompt-opacity);
  /* Right align prompt text, don't wrap to handle large prompt numbers */
  text-align: right;
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;
  /* Disable text selection */
  -webkit-user-select: none;
  -moz-user-select: none;
  -ms-user-select: none;
  user-select: none;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Placeholder
|----------------------------------------------------------------------------*/

.jp-Placeholder {
  display: flex;
  flex-direction: row;
  flex: 1 1 auto;
}

.jp-Placeholder-prompt {
  box-sizing: border-box;
}

.jp-Placeholder-content {
  flex: 1 1 auto;
  border: none;
  background: transparent;
  height: 20px;
  box-sizing: border-box;
}

.jp-Placeholder-content .jp-MoreHorizIcon {
  width: 32px;
  height: 16px;
  border: 1px solid transparent;
  border-radius: var(--jp-border-radius);
}

.jp-Placeholder-content .jp-MoreHorizIcon:hover {
  border: 1px solid var(--jp-border-color1);
  box-shadow: 0px 0px 2px 0px rgba(0, 0, 0, 0.25);
  background-color: var(--jp-layout-color0);
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Private CSS variables
|----------------------------------------------------------------------------*/

:root {
  --jp-private-cell-scrolling-output-offset: 5px;
}

/*-----------------------------------------------------------------------------
| Cell
|----------------------------------------------------------------------------*/

.jp-Cell {
  padding: var(--jp-cell-padding);
  margin: 0px;
  border: none;
  outline: none;
  background: transparent;
}

/*-----------------------------------------------------------------------------
| Common input/output
|----------------------------------------------------------------------------*/

.jp-Cell-inputWrapper,
.jp-Cell-outputWrapper {
  display: flex;
  flex-direction: row;
  padding: 0px;
  margin: 0px;
  /* Added to reveal the box-shadow on the input and output collapsers. */
  overflow: visible;
}

/* Only input/output areas inside cells */
.jp-Cell-inputArea,
.jp-Cell-outputArea {
  flex: 1 1 auto;
}

/*-----------------------------------------------------------------------------
| Collapser
|----------------------------------------------------------------------------*/

/* Make the output collapser disappear when there is not output, but do so
 * in a manner that leaves it in the layout and preserves its width.
 */
.jp-Cell.jp-mod-noOutputs .jp-Cell-outputCollapser {
  border: none !important;
  background: transparent !important;
}

.jp-Cell:not(.jp-mod-noOutputs) .jp-Cell-outputCollapser {
  min-height: var(--jp-cell-collapser-min-height);
}

/*-----------------------------------------------------------------------------
| Output
|----------------------------------------------------------------------------*/

/* Put a space between input and output when there IS output */
.jp-Cell:not(.jp-mod-noOutputs) .jp-Cell-outputWrapper {
  margin-top: 5px;
}

/* Text output with the Out[] prompt needs a top padding to match the
 * alignment of the Out[] prompt itself.
 */
.jp-OutputArea-executeResult .jp-RenderedText.jp-OutputArea-output {
  padding-top: var(--jp-code-padding);
}

.jp-CodeCell.jp-mod-outputsScrolled .jp-Cell-outputArea {
  overflow-y: auto;
  max-height: 200px;
  box-shadow: inset 0 0 6px 2px rgba(0, 0, 0, 0.3);
  margin-left: var(--jp-private-cell-scrolling-output-offset);
}

.jp-CodeCell.jp-mod-outputsScrolled .jp-OutputArea-prompt {
  flex: 0 0
    calc(
      var(--jp-cell-prompt-width) -
        var(--jp-private-cell-scrolling-output-offset)
    );
}

/*-----------------------------------------------------------------------------
| CodeCell
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| MarkdownCell
|----------------------------------------------------------------------------*/

.jp-MarkdownOutput {
  flex: 1 1 auto;
  margin-top: 0;
  margin-bottom: 0;
  padding-left: var(--jp-code-padding);
}

.jp-MarkdownOutput.jp-RenderedHTMLCommon {
  overflow: auto;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/* This file was auto-generated by ensurePackage() in @jupyterlab/buildutils */

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Variables
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------

/*-----------------------------------------------------------------------------
| Styles
|----------------------------------------------------------------------------*/

.jp-NotebookPanel-toolbar {
  padding: 2px;
}

.jp-Toolbar-item.jp-Notebook-toolbarCellType .jp-select-wrapper.jp-mod-focused {
  border: none;
  box-shadow: none;
}

.jp-Notebook-toolbarCellTypeDropdown select {
  height: 24px;
  font-size: var(--jp-ui-font-size1);
  line-height: 14px;
  border-radius: 0;
  display: block;
}

.jp-Notebook-toolbarCellTypeDropdown span {
  top: 5px !important;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Private CSS variables
|----------------------------------------------------------------------------*/

:root {
  --jp-private-notebook-dragImage-width: 304px;
  --jp-private-notebook-dragImage-height: 36px;
  --jp-private-notebook-selected-color: var(--md-blue-400);
  --jp-private-notebook-active-color: var(--md-green-400);
}

/*-----------------------------------------------------------------------------
| Imports
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Notebook
|----------------------------------------------------------------------------*/

.jp-NotebookPanel {
  display: block;
  height: 100%;
}

.jp-NotebookPanel.jp-Document {
  min-width: 240px;
  min-height: 120px;
}

.jp-Notebook {
  padding: var(--jp-notebook-padding);
  outline: none;
  overflow: auto;
  background: var(--jp-layout-color0);
}

.jp-Notebook.jp-mod-scrollPastEnd::after {
  display: block;
  content: '';
  min-height: var(--jp-notebook-scroll-padding);
}

.jp-Notebook .jp-Cell {
  overflow: visible;
}

.jp-Notebook .jp-Cell .jp-InputPrompt {
  cursor: move;
}

/*-----------------------------------------------------------------------------
| Notebook state related styling
|
| The notebook and cells each have states, here are the possibilities:
|
| - Notebook
|   - Command
|   - Edit
| - Cell
|   - None
|   - Active (only one can be active)
|   - Selected (the cells actions are applied to)
|   - Multiselected (when multiple selected, the cursor)
|   - No outputs
|----------------------------------------------------------------------------*/

/* Command or edit modes */

.jp-Notebook .jp-Cell:not(.jp-mod-active) .jp-InputPrompt {
  opacity: var(--jp-cell-prompt-not-active-opacity);
  color: var(--jp-cell-prompt-not-active-font-color);
}

.jp-Notebook .jp-Cell:not(.jp-mod-active) .jp-OutputPrompt {
  opacity: var(--jp-cell-prompt-not-active-opacity);
  color: var(--jp-cell-prompt-not-active-font-color);
}

/* cell is active */
.jp-Notebook .jp-Cell.jp-mod-active .jp-Collapser {
  background: var(--jp-brand-color1);
}

/* collapser is hovered */
.jp-Notebook .jp-Cell .jp-Collapser:hover {
  box-shadow: var(--jp-elevation-z2);
  background: var(--jp-brand-color1);
  opacity: var(--jp-cell-collapser-not-active-hover-opacity);
}

/* cell is active and collapser is hovered */
.jp-Notebook .jp-Cell.jp-mod-active .jp-Collapser:hover {
  background: var(--jp-brand-color0);
  opacity: 1;
}

/* Command mode */

.jp-Notebook.jp-mod-commandMode .jp-Cell.jp-mod-selected {
  background: var(--jp-notebook-multiselected-color);
}

.jp-Notebook.jp-mod-commandMode
  .jp-Cell.jp-mod-active.jp-mod-selected:not(.jp-mod-multiSelected) {
  background: transparent;
}

/* Edit mode */

.jp-Notebook.jp-mod-editMode .jp-Cell.jp-mod-active .jp-InputArea-editor {
  border: var(--jp-border-width) solid var(--jp-cell-editor-active-border-color);
  box-shadow: var(--jp-input-box-shadow);
  background-color: var(--jp-cell-editor-active-background);
}

/*-----------------------------------------------------------------------------
| Notebook drag and drop
|----------------------------------------------------------------------------*/

.jp-Notebook-cell.jp-mod-dropSource {
  opacity: 0.5;
}

.jp-Notebook-cell.jp-mod-dropTarget,
.jp-Notebook.jp-mod-commandMode
  .jp-Notebook-cell.jp-mod-active.jp-mod-selected.jp-mod-dropTarget {
  border-top-color: var(--jp-private-notebook-selected-color);
  border-top-style: solid;
  border-top-width: 2px;
}

.jp-dragImage {
  display: flex;
  flex-direction: row;
  width: var(--jp-private-notebook-dragImage-width);
  height: var(--jp-private-notebook-dragImage-height);
  border: var(--jp-border-width) solid var(--jp-cell-editor-border-color);
  background: var(--jp-cell-editor-background);
  overflow: visible;
}

.jp-dragImage-singlePrompt {
  box-shadow: 2px 2px 4px 0px rgba(0, 0, 0, 0.12);
}

.jp-dragImage .jp-dragImage-content {
  flex: 1 1 auto;
  z-index: 2;
  font-size: var(--jp-code-font-size);
  font-family: var(--jp-code-font-family);
  line-height: var(--jp-code-line-height);
  padding: var(--jp-code-padding);
  border: var(--jp-border-width) solid var(--jp-cell-editor-border-color);
  background: var(--jp-cell-editor-background-color);
  color: var(--jp-content-font-color3);
  text-align: left;
  margin: 4px 4px 4px 0px;
}

.jp-dragImage .jp-dragImage-prompt {
  flex: 0 0 auto;
  min-width: 36px;
  color: var(--jp-cell-inprompt-font-color);
  padding: var(--jp-code-padding);
  padding-left: 12px;
  font-family: var(--jp-cell-prompt-font-family);
  letter-spacing: var(--jp-cell-prompt-letter-spacing);
  line-height: 1.9;
  font-size: var(--jp-code-font-size);
  border: var(--jp-border-width) solid transparent;
}

.jp-dragImage-multipleBack {
  z-index: -1;
  position: absolute;
  height: 32px;
  width: 300px;
  top: 8px;
  left: 8px;
  background: var(--jp-layout-color2);
  border: var(--jp-border-width) solid var(--jp-input-border-color);
  box-shadow: 2px 2px 4px 0px rgba(0, 0, 0, 0.12);
}

/*-----------------------------------------------------------------------------
| Cell toolbar
|----------------------------------------------------------------------------*/

.jp-NotebookTools {
  display: block;
  min-width: var(--jp-sidebar-min-width);
  color: var(--jp-ui-font-color1);
  background: var(--jp-layout-color1);
  /* This is needed so that all font sizing of children done in ems is
    * relative to this base size */
  font-size: var(--jp-ui-font-size1);
  overflow: auto;
}

.jp-NotebookTools-tool {
  padding: 0px 12px 0 12px;
}

.jp-ActiveCellTool {
  padding: 12px;
  background-color: var(--jp-layout-color1);
  border-top: none !important;
}

.jp-ActiveCellTool .jp-InputArea-prompt {
  flex: 0 0 auto;
  padding-left: 0px;
}

.jp-ActiveCellTool .jp-InputArea-editor {
  flex: 1 1 auto;
  background: var(--jp-cell-editor-background);
  border-color: var(--jp-cell-editor-border-color);
}

.jp-ActiveCellTool .jp-InputArea-editor .CodeMirror {
  background: transparent;
}

.jp-MetadataEditorTool {
  flex-direction: column;
  padding: 12px 0px 12px 0px;
}

.jp-RankedPanel > :not(:first-child) {
  margin-top: 12px;
}

.jp-KeySelector select.jp-mod-styled {
  font-size: var(--jp-ui-font-size1);
  color: var(--jp-ui-font-color0);
  border: var(--jp-border-width) solid var(--jp-border-color1);
}

.jp-KeySelector label,
.jp-MetadataEditorTool label {
  line-height: 1.4;
}

/*-----------------------------------------------------------------------------
| Presentation Mode (.jp-mod-presentationMode)
|----------------------------------------------------------------------------*/

.jp-mod-presentationMode .jp-Notebook {
  --jp-content-font-size1: var(--jp-content-presentation-font-size1);
  --jp-code-font-size: var(--jp-code-presentation-font-size);
}

.jp-mod-presentationMode .jp-Notebook .jp-Cell .jp-InputPrompt,
.jp-mod-presentationMode .jp-Notebook .jp-Cell .jp-OutputPrompt {
  flex: 0 0 110px;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/* This file was auto-generated by ensurePackage() in @jupyterlab/buildutils */

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

</style>

    <style type="text/css">
/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*
The following CSS variables define the main, public API for styling JupyterLab.
These variables should be used by all plugins wherever possible. In other
words, plugins should not define custom colors, sizes, etc unless absolutely
necessary. This enables users to change the visual theme of JupyterLab
by changing these variables.

Many variables appear in an ordered sequence (0,1,2,3). These sequences
are designed to work well together, so for example, `--jp-border-color1` should
be used with `--jp-layout-color1`. The numbers have the following meanings:

* 0: super-primary, reserved for special emphasis
* 1: primary, most important under normal situations
* 2: secondary, next most important under normal situations
* 3: tertiary, next most important under normal situations

Throughout JupyterLab, we are mostly following principles from Google's
Material Design when selecting colors. We are not, however, following
all of MD as it is not optimized for dense, information rich UIs.
*/

:root {
  /* Elevation
   *
   * We style box-shadows using Material Design's idea of elevation. These particular numbers are taken from here:
   *
   * https://github.com/material-components/material-components-web
   * https://material-components-web.appspot.com/elevation.html
   */

  --jp-shadow-base-lightness: 0;
  --jp-shadow-umbra-color: rgba(
    var(--jp-shadow-base-lightness),
    var(--jp-shadow-base-lightness),
    var(--jp-shadow-base-lightness),
    0.2
  );
  --jp-shadow-penumbra-color: rgba(
    var(--jp-shadow-base-lightness),
    var(--jp-shadow-base-lightness),
    var(--jp-shadow-base-lightness),
    0.14
  );
  --jp-shadow-ambient-color: rgba(
    var(--jp-shadow-base-lightness),
    var(--jp-shadow-base-lightness),
    var(--jp-shadow-base-lightness),
    0.12
  );
  --jp-elevation-z0: none;
  --jp-elevation-z1: 0px 2px 1px -1px var(--jp-shadow-umbra-color),
    0px 1px 1px 0px var(--jp-shadow-penumbra-color),
    0px 1px 3px 0px var(--jp-shadow-ambient-color);
  --jp-elevation-z2: 0px 3px 1px -2px var(--jp-shadow-umbra-color),
    0px 2px 2px 0px var(--jp-shadow-penumbra-color),
    0px 1px 5px 0px var(--jp-shadow-ambient-color);
  --jp-elevation-z4: 0px 2px 4px -1px var(--jp-shadow-umbra-color),
    0px 4px 5px 0px var(--jp-shadow-penumbra-color),
    0px 1px 10px 0px var(--jp-shadow-ambient-color);
  --jp-elevation-z6: 0px 3px 5px -1px var(--jp-shadow-umbra-color),
    0px 6px 10px 0px var(--jp-shadow-penumbra-color),
    0px 1px 18px 0px var(--jp-shadow-ambient-color);
  --jp-elevation-z8: 0px 5px 5px -3px var(--jp-shadow-umbra-color),
    0px 8px 10px 1px var(--jp-shadow-penumbra-color),
    0px 3px 14px 2px var(--jp-shadow-ambient-color);
  --jp-elevation-z12: 0px 7px 8px -4px var(--jp-shadow-umbra-color),
    0px 12px 17px 2px var(--jp-shadow-penumbra-color),
    0px 5px 22px 4px var(--jp-shadow-ambient-color);
  --jp-elevation-z16: 0px 8px 10px -5px var(--jp-shadow-umbra-color),
    0px 16px 24px 2px var(--jp-shadow-penumbra-color),
    0px 6px 30px 5px var(--jp-shadow-ambient-color);
  --jp-elevation-z20: 0px 10px 13px -6px var(--jp-shadow-umbra-color),
    0px 20px 31px 3px var(--jp-shadow-penumbra-color),
    0px 8px 38px 7px var(--jp-shadow-ambient-color);
  --jp-elevation-z24: 0px 11px 15px -7px var(--jp-shadow-umbra-color),
    0px 24px 38px 3px var(--jp-shadow-penumbra-color),
    0px 9px 46px 8px var(--jp-shadow-ambient-color);

  /* Borders
   *
   * The following variables, specify the visual styling of borders in JupyterLab.
   */

  --jp-border-width: 1px;
  --jp-border-color0: var(--md-grey-400);
  --jp-border-color1: var(--md-grey-400);
  --jp-border-color2: var(--md-grey-300);
  --jp-border-color3: var(--md-grey-200);
  --jp-border-radius: 2px;

  /* UI Fonts
   *
   * The UI font CSS variables are used for the typography all of the JupyterLab
   * user interface elements that are not directly user generated content.
   *
   * The font sizing here is done assuming that the body font size of --jp-ui-font-size1
   * is applied to a parent element. When children elements, such as headings, are sized
   * in em all things will be computed relative to that body size.
   */

  --jp-ui-font-scale-factor: 1.2;
  --jp-ui-font-size0: 0.83333em;
  --jp-ui-font-size1: 13px; /* Base font size */
  --jp-ui-font-size2: 1.2em;
  --jp-ui-font-size3: 1.44em;

  --jp-ui-font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Helvetica,
    Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol';

  /*
   * Use these font colors against the corresponding main layout colors.
   * In a light theme, these go from dark to light.
   */

  /* Defaults use Material Design specification */
  --jp-ui-font-color0: rgba(0, 0, 0, 1);
  --jp-ui-font-color1: rgba(0, 0, 0, 0.87);
  --jp-ui-font-color2: rgba(0, 0, 0, 0.54);
  --jp-ui-font-color3: rgba(0, 0, 0, 0.38);

  /*
   * Use these against the brand/accent/warn/error colors.
   * These will typically go from light to darker, in both a dark and light theme.
   */

  --jp-ui-inverse-font-color0: rgba(255, 255, 255, 1);
  --jp-ui-inverse-font-color1: rgba(255, 255, 255, 1);
  --jp-ui-inverse-font-color2: rgba(255, 255, 255, 0.7);
  --jp-ui-inverse-font-color3: rgba(255, 255, 255, 0.5);

  /* Content Fonts
   *
   * Content font variables are used for typography of user generated content.
   *
   * The font sizing here is done assuming that the body font size of --jp-content-font-size1
   * is applied to a parent element. When children elements, such as headings, are sized
   * in em all things will be computed relative to that body size.
   */

  --jp-content-line-height: 1.6;
  --jp-content-font-scale-factor: 1.2;
  --jp-content-font-size0: 0.83333em;
  --jp-content-font-size1: 14px; /* Base font size */
  --jp-content-font-size2: 1.2em;
  --jp-content-font-size3: 1.44em;
  --jp-content-font-size4: 1.728em;
  --jp-content-font-size5: 2.0736em;

  /* This gives a magnification of about 125% in presentation mode over normal. */
  --jp-content-presentation-font-size1: 17px;

  --jp-content-heading-line-height: 1;
  --jp-content-heading-margin-top: 1.2em;
  --jp-content-heading-margin-bottom: 0.8em;
  --jp-content-heading-font-weight: 500;

  /* Defaults use Material Design specification */
  --jp-content-font-color0: rgba(0, 0, 0, 1);
  --jp-content-font-color1: rgba(0, 0, 0, 0.87);
  --jp-content-font-color2: rgba(0, 0, 0, 0.54);
  --jp-content-font-color3: rgba(0, 0, 0, 0.38);

  --jp-content-link-color: var(--md-blue-700);

  --jp-content-font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI',
    Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji',
    'Segoe UI Symbol';

  /*
   * Code Fonts
   *
   * Code font variables are used for typography of code and other monospaces content.
   */

  --jp-code-font-size: 13px;
  --jp-code-line-height: 1.3077; /* 17px for 13px base */
  --jp-code-padding: 5px; /* 5px for 13px base, codemirror highlighting needs integer px value */
  --jp-code-font-family-default: Menlo, Consolas, 'DejaVu Sans Mono', monospace;
  --jp-code-font-family: var(--jp-code-font-family-default);

  /* This gives a magnification of about 125% in presentation mode over normal. */
  --jp-code-presentation-font-size: 16px;

  /* may need to tweak cursor width if you change font size */
  --jp-code-cursor-width0: 1.4px;
  --jp-code-cursor-width1: 2px;
  --jp-code-cursor-width2: 4px;

  /* Layout
   *
   * The following are the main layout colors use in JupyterLab. In a light
   * theme these would go from light to dark.
   */

  --jp-layout-color0: white;
  --jp-layout-color1: white;
  --jp-layout-color2: var(--md-grey-200);
  --jp-layout-color3: var(--md-grey-400);
  --jp-layout-color4: var(--md-grey-600);

  /* Inverse Layout
   *
   * The following are the inverse layout colors use in JupyterLab. In a light
   * theme these would go from dark to light.
   */

  --jp-inverse-layout-color0: #111111;
  --jp-inverse-layout-color1: var(--md-grey-900);
  --jp-inverse-layout-color2: var(--md-grey-800);
  --jp-inverse-layout-color3: var(--md-grey-700);
  --jp-inverse-layout-color4: var(--md-grey-600);

  /* Brand/accent */

  --jp-brand-color0: var(--md-blue-700);
  --jp-brand-color1: var(--md-blue-500);
  --jp-brand-color2: var(--md-blue-300);
  --jp-brand-color3: var(--md-blue-100);
  --jp-brand-color4: var(--md-blue-50);

  --jp-accent-color0: var(--md-green-700);
  --jp-accent-color1: var(--md-green-500);
  --jp-accent-color2: var(--md-green-300);
  --jp-accent-color3: var(--md-green-100);

  /* State colors (warn, error, success, info) */

  --jp-warn-color0: var(--md-orange-700);
  --jp-warn-color1: var(--md-orange-500);
  --jp-warn-color2: var(--md-orange-300);
  --jp-warn-color3: var(--md-orange-100);

  --jp-error-color0: var(--md-red-700);
  --jp-error-color1: var(--md-red-500);
  --jp-error-color2: var(--md-red-300);
  --jp-error-color3: var(--md-red-100);

  --jp-success-color0: var(--md-green-700);
  --jp-success-color1: var(--md-green-500);
  --jp-success-color2: var(--md-green-300);
  --jp-success-color3: var(--md-green-100);

  --jp-info-color0: var(--md-cyan-700);
  --jp-info-color1: var(--md-cyan-500);
  --jp-info-color2: var(--md-cyan-300);
  --jp-info-color3: var(--md-cyan-100);

  /* Cell specific styles */

  --jp-cell-padding: 5px;

  --jp-cell-collapser-width: 8px;
  --jp-cell-collapser-min-height: 20px;
  --jp-cell-collapser-not-active-hover-opacity: 0.6;

  --jp-cell-editor-background: var(--md-grey-100);
  --jp-cell-editor-border-color: var(--md-grey-300);
  --jp-cell-editor-box-shadow: inset 0 0 2px var(--md-blue-300);
  --jp-cell-editor-active-background: var(--jp-layout-color0);
  --jp-cell-editor-active-border-color: var(--jp-brand-color1);

  --jp-cell-prompt-width: 64px;
  --jp-cell-prompt-font-family: 'Source Code Pro', monospace;
  --jp-cell-prompt-letter-spacing: 0px;
  --jp-cell-prompt-opacity: 1;
  --jp-cell-prompt-not-active-opacity: 0.5;
  --jp-cell-prompt-not-active-font-color: var(--md-grey-700);
  /* A custom blend of MD grey and blue 600
   * See https://meyerweb.com/eric/tools/color-blend/#546E7A:1E88E5:5:hex */
  --jp-cell-inprompt-font-color: #307fc1;
  /* A custom blend of MD grey and orange 600
   * https://meyerweb.com/eric/tools/color-blend/#546E7A:F4511E:5:hex */
  --jp-cell-outprompt-font-color: #bf5b3d;

  /* Notebook specific styles */

  --jp-notebook-padding: 10px;
  --jp-notebook-select-background: var(--jp-layout-color1);
  --jp-notebook-multiselected-color: var(--md-blue-50);

  /* The scroll padding is calculated to fill enough space at the bottom of the
  notebook to show one single-line cell (with appropriate padding) at the top
  when the notebook is scrolled all the way to the bottom. We also subtract one
  pixel so that no scrollbar appears if we have just one single-line cell in the
  notebook. This padding is to enable a 'scroll past end' feature in a notebook.
  */
  --jp-notebook-scroll-padding: calc(
    100% - var(--jp-code-font-size) * var(--jp-code-line-height) -
      var(--jp-code-padding) - var(--jp-cell-padding) - 1px
  );

  /* Rendermime styles */

  --jp-rendermime-error-background: #fdd;
  --jp-rendermime-table-row-background: var(--md-grey-100);
  --jp-rendermime-table-row-hover-background: var(--md-light-blue-50);

  /* Dialog specific styles */

  --jp-dialog-background: rgba(0, 0, 0, 0.25);

  /* Console specific styles */

  --jp-console-padding: 10px;

  /* Toolbar specific styles */

  --jp-toolbar-border-color: var(--jp-border-color1);
  --jp-toolbar-micro-height: 8px;
  --jp-toolbar-background: var(--jp-layout-color1);
  --jp-toolbar-box-shadow: 0px 0px 2px 0px rgba(0, 0, 0, 0.24);
  --jp-toolbar-header-margin: 4px 4px 0px 4px;
  --jp-toolbar-active-background: var(--md-grey-300);

  /* Input field styles */

  --jp-input-box-shadow: inset 0 0 2px var(--md-blue-300);
  --jp-input-active-background: var(--jp-layout-color1);
  --jp-input-hover-background: var(--jp-layout-color1);
  --jp-input-background: var(--md-grey-100);
  --jp-input-border-color: var(--jp-border-color1);
  --jp-input-active-border-color: var(--jp-brand-color1);
  --jp-input-active-box-shadow-color: rgba(19, 124, 189, 0.3);

  /* General editor styles */

  --jp-editor-selected-background: #d9d9d9;
  --jp-editor-selected-focused-background: #d7d4f0;
  --jp-editor-cursor-color: var(--jp-ui-font-color0);

  /* Code mirror specific styles */

  --jp-mirror-editor-keyword-color: #008000;
  --jp-mirror-editor-atom-color: #88f;
  --jp-mirror-editor-number-color: #080;
  --jp-mirror-editor-def-color: #00f;
  --jp-mirror-editor-variable-color: var(--md-grey-900);
  --jp-mirror-editor-variable-2-color: #05a;
  --jp-mirror-editor-variable-3-color: #085;
  --jp-mirror-editor-punctuation-color: #05a;
  --jp-mirror-editor-property-color: #05a;
  --jp-mirror-editor-operator-color: #aa22ff;
  --jp-mirror-editor-comment-color: #408080;
  --jp-mirror-editor-string-color: #ba2121;
  --jp-mirror-editor-string-2-color: #708;
  --jp-mirror-editor-meta-color: #aa22ff;
  --jp-mirror-editor-qualifier-color: #555;
  --jp-mirror-editor-builtin-color: #008000;
  --jp-mirror-editor-bracket-color: #997;
  --jp-mirror-editor-tag-color: #170;
  --jp-mirror-editor-attribute-color: #00c;
  --jp-mirror-editor-header-color: blue;
  --jp-mirror-editor-quote-color: #090;
  --jp-mirror-editor-link-color: #00c;
  --jp-mirror-editor-error-color: #f00;
  --jp-mirror-editor-hr-color: #999;

  /* Vega extension styles */

  --jp-vega-background: white;

  /* Sidebar-related styles */

  --jp-sidebar-min-width: 180px;

  /* Search-related styles */

  --jp-search-toggle-off-opacity: 0.5;
  --jp-search-toggle-hover-opacity: 0.8;
  --jp-search-toggle-on-opacity: 1;
  --jp-search-selected-match-background-color: rgb(245, 200, 0);
  --jp-search-selected-match-color: black;
  --jp-search-unselected-match-background-color: var(
    --jp-inverse-layout-color0
  );
  --jp-search-unselected-match-color: var(--jp-ui-inverse-font-color0);

  /* Icon colors that work well with light or dark backgrounds */
  --jp-icon-contrast-color0: var(--md-purple-600);
  --jp-icon-contrast-color1: var(--md-green-600);
  --jp-icon-contrast-color2: var(--md-pink-600);
  --jp-icon-contrast-color3: var(--md-blue-600);
}
</style>

<style type="text/css">
a.anchor-link {
   display: none;
}
.highlight  {
    margin: 0.4em;
}

/* Input area styling */
.jp-InputArea {
    overflow: hidden;
}

.jp-InputArea-editor {
    overflow: hidden;
}

@media print {
  body {
    margin: 0;
  }
}
</style>



<!-- Load mathjax -->
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.7/latest.js?config=TeX-MML-AM_CHTML-full,Safe"> </script>
    <!-- MathJax configuration -->
    <script type="text/x-mathjax-config">
    init_mathjax = function() {
        if (window.MathJax) {
        // MathJax loaded
            MathJax.Hub.Config({
                TeX: {
                    equationNumbers: {
                    autoNumber: "AMS",
                    useLabelIds: true
                    }
                },
                tex2jax: {
                    inlineMath: [ ['$','$'], ["\\(","\\)"] ],
                    displayMath: [ ['$$','$$'], ["\\[","\\]"] ],
                    processEscapes: true,
                    processEnvironments: true
                },
                displayAlign: 'center',
                CommonHTML: {
                    linebreaks: { 
                    automatic: true 
                    }
                },
                "HTML-CSS": {
                    linebreaks: { 
                    automatic: true 
                    }
                }
            });
        
            MathJax.Hub.Queue(["Typeset", MathJax.Hub]);
        }
    }
    init_mathjax();
    </script>
    <!-- End of mathjax configuration --></head>
<body class="jp-Notebook" data-jp-theme-light="true" data-jp-theme-name="JupyterLab Light">
<div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs jp-mod-noInput ">

</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs jp-mod-noInput ">

</div>
<div class="jp-Cell-inputWrapper"><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<h1 id="Vrti&#269;ki-in-pripadajo&#269;a-gesla">Vrti&#269;ki in pripadajo&#269;a gesla<a class="anchor-link" href="#Vrti&#269;ki-in-pripadajo&#269;a-gesla">&#182;</a></h1>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell  jp-mod-noInput ">

<div class="jp-Cell-outputWrapper">

<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain">
<pre>Hypertension : <span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>
Hypertension : <span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend ren disea</span>
Hypertension : <span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>
Hypertension : <span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hyperaldosteron</span>
Hypertension : <span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hyperaldosternon</span>
Hypertension : <span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ess hypertend</span>
Hypertension : <span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon hypertend</span>
Hypotension : <span class="ansi-blue-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypotend</span>
Ischemia : <span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>
Ischemia : <span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">chronic ischem heart diseas</span>
Ischemia : <span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischaem</span>
Arrhythmia : <span class="ansi-magenta-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">arrhythm</span>
Arrhythmia : <span class="ansi-magenta-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">conduc disord</span>
Arrhythmia : <span class="ansi-magenta-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">supraventricul rhythm disturb</span>
Arrhythmia : <span class="ansi-magenta-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">rhythm disturb</span>
Arrhythmia : <span class="ansi-magenta-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ventricul rhythm disturb</span>
Heart failure : <span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>
Heart failure : <span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">left ventricul fail</span>
Heart failure : <span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">right ventricul fail</span>
Heart failure : <span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">riventricul fail</span>
Heart failure : <span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">rongest heart fail</span>
Heart valve diseases : <span class="ansi-cyan-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart valv diseas</span>
Heart failure : <span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>
Heart failure : <span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valvulopa</span>
Heart failure : <span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>
Heart failure : <span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>
Heart failure : <span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">tricuspid</span>
Heart failure : <span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>
Heart failure : <span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">prosthet valv diseas</span>
Inflammatory diseases : <span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam diseas</span>
Inflammatory diseases : <span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">pericardit</span>
Inflammatory diseases : <span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">effus</span>
Inflammatory diseases : <span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>
Inflammatory diseases : <span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">tamponad</span>
Inflammatory diseases : <span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">pericard</span>
Inflammatory diseases : <span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">infecty pericardit</span>
Inflammatory diseases : <span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocardit</span>
Inflammatory diseases : <span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocard</span>
Inflammatory diseases : <span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">chronic rheum heart diseas</span>
Inflammatory diseases : <span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">rhe</span>
Inflammatory diseases : <span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocardit</span>
Inflammatory diseases : <span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>
Inflammatory diseases : <span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">vir cardit</span>
Inflammatory diseases : <span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">cardit</span>
Cardiomyopathy : <span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>
Cardiomyopathy : <span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">ischem cardiomyopathy</span>
Cardiomyopathy : <span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>
Cardiomyopathy : <span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">dil cardiomyopathy</span>
Cardiomyopathy : <span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">hyperthroph cardiomyopathy</span>
Cardiomyopathy : <span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">restrict cardiomyopathy</span>
Cardiomyopathy : <span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">diabet cardiomyopathy</span>
Cardiomyopathy : <span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">stress-induced</span>
Cardiomyopathy : <span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">takotsubo cardiomyopathy</span>
Cardiomyopathy : <span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">takotsubo</span>
Cardiomyopathy : <span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">tako-tsubo</span>
Cardiomyopathy : <span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomega</span>
Cardiomyopathy : <span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomeg</span>
Diseases of arteries : <span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">diseas of artery</span>
Diseases of arteries : <span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron vasospast diseas</span>
Diseases of arteries : <span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>
Diseases of arteries : <span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">vasospa</span>
Diseases of arteries : <span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">microvascul diseas</span>
Diseases of arteries : <span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron microvascul diseas</span>
Diseases of arteries : <span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">microvascul</span>
Diseases of arteries : <span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>
Diseases of arteries : <span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron atheroscleros</span>
Diseases of arteries : <span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>
Diseases of arteries : <span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">pulmon heart diseas</span>
Diseases of arteries : <span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlud</span>
Diseases of arteries : <span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>
Diseases of arteries : <span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">stenos</span>
Diseases of arteries : <span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>
Diseases of arteries : <span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">cerebrovascul</span>
Coagulopathies : <span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coagulopathy</span>
Coagulopathies : <span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">deep vein thrombosis</span>
Coagulopathies : <span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>
Coagulopathies : <span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>
Coagulopathies : <span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ven thrombembolism</span>
Coagulopathies : <span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">art thrombembolism</span>
Coagulopathies : <span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">art thrombosis</span>
</pre>
</div>
</div>

</div>

</div>

</div>
<div class="jp-Cell-inputWrapper"><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<h1 id="Grobi-rezultati">Grobi rezultati<a class="anchor-link" href="#Grobi-rezultati">&#182;</a></h1>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell  jp-mod-noInput ">

<div class="jp-Cell-outputWrapper">

<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">



<div class="jp-RenderedImage jp-OutputArea-output ">
<img src="data:image/png;base64,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
"
>
</div>

</div>

<div class="jp-OutputArea-child">



<div class="jp-RenderedImage jp-OutputArea-output ">
<img src="data:image/png;base64,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
"
>
</div>

</div>

<div class="jp-OutputArea-child">






<div id="76c16d4c-41f1-4812-97b8-8d728d768507" class="jupyter-widgets jp-OutputArea-output ">
<script type="text/javascript">
var element = document.getElementById('76c16d4c-41f1-4812-97b8-8d728d768507');
</script>
<script type="application/vnd.jupyter.widget-view+json">
{"model_id": "732f6fe363c845dcacdfc369bea18866", "version_major": 2, "version_minor": 0}
</script>
</div>

</div>

<div class="jp-OutputArea-child">

<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain">
<pre><span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 About one-tenth of patients with untreated chronic syphilis and tertiary syphilis develop structural complications involving the coronary ostia, ascending aorta, or aortic root. We describe a unique case of a large aortic root aneurysm of the noncoronary sinus with extrinsic compression of the right coronary artery, a complication of tertiary syphilis. Surgical intervention involved valve-sparing aortic root reconstruction with right coronary ostia reimplantation (hemi-Yacoub). The patient&#39;s postoperative course was uneventful; he is healthy approximately 2 years later.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocardit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocard</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">cardit</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Diseases of arteries,Coagulopathies,
 We report an intricate aortic root replacement in a young male patient suffering from native valve infective endocarditis due to Serratia marcescens. Further complicating the total root replacement, there was an unknown infected aortic thrombus and a concomitant anomalous right coronary artery with an intramural course. As a result of our more aggressive approach, we believe that we lowered the risk of recurrent infection of the bioprosthesis of the aortic root.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  Stanford Type A aortic dissection repair surgery is associated with high mortality and clinical practice remains variable among hospitals. Few studies have examined statewide practice variation. METHODS  Patients who had Stanford Type A aortic dissection repair surgery in Maryland between July 1, 2014 and June 30, 2018 were identified using the Maryland Cardiac Surgery Quality Initiative (MCSQI) database. Patient demographics, comorbidities, surgery details, and outcomes were compared between hospitals. We also explored the impact of arterial cannulation site and brain protection technique on outcome. RESULTS  A total of 233 patients were included from eight hospitals during the study period. Seventy-six percent of surgeries were done in two high-volume hospitals (&gt;/=10 cases per year), while the remaining 24% were done in low-volume hospitals. Operative mortality was 12.0% and varied between 0 and 25.0% depending on the hospital. Variables that differed significantly between hospitals included patient age, the percentage of patients in shock, left ventricular ejection fraction, creatinine level, arterial cannulation site, brain protection technique, tobacco use, and intraoperative blood transfusion. The percentage of patients who underwent aortic valve repair or replacement procedures differed significantly between hospitals (p &lt; 0.001), although the prevalence of moderate-to-severe aortic insufficiency was not significantly different (p = 0.14). There were no significant differences in clinical outcomes including mortality, renal failure, stroke, or gastrointestinal complications between hospitals or based on arterial cannulation site (all p &gt; 0.05). Patients who had aortic cross-clamping or endovascualr repair had more embolic strokes when compared with patients who had hypothermic circulatory arrest (p = 0.03). CONCLUSION  There remains considerable practice variation in Stanford Type A aortic dissection repair surgery within Maryland including some modifiable factors such as intraoperative blood transfusion, arterial cannulation site, and brain protection technique. Continued efforts are needed within MCSQI and nationally to evaluate and employ the best practices for patients having acute aortic dissection repair surgery.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,
 Endovascular treatment in thoracic aortic diseases has increased in use exponentially since Dake and colleagues first described the use of a home-made transluminal endovascular graft on 13 patients with descending thoracic aortic aneurysm at Stanford University in the early 1990s. Thoracic endovascular aneurysm repair (TEVAR) was initially developed for therapy in patients deemed unfit for open surgery. Innovations in endograft engineering design and popularization of endovascular techniques have transformed TEVAR to the predominant treatment choice in elective thoracic aortic repair. The number of TEVARs performed in the United States increased by 600% from 1998 to 2007, while the total number of thoracic aortic repairs increased by 60%. As larger multicenter trials and meta-analysis studies in the 2000s demonstrate the significant decrease in perioperative morbidity and mortality of TEVAR over open repair, TEVAR became incorporated into standard guidelines. The 2010 American consensus guidelines recommend TEVAR to be &#34;strongly considered&#34; when feasible for patients with degenerative or traumatic aneurysms of the descending thoracic aorta exceeding 5.5 cm, saccular aneurysms, or postoperative pseudoaneurysms. Nowadays, TEVAR is the predominant treatment for degenerative and traumatic descending thoracic aortic aneurysm repair. Although TEVAR has been shown to have decreased early morbidity and mortality compared with open surgical repair, endovascular manipulation of a diseased aorta with endovascular devices continues to have significant risks. Despite continued advancement in endovascular technique and devices since the first prospective trial examined the complications associated with TEVAR, common complications, two decades later, still include stroke, spinal cord ischemia, device failure, unintentional great vessel coverage, access site complications, and renal injury. In this article, we review common TEVAR complications with some corresponding radiographic imaging and their management.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 BACKGROUND  Body fat distribution influences the risk of cardio-metabolic disease in people with overweight. This study was aimed at identifying the anthropometric parameters more strongly associated with the majority of cardio-metabolic risk factors. METHODS  This study included 1214 subjects (840 women), with a body-mass-index (BMI) &gt;/= 25 Kg/m2, aged 39.2 +/- 13 years. Fasting blood glucose (FBG), triglycerides (TG), total, HDL- and LDL-cholesterol, uric acid, vitamin D, high-sensitive C-reactive protein (hs-CRP), white blood cells (WBC), platelets, insulin and insulin resistance (HOMA-IR), systolic (SBP) and diastolic blood pressure (DBP), smoking habit and snoring were evaluated as cardio-metabolic risk factors.We also included the Systematic COronary Risk Evaluation (SCORE) to estimate cardiovascular risk in our study population. BMI, waist circumference (WC), waist-to-height-ratio (WHtR) and neck circumference (NC) were evaluated as anthropometric parameters. RESULTS  All four anthropometric parameters were positively associated to SBP, DBP, TG, FBG, insulin, HOMA-IR, WBC, and snoring (p&lt;0.001), and negatively associated with HDL-cholesterol (p&lt;0.001). NC showed a positive association with LDL-cholesterol (beta = 0.76; p = 0.01; 95% C.I. 0.19 to 1.32), while vitamin D was negatively associated to WC (beta = -0.16; p&lt;0.001; 95% C.I. -0.24 to -0.09), BMI (beta = 0.42); p&lt;0.001; 95% C.I. -0.56 to -0.28) and WHtR (beta = -24.46; p&lt;0.001; 95% C.I. -37 to -11.9). Hs-CRP was positively correlated with WC (beta = 0.003; p = 0.003; 95% C.I. 0.001 to 0.006), BMI (beta = 0.01; p = 0.02; 95% C.I. 0.001 to 0.012) and WHtR (beta = 0.55; p = 0.01; 95% C.I. 0.14 to 0.96). SCORE was associated to NC (beta = 0.15; 95% CI 0.12 to 0.18; p&lt;0.001), BMI (beta = -0.18; 95% CI -0.22 to 0.14; p&lt;0.001) and WHtR (beta = 7.56; 95% CI 5.30 to 9.82; p&lt;0.001). CONCLUSIONS  NC, combined with BMI and WC or WHtR could represent an essential tool for use in clinical practice to define the cardio-metabolic risk in individuals with excess body weight.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-blue-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypotend</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Hypotension,Diseases of arteries,
 Amlodipine is a dihydropyridine calcium channel blocker widely used in the treatment of high blood pressure and coronary heart disease. Intoxication can lead to reflex tachycardia following massive hypotension and death. The objective of this work was to study the post-mortem concentrations of amlodipine in 62 patients in order to determine whether the use of the reference concentrations from the living patients was applicable in postmortem setting, and to define more precisely the fatal and non-fatal postmortem concentrations of amlodipine. The amlodipine concentrations were measured in femoral whole blood by LC-MS/MS validated method. When sufficient information was available, the data were classified into 2 different groups, based on the conclusions of the autopsy and toxicological results  G1  non-toxic death and G2  fatal poisoning involving amlodipine alone or as part of a multidrug poisoning. The median concentration of amlodipine [1st quartile - 3rd quartile] of the whole population (n = 62) was 81 [42-134] ng/mL. Twenty-two cases were classified as G1 and thirteen as G2. The observed median [1st quartile - 3rd quartile] concentration of amlodipine was 66 [40.5-79.5] ng/mL in G1 and 240 [170-404] ng/mL in G2. The median concentrations observed in &#34;non-toxic&#34; deaths (66 ng/mL) were three times higher than those usually observed in living patients. Amlodipine distribution ratio between plasma and whole blood concentrations seems insufficient to explain this difference and postmortem redistribution from organs should be considered, and could suggest the same redistribution pattern for other drugs belonging to the same family.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlud</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Diseases of arteries,Coagulopathies,
 INTRODUCTION  Differences in access to stroke care and compliance with standard of care stroke management among patients of varying racial and ethnic backgrounds and sex are well-characterized. However, little is known on the impact of telestroke in addressing disparities in acute ischemic stroke care. METHODS  We conducted a retrospective review of acute ischemic stroke patients evaluated over our 17-hospital telestroke network in Texas from 2015-2018. Patients were described as Non-Hispanic White (NHW) male or female, Non-Hispanic Black (NHB) male or female, or Hispanic (HIS) male or female. We compared frequency of tPA and mechanical thrombectomy (MT) utilization, door-to-consultation times, door-to-tPA times, and time-to-transfer for patients who went on to MT evaluation at the hub after having been screened for suspected large vessel occlusion at the spoke. RESULTS  Among 3873 patients (including 1146 NHW male (30%) and 1134 NHW female (29%), 405 NHB male (10%) and 491 NHB female (13%), and 358 HIS male (9%) and 339 HIS female (9%) patients), we did not find any differences in door-to consultation time, door-to-tPA time, time-to-transfer, frequency of tPA administration, or incidence of MT utilization. CONCLUSION  We did not find racial, ethnic, and sex disparities in ischemic stroke care metrics within our telestroke network. In order to fully understand how telestroke alleviates disparities in stroke care, collaboration among networks is needed to formulate a multicenter telestroke database similar to the Get-With-The Guidelines.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocardit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocard</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">cardit</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 BACKGROUND  Enterococcal bacteraemia (EB) is common, particularly in the nosocomial setting, and its management poses a challenge for clinicians and microbiologists. AIM  To summarise the more relevant features of EB and to provide a practical state-of-the-art on the topics that more directly affect its management. SOURCES  Pubmed, from inception to May 31, 2020. CONTENT  The following topics are covered  epidemiological, clinical and microbiological characteristics and factors associated to prognosis of EB; diagnosis and work-up including the use of echocardiography to rule out endocarditis; antibiotic management with special focus on antimicrobial resistance and complicated EB; and the role of infectious disease consultation and the use of bundles in EB. In addition, 3 clinical vignettes are presented to illustrate the practical application of the guidance provided, and major gaps in the current evidence supporting EB management are discussed. IMPLICATIONS  EB is associated to large burdens of morbidity and mortality, particularly among fragile and immunosuppressed patients presenting complicated bacteraemia due to multidrug-resistant enterococci. Most cases of EB are caused by E. faecalis, followed by E. faecium. EB often presents as polymicrobial bacteraemia. Rapidly identifying patients at risk of EB is crucial for timely application of diagnostic techniques and empiric therapy. Early alert systems and rapid diagnostic techniques such as MALDI-TOF, especially if used together with infectious disease consultation within bundles, appear to improve management and prognosis of EB. Echocardiography is also key in the work-up of EB and should probably be more extensively used, although its exact indications in EB still are debated. Multidisciplinary approaches are warranted due to the complexity and severity of EB.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  Botulinum toxin injection (BTI) reduces muscle hyperactivity but its effect on active upper limb function is limited. Intensive rehabilitation could optimize the effects; however, outpatient post-stroke rehabilitation is usually not intensive. One solution could be self-rehabilitation. OBJECTIVES  The aim of this randomized controlled trial was to determine the effects of a self-rehabilitation program combined with BTI on upper limb function in individuals with chronic hemiparesis. METHODS  Thirty-three outpatients were randomly allocated to receive either BTI + self-rehabilitation (R group  n=17) or BTI alone (C group  n=16). Outcomes evaluated just before the BTI and 4 weeks later included  Wolf Motor Function Test (WMFT time - Primary Outcome), Action Research Arm Test, fatigue and quality of life. RESULTS  Change in WMFT was not different between groups at 4 weeks (WMFT time  -14% for R group, -4 % for C group. WFMT score  +12 % for R group, 0 % in C group). WFMT time and score improved significantly (-14 %, p=0.01 and +12 %, p=0.02 respectively) in the R group only. In addition, the proportion of patients with improved WMFT time and scores was higher in the R group (71% improved score, 77% improved time, C group 43% improved score, 50% improved time). Passive range of shoulder flexion (p=0.03) and wrist extension (p=0.01) also improved only in the R group. No other variables changed significantly. Compliance was excellent; average daily training time was greater than that prescribed. CONCLUSIONS  The addition of a self-rehabilitation program to BTI did not significantly improve functional outcomes more than BTI alone, however movement quality and speed only improved in the self-rehabilitation group. Participants in the self-rehabilitation group trained more than they were asked to, suggesting they found the program worthwhile. These clinically relevant findings justify larger-scale studies into the effects of self-rehabilitation to enhance the effects of BTI.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Raised extracellular potassium ion (K(+)) concentration is associated with several disorders including migraine, stroke, neurotrauma and epilepsy. K(+) spatial buffering is a well-known mechanism for extracellular K(+) regulation/distribution. Astrocytic gap junction-mediated buffering is a controversial candidate for K(+) spatial buffering. To further investigate the existence of a K(+) spatial buffering and to assess the involvement of astrocytic gap junctional coupling in K(+) redistribution, we hypothesized that neocortical K(+) and concomitant spreading depolarization (SD)-like responses are controlled by powerful local K(+) buffering mechanisms and that K(+) buffering/redistribution occurs partially through gap junctional coupling. Herein, we show, in vivo, that a threshold amount of focally applied KCl is required to trigger local and/or distal K(+) responses, accompanied by a SD-like response. This observation indicates the presence of powerful local K(+) buffering which mediates a rapid return of extracellular K(+) to the baseline. Application of gap junctional blockers, carbenoxolone and Gap27, partially modulated the amplitude and shape of the K(+) response and noticeably decreased the velocity of the spreading K(+) and SD-like responses. Opening of gap junctions by trimethylamine, slightly decreased the amplitude of the K(+) response and markedly increased the velocity of redistribution of K(+) and SD-like events. We conclude that spreading K(+) responses reflect powerful local K(+) buffering mechanisms which are partially modulated by gap junctional communication. Gap junctional coupling mainly affected the velocity of the K(+) and SD-like responses.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,
 Early stages of atherosclerosis are characterizated for the uptake of oxidate low-density lipoprotein (oxLDL) by inflammatory macrophages in the arteries, promoting the foam cell formation. Drimys winteri is a native tree of Chile that produce drimane sesquiterpenoids, here it was evaluated the inhibitory foam cell formation by the total extract of barks of Drimys winteri and isodrimeninol, a sesquiterpenoid isolated from the tree. The results showed that Dw and isodrimeninol inhibited the foam cell formation on macrophage M1, by Oil Red O staining. Moreover, Dw reduced the gene expression of pro-inflammatory cytokine TNF-alpha, in contrast to isodrimeninol that showed not effect on the gene expression of this cytokine, also Dw enhanced the expression of the anti-inflammatory cytokine IL-10, in more significant manner than isodrimeninol at 20 mug/mL. While, Dw and isodrimeninol significantly reduced the expression of IL1-beta at concentrations of 20 mug/mL, but not affecting the MMP-9 levels, assessed by RT-qPCR. In conclusion, Drimys winteri and isodrimeninol induce anti-atherosclerotic effects, inhibiting foam cell formation, as well as promoting anti-inflammatory responses. This study confirm the relevance of this tree as a medicinal source for the Mapuche people, and suggesting that Drimys winteri could be used in early stages of atherosclerosis.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Diseases of arteries,
 There has been considerable debate on the extent to which the decline in coronary heart disease (CHD) mortality has been caused by better control of coronary risk factors in the general population or is the result of invasive coronary interventions in symptomatic individuals. Using the Myocardial Infarction Data Acquisition System (MIDAS), a statewide database of all cardiovascular hospital admissions in New Jersey, we examined time trends in incidence of death from CHD in the years 2000 to 2014 in persons with a history of hospitalization for CHD in the previous 10 years and those without such a history. Over the 10-year study period there was a marked decline in CHD related mortality in both persons with a history of CHD and persons without a history of CHD. The decline occurred across all gender, racial and age groups and was higher in those without a prior history of CHD. This adds more evidence that the decline in CHD was not only due to advanced invasive medical and surgical treatments but also equally due to improved lifestyle, pharmacologic treatment of risk factors for CHD, and public health interventions.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 The genus Uncaira (Rubiaceae) comprises of 34 species, many of which are usually used as traditional Chinese medicines (TCMs) to treat hypertension, fevers, headaches, gastrointestinal illnesses, and fungal infections. Over the past twenty years, Uncaira species have been paid the considerable attentions in phytochemical and biological aspects, and about 100 new secondary metabolites, including alkaloids, triterpenes, and flavonoids, have been elucidated. This review aims to present a comprehensive and up-to date overview of the biological source, structures and their biosynthetic pathways, as well as the pharmacological of the compounds reported in the genus Uncaria for the past two decades. It would provide an insight into the emerging pharmacological applications of the genus Uncaria.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">rhe</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Inflammatory diseases,
 ETHNOPHARMACOLOGICAL RELEVANCE  The Chinese traditional medicine of Siegesbeckia pubescens Makino (SM), which has the effect of healing rheumatism and promoting joint health, is often used to treat rheumatoid arthritis and ischemic stroke. AIM OF THE STUDY  To clarify the mechanisms underlying the anti-inflammatory and analgesic influence of active components in the ethanol extract of Siegesbeckia pubescens Makino (ESM). MATERIALS AND METHODS  The active ingredients in the ESM were identified practicing high-performance liquid chromatography-diode array detection (HPLC-DAD). Four models including xylene-induced ear oedema, complete Freund&#39;s adjuvant (CFA)-induced hind paw oedema, acetic acid-induced pain writhing and lipopolysaccharide (LPS)-induced RAW264.7 cell migration, were used to clarify the anti-inflammatory and analgesic mechanisms of the active ingredients in the ESM. RESULTS  (1) Three active ingredients of kirenol, darutoside and hesperidin were identified in the ESM, with relative proportion of 0.6%, 0.2% and 0.01%, respectively; hesperidin was reported for the first time in the ESM. (2) Both the ESM and its active ingredients could effectively alleviate the degree of swelling of the auricle and toes, increase the threshold of heat pain, decrease the overexpression of inflammatory protein cyclooxygenase-2 (COX-2) in the skin tissue of the tested parts of the toes, and reduce the number of writhes induced by acetic acid in mice. (3) ESM and its active ingredients also dose-dependently inhibited the migration of RAW264.7 cells. CONCLUSIONS  ESM and its active ingredients can effectively attenuate the expression of inflammatory factors induced by chemical inflammation, prevent the infiltration of inflammatory cells, and exert good anti-inflammatory and antinociceptive activities.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">cerebrovascul</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Ischemia,Heart failure,Diseases of arteries,
 BACKGROUND  Peripheral arterial disease (PAD) was reported to increase the risk of new cardiovascular events in patients with acute coronary syndromes (ACS). However, most of the evidence comes from randomized clinical trials. We aimed to assess the impact of PAD on cardiovascular outcome and treatment decisions in ACS patients in a current real-life setting. METHODS  START-ANTIPLATELET is a multicenter registry enrolling ACS patient. Baseline clinical characteristics and treatment at discharge were recorded and follow-up was repeated at 6-months and 1-year. PAD was defined as intermittent claudication and/or previous revascularization. RESULTS  Among 1442 patients enrolled, 103 (7.1%) had PAD. PAD patients were older (71.8+/-10.6vs66.2+/-12.6yrs., p&lt;0.0001), more frequently hypertensive (90.3vs68.6%, p&lt;0.0001), hypercholesterolemic (66vs52%, p=0.037), diabetic (51.5vs24%, p=0.0001), obese (28.2vs19.3%, p=0.029) and with previous TIA (7.8vs2.8%, p=0.005) or stroke (11.7vs3.1%, p&lt;0.0001). Clinical presentation and acute treatment were similar in non-PAD and PAD patients, but the latter were discharged significantly less frequently on dual antiplatelet therapy (DAPT) (68.9vs85%, p=0.005). After a median follow-up time of 11.1months, major cardio/cerebrovascular event-free survival [MACCE, including cardiovascular death, MI, TIA and stroke, target-vessel revascularization (TVR) and major arterial ischemic events] was significantly shorter (9.0vs11.2months, p=0.02; HR 3.2, 2.4-8.4) in PAD patients and net adverse cardiovascular events (NACE=MACCE plus major hemorrhages) were significantly more frequent (19.1%vs10.5%, p=0.049). CONCLUSIONS  PAD identifies a subgroup of ACS patients at significantly increased cardiovascular risk, but these patients tend to be undertreated. Patients admitted for ACS should be screened for PAD and optimal medical therapy at discharge should be implemented.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Coagulopathies,
 BACKGROUND  There is controversy as to whether patients with atrial fibrillation (AF) and perceived low risk of cerebral infarction should be treated with anticoagulants, especially at what age a cut-off treatment might be indicated. METHOD  We performed a retrospective, nationwide cohort study based on the Swedish National Patient Register and the Prescribed Drugs Register. Patients with a diagnosis of AF between July 1, 2005, and December 31, 2014, were included and divided into age categories (&lt;55, 55-59, 60-64 and 65-74years) and CHA2DS2-VA score of 0 and 1. Incidence rates (IR) of cerebral infarction and cerebral bleeding were calculated. Associations between outcomes from anticoagulant therapy and no therapy were calculated with Cox regression and given as hazard ratios (HR) with 95% confidence intervals (CI). RESULTS  The analyzed cohort consisted of 294,470 patients. All age categories older than 55years on anticoagulants had lower IR and HR for cerebral infarction compared to patients off anticoagulants, from HR 0.72, 95% CI (0.54-0.96) for patients 55-59years with 0 points according to the CHA2DS2-VA score, to HR 0.37, 95% CI (0.33-0.42) for patients 65-74years with 1 point. Anticoagulant therapy was associated to an increased risk of cerebral bleeding in three of seven categories, &lt;55years with 0 point, 55-59years with 1 point, and 65-74years with 1 point. CONCLUSION  Anticoagulant therapy in patients with AF and age 55years and older may be considered even if the patient has no other known risk factors for cerebral infarction.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Coagulopathies,
 OBJECTIVE  To explore the association between E-wave propagation index (EPI) as a marker of apical washout and the risk of left ventricular thrombus (LVT) formation in patients with ST-elevation myocardial infarction (STEMI). METHODS  We performed a post-hoc analysis on 364 prospectively enrolled STEMI patients from a single-center. Non-contrast transthoracic echocardiographic examinations were performed a median of 2days (IQR 1-3days) after PCI. The endpoint was LVT formation, identified retrospectively. Univariable and multivariable logistic regression was applied to assess the association between EPI and LVT formation. Multivariable adjustments included LVEF, LAD culprit, prior myocardial infarction, heart rate, and early myocardial relaxation velocity. Area under receiver operating characteristic curves (AUC) was used to assess the diagnostic ability. RESULTS AND CONCLUSIONS  Among 364 patients, 31 (8.5%) developed LVT. The mean age was 62years, 75% were men, and mean LVEF was 46%. Patients developing LVT had increased heart rate, lower LVEF, impaired GLS, and more frequently had prior myocardial infarction. Variables associated with low values of EPI included, among others, LVEF, LV aneurysm, and GLS. EPI and LVT formation were significantly associated in the univariable model (OR=1.87 (1.53-2.28), p&lt;0.001), and EPI showed an AUC of 0.90. After multivariable adjustments, EPI and LVT formation remained significantly associated (OR=1.79 (1.42-2.27), p&lt;0.001). Patients with an EPI&lt;1.0 had a 23 times higher likelihood of LVT formation (OR=23.41 (10.06-54.49), p&lt;0.001). EPI and LVT formation are strongly associated in patients with STEMI, with low values of EPI indicating a markedly increased probability of LVT formation.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Inflammatory diseases,Diseases of arteries,Coagulopathies,
 Background The current guidelines have recommended to shorten the dual antiplatelet therapy duration in patients at high bleeding risk (HBR) to minimize the bleeding complications. The impact of ischemic risk factors (IRF) on long-term ischemic events in patients with and without HBR after percutaneous coronary intervention remains unclear. Methods The study population comprised 1219 patients who were treated with everolimus-eluting stents between 2010 and 2011. The mean follow-up period was 2996+/-433days. HBR was defined as set by the Academic Research Consortium. IRF was defined as high-risk features of stent-driven recurrent ischemic events endorsed in the 2017 European Society of Cardiology Guidelines. Major bleeding was defined as the occurrence of Bleeding Academic Research Consortium type 3 or 5 bleeding. Primary ischemic events included myocardial infarction, definite stent thrombosis, and cardiac death. Results The 1219 patients were divided into two groups  614 patients at HBR (HBR group) and 605 patients at no HBR (non-HBR group). The rate of IRF patients was significantly higher in the HBR group than in the non-HBR group (81.4% versus 47.6%, P&lt;0.001). The cumulative rate of ischemic events in the HBR group was significantly higher in IRF patients than in non-IRF patients (21.0% versus 7.0%, log rank P&lt;0.001), whereas that in the non-HBR group was not significantly different between IRF and non-IRF patients (10.1% versus 6.3%, log rank P=0.09). Conclusions More than 80% of HBR patients treated with everolimus-eluting stents were at IRF. A combination of HBR and IRF may increase the risk of long-term ischemic events.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam diseas</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlud</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Inflammatory diseases,Diseases of arteries,
 Polyamidoamine dendrimer has been studied as an efficient gene carrier. Due to its anti-inflammatory properties, polyamidoamine is a useful gene carrier, especially for inflammatory diseases. However, the commonly used polyamidoamine generation 6 dendrimer (PG6) has higher cytotoxicity than low-molecular weight polyamidoamines, which limits its applications. Therefore, early-generation polyamidoamine dendrimers, such as generation 2 (PG2), have been investigated as an alternative to PG6, although PG2 has a lower transfection efficiency. In this study, to improve gene delivery efficiency, histidine and arginine were conjugated on the primary amines of PG2, synthesizing PG2HR. The gene delivery efficiency of PG2HR was higher than that of PG2 or of PG2 conjugated with only arginine (PG2R), which may be due to higher cellular uptake and endosomal escape of the plasmid DNA (pDNA)/PG2HR complex. In addition, PG2HR had lower cytotoxicity than polyethylenimine (25 kDa, PEI25k), PG2, and PG2R. Mechanism studies showed that PG2HR delivered pDNA into the cells mainly by clathrin-independent endocytosis and partly by macropinocytosis. The therapeutic potential of PG2HR-mediated gene delivery was evaluated in middle cerebral artery occlusion (MCAO)-reperfusion stroke animal models. Heme oxygenase-1 (HO-1) plasmid was delivered into the brain by local injection. The results showed that PG2HR had higher gene delivery efficiency in the brain than did PEI25k, PG2, or PG2R. Furthermore, compared to the pHO-1/PEI25k, pHO-1/PG2, and pHO-1/PG2R complexes, the pHO-1/PG2HR complex had reduced apoptosis levels and infarct sizes in ischemic brains. Therefore, because of its low cytotoxicity and high gene delivery efficiency, PG2HR may be useful for gene therapy of inflammatory diseases including ischemic stroke.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Inflammatory diseases,
 BACKGROUND  Interferon regulatory factor 7 (IRF7) plays a key role to regulate an inflammatory response, inhibits vascular smooth cell proliferation and promotes apoptosis. But its role in pulmonary hypertension (PH) pathology is essentially unknown. We hypothesized that downregulation IRF7 promotes pulmonary vascular remodeling and that overexpression of IRF7 could slow the progression of PH. METHODS  mRNA, and protein levels of IRF7 were assessed in the lung samples and isolated pulmonary artery smooth muscle cells (PASMCs) from MCT-induced PH in rats. The preventive effects of IRF7 up-regulation were tested in the MCT induced PH rat. The effects of IRF7 on inflammation, proliferation, apoptosis, and AFT3 signaling were tested in cultured rat PASMCs. RESULTS  mRNA and protein levels of IRF7 were decreased in vivo and in vitro in the pulmonary vascular from MCT induced PH rats. Genetically up-regulation IRF7 with adeno-associated virus attenuated pulmonary vascular remodeling, resulted in decreasing pulmonary artery systolic pressure and improving the right ventricular structure and function. The pulmonary vascular protective effect worked by reducing pro-inflammatory cytokine levels (TNF-alpha, IL-6), as well as abrogating PASMCS proliferation and apoptosis resistance via ATF3 signaling. ATF3 activation augmented the proliferation-dependent genes (PCNA1, Cyclin D1) and anti-apoptotic regulators (Capase-3 and Bax) in PASMCs. CONCLUSIONS  Our data provide evidence that down-regulation of IRF7 cold initiate inflammation response, cause PASMCs proliferation and apoptosis resistance via activation of ATF3 signaling pathway. Activation of IRF7 could be a potential therapeutic target for treating PH.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Coagulopathies,
 BACKGROUND AND PURPOSE  Previously, we discovered that activation of nucleotide-binding oligomerization domain 2 (NOD2) enhances platelet activation. We here investigated the antiplatelet and antithrombotic potential of GSK669, a NOD2 antagonist. EXPERIMENTAL  Approach Effects of GSK669 on platelet functions, reactive oxygen species (ROS) and proinflammation cytokine generation were detected. NOD2-/- platelets were used to confirm GSK669 target. The interaction between GSK669 and glycoprotein VI (GPVI) was detected using surface plasmon resonance (SPR) spectroscopy. GPVI downstream signaling was examined by Western blot. The antithrombotic and antioxidative effects were investigated using mouse mesenteric arteriole thrombosis model and pulmonary embolism model. Key Results GSK669 significantly inhibits platelet proinflammatory cytokine release induced by muramyl dipeptide, platelet aggregation, ATP release, and ROS generation induced by collagen and collagen related peptide (CRP). Platelet spreading and clot retraction are also inhibited. GSK669 also decreases collagen-induced phosphorylation of Src, Syk, PLCgamma2, and Akt. The antiplatelet effect of GSK669 is NOD2-independent and mediated by GPVI antagonism. Consistent with its antiplatelet activity as a GPVI antagonist, GSK669 inhibits platelet adhesion on collagen in flow condition. Notably, GSK669 inhibits mouse mesenteric arteriole thrombosis similarly to aspirin without bleeding. The antithrombotic effect of GSK669 is further confirmed in the pulmonary embolism model; decreased malonaldehyde (MDA) and increased superoxide dismutase (SOD) levels in mouse plasma reveal a significant antioxidant effect of GSK669. Conclusion and Implications Beyond its anti-inflammatory effect as a NOD2 antagonist, GSK669 is also an efficient and safe antiplatelet agent combined with antioxidant effect by targeting GPVI. An antiplatelet agent bearing antioxidative and anti-inflammatory activities without bleeding risk may have therapeutic advantage over current antiplatelet drugs for atherothrombosis.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Inflammatory diseases,
 Previously, we have shown that an increased cGMP-activated protein Kinase (PKG) activity after phosphodiesterase 5 (PDE5) inhibition by Sildenafil (SIL), leads to myocardial Na(+)/H(+) exchanger (NHE1) inhibition preserving its basal homeostatic function. Since NHE1 is hyperactive in the hypertrophied myocardium of spontaneous hypertensive rats (SHR), while its inhibition was shown to prevent and revert this pathology, the current study was aimed to evaluate the potential antihypertrophic effect of SIL on adult SHR myocardium. We initially tested the inhibitory capability of SIL on NHE1 in isolated cardiomyocytes of SHR by comparing H(+) efflux during the recovery from an acid load. After confirmed that effect, eight-month-old SHR were chronically treated for one month with SIL through drinking water. Compared to their littermate controls, SIL-treated rats presented a decreased NHE1 activity, which correlated with a reduction in its phosphorylation level assigned to activation of a PKG-p38 MAP kinase-PP2A signaling pathway. Moreover, treated animals showed a decreased oxidative stress that appears to be a consequence of a decreased mitochondrial NHE1 phosphorylation. Treated SHR showed a significant reduction in the pro-hypertrophic phosphatase calcineurin, despite slight tendency to decrease hypertrophy was detected. When SIL treatment was prolonged to three months, a significant decrease in myocardial hypertrophy and interstitial fibrosis that correlated with a lower myocardial stiffness was observed. In conclusion, the current study provides evidence concerning the ability of SIL to revert established cardiac hypertrophy in SHR, a clinically relevant animal model that resembles human essential hypertension.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocardit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">cardit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,
 BACKGROUND  There are no data on population-based epidemiological changes in acute myocarditis in Europe. Our aim was to evaluate temporal trends in incidence, clinical features and outcomes of hospital treated acute myocarditis (AM) in Spain from 2003 to 2015. METHODS  We conducted a retrospective longitudinal study using information of all hospital discharges of the Spanish National Health System. All episodes with a discharge diagnosis of AM from January 1, 2003 to December 31, 2015 were included. The risk-standardized in-hospital mortality ratio (RSMR) was calculated using a multilevel risk adjustment model developed by the Medicare and Medicaid Services. Temporal trends for in-hospital mortality were modelled using Poisson regression analysis. RESULTS  A total of 11,147 episodes of AM were analysed, most of them idiopathic (94.7%). The rate of AM discharges increased along the period, from 13 to 30/million inhabitants/year (2003 to 2015), and this increase was statistically significant when weighted by age and sex (incidence rate ratio, IRR 1.06,95%CI 1.04-1.08,p=0.001). In-hospital crude mortality rate was 3.1%, diminishing significantly along 2003 to 2015 (IRR 0.95,95%CI 0.92-0.99,p=0.02). RSMR also significantly diminished along the period (IRR 0.95,95%CI 0.92-0.99,p=0.01). Renal failure (OR 7.03,5.38-9.18,p=0.001), liver disease (OR 4.61,2.59-8.21,p=0.001), pneumonia (OR 4.13,2.75-6.20,p=0.001) and heart failure (OR 1.91,95%CI 1.47-2.47,p=0.001), were the strongest independent factors associated with in-hospital mortality. CONCLUSIONS  AM is an uncommon entity, although hospital discharges have increased in Spain along the study period. Most of AM were idiopathic. Adjusted mortality was low and seemed to decrease from 2003 to 2015, suggesting an improvement in AM management.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 Prior studies showed that calcium channel blockers (CCBs) could modify cancer risk, but data on gastric cancer (GC) are limited. We aimed to investigate whether CCBs could modify GC risk in Helicobacter pylori (H. pylori)-eradicated patients. H. pylori infected patients with hypertension who are aged &gt;/=50, and had received clarithromycin based triple therapy between 2003 and 2016 were identified from a territory-wide healthcare database. Patients with eradication failure, GC diagnosed within 6 months after HP eradication, and gastric ulcer were excluded. Time-fixed Cox model with one-to-one propensity score matching was used to calculate hazard ratio (HR) of GC with CCBs. Sensitivity analysis using time-dependent multivariable Cox model in which CCB use was treated as time-varying covariate was also performed to address immortal time bias. 17,622 (29.6%) H. pylori eradicated patients with hypertension were included. During a median follow-up of 8.6 years, 105 (0.6%) developed GC. After PS matching, CCBs were associated with a lower GC risk (HR 0.56; 95% CI 0.32-0.97). Time-dependent analysis showed consistent result (aHR 0.50; 95% CI 0.33-0.75). A longer duration of CCB use was associated with even lower GC risk (adjusted HR [aHR] 0.69; 95% CI 0.61-0.79 for every 1-year increase in use). Long-acting CCBs (aHR 0.47;95% CI 0.29-0.76) and dihydropyridines (aHR 0.49;95% CI 0.32-0.73) conferred greater benefit than shorting-acting ones (aHR 0.60;95% CI 0.36-1.03) and non-dihydropyridines (aHR 0.76;95% CI 0.24-2.48). The aHR was 0.57 (95% CI 0.34-0.97) for non-cardia and 0.59 (95% CI 0.27-1.31) for cardia cancer. Use of CCBs was associated with lower risk of GC development in H. pylori-eradicated patients, in a duration- and dose-response manner. This article is protected by copyright. All rights reserved.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,
 BACKGROUND  Cardiogenic shock (CS) and low cardiac output syndrome (LCOS) are potentially life-threatening complications of acute myocardial infarction (AMI), heart failure (HF) or cardiac surgery. While there is solid evidence for the treatment of other cardiovascular diseases of acute onset, treatment strategies in haemodynamic instability due to CS and LCOS remains less robustly supported by the given scientific literature. Therefore, we have analysed the current body of evidence for the treatment of CS or LCOS with inotropic and/or vasodilating agents. This is the second update of a Cochrane review originally published in 2014. OBJECTIVES  Assessment of efficacy and safety of cardiac care with positive inotropic agents and vasodilator agents in CS or LCOS due to AMI, HF or after cardiac surgery. SEARCH METHODS  We conducted a search in CENTRAL, MEDLINE, Embase and CPCI-S Web of Science in October 2019. We also searched four registers of ongoing trials and scanned reference lists and contacted experts in the field to obtain further information. No language restrictions were applied. SELECTION CRITERIA  Randomised controlled trials (RCTs) enrolling patients with AMI, HF or cardiac surgery complicated by CS or LCOS. DATA COLLECTION AND ANALYSIS  We used standard methodological procedures according to Cochrane standards. MAIN RESULTS  We identified 19 eligible studies including 2385 individuals (mean or median age range 56 to 73 years) and three ongoing studies. We categorised studies into 11 comparisons, all against standard cardiac care and additional other drugs or placebo. These comparisons investigated the efficacy of levosimendan versus dobutamine, enoximone or placebo; enoximone versus dobutamine, piroximone or epinephrine-nitroglycerine; epinephrine versus norepinephrine or norepinephrine-dobutamine; dopexamine versus dopamine; milrinone versus dobutamine and dopamine-milrinone versus dopamine-dobutamine. All trials were published in peer-reviewed journals, and analyses were done by the intention-to-treat (ITT) principle. Eighteen of 19 trials were small with only a few included participants. An acknowledgement of funding by the pharmaceutical industry or missing conflict of interest statements occurred in nine of 19 trials. In general, confidence in the results of analysed studies was reduced due to relevant study limitations (risk of bias), imprecision or indirectness. Domains of concern, which showed a high risk in more than 50% of included studies, encompassed performance bias (blinding of participants and personnel) and bias affecting the quality of evidence on adverse events. All comparisons revealed uncertainty on the effect of inotropic/vasodilating drugs on all-cause mortality with a low to very low quality of evidence. In detail, the findings were  levosimendan versus dobutamine (short-term mortality  RR 0.60, 95% CI 0.36 to 1.03; participants = 1701; low-quality evidence; long-term mortality  RR 0.84, 95% CI 0.63 to 1.13; participants = 1591; low-quality evidence); levosimendan versus placebo (short-term mortality  no data available; long-term mortality  RR 0.55, 95% CI 0.16 to 1.90; participants = 55; very low-quality evidence); levosimendan versus enoximone (short-term mortality  RR 0.50, 0.22 to 1.14; participants = 32; very low-quality evidence; long-term mortality  no data available); epinephrine versus norepinephrine-dobutamine (short-term mortality  RR 1.25; 95% CI 0.41 to 3.77; participants = 30; very low-quality evidence; long-term mortality  no data available); dopexamine versus dopamine (short-term mortality  no deaths in either intervention arm; participants = 70; very low-quality evidence; long-term mortality  no data available); enoximone versus dobutamine (short-term mortality RR 0.21; 95% CI 0.01 to 4.11; participants = 27; very low-quality evidence; long-term mortality  no data available); epinephrine versus norepinephrine (short-term mortality  RR 1.81, 0.89 to 3.68; participants = 57; very low-quality evidence; long-term mortality  no data available); and dopamine-milrinone versus dopamine-dobutamine (short-term mortality  RR 1.0, 95% CI 0.34 to 2.93; participants = 20; very low-quality evidence; long-term mortality  no data available). No information regarding all-cause mortality were available for the comparisons milrinone versus dobutamine, enoximone versus piroximone and enoximone versus epinephrine-nitroglycerine. AUTHORS&#39; CONCLUSIONS  At present, there are no convincing data supporting any specific inotropic or vasodilating therapy to reduce mortality in haemodynamically unstable patients with CS or LCOS. Considering the limited evidence derived from the present data due to a high risk of bias and imprecision, it should be emphasised that there is an unmet need for large-scale, well-designed randomised trials on this topic to close the gap between daily practice in critical care of cardiovascular patients and the available evidence. In light of the uncertainties in the field, partially due to the underlying methodological flaws in existing studies, future RCTs should be carefully designed to potentially overcome given limitations and ultimately define the role of inotropic agents and vasodilator strategies in CS and LCOS.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 PURPOSE  We sought to evaluate the behavior of cardiac mechanical synchrony as measured by phase SD (PSD) derived from gated MPI SPECT (gSPECT) in patients with super-response after CRT and to evaluate the clinical and imaging characteristics associated with super-response. METHODS  158 subjects were evaluated with gSPECT before and 6 months after CRT. Patients with an improvement of LVEF &gt; 15% and NYHA class I/II or reduction in LV end-systolic volume &gt; 30% and NYHA class I/II were labeled as super-responders (SR). RESULTS  34 patients were classified as super-responders (22%) and had lower PSD (32 degrees +/- 17 degrees ) at 6 months after CRT compared to responders (45 degrees +/- 24 degrees ) and non-responders 46 degrees +/- 28 degrees (P = .02 for both comparisons). Regression analysis identified predictors independently associated with super-response to CRT  absence of previous history of CAD (odds ratio 18.7; P = .002), absence of diabetes mellitus (odds ratio 13; P = .03), and history of hypertension (odds ratio .2; P = .01). CONCLUSION  LV dyssynchrony after CRT implantation, but not at baseline, was significantly better among super-responders compared to non-super-responders. The absence of diabetes, absence of CAD, and history of hypertension were independently associated with super-response after CRT.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,
 BACKGROUND  The use of myocardial perfusion imaging (MPI) in the management of coronary artery disease (CAD) is well established. Although prior studies have shown disparities in the use of invasive angiography in patients with acute MI, data on factors affecting referral to angiography post-MPI are lacking. We sought to evaluate the primary determinants of referral to invasive angiography post-MPI and specifically assess the role of non-traditional non-clinical factors such as race/ethnicity, socioeconomic factors, insurance status, and marital status. METHODS  All patients without known CAD who underwent stress SPECT MPI over 15 years were reviewed and the performance of coronary angiography within 90 days of their MPI was recorded. Multiple factors were analyzed for an association with referral to angiography, including exercise and MPI results, baseline demographics, traditional cardiac risk factors, and non-traditional factors such as ethnicity, insurance, marital and socioeconomic status. In a secondary analysis, these factors were assessed with regard to abnormal MPI results. RESULTS  Out of 27,895 total patients, 2,150 (7.7%) underwent invasive coronary angiography. On multivariate analysis, inpatient location, positive ECG response, and abnormal MPI results were the strongest predictors of angiography. Non-traditional factors such as race/ethnicity and insurance status had a significant association with referral to angiography with Caucasians (OR 1.42, 95% CI 1.18-1.71, P &lt; .0001) and those with private insurance (OR 1.35, 95% CI 1.13-1.62, P = .001) or Medicare (OR 1.30, 95% CI 1.08-1.56, P = .006) having higher rates of angiography despite controlling for traditional risk factors and test results. CONCLUSION  Our study results indicate that non-traditional factors such as race/ethnicity and insurance status influence patient management decisions and impact the performance of downstream cardiac invasive testing after stress MPI. Higher rates of angiography in Caucasians, privately insured and Medicare patients were seen despite controlling for traditional risk factors and abnormal test results. Further research is needed to better understand these disparities, especially in the current healthcare environment.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,
 BACKGROUND  The use of myocardial perfusion imaging (MPI) in the management of coronary artery disease (CAD) is well established. Although prior studies have shown disparities in the use of invasive angiography in patients with acute MI, data on factors affecting referral to angiography post-MPI are lacking. We sought to evaluate the primary determinants of referral to invasive angiography post-MPI and specifically assess the role of non-traditional non-clinical factors such as race/ethnicity, socioeconomic factors, insurance status, and marital status. METHODS  All patients without known CAD who underwent stress SPECT MPI over 15 years were reviewed and the performance of coronary angiography within 90 days of their MPI was recorded. Multiple factors were analyzed for an association with referral to angiography, including exercise and MPI results, baseline demographics, traditional cardiac risk factors, and non-traditional factors such as ethnicity, insurance, marital and socioeconomic status. In a secondary analysis, these factors were assessed with regard to abnormal MPI results. RESULTS  Out of 27,895 total patients, 2,150 (7.7%) underwent invasive coronary angiography. On multivariate analysis, inpatient location, positive ECG response, and abnormal MPI results were the strongest predictors of angiography. Non-traditional factors such as race/ethnicity and insurance status had a significant association with referral to angiography with Caucasians (OR 1.42, 95% CI 1.18-1.71, P &lt; .0001) and those with private insurance (OR 1.35, 95% CI 1.13-1.62, P = .001) or Medicare (OR 1.30, 95% CI 1.08-1.56, P = .006) having higher rates of angiography despite controlling for traditional risk factors and test results. CONCLUSION  Our study results indicate that non-traditional factors such as race/ethnicity and insurance status influence patient management decisions and impact the performance of downstream cardiac invasive testing after stress MPI. Higher rates of angiography in Caucasians, privately insured and Medicare patients were seen despite controlling for traditional risk factors and abnormal test results. Further research is needed to better understand these disparities, especially in the current healthcare environment.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,
 BACKGROUND  The use of myocardial perfusion imaging (MPI) in the management of coronary artery disease (CAD) is well established. Although prior studies have shown disparities in the use of invasive angiography in patients with acute MI, data on factors affecting referral to angiography post-MPI are lacking. We sought to evaluate the primary determinants of referral to invasive angiography post-MPI and specifically assess the role of non-traditional non-clinical factors such as race/ethnicity, socioeconomic factors, insurance status, and marital status. METHODS  All patients without known CAD who underwent stress SPECT MPI over 15 years were reviewed and the performance of coronary angiography within 90 days of their MPI was recorded. Multiple factors were analyzed for an association with referral to angiography, including exercise and MPI results, baseline demographics, traditional cardiac risk factors, and non-traditional factors such as ethnicity, insurance, marital and socioeconomic status. In a secondary analysis, these factors were assessed with regard to abnormal MPI results. RESULTS  Out of 27,895 total patients, 2,150 (7.7%) underwent invasive coronary angiography. On multivariate analysis, inpatient location, positive ECG response, and abnormal MPI results were the strongest predictors of angiography. Non-traditional factors such as race/ethnicity and insurance status had a significant association with referral to angiography with Caucasians (OR 1.42, 95% CI 1.18-1.71, P &lt; .0001) and those with private insurance (OR 1.35, 95% CI 1.13-1.62, P = .001) or Medicare (OR 1.30, 95% CI 1.08-1.56, P = .006) having higher rates of angiography despite controlling for traditional risk factors and test results. CONCLUSION  Our study results indicate that non-traditional factors such as race/ethnicity and insurance status influence patient management decisions and impact the performance of downstream cardiac invasive testing after stress MPI. Higher rates of angiography in Caucasians, privately insured and Medicare patients were seen despite controlling for traditional risk factors and abnormal test results. Further research is needed to better understand these disparities, especially in the current healthcare environment.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-magenta-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">arrhythm</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">tricuspid</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Arrhythmia,Heart failure,Diseases of arteries,
 AIMS  Cisplatin-based chemotherapy (CBCT) is essential in the treatment of metastatic testicular cancer (TC) but has been associated with long-term risk of cardiovascular morbidity and mortality. Furthermore, cisplatin can be detected in the body decades after treatment. We aimed to evaluate the long-term impact of CBCT on cardiac function and morphology in TC survivors 30 years after treatment. METHODS AND RESULTS  TC survivors treated with CBCT (1980-94) were recruited from the longitudinal Norwegian Cancer Study in Testicular Cancer Survivors and compared with a control group matched for sex, age, smoking status, and heredity for coronary artery disease. All participants underwent laboratory tests, blood pressure measurement, and 2D and 3D echocardiography including 2D speckle-tracking strain analyses. Ninety-four TC survivors, on average 60 +/- 9 years old, received a median cumulative cisplatin dose of 780 mg (IQR 600-800). Compared with controls, TC survivors more frequently used anti-hypertensive (55% vs. 24%, P &lt; 0.001) and lipid-lowering medication (44% vs. 18%, P &lt; 0.001). TC survivors had worse diastolic function parameters with higher E/e&#39;-ratio (9.8 +/- 3.2 vs. 7.7 +/- 2.5, P &lt; 0.001), longer mitral deceleration time (221 +/- 69 vs. 196 +/- 57ms, P &lt; 0.01), and higher maximal tricuspid regurgitation velocity (25 +/- 7 vs. 21 +/- 4 m/s, P = 0.001). The groups did not differ in left or right ventricular systolic function, prevalence of arrhythmias, or valvular heart disease. Cumulative cisplatin dose did not correlate with cardiac parameters. CONCLUSION  No signs of overt or subclinical reduction in systolic function were identified. Long-term cardiovascular adverse effects three decades after CBCT may be limited to metabolic dysfunction and worse diastolic function in TC survivors.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-magenta-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">arrhythm</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">tricuspid</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Arrhythmia,Heart failure,Diseases of arteries,
 AIMS  Cisplatin-based chemotherapy (CBCT) is essential in the treatment of metastatic testicular cancer (TC) but has been associated with long-term risk of cardiovascular morbidity and mortality. Furthermore, cisplatin can be detected in the body decades after treatment. We aimed to evaluate the long-term impact of CBCT on cardiac function and morphology in TC survivors 30 years after treatment. METHODS AND RESULTS  TC survivors treated with CBCT (1980-94) were recruited from the longitudinal Norwegian Cancer Study in Testicular Cancer Survivors and compared with a control group matched for sex, age, smoking status, and heredity for coronary artery disease. All participants underwent laboratory tests, blood pressure measurement, and 2D and 3D echocardiography including 2D speckle-tracking strain analyses. Ninety-four TC survivors, on average 60 +/- 9 years old, received a median cumulative cisplatin dose of 780 mg (IQR 600-800). Compared with controls, TC survivors more frequently used anti-hypertensive (55% vs. 24%, P &lt; 0.001) and lipid-lowering medication (44% vs. 18%, P &lt; 0.001). TC survivors had worse diastolic function parameters with higher E/e&#39;-ratio (9.8 +/- 3.2 vs. 7.7 +/- 2.5, P &lt; 0.001), longer mitral deceleration time (221 +/- 69 vs. 196 +/- 57ms, P &lt; 0.01), and higher maximal tricuspid regurgitation velocity (25 +/- 7 vs. 21 +/- 4 m/s, P = 0.001). The groups did not differ in left or right ventricular systolic function, prevalence of arrhythmias, or valvular heart disease. Cumulative cisplatin dose did not correlate with cardiac parameters. CONCLUSION  No signs of overt or subclinical reduction in systolic function were identified. Long-term cardiovascular adverse effects three decades after CBCT may be limited to metabolic dysfunction and worse diastolic function in TC survivors.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-magenta-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">arrhythm</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">tricuspid</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Arrhythmia,Heart failure,Diseases of arteries,
 AIMS  Cisplatin-based chemotherapy (CBCT) is essential in the treatment of metastatic testicular cancer (TC) but has been associated with long-term risk of cardiovascular morbidity and mortality. Furthermore, cisplatin can be detected in the body decades after treatment. We aimed to evaluate the long-term impact of CBCT on cardiac function and morphology in TC survivors 30 years after treatment. METHODS AND RESULTS  TC survivors treated with CBCT (1980-94) were recruited from the longitudinal Norwegian Cancer Study in Testicular Cancer Survivors and compared with a control group matched for sex, age, smoking status, and heredity for coronary artery disease. All participants underwent laboratory tests, blood pressure measurement, and 2D and 3D echocardiography including 2D speckle-tracking strain analyses. Ninety-four TC survivors, on average 60 +/- 9 years old, received a median cumulative cisplatin dose of 780 mg (IQR 600-800). Compared with controls, TC survivors more frequently used anti-hypertensive (55% vs. 24%, P &lt; 0.001) and lipid-lowering medication (44% vs. 18%, P &lt; 0.001). TC survivors had worse diastolic function parameters with higher E/e&#39;-ratio (9.8 +/- 3.2 vs. 7.7 +/- 2.5, P &lt; 0.001), longer mitral deceleration time (221 +/- 69 vs. 196 +/- 57ms, P &lt; 0.01), and higher maximal tricuspid regurgitation velocity (25 +/- 7 vs. 21 +/- 4 m/s, P = 0.001). The groups did not differ in left or right ventricular systolic function, prevalence of arrhythmias, or valvular heart disease. Cumulative cisplatin dose did not correlate with cardiac parameters. CONCLUSION  No signs of overt or subclinical reduction in systolic function were identified. Long-term cardiovascular adverse effects three decades after CBCT may be limited to metabolic dysfunction and worse diastolic function in TC survivors.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Ischemia,Heart failure,
 BACKGROUND  Nearly half of people with HIV in the United States are 50 years or older, and this proportion is growing. Between 2012 and 2016, the largest percent increase in the prevalence rate of HIV was among people aged 65 and older, the eligibility age for Medicare coverage for individuals without a disability or other qualifying condition. Previous work suggests that older people with HIV may have higher rates of chronic conditions and develop them more rapidly than older people who do not have HIV. This study compared the health status of older people with HIV with the older US population not living with HIV by comparing  (1) mortality; (2) prevalence of certain conditions, and (3) incidence of these conditions with increasing age. METHODS AND FINDINGS  We used a sample of Medicare beneficiaries aged 65 and older from the Medicare Master Beneficiary Summary File for the years 2011 to 2016, including 100% of individuals with HIV (N = 43,708), as well as a random 1% sample of individuals without diagnosed HIV (N = 1,029,518). We conducted a survival analysis using a Cox proportional hazards model to assess mortality and to determine the need to adjust for differential mortality in our analyses of the incidence of certain chronic conditions. These results showed that Medicare beneficiaries living with HIV have a significantly higher hazard of mortality compared to older people without diagnosed HIV (3.6 times the hazard). We examined the prevalence of these conditions using logistic regression analysis and found that people with HIV have a statistically significant higher odds of depression, chronic kidney disease, chronic obstructive pulmonary disease (COPD), osteoporosis, hypertension, ischemic heart disease, diabetes, chronic hepatitis, end-stage liver disease, lung cancer, and colorectal cancer. To look at the rate at which older people are diagnosed with conditions as they age, we used a Fine-Gray competing risk model and showed that for individuals without diagnosis of a given condition at age 65, the future incidence of that condition over the remaining study period was higher for people with HIV even after adjusting for differential hazard of mortality and for other demographic characteristics. Many of these results also varied by personal characteristics including Medicaid dual enrollment, sex, and race and ethnicity, as well as by condition. CONCLUSIONS  Increasing access to care and improving health outcomes for people with HIV is a critical goal of the National HIV/AIDS Strategy 2020. It is important for clinicians and policymakers to be aware that despite significant advances in the treatment and care of people with HIV, older people with HIV have a higher odds of having multiple chronic conditions at any point in time, a higher incidence of new diagnoses of these conditions over time, and a higher hazard of mortality than Medicare beneficiaries without HIV.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,
 BACKGROUND  An accurate prediction of tissue outcome in acute ischemic stroke patients is of high interest for treatment decision making. To date, various machine learning models have been proposed that combine multi-parametric imaging data for this purpose. However, most of these machine learning models were trained using voxel information extracted from the whole brain, without taking differences in susceptibility to ischemia into account that exist between brain regions. The aim of this study was to develop and evaluate a local tissue outcome prediction approach, which makes predictions using locally trained machine learning models and thus accounts for regional differences. MATERIAL AND METHODS  Multi-parametric MRI data from 99 acute ischemic stroke patients were used for the development and evaluation of the local tissue outcome prediction approach. Diffusion (ADC) and perfusion parameter maps (CBF, CBV, MTT, Tmax) and corresponding follow-up lesion masks for each patient were registered to the MNI brain atlas. Logistic regression (LR) and random forest (RF) models were trained employing a local approach, which makes predictions using models individually trained for each specific voxel position using the corresponding local data. A global approach, which uses a single model trained using all voxels of the brain, was used for comparison. Tissue outcome predictions resulting from the global and local RF and LR models, as well as a combined (hybrid) approach were quantitatively evaluated and compared using the area under the receiver operating characteristic curve (ROC AUC), the Dice coefficient, and the sensitivity and specificity metrics. RESULTS  Statistical analysis revealed the highest ROC AUC and Dice values for the hybrid approach. With 0.872 (ROC AUC; LR) and 0.353 (Dice; RF), these values were significantly higher (p &lt; 0.01) than the values of the two other approaches. In addition, the local approach achieved the highest sensitivity of 0.448 (LR). Overall, the hybrid approach was only outperformed in sensitivity (LR) by the local approach and in specificity by both other approaches. However, in these cases the effect sizes were comparatively small. CONCLUSION  The results of this study suggest that using locally trained machine learning models can lead to better lesion outcome prediction results compared to a single global machine learning model trained using all voxel information independent of the location in the brain.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 OBJECTIVE  We wished to determine the prevalence, etiology, presentation, and available management strategies for primary adrenal insufficiency (PAI) in South Africa (SA), hypothesizing a prevalence greater than the described 3.1 per million. There is great inequity in healthcare allocation, as two parallel healthcare systems exist, potentially modifying PAI patients&#39; clinical profiles, private being better resourced than public healthcare. METHODS  An online survey of physicians&#39; experience relating to PAI. RESULTS  The physicians were managing 811 patients, equal to a prevalence of 14.2 per million. Likely causes of PAI in public/ academic vs private settings included  AIDS-related [304 (44.8%) vs 5 (3.8%); p&lt;0.001], tuberculosis [288 (42.5%) vs 8 (6.0%); p&lt;0.001], autoimmune disease [50 (7.4%) vs 88 (66.2%); p&lt;0.001], malignancy [27 (4.0%) vs 7 (5.3%); p = 0.500], genetic including adrenoleukodystrophy (ALD) [5 (0.7%) vs 16 (12.0%); p&lt;0.001], respectively. Overall, more patients presented with nausea [101 (74.3%) and vomiting 89 (65.9%), than diarrhoea 76 (58.9%); p = 0.008 and 126 (15.5%) in adrenal crisis. Features suggestive of a crisis were hypoglycaemia [40 (78.4%) vs 42 (48.8%); p = 0.001], shock [36 (67.9%) vs 31(36.9%); p&lt;0.001], and loss of consciousness [25 (52.1%) vs 27 (32.9%); p = 0.031]. Greater unavailability of antibody testing in the public vs. the private sector [32 (66.7%) vs 30 (32.1%); p = 0.001], [serum-ACTH 25 (52.1%) vs 16 (19.5%); p&lt;0.001] and glucocorticoids were [26 (54.2%) vs 33 (40.2%); p = 0.015]. Many patients, 389(66.7%) were not using identification, indicating that they need steroids in an emergency. CONCLUSION  A survey of South African physicians suggests a higher prevalence than previously reported. Patients presented with typical symptoms, and 15.5% presented in adrenal crisis. Significant disparities in the availability of physicians&#39; expertise, diagnostic resources, and management options were noted in the public versus private settings. Greater awareness among health practitioners to timeously diagnose PAI is required to prevent a life-threatening outcome.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,
 BACKGROUND  Due to an aging population and the increasing proportion of patients with various comorbidities, the number of patients with acute ischemic heart disease (AIHD) who present to the emergency department (ED) with atypical chest pain is increasing. The aim of this study was to develop and validate a prediction model for AIHD in patients with atypical chest pain. METHODS AND RESULTS  A chest pain workup registry, ED administrative database, and clinical data warehouse database were analyzed and integrated by using nonidentifiable key factors to create a comprehensive clinical dataset in a single academic ED from 2014 to 2018. Demographic findings, vital signs, and routine laboratory test results were assessed for their ability to predict AIHD. An extreme gradient boosting (XGB) model was developed and evaluated, and its performance was compared to that of a single-variable model and logistic regression model. The area under the receiver operating characteristic curve (AUROC) was calculated to assess discrimination. A calibration plot and partial dependence plots were also used in the analyses. Overall, 4,978 patients were analyzed. Of the 3,833 patients in the training cohort, 453 (11.8%) had AIHD; of the 1,145 patients in the validation cohort, 166 (14.5%) had AIHD. XGB, troponin (single-variable), and logistic regression models showed similar discrimination power (AUROC [95% confidence interval]  XGB model, 0.75 [0.71-0.79]; troponin model, 0.73 [0.69-0.77]; logistic regression model, 0.73 [0.70-0.79]). Most patients were classified as non-AIHD; calibration was good in patients with a low predicted probability of AIHD in all prediction models. Unlike in the logistic regression model, a nonlinear relationship-like threshold and U-shaped relationship between variables and the probability of AIHD were revealed in the XGB model. CONCLUSION  We developed and validated an AIHD prediction model for patients with atypical chest pain by using an XGB model.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Ischemia,Diseases of arteries,Coagulopathies,
 To elucidate how variants in genetic risk loci previously implicated in Alzheimer&#39;s Disease (AD) and/or frontotemporal dementia (FTD) contribute to expression of disease phenotypes, a phenome-wide association study was performed in two waves. In the first wave, we explored clinical traits associated with thirteen genetic variants previously reported to be linked to disease risk using both the 23andMe and UKB cohorts. We tested 30 additional AD variants in UKB cohort only in the second wave. APOE variants defining epsilon2/epsilon3/epsilon4 alleles and rs646776 were identified to be significantly associated with metabolic/cardiovascular and longevity traits. APOE variants were also significantly associated with neurological traits. ABI3 variant rs28394864 was significantly associated with cardiovascular (e.g. (hypertension, ischemic heart disease, coronary atherosclerosis, angina) and immune-related trait asthma. Both APOE variants and CLU variant were significantly associated with nearsightedness. HLA- DRB1 variant was associated with diseases with immune-related traits. Additionally, variants from 10+ AD genes (BZRAP1-AS1, ADAMTS4, ADAM10, APH1B, SCIMP, ABI3, SPPL2A, ZNF232, GRN, CD2AP, and CD33) were associated with hematological measurements such as white blood cell (leukocyte) count, monocyte count, neutrophill count, platelet count, and/or mean platelet (thrombocyte) volume (an autoimmune disease biomarker). Many of these genes are expressed specifically in microglia. The associations of ABI3 variant with cardiovascular and immune-related traits are one of the novel findings from this study. Taken together, it is evidenced that at least some AD and FTD variants are associated with multiple clinical phenotypes and not just dementia. These findings were discussed in the context of causal relationship versus pleiotropy via Mendelian randomization analysis.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Diseases of arteries,
 BACKGROUND  Coronavirus disease 2019 (COVID-19) has spread to the world. Whether there is an association between lifestyle behaviors and the acquisition of COVID-19 remains unclear. METHODS  In this case-control study, we recruited 105 patients with SARS-CoV-2 infection as a case group from the Wuhan Tongji Hospital (Wuhan, China). For each case two control subjects were recruited. Participants were randomly selected from communities in Wuhan and matched for sex, age (+/- 2yrs), and pre-existing comorbidities (hypertension and diabetes). RESULTS  A total of 105 patients diagnosed with COVID-19 and 210 controls were included. Compared with control group, the case group had higher proportions of lack of sleep (30.5% vs. 14.8%, P = 0.001) and increased physical activities (56.2% vs. 32.9%, P &lt; 0.001). And patients in the case group were more likely to have alopecia (28.6% vs. 10.0%, P &lt; 0.001) than people from the control group. Overall, we found that lack of sleep [adjusted odds ratio (OR) 1.56, 95% confidence interval (CI) 1.03-2.39)], physical activities (&gt;/= 5 times a week) (adjusted OR 2.05, 95%CI 1.39-3.02) and alopecia (adjusted OR 1.73, 95%CI 1.13-2.66) were independent risk factors for COVID-19 infection. Conversely, low-dose alcohol intake (&lt;100g alcohol per week), hand hygiene, and fruits intake (daily) were significantly associated with a decrease in morbidity. CONCLUSIONS  Individual lifestyle behaviors and health status can affect the occurrence of COVID-19.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 INTRODUCTION  Indigo naturalis (IN) is a blue pigment extracted from Assam indigo and other plants and has been confirmed to be highly effective for ulcerative colitis (UC) treatment in several clinical studies. OBJECTIVE  We conducted a multicenter double-blind study to confirm the efficacy and safety of short-term IN administration. METHODS  A multicenter, randomized controlled trial was conducted between December 2015 and October 2018 in our facilities. Forty-six patients with mild to moderate active UC (Lichtiger index  5-10) were randomly assigned to the IN group or the placebo group and received 5 capsules (500 mg) twice a day for 2 weeks. We investigated the efficacy according to blood tests and the Lichtiger index before and after administration, and we also examined adverse events. RESULTS  The analysis included 42 patients (20 males, 22 females) with an average age of 45 years. Nineteen patients were assigned to the placebo group, and 23 were assigned to the IN group. After treatment administration, in the placebo group, no change in the Lichtiger index was observed (7.47 to 6.95, p = 0.359), and hemoglobin was significantly reduced (12.7 to 12.4, p = 0.031), while in the IN group, the Lichtiger index (9.04 to 4.48, p = 0.001) and albumin (4.0 to 4.12, p = 0.022) improved significantly. Mild headaches were observed in 5 patients and 1 patient in the IN and placebo groups, respectively. CONCLUSIONS  Short-term administration of IN is highly effective without serious adverse events such as pulmonary hypertension or intussusception and may prevent the occurrence of serious adverse events.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Ischemia,Heart failure,Coagulopathies,
 The COVID-19 is rapidly scattering worldwide, and the number of cases in the Eastern Mediterranean Region is rising. Thus, there is a need for immediate targeted actions. We designed a longitudinal study in a hot outbreak zone to analyze the serial findings between infected patients for detecting temporal changes from February 2020. In a hospital-based open-cohort study, patients are followed from admission until one year from their discharge (the 1st, 4th, 12th weeks, and the first year). The patient recruitment phase finished at the end of August 2020, and the follow-up continues by the end of August 2021. The measurements included demographic, socio-economics, symptoms, health service diagnosis and treatment, contact history, and psychological variables. The signs improvement, death, length of stay in hospital were considered primary, and impaired pulmonary function and psychotic disorders were considered main secondary outcomes. Moreover, clinical symptoms and respiratory functions are being determined in such follow-ups. Among the first 600 COVID-19 cases, 490 patients with complete information (39% female; the average age of 57+/-15 years) were analyzed. Seven percent of these patients died. The three main leading causes of admission were  fever (77%), dry cough (73%), and fatigue (69%). The most prevalent comorbidities between COVID-19 patients were hypertension (35%), diabetes (28%), and ischemic heart disease (14%). The percentage of primary composite endpoints (PCEP), defined as death, the use of mechanical ventilation, or admission to an intensive care unit was 18%. The Cox Proportional-Hazards Model for PCEP indicated the following significant risk factors  Oxygen saturation &lt; 80% (HR = 6.3; [CI 95%  2.5,15.5]), lymphopenia (HR = 3.5; [CI 95%  2.2,5.5]), Oxygen saturation 80%-90% (HR = 2.5; [CI 95%  1.1,5.8]), and thrombocytopenia (HR = 1.6; [CI 95%  1.1,2.5]). This long-term prospective Cohort may support healthcare professionals in the management of resources following this pandemic.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Coagulopathies,
 The real-world status of proton pump inhibitor (PPI) use in patients with atrial fibrillation (AF) receiving antithrombotic treatment is largely unknown. The All Nippon AF In the Elderly (ANAFIE) Registry, a prospective, multicenter, observational study, aimed to determine treatment patterns, risk factors, and outcomes among elderly (aged &gt;/=75 years) Japanese non-valvular AF (NVAF) patients in the real-world clinical setting. The present subanalysis of the ANAFIE Registry determined the PPI prescription status of 32,490 elderly Japanese NVAF patients. Patients were stratified by PPI use (PPI+) or no PPI use (PPI-). Risk scores for stroke (CHADS2, CHA2DS2-VASc) and bleeding (HAS-BLED), anticoagulant use, time in therapeutic range (TTR) for warfarin, and anticoagulant/antiplatelet combination use were evaluated. PPIs were used in 11,981 (36.9%) patients. Compared with the PPI- group, the PPI+ group included a greater proportion of female patients (45.2% vs 41.3%; P &lt;0.0001) and had significantly higher CHADS2, CHA2DS2-VASc, and HAS-BLED scores (P &lt;0.0001 for each) as well as higher prevalences of several comorbidities. In the PPI+ group, 54.6% of patients did not have gastrointestinal (GI) disorders and were likely prescribed a PPI to prevent GI bleeding events. Most of the patients with a GI disorder in the PPI+ group had reflux esophagitis. Compared with patients not receiving anticoagulants, a significantly higher proportion of patients receiving anticoagulants received PPIs. For patients receiving anticoagulants, antiplatelet drugs, and both drugs, rates of PPI use were 34.1%, 44.1%, and 53.5%, respectively (P &lt;0.01). Although the rate of PPI use was the highest for NVAF patients receiving both antiplatelet and anticoagulants, no clear differences were observed in the anticoagulants used. These data suggest that PPIs were actively prescribed in high-risk cases and may have been used to prevent GI bleeding among elderly NVAF patients receiving antithrombotic drugs. Trial registration  UMIN000024006.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">microvascul</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Inflammatory diseases,Diseases of arteries,
 AIMS  Coronary microvascular dysfunction (CMD) carries a poor cardiovascular prognosis and may explain angina in women without obstructive coronary artery disease (CAD). Currently, no evidence-based treatment for CMD exists. We investigated whether reducing cardiovascular risk factors improves symptoms and microvascular function in women with non-endothelial dependent CMD and no obstructive CAD. METHODS  We randomized 62 women aged 40-75, with body mass index (BMI) &gt;25 kg/m2, angina &gt;/=monthly, and coronary flow velocity reserve (CFVR) &lt;/=2.5 to a 24-week intervention comprising low energy diet, exercise training, and optimized treatment of hypertension, dyslipidemia and diabetes or to control. Patients were assessed before randomization and after 24 weeks. Primary outcomes were CFVR assessed by transthoracic Doppler stress-echocardiography and angina burden by Seattle Angina Questionnaire (SAQ). Secondary outcomes were exercise capacity, body composition, glycemic control, myocardial function, and anxiety and depression symptoms. RESULTS  Fifty-six participants (90%) completed the study. Median (IQR) age was 65.2 (57.1;70.7) years, BMI was 30.1 (28.4;32.7) kg/m2. The intervention resulted in relevant improvement in angina symptoms (9-21-point increase on SAQ-scales (all p&lt;0.01)) but had no effect on CFVR (p = 0.468). Mean (CI) weight loss was 9.6 (7.80;11.48) kg, (p&lt;0.0001). There was a significant mean (CI) decrease in depression symptoms = 1.16 (0.22;2.12), triglycerides = 0.52 (0.25;0.78) mmol/L, total cholesterol = 0.55 (0.12;0.98) mmol/L, and HbA1c in diabetics = 27.1 (1.60;52.6) mmol/mol but no effect on other secondary outcomes. CONCLUSION  A major weight loss and intensified risk factor control resulted in significantly improved angina burden but no improvement of coronary microvascular function among women with microvascular angina.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  Guidelines recommend reducing saturated fat (SFA) intake to decrease cardiovascular disease (CVD) risk, but there is limited evidence on scalable and effective approaches to change dietary intake, given the large proportion of the population exceeding SFA recommendations. We aimed to develop a system to provide monthly personalized feedback and healthier swaps based on nutritional analysis of loyalty card data from the largest United Kingdom grocery store together with brief advice and support from a healthcare professional (HCP) in the primary care practice. Following a hybrid effectiveness-feasibility design, we tested the effects of the intervention on SFA intake and low-density lipoprotein (LDL) cholesterol as well as the feasibility and acceptability of providing nutritional advice using loyalty card data. METHODS AND FINDINGS  The Primary Care Shopping Intervention for Cardiovascular Disease Prevention (PC-SHOP) study is a parallel randomized controlled trial with a 3 month follow-up conducted between 21 March 2018 to 16 January2019. Adults &gt;/=18 years with LDL cholesterol &gt;3 mmol/L (n = 113) were recruited from general practitioner (GP) practices in Oxfordshire and randomly allocated to &#34;Brief Support&#34; (BS, n = 48), &#34;Brief Support + Shopping Feedback&#34; (SF, n = 48) or &#34;Control&#34; (n = 17). BS consisted of a 10-minute consultation with an HCP to motivate participants to reduce their SFA intake. Shopping feedback comprised a personalized report on the SFA content of grocery purchases and suggestions for lower SFA swaps. The primary outcome was the between-group difference in change in SFA intake (% total energy intake) at 3 months adjusted for baseline SFA and GP practice using intention-to-treat analysis. Secondary outcomes included %SFA in purchases, LDL cholesterol, and feasibility outcomes. The trial was powered to detect an absolute reduction in SFA of 3% (SD3). Neither participants nor the study team were blinded to group allocation. A total of 106 (94%) participants completed the study  68% women, 95% white ethnicity, average age 62.4 years (SD 10.8), body mass index (BMI) 27.1 kg/m2 (SD 4.7). There were small decreases in SFA intake at 3 months  control = -0.1% (95% CI -1.8 to 1.7), BS = -0.7% (95% CI -1.8 to 0.3), SF = -0.9% (95% CI -2.0 to 0.2); but no evidence of a significant effect of either intervention compared with control (difference adjusted for GP practice and baseline  BS versus control = -0.33% [95% CI -2.11 to 1.44], p = 0.709; SF versus control = -0.11% [95% CI -1.92 to 1.69], p = 0.901). There were similar trends in %SFA based on supermarket purchases  control = -0.5% (95% CI -2.3 to 1.2), BS = -1.3% (95% CI -2.3 to -0.3), SF = -1.5% (95% CI -2.5 to -0.5) from baseline to follow-up, but these were not significantly different  BS versus control p = 0.379; SF versus control p = 0.411. There were small reductions in LDL from baseline to follow-up (control = -0.14 mmol/L [95% CI -0.48, 0.19), BS  -0.39 mmol/L [95% CI -0.59, -0.19], SF  -0.14 mmol/L [95% CI -0.34, 0.07]), but these were not significantly different  BS versus control p = 0.338; SF versus control p = 0.790. Limitations of this study include the small sample of participants recruited, which limits the power to detect smaller differences, and the low response rate (3%), which may limit the generalisability of these findings. CONCLUSIONS  In this study, we have shown it is feasible to deliver brief advice in primary care to encourage reductions in SFA intake and to provide personalized advice to encourage healthier choices using supermarket loyalty card data. There was no evidence of large reductions in SFA, but we are unable to exclude more modest benefits. The feasibility, acceptability, and scalability of these interventions suggest they have potential to encourage small changes in diet, which could be beneficial at the population level. TRIAL REGISTRATION  ISRCTN14279335.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  South Korea is one of the country that has succeeded in flattening the curve of new infections of COVID and second outbreak with multiple strategies from individual level to population level. The Korean government and society&#39;s response to the disease can deliver important messages to other countries suffering from the disease. OBJECTIVE  We object to provide the unique strategies and epidemiological characteristics of COVID-19 in South Korea and the summary of policies from the Korean Government. METHODS  We designed the cross-sectional study of epidemiological data published by Korea Centers for Disease Control and Prevention at September 30th, 2020. Number with detailed information of COVID-19 confirmed patients and deaths. RESULTS  Until September 30th, 2020, South Korea reported 23,889 confirmed patients and 415 deaths from COVID-19. In this study, we reported the epidemiological characteristics and transmission of the disease, and discuss the South Korean government and society&#39;s responses to COVID-19 outbreak. CONCLUSIONS  Understanding the epidemiological characteristics of the disease in Korea and the Korean government&#39;s succeeded efforts can give important lessons to other countries. CLINICALTRIAL 
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,
 We examined the effect of intravenous ascorbate administration (VitC) on exercise-induced redox balance, inflammation, exertional dyspnea, neuromuscular fatigue, and exercise tolerance in patients with chronic obstructive pulmonary disease (COPD). Eight COPD patients completed constant-load cycling (~80% of peak power output, 83+/-10W) to task-failure following intravenous VitC (2g) or saline (placebo, PL) infusion. All participants repeated the shorter of the two exercise trials (isotime), with the other infusate. Quadriceps fatigue was determined by pre- to post-exercise changes in quadriceps twitch-torque (Qtw, electrical femoral nerve stimulation). Corticospinal excitability before, during, and after exercise was assessed by changes in motor-evoked potentials triggered by transcranial magnetic stimulation. VitC increased superoxide dismutase (marker for endogenous antioxidant capacity) by 129% and mitigated C-reactive protein (marker for inflammation) in the plasma during exercise, but failed to alter the exercise-induced increase in lipid peroxidation (malondialdehyde) and free radicals (EPR-spectroscopy). While VitC did, indeed, decrease neuromuscular fatigue (Qtw PL  -29+/-5%, VitC  -23+/-6%, P&lt;0.05), there was no impact on corticospinal excitability and time to task-failure (~8min, P=0.8). Interestingly, in terms of pulmonary limitations to exercise, VitC had no effect on perceived exertional dyspnea (~8.5/10) and its determinants, including SpO2 (~92%) and respiratory muscle work (~650cmH2OYsYmin(-1)) (P&gt;0.3). Thus, although VitC facilitated indicators for antioxidant capacity, diminished inflammatory markers, and improved neuromuscular fatigue resistance, it failed to improve exertional dyspnea and cycling exercise tolerance in patients with COPD. As dyspnea is recognized to limit exercise tolerance in COPD, the otherwise beneficial effects of VitC may have been impacted by this unaltered sensation.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Diseases of arteries,
 Aging is associated with reductions in endothelial function, observations primarily reported using brachial artery ultrasound. There is growing interest in the use of peripheral artery tonometry (PAT) of microvessels in the fingertip to assess endothelial function because it is less technically demanding and has a high sensitivity and specificity for assessing coronary endothelial function. Moreover, similar to brachial artery flow mediated dilation (FMD), PAT predicts cardiovascular disease (CVD) outcomes. However, the relation between PAT and FMD have yet to be examined in the context of aging. To address this question, reactive hyperemic index (RHI) using EndoPAT and flow-mediated dilation (FMD) using brachial artery ultrasound were assessed after five minutes of forearm ischemia in twenty younger (18-40 years old; 29+/-4 years) and twenty older (60-75 years old; 65+/-4 years) healthy adult men. Higher values of both FMD and RHI indicate better endothelial function. Endothelial function assessed via brachial artery FMD was lower in older (4.8+/-2.1%), compared to younger (7.5+/-1.6%) men (p&lt;0.001). In contrast, the RHI assessed via PAT was greater in older (2.2+/-0.6), compared to younger (1.8+/-0.5) men (p=0.014). FMD and RHI were not correlated (r=-0.15; p=0.35). We conclude that PAT may not be an appropriate measure to evaluate age-associated changes in endothelial function.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-magenta-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">arrhythm</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Arrhythmia,Heart failure,Cardiomyopathy,
 Background - The X-linked Danon disease (DD) manifests by severe cardiomyopathy, myopathy, and neuropsychiatric problems. We designed this registry to generate a comprehensive picture of clinical presentations and outcome of patients with Danon disease (DD) in cardiomyopathy centers throughout Europe. Methods - Clinical and genetic data were collected in 16 cardiology centers from 8 European countries. Results - The cohort comprised 30 male and 27 female patients. The age at diagnosis was birth to 42 yr. in males and 2-65 in females. Cardiac involvement was observed in 96%. Extracardiac manifestations were prominent in males but not in females. Left ventricular (LV) hypertrophy was reported in 73% of male and 74% of female patients. LV systolic dysfunction was reported in 40% of males (who had LVEF 34+/-11%) and 59% of females (LVEF 28+/-13%). The risk of arrhythmia and heart failure (HF) were comparable among genders. The age of first HF hospitalization was lower in males (18 +/- 6 vs. 28 +/-17 yr., p&lt;0.003). HF was the leading cause of death (10/17, 59%), and LV systolic dysfunction predicted an adverse outcome. Eight males and 8 females (28%) underwent heart transplantation or received a left ventricular assist device (LVAD). Our cohort suggests better prognosis of female compared to male heart transplant recipients. Conclusions - DD presents earlier in males than females and runs a malignant course in both genders, due to cardiac complications. Cardiomyopathy features  heart failure and arrhythmia, are similar among the genders. Clinical diagnosis and management is extremely challenging in females due to phenotypic diversity and absence of extracardiac manifestations.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 OBJECTIVES  To explore the long-term (perceived) consequences of (severe pre-)eclampsia in rural Tanzania. METHODS  Women were traced for this mixed-methods study 6-7 years after the diagnosis of (severe pre-) eclampsia. Demographic and obstetric characteristics were noted, and blood pressure was recorded. Questionnaires were used to assess physical and mental health. The qualitative part consisted of semi-structured interviews (SSI). A reference group consisted of women without hypertensive disorders of pregnancy. RESULTS  Of 74 patients, 25 (34%) were available for follow-up, and 24 were included. Five (20%) had suffered from (pre-)eclampsia twice. Hypertension was more common after (pre-)eclampsia than in the reference group (29% vs 13%). Thirteen women (56%) had feelings of anxiety and depression, compared to 30% in the reference group. In SSIs, experiences during the index pregnancy were explored, as well as body functions, reproductive life course and limitations in daily functioning, which were shown to be long-lasting. CONCLUSIONS  Women who suffered from (severe pre-)eclampsia may experience long-term sequelae, including hypertension, depression and anxiety. Women lack information about their condition, and some are worried to conceive again. To address their specific needs, a strategy along the continuum of care is needed for women following a complicated pregnancy, starting with a late postnatal care visit six weeks after giving birth.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,
 BACKGROUND  Premature development of cardiovascular disease in children living with HIV-1 (CLWH) may be associated with compromised gut barrier function, microbial translocation, immune activation, systemic inflammation and endothelial activation. Biomarkers of these pathways may provide insights into pathogenesis of atherosclerotic disease in CLWH. METHODS  This was a cross-sectional study of CLWH enrolled in the multicentre Early Pediatric Initiation-Canadian Child Cure Cohort (EPIC(4) ) who were on antiretroviral therapy (ART) with undetectable viral load. Plasma biomarkers of intestinal epithelial injury [intestinal fatty acid binding protein-1 (IFABP)], systemic inflammation [tumour necrosis factor (TNF) and interleukin-6 (IL-6)] and endothelial activation [angiopoietin-2 (Ang2), soluble vascular endothelial growth factor-1 (sVEGFR1) and soluble endoglin (sEng)] were quantified by enzyme-linked immunosorbent assay. Correlation and factor analysis of biomarkers were used to examine associations between innate immune pathways. RESULTS  Among 90 CLWH, 16% of Ang2, 15% of sVEGFR1 and 23% of sEng levels were elevated relative to healthy historic controls. Pairwise rank correlations between the three markers of endothelial activation were statistically significant (rho = 0.69, rho = 0.61 and rho = 0.65, P &lt; 0.001 for all correlations). An endothelial activation index, derived by factor analysis of the three endothelial biomarkers, was correlated with TNF (rho = 0.47, P &lt; 0.001), IL-6 (rho = 0.60, P &lt; 0.001) and intestinal fatty acid binding protein-1 (rho = 0.67, P &lt; 0.001). Current or past treatment with ritonavir-boosted lopinavir (LPV/r) was associated with endothelial activation (odds ratio = 5.0, 95% CI  1.7-17, P = 0.0020). CONCLUSIONS  Endothelial activation is prevalent in CLWH despite viral suppression with combination ART and is associated with intestinal epithelial injury, systemic inflammation and treatment with LPV/r.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">microvascul</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlud</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 OBJECTIVE  We studied the effect of the glucagon-like peptide-1 receptor agonist (GLP-1RA) exenatide on skin microvascular function in patients with type 2 diabetes (T2DM) and coronary artery disease (CAD). METHODS  Thirty-five patients with T2DM, CAD and glycated hemoglobin (HbA1C) 42-86 mmol/mol were randomised to treatment with exenatide or conventional non-GLP-1 based therapy for 12 weeks. Skin microvascular function was examined in the forearm by laser Doppler fluxmetry and iontophoretic application of acetyl choline and sodium nitroprusside, and by post occlusive reactive hyperaemia (PORH) at baseline and after 12 weeks. Blood samples for fasting plasma glucose, HbA1C and lipid profile were collected. RESULTS  At 12 weeks, patients on exenatide showed reductions in HbA1C (from 63.5 +/-13 to 60.7 +/-14 mmol/mol, P=0.065), body weight (from 92.6 +/-16 to 89 +/-16 kg, P&lt;0.001) and systolic blood pressure (from 141 +/-13 to 134 +/-16 mmHg, P&lt;0.05) as compared to the conventionally treated group. There were no significant changes in skin microvascular function between or within the two groups at follow-up. CONCLUSIONS  Three months daily treatment with the GLP-1RA exenatide in T2DM patients with CAD showed no significant effects on skin microvascular function or blood glucose control, while this study confirms a reduction in body weight and blood pressure by exenatide, as compared to conventional antidiabetic drug treatment.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">cerebrovascul</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Diseases of arteries,
 Over the past several decades, it has become increasingly clear that women have distinct cardiovascular profiles compared to men. In this review, our goal is to provide an overview of the literature regarding the influences of female sex and reproductive hormones (primarily estradiol) on mechanisms of cardiovascular control relevant to regulation of blood pressure, body temperature, and cerebral blood flow. Young women tend to have lower resting blood pressure compared with men. This sex difference is reversed at menopause, when women develop higher sympathetic nerve activity and the risk of systemic hypertension increases sharply as postmenopausal women age. Vascular responses to thermal stress, including cutaneous vasodilation and vasoconstriction, are also affected by reproductive hormones in women, where estradiol appears to promote vasodilation and heat dissipation. The influence of reproductive hormones on cerebral blood flow and sex differences in the ability of the cerebral vasculature to increase its blood flow (cerebrovascular reactivity) are relatively new areas of investigation. Sex and hormonal influences on integrative blood flow regulation have further implications during challenges to physiological homeostasis, including exercise. We propose that increasing awareness of these sex-specific mechanisms is important for optimizing health care and promotion of wellness in women across the life span.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">microvascul</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">stenos</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Diseases of arteries,
 Percutaneous transluminal renal angioplasty (PTRA) has been used to treat renovascular disease (RVD), a chronic condition characterized by renal ischemia and metabolic abnormalities. Mitochondrial injury has been implicated as a central pathogenic mechanism in RVD, but whether it can be reversed by PTRA remains uncertain. We hypothesized that PTRA attenuates mitochondrial damage, renal injury, and dysfunction in pigs with coexisting renal artery stenosis (RAS) and metabolic syndrome (MetS). Four groups of pigs (n = 6 each) were studied after 16 weeks of diet-induced MetS and RAS (MetS + RAS), MetS + RAS treated 4 weeks earlier with PTRA, and Lean and MetS Sham controls. Single-kidney renal blood flow (RBF) and glomerular filtration rate (GFR) were assessed in vivo with multidetector computed tomography, and renal tubular mitochondrial structure and function and renal injury ex vivo. PTRA successfully restored renal artery patency, but mean arterial pressure remained unchanged. Stenotic kidney RBF and GFR, which fell in MetS + RAS compared to MetS, rose after PTRA. PTRA attenuated MetS + RAS-induced mitochondrial structural abnormalities in tubular cells and peritubular capillary endothelial cells, decreased mitochondrial H2 02 production, and increased renal cytochrome-c oxidase-IV activity and ATP production. PTRA also improved cortical microvascular and peritubular capillary density and ameliorated tubular injury and tubulointerstitial fibrosis in the poststenotic kidney. Importantly, renal mitochondrial damage correlated with poststenotic injury and dysfunction. Renal revascularization attenuated mitochondrial injury and improved renal hemodynamics and function in swine poststenotic kidneys. This study suggests a novel mechanism by which PTRA might be relatively effective in ameliorating mitochondrial damage and improving renal function in coexisting MetS and RAS.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 WHAT IS KNOWN  Medication non-adherence leads to negative health outcomes. Medication adherence is predicted if patients understand the necessity of medication use to control disease symptoms and progression. It could be expected then, that patients with diseases with symptoms which are managed with medications, such as chronic obstructive pulmonary disorder or gout, or diseases with high-mortality rates, such as cancer, would have higher adherence rates than asymptomatic diseases, such as hypertension. However, poor medication adherence remains problematic in both symptomatic and asymptomatic diseases. Further work is needed to explore patient experiences of medication adherence to understand the link between adherence and symptom control. OBJECTIVE  To explore patients&#39; lived experiences of medication adherence. METHODS  Participants were recruited from community pharmacies and general practices. Forty-one semi-structured interviews and three focus groups were used to collect data from patients with disease states that had different symptomatic and asymptomatic profiles. Inductive thematic analysis was used to identify key parts of the experience of using medications. RESULTS  Participants reported similar experiences of medication adherence despite having different disease symptoms. Participants said that they used medications because it was an expected part of everyday life and that medications &#39;must be needed&#39; because they had been supplied, rather than being used for a particular symptom. Participants reported short-term episodes of non-adherence were unlikely to lead to negative health outcomes but may result in negative social consequences. DISCUSSION  The findings broaden our understanding of patient experiences of medication use by indicating patients with symptomatic and asymptomatic diseases share similar experiences of medication use. The necessity to use medications appeared to come from &#39;the system&#39; of healthcare professionals, family and friends that supply and recommend medications. WHAT IS NEW  There were key similarities in experiences of medication adherence in patients with different disease states. The negative consequences of short-term episodes of non-adherence were normalized by healthcare professionals. CONCLUSION  Patients with symptomatic and asymptomatic diseases share similar experiences of medication adherence.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 WHAT IS KNOWN  Medication non-adherence leads to negative health outcomes. Medication adherence is predicted if patients understand the necessity of medication use to control disease symptoms and progression. It could be expected then, that patients with diseases with symptoms which are managed with medications, such as chronic obstructive pulmonary disorder or gout, or diseases with high-mortality rates, such as cancer, would have higher adherence rates than asymptomatic diseases, such as hypertension. However, poor medication adherence remains problematic in both symptomatic and asymptomatic diseases. Further work is needed to explore patient experiences of medication adherence to understand the link between adherence and symptom control. OBJECTIVE  To explore patients&#39; lived experiences of medication adherence. METHODS  Participants were recruited from community pharmacies and general practices. Forty-one semi-structured interviews and three focus groups were used to collect data from patients with disease states that had different symptomatic and asymptomatic profiles. Inductive thematic analysis was used to identify key parts of the experience of using medications. RESULTS  Participants reported similar experiences of medication adherence despite having different disease symptoms. Participants said that they used medications because it was an expected part of everyday life and that medications &#39;must be needed&#39; because they had been supplied, rather than being used for a particular symptom. Participants reported short-term episodes of non-adherence were unlikely to lead to negative health outcomes but may result in negative social consequences. DISCUSSION  The findings broaden our understanding of patient experiences of medication use by indicating patients with symptomatic and asymptomatic diseases share similar experiences of medication use. The necessity to use medications appeared to come from &#39;the system&#39; of healthcare professionals, family and friends that supply and recommend medications. WHAT IS NEW  There were key similarities in experiences of medication adherence in patients with different disease states. The negative consequences of short-term episodes of non-adherence were normalized by healthcare professionals. CONCLUSION  Patients with symptomatic and asymptomatic diseases share similar experiences of medication adherence.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 BACKGROUND  Cardiometabolic abnormalities are a leading cause of death among women, including women with cancer. METHODS  This study examined the association between prediagnosis cardiovascular health and total and cause-specific mortality among 12,076 postmenopausal women who developed local- or regional-stage invasive cancer in the Women&#39;s Health Initiative (WHI). Cardiovascular risk factors included waist circumference, hypertension, high cholesterol, and type 2 diabetes. Obesity-related cancers included breast cancer, colorectal cancer, endometrial cancer, kidney cancer, pancreatic cancer, ovarian cancer, stomach cancer, liver cancer, and non-Hodgkin lymphoma. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) adjusted for important predictors of survival. RESULTS  After a median follow-up of 10.0 years from the date of the cancer diagnosis, there were 3607 total deaths, with 1546 (43%) due to cancer. Most participants (62.9%) had 1 or 2 cardiometabolic risk factors, and 8.1% had 3 or 4. In adjusted models, women with 3 to 4 risk factors (vs none) had a higher risk of all-cause mortality (HR, 1.99; 95% CI, 1.73-2.30), death due to cardiovascular disease (CVD) (HR, 4.01; 95% CI, 2.88-5.57), cancer-specific mortality (HR, 1.37; 95% CI, 1.1-1.72), and other-cause mortality (HR, 2.14; 95% CI, 1.70-2.69). A higher waist circumference was associated with greater all-cause mortality (HR, 1.17; 95% CI, 1.06-1.30) and cancer-specific mortality (HR, 1.22; 95% CI, 1.04-1.42). CONCLUSIONS  Among postmenopausal women diagnosed with cancer in the WHI, cardiometabolic risk factors before the cancer diagnosis were associated with greater all-cause, CVD, cancer-specific, and other-cause mortality. These results raise hypotheses regarding potential clinical intervention strategies targeting cardiometabolic abnormalities that require future prospective studies for confirmation. LAY SUMMARY  This study uses information from the Women&#39;s Health Initiative (WHI) to find out whether cardiac risk factors are related to a greater risk of dying among older women with cancer. The WHI is the largest study of medical problems faced by older women in this country. The results show that women who have 3 or 4 risk factors are more likely to die of any cause, heart disease, or cancer in comparison with women with no risk factors. It is concluded that interventions to help to lower the burden of cardiac risk factors can have an important impact on survivorship among women with cancer.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 Pulmonary hypertension (PH) is defined as an elevated mean pulmonary artery pressure at rest (mPAP &gt;/= 25 mmHg), evaluated by right heart catheterization (RHC). The aim of the present study was to evaluate HRCT findings in relation to transthoracic echocardiographic data to better characterize PH in IPF patients and to identify a non-invasive composite index with high predictive value for PH in these patients. 37 IPF patients were enrolled in this retrospective study. All patients underwent a complete assessment for PH, including transthoracic Doppler echocardiography, HRCT scan and right heart catheterization. Right heart catheterization was done in 19 patients (51.3%) as pre-lung transplant assessment and in 18 patients (48.6%) to confirm PH, suspected on the basis of echocardiography. Twenty out of 37 patients (54%) were confirmed to have PH by RHC. Multivariate regression showed that the combination of sPAP, PA area measured by HRCT and the ratio of the diameter of the segmental artery to that of the adjacent bronchus in the apicoposterior segment of the left upper lobe was strongly correlated with mPAP (R(2) = 0.53; p = 0.0009). The ROC analysis showed that 931.6 was the ULN for PA area, with 86% sensitivity and 61% specificity (0.839 AUC); 20.34 was the ULN for the ratio of PA area to ascending aorta diameter, with 100% sensitivity and 50% specificity (0.804 AUC). The composite index proposed in the present study could help early detection of IPF patients suspected of PH requiring confirmation by RHC (if deemed clinically necessary).
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 Aberrant vascular smooth muscle cell (VSMCs) proliferation involves in the development of atherosclerosis. It reported that Long noncoding BRAF-activated noncoding RNA (BANCR) and miR-34c played opposite roles in the regulation of the proliferation of VSMCs, indicating that there might be a potential interaction between them. This study was to investigate the relationship between BANCR and miR-34c in atherosclerosis. Blood (5 ml) was obtained from 56 patients with atherosclerosis and 56 healthy volunteers after they were fasted overnight, and plasma was extracted from the blood. Human Aortic Smooth Muscle Cells (HASMCs) were used to perform in vitro cell experiments. RT-qPCR was performed to measure the expression of BANCR and miR-34c in plasma and HASMCs. Dual luciferase reporter assay detected the interaction between BANCR and miR-34c. CCK-8 assay was used to assess the effects of BANCR and miR-34c overexpression on the proliferation of HASMCs. Western blotting was used to assess the effects of BANCR and miR-34c overexpression on the protein expression of HMGB1, TNF-a and Bcl-2. In this study, we found that BANCR was upregulated, while miR-34c was downregulated in atherosclerosis. Bioinformatics analysis showed that BANCR and miR-34c could directly interact with each other. Moreover, overexpression of BANCR could decrease the expression of miR-34c in HASMCs, but overexpression of miR-34c could not affect the expression of BANCR. Furthermore, overexpression of BACNR increased miR-34c methylation, and knockdown of endogenous BANCR decreased miR-34c methylation. In addition, overexpression of BANCR reduced the effects of miR-34c on HASMCs proliferation and reversed the effects of miR-34c on HMGB1, TNF-a and Bcl-2 expression. BANCR overexpression could induce HASMCs proliferation by downregulating the miR-34c methylation. Therefore given BANCR upregulation in atherosclerosis, its expression may be considered as a novel and useful biomarker for atherosclerosis prevention and prognosis. However considering the possible effects of other underlying diseases on both BANCR expression and miR-34c in atherosclerosis, further investigation is suggested for future research.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 BACKGROUND  Optical coherence tomography showed a great ability to identify adverse features during percutaneous coronary intervention with drug-eluting stents and resulted in better clinical outcomes. The study aimed to assess the impact of optical coherence tomography on intraoperative decision-making during implantation of Absorb bioresorbable scaffolds versus everolimus drug-eluting stents. RESULTS  We performed an observational study that included 223 consecutive patients post optical coherence tomography-guided implantation of either Absorb bioresorbable scaffolds (162 patients) or everolimus drug-eluting stents (61 patients). We studied the influence of optical coherence tomography on intraoperative decision-making during implantation of bioresorbable scaffolds versus drug-eluting stents by analyzing the total rate of optical coherence tomography-dependent modifications in each device. After satisfactory angiographic results, the total rate of required intervention for optical coherence tomography detected complications was significantly higher in the bioresorbable scaffolds arm compared to drug-eluting stents arm (47.8% versus 32.9%, respectively; p = 0.019). The additional modifications encompassed further optimization in the case of device underexpansion or struts malapposition, and even stenting in the case of strut fractures, or significant edge dissection. CONCLUSIONS  Compared to drug-eluting stents, Absord scaffold was associated with a significantly higher rate of optical coherence tomography-identified intraprocedural complications necessitating further modifications. The study provides some hints on the reasons of scaffolds failure in current PCI practice; it offers a new insight for the enhancement of BRS safety and presents and adds to the growing literature for successful BRS utilization.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocardit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocard</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">cardit</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Coagulopathies,
 BACKGROUND  Staphylococcus lugdunensis is a coagulase-negative Staphylococcus species, which are weak pathogenic bacteria generally. However, the acute and severe pathogenicity of Staphylococcus lugdunensis infective endocarditis may be due to the rapid growth of large vegetation and consequent valve destruction. CASE PRESENTATION  The patient was an 81-year-old male who visited our hospital with chief complaints of low back pain and high fever. Four years before this visit, he had undergone aortic valve replacement for aortic regurgitation. He was found to be hypotensive. Although there is no heart murmur on auscultation and echocardiography revealed negative findings with aortic valve, a blood test showed increases in the white blood cell count and C-reactive protein concentration. On the next day, Gram-positive cocci were detected in a blood culture and echocardiography detected a large vegetation on the prosthetic valve with increased flow velocity. Therefore, he underwent redo aortic valve replacement emergently. Staphylococcus lugdunensis was identified in blood samples and vegetation culture. Consequently, the patient was treated with antibiotics for 5 weeks after the operation and discharged home. CONCLUSIONS  We experienced rapidly progressive prosthetic valve endocarditis caused by Staphylococcus lugdunensis. Hence, Staphylococcus lugdunensis infective endocarditis requires aggressive treatment, and the pathogenicity of this coagulase-negative Staphylococcus with high drug susceptibility should not be underestimated.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,
 Foam cell formation and inflammation in macrophages contribute to the development of atherosclerosis (AS). Clematichinenoside AR (AR) is a major active ingredient extracted from the traditional Chinese herb Clematis chinensis and has potent pharmacological effects on various diseases, including AS. However, little is known about the exact role and mechanism of AR in AS. RAW264.7 macrophages were exposed to oxidized low-density lipoprotein (ox-LDL) to induce AS in vitro. Cell viability was assessed by the CCK-8 assay. Foam cell formation was detected by Oil Red staining. Cholesterol levels were determined by corresponding commercial kits. The expression of inflammatory cytokines was detected by ELISA. Western blot and immunofluorescence assays were employed to detect the expression of corresponding genes. The results indicated that AR treatment inhibited the formation of foam cells and cholesterol accumulation but promoted cholesterol efflux by upregulating ABCA1/ABCG1 in ox-LDL-induced RAW264.7 macrophages. In addition, AR decreased the production of inflammatory cytokines by blunting the activation of the NLRP3 inflammasome and inducing autophagy. However, these effects of AR were weakened by the autophagy inhibitor bafilomycin A1 but were similar to those produced by the autophagy activator rapamycin. Collectively, our study provides novel insights into the beneficial effects of AR on promoting cholesterol efflux as well as inhibiting foam cell formation and inflammation by regulating autophagy, thus identifying AR as a promising therapeutic agent for the treatment of AS.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 PURPOSE  This study assessed the association between animal source foods (ASF) consumption and hypertension, a recognised risk factor for cardiovascular disease. Adverse effects of red and processed meat (RPM) consumption and beneficial effects of the consumption of dairy products and other ASF have been discovered separately; however, the constrained nature of food intake has been typically ignored. We assessed the effects of substituting RPM and other ASF. METHODS  We followed-up 5394 Chinese adults (age 18-60 years) at baseline using the China Health and Nutrition Survey from 2004 to 2011. Food consumption was assessed using individual-based consecutive 24-h recall and household-based food weighing approaches. Both traditional substitution analysis and substitution analysis based on compositional transformation were used to assess substitution effects. RESULTS  In total, 1267 participants were newly diagnosed with hypertension during the median follow-up time of 6.81 years (range, 2.97-6.99 years). The traditional substitution analysis found that substituting eggs for RPM was associated with a lower risk of hypertension. The compositional transformation substitution analysis revealed that replacing RPM with any other ASF was associated with a lower risk of hypertension; it implemented substitutions of one or many ASF for RPM; it also revealed different substitution effects of RPM and dairy products, and substituting dairy products for RPM was associated with reduced hypertension risks. CONCLUSION  The compositional transformation substitution analysis considers the constrained and relative nature of food consumption. It is a flexible approach to estimating substitution effects using different patterns to obtain personalised estimation effects and provide individualised dietary recommendations.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">stenos</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Diseases of arteries,
 BACKGROUND  Children with suspected renal artery stenosis (RAS) are screened with renal Doppler ultrasonography or computed tomography (CT) angiography/magnetic resonance (MR) angiography depending on institutional preference. CT angiography produces images with superior resolution, allowing higher quality multiplanar two-dimensional reformats and three-dimensional reconstructions. However, there is a paucity of data in the literature regarding the utility and diagnostic performance of renal CT angiography in pediatric RAS. OBJECTIVE  The objective of this study is to retrospectively review our experience with renal CT angiography in the diagnosis of pediatric RAS relative to digital subtraction angiography (DSA) as the reference standard. MATERIALS AND METHODS  All patients 0-18 years of age who underwent CT angiography for evaluation of RAS as a cause of hypertension between January 2012 and May 2019 were identified for the study. A total of 131 patients were identified, 23 of whom had DSA correlation. RESULTS  Twenty-three patients (17 boys, 6 girls) with a mean age of 6 years 3 months (range  3 months to 14 years 7 months) were included in this study. Of the 59 renal arteries studied by DSA, 22 were abnormal on CT angiography and 20 were abnormal on DSA. Of the 59 renal arteries, CT angiography was true positive in 18 and true negative in 35. The sensitivity and specificity of CT angiography for RAS diagnosis were 90.0% and 89.7%, respectively. CT angiography identified all cases of main RAS. CONCLUSION  Renal CT angiography has a high sensitivity and specificity for pediatric RAS diagnosis in patients referred for DSA.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">rhe</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Inflammatory diseases,
 Inflammation and autonomic dysfunction are common findings in chronic and end-stage kidney disease and contribute to a markedly increased risk of mortality in this patient population. The cholinergic anti-inflammatory pathway (CAP) is a vagal neuro-immune circuit that upholds the homoeostatic balance of inflammatory activity in response to cell injury and pathogens. CAP models have been examined in preclinical studies to investigate its significance in a range of clinical inflammatory conditions and diseases. More recently, cervical vagus nerve stimulation (VNS) implants have been shown to be of potential benefit for patients with chronic autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease. We have previously shown that dialysis patients have a functional CAP ex vivo. Here we review the field and the potential role of the CAP in acute kidney injury and chronic kidney disease (CKD) as well as in hypertension. We also present a VNS pilot study in haemodialysis patients. Controlling inflammation by neuroimmune modulation may lead to new therapeutic modalities for improved treatment, outcome, prognosis and quality of life for patients with CKD.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  B-lines have been associated with adverse clinical outcomes in patients with heart failure (HF) when found at hospital discharge or during outpatient visits. Whether lung unltrasound (LUS) assessed B-lines may predict in-hospital mortality in patients with acute HF is still undetermined. AIM  To evaluate the association between B-lines on admission and in-hospital mortality among patients admitted with acute HF. METHODS  Hand-held LUS was used to examine patients with acute HF. LUS was performed in 8 chest zones with a pocket ultrasound device and analyzed offline. The association between B-lines and in-hospital mortality was assessed using Cox regression models. RESULTS  We included 62 patients with median age 56 years, 69.4% men, and median left ventricle ejection fraction 25%. The sum of B-lines ranged from 0 to 53 (median 6.5). An optimal ROC-determined cut-off of &gt;/= 19 B-lines demonstrated a sensitivity of 57% and a specificity of 86% (AUC 0.788) for in-hospital mortality. The incremental prognostic value of LUS when compared with lung crackles or peripheral edema by integrated discrimination improvement was 12.96% (95% CI  7.0, 18.8, p = 0.02). Patients with &gt;/=19 B-lines had a four-fold higher risk of in-hospital mortality (HR 4.38; 95% CI  1.37, 13.95, p &lt; 0.01). CONCLUSION  In patients admitted with acute HF, point-of-care LUS measurements of pulmonary congestion (B-lines) are associated with in-hospital mortality.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Diseases of arteries,
 BACKGROUND  The COVID-19 pandemic has disrupted healthcare services around the world, which may have serious implications for the prognosis of patients with acute cardiovascular disease. We conducted a systematic review to assess the extent to which health services related to the care and management of acute cardiovascular events have been impacted during the COVID-19 pandemic. METHODS  PubMed, MedRxiv and Google Scholar were searched for observational studies published up to August 12, 2020 for studies that assessed the impact of the pandemic on the care and management of people with acute CVD. RESULTS  In total, 27 articles were included. Of these, 16 examined the impact on acute coronary syndromes (ACS), eight on strokes, one on ACS and strokes, and 2 on other types of CVD. When comparing the COVID-19 period to non-COVID-19 periods, eleven studies observed a decrease in ACS admissions ranging between 40 and 50% and five studies showed a decrease in stroke admissions of between 12 and 40%. Four studies showed a larger reduction in non-ST-segment elevation myocardial infarctions (NSTEMI) compared to ST-segment elevation myocardial infarctions (STEMI). A decrease in the number of reperfusion procedures, a shortening in the lengths of stay at the hospital, and longer symptom-to-door times were also observed. CONCLUSIONS  The COVID-19 pandemic has led to a substantial decrease in the rate of admissions for acute CVD, reductions in the number of procedures, shortened lengths of stay at the hospital and longer delays between the onset of the symptoms and hospital treatment. The impact on patient&#39;s prognosis needs to be quantified in future studies.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Diseases of arteries,
 BACKGROUND  The COVID-19 pandemic has disrupted healthcare services around the world, which may have serious implications for the prognosis of patients with acute cardiovascular disease. We conducted a systematic review to assess the extent to which health services related to the care and management of acute cardiovascular events have been impacted during the COVID-19 pandemic. METHODS  PubMed, MedRxiv and Google Scholar were searched for observational studies published up to August 12, 2020 for studies that assessed the impact of the pandemic on the care and management of people with acute CVD. RESULTS  In total, 27 articles were included. Of these, 16 examined the impact on acute coronary syndromes (ACS), eight on strokes, one on ACS and strokes, and 2 on other types of CVD. When comparing the COVID-19 period to non-COVID-19 periods, eleven studies observed a decrease in ACS admissions ranging between 40 and 50% and five studies showed a decrease in stroke admissions of between 12 and 40%. Four studies showed a larger reduction in non-ST-segment elevation myocardial infarctions (NSTEMI) compared to ST-segment elevation myocardial infarctions (STEMI). A decrease in the number of reperfusion procedures, a shortening in the lengths of stay at the hospital, and longer symptom-to-door times were also observed. CONCLUSIONS  The COVID-19 pandemic has led to a substantial decrease in the rate of admissions for acute CVD, reductions in the number of procedures, shortened lengths of stay at the hospital and longer delays between the onset of the symptoms and hospital treatment. The impact on patient&#39;s prognosis needs to be quantified in future studies.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlud</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Diseases of arteries,Coagulopathies,
 PURPOSE  Retinal Vein Occlusion (RVO) is a thrombotic process affecting retinal veins. The purpose of this research is to study demographic characteristics and prevalence of cardiovascular comorbidities among subjects affected by RVO. In addition, authors explore the role of each variable in determining occlusion type and severity. SUBJECTS, MATERIALS AND METHODS  This was a prospective observational study recruiting subjects affected by RVO and secondary macular edema. Exclusion criteria included pre-existing macular edema, recent ocular surgery (&lt;6 months), pregnancy, diagnosis other than RVO, diabetes mellitus type I, any systemic pathology that significantly reduced life expectancy. Each participant was studied through a comprehensive medical history, cardiovascular assessment, blood testing, ocular exam, and macular OCT imaging. RESULTS  A total of 145 eyes, 145 participants, thereof 80 males (55%) and 65 females. (45%) Mean age  62.5 +/- 14.3 SD. 61 eyes (42%) were affected by CRVO and 84 eyes (58%) by BRVO. No statistically significant differences were noted between genders. Hypertension was very prevalent (63%). Dyslipidemia was more associated with BRVO (p = 0.044). Subjects with hypertension had a mean central macular thickness (CMT) of 643 microm against a mean of 489 microm of those without hypertension. (p &lt; 0.05). No other variable was associated with macular edema severity. CONCLUSIONS  Older age and hypertension are strong risk factors for RVO. Dyslipidemia was strongly associated with BRVO. (p=0.044) Hypertension was not only associated with RVO incidence, but also with its severity. In fact, hypertensive subjects had significantly worse macular edema.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Diseases of arteries,
 BACKGROUND  Dyslipidaemia is a major modifiable risk factor for atherosclerotic cardiovascular disease. At the time the study was conducted, guidelines recommended a low-density lipoprotein cholesterol (LDL-C) target of less than 1.8 mmol/l and a reduction of at least 50% if the baseline LDL-C was between 1.8 and 3.5 mmol/l in patients with either very high cardiovascular risk or established atherosclerosis. In South Africa, there is a paucity of data on attainment of LDL-C goal in patients with very high cardiovascular risk who are on maximum tolerated statin with or without ezetimibe. OBJECTIVE  The aim was to assess the percentage of very high cardiovascular risk South African patients with dyslipidaemia not reaching an LDL-C goal of less than 1.8 mmol/l, despite maximum tolerated statin with or without ezetimibe. METHODS  This was a multi-centre, observational, cross-sectional study conducted at 15 private healthcare sector sites and one public sector site. Adults (&gt; 18 years) with very high cardiovascular risk of familial hypercholesterolaemia receiving stable, maximum-tolerated statin therapy for at least four weeks prior to their latest lipid profile were enrolled into the study, and electronic case report forms were completed after written informed consent was provided. LDL-C goal attainment was modelled, first assuming an increase in the statin dose to the registered maximum, followed by the addition of ezetimibe or a PCSK9-inhibitor. RESULTS  In total, 507 patients were screened, of whom 492 were eligible for study participation. One patient was excluded from the analysis because of a missing LDL-C value. Most participants were male (male 329, 67%; female 162, 33%). Most patients were either obese (223, 46.0%) or overweight (176, 36.3%). Hypertension and diabetes mellitus were frequent co-morbidities and were found in 381 (77.6%) and 316 (64.4%) patients, respectively. Eighty (16.3%) patients reported current smoking. Only 68 (13.8%) patients were taking ezetimibe in addition to a statin. Reasons for not using ezetimibe included no requirement for ezetimibe in the opinion of the treating physician (229, 48.7%), cost (149, 31.7%), Physician&#39;s choice (39, 8.3%), or other (53, 11.3%). Only 161 (32.8%) of the patients attained their goal LDL-C level. In our modelling analysis, increasing the statin dose to the registered maximum and adding ezetimibe brought an additional 34.5% of patients to goal, while adding a PCSK9-inhibitor, irrespective of any other changes to lipid-lowering therapy brought over 90% of not-at-goal patients to goal. CONCLUSIONS  Most study participants were not at LDL-C goal despite maximum-tolerated statin, highlighting the need for treatment intensification in this high-risk population. Although intensifying treatment by adding a PCSK9-inhibitor brought more patients to goal, the initial addition of ezetimibe would be more reasonable, given the cost of PCSK9-inhibitors.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 A link between periodontitis and cardiovascular disease has been reported in the literature. For this systematic review, the keywords &#34;cardiovascular disease&#34; (CVD) were combined with &#34;periodontitis&#34; and &#34;peri-implantitis&#34; and were used to search for literature published on MEDLINE and PubMed between 1990 and 2020. Hand searching was also performed. A total of 206 articles were identified, 51 of which were reviewed. A link between periodontal disease and CVD can be explained by both the infection and inflammatory pathways. Interventional studies on the treatment of periodontal disease related to CVD have shown conflicting results. Therefore, based on published studies, CVD should presently be considered a comorbidity of periodontitis (with an association but no direct cause and effect documented). The association of CVD with peri-implantitis has too few studies to draw any conclusions. More studies are necessary before any conclusions can be made between CVD and periodontitis and CVD and peri-implantitis regarding possible links and the extent of association.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,
 Short stature, ovarian dysgenesis, infertility, and cardiovascular malformations are classic features in Turner syndrome (TS), but the phenotypical spectrum is wide. Through early diagnosis and appropriate treatment, TS patients have a chance to achieve satisfactory adult height and sexual development. The doses of recombinant growth hormone (rGH) used are usually higher than the substitution dose. The safety aspects of this therapy are very important, especially in terms of the cardiovascular system. The presented study aimed to analyze how the rGH therapy may influence the cardiovascular system in TS based on current literature data. We conducted a systematic search for studies related to TS, cardiovascular system, and rGH therapy. The results show that rGH seems to have a positive effect on lipid parameters, reducing the risk of ischemic disease. It is additionally optimized by estradiol therapy. Although rGH may increase insulin resistance, the metabolic derangement is rare, probably due to lower fat content and an increase in lean body mass. Several studies showed that rGH treatment could cause aorta widening or increase the aorta growth rate. IGF-1 can be independently associated with increased aortic diameters. The studies analyzing the impact of GH on blood pressure show conflicting data. The proper cardiovascular imaging before and during rGH treatment and detecting the known risk factors for aorta dissection in every individual is very important. The long-term effects of growth hormone treatment on the heart and arteries are still not available and clearly estimated and have to be monitored in the future.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 Recently, an outbreak of a fatal coronavirus, SARS-CoV-2, has emerged from China and is rapidly spreading worldwide. Possible interaction of SARS-CoV-2 with DPP4 peptidase may partly contribute to the viral pathogenesis. An integrative bioinformatics approach starting with mining the biomedical literature for high confidence DPP4-protein/gene associations followed by functional analysis using network analysis and pathway enrichment was adopted. The results indicate that the identified DPP4 networks are highly enriched in viral processes required for viral entry and infection, and as a result, we propose DPP4 as an important putative target for the treatment of COVID-19. Additionally, our protein-chemical interaction networks identified important interactions between DPP4 and sitagliptin. We conclude that sitagliptin may be beneficial for the treatment of COVID-19 disease, either as monotherapy or in combination with other therapies, especially for diabetic patients and patients with pre-existing cardiovascular conditions who are already at higher risk of COVID-19 mortality.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,
 OBJECTIVES  Saffron (Crocus sativus L.) has been widely used in traditional medicine as a treatment of nervous disorders. Saffron as an antioxidant can be considered effective for treatment of oxidative stress in ischemia stroke. Therefore, the aim of the present study was to investigate the role of aqueous extract of saffron in reducing oxidative stress in ischemic strokes patients. METHODS  Forty patients with acute ischemic stroke were randomly divided into two groups including control group and saffron group. During 4 days of experiment, control group received routine stroke care and saffron group received routine care plus capsule of saffron 400 mg/day (200 mg twice per day). Then, two groups were compared using the National Institute of Health Stoke Scale (NIHSS) and serum oxidative stress biomarkers, at the time of hospital admission and 4 days later as well. RESULTS  On the fourth day after ischemic stroke onset, antioxidant enzymes activities and glutathione (GSH) and total antioxidant capacity (TAC) levels were higher in the saffron group compared to the control group, while malondialdehyde (MDA) level was lower. In addition, the severity of stroke, based on the NIHSS scores, was significantly reduced after 4 days in the saffron group. The severity of stroke was negatively correlated with the levels of GSH and TAC and positively correlated with MDA level. CONCLUSIONS  Saffron has modulatory effects on ischemic-induced oxidative stress due to its free radical scavenging and antioxidant properties. Thus, saffron extract can be considered as a potential candidate therapy of the ischemic brain.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Objective Out-of-hospital cardiac arrest (OHCA) is associated with poor survival. Studies have demonstrated improved survival with early bystander cardiopulmonary resuscitation (BCPR). This study evaluated the impact of a dispatcher-assisted CPR (DA-CPR) program on BCPR rate and outcomes of OHCA in a developing emergency medical services (EMS) system setting. Methods Data were extracted from the national cardiac arrest registry. A before-after analysis was performed between OHCA cases with cardiac etiology conveyed by EMS from April 2010-June 2012 (pre-intervention) and July 2012-December 2015 (post-intervention). Primary outcomes were survival-to-discharge/30(th) day post-arrest and favorable cerebral performance (Glasgow-Pittsburgh cerebral performance categories 1 and 2). Results 6365 OHCA cases were analyzed; 2129 in the pre-intervention group and 4236 post-intervention. In the post-intervention group, there was an increase in BCPR rates from 24.8% to 53.8% (p &lt; 0.001), adjusted OR 3.67 (aOR; 95%CI  3.26-4.13). OHCA outcomes also improved with survival-to-discharge rates increasing from 3.0%-4.5% (p &lt; 0.01), aOR 2.10 (95%CI  1.40- 3.17) and favorable cerebral performance increasing from 1.6% to 2.7% (p &lt; 0.05), aOR 2.82 (95%CI  1.65-4.82). In patients with initial shockable rhythm, BCPR without dispatcher assistance was associated with significantly higher odds of survival-to-discharge (aOR 1.67, 95%CI 1.06-2.64) and favorable cerebral performance (aOR 2.32, 95%CI 1.26-4.27) compared to no BCPR. Conclusion Our study showed that a simplified DA-CPR program can be successfully implemented in a developing EMS system and can contribute to higher BCPR rate and in turn, improve OHCA survival. Future studies can examine bystanders&#39; characteristics and the quality of the CPR performed to understand their impact on survival.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">stenos</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Diseases of arteries,
 Identifying acute MI in the setting of left bundle branch block (LBBB) is challenging because ST-segment elevation is often found at baseline. When faced with LBBB and ischemic symptoms, identifying which patients require urgent reperfusion therapy is critical. Sgarbossa et al. derived three criteria that can be used to help identify these patients, Smith et al. refined these criteria creating the Smith-modified Sgarbossa criteria. We present a case of LBBB meeting the Smith-modified Sgarbossa criteria, recognized by paramedics and used to activate the catheterization laboratory after normal business hours. The patient was found with 95% stenosis of the left anterior descending artery and received stenting.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,
 Obesity is one of major health burdens of modern society as it contributes to the growing prevalence of its related comorbidities, such as diabetes, cardiovascular diseases, and some cancers. A series of innate immune cells, especially macrophages, and adipocytes have been implicated in the pathogenesis of obesity. Mitochondrial dysfunction, which is induced by obesity, are critical mediators in initiating inflammation in macrophages and adipocytes, and subsequent systemic insulin resistance. In this review, we discuss new findings on how obesity impairs mitochondrial function in macrophages and adipocytes and how this dysfunction contributes to obesity and its comorbidities. We also summarize drugs that treat metabolic diseases by targeting mitochondrial dysfunction.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 Patients with Sickle Cell Disease (SCD) are living longer and subsequently more apt to develop cardiopulmonary dysfunction. NT-proBNP levels have been used in adults with SCD to assess for pulmonary hypertension and mortality. While the incidence of PH is low in pediatrics, it is reasonable to presume that NT-proBNP levels can be used to assess risk for the development of cardiopulmonary morbidity. We hypothesized that NT-proBNP levels would be increased in patients with SCD compared to age-adjusted healthy children; additionally, these levels would be associated with labs indicative of hemolysis and would demonstrate evidence of obstructive lung disease and cardiac dysfunction. We retrospectively evaluated patients with SCD, 8-18 years old, at a large, tertiary care children&#39;s hospital. NT-proBNP levels were assessed in correlation with hemolytic lab work, spirometry, and echocardiographic data. The age group 8-14 years old, 75% of our cohort&#39;s population, had a median NT-proBNP of 70pg/mL, greater than their age-adjusted counterparts (52pg/mL). NT-proBNP levels were associated with an increased degree of hemolysis when compared with hemoglobin (Hb) [r = -0.43, p &lt; 0.0001], reticulocyte count [r = 0.25, p = 0.01] and lactate dehydrogenase (LDH) levels [r = 0.47, p &lt; 0.0001]. An inverse trend was found between NT-proBNP and spirometric data. Lastly, a positive correlation was found between NT-proBNP and diastolic left ventricular size [r = 0.28, p = 0.047]. The correlations found suggest that NT-proBNP may be used prospectively to identify patients with SCD at increased risk for the development of cardiopulmonary dysfunction. This article is protected by copyright. All rights reserved.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 Patients with Sickle Cell Disease (SCD) are living longer and subsequently more apt to develop cardiopulmonary dysfunction. NT-proBNP levels have been used in adults with SCD to assess for pulmonary hypertension and mortality. While the incidence of PH is low in pediatrics, it is reasonable to presume that NT-proBNP levels can be used to assess risk for the development of cardiopulmonary morbidity. We hypothesized that NT-proBNP levels would be increased in patients with SCD compared to age-adjusted healthy children; additionally, these levels would be associated with labs indicative of hemolysis and would demonstrate evidence of obstructive lung disease and cardiac dysfunction. We retrospectively evaluated patients with SCD, 8-18 years old, at a large, tertiary care children&#39;s hospital. NT-proBNP levels were assessed in correlation with hemolytic lab work, spirometry, and echocardiographic data. The age group 8-14 years old, 75% of our cohort&#39;s population, had a median NT-proBNP of 70pg/mL, greater than their age-adjusted counterparts (52pg/mL). NT-proBNP levels were associated with an increased degree of hemolysis when compared with hemoglobin (Hb) [r = -0.43, p &lt; 0.0001], reticulocyte count [r = 0.25, p = 0.01] and lactate dehydrogenase (LDH) levels [r = 0.47, p &lt; 0.0001]. An inverse trend was found between NT-proBNP and spirometric data. Lastly, a positive correlation was found between NT-proBNP and diastolic left ventricular size [r = 0.28, p = 0.047]. The correlations found suggest that NT-proBNP may be used prospectively to identify patients with SCD at increased risk for the development of cardiopulmonary dysfunction. This article is protected by copyright. All rights reserved.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Coagulopathies,
 The anti-von Willebrand factor nanobody caplacizumab was licensed for adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP) based on prospective controlled trials. However, few data are available on post-marketing surveillance. We treated 90 iTTP patients with a compassionate frontline &#34;triplet regimen&#34; associating therapeutic plasma exchange (TPE), immunosuppression with corticosteroids and rituximab, and caplacizumab. Outcomes were compared to 180 historical patients treated with the standard frontline treatment (TPE and corticosteroids, with rituximab as salvage therapy). The primary outcome was a composite of refractoriness and death within 30 days since diagnosis. Key secondary outcomes were exacerbations, time to platelet count recovery, the number of TPE and the volume of plasma required to achieve durable remission. The percentage of patients in the triplet regimen with the composite primary outcome was 2.2% vs. 12.2% in historical patients (p=0.01). One elderly patient in the triplet regimen died of pulmonary embolism. Patients from this cohort experienced less exacerbations (3.4% vs. 44%, p&lt;0.01); they recovered durable platelet count 1.8 times faster than historical patients (95% confidence interval, 1.41-2.36, p&lt;0.01), with fewer TPE sessions and lower plasma volumes (p&lt;0.01 both). The number of days in hospital was 41% lower in the triplet regimen than in the historical cohort (13 days vs. 22 days, p &lt;0.01). Caplacizumab-related adverse events occurred in 46 patients (51%), including 13 major or clinically relevant non-major hemorrhagic events. Associating caplacizumab to TPE and immunosuppression, by addressing the three processes of iTTP pathophysiology, prevents unfavorable outcomes and alleviates the burden of care.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Ischemia,Heart failure,
 Supraclavicular nerve block is the most popular regional anesthesia approach for upper limb surgery. It also predispose some complications because of the adjacent neurovascular structures such as pleura, recurrent laryngeal and phrenic nerve, supraclavicular vessels, and spinal cord structures. The widespread use of ultrasound for peripheral nerve blocks has reduced the incidence of these complications. We aimed to present a case of brain edema developed after ultrasound-guided supraclavicular block which was not reported in the literature before. A 25 years old, American Society of Anesthesia (ASA) score I, male patient was admitted to our clinic to perform the replacement of external fixator with an internal fixator. The ultrasound guidance supraclavicular nerve block was performed. After the block, we observed disorientation, blurring in consciousness, paleness, tachycardia, hypertension and tachypnea. Upon this, we performed induction for general anesthesia and intubation. After the onset of myoclonic epileptic seizure, he was re-intubated in the recovery room. Bilateral cerebral parenchyma was edematous, the sulci were faint and venous structures were prominent on the brain computerized tomography. Because of magnetic resonance imaging (MRI) finding that restricted diffusion which was compatible with cortical-subcortical acute ischemia, mannitol, dexamethasone and furosamid were started as anti-edema treatment. On the third day in intensive care unit, the patient was extubated because of improvement in consciousness and marked decrease in brain swelling on the control radiologic imaging. It should be kept in mind that brain edema secondary to local anesthetic systemic toxicity (LAST) may develop as a complication after brachial plexus blocks. KEY WORDS  Brain Edema, Epileptic Seizure, Supraclavicular Nerve Block, Ultrasound.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Inflammatory diseases,
 The pathological role of adipose derived fatty acids following myocardial infarction has long been hypothesized. However, most methods for reducing adipocyte lipolysis have significant non-adipose effects. Atglistatin, a direct inhibitor of the initial lipase in the lipolysis cascade, has been recently shown to inhibit adipose tissue lipolysis after oral administration. To explore the ability of Atglistatin to impact the pathophysiology of cardiac ischemia we performed prophylactic treatment of mice with Atglistatin for 2 days before 1-hour cardiac ischemia. After 7 days of reperfusion, hearts of Atglistatin treated mice showed significantly improved systolic pump function while infarct and scar size were unaffected. Strain analysis of echocardiographic data revealed an enhanced performance of the remote myocardium as cause for overall improved systolic function. The present study provides evidence that inhibition of adipocyte adipose triglyceride lipase (ATGL) using Atglistatin is able to improve cardiac function after MI by targeting the remote myocardium.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Since the publication of the last American Heart Association scientific statement on air pollution and cardiovascular disease in 2010, unequivocal evidence of the causal role of fine particulate matter air pollution (PM2.5, or particulate matter &lt;/=2.5 mum in diameter) in cardiovascular disease has emerged. There is a compelling case to provide the public with practical personalized approaches to reduce the health effects of PM2.5. Such interventions would be applicable not only to individuals in heavily polluted countries, high-risk or susceptible individuals living in cleaner environments, and microenvironments with higher pollution exposures, but also to those traveling to locations with high levels of PM2.5. The overarching motivation for this document is to summarize the current evidence supporting personal-level strategies to prevent the adverse cardiovascular effects of PM2.5, guide the use of the most proven/viable approaches, obviate the use of ineffective measures, and avoid unwarranted interventions. The significance of this statement relates not only to the global importance of PM2.5, but also to its focus on the most tested interventions and viable approaches directed at particulate matter air pollution. The writing group sought to provide expert consensus opinions on personal-level measures recognizing the current uncertainty and limited evidence base for many interventions. In doing so, the writing group acknowledges that its intent is to assist other agencies charged with protecting public health, without minimizing the personal choice considerations of an individual who may decide to use these interventions in the face of ongoing air pollution exposure.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Since the publication of the last American Heart Association scientific statement on air pollution and cardiovascular disease in 2010, unequivocal evidence of the causal role of fine particulate matter air pollution (PM2.5, or particulate matter &lt;/=2.5 mum in diameter) in cardiovascular disease has emerged. There is a compelling case to provide the public with practical personalized approaches to reduce the health effects of PM2.5. Such interventions would be applicable not only to individuals in heavily polluted countries, high-risk or susceptible individuals living in cleaner environments, and microenvironments with higher pollution exposures, but also to those traveling to locations with high levels of PM2.5. The overarching motivation for this document is to summarize the current evidence supporting personal-level strategies to prevent the adverse cardiovascular effects of PM2.5, guide the use of the most proven/viable approaches, obviate the use of ineffective measures, and avoid unwarranted interventions. The significance of this statement relates not only to the global importance of PM2.5, but also to its focus on the most tested interventions and viable approaches directed at particulate matter air pollution. The writing group sought to provide expert consensus opinions on personal-level measures recognizing the current uncertainty and limited evidence base for many interventions. In doing so, the writing group acknowledges that its intent is to assist other agencies charged with protecting public health, without minimizing the personal choice considerations of an individual who may decide to use these interventions in the face of ongoing air pollution exposure.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Coagulopathies,
 AIM  To investigate the differences in the characteristics and clinical outcomes of recently diagnosed patients with atrial fibrillation (AF) receiving different types of anticoagulants in a real-life setting. METHODS  We retrospectively analyzed the charts of 1000 consecutive patients with non-valvular AF diagnosed at our institution or referred it to from 2013 to 2018. RESULTS  Over the observed period, the frequency of direct oral anticoagulation (DOAC) therapy use significantly increased (P = 0.002). Patients receiving warfarin had more unfavorable thromboembolic and bleeding risk factors than patients receiving DOAC. Predetermined stroke and major bleeding risks were similarly distributed among the dabigatran, rivaroxaban, and apixaban groups. Patients receiving warfarin had shorter time-to-major bleeding (TTB), time to thrombosis (TTT), and overall survival (OS) than patients receiving DOACs. After adjustment for factors unbalanced at baseline, the warfarin group showed significantly shorter OS (hazard ratio 2.27, 95% confidence interval 1.44-3.57, P&lt;0.001], while TTB and TTT did not significantly differ between the groups. Only 37% of patients on warfarin had optimal dosing control, and they did not differ significantly in TTB, TTT, and OS from patients on DOACs. CONCLUSION  Warfarin and DOACs are administered to different target populations, possibly due to socio-economic reasons. Patients receiving warfarin rarely obtain optimal dosing control, and experience significantly shorter survival compared with patients receiving DOACs.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">microvascul</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Diseases of arteries,
 Heart failure with preserved ejection fraction (HFpEF) has recently been recognized as the single greatest unmet need in cardiovascular medicine. As the population ages and the comorbidity increases, the prevalence of HFpEF increases considerably. Even though there have been large numbers of studies on pathophysiology, diagnosis, and treatment of HFpEF for latest years, there are no current pharmacologic interventions that can reduce mortality. HFpEF is currently understood as a heterogeneous syndrome originated from the interplay of cardiac and extracardiac abnormalities recognized by systemic inflammation, endothelial and coronary microvascular dysfunction, cardiomyocyte dysfunction and skeletal muscle dysfunction. The difficult &#34;jigsaw puzzle&#34; called HFpEF has been filled with some pieces, but it is still not enough to meet clinical needs. Here, we review recent evidences and unsolved problems about HFpEF to improve our understanding of HFpEF. Finally, we hope to accelerate to completion of the problematic &#34;jigsaw puzzle&#34;.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-blue-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypotend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Hypotension,Heart failure,
 AIMS  Cardiorenal syndrome (CRS) is a common problem of great morbidity and mortality. Hydralazine-isosorbide dinitrate (H-ISDN) may be used in renal failure and may improve exercise capacity in heart failure (HF). Our proof-of-concept study aimed to evaluate early evidence of efficacy, safety, and feasibility of H-ISDN compared with standard of care in CRS. METHODS AND RESULTS  This multi-centre, single-blind, randomized trial in Singapore enrolled CRS patients, defined as chronic HF with concomitant renal failure [estimated glomerular filtration rate (eGFR) &lt; 60 ml/min/1.73 m(2) ]. The primary outcome was 6 min walk test (6MWT) distance measured at 6 months. Secondary outcomes included study feasibility; efficacy outcomes which included renal, cardiac, and endothelial functions, health-related quality of life using Short Form-36, clinical outcomes; and adverse events. Forty-four patients [71 +/- 10 years; 75% male; median (inter-quartile range) N-terminal prohormone brain natriuretic peptide 1346 (481-2272) pg/mL] with CRS (left ventricular ejection fraction 42 +/- 12% and eGFR 46 +/- 15 ml/min/1.73 m(2) ) were randomized into two equal groups. Of these, 39 (89%) had hypertension, 27 (61%) had diabetes mellitus, and 17 (39%) had atrial fibrillation. Six (27%) discontinued H-ISDN owing to intolerance and poor compliance. There was a trend towards improved 6MWT distance with H-ISDN compared with standard of care at 6 months (mean difference 27 m; 95% CI, -12 to 66), with little differences in secondary efficacy outcomes. Giddiness and hypotension occurred more frequently with H-ISDN, but HF hospitalizations and mortality were less. CONCLUSIONS  Our pilot study does not support the addition of H-ISDN on top of standard medical therapy to improve exercise capacity in patients with CRS.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Cardiac fibrosis is characterized by the activation of cardiac fibroblasts and accumulation of extracellular matrix. METTL3, a component of methyltransferase complex, participates in multiple biological processes associated with mammalian development and disease progression. However, the role of METTL3 in cardiac fibrosis is still unknown. We performed fibroblasts activation with TGF-beta1 (20 ng/mL) in vitro and established in vivo mouse models with lentivirus to assess the effects of METTL3 on cardiac fibroblasts proliferation and collagen formation. Methylated RNA immunoprecipitation (MeRIP) was used to define the potential fibrosis-regulated gene. The expression level of METTL3 was increased in cardiac fibrotic tissue of mice with chronic myocardial infarction and cultured cardiac fibroblats (CFs) treated with TGF-beta1. Enforced expression of METTL3 promoted proliferation and fibroblast-to-myofibroblast transition and collagens accumulation, while silence of METTL3 did the opposite. Silence of METTL3 by lentivirus carrying METTL3 siRNA markedly alleviated cardiac fibrosis in MI mice. Transcriptome and N6-methyladenosine (m(6) A) profiling analyses revealed that the expression and m(6) A level of collagen-related genes were altered after silence of METTL3. METTL3-mediated m(6) A modification is critical for the development of cardiac fibrosis, providing a molecular target for manipulating fibrosis and the associated cardiac diseases.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 INTRODUCTION  Patients with kidney failure undergoing maintenance hemodialysis (HD) therapy are routinely counseled to reduce dietary sodium intake to ameliorate sodium retention, volume overload, and hypertension. However, low-sodium diet trials in HD are sparse and indicate that dietary education and behavioral counseling are ineffective in reducing sodium intake. This study aimed to determine whether 4 weeks of low-sodium, home-delivered meals in HD patients reduces interdialytic weight gain (IDWG). Secondary outcomes included changes in dietary sodium intake, thirst, xerostomia, blood pressure, volume overload, and muscle sodium concentration. METHODS  Twenty HD patients (55 +/- 12 years, body mass index [BMI] 40.7 +/- 16.6 kg/m(2) ) were enrolled in this study. Participants followed a usual (control) diet for the first 4 weeks followed by 4 weeks of three low-sodium, home-delivered meals per day. We measured IDWG, hydration status (bioimpedance), standardized blood pressure (BP), food intake (3-day dietary recall), and muscle sodium (magnetic resonance imaging) at baseline (0 M), after the 4-week period of usual diet (1 M), and after the meal intervention (2 M). FINDINGS  The low-sodium meal intervention significantly reduced IDWG when compared to the control period (-0.82 +/- 0.14 kg; 95% confidence interval, -0.55 to -1.08 kg; P &lt; 0.001). There were also 1 month (1 M) to 2 month (2 M) reductions in dietary sodium intake (-1687 +/- 297 mg; P &lt; 0.001); thirst score (-4.4 +/- 1.3; P = 0.003), xerostomia score (-6.7 +/- 1.9; P = 0.002), SBP (-18.0 +/- 3.6 mmHg; P &lt; 0.001), DBP (-5.9 +/- 2.0 mmHg; P = 0.008), and plasma phosphorus -1.55 +/- 0.21 mg/dL; P = 0.005), as well as a 0 M to 2 M reduction in absolute volume overload (-1.08 +/- 0.33 L; P = 0.025). However, there were no significant changes in serum or tissue sodium (all P &gt; 0.05). DISCUSSION  Low-sodium, home-meal delivery appears to be an effective method for improving volume control and blood pressure in HD patients. Future studies with larger sample sizes are needed to examine the long-term effects of home-delivered meals on these outcomes and to assess cost-effectiveness.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 AIMS  We investigated the sex-based risk of mortality across the spectrum of left ventricular ejection fraction (LVEF) in a large cohort of patients in Australia. METHODS AND RESULTS  Quantified levels of LVEF from 237,046 women (48.1%) and 256,109 men undergoing first-time, routine echocardiography (2000-2019) were linked to 119,232 deaths (median 5.6 years follow-up). Overall, 17.6% of men versus 8.3% women had an LVEF &lt;50%. An LVEF &lt;40% was associated with the highest crude cardiovascular-related and all-cause mortality at 5-years; ~20-30% and ~40-50%, respectively. Thereafter, actual cardiovascular-related and all-cause mortality at 5-years in both sexes steeply improved to a nadir LVEF of 65.0-69.9% (reference group). Below this LVEF level, the adjusted hazard ratio (HR) for cardiovascular-related mortality for a LVEF of 55.0-59.9% was 1.36 (95% CI 1.16, 1.59; p&lt;0.001) in women and 1.21 (95% CI 1.05, 1.39; p=0.008) in men. In women, an LVEF of 60.0-64.9% was also associated with a HR 1.33 (95% CI 1.16, 1.52; p&lt;0.001) for cardiovascular-related mortality. These associations were most striking women and men aged &lt;65 years and were replicated in those with suspected heart failure (32,403 cases aged 65.2+/-16.1 years, 57.0% women). For pre-existing heart failure (33,738 cases aged 67.6+/-16.9 years, 46.5% women), the specific threshold of increased mortality was at and below 50.0-54.9%. CONCLUSIONS  Among patients investigated for suspected or established cardiovascular disease, we found clinically relevant sex-based differences in the distribution and mortality associated with an LVEF below 65.0-69.9%. Specifically, they suggest a greater risk of mortality at higher LVEF levels among women. This article is protected by copyright. All rights reserved.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,
 COVID-19 is a multisystem disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has been declared a pandemic by the World Health Organization in March 2020 and the outbreak still keeps its impacts worldwide. Behcet&#39;s disease (BD) is a multi-systemic vasculitis involving the skin, mucosa, eyes, joints, nervous system, cardiovascular system, and gastrointestinal system. The precise etiopathogenesis of the disorder is unknown but autoimmunity is believed to play a key role. A considerable part of patients with BD are susceptible to immunosuppression and are more predisposed to infections than healthy individuals. Hence, the protection and control measures for patients with BD against the COVID-19 are of the utmost significance. Given the requirement to balance proper treatment of BD with the smallest risk of COVID-19 associated mortality and morbidity, we aimed to review the management of BD in the era of the pandemic with a special focus on treatment considerations. According to current expert recommendations, there is no reason to discontinue topical treatments, colchicine, and non-steroidal anti-inflammatory drugs. Systemic steroids can be used at the lowest possible dose if needed. Ongoing treatments can be continued unchanged in patients with no suspected or confirmed COVID-19. In cases with COVID-19 symptoms, immunosuppressive and biological agents can be temporarily stopped but the decision should be made on a case by case basis. Considering their potential beneficial effects on the course of COVID-19, colchicine, pentoxifylline, and dapsone can be considered as safe treatment options in BD. This article is protected by copyright. All rights reserved.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 OBJECTIVES  This study aimed to describe the clinical and diagnostic characteristics, as well as outcomes of radioiodine treatment in dogs with hyperthyroidism caused by a non-resectable ectopic thyroid tumour. MATERIALS AND METHODS  This retrospective study reviewed the medical records between 2008 and 2018 of dogs diagnosed with hyperthyroidism secondary to a non-resectable ectopic thyroid tumour and treated with radioiodine. RESULTS  Five dogs were included in the study. Three dogs had sublingual ectopic tumours, of which one also had a unilateral cervical thyroid tumour. The remaining two dogs were diagnosed with an ectopic thyroid tumour at the level of the caudal pharynx and the heart base, respectively. All cases were treated with radioiodine. The size of the ectopic masses decreased after radioiodine treatment. Total thyroxine concentrations returned to reference ranges in all dogs. Further, clinical signs of hyperthyroidism disappeared after treatment in all patients. One dog developed myelosuppression secondary to radioiodine treatment. The dog with metastasis had a very short survival compared to the four dogs without metastasis (3 months compared to 7, 36, 50 and 24 months, respectively) and succumbed most likely to thyroid-related problems. In the remaining four dogs, their quality of life improved. They died due to diseases unrelated to the ectopic thyroid tumour. CLINICAL SIGNIFICANCE  Radioiodine therapy should be considered as a treatment option in dogs diagnosed with hyperthyroidism due to a non-resectable ectopic thyroid tumour.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 BACKGROUND/OBJECTIVES  Traditional cardiovascular risk factors are less predictive in older age. High-sensitivity cardiac troponin I (hs-cTnI) is a marker of subclinical cardiomyocyte damage associated with cardiovascular risk in middle-aged adults. We hypothesized hs-cTnI would be indicative of mortality and cardiovascular risk beyond traditional cardiovascular risk factors in older adults and may be more discriminatory compared to hs-troponin T (hs-cTnT). DESIGN  Prospective cohort study. SETTING  Population-based Atherosclerosis Risk in Communities (ARIC) Study. PARTICIPANTS  We included 5,876 ARIC participants at Visit 5 (2011-2013). OUTCOMES AND MEASURES  We used Cox regression for the association of hs-cTnI categories (women  &lt;4, 4-&lt;10, &gt;/=10 ng/ml; men  &lt;6, 6-&lt;12, &gt;/=12 ng/ml, prevalent cardiovascular disease (CVD)) with mortality and incident CVD (atherosclerotic CVD [ASCVD]  coronary heart disease or stroke, or heart failure). RESULTS  Participants were ages 66 to 90, 23% black, 42% male, and 24% had prevalent CVD. There were 1,053 (321 CVD) deaths (median follow-up 6.3 years). Participants with elevated hs-cTnI and no CVD (7% of participants) had mortality risk similar to those with a history of CVD (55.6 vs 55.7 deaths/1,000 person-years, P = .99). After adjustment, elevated hs-cTnI and no CVD (hazard ratio (HR) = 2.38, 95% confidence interval (CI) = 1.85-3.06) and prevalent CVD (HR = 2.21, 95% CI = 1.90-2.57) remained associated with mortality, compared to low hs-cTnI and no CVD. Elevated hs-cTnI was independently associated with incident CVD (HR = 3.41, 95% CI = 2.58-4.51), ASCVD (HR = 2.02, 95% CI = 1.36-2.98), and heart failure (HR = 6.16, 95% CI = 4.24-8.95). The addition of hs-cTnI significantly improved C-statistics for all outcomes and added greater discrimination than hs-cTnT for cardiovascular mortality and incident heart failure. CONCLUSIONS  Hs-cTnI improves mortality and CVD risk stratification in older adults beyond traditional risk factors and improved model discrimination more than hs-cTnT for certain outcomes. Elevated hs-cTnI without CVD identifies a high-risk group with comparable mortality risk as those with a history of clinical CVD.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Pre-operative anaemia is associated with higher rates of transfusion and worse outcomes, including prolonged hospital stay, morbidity and mortality. Iron deficiency is associated with significantly lower haemoglobin levels throughout the peri-operative period and more frequent blood transfusion. Correction of iron stores before surgery forms part of the first pillar of patient blood management. We established a pre-operative anaemia clinic to aid identification and treatment of patients with iron deficiency anaemia scheduled for elective cardiac surgery. We present a retrospective observational review of our experience from January 2017 to December 2019. One-hundred and ninety patients received treatment with intravenous iron, a median of 21 days before cardiac surgery. Of these, 179 had a formal laboratory haemoglobin level measured before surgery, demonstrating a median rise in haemoglobin of 8.0 g.l(-1) . Patients treated with i.v. iron demonstrated a significantly higher incidence of transfusion (60%) compared with the non-anaemic cohort (22%) during the same time period, p &lt; 0.001. Significantly higher rates of new requirement for renal replacement therapy (6.7% vs. 0.6%, p &lt; 0.001) and of stroke (3.7% vs. 1.2%, p = 0.010) were also seen in this group compared with those without anaemia, although there was no significant difference in in-hospital mortality (1.6% vs. 0.8%, p = 0.230). In patients where the presenting haemoglobin was less than 130 g.l(-1) , but there was no intervention or treatment, there was no difference in rates of transfusion or of complications compared with the anaemic group treated with iron. In patients with proven iron deficiency anaemia, supplementation with intravenous iron showed only a modest effect on haemoglobin and this group still had a significantly higher transfusion requirement than the non-anaemic cohort. Supplementation with intravenous iron did not improve outcomes compared with patients with anaemia who did not receive intravenous iron and did not reduce peri-operative risk to non-anaemic levels. Questions remain regarding identification of patients who will receive most benefit, the use of concomitant treatment with other agents, and the optimum time frames for treatment in order to produce benefit in the real-world setting.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 INTRODUCTION  Our objective was to determine the effectiveness of a perindopril/indapamide (Per/Ind) single-pill combination (SPC) in a broad range of patient profiles, including subgroups with varying hypertension severity, age and cardiovascular risk profiles. METHODS  Patient data from four large prospective observational studies (FORTISSIMO, FORSAGE, PICASSO, ACES) were pooled. In each study, patients already treated for hypertension were switched to Per/Ind 10/2.5 mg SPC and systolic and diastolic blood pressure (SBP/DBP) measured at the 1-month (M1) and 3-month (M3) visits. Study endpoints included change in SBP and DBP from baseline to M1 and M3 and the percentage of patients achieving BP control (SBP/DBP &lt; 140/90 mmHg for patients without diabetes or &lt; 140/85 mmHg for patients with diabetes). RESULTS  A total of 16,763 patients were enrolled and received Per/Ind (94% received the full dose of 10/2.5). Mean patient age was 61.4 years (36% were &gt;/= 65 years old), 57% were women, and 16% had isolated systolic hypertension (ISH). Mean baseline office SBP/DBP was 162/94 mmHg, and mean duration of hypertension was 11 years. Cardiovascular risk factors and comorbid conditions were common in this population. Significant mean reductions in SBP (- 23 mmHg) and DBP (- 11 mmHg) were observed at M1 compared with baseline (P &lt; 0.001), which were maintained at M3 (- 30 mmHg and - 14 mmHg, respectively). At M3, BP control was achieved by 70% of patients (78% for ISH). In patients with SBP &gt;/= 180 mmHg at baseline (grade III hypertension), the mean SBP/DBP decrease was - 51/- 20 mmHg and 53% achieved BP control. Per/Ind was well tolerated with an overall rate of adverse events of 1.3%, most frequently cough and dizziness at rates of 0.3% and 0.2%, respectively. CONCLUSION  In this hypertensive population including difficult-to-control patient subgroups, switching to Per/Ind 10/2.5 mg SPC led to rapid and important reductions in BP. BP control was achieved in 70% of patients overall in an everyday practice context.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Diseases of arteries,
 Periodontal disease and arteriosclerotic disease are greatly affected by aging. In this study, the association of conventional risk factors and periodontal disease with atherosclerosis was longitudinally examined in Japanese older adults. Subjects in this study were 490 community-dwelling septuagenarians (69-71 years) randomly recruited from the Basic Resident Registry of urban or rural areas in Japan. At the baseline examination, all subjects underwent socioeconomic and medical interviews; medical examinations, including examinations for carotid atherosclerosis, hypertension, diabetes mellitus, and dyslipidemia; and conventional dental examinations, including a tooth count and measurement of probing pocket depth (PPD). After 3 years, 182 septuagenarians who had no atherosclerosis at the baseline examination were registered and received the same examination as at the baseline. In the re-examination conducted 3 years after the baseline survey, 131 (72.0%) of the 182 participants who had no atherosclerosis at the baseline examination were diagnosed with carotid atherosclerosis. Adjusting and analyzing the mutual relationships of the conventional risk factors for atherosclerosis by multiple logistic regression analysis for the 171 septuagenarians with a full set of data, the proportion of teeth with PPD &gt;/= 4 mm was independently related to the prevalence of atherosclerosis (odds ratio  1.029, P &lt; 0.022). This longitudinal study of Japanese older adults suggests that periodontal disease is associated with the onset/progression of atherosclerosis. Maintaining a healthy periodontal condition may be an important factor in preventing the development and progression of atherosclerosis.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,
 BACKGROUND  Left ventricular mechanical dyssynchrony has been shown to provide significant clinical values for chronic heart failure (HF) and cardiac resynchronization therapy (CRT). The purpose of this study was to evaluate whether electrical dyssynchrony combined with mechanical dyssynchrony has an incremental benefit over electrical dyssynchrony or mechanical dyssynchrony alone to predict clinical events in patients with acute heart failure (AHF). METHODS  Ninety-six AHF patients who received standard 12-lead ECG, gated single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI), and echocardiography were enrolled. Thirty-two normal subjects were collected as the control group to get the normal database of mechanical dyssynchrony. The end point is the composite of all-cause death and heart transplantation. Electrical dyssynchrony was defined as QRS duration &gt; 120 ms. Mechanical dyssynchrony was defined as &gt; mean + 2 x SD phase standard deviation (PSD) or phase bandwidth (PBW) based on our normal database. RESULTS  During the follow-up of 28 +/- 10 months, complete data were obtained in 92 patients. 26 (28.3%) Patients who reached the end point were classified into the event group. There were no significant differences in PSD or PBW between the event and non-event groups. However, PBW &gt; 77.76 degrees was independently associated with the end point in the univariate and multivariate analysis (hazard ratio 2.92, 95% confidence interval 1.00-8.47, P = .049; hazard ratio 3.89, 95% confidence interval 1.01-14.97, P = .048). The Kaplan-Meier curve with a log-rank test showed that the end point rate was significantly higher in the patients with PBW &gt; 77.76 degrees (log-rank P = .039). Moreover, the ROC curve analysis showed that the area under the curve (AUC) for predicting end point events by the integrative analysis of QRS &gt; 120 ms and PBW &gt; 77.76 degrees was significantly improved compared to QRS duration &gt; 120 ms (AUC  0.75 vs 0.68, P = .001) or PBW &gt; 77.76 degrees (AUC  0.75 vs 0.62, P = .049), respectively. The model of combined electrical and mechanical dyssynchrony yielded a further significantly improved risk prediction for adverse events in the global chi(2). CONCLUSIONS  The combination of QRS duration &gt; 120 ms and PBW &gt; 77.76 degrees was an independent predictor of all-cause death and heart transplantation in AHF patients. The integrative analysis of electrical and mechanical dyssynchrony provides incremental prognostic value for clinical use.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 PURPOSE  The relationship between 100% fruit juice (100%FJ) consumption and cardiovascular risk is object of debate  indeed, recently published investigations provided new but discrepant evidence on this important question and International dietary guidelines are not in agreement on recommendations about fruit juice consumption. Therefore, we performed a meta-analysis of the prospective studies and the randomised controlled trials (RCTs) that explored the relationship between 100%FJ intake, cardiovascular risk profile and risk of cardiovascular events. METHODS  We performed a systematic search of publications up to August 2019. Summary relative risks and exploration of linearity of the association were estimated for prospective studies and summary mean differences (MDs) calculated for RCTs. RESULTS  A total of 21 prospective studies and 35 RCTs met the inclusion criteria. Dose-response analysis detected a significant inverse association between low-moderate 100%FJ consumption and risk of stroke (up to 200 ml/day) or total CV events (up to 170 ml/day) compared with no consumption, with a non-linear relationship (p for non-linearity &lt; 0.05). No significant association was found for coronary heart disease and diabetes risk. In RCTs, a favorable and significant effect of 100%FJ intake was detected on blood pressure (systolic, MD  - 3.14 mmHg; diastolic, MD  - 1.68 mmHg), arterial compliance (carotid-femoral pulse wave velocity, - 0.38 m/s) and endothelial function (flow-mediated dilation, 2.10%). Neutral effects were found on body weight, blood lipids and glucose metabolism. CONCLUSIONS  The results of these analyses indicate that 100%FJ consumption is not associated with higher CV risk. A non-linear inverse dose-response relationship occurs between 100%FJ consumption and CV disease, in particular for risk of stroke, probably mediated by the decrease in blood pressure. TRIAL REGISTRATION  PROSPERO registration number (CRD42019135577).
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Diabetes is a key independent risk factor in the development of heart failure (HF) and a strong, adverse prognostic factor in HF patients. HF remains the primary cause of hospitalisation for diabetics and, as previous studies have shown, when HF occurs in these patients, intensive glycaemic control does not directly improve the prognosis. Recent clinical studies assessing a new class of antidiabetic drugs, sodium-glucose cotransporter 2 inhibitors (SGLT2is) showed some unexpected beneficial results. Patients treated with SGLT2is had a significant decrease in both cardiovascular (CV) and all-cause mortality and less hospitalisations due to HF compared to those given a placebo. These significant clinical benefits occurred quickly after the drugs were administered and were not solely due to improved glycaemic control. These groundbreaking clinical trials&#39; results have already changed clinical practice in the management of patients with diabetes at high CV risk. These trials have triggered numerous experimental studies aimed at explaining the mechanisms of action of this unique group of drugs. This article presents the current state of knowledge about the mechanisms of action of SGLT2is developed for the treatment of diabetes and which, thanks to their cardioprotective effects, may, in the future, become a treatment for patients with HF.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Coagulopathies,
 BACKGROUND AND PURPOSE  To date, vitamin K antagonists are the only available oral anticoagulants in patients with mechanical heart valves. In this way, we developed a pilot trial with rivaroxaban. METHODS  The RIWA study was a proof-of-concept, open-label, randomized clinical trial and was designed to assess the incidence of thromboembolic and bleeding events of the rivaroxaban-based strategy (15 mg twice daily) in comparison to dose-adjusted warfarin. Patients were randomly assigned in a 1 1 ratio and were followed prospectively for 90 days. RESULTS  A total of 72 patients were enrolled in the present study. Of these, 44 patients were randomized  23 patients were allocated to the rivaroxaban group and 21 to the warfarin group. After 90 days of follow-up, the primary outcome occurred in one patient (4.3%) in the rivaroxaban group and three patients (14.3%) in the warfarin group (risk ratio [RR] 0.27; 95% confidence interval [CI] 0.02-2.85; P = 0.25). Minor bleeding (without discontinuation of medical therapy) occurred in six patients (26.1%) in the rivaroxaban group versus six patients (28.6%) in the warfarin group (RR 0.88; 95% CI 0.23-3.32; P = 0.85). One patient in the warfarin group died from myocardial infarction. No cases of hemorrhagic stroke, valve thrombosis, peripheral embolic events, or new intracardiac thrombus were related in both groups. CONCLUSIONS  In this pilot study, rivaroxaban 15 mg twice daily had thromboembolic and bleeding events similar to warfarin in patients with mechanical heart valves. These data confirm the authors&#39; proof-of-concept and suggest that a larger trial with a similar design is not unreasonable. CLINICALTRIAL. GOV IDENTIFIER  NCT03566303.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">cerebrovascul</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Diseases of arteries,
 PURPOSE OF REVIEW  Research has consistently shown that type 2 diabetes (T2D) is associated with increased risk of all-cause dementia. Because one of the most common clinical presentations of early stage dementia is memory impairment, we examined the relationship of T2D with memory function, using the recently published scientific literature. RECENT FINDINGS  We conducted a structured review to identify studies of &#34;T2D and memory&#34; published since 2015. After review of the 129 articles retrieved, we identified 14 studies meeting the inclusion and exclusion criteria. Among the eight studies with a single assessment of memory function in time (mostly cross-sectional), six found an association of T2D with lower memory function, but mostly in select subgroups of persons. Separately, six studies included repeated measures of memory (longitudinal design). Four out of six longitudinal studies found that T2D was related with a faster decline in memory, while two did not. Among the four studies showing a relation with memory decline, two had sample sizes of 9000-10,000 persons. Further, three longitudinal studies controlled for hypertension and stroke as covariates, and results suggested that common vascular risk factors and diseases do not account for the relation. While mechanistic studies clearly support a role for cerebrovascular disease in the relation of T2D with cognition, emerging data suggest that insulin resistance in the brain itself may also play a role. Most, but not all, recently published studies suggest that T2D is associated with a lower level and faster decline in memory function. This association does not appear to be fully accounted for by common vascular processes. More research will clarify the mechanisms linking T2D to memory and dementia.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 BACKGROUND  In autosomal dominant polycystic kidney disease (ADPKD), hypertension is prevalent and cardiovascular events are the main cause of death. Thiazide diuretics are often prescribed as second-line antihypertensives, on top of renin-angiotensin-aldosterone system (RAAS) blockade. There is a concern, however, that diuretics may increase vasopressin concentration and RAAS activity, thereby worsening disease progression in ADPKD. We aimed to investigate the validity of these suggestions. METHODS  We analysed an observational cohort of 533 ADPKD patients. Plasma copeptin (surrogate for vasopressin), aldosterone and renin were measured by enzyme-linked immunosorbent assay and radioimmunoassay, respectively. Linear mixed models were used to assess the association of thiazide use with estimated glomerular filtration rate (eGFR) decline and Cox proportional hazards models for the association with the composite kidney endpoint of incident end-stage kidney disease, 40% eGFR decline or death. RESULTS  A total of 23% of participants (n = 125) used thiazide diuretics at baseline. Compared with non-users, thiazide users were older, a larger proportion was male, they had lower eGFRs and similar blood pressure under more antihypertensives. Plasma copeptin was higher, but this difference disappeared after adjustment for age and sex. Both renin and aldosterone were higher in thiazide users. There was no difference between thiazide users and non-users in the rate of eGFR decline {difference -0.35 mL/min/1.73 m2 per year [95% confidence interval (CI) -0.83 to -0.14], P = 0.2} during 3.9 years of follow-up (interquartile range 2.5-4.9). This did not change after adjustment for potential confounders [difference final model  0.08 mL/min/1.73 m2 per year [95% CI -0.46 to -0.62], P = 0.8). In the crude model, thiazide use was associated with a higher incidence of the composite kidney endpoint [hazard ratio (HR) 1.53 (95% CI 1.05-2.23), P = 0.03]. However, this association lost significance after adjustment for age and sex and remained unassociated after adjustment for additional confounders [final model  HR 0.80 (95% CI 0.50-1.29), P = 0.4]. CONCLUSIONS  These data do not show that thiazide diuretics have a detrimental effect on the rate of disease progression in ADPKD and suggest that these drugs can be prescribed as second-line antihypertensives.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 OBJECTIVE  Kawasaki disease (KD) is a vasculitis of unknown aetiology with a high risk of coronary aneurysms if untreated. Timely treatment with intravenous immunoglobulin decreases the risk for coronary artery aneurysms (CAA). In this study, we set out to elucidate the factors associated with the risk of developing CAA. METHODS  Records of all KD-diagnosed children in Skane between 2004 and 2014 were collected and clinical and demographic data were compiled. KD is defined according to the revised American Heart Association diagnostic criteria and classified as either complete KD (cKD) or incomplete KD (iKD). RESULTS  KD was diagnosed in 77 children and CAA was found in 31% (n = 24). Children with CAA were younger compared with children without (median; 20 vs 34 months) and intravenous immunoglobulin treatment within 10 days was less likely to be received (75% vs 91%). In children presenting with iKD, 47% developed CAA compared with 21% in cKD patients. Using multivariate analysis, an association between the risk of CAA with low age in children with iKD was observed. CONCLUSION  The risk of CAA development is disturbingly high in young children with iKD. This highlights the importance of rapid intense treatment and vigilance in infants, who are the most difficult to diagnose, in order to reduce the frequency of CAA.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Diseases of arteries,
 BACKGROUND  The new coronavirus (COVID-19) rapidly resulted in a pandemic. We report the characteristics of patients with severe or critical severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Wuhan city, China, and the risk factors related to infection severity and death. METHODS  We extracted the demographic and clinical data of 7283 patients with severe COVID-19 infection from designated Wuhan hospitals as of 25 February 2020. Factors associated with COVID-19 critical illness and mortality were analysed using logistic- and Cox-regression analyses. RESULTS  We studied 6269 patients with severe COVID-19 illness and 1014 critically ill patients. The median (IQR) age was 64 (53-71) years; 51.2% were male, 38.9% were retirees and 7.4% had self-reported histories of chronic disease. Up to the end of the study, 1180 patients (16.2%) recovered and were discharged, 649 (8.9%) died and the remainder were still receiving treatment. The number of daily confirmed critical cases peaked between 23 January and 1 February 2020. Patients with advanced age [odds ratio (OR), 1.03; 95% confidence intervals (CIs), 1.03-1.04], male sex (OR, 1.57; 95% CI, 1.33-1.86) and pre-existing diabetes (OR, 2.11), hypertension (OR, 2.72), cardiovascular disease (OR, 2.15) or respiratory disease (OR, 3.50) were more likely to be critically ill. Compared with those who recovered and were discharged, patients who died were older [hazard ratio (HR), 1.04; 95% CI, 1.03-1.05], more likely to be male (HR, 1.74; 95% CI, 1.44-2.11) and more likely to have hypertension (HR, 5.58), cardiovascular disease (HR, 1.83) or diabetes (HR, 1.67). CONCLUSION  Advanced age, male sex and a history of chronic disease were associated with COVID-19 critical illness and death. Identifying these risk factors could help in the clinical monitoring of susceptible populations.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 OBJECTIVES  Our goal was to compare the short-term outcomes of Stanford type A aortic dissection (TAAD), during the coronavirus disease 2019 (COVID-19) pandemic with those during normal times and summarize our perioperative management experience of patients with TAAD in the context of COVID-19. METHODS  From 17 January 2020 to 8 March 2020, a total of 27 patients with TAAD were operated on in 8 cardiovascular surgery centres in Hubei Province (COVID-19 group). The data from 91 patients with TAAD from the same centres during the same period last year were extracted from the Hubei Cardiac Surgery Registration System (control group). A propensity score matched subgroup of 26 pairs (1 2) was identified. Perioperative data and short-term outcomes were assessed. RESULTS  Nine patients in the COVID-19 group were categorized as suspicious for the disease (9/27, 33.3%), and others were excluded (18/27, 66.7%). No one was laboratory confirmed preoperatively. The average waiting, cross-clamp and circulatory arrest times were longer in the COVID-19 group (22.9 +/- 8.3 vs 9.7 +/- 4.0 h, P &lt; 0.001; 135 +/- 36 vs 103 +/- 45 min, P = 0.003; 24 +/- 9 vs 17 +/- 8 min, P &lt; 0.001, respectively). The 30-day or in-hospital deaths were 3.8% in both groups (P = 1.0). The COVID-19 group was associated with longer ventilation and intensive care unit times (81 +/- 71 vs 45 +/- 19 h, P &lt; 0.001; 7.4 +/- 3.8 vs 4.5 +/- 2.7 days; P &lt; 0.001, respectively). There were no statistical differences between the 2 groups in the incidence of complications such as stroke, neurological deficit, acute kidney injury, pulmonary infection and reoperation. Serum antibody tests for those patients showed 7 out of 9 suspected cases were Immunoglobulin G positive. No cross-infection occurred in other patients or associated medical staff. CONCLUSIONS  With adequate preparation and appropriate protection, satisfactory early outcomes can be achieved after emergency operations for patients with TAAD during the COVID-19 pandemic.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 OBJECTIVES  Our goal was to compare the short-term outcomes of Stanford type A aortic dissection (TAAD), during the coronavirus disease 2019 (COVID-19) pandemic with those during normal times and summarize our perioperative management experience of patients with TAAD in the context of COVID-19. METHODS  From 17 January 2020 to 8 March 2020, a total of 27 patients with TAAD were operated on in 8 cardiovascular surgery centres in Hubei Province (COVID-19 group). The data from 91 patients with TAAD from the same centres during the same period last year were extracted from the Hubei Cardiac Surgery Registration System (control group). A propensity score matched subgroup of 26 pairs (1 2) was identified. Perioperative data and short-term outcomes were assessed. RESULTS  Nine patients in the COVID-19 group were categorized as suspicious for the disease (9/27, 33.3%), and others were excluded (18/27, 66.7%). No one was laboratory confirmed preoperatively. The average waiting, cross-clamp and circulatory arrest times were longer in the COVID-19 group (22.9 +/- 8.3 vs 9.7 +/- 4.0 h, P &lt; 0.001; 135 +/- 36 vs 103 +/- 45 min, P = 0.003; 24 +/- 9 vs 17 +/- 8 min, P &lt; 0.001, respectively). The 30-day or in-hospital deaths were 3.8% in both groups (P = 1.0). The COVID-19 group was associated with longer ventilation and intensive care unit times (81 +/- 71 vs 45 +/- 19 h, P &lt; 0.001; 7.4 +/- 3.8 vs 4.5 +/- 2.7 days; P &lt; 0.001, respectively). There were no statistical differences between the 2 groups in the incidence of complications such as stroke, neurological deficit, acute kidney injury, pulmonary infection and reoperation. Serum antibody tests for those patients showed 7 out of 9 suspected cases were Immunoglobulin G positive. No cross-infection occurred in other patients or associated medical staff. CONCLUSIONS  With adequate preparation and appropriate protection, satisfactory early outcomes can be achieved after emergency operations for patients with TAAD during the COVID-19 pandemic.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  It is established that Alzheimer&#39;s disease (AD) patients experience sleep disruption. However, it remains unknown whether disruption in the quantity, quality or timing of sleep is a risk factor for the onset of AD. METHODS  We used the largest published genome-wide association studies of self-reported and accelerometer-measured sleep traits (chronotype, duration, fragmentation, insomnia, daytime napping and daytime sleepiness), and AD. Mendelian randomization (MR) was used to estimate the causal effect of self-reported and accelerometer-measured sleep parameters on AD risk. RESULTS  Overall, there was little evidence to support a causal effect of sleep traits on AD risk. There was some suggestive evidence that self-reported daytime napping was associated with lower AD risk [odds ratio (OR)  0.70, 95% confidence interval (CI)  0.50-0.99). Some other sleep traits (accelerometer-measured &#39;eveningness&#39; and sleep duration, and self-reported daytime sleepiness) had ORs of a similar magnitude to daytime napping, but were less precisely estimated. CONCLUSIONS  Overall, we found very limited evidence to support a causal effect of sleep traits on AD risk. Our findings provide tentative evidence that daytime napping may reduce AD risk. Given that this is the first MR study of multiple self-report and objective sleep traits on AD risk, findings should be replicated using independent samples when such data become available.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 Background  Chronic kidney disease (CKD) measures (estimated glomerular filtration rate [eGFR] and albuminuria) are frequently assessed in clinical practice and improve the prediction of incident cardiovascular disease (CVD), yet most major clinical guidelines do not have a standardized approach for incorporating these measures into CVD risk prediction. &#34;CKD Patch&#34; is a validated method to calibrate and improve the predicted risk from established equations according to CKD measures. Methods  Utilizing data from 4,143,535 adults from 35 datasets, we developed several &#34;CKD Patches&#34; incorporating eGFR and albuminuria, to enhance prediction of risk of atherosclerotic CVD (ASCVD) by the Pooled Cohort Equation (PCE) and CVD mortality by Systematic COronary Risk Evaluation (SCORE). The risk enhancement by CKD Patch was determined by the deviation between individual CKD measures and the values expected from their traditional CVD risk factors and the hazard ratios for eGFR and albuminuria. We then validated this approach among 4,932,824 adults from 37 independent datasets, comparing the original PCE and SCORE equations (recalibrated in each dataset) to those with addition of CKD Patch. Findings  We confirmed the prediction improvement with the CKD Patch for CVD mortality beyond SCORE and ASCVD beyond PCE in validation datasets (Deltac-statistic 0.027 [95% CI 0.018-0.036] and 0.010 [0.007-0.013] and categorical net reclassification improvement 0.080 [0.032-0.127] and 0.056 [0.044-0.067], respectively). The median (IQI) of the ratio of predicted risk for CVD mortality with CKD Patch vs. the original prediction with SCORE was 2.64 (1.89-3.40) in very high-risk CKD (e.g., eGFR 30-44ml/min/1.73m(2) with albuminuria &gt;/=30mg/g), 1.86 (1.48-2.44) in high-risk CKD (e.g., eGFR 45-59ml/min/1.73m(2) with albuminuria 30-299mg/g), and 1.37 (1.14-1.69) in moderate risk CKD (e.g., eGFR 60-89ml/min/1.73m(2) with albuminuria 30-299mg/g), indicating considerable risk underestimation in CKD with SCORE. The corresponding estimates for ASCVD with PCE were 1.55 (1.37-1.81), 1.24 (1.10-1.54), and 1.21 (0.98-1.46). Interpretation  The &#34;CKD Patch&#34; can be used to quantitatively enhance ASCVD and CVD mortality risk prediction equations recommended in major US and European guidelines according to CKD measures, when available. Funding  US National Kidney Foundation and the NIDDK.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Inflammatory diseases,Diseases of arteries,
 Background  Controversy exists as to whether low-dose aspirin use may give benefit in primary prevention of cardiovascular (CV) events. We hypothesized that the benefits of aspirin are underevaluated. Methods  We investigated 12,123 Caucasian patients presenting to hospital with acute coronary syndromes as first manifestation of CV disease from 2010 to 2019 in the ISACS-TC multicenter registry (ClinicalTrials.gov, NCT01218776). Individual risk of ST segment elevation myocardial infarction (STEMI) and its association with 30-day mortality was quantified using inverse probability of treatment weighting models matching for concomitant medications. Estimates were compared by test of interaction on the log scale. Findings  The risk of STEMI was lower in the aspirin users (absolute reduction  6.8%; OR  0.73; 95%CI  0.65-0.82) regardless of sex (p for interaction=0.1962) or age (p for interaction=0.1209). Benefits of aspirin were seen in patients with hypertension, hypercholesterolemia, and in smokers. In contrast, aspirin failed to demonstrate a significant risk reduction in STEMI among diabetic patients (OR 1.10;95%CI 0.89-1.35) with a significant interaction (p  &lt;0.0001) when compared with controls (OR 0.64,95%CI 0.56-0.73). Stratification of diabetes in risk categories revealed benefits (p interaction=0.0864) only in patients with concomitant hypertension and hypercholesterolemia (OR 0.87, 95% CI 0.65-1.15), but not in smokers. STEMI was strongly related to 30-day mortality (OR 1.93; 95%CI 1.59-2.35). Interpretation  Low-dose aspirin reduces the risk of STEMI as initial manifestation of CV disease with potential benefit in mortality. Patients with diabetes derive substantial benefit from aspirin only in the presence of multiple risk factors. In the era of precision medicine, a more tailored strategy is required. Funding  None.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,
 Importance  Pulmonary inflammatory myofibroblastic tumors (PIMTs) are primary lung tumors in children. Misdiagnosis easily occurs because of the nonspecific clinical manifestations, laboratory examination results, and imaging findings in affected patients. Objective  To summarize the clinical characteristics, diagnosis, and prognosis of children with PIMTs. Methods  This retrospective analysis included 23 children with PIMTs who received treatment in our hospital from January 2008 to January 2019. The clinical manifestations, laboratory examination results, and computed tomography findings were retrospectively analyzed. Results  The population included 13 boys and 10 girls, with a median age at onset of 78 months (range, 10-126 months). Fourteen patients had PIMT lesions in the right lung and nine patients had PIMT lesions in the left lung. The surgical procedures included pulmonary wedge resection, pulmonary lobectomy, and total pneumonectomy. The median operation time was 115 min (range, 45-235 min); the median intraoperative blood loss volume was 30 mL (range, 3-500 mL). During the operation, one patient each had pulmonary hemorrhage, vena cava hemorrhage, and thoracic duct injury. Postoperative complications included pulmonary embolism in one patient and tumor recurrence in two patients; neither of these complications recurred after reoperation. The median follow-up period was 49 months (range, 2-127 months). Interpretation  Children with PIMTs exhibited good prognoses and primarily underwent surgical resection as treatment. Complete preoperative evaluation should be performed in affected patients.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Background  Extracorporeal membrane oxygenation (ECMO) is a modification of cardiopulmonary bypass that allows prolonged support of patients with severe respiratory or cardiac failure. ECMO indications arse rapidly evolving and there is growing interest in its use for cardiac arrest and cardiogenic shock. However, ECMO training programs are limited. Training of emergency medicine and critical care clinicians could expand the use of this lifesaving intervention. Our objective was to develop and evaluate an abbreviated ECMO course that can be taught to emergency and critical care physicians and nurses. Methods  We developed a training model using Yorkshire swine (Sus scrofa), a procedure instruction checklist, a confidence assessment, and a knowledge assessment. Participants were assigned to teams of one emergency medicine or critical care physician and one nurse and completed an abbreviated 8-hour ECMO course. An ECMO specialist trained participants on preparation of the ECMO circuit and oversaw vascular access and ECMO initiation. We used the instruction checklist to evaluate performance. Participants completed confidence and knowledge assessments before and after the course. Results  Seventeen teams (34 clinicians) completed the abbreviated ECMO course. None had previously completed an ECMO certification course. Immediately following the course, all teams successfully primed and prepared the ECMO circuit. Fifteen teams (88%, 95% confidence interval [CI] = 64% to 99%) successfully initiated ECMO. Participants improved their knowledge (difference 21.2, 95% CI = 16.5 to 25.8) and confidence (difference 40.3, 95% CI = 35.6 to 45.0) scores after completing the course. Conclusions  We developed an accelerated 1-day ECMO course. Clinicians&#39; confidence and knowledge assessments improved and 88% of teams could successfully initiate venoarterial ECMO after the course.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Introduction  A widely used reference range for pulmonary function testing was derived from middle-aged, healthy, non-smoking adults in Japan. This study examined the effect of age-related diseases on pulmonary function tests for older Japanese adults. Methods  All patients aged &gt;/=65 years who underwent spirometry before general and orthopedic surgeries in Itoigawa General Hospital (Niigata, Japan) from January 2014 to June 2019 were identified, and their charts were reviewed. Results  This study included 1050 Japanese patients (median age  75 years). The median spirometric values of vital capacity, forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), and FEV1/FVC in all patients were 2.66 L [interquartile range; 2.24, 3.25], 2.57 L [2.13, 3.13], 1.98 L [1.66, 2.37], and 77.5% [72.2, 81.9], respectively. Multiple regression analyses revealed that spirometric values were significantly affected by age, body height, sex, smoking status, social dependency, dyslipidemia, diabetes, history of heart failure, peripheral artery disease, end-stage renal disease, neuromuscular disease, and psychiatric disorders. Male sex and height were positively correlated with FVC and FEV1. Other factors, such as a history of heart failure, neuromuscular disease, and independent physical activity, were negatively correlated with FVC and FEV1 to almost the same extent as that of age. Conclusions  These data will provide clinically useful information to accurately interpret pulmonary function test results in older Japanese adults.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">rhe</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Arrest of circulating leukocytes and subsequent diapedesis is a fundamental component of inflammation. In general, the leukocyte migration cascade is tightly regulated by chemoattractants, such as chemokines. Chemokines, small secreted chemotactic cytokines, as well as their G-protein-coupled seven transmembrane spanning receptors, control the migratory patterns, positioning and cellular interactions of immune cells. Increased levels of chemokines and their receptors are found in the blood and within inflamed tissue in patients with rheumatoid arthritis (RA) and vasculitis. Chemokine ligand-receptor interactions regulate the recruitment of leukocytes into tissue, thus contributing in important ways to the pathogenesis of RA and vasculitis. Despite the fact that blockade of chemokines and chemokine receptors in animal models have yielded promising results, human clinical trials in RA using inhibitors of chemokines and their receptors have generally failed to show clinical benefits. However, recent early phase clinical trials suggest that strategies blocking specific chemokines may have clinical benefits in RA, demonstrating that the chemokine system remains a promising therapeutic target for rheumatic diseases, such as RA and vasuculitis and requires further study.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Introduction  Development of cardiac disease-related diagnostic skills-including hypothesis-driven data gathering, heart sound interpretation, and ECG interpretation-is an important component of medical student training. Prior studies indicate trainees&#39; performance of these skills is limited. Simulation provides students with opportunities to practice integrating their developing knowledge in a relevant clinical context. We developed a simulated clinic activity for second-year medical students consisting of standardized patient (SP) cases representing cardiovascular (CV) diseases. Methods  Student small groups rotated through four SP encounters. For each case, one student performed the history, after which the whole small group listened to audio files of heart sounds, interpreted an ECG, and collaboratively developed a prioritized differential diagnosis. The CV course director met with students for a large-group debrief, highlighting key learning points. We collected learners&#39; evaluations of the event through an online survey. Results  Of students, 276 participated in this activity over the course of 2 years. Nearly all students assessed the activity as extremely or quite effective for applying learning content from the CV course (97%, 2018; 93%, 2019), and for practicing how to approach chest pain, shortness of breath, palpitations, and fatigue (100%, 2018; 95%, 2019). The most helpful aspects were reinforcement of CV disease illness scripts, hypothesis-driven data gathering practice, ECG interpretation, and applying knowledge and skills in a realistic context. Discussion  SP encounters representing CV conditions can effectively provide opportunities for students to integrate basic science knowledge and clinical skills. Students assessed the activity as helpful and engaging.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 Background  The cross-sectional study is aimed at investigating the relationship between cortisol, testosterone, and metabolic characteristics among male schizophrenics. Methods  174 patients were grouped based on their risk of metabolic syndrome (MetS) into the non-MetS, high-risk-MetS (HR-MetS), or MetS groups. Metabolic indices (body mass index (BMI), mean arterial pressure (MAP), cholesterol, triglyceride, and fasting blood glucose (FBG)) were associated with cortisol and testosterone levels using correlation analysis. Multiple linear regression analysis was used to associate the correlations between the WHO Quality of Life-BREF (WHOQOL-BREF) score and the five metabolic indices. Results  The WHOQOL-BREF score for the non-MetS group significantly differed from the scores of the HR-MetS and MetS groups. The triglyceride level was positively correlated with the cortisol level, while all five metabolic indices were negatively correlated with testosterone level. Stepwise regression analysis produced a model predicting WHOQOL-BREF scores with four variables including MAP, intelligence quotient (IQ), FBG, and age. The correlation analysis then showed that there was a weak linear correlation between the testosterone level and all five metabolic indices. Conclusions  Among the five metabolic indices, the risks of hypertension and hyperglycemia are correlated with the quality of life in male schizophrenics rather than those of obesity or hyperlipidemia.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">art thrombosis</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Coagulopathies,
 Systemic lupus erythematosus (SLE) is the prototypic multisystem autoimmune disorder with a broad spectrum of clinical presentations encompassing almost all organs and tissues(1). Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the occurrence of venous and/or arterial thrombosis and pregnancy morbidity in the presence of pathogenic autoantibodies known as antiphospholipid antibodies (aPL)(2). Chronic thromboembolism is one of the well-known established pathogenesis of pulmonary hypertension, known as chronic thromboembolic pulmonary hypertension (CTEPH)(3). APS may be also associated with other diseases, mainly systemic lupus erythematosus (SLE). The presence of secondary APS in SLE patients further aggravate the condition due to recurrent venous thromboembolic showers to the pulmonary vasculature. Pulmonary endarterectomy (PEA) is the treatment of choice for CTEPH with lifelong anticoagulation(4). We herein report a rare cause of CTEPH in a 42-year-old Egyptian man who presented with dyspnea WHO-FC III. The patient was diagnosed as a case of CTEPH due to secondary APS. He underwent PEA and was discharged on lifelong anticoagulation. Clinical follow-ups thereafter showed improvement of functional capacity and pulmonary artery pressures. In conclusion, management of such cases was combination of standard treatment of CTEPH, in addition to specific management of secondary APS to avoid recurrence of the disease.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">art thrombosis</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Coagulopathies,
 Systemic lupus erythematosus (SLE) is the prototypic multisystem autoimmune disorder with a broad spectrum of clinical presentations encompassing almost all organs and tissues(1). Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the occurrence of venous and/or arterial thrombosis and pregnancy morbidity in the presence of pathogenic autoantibodies known as antiphospholipid antibodies (aPL)(2). Chronic thromboembolism is one of the well-known established pathogenesis of pulmonary hypertension, known as chronic thromboembolic pulmonary hypertension (CTEPH)(3). APS may be also associated with other diseases, mainly systemic lupus erythematosus (SLE). The presence of secondary APS in SLE patients further aggravate the condition due to recurrent venous thromboembolic showers to the pulmonary vasculature. Pulmonary endarterectomy (PEA) is the treatment of choice for CTEPH with lifelong anticoagulation(4). We herein report a rare cause of CTEPH in a 42-year-old Egyptian man who presented with dyspnea WHO-FC III. The patient was diagnosed as a case of CTEPH due to secondary APS. He underwent PEA and was discharged on lifelong anticoagulation. Clinical follow-ups thereafter showed improvement of functional capacity and pulmonary artery pressures. In conclusion, management of such cases was combination of standard treatment of CTEPH, in addition to specific management of secondary APS to avoid recurrence of the disease.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">stenos</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Diseases of arteries,Coagulopathies,
 Chronic thromboembolic pulmonary hypertension (CTEPH) is one of the leading causes of severe pulmonary hypertension (PH). The disease is still underdiagnosed, and the true prevalence is unknown. CTEPH is characterized by intraluminal non-resolving thrombus organization and fibrous stenosis, or complete obliteration of pulmonary arteries, promoted by progressive remodeling of the pulmonary vasculature. One consequence of this is an increase in pulmonary vascular resistance and pressure, resulting in PH and progressive right heart failure, leading to death if left untreated. Endovascular disobliteration by pulmonary endarterectomy (PEA) is the preferred treatment for CTEPH patients. PEA surgery is the only technique that can potentially cure CTEPH disease, especially in patients with fresh or organized thrombi of the proximal branches of pulmonary arteries. However, not all patients are eligible for PEA surgery. Recent research has provided evidence suggesting balloon pulmonary angioplasty (BPA) and targeted medical therapy as additional promising available treatments options for inoperable CTEPH and recurrent/persistent PH after PEA surgery. Studies on BPA have shown it to improve pulmonary hemodynamics, symptoms, exercise capacity and RV function in inoperable CTEPH. Subsequently, BPA has developed into an essential component of the modern era of CTEPH treatment. Large randomized controlled trials have demonstrated varying significant improvements with targeted medical therapy in technically inoperable CTEPH patients. Thus, treatment of CTEPH requires a comprehensive multidisciplinary assessment, including an experienced PEA surgeon, PH specialist, BPA interventionist and CTEPH-trained radiologist at expert centers. In this comprehensive review, we address the latest developments in the fast-evolving field of CTEPH. These include advancements in imaging modalities and developments in operative and interventional techniques, which have widened the range of patients who may benefit from these procedures. The efficacy and safety of targeted medical therapies in CTEPH patients are also discussed. As the treatment options for CTEPH improve, hybrid management involving multiple treatments in the same patient may become a viable option in the near future.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Inflammatory diseases,
 This article reviews the scientific reasons that support the intriguing vision of pulmonary hypertension (PH) as a disease with a cancer-like nature and to understand whether this point of view may have fruitful consequences for the overall management of PH. This review compares cancer and PH in view of Hanahan and Weinberg&#39;s principles (i.e., hallmarks of cancer) with an emphasis on hyperproliferative, metabolic, and immune/inflammatory aspects of the disease. In addition, this review provides a perspective on the role of transcription factors and chromatin and epigenetic aberrations, besides genetics, as &#34;common driving mechanisms&#34; of PH hallmarks and the foreseeable use of transcription factor/epigenome targeting as multitarget approach against the hallmarks of PH. Thus, recognition of the widespread applicability and analogy of these concepts will increasingly affect the development of new means of PH treatment.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 Pulmonary arterial hypertension (PAH) is defined by a heterogenous pathobiology that corresponds to variable clinical presentation, treatment response, and prognosis across affected patients. The approach to pharmacotherapeutics in PAH has evolved since the introduction of the first prostacyclin replacement drug, which was trialed in patients with end-stage disease as a strategy by which to delay or prevent mortality. Subsequently, the aim of care in PAH has shifted toward minimizing symptoms, improving functional capacity, delaying disease progression, and prolonging life. Thus, treatments are now implemented earlier and according to the evidence base, which spans more than twenty years and includes patients at various stages of disease. Overall, the evidence supports multidrug therapy rather than monotherapy in the majority of PAH patients. Among incident patients, up-front combination therapy with ambrisentan and tadalafil or other comparable agents within these drug classes is recommended based on strong clinical trial data. In the near future, up-front triple therapy may be emerge as bona fide treatment approach in selected patients. Future goals that are already under consideration in PAH include stronger integration of pathobiological characteristics when considering the use of specific drugs, or the development of novel therapies, toward precision medicine-based clinical pharmacology.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 Pulmonary arterial hypertension (PAH) is defined by a heterogenous pathobiology that corresponds to variable clinical presentation, treatment response, and prognosis across affected patients. The approach to pharmacotherapeutics in PAH has evolved since the introduction of the first prostacyclin replacement drug, which was trialed in patients with end-stage disease as a strategy by which to delay or prevent mortality. Subsequently, the aim of care in PAH has shifted toward minimizing symptoms, improving functional capacity, delaying disease progression, and prolonging life. Thus, treatments are now implemented earlier and according to the evidence base, which spans more than twenty years and includes patients at various stages of disease. Overall, the evidence supports multidrug therapy rather than monotherapy in the majority of PAH patients. Among incident patients, up-front combination therapy with ambrisentan and tadalafil or other comparable agents within these drug classes is recommended based on strong clinical trial data. In the near future, up-front triple therapy may be emerge as bona fide treatment approach in selected patients. Future goals that are already under consideration in PAH include stronger integration of pathobiological characteristics when considering the use of specific drugs, or the development of novel therapies, toward precision medicine-based clinical pharmacology.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 Pulmonary arterial hypertension (PAH) is defined by a heterogenous pathobiology that corresponds to variable clinical presentation, treatment response, and prognosis across affected patients. The approach to pharmacotherapeutics in PAH has evolved since the introduction of the first prostacyclin replacement drug, which was trialed in patients with end-stage disease as a strategy by which to delay or prevent mortality. Subsequently, the aim of care in PAH has shifted toward minimizing symptoms, improving functional capacity, delaying disease progression, and prolonging life. Thus, treatments are now implemented earlier and according to the evidence base, which spans more than twenty years and includes patients at various stages of disease. Overall, the evidence supports multidrug therapy rather than monotherapy in the majority of PAH patients. Among incident patients, up-front combination therapy with ambrisentan and tadalafil or other comparable agents within these drug classes is recommended based on strong clinical trial data. In the near future, up-front triple therapy may be emerge as bona fide treatment approach in selected patients. Future goals that are already under consideration in PAH include stronger integration of pathobiological characteristics when considering the use of specific drugs, or the development of novel therapies, toward precision medicine-based clinical pharmacology.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 Pulmonary arterial hypertension (PAH) is defined by a heterogenous pathobiology that corresponds to variable clinical presentation, treatment response, and prognosis across affected patients. The approach to pharmacotherapeutics in PAH has evolved since the introduction of the first prostacyclin replacement drug, which was trialed in patients with end-stage disease as a strategy by which to delay or prevent mortality. Subsequently, the aim of care in PAH has shifted toward minimizing symptoms, improving functional capacity, delaying disease progression, and prolonging life. Thus, treatments are now implemented earlier and according to the evidence base, which spans more than twenty years and includes patients at various stages of disease. Overall, the evidence supports multidrug therapy rather than monotherapy in the majority of PAH patients. Among incident patients, up-front combination therapy with ambrisentan and tadalafil or other comparable agents within these drug classes is recommended based on strong clinical trial data. In the near future, up-front triple therapy may be emerge as bona fide treatment approach in selected patients. Future goals that are already under consideration in PAH include stronger integration of pathobiological characteristics when considering the use of specific drugs, or the development of novel therapies, toward precision medicine-based clinical pharmacology.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 The range of cell types identified in the pathogenesis of pulmonary arterial hypertension (PAH) has expanded substantially since the first pathological descriptions of this disease. This, in turn, has provided needed clarity on the gamut of molecular mechanisms that regulate vascular remodeling and promote characteristic cardiopulmonary hemodynamic changes that define PAH clinically. Insight derived from these scientific advances suggest that the PAH arteriopathy is due to the convergence of numerous molecular mechanisms driving cornerstone endophenotypes, such as plexigenic, hypertrophic, and fibrotic histopathological changes. Interestingly, while some endophenotypes are observed commonly in multiple cell types, such as dysregulated metabolism, other events such as endothelial-mesenchymal transition are cell type-specific. Integrating data from classical PAH vascular cell types with fresh information in pericytes, adventitial fibroblasts, and other PAH contributors recognized more recently has enriched the field with deeper understanding on the molecular basis of this disease. This added complexity, however, also serves as the basis for utilizing novel analytical strategies that emphasize functional signaling pathways when extracting information from big datasets. With these concepts as the backdrop, the current work offers a concise summary of cellular and molecular changes in the lung that drive PAH and may, thus, be important for discovering novel therapeutic targets or applications to clarify PAH onset and disease trajectory.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">rhe</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Inflammatory diseases,
 The epidemiology of pulmonary vascular disease (PVD) remains unclear in Africa, where health systems do not reach the majority of the population and heath information systems are poorly developed. In this context, registries are particularly important in gathering crucial information on PVD, aiming at improving knowledge of the epidemiology and/or quality of care. While population-based registries are the main tool to identify incident cases, and be a better indicator of pulmonary vascular disease burden, hospital-based registries can give an indication of the demand for specific care services, which is useful for health policy and planning. The only registry for pulmonary hypertension in Africa - the Pan African Pulmonary Hypertension Cohort (PAPUCO) - involved four countries, and was a pragmatic study that revealed a unique pattern of environmental risks, issues related to low access to health care, and ill-equipped health facilities for diagnosis and management of pulmonary hypertension. In addition, disease specific registries for conditions such as congenital heart disease and rheumatic heart disease uncovered high occurrence of PVD that can be managed and/or prevented with improvements in community awareness, surveillance, management and prevention. It is suggested that existing networks of experts and researchers develop regional registries to determine the epidemiology of PVD in Africa, assess geographic, environmental and seasonal differentials, as well as inform policy and care provision in the continent.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 Background  Hypertension and related complications are major contributors to morbidity and mortality in Nepal. Community health workers have been proposed as promising health cadres to meet the growing healthcare demand for non-communicable disease management in other developing countries. Objective  We aimed to explore existing workflows, needs and challenges for hypertension care coordination and to assess the feasibility of establishing a Female Community Health Volunteer (FCHV)-based hypertension management program in Kavre, Nepal. Design  We conducted one focus group discussion with eight FCHVs and twenty-three in-depth interviews with four FCHVs not attending FGD, nine individuals with hypertension, six health workers, and four health officials in two village development committees of Kavre District, Nepal. Applied thematic analysis was performed using NVivo 12. Results  Health literacy related to hypertension was low among both community members and FCHVs. Delay in treatment initiation and loss to follow-up were common patterns despite anti-hypertensive medication compliance. Major health system-related barriers included underutilization of primary healthcare institutions, communication gaps and lack of grass-roots level educational campaigns. Community pharmacies, monthly health camps and increasing governmental attention to NCDs were favorable for improving hypertension management. This study also supports that FCHVs should be provided with adequate training and financial incentives to promote hypertension education, screening and referral in their catchments. Conclusions  Barriers and facilitators identified in this study provide important implications for future hypertension management in Nepal. We recommend hypertension education and screening across Nepal at a grass-root level through FCHVs. Providing professional training and proper financial incentives for FCHVs are warranted. Highlights  Health literacy related to hypertension was low among both community members and Female Community Health Volunteers in Nepal.Delay in treatment initiation and loss to follow-up were common despite relatively high anti-hypertensive medication compliance.Health system-related barriers in research sites included underutilization of primary healthcare institutions, communication gaps, and lack of grass-roots level educational campaigns.Female Community Health Volunteers should be provided with adequate training and financial incentives to promote hypertension management.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Diseases of arteries,
 Highlights  Over half of male acute coronary syndrome patients were smokers in China.Smoking was associated with higher risk of critical cardiac symptoms at admission.Only 35.3% of smoking patients received smoking cessation interventions in China. Background  Smoking cessation is recognized as an effective and cost-effective strategy for improving the prognosis of patients with coronary heart disease. Despite this, few studies have evaluated the smoking prevalence and provision of smoking cessation interventions among patients with acute coronary syndrome (ACS) in China. Objectives  To evaluate the smoking prevalence, clinical conditions and in-hospital outcomes associated with smoking, and the provision of smoking cessation interventions among ACS patients in China. Methods  This registry study was conducted using data from the Improving Care for Cardiovascular Disease in China project, a collaborative nationwide registry of the American Heart Association and the Chinese Society of Cardiology. Our study sample comprised 92,509 ACS inpatients admitted between November 2014 and December 2018. A web-based data collection platform was used to report required data. Results  Smoking prevalence among male and female ACS patients was 52.4% and 8.0%, respectively. Patients younger than 45 years had the highest smoking rate (men  68.0%; women  14.9%). Compared with non-smokers, smokers had an earlier onset age of ACS and a greater proportion of severe clinical manifestations at admission, including ST-elevation myocardial infarction (67.8% versus 54.8%; p &lt; 0.001) and substantially elevated myocardial injury markers (86.1% versus 83.0%; p &lt; 0.001). After multivariable adjustment, smoking was associated with higher risk of critical cardiac symptoms at admission (OR = 1.14, 95% CI  1.08-1.20; p &lt; 0.001) and had no direct association with in-hospital outcomes (OR = 0.93, 95% CI  0.84-1.02; p = 0.107) of ACS patients. Of 37,336 smokers with ACS, only 35.3% received smoking cessation interventions before discharge. There was wide variation in provision of smoking cessation interventions across hospitals (0%-100%). Conclusions  Smoking is highly prevalent among ACS patients in China. However, smoking cessation interventions are not widely adopted in clinical practice in China as part of formal treatment strategies for ACS patients, indicating an important target for quality improvement. Clinical Trial Registration  URL  http //www.clinicaltrials.gov. Unique identifier  NCT02306616.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Cardiomyopathy,
 As the global COVID-19 pandemic advances, it increasingly impacts those vulnerable populations who already bear a heavy burden of neglected tropical disease. Chagas disease (CD), a neglected parasitic infection, is of particular concern because of its potential to cause cardiac, gastrointestinal, and other complications which could increase susceptibility to COVID-19. The over one million people worldwide with chronic Chagas cardiomyopathy require special consideration because of COVID-19&#39;s potential impact on the heart, yet the pandemic also affects treatment provision to people with acute or chronic indeterminate CD. In this document, a follow-up to the WHF-IASC Roadmap on CD, we assess the implications of coinfection with SARS-CoV-2 and Trypanosoma cruzi, the etiological agent of CD. Based on the limited evidence available, we provide preliminary guidance for testing, treatment, and management of patients affected by both diseases, while highlighting emerging healthcare access challenges and future research needs.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Diseases of arteries,
 Introduction  Substantial heterogeneity exists in reperfusion strategies for patients with ST-segment myocardial infarction (STEMI) in low- and middle-income countries (LMICs). We sought to compare outcomes associated with primary percutaneous coronary intervention (PPCI) and non-primary percutaneous coronary intervention (nPPCI) reperfusion strategies in patients with STEMI in Kerala, India. Methods  We performed a retrospective analysis of patients with STEMI (n = 8665) from the Acute Coronary Syndrome Quality Improvement in Kerala (ACS QUIK) randomized trial receiving either PPCI (n = 6623) or nPPCI (n = 2042). nPPCI included all PCI strategies implemented when PPCI was not available including all post-fibrinolysis PCI strategies and PCI without fibrinolysis. Clinical outcomes among patients undergoing PPCI and nPPCI were compared after propensity-score matching. The main outcomes were the rates of in-hospital and 30-day major adverse cardiovascular events (MACE), defined as the composite of death, reinfarction, stroke, and major bleeding. Results  In the propensity-score matched cohort (n = 1266 in each group), nPPCI had longer symptom onset to hospital arrival time (347.5 vs. 195.0 minutes, p &lt; 0.001), door to balloon time (108 minutes vs. 75 minutes, p &lt; 0.001), and were less likely to receive a coronary stent (89.4% vs. 95%, p &lt; 0.001), including drug-eluting stents (89.5% vs. 94.4%, p &lt; 0.001). There were no clinically meaningful differences in discharge medical therapy. However, patients treated with nPPCI were less commonly referred for cardiac rehabilitation (20.2% vs. 24.2%; p = 0.019). In-hospital (3.6% vs. 3.3%, p = 0.74%) and 30-day (4.4% vs. 4.6%, p = 0.77) MACE did not differ between nPPCI and PPCI matched groups. Conclusion  In a large, contemporary population of STEMI patients from a LMIC, patients treated with a nPPCI reperfusion strategy had comparable short- and intermediate-term outcomes compared to PPCI despite differences in hospital presentation time and coronary stent use. These findings are reassuring but highlight the need for continued quality improvement in the delivery of STEMI care in resource-limited settings.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Inflammatory diseases,
 The success of ST-segment elevation myocardial infarction (STEMI) networks application in Europe and the United States in delivering rapid reperfusion therapy in the community have become an inspiration to other developing countries to develop regional STEMI network in order to improve the STEMI care. Although barriers are found in the beginning phase of constructing the network, recent analysis from national or regional registries worldwide have shown improvement of the STEMI care in many countries over the years. To improve the overall care of patients with STEMI particularly in developing countries, improvements should be focusing on how to minimize the total ischemia time, and this includes care improvement at each step of care after the patient shows signs and symptoms of chest pain. Innovation in health technology to develop the electrocardiogram transmission and communication system, along with routine performance measures of the STEMI network may help bridging the disparities of STEMI system of care between guideline recommended therapy and the real world clinical practice.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 Aim  To systematically assess the association between adult sexual abuse (ASA) and cardiovascular diseases (CVDs) of heart attack and stroke, and their risk factors of hypertension, diabetes, dyslipidaemia and obesity. Methods  Two authors conducted a PubMed, Scopus and Web of Science review of the literature published prior to 1 October 2019. Relevant English language studies irrespective of study design and data collection techniques were included. Included articles needed to have examined ASA per se independent of physical or psychological/emotional abuse, and childhood sexual abuse. Results  Of the 3260 articles identified, nine were selected from 97 full-text articles assessed for eligibility (n = 855 206 women). Six studies were cross-sectional in design while three articles were from longitudinal studies; all emanated from the United States. One study only (n = 867) performed clinical assessments (heights and weights) to determine the relevant outcome (obesity), four presented self-reported outcomes (heart attack, stroke, hypertension, diabetes, obesity), two reviewed clinical records and two did not provide details on outcome assessments (obesity). Sexual abuse by an intimate partner was examined in five articles, three assessed military sexual trauma and a single study evaluated any perpetrator. A meta-analysis could not be conducted because of the heterogeneity across studies. The available evidence was insufficient to quantify the relationship, if any, between ASA and CVDs and their risk factors. Conclusions  Currently, no longitudinal studies of ASA in general populations have objectively investigated the development of CVDs and their risk factors using clinical and biochemical measurements. In view of the high CVD burden, and the frequency of ASA, it is important to fully understand the relationship between the two.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Diseases of arteries,
 Background  Whether cardiovascular disease (CVD) and its traditional risk factors predict severe coronavirus disease 2019 (COVID-19) is uncertain, in part, because of potential confounding by age and sex. Methods  We performed a systematic review of studies that explored pre-existing CVD and its traditional risk factors as risk factors of severe COVID-19 (defined as death, acute respiratory distress syndrome, mechanical ventilation, or intensive care unit admission). We searched PubMed and Embase for papers in English with original data (&gt;/=10 cases of severe COVID-19). Using random-effects models, we pooled relative risk (RR) estimates and conducted meta-regression analyses. Results  Of the 661 publications identified in our search, 25 papers met our inclusion criteria, with 76,638 COVID-19 patients including 11,766 severe cases. Older age was consistently associated with severe COVID-19 in all eight eligible studies, with RR &gt;~5 in &gt;60-65 versus &lt;50 years. Three studies showed no change in the RR of age after adjusting for covariate(s). In univariate analyses, factors robustly associated with severe COVID-19 were male sex (10 studies; pooled RR = 1.73, [95% CI 1.50-2.01]), hypertension (8 studies; 2.87 [2.09-3.93]), diabetes (9 studies; 3.20 [2.26-4.53]), and CVD (10 studies; 4.97 [3.76-6.58]). RR for male sex was likely to be independent of age. For the other three factors, meta-regression analyses suggested confounding by age. Only four studies reported multivariable analysis, but most of them showed adjusted RR ~2 for hypertension, diabetes, and CVD. No study explored renin-angiotensin system inhibitors as a risk factor for severe COVID-19. Conclusions  Despite the potential for confounding, these results suggest that hypertension, diabetes, and CVD are independently associated with severe COVID-19 and, together with age and male sex, can be informative for predicting the risk of severe COVID-19.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">rhe</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,
 Background  National and international political commitments have been made recently on rheumatic heart disease (RHD), a preventable heart condition that is endemic in low-resource countries. To inform best practice and identify evidence gaps, we assessed the effectiveness of RHD prevention and control programmes and the extent and nature of their integration into local health systems. Methods  We conducted a systematic review and meta-analysis using a previously published protocol that included electronic and manual searches for studies published between January 1990 and July 2019 reporting on prevention and control programmes for populations at risk for streptococcal pharyngitis, rheumatic fever, and/or RHD. We analysed programme integration according to a previously published framework and programme effectiveness using a results-chain framework. We meta-analysed secondary prophylaxis adherence using random-effects models. Study quality was assessed using peer-reviewed checklists (CASP and PRISM). PROSPERO registration  CRD42017076307. Findings  Five observational studies met with the inclusion criteria. Studies were similar in extent and nature of integration into health systems; no programme was completely integrated or non-integrated. A single study reported on programme impact. Secondary prophylaxis adherence improved among partially integrated RHD programmes (RR, 1.18 [95% CI, 1.03 to 1.36], 3 studies, n = 618). Risk of bias was low in two studies, and indeterminable in the remaining three studies. Interpretation  There is evidence that partially integrated RHD programmes are beneficial for a range of intermediate health outcomes. This review provides a starting point for the design and implementation of future RHD programmes by outlining current best practice for integration and identifying key gaps in knowledge. Funding  National Research Foundation of South Africa.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Introduction Stress is a phenomenon elicited in response to certain triggers that may be external or internal. Stress has been identified as a risk factor for various diseases, including cardiovascular disease. In this study, we aim to find an association between psychological stress and cardiovascular disease in the local setting Methods This case-control study was conducted in a tertiary care hospital in Pakistan from June 2019 to December 2019. One hundred and seventeen (117) patients with myocardial infarction and unstable angina were enrolled in the case group. One hundred and ten (110) patient&#39;s attendants were enrolled in the study as controlled. Results The risk of a cardiovascular event was higher in patients with a history of social isolation (OR, 2.47), marital stress (OR, 2.28), work stress (OR, 3.2), childhood abuse (OR, 2.78), or trauma (OR, 2.67). Conclusion Psychological stress is an important risk for cardiovascular disease, which is often overlooked. Efforts should be made to include questions related to psychological stress in the history-taking of patients at risk of a cardiovascular event and the management plan should include psychological counseling.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Background Assessment of essential tremor is often done by a trained clinician who observes the limbs during different postures and actions and subsequently rates the tremor. While this method has been shown to be reliable, the inter- and intra-rater reliability and need for training can make the use of this method for symptom progression difficult. Many limitations of clinical rating scales can potentially be overcome by using inertial sensors, but to date many algorithms designed to quantify tremor have key limitations. Methods We propose a novel algorithm to characterize tremor using inertial sensors. It uses a two-stage approach that 1) estimates the tremor frequency of a subject and only quantifies tremor near that range; 2) estimates the tremor amplitude as the portion of signal power above baseline activity during recording, allowing tremor estimation even in the presence of other activity; and 3) estimates tremor amplitude in physical units of translation (cm) and rotation ( degrees ), consistent with current tremor rating scales. We validated the algorithm technically using a robotic arm and clinically by comparing algorithm output with data reported by a trained clinician administering a tremor rating scale to a cohort of essential tremor patients. Results Technical validation demonstrated rotational amplitude accuracy better than +/-0.2 degrees and position amplitude accuracy better than +/-0.1 cm. Clinical validation revealed that both rotation and position components were significantly correlated with tremor rating scale scores. Conclusion We demonstrate that our algorithm can quantify tremor accurately even in the presence of other activities, perhaps providing a step forward for at-home monitoring.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 During cardiac surgery with cardiopulmonary bypass (CPB), adequate maintenance of cerebral blood flow (CBF) is vital in preventing postoperative neurological injury - i.e. stroke, delirium, cognitive impairment. Reductions in CBF large enough to impact cerebral energy metabolism can lead to tissue damage and subsequent brain injury. Current methods for neuromonitoring during surgery are limited. This study presents the clinical translation of a hybrid optical neuromonitor for continuous intraoperative monitoring of cerebral perfusion and metabolism in ten patients undergoing non-emergent cardiac surgery with non-pulsatile CPB. The optical system combines broadband near-infrared spectroscopy (B-NIRS) to measure changes in the oxidation state of cytochrome c oxidase (oxCCO) - a direct marker of cellular energy metabolism - and diffuse correlation spectroscopy (DCS) to provide an index of cerebral blood flow (CBFi). As the heart was arrested and the CPB-pump started, increases in CBFi (88.5 +/- 125.7%) and significant decreases in oxCCO (-0.5 +/- 0.2 microM) were observed; no changes were noted during transitions off CPB. Fifteen hypoperfusion events, defined as large and sustained reductions in CPB-pump flow rate, were identified across all patients and resulted in significant decreases in perfusion and metabolism when mean arterial pressure dropped to 30 mmHg or below. The maximum reduction in cerebral blood flow preceded the corresponding metabolic reduction by 18.2 +/- 15.0 s. Optical neuromonitoring provides a safe and non-invasive approach for assessing intraoperative perfusion and metabolism and has potential in guiding patient management to prevent adverse clinical outcomes.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 Background  Adherence to treatment is a primary determinant of treatment success. Nonadherence attenuates clinical benefits to the recipients of the treatment. However, monitoring adherence to long treatment regimens is not given due emphasis in low-income contexts. This study aimed to assess adherence to antihypertensive treatment and factors associated with it in Central Ethiopia. Method  This is an institution-based cross-sectional study conducted in 4 public hospitals in Central Ethiopia from December 4, 2016, to September 25, 2017. The Morisky Medication Adherence Scale (MMAS-8) was used to assess the level of adherence. The Revised Illness Perception Questionnaire (IPQ-R) was used to assess illness perception. The MMAS-8 score ranges from 0 to 8, a score of 8 reflects high adherence, 6 to 7 medium adherence, and &lt;6 low adherence. Results  A total of 989 hypertensive patients participated in the study, of which 36.0% were assessed to have high adherence, 31.7% medium adherence, and 32.3% low adherence. We found that treatment adherence was significantly and positively associated with having family support (AOR  1.65; 95% CI = 1.23, 2.22), high perception about consequences of hypertension (AOR  1.51; 95% CI = 1.17, 1.95), and high perception about the severity of the disease (AOR  1.42; 95% CI = 1.09, 1.86). Conclusion  The treatment adherence to antihypertensive medications is low in Central Ethiopia. Engaging family members in the treatment plan and improving patients&#39; understanding of the illness are critical in achieving high adherence to medication in this context.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Background  Diabetic kidney disease (DKD) is a progressive kidney disease and a leading cause of end-stage renal disease (ESRD). Diabetic kidney disease has been strongly associated with increased risk of cardiovascular morbidity and mortality. Despite their susceptibility to cardiovascular diseases (CVDs), patients with DKD are less likely to receive appropriate cardiovascular risk modification as they are generally excluded from major cardiovascular trials. Awareness of vulnerability of these patients necessitates investigating potential interventions that would lessen their risk of adverse outcomes. Objectives  This study aimed to explore the effect of bone marrow-derived mesenchymal stem cells (MSCs) in modulating cardiovascular risk factors that develop with the progression of DKD. Methods  A total of 60 adult female albino rats were allocated into 3 groups  control group, untreated DKD group, and mesenchymal stem cells-treated diabetic kidney disease (MSCs-DKD) group. Blood pressure, blood glucose level, lipid profile, and atherogenic index were used to assess cardiovascular risk. All rats were killed and subjected to in vitro aortic reactivity studies 8 weeks after induction of diabetes. The MSCs-DKD rats received a single intravenous injection of MSCs 4 weeks after diabetes induction. Results  Mesenchymal stem cells injection significantly decreased blood pressure, atherogenic index, and blood glucose compared with untreated rats. The MSCs-DKD aorta also exhibited significant enhancement of vascular reactivity parameters despite absence of improvement in kidney function. These findings conformed to tracked MSCs, which were found residing in aortic and pancreatic tissues and absent in kidneys. Conclusions  Mesenchymal stem cells hold hope of improving cardiovascular risk and mortality in patients with DKD, particularly those deteriorating to ESRD.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 The production and accumulation of advanced glycation end-products (AGEs) are hypothesized to have a causal role in the development of the complications associated with aging and lifestyle-related diseases, such as diabetes, atherosclerosis and hyperlipidemia. Therefore, it is important to reduce the production and accumulation of AGEs. In the present study, the ability of sodium 4-phenylbutyrate (PBA) on inhibition of glycation was assessed. In vitro, PBA inhibited the glycation of albumin and collagen by up to 42.1 and 36.9%, respectively. Furthermore, when spontaneously diabetic KK mice were administered PBA (20 mg/day) or vehicle orally, glycosuria developed rapidly in the control mice, but after 6 weeks, only one treated mouse was glycosuric. In addition, the weight gain and HbA1c levels were significantly lower in the treated mice compared with the untreated mice (weight gain, 36.0 g vs. 39.4 g, P&lt;0.01; HbA1C level, 3.96 vs. 4.78%, P&lt;0.01; respectively). These results suggested that PBA also inhibited glycation in vivo. Further studies are required to determine whether PBA may be effective for the therapy or prevention of aging or lifestyle-related diseases caused by the accumulation of AGEs. The method of administration and the side-effects of PBA have already been established as PBA is already used clinically. Therefore, the repurposing of PBA for reducing AGE levels may be a potential option to reduce complications associated with aging.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Background  Improving recognition of patients at increased risk of acute kidney injury (AKI) in the community may facilitate earlier detection and implementation of proactive prevention measures that mitigate the impact of AKI. The aim of this study was to develop and externally validate a practical risk score to predict the risk of AKI in either hospital or community settings using routinely collected data. Methods  Routinely collected linked datasets from Tayside, Scotland, were used to develop the risk score and datasets from Kent in the UK and Alberta in Canada were used to externally validate it. AKI was defined using the Kidney Disease  Improving Global Outcomes serum creatinine-based criteria. Multivariable logistic regression analysis was performed with occurrence of AKI within 1 year as the dependent variable. Model performance was determined by assessing discrimination (C-statistic) and calibration. Results  The risk score was developed in 273 450 patients from the Tayside region of Scotland and externally validated into two populations  218 091 individuals from Kent, UK and 1 173 607 individuals from Alberta, Canada. Four variables were independent predictors for AKI by logistic regression  older age, lower baseline estimated glomerular filtration rate, diabetes and heart failure. A risk score including these four variables had good predictive performance, with a C-statistic of 0.80 [95% confidence interval (CI) 0.80-0.81] in the development cohort and 0.71 (95% CI 0.70-0.72) in the Kent, UK external validation cohort and 0.76 (95% CI 0.75-0.76) in the Canadian validation cohort. Conclusion  We have devised and externally validated a simple risk score from routinely collected data that can aid both primary and secondary care physicians in identifying patients at high risk of AKI.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlud</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 Trichloroethylene exposure is a major risk factor for pulmonary veno-occlusive disease. We demonstrated that trichloroethylene alters the endothelial barrier integrity, at least in part, through vascular endothelial (VE)-Cadherin internalisation, and suggested that this mechanism may play a role in the development of pulmonary veno-occlusive disease.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Diseases of arteries,
 Background  Diabetes mellitus (DM) is an established risk factor for intermittent claudication (IC) and other manifestations of atherosclerotic peripheral arterial disease. Indications for surgery in infrainguinal IC are debated, and there are conflicting reports regarding its outcomes in patients with DM. Aims of this study were to compare both short- and long-term effects on total- and cardiovascular (CV) mortality, major adverse cardiovascular events (MACEs), acute myocardial infarction (AMI), stroke, and major amputation following infrainguinal endovascular surgery for IC in patients with and without DM. We also evaluated potential relationships between diabetic control and outcomes in patients with DM. Methods  Nationwide observational cohort study of patients registered in the Swedish Vascular Registry and the Swedish National Diabetes Registry. Propensity score adjusted comparison of total and CV mortality, MACE, AMI, stroke, and major amputation after elective infrainguinal endovascular surgery for IC in 626 patients with and 1112 without DM at 30 postoperative days and after median 5.2 [interquartile range (IQR) 4.2-6.3] years of follow-up for patients with DM, and 5.4 (IQR 4.3-6.5) years for those without. Results  In propensity score adjusted Cox regression after 30 postoperative days, there were no differences between groups in morbidity or mortality. At last follow-up, patients with DM showed higher rates of MACE [hazard ratio (HR) 1.26, confidence interval (CI) 1.07-1.48; p &lt; 0.01], AMI (HR 1.48, CI 1.09-2.00; p = 0.01), and major amputation (HR 2.31, CI 1.24-4.32; p &lt; 0.01). Among patients with DM, higher HbA1c was associated with higher total mortality during follow-up (HR 1.01, CI 1.00-1.03; p = 0.045). Conclusion  Patients with DM have higher rates of MACE, AMI, and major amputation in propensity score adjusted analysis during 5 years of follow-up after infrainguinal endovascular surgery for IC. Furthermore, HbA1c is associated with total mortality in patients with DM. Prevention and treatment of DM is important to improve cardiovascular and limb outcomes.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,
 Objectives  The aims of the present study were to investigate the expression of calcium sensing receptor (CaSR) at different times in acute myocardial infarction (AMI) rat myocardial tissue after mouse embryonic stem cells (mESCs) transplantation treatment and to assess its effects on apoptosis and oxidative stress of cardiomyocytes. Materials and Methods  The AMI rats were treated with mESCs, Calindol (a CaSR agonist) and Calhex231 (a CaSR inhibitor). Serum measurements, Echocardiographic analysis and TUNEL assay were performed. Myocardial ultrastructure changes were viewed by electron microscopy. Additionally, western blotting was used to detect the protein expressions. Results  Compared to the sham group, it was found that the expression levels of CaSR, caspase-3, cytoplasmic cytochrome C (cyt-C) and Bcl2-associated x (Bax), and the levels of Malondialdehyde (MDA) were significantly increased in both AMI and AMI + mESCs + Calindol groups with the development of myocardial infarction. Furthermore, the ultra-microstructure of cardiomyocyte was highly damaged, the expression levels of mitochondrial cyt-C and B-cell lymphoma 2 (Bcl-2) were significantly decreased, and there was decreased activity of superoxide dismutase (SOD). However, the combination of Calhex231 and mESCs transplantation could inhibit these changes. Conclusion  Our results suggested that CaSR expression in myocardial tissue of AMI rats was increased over time, and that Calhex231 could enhance the efficacy of ESCs transplantation for the treatment of AMI, which would be a new therapeutic strategy for the treatment of AMI.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlud</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Diseases of arteries,
 Objectives  Glutamate is the most widespread neurotransmitter in the central nervous system and has several functions as a neuromodulator in the brain although in pathological conditions like ischemia it is excessively released causing cell death. Under physiological conditions, glutamate is rapidly scavenged from the synaptic cleft by excitatory amino-acid transporters (EAATs). An imbalance in glutamatergic neurotransmission could influence the expression of glutamate transporters and is a pathological feature in several neurological disorders. It has been shown that estrogen and progesterone act as neuroprotective agents after brain injury. This study aims to investigate the role of hormone therapy after middle cerebral artery occlusion (tMCAO) in the expression of GLT-1 and EAAT3 as glutamate transporters. Materials and Methods  Middle cerebral artery occlusion technique was performed in Wistar rats in order to induce focal cerebral ischemia. Estrogen, progesterone, and a combination of both hormones were injected subcutaneously in the early minutes of reperfusion. Sensorimotor functional tests were performed and infarct volume was calculated by TTC staining of brain section. Gene and protein expression of EAAT3 and GLT-1 were evaluated by RT-PCR, immunoblotting, and immunohistochemistry. Results  Behavioral scores were increased and infarct volume was reduced by hormone therapy. RT-PCR, immunoblotting, and immunohistochemistry data showed that the expression of GLT-1 and EAAT3 increased after ischemia. Also, estrogen and progesterone treatment enhanced mRNA and protein expression levels of GLT-1 and EAAT3 compared with ischemia. Conclusion  Steroids may protect brain tissue against ischemia-induced tissue degeneration by decreasing extracellular glutamate levels through the induction of glutamate transporters.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Inflammatory diseases,
 Brain injury induced by cardiac arrest/cardiopulmonary resuscitation (CA/CPR) is the leading cause of death among patients who have recovery of spontaneous circulation (ROSC). Inflammatory response, apoptosis, and oxidative stress are proven pathological mechanisms implicated in neuronal damage. Methane-rich saline (MRS) has been proven that exerts a beneficial protectiveness impact in several models of ischemia-reperfusion injury. The goal of this paper is to ascertain the role of MRS in CA/CPR-induced brain injury and its potential mechanisms. The tracheal intubation of Sprague-Dawley (SD) rats was clamped for 6 min to establish an asphyxiating cardiac arrest model. After that, chest compressions were applied; then, MRS or saline was administered immediately post-ROSC, the rats were sacrificed, and brain tissue was collected at the end of 6 hours. We observed that MRS treatment attenuated neuronal damage in the hippocampal CA1 region by inhibiting microglial activation, leading to a decrease in the overexpression of proinflammatory cytokines such as TNF-alpha, IL-6, and iNOS. The results also illustrated that MRS treatment diminished apoptosis in the hippocampal CA1 region , reduced the expression of apoptosis-associated proteins Bax and cleaved caspase9, and increased Bcl-2 expression, as well as inhibited the expression of endoplasmic reticulum (ER) stress pathway-related proteins GRP78, ATF4, and CHOP. Further findings showed that MRS treatment significantly attenuated hippocampal ROS and MDA levels and increased GSH and SOD antioxidant factor levels, which indicated that MRS treatment could inhibit oxidative stress. Our results suggest that MRS exerts a protective effect against CA/CPR brain injury, by inhibiting oxidative stress, microglial activation-induced inflammatory responses, and ER stress-mediated apoptosis.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">cerebrovascul</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Diseases of arteries,
 Background  Cerebral ischemic stroke (CIS) is a common cerebrovascular disease whose main risks include necrosis, apoptosis, and cerebral infarction. But few therapeutic advances and prominent drugs seem to be of value for ischemic stroke in the clinic yet. In the previous study, notoginseng leaf triterpenes (PNGL) from Panax notoginseng stem and leaf have been confirmed to have neuroprotective effects against mitochondrial damages caused by cerebral ischemia in vivo. However, the potential mechanisms of mitochondrial protection have not been fully elaborated yet. Methods  The oxygen and glucose deprivation and reperfusion (OGD/R)-induced SH-SY5Y cells were adopted to explore the neuroprotective effects and the potential mechanisms of PNGL in vitro. Cellular cytotoxicity was measured by MTT, viable mitochondrial staining, and antioxidant marker detection in vitro.Mitochondrial functions were analyzed by ATP content measurement, MMP determination, ROS, NAD, and NADH kit in vitro. And the inhibitor FK866 was adopted to verify the regulation of PNGL on the target NAMPT and its key downstream. Results  In OGD/R models, treatment with PNGL strikingly alleviated ischemia injury, obviously preserved redox balance and excessive oxidative stress, inhibited mitochondrial damage, markedly alleviated energy metabolism dysfunction, improved neuronal mitochondrial functions, obviously reduced neuronal loss and apoptosis in vitro, and thus notedly raised neuronal survival under ischemia and hypoxia. Meanwhile, PNGL markedly increased the expression of nicotinamide phosphoribosyltransferase (NAMPT) in the ischemic regions and OGD/R-induced SH-SY5Y cells and regulated the downstream SIRT1/2-Foxo3a and SIRT1/3-MnSOD/PGC-1alpha pathways. And FK866 further verified that the protective effects of PNGL might be mediated by the NAMPT in vitro. Conclusions  The mitochondrial protective effects of PNGL are, at least partly, mediated via the NAMPT-NAD+ and its downstream SIRT1/2/3-Foxo3a-MnSOD/PGC-1alpha signaling pathways. PNGL, as a new drug candidate, has a pivotal role in mitochondrial homeostasis and energy metabolism therapy via NAMPT against OGD-induced SH-SY5Y cell injury.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Mitochondrial oxidative stress and dysfunction play an important role of atrial remodeling and atrial fibrillation (AF) in diabetes mellitus. Endoplasmic reticulum (ER) stress has been linked to both physiological and pathological states including diabetes. The aim of this project is to explore the roles of ER stress in hyperglycemia-induced mitochondrial dysfunction and cell death of atrial cardiomyocytes. High glucose upregulated ER stress, mitochondrial oxidative stress, and mitochondria-associated ER membrane (MAM)- enriched proteins (such as glucose-regulated protein 75 (GRP75) and mitofusin-2 (Mfn2)) of primary cardiomyocytes in vitro. Sodium phenylbutyrate (4-PBA) prevented the above changes. Silencing of Mfn2 in HL-1 cells decreased the Ca(2+) transfer from ER to mitochondria under ER stress conditions, which were induced by the ER stress agonist, tunicamycin (TM). Electron microscopy data suggested that Mfn2 siRNA significantly disrupted ER-mitochondria tethering in ER stress-injured HL-1 cells. Mfn2 silencing attenuated mitochondrial oxidative stress and Ca(2+) overload, increased mitochondrial membrane potential and mitochondrial oxygen consumption, and protected cells from TM-induced apoptosis. In summary, Mfn2 plays an important role in high glucose-induced ER stress in atrial cardiomyocytes, and Mfn2 silencing prevents mitochondrial Ca(2+) overload-mediated mitochondrial dysfunction, thereby decreasing ER stress-mediated cardiomyocyte cell death.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 Warfarin, a vitamin K antagonist (VKA), is known to promote arterial calcification (AC). In the present study, we conducted a case-cohort study within the Multi-Ethnic Study of Atherosclerosis (MESA); 6655 participants were included. From MESA data, we found that AC was related to both age and vitamin K; furthermore, the score of AC increased with SASP marker including interlukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) rising. Next, a total of 79 warfarin users in our center developed significantly more calcified coronary plaques as compared to non-VKA users. We investigated the role of warfarin in phosphate-induced AC in different ages by in vitro experimental study. Furthermore, dose-time-response of warfarin was positively correlated with AC score distribution and plasma levels of the SASP maker IL-6 among patients &lt; 65 years, but not among patients &gt;/= 65 years. In addition, in vitro research suggested that warfarin treatment tended to deteriorate calcification in young VSMC at the early stage of calcification. Our results suggested that aging and warfarin-treatment were independently related to increased AC. Younger patients were more sensitive to warfarin-related AC than older patients, which was possibly due to accumulated warfarin-induced cellular senescence.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Nonalcoholic fatty liver disease (NAFLD) is a pathology that contains a broad liver dysfunctions spectrum. These alterations span from noninflammatory isolated steatosis until nonalcoholic steatohepatitis (NASH), a more aggressive form of the disease characterized by steatosis, inflammatory status, and varying liver degrees fibrosis. NAFLD is the most prevalent chronic liver disease worldwide. The causes of NAFLD are diverse and include genetic and environmental factors. The presence of NASH is strongly associated with cirrhosis development and hepatocellular carcinoma, two conditions that require liver transplantation. The liver alterations during NAFLD are well described. Interestingly, this pathological condition also affects other critical tissues and organs, such as skeletal muscle and even the cardiovascular, renal, and nervous systems. Oxidative stress (OS) is a harmful state present in several chronic diseases, such as NAFLD. The purpose of this review is to describe hepatic and extrahepatic dysfunctions in NAFLD. We will also review the influence of OS on the physiopathological events that affect the critical function of the liver and peripheral tissues.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Coagulopathies,
 Cardiotoxicity as an off-target effect of doxorubicin therapy is a major limiting factor for its clinical use as a choice cytotoxic agent. Seeds of Irvingia gabonensis have been reported to possess both nutritional and medicinal values which include antidiabetic, weight losing, antihyperlipidemic, and antioxidative effects. Protective effects of Irvingia gabonensis ethanol seed extract (IGESE) was investigated in doxorubicin (DOX)-mediated cardiotoxicity induced with single intraperitoneal injection of 15 mg/kg of DOX following the oral pretreatments of Wistar rats with 100-400 mg/kg/day of IGESE for 10 days, using serum cardiac enzyme markers (cardiac troponin I (cTI) and lactate dehydrogenase (LDH)), cardiac tissue oxidative stress markers (catalase (CAT), malonyldialdehyde (MDA), superoxide dismutase (SOD), glutathione-S-transferase (GST), glutathione peroxidase (GSH-Px), and reduced glutathione (GSH)), and cardiac histopathology endpoints. In addition, both qualitative and quantitative analyses to determine IGESE&#39;s secondary metabolites profile and its in vitro antioxidant activities were also conducted. Results revealed that serum cTnI and LDH were significantly elevated by the DOX treatment. Similarly, activities of tissue SOD, CAT, GST, and GSH levels were profoundly reduced, while GPx activity and MDA levels were profoundly increased by DOX treatment. These biochemical changes were associated with microthrombi formation in the DOX-treated cardiac tissues on histological examination. However, oral pretreatments with 100-400 mg/kg/day of IGESE dissolved in 5% DMSO in distilled water significantly attenuated increases in the serum cTnI and LDH, prevented significant alterations in the serum lipid profile and the tissue activities and levels of oxidative stress markers while improving cardiovascular disease risk indices and DOX-induced histopathological lesions. The in vitro antioxidant studies showed IGESE to have good antioxidant profile and contained 56 major secondary metabolites prominent among which are gamma-sitosterol, Phytol, neophytadiene, stigmasterol, vitamin E, hexadecanoic acid and its ethyl ester, Phytyl palmitate, campesterol, lupeol, and squalene. Overall, both the in vitro and in vivo findings indicate that IGESE may be a promising prophylactic cardioprotective agent against DOX-induced cardiotoxicity, at least in part mediated via IGESE&#39;s antioxidant and free radical scavenging and antithrombotic mechanisms.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,
 In peripheral arterial disease (PAD), angiogenesis is a major process involved in repairing the microvasculature in the ischemic lower limb. MicroRNA-210 (miR-210) is a microRNA that is substantially increased in patients with PAD. However, the effects of miR-210 on angiogenesis following PAD remain elusive. In the present study, mice with hindlimb ischemia (HLI) were generated as an animal model of PAD, and miR-210 levels were overexpressed in the ischemic limb. The overexpression of miR-210 using microRNA mimics greatly improved angiogenesis and perfusion recovery; in contrast, the knockdown of miR-210 impaired perfusion recovery 28 days after HLI. Ischemic muscle tissue was harvested 7 days after experimental PAD in order to perform biochemical tests, and miR-210 antagonism resulted in increased malondialdehyde levels. In cultured endothelial cells under simulated ischemia, miR-210 mimic improved endothelial cell viability and enhanced tube formation; and a miR-210 inhibitor decreased cell survival, reduced tube formation and increased reactive oxygen species (ROS) levels. Furthermore, miR-210 antagonism increased the protein disulfide-isomerase levels in cultured endothelial cells. These results demonstrate that ischemia-induced miR-210 elevation is adaptive in PAD, and that miR-210 improves angiogenesis at least partially through decreasing ROS production.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 Obesity and its related diseases, such as type 2 diabetes, hypertension and cardiovascular disease, are steadily increasing worldwide. Over the past few decades, numerous studies have focused on the differentiation and function of brown and beige fat, providing evidence for their therapeutic potential in treating obesity. However, no specific novel drug has been developed to treat obesity in this way. Peptides are a class of chemically active substances, which are linked together by amino acids using peptide bonds. They have specific physiological activities, including browning of white fat. As signal molecules regulated by the neuroendocrine system, the role of polypeptides, such as neuropeptide Y, brain-gut peptide and glucagon-like peptide in obesity and its related complications has been revealed. Notably, with the rapid development of peptidomics, peptide drugs have been widely used in the prevention and treatment of metabolic diseases, due to their short half-life, small apparent distribution volume, low toxicity and low side effects. The present review summarizes the progress and the new trend of peptide research, which may provide novel targets for the prevention and treatment of obesity.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam diseas</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">pericardit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">pericard</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">rhe</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">cardit</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Interleukin 1 (IL-1), a central mediator of innate immunity, is considered a master cytokine of local and systemic inflammation. IL-1 has emerged as pivotal in the pathogenesis of autoinflammatory diseases (AIDs), and blockade of its pathway has become a crucial target for therapy. Anakinra (ANA), a recombinant IL-1beta receptor antagonist, was the first anti-IL-1 agent employed in clinical practice. ANA is currently approved for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, adult-onset Still&#39;s disease, and cryopyrin-associated autoinflammatory syndrome. It has also been successfully used for off-label treatment of various monogenic, polygenic, or undefined etiology systemic AIDs. This review describes currently available evidence for the off-label use of ANA in pediatric rheumatologic diseases. Specifically, the use of ANA in Kawasaki disease, idiopathic recurrent pericarditis, Behcet disease, monogenic AIDs, undifferentiated AIDs, chronic non-bacterial osteomyelitis, macrophage activation syndrome, and febrile infection-related epilepsy, in terms of its safety and efficacy. In selected pediatric rheumatic disorders, the off-label administration of ANA appears to be effective and safe. In order to control severe and/or relapsing disease, ANA should be considered as a valuable treatment option in children suffering from rare inflammatory diseases. However, currently available data consist of retrospective studies and short case series; thus, randomized controlled trials and larger series with long-term follow up are mandatory to better assess the efficacy and cost effectiveness of ANA in these challenging patients.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-magenta-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">arrhythm</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Arrhythmia,Inflammatory diseases,
 Previous studies have demonstrated that calcium-/calmodulin-dependent protein kinase II (CaMKII) and calcineurin A-nuclear factor of activated T-cell (CnA-NFAT) signaling pathways play key roles in cardiac hypertrophy (CH). However, the interaction between CaMKII and CnA-NFAT signaling remains unclear. H9c2 cells were cultured and treated with angiotensin II (Ang II) with or without silenced CaMKIIdelta (siCaMKII) and cyclosporine A (CsA, a calcineurin inhibitor) and subsequently treated with Wenxin Keli (WXKL). Patch clamp recording was conducted to assess L-type Ca(2+) current (ICa-L), and the expression of proteins involved in signaling pathways was measured by western blotting. Myocardial cytoskeletal protein and nuclear translocation of target proteins were assessed by immunofluorescence. The results indicated that siCaMKII suppressed Ang II-induced CH, as evidenced by reduced cell surface area and ICa-L. Notably, siCaMKII inhibited Ang II-induced activation of CnA and NFATc4 nuclear transfer. Inflammatory signaling was inhibited by siCaMKII and WXKL. Interestingly, CsA inhibited CnA-NFAT pathway expression but activated CaMKII signaling. In conclusion, siCaMKII may improve CH, possibly by blocking CnA-NFAT and MyD88 signaling, and WXKL has a similar effect. These data suggest that inhibiting CaMKII, but not CnA, may be a promising approach to attenuate CH and arrhythmia progression.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Diseases of arteries,
 To date, a growing number of clinical studies have demonstrated the safety and health benefits from Baduanjin intervention. Based on this, our objective is to systematically retrieve and summarize the clinical studies on Baduanjin, with a view to providing more evidence-based evidence in support of the application of Baduanjin for healthcare, and to identify the shortcomings of existing research and provide feasibility suggest for further clinical research. Both four English language and four Chinese language electronic databases were used to search articles related to Baduanjin during 2000-2019. SPSS 22.0 software was used to analyze the data, and the risk of bias tool in the RevMan 5.3.5 software was used to evaluate the methodological quality of randomized controlled trials. A total of 810 publications were identified, including 43 (5.3%) systematic reviews, 614 (75.8%) randomized controlled trials, 66 (8.1%) nonrandomized controlled clinical studies, 84 (10.4%) case series, and 3 (0.4%) case reports. The top 10 diseases/conditions included diabetes, chronic obstructive pulmonary disease, hypertension, low back pain, neck pain, stroke, coronary heart disease, cognitive impairment, insomnia, and osteoporosis or osteopenia. The style of State General Administration of Sport of China in 2003 was the most commonly used version of Baduanjin, and Baduanjin was practiced with an average of 35 minutes, 1 or 2 times a day, 3-5 days per week, and a 18-week average duration. It is also worth noting that there were no serious adverse events related to Baduanjin intervention. Most studies were small sample size research, and the methodological quality of randomized controlled trials is generally low. The clinical studies of Baduanjin have a substantial quantity and evidence base. However, there are significant differences among different studies in the specific intervention measures such as style, intensity, duration, learning, and practice methods, which need to be further standardized and unified. Further high-quality designed and reporting studies are recommended to further validate the clinical benefits of Baduanjin.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Qishen granule (QSG) is a frequently prescribed traditional Chinese medicine formula, which improves heart function in patients with heart failure (HF). However, the cardioprotective mechanisms of QSG have not been fully understood. The current study aimed to elucidate whether the effect of QSG is mediated by ameliorating cytoplasmic calcium (Ca(2+)) overload in cardiomyocytes. The HF rat model was induced by left anterior descending (LAD) artery ligation surgery. Rats were randomly divided into sham, model, QSG-low dosage (QSG-L) treatment, QSG-high dosage (QSG-H) treatment, and positive drug (diltiazem) treatment groups. 28 days after surgery, cardiac functions were assessed by echocardiography. Levels of norepinephrine (NE) and angiotensin II (AngII) in the plasma were evaluated. Expressions of critical proteins in the calcium signaling pathway, including cell membrane calcium channel CaV1.2, sarcoendoplasmic reticulum ATPase 2a (SERCA2a), calcium/calmodulin-dependent protein kinase type II (CaMKII), and protein phosphatase calcineurin (CaN), were measured by Western blotting (WB) and immunohistochemistry (IHC). Echocardiography showed that left ventricular ejection fraction (EF) and fractional shortening (FS) value significantly decreased in the model group compared to the sham group, and illustrating heart function was severely impaired. Furthermore, levels of NE and AngII in the plasma were dramatically increased. Expressions of CaV1.2, CaMKII, and CaN in the cardiomyocytes were upregulated, and expressions of SERCA2a were downregulated in the model group. After treatment with QSG, both EF and FS values were increased. QSG significantly reduced levels of NE and AngII in the plasma. In particular, QSG prevented cytoplasmic Ca(2+) overload by downregulating expression of CaV1.2 and upregulating expression of SERCA2a. Meanwhile, expressions of CaMKII and CaN were inhibited by QSG treatment. In conclusion, QSG could effectively promote heart function in HF rats by restoring cardiac Ca(2+) homeostasis. These findings revealed novel therapeutic mechanisms of QSG and provided potential targets in the treatment of HF.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 Aims  Omentin-1, a newly identified adipokine, has been demonstrated to be associated with bone metabolism, but the results have been inconsistent. Moreover, the potential relationship of circulating omentin-1 with diabetic osteoporosis has never been reported. This study is intended for studying the association between circulating omentin-1, bone mineral density (BMD), prior fragility fractures, and other bone metabolic-related parameters. Methods  Circulating omentin-1 levels were measured in 172 patients with type 2 diabetes mellitus (T2DM), and participants were divided into the normal BMD group (n = 52), the osteopenia group (n = 66), and the osteoporosis group (n = 54). The relationship between circulating omentin-1 and diabetic osteoporosis and other parameters was analyzed. Results  Circulating omentin-1 was significantly higher in the osteoporosis group than in the normal group and in the osteopenia group (both P &lt; 0.05). Circulating omentin-1 levels were correlated significantly and positively with sex; high-density lipoprotein cholesterol; apolipoprotein A; and prevalence of prior fragility fractures, diabetic nephropathy, and retinopathy; they were correlated negatively with diastolic blood pressure, triglyceride, hemoglobin, atherogenic index of plasma, osteoporosis self-assessment tool for Asians, BMD at different skeletal sites, and corresponding T scores, irrespective of age, sex, and body mass index (P &lt; 0.01 or P &lt; 0.05). Moreover, circulating omentin-1 was an independent decisive factor for the presence of osteoporosis only in women after multivariate adjustment (odds ratio  1.069; 95% confidence interval  1.003-1.139; P &lt; 0.05). Lastly, the analysis of receiver operating characteristic curves revealed that the best cutoff value for circulating omentin-1 to predict diabetic osteoporosis was 15.37 ng/mL (sensitivity  71.7%; specificity  58.5%) in female subjects. Conclusions  High levels of circulating omentin-1 may be associated with the development of osteoporosis in female diabetic subjects and may be a potential biomarker for diabetic osteoporosis in women.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 Purpose  Medication patterns include all medications in an individual&#39;s clinical profile. We aimed to identify chronic co-morbidity treatment patterns through medication use among COPDGene participants and determine whether these patterns were associated with mortality, acute exacerbations of chronic obstructive pulmonary disease (AECOPD) and quality of life. Materials and Methods  Participants analyzed here completed Phase 1 (P1) and/or Phase 2 (P2) of COPDGene. Latent class analysis (LCA) was used to identify medication patterns and assign individuals into unobserved LCA classes. Mortality, AECOPD, and the St. George&#39;s Respiratory Questionnaire (SGRQ) health status were compared in different LCA classes through survival analysis, logistic regression, and Kruskal-Wallis test, respectively. Results  LCA identified 8 medication patterns from 32 classes of chronic comorbid medications. A total of 8110 out of 10,127 participants with complete covariate information were included. Survival analysis adjusted for covariates showed, compared to a low medication use class, mortality was highest in participants with hypertension+diabetes+statin+antiplatelet medication group. Participants in hypertension+SSRI+statin medication group had the highest odds of AECOPD and the highest SGRQ score at both P1 and P2. Conclusion  Medication pattern can serve as a good indicator of an individual&#39;s comorbidities profile and improves models predicting clinical outcomes.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Diseases of arteries,
 Purpose of Review  Type 2 diabetes mellitus (T2DM) is a prevalent disease with the severe clinical implications including myocardial infarction, stroke, and kidney disease. Therapies focusing on glycemic control in T2DM such as biguanides, sulfonylureas, thiazolidinediones, and insulin-based regimens have largely failed to substantially improve cardiovascular and kidney outcomes. We review the recent findings on sodium-glucose co-transporter type 2 (SGLT2) inhibitors which have shown to have beneficial cardiovascular and kidney-related effects. Recent Findings  SGLT2 inhibitors are a new class of diabetic medications that reduce the absorption of glucose in the kidney, decrease proteinuria, control blood pressure, and are associated with weight loss. SGLT2 inhibitors provide complementary therapy independent of insulin secretion or action with proved glucose-lowering effects. Recent placebo-controlled clinical trials have demonstrated that these medications can decrease cardiovascular death, progression of kidney disease, and all-cause mortality in diabetic and non-diabetic patients. Interestingly, SGT2 inhibitors such as dapagliflozin have also proven to decrease heart failure admissions and cardiovascular endpoints in non-diabetic patients, suggesting pleiotropic effects. The exact mechanisms responsible for reductions in atherosclerotic heart disease, need for kidney replacement therapy, and progressive kidney disease remain unknown. While regulation of glomerular hyperfiltration, albuminuria, and natriuresis may be part of the explanation, it is possible that complex cellular effects including energy balance optimization, downregulation of oxidative stress, and modulation of pro-inflammatory signaling pathways are associated with favorable outcomes observed in large clinical studies. Conclusion  SGLT2 inhibitors are novel antidiabetic medications with immense utility in the management of patients with T2DM. Furthermore, SGLT2 inhibitors have demonstrated to reduce the progression to advanced forms of kidney disease and its associated complications. These medications should be front and center in the management of patients with diabetic kidney disease with and without chronic kidney disease as they confer protection against cardiovascular/renal death and improve all-cause mortality. Future studies should evaluate the benefits and implications of early initiation of SGLT2 inhibitors, as well as the long-term effects of this therapy.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Diseases of arteries,Coagulopathies,
 Coronavirus disease 2019 (COVID-19) has spread rapidly throughout the world. The range of the disease is broad but among hospitalized patients with COVID-19 are coagulation disorders, pneumonia, respiratory failure, and acute respiratory distress syndrome (ARDS). The excess production of early response proinflammatory cytokines results in what has been described as a cytokine storm, leading to an increased risk of thrombosis, inflammations, vascular hyperpermeability, multi-organ failure, and eventually death over time. As the pandemic is spreading and the whole picture is not yet clear, we highlight the importance of coagulation disorders in COVID-19 infected subjects and summarize it. COVID-19 infection could induce coagulation disorders leading to clot formation as well as pulmonary embolism with detrimental effects in patient recovery and survival. Coagulation and inflammation are closely related. In this review, we try to establish an association between virus infections associated with innate immune activation, inflammation and coagulation activation.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Inflammatory diseases,
 Background  Urinary tract infection (UTI) is common in pediatrics. Infection of the upper urinary tract may cause renal scarring, and subsequently renal failure and hypertension. Permanent renal damage has been suggested to be caused by the host inflammatory response. Therefore, it is crucial to understand the host defense mechanisms against such infection in order to make timely diagnosis. The aim of this study was to evaluate interleukin-6 (IL-6) and IL-8 as potential biomarkers in differentiating acute pyelonephritis (AP) from cystitis (Cys) in children. Methods  Forty-three children (21 with AP and 22 with Cys) were included. Serum and urinary IL-6 and IL-8 were measured during the acute phase (within 12 hours of presentation) and the convalescent phase (8 weeks post-infection). Thirty-eight healthy children were included as controls. Results  During the acute phase, the mean urinary IL-6 level in the Cys group was significantly higher than that in the controls (17.8 pg/mL vs 14.8 pg/mL, P=0.03), while the serum levels were significantly higher in both the Cys and AP groups than in the controls (19.5 pg/mL, 19.4 pg/mL, 15 pg/mL, P=0.005 and 0.02, respectively). During the convalescent phase, serum and urinary IL-6 levels were higher in patients than in controls. Urinary IL-8 levels were significantly higher in both the AP and Cys groups compared to controls (206.5 pg/mL, 291.8 pg/mL, 89.4 pg/mL, P=0.05 and 0.02, respectively) during the acute phase. Serum IL-8 was not significantly different between the 3 groups. Nonetheless, no significant differences were found between the AP and Cys groups, in urinary or serum levels of IL-6 or IL-8, during both phases. Conclusion  IL-6 and IL-8 levels are elevated in patients with UTI. However, the levels did not differentiate between AP and cystitis. Further studies are warranted to evaluate their roles as indicators of the site of UTIs.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">diabet cardiomyopathy</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Cardiomyopathy,
 Background  In this study, we explored the clinical significance of serum peroxisome proliferator-activated receptor gamma co-activator 1 (PGC-1) alpha levels in diabetes mellitus with myocardial infarction (DMMI) patients and investigated the possible mechanism. Materials and Methods  Serum samples were obtained from patients with DMMI or normal volunteer in Baoding First Center Hospital. C57BL/6 mice were induced by a single intraperitoneal (i.p.) injection of 100 mg/kg STZ (streptozocin) for in vivo model. Human myocardial cell lines H9C2 cells were induced with high glucose medium (33 mmol/L glucose) for in vitro model. Western blot was used to analyze the protein expressions in this study. Results  Serum PGC-1 alpha levels were down-regulated in patients with DMMI. There was negative correlation between serum PGC-1 alpha levels and glycated hemoglobin, blood glucose or glucagon in DMMI patients. Recombination of PGC-1 alpha protein decreased the levels of glycated hemoglobin, blood glucose and glucagon, and inhibited oxidative stress and myocardial damage in mice of DMMI. Over-expression of PGC-1 alpha reduced reactive oxygen species (ROS)-oxidative stress, while down-regulation of PGC-1 alpha promoted ROS-oxidative stress via regulation of hemeoxygenase-1 (HO-1) expression in in vitro model of DMMI. The inhibition of HO-1 expression attenuated the anti-oxidation effects of PGC-1 alpha in vitro. Conclusion  PGC-1 alpha attenuated ROS-oxidative stress in diabetic cardiomyopathy model, and PGC-1 alpha served as a potential intervention to alleviate DMMI in clinical applications.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 Background  In the past decade, the prevalence of diabetes has grown more rapidly in low- and middle-income countries than in high-income countries. In 2019, Ethiopia is the fourth highest contributor to cases with diabetes in Africa with 1.7 million total cases. The present study was aimed to determine the prevalence of abnormal glucose metabolism and associated factors in Mekelle city, Northern Ethiopia. Methods and Materials  Community-based cross-sectional study was conducted among 321 randomly selected participants aged 20 years and above. Sociodemographic, lifestyle, clinical, and anthropometric data were collected in accordance with the STEPwise approach as recommended by the World Health Organization (WHO) for non-communicable disease (NCDs) surveillance. Blood glucose and lipid profiles were determined using a fasting venous blood sample. Bivariate and multivariable logistic regression analysis was used to identify factors associated with abnormal glucose metabolism. The level of statistical significance was set at p &lt;/=0.05. Results  More than half (54.8%) of the participants were women with an overall mean (+/-SD) age of 39.0 (+/-14.2) years. The overall prevalence of pre-diabetes and diabetes was 12.5% and 9.3%, respectively, with a mean (+/-SD) fasting blood glucose of 97.42 (+/-38.03) mg/dL. More than two-thirds (70.0%) of adults with diabetes were not aware of being diabetes. Advanced age, hypercholesterolemia, medium and high rank of heart rate, and raised waist to height ratio were significantly associated with a higher risk of pre-diabetes, whereas having house servant, systolic hypertension, and hypercholesterolemia were significantly associated with diabetes. Conclusion  We found a high prevalence of prediabetes and diabetes with more than two-thirds (70.0%) of newly diagnosed adults with diabetes, which showed a lack of awareness in the community. Awareness creation together with access to basic diagnostics in the primary health-care settings should therefore be a top priority to prevent its progression and complication.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 Background  Diabetes Mellitus is a complex, chronic disease that requires a coordinated management practice beyond blood glucose control. The disease causes chronic complications that affect the quality of the life of patients, place major pressure on the health-care system and cause a rise in diabetes-related mortality. Objective  To determine the prevalence of chronic diabetes mellitus complications, related risk factors, and management practice among adult type 2 diabetes mellitus outpatients at Tikur Anbessa Specialized Hospital (TASH). Methods  A cross-sectional study design was carried out from July to September 2018. The pre-tested data abstraction format was used to gather demographic and clinical information. We also used a balance of weight measurement, upright placed meter for height measurement, waist circumference measurement meter and BP equipment. Statistical analysis was accomplished using Statistical Package for the Social Sciences (SPSS) 25((R)) software. The significance level for statistics was set at p&lt;0.05. Results  In this study, 320 patients were involved. Of these, about 57% were female and had a mean age of 58 +/-11.2 years. About 85% of the study participants had comorbidity and 42.5% had complications. Hypertension and neuropathy were the most common comorbidity and complication, respectively. The usage of vascular preventive medication among study participants was 74.7% and 55.3% for statins and ASAs, respectively. Participants in the study who had disease duration of 5-10 years (AOR=3.50, 95% CI  1.19-10.28) and fifteen and above (AOR= 3.59, 95% CI  1.36-9.49) were at higher risk of diabetes complication as compared to less than five years. Conclusion  The prevalence of chronic complications was high among adult T2DM outpatients. The duration of disease and the number of medications used were the factors associated with chronic complications. The use of vascular preventive medications was low among study participants.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlud</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 Purpose  There is no well-accepted classification system of overall sickle cell disease (SCD) severity. We sought to develop a system that could be tested as a clinical outcome predictor. Patients and Methods  Using validated methodology (RAND/UCLA modified Delphi panel), 10 multi-disciplinary expert clinicians collaboratively developed 180 simplified patient histories and rated each on multiple axes (estimated clinician follow-up frequency, risk of complications or death, quality of life, overall disease severity). Using ratings on overall disease severity, we developed a 3-level severity classification system ranging from Class I (least severe) to Class III (most severe). Results  The system defines patients as Class I who are 8-40 years with no end organ damage, no chronic pain, and &lt;/=4 unscheduled acute care visits due to vaso-occlusive crises (VOC) in the last year. Patients &lt;8 or &gt;40 years with no end organ damage, no chronic pain, and &lt;2 unscheduled acute care visits are also considered Class I. Patients any age with &gt;/=5 unscheduled acute care visits and/or with severe damage to bone, retina, heart, lung, kidney, or brain are classified as Class III (except patients &gt;/=25 years with severe retinopathy, no chronic pain, and 0-1 unscheduled acute care visits, who are considered Class II). Patients not meeting these Class I or III definitions are classified as Class II. Conclusion  This system consolidates patient characteristics into homogenous groups with respect to disease state to support clinical decision-making. The system is consistent with existing literature that increased unscheduled acute care visits and organ damage translate into clinically significant patient morbidity. Studies to further validate this system are planned.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,
 Purpose  To evaluate a model for calculating the risk of AF and its relationship with the incidence of ischemic stroke and prevalence of cognitive decline. Materials and Methods  It was a multicenter, observational, retrospective, community-based study of a cohort of general population &gt;/=6ct 35 years, between 01/01/2016 and 31/12/2018. Setting  Primary Care. Participants  46,706 people &gt;/=65 years with an active medical history in any of the primary care teams of the territory, information accessible through shared history and without previous known AF. Interventions  The model to stratify the risk of AF (PI) has been previously published and included the variables sex, age, mean heart rate, mean weight and CHA2DS2VASc score. Main measurements  For each risk group, the incidence density/1000 person/years of AF and stroke, number of cases required to detect a new AF, the prevalence of cognitive decline, Kendall correlation, and ROC curve were calculated. Results  The prognostic index was obtained in 37,731 cases (80.8%) from lowest (Q1) to highest risk (Q4). A total of 1244 new AFs and 234 stroke episodes were diagnosed. Q3-4 included 53.8% of all AF and 69.5% of strokes in men; 84.2% of all AF and 85.4% of strokes in women; and 77.4% of cases of cognitive impairment. There was a significant linear correlation between the risk-AF score and the Rankin score (p &lt; 0.001), the Pfeiffer score (p &lt; 0.001), but not NIHSS score (p 0.150). The overall NNS was 1/19. Conclusion  Risk stratification allows identifying high-risk individuals in whom to intervene on modifiable risk factors, prioritizing the diagnosis of AF and investigating cognitive status.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Purpose  Wound healing, especially of infected wounds, remains a clinical challenge in plastic surgery. This study aimed to manufacture a novel and multifunctional wound dressing by combining graphene oxide/copper nanocomposites (GO/Cu) with chitosan/hyaluronic acid, providing significant opportunities for the therapy of wound repair in wounds with a high risk of bacterial infection. Methods  In this study, GO/Cu-decorated chitosan/hyaluronic acid dressings (C/H/GO/Cu) were prepared using sodium trimetaphosphate (STMP) crosslinking and the vacuum freeze-drying method, and chitosan/hyaluronic acid dressings (C/H) and GO-incorporated chitosan/hyaluronic acid dressings (C/H/GO) served as controls. The surface characterization, in vitro degradation under various pH values, antimicrobial potential, cytocompatibility and in vivo therapeutic efficacy in a bacteria-infected full-thickness skin defect model were systematically evaluated. Results  Our experimental results indicated that the acidic environment facilitated the release of copper (CuNPs and Cu(2+)) from the dressings, and prepared C/H/GO/Cu dressings exhibited significant in vitro antimicrobial activities against the two tested bacterial strains (ATCC35984 and ATCC25923). All three dressings showed satisfactory cytocompatibility with mouse fibroblasts (NIH/3T3-L1). Moreover, remarkably accelerated wound healing was found in the C/H/GO/Cu group, with controlled inflammatory infiltration and improved angiogenesis in granulation tissues. In addition, no pathological damage was noted in the tissue structures of the tested organs (heart, lung, liver and kidney) in any of the four groups. Conclusion  Collectively, GO/Cu-incorporated chitosan/hyaluronic acid dressings suggested a synergistic antimicrobial efficacy and acceptable biocompatibility both in vitro and in vivo, as well as a significantly accelerated healing process of bacteria-infected wounds. Thus, the multifunctional C/H/GO/Cu composite is expected to be a potential alternative for wound dressings, especially for the management of intractable wounds caused by bacterial infection.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Background  Comorbid congestive heart failure (CHF) was associated with worse prognosis in patients with chronic obstructive pulmonary disease (COPD), while few studies specially investigated critically ill patients. This study investigated the associations between comorbid COPD with or without CHF and prognosis of patients admitted to intensive care units (ICU). Methods  We conducted a retrospective cohort study in the Medical Information Mart for Intensive Care III database. Adult ICU patients were included and categorized as patients without COPD and CHF, patients with COPD but without CHF, patients with CHF but without COPD, and patients with both COPD and CHF. The study outcomes were 28-day mortality and 90-day mortality after ICU admission. Kaplan-Meier curves were plotted to estimate the survival distributions between groups and multivariable Cox regression analyses were employed to evaluate the associations between comorbid COPD and/or CHF and the study outcomes. Results  A total of 29,589 patients were included with 20,507 patients without COPD and CHF, 1575 patients with COPD, 6190 patients with CHF, and 1317 patients with both COPD and CHF. The highest 28-day mortality rate and 90-day mortality rate were found in patients with both COPD and CHF (15.95% and 25.74%, respectively), while patients with COPD and patients with CHF had similar mortality rates, also observed in Kaplan-Meier curves. Compared with patients without COPD or CHF, comorbid COPD or CHF both significantly increased the risk of 28-day mortality and 90-day mortality, but comorbid COPD and CHF together was associated with the highest risk of mortality (hazard ratio 1.55 (95% confidence interval (CI) 1.33-1.80) and 1.25 (95% CI 1.16-1.35) for 28-day mortality and 90-day mortality, respectively), while no significant interaction between COPD and CHF was found. Conclusion  ICU patients with comorbid COPD or CHF both experienced greater mortalities, while these two risk factors seemed to play an independent role.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischaem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,
 Background  Reducing the need for hospitalisation in patients with chronic obstructive pulmonary disease (COPD) is an important goal in COPD management. The aim of this study was to evaluate re-hospitalisation, treatment, comorbidities and mortality in patients with COPD who were hospitalised for the first time due to a COPD exacerbation. Methods  This was a retrospective, population-based observational cohort study of Swedish patients using linked data from three mandatory national health registries to assess re-hospitalisation rates, medication use and mortality. Rate of hospitalisation was calculated using the number of events divided by the number of person-years at risk; risk of all-cause and COPD-related mortality were assessed using Cox proportional hazard models. Results  In total, 51,247 patients were identified over 10 years; 35% of patients were not using inhaled corticosteroid, long-acting muscarinic antagonist or long-acting beta2-agonist treatment prior to hospitalisation, 38% of whom continued without treatment after being discharged. Re-hospitalisation due to a second severe exacerbation occurred in 11.5%, 17.8% and 24% of the patients within 30, 90 and 365 days, respectively. Furthermore, 24% died during the first year following hospitalisation and risk of all-cause and COPD-related mortality increased with every subsequent re-hospitalisation. Comorbidities, including ischaemic heart disease, heart failure and pneumonia, were more common amongst patients who were re-hospitalised than those who were not. Conclusion  Following hospitalisation for first severe COPD exacerbation, many patients did not collect the treatment recommended by current guidelines. Risk of mortality increased with every subsequent re-hospitalisation. Patients with concurrent comorbidities had an increased risk of being re-hospitalised.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Diseases of arteries,
 Purpose  This multicenter study evaluated 2-year effectiveness and safety following implantation of two second-generation trabecular micro-bypass stents (iStent inject ((R))) with phacoemulsification. Materials and Methods  This was a retrospective study of iStent inject implantation with phacoemulsification by nine surgeons across Australia. Eyes had mild to advanced glaucoma (predominantly primary open-angle/POAG, appositional angle-closure/ACG, or normal-tension/NTG) or ocular hypertension (OHT), and cataract. Evaluations included intraocular pressure (IOP); medications; proportions of eyes with 0 or &gt;/=2 medications, reduced/stable medications versus preoperative, and IOP &lt;/=15 mmHg; visual acuity; cup-to-disc ratio (CDR); visual fields (VF); adverse events; and secondary surgery. Results  A total of 340 eyes underwent surgery and had 24-month follow-up data. At 24 months, mean IOP decreased by 16% from 16.4+/-4.7 mmHg preoperatively to 13.7+/-3.1 mmHg (p&lt;0.001), and 77% of eyes achieved IOP of &lt;/=15 mmHg versus 49% preoperatively (p&lt;0.001). Mean number of medications decreased by 67% to 0.49+/-0.95 versus 1.49+/-1.20 preoperatively (p&lt;0.001), with 74% of eyes medication-free versus 25% preoperatively (p&lt;0.001), and 14% of eyes on &gt;/=2 medications versus 46% preoperatively (p&lt;0.001). Medication burden was reduced or stable in 98% of eyes versus preoperative. Stratified analyses showed significant IOP and medication reductions across glaucoma subtypes (POAG, ACG, NTG, OHT)  13-22% for IOP (p&lt;0.01 for all) and 62-100% for medication (p&lt;0.001 for all). Favorable safety included few adverse events; stable CDR, VF, and visual acuity; and filtering surgery in only 8 eyes (2.4%) over 2 years. Conclusion  This 340-eye multicenter dataset provides robust evidence of the safety and efficacy of iStent inject implantation with phacoemulsification, with significant and sustained IOP and medication reductions through 2 years. Results were similarly favorable across glaucoma subtypes (including POAG, ACG, NTG, OHT) and were attained across various glaucoma severities, clinical sites, and surgeons, highlighting the real-world versatility and utility of this treatment modality.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Coagulopathies,
 Perioperative acute pulmonary embolism represents a relatively rare complication; however, it could be very serious and devastating in some cases. Its diagnosis could be particularly challenging, especially in the intraoperative period. Herein, we emphasize some key concepts with the aim to perform an early and appropriate risk stratification, diagnostic and therapeutic approach in a multidisciplinary fashion, a brief overview on thromboprophylaxis, with the main objective to improve outcomes and survival in these challenging patients.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">cerebrovascul</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 Background  There is emerging interest and increasing amount of evidence that support the interrelationship between periodontitis and systemic conditions. Epidemiological and microbiological-immunological studies have lent credence to the concept that periodontal disease may be a separate risk factor for cardiovascular disease, cerebrovascular disease, and respiratory disease, as well as preterm delivery of low-birth-weight infants. Aim  The aim of this study was to evaluate the influence of periodontal infection as a possible risk factor for preterm low birth weight (LBW) based on age, literacy, and hemoglobin level of mother. Materials and Methods  The observational study was conducted on 200 subjects, which were selected from the free labor ward, District Hospital, Saifai, Etawah, UP, India. Periodontal examinations were performed using the World Health Organization criteria. The periodontal status of the mother was recorded using Community Periodontal Index. Results  For this study, chi-square test was performed to know the effect of variables and to find out the statistical significance of the study. Age of mother shows statistical insignificant association with periodontal disease, whereas literacy of mothers showed statistical significant association with periodontal disease, and periodontal status and hemoglobin levels of the mothers also showed a significant association. Conclusion  The prevalence of LBW infants was considerably less in mothers with a healthy periodontium and increased with progressive periodontal disease.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">rhe</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Background and Objectives  It has been found that the microorganism behind the failure of root-filled teeth is Enterococcus faecalis, which shows resistance to most of the intra-canal medicaments. Therefore, the purpose of this study was to evaluate the antibacterial efficacy of three intra-canal medications-calcium hydroxide with saline, combinations of calcium hydroxide with 2% chlorhexidine (CHX), and calcium hydroxide with 5% povidone-iodine-against E. faecalis in dentinal tubules of human incisors. Materials and Methods  Forty permanent maxillary central incisors were made into standardized segments and infected with E. faecalis. They were treated with a paste made of calcium hydroxide and 2% CHX, calcium hydroxide and 5% povidone-iodine, and calcium hydroxide and saline for 1 week. Dentinal shavings collected from the canal were suspended in thioglycollate broth solution and spread on brain heart infusion agar. Colony-forming units (CFUs) were enumerated and the CFU per milligram of dentin was calculated. The pH of the medicaments used was measured with the help of pH meter. Results  The results showed that the paste made from calcium hydroxide and 2% CHX was significantly more effective than that made from calcium hydroxide and povidone-iodine, and calcium hydroxide and saline. The addition of CHX or povidone-iodine did not affect the alkalinity of calcium hydroxide. Conclusion  This study concludes that Ca(OH)2 + 2% CHX are effective against E. faecalis. Combinations of calcium hydroxide and 5% povidone-iodine showed better antibacterial effect than calcium hydroxide and saline. Ca(OH)2 + saline was ineffective against E. faecalis.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">rhe</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Background and Objectives  It has been found that the microorganism behind the failure of root-filled teeth is Enterococcus faecalis, which shows resistance to most of the intra-canal medicaments. Therefore, the purpose of this study was to evaluate the antibacterial efficacy of three intra-canal medications-calcium hydroxide with saline, combinations of calcium hydroxide with 2% chlorhexidine (CHX), and calcium hydroxide with 5% povidone-iodine-against E. faecalis in dentinal tubules of human incisors. Materials and Methods  Forty permanent maxillary central incisors were made into standardized segments and infected with E. faecalis. They were treated with a paste made of calcium hydroxide and 2% CHX, calcium hydroxide and 5% povidone-iodine, and calcium hydroxide and saline for 1 week. Dentinal shavings collected from the canal were suspended in thioglycollate broth solution and spread on brain heart infusion agar. Colony-forming units (CFUs) were enumerated and the CFU per milligram of dentin was calculated. The pH of the medicaments used was measured with the help of pH meter. Results  The results showed that the paste made from calcium hydroxide and 2% CHX was significantly more effective than that made from calcium hydroxide and povidone-iodine, and calcium hydroxide and saline. The addition of CHX or povidone-iodine did not affect the alkalinity of calcium hydroxide. Conclusion  This study concludes that Ca(OH)2 + 2% CHX are effective against E. faecalis. Combinations of calcium hydroxide and 5% povidone-iodine showed better antibacterial effect than calcium hydroxide and saline. Ca(OH)2 + saline was ineffective against E. faecalis.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">rhe</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Background and Objectives  It has been found that the microorganism behind the failure of root-filled teeth is Enterococcus faecalis, which shows resistance to most of the intra-canal medicaments. Therefore, the purpose of this study was to evaluate the antibacterial efficacy of three intra-canal medications-calcium hydroxide with saline, combinations of calcium hydroxide with 2% chlorhexidine (CHX), and calcium hydroxide with 5% povidone-iodine-against E. faecalis in dentinal tubules of human incisors. Materials and Methods  Forty permanent maxillary central incisors were made into standardized segments and infected with E. faecalis. They were treated with a paste made of calcium hydroxide and 2% CHX, calcium hydroxide and 5% povidone-iodine, and calcium hydroxide and saline for 1 week. Dentinal shavings collected from the canal were suspended in thioglycollate broth solution and spread on brain heart infusion agar. Colony-forming units (CFUs) were enumerated and the CFU per milligram of dentin was calculated. The pH of the medicaments used was measured with the help of pH meter. Results  The results showed that the paste made from calcium hydroxide and 2% CHX was significantly more effective than that made from calcium hydroxide and povidone-iodine, and calcium hydroxide and saline. The addition of CHX or povidone-iodine did not affect the alkalinity of calcium hydroxide. Conclusion  This study concludes that Ca(OH)2 + 2% CHX are effective against E. faecalis. Combinations of calcium hydroxide and 5% povidone-iodine showed better antibacterial effect than calcium hydroxide and saline. Ca(OH)2 + saline was ineffective against E. faecalis.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 High pulmonary blood pressure contributes to exercise-induced pulmonary hemorrhage. The objective of this study was to use bioimpedance spectroscopy to assess body fluid compartment volumes under 3 conditions in 6 racehorses  i) Pre- and post-supramaximal treadmill exercise (control); ii) Exercise 4 hours after furosemide (0.5 mg/kg body weight, IV); iii) Exercise, removal of ~14 L of blood and subsequent reinfusion of the blood. Statistical analysis used linear mixed effects models. Body compartment volumes did not change during the control runs. Total body water (TBW) (P = 0.007, P = 0.007), extracellular fluid (ECF) (P = 0.003, P = 0.003), and intracellular fluid (ICF) volumes (P = 0.04, P = 0.04) decreased pre- and post-exercise following furosemide administration. The ICF trended to decrease (P = 0.07) after slow removal of blood. Blood reinfusion increased TBW (P = 0.02, P = 0.02) and ICF (P = 0.005, P = 0.005) pre- and post-exercise.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 The central nervous system has historically been viewed as an immune-privileged site, but recent data have shown that the meninges-the membranes that surround the brain and spinal cord-contain a diverse population of immune cells(1). So far, studies have focused on macrophages and T cells, but have not included a detailed analysis of meningeal humoral immunity. Here we show that, during homeostasis, the mouse and human meninges contain IgA-secreting plasma cells. These cells are positioned adjacent to dural venous sinuses  regions of slow blood flow with fenestrations that can potentially permit blood-borne pathogens to access the brain(2). Peri-sinus IgA plasma cells increased with age and following a breach of the intestinal barrier. Conversely, they were scarce in germ-free mice, but their presence was restored by gut re-colonization. B cell receptor sequencing confirmed that meningeal IgA(+) cells originated in the intestine. Specific depletion of meningeal plasma cells or IgA deficiency resulted in reduced fungal entrapment in the peri-sinus region and increased spread into the brain following intravenous challenge, showing that meningeal IgA is essential for defending the central nervous system at this vulnerable venous barrier surface.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-magenta-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">arrhythm</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Arrhythmia,Inflammatory diseases,
 Atrial fibrillation, the most common cardiac arrhythmia, is an important contributor to mortality and morbidity, and particularly to the risk of stroke in humans(1). Atrial-tissue fibrosis is a central pathophysiological feature of atrial fibrillation that also hampers its treatment; the underlying molecular mechanisms are poorly understood and warrant investigation given the inadequacy of present therapies(2). Here we show that calcitonin, a hormone product of the thyroid gland involved in bone metabolism(3), is also produced by atrial cardiomyocytes in substantial quantities and acts as a paracrine signal that affects neighbouring collagen-producing fibroblasts to control their proliferation and secretion of extracellular matrix proteins. Global disruption of calcitonin receptor signalling in mice causes atrial fibrosis and increases susceptibility to atrial fibrillation. In mice in which liver kinase B1 is knocked down specifically in the atria, atrial-specific knockdown of calcitonin promotes atrial fibrosis and increases and prolongs spontaneous episodes of atrial fibrillation, whereas atrial-specific overexpression of calcitonin prevents both atrial fibrosis and fibrillation. Human patients with persistent atrial fibrillation show sixfold lower levels of myocardial calcitonin compared to control individuals with normal heart rhythm, with loss of calcitonin receptors in the fibroblast membrane. Although transcriptome analysis of human atrial fibroblasts reveals little change after exposure to calcitonin, proteomic analysis shows extensive alterations in extracellular matrix proteins and pathways related to fibrogenesis, infection and immune responses, and transcriptional regulation. Strategies to restore disrupted myocardial calcitonin signalling thus may offer therapeutic avenues for patients with atrial fibrillation.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 In recent years, the increase in blood pressure at high altitudes has become an interesting topic among high-altitude researchers. In our animal studies using Wistar rats, we observed the existence of two rat populations that exhibit differential physiological responses during hypoxic exposure. These rats were classified as hypoxia-induced hypertensive rats and nonhypertensive rats. A decrease in nitric oxide levels was reported in different hypertension models associated with increased concentrations of asymmetric dimethylarginine (ADMA) and homocysteine, and we recently described an increase in arginase type II expression under hypoxia. ADMA and homocysteine decrease nitric oxide (NO) bioavailability; however, whether ADMA and homocysteine have a regulatory effect on arginase activity and therefore regulate another NO synthesis pathway is unknown. Therefore, the aim of this study was to measure basal ADMA and homocysteine levels in hypoxia-induced hypertensive rats and evaluate their effect on arginase II activity. Our results indicate that hypoxia-induced hypertensive rats presented lower nitric oxide concentrations than nonhypertensive rats, associated with higher concentrations of homocysteine and ADMA. Hypoxia-induced hypertensive rats also presented lower dimethylarginine dimethylaminohydrolase-2 and cystathionine beta-synthase levels, which could explain the high ADMA and homocysteine levels. In addition, we observed that both homocysteine and ADMA had a significant effect on arginase II activation in the hypertensive rats. Therefore, we suggest that ADMA and homocysteine have dual regulatory effects on NO synthesis. The former has an inhibitory effect on eNOS, and the latter has a secondary activating effect on arginase II. We propose that arginase II is activated by AMDA and homocysteine in hypoxia-induced hypertensive rats.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-magenta-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">arrhythm</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Arrhythmia,Heart failure,
 The immature phenotype of human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) is a major limitation to the use of these valuable cells for pre-clinical toxicity testing and for disease modeling. Here we tested the hypothesis that human perinatal stem cell derived extracellular matrix (ECM) promotes hiPSC-CM maturation to a greater extent than mouse cell derived ECM. We refer to the human ECM as Matrix Plus (Matrix Plus) and compare effects to commercially available mouse ECM (Matrigel). hiPSC-CMs cultured on Matrix Plus mature functionally and structurally seven days after thaw from cryopreservation. Mature hiPSC-CMs showed rod-shaped morphology, highly organized sarcomeres, elevated cTnI expression and mitochondrial distribution and function like adult cardiomyocytes. Matrix Plus also promoted mature hiPSC-CM electrophysiological function and monolayers&#39; response to hERG ion channel specific blocker was Torsades de Pointes (TdP) reentrant arrhythmia activations in 100% of tested monolayers. Importantly, Matrix Plus enabled high throughput cardiotoxicity screening using mature human cardiomyocytes with validation utilizing reference compounds recommended for the evolving Comprehensive In Vitro Proarrhythmia Assay (CiPA) coordinated by the Health and Environmental Sciences Institute (HESI). Matrix Plus offers a solution to the commonly encountered problem of hiPSC-CM immaturity that has hindered implementation of these human based cell assays for pre-clinical drug discovery.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,
 Bronchopulmonary dysplasia (BPD) is a chronic disease of preterm babies with poor clinical outcomes. Nrf2 transcription factor is crucial for cytoprotective response, whereas Keap1-an endogenous inhibitor of Nrf2 signaling-dampens these protective responses. Nrf2-sufficient (wild type) newborn mice exposed to hyperoxia develop hypoalveolarization, which phenocopies human BPD, and Nrf2 deficiency worsens it. In this study, we used PND1 pups bearing bearing hypomorphic Keap1 floxed alleles (Keap1(f/f)) with increased levels of Nrf2 to test the hypothesis that constitutive levels of Nrf2 in the premature lung are insufficient to mitigate hyperoxia-induced hypoalveolarization. Both wildtype and Keap1(f/f) pups at PND1 were exposed to hyperoxia for 72 h and then allowed to recover at room air for two weeks (at PND18), sacrificed, and lung hypoalveolarization and inflammation assessed. Hyperoxia-induced lung hypoalveolarization was remarkably lower in Keap1(f/f) pups than in wildtype counterparts (28.9% vs 2.4%, wildtype vs Keap1(f/f)). Likewise, Keap1(f/f) pups were protected against prolonged (96 h) hyperoxia-induced hypoalveolarization. However, there were no differences in hyperoxia-induced lung inflammatory response immediately after exposure or at PND18. Lack of hypoalveolarization in Keap1(f/f) pups was accompanied by increased levels of expression of antioxidant genes and GSH as assessed immediately following hyperoxia. Keap1 knockdown resulted in upregulation of lung cell proliferation postnatally but had opposing effects following hyperoxia. Collectively, our study demonstrates that augmenting endogenous Nrf2 activation by targeting Keap1 may provide a physiological way to prevent hypoalveolarization associated with prematurity.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 In children, soil-transmitted helminth infections have been linked to poor nutritional status and growth retardation in association with lower levels of IGF-1. In adults, IGF-1 has an anabolic and metabolic function and is related to nutritional status. Here, we assessed the impact of helminth infection on free IGF-1 and its major binding protein, IGFBP-3, in adults. The levels of IGF-1 and IGFBP3 were measured in 1669 subjects aged &gt;/= 16 years, before and after receiving four rounds of albendazole 400 mg/day or matching placebo for three consecutive days. Helminth infection status was assessed by microscopy (Kato-Katz) and PCR. Serum free IGF-1 level was significantly lower in helminth-infected subjects [mean difference and 95% CI - 0.068 (- 0.103; - 0.033), P &lt; 0.001 after adjustment for age, sex, body mass index, and fasting insulin level]. There was no difference in IGFBP-3 level between helminth infected versus non-infected subjects. In the whole study population, albendazole treatment significantly increased serum free IGF-1 level [estimate and 95% CI 0.031 (0.004; - 0.057), P = 0.024] whereas no effect was found on the IGFBP-3 level. Our study showed that helminth infection in adults is associated with lower free IGF-1 levels but not with IGFBP-3 and albendazole treatment significantly increases free IGF-1 levels in the study population.Clinical Trial Registration  https //www.isrctn.com/ISRCTN75636394 .
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Heparin and low molecular weight heparin (LMWH) have recently been considered useful treatment tools for inflammation. Heparin has antifibrotic activity, mediated by cellular secretion of hepatocyte growth factor (HGF). HGF has antifibrotic properties demonstrated in experimental models of lung, kidney, heart, skin, and liver fibrosis. The ability of LMWH for HGF secretion is similar to that of normal heparin. Poly (lactic-co-glycolic acid) (PLGA) is widely used for sustained drug release, because of its biocompatibility and low toxicity. LMWH-loaded PLGA microparticles are prepared by a conventional water-in-oil-in-water emulsion method. Interstitial pneumonia is a life-threatening pathological condition that causes respiratory failure when it progresses. In the present study, we investigated the therapeutic effect of LMWH-loaded PLGA microparticles in a mouse model of bleomycin-induced lung fibrosis. The ratios of fibrotic area to total area were significantly lower in mice administered LMWH-loaded microparticles than in mice administered bleomycin alone. The microparticle administration did not further enhance the gene expression for inflammatory cytokines. In a cell culture study, HGF secretion by mouse and human lung fibroblasts was significantly increased by LMWH addition. We conclude that LMWH showed anti-inflammatory activity, through the effects of LMWH-loaded PLGA microparticles on cells at sites of inflammation.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">cerebrovascul</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 Assessment of the cerebral blood-flow-reserve in patients with cerebrovascular diseases is extremely important in terms of making prognosis, determining treatment tactics, and controlling the revascularization outcome in the case of reconstructive interventions on the brain vessels. However, there is no easy-to-use, contactless method for either assessing the functional reserve of the cortical vascular network or intraoperative monitoring of surgical intervention. Our study aims to demonstrate feasibility of green-light imaging photoplethysmography (iPPG) to estimate cerebrovascular functional reserve in animal model of craniosurgical intervention. Custom-made iPPG system was exploited to visualize intracranial vessels in anesthetized Wistar rats (n = 15). Video frames of rat&#39;s cortex were recorded concurrently with systemic blood pressure, end-tidal CO2, and electrocardiogram. We found that injection of dorzolamide (carbonic-anhydrase inhibitor) significantly increased the blood-pulsations amplitude in all animals by 35 +/- 19% (p &lt; 0.001). Such an increase negatively correlated with significant decrease in end-tidal CO2 by 32 +/- 7% (p &lt; 0.001). It is noteworthy that the dorzolamide injection did not lead to significant changes in systemic blood pressure. Concluding, pulsations amplitude is a marker of the vascular tone that can be used to evaluate the functional cerebrovascular reserve. Imaging PPG is a simple and convenient method to assess cerebral blood flow, including during various neurosurgical interventions.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Inflammatory diseases,
 This study was performed to evaluate the long-term cardiovascular safety of gemigliptin in patients with type 2 diabetes mellitus (T2DM). After screening, eligible patients with T2DM were enrolled, received gemigliptin, and were followed up for a median of 2.50 years. The primary outcome was a composite of confirmed cardiovascular death, nonfatal myocardial infarction, or nonfatal ischemic stroke (3-point major adverse cardiovascular event [MACE]). The key secondary outcomes were incidence of all-cause mortality and any other cardiovascular events. A total of 5179 patients were included in the study and 5113 were treated with gemigliptin. Overall, the primary outcome occurred in 26 patients within 12 months (estimated incidence by Cox proportional hazard model 0.49%, 95% CI 0.29-0.69%) and in 54 patients within 54 months (estimated incidence from Cox proportional hazard model 1.35%, 95% CI 0.92-1.77%). During the study period, the incidence rates of each component of the primary composite outcome were 0.04% (0.2 events per 1000 person-years) for cardiovascular death, 0.51% (2.2 events per 1000 person-years) for nonfatal myocardial infarction, and 0.61% (2.5 events per 1000 person-years) for nonfatal ischemic stroke. The incidence of all-cause mortality was 0.82% (3.2 events per 1000 person-years) and the incidences of other cardiovascular events were all less than 0.3%. In conclusion, T2DM patients who received gemigliptin exhibited a low incidence of the primary composite MACE and all-cause mortality. Therefore, the use of gemigliptin is expected to be safe without an increase in cardiovascular risk.Trial registration  The study was registered at ClinicalTrials.gov (identifier  NCT02290301).
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,
 Tuberculosis (TB) is a leading cause of mortality due to infectious disease, but the factors determining disease progression are unclear. Transcriptional signatures associated with type I IFN signalling and neutrophilic inflammation were shown to correlate with disease severity in mouse models of TB. Here we show that similar transcriptional signatures correlate with increased bacterial loads and exacerbate pathology during Mycobacterium tuberculosis infection upon GM-CSF blockade. Loss of GM-CSF signalling or genetic susceptibility to TB (C3HeB/FeJ mice) result in type I IFN-induced neutrophil extracellular trap (NET) formation that promotes bacterial growth and promotes disease severity. Consistently, NETs are present in necrotic lung lesions of TB patients responding poorly to antibiotic therapy, supporting the role of NETs in a late stage of TB pathogenesis. Our findings reveal an important cytokine-based innate immune effector network with a central role in determining the outcome of M. tuberculosis infection.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 Ambulatory blood pressure (BP) monitoring is recommended to improve the management of hypertension. Here, we investigated the accuracy of BP estimated using a wearable cuff-less device, InBodyWATCH, compared with BP measured using a manual sphygmomanometer. Thirty-five adults were enrolled (age 57.1 +/- 17.9 years). The BP was estimated using InBodyWATCH with an individualized estimation based on a neural network model. Three paired sets of BPs from the two devices were compared using correlation analysis and Bland-Altman plots (n = 105 paired BP readings). The correlations for both systolic and diastolic BP (SBP and DBP) between the two devices were high (r = 0.964 and 0.939, both P &lt; 0.001). The mean difference was 2.2 +/- 6.1 mmHg for SBP and -0.2 +/- 4.2 mmHg for DBP; these were not significant (P = 0.472 for SBP and P = 0.880 for DBP). The proportions of estimated SBP/DBP obtained from the InBodyWATCH within +/- 5 mmHg of manual SBP/DBP were 71.4%/83.8%; within +/- 10 mmHg they were 86.7%/98.1%; and within +/- 15 mmHg they were 97.1%/99.0%. The estimated BP from this wearable cuff-less device correlated highly with the manual BP and showed good accuracy, suggesting its potential to be used in ambulatory BP monitoring.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 Inhaled corticosteroids (ICS) might lower the risk of coronary heart disease (CHD) in patients with chronic obstructive pulmonary disease (COPD). This study aimed to assess the association of ICS with the development of CHD in COPD patients by using data from the Korean Nationwide study. Patients who were newly diagnosed with COPD between 2004 and 2013 and who were not diagnosed with coronary heart disease before their diagnosis of COPD were included. Exposure of ICS was incorporated into multivariable Cox regression models using time-dependent methods. To accurately estimate ICS-exposure accumulation, a washout period of 2 years from 2002 to 2003 was applied. Among a total of 4,400 newly diagnosed COPD patients, 771 patients were diagnosed as CHD incident cases during a median follow-up of one year (interquartile range 0.1-2.9). The cumulative dose of ICS was associated with a reduced risk of CHD (adjusted hazard ratio [aHR], 0.68; 95% confidence interval [CI], 0.52-0.89). When the cumulative exposure dose of ICS was divided into quartiles, the aHR for CHD incidence was 0.70 (95% CI, 0.55-0.88) in the highest quartile ICS dose use. The effect of ICS on reducing CHD incidence was pronounced in adults over 55 years, men under 55 years, and former smokers. Our findings demonstrate the role of ICS for the prevention of CHD in COPD patients without a history of CHD. Further research is needed to determine whether a certain amount of ICS exposure in COPD patients is protective against CHD.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 OBJECTIVE  Gestational hypertension is characterized by an imbalance in angiogenic factors. The goal of the current study was to evaluate whether circulating concentrations of proangiogenic and antiangiogenic factors are associated with the risk of progression to preeclampsia and development of adverse outcomes in women with gestational hypertension. METHODS  We studied 496 women with gestational hypertension. Patients were divided into three groups based on their degree of angiogenic imbalance, evaluated by the soluble fms-like tyrosine kinase-1/placental growth factor ratio  no angiogenic imbalance (&lt;/=38), mild angiogenic imbalance (&gt;38-&lt;85), and severe angiogenic imbalance (&gt;/=85) or stratified into tertiles according to soluble endoglin (sEng) levels. RESULTS  The concentrations of all angiogenic factors were significantly different in patients with gestational hypertension than in healthy pregnancy. A significant trend towards higher serum sEng levels was observed as the degree of angiogenic imbalance increased. Patients with severe angiogenic imbalance had higher rates of adverse maternal and perinatal outcomes and progression to preeclampsia (P &lt; 0.001) when compared with patients with no or mild angiogenic imbalance. The risk of combined adverse maternal outcomes and specific adverse outcomes (hemolysis, elevated liver enzymes, low platelet count syndrome, preterm delivery, small-for-gestational-age infant, perinatal death, and progression to preeclampsia within 7, 14, 28, and 56 days) was higher in patients with severe angiogenic imbalance or sEng values in the highest tertile (odds ratio &gt;/=5.6 and &gt;/=2.0, respectively), compared with no angiogenic imbalance or the lowest tertile. CONCLUSION  In women with gestational hypertension at the time of initial evaluation, circulating concentrations of the soluble fms-like tyrosine kinase-1/placental growth factor ratio and sEng appear to be suitable markers to assess the risk of adverse maternal and perinatal outcomes and progression to preeclampsia.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 OBJECTIVE  Gestational hypertension is characterized by an imbalance in angiogenic factors. The goal of the current study was to evaluate whether circulating concentrations of proangiogenic and antiangiogenic factors are associated with the risk of progression to preeclampsia and development of adverse outcomes in women with gestational hypertension. METHODS  We studied 496 women with gestational hypertension. Patients were divided into three groups based on their degree of angiogenic imbalance, evaluated by the soluble fms-like tyrosine kinase-1/placental growth factor ratio  no angiogenic imbalance (&lt;/=38), mild angiogenic imbalance (&gt;38-&lt;85), and severe angiogenic imbalance (&gt;/=85) or stratified into tertiles according to soluble endoglin (sEng) levels. RESULTS  The concentrations of all angiogenic factors were significantly different in patients with gestational hypertension than in healthy pregnancy. A significant trend towards higher serum sEng levels was observed as the degree of angiogenic imbalance increased. Patients with severe angiogenic imbalance had higher rates of adverse maternal and perinatal outcomes and progression to preeclampsia (P &lt; 0.001) when compared with patients with no or mild angiogenic imbalance. The risk of combined adverse maternal outcomes and specific adverse outcomes (hemolysis, elevated liver enzymes, low platelet count syndrome, preterm delivery, small-for-gestational-age infant, perinatal death, and progression to preeclampsia within 7, 14, 28, and 56 days) was higher in patients with severe angiogenic imbalance or sEng values in the highest tertile (odds ratio &gt;/=5.6 and &gt;/=2.0, respectively), compared with no angiogenic imbalance or the lowest tertile. CONCLUSION  In women with gestational hypertension at the time of initial evaluation, circulating concentrations of the soluble fms-like tyrosine kinase-1/placental growth factor ratio and sEng appear to be suitable markers to assess the risk of adverse maternal and perinatal outcomes and progression to preeclampsia.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 OBJECTIVE  Gestational hypertension is characterized by an imbalance in angiogenic factors. The goal of the current study was to evaluate whether circulating concentrations of proangiogenic and antiangiogenic factors are associated with the risk of progression to preeclampsia and development of adverse outcomes in women with gestational hypertension. METHODS  We studied 496 women with gestational hypertension. Patients were divided into three groups based on their degree of angiogenic imbalance, evaluated by the soluble fms-like tyrosine kinase-1/placental growth factor ratio  no angiogenic imbalance (&lt;/=38), mild angiogenic imbalance (&gt;38-&lt;85), and severe angiogenic imbalance (&gt;/=85) or stratified into tertiles according to soluble endoglin (sEng) levels. RESULTS  The concentrations of all angiogenic factors were significantly different in patients with gestational hypertension than in healthy pregnancy. A significant trend towards higher serum sEng levels was observed as the degree of angiogenic imbalance increased. Patients with severe angiogenic imbalance had higher rates of adverse maternal and perinatal outcomes and progression to preeclampsia (P &lt; 0.001) when compared with patients with no or mild angiogenic imbalance. The risk of combined adverse maternal outcomes and specific adverse outcomes (hemolysis, elevated liver enzymes, low platelet count syndrome, preterm delivery, small-for-gestational-age infant, perinatal death, and progression to preeclampsia within 7, 14, 28, and 56 days) was higher in patients with severe angiogenic imbalance or sEng values in the highest tertile (odds ratio &gt;/=5.6 and &gt;/=2.0, respectively), compared with no angiogenic imbalance or the lowest tertile. CONCLUSION  In women with gestational hypertension at the time of initial evaluation, circulating concentrations of the soluble fms-like tyrosine kinase-1/placental growth factor ratio and sEng appear to be suitable markers to assess the risk of adverse maternal and perinatal outcomes and progression to preeclampsia.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 OBJECTIVE  Gestational hypertension is characterized by an imbalance in angiogenic factors. The goal of the current study was to evaluate whether circulating concentrations of proangiogenic and antiangiogenic factors are associated with the risk of progression to preeclampsia and development of adverse outcomes in women with gestational hypertension. METHODS  We studied 496 women with gestational hypertension. Patients were divided into three groups based on their degree of angiogenic imbalance, evaluated by the soluble fms-like tyrosine kinase-1/placental growth factor ratio  no angiogenic imbalance (&lt;/=38), mild angiogenic imbalance (&gt;38-&lt;85), and severe angiogenic imbalance (&gt;/=85) or stratified into tertiles according to soluble endoglin (sEng) levels. RESULTS  The concentrations of all angiogenic factors were significantly different in patients with gestational hypertension than in healthy pregnancy. A significant trend towards higher serum sEng levels was observed as the degree of angiogenic imbalance increased. Patients with severe angiogenic imbalance had higher rates of adverse maternal and perinatal outcomes and progression to preeclampsia (P &lt; 0.001) when compared with patients with no or mild angiogenic imbalance. The risk of combined adverse maternal outcomes and specific adverse outcomes (hemolysis, elevated liver enzymes, low platelet count syndrome, preterm delivery, small-for-gestational-age infant, perinatal death, and progression to preeclampsia within 7, 14, 28, and 56 days) was higher in patients with severe angiogenic imbalance or sEng values in the highest tertile (odds ratio &gt;/=5.6 and &gt;/=2.0, respectively), compared with no angiogenic imbalance or the lowest tertile. CONCLUSION  In women with gestational hypertension at the time of initial evaluation, circulating concentrations of the soluble fms-like tyrosine kinase-1/placental growth factor ratio and sEng appear to be suitable markers to assess the risk of adverse maternal and perinatal outcomes and progression to preeclampsia.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 OBJECTIVE  Gestational hypertension is characterized by an imbalance in angiogenic factors. The goal of the current study was to evaluate whether circulating concentrations of proangiogenic and antiangiogenic factors are associated with the risk of progression to preeclampsia and development of adverse outcomes in women with gestational hypertension. METHODS  We studied 496 women with gestational hypertension. Patients were divided into three groups based on their degree of angiogenic imbalance, evaluated by the soluble fms-like tyrosine kinase-1/placental growth factor ratio  no angiogenic imbalance (&lt;/=38), mild angiogenic imbalance (&gt;38-&lt;85), and severe angiogenic imbalance (&gt;/=85) or stratified into tertiles according to soluble endoglin (sEng) levels. RESULTS  The concentrations of all angiogenic factors were significantly different in patients with gestational hypertension than in healthy pregnancy. A significant trend towards higher serum sEng levels was observed as the degree of angiogenic imbalance increased. Patients with severe angiogenic imbalance had higher rates of adverse maternal and perinatal outcomes and progression to preeclampsia (P &lt; 0.001) when compared with patients with no or mild angiogenic imbalance. The risk of combined adverse maternal outcomes and specific adverse outcomes (hemolysis, elevated liver enzymes, low platelet count syndrome, preterm delivery, small-for-gestational-age infant, perinatal death, and progression to preeclampsia within 7, 14, 28, and 56 days) was higher in patients with severe angiogenic imbalance or sEng values in the highest tertile (odds ratio &gt;/=5.6 and &gt;/=2.0, respectively), compared with no angiogenic imbalance or the lowest tertile. CONCLUSION  In women with gestational hypertension at the time of initial evaluation, circulating concentrations of the soluble fms-like tyrosine kinase-1/placental growth factor ratio and sEng appear to be suitable markers to assess the risk of adverse maternal and perinatal outcomes and progression to preeclampsia.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 OBJECTIVE  Gestational hypertension is characterized by an imbalance in angiogenic factors. The goal of the current study was to evaluate whether circulating concentrations of proangiogenic and antiangiogenic factors are associated with the risk of progression to preeclampsia and development of adverse outcomes in women with gestational hypertension. METHODS  We studied 496 women with gestational hypertension. Patients were divided into three groups based on their degree of angiogenic imbalance, evaluated by the soluble fms-like tyrosine kinase-1/placental growth factor ratio  no angiogenic imbalance (&lt;/=38), mild angiogenic imbalance (&gt;38-&lt;85), and severe angiogenic imbalance (&gt;/=85) or stratified into tertiles according to soluble endoglin (sEng) levels. RESULTS  The concentrations of all angiogenic factors were significantly different in patients with gestational hypertension than in healthy pregnancy. A significant trend towards higher serum sEng levels was observed as the degree of angiogenic imbalance increased. Patients with severe angiogenic imbalance had higher rates of adverse maternal and perinatal outcomes and progression to preeclampsia (P &lt; 0.001) when compared with patients with no or mild angiogenic imbalance. The risk of combined adverse maternal outcomes and specific adverse outcomes (hemolysis, elevated liver enzymes, low platelet count syndrome, preterm delivery, small-for-gestational-age infant, perinatal death, and progression to preeclampsia within 7, 14, 28, and 56 days) was higher in patients with severe angiogenic imbalance or sEng values in the highest tertile (odds ratio &gt;/=5.6 and &gt;/=2.0, respectively), compared with no angiogenic imbalance or the lowest tertile. CONCLUSION  In women with gestational hypertension at the time of initial evaluation, circulating concentrations of the soluble fms-like tyrosine kinase-1/placental growth factor ratio and sEng appear to be suitable markers to assess the risk of adverse maternal and perinatal outcomes and progression to preeclampsia.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 OBJECTIVE  Gestational hypertension is characterized by an imbalance in angiogenic factors. The goal of the current study was to evaluate whether circulating concentrations of proangiogenic and antiangiogenic factors are associated with the risk of progression to preeclampsia and development of adverse outcomes in women with gestational hypertension. METHODS  We studied 496 women with gestational hypertension. Patients were divided into three groups based on their degree of angiogenic imbalance, evaluated by the soluble fms-like tyrosine kinase-1/placental growth factor ratio  no angiogenic imbalance (&lt;/=38), mild angiogenic imbalance (&gt;38-&lt;85), and severe angiogenic imbalance (&gt;/=85) or stratified into tertiles according to soluble endoglin (sEng) levels. RESULTS  The concentrations of all angiogenic factors were significantly different in patients with gestational hypertension than in healthy pregnancy. A significant trend towards higher serum sEng levels was observed as the degree of angiogenic imbalance increased. Patients with severe angiogenic imbalance had higher rates of adverse maternal and perinatal outcomes and progression to preeclampsia (P &lt; 0.001) when compared with patients with no or mild angiogenic imbalance. The risk of combined adverse maternal outcomes and specific adverse outcomes (hemolysis, elevated liver enzymes, low platelet count syndrome, preterm delivery, small-for-gestational-age infant, perinatal death, and progression to preeclampsia within 7, 14, 28, and 56 days) was higher in patients with severe angiogenic imbalance or sEng values in the highest tertile (odds ratio &gt;/=5.6 and &gt;/=2.0, respectively), compared with no angiogenic imbalance or the lowest tertile. CONCLUSION  In women with gestational hypertension at the time of initial evaluation, circulating concentrations of the soluble fms-like tyrosine kinase-1/placental growth factor ratio and sEng appear to be suitable markers to assess the risk of adverse maternal and perinatal outcomes and progression to preeclampsia.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 OBJECTIVE  Gestational hypertension is characterized by an imbalance in angiogenic factors. The goal of the current study was to evaluate whether circulating concentrations of proangiogenic and antiangiogenic factors are associated with the risk of progression to preeclampsia and development of adverse outcomes in women with gestational hypertension. METHODS  We studied 496 women with gestational hypertension. Patients were divided into three groups based on their degree of angiogenic imbalance, evaluated by the soluble fms-like tyrosine kinase-1/placental growth factor ratio  no angiogenic imbalance (&lt;/=38), mild angiogenic imbalance (&gt;38-&lt;85), and severe angiogenic imbalance (&gt;/=85) or stratified into tertiles according to soluble endoglin (sEng) levels. RESULTS  The concentrations of all angiogenic factors were significantly different in patients with gestational hypertension than in healthy pregnancy. A significant trend towards higher serum sEng levels was observed as the degree of angiogenic imbalance increased. Patients with severe angiogenic imbalance had higher rates of adverse maternal and perinatal outcomes and progression to preeclampsia (P &lt; 0.001) when compared with patients with no or mild angiogenic imbalance. The risk of combined adverse maternal outcomes and specific adverse outcomes (hemolysis, elevated liver enzymes, low platelet count syndrome, preterm delivery, small-for-gestational-age infant, perinatal death, and progression to preeclampsia within 7, 14, 28, and 56 days) was higher in patients with severe angiogenic imbalance or sEng values in the highest tertile (odds ratio &gt;/=5.6 and &gt;/=2.0, respectively), compared with no angiogenic imbalance or the lowest tertile. CONCLUSION  In women with gestational hypertension at the time of initial evaluation, circulating concentrations of the soluble fms-like tyrosine kinase-1/placental growth factor ratio and sEng appear to be suitable markers to assess the risk of adverse maternal and perinatal outcomes and progression to preeclampsia.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  Heart failure with reduced ejection fraction (HFrEF) and chronic obstructive pulmonary disease (COPD) are relatively common conditions with similar symptoms of exercise intolerance and dyspnea. The aim of this study was to compare exercise capacity, ventilatory response, and breathing pattern in patient groups with either advanced HFrEF or COPD before and after exercise training. METHODS  An observational study was conducted with parallel groups of 25 HFrEF and 25 COPD patients who took part in 6 wk of inpatient rehabilitation with exercise training. All patients underwent cardiopulmonary exercise tests at the start and end of the training, with resting arterial blood gas measurements. RESULTS  The average peak oxygen uptake (V o2) was low at the start of the study but increased significantly after training in both groups, or by 2.2 +/- 2.1 mL/kg/min in HFrEF patients and 1.2 +/- 2.2 mL/kg/min in COPD patients. At ISO-V o2 (ie, same level of V o2 in pre- and post-exercise tests), carbon dioxide production (V co2) decreased after exercise training in both groups. Similarly, at ISO-V E (ie, same level of ventilation), breathing frequency (f) decreased and tidal volume (VT) increased, resulting in an improved breathing pattern (lower f/VT ratio) after training. CONCLUSION  The findings of this study show that exercise training in severely affected patient groups with HFrEF or COPD led to an increase in maximal exercise capacity, a more favorable breathing pattern, and a diminished V co2 during exercise. Therefore, comparisons of V co2 and breathing pattern at ISO-levels of V o2 or V E before and after training are valuable and underutilized outcome measures in treatment studies.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Cardiomyopathy,
 BACKGROUND  Heart disease in children and adolescents is common, approaching 1.0% of the population. In those patients with complex physiology and severe cardiac dysfunction, the inability to participate in physical activity results in significant obstacles to normal acts of daily living and significantly diminished quality of life. Attempts to study the practicality and benefits of cardiopulmonary rehabilitation (CR) programs in this population have been hampered by the heterogeneity of lesions, lack of facilities, and trained personnel to supervise these types of programs. Although there are numerous articles on CR in children with cardiac disease, all suffer from the same basic problems of small sample size, short duration of study, and heterogeneous study populations. PURPOSE  The purpose of this review was to first evaluate the current rehabilitation literature on both congenital cardiac defects and acquired abnormalities-in this latter group placing a significant emphasis on cardiomyopathies, as well as the special populations in the peri-transplant period and/or mechanical circulatory support. Second, we discussed what is known about practical approaches to CR for the various types of pediatric-specific cardiac conditions. This limited data will be supplemented by the current approach of our institution to CR in these populations with the understanding that this is by no means a consensus approach to these patients. Finally, we summarized research goals for this growing group of patients. CONCLUSION  Cardiopulmonary rehabilitation in pediatric congenital and acquired heart disease is currently a field in its infancy. Significant strides have been made for complex heart disease and impaired myocardial function. Current research holds the promise for the development of programs that are practical, scalable, and can be implemented in most clinical sites within the foreseeable future.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,
<span class="ansi-bold">Embeded topics: </span>Cardiomyopathy,
 We report a successful pediatric bridge to transplant following application of the ProTekDuo Cannula to provide right ventricular support in a 12-year-old child with biventricular cardiomyopathy and on left ventricular assist device support. We are unaware of any other reports of pediatric use of this device in the medical literature.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,
 Peripheral vascular disease (PVD) is highly prevalent in patients on the waiting list for kidney transplantation (KT) and after transplantation and is associated with impaired transplant outcomes. Multiple traditional and non-traditional risk factors, as well as uremia- and transplant-related factors, affect two processes that can coexist, atherosclerosis and arteriosclerosis, leading to PVD. Some pathogenic mechanisms, such as inflammation-related endothelial dysfunction, mineral metabolism disorders, lipid alterations, or diabetic status, may contribute to the development and progression of PVD. Early detection of PVD before and after KT, better understanding of the mechanisms of vascular damage, and application of suitable therapeutic approaches could all minimize the impact of PVD on transplant outcomes. This review focuses on the following issues  a) definition, epidemiological data, diagnosis, risk factors and pathogenic mechanisms in KT candidates and recipients; b) adverse clinical consequences and outcomes; and c) classical and new therapeutic approaches.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 BACKGROUND  The prevalence of hypertension (HTN) in Blacks is among the highest in the world. For Black women, 46% experience stage 2 HTN (blood pressure [BP] &gt;/=140/90 mm Hg) as compared with 42% of Black men. Because of higher rates of stage 2 HTN, Black women have greater rates of cardiovascular disease and stroke. For reasons unknown, nonadherence to lifestyle modifications and antihypertensive medications continues. An understudied potential factor associated with poor adherence to the treatment regimen and negative health outcomes is stigma. OBJECTIVE  The aim of this study was to gain insight and describe the psychological factor of stigma as an influence on poorly controlled HTN in Black women. METHODS  Hypertensive Black women attending a 6-week self-management program were invited to participate in an open-ended questionnaire. Six groups were held with 62 women aged 24 to 70 years, with group size ranging from 10 to 15. Women anonymously wrote their answer to 2 questions to capture individual responses without group persuasion. Data were analyzed using thematic analysis. RESULTS  Five themes were generated inductively from the data and included (1) desire to get control, (2) shame and embarrassment, (3) obesity characterizations, (4) stereotype threats, and lastly, (5) disrupted normality. During member checking, younger participants were more vocal about stigma, whereas older participants did not view stigma as problematic. CONCLUSIONS  Hypertension stigma could potentially deter adherence to high BP treatment. Further research is needed to explore the prevalence of stigma in this population and its impact on behaviors that hinder BP control.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 BACKGROUND  The associations of depression with incident heart failure (HF) risk based on epidemiological studies have been inconsistent. OBJECTIVE  We aimed to quantitatively estimate the relative effect of depression on the development of HF. METHODS  We performed a systematic review and meta-analysis of cohort studies published between January 1, 1950, and August 31, 2019, from PubMed, Embase, and the Science Citation Index databases. We selected prospective cohort studies reporting the relationship between depression and incident HF. Maximally adjusted hazard ratios and their 95% confidence intervals were combined using a random-effects model. The heterogeneity across studies was calculated by the I statistic. This meta-analysis was registered in PROSPERO (number CRD42020149274). RESULTS  Six population-based, prospective cohort studies with 4727 HF events among 131 282 participants were eligible for meta-analysis. Compared with participants reporting no depression, those with depression had a 23% increased risk of developing HF (pooled hazard ratio, 1.23; 95% confidence interval, 1.08-1.41). There was no significant heterogeneity across studies (chi = 7.75, df = 5, P = .17, I = 35.5%). CONCLUSION  Published literature supports a significant association of depression with an increased incidence of HF in the general population.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Coagulopathies,
 OBJECTIVES  Stroke is commonly reported in patients receiving venovenous extracorporeal membrane oxygenation, but risk factors are not well described. We sought to determine preextracorporeal membrane oxygenation and on-extracorporeal membrane oxygenation risk factors for both ischemic and hemorrhagic strokes in patients with venovenous extracorporeal membrane oxygenation support. DESIGN  Retrospective analysis. SETTING  Data reported to the Extracorporeal Life Support Organization by 366 extracorporeal membrane oxygenation centers from 2013 to 2019. PATIENTS  Patients older than 18 years supported with a single run of venovenous extracorporeal membrane oxygenation. INTERVENTIONS  None. MEASUREMENTS AND MAIN RESULTS  Of 15,872 venovenous extracorporeal membrane oxygenation patients, 812 (5.1%) had at least one type of acute brain injury, defined as ischemic stroke, hemorrhagic stroke, or brain death. Overall, 215 (1.4%) experienced ischemic stroke and 484 (3.1%) experienced hemorrhagic stroke. Overall inhospital mortality was 36%, but rates were higher in those with ischemic or hemorrhagic stroke (68% and 73%, respectively). In multivariable analysis, preextracorporeal membrane oxygenation pH (adjusted odds ratio = 0.10; 95% CI, 0.03-0.35; p &lt; 0.001), hemolysis (adjusted odds ratio = 2.27; 95% CI, 1.22-4.24; p = 0.010), gastrointestinal hemorrhage (adjusted odds ratio = 2.01; 95% CI 1.12-3.59; p = 0.019), and disseminated intravascular coagulation (adjusted odds ratio = 3.61; 95% CI, 1.51-8.66; p = 0.004) were independently associated with ischemic stroke. Pre-extracorporeal membrane oxygenation pH (adjusted odds ratio = 0.28; 95% CI, 0.12-0.65; p = 0.003), preextracorporeal membrane oxygenation PO2 (adjusted odds ratio = 0.96; 95% CI, 0.93-0.99; p = 0.021), gastrointestinal hemorrhage (adjusted odds ratio = 1.70; 95% CI, 1.15-2.51; p = 0.008), and renal replacement therapy (adjusted odds ratio=1.57; 95% CI, 1.22-2.02; p &lt; 0.001) were independently associated with hemorrhagic stroke. CONCLUSIONS  Among venovenous extracorporeal membrane oxygenation patients in the Extracorporeal Life Support Organization registry, approximately 5% had acute brain injury. Mortality rates increased two-fold when ischemic or hemorrhagic strokes occurred. Risk factors such as lower pH and hypoxemia during the pericannulation period and markers of coagulation disturbances were associated with acute brain injury. Further research on understanding preextracorporeal membrane oxygenation and on-extracorporeal membrane oxygenation risk factors and the timing of acute brain injury is necessary to develop appropriate prevention and management strategies.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 PURPOSE OF REVIEW  Gut dysbiosis has been implicated in the pathogenesis of chronic kidney disease (CKD). Interventions aimed at restoring gut microbiota have emerged as a potential therapeutic option in CKD. This review summarizes the current evidence on gut microbiota-targeted strategies in patients with CKD. RECENT FINDINGS  A growing number of studies have shown that plant-based diets, low-protein diets, prebiotic, probiotic, and synbiotic supplementation, and constipation treatment may lead to favorable alterations in the gut microbiota. Current evidence suggests that the implementation of both plant-based and low-protein diets has potential benefits for the primary prevention of CKD, and for slowing CKD progression, with minimal risk of hyperkalemia and/or cachexia. The use of prebiotics, probiotics, and synbiotics and laxatives may have beneficial effects on uremic toxin generation, but their evidence is limited for the prevention and treatment of CKD. Recent advances in diagnostic technologies (e.g., high-throughput sequencing and nanotechnology) could enhance rapid diagnosis, monitoring, and design of effective therapeutic strategies for mitigating gut dysbiosis in CKD. SUMMARY  Plant-based and low-protein diets, prebiotic, probiotic, and synbiotic supplementation, and constipation treatment represent novel gut microbiota-targeted strategies in the conservative management of CKD, which could improve clinical outcomes in CKD.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 PURPOSE OF REVIEW  Chronic kidney disease (CKD) is associated with increased risk of progression to end-stage kidney disease and cardiovascular events. There is limited evidence that available treatments have beneficial effects on cardiorenal outcomes in all people with nondiabetic CKD. Neprilysin inhibition (NEPi) is a new therapeutic strategy with potential to improve outcomes for patients with CKD. RECENT FINDINGS  NEPi enhances the activity of the natriuretic peptide system producing natriuresis, diuresis and inhibition of the renin-angiotensin system and sympathetic nervous system. Sacubitril/valsartan is the first Angiotensin receptor-neprilysin inhibitor (ARNI) to be produced and has been shown to substantially improve cardiovascular outcomes in heart failure and delay progression of kidney disease in this population. Although ARNIs have not shown similar effects on kidney function in the short-to-medium term in people with CKD, they are associated with substantial reductions in cardiac biomarkers and blood pressure in CKD. SUMMARY  These data suggest that NEPi with an ARNI could benefit patients with CKD by reducing the risk of cardiovascular disease and have the possibility of retarding the progression of CKD (hence delaying the need for renal replacement therapy).
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  Congenital heart disease (CHD) is often diagnosed prenatally using fetal echocardiography, but few studies have evaluated the accuracy of these fetal cardiac diagnoses in detail. We investigated the discrepancy between pre- and postnatal diagnoses of CHD and the impact of discrepant diagnoses.Methods and Results This retrospective study at a tertiary institution included data from the medical records of 207 neonates with prenatally diagnosed CHD admitted to the cardiac neonatal intensive care unit between January 2011 and December 2016. Pre- and postnatal diagnoses of CHD differed in 12% of neonates. Coarctation of the aorta and ventricular septal defects were the most frequent causes of discrepant diagnosis. Unexpected treatments were added to 38% of discrepant diagnostic cases. However, discrepant diagnoses did not adversely affect the clinical course. The 9% of the 207 neonates who required invasive intervention within 24 h of delivery were accurately diagnosed prenatally. CONCLUSIONS  Pre- and postnatal diagnoses differed in only a few neonates, with differences not adversely affecting the clinical course. Neonates who required invasive intervention immediately after delivery were accurately diagnosed prenatally. Prenatal diagnosis thus seems to contribute to improved prognosis in neonates with CHD.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 OBJECTIVES  Several factors determining differences between types A and B aortic dissection (AD) have been reported; however, little data exist examining their differences in left ventricular hypertrophy (LVH). We compared the prevalence of LVH in patients with types A and B AD. METHODS  We retrospectively analyzed 334 patients with acute AD (227 type A; 107 type B). Concentric hypertrophy (CH; increased left ventricular mass index [LVMI] and relative wall thickness [RWT]) is one of four types of left ventricular (LV) geometry thought to be most associated with hypertension. We compared LVMI and the prevalence of CH in patients with types A or B AD. Multivariate logistic regression analyses of variables associated with type B AD were performed. RESULTS  Comparing type A and B AD, LVMI (95 +/- 26 vs.107 +/- 28, p &lt;0.001) and prevalence of CH (26% vs. 44%, p = 0.001) were higher in type B AD. In multivariate analysis, CH was an independent factor associated with type B AD (odds ratio  2.62, confidence interval  1.54-4.47, p &lt;0.001). CONCLUSIONS  Our data suggested LVH was more prevalent in type B than in type A AD. Considering LVH usually results from hypertension, patients with type B AD may be more affected by hypertension than those with type A.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 A 40-year-old woman with idiopathic pleuroparenchymal fibroelastosis (IPPFE) and flat chest underwent left single lung transplantation (SLT). Although she had developed over-systemic pulmonary arterial pressure (PAP) at transplantation, it was alleviated. However, her PAP gradually increased again. Her transplanted lung was well-inflated, but progression of fibrosis in her right native lung appeared to have caused a mediastinal shift, and her flat chest caused obstruction of the outflow tract of the pulmonary vein. She died of heart failure and associated infection 1.5 years after transplantation. An autopsy confirmed irreversible pulmonary arterial and venous changes in the transplanted lung, suggestive of chronic pressure overload. The flat chest associated with IPPFE can affect pulmonary circulation after SLT.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlud</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Diseases of arteries,Coagulopathies,
 Optimal treatment of patients with intracranial subocclusive thrombus remains unclear. Such a rare case successfully managed with endovascular mechanical thrombectomy is presented. A 71-year-old man experienced a sudden onset of dysarthria and motor deficits. At the time of admission his National Institutes of Health Stroke Scale (NIHSS) score was 4. DWI demonstrated incomplete infarction within the left lenticulostriate artery (LSA) territory, MRA showed partial flow defect in the distal left M1 segment and non-visualization of the LSA, and ECG revealed atrial fibrillation, thus ischemic stroke caused by cardiogenic embolism was diagnosed. Tissue plasminogen activator was administered, but symptoms progressed and NIHSS score increased up to 8. Diagnostic angiogrpahy confirmed presence of the subocclusive thrombus within the distal left M1 segment and complete occlusion of LSA at its origin. Since conservative therapy was ineffective, mechanical thrombectomy utilizing ADAPT (a direct aspiration first-pass thrombectomy) technique was performed resulting in compete recanalization of the LSA accompanied by the prompt regress of neurological symptoms. Eventally, the patient demonstrated nearly full recovery (modified Rankin Scale score 1). Thus, mechanical thrombectomy should be considered as a reasonable option in cases of acute cerebral stroke caused by subocclusive thrombus and progressive neurological deficits despite standard conservative therapy. J. Med. Invest. 67   372-374, August, 2020.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">takotsubo</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Cardiomyopathy,
 The direct relationship between a hypoglycemic attack and cerebral infarction remains unknown. It has been reported that a hypoglycemic attack can result in takotsubo syndrome, leading to cerebral infarction. We report a case of a cardiogenic cerebral embolism caused by a hypoglycemic attack, with additional literature review. A 71-year-old woman was admitted to our hospital in a semi-comatose state due to a severe hypoglycemic attack ; she developed hemiplegia one day after admission. Magnetic resonance imaging revealed cerebral infarction in the area supplied by the left middle cerebral artery. Takotsubo syndrome was suspected based on echocardiography. We diagnosed cerebral embolism due to takotsubo syndrome, caused by the hypoglycemic attack. J. Med. Invest. 67   362-364, August, 2020.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 Autosomal dominant polycystic kidney disease (ADPKD) develops into end-stage kidney disease by 65 years of age in an estimated 45%-70% of patients. Recent trials revealed that tolvaptan inhibits disease progression both in early-stage or late-stage ADPKD ; however, stratified analysis showed a difference of favorable factors correlated with tolvaptan efficacy between early-stage and late-stage ADPKD. Thus, we examined the efficacy of tolvaptan in ADPKD with a wide range of estimated glomerular filtration rates (eGFR). We enrolled 24 patients with eGFR 35.3 (28.0-65.5) ml / min / 1.73m2 and evaluated treatment effect as DeltaDeltaeGFR (ml / min / 1.73m2 / year) or DeltaDeltatotal kidney volume (TKV) (% / year) that was calculated as post-treatment annual change - pre-treatment annual change. Pre DeltaeGFR was significantly low in eGFR responders, defined as DeltaDeltaeGFR &gt; 0 ml / min / 1.73m2 / year. In eGFR responders, pre DeltaeGFR, post DeltaeGFR, eGFR, TKV, and proteinuria were significantly correlated with DeltaDeltaeGFR. In TKV responders defined as DeltaDeltaTKV &gt; 5 % / year, we identified hypertension history, proteinuria, TKV, and post DeltaTKV as significantly correlated factors with DeltaDeltaTKV. In conclusion, pre DeltaeGFR may be a predictive factor of therapeutic efficacy on kidney function. Tolvaptan may have greater efficacy in early-stage ADPKD with rapid GFR decline or with well-controlled blood pressure. J. Med. Invest. 67   315-320, August, 2020.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">microvascul</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 Arteriovenous malformations (AVMs) are high-flow lesions directly connecting arteries and veins. In the brain, AVM rupture can cause seizures, stroke, and death. Patients with AVMs exhibit reduced coverage of the vessels by pericytes, the mural cells of microvascular capillaries; however, the mechanism underlying this pericyte reduction and its association with AVM pathogenesis remains unknown. Notch signaling has been proposed to regulate critical pericyte functions. We hypothesized that Notch signaling in pericytes is crucial to maintain pericyte homeostasis and prevent AVM formation. We inhibited Notch signaling specifically in perivascular cells and analyzed the vasculature of these mice. The retinal vessels of mice with deficient perivascular Notch signaling developed severe AVMs, together with a significant reduction in pericytes and vascular smooth muscle cells (vSMC) in the arteries, while vSMCs were increased in the veins. Vascular malformations and pericyte loss were also observed in the forebrain of embryonic mice deficient for perivascular Notch signaling. Moreover, the loss of Notch signaling in pericytes downregulated Pdgfrb levels and increased pericyte apoptosis, pointing to a critical role for Notch in pericyte survival. Overall, our findings reveal a mechanism of AVM formation and highlight the Notch signaling pathway as an essential mediator in this process.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">stenos</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 OBJECTIVE  75% of men with coronary artery disease confirmed by coronarography have erectile dysfunction in history, while 75% of patients with a vascular etiology of ED have significant stenoses in penile arterial vascularization. Patients with coronary artery disease have shown a relationship between the range of the lesions in the coronary vessels and erectile dysfunction intensity. This paper aims at attempting to systematize the knowledge of the benefits and drawbacks of nonsurgical endovascular treatment methods for erectile dysfunction with confirmed vascular causes. It analyzes seven studies which assess the results of erectile dysfunction treatment with percutaneous angioplasty. It also mentions the limitations of the cited works and formulates relevant conclusions. CONCLUSION  Conclusions  The analysis shows that endovascular procedures in erection-related arteries are safe in a specially selected group of men. It is necessary to conduct further studies to define an appropriate group of patients who have a chance of benefiting optimally from the endovascular treatment of erectile dysfunction in a long-term follow-up.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">cerebrovascul</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,Coagulopathies,
 OBJECTIVE  The aim  Is to determine the main causes of adverse outcomes of the patients&#39; treatment with acute ulcerative gastroduodenal bleeding and to develop preventive measures to improve the quality of the patients&#39; treatment with this pathology. PATIENTS AND METHODS  Materials and methods  A retrospective analysis of the treatment results of 1323 patients with bleeding of ulcerative etiology has been carried out. There are 375 patients with gastric ulcer (28.3%) and 948 patients (71.7%) with duodenal ulcer among them. The patients&#39; age ranged from 15 to 93 years old. Concomitant pathology was observed in 623 (47.1%) patients, the most common of which were coronary heart disease, chronic non-specific lung diseases and cerebrovascular diseases. Mild severity of blood loss was detected in 404 (30.5%) patients, moderate severity 693 (52.5%), severe 145 (10.9%) and extremely severe 81 (6.1%). Overall mortality was 5.9%, postoperative mortality 6.3%, the mortality in conservative treatment only 6.1%. RESULTS  Results  The main cause of the patients&#39; mortality with acute ulcerative gastroduodenal bleeding was decompensated hemorrhagic shock which developed at the prehospital stage in 45.3% and as a result of bleeding recurrence during treatment 44.2% of the patients. Inadequate drug therapy increases the risk of bleeding recurrence from 15.8 to 32.7%. The use of proton pump blockers and the combination of bolus and prolonged use of proton pump blockers allow to reduce the risk of bleeding recurrence by half (up to 6.8%). CONCLUSION  Conclusions  Endoscopic hemostasis in combination with the injection method with diathermocoagulation or thermal coagulation can be considered as full-fledged, and when performing endoscopic monitoring the preference should be given to coagulation methods of diathermo- and hydrodietermocoagulation.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,
 OBJECTIVE  The aim  Is to evaluate copetin&#39;s, MRproADM&#39;s and troponin&#39;s I dynamic in patients with acute myocardial infarction depending on the degree of concomitant obesity. PATIENTS AND METHODS  Material and methods  The study included 105 patients with AMI. There were formed 2 groups  1st group of patients with AMI and concomitant obesity (n=75), 2nd group - patients with AMI without obesity (n=30). 37 patients had obesity of the I degree, 38 patients - II degree. The groups were comparable in age and gender. Copeptin, MRproADM, troponin I were determined by enzyme immunoassay method. Data are presented as mean values and the error of the mean (M+/-m). Differences were considered statistically significant at p&lt;0,05. RESULTS  Results  It was found an increased copeptin&#39;s level by 73,8 % (p&lt;0,001) in obesity I degree and by 205,9 % in obesity II degree compared with group with isolated AMI, MRproADM - by 30,68 % (p&lt;0,001) and 54,5 % (p&lt;0,001) respectively. Concentration of copeptin was higher by 76 % (p&lt;0,001) in patients with AMI and II degree obesity comparing to patients with obesity of I degree, and MRproADM - by 18,3% (p&lt;0,001) respectively. Troponin I value fully corresponded the comparison group both in obesity of I degree and II degree (p&gt;0,05). CONCLUSION  Conclusions  The present study provides evidence that a high activity of copeptin and MRproADM in patients with AMI and obesity of I degree with an excessive activity of a marker of vasoconstriction copeptin in conditions of moderate inadequate to the needs MRproADM functioning in patients with obesity of II degree.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 OBJECTIVE  Introduction  The work presents a research project carried out in John Paul II Hospital in Cracow in Clinical Department of Cardiac and Vascular Diseases with the Intensive Cardiac Supervision Subdivision, with participation of 100 (50 F, 50 M) patients with congenital heart defects. The purpose of the work is to resolve the issue of personality specifics, and thus the different characteristics of people who suffer from congenital heart defects. Therefore, the following questions should be answered  Is there a relationship between personality traits and the occurrence of a congenital heart defect? What personality traits are characteristic for patients with congenital heart defects? The aim  We aimed to assess personality traits of clients suffering from PFO and ASD. The article also talks about how coronavirus pandemic affects patients with congenital heart disease. PATIENTS AND METHODS  Materials and methods  The research was conducted by psychologist Adrianna Skoczek. We performed a psychological clinical assessment and conducted the psychological tests like Eysenck Personality Questionnaire-Revised Short Version [EPQ-R(S)] and Eysenck&#39;s Impulsivity Inventory [IVE] by Hans J. Eysenck and Sybil G. Eysenck, the State-Trait Anxiety Inventory [STAI] by C. D. Spielberger, R. L. Gorsuch, R. E. Lushene describing personality traits of patients. Patients (F=50, M=50), with ASD (n=70) and with PFO (n=30). RESULTS  Results  In people suffering from ASD, the level of declared empathy was statistically significantly higher than the levels of impulsiveness and tendency to risk-taking. In people suffering from PFO, a statistically significant difference was observed only between the level of psychoticism and other variables. The level of declared empathy was statistically significantly higher than the levels of impulsiveness and tendency to risk-taking, a statistically significant difference was found between the analyzed variables - anxiety as a trait and anxiety as a condition. CONCLUSION  Conclusions  The results of the study allowed us to isolate the specific personality traits of patients suffering from congenital heart defects.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-magenta-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">arrhythm</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">cerebrovascul</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Arrhythmia,Diseases of arteries,
 OBJECTIVE  Introduction  Lifestyle modification, including changing eating habits, plays an essential role in the prevention of stroke. The aim  The study aimed to assess the nutritional prevention of cerebrovascular diseases in adult inhabitants of Poland. PATIENTS AND METHODS  Material and Methods  The study was conducted using the author&#39;s questionnaire among 145 women and 76 men, aged 18 - 30 (53.9%) and 50 - 70 (46.1%) years. RESULTS  Results  The following stroke risk factors were found in the examined group  overweight or obesity (46.6%), lack of regular physical activity (48%), smoking (33%), hypertension (22.1%), dyslipidemia (8.6%), diabetes (5.9%), and cardiac arrhythmias (6.3%). The younger subjects compared to older ones more often declared the daily consumption of whole-grain cereal products and vegetables, fish at least once a week, and they preferred vegetable oils. On the other hand, older subjects declared the consumption of sweets, sweet drinks, salt, and fast food less frequently than younger ones. Also, fruits were more often chosen by older people. Both groups declared similar moderate consumption of milk and dairy products with reduced fat content, lean meat, and alcohol. Only 38% of respondents considered their eating habits to be appropriate. CONCLUSION  Conclusions  The eating habits of examined adults only partially met the recommendations regarding the nutritional prevention of stroke. In some elements, younger people were more likely to follow appropriate dietary recommendations, while older people were more appropriate in others. The education regarding the principles of the nutritional prevention of cerebrovascular diseases is still necessary and should be age-appropriate.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischaem</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">stenos</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Ischemia,Diseases of arteries,
 INTRODUCTION  Unruptured intracranial aneurysms (UIAs) are common incidental imaging findings, but there are few data in patients with transient ischaemic attack (TIA)/stroke. The frequency of UIA might be higher due to shared risk factors, but rupture risk might be reduced by intensive secondary prevention. We determined the prevalence and prognosis of UIA in patients with suspected TIA/minor stroke. METHODS  All patients referred to the population-based Oxford Vascular Study (2011-2020) with suspected TIA/minor stroke and non-invasive angiography were included. We determined the prevalence of incidental asymptomatic UIA and the risk of subsequent subarachnoid haemorrhage (SAH) by follow-up on intensive medical treatment, with guideline-based monitoring/management. We also did a systematic review of UIA prevalence/prognosis in cohorts with TIA/stroke. FINDINGS  Among 2013 eligible patients, 95 (4.7%) had 103 previously unknown asymptomatic UIA. Female sex (OR 2.3, 95% CI 1.5 to 3.7), smoking (2.1, 1.2 to 3.6) and hypertension (1.6, 1.0 to 2.5) were independently predictive of UIA, with a prevalence of 11.1% in those with all three risk factors. During mean follow-up of 4.5 years, only one SAH occurred  2.3 (95% CI 0.3 to 16.6) per 1000 person-years. We identified 19 studies of UIA in TIA/stroke cohorts (n=12 781), all with either symptomatic carotid stenosis or major acute stroke. The pooled mean UIA prevalence in patients with TIA/stroke was 5.1% (95% CI 4.8 to 5.5) and the incidence of SAH was 4.6 (95% CI 1.9 to 11.0) per 1000 person-years. INTERPRETATION  The 5% prevalence of UIA in patients with confirmed TIA/minor stroke is likely higher than that in the general population. However, the risk of SAH on intensive medical treatment and guideline-based management/monitoring is low.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischaem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Coagulopathies,
 Investigators acknowledge the limitations of rodent or non-human primate stroke models, hundreds of putative neuroprotectants have been evaluated in preclinical models, but not one has entered the clinical realm. Initial studies focused on the neuron, but in recent years the focus has widened to also include other neural cells including astrocytes, pericytes and endothelial cells, which together form the neurovascular unit. Some new developments raise renewed hope for neuroprotection  the appearance of new compounds with multiple mechanisms of action, or the promulgation of new standards for a rigorous preclinical testing. At the bedside in the last 5 years, uric acid and nerinetide are the only compounds tested for clinical efficacy in randomised controlled trials (RCTs), where all patients had to receive reperfusion therapies, either intravenous thrombolysis and/or mechanical thrombectomy. In addition, otaplimastat, 3K3A-activated protein C (APC), intra-arterial verapamil and intra-arterial hypothermia were also assessed in combination with reperfusion therapy, but in RCTs that only included feasibility or safety outcomes. Some of these compounds yielded promising results which are discussed in this review. Altogether, a deeper knowledge of the mechanisms involved in the ischaemic death process at the neurovascular unit, an improved preselection and evaluation of drugs at the preclinical stage and the testing of putative neuroprotectants in enriched clinical studies of patients receiving reperfusion therapies, might prove more effective than in the past to reverse a dismal situation that has lasted already too long.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 OBJECTIVE  To evaluate the role of continuous positive air pressure (CPAP) in the management of respiratory failure associated with COVID-19 infection. Early clinical management with limited use of CPAP (3% of patients) was compared with a later clinical management strategy which had a higher proportion of CPAP use (15%). DESIGN  Retrospective case-controlled service evaluation for a single UK National Health Service (NHS) Trust during March-June 2020 designed and conducted solely to estimate the effects of current care. SETTING  The acute inpatient unit in Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust, a medium-sized English NHS Trust. PARTICIPANTS  206 patients with antigen confirmed COVID-19 disease and severe acute respiratory syndrome admitted between 17 March 2020 and 3 April 2020 for the early group (controls), and between 10 April 2020 and 11 May 2020 for the late group (cases). Follow-up for all cases was until 11 June by which time all patients had a final outcome of death or discharge. Both groups were composed of 103 patients. Cases and controls were matched by age and sex. OUTCOME MEASURE  The outcome measure was the proportion of patients surviving at time t (time from the positive result of COVID-19 test to discharge/death date). The predictors were CPAP intervention, intubation, residence in care homes and comorbidities (renal, pulmonary, cardiac, hypertension and diabetes). A stratified Cox proportional hazard for clustered data (via generalised estimating equations) and model selection algorithms were employed to identify the effect of CPAP on patients&#39; survival and the effect on gas exchange as measured by alveolar arterial (A-a) gradient and timing of CPAP treatment on CPAP patients&#39; survival. RESULTS  CPAP was found to be significantly (HR 0.38, 95% CI 0.36 to 0.40) associated with lower risk of death in patients with hospital stay equal to, or below 7 days. However, for longer hospitalisation CPAP was found to be associated with increased risk of death (HR 1.72, 95% CI 1.40 to 2.12). When CPAP was initiated within 4 days of hospital admission, the survival probability was above 73% (95% CI 53% to 99%). In addition, lower A-a gradient was associated with lower risk of death in CPAP patients (HR 1.011, 95% CI 1.010 to 1.013). The selected model (best fit) was stratified by sex and clustered by case/control groups. The predictors were age, intubation, hypertension and the residency from care homes, which were found to be statistically significantly associated with patient&#39;s death/discharge. CONCLUSIONS  CPAP is a simple and cost-effective intervention. It has been established for care of other respiratory disorders but not for COVID-19 respiratory failure. This evaluation establishes that CPAP as a potentially viable treatment option for this group of patients during the first days of hospital admission. As yet there is limited availability of quantitative research on CPAP use for COVID-19. Whist this work is hampered by both the relatively small sample size and retrospective design (which reduced the ability to control potential confounders), it represents evidence of the significant benefit of early CPAP intervention. This evaluation should stimulate further research questions and larger study designs on the potential benefit of CPAP for COVID-19 infections. Globally, this potentially beneficial low cost and low intensity therapy could have added significance economically for healthcare provision in less developed countries.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 OBJECTIVES  To assess the prevalence and risk factors of overweight and obesity among type 2 diabetes mellitus (T2DM) patients in Uganda. DESIGN  Retrospective chart review. SETTING  This study was conducted in the outpatient&#39;s T2DM clinic in St. Francis Hospital-Nsambya, Uganda between March and May 2017. PARTICIPANTS  Type 2 diabetes patients registered in the diabetes clinic between July 2003 and September 2016. OUTCOME MEASURES  Overweight and obesity defined as body mass index (kg/m(2)) of 25.0-29.9 and obesity as 30.0 or higher. RESULTS  Of 1275 T2DM patients, the median age was 54 (IQR  44-65) years, 770 (60.40%) were females, 887 (69.6%) had hypertension, 385 (28%) had controlled glycaemia, 349 (27%) were obese, while 455 (36%) were overweight. Overweight/obesity were lower among men (OR  0.45, 95% CI  0.340 to 0.593, p&lt;/=0.001) and among patients aged &gt;/=65 years (OR  0.52, 95% CI  0.350 to 0.770, p=0.001); patients who rarely ate fruits and vegetables (OR  0.66, 95% CI  0.475 to 0.921, p=0.014) but higher among patients of middle (OR  1.83, 95% CI  1.320 to 2.550, p&lt;/=0.001) and upper (OR  2.10, 95% CI  1.450 to 2.990, p&lt;/=0.001) socioeconomic status; on dual therapy (OR  2.17, 95% CI  1.024 to 4.604, p=0.043); with peripheral neuropathy (OR  1.40, 95% CI  1.039 to 1.834, p=0.026) and hypertension (OR  1.70, 95% CI  1.264 to 2.293, p&lt;/=0.001). CONCLUSIONS  Overweight and obesity are high among T2DM patients in this population and may contribute significantly to poor outcomes of T2DM. Therefore, strategies to address this problem are urgently needed.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 OBJECTIVE  To quantify postinjury cardiovascular-related health service use experienced by mid to older aged adults hospitalised for injury, compared with uninjured adults. Additionally, to explore the effect of beta-blocker medications on postinjury cardiovascular hospitalisations among injury patients, given the potential cardioprotective effects of beta blockers. DESIGN  A retrospective cohort study using linked administrative and survey data. PARTICIPANTS  Records of 35 026 injured and 60 823 uninjured matched adults aged over 45 from New South Wales, Australia, who completed the 45 and up survey. PRIMARY AND SECONDARY OUTCOME MEASURES  Admission rates and cumulative lengths of stay for cardiovascular hospitalisations, and prescription rates for cardiovascular medications. Negative binomial and Cox proportional hazards regression modelling were used to generate incident rate ratios (IRRs) and HR. RESULTS  Compared with the uninjured, those with injury had a 19% higher adjusted rate of postinjury cardiovascular admissions (IRR 1.19, 95% CI 1.14 to 1.25), spent 40% longer in hospital for ardiovascular disease (IRR 1.40, 95% CI 1.26 to 1.57) and had slightly higher cardiovascular prescription rates (IRR 1.04, 95% CI 1.02 to 1.06), during study follow-up. Those in the injury cohort that used beta blockers both prior to and after injury (continuous) appeared to have reduced need for post-injury cardiovascular hospitalisation (IRR 1.09, 95% CI 1.17 to 1.42) compared with those commencing on beta blockers after injury (after 30 days  IRR 1.69, 95% CI 1.37 to 2.08). CONCLUSIONS  Apparent increased postinjury hospitalisation rates and prolonged length of stay related to cardiovascular disease suggest that injury patients may require clinical support for an extended period after injury. Additionally, injury patients who were on continuous beta blocker treatment appeared to have lower need for post-injury cardiovascular hospitalisations. However, the data do not allow us to draw clear conclusions and further clinical research is required.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 OBJECTIVE  To assess differences in weight status and movement behaviour guideline compliance among children aged 5-12 years with and without a family history of non-communicable diseases (NCDs). DESIGN  Prospective. SETTING AND PARTICIPANTS  Women born between 1973 and 1978 were recruited to the Australian Longitudinal Study on Women&#39;s Health (ALSWH) via the database of the Health Insurance Commission (now Medicare; Australia&#39;s universal health insurance scheme). In 2016-2017, women in that cohort were invited to participate in the Mothers and their Children&#39;s Health Study and reported on their three youngest children (aged &lt;13 years). Data from children aged 5-12 years (n=4416) were analysed. MEASURES  Mothers reported their children&#39;s height and weight, used to calculate body mass index (kg/m(2)), physical activity, screen time and sleep. In the 2015 ALSWH Survey, women reported diagnoses and family history of type 2 diabetes, heart disease and hypertension. Logistic regression models determined differences between outcomes for children with and without a family history of NCDs. RESULTS  Boys with a family history of type 2 diabetes had 30% (95% CI  0.51%-0.97%) and 43% lower odds (95% CI  0.37%-0.88%) of meeting the sleep and combined guidelines, respectively, and 40% higher odds (95% CI  1.01%- 1.95%) of being overweight/obese. Girls with a family history of hypertension had 27% lower odds (95% CI  0.57%-0.93%) of meeting the screen time guidelines. No associations were observed for family history of heart disease. CONCLUSIONS  Children who have a family history of type 2 diabetes and hypertension may be at risk of poorer health behaviours from a young age. Mothers with a diagnosis or a family history of these NCDs may need additional support to help their children develop healthy movement behaviours and maintain healthy weight.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 OBJECTIVES  Patients with uremia are prone to infection; however, end-stage renal disease (ESRD) as a risk factor for acute epiglottitis warrants study. We investigated the risk of severe epiglottitis requiring hospitalisation in patients with ESRD. SETTING  We conducted a retrospective matched cohort study by using the claims data of Taiwan&#39;s National Health Insurance Research Database. PARTICIPANTS  We identified an ESRD cohort with 87 908 patients newly diagnosed in 2000-2013 and underwent dialysis. The non-ESRD cohort comprised patients who had not received a diagnosis of ESRD, and they were matches to the ESRD cohort (1 1) by sex, age, residence urbanisation level, monthly income, and diabetes and hypertension status. PRIMARY AND SECONDARY OUTCOME MEASURES  The cumulative incidence of epiglottitis at the end of 2013 was analysed with Kaplan-Meier methods and log-rank tests. The HR of epiglottitis was calculated using the Cox proportional hazards model after adjustment for confounding factors. RESULTS  The overall epiglottitis incidence rate was 94% greater in the ESRD cohort than in the non-ESRD cohort (10.3 vs 5.3 cases per 100 000 person-years, p=0.002), with an adjusted HR of 1.89 (95% CI  1.23 to 2.91, p=0.004). In the log-rank analysis, compared with the non-ESRD group, the epiglottitis cumulative incidence was significantly higher in the ESRD group (p=0.003). Epiglottitis did not exhibit an association with higher rates of airway interventions, intensive care unit admissions or longer hospitalisation in patients with ESRD than in controls. CONCLUSIONS  This nationwide matched cohort study indicated that ESRD patients should be monitored for the risk of severe epiglottitis requiring hospitalisation.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 INTRODUCTION  Exergames training, as an additional therapy to standard care, has been widely used for motor recovery after patients who had a stroke, and it is a valuable and positive tool in the rehabilitation of this population. This study describes a single-blind randomised clinical trial that will aim to investigate the effects of exergames training on postural balance in patients with chronic stroke. METHODS AND ANALYSIS  Forty-two individuals with chronic stroke (&gt;6 months), aged 20-75 years, will be randomised into two groups  the experimental group, which will be subjected to an exergames protocol, and control group, which will undergo a kinesiotherapy protocol. Both protocols are based on postural balance. The intervention will consist of 40-minute sessions two times per week for 10 consecutive weeks. The volunteers will be evaluated before the treatment, at the end of the interventions and 8 weeks thereafter. The primary outcome will be postural balance (Berg Balance Scale, Functional Reach Test, Timed Up and Go test and Centre of Pressure variables) and secondary outcomes will include gait (6 m timed walk and Kinovea Software), cortical activation patterns (electroencephalography Emotiv EPOC), functional independence (Functional Independence Measure), quality of life (Stroke-Specific Quality of Life Scale) and motivation (Intrinsic Motivation Inventory). ETHICS AND DISSEMINATION  This protocol was approved by the Ethics Committee of the Federal University of Rio Grande do Norte (number 3.434.350). The results of the study will be disseminated to participants through social networks and will be submitted to a peer-reviewed journal and scientific meetings. TRIAL REGISTRATION NUMBER  Brazilian Registry of Clinical Trials (RBR-78v9hx).
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">deep vein thrombosis</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Coagulopathies,
 OBJECTIVES  To evaluate the short-term (12 weeks) safety and utilisation of rivaroxaban prescribed to new-user adult patients for the treatment of deep vein thrombosis and pulmonary embolism and for the prevention of recurrent deep vein thrombosis and pulmonary embolism in a secondary care setting in England and Wales. DESIGN  An observational cohort study using the technique of Specialist Cohort Event Monitoring. SETTING  The Rivaroxaban Observational Safety Evaluation study was conducted across 87 participating National Health Service secondary care trusts in England and Wales. PARTICIPANTS  1532 patients treated with rivaroxaban for the prevention and treatment of deep vein thrombosis/pulmonary embolism from September 2013 to January 2016. INTERVENTIONS  Non-interventional postauthorisation safety study of rivaroxaban. PRIMARY AND SECONDARY OUTCOME MEASURES  (1) Risk of major bleeding in gastrointestinal, intracranial, and urogenital sites and (2) risk of all major and clinically relevant non-major bleeds. RESULTS  Of a total of 4846 patients enrolled in the study from September 2013 to January 2016, 1532 were treated with rivaroxaban for the prevention and treatment of deep vein thrombosis/pulmonary embolism. The median age of the deep vein thrombosis/pulmonary embolism cohort was 63 years, and 54.6% were men. The risk of major bleeding within the gastrointestinal, urogenital and intracranial primary sites was 0.7% (n=11), 0.3% (n=5) and 0.1% (n=1), respectively. The risk of major bleeding in all sites was 1.5% (n=23) at a rate of 8.3 events per 100 patient-years. CONCLUSIONS  In terms of the primary outcome risk of major bleeding in gastrointestinal, intracranial and urogenital sites, the risk estimates in the population using rivaroxaban for deep vein thrombosis/pulmonary embolism were low (&lt;1%) and consistent with the risk estimated from clinical trial data and in routine clinical practice. TRIAL REGISTRATION NUMBERS  ClinicalTrials.gov Registry (NCT01871194); ENCePP Registry (EUPAS3979).
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 OBJECTIVE  In 2011, The National Department of Health introduced the Integrated Chronic Disease Management (ICDM) model as a pilot programme in selected primary healthcare facilities in South Africa. The objective of this study was to determine individual-level and facility-level predictors of controlled CD4 count and blood pressure (BP) in patients receiving treatment for HIV and hypertension, respectively. DESIGN  A panel study. SETTING AND PARTICIPANTS  This study was conducted in the Bushbuckridge Municipality, South Africa from 2011 to 2013. Facility records of patients aged &gt;/=18 years were retrieved from the integrated chronic disease management (ICDM) pilot (n=435) and comparison facilities (n=443) using a three-step probability sampling process. CD4 count and BP control are defined as CD4 count &gt;350 cells/mm(3) and BP &lt;140/90 mm Hg. A multilevel Least Absolute Shrinkage and Selection Operator binary logistic regression analysis was done at a 5% significance level using STATA V.16. PRIMARY OUTCOME MEASURES  CD4 (cells/mm(3)) count and BP (mm Hg). RESULTS  Compared with the comparison facilities, patients receiving treatment in the pilot facilities had increased odds of controlling their CD4 count (OR=5.84, 95% CI 3.21-8.22) and BP (OR=1.22, 95% CI 1.04-2.14). Patients aged 50-59 (OR=6.12, 95% CI 2.14-7.21) and &gt;/=60 (OR=7.59, 95% CI 4.75-11.82) years had increased odds of controlling their CD4 counts compared with those aged 18-29 years. Likewise, patients aged 40-49 (OR=5.73, 95% CI 1.98-8.43), 50-59 (OR=7.28, 95% CI 4.33-9.27) and &gt;/=60 (OR=9.31, 95% CI 5.12-13.68) years had increased odds of controlling their BP. In contrast, men had decreased odds of controlling their CD4 count (OR=0.12, 95% CI 0.10-0.46) and BP (OR=0.21, 95% CI 0.19-0.47) than women. CONCLUSION  The ICDM model had a small but significant effect on BP control, hence, the need to more effectively leverage the HIV programme for optimal BP control in the setting.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 OBJECTIVE  To examine the association between polarity of atrial premature complexes (APCs) and stroke. DESIGN  A prospective study. SETTING AND PARTICIPANTS  A total of 11 092 participants in the Jichi Medical School cohort study were included after excluding patients with atrial fibrillation. We analysed stroke events in patients with (n=136) and without (n=10 956) APCs. With regard to polarity of APCs, patients were subcategorised into having (1) negative (n=39) or non-negative (n=97) P waves in augmented vector right (aVR), and (2) positive (n=28) or non-positive (n=108) P waves in augmented vector left (aVL). OUTCOME MEASURES  The primary endpoint was stroke. RESULTS  Patients with APCs were significantly older than those without APCs (64.1+/-9.2 vs 55.1+/-11.6 years, p&lt;0.001). The mean follow-up period was 11.8+/-2.4 years. Stroke events were observed in patients with (n=13 events) and without (n=411 events) APCs. This difference was significant (log-rank 12.9, p&lt;0.001); however, APCs were not an independent predictor of stroke after adjusting for age, sex, height, body mass index, current drinking, diabetes, systolic blood pressure, prior myocardial infarction, prior stroke and high-density lipoprotein-cholesterol (p=0.15). The incidence of stroke in patients with APCs and non-negative P wave in aVR was significantly higher than in patients without APCs (log-rank 20.1, p&lt;0.001), and non-negative P wave in aVR was revealed to be an independent predictor of stroke (HR 1.84, 95% CI 1.02 to 3.30). The incidence of stroke in patients with APC with non-positive P wave in aVL was also significantly higher than in patients without APC (log-rank 15.3, p&lt;0.001), and non-positive P wave in aVL was an independent predictor of stroke (HR 1.92, 95% CI 1.05 to 3.54). CONCLUSIONS  The presence of APCs with non-negative P wave in aVR or non-positive P wave in aVL on 12-lead ECG was associated with a higher risk of incident stroke.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 Currently, there is a need for reliable tests that allow identification of individuals that have been infected with SARS-CoV-2 even if the infection was asymptomatic. To date, the vast majority of the serological tests for SARS-CoV-2-specific Abs are based on serum detection of Abs to either the viral spike glycoprotein (the major target for neutralizing Abs) or the viral nucleocapsid protein that is known to be highly immunogenic in other coronaviruses. Conceivably, exposure of Ags released from infected cells could stimulate Ab responses that might correlate with tissue damage and, hence, they may have some value as a prognostic indicator. We addressed whether other nonstructural viral proteins, not incorporated into the infectious viral particle, specifically the viral cysteine-like protease, might also be potent immunogens. Using ELISA tests, coating several SARS-CoV-2 proteins produced in vitro, we describe that COVID-19 patients make high titer IgG, IgM, and IgA Ab responses to the Cys-like protease from SARS-CoV-2, also known as 3CLpro or Mpro, and it can be used to identify individuals with positive serology against the coronavirus. Higher Ab titers in these assays associated with more-severe disease, and no cross-reactive Abs against prior betacoronavirus were found. Remarkably, IgG Abs specific for Mpro and other SARS-CoV-2 Ags can also be detected in saliva. In conclusion, Mpro is a potent Ag in infected patients that can be used in serological tests, and its detection in saliva could be the basis for a rapid, noninvasive test for COVID-19 seropositivity.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 Currently, there is a need for reliable tests that allow identification of individuals that have been infected with SARS-CoV-2 even if the infection was asymptomatic. To date, the vast majority of the serological tests for SARS-CoV-2-specific Abs are based on serum detection of Abs to either the viral spike glycoprotein (the major target for neutralizing Abs) or the viral nucleocapsid protein that is known to be highly immunogenic in other coronaviruses. Conceivably, exposure of Ags released from infected cells could stimulate Ab responses that might correlate with tissue damage and, hence, they may have some value as a prognostic indicator. We addressed whether other nonstructural viral proteins, not incorporated into the infectious viral particle, specifically the viral cysteine-like protease, might also be potent immunogens. Using ELISA tests, coating several SARS-CoV-2 proteins produced in vitro, we describe that COVID-19 patients make high titer IgG, IgM, and IgA Ab responses to the Cys-like protease from SARS-CoV-2, also known as 3CLpro or Mpro, and it can be used to identify individuals with positive serology against the coronavirus. Higher Ab titers in these assays associated with more-severe disease, and no cross-reactive Abs against prior betacoronavirus were found. Remarkably, IgG Abs specific for Mpro and other SARS-CoV-2 Ags can also be detected in saliva. In conclusion, Mpro is a potent Ag in infected patients that can be used in serological tests, and its detection in saliva could be the basis for a rapid, noninvasive test for COVID-19 seropositivity.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 The human body is colonized by the microbial cells that are estimated to be as abundant as human cells, yet their genome is roughly 100 times the human genome, providing significantly more genetic diversity. The past decade has observed an explosion of interest in examining the existence of microbiota in the human body and understanding its role in various diseases including inflammatory bowel disease, neurologic diseases, cardiovascular disorders, and cancer. Many studies have demonstrated differential community composition between normal tissue and cancerous tissue, paving the way for investigations focused on deciphering the cause-and-effect relationships between specific microbes and initiation and progression of various cancers. Also, evolving are the strategies to alter tumor-associated dysbiosis and move it towards eubiosis with holistic approaches to change the entire neighborhood or to neutralize pathogenic strains. In this review, we discuss important pathogenic bacteria and the underlying mechanisms by which they impact cancer progression. We summarize key microbiota alterations observed in multiple tumor niches, their association with clinical stages, and their potential use in cancer diagnosis and management. Finally, we discuss microbiota-based therapeutic approaches.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 A recent study reported that coronary artery calcification (CAC) and serum homocysteine were well associated; however, no report is available for the cut-off value of serum homocysteine according to increase of coronary-artery calcification volume score (CVS). The data of 469 out of 777 subjects in 1 health promotion center located in Seoul were selected after exclusion of the missing data of serum homocysteine and CVS. CVS was categorized into 2 groups  CVS=0 and CVS&gt;0. Serum homocysteine according to the CVS groups was compared, and the cut-off value of serum homocysteine according to the increase of CVS (&gt;0) was calculated using the receiver operating characteristic curve. Mean age was 54.5 years and the proportion of females was 22.2%. Mean serum homocysteine concentration and CVS were 11.2 mumol/L and 50.4, respectively. After adjustments for age and sex, serum homocysteine was associated with CVS (r=0.167, p=0.001), and Log(Homocysteine) also showed a significant difference according to the CVS groups. The cut-off value of serum homocysteine according to the increase of CVS (&gt;0) was 9.45 mumol/L (area under the curve=0.569 (95% CI 0.512 to 0.625), p=0.015). The cut-off value of serum homocysteine was 9.45 mumol/L according to the increase of coronary-artery CVS.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 Acromegaly is a rare disease associated with comorbidities that are common in the general population. Most patients undergo screening for classic phenotypical (CP) or mass effect manifestations. By retrospective review of pituitary tumor surgeries performed between 1994 and 2016 (1836), we identified patients with acromegaly (112). Main presentations were  CP (43%), mass effect (26%), incidentally detected (ID) tumors (17%), and other (14%). We compared the ID and CP groups regarding prevalence, clinical, biochemical, radiological and histopathological characteristics, and postoperative outcomes. The prevalence of ID among all surgeries increased after 2011 from 0.6% to 1.9% (p=0.01), while prevalence of CP remained stable (2.8% and 2.33%, p=0.65). Almost half of ID (47.4%) presented with otolaryngological manifestations. The ID and CP groups were similar regarding age, gender, comorbidities (hypertension, diabetes, hypopituitarism), tumor diameter and cavernous sinus invasion. Median insulin-like growth factor (IGF-1) and growth hormone (GH) levels were lower in the ID than CP (p&lt;0.05 and p=0.07). Patients younger than 40 had smaller tumors in the ID than CP, while the opposite was true for older patients. The 3-month biochemical remission rates were similar (68% ID and 58% CP). A similar number of patients had normal IGF-1 at last follow-up (89.5% ID and 81.25% CP) after surgery alone and multimodality treatment. In conclusion, an increased number of patients with GH-secreting adenomas were ID in recent years. Education of physicians other than endocrinologists regarding presentation and comorbidity clustering may lead to an earlier diagnosis of acromegaly and improved outcomes.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">tricuspid</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocardit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocard</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">cardit</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Coagulopathies,
 Acute bacterial endocarditis is a rapid, difficult to manage, and frequently lethal disease. Potent antibiotics often cannot efficiently kill Staphylococcus aureus that colonizes the heart&#39;s valves. S. aureus relies on virulence factors to evade therapeutics and the host&#39;s immune response, usurping the host&#39;s clotting system by activating circulating prothrombin with staphylocoagulase and von Willebrand factor-binding protein. An insoluble fibrin barrier then forms around the bacterial colony, shielding the pathogen from immune cell clearance. Targeting virulence factors may provide previously unidentified avenues to better diagnose and treat endocarditis. To tap into this unused therapeutic opportunity, we codeveloped therapeutics and multimodal molecular imaging to probe the host-pathogen interface. We introduced and validated a family of small-molecule optical and positron emission tomography (PET) reporters targeting active thrombin in the fibrin-rich environment of bacterial colonies. The imaging agents, based on the clinical thrombin inhibitor dabigatran, are bound to heart valve vegetations in mice. Using optical imaging, we monitored therapy with antibodies neutralizing staphylocoagulase and von Willebrand factor-binding protein in mice with S. aureus endocarditis. This treatment deactivated bacterial defenses against innate immune cells, decreased in vivo imaging signal, and improved survival. Aortic or tricuspid S. aureus endocarditis in piglets was also successfully imaged with clinical PET/magnetic resonance imaging. Our data map a route toward adjuvant immunotherapy for endocarditis and provide efficient tools to monitor this drug class for infectious diseases.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 OBJECTIVE  To assess the consistency of machine learning and statistical techniques in predicting individual level and population level risks of cardiovascular disease and the effects of censoring on risk predictions. DESIGN  Longitudinal cohort study from 1 January 1998 to 31 December 2018. SETTING AND PARTICIPANTS  3.6 million patients from the Clinical Practice Research Datalink registered at 391 general practices in England with linked hospital admission and mortality records. MAIN OUTCOME MEASURES  Model performance including discrimination, calibration, and consistency of individual risk prediction for the same patients among models with comparable model performance. 19 different prediction techniques were applied, including 12 families of machine learning models (grid searched for best models), three Cox proportional hazards models (local fitted, QRISK3, and Framingham), three parametric survival models, and one logistic model. RESULTS  The various models had similar population level performance (C statistics of about 0.87 and similar calibration). However, the predictions for individual risks of cardiovascular disease varied widely between and within different types of machine learning and statistical models, especially in patients with higher risks. A patient with a risk of 9.5-10.5% predicted by QRISK3 had a risk of 2.9-9.2% in a random forest and 2.4-7.2% in a neural network. The differences in predicted risks between QRISK3 and a neural network ranged between -23.2% and 0.1% (95% range). Models that ignored censoring (that is, assumed censored patients to be event free) substantially underestimated risk of cardiovascular disease. Of the 223 815 patients with a cardiovascular disease risk above 7.5% with QRISK3, 57.8% would be reclassified below 7.5% when using another model. CONCLUSIONS  A variety of models predicted risks for the same patients very differently despite similar model performances. The logistic models and commonly used machine learning models should not be directly applied to the prediction of long term risks without considering censoring. Survival models that consider censoring and that are explainable, such as QRISK3, are preferable. The level of consistency within and between models should be routinely assessed before they are used for clinical decision making.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 Hypertension is considered one of the most common medical disorders causing complexities in pregnancy. It could be a newly developed pregnancy-induced hypertension (PIH) or a pre-existing hypertension developing into superimposed pre-eclamptic toxaemia. PIH affects approximately 10% of pregnancies and can have a serious impact on both maternal and fetal well-being; hence requires frequent monitoring and timely intervention. National Institute for Health and Care Excellence (NICE) guidelines recommends once or twice weekly monitoring of blood pressure for such patients. The required frequent monitoring comes with certain implications for patients and healthcare services. An average patient with PIH would need to see her healthcare provider once or twice a week until delivery and 6 weeks thereafter. This certainly increases pressure on limited National Health Service (NHS) resources. Home-based monitoring using Telehealth technology can represent a potential solution for achieving good-quality care for the patient without increasing the workload for healthcare providers. We used &#39;Florence&#39;, a text-based technology platform to support home monitoring. We tested its acceptability, feasibility and safety to replace face-to-face appointments for blood pressure monitoring in selected patients with PIH. We implemented our project in three progressive phases using a plan, do, study, act methodology. Florence, telehealth technology was used for blood pressure monitoring instead of face-to-face appointments, and the effect of this innovative technology on the services and the patient experience was studied and necessary modifications were made before progression into the next phase. We recruited 75 patients over 12 months through the progressive phases and replaced around 800 face-to-face appointments by remotely supervised monitoring sessions with Florence successfully, with improved care and patient satisfaction. We also achieved better compliance with the NICE guidelines for blood pressure monitoring in PIH. Our project concluded that Telehealth can be a potential solution for improving care in maternity services, with lesser burden on NHS resources.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 A 44-year-old obese woman presented with decrease in vision in the right eye (RE) for 3 days. She reported a simultaneous onset of holocranial headache that worsened on bending forward. She denied eye pain, pain on eye movements, and other ocular or neurological complaints. On examination, her distance best-corrected visual acuity was counting fingers at 1 m in the RE and 20/20 in the left eye (LE). Colour vision was subnormal in both eyes (BE). There was grade II relative afferent pupillary defect in the RE. Fundus examination showed disc oedema in BE . Visual fields in the LE showed central scotoma extending nasally. A provisional diagnosis of papillitis was considered. However, contrast-enhanced MRI of the brain and orbits showed evidence of elevated intracranial pressure. Cerebrospinal fluid (CSF) opening pressure was 42 cm H2O while rest of the CSF analysis was normal. Diagnosis was revised to fulminant idiopathic intracranial hypertension. Management with medical therapy and urgent thecoperiteoneal shunt improved visual function in BE.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">stenos</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 A boy aged 19 years presented to emergency room with severe postprandial upper abdominal pain and recent significant weight loss, with history of decompressive craniotomy for post-traumatic frontal lobe haemorrhage. CT scan revealed an acute indentation of coeliac artery with high-grade stenosis and post-stenotic dilatation, diagnostic of median arcuate ligament syndrome (MALS). MALS, a diagnosis of exclusion, is identified using patient&#39;s accurate symptomatic description. Exclusion of other causes of abdominal angina in a patient with frontal lobe syndrome was a challenging job, as they lack critical decision-making ability. Hence, the decision to proceed with the complex laparoscopic procedure was made by the patient&#39;s parents and the surgeon, with the patient&#39;s consent. Laparoscopic release of the median arcuate ligament resulted in relief of the patient symptoms much to the relief of his parents and the surgeon.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Coagulopathies,
 An 83-year-old woman presented with rapid onset unilateral nasal obstruction after sneezing. She had a history of hypertension and atrial fibrillation, and was on rivaroxaban. Examination revealed a dark red polypoidal lesion completely obstructing the left nostril. She underwent CT and MRI, and proceeded to urgent excision biopsy of the lesion. Intraoperative appearance was in keeping with a haemorrhagic polyp arising from the nasal septum. Histology revealed haematoma within a layer of nasal mucosa. There was no evidence of haemangioma underlying the polyp. Our literature search has identified this case as the first described haemorrhagic polyp of the nasal septum. It is likely that rivaroxaban contributed to the formation of this haemorrhagic polyp, and it is important to differentiate benign haemorrhagic lesions from malignant conditions such as melanoma. Similar cases may become more common in the future as the proportion of the population on anticoagulants increases.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocardit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocard</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">cardit</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Inflammatory diseases,Diseases of arteries,Coagulopathies,
 A 60-year-old man recently admitted for bipedal oedema, endocarditis and a persistently positive COVID-19 swab with a history of anticoagulation on rivaroxaban for atrial fibrillation, transitional cell carcinoma, cerebral amyloid angiopathy, diabetes and hypertension presented with sudden onset diplopia and vertical gaze palsy. Vestibulo-ocular reflex was preserved. Simultaneously, he developed a scotoma and sudden visual loss, and was found to have a right branch retinal artery occlusion. MRI head demonstrated a unilateral midbrain infarct. This case demonstrates a rare unilateral cause of bilateral supranuclear palsy which spares the posterior commisure. The case also raises a question about the contribution of COVID-19 to the procoagulant status of the patient which already includes atrial fibrillation and endocarditis, and presents a complex treatment dilemma regarding anticoagulation.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocardit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocard</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">cardit</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Inflammatory diseases,Diseases of arteries,Coagulopathies,
 A 60-year-old man recently admitted for bipedal oedema, endocarditis and a persistently positive COVID-19 swab with a history of anticoagulation on rivaroxaban for atrial fibrillation, transitional cell carcinoma, cerebral amyloid angiopathy, diabetes and hypertension presented with sudden onset diplopia and vertical gaze palsy. Vestibulo-ocular reflex was preserved. Simultaneously, he developed a scotoma and sudden visual loss, and was found to have a right branch retinal artery occlusion. MRI head demonstrated a unilateral midbrain infarct. This case demonstrates a rare unilateral cause of bilateral supranuclear palsy which spares the posterior commisure. The case also raises a question about the contribution of COVID-19 to the procoagulant status of the patient which already includes atrial fibrillation and endocarditis, and presents a complex treatment dilemma regarding anticoagulation.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischaem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Inflammatory diseases,
 BACKGROUND  Long-term outcomes for Medicare beneficiaries hospitalised with transient ischaemic attack (TIA) and role of ABCD(2) score in identifying high-risk individuals are not studied. METHODS  We identified 40 825 Medicare beneficiaries hospitalised from 2011 to 2014 for a TIA to a Get With The Guidelines (GWTG)-Stroke hospital and classified them using ABCD(2) score. Proportional hazards models were used to assess 1-year event rates of mortality and rehospitalisation (all-cause, ischaemic stroke, haemorrhagic stroke, myocardial infarction, and gastrointestinal and intracranial haemorrhage) for high-risk versus low-risk groups adjusted for patient and hospital characteristics. RESULTS  Of the 40 825 patients, 35 118 (86%) were high risk (ABCD(2) &gt;/=4) and 5707 (14%) were low risk (ABCD(2)=0-3). Overall rate of mortality during 1-year follow-up after hospital discharge for the index TIA was 11.7%, 44.3% were rehospitalised for any reason and 3.6% were readmitted due to stroke. Patients with ABCD(2) score &gt;/=4 had higher mortality at 1 year than not (adjusted HR 1.18, 95% CI 1.07 to 1.30). Adjusted risks for ischaemic stroke, all-cause readmission and mortality/all-cause readmission at 1 year were also significantly higher for patients with ABCD(2) score &gt;/=4 vs 0-3. In contrast, haemorrhagic stroke, myocardial infarction, gastrointestinal bleeding and intracranial haemorrhage risk were not significantly different by ABCD(2) score. CONCLUSIONS  This study validates the use of ABCD(2) score for long-term risk assessment after TIA in patients aged 65 years and older. Attentive efforts for community-based follow-up care after TIA are needed for ongoing prevention in Medicare beneficiaries who were hospitalised for TIA.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Diseases of arteries,
 OBJECTIVES  We aimed to examine the relationship between access to medicine for cardiovascular disease (CVD) and major adverse cardiovascular events (MACEs) among people at high risk of CVD in high-income countries (HICs), upper and lower middle-income countries (UMICs, LMICs) and low-income countries (LICs) participating in the Prospective Urban Rural Epidemiology (PURE) study. METHODS  We defined high CVD risk as the presence of any of the following  hypertension, coronary artery disease, stroke, smoker, diabetes or age &gt;55 years. Availability and affordability of blood pressure lowering drugs, antiplatelets and statins were obtained from pharmacies. Participants were categorised  group 1-all three drug types were available and affordable, group 2-all three drugs were available but not affordable and group 3-all three drugs were not available. We used multivariable Cox proportional hazard models with nested clustering at country and community levels, adjusting for comorbidities, sociodemographic and economic factors. RESULTS  Of 163 466 participants, there were 93 200 with high CVD risk from 21 countries (mean age 54.7, 49% female). Of these, 44.9% were from group 1, 29.4% from group 2 and 25.7% from group 3. Compared with participants from group 1, the risk of MACEs was higher among participants in group 2 (HR 1.19, 95% CI 1.07 to 1.31), and among participants from group 3 (HR 1.25, 95% CI 1.08 to 1.50). CONCLUSION  Lower availability and affordability of essential CVD medicines were associated with higher risk of MACEs and mortality. Improving access to CVD medicines should be a key part of the strategy to lower CVD globally.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 BACKGROUND  We assessed whether the results of quadruple screening during pregnancy are associated with an increased risk of adverse pregnancy outcomes. METHODS  We measured serum marker concentrations using quadruple screening in the second trimester of pregnancy and analyzed the relationship between adverse perinatal outcomes and serum markers in 12,124 pregnant women. A multivariate logistic regression analysis was used to evaluate the relative risk of quadruple screening and adverse pregnancy outcomes. RESULTS  Compared with the control group, increased concentrations of alpha-fetoprotein (AFP) and inhibin A were risk factors for preeclampsia and preterm delivery; low concentrations of unconjugated estriol and high inhibin A were risk factors for pregnancy hypertension; an increased concentration of human chorionic gonadotropin (hCG) was a risk factor for gestational diabetes mellitus; high AFP, low hCG, and high inhibin A were risk factors for low birth weight; and low AFP and high hCG were risk factors for macrosomia. CONCLUSIONS  Quadruple screening in the second trimester of pregnancy can provide early warning signs for maternal and fetal adverse pregnancy outcomes.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Cardiomyopathy,
 Quantification of parasites in the context of Chagas disease is required to monitor the treatment with benznidazole, disease-associated cardiomyopathies and graft rejection after heart transplantation. As parasitological exams lack sensitivity, Real Time Polymerase Chain Reaction (rt-PCR) has emerged to evaluate the parasite load in blood samples and cardiac biopsies. However, despite its higher sensitivity, rt-PCR does not provide information on the location and distribution of amastigote nests within infected tissues, the characterization of inflammatory infiltrates or changes to tissue architecture. On the contrary, a sensitive immunohistochemistry technique (IHC) could fill these gaps. In the present study, a quantitative IHC exam was standardized and validated by testing adipose and cardiac tissues of experimentally infected mice containing variable parasite load levels of T. cruzi assessed by a sensitive Sybr Green rt-PCR with kDNA primers. Tissues were divided into four groups according to the parasite load  group A- 100 parasites/50 ng of DNA; group B -10 parasites; group C - around 1 parasite and group D - less than 1 parasite/50 ng/DNA. IHC was able to detect T. cruzi in the four groups, even in group D tissues containing fractions of a single parasite/50 ng of DNA sample according to rt-PCR. In conclusion, a highly sensitivity and reliable quantitative immunohistochemistry technique was developed and is proposed to estimate the percentage of T. cruzi-infected tissue area in chagasic patients presenting with cardiomyopathies, as a complementary test to rt-PCR.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Inflammatory diseases,Diseases of arteries,Coagulopathies,
 Positive calorie balance disrupts the function of visceral adipose tissue, including the cardiac adipose tissue and the perivascular adipose tissue. The inflammatory and hormonal factors, which are released from adipose tissue, play a central role in inter-organ cross talk, affecting the development of obesity. Excess fat in visceral adipocytes impairs endocrine as well as immune response, leading to multiple aberrant status and posing serious risks to the future health of humans. As confirmed in previous studies, up-regulated pro-inflammatory and down-regulated anti-inflammatory cytokines disturb the communication among muscle, liver, and vasculature. In other words, adiposopathy promote cardio-metabolic risk factors, such as atherosclerosis, hypertension, insulin resistance, dyslipidemia, and pro-thrombotic state, which in turn directly and indirectly promote cardio-metabolic disorder diseases. Increasing evidence from human and animal studies has shown that physical activity restores the size of adipocytes and helps in re-browning of white adipose tissue (WAT). This review summarizes the current evidence on the roles of adiposopathy on cardio-metabolic disorder diseases and the importance of physical activity in restoring the function of adipocytes.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 In the United States (US), chronic disease risk factors are highly prevalent among Asian immigrant communities, who also exhibit low health screening rates. Perceived neighborhood social cohesion (NSC) has been associated with preventive healthcare use in the general US population, although it remains unexplored among Asian Americans (AAs). The aim of this study is to evaluate the association between NSC and preventive screening for hypertension, high cholesterol, diabetes, and depression among East, South and Southeast Asian American (EAA, SAA, SEAA) communities in New York City (NYC) using cross-sectional, locally collected data from 2013 to 2016. NSC was assessed using a 4-question scale to create an additive score between 4 and 16 and was analyzed both as a continuous and categorial variable (High, Medium, and Low tertiles). Recent screening was defined as a check-up within the last year for each of the included health conditions. A one-unit increase in NSC score was associated with increased odds of recent screening for high cholesterol in EAAs (AOR = 1.09, 95%CI 1.00-1.20); for high cholesterol, diabetes, and depression in SAAs (AOR = 1.08, 95%CI 1.00-1.20; AOR = 1.07, 95%CI 1.00-1.15; AOR = 1.15, 95%CI 1.06-1.25); and with high cholesterol among SEAAs (AOR = 1.12, 95%CI 1.00-1.25). Overall, NSC was an important facilitator for preventive screening behaviors for specific conditions in different groups, though was consistently associated with screening for high cholesterol in our sample. Enhancing NSC through family and community-based programming may be one strategy to encourage screening for preventive behaviors, though more research is needed to elucidate a precise mechanism.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Cardiomyopathy,
 BACKGROUND  The clinical outcome of hypertrophic cardiomyopathy patients is not only determined by the disease-causing mutation but influenced by a variety of disease modifiers. Here, we defined the role of the mutation location and the mutant protein dose of the troponin T mutations I79N, R94C and R278C. METHODS AND RESULTS  We determined myofilament function after troponin exchange in permeabilized single human cardiomyocytes as well as in cardiac patient samples harboring the R278C mutation. Notably, we found that a small dose of mutant protein is sufficient for the maximal effect on myofilament Ca(2+)-sensitivity for the I79N and R94C mutation while the mutation location determines the magnitude of this effect. While incorporation of I79N and R94C increased myofilament Ca(2+)-sensitivity, incorporation of R278C increased Ca(2+)-sensitivity at low and intermediate dose, while it decreased Ca(2+)-sensitivity at high dose. All three cTnT mutants showed reduced thin filament binding affinity, which coincided with a relatively low maximal exchange (50.5 +/- 5.2%) of mutant troponin complex in cardiomyocytes. In accordance, 32.2 +/- 4.0% mutant R278C was found in two patient samples which showed 50.0 +/- 3.7% mutant mRNA. In accordance with studies that showed clinical variability in patients with the exact same mutation, we observed variability on the functional single cell level in patients with the R278C mutation. These differences in myofilament properties could not be explained by differences in the amount of mutant protein. CONCLUSIONS  Using troponin exchange in single human cardiomyocytes, we show that TNNT2 mutation-induced changes in myofilament Ca(2+)-sensitivity depend on mutation location, while all mutants show reduced thin filament binding affinity. The specific mutation-effect observed for R278C could not be translated to myofilament function of cardiomyocytes from patients, and is most likely explained by other (post)-translational troponin modifications. Overall, our studies illustrate that mutation location underlies variability in myofilament Ca(2+)-sensitivity, while only the R278C mutation shows a highly dose-dependent effect on myofilament function.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Inflammatory diseases,
 Medicinal plants are well-known in affording clinically useful agents, with rich medicinal values by combining with disease targets through various mechanisms. Plant secondary metabolites as lead compounds lay the foundation for the discovery and development of new drugs in disease treatment. Genus Uncaria from Rubiaceae family is a significant plant source of active alkaloids, with anti-hypertensive, sedative, anti-Alzheimer&#39;s disease, anti-drug addiction and anti-inflammatory effects. This review summarizes and discuss the research progress of Uncaria based on alkaloids in the past 15 years, mainly in the past 5 years, including biosynthesis, phytochemistry, pharmacology and structural chemistry. Among, focusing on representative compounds rhynchophylline and isorhynchophylline, the pharmacological activities surrounding the central nervous system and cardiovascular system are described in detail. On the basis of case studies, this article provides a brief overview of the synthesis and analogues of representative compounds types. In summary, this review provides an early basis for further searching for new targets and activities, discussing the mechanisms of pharmacological activity and studying the structure-activity relationships of active molecules.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 BACKGROUND &amp; AIMS  The role of serum calcium on the risk of stroke is still uncertain. We aimed to evaluate the effect of serum calcium on first stroke risk, and on the efficacy of folic acid treatment in prevention of first stroke among hypertensive patients. METHODS  Our analyses included a total of 19,644 eligible hypertensive adults from the China Stroke Primary Prevention Trial (CSPPT). In the CSPPT, a total of 20,702 hypertensive patients were randomly assigned to a double-blind, daily treatment with either 10 mg enalapril and 0.8 mg folic acid or 10 mg enalapril alone. The primary outcome was a first stroke. RESULTS  Over a median of 4.5 years, among those not receiving folic acid, a significantly higher risk of first stroke was found in hypertensive males with baseline albumin-corrected serum calcium &gt;/=2.43 mmol/L (median) (vs. &lt;2.43 mmol/L; 6.5% vs. 2.3%; adjusted HR, 2.47; 95% CI  1.72, 3.55). For those with enalapril and folic acid treatment, compared with the enalapril only group, the risk of first stroke was reduced from 6.5% to 3.0% (adjusted HR, 0.49; 95% CI  0.35, 0.68) in hypertensive males with baseline albumin-corrected serum calcium &gt;/=2.43 mmol/L, whereas there was no significant effect among hypertensive males with baseline albumin-corrected serum calcium &lt;2.43 mmol/L. However, among hypertensive females, serum calcium did not significantly affect the first stroke risk and the efficacy of folic acid in prevention of first stroke. CONCLUSIONS  Among Chinese hypertensive males, those with elevated serum calcium levels had increased risk of first stroke, and this risk was reduced by 51% with folic acid treatment.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">takotsubo cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">takotsubo</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Cardiomyopathy,Diseases of arteries,
 Takotsubo cardiomyopathy or takotsubo syndrome (TTS) has become a well-known disease not only in Japan but also in the rest of the world. Early reports suggested that TTS is a self-limiting disease with better prognosis than acute coronary syndrome. However, recent data showed that TTS is not a benign disease as compared with acute coronary syndrome. In addition to the apical ballooning, several other types of wall motion abnormalities have been classified as variants of TTS. In particular, right ventricular involvement, or biventricular TTS, is not uncommon and is associated with poor in-hospital as well as long-term outcomes. With respect to the pathophysiology, modulation (desensitization) of the beta-adrenergic receptor is suspected as a possible mechanism for transiently depressed myocardial contraction. Although specific treatments to improve prognosis of TTS are still uncertain, observational data suggest favorable impact of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Finally, in the era of COVID-19, we should pay attention to a variety of cardiovascular conditions related to COVID-19. TTS is one of these conditions that can be triggered by both emotional and physical impact of the COVID-19 pandemic.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,
 Aortic dissection (AD) is a medical emergency, in which acute destruction of aortic wall occurs with unknown etiology. Recent studies have uncovered the critical role of inteleukin-6 (IL-6) and inflammatory cells including macrophages in the disease mechanism of AD. IL-6 activates janus kinase and signal transducer and activator of transcription 3 (STAT3) to alter the gene expression program in many cell types, thus regulating various aspects of inflammatory response. We found that in human AD tissue, STAT3 was activated in infiltrating macrophages and in medial smooth muscle cells (SMCs), suggesting that STAT3 may regulate the response of these cell types. However, it is unknown how Stat3 regulates the cell type-specific response in pathogenesis of AD. The role of STAT3 was examined in genetically modified mice in which STAT3 sensitivity was enhanced specifically in macrophages or in SMCs by tissue-specific deletion of suppressor of cytokine signaling 3 (Socs3), a negative regulator of STAT3. Macrophage-specific deletion of Socs3 caused acute enhancement of STAT3 activation, M1-dominant differentiation of macrophages, suppression of tissue repair response of SMCs, and exaggerated AD. In contrast, SMC-specific deletion of Socs3 caused chronic STAT3 activation and low-grade inflammatory response in aortic walls, activation of fibroblasts, M2-dominant differentiation of macrophages, increase in adventitial collagen deposition, resulting in the protection of aorta from AD by reinforcing the tensile strength of the aortic walls. Therefore, STAT3 regulates the balance between the destruction and the reinforcement of the aortic tissue, depending on the cell types and the time course of STAT3 activation, which ultimately regulates the development of AD. Elucidating such a dynamic mechanism to regulate the aortic tissue integrity would be essential to decipher the molecular pathogenesis of AD.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">tricuspid</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  Fontan outcomes data from large volume Middle Eastern Centres are lacking. We report our experience after the Fontan operation from a tertiary cardiac centre in Saudi Arabia. METHOD  All 458 consecutive patients who had Fontan surgery 1986 through 2015 at the Prince Sultan Cardiac Centre, Riyadh [PSCC], Saudi Arabia, were evaluated for baseline, early and late post-operative outcomes and their uni and multivariate determinants. RESULTS  The mean age at Fontan operation was 7 years [IQR 4.8-9.0]. The most common anatomic diagnoses were tricuspid atresia (104 [23%]) and double-inlet left ventricle (81 [18%]). Only 3 patients in the present series had hypoplastic left heart syndrome [HLHS]. Early mortality [i.e. during Fontan surgical admission] was 3.1%. At late follow-, 35 (8%) patients were lost to follow up. The 1, 5, 10, 20 and 30 year survival was 96%, 94%, 93% and 85%, respectively. In the modern surgical era, 5, 10 and 15 year survival were 96%, 95% and 93% respectively. Univariate determinants of death or transplant were hypoalbuminemia, elevated NtProBNP &gt;500, surgical era prior to 1999, the lack of Fontan fenestration, and prior atriopulmonary Fontan [APF] procedure. On multivariate analysis, surgical era before 1999 and prior APF procedure were independently associated with death or transplant. CONCLUSIONS  Fontan patients from this large volume Middle Eastern centre have comparable early and late mortality outcomes compared to prior published reports. Rigorous selection criteria at the time of Fontan, and Fontan specific dedicated care teams are likely contributors to this success.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 OBJECTIVE  Cardiac paraganglioma is a rare tumor that most surgeons have limited experience treating. The objective of this study is to examine the management and outcomes for cardiac paraganglioma treatment when cared for by a multidisciplinary cardiac tumor team. METHODS  We reviewed our institutionally approved cardiac tumor database from March 2004 to June 2020 for cardiac paraganglioma. These prospectively collected data were retrospectively reviewed. Patient characteristics were presented for individual patients and as summary statistics. Demographic and clinical data were also reported as median and interquartile range for continuous variables and frequencies and proportions for categoric variables. Kaplan-Meier curves were used to depict the patient survival from surgery. RESULTS  There were 21 cases of primary cardiac paraganglioma, 19 of whom had surgical resection with 3 refusing offered surgery. Of 19 resected tumors, 13 originated from the left atrium and 6 originated from the roots of the pulmonary artery and the aorta. Complex procedures were required, including aortic and pulmonary root replacement and 8 autotransplants. All tumors had complete gross resection with no identifiable disease left behind, but 4 of these had microscopically positive margins. None of the patients had local recurrence of disease. There was 1 case of metastatic paraganglioma with death at 4 years postsurgery. Operative mortality was 10.6%. Survival from surgery was 88.2%, 71.8%, and 71.8% and 1, 5, and 10 years, respectively. CONCLUSIONS  Cardiac paraganglioma presents a surgical challenge. Mortality and long-term survival after surgical resection are acceptable but may require complex resection and reconstruction.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,
 BACKGROUND  Ageing is characterized by a decline in cognitive and bodily functions. Metformin, the most commonly prescribed antidiabetic agent today, has proved to be able to modulate oxidative stress, several inflammatory pathways and cellular senescence to promote anti-ageing. This review aims to explore and summarize the effects of metformin on ageing. RESULTS  Metformin, a longstanding treatment for diabetes, has been shown to increase lifespan in both vertebrate and mammalian models. This pleiotropic effect is hypothesized to mimic calorie restriction, a currently proven means of slowing ageing, by decreasing insulin and insulin-like growth factor (IGF)-1 levels and improving insulin sensitivity. However, studies have shown that metformin is also able to target several other ageing pathways, thereby inhibiting mammalian target of rapamycin (mTOR), increasing AMPK activity and improving DNA repair. Clinical studies, such as those supported by the UK Clinical Practice Research Datalink service, have reported that diabetes patients treated with metformin live longer than patients without diabetes. Metformin use can also reduce type 2 diabetes mellitus (T2DM) incidence among those at risk, lower cancer incidence, and improve cognitive function, cardiovascular disease (CVD) risk factors and atherosclerosis. CONCLUSION  Various studies have found that metformin can target several nutrient-sensing, anti-ageing and immune pathways, leading to reductions in oxidative stress, inflammation and DNA damage as well as providing effects similar to those of calorie restriction. However, further trials are still needed to confirm these findings.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,
 BACKGROUND  Patients with diabetes have more extensive coronary disease, resulting in higher risks of adverse clinical events following stenting. In all-comer patients, contemporary DES have shown excellent safety and efficacy, but data on diabetic patients are scarce. Separately for the BIO-RESORT and BIONYX trials, we assessed the 2-year clinical outcomes of diabetic patients, treated with various contemporary drug-eluting stents (DES). METHODS  We performed two prespecified secondary analyses of two randomized DES trials, which both stratified for diabetes. The main endpoint was target vessel failure (TVF), a composite of cardiac death, target vessel myocardial infarction, or target vessel revascularization. Follow-up was finished before the COVID-19 pandemic. RESULTS  In BIO-RESORT, 624/3514 (17.8%) had diabetes  211 received Orsiro sirolimus-eluting stents (SES), 203 Synergy everolimus-eluting stents (EES), and 210 Resolute Integrity zotarolimus-eluting stents (RI-ZES). TVF did not differ between SES (10.2%) and EES (10.0%) versus RI-ZES (12.7%) (SES vs. RI-ZES HR 0.78, 95%-CI [0.44-1.40]; p = 0.40, EES vs. RI-ZES HR 0.79, 95%-CI [0.44-1.40]; p = 0.42). In BIONYX, 510/2488 (20.5%) patients had diabetes  250 received SES and 260 Resolute Onyx zotarolimus-eluting stents (RO-ZES). There was no difference in TVF between SES (10.7%) versus RO-ZES (12.2%) (HR 0.88, 95%-CI [0.52-1.48]; p = 0.63). CONCLUSIONS  There was no difference in 2-year clinical outcome among patients with diabetes, who were treated with SES, or EES, versus RI-ZES. In addition there was no difference in clinical outcome in diabetic patients, who were treated with SES versus RO-ZES. These findings may be considered as a signal of safety and efficacy of the studied DES in patients with diabetes.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischaem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlud</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Diseases of arteries,
 AIMS  Exercise training has a neuroprotective effect against ischaemic injury, but the underlying mechanism is not completely clear. This study explored the potential mechanisms underlying the protective effects of treadmill training and caveolin-1 regulation against mitochondrial dysfunction in cerebral ischaemic injury. MAIN METHODS  After middle cerebral artery occlusion (MCAO) surgery, rats were subjected to treadmill training and received daidzein injections and combined therapy. A series of analyses, including neurological function scoring; body weight measurement; Nissl, haematoxylin and eosin staining; cerebral infarction volume assessment; mitochondrial morphology examination; caveolin-1, cytoplasmic and mitochondrial cytochrome C (CytC), and translocase of outer membrane 20 (TOM20) expression analysis; apoptosis index analysis; and transmission electron microscopy were conducted. KEY FINDINGS  Treadmill training increased caveolin-1 expression, reduced neurobehavioral scores and cerebral infarction volumes, improved tissue morphology, reduced neuronal loss, inhibited mitochondrial outer membrane permeabilization (MOMP) through the caveolin-1 pathway, prevented excessive Cyt-C release from mitochondria, and reduced the degrees of apoptosis and mitochondrial damage. In addition, treadmill training increased the expression of TOM20 through the caveolin-1 pathway and maintained import signal function, thereby protecting mitochondrial integrity. SIGNIFICANCE  Treadmill exercise protected mitochondrial integrity and inhibited the endogenous mitochondrial apoptosis pathway. The damage of cerebral ischaemia was alleviated in rats through enhancement of caveolin-1 by treadmill exercise.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-magenta-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">arrhythm</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Arrhythmia,Heart failure,Inflammatory diseases,
 AIMS  During heart ischemia, the lack of oxygen in the myocardial cells causes pH and ion disturbances and cell death through opening mitochondrial permeability transition pores (mPTP). Considering the inhibitory effects of mitochondrial ATP-dependent potassium channels (mt-KATP) on these pores and anti-ischemic effects of morin, we hypothesized that it may exert its positive effects via activating mt-KATP as well as its anti-oxidative effects. MAIN METHODS  Isolated rat hearts were perfused by Krebs-Henseleit solution enriched with the morin (0.25, 0.5 and 1 mg/L) or 5-hydroxydecanoate (5-HD, a mt-KATP blocker;100 muM) or both as needed 5 min before starting regional ischemia till the first 10 min of the reperfusion period. The reperfusion was developed with Krebs-Henseleit solution 60 or 120 min respectively for biochemical evaluations (lactate dehydrogenase and malondialdehyde level) or the assessment of myocardial infarct size. During the experiments, hemodynamic functions were recorded and cardiac arrhythmias were determined. KEY FINDINGS  Our findings demonstrated that morin reduced the infarct size. Also, morin perfusion could remarkably prevent the malondialdehyde over-production during ischemia. Total ventricular ectopic beats had the same significant changes as the malondialdehyde level, in both ischemia and reperfusion phases. Morin could also relatively improve the ischemia-induced hemodynamic dysfunction. All mentioned protective effects of morin were reversed by concomitant perfusion of 5-HD. SIGNIFICANCE  Morin has protective effects against ischemic hearts through anti-oxidative effects. It also suggests a link between the cardioprotective effects of morin and mt-KATP. However, additional studies are required to prove this preliminary hypothesis.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlud</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Diseases of arteries,
 AIMS  Circular RNAs (circRNAs) have been shown to play crucial roles in various biological processes and human diseases. However, their exact functions in ischemic stroke remain largely unknown. In this study, we explored the functional role of circRNA HECTD1 (circ-HECTD1) and its underlying mechanism in cerebral ischemia/reperfusion injury. METHODS  Mouse middle cerebral artery occlusion (MCAO) model and oxygen-glucose deprivation (OGD) model in HT22 cells were used to mimic the cerebral ischemia/reperfusion injury. Brain infarct volume, flow cytometry, caspase 3 activity, NF-kappaB activity, and TUNEL staining were performed to evaluate the function of circ-HECTD1. Luciferase report assay was used to explore the regulatory mechanism. FINDINGS  The results showed that the expression of circ-HECTD1 and tumor necrosis factor receptor-associated factor 3 (TRAF3) was remarkably up-regulated, while miR-133b was down-regulated in oxygen-glucose deprivation (OGD)-induced HT22 cells and mouse middle cerebral artery occlusion (MCAO) model. circ-HECTD1 knockdown relieved OGD-caused neuronal cell death in vitro. Simultaneously, circ-HECTD1 knockdown improved cerebral infarction volume and neuronal apoptosis in MCAO mice. circ-HECTD1 was able to negatively regulate the expression of miR-133b, and TRAF3 is one of the targets of miR-133b. Upregulation of miR-133b inhibited the expression of TRAF3 in OGD-stimulated cells, whereas circ-HECTD1 upregulation reversed this effect. Furthermore, upregulation of miR-133 was able to inhibit OGD-caused cell apoptosis and NF-kappaB activation, whereas upregulation of circ-HECTD1 attenuated these effects of miR-133b mimics. SIGNIFICANCE  Taken together, circ-HECTD1 knockdown inhibited the expression of TRAF3 by targeting miR-133b, thereby attenuating neuronal injury caused by cerebral ischemia.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">diabet cardiomyopathy</span>,
<span class="ansi-bold">Embeded topics: </span>Cardiomyopathy,
 Objective To investigate the expression levels of microRNA-186-5p (miR-186-5p) and Toll-like receptor 3 (TLR3) and their relationships with the apoptosis in high-glucose (HG)-treated AC16 cardiomyocytes. Methods Target Scan7.1 database predicted that miR-186-5p could act directly on TLR3. Diabetic cardiomyopathy model was established in cardiomyocytes stimulated by HG. The expression of miR-186-5p was detected by real-time quantitative PCR and the expression of TLR3 was detected by Western blot analysis. The expression of miR-186-5p or TLR3 was enhanced or reduced by cell transfection. The apoptosis of cardiomyocytes was detected by flow cytometry. The expression of cleaved caspase-3(c-caspase-3) was detected by Western blot analysis, and the interaction between miR-186-5p and TLR3 was analyzed by luciferase activity assay. Results The bioinformatics analysis and luciferase activity assay showed that TLR3 was a direct target gene of miR-186-5p. The expression of miR-186-5p was down-regulated in HG-treated cardiomyocytes, and the over-expression of miR-186-5p reversed HG-induced cardiomyocyte apoptosis and reduced the protein level of c-caspase-3. Down-regulation of TLR3 inhibited HG-induced apoptosis and reduced protein level of c-caspase-3 in cardiomyocytes. Over-expression of TLR3 increased HG-induced cardiomyocyte apoptosis and reversed the effect of miR-186-5p. Conclusion The miR-186-5p can inhibit the apoptosis of cardiomyocytes induced by HG via down-regulating TLR3 expression.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 OBJECTIVE  Compare the efficacy of two interventions addressing emotional and existential well-being in early life-limiting illness. METHOD  Primary trial analysis (n = 135) included patients with advanced cancer, congestive heart failure, or end-stage renal disease; Arm 1 received the Outlook intervention, addressing issues of life completion and preparation, and Arm 2 received relaxation meditation (RM). Primary outcomes at five weeks (primary endpoint) and seven weeks (secondary)  completion and preparation (QUAL-E); secondary outcomes  anxiety (POMS) quality of life (FACT-G) and spiritual well-being (FACIT-Sp) subscales of faith, meaning, and peace. RESULTS  Average age was 62; 56% were post-high school-educated, 54% were married, 52% white, 44% female, and 70% had a cancer diagnosis. At baseline, participants demonstrated low levels of anxiety (&lt;5 on POMS subscale) and depression (&lt;10 on CESD) relative to population norms. Results of the primary analysis revealed no significant differences in mean Preparation by treatment arm at five weeks (14.4 Outlook vs. 14.8 RM; between-group difference -0.4 [95% CI, -1.6, 0.8], p = 0.49) or seven weeks (15.2 vs.15.4; between-group difference -0.2 [95% CI, -1.5, 1.0], p = 0.73). There were also no significant differences in mean Life Completion by treatment arm between five weeks (26.6 Outlook vs. 26.3 RM; between-group difference 0.2 [95% CI, -1.2, 1.7], p = 0.76) or seven weeks (26.5 vs. 27.5; between-group difference -1.0 [95% CI, -2.7, 0.7], p = 0.23). Compared to RM, Outlook participants did not have significant differences over time in the secondary outcomes of overall quality of life, anxiety, depression, FACT-G subscales, and FACIT-Sp subscales. DISCUSSION  In early-stage life-limiting illness, Outlook did not demonstrate a significant difference in primary or secondary outcomes relative to RM. Results underscore the importance of pre-screening for distress. Qualitatively, Outlook participants were able to express suppressed emotions, place illness context, reflect on adaptations, and strengthen identity. Screening for distress and identifying specified measures of distress, beyond anxiety and depression, is essential in our ability to adequately assess the multi-dimensional mechanisms that decrease existential suffering.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 OBJECTIVE  Compare the efficacy of two interventions addressing emotional and existential well-being in early life-limiting illness. METHOD  Primary trial analysis (n = 135) included patients with advanced cancer, congestive heart failure, or end-stage renal disease; Arm 1 received the Outlook intervention, addressing issues of life completion and preparation, and Arm 2 received relaxation meditation (RM). Primary outcomes at five weeks (primary endpoint) and seven weeks (secondary)  completion and preparation (QUAL-E); secondary outcomes  anxiety (POMS) quality of life (FACT-G) and spiritual well-being (FACIT-Sp) subscales of faith, meaning, and peace. RESULTS  Average age was 62; 56% were post-high school-educated, 54% were married, 52% white, 44% female, and 70% had a cancer diagnosis. At baseline, participants demonstrated low levels of anxiety (&lt;5 on POMS subscale) and depression (&lt;10 on CESD) relative to population norms. Results of the primary analysis revealed no significant differences in mean Preparation by treatment arm at five weeks (14.4 Outlook vs. 14.8 RM; between-group difference -0.4 [95% CI, -1.6, 0.8], p = 0.49) or seven weeks (15.2 vs.15.4; between-group difference -0.2 [95% CI, -1.5, 1.0], p = 0.73). There were also no significant differences in mean Life Completion by treatment arm between five weeks (26.6 Outlook vs. 26.3 RM; between-group difference 0.2 [95% CI, -1.2, 1.7], p = 0.76) or seven weeks (26.5 vs. 27.5; between-group difference -1.0 [95% CI, -2.7, 0.7], p = 0.23). Compared to RM, Outlook participants did not have significant differences over time in the secondary outcomes of overall quality of life, anxiety, depression, FACT-G subscales, and FACIT-Sp subscales. DISCUSSION  In early-stage life-limiting illness, Outlook did not demonstrate a significant difference in primary or secondary outcomes relative to RM. Results underscore the importance of pre-screening for distress. Qualitatively, Outlook participants were able to express suppressed emotions, place illness context, reflect on adaptations, and strengthen identity. Screening for distress and identifying specified measures of distress, beyond anxiety and depression, is essential in our ability to adequately assess the multi-dimensional mechanisms that decrease existential suffering.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 Higher intake of ultra-processed foods (UPF), which have undergone multiple processes and have poor nutrient quality, is associated with higher incidence of non-communicable diseases. Yet, its association with hypertension has scarcly been studied, especially in low- and middle-income countries. We aimed to estimate the associations between consumption of UPF (total, liquid and solid) and UPF food subgroups and incident hypertension in a prospective cohort study. We used data from the Mexican Teachers&#39; Cohort including 64,934 women aged &gt;/=25 y, free of hypertension, cardiovascular disease, and cancer at baseline. We assessed usual dietary intake using a validated food frequency questionnaire (FFQ) at baseline. Each FFQ item was categorized according to NOVA, a degree of food processing classification system. UPF and UPF subgroups were categorized according to the distribution of their contribution to total energy intake. Hypertension was self-reported. We used Poisson regression models to estimate incidence rate ratios (IRR) and their 95% confidence intrevals (95%CI). During a median follow-up of 2.2y (IQR 1.8, 4.4) we identified 3,752 incident cases of hypertension. The mean contribution of UPF to total energy intake was 29.8+/-9.4% kcal (23.4+/-8.9% solid, 6.4+/-4.8% liquid). In multivariable analyses, comparing extreme categories showed that higher total and solid UPF consumption were not associated with incident hypertension (IRR  0.96; 95%CI 0.79,1.16; IRR  0.91; 95%CI 0.82,1.01; respectively). However, liquid UPF and processed meats were associated with increased rate of hypertension (IRR  1.32; 95%CI 1.10,1.65; IRR  1.17; 95%CI 1.01,1.36; respectively). Addressing intake of liquid UPF and processed meats may help in managing hypertension in LMIC.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">deep vein thrombosis</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Coagulopathies,
 BACKGROUND  While multiple studies have demonstrated a lower venous thromboembolism disease (VTED) risk for unicompartmental knee arthroplasty (UKA) compared to primary total knee arthroplasty (TKA), recent reports have shown that revision TKA also had a lower VTED risk compared to primary TKA, an unexpected finding because of its theoretical increased risk. Given the paucity of up-to-date comparative studies, our goal was to perform a high-powered VTED risk comparison study of UKA and revision TKA to primary TKA using recent data. METHODS  The National Surgical Quality Improvement Program (NSQIP) database was queried between 2011 and 2018, and we identified 213,234 patients for inclusion  191,810 primary TKA, 9294 UKA, and 12,130 revision TKA. Demographics, medical comorbidities, and possible VTE risk factors were collected. Thirty-day outcomes, including deep vein thrombosis (DVT), pulmonary embolism (PE), and all-cause VTED were compared between knee arthroplasty types. RESULTS  On multivariate analysis, UKA was significantly associated with lower rates of DVT [OR 0.44 (0.31-0.61); P &lt; 0.001], PE [OR 0.42 (0.28-0.65); P &lt; 0.001], and all-cause VTED [OR 0.42 (0.32-0.55); P &lt; 0.001] when compared to primary TKA. Revision TKA was significantly associated with lower rates of PE [OR 0.62 (0.47-0.83); P = 0.002], and all-cause VTED [OR 0.82 (0.70-0.98); P = 0.029] when compared to primary TKA. CONCLUSIONS  Utilizing recent data from a nationwide patient cohort and controlling for confounding variables, our results showed that both revision TKA and UKA had a lower risk of VTED compared to primary TKA, corroborating the results of recent investigations. Additional prospective investigations are needed to explain this unexpected result.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">rhe</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Inflammatory diseases,Diseases of arteries,
 BACKGROUND  Inappropriate laboratory test ordering poses an important burden for healthcare. Clinical decision support systems (CDSS) have been cited as promising tools to improve laboratory test ordering behavior. The objectives of this study were to evaluate the effects of an intervention that integrated a clinical decision support service into a computerized physician order entry (CPOE) on the appropriateness and volume of laboratory test ordering, and on diagnostic error in primary care. METHODS  This study was a pragmatic, cluster randomized, open-label, controlled clinical trial. SETTING  Two hundred eighty general practitioners (GPs) from 72 primary care practices in Belgium. PATIENTS  Patients aged &gt;/= 18 years with a laboratory test order for at least one of 17 indications  cardiovascular disease management, hypertension, check-up, chronic kidney disease (CKD), thyroid disease, type 2 diabetes mellitus, fatigue, anemia, liver disease, gout, suspicion of acute coronary syndrome (ACS), suspicion of lung embolism, rheumatoid arthritis, sexually transmitted infections (STI), acute diarrhea, chronic diarrhea, and follow-up of medication. INTERVENTIONS  The CDSS was integrated into a computerized physician order entry (CPOE) in the form of evidence-based order sets that suggested appropriate tests based on the indication provided by the general physician. MEASUREMENTS  The primary outcome of the ELMO study was the proportion of appropriate tests over the total number of ordered tests and inappropriately not-requested tests. Secondary outcomes of the ELMO study included diagnostic error, test volume, and cascade activities. RESULTS  CDSS increased the proportion of appropriate tests by 0.21 (95% CI 0.16-0.26, p &lt; 0.0001) for all tests included in the study. GPs in the CDSS arm ordered 7 (7.15 (95% CI 3.37-10.93, p = 0.0002)) tests fewer per panel. CDSS did not increase diagnostic error. The absolute difference in proportions was a decrease of 0.66% (95% CI 1.4% decrease-0.05% increase) in possible diagnostic error. CONCLUSIONS  A CDSS in the form of order sets, integrated within the CPOE improved appropriateness and decreased volume of laboratory test ordering without increasing diagnostic error. TRIAL REGISTRATION  ClinicalTrials.gov Identifier  NCT02950142 , registered on October 25, 2016.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">stenos</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Inflammatory diseases,Diseases of arteries,
 BACKGROUND  The purpose of this study was to evaluate left ventricular systolic function in patients with different types of ischemic heart disease using two-dimensional speckle tracking imaging (2D-STI). METHODS  We retrospectively studied patients who were admitted to Peking University Third Hospital from January 2011 to December 2017 due to chest tightness and chest pain. Two hundred forty-two patients were divided into control group, CMD group and obstructive CAD group. The main coronary artery stenosis was confirmed by coronary angiography or coronary computed tomography and coronary flow reserve (CFR) in patients was measured by transthoracic Doppler echocardiography. Left ventricular strain and strain rate (SR) measured by 2D-STI. Cardiac structure and function were measured by conventional echocardiography. RESULTS  Conventional echocardiography showed that there was no significant difference in cardiac structure and function among the three groups (P &gt; 0.05). Moreover, the longitudinal strain (LS) of each ventricular wall in CMD group was notably lower than that in control group (P &lt; 0.01). In addition, global longitudinal SR and longitudinal SR in CMD group and obstructive CAD group were obviously lower than those in control group (P &lt; 0.01). GLS, endocardial LS and epicardial LS were negatively correlated with CFR (P &lt; 0.01). CONCLUSIONS  Early left ventricular systolic dysfunction was found in patients with CMD and patients with obstructive CAD, with similar degree. CFR is an independent influencing factor of GLS. GLS and stratified LS have certain diagnostic value for CMD.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Coagulopathies,
 BACKGROUND  Despite being one of the few evidence-based treatments for acute ischemic stroke, intravenous thrombolysis has low implementation rates-mainly due to a narrow therapeutic window and the health system changes required to deliver it within the recommended time. This systematic review and meta-analyses explores the differential effectiveness of intervention strategies aimed at improving the rates of intravenous thrombolysis based on the number and type of behaviour change wheel functions employed. METHOD  The following databases were searched  MEDLINE, EMBASE, PsycINFO, CINAHL and SCOPUS. Multiple authors independently completed study selection and extraction of data. The review included studies that investigated the effects of intervention strategies aimed at improving the rates of intravenous thrombolysis and/or onset-to-needle, onset-to-door and door-to-needle time for thrombolysis in patients with acute ischemic stroke. Interventions were coded according to the behaviour change wheel nomenclature. Study quality was assessed using the QualSyst scoring system for quantitative research methodologies. Random effects meta-analyses were used to examine effectiveness of interventions based on the behaviour change wheel model in improving rates of thrombolysis, while meta-regression was used to examine the association between the number of behaviour change wheel intervention strategies and intervention effectiveness. RESULTS  Results from 77 studies were included. Five behaviour change wheel interventions, &#39;Education&#39;, &#39;Persuasion&#39;, &#39;Training&#39;, &#39;Environmental restructuring&#39; and &#39;Enablement&#39;, were found to be employed among the included studies. Effects were similar across all intervention approaches regardless of type or number of behaviour change wheel-based strategies employed. High heterogeneity (I(2) &gt; 75%) was observed for all the pooled analyses. Publication bias was also identified. CONCLUSION  There was no evidence for preferring one type of behaviour change intervention strategy, nor for including multiple strategies in improving thrombolysis rates. However, the study results should be interpreted with caution, as they display high heterogeneity and publication bias.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlud</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Diseases of arteries,
 INTRODUCTION  Glycemic variability (GV) represents the amplitude of oscillations in glucose levels over time and is associated with higher mortality in critically ill patients. Our aim is to evaluate the impact of GV on acute ischemic stroke (IS) outcomes in humans and explore the impact of two different insulin administration routes on GV in an animal model. METHODS  This translational study consists of two studies conducted in parallel  The first study is an observational, multicenter, prospective clinical study in which 340 patients with acute IS will be subcutaneously implanted a sensor to continuously monitor blood glucose levels for 96 h. The second study is a basic experimental study using an animal model (rats) with permanent occlusion of the middle cerebral artery and induced hyperglycemia (through an intraperitoneal injection of nicotinamide and streptozotocin). The animal study will include the following 6 groups (10 animals per group)  sham; hyperglycemia without IS; IS without hyperglycemia; IS and hyperglycemia without treatment; IS and hyperglycemia and intravenous insulin; and IS and hyperglycemia and subcutaneous insulin. The endpoint for the first study is mortality at 3 months, while the endpoints for the animal model study are GV, functional recovery and biomarkers. DISCUSSION  The GLIAS-III study will be the first translational approach analyzing the prognostic influence of GV, evaluated by the use of subcutaneous glucose monitors, in acute stroke. Trial registration https //www.clinicaltrials.gov (NCT04001049).
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 BACKGROUND  The use of statins for primary prevention of cardiovascular diseases is associated with different benefit and harm outcomes. The aime of this study is how important these outcomes are for people and what people&#39;s preferences are. METHODS  We conducted a preference-eliciting survey incorporating a best-worst scaling (BWS) instrument in Iran from June to November 2019. The relative importance of 13 statins-related outcomes was assessed on a sample of 1085 participants, including 913 general population (486 women) and 172 healthcare providers from the population covered by urban and rural primary health care centers. The participants made trade-off decisions and selected the most and least worrisome outcomes concurrently from 13 choice sets; each contains four outcomes generated using the balanced incomplete block design. RESULTS  According to the mean (SD) BWS scores, which can be (+ 4) in maximum and (- 4) in minimum, in the general population, the most worrisome outcomes were severe stroke (3.37 (0.8)), severe myocardial infarction (2.71(0.7)), and cancer (2.69 (1.33)). While myopathy (- 3. 03 (1.03)), nausea/headache (- 2.69 (0.94)), and treatment discontinuation due to side effects (- 2.24 (1.14)) were the least worrisome outcomes. Preferences were similar between rural and urban areas and among health care providers and the general population with overlapping uncertainty intervals. CONCLUSION  The rank of health outcomes may be similar in various socio-cultural contexts. The preferences for benefits and harms of statin therapy are essential to assess benefit-harm balance when recommending statins for primary prevention of cardiovascular diseases.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-magenta-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">arrhythm</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Arrhythmia,Heart failure,
 BACKGROUND  Although cardiovascular diseases in particular Pulmonary Arterial Hypertension (PAH) is associated with, high morbid-mortality in chronic hemodialysis, but its magnitude remains paradoxically unknown in sub-Saharan Africa. The aim of this study was to evaluate the prevalence of PAH and associated factors in chronic hemodialysis in Sub-Saharan African population. METHOD  In a cross-sectional study, patients treated with HD for at least 6 months in 4 hemodialysis centers were examined. PAH was defined as estimated systolic pulmonary arterial pressure (sPAP) &gt;/= 35 mmHg using transthoracic Doppler echocardiography performed 24 h after the HD session. RESULTS  Eighty-five HD patients were included; their average age was 52.6 +/- 15.9 years. Fifty-seven patients (67.1%) were male. Mean duration of HD was 13.3 +/- 11 months. With reference to vascular access, 12 (14.1%), 29 (34.1%) and 44 (51.8%) patients had AVF, tunneled cuff and temporary catheter, respectively. The underlying cause of ESRD was diabetes in 30 patients (35.3%). The prevalence of PAH was 29.4%. Patients with PAH had more hyponatremia (11 (44%) vs 10 (16.7%), p = 0.010). In multivariate analysis, unsecured healthcare funding (aOR 4, 95% CI [1.18-6.018]), arrhythmia (aOR 3, 95% CI [1.29-7.34]), vascular access change (aOR 4, 95% CI [1.18-7.51]) and diastolic dysfunction (aOR 5, 95% CI [1.35-9.57] were independently associated with PAH. CONCLUSION  One third of hemodialysis patients exhibit PAH, which is independently associated with low socioeconomic status (unsecured funding, vascular access change) and cardiovascular complications (arrhythmia, diastolic dysfunction).
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Inflammatory diseases,
 BACKGROUND  BRD4 and PIN1 have been described to be involved in inflammation and vascular endothelial cell dysfunction, which in turn may increase pulse pressure. HYPOTHESIS  Genetic mutations within the BRD4 and PIN1 genes could affect the risk of high pulse pressure. METHODS  A total of four single nucleotide polymorphisms (SNPs) (BRD4  rs4808278; PIN1  rs2233678, rs2287838, and rs2233682) were genotyped in a cohort of 666 hypertensive patients and 232 normotensive controls with Chinese Han origin. Generalized multifactor dimensionality reduction (GMDR) was used to screen the best interaction combination among the four SNPs within the BRD4 and PIN1 genes and diabetes. Logistic regression analysis was performed to calculate the odds ratio (ORs) (95% confidence interval (CI)) for the association between the four SNPs. RESULTS  Adjusted for age, weight, waist circumference, drinking, smoking, hypertension, and diabetes, high pulse pressure risk was significantly higher for carriers with the rs4808278-TT genotype in BRD4 than those with wild genotypes (OR  0.400, 95% CI  0.217-0.737, P* &lt; 0.05). However, we did not find any significant association of rs2233678, rs2287838, and rs2233682 in PIN1 with high pulse pressure susceptibility after covariate adjustment. GMDR analysis indicated a significant three-locus model (P = 0.0107) involving rs4808278, rs2233678, and diabetes, the cross-validation consistency of the three-locus models was 9/10, and the testing accuracy was 57.47%. CONCLUSIONS  Genetic mutations within BRD4 (rs4808278) could affect the susceptibility to high pulse pressure in a southeastern Chinese population.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Ischemia,
 BACKGROUND  In the aging population, chronic diseases and multimorbidity are common. Therefore, it is important to engage patients in their self-care. The aim of this study was to analyze the relationship between activity in self-care and self-rated health among primary care patients with chronic diseases. METHODS  The data of the present study were derived from a research project on the Participatory Patient Care Planning in Primary Care (4PHC). A total of 605 patients were recruited in the Siilinjarvi Health Center from those patients who were being monitored due to the treatment of hypertension, ischemic heart disease or diabetes. We evaluated the level of patient&#39;s activity in self-care with the Patient Activation Measurement (PAM). Self-rated health (SRH) was measured with the 5-item Likert scale. An adjusted hypothesis of linearity across categories of PAM and self-rated health was estimated using analysis of covariance (ANCOVA). RESULTS  It was found that 76 patients had low activity, 185 had moderate while 336 patients had high activity as measured with PAM. Patients with the highest activity were younger, less depressed, had a lower body mass index and a higher level of physical activity than those with the lower activity. Correspondingly, good SRH was perceived by 29, 45 and 67% of the patients in these three PAM groups adjusted with sex, age, depressive symptoms (BDI) and number of diseases. There was a significant linear trend (adjusted with age, number of diseases and depressive symptoms) between SRH and PAM, p &lt; 0.001. CONCLUSIONS  Activity in self-care had an independent, linear relationship with the self-rated health. The present findings suggest that Patient Activation Measurement has the potential to categorize the patients according to their perceived health and their needs related to their disease management and self-care. The present results warrant longitudinal studies on the impact of promoting patient activation levels. TRIAL REGISTRATION  ClinicalTrials.gov Identifier  NCT02992431 . Registered 14 December 2016 https //clinicaltrials.gov/ct2/show/NCT02992431.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 BACKGROUND  Hemoglobin glycation index (HGI) is considered to be a convenient measurable indicator to assess the inter-individual variation of HbA1c. In the present study, we tested the relationship between HGI and risk of hypertension, and further explored the possible interacting influences of HGI with other such factors on hypertension risk among Chinese individuals. METHODS  The eligible subjects were chosen from a community-based cross-sectional survey in China. We collected relevant data and clinical indicators for each participant. HGI was calculated as &#34;measured HbA1c-predicted HbA1c&#34; and divided into four categories according to quartile. The following indicators were used to assess interactive effects  (1) relative excess risk due to interaction (RERI); (2) attributable proportion due to interaction (AP); and (3) synergy index (SI). Statistical analysis was performed using R software. RESULTS  Specifically, 1777 eligible participants were selected in this cross-sectional survey. There were 433 subjects who were identified to have hypertension (24.4%). A significant increase in the prevalence of hypertension from Q1 to Q4 of HGI was observed (p &lt; 0.001). Multivariable logistic model demonstrated that subjects at the highest HGI group had a substantially increased risk of being hypertensive than subjects in the first quartile of HGI, as indicated by the OR value of 1.87 (95% CI 1.26-2.78). Moreover, a significant interaction between family history of hypertension and HGI on hypertension risk was detected (RERI  1.36, 95% CI 0.11-2.63; AP  0.43, 95% CI 0.17-0.69; and SI 2.68, 95% CI 1.10-6.48). The interactive effect between HGI and abdominal obesity was also found to be significant, as estimated by the value of RERI (1.04, 95% CI 0.24-1.85), AP (0.33, 95% CI 0.11-0.56) and SI (1.96, 95% CI 1.01-3.79). However, in the analysis of the interaction between HGI and general obesity, only the AP value (0.28, 95% CI 0.01-0.54) was observed to be significant. CONCLUSION  High HGI was independently associated with the risk of hypertension. Moreover, HGI significantly shared interactions with obesity and family history of hypertension that influenced the risk of hypertension.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">stenos</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Cardiomyopathy,Diseases of arteries,
 BACKGROUND  Coronary artery spasm (CAS) and stress cardiomyopathy (SC) have different characteristic clinical manifestations in the case of suspicious myocardial infarction with nonobstructive coronary arteries. Established recurrence rates of both conditions have been reported, however, alternate recurrent CAS and SC in the same individual have not been described. CASE PRESENTATION  A 59-year-old man suffered from atypical chest pain in the first episode, acute heart attack in the second and third episodes (totally 3 times over a period of approximately 5 years). During the first episode, he visited our hospital with mild paroxysmal chest pain without obvious inducement for approximately 2 years. He was underdiagnosed at that time without other obvious findings except the poor R wave progression in V1-3 leads revealed in electrocardiogram. At 4 months after the first episode, he suffered from a heart attack (the second episode) and was diagnosed with SC based on the coronary angiography (CAG) and left ventriculography findings of nonobstructive coronary arteries combined with a classic apical ballooning shape. At 31 months after the second episode, he suffered another heart attack (the third episode) and was diagnosed with CAS based on the CAG results of recoverable severe multivessel stenoses. During the episodes, partial reversible nature of apical hypokinesis was observed in echocardiogram. In retrospect, the patient suffered silent CAS in the first episode, SC in the second episode, and severe multivessel CAS in the third episode. CONCLUSION  The unusual presentations observed in this case have not been reported. This case suggests that cardiologists should be aware of the possibility of alternate recurrent CAS and SC in the same individual. Provocative tests for spasm and cardiac magnetic resonance imaging might help gain more insights into this issue.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 BACKGROUND  Leptin can have a direct effect on endothelial and vascular smooth muscle cells and high level of leptin is involved in the pathogenesis of atherosclerosis. This study aimed to determine the relationship between leptin/adiponectin (L/A) ratio and the extent and severity of coronary artery disease (CAD). METHODS  This case-control study was conducted in an educational hospital in Ilam, Iran from June 2014 to September 2015. Totally 300 participants including 150 patients with CAD (case group) and 150 healthy individuals (control group) were selected and their plasma leptin, adiponectin and leptin/adiponectin ratio was measured. The extent and severity of coronary artery disease were assayed based on the number of involved vessels and Gensini score (GS) and the relation between scores and L/A findings were compared between cases and controls. RESULTS  Totally, 300 participants including 150 (42.7% male), mean age 59.5 +/- 11.4 years as cases and 150 (50.7% male), mean age 59.8 +/- 10.7 as controls were analyzed. Plasma level of leptin and L/A ratio were higher in cases compared to controls, but level of adiponectin was significantly lower in CAD patients than the control group. More number of involved coronary vessels was significantly correlated to higher level of plasma leptin, L/A ratio and lower level of adiponectin among case group. Moreover, adiponectin was negatively and leptin or L/A ratio were positively correlated with number of involved vessels. 7.3% of cases had only one involved vessel, 42.7% had two involved vessels, and 50% of total patients had involved vessels and the mean +/- SD of GS in the case group was 23.6 +/- 6.9. CONCLUSIONS  Plasma levels of leptin, and adiponectin can indicate the extent of coronary artery diseases but leptin may be a better marker of extent of CAD than either L/A ratio or adiponectin separately.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 OBJECTIVE  Our previous studies showed the antihypertensive effect of Ribes khorassanicum (R. khorassanicum), a medicinal herb growing in the North Khorasan Province of Iran. For further evaluation, the present study investigated the effect of n-hexane (HX), ethyl acetate (EA), and aqueous (AQ) fractions of hydroalcoholic R. khorassanicum extract on cardiovascular responses in angiotensin II (AngII) and NG-nitro-L-arginine methyl ester (L-NAME) hypertensive rats. METHODS  Wistar rats were randomly divided into 11 groups (n=5)  1) control, 2) AngII (50 ng/kg, i.v), 3) AngII + losartan (10 mg/kg, i.p), 4) L-NAME (10 mg/kg, i.v), 5) L-NAME+ sodium nitroprusside (SNP) (50 mg/kg, i.p), 6,7,8) one dose of each fraction of R. khorassanicum (AQ/EA/HX (50 mg/kg, i.p)) +AngII, and 9,10,11) one dose of each fraction of R. khorassanicum (AQ/EA/HX (50 mg/kg, i.p)) + L-NAME. Treated rats received three fractions 30 min before the injection of L-NAME and AngII in separate groups. The cardiovascular parameters were recorded by the Power Lab instrument via an angiocath inserted into the femoral artery. The peak changes () of mean arterial pressure (MAP), systolic blood pressure (SBP), and heart rate (HR) in treated groups were compared with those of the hypertensive and control groups. RESULT  AngII and L-NAME significantly increased MAP and SBP and attenuated by pretreatment of LOS and SNP, respectively. Pretreatment with polar (AQ) and semipolar (EA) fractions of R. khorassanicum reduced the peak changes of MAP and SBP in both AngII and L-NAME-treated groups. Only the fraction of the herb attenuated the HR increased in the L-NAME group. The HR in other groups did not demonstrate any significant difference. CONCLUSION  All fractions of R. khorassanicum have an antihypertensive effect. However, the effect of polar fractions is more salient. It is also conceivable that the antihypertensive effect of fractions is mostly mediated by the inhibition of AngII.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Coagulopathies,
 BACKGROUND AND PURPOSE  Cerebral microbleeds (CMB) are associated with stroke and cognitive impairment. We previously reported a high prevalence of CMB in people with Streptococcus mutans expressing Cnm, a collagen-binding protein in the oral cavity. S. mutans is a major pathogen responsible for dental caries. Repeated challenge with S. mutans harboring the cnm gene encoding Cnm induced cerebral bleeding in stroke-prone spontaneously hypertensive rats. The purpose of this longitudinal study is to examine the relationship of cnm-positive S. mutans to the development of CMB. METHODS  We retrospectively investigated patients with stroke receiving oral microbiological examination and head 3T magnetic resonance imaging evaluations twice in the period 2014 to 2019, allowing &gt;180-day interval. Patients with cnm-positive S. mutans were compared with those without. Quasi-Poisson regression models were used to explore associations between cnm-positive S. mutans and the increase in number of CMB between the 2 magnetic resonance imaging scans. RESULTS  A total of 111 patients were identified; 21 (19%) with cnm-positive S. mutans and 90 (81%) without. Clinical history, including blood pressure and the use of antithrombotic agents, were comparable between the 2 groups. New CMB were more commonly observed in patients with cnm-positive S. mutans (52% versus 23%; P=0.008). The incidence of CMB was significantly higher in the group with cnm-positive S. mutans, especially in deep areas, (incidence rate ratios [95% CI], 5.1 [1.9-13.6] for CMB in any brain region; 15.0 [5.4-42.0] for deep CMB), which persisted after adjusting for age, sex, hypertension, and renal impairment (4.7 [1.8-11.9] for CMB in any brain region; 13.9 [4.3-44.5] for deep CMB). CONCLUSIONS  This study demonstrates that cnm-positive S. mutans is associated with an increased incidence of CMB. Treatment for cnm-positive S. mutans infection may be a novel microbiota-based therapeutic approach for stroke and cognitive impairment.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,
 BACKGROUND AND PURPOSE  The purpose of this study was to replicate the top loci associated with white matter hyperintensity (WMH) phenotypes identified by large genome-wide association studies and the loci identified from the previous candidate gene studies. METHODS  A total of 946 Geisinger MyCode patients with acute ischemic stroke with validated European ancestry and magnetic resonance imaging data were included in this study. Log-transformed WMH volume, as a quantitative trait, was calculated by a fully automated quantification process. The genome-wide association studies was carried out by a linear mixed regression model (GEMMA). A candidate-single nucleotide polymorphism analysis by including known single nucleotide polymorphisms, reported from a meta-analysis and several large GWAS for WMH, was conducted in all cases and binary converted extreme cases. RESULTS  No genome-wide significantly associated variants were identified. In a candidate-single nucleotide polymorphism study, rs9515201 (COL4A2) and rs3744028 (TRIM65), 2 known genetic loci, showed nominal or trend of association with the WMH volume (beta=0.13 and P=0.001 for rs9515201; beta=0.094 and P=0.094 for rs3744028), and replicated in a subset of extreme cases versus controls (odds ratio=1.78, P=7.74x10(-)(4) for rs9515201; odds ratio=1.53, P=0.047 for rs3744028, respectively). MTHFR677 cytosine/thymine (rs1801133) also showed an association with the binary WMH with odds ratio=1.47 for T allele (P=0.019). CONCLUSIONS  Replication of COL4A1/2 associated with WMH reassures that the genetic risk factors for monogenic and polygenic ischemic stroke are shared at gene level.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,
 BACKGROUND AND PURPOSE  Although it has been reported that the amount of alcohol consumption has a J-shaped association with ischemic stroke, it is unclear whether differences in drinking patterns affect this relationship. We aimed to clarify the impact of drinking patterns on ischemic stroke in midlife. METHODS  We used data from the National Health Insurance Service-National Sample Cohort, which is a large-sized, standardized population cohort in Korea. Five different drinking patterns were defined by combining the frequency of alcohol consumption and quantity of alcohol consumed per occasion, that is, abstainers, not drinking alcohol; drinker group I, &lt;/=30 g/d and &lt;5 d/wk; drinker group II, &lt;/=30 g/d and &gt;/=5 d/wk; drinker group III, &gt;30 g/d and &lt;5 d/wk; and drinker group IV, &gt;30 g/d and &gt;/=5 d/wk. The association between the drinking patterns and ischemic stroke occurrence was analyzed using the Cox proportional hazard model. RESULTS  A total of 152 469 middle-aged participants (mean age, 50.2 years; 72 285 men [47.4%]) were eligible for the analyses. The median follow-up time was 9.0 years. Compared with abstainers, those who drank &lt;5 d/wk (drinker groups I and III) had a significantly lower risk of ischemic stroke (group I hazard ratio, 0.71 [95% CI, 0.59-0.85]; group III hazard ratio, 0.80 [95% CI, 0.68-0.93]) during the first 7 years from the baseline, while other drinker groups showed no such differences. However, the effect of drinking patterns on ischemic stroke risk was attenuated after the first 7 years. CONCLUSIONS  Reduced risk of ischemic stroke was observed in middle-aged participants with specific drinking patterns, but it was limited to the earlier period. Physicians should be cautious in educating patients on alcohol consumption, considering the long-term association between drinking patterns and ischemic stroke.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Diseases of arteries,
 Stanford type A acute aortic dissection (AAD) is a life-threatening illness that presents with chest pain and hemodynamic instability. AAD prompt and accurate evaluation and management are critical for survival as it is a cardiac surgical emergency. The initial treatment of AAD mandates strict blood pressure stabilization with intravenous antihypertensive medications. The progressive nature of the disease will increase the mortality as time elapses between diagnosis and surgical intervention. In addition, the patient&#39;s blood pressure control is challenged in the presence of renal failure requiring hemodialysis. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or named 2019-nCoV) pneumonia was a newly underrecognized illness (COVID-19 [coronavirus disease 2019]). COVID-19 can cause severe acute respiratory distress syndrome, acute kidney injury, heart injury, and liver dysfunction, which would aggravate the progress of aortic dissection. In this article, we report the successful anesthesia management in a pneumonia patient with AAD complicated with renal failure during the COVID-19 epidemic period, who underwent emergency surgery and deep hypothermic circulatory arrest repair.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 BACKGROUND  The Brief-BESTest is the short version of the BESTest used to evaluate balance and fall risk in a multiple disease populations. The clinicians need practical, short application scales to evaluate the risk of falling, balance and rehabilitation results. OBJECTIVE  This study aims to investigate the validity and reliability of the Turkish version of the Brief-BESTest (Brief-BESTest-T) in stroke patients. METHODS  This study included a total of 40 subacute and chronic stroke patients (mean age of 60.28 +/- 9.96 years). The Brief-BESTest, Berg Balance Scale (BBS), Timed Up and Go Test (TUG), Functional Reach Test (FRT), Falls Efficacy Scale (FES) and 10 m walking test were applied to the patients. RESULTS  A strong correlation was observed between the1st and 2nd evaluation Brief-BESTest-T total scores (r = 0.933). Cronbach&#39;s alpha coefficient was excellent. According to the correlation analysis performed to test the inter-rater reliability, a very high correlation (r = 0.906) was observed between the Brief-BESTest-T total scores. A high correlation was found between the Brief-BESTest-T and BBS and TUG, while a moderate correlation was found between the FRT, FES, and 10 m walking test. The clinical cutoff point for the Brief-BESTest - T was determined to be 9 points with an AUC of 0.872. There were no floor and ceiling effects found. CONCLUSIONS  This study showed that the Brief-BESTest-T had excellent internal consistency, intra-rater, and inter-rater reliability. Its concurrent, discriminant, and known-groups validity were also good and had no substantial floor and ceiling effects.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 INTRODUCTION  Impairments in visual search are a common symptom in visuospatial neglect (VSN). The severity of the lateralized attention bias in visual search tasks can vary depending on the number of distractors  the more distractors, the more targets are missed. However, little is known about how the number of targets affect search performance in VSN. The aim of the current study was to examine the effect of the number of targets on hit rate in VSN. METHODS  We included 23 stroke patients with right-brain damage and VSN, 55 with right-brain damage without VSN, and 49 with left-brain damage without VSN, all admitted for inpatient rehabilitation. In a visual search task, patients had to find and tap targets, presented along with non-targets. The location and number of targets varied from trial to trial, allowing the evaluation of the effects of number and location of targets on hit rate. RESULTS  VSN patients detected a lower percentage of targets when more targets were present. For patients with right-brain damage without VSN, adding targets only reduced the hit rate of the most contralesional target. No effect of number of targets on hit rate was seen in patients with left-brain damage. Additionally, VSN patients found less contralesional targets than ipsilesional targets, made more delayed revisits, and had an initial rightward bias when compared to the other groups. There were no differences in search time, search consistency, or immediate revisits between groups. There was a moderate positive relation between the hit rate asymmetry score in our search task and conventional paper-and-pencil VSN tasks, and neglect behavior in daily life. CONCLUSIONS  In VSN patients, a higher number of targets reduces the hit rate. The reduced hit rate in visual search evoked by additional targets should be taken into account when assessing visual search in VSN.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 Pseudotumor cerebri also known as idiopathic intracranial hypertension is a relatively uncommon disorder of unknown pathophysiology. Although pseudotumor cerebri occurs in both children and adults, the pseudotumor cerebri literature is heavily dominated by adult studies. The aim of this study is to retrospectively describe the clinical presentation, imaging, treatment, and outcomes of a large pediatric pseudotumor cerebri population over a 23-year period. We also discuss secondary pseudotumor cerebri (44%) as well as the increasingly recognized patient subgroups without headache (13.3%) and without papilledema (7.3%). Female sex, obesity, and initial symptoms were consistent with the literature; however radiographic findings were surprisingly low in this cohort. Headache outcomes at 1 week, 1 month, and 3 months following initial lumbar puncture/treatment and visual function outcomes are reported.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 OBJECTIVE  To evaluate the prevalence and risk factors for endometrial malignancies in asymptomatic postmenopausal women. METHODS  Multicentric retrospective analytical study in two Brazilian Reference Centers. All women without postmenopausal bleeding who were submitted to hysteroscopy with biopsy were included (1665). Excluded women without anatomopathological results (625) and whose medical records were incomplete (37). The variables analyzed were age; parity; body mass index; duration of menopausal status; systemic arterial hypertension; diabetes mellitus; use of hormone replacement therapy; use of tamoxifen; duration of use of tamoxifen; endometrial thickness and biopsy results. RESULTS  The frequency of endometrial malignancies in asymptomatic postmenopausal women was 2.39%. Endometrial thickness &gt;/=8 mm increased the chance of endometrial malignancies, even more, with an endometrial thickness &gt;/=12.55 mm the chance of endometrial malignancies increased by 4.68 times (p &lt; .001 and 95% CI  1.99-11.03). CONCLUSION  The prevalence of endometrial malignancies was low and the only risk factor for endometrial malignancies in asymptomatic postmenopausal women was endometrial thickness.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Inflammatory diseases,
 Elevated mitochondrial matrix superoxide and/or hydrogen peroxide concentrations drive a wide range of physiological responses and pathologies. Concentrations of superoxide and hydrogen peroxide in the mitochondrial matrix are set mainly by rates of production, the activities of superoxide dismutase-2 (SOD2) and peroxiredoxin-3 (PRDX3), and by diffusion of hydrogen peroxide to the cytosol. These considerations can be used to generate criteria for assessing whether changes in matrix superoxide or hydrogen peroxide are both necessary and sufficient to drive redox signaling and pathology  is a phenotype affected by suppressing superoxide and hydrogen peroxide production; by manipulating the levels of SOD2, PRDX3 or mitochondria-targeted catalase; and by adding mitochondria-targeted SOD/catalase mimetics or mitochondria-targeted antioxidants? Is the pathology associated with variants in SOD2 and PRDX3 genes? Filtering the large literature on mitochondrial redox signaling using these criteria highlights considerable evidence that mitochondrial superoxide and hydrogen peroxide drive physiological responses involved in cellular stress management, including apoptosis, autophagy, propagation of endoplasmic reticulum stress, cellular senescence, HIF1alpha signaling, and immune responses. They also affect cell proliferation, migration, differentiation, and the cell cycle. Filtering the huge literature on pathologies highlights strong experimental evidence that 30-40 pathologies may be driven by mitochondrial matrix superoxide or hydrogen peroxide. These can be grouped into overlapping and interacting categories  metabolic, cardiovascular, inflammatory, and neurological diseases; cancer; ischemia/reperfusion injury; aging and its diseases; external insults, and genetic diseases. Understanding the involvement of mitochondrial matrix superoxide and hydrogen peroxide concentrations in these diseases can facilitate the rational development of appropriate therapies.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Diseases of arteries,
 Background  Patients with elevated triglycerides despite statin therapy have increased risk for ischemic events, including coronary revascularizations. Methods  REDUCE-IT, a multicenter, double-blind, placebo-controlled trial, randomized statin-treated patients with elevated triglycerides (135-499 mg/dL), controlled LDL (41-100 mg/dL), and either established cardiovascular disease or diabetes plus other risk factors to receive icosapent ethyl 4 g daily or placebo. The primary and key secondary composite endpoints were significantly reduced. Prespecified analyses examined all coronary revascularizations, recurrent revascularizations, and revascularization subtypes. Results  A total of 8,179 randomized patients were followed for 4.9 years (median). First revascularizations were reduced to 9.2% (22.5/1000 patient-years) with icosapent ethyl versus 13.3% (33.7/1000 patient-years) with placebo (hazard ratio [HR]=0.66; 95% confidence interval (CI), 0.58-0.76; p&lt;0.0001; number needed to treat [NNT4.9y]=24); similar reductions were observed in total (first and subsequent) revascularizations (negative binomial rate ratio [RR] 0.64; 95% CI, 0.56-0.74; p&lt;0.0001), and across elective, urgent, and emergent revascularizations. Icosapent ethyl significantly reduced percutaneous coronary intervention (PCI) (HR=0.68; 95% CI, 0.59-0.79; p&lt;0.0001) and coronary artery bypass grafting (CABG) (HR=0.61; 95% CI, 0.45-0.81; p=0.0005). Conclusions  Icosapent ethyl reduced the need for first and subsequent coronary revascularizations in statin-treated patients with elevated triglycerides and increased cardiovascular risk. To our knowledge, icosapent ethyl is the first non-LDL-lowering treatment that has been shown to reduce CABG in a blinded, randomized trial. Clinical Trial Registration  URL  https //clinicaltrials.gov Unique Identifier  NCT01492361.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">stenos</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Diseases of arteries,Coagulopathies,
 OBJECTIVE  To evaluate clinical literature for direct oral anticoagulants (DOACs) therapy for non-Food and Drug Administration approved indications. DATA SOURCES  Articles from MEDLINE, Cochrane Library, Google Scholar, and OVID databases were reviewed from 1946 through September 4, 2020. STUDY SELECTION AND DATA EXTRACTION  Fully published studies assessing DOACs for atrial fibrillation (AF) with valvular heart disease (VHD), heart failure (HF), left ventricular thrombus (LVT), superficial vein thrombosis (SVT), or pulmonary hypertension (PH) were evaluated. DATA SYNTHESIS  Our review showed that DOACs are safe to use in patients with AF and VHD except for mitral stenosis or mechanical heart valve. Rivaroxaban 2.5 mg twice daily should be used with caution in patients with HF with reduced ejection fraction until further evaluation is performed. Four retrospective studies for DOAC use in patients with LVT showed conflicting results. One phase 3 randomized controlled trial showed noninferiority of rivaroxaban to fondaparinux for SVT treatment. The use of DOACs for pulmonary arterial hypertension was not evaluated in any clinical study, but 2 retrospective studies for the use of DOACs in patients with chronic thromboembolic PH (CTEPH) showed similar efficacy between DOACs and warfarin. RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE  This review provides clinicians with a comprehensive literature review surrounding DOAC use in common off-label indications. CONCLUSION  DOACs can be considered for AF complicated by VHD except for mitral stenosis or mechanical valve replacement. DOACs (especially rivaroxaban) are considered as an alternative therapy for SVT and CTEPH. Further prospective studies for DOAC uses are needed for HF or LVT.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Inflammatory diseases,Diseases of arteries,Coagulopathies,
 Background The ENGAGE AF-TIMI 48 trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) demonstrated noninferiority of once-daily 60 mg (30 mg dose-reduced) edoxaban compared with warfarin for prevention of stroke/systemic embolism in patients with atrial fibrillation. No previous analysis has explored the impact of treatment with edoxaban versus warfarin on rates of hospitalizations. Methods Detailed healthcare resource utilization data from ENGAGE AF-TIMI 48 for the 14 024 randomized patients who received at least one dose of study drug were used to compare the rates of bleeding- and cardiovascular-related hospitalizations for edoxaban versus warfarin. Hospitalization rates were calculated for each treatment group, and relative rates were estimated using Poisson regression. The influence of patient characteristics on the impact of edoxaban versus warfarin was evaluated through the inclusion of interaction terms. Results The overall rate of cardiovascular- or bleeding-related hospitalization was significantly lower for edoxaban than warfarin (relative rate [RR], 0.91 [95% CI, 0.85-0.97], P=0.003). Rates of hospitalizations for cardiovascular reasons (RR, 0.91 [95% CI, 0.85-0.97], P=0.004), stroke (RR, 0.80 [95% CI, 0.72-0.88], P&lt;0.0001), and for each stroke subtype (ischemic  RR, 0.89 [95% CI, 0.81-0.99], P=0.03; hemorrhagic  RR, 0.60 [95% CI, 0.54-0.68], P&lt;0.0001) were also lower for edoxaban. Notably, significantly greater reductions with edoxaban versus warfarin were seen for ischemic stroke-related hospitalizations in vitamin K antagonist naive patients and patients with CHADS2 scores 4 to 6, previous stroke or transient ischemic attack, age &gt;/=75, and no previous coronary artery disease. For nonstroke bleeding-related hospitalizations, greater reductions with edoxaban were seen in vitamin K antagonist naive patients, patients with CHADS2 scores 4 to 6, and patients with moderate renal dysfunction. Conclusions Edoxaban 60 mg (30 mg dose-reduced) was associated with a significantly lower overall rate of cardiovascular- or bleeding-related hospitalization and significant reductions in the subcategories of cardiovascular-related, stroke-related, bleed-related, and nonstroke cardiovascular-related hospitalizations, when compared with warfarin. These results suggest the potential for cost offsets with edoxaban, with even greater reductions in higher-risk patients. REGISTRATION  URL  https //www.clinicaltrials.gov; Unique identifier  NCT00781391.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 OBJECTIVE  To evaluate netarsudil&#39;s role as first-line therapy for the treatment of open-angle glaucoma (OAG) and ocular hypertension (OHT). DATA SOURCES  A literature search utilizing MEDLINE and CINAHL was performed using netarsudil and AR-13324 as keywords. Studies published from January 1970 to September 2020 were eligible. STUDY SELECTION AND DATA EXTRACTION  For inclusion, articles were required to be published in English and participants enrolled in phase I, II, or III clinical trials. Articles were excluded if netarsudil was coformulated with another medication. Preclinical research, case reports, case series, review articles, citations without an abstract, and newsletters were excluded. LITERATURE REVIEW  The search retrieved 97 unique citations; 90 results were excluded, and 7 studies were included for analysis. RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE  In all, 20 years elapsed between the Food and Drug Administration&#39;s approvals of distinct medications to treat OAG. Existing first-line therapies target the uveoscleral pathway, which is responsible for a small amount of aqueous humor outflow. Rho kinase inhibitors target the trabecular pathway, which is responsible for 90% of aqueous humor outflow; thus, Rho kinase inhibitors may significantly reduce intraocular pressure and improve clinical outcomes for patients with OAG or OHT. CONCLUSIONS  Evidence demonstrates that netarsudil is inferior to prostaglandin analogues and noninferior to topical beta-blockers in the treatment of OAG and OHT. Hyperemia is a common adverse drug reaction, which often resolves after medication discontinuation. Additional phase III clinical trials and evidence-based guidelines are necessary to determine netarsudil&#39;s position in OAG and OHT management.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 In 2010, the American Heart Association published a statement concluding that the existing scientific evidence was consistent with a causal relationship between exposure to fine particulate matter and cardiovascular morbidity and mortality, and that fine particulate matter exposure is a modifiable cardiovascular risk factor. Since the publication of that statement, evidence linking air pollution exposure to cardiovascular health has continued to accumulate and the biological processes underlying these effects have become better understood. This increasingly persuasive evidence necessitates policies to reduce harmful exposures and the need to act even as the scientific evidence base continues to evolve. Policy options to mitigate the adverse health impacts of air pollutants must include the reduction of emissions through action on air quality, vehicle emissions, and renewable portfolio standards, taking into account racial, ethnic, and economic inequality in air pollutant exposure. Policy interventions to improve air quality can also be in alignment with policies that benefit community and transportation infrastructure, sustainable food systems, reduction in climate forcing agents, and reduction in wildfires. The health care sector has a leadership role in adopting policies to contribute to improved environmental air quality as well. There is also potentially significant private sector leadership and industry innovation occurring in the absence of and in addition to public policy action, demonstrating the important role of public-private partnerships. In addition to supporting education and research in this area, the American Heart Association has an important leadership role to encourage and support public policies, private sector innovation, and public-private partnerships to reduce the adverse impact of air pollution on current and future cardiovascular health in the United States.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,
 Atherosclerosis is characterized by incessant inflammation in the arterial wall in which monocytes and macrophages play a crucial role. During the past few years, it has been reported that cells from the innate immune system can develop a long-lasting proinflammatory phenotype after brief stimulation not only with microbial products but also endogenous atherogenic stimuli. This persistent hyperactivation of the innate immune system is termed trained immunity and can contribute to the pathophysiology of atherosclerosis. Trained immunity is mediated via epigenetic and metabolic reprogramming and occurs both in mature innate immune cells as well as their bone marrow progenitors. In addition to monocytes, other innate immune and nonimmune cells involved in different stages of atherosclerosis can develop comparable memory characteristics. This mechanism provides exciting novel pharmacological targets that can be used to prevent or treat cardiovascular diseases.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Diseases of arteries,
 OBJECTIVE  Abdominal aortic aneurysm (AAA) is a vascular degenerative disease causing sudden rupture of aorta and significant mortality in elders. Nevertheless, no prognostic and therapeutic target is available for disease management. Gal-1 (galectin-1) is a beta-galactoside-binding lectin constitutively expressed in vasculature with roles in maintaining vascular homeostasis. This study aims to investigate the potential involvement of Gal-1 in AAA progression. Approach and Results  Gal-1 was significantly elevated in circulation and aortic tissues of Ang II (angiotensin II)-infused apoE-deficient mice developing AAA. Gal-1 deficiency reduced incidence and severity of AAA with lower expression of aortic MMPs (matrix metalloproteases) and proinflammatory cytokines. TNFalpha (tumor necrosis factor alpha) induced Gal-1 expression in cultured vascular smooth muscle cells and adventitial fibroblasts. Gal-1 deletion enhanced TNFalpha-induced MMP9 expression in fibroblasts but not vascular smooth muscle cells. Cysteinyl-labeling assay demonstrated that aortic Gal-1 exhibited susceptibility to oxidation in vivo. Recombinant oxidized Gal-1 induced expression of MMP9 and inflammatory cytokines to various extents in macrophages, vascular smooth muscle cells, and fibroblasts through activation of MAP kinase signaling. Clinically, serum MMP9 level was significantly higher in both patients with AAA and coronary artery disease than in control subjects, whereas serum Gal-1 level was elevated in patients with AAA but not coronary artery disease when compared with controls. CONCLUSIONS  Gal-1 is highly induced and contributes to AAA by enhancing matrix degradation activity and inflammatory responses in experimental model. The pathological link between Gal-1 and AAA is also observed in human patients. These findings support the potential of Gal-1 as a disease biomarker and therapeutic target of AAA.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Inflammatory diseases,
 OBJECTIVE  To determine whether global reduction of CD68 macrophages impacts the development of experimental pulmonary arterial hypertension (PAH) and whether this reduction affects the balance of pro- and anti-inflammatory macrophages within the lung. Additionally, to determine whether there is evidence of an altered macrophage polarization in patients with PAH. Approach and Results  Macrophage reduction was induced in mice via doxycycline-induced CD68-driven cytotoxic diphtheria toxin A chain expression (macrophage low [MacLow] mice). Chimeric mice were generated using bone marrow transplant. Mice were phenotyped for PAH by echocardiography and closed chest cardiac catheterization. Murine macrophage phenotyping was performed on lungs, bone marrow-derived macrophages, and alveolar macrophages using immunohistochemical and flow cytometry. Monocyte-derived macrophages were isolated from PAH patients and healthy volunteers and polarization capacity assessed morphologically and by flow cytometry. After 6 weeks of macrophage depletion, male but not female MacLow mice developed PAH. Chimeric mice demonstrated a requirement for both MacLow bone marrow and MacLow recipient mice to cause PAH. Immunohistochemical analysis of lung sections demonstrated imbalance in M1/M2 ratio in male MacLow mice only, suggesting that this imbalance may drive the PAH phenotype. M1/M2 imbalance was also seen in male MacLow bone marrow-derived macrophages and PAH patient monocyte-derived macrophages following stimulation with doxycycline and IL (interleukin)-4, respectively. Furthermore, MacLow-derived alveolar macrophages showed characteristic differences in terms of their polarization and expression of diphtheria toxin A chain following stimulation with doxycycline. CONCLUSIONS  These data further highlight a sex imbalance in PAH and further implicate immune cells into this paradigm. Targeting imbalance of macrophage population may offer a future therapeutic option.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,Coagulopathies,
 OBJECTIVE  Obesity is associated with a proinflammatory and prothrombotic state that supports atherosclerosis progression. The goal of this study was to gain insights into the phosphorylation events related to platelet reactivity in obesity and identify platelet biomarkers and altered activation pathways in this clinical condition. Approach and Results  We performed a comparative phosphoproteomic analysis of resting platelets from obese patients and their age- and gender-matched lean controls. The phosphoproteomic data were validated by mechanistic, functional, and biochemical assays. We identified 220 differentially regulated phosphopeptides, from at least 175 proteins; interestingly, all were up-regulated in obesity. Most of the altered phosphoproteins are involved in SFKs (Src-family kinases)-related signaling pathways, cytoskeleton reorganization, and vesicle transport, some of them validated by targeted mass spectrometry. To confirm platelet dysfunction, flow cytometry assays were performed in whole blood indicating higher surface levels of GP (glycoprotein) VI and CLEC (C-type lectin-like receptor) 2 in platelets from obese patients correlating positively with body mass index. Receiver operator characteristics curves analysis suggested a much higher sensitivity for GPVI to discriminate between obese and lean individuals. Indeed, we also found that obese platelets displayed more adhesion to collagen-coated plates. In line with the above data, soluble GPVI levels-indicative of higher GPVI signaling activation-were almost double in plasma from obese patients. CONCLUSIONS  Our results provide novel information on platelet phosphorylation changes related to obesity, revealing the impact of this chronic pathology on platelet reactivity and pointing towards the main signaling pathways dysregulated.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-blue-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypotend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">rhe</span>,
<span class="ansi-bold">Embeded topics: </span>Hypotension,Heart failure,Inflammatory diseases,
 CONTEXT  Indigenous children and adolescents in Australia and globally bear the burden of acute rheumatic fever (ARF). It has been virtually eliminated in well-resourced, developed settings. ARF is an autoimmune response to infection with group A Streptococcus. The mainstay of management is long-acting intramuscular penicillin injections to prevent recurrence of ARF and development of rheumatic heart disease (RHD), comprising valvular pathology and attendant complications. In Australia, penicillin injections are currently prescribed every 28 days for 5-10 years after diagnosis of ARF, depending on cardiac involvement. Adherence to this regimen reduces ARF recurrences and RHD progression. &#39;Days at risk&#39; of ARF recurrence are calculated as the number of days after day 28 that an injection is not received. Adherence to the injection schedule has been reported as difficult in most global locations due to the painful nature of the injections, the long timeframes of the prescription, young age of patients, access problems and costs in some locations. The newly updated Australian guideline on the prevention, diagnosis and management of ARF and RHD has a chapter dedicated to secondary prophylaxis. This chapter takes into account cultural considerations and advises on ways to minimise pain and distress of injections in children such as pain gate strategies, distraction techniques and concurrent injection of local anaesthetic. ISSUES  Some children continue to find the injection regimen traumatising despite strategies to reduce pain and fear. Clinicians providing the injections to children also find the injecting episodes distressing if pain is not effectively minimised. An Aboriginal Community Controlled Health Service in a remote setting in northern Australia addressed the issue of severe trauma of injection episodes experienced by an Aboriginal boy aged 7 years. Usual strategies were not effective, so advice was sought from an expert anaesthetist at a tertiary hospital. As a result, oral clonidine 3 &amp;micro;g/kg was trialled 45 minutes prior to the penicillin injection. Procedural coaching and monitoring protocols specific to administration of clonidine in children under their care were created by the health service. The initial dose of clonidine was delivered with the child as an inpatient. LESSONS LEARNED  Clonidine was successful in reducing pain related distress and facilitating adherence to the penicillin regimen. Subsequent doses were delivered and monitored in a remote setting by nurses. After 18 months, the boy no longer required clonidine due to his increased coping capacity. A second child was recognised with similar trauma and has been taking clonidine for pre-procedural sedation for 6 months with good effect and no adverse effects. An additional child was similarly prescribed clonidine without success. Failure in that instance was attributed to lack of procedural coaching and receiving the initial dose of clonidine in an emergency department in hurried circumstances. Individualised child-focused and culturally appropriate care in remote settings is feasible  in this instance team planning for use of clonidine and procedural coaching when other measures have failed. However, for children with RHD, or other comorbidities, advice from the child&#39;s treating cardiologist is required prior to prescribing clonidine due to possible adverse consequences. These include hypotension and atrioventricular block, which could lead to haemodynamic compromise in the setting of moderate to severe RHD.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Diseases of arteries,
 Objective  To investigate the comprehensive control situation and related factors of diabetes mellitus. Methods  From August to December of 2017, 13 259 residents aged 18 to 79 years old were randomly selected as the subjects by stratified multi-stage cluster sampling method. Questionnaire, physical examination and laboratory tests were conducted. The effective sample size was 13 240. A total of 1 592 diabetes patients were found. In this study, 917 diabetes patients who had been diagnosed before the investigation were selected as subjects. The comprehensive control of diabetes patients was analyzed. The situation of diabetes patients with hypertension, dyslipidemia, overweight and obesity, coronary heart diseases was analyzed. Logistic regression analysis of complex sampling was used to analyze the related factors of diabetes comprehensive control. Results  The average age of 917 patients with diabetes was (58.5+/-0.7) years old. The proportion of people who participated in diabetes follow-up management was 29.0%. There were 89.5% diabetes patients with one or more chronic diseases. The comprehensive control rate of diabetes mellitus was 2.0%, men and women were 1.8% and 2.3%, respectively (P&gt;0.05). The rate of comprehensive control among those diabetes patients with chronic diseases was 0.4%, lower than that of those without chronic diseases (15.6%, P&lt;0.05). The comprehensive control rate of people who participated in diabetes follow-up management was 1.4%. The control rate of blood glucose, blood pressure, blood lipid and weight of diabetes mellitus was 30.9%, 30.2%, 17.4% and 27.7%, respectively. Logistic regression analysis of complex sampling showed that excessive intake of red meat, with chronic diseases and qualified core knowledge were all related with comprehensive control of diabetes mellitus, OR value was 31.41, 39.98 and 0.29, P&lt;0.05. Conclusion  The comprehensive control rate of diabetes mellitus was low. Excessive intake of red meat, with chronic diseases and qualified core knowledge were all related with comprehensive control of diabetes mellitus.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Cardiomyopathy,
 BACKGROUND  The objective of this quasi-experimental study was to determine whether bolus vitamin D supplementation taken either regularly over the preceding year or after the diagnosis of COVID-19 was effective in improving survival among hospitalized frail elderly COVID-19 patients. METHODS  Seventy-seven patients consecutively hospitalized for COVID-19 in a geriatric unit were included. Intervention groups were participants regularly supplemented with vitamin D over the preceding year (Group 1), and those supplemented with vitamin D after COVID-19 diagnosis (Group 2). The comparator group involved participants having received no vitamin D supplements (Group 3). Outcomes were 14-day mortality and highest (worst) score on the ordinal scale for clinical improvement (OSCI) measured during COVID-19 acute phase. Potential confounders were age, gender, functional abilities, undernutrition, cancer, hypertension, cardiomyopathy, glycated hemoglobin, number of acute health issues at admission, hospital use of antibiotics, corticosteroids, and pharmacological treatments of respiratory disorders. RESULTS  The three groups (n = 77; mean +/- SD, 88 +/- 5years; 49% women) were similar at baseline (except for woman proportion, p = 0.02), as were the treatments used for COVID-19. In Group 1 (n = 29), 93.1% of COVID-19 participants survived at day 14, compared to 81.2% survivors in Group 2 (n = 16) (p = 0.33) and 68.7% survivors in Group 3 (n = 32) (p = 0.02). While considering Group 3 as reference (hazard ratio (HR) = 1), the fully-adjusted HR for 14-day mortality was HR = 0.07 (p = 0.017) for Group 1 and HR = 0.37 (p = 0.28) for Group 2. Group 1 had longer survival time than Group 3 (log-rank p = 0.015), although there was no difference between Groups 2 and 3 (log-rank p = 0.32). Group 1, but not Group 2 (p = 0.40), was associated with lower risk of OSCI score &gt;/=5 compared to Group 3 (odds ratio = 0.08, p= 0.03). CONCLUSIONS  Regular bolus vitamin D supplementation was associated with less severe COVID-19 and better survival in frail elderly.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Inflammatory diseases,
 The complement system has a significant role in myocardial ischemia/reperfusion injury, being responsible for cell lysis and amplification of inflammatory response. In this context, several studies highlight that terminal complement complex C5b-9, also known as the membrane attack complex (MAC), is a significant contributor. The MAC functions were studied by many researchers analyzing the characteristics of its activation in myocardial infarction. Here, a systematic literature review was reported to evaluate the principal features, advantages, and limits (regarding the application) of complement components and MAC in post mortem settings to perform the diagnosis of myocardial ischemia/infarction. The review was performed according to specific inclusion and exclusion criteria, and a total of 26 studies were identified. Several methods studied MAC, and each study contributes to defining better how and when it affects the myocardial damage in ischemic/reperfusion injury. The articles were discussed, focusing on the specificity, sensibility, and post mortem stability of MAC as a marker of myocardial ischemia/infarction, supporting the usefulness in routine post mortem investigations.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Coagulopathies,
 Peripheral artery disease (PAD) is highly prevalent among patients with chronic kidney disease (CKD) and portends a very poor prognosis. Indoxyl sulfate has been shown to induce atherothrombosis and impaired neovascularization in uremic mice. However, there is no clinical evidence regarding the role of indoxyl sulfate in PAD associated with CKD. We examined associations between indoxyl sulfate and incident symptomatic lower extremity PAD events as well as major adverse cardiovascular events (MACE) and all-cause mortality using Cox proportional hazards models in a prospective cohort of 200 hemodialysis patients free of PAD at baseline. Patients were considered as having PAD if they developed PAD symptoms confirmed by an ankle-brachial index with waveforms, duplex ultrasound or angiography, and/or major adverse limb events including revascularization and amputation. During a median follow-up of 6.5 years, 37 patients (18.5%) experienced incident symptomatic PAD. MACE occurred in 52 patients, and a total of 85 patients died. After adjusting for traditional risk factors for PAD, including age, current smoking, diabetes, and cardiovascular disease, indoxyl sulfate was significantly associated with the risk of PAD (hazard ratio (HR), 1.19 for every 10-mug/mL increase in indoxyl sulfate; 95% confidence interval (CI), 1.05-1.35). However, indoxyl sulfate was not associated with risk of MACE (HR, 1.00; 95% CI, 0.90-1.12) or death from any cause (HR, 0.98; 95% CI, 0.90-1.07). Indoxyl sulfate was associated with incident symptomatic PAD but not with MACE or all-cause mortality, suggesting that indoxyl sulfate toxicity may be unique to PAD among hemodialysis patients.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 The progressive ageing of the working population and the increase in related chronic diseases tend to affect working capacity. The aim of this study was to evaluate a Workplace Disability Management Program (WDMP) within a pediatric hospital. Absenteeism due to healthcare workers&#39; (HCWs) pre- and post- WDMP and the related costs were used for the program evaluation. The Return on Investment (ROI), the Break-Even Analysis (BEA) and the value of the average annual productivity of HCWs who took advantage of the Disability Management (DM) interventions to assess the economic impact of the program, were also used. The HCWs enrolled in the program were 131 (approximately 4% of hospital staff), of which 89.7% females and with an average age of 50.4 years (SD +/- 8.99). Sick leave days of the HCWs involved decreased by 66.6% in the year following the end of WDMP compared to the previous one (p &lt; 0.001). The total estimated cost reduction of absenteeism is 427,896euro over a year. ROI was equal to 27.66euro. BEA indicated that the break-even point was reached by implementing the program on 3.27 HCWs. The program evaluation demonstrated the particular effectiveness of the implemented WDMP model, acting positively on the variables that affect productivity and the limitation to work.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam diseas</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Inflammatory diseases,Diseases of arteries,
 Continuous oxidation of carbohydrates, lipids, and amino acids generate extremely reactive carbonyl species (RCS). Human body comprises some important RCS namely hexanal, acrolein, 4-hydroxy-2-nonenal, methylglyoxal, malondialdehyde, isolevuglandins, and 4-oxo-2- nonenal etc. These RCS damage important cellular components including proteins, nucleic acids, and lipids, which manifests cytotoxicity, mutagenicity, multitude of adducts and crosslinks that are connected to ageing and various chronic diseases like inflammatory disease, atherosclerosis, cerebral ischemia, diabetes, cancer, neurodegenerative diseases and cardiovascular disease. The constant prevalence of RCS in living cells suggests their importance in signal transduction and gene expression. Extensive knowledge of RCS properties, metabolism and relation with metabolic diseases would assist in development of effective approach to prevent numerous chronic diseases. Treatment approaches for RCS associated diseases involve endogenous RCS metabolizers, carbonyl metabolizing enzyme inducers, and RCS scavengers. Limited bioavailability and bio efficacy of RCS sequesters suggest importance of nanoparticles and nanocarriers. Identification of RCS and screening of compounds ability to sequester RCS employ several bioassays and analytical techniques. Present review describes in-depth study of RCS sources, types, properties, identification techniques, therapeutic approaches, nanocarriers, and their role in various diseases. This study will give an idea for therapeutic development to combat the RCS associated chronic diseases.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Xylitol is a white crystalline, amorphous sugar alcohol and low-calorie sweetener. Xylitol prevents demineralization of teeth and bones, otitis media infection, respiratory tract infections, inflammation and cancer progression. NADPH generated in xylitol metabolism aid in the treatment of glucose-6-phosphate deficiency-associated hemolytic anemia. Moreover, it has a negligible effect on blood glucose and plasma insulin levels due to its unique metabolism. Its diverse applications in pharmaceuticals, cosmetics, food and polymer industries fueled its market growth and made it one of the top 12 bio-products. Recently, xylitol has also been used as a drug carrier due to its high permeability and non-toxic nature. However, it become a challenge to fulfil the rapidly increasing market demand of xylitol. Xylitol is present in fruit and vegetables, but at very low concentrations, which is not adequate to satisfy the consumer demand. With the passage of time, other methods including chemical catalysis, microbial and enzymatic biotransformation, have also been developed for its large-scale production. Nevertheless, large scale production still suffers from high cost of production. In this review, we summarize some alternative approaches and recent advancements that significantly improve the yield and lower the cost of production.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 INTRODUCTION  Elevated pulmonary vascular resistance (PVR) unresponsive to vasodilator treatment is a marker of heart failure (HF) severity, and an important predictor of poor results of heart transplantation (HT). OBJECTIVE  We sought to analyze factors associated with ineffectiveness of sildenafil treatment in end-stage HF patients with elevated PVR with particular emphasis placed on tenascin-C (TNC) serum concentrations. PATIENTS AND METHODS  The study is an analysis of 132 end-stage HF patients referred for HT evaluation in the Cardiology Department between 2015 and 2018. TNC was measured by sandwich enzyme-linked immunosorbent assay (Human TNC, SunRedBio Technology, Shanghai, China). The endpoint was PVR &gt; 3 Wood units after the six-month sildenafil therapy. RESULTS  The median age was 58 years, and 90.2% were men. PVR &gt;3 Wood units after 6 months of sildenafil treatment were found in 36.6% patients. The multivariable logistic regression analysis confirmed that TNC (OR = 1.004 (1.002-1.006), p = 0.0003), fibrinogen (OR= 1.019 (1.005-1.033), p = 0.085), creatinine (OR =1.025 (1.004-1.047), p = 0.0223) and right ventricular end-diastolic dimension (RVEDd) (OR = 1.279 (1.074-1.525), p = 0.0059) were independently associated with resistance to sildenafil treatment. Area under the ROC curves indicated an acceptable power of TNC (0.9680 (0.9444-0.9916)), fibrinogen (0.8187 (0.7456-0.8917)) and RVEDd (0.7577 (0.6723-0.8431)), as well as poor strength of creatinine (0.6025 (0.4981-0.7070)) for ineffectiveness of sildenafil treatment. CONCLUSIONS  Higher concentrations of TNC, fibrinogen and creatinine, as well as a larger RVEDd are independently associated with the ineffectiveness of sildenafil treatment. TNC has the strongest predictive power, sensitivity and specificity for evaluation of resistance to sildenafil treatment.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlud</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,
 Ocular manifestations are a feature of West Nile virus infection. They mostly occur in association with severe neuroinvasive disease. Linear chorioretinitis is suggestive of the diagnosis and may raise diagnostic suspicion when associated with evocative systemic signs, and in an epidemic context. Various other less specific inflammatory ocular manifestations have been reported, including anterior uveitis, occlusive retinal vasculitis, optic neuritis, and diplopia. The pathophysiology of ocular disease remains unclear, but it reflects the neuroinvasiveness of the disease. Although ocular involvement most often resolves without visual sequelae, some patients may have permanent loss of vision, adding to the need for the development of a specific treatment and/or vaccines.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Inflammatory diseases,
 AIM  Previous research in our laboratory found that a biologically active sphingomyelin metabolite, sphingosylphosphorylcholine (SPC), can inhibit myocardial cell apoptosis caused by ischemia with an unknown mechanism. Here, we aimed to study the possible participation of EPAS1 in the protection process of SPC. METHODS  The rat cardiomyocytes deprived of serum were used to mimic ischemic-caused apoptosis, then treated with or without SPC. The expression and nuclear shift of EPAS1 were detected by western blot and immunofluorescence, and its function was studied using its siRNA. KEY FINDING  Our research shows that SPC inhibited serum starvation caused cardiomyocyte apoptosis, accompanied by the up-regulation and nucleus translocation of EPAS1. EPAS1 levels did not change when its transcript was blocked by Actinomycin D, which prompted us to search for a post-transcription mechanism for its increased expression, and finally found that miR-155-5p, regulated by STAT3, was a new post-transcription regulator to EPAS1. Further investigation found that EPAS1 participated in the protective effect of SPC is mainly achieved by activating the downstream target gene, interleukin-6 (IL-6). SIGNIFICANCE  Our results expand our understanding of the biological functions of SPC, and bring a new pathway as a potential therapeutic target to the treatment of cardiovascular diseases caused by myocardial apoptosis.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Inflammatory diseases,
 AIM  Previous research in our laboratory found that a biologically active sphingomyelin metabolite, sphingosylphosphorylcholine (SPC), can inhibit myocardial cell apoptosis caused by ischemia with an unknown mechanism. Here, we aimed to study the possible participation of EPAS1 in the protection process of SPC. METHODS  The rat cardiomyocytes deprived of serum were used to mimic ischemic-caused apoptosis, then treated with or without SPC. The expression and nuclear shift of EPAS1 were detected by western blot and immunofluorescence, and its function was studied using its siRNA. KEY FINDING  Our research shows that SPC inhibited serum starvation caused cardiomyocyte apoptosis, accompanied by the up-regulation and nucleus translocation of EPAS1. EPAS1 levels did not change when its transcript was blocked by Actinomycin D, which prompted us to search for a post-transcription mechanism for its increased expression, and finally found that miR-155-5p, regulated by STAT3, was a new post-transcription regulator to EPAS1. Further investigation found that EPAS1 participated in the protective effect of SPC is mainly achieved by activating the downstream target gene, interleukin-6 (IL-6). SIGNIFICANCE  Our results expand our understanding of the biological functions of SPC, and bring a new pathway as a potential therapeutic target to the treatment of cardiovascular diseases caused by myocardial apoptosis.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Inflammatory diseases,
 AIM  Previous research in our laboratory found that a biologically active sphingomyelin metabolite, sphingosylphosphorylcholine (SPC), can inhibit myocardial cell apoptosis caused by ischemia with an unknown mechanism. Here, we aimed to study the possible participation of EPAS1 in the protection process of SPC. METHODS  The rat cardiomyocytes deprived of serum were used to mimic ischemic-caused apoptosis, then treated with or without SPC. The expression and nuclear shift of EPAS1 were detected by western blot and immunofluorescence, and its function was studied using its siRNA. KEY FINDING  Our research shows that SPC inhibited serum starvation caused cardiomyocyte apoptosis, accompanied by the up-regulation and nucleus translocation of EPAS1. EPAS1 levels did not change when its transcript was blocked by Actinomycin D, which prompted us to search for a post-transcription mechanism for its increased expression, and finally found that miR-155-5p, regulated by STAT3, was a new post-transcription regulator to EPAS1. Further investigation found that EPAS1 participated in the protective effect of SPC is mainly achieved by activating the downstream target gene, interleukin-6 (IL-6). SIGNIFICANCE  Our results expand our understanding of the biological functions of SPC, and bring a new pathway as a potential therapeutic target to the treatment of cardiovascular diseases caused by myocardial apoptosis.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 OBJECTIVES  To compare body composition in PsA with metabolic disease free (MDF) controls and type 2 diabetes and assess body-composition predicted propensity for cardiometabolic disease. METHODS  Detailed MRI body composition profiles of 26 PsA participants from the IMAPA study were compared with 130 age, sex and BMI-matched MDF controls and 454 individuals with type 2 diabetes from UK Biobank. The body-composition predicted propensity for coronary heart disease (CHD) and type 2 diabetes was compared between PsA and matched MDF controls. RESULTS  PsA participants had a significantly greater visceral adipose tissue (VAT) volume [mean 5.89 l (s.d. 2.10 l)] compared with matched-MDF controls [mean 4.34 l (s.d. 1.83 l)] (P &lt;0.001) and liver fat percentage [median 8.88% (interquartile range 4.42-13.18%)] compared with MDF controls [3.29% (1.98-7.25%)] (P &lt;0.001). These differences remained significant after adjustment for age, sex and BMI. There were no statistically significant differences in VAT, liver fat or muscle fat infiltration (MFI) between PsA and type 2 diabetes. PsA participants had a lower thigh muscle volume than MDF controls and those with type 2 diabetes. Body composition-predicted propensity for CHD and type 2 diabetes was 1.27 and 1.83 times higher, respectively, for PsA compared with matched-MDF controls. CONCLUSION  Individuals with PsA have an adverse body composition phenotype with greater visceral and ectopic liver fat and lower thigh muscle volume than matched MDF controls. Body fat distribution in PsA is more in keeping with the pattern observed in type 2 diabetes and is associated with greater propensity to cardiometabolic disease. These data support the need for greater emphasis on weight loss in PsA management to lessen CHD and type 2 diabetes risk.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  There is a lack of new promising therapies to improve the dismal outcomes from cardiac arrest. The objectives of this study were  (1) To identify novel pharmacological therapies investigated in experimental animal studies and (2) to identify pharmacological therapies translated from experimental studies to clinical trials. METHODS  PubMed was searched to first identify relevant experimental cardiac arrest animal models published within the last 20 years. Based on this, a list of interventions was created and a second search was performed to identify clinical trials testing one of these interventions. Data extraction was performed using standardised data extraction forms. RESULTS  We identified 415 animal studies testing 190 different pharmacological interventions. The most commonly tested interventions were classified as vasopressors, anaesthetics/gases, or interventions aimed at molecular targets. We found 43 clinical trials testing 26 different interventions identified in the animal studies. Of these, 13 trials reported positive findings and 30 trials reported neutral findings with regards to the primary endpoint. No study showed harm of the intervention. Some interventions tested in human clinical trials, had previously been tested in animal studies without a positive effect on outcomes. A large number of animal studies was performed after publication of a clinical trial. CONCLUSION  Numerous different pharmacological interventions have been tested in experimental animal models. Despite this only a limited number of these interventions have advanced to clinical trials, however several of the clinical trials tested interventions that were first tested in experimental animal models.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Inflammatory diseases,
 Glaucoma is the leading cause of irreversible blindness and is characterized by the death of retinal ganglion cells (RGCs). Recent studies have implicated pro-inflammatory microglia, macrophages, and A1 astrocytes in the pathogenesis of neurodegenerative diseases. The role of pro-inflammatory, neurotoxic A1 astrocytes in glaucoma is just beginning to be explored. Using a mouse model of glaucoma, we demonstrate that ocular hypertension is sufficient to trigger production of C1q, interleukin-1alpha (IL-1alpha), and tumor necrosis factor alpha (TNF-alpha), three cytokines necessary and sufficient to drive the formation of A1 astrocytes. Upregulation of these cytokines occurs first in CD11b(+) CD11c(+) cells followed by CD11b(+) CD11c(-) cells. Ablation of this pathway, by either genetic deletions of C1qa, IL-1alpha, and TNF-alpha, or treatment with glucagon-like peptide-1 receptor agonist NLY01, reduces A1 astrocyte transformation and RGC death. Together, these results highlight a neuroinflammatory mechanism of glaucomatous neurodegeneration that can be therapeutically targeted by NLY01 administration.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 Identification of host genes essential for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may reveal novel therapeutic targets and inform our understanding of coronavirus disease 2019 (COVID-19) pathogenesis. Here we performed genome-wide CRISPR screens in Vero-E6 cells with SARS-CoV-2, Middle East respiratory syndrome CoV (MERS-CoV), bat CoV HKU5 expressing the SARS-CoV-1 spike, and vesicular stomatitis virus (VSV) expressing the SARS-CoV-2 spike. We identified known SARS-CoV-2 host factors, including the receptor ACE2 and protease Cathepsin L. We additionally discovered pro-viral genes and pathways, including HMGB1 and the SWI/SNF chromatin remodeling complex, that are SARS lineage and pan-coronavirus specific, respectively. We show that HMGB1 regulates ACE2 expression and is critical for entry of SARS-CoV-2, SARS-CoV-1, and NL63. We also show that small-molecule antagonists of identified gene products inhibited SARS-CoV-2 infection in monkey and human cells, demonstrating the conserved role of these genetic hits across species. This identifies potential therapeutic targets for SARS-CoV-2 and reveals SARS lineage-specific and pan-CoV host factors that regulate susceptibility to highly pathogenic CoVs.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,
 PURPOSE  This study was designed to determine the probable protection mechanisms of nitroglycerin, a widely used medication for treatment of heart failure and angina, in amelioration of testicular ischemia/reperfusion damage. METHODS  24 adult male rats were randomly divided into three equal groups; with eight rats in each group  Group 1 (Sham) was sham-operated. Group 2 (T_D)  2 h testicular torsion was induced, afterward detorsion was performed and maintained for 2 h. Group 3 (NG)  Nitroglycerin was administered immediately after detorsion. Sperm quality parameters such as viability, motility, morphology, and concentration, levels of antioxidant enzymes (glutathione peroxidase (GPX), catalase (CAT), and total antioxidant capacity (TAC)), and amount of malondialdehyde (MDA) in the blood plasma were examined in each group, thereafter histopathological parameters including germinal epithelial cell thickness (GECT), mean seminiferous tubular diameter (MSTD), Johnson&#39;s score and Cosentino&#39;s score were assessed. RESULTS  Testicular T_D significantly reduced sperm viability, motility, and normal morphology, whereas the NG administration remarkably increased the percentage of live, motile, and normal spermatozoa (p &lt; 0.05). Levels of GPx, CAT, and TAC significantly reduced and the MDA level significantly increased in the T_D group in comparison to the sham group (p &lt; 0.05). The NG treated group demonstrated significantly reduced MDA concentrations as well as elevated levels of GPx and CAT compared to the T_D group (p &lt; 0.05). Induction of testicular torsion significantly reduced Johnson&#39;s score, GESCT (mum), and MSTD (mum), and remarkably increased the Cosentino&#39;s score (P &lt; 0.05), while NG injection significantly increased Johnson&#39;s score, GESCT (mum), and MSTD (mum) and reduced the Cosentino&#39;s score (P &lt; 0.05). CONCLUSION  According to the findings in this research, nitroglycerin was able to protect the testicular tissue from ischemia-reperfusion damage caused by induced torsion/detorsion.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,
 Previous studies have reported worse outcomes for patients with right bundle branch block (RBBB) complicating acute ST-segment elevation myocardial infarction (STEMI). There is a paucity of data examining outcomes with RBBB and STEMI in contemporary large-scale studies. This study aims to explore the outcomes of patients with anterior wall STEMI (AW-STEMI) and RBBB. Using ICD-9 codes, we queried the National Inpatient Sample (NIS) of 1999-2014 to identify AW-STEMI admissions and stratified them for the presence of RBBB. Primary outcome was in-hospital mortality within 30 days. Secondary outcomes included acute heart failure, complete heart block and permanent pacemaker (PPM) implantation. Cox-proportional logistic regression models were used to determine the hazard ratios of the primary outcome and secondary outcomes and interventions. Among 1,075,875 weighted anterior wall STEMI (AW-STEMI) admissions, 19,153 (1.8%) had RBBB. Compared to patients without RBBB, mortality was significantly higher for patients with RBBB (9.2% vs. 15.3%; P&lt;.0001). RBBB in the setting of AW-STEMI was associated with a 66% increased risk of 30-day in-hospital mortality (HR, 1.66; 95% CI, 1.52-1.81; P&lt;.0001) and a higher likelihood of acute heart failure (HR, 1.37; 95% CI, 1.29-1.45; P&lt;.0001), complete heart block (HR, 2.90; 95% CI, 2.64-3.18; P&lt;.0001) and utilization of a permanent pacemaker (HR, 2.51; 95% CI, 1.89-3.35; P&lt;.0001). In conclusion, the presence of RBBB in the setting of an AW-STEMI is a significant independent predictor of a poor prognosis, including a higher rate of acute heart failure, complete heart block, need for a permanent pacemaker, and a higher 30-day in-hospital mortality.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 Impella(R) devices are increasingly utilized for hemodynamic support in high risk percutaneous coronary intervention or cardiogenic shock despite a lack of randomized clinical trial data showing clinical benefit and newer observational data suggesting harm. In this retrospective analysis, our aim was to determine the most common adverse events associated with Impella(R) usage reported annually to the Food and Drug Administration Manufacturer and User Facility Device Experience (MAUDE) database and to estimate via the National Inpatient Sample (NIS) database the number of percutaneous ventricular assist devices (pVAD) utilized and associated with inpatient mortality since introduction of the Impella(R). Among the 885 complete reports submitted to the MAUDE database between 2008 and 2019 related to Impella(R) usage, there were 1206 complications coded; 88.2% of reports occurred between 2016 and 2019. Among patients with adverse events reported, bleeding (32.8%), device deployment or retrieval issues (18.2%), vascular complications (15.8%), and death (12.4%) were the most common, and 7.9% of all complications were attributable to operator decision-making or technique. Between 2007 and 2017 there was a &gt;100-fold increase in pVAD use with an increase and plateau in in-hospital mortality to 31% between 2012-2016 based on NIS data. In conclusion, Impella(R) use has increased substantially over the last decade but remains associated with high inpatient mortality and serious complications based on data from the NIS and MAUDE databases. These findings emphasize the need for high quality randomized controlled trials to determine the clinical utility of Impella(R) in high risk percutaneous coronary intervention and cardiogenic shock.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">rhe</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,
 Introduction  Behcet&#39;s disease uveitis (BDU) is a potentially blinding disorder. Systemic treatment with disease-modifying anti-rheumatic drugs (DMARDs) is mandatory in patients with intraocular inflammation involving the posterior segment of the eye. Areas covered  This article discusses existing systemic treatment with corticosteroids and conventional and biologic DMARDs as well as adjunctive local therapy in BDU. An overview is provided for a wide range of biologic DMARDs that have shown promise or investigated in clinical trials. Most recently introduced biologic DMARDs and targeted synthetic DMARDs are also reviewed for their potential in the treatment of BDU. Expert opinion  The prognosis of patients with BDU has remarkably improved after the introduction of biologic DMARDs. An expanding therapeutic armamentarium will allow treatment of most refractory cases. The ultimate goal is to provide drug-free remission with preservation of 20/20 vision.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 PURPOSE  Clinical practice guidelines for paediatric neuromuscular disorders (NMDs) recommend timely provision of wheelchair equipment. The aim of this qualitative study was to understand healthcare professionals&#39; clinical perspectives and practices when recommending wheelchair equipment for the first time, as well as perceived barriers and enablers to timely wheelchair provision. METHODS  Twenty-one healthcare professionals (HCPs) from Australia and the United States participated in an interview (response rate  88%, 16/21 women). Participants were from diverse disciplines, based in hospital or community health settings, and had at least one year of experience working in paediatric neuromuscular care. RESULTS  Child fatigue, falls and engagement in age-appropriate activity were common reasons for HCP&#39;s wheelchair recommendation. HCPs were acutely aware of parents&#39; experiences of grief and loss throughout the wheelchair prescription process, and over half acknowledged the lack of psychological care available to families affected by NMDs. Multi-disciplinary collaboration, psychologically-informed care, and shared decision-making with stakeholders were perceived enablers of wheelchair transition. Barriers included limited access to equipment, lengthy funding processes and lack of funding for home and vehicle modifications. CONCLUSIONS  Integrated psychosocial care is needed to support families throughout their child&#39;s disease progression, including wheelchair transition. Implementation of readiness for change tools, and development of tailored informational resources is recommended. Improved access to equipment options and trials, and more efficient funding processes are highly likely to improve parental engagement throughout the wheelchair prescription process. Implications for rehabilitation Healthcare professionals express a strong demand for integrated psychosocial care within paediatric neuromuscular clinics to support families throughout transitions, including wheelchair introduction. Identifying parents&#39; readiness for change can inform their information and support needs, strengthen their decision-making capacity and facilitate timely wheelchair introduction. Stronger collaboration between hospital- and community-based health professionals working in paediatric neuromuscular care is recommended to facilitate knowledge exchange and support families&#39; transition to wheelchair use. Access to equipment options for extended loan or trial in the community can support timely wheelchair introduction.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 The enzyme phenylethanolamine N-methyltransferase (PNMT, EC 2.1.1.28) catalyzes the final step in the biosynthesis of epinephrine and is a potential drug target, primarily for the control of hypertension. Unfortunately, many potent PNMT inhibitors also possess significant affinity for the a2-adrenoceptor, which complicates the interpretation of their pharmacology. A bisubstrate analogue approach offers the potential for development of highly selective inhibitors of PNMT. This paper documents the design, synthesis, and evaluation of such analogues, several of which were found to possess human PNMT (hPNMT) inhibitory potency &lt;5 nM versus AdoMet. Site-directed mutagenesis studies were consistent with bisubstrate binding. Two of these compounds (19 and 29) were co-crystallized with hPNMT and the resulting structures revealed both compounds bound as predicted, simultaneously occupying both substrate binding domains. This bisubstrate inhibitor approach has resulted in one of the most potent (20) and selective (vs the a2-adrenoceptor) inhibitors of hPNMT yet reported.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  Chronic heart failure is one of the most common medical conditions, affecting more than 23 million people worldwide. Despite established guideline-based, multidrug pharmacotherapy, chronic heart failure is still the cause of frequent hospitalisation, and about 50% die within five years of diagnosis. OBJECTIVES  To assess the effectiveness and safety of ivabradine in individuals with chronic heart failure. SEARCH METHODS  We searched CENTRAL, MEDLINE, Embase, and CPCI-S Web of Science in March 2020. We also searched ClinicalTrials.gov and the WHO ICTRP. We checked reference lists of included studies. We did not apply any time or language restrictions. SELECTION CRITERIA  We included randomised controlled trials in which adult participants diagnosed with chronic heart failure were randomly assigned to receive either ivabradine or placebo/usual care/no treatment. We distinguished between type of heart failure (heart failure with a reduced ejection fraction or heart failure with a preserved ejection fraction) as well as between duration of ivabradine treatment (short term (&lt; 6 months) or long term (&gt;/= 6 months)). DATA COLLECTION AND ANALYSIS  Two review authors independently assessed trials for inclusion, extracted data, and checked data for accuracy. We calculated risk ratios (RR) using a random-effects model. We completed a comprehensive &#39;Risk of bias&#39; assessment for all studies. We contacted authors for missing data. Our primary endpoints were  mortality from cardiovascular causes; quality of life; time to first hospitalisation for heart failure during follow-up; and number of days spent in hospital due to heart failure during follow-up. Our secondary endpoints were  rate of serious adverse events; exercise capacity; and economic costs (narrative report). We assessed the certainty of the evidence applying the GRADE methodology. MAIN RESULTS  We included 19 studies (76 reports) involving a total of 19,628 participants (mean age 60.76 years, 69% male). However, few studies contributed data to meta-analyses due to inconsistency in trial design (type of heart failure) and outcome reporting and measurement. In general, risk of bias varied from low to high across the included studies, with insufficient detail provided to inform judgement in several cases. We were able to perform two meta-analyses focusing on participants with heart failure with a reduced ejection fraction (HFrEF) and long-term ivabradine treatment. There was evidence of no difference between ivabradine and placebo/usual care/no treatment for mortality from cardiovascular causes (RR 0.99, 95% confidence interval (CI) 0.88 to 1.11; 3 studies; 17,676 participants; I(2) = 33%; moderate-certainty evidence). Furthermore, we found evidence of no difference in rate of serious adverse events amongst HFrEF participants randomised to receive long-term ivabradine compared with those randomised to placebo, usual care, or no treatment (RR 0.96, 95% CI 0.92 to 1.00; 2 studies; 17,399 participants; I(2) = 12%; moderate-certainty evidence). We were not able to perform meta-analysis for all other outcomes, and have low confidence in the findings based on the individual studies. AUTHORS&#39; CONCLUSIONS  We found evidence of no difference in cardiovascular mortality and serious adverse events between long-term treatment with ivabradine and placebo/usual care/no treatment in participants with heart failure with HFrEF. Nevertheless, due to indirectness (male predominance), the certainty of the available evidence is rated as moderate.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 Background Studies of self-administered medications associated with hospital admissions are limited. Objective This study aimed to identify drug-related hospital admissions among elderly patients with diabetes, hypertension and chronic obstructive pulmonary disease and its association with self-administered medications. Method This was a prospective study of 335 patients admitted to a district hospital in Thailand from October 2018 to April 2019. The patients were divided into two groups  one with self-administered medication and the other with caregiver-administered medication. Pharmaceutical Care Network Europe V8.02-defined drug-related problems were identified. Those that conformed to the Hallas contribution and causality criteria were deemed drug-related hospital admissions and causes of the problems were examined. Main outcome measure An association between self-administration of medications and hospital admission was determined using a multivariable logistic regression analysis. Results The prevalence of drug-related hospital admissions was 20.6% (95% confidence interval, CI 16.4-25.3%) as an overall and was significantly higher in the self-administration group (25.4%) than in the caregiver administration group (12.7%). Among the drug-related hospital admissions in the self-administration and caregiver administration groups respectively, 71.7 and 62.5% were preventable, 63.2 and 37.7% were caused by patient themselves, and 26.3 and 37.5% were from adverse drug reactions. Medical conditions frequently caused by the patients included the exacerbation of chronic obstructive pulmonary disease due to using inhalers less than prescribed or administering drugs in the wrong manner in the self-administration group and hypoglycemia due to a long interval between insulin injection and meal consumption in the caregiver administration group. Compared to caregiver-administered medications, self-administration of medications increased the odds of hospital admission by approximately two-fold (adjusted odds ratio, OR 2.24, 95% CI 1.13-4.43). Other independent risk factors included the use of five or more medications a day (OR 2.65, 95% CI 1.16-6.07), the presence of underlying chronic obstructive pulmonary disease (OR 2.11, 95% CI 1.05-4.23) and self-medication (OR 2.59, 95% CI 1.12-5.99). Conclusion Self-administered medication was associated with hospital admissions in elderly patients with chronic diseases. To prevent problems, priority should be given to interventions to ensure the appropriate administration of inhaled medications for chronic obstructive pulmonary disease and antihyperglycemic agents.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 BACKGROUND  A new lipoprotein testing method based on anion-exchange HPLC (AEX-HPLC) was recently established. We verified the accuracy of LDL-C levels, a primary therapeutic target for the prevention of cardiovascular disease (CVD), measured by AEX-HPLC comparing with LDL-C levels measured by beta quantification-reference measurement procedure (BQ-RMP), homogenous assays, and calculation methods. METHODS  We compared LDL-C levels measured by AEX-HPLC (adLDL-Ch  LDL-Ch and IDL-Ch) and BQ-RMP using blood samples from 52 volunteers. AdLDL-Ch levels were also compared with those measurements by homogeneous assays and calculation methods (Friedewald equation, Martin equation, and Sampson equation) using blood samples from 411 participants with dyslipidemia and/or type 2 diabetes. RESULTS  The precision and accuracy of adLDL-Ch were verified by BQ-RMP. The mean percentage bias [bias (%)] for LDL-C was 1.2%, and the correlation was y = 0.990x + 3.361 (r = 0.990). These results met the acceptable range of accuracy prescribed by the National Cholesterol Education Program. Additionally, adLDL-Ch levels were correlated with LDL-C levels measured by the 2 homogeneous assays (r &gt; 0.967) and the calculation methods (r &gt; 0.939), in serum samples from patients with hypertriglyceridemia. CONCLUSIONS  AEX-HPLC is a reliable method for measuring LDL-C levels for CVD risk in daily clinical laboratory analyses.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Diseases of arteries,
 OBJECTIVES  Aging causes stiffness and decreased function of the renal artery (RA). Histological study with light microscopy can reveal microscopic structural remodeling but no functional changes. The present study aimed to clarify the association between structural and functional aging of the RA through the use of scanning acoustic microscopy. METHODS  Formalin-fixed, paraffin-embedded cross-sections of renal arteries from 64 autopsy cases were examined. Speed-of-sound (SOS) values of three layers, which correspond to the stiffness, were compared among different age groups. SOS of the tunica media was examined in terms of blood pressure (BP) and SOS of the ascending aorta. Vulnerability to proteases was assessed by SOS reduction after collagenase treatment. RESULTS  The tunica intima presented inward hypertrophy with luminal narrowing, and the tunica media showed outward hypertrophic remodeling with aging. SOS of the tunica media and internal and external elastic laminae showed a reverse correlation with age. SOS of the tunica media was negatively correlated with BP and strongly associated with that of the aorta. The tunica media of young RAs were more sensitive to collagenase compared with the old ones. CONCLUSIONS  Scanning acoustic microscopy is useful for observing the aging process of the RA. This technique simultaneously shows structural and mechanical information from each portion of the RA. In the process of aging, the RA loses contractile function and elasticity as a result of protease digestion. The tunica media and the internal and external elastic laminae exhibit reduced stiffness, but the tunica intima stiffens with atherosclerosis. As a consequence, the RA&#39;s outer shape changes from round to oval with inward and outward hypertrophy. This indicates that the inner resistant intima supports the mechanical weakness of the tunica media to compensate for an increase in BP with aging.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Diseases of arteries,
 A cluster of patients with coronavirus disease 2019 (COVID-19) underwent repeated positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA tests after they were discharged from the hospital. We referred to them as re-positive (RP) patients in this study. We aimed to describe the clinical characteristics of these patients in a retrospective cohort study. After being treated for COVID-19, the patients underwent 14 days of quarantine following their discharge from the Huangshi Hospital of Traditional Chinese Medicine and the Huangshi Hospital of Youse. Two additional sequential SARS-CoV-2 RNA tests were performed at the end of quarantine. The median age of the 368 patients was 51 years, and 184 (50%) patients were female. A total of 23 RP patients were observed at follow-up. Using multivariate Cox regression analysis, risk factors associated with RP included a higher ratio of lymphocyte/white blood cell on admission (adjusted HR 7.038; 95% CI, 1.911-25.932; P = 0.0034), lower peak temperature during hospitalization (adjusted HR, 0.203; 95% CI, 0.093-0.443; P&lt;0.0001), and the presence of comorbidities, particularly hypertension or chronic diseases in the respiratory system (adjusted HR, 3.883; 95% CI, 1.468-10.273; P = 0.0063). Antivirus treatment with arbidol was associated with a lower likelihood of re-positive outcomes (adjusted HR, 0.178; 95% CI, 0.045-0.709; P = 0.0144).
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 BACKGROUND  Post-operative atrial fibrillation (POAF) is a frequent cardiothoracic surgery complication that increases hospital stay, mortality and costs. Despite decades of research, there has been no systematic overview and meta-analysis of preclinical therapies for POAF in animal models. METHODS  We performed a systematic search of MEDLINE and EMBASE from their inception through September 2020 to determine the effect of preclinical POAF therapies on primary efficacy outcomes using a prospectively registered protocol (CRD42019155649). Bias was assessed using the SYRCLE tool and CAMARADES checklist. RESULTS  Within the 26 studies that fulfilled our inclusion criteria, we identified 4 prevention strategies including biological (n = 5), dietary (n = 2), substrate modification (n = 2), and pharmacological (n = 17) interventions targeting atrial substrate, cellular electrophysiology or inflammation. Only one study altered more than 1 pathophysiological mechanism. 73% comprised multiple doses of systemic therapies. Large animal models were used in 81% of the studies. Preclinical therapies altogether attenuated atrial fibrosis (SMD -2.09; 95% confidence interval [CI] -2.95 to -1.22; p &lt; 0.00001; I2 = 47%), AF inducibility (RR 0.40; 95% CI 0.21 to 0.79; p = 0.008; I2 = 39%), and AF duration (SMD -2.19; 95% CI -3.05 to -1.32; p &lt; 0.00001; I2 = 50%). However, all the criteria needed to evaluate the risk of bias was unclear for many outcomes and only few interventions were independently validated by more than 1 research group. CONCLUSION  Treatments with therapies targeting atrial substrate, cellular electrophysiology or inflammation reduced POAF in preclinical animal models compared to controls. Improving the quality of outcome reporting, independently validating promising approaches and targeting complimentary drivers of POAF are promising means to improve the clinical translation of novel therapies for this highly prevalent and clinically meaningful disease.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Coagulopathies,
 INTRODUCTION  IgA nephropathy (IgAN) is the most common primary glomerulopathy worldwide. According to the Oxford Classification, changes in the kidney vascular compartment are not related with worse outcomes. This paper aims to assess the impact of thrombotic microangiopathy (TMA) in the outcomes of Brazilian patients with IgAN. MATERIALS AND METHODS  Analysis of clinical data and kidney biopsy findings from patients with IgAN to assess the impact of TMA on renal outcomes. RESULTS  The majority of the 118 patients included were females (54.3%); mean age of 33 years (25;43); hypertension and hematuria were observed in 67.8% and 89.8%, respectively. Median creatinine  1.45mg/dL; eGFR  48.8ml/min/1.73m2; 24-hour proteinuria  2.01g; low serum C3  12.5%. Regarding to Oxford Classification  M1  76.3%; E1  35.6%; S1  70.3%; T1/T2  38.3%; C1/C2  28.8%. Average follow-up  65 months. Histologic evidence of TMA were detected in 21 (17.8%) patients and those ones presented more frequently hypertension (100% vs. 61%, p &lt;0.0001), hematuria (100% vs 87.6%, p = 0.0001), worse creatinine levels (3.8 vs. 1.38 mg/dL, p = 0.0001), eGFR (18 vs. 60 ml/min/1.73m2), p = 0.0001), low serum C3 (28.5% vs. 10.4%, p = 0.003), lower hemoglobin levels (10.6 vs. 12.7g/dL, p&lt;0.001) and platelet counts (207,000 vs. 267,000, p = 0.001). Biopsy findings of individuals with TMA revealed only greater proportions of E1 (68% vs. 32%, p = 0.002). Individuals with TMA were followed for less time (7 vs. 65 months, p&lt;0.0001) since they progressed more frequently to chronic kidney disease (CKD) requiring kidney replacement therapy (KRT) (71.4% vs. 21,6%, p&lt;0.0001). Male sex, T1/T2, and TMA were independently associated with progression to CKD-KRT. CONCLUSIONS  In this study patients with TMA had worse clinical manifestations and outcomes. In terms of histologic evidence, E1 distinguished patients with TMA from other patients. Further studies are necessary to analyze the impact of vascular lesions on IgAN prognosis.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-magenta-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">arrhythm</span>,
<span class="ansi-bold">Embeded topics: </span>Arrhythmia,
 The pumping of blood through the heart is due to a wave of muscle contractions that are in turn due to a wave of electrical activity initiated at the sinoatrial node. At the cellular level, this wave of electrical activity corresponds to the sequential excitation of electrically coupled cardiac cells. Under some conditions, the normally-long action potentials of cardiac cells are extended even further by small oscillations called early afterdepolarizations (EADs) that can occur either during the plateau phase or repolarizing phase of the action potential. Hence, cellular EADs have been implicated as a driver of potentially lethal cardiac arrhythmias. One of the major determinants of cellular EAD production and repolarization failure is the size of the overlap region between Ca2+ channel activation and inactivation, called the window region. In this article, we interpret the role of the window region in terms of the fast-slow structure of a low-dimensional model for ventricular action potential generation. We demonstrate that the effects of manipulation of the size of the window region can be understood from the point of view of canard theory. We use canard theory to explain why enlarging the size of the window region elicits EADs and why shrinking the window region can eliminate them. We also use the canard mechanism to explain why some manipulations in the size of the window region have a stronger influence on cellular electrical behavior than others. This dynamical viewpoint gives predictive power that is beyond that of the biophysical explanation alone while also uncovering a common mechanism for phenomena observed in experiments on both atrial and ventricular cardiac cells.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,
 BACKGROUND  The impact of the COVID-19 pandemic has varied widely across nations and even in different regions of the same nation. Some of this variability may be due to the interplay of pre-existing demographic, psychological, social and health-related factors in a given population. OBJECTIVE  To examine the statistical associations between the state-wise prevalence, mortality and case fatality of COVID-19 in 24 Indian states and key demographic, socio-economic and health-related indices. METHODS  Data on the COVID-19 prevalence, crude mortality and case fatality rates were obtained from official government statistics for 24 states of India as of June 30, 2020. The relationship between these parameters and demographic, social, psychological and health-related indices in these states was examined using both bivariate and multivariate analyses. RESULTS  COVID-19 prevalence was negatively associated with the sex ratio (defined as the number of females per 1000 male population) and positively associated with the presence of an international airport in a particular state, while COVID-19 crude mortality rate was negatively associated with the sex ratio and the state-wise burden of diarrhoeal disease, and positively associated with the state-wise burden of ischemic heart disease. On multivariate analyses, COVID-19 crude mortality rate was significantly and negatively associated with the sex ratio. CONCLUSIONS  These results suggest that the transmission and impact of COVID-19 in a given population may be influenced by a number of variables, with demographic factors showing the most consistent association. CLINICALTRIAL 
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-magenta-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">arrhythm</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Arrhythmia,Diseases of arteries,
 BACKGROUND  The clinical characteristics and outcomes associated with non-intensive care unit (non-ICU) hospitalizations for coronavirus disease 2019 (COVID-19) outside disease epicenters remain poorly characterized. METHODS  Systematic analysis of all non-ICU patient hospitalizations for COVID-19 completing discharge between March 13 and May 1, 2020, in a large US health care system utilizing off-site central monitoring. Variables of interest were examined in relation to a composite event rate of death, ICU transfer, or increased oxygen requirement to high-flow nasal cannula, noninvasive ventilation, or mechanical ventilation. RESULTS  Among 350 patients (age, 64 +/- 16 years; 55% male), most (73%) required 3 L/min or less of supplemental oxygen during admission. Telemetry was widely utilized (79%) yet arrhythmias were uncommon (14%) and were predominantly (90%) among patients with abnormal troponin levels or known cardiovascular disease. Ventricular tachycardia was rare (5%), nonsustained, and not associated with hydroxychloroquine/azithromycin treatment. Adverse events occurred in 62 patients (18%), including 22 deaths (6%), 48 ICU transfers (14%), and 49 patients with increased oxygen requirement (14%) and were independently associated with elevated C-reactive protein (odds ratio, 1.09 per 1 mg/dL; 95% CI, 1.01-1.18; P = .04) and lactate dehydrogenase (OR, 1.006 per 1U/L; 95% CI, 1.001-1.012; P = .03) in multivariable analysis. CONCLUSION  Among non-critically ill patients hospitalized within a nonepicenter health care system, overall survival was 94% with the development of more severe illness or death independently associated with higher levels of C-reactive protein and lactate dehydrogenase on admission. Clinical decompensation was largely respiratory-related, while serious cardiac arrhythmias were rare, which suggests that telemetry can be prioritized for high-risk patients.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 PURPOSE  Despite the existence of expert recommendations that can improve morbidity and mortality, reduce the need for hospitalization or readmission, and enhance quality of life in patients with heart failure (HF), many patients do not receive optimal medical therapy (OMT). The goal of this initiative, titled RightSTEPS, was to help physicians take the right steps to apply-evidence-based HF management strategies in clinical practice. METHODS  Using the PRECEDE-PROCEED Model aimed at improving the clinical behavior of the learner, the instructional design featured 23 online and live face-to-face activities offering up to 16 credit hours of CME/CNE credit. These activities were delivered sequentially in three phases  predisposing, enabling and reinforcing. The lessons provided concise, pragmatic, stepwise management strategies aimed at empowering clinicians to prescribe evidence-based, guideline-directed OMT for patients with HF. RESULTS  The predisposing and reinforcing online activities within the initiative reached a total of 71,510 learners with 23,902 successfully completed activities and post-tests; the enabling face-to-face activities reached a total audience of 763 clinicians. This initiative resulted in a statistically significant (p &lt; 0.0001) increase in knowledge and competence related to HF OMT among the clinician learners. Furthermore, follow-up surveys indicated a commitment from learners to implement these guideline-directed strategies in their clinical practice. CONCLUSIONS  This initiative demonstrated that the design of the RightSTEPS curriculum, using the Precede-Proceed model with sequentially-delivered, blended learning, provides a methodological framework to help learners translate knowledge into improvements in clinical behavior with the potential to improve patient health outcomes.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 Purpose  To detect the presence of urotensin-2 (U-II) in the aqueous humor and evaluate the relationship between aqueous humor level and systemic diseases and pupil size. Methods  The study included 88 patients who underwent cataract surgery. Those with a pupil diameter (PD) of up to 4 mm were considered to have small dilation, those with 4-7 mm of dilatation were considered to have moderate dilation, and those with a PD of more than 7 mm considered to have large dilation. Patients with HT (hypertension) were classified as group 1, those with DM (diabetes mellitus) as group 2, and those with HT+DM as group 3, and those without any systemic disease as group 4. The U-II levels in humor aqueous samples taken from anterior chamber were measured. Results  When compared with the control group, it was observed that the level of U-II in the aqueous humor of the HT, DM, and DM+HT groups was significantly higher (P &lt; 0.05). At the same time, when we compared the DM+HT group with the other groups, the level of U-II in the aqueous humor was significantly higher compared to the group with DM (P &lt; 0.05). The U-II levels of the aqueous humor were higher in the patients with small pupils compared to the remaining groups (P &lt; 0.005). Conclusion  U-II may play a role in small pupil pathophysiology. In addition, it was determined that patients with HT and/or diabetes had higher U-II levels in the aqueous humor than healthy individuals.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 Postinfection complications of coronavirus disease 2019 (COVID-19) are still unknown, and one of the long-term concerns in infected people are brain pathologies. The question is that severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection may be an environmental factor in accelerating the sporadic neurodegeneration in the infected population. In this regard, induction of protein aggregation in the brain by SARS-CoV-2 intact structure or a peptide derived from spike protein subunits needs to be considered in futures studies. In this paper, we discuss these possibilities using pieces of evidence from other viruses.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">stenos</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 INTRODUCTION  Identification of asymptomatic patients with high risk for internal carotid artery (ICA) stenosis destabilization and symptoms occurrence is important for the prognosis estimation. OBJECTIVES  To identify the differences between the patients with symptomatic and asymptomatic ICA stenosis and to develop a predictive model for the risk of symptomatic stenosis based on the data accumulated in routine clinical practice. PATIENTS AND METHODS  The study included 163 patients with asymptomatic and 182 patients with symptomatic ICA stenosis &gt;70%. Comparisons between the groups were made in terms of stroke risk factors and comorbidities, coexisting ICA stenosis on the contralateral side, atherosclerosis in other arterial areas and morphology of the atherosclerotic plaque by transcervical ultrasound. RESULTS  Independent risk factors for symptomatic ICA stenosis were  male sex [odds ratio (OR) 2.94, 95% confidence intervals (CI)  1.87-4.32, p&lt;0.001], diabetes mellitus (OR 2.86, 95% CI  1.62-5.12, p&lt;0.001), body mass index &gt;25 kg/m2 (OR 1.81, 95% CI  1.72-1.86, p&lt;0.001), chronic kidney disease (OR 3.34, 95% CI  1.34-8.87, p=0.007), increased-risk features of ultrasound plaque morphology (OR 2.52, 95% CI  1.29-3.72, p=0.009) and coexisting atherosclerosis in three or four vascular areas (OR 3.72, 95% CI  1.77-7.23, p&lt;0.001).The sensitivity and specificity for the scoring model created to estimate the risk of symptomatic ICA stenosis were 77.6% and 76.9%, respectively. CONCLUSIONS  This cross-sectional study indicates that analysis of selected imaging and clinical parameters may allow to estimate the risk of ICA stenosis symptomatic conversion. The scoring system we propose requires further, prospective validation.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlud</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,
 INTRODUCTION  There is a paucity of real-world registries concerning patients with chronic coronary syndromes (CCS). OBJECTIVES  Assessment of long-term results of patients with CCS and after coronarography performed in accordance with the treatment strategy. PATIENTS AND METHODS  The analysis involved 11,021 single-center patients treated between 2006-2016, and enrolled into the ongoing PRESAGE Registry. Based on coronarography outcomes and treatment strategy, patients were classified into 4 groups  non-significant lesions (n=3,637 patients), percutaneous coronary intervention (PCI; n=4,678 patients), coronary artery bypass graft surgery (CABG; n=997 patients), and conservative treatment (notwithstanding significant lesions in the angiogram, n=1,709 patients). The primary outcome measure was death defined as death from any cause, assessed in every group during a 1-, 3-, and 5-year follow-up period. RESULTS  The mean age of study patients was 64.6 (9.5) years, and 35.0% of them were women. Patients treated conservatively were the oldest (64.9 [9.3] years) with the highest prevalence of previous myocardial infarction (50.5%), CABG (31.8%), diabetes mellitus (40.3%), chronic total occlusion (65.5%), and the percentage of left ventricular ejection fraction &lt;35% (24.4%). The death from any cause in the non-significant lesions, PCI, CABG, and conservative treatment groups 5 years after index hospitalization occurred in 11.2%, 16.2%, 9.7%, and 21.0% patients, respectively. CONCLUSIONS  The PRESAGE registry offers valuable information about clinical characteristics and long-term results of patients with CCS. The population of CCS patients and their distant prognosis is differential with the poorest characteristics and outcomes in those with significant lesions and disqualified from revascularization procedures.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Inflammatory diseases,
 Lithium is neuroprotective in preclinical stroke models. In addition to that, poststroke neuroregeneration is stimulated upon transplantation of mesenchymal stem cells (MSCs). Preconditioning of MSCs with lithium further enhances the neuroregenerative potential of MSCs, which act by secreting extracellular vesicles (EVs). The present work analyzed, whether MSC preconditioning with lithium modifies EV secretion patterns, enhancing the therapeutic potential of such derived EVs (Li-EVs) in comparison with EVs enriched from native MSCs. Indeed, Li-EVs significantly enhanced the resistance of cultured astrocytes, microglia, and neurons against hypoxic injury when compared with controls and to native EV-treated cells. Using a stroke mouse model, intravenous delivery of Li-EVs increased neurological recovery and neuroregeneration for as long as 3 months in comparison with controls and EV-treated mice, albeit the latter also showed significantly better behavioral test performance compared with controls. Preconditioning of MSCs with lithium also changed the secretion patterns for such EVs, modifying the contents of various miRNAs within these vesicles. As such, Li-EVs displayed significantly increased levels of miR-1906, which has been shown to be a new regulator of toll-like receptor 4 (TLR4) signaling. Li-EVs reduced posthypoxic and postischemic TLR4 abundance, resulting in an inhibition of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) signaling pathway, decreased proteasomal activity, and declined both inducible NO synthase and cyclooxygenase-2 expression, all of which culminating in reduced levels of poststroke cerebral inflammation. Conclusively, the present study for the first time demonstrates an enhanced therapeutic potential of Li-EVs compared with native EVs, interfering with a novel signaling pathway that yields both acute neuroprotection an enhanced neurological recovery.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 INTRODUCTION  The coronavirus disease 2019 (COVID-19) pandemic has resulted in a significant decrease in volume of electrophysiology (EP) procedures. There has been concern that trainees may not achieve the procedural numbers required to graduate as independent electrophysiologists within the usual timeline. We sought to determine the impact of the COVID-19 pandemic on the percentage of clinical cardiac EP (CCEP) fellows in jeopardy of not meeting procedural volume requirements and overall sentiments regarding preparedness of fellows for independent practice. METHODS  We surveyed CCEP fellows and program directors about baseline procedural volumes, curriculum changes due to the pandemic, and attitudes about preparedness for board examinations and independent practice. RESULTS  Ninety-nine fellows and 27 program directors responded to the survey. Ninety-eight percent of responding fellows reported a decrease in procedural volume as a result of the pandemic. Program directors reported an overall decrease in annual number of ablations and device procedures performed by each fellow during the 2019-2020 academic year compared to the preceding year. Despite this, a minority of fellows and program directors reported concerns about meeting Accreditation Council for Graduate Medical Education procedural requirements for devices (9%, 4%, respectively) and ablation (19%, 9%) or preparedness for independent practice after a two-year fellowship. CONCLUSIONS  The COVID-19 pandemic has resulted in a decrease in procedural volume for CCEP trainees, but the majority of fellows and program directors do not anticipate major barriers to timely graduation. This may change with COVID-19 resurgence and further interruptions in training. This article is protected by copyright. All rights reserved.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlud</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">stenos</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 BACKGROUND AND PURPOSE  Dynamic susceptibility perfusion MR imaging (DSC MRP) has been used to assess changes in cerebral perfusion attributable to vascular stenosis or occlusion that may predict stroke risk. However, DSC MRP is not validated for identifying hemodynamic compromise in the posterior circulation. We investigated the clinical utility of DSC MRP in vertebrobasilar (VB) atherosclerotic disease in the observational VERiTAS study. METHODS  VERiTAS enrolled patients with symptomatic &gt;/=50% VB stenosis/occlusion. Posterior circulation hemodynamic status was designated as low or normal based on large vessel flow measured using quantitative magnetic resonance angiography (QMRA) and was predictive of future stroke risk. In this study, DSC MRP conducted concurrently with QMRA was used to evaluate posterior circulation perfusion. The primary outcome was the mean transit time (MTT) and relative cerebral blood volume (rCBV) in the posterior circulation normalized to the anterior circulation, compared between patients with low and normal blood flow as determined on QMRA. RESULTS  Twenty-six subjects had 47 DSC MRP studies for review. There was no statistically or clinically significant difference in the rCBV ratio (1.02 vs. .96 P = .89), or MTT ratio (1.04 vs. 1.04 P = .96) relative to normal or low VB territory flow. CONCLUSIONS  In this study, we did not find that DSC MRP adequately distinguished between patients with low or normal flow status based on large-vessel flow measurements.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,
 BACKGROUND  Diabetes mellitus (DM) is associated with increased cardiovascular (CV) risk. We compared health-related quality of life (HRQoL), healthcare resource utilization (HRU), and clinical outcomes of stable post-myocardial infarction (MI) patients with and without DM. HYPOTHESIS  In post-MI patients, DM is associated with worse HRQoL, increased HRU, and worse clinical outcomes. METHODS  The prospective, observational long-term risk, clinical management, and healthcare Resource utilization of stable coronary artery disease study obtained data from 8968 patients aged &gt;/=50 years 1 to 3 years post-MI (369 centers; 25 countries). Patients with &gt;/=1 of the following risk factors were included  age &gt;/=65 years, history of a second MI &gt;1 year before enrollment, multivessel coronary artery disease, creatinine clearance &gt;/=15 and &lt;60 mL/min, and DM treated with medication. Self-reported health status was assessed at baseline, 1 and 2 years and converted to EQ-5D scores. The main outcome measures were baseline HRQoL and HRU during follow-up. RESULTS  DM at enrollment was 33% (2959 patients, 869 insulin treated). Mean baseline EQ-5D score (0.86 vs 0.82; P &lt; .0001) was higher; mean number of hospitalizations (0.38 vs 0.50, P &lt; .0001) and mean length of stay (LoS; 9.3 vs 11.5; P = .001) were lower in patients without vs with DM. All-cause death and the composite of CV death, MI, and stroke were significantly higher in DM patients, with adjusted 2-year rate ratios of 1.43 (P &lt; .01) and 1.55 (P &lt; .001), respectively. CONCLUSIONS  Stable post-MI patients with DM (especially insulin treated) had poorer EQ-5D scores, higher hospitalization rates and LoS, and worse clinical outcomes vs those without DM. Strategies focusing specifically on this high-risk population should be developed to improve outcomes. TRIAL REGISTRATION  ClinicalTrials.gov  NCT01866904 (https //clinicaltrials.gov).
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Diabetes and metabolic syndrome are associated with the typical American high glycemia diet and result in accumulation of high levels of advanced glycation end products (AGEs), particularly upon aging. AGEs form when sugars or their metabolites react with proteins. Associated with a myriad of age-related diseases, AGEs accumulate in many tissues and are cytotoxic. To date, efforts to limit glycation pharmacologically have failed in human trials. Thus, it is crucial to identify systems that remove AGEs, but such research is scanty. Here, we determined if and how AGEs might be cleared by autophagy. Our in vivo mouse and C. elegans models, in which we altered proteolysis or glycative burden, as well as experiments in five types of cells, revealed more than six criteria indicating that p62-dependent autophagy is a conserved pathway that plays a critical role in the removal of AGEs. Activation of autophagic removal of AGEs requires p62, and blocking this pathway results in accumulation of AGEs and compromised viability. Deficiency of p62 accelerates accumulation of AGEs in soluble and insoluble fractions. p62 itself is subject to glycative inactivation and accumulates as high mass species. Accumulation of p62 in retinal pigment epithelium is reversed by switching to a lower glycemia diet. Since diminution of glycative damage is associated with reduced risk for age-related diseases, including age-related macular degeneration, cardiovascular disease, diabetes, Alzheimer&#39;s, and Parkinson&#39;s, discovery of methods to limit AGEs or enhance p62-dependent autophagy offers novel potential therapeutic targets to treat AGEs-related pathologies.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Coagulopathies,
 BACKGROUND  Chronic subdural hematoma (CSDH) is a common illness in neurosurgical practice with a substantial recurrence rate. Previous studies found that serum lipids were associated with the risk of stroke and subarachnoid hemorrhage. In the current study, we aimed to identify the relationship between serum lipids and CSDH recurrence. METHODS  The medical records of 274 consecutive surgical patients with CSDH in our department were reviewed and analyzed. Patients were separated into recurrence and non-recurrence groups. Univariable and multivariable Cox proportional hazards regression analyses were performed to identify serum lipids (triglycerides, total cholesterol, LDL, HDL) and other potential predictors associated with CSDH recurrence, and the performance of predictors was assessed with receiver operating characteristic (ROC) curve. RESULTS  Of the 274 patients included in the study, 42 (15.3%) experienced at least 1 recurrence of CSDH. Univariate analysis showed that age, hypertension, diabetes mellitus, anticoagulant use, triglycerides, HDL, and midline shift were all significantly associated with CSDH recurrence. Multivariable Cox regression analysis found that only age, diabetes mellitus, midline shift, and HDL level were independent risk factors for CSDH recurrence. A higher HDL level (HR = 0.929, 95% CI 0.905-0.953) was significantly associated with a lower risk of recurrence, and ROC curve analysis revealed that the optimal HDL cut-off value as a predictor was 37.45 mg/dl. CONCLUSIONS  Low level of high-density lipoprotein is significantly associated with recurrence of chronic subdural hematoma.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Coagulopathies,
 The prevalence of hypertension has increased rapidly in recent years. Currently, increasing attention has been paid to the relationship between hypertension and platelet abnormalities. As a simple and available platelet parameter, platelet distribution width (PDW) can reflect platelet abnormalities and further reflect the risk of thrombotic diseases. However, the views on PDW and hypertension are controversial at present studies. Hence, we aimed to find the associations between PDW and hypertension subtypes in this study. 73469 participants (44665 males and 28804 females) were enrolled. We found that PDW was a risk factor for isolated systolic hypertension (ISH), and the risk of ISH increased with PDW quartiles among women. In men, high PDW might be a risk factor for isolated diastolic hypertension and systolic-diastolic hypertension.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">cerebrovascul</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,
 Importance  Human genetics and studies in experimental models support a key role of monocyte-chemoattractant protein-1 (MCP-1) in atherosclerosis. Yet, the associations of circulating MCP-1 levels with risk of coronary heart disease and cardiovascular death in the general population remain largely unexplored. Objective  To explore whether circulating levels of MCP-1 are associated with risk of incident coronary heart disease, myocardial infarction, and cardiovascular mortality in the general population. Data Sources and Selection  Population-based cohort studies, identified through a systematic review, that have examined associations of circulating MCP-1 levels with cardiovascular end points. Data Extraction and Synthesis  Using a prespecified harmonized analysis plan, study-specific summary data were obtained from Cox regression models after excluding individuals with overt cardiovascular disease at baseline. Derived hazard ratios (HRs) were synthesized using random-effects meta-analyses. Main Outcomes and Measures  Incident coronary heart disease (myocardial infarction, coronary revascularization, and unstable angina), nonfatal myocardial infarction, and cardiovascular death (from cardiac or cerebrovascular causes). Results  The meta-analysis included 7 cohort studies involving 21401 individuals (mean [SD] age, 53.7 [10.2] years; 10012 men [46.8%]). Mean (SD) follow-up was 15.3 (4.5) years (326392 person-years at risk). In models adjusting for age, sex, and race/ethnicity, higher MCP-1 levels at baseline were associated with increased risk of coronary heart disease (HR per 1-SD increment in MCP-1 levels  1.06 [95% CI, 1.01-1.11]; P = .01), nonfatal myocardial infarction (HR, 1.07 [95% CI, 1.01-1.13]; P = .02), and cardiovascular death (HR, 1.12 [95% CI, 1.05-1.20]; P &lt; .001). In analyses comparing MCP-1 quartiles, these associations followed dose-response patterns. After additionally adjusting for vascular risk factors, the risk estimates were attenuated, but the associations of MCP-1 levels with cardiovascular death remained statistically significant, as did the association of MCP-1 levels in the upper quartile with coronary heart disease. There was no significant heterogeneity; the results did not change in sensitivity analyses excluding events occurring in the first 5 years after MCP-1 measurement, and the risk estimates were stable after additional adjustments for circulating levels of interleukin-6 and high-sensitivity C-reactive protein. Conclusions and Relevance  Higher circulating MCP-1 levels are associated with higher long-term cardiovascular mortality in community-dwelling individuals free of overt cardiovascular disease. These findings provide further support for a key role of MCP-1-signaling in cardiovascular disease.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">cerebrovascul</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,
 Importance  Human genetics and studies in experimental models support a key role of monocyte-chemoattractant protein-1 (MCP-1) in atherosclerosis. Yet, the associations of circulating MCP-1 levels with risk of coronary heart disease and cardiovascular death in the general population remain largely unexplored. Objective  To explore whether circulating levels of MCP-1 are associated with risk of incident coronary heart disease, myocardial infarction, and cardiovascular mortality in the general population. Data Sources and Selection  Population-based cohort studies, identified through a systematic review, that have examined associations of circulating MCP-1 levels with cardiovascular end points. Data Extraction and Synthesis  Using a prespecified harmonized analysis plan, study-specific summary data were obtained from Cox regression models after excluding individuals with overt cardiovascular disease at baseline. Derived hazard ratios (HRs) were synthesized using random-effects meta-analyses. Main Outcomes and Measures  Incident coronary heart disease (myocardial infarction, coronary revascularization, and unstable angina), nonfatal myocardial infarction, and cardiovascular death (from cardiac or cerebrovascular causes). Results  The meta-analysis included 7 cohort studies involving 21401 individuals (mean [SD] age, 53.7 [10.2] years; 10012 men [46.8%]). Mean (SD) follow-up was 15.3 (4.5) years (326392 person-years at risk). In models adjusting for age, sex, and race/ethnicity, higher MCP-1 levels at baseline were associated with increased risk of coronary heart disease (HR per 1-SD increment in MCP-1 levels  1.06 [95% CI, 1.01-1.11]; P = .01), nonfatal myocardial infarction (HR, 1.07 [95% CI, 1.01-1.13]; P = .02), and cardiovascular death (HR, 1.12 [95% CI, 1.05-1.20]; P &lt; .001). In analyses comparing MCP-1 quartiles, these associations followed dose-response patterns. After additionally adjusting for vascular risk factors, the risk estimates were attenuated, but the associations of MCP-1 levels with cardiovascular death remained statistically significant, as did the association of MCP-1 levels in the upper quartile with coronary heart disease. There was no significant heterogeneity; the results did not change in sensitivity analyses excluding events occurring in the first 5 years after MCP-1 measurement, and the risk estimates were stable after additional adjustments for circulating levels of interleukin-6 and high-sensitivity C-reactive protein. Conclusions and Relevance  Higher circulating MCP-1 levels are associated with higher long-term cardiovascular mortality in community-dwelling individuals free of overt cardiovascular disease. These findings provide further support for a key role of MCP-1-signaling in cardiovascular disease.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,
 Importance  Volumetric measurements by transthoracic echocardiogram may better reflect left ventricular (LV) remodeling than conventional linear LV dimensions. However, the association of LV volumes with mortality in patients with chronic hemodynamically significant aortic regurgitation (AR) is unknown. Objective  To assess whether LV volumes and volume-derived LV ejection fraction (Vol-LVEF) are determinants of mortality in AR. Design, Setting, and Participants  This cohort study included consecutive asymptomatic patients with chronic moderately severe to severe AR from a tertiary referral center (January 2004 through April 2019). Exposures  Clinical and echocardiographic data were analyzed retrospectively. Aortic regurgitation severity was graded by comprehensive integrated approach. De novo disk-summation method was used to derive LV volumes and Vol-LVEF. Main Outcome and Measures  Associations between all-cause mortality under medical surveillance and the following LV indexes  linear LV end-systolic dimension index (LVESDi), linear LVEF, LV end-systolic volume index (LVESVi), and Vol-LVEF. Results  Of 492 asymptomatic patients (mean [SD] age, 60 [17] years; 425 men [86%]), ischemic heart disease prevalence was low (41 [9%]), and 453 (92.1%) had preserved linear LVEF (&gt;/=50%) with mean (SD) LVESVi of 41 (15) mL/m2. At a median (interquartile range) of 5.4 (2.5-10.1) years, 66 patients (13.4%) died under medical surveillance; overall survival was not different than the age- and sex-matched general population (P = .55). Separate multivariate models, adjusted for age, sex, Charlson Comorbidity Index, and AR severity, demonstrated that in addition to linear LVEF and LVESDi, LVESVi and Vol-LVEF were independently associated with mortality under surveillance (all P &lt; .046) with similar C statistics (range, 0.83-0.84). Spline curves showed that continuous risks of death started to rise for both linear LVEF and Vol-LVEF less than 60%, LVESVi more than 40 to 45 mL/m2, and LVESDi above 21 to 22 mm/m2. As dichotomized variables, patients with LVESVi more than 45 mL/m2 exhibited increased relative death risk (hazard ratio, 1.93; 95% CI, 1.10-3.38; P = .02) while LVESDi more than 20 mm/m2 did not (P = .32). LVESVi more than 45 mL/m2 showed a decreased survival trend compared with expected population survival. Conclusions and Relevance  In this large asymptomatic cohort of patients with hemodynamically significant AR, LVESVi and Vol-LVEF worked equally as well as LVESDi and linear LVEF in risk discriminating patients with excess mortality. A LVESVi threshold of 45 mL/m2 or greater was significantly associated with an increased mortality risk.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Diseases of arteries,
 Importance  After disparate results from observational and small randomized studies, the COMPLETE trial demonstrated superiority of multivessel (MV) percutaneous coronary intervention (PCI) over culprit-only PCI for ST-elevation myocardial infarction (STEMI). Objective  To describe temporal trends and institutional variation of MV PCI use for STEMI in the United States to inform how new evidence may influence clinical practice. Design, Setting, and Participants  This cohort study included STEMI admissions involving MV disease from 1598 institutions in the National Cardiovascular Data Registry CathPCI Registry from the third quarter of 2009 to the first quarter of 2018. An MV PCI was defined as a PCI to a nonculprit lesion within 45 days of the index procedure. Exposures  Multivessel PCI, defined as placement of coronary stents in 2 or more major epicardial vessels or the staged placement of 1 or more coronary stents in a major epicardial vessel distinct from the index culprit vessel, within 45 days of the index PCI. Main Outcomes and Measures  Outcomes included the proportional use of MV PCI among STEMI admissions with MV disease, and the timing of MV PCI (an index procedure, a staged procedure during index hospitalization, or a postdischarge procedure within 45 days). Results  Among 359879 admissions with STEMI and MV disease, MV PCI was performed in 38.5% (n = 138380; mean [SD] age of patients, 62.3 [12.3] years; 102266 men [73.9%]) within 45 days. Of those receiving MV PCIs, 30.8% (n = 42629) had a procedure performed during the index procedure, 31.6% (n = 43696) as a staged procedure during the index hospitalization, and 37.6% (n = 52055) within 45 days of discharge. Complete revascularization of all diseased arteries was performed in 76.2% (n = 105389). From the third quarter of 2009 to the second quarter of 2013, MV PCI use declined by 10%, from 42.7% (3230 of 7572 cases) to a nadir of 32.7% (3386 of 10342 cases), followed by an increase to 44.0% (5062 of 11497 cases) by the fourth quarter of 2017. During this time, there was a 13.6% decline in use of postdischarge staged MV PCI (from 23.4% of STEMI cases [1772 of 7572 cases] in the third quarter of 2009 to 9.9% [1094 of 11171 cases] in the fourth quarter of 2014) and an 12.5% increase in MV PCI performed during the index admission (from 19.3% [1458 of 7572 cases] in the third quarter of 2009 to 31.8% [3557 of 11171 cases] in the first quarter of 2018). Multivessel PCI use varied substantially across institutions, with a median use of 37.9% (interquartile range, 30.0%-46.5%). Conclusions and Relevance  In this large, nationwide analysis, MV PCI use for patients with STEMI has been increasing through early 2018 but was used in the minority of patients and with wide variability across US institutions. The adoption of new trial results into guidelines and practice may further promote the growth of MV PCI.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Senescence of smooth muscle cells (SMCs) has a crucial role in the pathogenesis of abdominal aortic aneurysm (AAA), a disease of vascular degeneration. Perturbation of cellular ribosomal DNA (rDNA) transcription triggers nucleolar stress response. Previously we demonstrated that induction of nucleolar stress in SMCs elicited cell cycle arrest via the ataxia-telangiectasia mutated (ATM)/ATM- and Rad3-related (ATR)-p53 axis. However, the specific roles of nucleolar stress in vascular degeneration remain unexplored. In the present study, we demonstrated for the first time that in both human and animal AAA tissues, there were non-coordinated changes in the expression of RNA polymerase I machinery components, including a downregulation of transcription initiation factor-IA (TIF-IA). Genetic deletion of TIF-IA in SMCs in mice (smTIF-IA(-/-)) caused spontaneous aneurysm-like lesions in the aorta. In vitro, induction of nucleolar stress triggered a non-canonical DNA damage response, leading to p53 phosphorylation and a senescence-like phenotype in SMCs. In human AAA tissues, there was increased nucleolar stress in medial cells, accompanied by localized DNA damage response within the nucleolar compartment. Our data suggest that perturbed rDNA transcription and induction of nucleolar stress contribute to the pathogenesis of AAA. Moreover, smTIF-IA(-/-) mice may be a novel animal model for studying spontaneous AAA-like vascular degenerations.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 Objectives Cardiovascular disease (CVD) complication is common among chronic kidney disease (CKD) patients. Thus, knowledge about CVD and ECG abnormalities in CKD are essential due to progressive nature of the disease and increased risk of sudden cardiac death. This study aims to scrutinize the ECG abnormalities among nondialysis late-stage CKD patients. Methods A descriptive observational study was conducted at Dr. Soetomo General Hospital, Surabaya, Indonesia. Subjects were hospitalized patients with late-stage CKD between 1 January and 31 December 2019, who were consulted at the department of cardiology and vascular medicine during their initial admission at emergency room. ECG interpretation for this study was done by qualified cardiologist. Results There were 191 patients included in this study. Mean ages were 52.2 +/- 11.8 years old and 51% were males. Total 143 (74.9%) patients had anemia, 111 (58.1%) had hypertension and 75 (39.3%) had type 2 diabetes mellitus. Mean serum creatinine was 10.5 +/- 8.0 mg/dL. There were 176 (92.1%) patients with at least one form of ECG abnormalities. Prolonged QTc interval (36.6%), fragmented QRS complex (29.8%), poor R wave progression (24.6%), peaked T wave (22.0%) and left ventricular hypertrophy (16.7%) were the most common abnormalities. Conclusions ECG abnormalities are common among nondialysis late-stage CKD patients. Given the fact that long-term CKD influences the pathogenesis cardiovascular diseases and substantial cardiovascular mortality, there is a need to screen Indonesian CKD patients who are at risks of getting earlier complications.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 BACKGROUND  Based on high-quality evidence, guidelines recommend the long-term use of secondary prevention medications post-myocardial infarction (MI) to avoid recurrent cardiovascular events and death. Unfortunately, discontinuation of recommended medications post-MI is common. Observational evidence suggests that prescriptions covering a longer duration at discharge from hospital are associated with greater long-term medication adherence. The following is a proposal for the first interventional study to evaluate the impact of longer prescription duration at discharge post-MI on long-term medication adherence. OBJECTIVE  The overarching goal of this study is to reduce morbidity and mortality among post-MI patients through improved long-term cardiac medication adherence. The specific objectives include the following. First, we will assess whether long-term cardiac medication adherence improves among elderly, post-MI patients following the implementation of (1) standardized discharge prescription forms with 90-day prescriptions and 3 repeats for recommended cardiac medication classes, in combination with education and (2) education alone compared to (3) usual care. Second, we will assess the cost implications of prolonged initial discharge prescriptions compared with usual care. Third, we will compare clinical outcomes between longer (&gt;60 days) versus shorter prescription durations. Fourth, we will collect baseline information to inform a multicenter interventional study. METHODS  We will conduct a quasiexperimental, interrupted time series design to evaluate the impact of a multifaceted intervention to implement longer duration prescriptions versus usual care on long-term cardiac medication adherence among post-MI patients. Intervention groups and their corresponding settings include  (1) intervention group 1  1 cardiac center and 1 noncardiac hospital allocated to receive standardized discharge prescription forms supporting the dispensation of 90 days&#39; worth of cardiac medications with 3 repeats, coupled with education; (2) intervention group 2  4 sites (including 1 cardiac center) allocated to receive education only; and (3) control group  all remaining hospitals within the province that did not receive an intervention (ie, usual care). Administrative databases will be used to measure all outcomes. Adherence to 4 classes of cardiac medications - statins, beta blockers, angiotensin system inhibitors, and secondary antiplatelets (ie, prasugrel, clopidogrel, or ticagrelor) - will be assessed. RESULTS  Enrollment began in September 2017, and results are expected to be analyzed in late 2020. CONCLUSIONS  The results have the potential to redefine best practices regarding discharge prescribing policies for patients post-MI. A policy of standardized maximum-duration prescriptions at the time of discharge post-MI is a simple intervention that has the potential to significantly improve long-term medication adherence, thus decreasing cardiac morbidity and mortality. If effective, this low-cost intervention to implement longer duration prescriptions post-MI could be easily scaled. TRIAL REGISTRATION  ClinicalTrials.gov NCT03257579; https //clinicaltrials.gov/ct2/show/NCT03257579. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)  DERR1-10.2196/18981.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischaem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlud</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">art thrombosis</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Ischemia,Heart failure,Diseases of arteries,Coagulopathies,
 Tranexamic acid (TXA) is widely used to limit the blood loss during total joint arthroplasty without an increased risk of thromboembolic events. We present a case of acute limb ischaemia due to thrombotic occlusion of the superficial femoral artery on the non-operated limb following a total hip arthroplasty in a 64-year-old male patient. Untreated peripheral artery disease, intravenous TXA administration, surgery, obesity and hypertension were identified as predisposing factors of the occlusion. Good reperfusion of the limb was obtained after mechanical thrombectomy. Other cases report that antifibrinolytic agents such as TXA could be associated with arterial thrombosis. The necessity to detect the risk factors of thrombotic events in each patient scheduled for total joint arthroplasty is emphasized. Therefore, topical TXA administration could be a reasonable alternative in a high-risk patient. Key words  tranexamic acid complications, total hip arthroplasty, arterial thrombosis.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Inflammatory diseases,
 RATIONALE  Endogenously cycling adult cardiomyocytes (CMs) increase after myocardial infarction (MI) but remain scare, and are generally thought not to contribute to myocardial function. However, this broadly held assumption has not been tested, mainly because of the lack of transgenic reporters that restrict Cre expression to adult CMs that reenter the cell cycle. OBJECTIVE  We created and validated a new transgenic mouse, alphaMHC-MerDreMer-Ki67p-RoxedCre  Rox-Lox-tdTomato-eGFP (denoted alphaDKRC) that restricts Cre expression to cycling adult CMs and uniquely integrates spatial and temporal adult CM cycling events based on the DNA specificities of orthologous Dre- and Cre recombinases. We then created mice that expressed an inducible Diphtheria toxin (DTA), alphaDKRC  DTA mice, in adult cycling CMs and examined the effects of ablating these endogenously cycling CMs on myocardial function after Ischemic-Reperfusion (I/R) MI. METHODS AND RESULTS  A tandem alphaDKRC transgene was designed, validated in cultured cells, and used to make transgenic mice. The alphaDKRC transgene integrated between MYH6 and MYH7 and did not disrupt expression of the surrounding genes. Compared to controls, alphaDKRC  RLTG mice treated with Tamoxifen expressed tdTomato+ in CMs with rare Bromodeoxyuridine (BrdU)+, eGFP+ CMs, consistent with reentry of the cell cycle. We then pre-treated alphaDKRC  RLTG mice with Tamoxifen to activate the reporter before sham or reperfusion (I/R) myocardial infarction (MI) surgeries. Compared to Sham surgery, the I/R MI group had increased single and paired eGFP+ CMs predominantly in the border zones (5.8 {plus minus} 0.5 vs. 3.3 {plus minus} 0.3 CMs per ten-micron section, N = 8-9 mice per group, n = 16-24 sections per mouse), indicative of cycled CMs. The single to paired eGFP+ CM ratio was ~9 to 1 (5.2 {plus minus} 0.4 single vs. 0.6 {plus minus} 0.2 paired CMs) in the I/R MI group after MI, suggesting that cycling CMs were more likely to undergo polyploidy than replication. The ablation of endogenously cycling adult CMs in alphaDKRC  DTA mice caused progressive worsening left ventricular chamber size and function after I/R MI, compared to controls. CONCLUSIONS  Although scarce, endogenously cycling adult CMs contribute to myocardial function after injury, suggesting that these cells may be physiologically relevant.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam diseas</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,
 Despite advances in the pathophysiology of Chronic Obstructive Pulmonary Disease (COPD), there is a distinct lack of biochemical markers to aid clinical management. Microvesicles (MVs) have been implicated in the pathophysiology of inflammatory diseases including COPD but their association to COPD disease severity remains unknown. We analysed different MV populations in plasma and bronchoalveolar lavage fluid (BALF) taken from sixty-two patients with mild to very severe COPD (51% male; mean age  65.9 years). These patients underwent comprehensive clinical evaluation (symptom scores, lung function, exercise testing) and the capacity of MVs to be clinical markers of disease severity was assessed. We successfully identified various MV subtype populations within BALF (leukocyte, PMN (polymorphonuclear leukocyte i.e. neutrophil), monocyte, epithelial and platelet MVs) and plasma (leukocyte, PMN, monocyte and endothelial MVs), and compared each MV population to disease severity. BALF neutrophil MVs were the only population to significantly correlate with the clinical evaluation scores including FEV1, mMRC dyspnoea score, 6-minute walk test, hyperinflation and gas transfer. BALF neutrophil MVs, but not neutrophil cell numbers, also strongly correlated with BODE index. We have undertaken, for the first time, a comprehensive evaluation of MV profiles within BALF/plasma of COPD patients. We demonstrate that BALF levels of neutrophil-derived MVs are unique in correlating with a number of key functional and clinically-relevant disease severity indices. Our results show the potential of BALF neutrophil MVs for a COPD biomarker that tightly links a key pathophysiological mechanism of COPD (intra-alveolar neutrophil activation) with clinical severity/outcome.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">dil cardiomyopathy</span>,
<span class="ansi-bold">Embeded topics: </span>Cardiomyopathy,
 Long noncoding RNAs (lncRNAs) may serve as potential molecular diagnostic markers to improve the capacity of earlier and more accurate diagnosis of dilated cardiomyopathy (DCM). We integrated five independent transcriptomic datasets (n = 504) from Gene Expression Omnibus for systematic identification of lncRNA-based diagnostic biomarkers in DCM. The multivariate logistic regression model based on the six lncRNAs (AC016722.3, AL589986.2, AC006007.1, AC092687.3, GS1-124K5.4, and AC007126.1) in the ceRNA networks showed high sensitivity and specificity (area under curves &gt;0.8, p &lt; 0.0001) of DCM diagnosis in the training and validation datasets. Functional analysis revealed that the autophagy, protein acetyltransferase, and DNA polymerase activity were associated with high levels of the six-lncRNA signature, while the collagen trimer, extracellular matrix structural constituent, and MHC protein complex were associated with low levels of the signature. Pathway analysis showed that high levels of the six-lncRNA signature were associated with upregulated selective autophagy, interleukin 17 signalings, and extracellular matrix interactions, while were associated with downregulated extracellular matrix organization and collagen formation. The identified six-lncRNA signature, with high performance in molecular diagnosis of DCM, might be applied in future clinical practices combined with traditional markers.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 Elevated sympathetic vasomotor activity is a common feature of cardiorenal diseases. Therefore, the sympathetic nervous system is an important therapeutic target, particularly the fibers innervating the kidneys. In fact, renal denervation has been applied clinically and shown promising results in patients with hypertension and chronic kidney disease. However, the underlying mechanisms involved in the cardiorenal protection induced by renal denervation have not yet been fully clarified. This mini-review highlights historical and recent aspects related to the role of renal sensory fibers in the control of cardiorenal function under normal conditions and in experimental models of cardiovascular disease. Results have demonstrated that alterations in renal sensory function participate in the maintenance of elevated sympathetic vasomotor activity and cardiorenal changes; as such, renal sensory fibers may be a potential therapeutic target for the treatment of cardiorenal diseases. Although it has not yet been applied in clinical practice, selective afferent renal denervation may be promising, since such an approach maintains efferent activity and can provide more refined control of renal function compared to total renal denervation. However more studies are needed to understand the mechanisms by which renal afferents partially contribute to such changes, in addition to the need to evaluate the safety and advantages of the approach for application in the clinical practice.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  Cardiovascular diseases (CV) are the most common factor affecting prognosis in cancer survivors. Cardio-oncology (CO) services have developed to solve this issue. The paucity of outcomes regarding patient demographics and clinical findings prevails and the available data are limited to CO services evaluating patients undergoing only chemotherapy. AIMS  To show initial experiences of the CO service implemented in tertiary oncology center. METHODS  The CO service was designed to include two major domains  general CO and electrotherapy consultations. Patients referred to the CO service with a collection of baseline demographics, cancer type, the reason for referral, cardiac evaluation, and initial clinical outcomes were included in this observational study. RESULTS  All cancer patients referred to our CO service between March 2016 and December 2019 were included in the study. A total of 2762 (77% females) patients at the mean (SD) age of 62 (12) years were referred (63% on an out-patient basis) for general consultations. The most frequent diagnosis was breast cancer (66%). In 18% of patients, the reason of referral to the CO service was cancer treatment related CV complications. A total of 652 patients (515 patients with a cardiac implantable electronic device (CIED) qualified for radiotherapy (RT), 48 patients with CIEDs diagnosed with magnetic resonance imaging (MRI), and 89 patients with CIED treated with cancer surgery) were evaluated by the CO-CIED team. During the total of 5,872 RT sessions, two harmful interactions and no other complications during MRI and surgery were recorded. CONCLUSIONS  The CO-service established within the cancer center seems to be safe and feasible.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  Cardiovascular diseases (CV) are the most common factor affecting prognosis in cancer survivors. Cardio-oncology (CO) services have developed to solve this issue. The paucity of outcomes regarding patient demographics and clinical findings prevails and the available data are limited to CO services evaluating patients undergoing only chemotherapy. AIMS  To show initial experiences of the CO service implemented in tertiary oncology center. METHODS  The CO service was designed to include two major domains  general CO and electrotherapy consultations. Patients referred to the CO service with a collection of baseline demographics, cancer type, the reason for referral, cardiac evaluation, and initial clinical outcomes were included in this observational study. RESULTS  All cancer patients referred to our CO service between March 2016 and December 2019 were included in the study. A total of 2762 (77% females) patients at the mean (SD) age of 62 (12) years were referred (63% on an out-patient basis) for general consultations. The most frequent diagnosis was breast cancer (66%). In 18% of patients, the reason of referral to the CO service was cancer treatment related CV complications. A total of 652 patients (515 patients with a cardiac implantable electronic device (CIED) qualified for radiotherapy (RT), 48 patients with CIEDs diagnosed with magnetic resonance imaging (MRI), and 89 patients with CIED treated with cancer surgery) were evaluated by the CO-CIED team. During the total of 5,872 RT sessions, two harmful interactions and no other complications during MRI and surgery were recorded. CONCLUSIONS  The CO-service established within the cancer center seems to be safe and feasible.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  Cardiovascular diseases (CV) are the most common factor affecting prognosis in cancer survivors. Cardio-oncology (CO) services have developed to solve this issue. The paucity of outcomes regarding patient demographics and clinical findings prevails and the available data are limited to CO services evaluating patients undergoing only chemotherapy. AIMS  To show initial experiences of the CO service implemented in tertiary oncology center. METHODS  The CO service was designed to include two major domains  general CO and electrotherapy consultations. Patients referred to the CO service with a collection of baseline demographics, cancer type, the reason for referral, cardiac evaluation, and initial clinical outcomes were included in this observational study. RESULTS  All cancer patients referred to our CO service between March 2016 and December 2019 were included in the study. A total of 2762 (77% females) patients at the mean (SD) age of 62 (12) years were referred (63% on an out-patient basis) for general consultations. The most frequent diagnosis was breast cancer (66%). In 18% of patients, the reason of referral to the CO service was cancer treatment related CV complications. A total of 652 patients (515 patients with a cardiac implantable electronic device (CIED) qualified for radiotherapy (RT), 48 patients with CIEDs diagnosed with magnetic resonance imaging (MRI), and 89 patients with CIED treated with cancer surgery) were evaluated by the CO-CIED team. During the total of 5,872 RT sessions, two harmful interactions and no other complications during MRI and surgery were recorded. CONCLUSIONS  The CO-service established within the cancer center seems to be safe and feasible.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 BACKGROUND  A small number of female cardiologists work in the interventional cardiology (IC) field. This disparity is observed in most European countries. AIMS  We present the first national report on the practice patterns and outcomes of percutaneous coronary interventions (PCIs) performed by female operators (FOs) in Poland. METHODS  Data were collected from the National Registry of Invasive Cardiology Procedures (ORPKI) between January 2014 and December 2017. RESULTS  A total of 31 (4.1%) FOs performed 12 935 (2.8%) PCIs. The median number of PCIs performed by FOs per year was 75 (interquartile range [IQR]  43 - 154), whereas that by male operators (MOs) was 139 (IQR  67 - 216) (P &lt; 0.01). FOs&#39; patients were characterized with a lower prevalence of cardiovascular risk factors and previous coronary artery interventions. The main indication for treatment was acute coronary syndrome (74.66%). Compared with MOs, FOs handled significantly more patients with single-vessel disease (87.02% vs 84.72%, P &lt; 0.001). FOs used smaller contrast doses during PCIs (170.36 [77.54] ccm vs 173.48 [77.54] ccm, P &lt; 0.001) but higher radiation exposures (843 [IQR  472 - 1409] mGy vs 815 [IQR  458 - 1390] mGy, P = 0.01). There was no difference in clinical outcomes (a composite of all-cause death, bleeding at puncture site, or coronary artery perforation) based on operators&#39; gender. CONCLUSIONS  Women represent a minority of operators in IC and are responsible for a small percentage of PCIs. Nonetheless, the practice patterns and outcomes of PCIs performed by FOs are comparable with those of male operators.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 BACKGROUND  It is well known that the prevalence of obesity, cardiovascular disease, and metabolic syndrome is increasing during the transition to menopausal stages. The aim of this study was to investigate the effects of acute step-aerobic exercise on levels of leptin and adiponectin, which are adipose tissue-derived adipocytokines, and associated with obesity and hypertension, etc, in sedentary premenopausal women. METHODS  Twenty-four sedentary pre-menopausal volunteer women between the ages of 40-45 (pre-menopause group) and 24 healthy adults between the ages of 21-39 (control group) were enrolled in this study. Moderate intensity step-aerobic exercise (50-60 % of HRMax) was applied for 60 min to the premenopausal subjects. Venous blood samples were obtained before and after the exercise. Adiponectin and leptin levels were determined, using the ELISA method. RESULTS  No statistically significant difference was found in terms of BMI values, and leptin levels between the pre-menopause and control group, while differences of adiponectin were statistically significant. Plasma leptin levels of the pre-menopausal women decreased whereas adiponectin levels increased meaningfully after the acute aerobic exercise (p&lt;0.05). When the pre-menopausal women were grouped according to BMI, there were no significant differences between BMI &lt;/=30 and&gt; 30 groups in terms of leptin and adiponectin levels measured before and after exercise. CONCLUSIONS  In conclusion, our results may suggest that acute step aerobic exercise in premenopausal women alters leptin and adiponectin levels in favor of the organism, but further studies are needed.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 BACKGROUND  It is well known that the prevalence of obesity, cardiovascular disease, and metabolic syndrome is increasing during the transition to menopausal stages. The aim of this study was to investigate the effects of acute step-aerobic exercise on levels of leptin and adiponectin, which are adipose tissue-derived adipocytokines, and associated with obesity and hypertension, etc, in sedentary premenopausal women. METHODS  Twenty-four sedentary pre-menopausal volunteer women between the ages of 40-45 (pre-menopause group) and 24 healthy adults between the ages of 21-39 (control group) were enrolled in this study. Moderate intensity step-aerobic exercise (50-60 % of HRMax) was applied for 60 min to the premenopausal subjects. Venous blood samples were obtained before and after the exercise. Adiponectin and leptin levels were determined, using the ELISA method. RESULTS  No statistically significant difference was found in terms of BMI values, and leptin levels between the pre-menopause and control group, while differences of adiponectin were statistically significant. Plasma leptin levels of the pre-menopausal women decreased whereas adiponectin levels increased meaningfully after the acute aerobic exercise (p&lt;0.05). When the pre-menopausal women were grouped according to BMI, there were no significant differences between BMI &lt;/=30 and&gt; 30 groups in terms of leptin and adiponectin levels measured before and after exercise. CONCLUSIONS  In conclusion, our results may suggest that acute step aerobic exercise in premenopausal women alters leptin and adiponectin levels in favor of the organism, but further studies are needed.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 BACKGROUND  Patients with chronic kidney disease (CKD) often have multivessel coronary artery disease and the risk of acute kidney injury (AKI) after percutaneous coronary interventions (PCI) is high. The aim of this study was to evaluate the risk of AKI in patients with CKD who underwent single vessel PCI versus multivessel PCI. METHODS  We retrospectively screened all PCI performed from January 2011 to December 2017 and we included all the procedures performed in patients with a baseline glomerular filtration rate &lt;60 ml/min/1.73 m2. PCI were divided in two groups according to the treatment of a single vessel (Mono Group) or multivessel PCI (Multi Group). The Multi Group was also divided in two subgroups according to the modality of PCI  multivessel PCI performed in one procedure (Multi-Single session Group) or in multiple staged procedures (Multi-Staged Group). RESULTS  From a total of 4517 PCI screened, 848 PCI were included, 530 in the Mono Group and 318 in the Multi Group. The global rate of AKI was around 15% without significant differences between the Mono and the Multi Group (15.5% in the Mono and 14.8% in the Multi Group, p=0.786). In the Multi Group the risk of AKI was significantly higher in the Single session sub-group (21.4%) compared to the staged sub-group (11.2%, p= 0.014). CONCLUSIONS  In patients with CKD, the risk of AKI did not differ in patients who underwent single vessel versus multivessel PCI, but multivessel PCI should be performed in multiple staged procedures rather than in a single session.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 BACKGROUND  Long term efficacy and safety of either surgical or percutaneous treatment left main coronary artery disease treatment is lacking. METHODS  We conducted a systematic review and meta-analysis of the most updated randomized clinical trials that compared the efficacy of coronary artery bypass surgery (CABG) or percutaneous coronary intervention (PCI) for the Left Main Coronary Artery (LMCA) disease. RESULTS  We identified 6 studies, providing data on 5812 patients. The mean follow-up was 6.7 years. PCI was associated with an increased risk of major vascular events (MACE) (IRR 1.24, 95% confidence interval (CI) [1.03-1.67], p&lt;0.01), and coronary revascularization (IRR 1.69, 95% CI [1.42-2.03], p&lt;0.01) compared to CABG. Furthermore, all-cause death, MI and stroke events were not statistically different between the two therapeutic revascularization methodologies (IRR 1.06, 95% CI [0.90-1.24], p=0.47, IRR 1.35, 95% CI [0.84-2.16], p=0.03 and IRR 0.66, 95% CI [0.43-1.01], p=0.05, respectively). CONCLUSIONS  LMCA PCI has an overall same survival compared to CABG in the long term follow up. Nevertheless, MACE and revascularization events were more frequent in PCI compared to CABG.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,
 OBJECTIVE  To investigate pulmonary histopathologic features in a cohort of pediatric patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) who underwent a lung biopsy as part of their evaluation. We report the safety and the findings of lung biopsies in this population. METHODS  After IRB approval, we performed a retrospective chart review of all patients &lt;18 years of age presenting to our institution with a diagnosis of pediatric AAV (pAAV) who underwent lung biopsy. We reviewed histopathologic features, serologies, the timing of biopsy, and complications. RESULTS  Fourteen patients met inclusion criteria, nine patients with microscopic polyangiitis (MPA), and five patients with granulomatosis with polyangiitis (GPA). All patients had positive ANCA serology. 13/14 patients required admission on initial presentation for respiratory symptoms; 11/13 required respiratory support. The indication for biopsy was confirmation of diagnosis before initiating therapy in 11 patients (78%), part of the infectious evaluation in two (14%), and part of interstitial lung disease evaluation in one (7%). 11/14 (78%) biopsies had findings consistent with AAV diagnosis  6/9 (67%) of the MPA patients compared with 5/5 (100%) of the GPA patients. The most common findings on histopathology were vascular inflammation and signs of alveolar hemorrhage. The only reported complication after lung biopsy was pneumothorax in four patients (28%). CONCLUSION  Lung biopsy had a higher diagnostic yield in GPA compared with MPA patients. In our cohort, a diagnosis of AAV could be made with clinical features and positive serology but was confirmed by lung histopathology in the majority of cases. Obtaining a lung biopsy for diagnostic purposes in pAAV should be reserved for uncertain cases where the diagnosis cannot be confirmed clinically and with serology.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlud</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Inflammatory diseases,Diseases of arteries,Coagulopathies,
 BACKGROUND  Left atrial appendage closure (LAAC) became an alternative method for stroke prevention in patients with non-valvular atrial fibrillation (AF) intolerant to long term oral anticoagulation therapy. This study aimed to compare endocardial (Amulet and LAmbere occluders) and epicardial (Lariat) LAAC techniques. METHODS  A retrospective, observational case control study included 223 consecutive CHA2 DS2 -VAS-score matched patients with AF who underwent LAAC in two centers. RESULTS  There were 55 matched cases with the mean CHA2 DS2 - VASs score 4.4 +/- 1.22 (p=1). Overall follow-up was 308.2 patient-years. The Endocardial group patients were older and more often females with congestive heart failure and peripheral vascular disease. The epicardial group more frequently had a stroke/TIA history. There were no differences in hypertension, diabetes mellitus and indications for procedure between both groups. The mean HAS-BLED score was significantly higher in the Endocardial group than in the Epicardial group (4.3 +/- 0.9 vs. 3.7 +/- 1.3, p=0.011). There were no differences in annual rates of thromboembolic events (2.6% vs 0.5%) and annual stroke (0.87% vs. 0%) between the Endocardial and Epicardial groups. CONCLUSION  Endocardial and Epicardial LAAC techniques shows comparable implantation outcomes and safety profile and stroke prevention in patients with AF. Future randomized studies are needed to corroborate these initial results and assess long term mortality. This article is protected by copyright. All rights reserved.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">stenos</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Diseases of arteries,
 OBJECTIVE  In hypertension, indexes of midwall left ventricular (LV) function may identify patients at higher cardiovascular (CV) risk independent of normal LV ejection fraction (EF). We analyzed the association of baseline and new-onset LV midwall dysfunction with CV outcome in a large population of patients with asymptomatic aortic stenosis (AS). METHODS  One thousand four hundred seventy-eight patients with asymptomatic AS and normal EF (&gt;/=50%) at baseline in the Simvastatin Ezetimibe in Aortic Stenosis (SEAS) study were followed for a median of 4.3 years. LV systolic function was assessed by biplane EF and midwall shortening (MWS, low if &lt;14% in men/16% in women) at baseline and annual echocardiographic examinations. RESULTS  One hundred twenty-three CV deaths and heart failure hospitalizations occurred during follow-up. In Cox analyses, adjusting for age, gender, body mass index, hypertension, EF, AS severity, LV hypertrophy and systemic arterial compliance, low baseline MWS predicted 61% higher risk of a major CV event and a twofold higher risk of death and heart failure hospitalization (P &lt; .05). New-onset low MWS developed in 574 patients, particularly in elderly women with higher blood pressure and more severe AS (P &lt; .05). In time-varying Cox analysis, new-onset low MWS was associated with a twofold higher risk of CV death and heart failure hospitalization, independent of changes over time in EF, AS severity, LV hypertrophy and systemic arterial compliance (P &lt; .05). CONCLUSIONS  Low MWS develops in a large proportion of patients with AS and normal EF during valve disease progression and is a marker of increased CV risk.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Vitamin D deficiency is associated with acute myocardial infarction (AMI), thus we aimed to explore improvement effects of 1, 25-dihydroxyvitamin D3 (VD3) on the AMI and its potential mechanism. AMI models were constructed using male C57/BL6J mice and randomly treated with normal saline or VD3, using sham rats as control. Heart functions, myocardial damage, apoptosis and inflammation were evaluated. Cardiomyocytes isolated from 3-days-old suckling mice were used for in vitro verification. After VD3 treatment, AMI-induced cardiac dysfunction was reversed with better cardiac function parameters. VD3 treatment reduced inflammatory cell infiltration and myocardial infarction area accompanied by reduction of inflammatory factors and myocardial infarction markers compared to AMI group. VD3 treatment obviously alleviated AMI-induced myocardial apoptosis, along with Bcl-2 up-regulation and down-regulation of caspase-3, caspase-9 and Bax. Both in vivo and in vitro experiments revealed that VD3 enhanced expression of LC3II and Beclin-1 and decreased soluble p62. Furthermore, VD3 enhanced the AMI-caused inhibition of PI3K, p-AKT and p-mTOR expression, which was conversely reversed by addition of 3-methyladenine in vitro. The study highlights the improvement effects of VD3 on cardiac functions. We proposed a potential mechanism that VD3 protects against myocardial damage, inflammation and apoptosis by promoting autophagy through PI3K/AKT/mTOR pathway. This article is protected by copyright. All rights reserved.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 BACKGROUND  Obesity is a global pandemic characterized by multiple comorbidities, including cardiovascular and metabolic diseases. The aim of this study was to define the associations between blood donor body mass index (BMI) and RBC measurements of metabolic stress and hemolysis. STUDY DESIGN AND METHODS  The associations between donor BMI (&lt;25 kg/m(2) , normal weight; 25-29.9 kg/m(2) , overweight; and &gt;/=30 kg/m(2) , obese) and hemolysis (storage, osmotic, and oxidative; n = 18 donors) or posttransfusion recovery (n = 14 donors) in immunodeficient mice were determined in stored leukocyte-reduced RBC units. Further evaluations were conducted using the National Heart, Lung, and Blood Institute RBC-Omics blood donor databases of hemolysis (n = 13 317) and metabolomics (n = 203). RESULTS  Evaluations in 18 donors revealed that BMI was significantly (P &lt; 0.05) and positively associated with storage and osmotic hemolysis. A BMI of 30 kg/m(2) or greater was also associated with lower posttransfusion recovery in mice 10 minutes after transfusion (P = 0.026). Multivariable linear regression analyses in RBC-Omics revealed that BMI was a significant modifier for all hemolysis measurements, explaining 4.5%, 4.2%, and 0.2% of the variance in osmotic, oxidative, and storage hemolysis, respectively. In this cohort, obesity was positively associated (P &lt; 0.001) with plasma ferritin (inflammation marker). Metabolomic analyses on RBCs from obese donors (44.1 +/- 5.1 kg/m(2) ) had altered membrane lipid composition, dysregulation of antioxidant pathways (eg, increased oxidized lipids, methionine sulfoxide, and xanthine), and dysregulation of nitric oxide metabolism, as compared to RBCs from nonobese (20.5 +/- 1.0 kg/m(2) ) donors. CONCLUSIONS  Obesity is associated with significant changes in RBC metabolism and increased susceptibility to hemolysis under routine storage of RBC units. The impact on transfusion efficacy warrants further evaluation.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocardit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">cardit</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 BACKGROUND  The ventricular septum (VS) is considered a single functional wall. However, a line with high echogenicity in the middle of the VS could be detected with the recent echocardiographic modalities which separate the left from the right side of the VS. Our study aimed to evaluate functional differences between both sides of VS by tissue Doppler and Speckle Tracking Imaging (STI) in children with Systemic lupus erythematosus (SLE). SUBJECTS AND METHODS  This is a case-control study that included 40 children divided into 20 active SLE patients and 20 healthy children matched for age and sex as controls. Tissue Doppler imaging from the VS was performed with the region of interest was positioned in both sides at the mid-part of the septum. Longitudinal strain of both sides of the VS was obtained by (STI). Ejection fraction (EF) of the right and left ventricles were assessed by real-time 3-dimensional echocardiography. RESULTS  There was significant impaired S`, E, A, compared with controls. STI of the VS showed significant affection of the left side regarding systolic strain (SS) and strain rate late diastole (SRDA). However, strain rate systole (SRS) and strain rate early diastole (SRED) are affected on both sides of VS compared with control. A and SRDE of the left VS correlated significantly with SLEDAI (P &lt;/= .05). E of the right VS correlated with the duration of the disease (P &lt;/= .05). CONCLUSION  Bilayer analysis of VS could helps in the evaluation of right and left ventricular functions in subclinical myocarditis in SLE patients.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Cardiomyopathy,
 Exposure to air pollutants such as ozone (O3) is associated with adverse pregnancy outcomes, including higher incidence of gestational hypertension, preeclampsia and peripartum cardiomyopathy; however, the underlying mechanisms of this association remain unclear. We hypothesized that O3 exposures during early placental formation would lead to more adverse cardiovascular effects at term for exposed dams, as compared to late-term exposures. Pregnant Sprague-Dawley rats were exposed (4 h) to either filtered air (FA) or O3 (0.3 or 1.0 ppm) at either gestational day (GD)10 or GD20, with longitudinal functional assessments and molecular endpoints conducted at term. Exposure at GD10 led to placental transcriptional changes at term that were consistent with markers in human preeclampsia, including reduced mmp10 and increased cd36, fzd1, and col1a1. O3 exposure, at both early and late gestation, induced a significant increase in maternal circulating soluble FMS-like tyrosine kinase-1 (sFlt-1), a known driver of preeclampsia. Otherwise, exposure to 0.3 ppm O3 at GD10 led to several late-stage cardiovascular outcomes in dams that were not evident in GD20-exposed dams, including elevated uterine artery resistance index and reduced cardiac output and stroke volume. GD10 O3 exposure proteomic profile in maternal hearts characterized by a reduction in proteins with essential roles in metabolism and mitochondrial function, while phosphoproteomic changes were consistent with pathways involved in cardiomyopathic responses. Thus, the developing placenta is an indirect target of inhaled O3 and that systemic maternal cardiovascular abnormalities may be induced by O3 exposure at a specific window of gestation.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Cardiomyopathy,
 Exposure to air pollutants such as ozone (O3) is associated with adverse pregnancy outcomes, including higher incidence of gestational hypertension, preeclampsia and peripartum cardiomyopathy; however, the underlying mechanisms of this association remain unclear. We hypothesized that O3 exposures during early placental formation would lead to more adverse cardiovascular effects at term for exposed dams, as compared to late-term exposures. Pregnant Sprague-Dawley rats were exposed (4 h) to either filtered air (FA) or O3 (0.3 or 1.0 ppm) at either gestational day (GD)10 or GD20, with longitudinal functional assessments and molecular endpoints conducted at term. Exposure at GD10 led to placental transcriptional changes at term that were consistent with markers in human preeclampsia, including reduced mmp10 and increased cd36, fzd1, and col1a1. O3 exposure, at both early and late gestation, induced a significant increase in maternal circulating soluble FMS-like tyrosine kinase-1 (sFlt-1), a known driver of preeclampsia. Otherwise, exposure to 0.3 ppm O3 at GD10 led to several late-stage cardiovascular outcomes in dams that were not evident in GD20-exposed dams, including elevated uterine artery resistance index and reduced cardiac output and stroke volume. GD10 O3 exposure proteomic profile in maternal hearts characterized by a reduction in proteins with essential roles in metabolism and mitochondrial function, while phosphoproteomic changes were consistent with pathways involved in cardiomyopathic responses. Thus, the developing placenta is an indirect target of inhaled O3 and that systemic maternal cardiovascular abnormalities may be induced by O3 exposure at a specific window of gestation.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 Angiotensin converting enzyme (ACE) is well-known for its role in blood pressure regulation via the renin-angiotensin aldosterone system (RAAS) but also functions in fertility, immunity, haematopoiesis and diseases such as obesity, fibrosis and Alzheimer&#39;s dementia. Like ACE, the human homologue ACE2 is also involved in blood pressure regulation and cleaves a range of substrates involved in different physiological processes. Importantly, it is the functional receptor for severe acute respiratory syndrome (SARS)-coronavirus (CoV)-2 responsible for the 2020, coronavirus infectious disease 2019 (COVID-19) pandemic. Understanding the interaction between SARS-CoV-2 and ACE2 is crucial for the design of therapies to combat this disease. This review provides a comparative analysis of methodologies and findings to describe how structural biology techniques like X-ray crystallography and cryo-electron microscopy have enabled remarkable discoveries into the structure-function relationship of ACE and ACE2. This, in turn, has enabled the development of ACE inhibitors for the treatment of cardiovascular disease and candidate therapies for the treatment of COVID-19. However, despite these advances the function of ACE homologues in non-human organisms is not yet fully understood. ACE homologues have been discovered in the tissues, body fluids and venom of species from diverse lineages and are known to have important functions in fertility, envenoming and insect-host defence mechanisms. We, therefore, further highlight the need for structural insight into insect and venom ACE homologues for the potential development of novel anti-venoms and insecticides.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocardit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocard</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">cardit</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Bartonella spp. are re-emerging and neglected bacterial pathogens. The natural reservoirs for several species of this genus are domestic animals such as cats and dogs, the most common pets in the USA and Brazil. Some cat studies suggest that the infection is more prevalent in tropical and poverty-stricken areas. These bacteria were associated with a wide spectrum of clinical manifestations  fever of unknown origin, endocarditis, angiomatosis, chronic lymphadenopathy, hepatitis, fatigue, paresthesia and pain. Our group has already demonstrated that B. henselae -infected sickle cell disease mice present with hyperalgesia. We hypothesized that even immunocompetent mice infected by B. henselae would show an increased and persistent mechanical sensitivity. Five ten-week old male BALB/c mice were intraperitoneally inoculated with a 30 microL of suspension containing 10 4 CFU/mL of B. henselae, while five others were inoculated with an equal volume of saline solution. Four days after bacterial inoculation, the mechanical paw withdrawal threshold was measured using von Frey filaments in all animals, for five consecutive days. The infected animals showed hypersensitivity to mechanical stimuli for five consecutive days. The present study has demonstrated that B. henselae infection induces persistent mechanical hypersensitivity, a signal consistent with pain.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 OBJECTIVE  To present the methodological approach used in a research that analyzed the use and performance of specialized health care, from primary care access, in four major Brazilian cities  Fortaleza (CE), Campinas (SP), Sao Paulo (SP) and Porto Alegre (RS). METHODS  Presentation and discussion of the quantitative-qualitative components of the proposed research strategy. RESULTS  Four tracing conditions were studied  systemic arterial hypertension, high-risk pregnancy, breast cancer and severe mental disorder. For each health condition, indicators were constructed based on health information systems data, pointing out frequencies, temporal trends and local differences. This initial contextualization was enriched with a descriptive-qualitative study of the performance of each municipal health service network. Next, a cross-sectional study was conducted through a survey of 7,053 users of specialized services for each health condition. Finally, in-depth interviews were conducted with key actors to complement selected operational aspects of each municipality&#39;s network. The results of all these data sources were triangulated, allowing us to explore the variability of SUS implementations in different regional scenarios. CONCLUSIONS  The multifaceted analytical model presented allows us to understand relevant aspects of the Unified Health System performance, paying attention to the singularities, heterogeneities and inequalities that characterize its implementation in Brazil and emphasizing the performance of local networks for the addressed health conditions.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Coagulopathies,
 Intracerebral hemorrhage (ICH), defined as bleeding into the brain parenchyma, is a significant public health issue. Although it accounts for only 10 to 15% of strokes, it is associated with the highest morbidity and mortality rates. Despite advances in the field of stroke and neurocritical care, the principles of acute management have fundamentally remained the same over many years. The main treatment strategies include aggressive blood pressure control, early hemostasis, reversal of coagulopathies, clot evacuation through open surgical or minimally invasive surgical techniques, and the management of raised intracranial pressure.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 The sympathetic nervous system (SNS) plays a fundamental role in the pathophysiology of cardiovascular diseases, including primary arterial hypertension. In this study, we aimed to investigate whether the expression of the rate-limiting enzyme in catecholamine synthesis, tyrosine hydroxylase (TH), and the beta2-adrenergic receptor (beta2-AR) in immune cells from peripheral blood, reflect central SNS activity in spontaneously hypertensive rats (SHR). TH expression in the lower brainstem and adrenal glands and beta2-AR expression in the lower brainstem were analyzed by western blot analyses. In the leukocytes, TH and beta2-AR expression was evaluated by flow cytometry before and after chronic treatment with the centrally-acting sympathoinhibitory drug clonidine. Western blot analyses showed increased TH and beta2-AR expression in the lower brainstem and increased TH in adrenal glands from SHR compared to normotensive Wistar Kyoto rats (WKY). Lower brainstem from SHR treated with clonidine presented reduced TH and beta2-AR levels, and adrenal glands had decreased TH expression compared to SHR treated with vehicle. Flow cytometry showed that the percentage of leukocytes that express beta2-AR is higher in SHR than in WKY. However, the percentage of leukocytes that expressed TH was higher in WKY than in SHR. Moreover, chronic treatment with clonidine normalized the levels of TH and beta2-AR in leukocytes from SHR to similar levels of those of WKY. Our study demonstrated that the percentage of leukocytes expressing TH and beta2-AR was altered in arterial hypertension and can be modulated by central sympathetic inhibition with clonidine treatment.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">stenos</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Diseases of arteries,
 This study aimed to explore the association between serum non-high-density lipoprotein cholesterol (non-HDL-C) and cognitive dysfunction risk in patients with acute ischemic stroke (AIS). This cross-sectional study enrolled 583 AIS patients. Biochemical markers and lipid profile were collected after admission. AIS patients were classified into high group (non-HDL-C &gt;/=3.4 mM) and normal group (non-HDL-C &lt;3.4 mM). Mini-Mental State Examination scale (MMSE), Montreal Cognitive Assessment scale (MoCA), Activities of Daily Living (ADL) scale, Neuropsychiatric Inventory (NPI), and Hamilton Depression scale 21 version (HAMD-21) were applied on the third day after admission. Compared with the control group, patients of the high group had higher body mass index and higher frequency of intracranial artery stenosis, and exhibited higher levels of non-HDL-C, total cholesterol, triglycerides, low-density lipoprotein cholesterol, homocysteine, fasting blood glucose, and glycosylated hemoglobin (HbA1c), and lower levels of high-density lipoprotein cholesterol (all P&lt;0.05). Compared with the control group, patients of the high group had significantly lower MMSE and MoCA scores (MMSE  26.01+/-4.17 vs 23.12+/-4.73, P&lt;0.001; MoCA  22.28+/-5.28 vs 20.25+/-5.87, P&lt;0.001) and higher scores on the NPI and HAMD-21 (both P&lt;0.001). MMSE (r=-0.306, P&lt;0.001) and MoCA scores (r=-0.251, P&lt;0.001) were negatively associated with non-HDL-C level. Multivariate regression analysis revealed that non-HDL-C level (OR=1.361, 95%CI  1.059-1.729, P=0.016) was independently associated with the presence of cognitive dysfunction after adjusting for confounding factors. High serum non-HDL-C level might significantly increase the risk of cognitive dysfunction after AIS.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">dil cardiomyopathy</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Cardiomyopathy,
 We aimed to investigate the association of CD14 -260C/T (rs2569190) polymorphism and Chagas cardiomyopathy and the functional characteristics of CD14+ and CD14- monocytes upon infection with Trypanosoma cruzi. We observed an association between the T- genotype (absence of allele -260T) related to low CD14 expression and the dilated cardiomyopathy type of Chagas disease. Furthermore, we observed that CD14- monocytes showed a more activated profile upon in vitro infection with T. cruzi than CD14+ monocytes. Our findings suggest that T- genotype is associated with susceptibility to develop Chagas dilated cardiomyopathy, likely linked to the T. cruzi-induced inflammatory profile of CD14- monocytes.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 BACKGROUND  Population-wide screening for prostate cancer remains a controversial topic, given the need for an individualized approach to patients regarding the risks and benefits of prostate-specific antigen testing and digital rectal examination. OBJECTIVE  The aim of this study was to investigate the prevalence of, and factors associated with, prostate examination among men aged 45 or older. DESIGN AND SETTING  Cross-sectional population-based study developed in the city of Rio Grande (RS), Brazil. METHODS  The outcome of interest was a history of prostate examination (prostate-specific antigen testing or digital rectal examination). The following independent variables were analyzed  age group, skin color, marital status, schooling, economic level, leisure-time physical activity, smoking habits, excessive alcohol consumption, overweight, health insurance, visits to the doctor during the preceding year, hypertension and diabetes. After a two-stage sampling process, the final sample consisted of 281 male individuals. RESULTS  The prevalence of a history of prostate-specific antigen testing or digital rectal examination was 68.3% (95% confidence interval (CI)  62.2 to 74.5). The highest prevalence rates were observed among men aged 70 years or older (88%) and the lowest among smokers (36%). The following characteristics were found to be associated with the outcome  advanced age; marital status other than single; more schooling and higher economic status; practicing physical activity; non-smoking habits; overweight; having health insurance; and having visited a doctor during the preceding year. CONCLUSION  Approximately two thirds of the study population had been screened for prostate examination, mostly older individuals, with higher socioeconomic status and a healthier lifestyle.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Prosthetic heart valve replacement is an effective therapy for patients with valvular heart disease. New-type polymer materials provide potential choices of material for preparing prosthetic heart valves. In this study, we focused on enhancing the biocompatibility of polystyrene-block-isobutylene-block-styrene (SIBS) by surface modification with an extracellular matrix (ECM). Experimental results demonstrated that the ECM coating increased the adsorption resistance against protein and platelets. SIBS coated with an ECM adsorbed much less bovine serum albumin and fibrinogen (5.38 mug cm-2 and 31.53 mug cm-2, respectively) than the original material (90.84 mug cm-2 and 132.38 mug cm-2, respectively). The relative platelet adsorption of the ECM-modified SIBS was lower than that of SIBS (0.04 versus 0.10). Moreover, the surface coating could also reduce endothelial cytotoxicity, suppress the immune response, and potentially induce tissue regeneration. In conclusion, ECM coating improved the biocompatibility of SIBS effectively.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">stenos</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 AIMS  The objective of this study is to assess the prognostic effects of T ranscatheter aortic valve replacement (TAVR) on the patients with different degrees of left ventricular systolic (LVS) function and severe symptomatic aortic stenosis. Also examines the prognostic association of LV remodelling after TAVR. METHODS AND RESULTS  Patients stratified into four subgroups with respect to baseline LV ejection fraction (LVEF) (LVEF &gt; 25%, LVEF 25%-40%, LVEF 41%-49% and LVEF &gt;/= 50%). We compared the baseline characteristics and temporal changes in echocardiographic parameters of the patients after TAVR, and determined all-cause mortality (ACM) in a follow-up period of mean 20.7 +/- 15.8 months (up to 84). There were 495 patients at 8 centres. ACM was similar in all groups (28.1%, 29.5%, 22.5% and 24.1% respectively; p = .44). Immediately after TAVR, there was an improvement in LVEF (from 38.7 +/- 9.4 to 44.9% +/- 10.9%, p &lt; .001). The percent change in LVEF (pDelta-EF) immediately after TAVR was more prominent in the patients with LVEF &lt; 25% (48.1 +/- 49.6, 21.9 +/- 29.6), (8.4% +/- 15.2%) and (2.1 +/- 7)) (p &lt; .01). Importantly, a 12% increase in absolute Delta-EF was observed in patients with LVEF&lt; 25% with 100% sensitivity and 42.5% specificity for the prediction of ACM. CONCLUSION  This study shows that TAVR is beneficial in the whole range of LVS function, irrespective of the baseline EF. Early recovery in LVEF after TAVR is critical for survival, however, it seems to be more eye catching in the patients with advanced heart failure with reduced EF.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-magenta-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">arrhythm</span>,
<span class="ansi-bold">Embeded topics: </span>Arrhythmia,
 Background &#34;Palpitations&#34; are one of the most common complaints prompting medical attention. Textbooks of medicine and cardiology as well as guideline documents and position papers describe palpitations as a common symptom of ventricular tachycardia (VT). However, data to support this description are lacking. The aim of our study was to evaluate the symptomatology of sustained monomorphic VT with emphasis on the prevalence of palpitations. Methods and Results Consecutive patients presenting to our center with a first event of a regular sustained monomorphic VT (n=59) or a regular supraventricular tachycardia (SVT; n=109) between January 2012 and September 2019 were interviewed regarding their symptoms during the arrhythmic event. We included only patients with a first arrhythmic event to avoid the influence of previous medical encounters on our patients&#39; terminology. As expected, patients with VT were older (age 68.8+/-13.6 versus 52.6+/-16.8 years; P&lt;0.001), more often of male sex (94.9% versus 37.6%; P&lt;0.001), had lower left ventricular ejection fraction (37+/-11% versus 59+/-2%, P&lt;0.001) and more comorbidities (87.6% versus 40.5%; P&lt;0.001) compared with patients with SVT. Importantly, even though the heart rate upon presentation did not differ between the 2 groups (165+/-26 beats/min during VT versus 171+/-32 beats/min during SVT; P=0.16), symptomatology differed significantly; specifically, palpitations were reported in only 8.8% of VT patients, compared with 90.7% of SVT patients (P&lt;0.001). Common symptoms in the VT group included chest pain (64%), dyspnea (21%), and dizziness (26%). Conclusions Despite similar heart rate, patients with VT rarely report having palpitations, whereas patients with SVT do so commonly. This finding may assist with decision making in patients reporting palpitations in whom an ECG tracing is not available.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 Background We investigated changes in right atrial pressure (RAP) during exercise and their prognostic significance in patients assessed for pulmonary hypertension (PH). Methods and Results Consecutive right heart catheterization data, including RAP recorded during supine, stepwise cycle exercise in 270 patients evaluated for PH, were analyzed retrospectively and compared among groups of patients with PH (mean pulmonary artery pressure [mPAP] &gt;/=25 mm Hg), exercise-induced PH (exPH; resting mPAP &lt;25 mm Hg, exercise mPAP &gt;30 mm Hg, and mPAP/cardiac output &gt;3 Wood Units (WU)), and without PH (noPH). We investigated RAP changes during exercise and survival over a median (quartiles) observation period of 3.7 (2.8-5.6) years. In 152 patients with PH, 58 with exPH, and 60 with noPH, median (quartiles) resting RAP was 8 (6-11), 6 (4-8), and 6 (4-8) mm Hg (P&lt;0.005 for noPH and exPH versus PH). Corresponding peak changes (95% CI) in RAP during exercise were 5 (4-6), 3 (2-4), and -1 (-2 to 0) mm Hg (noPH versus PH P&lt;0.001, noPH versus exPH P=0.027). RAP increase during exercise correlated with mPAP/cardiac output increase (r=0.528, P&lt;0.001). The risk of death or lung transplantation was higher in patients with exercise-induced RAP increase (hazard ratio, 4.24; 95% CI, 1.69-10.64; P=0.002) compared with patients with unaltered or decreasing RAP during exercise. Conclusions In patients evaluated for PH, RAP during exercise should not be assumed as constant. RAP increase during exercise, as observed in exPH and PH, reflects hemodynamic impairment and poor prognosis. Therefore, our data suggest that changes in RAP during exercise right heart catheterization are clinically important indexes of the cardiovascular function.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">stenos</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 Background Failure rates after revascularization surgery remain high, both in vein grafts (VG) and arterial interventions. One promising approach to improve outcomes is endogenous upregulation of the gaseous transmitter-molecule hydrogen sulfide, via short-term dietary restriction. However, strict patient compliance stands as a potential translational barrier in the vascular surgery patient population. Here we present a new therapeutic approach, via a locally applicable gel containing the hydrogen sulfide releasing prodrug (GYY), to both mitigate graft failure and improve arterial remodeling. Methods and Results All experiments were performed on C57BL/6 (male, 12 weeks old) mice. VG surgery was performed by grafting a donor-mouse cava vein into the right common carotid artery of a recipient via an end-to-end anastomosis. In separate experiments arterial intimal hyperplasia was assayed via a right common carotid artery focal stenosis model. All mice were harvested at postoperative day 28 and artery/graft was processed for histology. Efficacy of hydrogen sulfide was first tested via GYY supplementation of drinking water either 1 week before VG surgery (pre-GYY) or starting immediately postoperatively (post-GYY). Pre-GYY mice had a 36.5% decrease in intimal/media+adventitia area ratio compared with controls. GYY in a 40% Pluronic gel (or vehicle) locally applied to the graft/artery had decreased intimal/media area ratios (right common carotid artery) and improved vessel diameters. GYY-geltreated VG had larger diameters at both postoperative days 14 and 28, and a 56.7% reduction in intimal/media+adventitia area ratios. Intimal vascular smooth muscle cell migration was decreased 30.6% after GYY gel treatment, which was reproduced in vitro. Conclusions Local gel-based treatment with the hydrogen sulfide-donor GYY stands as a translatable therapy to improve VG durability and arterial remodeling after injury.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-magenta-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">arrhythm</span>,
<span class="ansi-bold">Embeded topics: </span>Arrhythmia,
 Background Studies have shown that short-term exposure to air pollution is associated with cardiac arrhythmia hospitalization and mortality. However, the relationship between long-term particulate matter air pollution and arrhythmias is still unclear. We evaluate the prospective association between particulate matter (PM) air pollution and the risk of incident arrhythmia and its subtypes. Methods and Results Participants were drawn from a prospective cohort study of 178 780 men and women who attended regular health screening exams in Seoul and Suwon, South Korea, from 2002 to 2016. Exposure to PM with an aerodynamic diameter of &lt;/=10 and &lt;/=2.5 mum (PM10 and PM2.5, respectively) was estimated using a land-use regression model. The associations between long-term PM air pollution and arrhythmia were examined using pooled logistic regression models with time-varying exposure and covariables. In the fully adjusted model, the odds ratios (ORs) for any arrhythmia associated with a 10 mug/m(3) increase in 12-, 36-, and 60-month PM10 exposure were 1.15 (1.09, 1.21), 1.12 (1.06, 1.18), and 1.14 (1.08, 1.20), respectively. The ORs with a 10 mug/m(3) increase in 12- and 36-month PM2.5 exposure were 1.27 (1.15, 1.40) and 1.10 (0.99, 1.23). PM10 was associated with increased risk of incident bradycardia and premature atrial contraction. PM2.5 was associated with increased risk of incident bradycardia and right bundle-branch block. Conclusions In this large cohort study, long-term exposure to outdoor PM air pollution was associated with increased risk of arrhythmia. Our findings indicate that PM air pollution may be a contributor to cardiac arrhythmia in the general population.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coagulopathy</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Coagulopathies,
 BACKGROUND  Headache is a frequent complaint in COVID-19 patients. However, no detailed information on headache characteristics is provided in these reports. Our objective is to describe the characteristics of headache and the cerebrospinal fluid (CSF) profile in COVID-19 patients, highlighting the cases of isolated intracranial hypertension. METHODS  In this cross-sectional study, we selected COVID-19 patients who underwent lumbar puncture due to neurological complaints from April to May 2020. We reviewed clinical, imaging, and laboratory data of patients with refractory headache in the absence of other encephalitic or meningitic features. CSF opening pressures higher than 250 mmH2O were considered elevated, and from 200 to 250 mmH2O equivocal. RESULTS  Fifty-six COVID-19 patients underwent lumbar puncture for different neurological conditions. A new, persistent headache that prompted a CSF analysis was diagnosed in 13 (23.2%). The pain was throbbing, holocranial or bilateral in the majority of patients. All patients had normal CSF analysis and RT-qPCR for SARS-CoV-2 was negative in all samples. Opening pressure &gt;200 mmH2O was present in 11 patients and, in six of these, &gt; 250 mmH2O. 6/13 patients had complete improvement of the pain, five had partial improvement, and two were left with a daily persistent headache. CONCLUSIONS  In a significant proportion of COVID-19 patients, headache was associated to intracranial hypertension in the absence of meningitic or encephalitic features. Coagulopathy associated with COVID-19 could be an explanation, but further studies including post-mortem analysis of areas of production and CSF absorption (choroid plexuses and arachnoid granulations) are necessary to clarify this issue.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 INTRODUCTION  Limited information exists about the relationship between body mass index (BMI) and the outcome of acute respiratory distress syndrome (ARDS). OBJECTIVE  To evaluate the hospital mortality of patients with ARDS in relation to BMI. MATERIALS AND METHODS  We conducted a retrospective, multicenter study including patients with ARDS. ARDS was defined according to the Berlin criteria. Body weight and height were obtained to calculate BMI. The primary outcome was in-hospital mortality. Secondary outcomes were intensive care unit (ICU) mortality, invasive positive pressure ventilation (IPPV) free days within 28 days, and length of stays in the ICU and hospital. RESULTS  Among 523 patients, 28 (5%) were underweight (BMI &lt;18.5 kg/m(2) ), 299 (57%) were normal weight (BMI 18.5-24.9 kg/m(2) ), 159 (30%) were overweight (BMI 25-29.9 kg/m(2) ) and 37 (7%) were obese (BMI &gt;/=30 kg/m(2) ). Increasing BMI was associated with younger age (p=0.017), hypertension (p=0.003) and diabetes (p=0.02). Compared with normal weight, being overweight and obese resulted in lower mortality regardless of whether in the hospital (p=0.019) or ICU (p=0.044). However, after risk adjustment, only obesity was associated with lower hospital mortality (OR 0.393, 95% CI 0.169-0.914, p=0.030). With the increase of BMI, the in-hospital mortality and ICU mortality of ARDS dropped gradually (from 57.1% to 24.3%, p=0.021, and from 53.6% to 24.3%, p=0.035). CONCLUSIONS  Obesity is associated with lower mortality in patients with ARDS. With the increase of BMI, the mortality of ARDS drops gradually.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">rhe</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Inflammatory diseases,
 OBJECTIVE  To elucidate the association between sleep disturbances and blood pressure as well as uterine artery Doppler during pregnancy in women with no pre-existing hypertension. DESIGN  Prospective cohort study. SETTING  Outpatient specialist clinics at KK Women&#39;s and Children&#39;s Hospital, Singapore. POPULATION  Women with viable singleton pregnancies confirmed by ultrasonography at less than 14 weeks of amenorrhea at first visit. METHODS  926 subjects were recruited for this study in the outpatient specialist clinics at KK Women&#39;s and Children&#39;s Hospital, Singapore, between September 1, 2010, and August 31, 2014. They were followed up throughout pregnancy with sleep quality, blood pressure and uterine artery Doppler assessed at each visit. MAIN OUTCOME MEASURES  sleep quality, blood pressure and uterine artery Doppler. RESULTS  Sleep progressively worsened as pregnancy advances. Shorter sleep duration and poorer sleep efficiency were associated with higher blood pressure, especially in the first trimester. Mixed model analysis demonstrated overall positive association between sleep quality represented by Pittsburgh Sleep Quality Index (PSQI) score and diastolic blood pressure (DBP) (p&lt;0.001) and mean arterial pressure (MAP) (p=0.005) during pregnancy after considering all trimesters. Sleep duration was found to be negatively associated with both systolic blood pressure (SBP) (p=0.029) and DBP (p=0.002) while sleep efficiency is negatively correlated with DBP (p=0.002) only. Overall poor sleep during pregnancy was also found to be associated with higher uterine artery pulsatility index. CONCLUSION  Our prospective study demonstrated that poor sleep quality is significantly associated with higher blood pressure and uterine artery pulsatility index during pregnancy.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Due to their unique active movement ability, micro/nanomotors have brought about the possibility of breaking through the limitations of traditional passive drug delivery system for the treatment of many diseases, attracting more and more attention of researchers. However, at present, the realization of many advantages of micro/nanomotors in disease treatment in vivo is still in their infancy, which is caused by the complexity and particularity of diseases in different parts of human body. In this review, firstly, we focus on the biosafety and functionality of micro/nanomotors as a biomedical treatment system. Then, we address the treatment difficulties of various diseases in vivo (such as ophthalmic disease, orthopedic disease, gastrointestinal disease, cardiovascular disease and cancer), and then review the research progress of biomedical micro/nanomotors in the past 20 years, Finally, we propose the challenges faced in this field and possible future development directions.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">microvascul</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Inflammatory diseases,Diseases of arteries,
 Non-invasive screening for early diagnosis of coronary artery disease (CAD) represents a key element in the never-ending challenge to reduce cardiac death. Stress/rest electrocardiogram often lacks diagnostic accuracy, especially in asymptomatic patients, in fact the latest guidelines for the diagnosis and management of chronic coronary syndromes (CCS) stated the superiority of functional imaging techniques for the detection of subtle myocardial ischemia and the evaluation of myocardial viability (MV). Stress echocardiography is the most accessible and inexpensive imaging method for the study of CAD, either with pharmacological or with exercise provocative stress, based on visual wall-motion assessment. However, in some cases, such as small coronary lesions or microvascular angina, it loses its diagnostic power, therefore requiring a more sensitive approach. Accordingly, in the last years many authors investigated the possible additive value provided by the integration of an advanced but easy-to-obtain technique, that is speckle tracking imaging, to stress echocardiography, reaching promising results; nevertheless, its use is not included in the latest recommendations for CCS. The present review discusses the potential benefits from using a combination of speckle tracking and stress echocardiography for the early detection of myocardial ischemia and the assessment of MV and its suitability in different clinical scenarios, basing on the available evidence.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Cardiomyopathy,
 BACKGROUND  We previously reported that a high score (2 or 3 points) according to the Kumamoto criteria, a combination of high-sensitivity cardiac troponin T (hs-cTnT) &gt;/=0.308 ng/mL, the length of QRS &gt;/= 120 ms in electrocardiogram, and left ventricular (LV) posterior wall thickness &gt;/= 13.6 mm, increases the pretest probability of (99m) Tc-labeled pyrophosphate ((99m) Tc-PYP) scintigraphy in patients with suspected transthyretin amyloid cardiomyopathy (ATTR-CM). However, some patients with a low score (0 or 1 point) show positive findings on (99m) Tc-PYP scintigraphy. Therefore, we evaluated the usefulness of additional examinations, including echocardiographic assessment of myocardial strain, to raise the pretest probability of (99m) Tc-PYP scintigraphy for these patients. METHODS AND RESULTS  We examined 109 consecutive patients aged &gt;/=70 years with low scores according to the Kumamoto criteria who underwent (99m) Tc-PYP scintigraphy. Nineteen patients (17%) had positive (99m) Tc-PYP scintigraphy findings. The relative apical longitudinal strain (LS) index (apical LS/ basal LS + mid LS) (RapLSI) was significantly higher in patients with positive than negative (99m) Tc-PYP scintigraphy findings (1.04 +/- 0.37 vs 0.70 +/- 0.28, P &lt; .01). Multivariable logistic regression analysis revealed that a high RapLSI (&gt;/=1.04) was significantly associated with (99m) Tc-PYP positivity (odds ratio, 14.14; 95% confidence interval, 3.36-59.47; P &lt; .01). The sensitivity, specificity, and accuracy of the diagnostic model using the RapLSI for identification of (99m) Tc-PYP positivity were 53%, 94%, and 87%, respectively. CONCLUSIONS  A high RapLSI can raise the pretest probability of (99m) Tc-PYP scintigraphy in patients with a low score according to the Kumamoto criteria. The RapLSI can assist clinicians in determining strategies for these patients.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Inflammatory diseases,
 Mucopolysaccharidosis type I (MPS I) is a lysosomal storage disorder caused by mutations in the IDUA gene, that codifies the alpha-L-iduronidase enzyme, which deficiency leads to storage of glycosaminoglycans, with multiple clinical manifestations. One of the leading causes of death in MPS I patients are cardiac complications such as cardiac valve thickening, conduction abnormalities, myocardial dysfunction, and cardiac hypertrophy. The mechanism leading to cardiac dysfunction in MPS I is not entirely understood. In a previous study, we have demonstrated that losartan and propranolol improved the cardiac function in MPS I mice. Thus, we aimed to investigate whether the pathways influenced by these drugs may modulate the cardiac remodeling process in MPS I mice. According to our previous observation, losartan and propranolol restore the heart function, without altering valve thickness. MPS I mice presented reduced activation of AKT and ERK1/2, increased activity of cathepsins, but no alteration in metalloproteinase activity was observed. Animals treated with losartan showed a reduction in cathepsin activity and restored ERK1/2 activation. While both losartan and propranolol improved heart function, no mechanistic evidence was found for propranolol so far. Our results suggest that losartan or propranolol could be used to ameliorate the cardiac disease in MPS I and could be considered as adjuvant treatment candidates for therapy optimization. This article is protected by copyright. All rights reserved.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Apoptosis antagonizing transcription factor (AATF), an interacting partner of RNA polymerase II is a multifunctional protein that is highly conserved in eukaryotes. In addition to the regulation of gene expression as a transcriptional coactivator, AATF is shown to play a dual role in regulating the cell cycle by displacing histone deacetylases 1 (HDAC1) from the retinoblastoma-E2F transcription factor (Rb-E2F) complex and also from the specificity protein 1 (Sp1) transcription factor responsible for p21 expression, thereby ensuring cell proliferation and growth arrest, respectively, at different checkpoints of the cell cycle. Notably, AATF has emerged as one of the most important modulators of various cellular responses such as proliferation, apoptosis, and survival. Studies have demonstrated that AATF protects cells from multiple stress stimuli such as DNA damage, ER stress, hypoxia, or glucose deprivation by inducing cell cycle arrest, autophagy, or apoptosis inhibition. Furthermore, AATF serves as a critical regulator in various cancers and promotes tumorigenesis by protecting cancer cells from apoptosis induction, favoring cell proliferation, or promoting cell survival by autophagy. Recent studies have demonstrated the key role of AATF in ribosome biosynthesis and have also provided insights into the mechanistic role of AATF, offering impressive cytoprotection in myocardial infarction, neurologic diseases, and nephronophthisis. In this review, we will provide a comprehensive overview of the role of AATF and shed light on its emerging roles underlining the potential use of AATF as a novel biomarker and as an effective therapeutic target.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 PURPOSE  The present study aimed to clarify the relationship between community-dwelling older women&#39;s participation period in community-based exercise programs and their oral and physical functioning. METHODS  From May to September 2019, we recruited 205 older women (mean age  77.6 +/- 5.5 years) who had joined weekly long-term care prevention programs such as community-based exercise programs that included oral and physical exercises, in Hiroshima Prefecture, Japan. Physical function was evaluated using a handgrip strength test, a Timed Up &amp; Go test, a one-leg standing test, and a 30-s chair stand test. Tongue pressure, oral diadochokinesis, and Dysphagia Risk Assessment for the Community-dwelling Elderly were measured to evaluate oral functioning. After adjusting for clinical factors (i.e., age, BMI, hypertension, diabetes, stroke, heart disease, joint disease, osteoporosis, remaining teeth, denture use, oral wetness, history of dental examinations in the last year, use of interdental brush and/or dental floss), we compared the oral and physical function parameters of participants from varying program engagement periods using propensity score matching. RESULTS  A significant increase in mean handgrip strength was found in people who had been participating for &gt;/= 5 years compared with those who had been participating for &lt; 5 years (p = 0.01). Furthermore, repetition of the monosyllable/ka/was significantly greater for people in the &gt;/= 5 years group compared with those in the &lt; 5 years group (p = 0.03). CONCLUSION  Long-term participation in an exercise program is positively associated with handgrip strength and tongue motor function in independent older women.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">stenos</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 BACKGROUND  Previous studies have suggested the role of microcalcifications in plaque vulnerability. This exploratory study sought to assess the potential of hybrid positron-emission tomography (PET)/magnetic resonance imaging (MRI) using (18)F-sodium fluoride ((18)F-NaF) to check simultaneously (18)F-NaF uptake, a marker of microcalcifications, and morphological criteria of vulnerability. METHODS AND RESULTS  We included 12 patients with either recently symptomatic or asymptomatic carotid stenosis. All patients underwent (18)F-NaF PET/MRI. (18)F-NaF target-to-background ratio (TBR) was measured in culprit and nonculprit (including contralateral plaques of symptomatic patients) plaques as well as in other arterial walls. Morphological criteria of vulnerability were assessed on MRI. Mineral metabolism markers were also collected. (18)F-NaF uptake was higher in culprit compared to nonculprit plaques (median TBR 2.6 [2.2-2.8] vs 1.7 [1.3-2.2]; P = 0.03) but was not associated with morphological criteria of vulnerability on MRI. We found a positive correlation between (18)F-NaF uptake and calcium plaque volume and ratio but not with circulating tissue-nonspecific alkaline phosphatase (TNAP) activity and inorganic pyrophosphate (PPi) levels. (18)F-NaF uptake in the other arterial walls did not differ between symptomatic and asymptomatic patients. CONCLUSIONS  (18)F-NaF PET/MRI may be a promising tool for providing additional insights into the plaque vulnerability.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Inflammatory diseases,
 The way by which subcutaneous adipose tissue (SAT) expands and undergoes remodeling by storing excess lipids through expansion of adipocytes (hypertrophy) or recruitment of new precursor cells (hyperplasia) impacts the risk of developing cardiometabolic and respiratory diseases. In unhealthy obese subjects, insulin resistance, type 2 diabetes, hypertension, and obstructive sleep apnoea are typically associated with pathologic SAT remodeling characterized by adipocyte hypertrophy, as well as chronic inflammation, hypoxia, increased visceral adipose tissue (VAT), and fatty liver. In contrast, metabolically healthy obese individuals are generally associated with SAT development characterized by the presence of smaller and numerous mature adipocytes, and a lower degree of VAT inflammation and ectopic fat accumulation. The remodeling of SAT and VAT is under genetic regulation and influenced by inherent depot-specific differences of adipose tissue-derived stem cells (ASCs). ASCs have multiple functions such as cell renewal, adipogenic capacity, and angiogenic properties, and secrete a variety of bioactive molecules involved in vascular and extracellular matrix remodeling. Understanding the mechanisms regulating the proliferative and adipogenic capacity of ASCs from SAT and VAT in response to excess calorie intake has become a focus of interest over recent decades. Here, we summarize current knowledge about the biological mechanisms able to foster or impair the recruitment and adipogenic differentiation of ASCs during SAT and VAT development, which regulate body fat distribution and favorable or unfavorable metabolic responses.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Diseases of arteries,Coagulopathies,
 In patients with coronavirus disease 2019 (COVID-19), the prevalence of pre-existing cardiovascular diseases is elevated. Moreover, various features, also including pro-thrombotic status, further predispose these patients to increased risk of ischemic cardiovascular events. Thus, the identification of optimal antithrombotic strategies in terms of the risk-benefit ratio and outcome improvement in this setting is crucial. However, debated issues on antithrombotic therapies in patients with COVID-19 are multiple and relevant. In this article, we provide ten questions and answers on risk stratification and antiplatelet/anticoagulant treatments in patients at risk of/with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection based on the scientific evidence gathered during the pandemic.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 Coronary flow induces hemodynamic alterations in the aortic sinus region. The objectives of this study are to  (1) investigate the differences among sinus hemodynamics and leaflet wall shear stresses engendered by the left versus right versus non-coronary flow and (2) correlate respective wall shear stresses with leaflet calcification in patients. A left heart simulator flow loop with a tunable coronary circuit provided physiological coronary flow waveforms corresponding to the left coronary cusp case (LCC), right coronary cusp case (RCC), and non-coronary cusp case (NCC). High spatio-temporal resolution particle image velocimetry was conducted to quantify leaflet wall shear stress and sinus vorticity fields and to measure aortic leaflet tip kinematics. Thirty-one patients with severe calcific aortic valve disease were segmented from CT data for the calcific volumes in their respective left, right, and non-coronary cusps. Leaflet tip position during systole shows the RCC has a wider leaflet opening compared to LCC and NCC. Velocity and vorticity fields combined with leaflet position data show that sinus vorticity is diminished (peak ~ 43 s(-1)) in the LCC while RCC and NCC maintain high vorticity (~ 1200 and ~ 950 s(-1) respectively). WSS magnitudes greater than 0.3 Pa show 20 and 81% greater occurrences in the LCC and RCC respectively compared to NCC. Significant differences [X(2) (2, n = 31) = 7.31, p = 0.0258] between the calcification levels in each cusp of the patient population. Coronary flow differences between LCC, RCC, and NCC show significant impact on leaflet kinematics and sinus flow hemodynamics. Clinical data correlations of the coronary flow cases indicate the left coronary cusp has a higher likelihood of calcification compared to the right.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Subpleural consolidations have been found in lung ultrasound in patients with COVID-19, possibly deriving from pulmonary embolism (PE). The diagnostic utility of impact of lung ultrasound in critical-ill patients with COVID-19 for PE diagnostics however is unclear. We retrospectively evaluated all SARS-CoV2-associated ARDS patients admitted to our ICU between March 8th and May 31th 2020. They were enrolled in this study, when a lung ultrasound and a computed tomography pulmonary angiography (CTPA) were documented. In addition, wells score was calculated to estimate the probability of PE. The CTPA was used as the gold standard for the detection of PE. Twenty out of 25 patients met the inclusion criteria. In 12/20 patients (60%) (sub-) segmental PE were detected by CT-angiography. Lung ultrasound found subpleural consolidations in 90% of patients. PE-typical large supleural consolidations with a size &gt;/= 1 cm were detectable in 65% of patients and were significant more frequent in patients with PE compared to those without (p = 0.035). Large consolidations predicted PE with a sensitivity of 77% and a specificity of 71%. The Wells score was significantly higher in patients with PE compared to those without (2.7 +/- 0.8 and 1.7 +/- 0.5, respectively, p = 0.042) and predicted PE with an AUC of 0.81. When combining the two modalities, comparing patients with considered/probable PE using LUS plus a Wells score &gt;/= 2 to patients with possible/unlikely PE in LUS plus a Wells score &lt; 2, PE could be predicted with a sensitivity of 100% and a specificity of 80%. Large consolidations detected in lung ultrasound were found frequently in COVID-19 ARDS patients with pulmonary embolism. In combination with a Wells score &gt; 2, this might indicate a high-risk for PE in COVID-19.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlud</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,Coagulopathies,
 BACKGROUND  In acute stroke, large vessel occlusion (LVO) should be promptly identified to guide patient&#39;s transportation directly to comprehensive stroke centers (CSC) for mechanical thrombectomy (MT). In many cases, prehospital multi-parameter scores are used by trained emergency teams to identify patients with high probability of LVO. However, in several countries, the first aid organization without intervention of skilled staff precludes the on-site use of such scores. Here, we assessed the accuracy of LVO prediction using a single parameter (i.e. complete hemiplegia) obtained by bystander&#39;s telephone-based witnessing. PATIENTS AND METHODS  This observational, single-center study included consecutive patients who underwent intravenous thrombolysis at the primary stroke center and/or were directly transferred to a CSC for MT, from January 1, 2015 to March 1, 2020. We defined two groups  patients with initial hemiplegia (no movement in one arm and leg and facial palsy) and patients without initial hemiplegia, on the basis of a bystander&#39;s witnessing. RESULTS  During the study time, 874 patients were included [mean age 73 years (SD 13.8), 56.7% men], 320 with initial hemiplegia and 554 without. The specificity of the hemiplegia criterion to predict LVO was 0.88, but its sensitivity was only 0.53. CONCLUSION  Our results suggest that the presence of hemiplegia as witnessed by a bystander can predict LVO with high specificity. This single criterion could be used for decision-making about direct transfer to CSC for MT when the absence of emergency skilled staff precludes the patient&#39;s on-site assessment, especially in regions distant from a CSC.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 Alternative splicing of exon 24 (E24) of the myosin phosphatase regulatory subunit (Mypt1) tunes smooth muscle sensitivity to NO/cGMP-mediated vasorelaxation and thereby controls blood pressure (BP) in otherwise normal mice. This occurs via the toggling in or out of a C-terminal leucine zipper (LZ) motif required for hetero-dimerization with and activation by cGMP-dependent protein kinase cGK1alpha. Here we tested the hypothesis that editing (deletion) of E24, by shifting to the LZ positive isoform of Mypt1, would suppress the hypertensive response to angiotensin II (AngII). To test this, mice underwent tamoxifen-inducible and smooth muscle-specific deletion of E24 (E24 cKO) at age 6 weeks followed by a chronic slow-pressor dose of AngII (400 ng/kg/min) plus additional stressors. E24 cKO suppressed the hypertensive response to AngII alone or with the addition of a high salt diet. This effect was not a function of altered salt balance as there were no differences in intake or renal excretion of sodium. This effect was NO dependent as L-NAME in the drinking water caused an exaggerated hypertensive response in the E24cKO mice. E24cKO mouse mesenteric arteries were more sensitive to DEA/NO-induced vasorelaxation and less responsive to AngII- and alpha-adrenergic-induced vasoconstriction at baseline. Only the latter two effects were still present after 2 weeks of chronic AngII treatment. We conclude that editing of Mypt1 E24, by shifting the expression of naturally occurring isoforms and sensitizing to NO-mediated vasodilation, could be a novel approach to the treatment of human hypertension.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlud</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Diseases of arteries,
 Objective  Stroke severity screens typically include cortical signs, such as field cut, aphasia, neglect, gaze preference, and dense hemiparesis (FANG-D). The accuracy and reliability of these signs, when assessed by emergency physicians, to identify patients with anterior circulation large vessel occlusion (ACLVO) acute ischemic stroke (AIS) is unknown. We hypothesized that the FANG-D screen applied by emergency physicians would be sensitive and reliable for identifying ACLVO AIS. Methods  We conducted a prospective cohort study enrolling consecutive patients with suspected AIS presenting within 4.5 hours of last known well to the emergency department (ED). Emergency physicians performed the FANG-D screen prior to, and blinded to the results of, imaging. The imaging standard was defined as a non-contrast computed tomography (CT) for identifying hemorrhage and CT angiography for identifying large vessel occlusion. ACLVO was defined as an occlusion of the internal carotid artery, the middle cerebral artery, or its first branch. A convenience sample of patients had a duplicate FANG-D screen performed by a second emergency physician to assess interobserver agreement. Results  We performed 608 FANG-D assessments on 491 patients presenting to the ED, of whom 64 (10%) had an ACLVO. FANG-D had a sensitivity of 91% (confidence interval [CI] = 81%-96%) and a specificity of 35% (CI = 31%-39%) for identifying ACLVO. Interobserver agreement was tested on 133 patients and was found to be substantial, with a Fleiss&#39; kappa of 0.77 (CI = 0.64-0.88). Conclusions  The FANG-D screen is a sensitive test for identifying ACLVO when performed by emergency physicians and demonstrates substantial interrater reliability.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">cerebrovascul</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 Objective  eCTAS is a real-time electronic decision-support tool designed to standardize the application of the Canadian Triage and Acuity Scale (CTAS). This study addresses the variability of CTAS score distributions across institutions pre- and post-eCTAS implementation. Methods  We used population-based administrative data from 2016-2018 from all emergency departments (EDs) that had implemented eCTAS for 9 months. Following a 3-month stabilization period, we compared 6 months post-eCTAS data to the same 6 months the previous year (pre-eCTAS). We included triage encounters of adult (&gt;/=17 years) patients who presented with 1 of 16 pre-specified, high-volume complaints. For each ED, consistency was calculated as the absolute difference in CTAS distribution compared to the average of all included EDs for each presenting complaint. Pre-eCTAS and post-eCTAS change scores were compared using a paired-samples t-test. We also assessed if eCTAS modifiers were associated with triage consistency. Results  There were 363,214 (183,231 pre-eCTAS, 179,983 post-eCTAS) triage encounters included from 35 EDs. Triage scores were more consistent (P &lt; 0.05) post-eCTAS for 6 (37.5%) presenting complaints  chest pain (cardiac features), extremity weakness/symptoms of cerebrovascular accident, fever, shortness of breath, syncope, and hyperglycemia. Triage consistency was similar pre- and post-eCTAS for altered level of consciousness, anxiety/situational crisis, confusion, depression/suicidal/deliberate self-harm, general weakness, head injury, palpitations, seizure, substance misuse/intoxication, and vertigo. Use of eCTAS modifiers was associated with increased triage consistency. Conclusions  eCTAS increased triage consistency across many, but not all, high-volume presenting complaints. Modifier use was associated with increased triage consistency, particularly for non-specific complaints such as fever and general weakness.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlud</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 Resuscitative endovascular balloon occlusion of the aorta (REBOA) has been proposed as a novel approach to managing non-traumatic cardiac arrest (NTCA). During cardiac arrest, cardiac output ceases and perfusion of vital organs is compromised. Traditional advanced cardiac life support (ACLS) measures and cardiopulmonary resuscitation are often unable to achieve return of spontaneous circulation (ROSC). During insertion of REBOA a balloon-tipped catheter is placed into the femoral artery and advanced in a retrograde manner into the aorta while the patient is undergoing cardiopulmonary resuscitation (CPR). The balloon is then inflated to fully occlude the aorta. The literature surrounding the use of aortic occlusion in non-traumatic cardiac arrest is limited to animal studies, case reports and one recent non-controlled feasibility trial. In both human and animal studies, preliminary data show that REBOA may improve coronary and cerebral perfusion pressures and key physiologic parameters during cardiac arrest resuscitation, and animal data have demonstrated improved rates of ROSC. Multiple questions remain before REBOA can be considered as an adjunct to ACLS. If demonstrated to be effective clinically, REBOA represents a potentially cost-effective and generalizable intervention that may improve quality of life for patients with non-traumatic cardiac arrest.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,
 Objective  Chest pain scores allow emergency department (ED) physicians to identify low-risk patients for whom discharge can be safely expedited. Although these have been extensively validated in Western cohorts, data in patients of Asian heritage are lacking. This study aimed to determine the accuracy of HEART, ED Assessment of Chest Pain Score (EDACS), and Global Registry of Acute Coronary Events (GRACE) in risk-stratifying which chest pain patients are at risk of major adverse cardiovascular events within 30 days (composite of all-cause mortality, acute myocardial infarction and coronary revascularization). Methods  This single-center prospective cohort-study that enrolled 1200 patients was conducted by a large urban tertiary center in Singapore. Chest pain scores were reported before disposition by research assistants blinded to the physician&#39;s clinical assessment. Outcomes were assessed independently by a blinded cardiologist and emergency physician, while another cardiologist adjudicated in the case of discrepancies. Results  Of the 1195 patients analyzed, 135 (11.3%) suffered major adverse cardiovascular events within 30 days. HEART, which ruled out major adverse cardiovascular events in 52.8% of patients with 88.1% sensitivity, and EDACS, which ruled out major adverse cardiovascular events in 57.5% of patients with 83.7% sensitivity, proved comparable to clinical judgment that ruled out major adverse cardiovascular events in 73.0% of patients with 85.5% sensitivity. GRACE was weaker-ruling out major adverse cardiovascular events in 79.2% of patients with a dismal sensitivity of 45.0%. The correlation-statistic for HEART (79.4%) was superior to EDACS (69.9%) and GRACE (69.2%). Conclusions  HEART more accurately identified low-risk chest pain patients in an Asian ED, demonstrating comparable performance characteristics to clinical judgment. This has major implications on the use of chest pain scores to safely expedite disposition decisions for low-risk chest pain patients.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">chronic ischem heart diseas</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Inflammatory diseases,
 Study Objective  Patients with syncope are frequently admitted to the hospital, but whether this improves outcome is unknown. We tested whether hospitalization reduced mortality in patients who presented to emergency departments (EDs) with syncope. Methods  We conducted a propensity analysis of the outcomes of patients &gt;/=18 years old presenting to EDs with a primary diagnosis of syncope in April 2004-March 2013. The model used 1 1 nearest-neighbor matching to predicted admission using age, sex, urban residence, household income, and 14 significant comorbidities from 4 administrative databases of the province of Alberta. The primary outcome was death. Results  There were 57,417 ED patients with a primary diagnosis of syncope; 8864 were admitted, and 48,553 were discharged in &lt;24 hours. Admitted patients were older (median 76 vs 49 years), male (53% vs 45%), rural (23% vs 18%), and had lower income (median $58,599 vs $61,422); all P &lt; 0.001. All comorbidities were higher in admitted patients (mean Charlson scores, 1.9 vs 0.7; P &lt; 0.001). The propensity-matched hospitalized patients had higher 30-day mortality (3.5% vs 1.0%) and 1-year mortality (14.1% vs 8.6%); both P &lt; 0.001. Mortality in all propensity quintiles was higher in the hospitalized group (all P &lt; 0.001). The most common causes of death in 2719 patients included chronic ischemic heart disease, 14%; lung cancer, 7.1%; acute myocardial infarction, 6.9%; stroke, 3.7%; chronic obstructive pulmonary disease, 3.6%; dementia, 2.6%; and heart failure, 2.5%. Conclusions  Hospital admission did not reduce early or late mortality in patients who presented to the ED with syncope. Mortality is associated with comorbidities.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,Coagulopathies,
 There remains a high risk of thrombosis in patients affected by the SARS-CoV-2 virus and recent reports have shown pulmonary embolism (PE) as a cause of sudden death in these patients. However, the pooled rate of this deadly and frequently underdiagnosed condition among COVID-19 patients remains largely unknown. Given the frequency with which pulmonary embolism has been reported as a fatal complication of severe coronavirus disease, we sought to ascertain the actual prevalence of this event in COVID-19 patients. Using PubMed/Medline, EMBASE, and SCOPUS, a thorough literature search was performed to identify the studies reporting rate of PE among COVID-19. Random effects models were obtained to perform a meta-analysis, and I (2) statistics were used to measure inter-study heterogeneity. Among 3066 COVID-19 patients included from 9 studies, the pooled prevalence of PE was 15.8% (95% CI (6.0-28.8%), I (2) = 98%). The pooled rate in younger cohort (age &lt; 65 years) showed a higher prevalence of 20.5% (95% CI (17.6-24.8%)) as compared to studies including relatively older cohort (age &gt; 65 years) showing 14.3% (95% CI (2.9-30.1%)) (p &lt; 0.05). Single-center studies showed a prevalence of 12.9% (95% CI 1.0-30.2%), while that of multicenter studies was 19.5% (95% CI 14.9-25.2%) (p &lt; 0.05). Pulmonary embolism is a common complication of severe coronavirus disease and a high degree of clinical suspicion for its diagnosis should be maintained in critically ill patients.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam diseas</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Inflammatory diseases,Coagulopathies,
 Background Extended duration thromboprophylaxis (ET) for approximately 30 days can effectively and safely reduce venous thromboembolism (VTE) risk in appropriately selected medically ill patients. We sought to estimate the proportion of hospitalized medically ill patients potentially qualifying for ET and assess their post-discharge clinical and economic outcomes using a large claims database. Methods Using MarketScan claims from January 2012 to September 2018, we identified medically ill patients hospitalized with a primary diagnosis of heart failure, respiratory insufficiency, ischemic stroke, infection, or inflammatory disease and &gt;/=1-additional risk factor for VTE. Patients &lt; 40 years old, a length-of-stay &lt; 3 or &gt;30 days, receiving oral anticoagulation prior to index hospitalization or having an indication for full-dose anticoagulation were excluded, as were patients deemed high-risk for bleeding due to active, in-hospital treated cancer, gastroduodenal ulcer or bleeding within the prior 3 months, bronchiectasis, pulmonary cavitation or hemorrhage, or dual antiplatelet therapy use. Results We identified 2,782,988 patients &gt;/=40 years of age and admitted for a high-risk medical illness. Of these, 724,531 patients (26.0%) were identified as ET candidates. Patients&#39; VTE risk appeared highest in the first 30 days post-discharge (1,532/724,531, 0.2%). Adjusted post-index hospitalization costs (2018 US$) for patients with a VTE within 30 days were higher than those without VTE (Delta = $32,623 at 30 days, Delta = $43,325 at 90 days, Delta = $53,668 at 365 days; p &lt; 0.001 for all). Conclusion Post-discharge VTE in high-risk patients with medical illness is associated with substantially increased costs.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Circulating protein biomarkers provide information regarding pathways in heart failure (HF) and can add important value to clinicians. Advancements in proteomics allow researchers to measure a multitude of proteins simultaneously with excellent sensitivity and selectivity to detect low abundance proteins. This helps identify previously unrecognized pathways in HF and discover biomarkers and potential targets for HF therapies. Although several proteomic methods exist, including mass spectrometry, protein microarray, aptamer, and proximity extension assay-based techniques, each have their unique advantages. This paper provides an overview of the various proteomic methods, with examples of how each has contributed to understanding the pathways in HF.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Genetic variants are major determinants of susceptibility to disease, response to therapy, and clinical outcomes. Advances in the short-read sequencing technologies, despite some shortcomings, have enabled identification of the vast majority of the genetic variants in each genome. The major challenge is in identifying the pathogenic variants in cardiovascular diseases. The yield of the genetic testing has been limited because of technological shortcomings and our incomplete understanding of the genetic basis of cardiovascular disorders. To advance the field, a shift to long-read sequencing platforms is necessary. In addition, to discern the pathogenic variants, genetic diseases should be considered as a continuum and the genetic variants as probabilistic factors with a gradient of effect sizes. Moreover, disease-specific physician-scientists with expertise in the clinical medicine and molecular genetics are best equipped to discern functional and clinical significance of the genetic variants. The changes would be expected to enhance clinical utilities of the genetic discoveries.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 This study used in vivo molecular imaging to characterize endotheliall activation attributable to von Willebrand factor (vWF)-mediated platelet adhesion in atherosclerosis. In atherosclerotic mice lacking the low-density lipoprotein receptor on Western diet, the additional genetic deletion of the ADAMTS13, which cleaves endothelial-associated vWF, produced greater aortic molecular imaging signal for not only vWF and platelets, but also for endothelial adhesion molecules VCAM1 and P-selectin, larger plaque size, and lower aortic distensibility. Sustained ADAMTS13 therapy reduced signal for all 4 molecular targets and plaque size. We conclude that excess endothelial-associated vWF contributes to not only platelet adhesion, but also to up-regulation of endothelial cell adhesion molecules.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Cardiomyopathy,Diseases of arteries,
 Debulking of left ventricular septal mass is typically accomplished using surgical myectomy, which is morbid, or using transcoronary alcohol septal ablation, which can result in geographic miss and occasional catastrophic nontarget coronary injury. The authors developed and tested operational parameters in vitro and vivo for a device to accomplish transvenous intraseptal radiofrequency ablation to reduce ventricular septal mass using a technique derived from mitral cerclage, which the authors call cerclage ablation. Cerclage ablation appeared feasible in vitro and safe and effective in vivo. Cerclage ablation is an attractive new approach to debulk the interventricular septum in obstructive hypertrophic cardiomyopathy. These data support clinical investigation.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 This study hypothesized that dorsal root ganglion (DRG) stimulation would reduce sympathetic nerve activity and would alter hemodynamic variables. This study directly recorded muscle sympathetic nerve activity during ON and OFF stimulation of the DRG while measuring hemodynamic parameters. DRG stimulation significantly reduced the firing frequency of sympathetic nerves, as well as significantly reducing blood pressure, with greater reductions evident when stimulation was left-sided. Left-sided DRG stimulation lowers sympathetic nerve activity, leading to long-term phenotypic changes. This raises the potential of DRG stimulation being used to treat de novo autonomic disorders such as hypertension or heart failure.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 Familial hypercholesterolaemia (FH) is a common inherited disorder, causing lifelong elevated low-density lipoprotein cholesterol (LDL-C). Most individuals with FH remain undiagnosed, precluding opportunities to prevent premature heart disease and death. Some machine-learning approaches improve detection of FH in electronic health records, though clinical impact is under-explored. We assessed performance of an array of machine-learning approaches for enhancing detection of FH, and their clinical utility, within a large primary care population. A retrospective cohort study was done using routine primary care clinical records of 4,027,775 individuals from the United Kingdom with total cholesterol measured from 1 January 1999 to 25 June 2019. Predictive accuracy of five common machine-learning algorithms (logistic regression, random forest, gradient boosting machines, neural networks and ensemble learning) were assessed for detecting FH. Predictive accuracy was assessed by area under the receiver operating curves (AUC) and expected vs observed calibration slope; with clinical utility assessed by expected case-review workload and likelihood ratios. There were 7928 incident diagnoses of FH. In addition to known clinical features of FH (raised total cholesterol or LDL-C and family history of premature coronary heart disease), machine-learning (ML) algorithms identified features such as raised triglycerides which reduced the likelihood of FH. Apart from logistic regression (AUC, 0.81), all four other ML approaches had similarly high predictive accuracy (AUC &gt; 0.89). Calibration slope ranged from 0.997 for gradient boosting machines to 1.857 for logistic regression. Among those screened, high probability cases requiring clinical review varied from 0.73% using ensemble learning to 10.16% using deep learning, but with positive predictive values of 15.5% and 2.8% respectively. Ensemble learning exhibited a dominant positive likelihood ratio (45.5) compared to all other ML models (7.0-14.4). Machine-learning models show similar high accuracy in detecting FH, offering opportunities to increase diagnosis. However, the clinical case-finding workload required for yield of cases will differ substantially between models.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Regular aerobic physical activity is of utmost importance in maintaining a good health status and preventing cardiovascular diseases (CVDs). Although cardiopulmonary exercise testing (CPX) is an essential examination for noninvasive estimation of ventilatory threshold (VT), defined as the clinically equivalent to aerobic exercise, its evaluation requires an expensive respiratory gas analyzer and expertize. To address these inconveniences, this study investigated the feasibility of a deep learning (DL) algorithm with single-lead electrocardiography (ECG) for estimating the aerobic exercise threshold. Two hundred sixty consecutive patients with CVDs who underwent CPX were analyzed. Single-lead ECG data were stored as time-series voltage data with a sampling rate of 1000 Hz. The data of preprocessed ECG and time point at VT calculated by respiratory gas analyzer were used to train a neural network. The trained model was applied on an independent test cohort, and the DL threshold (DLT; a time of VT estimated through the DL algorithm) was calculated. We compared the correlation between oxygen uptake of the VT (VT-VO2) and the DLT (DLT-VO2). Our DL model showed that the DLT-VO2 was confirmed to be significantly correlated with the VT-VO2 (r = 0.875; P &lt; 0.001), and the mean difference was nonsignificant (-0.05 ml/kg/min, P &gt; 0.05), which displayed strong agreements between the VT and the DLT. The DL algorithm using single-lead ECG data enabled accurate estimation of VT in patients with CVDs. The DL algorithm may be a novel way for estimating aerobic exercise threshold.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Cardiomyopathy,
 Cirrhosis-induced heart injury and cardiomyopathy is a serious consequence of this disease. It has been shown that bile duct ligated (BDL) animals could serve as an appropriate experimental model to investigate heart tissue injury in cirrhosis. The accumulation of cytotoxic chemicals (e.g., bile acids) could also adversely affect the heart tissue. Oxidative stress and mitochondrial impairment are the most prominent mechanisms of bile acid cytotoxicity. Taurine (Tau) is the most abundant non-protein amino acid in the human body. The cardioprotective effects of this amino acid have repeatedly been investigated. In the current study, it was examined whether mitochondrial dysfunction and oxidative stress are involved in the pathogenesis of cirrhosis-induced heart injury. Rats underwent BDL surgery. BDL animals received Tau (50, 100, and 500 mg/kg, i.p.) for 42 consecutive days. A significant increase in oxidative stress biomarkers was detected in the heart tissue of BDL animals. Moreover, it was found that heart tissue mitochondrial indices of functionality were deteriorated in the BDL group. Tau treatment significantly decreased oxidative stress and improved mitochondrial function in the heart tissue of cirrhotic animals. These data provide clues for the involvement of mitochondrial impairment and oxidative stress in the pathogenesis of heart injury in BDL rats. On the other hand, Tau supplementation could serve as an effective ancillary treatment against BDL-associated heart injury. Mitochondrial regulating and antioxidative properties of Tau might play a fundamental role in its mechanism of protective effects in the heart tissue of BDL animals.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 Purpose  Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in the Saudi Arabia (KSA). Over the last decade dyslipidemia has been the predominant risk factor in KSA. The linear relationship between low density lipoprotein cholesterol (LDL-C) levels, a marker for dyslipidemia, and progression of ASCVD is well established. The objective of this paper is to to provide an overview of the burden of disease, outline current clinical practice guidelines (CPG), examine gaps in care, and provide actionable recommendations to prevent, diagnose, and treat dyslipidemia in KSA. Results  Saudi Arabia has the highest prevalence of ASCVD in the Gulf region. Several gaps in the implementation of CPGs, including the underdiagnosis and undertreatment of dyslipidemia, inadequate primary and secondary prevention efforts, complicated by a fragmented health system have been identified. Compelling evidence indicates that target LDL-C levels are not achieved throughout the Middle East region. In addition, high-risk patients are often left unidentified with adequate treatment. Conclusion  This statement recommends specific multilevel interventions to optimize the prevention, diagnosis, and treatment of ASCVD. These recommendations focus on strengthening primary and secondary prevention through education initiatives, establishment of specialized prevention and treatment centers, and development of local and regional CPGs.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Background  The interaction between cardiorespiratory fitness (CRF) and incidence of atrial fibrillation (AF) and the interaction between obesity and incidence of AF have been explored separately. Therefore, we evaluated the association between CRF, body mass index (BMI), and risk of developing AF in a cohort of middle-aged and older US Veterans. Methods  Symptom limited exercise tests (ETT) were conducted among 16,397 Veterans (97% male) from January 9,1987 to December 31,2017. No history of AF was evident at the time of the ETTs. CRF was expressed as quartiles of peak metabolic equivalents (METs) achieved within each age decile. Weight status was classified as normal (BMI &lt; 25 kg/m(2)), overweight (BMI 25-30 kg/m(2)), obese (BMI 30-35 kg/m(2)), or severely obese (BMI &gt; 35 kg/m(2)). Multivariable Cox proportional hazards regression models were used to compare the association between BMI, CRF categories, and incidence of AF. Results  Over a median follow-up of 10.7 years, 2,155 (13.1%) developed AF. Obese and severely obese subjects had 13% and 32% higher risks for incidence of AF, respectively, vs. normal weight subjects. Overweight and obese subjects in the most fit quartile had 50% decline in AF risk compared to the least-fit subjects. Severely obese subjects had marked increases in AF risk (~50-60%) regardless of fitness level. Risk of developing AF increases with higher BMI and lower CRF. Conclusion  Improving CRF should be advocated when assessing those at risk for developing AF.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Background  The interaction between cardiorespiratory fitness (CRF) and incidence of atrial fibrillation (AF) and the interaction between obesity and incidence of AF have been explored separately. Therefore, we evaluated the association between CRF, body mass index (BMI), and risk of developing AF in a cohort of middle-aged and older US Veterans. Methods  Symptom limited exercise tests (ETT) were conducted among 16,397 Veterans (97% male) from January 9,1987 to December 31,2017. No history of AF was evident at the time of the ETTs. CRF was expressed as quartiles of peak metabolic equivalents (METs) achieved within each age decile. Weight status was classified as normal (BMI &lt; 25 kg/m(2)), overweight (BMI 25-30 kg/m(2)), obese (BMI 30-35 kg/m(2)), or severely obese (BMI &gt; 35 kg/m(2)). Multivariable Cox proportional hazards regression models were used to compare the association between BMI, CRF categories, and incidence of AF. Results  Over a median follow-up of 10.7 years, 2,155 (13.1%) developed AF. Obese and severely obese subjects had 13% and 32% higher risks for incidence of AF, respectively, vs. normal weight subjects. Overweight and obese subjects in the most fit quartile had 50% decline in AF risk compared to the least-fit subjects. Severely obese subjects had marked increases in AF risk (~50-60%) regardless of fitness level. Risk of developing AF increases with higher BMI and lower CRF. Conclusion  Improving CRF should be advocated when assessing those at risk for developing AF.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 Background  On March 11, 2020, the World Health Organization (WHO) officially announced that the coronavirus disease 2019 (COVID-19) had reached global pandemic status. Current studies have found that angiotensin-converting enzyme 2 (ACE2) is a cell surface receptor of the novel coronavirus that plays a vital role in the pathogenesis of COVID-19. It is of immense importance for the prevention of virus transmission and treatment to clarify the distribution and expression of ACE2 in various tissues and organs of the body. Methods  RNAseq transcriptome data and sex data were obtained from the genotype-tissue expression (GTEx) and the Cancer Genome Atlas (TCGA) databases. We separately analyzed the distribution of ACE2 expression in different tissues in the GTEx and TCGA database, and explored the correlation between sex and ACE2 expression levels. Next, the expression levels of ACE2 in different tissues and organs and its correlation with sex were analyzed once again after combing all samples from the two databases. Results  ACE2 expression data were collected from the GTEx database for 6738 normal tissues. Six hundred eighteen tumor tissue data were collected from the TCGA database. The results of the analysis are consistent from different databases. The results indicated that the expression of ACE2 was the highest in the small intestines, higher in tissues such as salivary glands in the testicular, kidney, heart, thyroid and adipose tissues, while the expression of ACE2 was lower in tissues such as the spleen, brain, muscle, pituitary, and skin. There were no significant differences in the expression of ACE2 in the different organs when it came to the individual&#39;s sex. Conclusions  Our study deeply explored the distribution and expression of ACE2 in various tissues of the human body. The tissues and organs with high ACE2 expression were consistent with the current clinical and basic research results of the novel coronavirus. Our study is conducive to the discovery of potential target organs for viral infection, to provide a reference for the development of clinical progress of patients with novel coronavirus infection.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 Background  Pathological cardiac hypertrophy is a major risk factor for cardiovascular diseases, including heart failure. However, limited pharmacological therapies are available for reversing the maladaptive process and restoring cardiac function. Citri reticulatae Pericarpium (CRP) has been used in traditional Chinese medicine prescriptions for clinical treatment. Previous studies have shown that CRP and its ingredients have beneficial effects on the cardiovascular system. However, whether CRP has a protective effect against pathological cardiac hypertrophy remains unknown. Methods  Primary neonatal rat cardiomyocytes (NRCMs) were treated with angiotensin II (Ang II) to induce pathological hypertrophy in vitro. Immunofluorescent staining and quantitative real-time PCR (qRT-PCR) were used to determine the cell size and the expression of hypertrophic gene markers (Anp and Bnp), respectively. Male C57BL/6 mice were subjected to the investigation of cardiac hypertrophy induced by Ang II (2.5 mg/kg/d for 4 weeks). CRP (0.5 g/kg/d for 4 weeks) was administrated to treat mice with or without peroxisome proliferator-activated receptors gamma (PPARgamma) inhibitor T0070907 (1 mg/kg/d for 4 weeks treatment) infused with Ang II. Cardiac hypertrophy (hematoxylin-eosin staining and qRT-PCR), fibrosis (Masson&#39;s Trichrome staining, qRT-PCR, and western blot), and cardiac function (echocardiography) were examined in these mice. Western blot was used to determine the protein level of PPARgamma and PGC-1alpha both in NRCMs and in mice. Results  We found that CRP could prevent Ang II-induced pathological cardiac hypertrophy evidenced by improving cardiac function, decreasing hypertrophic growth and reducing cardiac fibrosis. Also, we demonstrated that PPARgamma was upregulated by CRP both in NRCMs and in hearts. Moreover, PPARgamma inhibitor could abolish the inhibitory effects of CRP on Ang II-induced pathological cardiac hypertrophy. Conclusions  CRP attenuates Ang II-induced pathological cardiac hypertrophy by activating PPARgamma.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 Background  The prognosis for advanced hepatocellular carcinoma (HCC) remains clinically unsatisfying. Apatinib has proven to be a very effective treatment for advanced HCC in our previous retrospective study. Our aim in this study was to evaluate the efficacy, safety, and toxicity of apatinib in patients with advanced HCC. Methods  This single-arm, open-label phase II clinical trial enrolled patients with advanced HCC. These patients received apatinib, 500 mg once daily, until disease progression, unacceptable toxicity, consent withdrawal, or death. One treatment cycle consisted of 4 weeks of apatinib treatment. The response evaluation criteria in solid tumors (RECIST) was used to assess tumor response every 1-2 cycles. The primary endpoint was the objective response rate (ORR), while the secondary endpoints were the overall survival (OS), progression-free survival (PFS), disease control rate (DCR), and toxicity. Results  Between December 2016 and June 2018, 23 patients were enrolled in the study, 22 of whom were available for response evaluation. The cutoff date was August 10, 2018. The overall ORR and DCR were 30.4% and 65.2%, respectively. The median OS and PFS were 13.8 (95% CI  5.3-22.3) and 8.7 (95% CI  5.9-11.1) months, respectively. The most common treatment-related adverse events were proteinuria (39.1%), hypertension (34.8%), and hand-foot-skin reaction (34.8%). Conclusions  Apatinib showed robust clinical activity in patients with advanced HCC. Moreover, apatinib was safe to use, well tolerated, and had acceptable toxicity. (NCT03046979).
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Purpose  COVID-19, a disease that can be transmitted from person to person and with serious health problems, can be associated with mental health disorders. In this study, we evaluated the prevalence and severity of depression, anxiety, stress, and stress perception among a group of patients with COVID-19 who were hospitalized. Methods  In this cross-sectional study, 106 inpatients with COVID-19 who had stable clinical conditions were evaluated psychologically by two questionnaires  Depression, Anxiety and Stress Scales-21 (DASS-21) and Perceived Stress Scale (PSS-4). Results  More than one third of patients had underlying disease. Overall, 97.2% of patients with COVID-19 had some degree of depression. Severity of depression, according to the DASS questionnaire, was 85.8%. All patients (100%) had severe (0.9%) and very severe (99.1%) anxiety. Regarding to stress levels, 97.1% of patients had some degree of stress. In the severity of stress category, 84.9% of patients had severe and very severe stress. In terms of perceived stress, 73.6% of patients had high levels and 22.6% had moderate levels. A positive strong correlation was found between depression and perceived stress (Coefficient  0.33, P-value  0.001). Correlation between anxiety and perceived stress was statistically significant (Coefficient  0.2, P-value  0.04). Conclusions  The existence of such a high prevalence and severity of psychiatric disorders among hospitalized patients with COVID-19 underscores the need for serious attention to the mental health status of these patients. It seems that health policymakers need to have coherent plans for screening cases and managing related situations.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 Objectives  Decompressive craniectomy (DC) is an emergency life-saving procedure used to treat refractory intracranial hypertension (RICH). The authors aim to analyze their experience with protocol-based early DC (&lt;24 h) in RICH cases diagnosed based on clinical and radiological evidence, without preoperative intracranial pressure monitoring done over 10 years. Materials and Methods  This is a retrospective, observational study which includes 58 consecutive patients who underwent protocol-based early DC by the senior author at a single institution between 2007 and 2017. Background variables and outcome in the form of Glasgow Outcome Score-Extended (GOS-E) at 6 months and 1 year were analyzed. Results  Fourteen patients had traumatic brain injury (TBI), 17 had intracranial hemorrhage (ICH), 14 had malignant cerebral infarcts (MCI), and the reminder 13 patients had other causes. At 6 months, the mortality rate was 22.4%. Good recovery, moderate disability, and severe disability were seen in 13.8%, 17.2%, and 43.1% of patients, respectively. Two patients were in vegetative state. The cutoff for favorable/unfavorable outcome was defined as GOS-E 4-8/1-3. By this application, 63.8% of patients had favorable outcome at 6 months. The favorable outcome in patients of TBI, ICH, and MCI was 57.1%, 58.8%, and 85.7%, respectively. Conclusions  DC helps in obtaining a favorable outcome in selected patients with a defined pathology. The diagnosis of RICH based on clinical and radiological parameters, and protocol-based early DC, is reasonably justified as the way forward for resource-constrained environments. The risk of vegetative state is small.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlud</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">stenos</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">cerebrovascul</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Diseases of arteries,
 Objective  The objective is to demonstrate change of cerebral perfusion and cerebrovascular reserve (CVR) in treating patients with cerebrovascular steno-occlusive disease stratified by change of cerebral perfusion and CVR. Methods  Retrospective review patients with radiographic proven major cerebrovascular steno-occlusive disease whom underwent cerebral perfusion imaging with vasoactive stimuli stress test in Siriraj Hospital and Bangkok General Hospital during 2010-2018. Medical records were also reviewed. Radiographic findings, cerebral perfusion parameters and signal change during the stress test were reviewed and used to categorize into three groups. Results  There were 40 patients sent to radiology department for the evaluation of CVR. One patient had airway problem during the procedure and was excluded. Remaining 39 patients were included in this study (32 males and 7 females, mean age of 54.55 years). In 42 sites involved, 28 (66%) were internal carotid artery, 14 (33%) were middle cerebral arteries. Laterality is left side in 20 cases, right side in 14 cases, and bilateral in 5 cases. Poor CVR response (increased cerebral blood flow &lt;10%) was found in 9 patients (2 severe stenoses and 7 total occlusions). The mean follow-up time was 28.9 months. Eight cases (20.5%) underwent surgical treatment; surgical bypasses and endovascular interventions. Only one patient had subsequential ischemic symptom at immediate postoperative vascular bypass surgery. The remaining patients had no report of progressive or recurrent neurological deficit symptom. Conclusion  Poor CVR response is more often found in higher degree of steno-occlusion. Even inconclusive predicting incidence of recurrent ischemic stroke, CVR that reflects the capacity of neuro-autoregulation.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlud</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">cerebrovascul</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Diseases of arteries,
 Background  Extracranial-intracranial (EC-IC) arterial bypass has been used in the treatment of various cerebrovascular ischemic disease due to atherosclerosis or Moyamoya disease, skull base tumors encasing large IC artery or complex IC aneurysms. Aim  The aim is to analyze surgical technique (EC-IC bypass) and its outcome with intraoperative use of dual image video angiography (DIVA) and Doppler ultrasound. Materials and Methods  We studied in this article a series of 23 patients operated in Banbuntane Hotokukai Hospital, Fujita Health University, for which a superficial temporal artery-middle cerebral artery anastomosis was done for steno-occlusive disease, giant IC aneurysm or Moyamoya disease. The study was conducted between 2018 and 2020. We used dual-image video angiography (DIVA) and Doppler ultrasound to assess the luminal patency of anastomosis during the procedure. Results  In this study, three patients presented with Moyamoya disease, 4 had aneurysm, whereas 16 patients presented with the vascular steno-occlusive disease. The patients were divided into three categories (steno-occlusive disease, Moyamoya, and flow replacement for giant aneurysm). Dual image video angiography, along with intraoperative Doppler, helped us in the assessment of luminal patency of the anastomosis. Conclusion  Hemodynamic recovery after cerebrovascular bypass brings about a better outcome in ischemic stroke. The result of surgery improves with proper selection of patients with hemodynamic impairment (in Stage 2). With various modalities such as intraoperative Doppler, DIVA (Dual-image Video Angiography) and improved surgical techniques may aid in the reduction of complications and improve clinical outcome.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">microvascul diseas</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">microvascul</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Diseases of arteries,
 While the beneficial impact of moderate-vigorous physical activity (MVPA) on blood pressure is well-understood, the relationship between sedentary time (ST) and blood pressure is less clear. We aimed to evaluate the associations between ST and BP in reproductive-age women. This cross-sectional analysis consisted of 431 women enrolled in the Placenta as a Window to Maternal Microvascular Disease Risk study at Magee-Womens Hospital. Blood pressure and self-reported physical activity and ST were collected 8-10 years after delivery at study enrollment. Logistic and linear regression models examined associations between ST and blood pressure and adjusted for MVPA. Women with the highest amount of ST were less likely to be normotensive and more likely to have elevated blood pressure and Stage II hypertension (p = 0.02). Each additional hour of ST was associated with an increased risk of Stage II hypertension (OR 1.12 [1.01-1.24]) and higher systolic blood pressure (0.45 mmHg [0.08-0.82]), diastolic blood pressure (0.29 mmHg [0.02-0.56]), and mean arterial pressure (0.34 mmHg [0.05-0.63]), after adjustment for covariates. This relationship was more apparent in women who participated in less MVPA (bottom 50th percentile) versus more MVPA (top 50th percentile). ST is associated with higher blood pressure, particularly in women who engage in less aerobic activity, and could serve as an important intervention target for reducing blood pressure and hypertension during the reproductive years.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 Background The aim of this study was to determine the frequency of coronary artery anomalies (CAAs) in Tetralogy of Fallot (TOF) patients undergoing computed tomography (CT)-angiography in a tertiary care hospital. Methodology In this observational study, we included consecutive TOF patients undergoing CT-angiography without prior history of cardiac surgery or congenital heart disease. CAAs were defined based on either origin or course of the artery. Results Out of 441 TOF patients, the prevalence of CCAs was 3.6% (16), of which 13 were below 18 years of age. Anomalous left main artery was observed in six (1.4%) patients, followed by left anterior descending artery and right coronary artery, observed in four (0.9%) patients each, and two (0.5%) patients had a single coronary artery originating from the left coronary cusp with an interarterial course. Conclusions CAAs were observed in a significant number (3.6%) of TOF patients. A CT-angiographic assessment before surgical correction would help identify the exact anatomy for better surgical planning to minimize complications.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Objectives  Peripheral artery disease (PAD) is a significant prognostic marker of poor long-term survival due to limited physical activity associated with various functional problems, such as intermittent claudication. A physically active lifestyle has the potential to modify peripheral artery risk factors and promote general health. While low daily physical activity levels have been recognized in the population of PAD, the exact level has yet to be quantified due to lack of research. The aim of the present study was to compare physical activity level (PAL) and time spent at activities of different intensity levels between patients with PAD and healthy individuals. The study subjects were 10 patients with PAD and 10 age-matched healthy control subjects. We measured the time spent at light, moderate, or vigorous physical activity using triaxial accelerometer and calculated PAL. Intermittent claudication onset distance and maximum walking distance were defined as the distance walked at which the subject first reported leg pain and the distance at which the subject was unable to continue walking because of leg pain, respectively. Results  Our results showed (i) lower PAL in patients with PAD compared with the controls; (ii) while there was no significant difference in the high-intensity activity between the two groups, the light- and moderate-intensity activities of the PAD group were significantly lower than the controls, the time spent at moderate-intensity activity was approximately 50% less; and (iii) among patients with PAD, low PAL did not correlate directly with intermittent claudication. Conclusions  PAD patients limit the amount of their physical activity, especially light and moderate intensities. Our study highlights the importance of spending more time walking in daily life.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">stenos</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Diseases of arteries,
 Hypertension is a disease classified as primary or secondary, manifested not only by elevation of blood pressure but also involved in structural and functional changes of target organs. Renal artery stenosis is a leading factor of secondary hypertension, and its progress is associated with overactivation of the renin-angiotensin-aldosterone system (RAAS). Aliskiren is a renin inhibiting drug that suppresses RAAS and culminates in decreased renin release, plasma angiotensin II concentration, and inhibition of aldosterone secretion. In this sense, the aim of the present study was to analyze the structural and ultrastructural morphophysiology of the adrenal glomerular zone, after treatment with aliskiren in Wistar rats with 2K1C hypertension. Parameters as structure and ultrastructure of the adrenal glomerular zone, cellular apoptosis, nuclear cell proliferation, and AT1 receptor expression were analyzed by immunostaining and electron microscopy. Our results showed that the hypertensive animals treated with aliskiren presented a reestablishment of AT1 receptor expression and decrease in apoptosis and autophagy. In addition, treatment with aliskiren improves the cell aspects in the adrenal glomerular zone, evidenced by ultrastructural analysis through preserved nuclei and well-developed mitochondria. Therefore, our evidence suggests that aliskiren has a beneficial effect on the adrenal glomerular zone remodeling in animals with renovascular hypertension.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 Objective  Hypertension (HTN) remains a major risk factor for cardiovascular diseases globally. Despite considerable improvement in increasing awareness, treatment, and control of HTN, undiagnosed and uncontrolled HTN remains a major public health challenge. Our focus was on studying the knowledge, attitude, and practice regarding HTN in adult hypertensive patients at a tertiary care hospital in Sri Lanka. Methodology. A descriptive study on knowledge, attitude, and practice of hypertensive patients on antihypertensive medications attending the hypertensive clinic was carried out from January 2016 to June 2016 at THP. Results  The study was on a total of 371 hypertensive patients comprising 253 (68.2%) females and 118 (31.8%) males. Among the total participants, 12 (3.2%), all females, had never been to school. About half of them (47.7%) had not even reached GCE (ordinary level). More than two-thirds (77%) of the study population were aware of the complications of HTN as they were informed by a health care team member. About 74% of them were taking all their prescribed medications. Almost all (95%) patients had checked their blood pressure (BP) during the previous 12 months, and almost the same percentage had visited their doctor for BP checkups every 1-3 months. Conclusion  Our patients were well aware of the importance of regular follow-ups and also knowledgeable about the complications related to HTN. Almost 75% of the patients had optimum drug compliance. It was revealed that forgetfulness was the frequent cause for poor drug compliance.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 Background  Scientific references lack sufficient amount of data on analyses of the reasons for hospital admissions or assessment of efficacy of arterial hypertension treatment at hospitals. Objectives  The aim of the study was to evaluate the efficacy of antihypertensive drug therapy on the blood pressure control among hospitalized hypertensive patients. Methodology. A cross-sectional retrospective study consisted of 204 patients aged 18-65 years admitted to the hospital due to hypertension between January 2018 and December 2018. The study was based on analysis of electronic records, obtained from the medical database of the selected healthcare facility. Results  As a result of the treatment applied at the hospital, 65.19% of the patients achieved the desired degree of blood pressure normalization (&lt;/=130/80 mmHg). Vast majority of the patients during their stay at the ward would receive three or more hypertensive drugs (63.73%). The most frequently prescribed antihypertensive drug combinations included bitherapies such as diuretics + ACEI and ACEI + beta-blockers and tritherapy such as diuretics + beta-blockers and calcium channel antagonists and diuretics + ACEI and ARBs. The highest blood-pressure lowering effects were observed among patients receiving combination therapy of a ACEI, a diuretic, and a ARBs. Tritherapy induced a significant mean reduction of inpatients`s SBP compared with bitherapy (p=0.0001). Conclusion  During their hospital stay, vast majority of patients (65.19%) achieved normal values of blood pressure, mostly owing to combined treatment with several hypertensive drugs. Efficacy of the most frequently used combinations of hypertensive drugs in normalizing arterial pressure varies.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 Both exercise training (Ex) and superoxide dismutase (SOD) mimetic tempol have antihypertensive and renal protective effects in rodent models of several hypertensions. We recently reported that Ex increases nitric oxide (NO) production and the expression levels of endothelial and neuronal NO synthase (eNOS and nNOS) in the kidney and aorta of the spontaneously hypertensive rats (SHR) and normotensive Wistar-Kyoto rats (WKY). We also found that endogenous hydrogen peroxide (H2O2) upregulates the expression levels of eNOS and nNOS in SHR. To elucidate the mechanism of the Ex-upregulated NO system in the kidney, we examined the additive effect of Ex and tempol on the renal NO system in SHR and WKY. Our data showed that, in SHR, both Ex and tempol increase the levels of H2O2 and nitrate/nitrite (NOx) in plasma and urine. We also observed an increased renal NOS activity and upregulated expression levels of eNOS and nNOS with decreased NADPH oxidase activity. The effects of the combination of Ex and tempol on these variables were cumulate in SHR. On the other hand, we found that Ex increases these variables with increased renal NADPH oxidase activity, but tempol did not change these variables or affect the Ex-induced upregulation in the activity and expression of NOS in WKY. The SOD activity in the kidney and aorta was activated by tempol only in SHR, but not in WKY; whereas Ex increased SOD activity only in the aorta in both SHR and WKY. These results indicate that Ex-induced endogenous H2O2 produced in the blood vessel and other organs outside of the kidney may be carried to the kidney by blood flow and stimulates the NO system in the kidney.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ess hypertend</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 Objective  Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme of homocysteine metabolism and is closely related to the occurrence of hypertension. The aim of this study was to investigate the polymorphism of the (MTHFR) C677T and the factors influencing the severity of hypertension. Material and Methods. A total of 985 subjects were enrolled to analyze the polymorphisms of the MTHFR C677T gene by polymerase chain reaction (PCR). 306 people with essential hypertension were selected from 985 subjects to estimate the severity of hypertension by the ordinal multivariate logistical regression model. Results  The frequencies of CC, CT, and TT genotypes were 19.5%, 49.95%, and 30.46%, respectively. The allelic frequency of mutant T was 55.43%. The plasma homocysteine level of the homozygous TT in individuals was significantly higher than in those with CC or CT (P &lt; 0.01). MTHFR677CT genotype, MTHFR677TT genotype, smoking, family history of hypertension, Hcy, and triglycerides (TG) were independent risk factors for the severity of hypertension (OR = 2.29, 2.24, 2.04, 1.81, 1.04, 1.26). Conclusion  MTHFR gene, smoking, family history of hypertension, Hcy, and triglycerides could be important genetic and high-risk factors of the development of severe hypertension in northern Chinese. These factors will contribute to the identification of high-risk populations of hypertension and facilitate the development of hypertension control strategies.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 The functional receptor to SARS-CoV-2, the virus responsible for the coronavirus disease 2019 (COVID-19) pandemic, is angiotensin-converting enzyme-2 (ACE-2), the same enzyme that physiologically counters the renin-angiotensin system (RAS) activation. Some researchers have questioned RAS inhibitors&#39; safety in COVID-19 patients since these drugs have demonstrated an increase in ACE-2 expression in preclinical studies; therefore, they may facilitate viral invasion. On the contrary, others have hypothesized a protective role of RAS inhibitors against COVID-19-associated lung injury. Overall, the data are grossly inadequate to reach any conclusion since no human trials have yet evaluated the effects of RAS inhibitors in COVID-19. We review the current data and pathophysiological mechanisms behind this intriguing interplay between the RAS inhibitors and the COVID-19.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">effus</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">rhe</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,
 In the era of Precision Medicine, diagnostic imaging plays a key role in initial diagnosis and treatment response assessment in thoracic manifestation of various rheumatic disorders; resulting in increased dependency on imaging for treatment planning. Chest radiographs serve as a good initial screening tool for assessment of emergent and urgent thoracic conditions, e.g., pneumothorax, pulmonary edema, consolidation and pleural effusions. Cross-sectional imaging techniques, e.g., computed tomography (CT) and positron emission tomography-computed tomography (PET-CT) are most commonly utilized to evaluate more detailed pulmonary and mediastinal manifestations of rheumatic conditions. Magnetic resonance imaging (MRI) and ultrasound are most commonly used in cardiovascular, neural and musculoskeletal structures. This review article aims to highly key common thoracic imaging findings of rheumatic disorders, highlighting imaging test of choice for the particular disorder.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">stenos</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Diseases of arteries,
 Background  Clinical workup for chest pain varies among institutions. Acute coronary syndrome (ACS) is the primary diagnosis to rule out in the differential diagnosis, due to its associated mortality and morbidity. Although studies have demonstrated efficacy of coronary computed tomographic angiography (CCTA) in diagnosis obstructive coronary artery disease (CAD), there is limited evidence in the clinical value of performing cardiac nuclear stress perfusion imaging [myocardial perfusion imaging (MPI)] exam in patients with chest pain after undergoing CCTA. We aim to evaluate clinical value of follow-up nuclear cardiac MPI in patients with chest pain who have undergone recent CCTA. Methods  A total of 1,000 patients were evaluated in this IRB approved retrospective study who presented with symptoms of ACS. Patients who had elevated troponin or abnormal electrocardiogram (ECG) findings at initial presentation or prior to cardiac nuclear MPI were excluded from the study. All patients who underwent 64- or 320-detector row ECG-gated CCTA as well as a follow-up nuclear MPI. Patients who had diagnostics studies limited by artifact [e.g., suboptimal intravenous (IV) contrast bolus in CCTA, motion artifact on CCTA or MPI, etc.] were excluded. Results  One hundred patients met the inclusion criteria. Patient demographics include average age 64.3 [32-89] years, 59 male, 41 females. Ninety-five/100 patients had at least one vessel with 50-70% coronary artery diameter stenosis measured on CCTA. There were no focal perfusion abnormalities identified on cardiac nuclear MPI in patients with less than 70% stenosis diagnosed on CCTA. Five percent of patients were identified with coronary arterial narrowing greater than 70% on CCTA and all 5 of these patients have evidence of abnormal cardiac nuclear stress test (perfusion abnormalities, chest pain, abnormal ECG). Conclusions  In low-to-intermediate risk patients with chest pain and evidence of non-critical coronary artery stenosis (i.e., less than 70% stenosis) diagnosed on CCTA, a follow-up cardiac nuclear perfusion imaging is of limited value.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Obstructive sleep apnoea (OSA) is a growing and serious worldwide health problem with significant health and socioeconomic consequences. Current diagnostic testing strategies are limited by cost, access to resources and over reliance on one measure, namely the apnoea-hypopnoea frequency per hour (AHI). Recent evidence supports moving away from the AHI as the principle measure of OSA severity towards a more personalised approach to OSA diagnosis and treatment that includes phenotypic and biological traits. Novel advances in technology include the use of signals such as heart rate variability (HRV), oximetry and peripheral arterial tonometry (PAT) as alternative or additional measures. Ubiquitous use of smartphones and developments in wearable technology have also led to increased availability of applications and devices to facilitate home screening of at-risk populations, although current evidence indicates relatively poor accuracy in comparison with the traditional gold standard polysomnography (PSG). In this review, we evaluate the current strategies for diagnosing OSA in the context of their limitations, potential physiological targets as alternatives to AHI and the role of novel technology in OSA. We also evaluate the current evidence for using newer technologies in OSA diagnosis, the physiological targets such as smartphone applications and wearable technology. Future developments in OSA diagnosis and assessment will likely focus increasingly on systemic effects of sleep disordered breathing (SDB) such as changes in nocturnal oxygen and blood pressure (BP); and may also include other factors such as circulating biomarkers. These developments will likely require a re-evaluation of the diagnostic and grading criteria for clinically significant OSA.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 Background  In the present post hoc analysis of the DACAB trial, we evaluated the effects of ticagrelor with or without aspirin on 1-year vein graft outcomes after coronary artery bypass grafting (CABG) with and without cardiopulmonary bypass (CPB) (on-pump and off-pump). Methods  The DACAB trial was a multicenter, randomized, open-label, parallel control study enrolling 500 patients with 1,460 vein grafts undergoing CABG. For current post-hoc study, all patients in the DACAB study were included in the analysis to compare the effects of different antiplatelet regimens under on/off pump. Patients were randomly assigned to 1 of 3 antiplatelet treatment regimens (ticagrelor plus aspirin, T + A; ticagrelor alone, T; or aspirin alone, A) within 24 hours after CABG, and were stratified into on-pump and off-pump subgroups. The primary outcome was 1-year vein graft patency rate. Results  Totally 121 patients underwent on-pump CABG (39 with 121 vein grafts in T + A, 36 with 101 vein grafts in T, and 46 with 137 vein grafts in A) and 379 patients underwent off-pump CABG (129 with 336 vein grafts in T + A, 130 with 387 vein grafts in T, and 120 with 348 vein grafts in A). Compared with A, T + A showed a higher 1-year vein graft patency rate in both on-pump (adjusted OR for non-patency =0.62, 95% CI  0.16-2.45) and off-pump (adjusted OR for non-patency =0.35, 95% CI  0.20-0.62) subgroups, P interaction =0.647; whereas T did not in either on-pump (adjusted OR for non-patency = 0.92, 95% CI  0.31-2.76) or off-pump (adjusted OR for non-patency =0.58, 95% CI  0.34-1.00) subgroups, P interaction =0.430. Conclusions  In the DACAB trial, for patients underwent either on-pump or off-pump CABG, ticagrelor plus aspirin showed consistent benefit for achieving 1-year vein graft patency, with particular benefit being seen in the off-pump.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon hypertend</span>,<span class="ansi-cyan-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart valv diseas</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">tricuspid</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocardit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocard</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">cardit</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart valve diseases,Heart failure,Inflammatory diseases,Diseases of arteries,
 Background  To analyze the risk factors of chronic left ventricular dysfunction (LVD) after cardiac valve surgery. Methods  A retrospective analysis of 860 patients who underwent heart valve surgery in our center from January 2017 to December 2018, including 650 males and 210 females, aged 58+/-5.8 years. Inclusion criteria  (I) the patient was clinically diagnosed with heart valve disease and met the surgical indications for mitral valve replacement (MVR), mitral valve repair (MVP), aortic valve replacement (AVR) and double valve replacement (DVR); (II) if atrial fibrillation, coronary artery disease, and tricuspid regurgitation are combined before surgery, radiofrequency ablation, coronary bypass and tricuspid angioplasty were performed contemporarily. Exclusion criteria  (I) preoperative LVEF &lt;50%; (II) aortic dissection underwent Bentall and right heart valve replacement procedures; (III) cardiopulmonary resuscitation and death during perioperative period and 6 months after operation; (IV) postoperative CRRT, IABP, or ECMO assistance; (V) postoperative cardiac dysfunction due to valvular dysfunction, perivalvular leak, or infective endocarditis. Patients were divided into LVD group (LVEF &lt;40%) and control group (LVEF &gt;/=40%) based on cardiac LVEF at 6 months after surgery. Logistic regression was used to analyze the risk factors of postoperative LVD. Results  There were 126 cases in LVD group and 734 cases in control group. There were significant differences in preoperative coronary artery disease, atrial fibrillation, pulmonary hypertension, NYHA classification, left ventricular end diastolic diameter (LVEDD), and left ventricular end systolic diameter (LVESD) between the two groups (P&lt;0.05). The differences in the changes of LVEDD and LVESD before and after operation between the two groups were statistically significant (P&lt;0.05). Logistic regression analysis showed that preoperative LVEDD &gt;55 mm, preoperative LVESD &gt;40 mm, preoperative combined atrial fibrillation, preoperative combined pulmonary hypertension, preoperative NYHA III-IV, and preoperative combined coronary artery disease were the risks of postoperative chronic LVD. Conclusions  The left ventricular diameter, preoperative coronary artery disease, NYHA III-IV, preoperative atrial fibrillation, and preoperative pulmonary hypertension are risk factors for chronic LVD after heart valve surgery.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Background  Aortic dissection is one of the most detrimental cardiovascular diseases with a high risk of mortality and morbidity. This study aimed to examine the key genes and microRNAs associated with Stanford type A aortic dissection (AAD). Methods  The expression data of AAD and healthy samples were downloaded from two microarray datasets in the Gene Expression Omnibus (GEO) database to identify highly preserved modules by weighted gene co-expression network analysis (WGCNA). Differentially expressed genes (DEGs) and differentially expressed miRNAs (DEmiRNAs) were selected and functionally annotated. The predicted interactions between the DEGs and DEmiRNAs were further illustrated. Results  In two highly preserved modules, 459 DEGs were identified. These DEGs were functionally enriched in the HIF1, Notch, and PI3K/Akt pathways. Furthermore, 6 DEmiRNAs that were enriched in the regulation of vasculature development and HIF1 pathway, were predicted to target 23 DEGs. Conclusions  Our study presented several promising modulators, both DEGs and DEmiRNAs, as well as possible pathological pathways for AAD, which narrows the scope for further fundamental research.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Background  Adults with unrepaired tetralogy of Fallot (ToF) are common in developing countries. Long-term overload of the right ventricle places adult patients at risk for postoperative right heart failure after primary repair, which contributes to morbidity and mortality. The effect of pulmonary valve replacement (PVR) in reducing postoperative morbidity and mortality in adults has never been validated. Methods  We conducted a retrospective cohort study in adults (age &gt;/=18 years) with ToF undergoing primary repair from January 2014 to December 2019 at our institution. Patients were divided into three groups according to techniques used to enlarge the right ventricle outflow tract (RVOT). Baseline variables and perioperative outcomes were collected. The primary endpoint was operative mortality. Secondary endpoints were incidences of right heart failure and stage 3 acute kidney injury (AKI). Results  A total of 56 patients were enrolled (mean age 41.5+/-11.7 years, 30 females, 53.6%). They were divided into three groups designated as the following  TA-PVR group for trans-annular patch enlargement with PVR; TA group for trans-annulus patch enlargement without PVR; and group AP for annulus preservation. Four patients (7.1%) died postoperatively, all due to right heart failure. All twelve patients in the TA-PVR group survived. There was no significant difference in mortalities among groups. Ten patients (17.9%) developed right heart failure after surgery with no significant difference among groups. Three patients (5.4%) developed stage 3 AKI after surgery, none belonging to the TA-PVR group, however, not statistically significant. Conclusions  Right heart failure is a common complication after primary repair of adult ToF. Trans-annulus patch enlargement should be cautiously selected in this population. PVR with trans-annulus patch enlargement may be a promising technique to protect against postoperative right heart failure and mortality when annulus preservation is not feasible.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">tamponad</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,
 Background  Delayed extubation after cardiac surgery is associated with high morbidity and mortality, increased intensive care unit length of stay, and healthcare cost. Acute type A aortic dissection (ATAAD) generally results in prolonged mechanical ventilation due to the complexity of surgical management and some postoperative complications. This study aimed to elucidate the perioperative risk factors for delayed extubation in patients undergoing ATAAD surgery. Methods  A retrospective cohort study including 239 patients who were diagnosed with ATAAD and underwent emergency surgery from October 2004 to January 2018 was performed. The potential perioperative risk factors for delayed extubation were collected. This study defined delayed extubation as the time to commence extubation being greater than 48 hours. The clinical data were analyzed with univariate and multivariate analyses to identify risk factors for delayed extubation following ATAAD surgery. Results  The incidence of delayed extubation was 48.5% (n=116). Multiple logistic regression analysis showed perioperative risk factors for delayed extubation included preoperative cardiac tamponade [odds ratio (OR) 3.94, 95% confidence interval (CI) 1.39-11.17, P=0.010], central arterial cannulation (ascending aorta and proximal aortic arch) for cardiopulmonary bypass (CPB) (OR 4.04, 95% CI  1.03-15.91, P=0.046), postoperative stroke (OR 10.58, 95% CI  2.65-42.25, P=0.001), postoperative renal dysfunction that required temporary hemodialysis (OR 6.60 95% CI  1.97-22.11, P=0.002), and re-exploration to stop bleeding (OR 2.65, 95% CI  1.00-6.99, P=0.050). Conclusions  Preoperative cardiac tamponade, central arterial cannulation for CPB, postoperative stroke, postoperative renal dysfunction that required temporary hemodialysis, and re-exploration to stop bleeding are perioperative risk factors for delayed extubation. Identification of the potential risk factors for delayed extubation may help optimize the perioperative management and improve postoperative outcomes of patients undergoing ATAAD surgery.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 Background  Persistent cardiac hypertrophy threatens health worldwide. Long non-coding RNAs (lncRNAs) attracted lots of attention in cardiac diseases such as cardiac hypertrophy. In this study, we aimed to study the function of KCNQ1OT1 in cardiac hypertrophy. Methods  We first used qRT-PCR to detect the expression of KCNQ1OT1 in Ang-II-induced cardiomyocytes and mouse cardiac hypertrophy models. The function of KCNQ1OT1 was investigated by a loss-of-function test. Analysis of the luciferase reporter gene and RNA pulldown confirmed the interaction between KCNQ1OT1 and miR-2054. The target gene of miR-2054 was predicted by bioinformatics analysis and confirmed by luciferase reporter gene detection. Rescue experiments were performed to evaluate the role of miR-2054/AKT3 in the function of KCNQ1OT1. Results  Our results suggested that KCNQ1OT1 was up-regulated in Ang-II-induced cardiomyocytes and transverse aortic constriction (TAC) mice. Knocking down of KCNQ1OT1 can reduce cell size and downregulate the expression of ANF, BNP and alpha-MHC in response to Ang-II. KCNQ1OT1 has been shown to compete competitively with miR-2054 and has a negative correlation with its expression. The combination of miR-2054 can reverse the effect of the KCNQ1OT1 combination in Ang-II-induced cardiomyocytes. In addition, AKT3 is a target of miR-2054 and mediates its effect on Ang-II-induced cardiomyocytes. Conclusions  Knockdown of KCNQ1OT1 could attenuate cardiac hypertrophy through modulation of the miR-2054/AKT3 axis.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Background  Valve-sparing aortic root replacement (VSARR), which includes reimplantation and remodeling techniques, has been developed as an important treatment for aortic root aneurysms. We aimed to evaluate the outcomes of reimplantation versus remodeling techniques in valve-sparing surgery for aortic root aneurysms. Methods  A systematic review and meta-analysis was performed by searching PubMed, Embase and the Cochrane Library until November 2019. Fourteen retrospective cohort studies comparing reimplantation with remodeling techniques for aortic root aneurysms were included and contained at least one of the following outcomes  early mortality, late mortality, aortic valve-related reoperation, and postoperative moderate to severe aortic regurgitation (AR). Results  The outcomes of 1,672 patients (1,011 underwent reimplantation surgery, and 661 underwent remodeling) were analyzed. Compared with remodeling, the reimplantation technique was associated with a significantly lower risk of late mortality (RR =0.34; 95% CI, 0.17-0.71; P=0.004; I(2)=37%) and reoperation (RR =0.31; 95% CI, 0.12-0.76; P=0.01; I(2)=55%). There was no significant difference in early mortality (RR =0.69; 95% CI, 0.31-1.53; P=0.36; I(2)=0%), postoperative moderate to severe AR (RR =0.64; 95% CI, 0.31-1.32; P=0.22; I(2)=36%) or postoperative stroke (RR =1.26; 95% CI, 0.58-2.75; P=0.56; I(2)=0%) between the two groups. No evidence of publication bias was detected. Conclusions  The current meta-analysis indicate that patients who undergo reimplantation procedures have a significantly lower risk of late mortality and reoperation than those who undergo remodeling procedures. Early mortality, postoperative moderate to severe AR and stroke were comparable between the two techniques.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 Background  Aortic arch disease with Kommerell&#39;s diverticulum is an uncommon but troublesome condition, and there are a variety of therapeutic modalities for treating this. We retrospectively analyzed cases who underwent open surgery to summarize different situations and approaches. Methods  From November 2015 to January 2019, nine patients underwent operation for the mentioned disorder. Four patients with aortic dissection received total arch replacement. Two patients suffering from type B aortic dissection (TBAD) have accepted graft replacement from ascending aorta (aAO) to descending aorta. Two patients with true aneurysm and congenital malformation underwent graft bypass from aAO to descending aorta. One patient had graft replacement of descending aorta. Results  There were nine (eight males and one female) patients with median age of 45 (from 14 to 54) years. The 30-day mortality was 11.1% (1 patient) due to refractory respiratory failure caused by compression of bronchus. One patient had complication of peripheral neuropathy and recovered eventually. Eight patients were followed-up for a median period of 20 [9-46] months. All patients were alive and had no long-term complications except one patient who received re-intervention due to delayed dilation of downstream aorta. Conclusions  Treatment for different arch lesions with Kommerell&#39;s diverticulum should follow corresponding indications. Open surgery is the preferred choice and detailed therapeutic strategy depends on the extension of aneurysm, classification and phase of dissection. Stenting might cause airway compression when right-sided arch and vascular ring exist.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Background  The Type D Personality (TDP) has been specifically linked to acute myocardial infarction (AMI). However, the impact on prehospital delay of AMI patients is unclear. The aim of this study was to assess the relationship between TDP and pre-hospital delay time (PHT) in a Chinese population. Methods  A total of 256 AMI patients (47 women and 209 men) were taken from the Multicenter Delay in Patients Experiencing AMI in Shanghai (MEDEA FAR-EAST) study. Sociodemographic and psycho-behavioral characteristics were assessed by bedside interviews and questionnaires. TDP was evaluated according to the Type D Personality Scale (DS14) subdivided in social inhibition (SI) and negative affectivity (NA). Based on a significant interaction analysis of TDP and sex on PHT, all analyses were stratified by sex. Results  PHT of female patients with TDP were substantially shorter compared to non-TDP female patients (108 vs. 281 min, P=0.029). In male patients, no effect of TDT on PHT was found. Spearman correlation analysis suggests that NA was negatively correlated with PHT (r=-0.358, P=0.014). Further age-adjusted logistic regression analyses showed that female patients with TDP were generally less likely to prehospital delay compared with non-TDP patients (OR =0.28; 95% CI, 0.08-0.98) and had a lower risk of PHT &gt;360 minutes (OR =0.10; 95% CI, 0.01-0.91). However, statistical significance disappeared after adjustment for psychological factors (anxiety, depression, suboptimal wellbeing, cardiac denial and stress event). Conclusions  TDP is associated with less prehospital delay in female patients during AMI-an effect which may be particularly mediated by NA.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Background  While there is an increasing number of early-stage non-small cell lung cancer (NSCLC) patients with chronic obstructive pulmonary disease (COPD), there are no specific clinical guidelines for treating them. This study aims to evaluate different treatment modalities and corresponding clinical outcomes among early-stage NSCLC patients with COPD. Methods  We retrospectively reviewed 692 patients with stage I and II NSCLC and COPD from January 2012 to June 2014. Patients were categorized into four groups according to primary treatment modality  surgery only group (n=442), surgery with adjuvant treatment group (n=157), radiotherapy (RT) group (n=48), and supportive care (SC)-only group (n=45). Results  Overall, mortality rate was the highest in the SC-only group (35.7 deaths per 100 person-years), followed by RT group (21.5 deaths per 100 person-years), surgery with adjuvant treatment group (8.9 deaths per 100 person-years) and surgery only group (7.2 deaths per 100 person-years). The adjusted hazard ratios (HR) for all-cause mortality compared to the surgery only group were 1.18 (95% CI, 0.84-1.67) in surgery with adjuvant treatment group, 1.61 (95% CI, 1.01-2.57) in RT group and 3.23 (95% CI, 1.99-5.23) in SC-only group. Conclusions  Surgical resection should be considered as the first choice for early-stage NSCLC with COPD. Despite poor lung function or general patient condition, RT rather than SC can be an alternative option if surgery is not feasible. A multi-disciplinary approach and active communication between patients and physicians might be helpful for adequate decision-making regarding treatment for patients with early-stage NSCLC and COPD.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Background  Surgical manipulation of a tumor can lead to shedding of tumor cells that can enter the circulation and lead to metastasis. The present study evaluated the clinical relevance of circulating tumor cells (CTCs) that were identified immediately after non-small cell lung cancer resection in patients without preoperative CTCs, and whether postoperative CTC detection was associated with recurrence. Methods  Immediate preoperative testing for CTCs was performed for 147 patients with pulmonary nodules. This study included 81 lung cancer patients (55.1%) with negative preoperative results for CTCs and who completed postoperative testing for CTCs. The clinical relevance of postoperative CTC detection was evaluated based on the clinicopathological characteristics and recurrence patterns. Results  Among the eligible patients, the postoperative CTC results were none detected in 58 patients (71.6%, &#34;Group N&#34;), only a single CTC detected in 6 patients (7.4%, &#34;Group S&#34;), and CTC clusters detected in 17 patients (21.0%, &#34;Group C&#34;). The presence of postoperative CTCs was associated with tumor vessel invasion, lymph duct invasion, and pleural invasion. Distant metastasis was very common in cases with postoperatively detected CTC clusters. The 2-year recurrence-free survival rates were 94.6% for Group N, 62.5% for Group S, and 52.9% for Group C (P&lt;0.01). Multivariate analysis revealed that recurrence was independently related to the postoperative detection of single CTCs and CTC clusters. Conclusions  In cases without preoperative CTCs, we postoperatively detected CTCs and the postoperative CTC results were an independent predictor of recurrence.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,
 Interest in the use of cell-free nucleic acids (CFNAs) as clinical non-invasive biomarker panels for prediction and prevention of multiple diseases has greatly increased over the last decade. Indeed, circulating CFNAs are attributable to many physiological and pathological processes such as imbalanced stress conditions, physical activities, extensive apoptosis of different origin, systemic hypoxic-ischemic events and tumour progression, amongst others. This article highlights the involvement of circulating CFNAs in local and systemic processes dealing with the question, whether specific patterns of CFNAs in blood, their detection, quantity and quality (such as their methylation status) might be instrumental to predict a disease development/progression and could be further utilised for accompanying diagnostics, targeted prevention, creation of individualised therapy algorithms, therapy monitoring and prognosis. Presented considerations conform with principles of 3P medicine and serve for improving individual outcomes and cost efficacy of medical services provided to the population.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,
 Huangqi Jianzhong Tang (HQJZT) is a traditional Chinese herbal formula consisting of seven different herbs  Radix Astragali, Radix Paeoniae Alba, Ramulus Cinnamomi, Fructus Jujubae, Glycyrrhizae Radix Et Rhizoma Praeparata Cum Melle, Rhizoma Zingiberis Recens, and Saccharum Granorum. The present study aims to evaluate the possible effects of HQJZT on cardiac function in acute myocardial infarction (AMI) and related mechanism. AMI model was established by ligation of the left anterior descending coronary artery followed by one-week HQJZT treatment. Survival rate was calculated. Rat heart function was assessed by heart performance analysis system. 5-Triphenyltetrazolium chloride (TTC) staining was used to observe myocardial infarct size. Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) staining and western blot were applied to evaluate tissue apoptotic level. Treatment with high dose of HQJZT improved cardiac function, reduced infarct size, number of apoptotic cells and expression of apoptotic proteins, Bax (a proapoptotic protein), and increased expression of antiapoptotic protein, Bcl2. However, enalapril (an angiotensin-converting enzyme inhibitor) treatment did not show marked improvement of these parameters. Our present data suggest that HQJZT has potential therapeutic effects to improve cardiac function by regulation of apoptotic signaling pathway.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Growth differentiation factor 15 (GDF-15), a member of the transforming growth factor-beta superfamily, participates in processes associated with myeloma development and its end-organ complications. It plays a significant role in both physiological and abnormal erythropoiesis and regulates iron homeostasis through modulation of hepcidin. It is abnormally secreted in marrow stromal cells of patients with multiple myeloma (MM), which may reflect the tumor microenvironment. We analyzed the associations of serum GDF-15 with clinical characteristics of 73 MM patients (including asymptomatic MM) and the laboratory indices of renal function, anemia, and inflammation. Baseline serum GDF-15 was studied as the predictor of two-year survival. We defined five clinically relevant subgroups of patients (symptomatic MM only, patients with and without remission, patients on chemotherapy, and without treatment). Increased GDF-15 concentrations were associated with more advanced MM stage, anemia, renal impairment (lower glomerular filtration and higher markers of tubular injury), and inflammation. Most of the results were confirmed in the subgroup analysis. Serum cystatin C and urine neutrophil gelatinase-associated lipocalin were associated with GDF-15 independently of other variables. In the studied MM patients, GDF-15 did not significantly predict survival (p = 0.06). Our results suggest that serum GDF-15 reflects myeloma burden and shares a relationship with several markers of prognostic significance, as well as major manifestations.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Growth differentiation factor 15 (GDF-15), a member of the transforming growth factor-beta superfamily, participates in processes associated with myeloma development and its end-organ complications. It plays a significant role in both physiological and abnormal erythropoiesis and regulates iron homeostasis through modulation of hepcidin. It is abnormally secreted in marrow stromal cells of patients with multiple myeloma (MM), which may reflect the tumor microenvironment. We analyzed the associations of serum GDF-15 with clinical characteristics of 73 MM patients (including asymptomatic MM) and the laboratory indices of renal function, anemia, and inflammation. Baseline serum GDF-15 was studied as the predictor of two-year survival. We defined five clinically relevant subgroups of patients (symptomatic MM only, patients with and without remission, patients on chemotherapy, and without treatment). Increased GDF-15 concentrations were associated with more advanced MM stage, anemia, renal impairment (lower glomerular filtration and higher markers of tubular injury), and inflammation. Most of the results were confirmed in the subgroup analysis. Serum cystatin C and urine neutrophil gelatinase-associated lipocalin were associated with GDF-15 independently of other variables. In the studied MM patients, GDF-15 did not significantly predict survival (p = 0.06). Our results suggest that serum GDF-15 reflects myeloma burden and shares a relationship with several markers of prognostic significance, as well as major manifestations.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Growth differentiation factor 15 (GDF-15), a member of the transforming growth factor-beta superfamily, participates in processes associated with myeloma development and its end-organ complications. It plays a significant role in both physiological and abnormal erythropoiesis and regulates iron homeostasis through modulation of hepcidin. It is abnormally secreted in marrow stromal cells of patients with multiple myeloma (MM), which may reflect the tumor microenvironment. We analyzed the associations of serum GDF-15 with clinical characteristics of 73 MM patients (including asymptomatic MM) and the laboratory indices of renal function, anemia, and inflammation. Baseline serum GDF-15 was studied as the predictor of two-year survival. We defined five clinically relevant subgroups of patients (symptomatic MM only, patients with and without remission, patients on chemotherapy, and without treatment). Increased GDF-15 concentrations were associated with more advanced MM stage, anemia, renal impairment (lower glomerular filtration and higher markers of tubular injury), and inflammation. Most of the results were confirmed in the subgroup analysis. Serum cystatin C and urine neutrophil gelatinase-associated lipocalin were associated with GDF-15 independently of other variables. In the studied MM patients, GDF-15 did not significantly predict survival (p = 0.06). Our results suggest that serum GDF-15 reflects myeloma burden and shares a relationship with several markers of prognostic significance, as well as major manifestations.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Background Adult primary intraventricular hemorrhage (PIVH) is a rare type of hemorrhagic stroke that is poorly understood. The study attempts to define the clinical profile, yield of diagnostic cerebral angiography, and prognosis of patients with PIVH. Patients and Methods Retrospective data analysis of all patients with PIVH admitted between February 2015 and February 2019 at a tertiary care center. Outcome was assessed using the modified Rankin scale (mRS) at 6 months. Results and Discussion Our study group of 30 patients constituted 3.3% (30/905) of our spontaneous intracerebral hemorrhage (SICH) patients in the study period. The mean Glasgow Coma Score on admission was 11 +/- 3.33 and the mean IVH Graeb score was 5.2+/-2.4. All patients underwent angiography. Angiography detected moyamoya disease in four patients (13.3%) and aneurysms in two patients (6.6%) and these patients were managed surgically. Extraventricular drainage with intraventricular instillation of Streptokinase was performed in five patients. The rest of the patients was managed conservatively. At 6-month follow-up, 25 patients (83.33%) achieved favorable outcome (mRS score of 0.1 or 2), whereas five (16.66%) patients had a poor outcome (mRS score of 3 or more. Three patients succumbed to the illness. IVH Graeb score and presence of hydrocephalus have significant correlation with poor outcome. Conclusion PIVH is an uncommon entity but carries a better long-term prognosis than SICH angiography helps in diagnosing surgically remediable underlying vascular anomalies and is indicated in all cases of PIVH.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Objective Determine predictors of in-hospital mortality in patients with severe traumatic brain injury (TBI) who underwent decompressive craniectomy. Materials and Methods This retrospective study reviewed consecutive patients who underwent a decompressive craniectomy between March 2017 and March 2020 at our institution, and analyzed clinical characteristics, brain tomographic images, surgical details and morbimortality associated with this procedure. Results Thirty-three (30 unilateral and 3 bifrontal) decompressive craniectomies were performed, of which 27 patients were male (81.8%). The mean age was 52.18 years, the mean Glasgow coma scale (GCS) score at admission was 9, and 24 patients had anisocoria (72.7%). Falls were the principal cause of the trauma (51.5%), the mean anterior-posterior diameter (APD) of the bone flap in unilateral cases was 106.81 mm (standard deviation [SD] 20.42) and 16 patients (53.3%) underwent a right-sided hemicraniectomy. The temporal bone enlargement was done in 20 cases (66.7%), the mean time of surgery was 2 hours and 27 minutes, the skull flap was preserved in the subcutaneous layer in 29 cases (87.8%), the mean of blood loss was 636.36 mL,and in-hospital mortality was 12%. Univariate analysis found differences between the APD diameter (120.3 mm vs. 85.3 mm; p = 0.003) and the presence of midline shift &gt; 5 mm ( p = 0.033). Conclusion The size of the skull flap and the presence of midline shift &gt; 5 mm were predictors of mortality. In the absence of intercranial pressure (ICP) monitoring, clinical and radiological criteria are mandatory to perform a decompressive craniectomy.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 Objective This study aimed to assess the prevalence of cognitive impairment and psychiatric morbidity among the patients attending the rural noncommunicable disease clinic after controlling for various confounders (i.e., psychological morbidity, obesity, gender, level of education, duration of the illness and age). Materials and Methods One-hundred twenty-four patients were evaluated on the Hindi Mental State Examination for the cognitive function, Physical Health Questionnaire-9 for depression, and Generalized Anxiety Disorder-7 for anxiety disorders. Results About one-fourth (26.6%) of the participants had cognitive impairment. The prevalence of cognitive impairment was more among patients with hypertension (35.5%) as compared with the diabetes mellitus (13.6%) and those with comorbid hypertension and diabetes mellitus (26.6%). About one of the participants had depression (35.5%) and 29% of the patients had anxiety disorder. No significant difference was found in the level of cognitive deficits between those with hypertension and diabetes mellitus, when the confounding factors were not taken into account in the analysis. However, after controlling for psychiatric morbidity, obesity, gender, level of education, duration of the illness and age, those with hypertension were found to have significantly higher level of cognitive impairment compared with those with diabetes mellitus. A higher level of dysfunction was seen in the domains of orientation, registration, attention, recall, language, and visuospatial domains. Conclusion Present study suggests that patients of hypertension have higher level of cognitive impairment, when compared with those with diabetes mellitus, even after controlling for various confounders. Lack of difference between the two groups can be accounted by the confounding variables.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 The article focuses on scientific disagreement about the use of statin-related drugs in the prevention of cardiovascular events. The study forms part of an exploration of the broader principle of research polarization, foremost in medicine. The hypothesis is that statin-positive and statin-critical researchers publish in different committed central journals, and that they are financially supported by different dedicated corporate sources. Methodologically we use Web of Science (WoS) analytic tools to perform publication analysis of a time series covering 1998-2018 in three seven-year windows. For each window data is captured based on sets of known statin-positive and statin-critical articles and researchers, and their primary and secondary co-authors. Standard deviation is used as a focused normalization and visual instrument together with Spearman&#39;s correlation coefficient in order to compare frequency distributions of statin-positive and critical journal and sponsor articles. Z-test p-values are used to assess the probability of error concerning the distributions. Findings at general topical level showed that a few journals consistently and significantly occupied top positions, 2 of which, American Journal of Cardiology and Circulation, published articles from both positions. Besides, Journal of the American College of Cardiology served as a major publisher of statin-positive research from 2005, as did European Heart Journal from 2012, replacing American Journal of Cardiology at the top. From 2012 Atherosclerosis and European Journal of Preventive Cardiology served as top-publishers of statin-critical articles. Two central US funding agencies, US Department of Health Human Services and National Institutes of Health (NIH), operated at general topical level across the time series, but the agencies played only a minor role in the divergent research positions. From 2005 statin-positive as well as statin-critical research was mainly sponsored by multinational pharmaceutical companies, predominantly Merck, AstraZeneca and Pfizer. In conclusion, the initial hypothesis about dedicated journals and sponsors was entirely substantiated at the general topical level and at the journal level of research disagreement, but not at sponsor level. Distinct dedicated journals were extracted separately from the 2 divergent statin positions. Since the WoS coverage of sponsor data 1998-2004 was sporadic sponsor data are analyzed from 2005. Only from 2012 the WoS sponsor coverage of the topic is consistently at 60%.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 To determine if metabolic characteristics differed in women with and without polycystic ovary syndrome (PCOS) between a Caucasian and Middle East population. Comparative cross-sectional analysis. Demographic and metabolic data from Middle Eastern women from Qatar Biobank (97 with PCOS, 622 controls) were compared to a Caucasian PCOS biobank in Hull UK (108 with PCOS, 69 controls). In both populations, PCOS women showed a worse cardiovascular risk profile of increased systolic and diastolic blood pressure, increased C-reactive protein (CRP), reduced HDL, insulin resistance as well as increased androgens compared to their respective controls without PCOS. UK women without PCOS had higher systolic and diastolic blood pressures, and increased testosterone results (p &lt; 0.01) compared to Middle Eastern women without PCOS who had higher inflammatory markers (WBC and CRP), HDL and insulin resistance (p &lt; 0.001). UK PCOS women had a higher body mass index, systolic and diastolic blood pressures, triglycerides (p &lt; 0.01), whilst Middle Eastern PCOS women showed increased testosterone, free androgen index, HDL and CRP (P &lt; 0.01). There was no difference in insulin or insulin resistance between the two PCOS cohorts. This study highlights ethnic population differences because, whilst cardiovascular risk indices were increased for both PCOS cohorts, this may be for different reasons  BMI, waist and hip measurements, systolic and diastolic blood pressure, and triglycerides were higher in the UK cohort whilst testosterone, HDL and CRP were higher in the Middle East population. Insulin resistance did not differ between the two PCOS populations despite differences in BMI.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">rhe</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Shiga-toxigenic Escherichia coli (STEC) infection causes severe bloody diarrhea, renal failure, and hemolytic uremic syndrome. Recent studies showed global increases in Locus for Enterocyte Effacement (LEE)-negative STEC infection. Some LEE-negative STEC produce Subtilase cytotoxin (SubAB), which cleaves endoplasmic reticulum (ER) chaperone protein BiP, inducing ER stress and apoptotic cell death. In this study, we report that SubAB induces expression of a novel form of Lipocalin-2 (LCN2), and describe its biological activity and effects on apoptotic cell death. SubAB induced expression of a novel LCN2, which was regulated by PRKR-like endoplasmic reticulum kinase via the C/EBP homologous protein pathway. SubAB-induced novel-sized LCN2 was not secreted into the culture supernatant. Increased intracellular iron level by addition of holo-transferrin or FeCl3 suppressed SubAB-induced PARP cleavage. Normal-sized FLAG-tagged LCN2 suppressed STEC growth, but this effect was not seen in the presence of SubAB- or tunicamycin-induced unglycosylated FLAG-tagged LCN2. Our study demonstrates that SubAB-induced novel-sized LCN2 does not have anti-STEC activity, suggesting that SubAB plays a crucial role in the survival of LEE-negative STEC as well as inducing apoptosis of the host cells.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 In patients with aortic coarctation it would be desirable to assess pressure gradients as well as information about blood flow profiles at rest and during exercise. We aimed to assess the hemodynamic responses to physical exercise by combining MRI-ergometry with computational fluid dynamics (CFD). MRI was performed on 20 patients with aortic coarctation (13 men, 7 women, mean age 21.5 +/- 13.7 years) at rest and during ergometry. Peak systolic pressure gradients, wall shear stress (WSS), secondary flow degree (SFD) and normalized flow displacement (NFD) were calculated using CFD. Stroke volume was determined based on MRI. On average, the pressure gradient was 18.0 +/- 16.6 mmHg at rest and increased to 28.5 +/- 22.6 mmHg (p &lt; 0.001) during exercise. A significant increase in cardiac index was observed (p &lt; 0.001), which was mainly driven by an increase in heart rate (p &lt; 0.001). WSS significantly increased during exercise (p = 0.006), whereas SFD and NFD remained unchanged. The combination of MRI-ergometry with CFD allows assessing pressure gradients as well as flow profiles during physical exercise. This concept has the potential to serve as an alternative to cardiac catheterization with pharmacological stress testing and provides hemodynamic information valuable for studying the pathophysiology of aortic coarctation.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">vasospa</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Diseases of arteries,Coagulopathies,
 OBJECTIVE  To determine whether thrombectomy is safe in children up to 24 hours after onset of symptoms when selected by mismatch between clinical deficit and infarct. METHODS  A secondary analysis of the Save ChildS Study (01/2000-12/2018) was performed, including all pediatric patients (&lt;18 years), diagnosed with Arterial Ischemic Stroke who underwent endovascular recanalization at 27 European and United States stroke centers. Patients were included if they had a relevant mismatch between clinical deficit and infarct. RESULTS  Twenty children with a median age of 10.5 years (interquartile range; IQR 7-14.6) were included. Of those 7 were male (35%) and median time from onset to thrombectomy was 9.8 hours (IQR 7.8-16.2). Neurologic outcome improved from a median Pediatric National Institutes of Health Stroke Scale (PedNIHSS) score of 12.0 (IQR, 8.8-20.3) at admission to 2.0 (IQR, 1.2-6.8) at day 7. Median modified Rankin Scale (mRS) score was 1.0 (IQR, 0-1.6) at 3 months and 0.0 (IQR, 0-1.0) at 24 months. One patient developed transient peri-interventional vasospasm; no other complications were observed. A comparison of the mRS to the mRS in the DAWN and DEFUSE 3 trials revealed a higher proportion of good outcomes in the pediatric compared to the adult study population. CONCLUSIONS  Thrombectomy in pediatric ischemic stroke in an extended time window of up to 24 hours after onset of symptoms seems safe and neurological outcomes are generally good, if patients are selected by a mismatch between clinical deficit and infarct. CLASSIFICATION OF EVIDENCE  This study provides Class IV evidence that for children with acute ischemic stroke with a mismatch between clinical deficit and infarct size, thrombectomy is safe.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischaem</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Coagulopathies,
 OBJECTIVE  This tertiary analysis from AVERT examined fatal and non-fatal Serious Adverse Events (SAEs) at 14 days. METHOD  AVERT was a prospective, parallel group, assessor blinded, randomized international clinical trial comparing mobility training commenced &lt;24 hours post stroke, termed very early mobilization (VEM) to usual care (UC). Primary outcome was assessed at 3 months. Included  Patients with ischaemic and haemorrhagic stroke within 24 hours of onset. Treatment with thrombolytics allowed. Excluded  Patients with severe premorbid disability and/or comorbidities. Interventions continued for 14 days or hospital discharge if less. The primary early safety outcome was fatal SAEs within 14 days. Secondary outcomes were non-fatal SAEs classified as neurologic, immobility-related, and other. Mortality influences were assessed using binary logistic regression adjusted for baseline stroke severity (NIHSS) and age. RESULTS  2,104 participants were randomized to VEM (n = 1,054) or UC (n = 1,050) with a median age of 72 years (IQR 63-80) and NIHSS 7 (IQR 4-12). By 14 days, 48 had died in VEM, 32 in UC, age and stroke severity adjusted Odds Ratio of 1.76 (95% CI 1.06-2.92, p = 0.029). Stroke progression was more common in VEM. Exploratory subgroup analyses showed higher odds of death in intracerebral haemorrhage and &gt;80 years subgroups, but there was no significant treatment by subgroup interaction. No difference in non-fatal SAEs found. CONCLUSION  While the overall case fatality at 14 days post-stroke was only 3.8%, mortality adjusted for age and stroke severity was increased with high dose, intensive training compared to usual care. Stroke progression was more common in VEM. CLASSIFICATION OF EVIDENCE  This study provides Class I evidence that very early mobilization increases mortality at 14 days post stroke. TRIAL REGISTRATION  Australian New Zealand Clinical Trials Registry, ACTRN12606000185561.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Poor metabolic control and host genetic predisposition are critical for diabetic kidney disease (DKD) development. The epigenome integrates information from sequence variations and metabolic alterations. Here, we performed a genome-wide methylome association analysis in 500 subjects with DKD from the Chronic Renal Insufficiency Cohort for DKD phenotypes, including glycemic control, albuminuria, kidney function, and kidney function decline. We show distinct methylation patterns associated with each phenotype. We define methylation variations that are associated with underlying nucleotide variations (methylation quantitative trait loci) and show that underlying genetic variations are important drivers of methylation changes. We implemented Bayesian multitrait colocalization analysis (moloc) and summary data-based Mendelian randomization to systematically annotate genomic regions that show association with kidney function, methylation, and gene expression. We prioritized 40 loci, where methylation and gene-expression changes likely mediate the genotype effect on kidney disease development. Functional annotation suggested the role of inflammation, specifically, apoptotic cell clearance and complement activation in kidney disease development. Our study defines methylation changes associated with DKD phenotypes, the key role of underlying genetic variations driving methylation variations, and prioritizes methylome and gene-expression changes that likely mediate the genotype effect on kidney disease pathogenesis.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocard</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Inflammatory diseases,Coagulopathies,
 BACKGROUND/AIM  Cardiac papillary fibroelastomas (CPF) are benign tumors, frequently asymptomatic, characterized by a mobile pedunculated mass that arises from the endocardium. When CPF is located in the left ventricle, it may protrude into the left ventricular outflow tract and affect hemodynamics. They are highly thrombogenic, and can also cause some life-threatening events such as cerebral and peripheral embolization. CASE REPORT  We herein report a case of a 74-year-old female admitted to our center with palpitations and dyspnea on exertion. Her past medical history revealed that she had had a transient ischemic attack 7 months before presentation. Echocardiography and cardiac magnetic resonance imaging revealed an intracardiac mass anchored in the anteroapical interventricular septum without interference with aortic or mitral valve functionality. Surgical resection of the left ventricular mass was performed through the left apical ventriculotomy approach. Histopathological examination of the tumor was suggestive of papillary fibroelastoma. The postoperative course was uneventful. The patient was discharged home on the eighth postoperative day, with no recurrence at 6 months. CONCLUSION  Although left ventricular papillary fibroelastomas are benign tumors, they carry a high risk for embolic complications and therefore surgery should be proposed, the transapical approach being a safe and effective method.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Diseases of arteries,
 BACKGROUND  Little is known about the clinical outcomes of acute myocardial infarction (AMI) in patients with a history of malignant tumor (MT). PATIENTS AND METHODS  We retrospectively studied 1,295 consecutive patients with AMI who underwent primary percutaneous coronary intervention within 24 hours of onset. The patients were divided into two groups  those with a history of MT (MT group, n=50) and those without (non-MT group, n=1,245). RESULTS  The MT group was older, and had lower hemoglobin, total protein, and albumin levels. All-cause mortality and re-admission rates due to acute decompensated heart failure (ADHF) were significantly higher in the MT group. Multivariate analysis showed that a history of MT was an independent predictor for all-cause mortality and re-admission due to ADHF. CONCLUSION  The clinical outcomes of patients with AMI with a history of MT are poor, and a history of MT is an independent predictor for all-cause mortality and re-admission due to ADHF. These patients may need careful risk management for heart failure to avoid re-admissions due to ADHF.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Diseases of arteries,
 BACKGROUND  Survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT) has increased but so have long-term sequelae. New-onset post-transplant diabetes mellitus (PTDM) occurs frequently following allo-HSCT. PATIENTS AND METHODS  Study endpoints were incidence and risk factors of PDTM. We studied 599 adult patients suffering from either acute myeloid leukemia n=220), acute lymphoblastic leukemia (n=79), chronic myeloid leukemia (n=22), myelodysplastic syndrome/myeloproliferative neoplasm (n=105), chronic lymphocytic leukemia (n=37), lymphoma/myeloma (n=116, or non-malignant disorders (e.g. bone marrow failure, hemoglobinopathies) (n=20) who underwent myeloablative (466; 77.8%) or non-myeloablative (131; 21.9%) allo-HSCT between 2006 and 2016. RESULTS  Altogether, 39 patients (6.5%) developed PTDM. In a competing-risk analysis, time to PTDM was associated with acute grade 2-4 graft-versus-host-disease (p=0.017). Further cardiovascular risk factors were hypertension (n=145; 24.2%), coronary artery disease (n=36, 6%), dyslipidemia (n=139; 23.3%), and stroke (n=12; 2%). CONCLUSION  After allo-HSCT, a significant number of patients developed PTDM and patients with acute graft-versus-host-disease were found to have a higher risk for PTDM. Long-term and continuous follow-up for diabetes and cardiovascular risk factors after HSCT is important in order to be able to provide timely and appropriate treatment.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Diseases of arteries,
 BACKGROUND/AIM  Thyroid dysfunction, both hypo- and hyperthyroidism, has been associated with cardiovascular disease. The aim of this study was to evaluate the association between thyroid dysfunction and atherosclerosis measured mostly by carotid intima-media thickness, as well as discuss whether L-T4 replacement is able to reverse or slow down the progression of atherosclerosis. MATERIALS AND METHODS  The review was conducted according the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. We performed on PubMed a literature search from May 2004 to January 2020, using the search terms &#39;subclinical hypothyroidism&#39; or &#39;thyroid disorders&#39; and &#39;carotid artery&#39;, &#39;carotid intima-media thickness (IMT)&#39;, &#39;levothyroxine&#39;, and &#39;atherosclerosis&#39;. RESULTS  Twenty-six studies were eligible and included in the analysis. Overall, the studies encompassed a total of 36.434 patients included in this review. Most studies indicated a proportional correlation between IMT and thyroid dysfunction. Levothyroxine (L-T4) replacement led to significant decrease of IMT after 1 year in most studies. CONCLUSION  Most studies have concluded that thyroid dysfunction is associated with arterial wall remodeling and, thus, with increased cardiovascular risk. However, the exact mechanistic background of pathological structural changes in the arterial wall is still unsettled. Large randomized controlled studies are required to definitively address the extent to which T4 replacement therapy might benefit patients with subclinical thyroid disorders.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 BACKGROUND/AIM  Lipid-lowering drugs have been suggested to affect neurocognitive function. This review aimed to give the latest evidence on the way these agents affect neurocognitive function based on clinical trials. MATERIALS AND METHODS  A systematic search concerning original studies from 2015 to 2020 was performed through the databases PubMed, EMBASE and Cochrane, according to the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines. The trials enrolled numerous patients and were conducted in different areas of the world. The terms used are cholesterol, lipid-lowering drugs, statins and cognitive function. RESULTS  Eleven randomized trials met the inclusion criteria. The trials included patients suffering from cardiovascular conditions. In particular, patients with coronary heart disease, coronary heart disease risk equivalents and hypercholesterolemia were tested. The trials included evolocumab, alirocumab, statin, ezetimibe or placebo. CONCLUSION  Lipid-lowering drugs seem to have no significant effect on neurocognitive function, but further research specifically focused on this matter is needed.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">cerebrovascul</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Diseases of arteries,Coagulopathies,
 BACKGROUND  Many factors are driving total knee arthroplasty to be performed more commonly as an outpatient (&lt;24 hour discharge) procedure. Nonetheless, the safety of total knee replacements performed in the outpatient setting is not well established when compared with inpatient setting. The purpose of this study is to compare the postoperative outcomes of outpatient and inpatient total knee arthroplasties. METHODS  The 2015 and 2016 American College of Surgeons National Surgical Quality Improvement Program data sets were queried to extract patients who underwent primary, elective, unilateral total knee arthroplasty. The primary outcome was serious adverse events defined by a composite outcome including  return to operating room, wound-related infection, thromboembolic event, renal failure, myocardial infarction, cardiac arrest requiring cardiopulmonary resuscitation, cerebrovascular accident, use of ventilator &gt;48 hours, unplanned intubation, sepsis/septic shock, and death. Propensity matched analysis was used to adjust for potential confounding covariates. RESULTS  1099 patients undergoing outpatient total knee arthroplasty (1% of total cases) were successfully matched to 1099 patients undergoing inpatient surgeries. The composite rate of serious adverse events was greater in outpatient procedures compared with inpatient procedures (3.18% vs 1.36%, p=0.005). In contrast, failure to rescue and readmission rates were not different between groups. CONCLUSIONS  Outpatient total knee arthroplasty is associated with a higher composite risk of serious adverse events than inpatient procedures. Anesthesiologists and surgeons should inform patients and discuss this information when obtaining consent for surgery and planning for discharge timing.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 The inability of the adult mammalian heart to regenerate represents a fundamental barrier in heart failure management. In contrast, the neonatal heart retains a transient regenerative capacity, but the underlying mechanisms for the developmental loss of cardiac regenerative capacity in mammals are not fully understood. Wnt/beta-catenin signaling has been proposed as a key cardio-regenerative pathway driving cardiomyocyte proliferation. Here, we show that Wnt/beta-catenin signaling potentiates neonatal mouse cardiomyocyte proliferation in vivo and immature human pluripotent stem cell-derived cardiomyocyte (hPSC-CM) proliferation in vitro In contrast, Wnt/beta-catenin signaling in adult mice is cardioprotective but fails to induce cardiomyocyte proliferation. Transcriptional profiling and chromatin immunoprecipitation sequencing of neonatal mouse and hPSC-CM revealed a core Wnt/beta-catenin-dependent transcriptional network governing cardiomyocyte proliferation. In contrast, beta-catenin failed to re-engage this neonatal proliferative gene network in the adult heart despite partial transcriptional re-activation of a neonatal glycolytic gene program. These findings suggest that beta-catenin may be repurposed from regenerative to protective functions in the adult heart in a developmental process dependent on the metabolic status of cardiomyocytes.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 RASA1, a negative regulator of Ras-MAPK signaling, is essential for the development and maintenance of lymphatic vessel valves. However, whether RASA1 is required for the development and maintenance of lymphovenous valves (LVV) and venous valves (VV) is unknown. In this study we show that induced disruption of Rasa1 in mouse embryos did not affect initial specification of LVV or central VV but did affect their continued development. Similarly, switch to expression of a catalytically inactive form of RASA1 resulted in impaired LVV and VV development. Blocked development of LVV was associated with accumulation of the basement membrane protein, collagen IV, in LVV-forming EC and could be partially or completely rescued by MAPK inhibitors and drugs that promote collagen IV folding. Disruption of Rasa1 in adult mice resulted in venous hypertension and impaired VV function that was associated with loss of EC from VV leaflets. In conclusion, RASA1 functions as a negative regulator of Ras signaling in EC that is necessary for EC export of collagen IV, thus permitting the development of LVV and the development and maintenance of VV.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 BACKGROUND  Due to the rising disease burden of cardiometabolic diseases (CMD), prevention programs for CMD are increasingly implemented in primary care. Organizational practice characteristics and availability of preventive services may be associated with a more effective program. AIM  To identify possible organizational success factors from general practices related to an effective primary prevention program for CMD. DESIGN &amp; SETTING  A prospective intervention study involving 37 Dutch general practices. METHOD  Patients aged 45-70 years without known CMD, hypertension or hypercholesterolemia were invited for the prevention program. The outcome measures were an improvement (yes/no) in four different CMD risk factors between baseline and one year follow-up on individual level (BMI, smoking, systolic blood pressure and cholesterol ratio). Multivariate logistic regression analysis was used for assessing associations between practice organizational characteristics and outcomes. RESULTS  Just over half of the participants showed an improvement on one or more risk factors. Marginal differences were found in the four different outcomes between the practices with different organizational characteristics. None of the practice characteristics we tested showed a significant association with an improvement in one of the outcome measures. CONCLUSION  In this study general practice organizational and preventive services characteristics showed no impact on the effectiveness of a CMD prevention program. Possible explanations could be the effectiveness of protocolized pharmaceutical treatment and only limited contribution of lifestyle programs on the improvement of CMD risk factors. Key words  general practice; primary health care; primary prevention; cardiovascular diseases; risk assessment; organization and administration.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 BACKGROUND  Home self-monitoring of blood pressure is widely used in primary care to assist in the diagnosis of hypertension, as well as to improve clinical outcomes and support adherence to medication. NICE care pathways for hypertension recommend specific guidelines, although they lack detail on supporting patients to self-monitor. AIM  We aimed to elicit primary care practitioners&#39; experiences of managing patients&#39; home blood pressure self-monitoring, across surgeries located in different socio-economic areas. DESIGN AND SETTING  A qualitative focus group study was conducted with a total of 21 primary care professionals. METHODS  Participants were general practitioners and practice nurses, purposively recruited from surgeries in areas of low and high deprivation, according to the English indices of multiple deprivation. We developed six vignettes featuring data from interviews with people who self-monitor and used these in five focus groups. Results were thematically analysed. RESULTS  Themes derived in the thematic analysis largely reflected topics covered by the vignettes. These included  advice onsing purchase of a device, supporting home monitoring, mitigating patient anxiety experienced as a result of home monitoring, valuing patients&#39; data, and effect of socioeconomic factors. CONCLUSION  Our work provides an account of methods used by primary care practitioners in the management of home blood pressure self-monitoring, where guidance may be lacking and primary care practitioners act on their own judgment. Findings complement recent policy documentation, which recognises the need to adopt new ways of working to empower patients (e.g. additional support from healthcare assistants) but lacks detail on how this should be done.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 BACKGROUND  Familial Hypercholesterolaemia (FH), an inherited lipid disorder causing premature heart disease, is severely underdiagnosed. AIM  To evaluated the accuracy of a clinical tool (FAMCAT) for identifying FH in primary care. DESIGN AND SETTING  Retrospective cohort study of 1,030,183 patients, from the UK Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) database, aged over 16 years. METHOD  The FAMCAT algorithm was compared to methods of FH detection recommended by national guidelines (Simon-Broome and Dutch Lipid Clinic Score diagnostic criteria and cholesterols levels &gt;99th centile). Discrimination and calibration were assessed by area under the receiver operating curve (AUC) and comparing observed versus predicted cases. RESULTS  1,707 patients had a diagnosis of FH. FAMCAT showed high levels of discrimination (AUC 0.844, 95% CI 0.834-0.854), performing significantly better than Simon-Broome criteria (AUC 0.730, 95% CI 0.719-0.741), Dutch Lipid Clinic Score (AUC 0.766, 95% CI 0.755-0.778), and screening cholesterols &gt;99th centile (AUC 0.579, 95% CI 0.571-0.588). Inclusion of premature myocardial infarction and fitting cholesterol as a continuous variable improved the accuracy of FAMCAT (AUC 0.894, 95% CI, 0.885-0.903). CONCLUSION  Better performance of the FAMCAT algorithm, compared to other approaches for case-finding of FH in primary care, has been confirmed in a separate population cohort.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 BACKGROUND  A growing interest in reducing occupational sitting has resulted in public health efforts to encourage intermittent standing in workplaces. However, concerns have been raised that standing for prolonged periods may expose individuals to new health hazards, including lower limb atherosclerosis. These concerns have yet to be corroborated or refuted. The purpose of this study was to investigate the association between occupational standing and adverse changes in the Ankle-Brachial Index (ABI). METHODS  We studied 2121 participants from the Jackson Heart Study, a single-site community-based study of African-Americans residing in Jackson, MS. Occupational standing (&#39;never/seldom&#39;, &#39;sometimes&#39;, &#39;often/always&#39;) was self-reported at baseline (2000-2004). ABI was measured at baseline and again at follow-up (2009-2013). RESULTS  Over a median follow-up of 8 years, 247 participants (11.6%) exhibited a significant decline in ABI (eg, ABI decline &gt;0.15). In multivariable-adjusted models, higher occupational standing was not significantly associated with ABI decline (occupational standing sometimes vs never/seldom  OR 1.05; 95% CI 0.67, 1.66; occupational standing often/always vs never/seldom  OR 1.22; 95% CI 0.77, 1.94). Similarly, higher occupational standing was not associated with low ABI at follow-up reflective of peripheral artery disease (ABI &lt;0.90) or high ABI at follow-up reflective of incompressible vessels (ABI &gt;1.40). CONCLUSIONS  In this community-based study of African-Americans, we found no evidence that occupational standing is deleteriously associated with adverse changes in ABI over a median follow-up of 8.0 years. These findings do not provide evidence implicating occupational standing as a risk factor for lower limb atherosclerosis.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 OBJECTIVE  The effects of preventive interventions on cardiovascular autonomic neuropathy (CAN) remain unclear. We examined the effect of intensively treating traditional risk factors for CAN, including hyperglycemia, hypertension, and dyslipidemia, in individuals with type 2 diabetes (T2D) and high cardiovascular risk participating in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. RESEARCH DESIGN AND METHODS  CAN was defined as heart rate variability indices below the fifth percentile of the normal distribution. Of 10,251 ACCORD participants, 71% (n = 7,275) had a CAN evaluation at study entry and at least once after randomization. The effects of intensive interventions on CAN were analyzed among these subjects through generalized linear mixed models. RESULTS  As compared with standard intervention, intensive glucose treatment reduced CAN risk by 16% (odds ratio [OR] 0.84, 95% CI 0.75-0.94, P = 0.003)-an effect driven by individuals without cardiovascular disease (CVD) at baseline (OR 0.73, 95% CI 0.63-0.85, P &lt; 0.0001) rather than those with CVD (OR 1.10, 95% CI 0.91-1.34, P = 0.34) (P interaction = 0.001). Intensive blood pressure (BP) intervention decreased CAN risk by 25% (OR 0.75, 95% CI 0.63-0.89, P = 0.001), especially in patients &gt;/=65 years old (OR 0.66, 95% CI 0.49-0.88, P = 0.005) (P interaction = 0.05). Fenofibrate did not have a significant effect on CAN (OR 0.91, 95% CI 0.78-1.07, P = 0.26). CONCLUSIONS  These data confirm a beneficial effect of intensive glycemic therapy and demonstrate, for the first time, a similar benefit of intensive BP control on CAN in T2D. A negative CVD history identifies T2D patients who especially benefit from intensive glycemic control for CAN prevention.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Inflammatory diseases,
 OBJECTIVE  Diabetes is a risk factor for severe limb ischemia (SLI), a condition associated with high mortality, morbidity, and limb loss. The reactive glucose-derived dicarbonyl methylglyoxal (MGO) is a major precursor for advanced glycation end products (AGEs) and a potential driver of cardiovascular disease. We investigated whether plasma MGO levels are associated with poor outcomes in SLI. RESEARCH DESIGN AND METHODS  We measured plasma levels of MGO, free AGEs, and d-lactate, the detoxification end product of MGO, with ultraperformance liquid chromatography-tandem mass spectrometry at baseline in 160 patients (64.8 +/- 13.3 years, 67.5% male, 37.5% with diabetes) with no-option SLI and recorded major adverse outcomes (n = 86, comprising death n = 53 or amputations n = 49 [first event counted]) over 5-year follow-up. Data were analyzed with linear or Cox regression, after Ln-transformation of the independent variables, adjusted for sex, age, trial arm, diabetes, estimated glomerular filtration rate, systolic blood pressure, cholesterol levels, and BMI. Associations are reported per 1 SD plasma marker. RESULTS  Higher plasma MGO levels were associated with more adverse outcomes (relative risk 1.44; 95% CI 1.11-1.86) and amputations separately (1.55; 1.13-2.21). We observed a similar but weaker trend for mortality (1.28; 0.93-1.77). The MGO-derived AGE N(epsilon)-(carboxyethyl)lysine was also associated with more adverse outcomes (1.46; 1.00-2.15) and amputations (1.71; 1.04-2.79). d-Lactate was not associated with adverse incident outcomes. Higher plasma MGO levels were also associated with more inflammation and white blood cells and fewer progenitor cells. CONCLUSIONS  Plasma MGO levels are associated with adverse outcomes in SLI. Future studies should investigate whether MGO-targeting therapies improve outcomes in SLI.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 Adiponectin, an adipocyte-derived protein, has anti-atherogenic and anti-diabetic effects, but how it confers the anti-atherogenic effects is not well understood. To study the anti-atherogenic mechanisms of adiponectin, we examined whether it interacts with atherogenic low-density lipoprotein (LDL) to attenuate LDL&#39;s atherogenicity. L5, the most electronegative subfraction of LDL, induces atherogenic responses similarly to copper-oxidized LDL (oxLDL). Unlike native LDL endocytosed via the LDL receptor, L5 and oxLDL are internalized by cells via the lectin-like oxidized LDL receptor-1 (LOX-1). Using enzyme-linked immunosorbent assays (ELISAs), we showed that adiponectin preferentially bound oxLDL but not native LDL. In Chinese hamster ovary (CHO) cells transfected with LOX-1 or LDL receptor, adiponectin selectively inhibited the uptake of oxLDL but not of native LDL, respectively. Furthermore, adiponectin suppressed the internalization of oxLDL in human coronary artery endothelial cells (HCAECs) and THP-1-derived macrophages. Western blot analysis of human plasma showed that adiponectin was abundant in L5 but not in L1, the least electronegative subfraction of LDL. Sandwich ELISAs with anti-adiponectin and anti-apolipoprotein B antibodies confirmed the binding of adiponectin to L5 and oxLDL. In LOX-1-expressing CHO cells, adiponectin inhibited cellular responses to oxLDL and L5, including nuclear factor-kappaB activation and ERK phosphorylation. In HCAECs, adiponectin inhibited oxLDL-induced endothelin-1 secretion and ERK phosphorylation. Conversely, oxLDL suppressed the adiponectin-induced activation of adenosine monophosphate-activated protein kinase in COS-7 cells expressing adiponectin receptor AdipoR1. Our findings suggest that adiponectin binds and inactivates atherogenic LDL, providing novel insight into the anti-atherogenic mechanisms of adiponectin.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Diseases of arteries,
 BACKGROUND  Kawasaki disease (KD) is a systemic vasculitis syndrome that occurs most frequently in children. Most clinical and pathological studies have focused on its coronary artery lesions. To date, no detailed studies of the aorta have been conducted. We studied KD autopsy cases with the aims of clarifying the time-course of changes in aortic lesions, the differences in the inflammatory cells and degree of inflammation at various aortic sites, and the progression of the inflammation. MATERIALS AND METHODS  The study materials were aortic specimens taken from 37 KD autopsy cases (acute phase  19; remote phase  18). Twenty-seven of the cases also had coronary aneurysms. We chose 3 aortic sites, i.e., the thoracic aorta, aortic root and aortic bifurcation, and we histologically observed and compared those sites in regard to the changes with time, the kinds of infiltrating cells and the number of inflammatory cells. We also observed the relationship between the vasa vasorum and inflammatory cell localization in the tunica media, and examined the progression of inflammation in the tunica media. RESULTS  Destruction of the vascular architecture was not seen in any of the 37 cases, but inflammatory cell infiltration was observed in 90% of the acute-phase cases. The inflammatory cell infiltration involved the tunica intima and tunica adventitia of the aorta on the 6(th) disease-day, and all layers of the aorta on the 13(th) disease-day; the infiltration peaked on the 18(th) disease-day. The infiltration gradually disappeared thereafter, and no significant infiltration was seen in the remote phase. The infiltrating inflammatory cells consisted mainly of CD163-positive macrophages. Comparison of the three sites of the aorta showed that the inflammatory cell infiltration was more severe in the aortic root and aortic bifurcation than in the thoracic aorta. The progression of inflammation to the aortic tunica media from the adventitia showed two patterns  one in which macrophages were aggregated around the vasa vasorum; and a second in which there was no such aggregation around the vasa vasorum, but there was diffuse inflammatory cell infiltration of the tunica media. In addition to this, there were findings of direct infiltration of cells from the tunica intima into the tunica media. CONCLUSION  Inflammation in KD occurs in the aorta. The changes with time and the kinds of infiltrating cells were the same as reported to date for coronary arteries in KD. There were differences in the degree of inflammation among the 3 aortic sites. It can be thought that the inflammation from the adventitia to the media progresses via the vas vasorum, and also, there is a possibility of spreading directly. From the intima to the media, inflammation spreads directly. However, formation of aneurysms and destruction of the vascular architecture of the aorta were absent in this study, unlike in coronary arteries.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 Preeclampsia is a pregnancy-specific hypertensive disorder characterized by proteinuria, and vascular injury in the second half of pregnancy. We hypothesized that endothelium-dependent vascular dysfunction is present in a murine model of preeclampsia based on administration of human preeclamptic sera to interleukin -10-/- mice and studied mechanisms that underlie vascular injury. Pregnant wild type and IL-10-/- mice were injected with either normotensive or severe preeclamptic patient sera (sPE) during gestation. A preeclampsia-like phenotype was confirmed by blood pressure measurements; assessment of albuminuria; measurement of angiogenic factors; demonstration of foot process effacement and endotheliosis in kidney sections; and by accumulation of glycogen in placentas from IL-10-/- mice injected with sPE sera (IL-10-/-sPE). Vasomotor function of isolated aortas was assessed. The IL-10-/-sPE murine model demonstrated significantly augmented aortic contractions to phenylephrine and both impaired endothelium-dependent and, to a lesser extent, endothelium-independent relaxation compared to wild type normotensive mice. Treatment of isolated aortas with indomethacin, a cyclooxygenase inhibitor, improved, but failed to normalize contraction to phenylephrine to that of wild type normotensive mice, suggesting the additional contribution from nitric oxide downregulation and effects of indomethacin-resistant vasoconstricting factors. In contrast, indomethacin normalized relaxation of aortas derived from IL-10-/-sPE mice. Thus, our results identify the role of IL-10 deficiency in dysregulation of the cyclooxygenase pathway and vascular dysfunction in the IL-10-/-sPE murine model of preeclampsia, and point towards a possible contribution of nitric oxide dysregulation. These compounds and related mechanisms may serve both as diagnostic markers and therapeutic targets for preventive and treatment strategies in preeclampsia.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 AIMS  Hepatic venous pressure gradient (HVPG) is critical for staging and prognosis prediction of portal hypertension (PH). However, HVPG measurement has limitations (e.g., invasiveness). This study examined the value of non-invasive, imaging-based approaches including magnetic resonance elastography (MRE) and intravoxel incoherent motion (IVIM) diffusion-weighted imaging (DWI) for the prediction of HVPG in a porcine model of liver cirrhosis and PH. MAIN METHODS  Male Bama miniature pigs were used to establish a porcine model of liver cirrhosis and PH induced by embolization. They were randomly assigned to an experimental group (n=12) and control group (n=3). HVPG was examined before and after transjugular intrahepatic portosystemic shunt (TIPS). MRE and IVIM-DWI were performed to obtain quantitative parameters including liver stiffness (LS) in MRE, tissue diffusivity (D), pseudo-diffusion coefficient (D*), and perfusion fraction (f) in IVIM-DWI. The correlation between HVPG and the parameters was assessed. KEY FINDINGS  LS values were significantly greater in the experimental group, while f values were significantly decreased at 4, 8, and 12weeks after embolization compared to the control group. Furthermore, HVPG was significantly lower immediately after versus before TIPS. In parallel, LS and f values showed significant alterations after TIPS, and these changes were consistent with a reduction in HVPG. Spearman analysis revealed a significant correlation between the parameters (LS and f) and HVPG. The equation was eventually generated for prediction of HVPG. SIGNIFICANCE  The findings show a good correlation between HVPG and the quantitative parameters; thus, imaging-based techniques have potential as non-invasive methods for predicting HVPG.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Diseases of arteries,
 BACKGROUND  Left main coronary arterial atresia is a rare coronary arterial anomaly with extremely limited data on the optimal management. We aimed to report our single surgeon experience of the ostioplasty in patients with left main coronary arterial atresia. METHODS  From Jul 2018 to Dec 2019, pediatric patients who presented with left main coronary arterial atresia and subsequently underwent surgical coronary ostioplasty were recruited into this retrospective study. Concomitant mitral repair was applied when the regurgitation was moderate or more. RESULTS  A total of 9 patients diagnosed as left coronary arterial atresia were included. Mitral regurgitation was found in all of them, including 6 (66.7%) severe and 1 (11.1%) moderate and 2 (22.2%) mild. In addition to ischemic lesions which was found in 7 (77.8%) patients, structural mitral problem was also common (presented in 7 (77.8%) patients). All the patients underwent coronary ostioplasty with autologous pulmonary arterial patch augmenting anterior wall of the neo-ostium. Mean Aortic cross clamp time and CPB time was 88.1 +/- 18.9 and 124.6 +/- 23.6 min, respectively. During a median of 10.9 (range, 3.3 - 17.2) months follow-up, there was only 1 death at 5 months after surgery. All survivors were recovered uneventfully with normal left ventricular function, however, with 4 (50.0%) significant recurrence of MR. CONCLUSIONS  With favorable surgical outcomes, coronary ostioplasty for LMCA atresia may be an option of revascularization. Structural mitral problems presented in majority patients, resulting in the requirement of concomitant mitral repair. However, the optimal technique of mitral repair remains unclear.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">pericard</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Coagulopathies,
 ETHNOPHARMACOLOGICAL RELEVANCE  Clerodendrum cyrtophyllum Turcz has been used in traditional medicine for the treatment of various diseases. In spite of its therapeutic applications, research on its toxicity and teratogenicity is still limited. AIM OF THE STUDY  The study aimed to investigate the developmental toxicity of the ethanol extract of C. cyrtophyllum (EE) in zebrafish embryo model. MATERIAL AND METHODS  Major compounds from crude ethanol extract of Clerodendron cyrtophyllum Turcz leaves were determined using HPLC-DAD-Orbitrap-MS analysis. The developmental toxicity of EE were investigated using zebrafish embryo model. Zebrafish embryos at 6 h post-fertilization (hpf) were treated with EE at different concentrations. Egg coagulation, mortality, hatching, yolk sac oedema, pericardial oedema and teratogenicity were recorded each day for during a 5-day exposure. At time point 120 hpf, body length, pericardial area, heartbeat and yolk sac area were assessed. In order to elucidate molecular mechanisms for the developmental toxicity of EE, we further evaluated the effects of the EE on the expression of genes involved on signaling pathways affecting fish embryo&#39;s development such as heart development (gata5, myl7, myh6, has2, hand2, nkx 2.5), oxidative stress (cat, sod1, gpx4, gstp2), wnt pathway (beta-catenin, wnt3a, wnt5, wnt8a, wnt11), or cell apoptosis (p53, bax, bcl2, casp3, casp8, casp9, apaf-1, gadd45bb) using qRT-PCR analysis. RESULTS  Our results demonstrated that three major components including acteoside, cirsilineol and cirsilineol-4&#39;-O-beta-D-glucopyranoside were identified from EE. EE exposure during 6- 96 h post-fertilization (hpf) at doses ranging from 80 - 200 mug/ml increased embryo mortality and reduced hatching rate. EE exposure at 20 and 40 mug/ml until 72 - 120 hpf induced a series of malformations, including yolk sac oedema, pericardial oedema, spine deformation, shorter body length. Based on two prediction models using a teratogenic index (TI), a 25% lethality concentration (LD25) and the no observed-adverse-effect level (NOAEL), EE is considered as teratogenic for zebrafish embryos with TI (LC50/EC50) and LD25/NOAEC values at 96 hpf reaching 3.87 and 15.73 respectively. The mRNA expression levels of p53, casp8, bax/bcl2, gstp2, nkx2.5, wnt3a, wnt11, gadd45bb and gata5 were significantly upregulated by EE exposure at 20 and 40 mug/ml while the expression of wnt5, hand2 and bcl2 were downregulated. CONCLUSIONS  These results provide evidence for toxicity effects of EE to embryo stages and provide an insight into the potential toxicity mechanisms on embryonic development.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,
 Percutaneous coronary intervention (PCI) is common in patients with prior coronary artery bypass graft surgery (CABG), however the data on the association between the PCI target-vessel and clinical outcomes are not clear. We aimed to investigate long-term clinical outcomes of patients with prior CABG who underwent PCI of either bypass graft or native artery. We performed a systematic review and meta-analysis of observational studies comparing PCI of either bypass graft or native artery in patients with prior CABG. Twenty-two studies comprising 40,984 patients were included. The median follow-up duration was 2 (1-3) years. Compared with bypass graft PCI, native artery PCI was frequent (61% vs. 39%) and was associated with lower major adverse cardiac events (MACE) (OR 0.51, 95%CI 0.45-0.57, P&lt;0.001), lower all-cause death (OR 0.65, 95%CI 0.49-0.87, P=0.004), lower myocardial infarction (OR 0.56, 95%CI 0.45-0.69, P&lt;0.001), and lower target vessel revascularization (TVR) (OR 0.62, 95%CI 0.51-0.76, P&lt;0.001). There was no significant difference in the early incidence of major bleeding or stroke between the 2 cohorts. In 6 studies involving 2,919 patients with ST-elevation myocardial infarction, there was no significant differences between the 2 cohorts. The increase in TVR risk with bypass graft PCI was associated with MACE. In conclusion, in observational studies involving patients with prior CABG, native artery PCI was associated with lower MACE, all-cause death, myocardial infarction, and TVR compared with bypass graft PCI at a median follow-up of 2 years. Native artery PCI might be considered the preferred treatment for bypass graft failure.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Cardiac output (CO) is routinely assessed by pulsed-wave Doppler echocardiography, yet reference values in adults are lacking. We aim to establish normative values of CO and cardiac index (CI) by pulsed-wave Doppler-echocardiography and to analyze their relationship with gender and age in non-obese and obese adults. We included 4040 adults (mean age  55 years, 53% women, 950 obese [BMI &gt;/=30kg/m(2)]) with normal blood pressure, no history of cardiovascular disease, and normal transthoracic echocardiography. Normative reference CO and CI values for were calculated in 3090 non-obese individuals by quantile regression. CO normal limits were lower in females than in males (lower limit  3.3 vs. 3.5 l/min, upper limit  7.3 vs. 8.2 l/min). CI normal limits were identical for both genders (lower limit  1.9 l/min/m(2), upper limit  4.3 l/min/m(2)). While the relationship of CO to age was weak and observed only in women, CI of both genders was not influenced by age. CO of obese individuals was significantly greater than that of their non-obese counterparts. CI of obese individuals was not influenced by age and gender and was not significantly different than that of non-obese individuals (lower limit 1.8 l/min/m(2), upper limit 4.1 l/min/m(2) for both genders). In conclusion, in a large adult population we establish normative reference values for CO and CI measured by Doppler-echocardiography. CI is a remarkably stable parameter that is not influenced by age, gender, and body size and should be used to define low- and high-output states.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Diseases of arteries,
 Type 2 diabetes mellitus (DM) has a detrimental impact on cardiovascular outcomes, with implications for prognosis following ST elevation myocardial infarction (STEMI).The aim was to evaluate the impact of DM and myocardial perfusion on the long-term risk of heart failure (HF) and/or all-cause mortality following primary percutaneous coronary intervention (pPCI) for STEMI. A total of 406 STEMI patients (104 with DM) treated with pPCI were enrolled in this observational study. Myocardial perfusion was reassessed with the Quantitative Myocardial Blush Evaluator (QuBE). Follow-up data on HF (ICD10 (International Statistical Classification of Diseases) codes I50.0 - I50.9) and all-cause mortality were obtained from the National Health Fund. During a 6-year follow-up, 36 (35%) patients with DM died compared to 45 (15%) patients without DM (P&lt;0.001). Also, 24 (23%) patients with DM developed HF compared to 51 (17%) patients without DM (P=0.20). Patients with DM and HF had the highest mortality rate (75%), and those with DM and a QuBE score below the median value (9.0 arb. units) had significantly higher risk of HF (hazard ratio HR=1.96, 95% CI 1.18-3.27, P=0.0099) and the composite of HF and/or all-cause mortality (HR=1.89, 95% CI 1.33-2.69, P=0.0004). In conclusion DM (type 2) and diminished myocardial perfusion increase the risk of HF and/or all-cause mortality during a 6-year follow-up following pPCI for STEMI.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,
 Peripheral artery disease (PAD) is associated with impaired lower extremity function. We hypothesized that contrast-enhanced magnetic resonance imaging (CE-MRI) based arterial signal enhancement (SE) measures are associated with markers of PAD. A total of 66 participants were enrolled, 10 were excluded due to incomplete data, resulting in 56 participants for the final analyses (36 PAD, 20 matched controls). MR imaging was performed post reactive hyperemia using bilateral thigh blood-pressure cuffs. First pass-perfusion images were acquired at the mid-calf region with a high-resolution saturation recovery gradient echo pulse sequence, and arterial SE was measured for the lower extremity arteries. As expected, peak walking time (PWT) was reduced in PAD patients compared to controls (282 (248-317) sec, vs. 353 (346-360) sec; p=0.002), and post-exercise ankle brachial index (ABI) decreased in PAD patients but not in controls (PAD  0.75 +/- 0.2, 0.60 (0.5-0.7); p&lt;0.001; vs. Controls  1.17 +/- 0.1, 1.19 (1.1-1.2); p=0.50). Intraclass correlation coefficients were excellent for inter- and intra-observer variability of arterial tracings (n=10  0.95 (95%-confidence interval [CI]  0.94-0.96), n=9  1.0 (CI  1.0-1.0). Minimum arterial SE was reduced in PAD patients compared with matched controls (128 (110-147) A.U. vs. 192 (149-234) A.U., p=0.003). Among PAD patients but not in controls the maximum arterial SE was associated with the estimated glomerular filtration rate (eGFR), a marker of renal function (n=36, ss=1.37, R(2)=0.12, p=0.025). In conclusion, CE-MRI first-pass arterial perfusion is impaired in PAD patients compared to matched controls and associated with markers of lower extremity ischemia.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Diseases of arteries,
 Individuals with atrial fibrillation (AF) have risk factors that predispose to thoracic aneurysmal disease (TAD) and atherosclerosis. In this study in individuals with AF, we assessed the occurrence of incidental TAD and assessed if a validated predictive score used to predict AF, the CHARGE-AF score, was associated with greater aortic dimensions. We also assessed the prevalence of coronary calcification. We conducted a cross-sectional study of 1,000 consecutive individuals with AF undergoing chest multidetector CT during evaluation for pulmonary vein isolation. A dilated aortic root (AR) or ascending aorta (AA, dimension/ body surface area &gt;2.05cm/m(2)) were found in 195 (20%). A total of 12 (1%) had significant aortic aneurysmal enlargement of &gt; 5.0cm. Advancing age, a bicuspid aortic valve, hypertension and male gender were associated with increased aortic dimensions. Aortic root dimensions increased linearly (P&lt;0.001) and ascending aortic dimensions increased non-linearly across CHARGE-AF deciles (P&lt;0.001). Nearly two-thirds (63%) had coronary calcification, 38% of whom were not on lipid-lowering therapy. In conclusion, in individuals with AF undergoing gated chest CT, 1 in 5 had previously undetected TAD, with a small proportion having significantly aneurysmal dimensions approaching surgical thresholds. Risk factors previously established to increase the propensity to develop AF are also associated with increased TAD. These findings raise the need to consider a surveillance strategy for TAD in patients with AF, particularly in those with other risk factors for aortic disease. A high prevalence of coronary calcium was also detected, representing an opportunity to optimize statin therapy in patients with AF.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Cardiomyopathy,
 Residence in socioeconomically deprived neighborhoods may influence patient&#39;s health-related behaviors and overall health. We evaluated the association of neighborhood disadvantage on heart failure (HF) symptom burden and hospitalization rates. We characterized neighborhood deprivation in 359 HF subjects (age 56 +/- 13 years, 52% black) in metropolitan Atlanta using the Area Deprivation Index (ADI). ANOVA was used to compare HF symptoms measured using the Kansas City Cardiomyopathy Questionnaire (KCCQ), and HF Self-Care Index across ADI tertiles. Zero-inflated Poisson regression was used to compare rates of recurrent HF hospitalization (HFH) across ADI tertiles. Subjects living in more deprived neighborhoods were more likely to be black, have Medicare or Medicaid insurance, and have a lower ejection fraction than those living in less deprived neighborhoods (all P&lt;/= 0.005). Subjects in more deprived neighborhoods had more severe HF symptoms (P&lt; 0.001), but there was no difference in HF Self-Care Index scores across ADI tertiles. Subjects living in more deprived neighborhoods had a higher odds of being hospitalized for HF than subjects in less deprived neighborhoods. Once subjects had experienced a HFH, however, the association between ADI and the risk of recurrent HFH varied by racial group. Among whites, increasing ADI was associated with a marginally decreased risk of recurrent HFH, while there was no association between ADI and recurrent HFH among blacks. In conclusion, individuals with HF living in more deprived neighborhoods have greater symptom burden and are more likely to experience a HFH than those living in less deprived neighborhoods.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">rhe</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Inflammatory diseases,Diseases of arteries,
 RA is the most common inflammatory arthritis and is associated with increased risk of cardiovascular events and mortality. Evidence regarding outcomes following PCI is limited. This study aimed to assess differences in outcomes following percutaneous coronary intervention (PCI) between patients with and without rheumatoid arthritis (RA). The Melbourne Interventional Group PCI registry (2005-2018) was used to identify 756 patients with RA. Outcomes were compared to the remaining cohort (N=38,579). Patients with RA were older, more often female, with higher rates of hypertension, previous stroke, peripheral vascular disease, obstructive sleep apnoea, chronic lung disease, myocardial infarction, and renal impairment, while rates of dyslipidaemia and current smoking were lower, all p&lt;0.05. Lesions in patients with RA were more frequently complex (ACC/AHA type B2/C), requiring longer stents, with higher rates of no reflow, all p&lt;0.05. Risk of long-term mortality, adjusted for potential confounders, was higher for patients with RA (Hazard Ratio 1.53, 95%CI 1.30-1.80; median follow-up 5.0 years), while 30-day outcomes including mortality, major adverse cardiovascular events, bleeding, stroke, myocardial infarction, coronary artery bypass surgery and target vessel revascularisation were similar. In subgroup analysis, patients with RA and lower BMI (Pfor interaction&lt;0.001) and/or acute coronary syndromes (Pfor interaction=0.05) had disproportionately higher risk of long-term mortality compared to patients without RA. In conclusion, patients with RA undergoing PCI had more comorbidities and longer, complex coronary lesions. Risk of short-term adverse outcomes were similar, while risk of long-term mortality was higher, especially among patients with acute coronary syndromes and lower BMI.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Diseases of arteries,
 The association between serum adiponectin levels and cardiovascular events, particularly how adiponectin predicts the development of cardiovascular events and mortality in acute coronary syndrome (ACS) patients remains unresolved. Hence, we aimed to determine whether higher adiponectin levels predict cardiovascular events and mortality in these patients. Regression analyses were performed to clarify adiponectin&#39;s ability to predict cardiovascular events and mortality among 1641 ACS patients. Subgroup analyses were performed according to sex, age, and body mass index (BMI). The primary endpoint was a composite of the first all-cause death, non-fatal myocardial infarction, or non-fatal stroke event. The secondary endpoint was all-cause death. Hazard ratios (HRs) for the primary and secondary endpoints per 5-microg/ml increase in adiponectin levels were 1.31 [95% confidence interval (CI), 1.13-1.47; p=0.0007] and 1.32 [95% CI, 1.13-1.51; p=0.001], respectively. Higher adiponectin levels were associated with increased cardiovascular events in men, patients aged &gt;/=65 years, and those with BMI &lt;25 kg/m(2). In conclusion, higher adiponectin levels were associated with increased cardiovascular events and all-cause mortality in ACS patients. Its predictive ability might be limited in women, patients aged &lt;65 years, and patients with BMI &gt;/=25 kg/m(2).
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 In patients undergoing transcatheter aortic valve implantation (TAVI), vascular disease is associated with increased risk of mortality. Thoracic aortic calcification (TAC), an objective surrogate of vascular disease, could be a predictor of mortality after TAVI. We aimed to analyze the association between TAC burden and 1-year all-cause mortality in patients undergoing TAVI in a US population. From July 2015 through July 2017, a retrospective review of TAVI procedures was performed at Baylor Scott &amp; White-The Heart Hospital, Plano, Texas. Patients were analyzed for comorbidities, cardiac risk factors, and 30-day and 1-year all-cause mortality. Restricted cubic splines (RCS) analysis was used to define low, moderate, and high TAC categories. The association between TAC and survival was evaluated using unadjusted and adjusted Cox models. A total of 431 TAVI procedures were performed, of which TAC was measured in 374 (81%) patients. Median [IQR] age was 82 [77, 87] years, and 51% were male. Median [IQR] STS PROM was 5.6 [4.1, 8.2] %. Overall 30-day and 1-year all-cause mortality was 1% and 10%, respectively. TAC was categorized as low (&lt;1.6 cm3), moderate (1.6 - 2.9 cm3), and high (&gt;2.9 cm3). At 1 year, all-cause mortality was 16% in patients with high TAC compared to 6% in the low and moderate TAC categories (p=0.008). Unadjusted and adjusted Cox regression analysis showed a significant increase in mortality for patients with high TAC compared with low TAC (HR 2.98, 95% CI [1.34-6.63]), but not significant compared with moderate TAC group. TAC is a predictor of late mortality after TAVI. In conclusion, adding TAC to pre-operative evaluation may provide an objective, reproducible, and potentially widely available tool that can help in shared-decision making.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Over 60% of people over the age of 65 will suffer from multiple diseases concomitantly but the common approach is to treat each disease separately. As age-associated diseases have common underlying mechanisms there is potential to tackle many diseases with the same pharmacological intervention. These are known as geroprotectors and could overcome the problems related to polypharmacy seen with the use of the single disease model. With some geroprotectors now reaching the end stage of preclinical studies and early clinical trials, there is a need to review the evidence and assess how they can be translated practically and effectively into routine practice. Despite promising evidence, there are many gaps and challenges in our understanding that must be addressed to make geroprotective medicine effective in the treatment of age-associated multimorbidity. Here we highlight the key barriers to clinical translation and discuss whether geroprotectors such as metformin, rapamycin and senolytics can tackle all age-associated diseases at the same dose, or whether a more nuanced approach is required. The evidence suggests that geroprotectors&#39; mode of action may differ in different tissues or in response to different inducers of accelerating ageing, suggesting that a blunt &#39;one drug for many diseases&#39; approach may not work. We make the case for the use of artificial intelligence to better understand multimorbidity, allowing identification of clusters and networks of diseases that are significantly associated beyond chance and the underpinning molecular pathway of ageing causal to each cluster. This will allow us to better understand the development of multimorbidity, select a more homogenous group of patients for intervention, match them with the appropriate geroprotector and identify biomarkers specific to the cluster.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 BACKGROUND  High sodium intake can up-regulate the level of renal serum- and glucocorticoid-inducible kinase-1 (SGK1), which plays a pivotal role in controlling blood pressure via activation of the epithelial sodium channel (ENaC), which can lead to salt-sensitive hypertension. Increased potassium intake, or a vegetarian diet, counteracts salt-sensitive hypertension, but the underlying mechanisms are not fully understood. METHODS  Bioinformatics and molecular modeling were used to identify G-quadruplex (G4) and their conformations in the SGK1 promoter. CD spectra and UV melting dynamics were measured to study the stability of G4 as influenced by potassium/sodium balance and resveratrol. RT-PCR and Western blot were employed to study the effects of potassium and resveratrol on the SGK1 isoform expression. RESULTS  The SGK1 gene encodes a G4 structure in the proximal upstream of promoter-2; the G4 structure is stabilized by potassium or resveratrol, but destabilized by sodium. Super-physiological levels of sodium stimulate the transcription of all SGK1 isoforms, whereas resveratrol or potassium supplementation inhibits the transcription of iso-2 and iso-3, but not iso-1. CONCLUSIONS  Stabilizing the G4 by potassium or resveratrol induces alternative promoter usage and/or pre-mRNA splicing in the transcription of SGK1. GENERAL SIGNIFICANCE  Potassium/sodium ion balance or resveratrol binding can act to regulate G4 molecular switches for controlling SGK1 gene expression, thereby presenting a new avenue for drug development.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  Small studies have noted benefit with use of catheter-directed therapy (CDT) versus standard of care in treatment of pulmonary embolism, but none have focused on the variability of clinical practice with this modality. METHODS  ICD codes were used to retrospectively identify consecutive adult patients admitted to an intensive care unit (ICU) with pulmonary embolism over a 2-year period. We evaluated inpatient mortality and major bleeding and assessed treatment variation. RESULTS  Of 284 patients included, 46 underwent CDT (9 massive pulmonary embolism, 37 submassive pulmonary embolism). Significantly more patients who underwent standard treatment had a history of congestive heart failure and diabetes. Obesity, higher troponin levels, and right heart strain were significantly more likely in the CDT group. No significant difference in inpatient mortality or major bleeding events was observed between the treatment groups. Tissue plasminogen activator use varied widely in the CDT group, and inferior vena cava filter utilization was significantly more common in the CDT group (18; 41%) compared to the standard group (40; 17%) (p &lt;0.01). CONCLUSIONS  In this study, no significant difference in inpatient mortality or major bleeding was found in ICU pulmonary embolism patients who underwent CDT compared with standard care. It may be beneficial to standardize this procedure, given the potential benefit of CDT in patients with submassive pulmonary embolism.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 INTRODUCTION AND OBJECTIVES  The ankle-brachial index (ABI) is an indicator of peripheral artery disease (PAD). The aim of this study was to assess the association between PAD, measured with the ABI, and cognitive function in persons with overweight or obesity and metabolic syndrome. METHODS  Cross-sectional study conducted with baseline data from the PREDIMED-Plus study, which included 4898 participants (after exclusion of those without ABI measurements) aged between 55 and 75 years, and with overweight or obesity and metabolic syndrome. At the baseline assessment, we measured the ABI with a standardized protocol and assessed the presence of other cardiovascular risk factors (eg, diabetes, dyslipidemia, hypertension). Cognitive function was evaluated using several tests validated for the Spanish population (mini-mental state examination [MMSE], phonological and semantic verbal fluency test, WAIS-III working memory index [WMI], parts A and B of the trail making test (TMT), and clock drawing test). Generalized linear models were used to assess the association between the ABI and cognitive function. RESULTS  Among the participants, 3.4% had PAD defined as ABI &lt;/= 0.9, and 3.3% had arterial calcification defined as ABI &gt;/= 1.4. PAD was associated with age, systolic blood pressure and obesity indicators, while arterial calcification was also associated with obesity and diabetes. No significant associations were observed between cognitive function and ABI or PAD. CONCLUSIONS  In our sample, the presence of PAD increased with age, blood pressure, and obesity. No significant association was observed between ABI, PAD, or cognitive function.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-magenta-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">arrhythm</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Arrhythmia,Heart failure,Coagulopathies,
 BACKGROUND  Direct oral anticoagulants (DOACs) have emerged as the preferred choice of oral anticoagulation in patients with atrial fibrillation. Randomized trials have demonstrated the efficacy and safety of DOAC in patients undergoing electrical cardioversion (ECV); however, there is limited real-world data. OBJECTIVE  To evaluate the outcome of patients undergoing an elective ECV for atrial tachyarrhythmia in a tertiary referral center who were treated with DOAC or vitamin K antagonist (VKA) without routine trans esophageal echocardiography (TEE). METHODS  This was a retrospective single-center cohort study of consecutive patients undergoing an elective ECV for atrial tachyarrhythmia from January 2013 to February 2020. The primary endpoints were thromboembolism (composite of stroke, transient ischemic attack or systemic embolism) and major bleeding events within 60days. RESULTS  A total of 1431 ECV procedures were performed in 920 patients. One-third of the procedures were performed under DOAC (N=488, 34%) and the remainder of the procedures was performed under VKA (N=943, 66%). There were no differences between groups with regard to demographic variables (mean age 62.4+/-11.7, 72% men) and mean CHA2DS2-VASc score (2.3+/-1.6); however, the VKA group had a higher proportion of patients with co-morbidity. Thromboembolism occurred in 0.41% in the DOAC group versus 0.64% in the VKA group (P=0.72). Major bleeding events occurred in 0.41% in the DOAC group versus 0.11% in the VKA group (P=0.27). CONCLUSION  In a real-world population, the rates of thromboembolism and major bleeding events were low after elective ECV in patients using DOAC or VKA, even without routine TEE.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-magenta-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">arrhythm</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Arrhythmia,Heart failure,Coagulopathies,
 BACKGROUND  Direct oral anticoagulants (DOACs) have emerged as the preferred choice of oral anticoagulation in patients with atrial fibrillation. Randomized trials have demonstrated the efficacy and safety of DOAC in patients undergoing electrical cardioversion (ECV); however, there is limited real-world data. OBJECTIVE  To evaluate the outcome of patients undergoing an elective ECV for atrial tachyarrhythmia in a tertiary referral center who were treated with DOAC or vitamin K antagonist (VKA) without routine trans esophageal echocardiography (TEE). METHODS  This was a retrospective single-center cohort study of consecutive patients undergoing an elective ECV for atrial tachyarrhythmia from January 2013 to February 2020. The primary endpoints were thromboembolism (composite of stroke, transient ischemic attack or systemic embolism) and major bleeding events within 60days. RESULTS  A total of 1431 ECV procedures were performed in 920 patients. One-third of the procedures were performed under DOAC (N=488, 34%) and the remainder of the procedures was performed under VKA (N=943, 66%). There were no differences between groups with regard to demographic variables (mean age 62.4+/-11.7, 72% men) and mean CHA2DS2-VASc score (2.3+/-1.6); however, the VKA group had a higher proportion of patients with co-morbidity. Thromboembolism occurred in 0.41% in the DOAC group versus 0.64% in the VKA group (P=0.72). Major bleeding events occurred in 0.41% in the DOAC group versus 0.11% in the VKA group (P=0.27). CONCLUSION  In a real-world population, the rates of thromboembolism and major bleeding events were low after elective ECV in patients using DOAC or VKA, even without routine TEE.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Diseases of arteries,
 BACKGROUND  Most studies of patients with isolated proximal left anterior descending (PLAD) coronary artery disease do not include all three procedural options (percutaneous coronary intervention (PCI), conventional coronary artery bypass graft (CABG) surgery, minimally invasive CABG). METHODS  New York&#39;s cardiac registries were used to identify patients who underwent revascularization for isolated PLAD disease between January 1, 2010 and Nov 30, 2016 in New York State. After exclusions, 14,327 patients, of whom 13,115 received PCI, 1,001 of whom underwent CABG surgery, and 211 of whom underwent minimally invasive CABG were followed through the end of 2017 to compare outcomes. Registry data were matched to vital statistics data to obtain deaths occurring after discharge and matched to claims data to obtain subsequent admissions for myocardial infarction and stroke. RESULTS  There were no significant differences in mortality or in mortality/MI/stroke after seven years (with median follow-up times in excess of 4 years) among the three procedures after adjusting for differences in patient risk factors. However, conventional CABG surgery was associated with a lower subsequent revascularization rate than PCI (adjusted hazard ratio (AHR) = 0.45 (95% CI (0.35, 0.58)), and minimally invasive CABG surgery (AHR = 0.46 (0.32, 0.66)). CONCLUSIONS  Among patients with isolated PLAD disease undergoing any of three revascularization options (PCI, conventional CABG surgery, minimally invasive CABG surgery), conventional CABG surgery was associated with lower subsequent revascularization rates, but there were no differences in mortality or mortality/MI/stroke rates.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">stenos</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Diseases of arteries,
 BACKGROUND  Limited surgical options are available for patients with extensive mitral annular calcification. Several reports have shown the feasibility of surgical mitral valve replacement utilizing a transcatheter aortic valve in the mitral position (MVR-TAVR). We review our 30-day and 1-year outcomes utilizing a minimally invasive approach for MVR-TAVR. METHODS  Between 2017-2019, 16 patients underwent MVR-TAVR under direct vision. Primary endpoints included overall survival, technical success, and effectiveness. Secondary endpoints included valve and cardiac hemodynamics post-operatively and during follow-up. RESULTS  The 16 patients (69% females) were from ages 53 to 88 years (average 77+/-9). Comorbidities on presentation  31% (5/16) were reoperative surgeries, 13% (3/16) had right ventricular dysfunction, 31% (5/16) had severe pulmonary hypertension, and 20% (3/16) had chronic kidney disease. Isolated surgery was performed on 69% (11/16) of patients, with a cross-clamp (58%[7/12]) or on a fibrillating heart (42%[5/12]), while concomitant surgery was performed in 31% (5/16) of patients with a cross-clamp. Upon follow up, the estimated 30-day mortality rate was 12.5% and the 1-year mortality rate was 36.2%. A moderate post-operative paravalvular leak (PVL) was evident immediately in one patient and a severe PVL after 30-day follow-up in another. In addition, one patient had mild LVOTO and another had moderate mitral valve stenosis. At 1-year follow up, there were no changes to the mild PVL and moderate stenosis identified post-surgery. CONCLUSIONS  Mini-thoracotomy MVR-TAVR is an acceptable alternative to conventional and transcatheter MVR in patients with mitral valve disease and extensive mitral annular calcification.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Diffusion Magnetic Resonance Imaging (dMRI) is one of the most important contemporary non-invasive modalities for probing tissue structure at the microscopic scale. The majority of dMRI techniques employ standard single diffusion encoding (SDE) measurements, covering different sequence parameter ranges depending on the complexity of the method. Although many signal representations and biophysical models have been proposed for SDE data, they are intrinsically limited by a lack of specificity. Advanced dMRI methods have been proposed to provide additional microstructural information beyond what can be inferred from SDE. These enhanced contrasts can play important roles in characterizing biological tissues, for instance upon diseases (e.g. neurodegenerative, cancer, stroke), aging, learning, and development. In this review we focus on double diffusion encoding (DDE), which stands out among other advanced acquisitions for its versatility, ability to probe more specific diffusion correlations, and feasibility for preclinical and clinical applications. Various DDE methodologies have been employed to probe compartment sizes (Section 3), decouple the effects of microscopic diffusion anisotropy from orientation dispersion (Section 4), probe displacement correlations, study exchange, or suppress fast diffusing compartments (Section 6). DDE measurements can also be used to improve the robustness of biophysical models (Section 5) and study intra-cellular diffusion via magnetic resonance spectroscopy of metabolites (Section 7). This review discusses all these topics as well as important practical aspects related to the implementation and contrast in preclinical and clinical settings (Section 9) and aims to provide the readers a guide for deciding on the right DDE acquisition for their specific application.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Coagulopathies,
 BACKGROUND  Outcomes of redo aortic valve intervention (AVI) following transcatheter aortic valve replacement (TAVR) have not been well described. We thought to investigate the incidence, predictors, and outcomes of redo AVI after TAVR. METHODS  The Nationwide Readmission Database (from 2012 to 2017) was queried to identify admissions for TAVR. Redo AVI was defined as readmissions that required either TAVR or balloon aortic valvuloplasty (BAV) or surgical aortic valve replacement (SAVR). A multivariable regression model was used to identify independent predictors of redo AVI. In-hospital outcomes of redo TAVR or BAV and redo SAVR were compared in the unadjusted model. RESULTS  A total of weighted 148,200 (unweighted redo AVI 297, no redo AVI 73,804) index TAVRs were identified. A weighted 593 (435 TAVR or BAV and 158 SAVR) redo AVI was included with an incidence of 1.0 per 100 person-year during a median of 105 (interquartile range 41-195) days follow-up. Predictors of redo AVI were female, heart failure, obesity, atrial fibrillation, transapical approach, oral anticoagulant use, and acute kidney injury. In-hospital mortality of redo AVI was 7.6% (5.3% for redo TAVR or BAV vs. 13.8% for redo SAVR, unadjusted p = 0.10). Stroke, myocardial infarction, bleeding requiring transfusion, new pacemaker, and acute kidney injury rates were 4.7%, 2.6%, 9.3%, 10.0%, and 31.2%, respectively in redo AVI. Length of stay and hospital cost was 4.8 days and 55,826 U.S. dollars, respectively. CONCLUSIONS  The incidence of redo AVI was low following TAVR but was associated with high mortality and morbidities.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Coagulopathies,
 IMPORTANCE  Potent antithrombotic therapy has significantly improved prognosis for patients with acute myocardial infarction (AMI), however, at a price of increased bleeding risk. Chronic gastric infection with Helicobacter pylori (Hp) commonly causes upper gastrointestinal bleeding and is proposed as a risk factor for subsequent bleeding post AMI. The prevalence of active Hp in a current AMI population and the feasibility of Hp screening as part of routine clinical care are unclear. OBJECTIVE  To determine the prevalence of active Hp infection in a contemporary AMI cohort and to establish the feasibility of Hp diagnosis as part of routine clinical MI care. DESIGN  Multicenter, prospective cohort study. SETTING  Two university hospitals in Stockholm, Sweden. PARTICIPANTS  Patients admitted for AMI between Nov 6th, 2019 and Apr 4th, 2020. After written informed consent, Hp diagnostics was performed with a bedside urea breath test (Diabact(R), Mayoly Spindler) incorporated into routine care during the hospitalization period. EXPOSURE  Positive test for Hp infection. MAIN OUTCOMES AND MEASURES  The primary outcome was the prevalence of Hp infection. Secondary aims included predictive factors in patient characteristics and outcomes which were obtained from linkage with national registries. Predefined subgroup analyses included stratification for proton pump inhibitor use and infarct type. RESULTS  310 consecutive AMI patients (median age 67; 23% female; 41% ST-elevation MI [STEMI]) were enrolled. Overall, the Hp prevalence was 20% (95% CI, 15.5-24.7). Hp positive status was significantly more common in smokers compared with non-smokers (36% vs. 21%, respectively; p&lt;0.05) and in patients presenting with STEMI compared with Non-STEMI (26% vs. 15%, respectively; p=0.02). The latter observation remained significant after multivariable adjustment. After exclusion of 97 subjects with current proton pump inhibitor use, the Hp prevalence was 24% (95% CI, 18.9-31.0). CONCLUSION AND RELEVANCE  Active Hp infection is common in a contemporary AMI population and may represent a modifiable risk factor for upper gastrointestinal bleeding, which has been hitherto disregarded. Hp screening as part of clinical routine during AMI hospitalization was feasible. A future randomized trial is needed to determine whether routine Hp screening and subsequent eradication therapy reduces bleeding complications and improves prognosis. CLINICALTRIALS. GOV IDENTIFIER  NCT04289012.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, reduces cardiovascular death and worsening heart failure in patients with chronic heart failure and reduced ejection fraction. Early initiation during an acute heart failure (AHF) hospitalization may facilitate decongestion, improve natriuresis, and facilitate safe transition to a beneficial outpatient therapy for both diabetes and heart failure. OBJECTIVE  The objective is to assess the efficacy and safety of initiating dapagliflozin within the first 24-hours of hospitalization in patients with AHF compared to usual care. METHODS  DICTATE-AHF is a prospective, multicenter, open-label, randomized trial enrolling a planned 240 patients in the United States. Patients with type 2 diabetes hospitalized with hypervolemic AHF and an estimated glomerular filtration rate of at least 30 ml/min/1.73m(2) are eligible for participation. Patients are randomly assigned 1 1 to dapagliflozin 10mg once daily or structured usual care until day 5 or hospital discharge. Both treatment arms receive protocolized diuretic and insulin therapies. The primary endpoint is diuretic response expressed as the cumulative change in weight per cumulative loop diuretic dose in 40mg intravenous furosemide equivalents. Secondary and exploratory endpoints include inpatient worsening AHF, 30-day hospital readmission for AHF or diabetic reasons, change in NT-proBNP, and measures of natriuresis. Safety endpoints include the incidence of hyper/hypoglycemia, ketoacidosis, worsening kidney function, hypovolemic hypotension, and inpatient mortality. CONCLUSION  The DICTATE-AHF trial will establish the efficacy and safety of early initiation of dapagliflozin during AHF across both AHF and diabetic outcomes in patients with diabetes.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,
 BACKGROUND  Atrial fibrillation (AF) in heart failure (HF) patients has been associated with a worse outcome. Similarly, excessive supraventricular ectopic activity (ESVEA) has been linked to development of AF, stroke and death. This study aimed to investigate AF and ESVEA&#39;s association with outcomes and effect of prophylactic implantable cardioverter defibrillator (ICD) implantation in non-ischemic HF patients. METHODS  A total of 850 patients with non-ischemic HF, left ventricle ejection fraction &lt;/=35%, and elevated N-terminal pro-brain natriuretic peptides underwent 24-hours Holter recording. The presence of AF (&gt;/=30 seconds) and ESVEA (&gt;/=30 supraventricular ectopic complexes (SVEC) per hour or run of SVEC &gt;/=20 beats) were registered. Outcomes were all-cause mortality, cardiovascular death (CVD) and sudden cardiac death (SCD). RESULTS  AF was identified in 188 patients (22%), and ESVEA in 84 patients (10%). After 4 years and 11 months of follow-up, a total of 193 patients (23%) had died. AF was associated with all-cause mortality (HR 1.44; CI 1.04-1.99; P=0.03) and CVD (HR 1.59; CI 1.07-2.36; P=0.02). ESVEA was associated with all-cause mortality (HR 1.73; CI 1.16-2.57; P=0.0073) and CVD (HR 1.76; CI 1.06-2.92; P=0.03). Neither AF nor ESVEA was associated with SCD. ICD implantation was not associated with an improved prognosis for neither AF (P-value for interaction=0.17), nor ESVEA (P-value for interaction=0.68). CONCLUSION  Both AF and ESVEA were associated with worsened prognosis in non-ischemic HF. However, ICD implantation was not associated with an improved prognosis for either group.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Coagulopathies,
 Stroke is the leading cause of disability and the second leading cause of death worldwide. With the global population aged 65 and over growing faster than all other age groups, the incidence of stroke is also increasing. In addition, there is a shift in the overall stroke burden towards younger age groups, particularly in low and middle-income countries. Stroke in most cases is caused due to an abrupt blockage of an artery (ischemic stroke), but in some instances stroke may be caused due to bleeding into brain tissue when a blood vessel ruptures (hemorrhagic stroke). Although treatment options for stroke are still limited, with the advancement in recanalization therapy using both pharmacological and mechanical thrombolysis some progress has been made in helping patients recover from ischemic stroke. However, there is still a substantial need for the development of therapeutic agents for neuroprotection in acute ischemic stroke to protect the brain from damage prior to and during recanalization, extend the therapeutic time window for intervention and further improve functional outcome. The current review has assessed the past challenges in developing neuroprotective strategies, evaluated the recent advances in clinical trials, discussed the recent initiative by the National Institute of Neurological Disorders and Stroke in USA for the search of novel neuroprotectants (Stroke Preclinical Assessment Network, SPAN) and identified emerging neuroprotectants being currently evaluated in preclinical studies. The underlying molecular mechanism of each of the neuroprotective strategies have also been summarized, which could assist in the development of future strategies for combinational therapy in stroke treatment.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 BACKGROUND  A growing body of evidence suggests that Non-alcoholic fatty liver disease (NAFLD) and liver fibrosis are associated with cardiovascular disease (CVD). However, the independent role of liver fibrosis markers in the prediction of CVD in the general population is seldom tested. AIMS  To assess whether a marker of liver fibrosis predicts the first occurrence of a CVD event in a large sample of community-based general population. METHODS  Historical cohort using data from a large health provider that operates a centralized computerized medical record. The level of liver fibrosis was measured by the fibrosis-4 (FIB-4) score, and the association with CVD was adjusted for the European Systematic Coronary Risk Evaluation calculator (SCORE). RESULTS  The study included 8,511 individuals, 3,292 with inconclusive fibrosis and 195 with advanced fibrosis (FIB-4&gt;/=2.67). People with advanced fibrosis had higher risk for CVD, after adjustment for sociodemographic characteristics, the SCORE, use of statins and aspirin (HR [95%CI], 1.63 [1.29-2.06]). The association persisted in both women and men. Using age-specific cut-offs, there was a dose-response association between inconclusive and advanced fibrosis and CVD (HR [95%CI], 1.15 [1.01-1.31]) and HR [95%CI], 1.60 [1.27-2.01], respectively, P for trend&lt;0.001). CONCLUSIONS  A simple fibrosis score is independently associated with CVD, suggesting that fibrosis markers should be considered in primary-care risk assessment.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 AIMS  To determine the relative incidence and predictors of pulmonary arterial hypertension (PAH) in type 2 diabetes. METHODS  Hospitalizations for/with and death from/with PAH, and all-cause mortality, were ascertained from validated databases for participants from the longitudinal, community-based Fremantle Diabetes Study Phase I (FDS1; n=1287) and age-, sex- and zip code-matched people without diabetes (n=5153) between entry (1993-1996) and end-2017. Incidence rates (IRs) and IR ratios (IRRs) were calculated. Cox proportional hazards and competing risk models generated cause-specific (cs) and subdistribution (sd) hazard ratios (HRs) for incident PAH. RESULTS  In the pooled cohort (mean age 64.0years, 49% males), 49 (3.8%) of the type 2 diabetes participants and 133 (2.6%) of those without diabetes developed PAH during 106,556 person-years of follow-up (IRs (95% CI) 262 (194-346) and 151 (127-179) /100,000 person-years, respectively; IRR 1.73 (1.22-2.42), P=0.001). Type 2 diabetes was associated with an unadjusted csHR of 1.97 (1.42-2.74) and sdHR of 1.44 (1.04-2.00) (P&lt;/=0.03); after adjustment for age, sex, and co-morbidities, these were 1.43 (0.83-2.47) and 1.36 (0.97-1.91), respectively (P&gt;/=0.07). CONCLUSIONS  Type 2 diabetes is associated with an increased risk of PAH but this is no longer significant after adjustment for other explanatory variables and the competing risk of death.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 BACKGROUND  Diabetes was regarded as an independent risk factor for abnormal left heart remodeling. However, there was lacking population-based data on the relationship of glucose status with left ventricular hypertrophy (LVH) or left atrial enlargement (LAE). This study intended to clarify the influence of diabetes and prediabetes on the prevalence and incidence of LVH and LAE based on a northeast rural population of China. METHODS  We analyzed clinical, laboratory and echocardiographic data of a total of 2824 participants aged over 35years from a population-based prospective cohort NCRCHS study with 2years of follow-up, which was carried out in rural areas of northeast China. All measurements were performed according to standardized protocols. RESULTS  There were 2179 controls, 342 subjects with prediabetes and 303 ones with diabetes. The baseline distribution of LAD, IVSd, LVIDd, LVIDs, LVMI, E wave, A wave, E/A, E/e&#39;, diastolic dysfunction, LVEDV, LVESV and SV was significantly different among three groups (all Ptrend&lt;0.05). After the adjustment for age, gender, BMI, waist circumference, heart rate, hypertension and dyslipidemia, glucose status remained associated with LVIDd and E/e&#39; (all P&lt;0.05). At baseline, diabetes was independently related to the prevalence of LVH (OR=1.53; 95%CI=1.12-2.10; P&lt;0.01) and LAE (OR=1.71; 95%CI=1.19-2.43; P&lt;0.01) in the overall population, and the same significant results were also found in gender specific subgroups. During the 2-year follow-up, Cox regression models revealed that baseline diabetes had an independent association with the incidence of LAE in the total subjects (HR=1.83; 95%CI=1.10-3.06; P=0.02) and females (HR=1.90; 95%CI=1.05-3.46; P=0.04) after adjusting the potential confounders. CONCLUSION  Diabetes, but not prediabetes, is an independent predictor for the prevalence of LVH and LAE, and for the new-onset LAE, it should be considered in the assessment of diabetes and cardiac structural remodeling.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Recent prospective controlled studies have demonstrated that transcatheter closure of a patent foramen ovale (PFO) reduces recurrent stroke risk in select patients, especially in patients younger than 60 years with PFO and embolic-appearing infarct and where no other mechanism of stroke was identified. Detection of PFO depends on the intensity of the Valsalva maneuver, and not all PFOs can be diagnosed using transesophageal echocardiography. Transthoracic contrast echocardiography using abdominal compression during the Valsalva maneuver is an easy method that can increase the detection sensitivity of PFO shunt. PFO with two or more of the following factors is most likely considered a &#34;high-risk PFO&#34; and as such, has a significantly higher probability of cryptogenic stroke  (1) a long-tunnel PFO (&gt;/=10 mm in length), (2) atrial septal aneurysm and/or hypermobile interatrial septum, (3) prominent Eustachian valve or Chiari&#39;s network, (4) large right-to-left shunt at rest and during the Valsalva maneuver, and (5) low-angle PFO. In order to establish the benefit of catheter-based PFO closure as a safe and effective treatment in clinical practice, the degree of accuracy of PFO diagnosis and its long-term safety need to be confirmed.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,
 OBJECTIVES  The aim of this study was to evaluate the prognostic impact of cerebral regional oxygen saturation (crSO2) in patients undergoing surgery for Stanford type A aortic dissection (TAAD). DESIGN  Observational, retrospective, institutional study. SETTING  University hospital. PARTICIPANTS  A total of 152 patients who underwent surgery for TAAD from June 2009 to December 2018 at the authors&#39; institution. INTERVENTIONS  Surgery for TAAD using continuous perioperative monitoring of crSO2 with near-infrared cerebral oximetry (INVOS, Medtronic, MN). MEASUREMENTS AND RESULTS  The rates of postoperative stroke/global brain ischemia were 22.4% and of hospital mortality 14.5%. Age, hemoglobin, and cardiogenic shock were independent predictors of nadir crSO2 from both frontal areas at arrival to the operating room. Repeated measures test showed that changes in crSO2 between the first measurement at operating room arrival, at the start of surgery, and at the end of surgery were not significant when measured on the right frontal area (p=0.632), left frontal area (p=0.608), as a nadir value from both frontal areas (p=0.690), and as a difference between frontal areas (p=0.826) in patients with and without major neurologic complications. Patients who had a nadir crSO2 &lt;40% anytime during the perioperative period, had a numerically higher rate of major neurologic complications (27.3% v 20.4%, p=0.354), but this difference did not reach statistical significance. The incidence of nadir of crSO2 value &lt;40% at operating room arrival (5.9%, p=1.000), at the start of surgery (5.3%, p=0.685), and at the end of surgery (1.3%, p=1.000) was rather low and not associated with these adverse events. CONCLUSIONS  Derangements in crSO2 detected by cerebral oximetry before and during surgery for TAAD did not predict postoperative stroke and/or global brain ischemia.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,
 OBJECTIVES  The aim of this study was to evaluate the prognostic impact of cerebral regional oxygen saturation (crSO2) in patients undergoing surgery for Stanford type A aortic dissection (TAAD). DESIGN  Observational, retrospective, institutional study. SETTING  University hospital. PARTICIPANTS  A total of 152 patients who underwent surgery for TAAD from June 2009 to December 2018 at the authors&#39; institution. INTERVENTIONS  Surgery for TAAD using continuous perioperative monitoring of crSO2 with near-infrared cerebral oximetry (INVOS, Medtronic, MN). MEASUREMENTS AND RESULTS  The rates of postoperative stroke/global brain ischemia were 22.4% and of hospital mortality 14.5%. Age, hemoglobin, and cardiogenic shock were independent predictors of nadir crSO2 from both frontal areas at arrival to the operating room. Repeated measures test showed that changes in crSO2 between the first measurement at operating room arrival, at the start of surgery, and at the end of surgery were not significant when measured on the right frontal area (p=0.632), left frontal area (p=0.608), as a nadir value from both frontal areas (p=0.690), and as a difference between frontal areas (p=0.826) in patients with and without major neurologic complications. Patients who had a nadir crSO2 &lt;40% anytime during the perioperative period, had a numerically higher rate of major neurologic complications (27.3% v 20.4%, p=0.354), but this difference did not reach statistical significance. The incidence of nadir of crSO2 value &lt;40% at operating room arrival (5.9%, p=1.000), at the start of surgery (5.3%, p=0.685), and at the end of surgery (1.3%, p=1.000) was rather low and not associated with these adverse events. CONCLUSIONS  Derangements in crSO2 detected by cerebral oximetry before and during surgery for TAAD did not predict postoperative stroke and/or global brain ischemia.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 OBJECTIVES  There are limited non-invasive methods to assess lower extremity arterial injuries in the emergency department (ED) and pre-hospital setting. The ankle-brachial index (ABI) requires careful auscultation by Doppler, an approach made difficult in noisy environments. We sought to determine the agreement of the ABI measured using the pulse oximeter plethysmograph waveform (Pleth) with auscultation by Doppler in a controlled setting. A secondary outcome sought to examine the agreement of ABI by automated oscillometric sphygmomanometer (AOS) with Doppler. METHODS  We measured blood pressure in the right upper and lower extremities of healthy volunteers using  (1) Doppler and manual sphygmomanometer; (2) Pleth and manual sphygmomanometer; and (3) AOS. The Bland-Altman approach to assessing agreement between methods was used comparing mean differences between ABI pairs to their means for Doppler versus Pleth and Doppler versus AOS. The intraclass correlation coefficient (ICC) from mixed effects models examined intra- and inter-rater reliability. RESULTS  Among 100 participants with normal ABI the mean ABI (95%CI) were Doppler 1.11 (0.90-1.33), Pleth 1.10 (0.91-1.30), and AOS 1.10 (0.90-1.30). The ABI difference (95% CI for limits of agreement) were 0.01 (-0.20,0.18) for Doppler-Pleth and 0.02 (-0.26, 0.22) for Doppler-AOS. The ICC for the Doppler-Pleth comparison (ICC = 0.56, 95% CI 0.47-0.63) was greater than for the Doppler-AOS (ICC = 0.32, 95% CI 0.19-0.43). CONCLUSIONS  The ABI measured using the Pleth has a high level of agreement with measurement by Doppler. The AOS and Doppler have good agreement with greater measurement variability. Pleth and AOS may be reasonable alternatives to Doppler for ABI.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 &#39;Epigenetic&#39; regulation of genes via post-translational modulation of proteins is the current mainstay approach for the disease therapies, particularly explored in the Histone Deacetylase (HDAC) class of enzymes. Mainly sight saw in cancer chemotherapeutics, HDAC inhibitors have also found a promising role in other diseases (neurodegenerative disorders, cardiovascular diseases, and viral infections) and successfully entered in various combination therapies (pre-clinical/clinical stages). The prevalent flexibility in the structural design of HDAC inhibitors makes them easily tuneable to merge with other pharmacophore modules for generating multi-targeted single hybrids as a novel tactic to overcome drawbacks of polypharmacy. Herein, we reviewed the putative role of prevalent HDAC hybrids inhibitors in the current and prospective stage as a translational approach to overcome the limitations of the existing conventional drug candidates (parent molecule) when used either alone (drug resistance, solubility issues, adverse side effects, selectivity profile) or in combination (pharmacokinetic interactions, patient compliance) for treating various diseases.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Coagulopathies,
 BACKGROUND  This study aimed to quantify the learning curve of piggyback liver transplantation and to identify factors that impact the operative time and blood transfusion during the learning curve. METHODS  A retrospective review was performed on consecutive cases of patients&#39; first piggyback liver transplantations that were performed by a single surgeon. The learning curve for the operative time was evaluated using the cumulative sum method. RESULTS  There were 181, consecutive, first-time piggyback liver transplantations. The median operative time was 345 minutes (range  180-745 minutes) with a median transfusion rate of 4 packed red blood cell units (range  2-23 units). The cumulative sum learning curve identified 3 phases  an initial phase (1-70 piggyback liver transplantations), a plateau phase (71-101 piggyback liver transplantations), and a stable phase (102-181 piggyback liver transplantations). Over the 3 phases, there were significant decreases in the median duration of the surgery (388.8 vs 344.8 vs 326.9 minutes; P = .004, P = .0004, P &lt;/= .0001) and the number of red blood cell units transfused (6.00 vs 3.90 vs 3.71; P = .02, P = .79, P = .0006). Multivariable analysis identified that the following factors impacted the operative time  surgeon experience (P = .00006), previous upper abdominal surgery (P = .01), portocaval shunt fashioning (P = .0003), early portal section (P = .00001), multiple arterial graft reconstruction (P = .03), and the length of the retrohepatic inferior vena covered by segment 1 (P = .0006). Independent risk factors for increased blood loss were surgeon experience (P = .0001), previous upper abdominal surgery (P = .002), the retrohepatic inferior vena cava encirclement by segment 1 (P = .0001), severe portal hypertension (P = .01), early portal section (P = .001), and low prothrombin time (P = .00001). CONCLUSION  Easily identifiable factors related to recipients (segment 1 morphology, previous upper abdominal surgery, severe portal hypertension) and to surgeon (operative experience, portocaval shunt fashioning, early portal section, and multiple arterial reconstructions) impact operative time and blood loss during the learning curve of piggyback liver transplantation. These factors can be used for grading the difficulties of liver transplantation to tailor the surgical strategy.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND &amp; AIMS  Although disorders of iron metabolism are among the most common diseases and dietary intakes of vitamin A, B2, B6, C, E, and folic acid are known to affect the absorption or oxidation of iron, limited data are available on the association of dietary iron and these vitamins with mortality in the same population. Specifically, the holistic dietary vitamins intake and its combined effect with iron on mortality are unclear. The purpose of this study was to evaluate the association of dietary iron, holistic dietary vitamins, and their interactive effect with total and cause-specific mortality. METHODS  We evaluated the effects of dietary total/heme/non-heme iron, vitamins, and their interaction on all-cause/cardiovascular disease (CVD)/cancer mortality among 14,826 US adults in the National Health and Nutrition Examination Survey (NHANES), a population-based nationally representative study. We developed a vitamin score to represent the holistic dietary intakes of vitamin A, B2, B6, C, E, and folic acid. RESULTS  A total of 2154 deaths occurred during a median follow-up of 9.3 years. Results from multivariate Cox proportional hazards models showed that higher vitamin score was associated lower risk of all-cause mortality (P-trend = 0.027). Negative interactions between dietary heme iron and vitamin score were observed on all-cause/CVD mortality. Dietary higher vitamins combined with lower heme iron was associated with lower risk of all-cause and CVD mortality (HR (95% confidence intervals (CIs))  0.80 (0.64-0.98) and 0.55 (0.31-0.98), respectively). Higher dietary vitamins combined with higher total/non-heme iron was associated with lower risk of CVD mortality (HR (95%CIs)  0.69 (0.48-0.99) and 0.70 (0.48-0.99), respectively). These results remained significant even excluding participants with iron supplementation. CONCLUSION  Our findings suggested that interactive effect of holistic dietary vitamins and iron play a protective role in decreasing all-cause and CVD mortality. Future studies, including cohort studies and clinical trials, are necessary to confirm these findings.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">takotsubo cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">takotsubo</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Cardiomyopathy,
 The prevalence of takotsubo cardiomyopathy (TCM) has been on the rise, but co-occurrence with hypertrophic cardiomyopathy (HOCM) remains rare. Although presenting patient demographics were similar to those in TCM, the potential for hemodynamic compromise was significantly compounded by the presence of underlying HOCM. Management was similar to standalone TCM, although use of inotropic agents and mechanical support appears to be more prevalent. Despite the increased potential for complications and the paucity of data regarding management, outcomes appear to be mostly favorable in both the hospitalization period and at follow-up. Interestingly, despite a new diagnosis of HOCM in about half the cases described, which signifies no significant left ventricular outflow tract (LVOT) gradient prior to TCM, half of those patients had a persistently elevated LVOT gradient after resolution of TCM. This poses a question of whether or not TCM can predispose to LVOT obstruction in HOCM patients even after its resolution.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 We performed a retrospective analysis of the patients assessed at our memory unit for whom Alzheimer disease (AD) cerebrospinal fluid biomarker results were available. We selected patients diagnosed with mild cognitive impairment due to AD (National Institute on Aging-Alzheimer&#39;s Association clinical criteria), confirmed neuropsychological deficit, a Global Deterioration Scale score of 3, and an abnormal profile of cerebrospinal fluid biomarkers. Of the 588 cases reviewed, 110 met the inclusion criteria. During follow-up, 50 cases (45.45%) progressed to dementia due to AD. Baseline levels of total and phosphorylated tau were higher in the group of patients that progressed to dementia than in those remaining with mild cognitive impairment. After adjusting for age, sex, history of hypertension, diabetes, and educational level, a 10% increase in total tau protein values was associated with a 7.60% increase in the risk of progression to dementia (hazard ratio  2.22; 95% confidence interval, 1.28-3.84]; P = .004). Among patients with mild cognitive impairment due to AD and abnormal cerebrospinal fluid biomarker profiles, progressively higher concentrations of total or phosphorylated tau were associated with increased risk of progression to dementia.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,
 The &#39;Stroke Complications after Traumatic Experiences and Stress&#39; (SATURN) study was designed to investigate the effects of a prior traumatic event on PTSD symptoms triggered by a subsequent stroke. First-ever ischemic stroke patients were surveyed 9-13 months after hospitalization at the Charite University Medical Center. Stroke-induced PTSD symptoms were measured using the Impact of Event Scale-revised (IES-R). Prior traumatization together with past PTSD symptoms was assessed retrospectively with the Brief Trauma Questionnaire (BTQ) and the 7-item Short Screening Scale for PTSD. Depressive symptoms were assessed with the Beck Depression Inventory (BDI-II). The Short Form (SF)-36 was used to evaluate physical and mental health outcomes. We received 258 responses from 636 eligible patients (~41%). Based on respondents&#39; scores on the IES-R, the prevalence of probable PTSD due to the stroke event was 11% in our sample. Female sex and younger age were associated with more severe PTSD symptoms. Psychological endpoints did not differ between patients who denied prior trauma exposure and those who reported earlier trauma exposure but denied subsequent PTSD symptoms. However, a history of trauma exposure in tandem with endorsing subsequent PTSD symptoms was linked with significantly increased post-stroke PTSD and depressive symptoms together with decreased psychological well-being. Self-reported physical health did not differ across groups. Younger age, being a woman, and having developed PTSD symptoms in the aftermath of a prior trauma were associated with adverse psychological outcomes after stroke.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 OBJECTIVE  To determine the pulmonary functions in patients with chronic kidney diseases (CKD) and factors affecting them. STUDY DESIGN  Observational study. PLACE AND DURATION OF STUDY  Nephrology Department, Mayo Hospital, Lahore, from October 2018 to April 2019. METHODOLOGY  All patients of CKD, coming in Nephrology OPD, were included. Patients on maintenance hemodialysis (HD), chronic obstructive pulmonary disease (COPD), smokers, chronic heart disease, and neuromuscular diseases were excluded from the study. Demographic data, physical examination findings and laboratory parameters were taken. Patients underwent spirometry at Pulmonology Department for measurement of forced expiratory volume in the first second (FEV1), forced vital capacity (FVC) and FEV1/FVC. RESULTS  One hundred and forty patients were included in the study. Mean GFR was 27.75 +/- 17.49 ml/min/1.73m2 and 7(5%) patients belonged to stage 2 CKD, 48 (34.3%) belonged to stage 3 CKD, 45 (32.1%) belonged to stage 4 CKD and rest 40 (28.6%) were from stage 5 CKD. Pulmonary functions were FEV1 (90.81+/-25.84), FVC (88.91+/-28.54), and FEV1/FVC (108.57+/-13.0). According to laid down criteria, 62 (44.3%) cases had restrictive lung disease (RLD), 5 (3.6%) cases had mixed and 78 (55.7%) cases normal lung function status. Important factors affecting pulmonary functions were GFR (p=0.038), monthly income (p=0.017) and education (p=0.041). Drop in GFR and anemia have negative correlation and age has positive correlation with pulmonary dysfunctions. CONCLUSION  Pulmonary functions were abnormal in almost half of the patients and restrictive lung disease was the most common pattern in these patients. Factors affecting the pulmonary functions were progression of CKD, falling hemoglobin level, monthly income and education. Drop in GFR and anemia had negative correlation and age had positive correlation with pulmonary functions. Key Words  CKD, Pulmonary functions, Restrictive lung disease, GFR, Anemia.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 Parachute mitral valve is a rare congenital heart defect characterised by a distorted mitral geometry with a single papillary muscle for all mitral chords to attach. It may develop in isolation or as a constillation of Shone syndrome. By comprehensive retrieval of the pertinent articles published since 2000, 22 articles with 149 cases of parachute mitral valve were recruited into this study. The present article revealed that most patients with a parachute mitral valve had a stenotic or regurgitant mitral valve, which is often associated with left heart obstructions, thereby leading to haemodynamic compromise. Therefore, multiple surgical maneuvers are warranted for such patients. Mitral valve repair is preferred over mitral valve replacement for the mitral valve abnormalities so as to avoid the associated complications of valve replacement procedure. The patients&#39; outcomes are satisfactory with a total event-free survival of surgical patients of 84.8%. Key Words  Cardiac surgical procedures, Congenital heart defects, Mitral valve.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 INTRODUCTION  The use of a long backboard and cervical collar are commonly recommended by international guidelines for spinal immobilization, but both devices may cause several side effects. In a recent study, it was reported that spinal immobilization at 20 degrees eliminated the decrease in pulmonary function secondary to spinal immobilization performed at 0 degrees . Spinal immobilization at 20 degrees is a new recommendation, but other potential effects need to be explored before it can be implemented in clinical use. STUDY OBJECTIVE  Hemodynamic observation is important in the management of trauma patients. The aim of this study was to investigate the effect of spinal immobilization at a 20 degrees position instead of 0 degrees on hemodynamic parameters. METHODS  This study included 53 healthy volunteers who underwent spinal immobilization in the supine position (00) and in an elevated position (200). Systolic arterial pressure (SAP), diastolic arterial pressure (DAP), mean arterial pressure (MAP), heart rate (HR), left ventricular outflow tract velocity time integral (LVOT-VTI), left ventricular stroke volume (LVSV), cardiac output (CO), inferior vena cava diameter inspiration (IVC diameter insp), IVC diameter expiration (IVC diameter exp), and inferior vena cava collapsibility index (IVC-CI) were measured at the 0th and 30th minutes of spinal immobilization in both positions. The data were compared for demonstrating the efficiency of both positions in spinal immobilization. RESULTS  A statistically significant difference was found in the parameters of the IVC diameter (exp), IVC diameter (insp), LVOT-VTI, LVSV, and CO through the measurements starting in the 0th minute of the transition from 0 degrees to 20 degrees (P &lt;.001). Delta values () of hemodynamic parameters (IVC diameter [exp], IVC diameter [insp], LVOT-VTI, SV, CO, IVC-CI, MAP, SAP, DAP, and HR) were similar in spinal immobilization at 0 degrees and 20 degrees . CONCLUSION  The findings obtained from this study illustrate that spinal immobilization at 20 degrees does not cause clinically significant hemodynamic changes in healthy subjects compared to spinal immobilization at 0 degrees .
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 Chinese visceral adiposity index (CVAI) is a novel indicator of visceral obesity, but little is known about the association between CVAI and risk of hypertension. This study aimed to investigate the association of CVAI and its 6-year change with hypertension risk and compare the ability of CVAI and other obesity indices to predict hypertension based on the Rural Chinese Cohort Study. Study participants were randomly recruited by a cluster sampling procedure, and 10,304 participants &gt;/=18 years were included. Modified Poisson regression was used to derive adjusted relative risks (RRs) and 95% confidence intervals (CIs). We identified 2,072 hypertension cases during a median of 6.03 years of follow-up. The RRs (95% CIs) for the highest versus lowest CVAI quartile were 1.29 (1.05-1.59) for men and 1.53 (1.22-1.91) for women. Per-standard deviation (SD) increase in CVAI associated with hypertension for both men (RR 1.09, 95% CI 1.02-1.16) and women (1.14, 1.06-1.22). Also, the area under the receiver operating characteristic curve value for hypertension was higher for CVAI than the four other obesity indices for both sexes (all P &lt; 0.05). Finally, per-SD increase in CVAI change associated with hypertension for both men (RR 1.26, 95% CI 1.16-1.36) and women (1.23, 1.15-1.30). Similar results were observed in sensitivity analyses. CVAI and its 6-year change are positively associated with hypertension risk. CVAI has better performance in predicting hypertension than other visceral obesity indices for both sexes. The current findings suggest CVAI as a reliable and applicable predictor of hypertension in rural Chinese adults.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 High cost of nutritious foods and eating out of home (OH) might be barriers to healthy and sustainable diets. We examined adherence to Dietary Approaches to Stop Hypertension (DASH), EAT-Lancet reference diet (EAT), and Mediterranean diet score (MDS) and the associations with dietary cost and eating OH. We evaluated cross-sectional data from single multiple-pass 24-hour diet recalls from 289 young adults (18-24 years) in Tirana, Albania. Dietary cost [in Albanian Lek (ALL)] was estimated by matching food consumption data with retail prices from local fast-food chains, supermarkets, restaurants, and food vendors. Poisson regression were fit to models that included DASH, EAT, and MDS as dependent variables to assess associations between healthy sustainable diet indicators and dietary cost and OH eating. Adjusted models controlled for BMI, sex, and total energy intake (kcal) using the residual method. Our findings indicate relatively poor adherence to healthy and sustainable dietary patterns among young men and women in Albania. Furthermore, better adherence to DASH, EAT, or MDS was not associated with dietary cost (per 100 ALL; range incidence rate ratios (IRRs)  0.97-1.00; all (un-)adjusted P&gt;0.05). Nonetheless, eating OH was related to lower adherence to DASH (IRR  0.79; P=0.003) and MDS (IRR  0.69; P&lt;0.001). In conclusion, adherence to health and sustainable dietary patterns was poor and not differentiated by cost, but rather source of foods (i.e. OH or at home). Further research on the potential public and environmental health effects of these findings are warranted in Albania.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 BACKGROUND  Inflammatory smooth muscle cells (iSMCs) generated from adventitial stem/progenitor cells (AdSPCs) have been recognised as a new player in cardiovascular disease, and microRNA-214-3p (miR-214-3p) has been implicated in mature vascular SMC functions and neointimal hyperplasia. Here, we attempted to elucidate the functional involvements of miR-214-3p in iSMC differentiation from AdSPCs and unravel the therapeutic potential of miR-214-3p signalling in AdSPCs for injury-induced neointimal hyperplasia. METHODS  The role of miR-214-3p in iSMC differentiation from AdSPCs was evaluated by multiple biochemistry assays. The target of miR-214-3p was identified through binding site mutation and reporter activity analysis. A murine model of injury-induced arterial remodelling and stem cell transplantation was conducted to study the therapeutic potential of miR-214-3p. RT-qPCR analysis was performed to examine the gene expression in healthy and diseased human arteries. RESULTS  miR-214-3p prevented iSMC differentiation/generation from AdSPCs by restoring sonic hedgehog-glioma-associated oncogene 1 (Shh-GLI1) signalling. Suppressor of fused (Sufu) was identified as a functional target of miR-214-3p during iSMC generation from AdSPCs. Mechanistic studies revealed that miR-214-3p over-expression or Sufu inhibition can promote nuclear accumulation of GLI1 protein in AdSPCs, and the consensus sequence (GACCACCCA) for GLI1 binding within smooth muscle alpha-actin (SMalphaA) and serum response factor (SRF) gene promoters is required for their respective regulation by miR-214-3p and Sufu. Additionally, Sufu upregulates multiple inflammatory gene expression (IFNgamma, IL-6, MCP-1 and S100A4) in iSMCs. In vivo, transfection of miR-214-3p into the injured vessels resulted in the decreased expression level of Sufu, reduced iSMC generation and inhibited neointimal hyperplasia. Importantly, perivascular transplantation of AdSPCs increased neointimal hyperplasia, whereas transplantation of AdSPCs over-expressing miR-214-3p prevented this. Finally, decreased expression of miR-214-3p but increased expression of Sufu was observed in diseased human arteries. CONCLUSIONS  We present a previously unexplored role for miR-214-3p in iSMC differentiation and neointima iSMC hyperplasia and provide new insights into the therapeutic effects of miR-214-3p in vascular disease.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  Primary nasopharyngeal lymphoma (NPL) is a very rare tumor of Waldeyer ring (WR) lymphoid tissue. It is challenging to differentiate lymphoma infiltration of pituitary from a pituitary adenoma, meningioma infiltration, and other sellar lesions to plan a suitable treatment strategy. We presented for the first time a unique case of NPL with an unusual presentation of oculomotor nerve palsy associated with pan-pituitary involvement in a diabetic patient. CASE PRESENTATION  A 64-year old diabetic woman with no previous history of malignancy presented with intermittent diplopia for about the last nine months. Severe headache, left eye ptosis and hypoglycemic episodes were added to her symptoms after a while. Further complaints include generalized weakness, loss of appetite, generalized musculoskeletal pain, and 6-7 kg weight loss within six months. Her family history was unremarkable. Physical examinations of eyes indicated left eye 3rd, 4th, and 6th nerve palsy. But, she was not anisocoric, and the pupillary reflexes were normal on both eyes. No lymphadenopathy, organomegaly and other abnormalities were found. Magnetic resonance imaging (MRI) showed a heterogeneous enhancement in the seller and suprasellar regions, enlargement of the stalk, parasellar dural enhancement and thickening of the sphenoid sinus without bone erosion. Also, both cavernous sinuses were infiltrated and both internal carotid arteries were encased by the neoplastic lesion. It suggested an infiltrative neoplastic lesion which compressed the cranial nerves. Pituitary hormone levels assessment indicated a pan-hypopituitarism. Following nasopharyngeal mucosal biopsy, the immunohistochemistry (IHC) findings revealed a low-grade non-Hodgkin&#39;s B-cell lymphoma. Systemic workup, including cerebrospinal fluid (CSF) studies, bone marrow aspiration, chest and abdominopelvic high-resolution computed tomography (HRCT) indicated no other involvement by the lymphoma. After chemotherapy courses, central adrenal insufficiency, partial central diabetes incipidious (CDI) and central hypothyroidism have been resolved. To our best knowledge, we found 17 cases of NPL with cranial nerve palsy, 1 case of NPL with pan-hypopituitarism and no NPL case with both cranial nerve palsy and pituitary dysfunction. CONCLUSIONS  The incidence of cranial neuropathy in patients with diabetes should not merely be attributed to diabetic neuropathy without further evaluation.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 BACKGROUND  Data on the relationship between nontraditional lipid profiles [total cholesterol (TC)/high-density lipoprotein cholesterol (HDL-C) ratio, triglyceride (TG)/HDL-C ratio, low-density lipoprotein cholesterol (LDL-C)/HDL-C ratio, non-high-density lipoprotein cholesterol (non-HDL-C)] and the risk of peripheral artery disease (PAD) are limited. The present study investigated the relationship of nontraditional lipid indices with PAD in hypertensive patients. METHODS  This cross-sectional study was performed among 10,900 adults with hypertension. Participants were diagnosed with PAD when their ankle-brachial index (ABI) was &lt; 0.9. The association between nontraditional lipid profiles and PAD was examined using multivariate logistic regression analysis and the restricted cubic spline. RESULTS  All nontraditional lipid indices were independently and positively associated with PAD in a dose-response fashion. After multivariable adjustment, the per SD increments of the TC/HDL-C, TG/HDL-C, LDL-C/HDL-C ratios and non-HDL-C were all significantly associated with 37, 14, 40, and 24% higher risk for PAD, respectively. The adjusted ORs (95% CI) for PAD were 1.77 (1.31, 2.40), 1.71 (1.25, 2.34), 2.03 (1.50, 2.74), and 1.70 (1.25, 2.31) when comparing the highest tertile to the lowest tertile of the TC/HDL-C, TG/HDL-C, LDL-C/HDL-C ratios and non-HDL-C, respectively. CONCLUSIONS  Among Chinese hypertensive adults, all nontraditional lipid indices were positively associated with PAD, and the LDL-C/HDL-C and TC/HDL-C ratios were better than the other nontraditional lipid indices for predicting PAD. These findings may improve the risk stratification of cardiovascular disease and dyslipidemia management. TRIAL REGISTRATION  CHiCTR, ChiCTR1800017274 . Registered 20 July 2018.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 BACKGROUND  Pediatric patients with genetic disorders have a higher incidence of pulmonary arterial hypertension (PAH) regardless of their heart defects. Filamin A (FLNA) mutation is recently recognized to be associated with pediatric pulmonary disorders, however, the clinical courses of PAH related to the mutation were reported in limited cases. Here, we presented a case and pooled data for better understanding of the correlation between FLNA mutation and pediatric PAH. CASE PRESENTATION  The patient was a 8-month-old female with repeated episodes of pneumonia. Physical examination revealed cleft lip, cleft palate and developmental retardation. Imaging examination showed a small atrial septal defect (ASD), central pulmonary artery enlargement, left upper lobe of lung atelectasis, and pulmonary infiltration. Genetic test showed she carried a de novo pathogenic variant of FLNA gene (c.5417-1G &gt; A, p.-). Oral medications didn&#39;t slow the progression of PAH in the patient, and she died two years later. CONCLUSIONS  FLNA mutation causes rare but progressive PAH in addition to a wide spectrum of congenital heart disease and other comorbidities in pediatric patients. We highly recommend genetic testing for pediatric patients when suspected with PAH. Given the high mortality in this group, lung transplantation may offer a better outcome.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,
 INTRODUCTION  Studies have been performed to identify the association between ABO blood groups and coronary artery disease. However, data is scarce about the impact of ABO blood groups on heart rupture (HR) after acute myocardial infarction (AMI). METHODS  We conducted a retrospective case-control study that included 61 consecutive patients with HR after AMI during a period from 1 January 2012 to 1 December 2019. The controls included 600 patients who were selected randomly from 8143 AMI patients without HR in a ratio of 1 10. Univariate and multivariate logistic regression analysis were used to identify the association between ABO blood groups and HR. RESULTS  Patients with blood group A had a greater risk of HR after AMI than those with non-A blood groups (12.35% vs 7.42%, P &lt; 0.001). After adjusting for age, gender, heart rate at admission, body mass index (BMI), and systolic blood pressure (SBP), blood group A was independently related to the increased risk of HR after AMI (OR = 2.781, 95% CI 1.174-7.198, P = 0.035), and remained as an independent risk factor of HR after AMI in different multivariate regression models. CONCLUSION  Blood group A is significantly associated with increased HR risk after AMI.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 BACKGROUND  To investigate the midterm postoperative prognosis of patients with severe left heart valvular disease combined with moderate or severe pulmonary hypertension (PAH) using subcutaneous injection of treprostinil. METHODS  A retrospective study was conducted on 61 patients with severe left heart valvular disease combined with moderate or severe PAH who had undergone mechanical mitral and/or aortic valve replacement from April 2018 to October 2018. The patients were divided into the treprostinil group and the conventional treatment group according to whether they received treprostinil. The patients were assessed by SwanGanz catheterization, echocardiography, the 6-min walk test (6-MWT), the Borg dyspnoea score and the SF-36 questionnaire. RESULTS  Compared with the preoperative data, the mPAP measured by SwanGanz catheterization, the results of the 6-MWT and the Borg score were significantly improved in both groups during the 1 year follow-up (P &lt; 0.05). Regarding the comparison between the groups, the results in group T were significantly better than those in group C, including the results of the 6-MWT and the general health, vitality and mental health of SF-36 during the 1 year follow-up (P &lt; 0.05). CONCLUSIONS  Continuous subcutaneous infusion of treprostinil was not capable of decreasing pulmonary pressures in patients with severe left heart valvular disease combined with moderate or severe PAH during 1 year follow-up, although which some of our data suggest that might improve the symptoms and quality of life of these patients.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  Ruptured sinus of Valsalva aneurysm (SVA) is a rare cardiovascular disease in which some patients exhibit aortic valve insufficiency. SVA repair and valve replacement are usually required for treatment. Here, we report 5 cases of ruptured SVA with severe post-anaesthesia aortic regurgitation (AR). To the best of our knowledge, this is the first report of ruptured SVA with severe post-anaesthesia AR. CASE PRESENTATION  From 2018 to 2020, there were 5 cases of ruptured SVA with severe AR after anaesthesia in our hospital. The main symptoms were palpitation and shortness of breath. Transthoracic echocardiography (TTE) with colour-flow Doppler showed ruptured aortic sinus aneurysms without AR. Post-anaesthesia echocardiography showed severe AR. Direct patch closure of the ruptured aneurysm resolved the left-to-right shunt and AR, and the aortic valve was not replaced. CONCLUSIONS  Post-anaesthesia AR without obvious structural defects may occur in patients with ruptured SVAs. Valve replacement may not be necessary.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Diseases of arteries,
 BACKGROUND  Coarctation of the aorta is a rare congenital disease. In adults, the main manifestations include hypertension, weak or absent femoral pulses, heart failure, and left ventricular hypertrophy. CASE PRESENTATION  We present a case involving a late diagnosis of coarctation of the aorta detected during aortography in a 44-year-old man. The patient underwent stent implantation and aortoplasty. After 2 years of follow-up, the patient was in good condition. CONCLUSIONS  This case shows that coarctation of the aorta can be cured and that hypertension caused by the condition can be controlled to some extent with medication. Based on our findings, we recommend a detailed physical examination for all patients suspected of having coarctation of the aorta; the examination should include blood pressure measurements of both the upper and lower extremities. The case of coarctation of the aorta is not common or easy to be found in medium-aged population. Better BP control, earlier repair, and transcatheter intervention may result in a good outcome in that case.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,
 ASBTRACT  BACKGROUND  There are limited neuroprotective treatment options for patients with aneurysmal subarachnoid hemorrhage (SAH). Cerebrolysin, a brain-specific proposed pleiotropic neuroprotective agent, has been suggested to improve global functional outcomes in ischemic stroke. We investigated the efficacy, safety and feasibility of administering Cerebrolysin for SAH patients. METHODS  This was a prospective, randomized, double-blind, placebo-controlled, single-center, parallel-group pilot study. Fifty patients received either daily Cerebrolysin (30 ml/day) or a placebo (saline) for 14 days (25 patients per study group). The primary endpoint was a favorable Extended Glasgow Outcome Scale (GOSE) of 5 to 8 (moderate disability to good recovery) at six-months. Secondary endpoints included the modified Ranking Scale (mRS), the Montreal Cognitive Assessment (MOCA) score, occurrence of adverse effects and the occurrence of delayed cerebral ischemia (DCI). RESULTS  No severe adverse effects or mortality attributable to Cerebrolysin were observed. No significant difference was detected in the proportion of patients with favorable six-month GOSE in either study group (odds ratio (OR)  1.49; 95% confidence interval (CI)  0.43-5.17). Secondary functional outcome measures for favorable six-month recovery i.e. a mRS of 0 to 3 (OR  3.45; 95% CI 0.79-15.01) were comparable for both groups. Similarly, there was no difference in MOCA neurocognitive performance (p-value  0.75) and in the incidence of DCI (OR  0.85 95% CI  0.28-2.59). CONCLUSIONS  Use of Cerebrolysin in addition to standard-of-care management of aneurysmal SAH is safe, well tolerated and feasible. However, the neutral results of this trial suggest that it does not improve the six-month global functional performance of patients. CLINICAL TRIAL REGISTRATION  Name of Registry  ClinicalTrials.gov Trial Registration Number  NCT01787123 . Date of Registration  8th February 2013.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">cerebrovascul</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Diseases of arteries,Coagulopathies,
 Diabetic Mellitus (DM) is a metabolic disorder that has attracted worldwide concern. DM is caused due to lack of insulin or ineffective production of insulin in the pancreas. A total of 463 million people have diabetes mellitus in 2019 and it was predictedto raise upto 578 million by 2030 and 700 million by 2045. High blood sugar gives rise to many complications like diabetic retinopathy, diabetic nephropathy, atherosclerosis, hypercoagulability, cardiovascular disease, coronary heart disease, abdominal obesity, hypertension, hyperlipidemia, cerebrovascular disease, coronary artery disease, foot damage, skin complications, Alzheimer&#39;s disease, hearing impairment, and depression. These life-threatening complications make diabetes more severe than other diseases. Many synthetic drugs are developed, but still cure is not provided by any of the molecules up to this date. Continuous use of some synthetic agents caused many severe side effects, and thus the demands for non-toxic, affordable drugs are still awaited. Traditional treatments have been an extremely valued source of medicine all over the human history. These are extensively used throughout the world indicating that herbs are a growing part of modern and high-tech medicines. The World Health Organization (WHO) has listed a total of 21,000 plants, which are used for medicinal purposes around the world, among them more than 400 plants are available for the treatment of diabetes. Despite the fact that there are many herbal drugs are available for treating diabetes, only a small number of these plants have received scientific and medical evaluation to assess their efficacy. Trigonella foenum-graecum, Allium sativum, Caesalpinia bonduc, Ferrulaassafoetida, etc., are some of the medicinal plants used for antidiabetic therapy. The presence of phenolic compounds, flavonoids, terpenoids and coumarins are responsible for the antidiabetic nature of the medicinal plants. These constituents have shown a reduction in blood glucose levels. Picnogenol, acarbose, miglitol, and voglibose are some of the examples of marketed drugs, which are obtained from the natural origin and used as antidiabetic drugs. The active principles derived from the plants work through many antidiabetic mechanisms, which include inhibition of alpha-glucosidase, alpha-amylase, and protein tyrosine phosphatase 1B activities. One of the major advantages of herbal drugs is the low level of side effects attributed to these medicines, and this attracted the various researchers to develop new molecules for treatment of diabetes. In this review, emphasis will be given on the recent advances in the field of herbal drugs to treat diabetes, to prevent the secondary complications arising due to diabetes, and various herbal molecules in different stages of clinical trials.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">microvascul</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,Coagulopathies,
 Modern lifestyle, changing eating habits and reduced physical work have been known to culminate into making diabetes a global pandemic. Hyperglycemia during the course of diabetes is an important causative factor for the development of both microvascular (retinopathy, nephropathy and neuropathy) and macrovascular (coronary artery disease, stroke and peripheral artery disease) complications. In this article, we summarize several mechanisms accountable for the development of both microvascular and macrovascular complications of diabetes. Several metabolic and cellular events are linked to the augmentation of oxidative stress like the activation of advanced glycation endproducts (AGE) pathway, polyol pathway, protein kinase C (PKC) pathway, poly-ADP ribose polymerase (PARP) and hexosamine pathway. Oxidative stress also leads to production of reactive oxygen species (ROS) like hydroxyl radical, superoxide anion and peroxides. Enhanced levels of ROS rescind the anti-oxidant defence mechanisms associated with superoxide dismutase, glutathione and ascorbic acid. Moreover, ROS triggers oxidative damages at the level of DNA, protein and lipids which eventually cause cell necrosis or apoptosis. These physiological insults may be related to the microvascular complications of diabetes by negatively impacting the eyes, kidneys and brain. While underlying pathomechanism of the macrovascular complications is quite complex, hyperglycemia associated atherosclerotic abnormalities like changes in the coagulation system, thrombin formation, fibrinolysis, platelet and endothelial function and vascular smooth muscle is well proven. Since hyperglycemia also modulates the vascular inflammation, cytokines, macrophage activation and gene expression of growth factors, elevated blood glucose level may play a central role in the development of macrovascular complications of diabetes. Taken collectively, chronic hyperglycemia and increased production of ROS are the miscreants for the development of microvascular and macrovascular complications of diabetes.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,
 BACKGROUND  Type 2 diabetes mellitus (DM) is associated with a considerable risk of cardiovascular and renal disease, including heart failure. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated unprecedented cardiorenal protective effects in large scale clinical trials of patients with or without diabetes and either established cardiovascular disease (CV) or multiple CV risk factors. OBJECTIVE  Herein we aim to focus on the role of SGLT2 inhibitors regarding the improvement in heart failure outcomes and the proposed mechanisms of action by which these drugs confer their beneficial effect. METHODS  PubMed, Embase and Google Scholar databases were searched to identify eligible articles which are comprehensively summarized and discussed. RESULTS  The most commonly discussed mechanisms of action are diuresis and natriuresis, reduction in preload, afterload, and ventricular mass, as well as stimulation of erythropoietin production and improved myocardial energetics. SGLT2 inhibitors improve outcomes in patients with established heart failure (HF) and reduce the risk of death and HF admissions in patients with established chronic HF with reduced ejection fraction (HFrEF), either with or without diabetes. CONCLUSION  Potential key mechanisms that may explain the notable cardioprotective benefits of SGLT2 inhibitors have been outlined. These agents have recently received class Ia recommendation in specific groups of people with DM to lower the risk of hospitalization for HF and risk of death, while these benefits may also extend to people without diabetes. It remains to be seen whether they will also emerge as treatment approaches in the acute phase of CV episodes.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-magenta-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">arrhythm</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Arrhythmia,Inflammatory diseases,Diseases of arteries,
 Coronavirus disease 2019 (COVID-19) first emerged in a group of patients who presented with severe pneumonia in Wuhan, China in December 2019. A novel virus, now called SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) was isolated from lower respiratory tract samples. The current outbreak of infection has spread to over 100 countries and killed more 340,000 people as of 25th May, 2020. The predominant clinical manifestation of COVID-19 is respiratory disease- ranging from mild flu-like symptoms to fulminant pneumonia and Acute Respiratory Distress Syndrome (ARDS). Patients with pre-existing cardiovascular risk factors are considered more susceptible to the virus, and these conditions are often worsened by the infection. Further, COVID-19 infection has led to de novo cardiac complications like acute myocardial injury and arrhythmias. In this review, we have focused on the cardiovascular manifestations of COVID-19 infection that have been reported in literature so far. We have also outlined the effect of pre-existing cardiovascular disease and well as risk factors on the clinical course and outcomes of COVID-19 infection.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">diabet cardiomyopathy</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">stenos</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Cardiomyopathy,Diseases of arteries,
 BACKGROUND  Having in mind that diabetes mellitus (DM) and obesity are some of the greatest health challenges of the modern era, diabetic cardiomyopathy (DCM) is becoming more and more recognized in clinical practice. Main text  Initially DM is asymptomatic, but it may progresses to diastolic, and then systolic left ventricular dysfunction, which results in congestive heart failure. A basic feature of this DM complication is the absence of haemodynamically sig-nificant stenosis of the coronary blood vessels. Clinical manifestations are the result of several metabolic disorders which are present during DM progression. The complexity of metabolic processes, along with numerous regulatory mechanisms, has been the subject of research which aims at discovering new diagnostic (e.g. myocardial strain with echocardiography and cardiac magnetic resonance) and treatment options. Adequate glycaemic control is not sufficient to prevent or reduce the progression of DCM. Contemporary hypoglycaemic medications, such as sodium-glucose transport protein 2 inhibitors significantly reduce the frequency of cardiovascular complications in patients with DM. Several studies have shown that, unlike the above stated medications, thiazolidinediones and dipeptidyl peptidase-4 inhibitors are associated with deteriora-tion of heart failure. CONCLUSION  Imaging procedures, especially myocardial strain with echocardiography and cardiac magnetic resonance are useful to identify the early signs of DCM. Research and studies regarding new treatment options are still &#34;in progress&#34;.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 OBJECTIVES  With the declaration of COVID-19 as a pandemic, many studies have indicated that elective surgeries should be postponed. However, postponement of transplants may cause diseases to get worse and increase the number in wait lists. We believe that, with precautions, transplant does not pose a risk during pandemic. Here, we aimed to evaluate our transplant results, which we safely performed during a 6-month pandemic period. MATERIALS AND METHODS  Until September 2020, 3140 kidney and 667 liver transplants have been performed in our centers. We evaluated 38 kidney transplants and 9 liver transplants procedures performed during the pandemic (March 1 to September 2, 2020). Recipient and donor candidates were screened for COVID-19 with polymerase chain reaction and thoracic computed tomography. All recipients had routine immunosuppressive protocol. During hospitalization at our COVID-19-free transplant facility, we restricted the interactions during multidisciplinary rounds. RESULTS  During the pandemic, 38 kidney transplants with an average length of hospital stay of 8.1 days were performed. Mean serum creatinine values of recipients were 0.91, 0.86, and 0.74 mg/dL on postoperative days 7, 30, and 90, respectively. During the pandemic, 9 living donor liver transplants (1 adult, 8 pediatric) were performed with an average length of hospital stay of 17.1 days. Mean serum total bilirubin levels were 0.9, 0.5, and 0.4 mg/dL on postoperative days 7, 30, and 90, respectively. Mean serum aspartate aminotransferase levels were 38.1, 28.3, and 22.3 U/L on postoperative days 7, 30, and 90, respectively. All recipients and donors were successfully discharged. Only 1 liver recipient died (on day 55 after discharge as a result of oxalosis-induced heart failure). CONCLUSIONS  According to our results, when precautions are taken, transplant does not pose a risk to patients during the pandemic period. We attribute the safety and success shown to our newly developed protocol in response to the COVID-19 pandemic.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  Similar to poorly differentiated thyroid carcinoma (PDTC), papillary thyroid carcinoma with high-grade features (PTC HGF) demonstrates increased mitotic activity and/or necrosis; however, PTC HGF is excluded from the WHO definition of PDTC based on maintained nuclear features of PTC. METHODS  Consecutive tumors that met criteria for PTC HGF, defined as tumors with maintained nuclear features of PTC and mitoses numbering 5 or more per 10 contiguous high power fields and/or tumor necrosis, and PDTC (defined per WHO criteria) were identified. Clinicopathologic characteristics, follow-up data, and targeted next generation sequencing results were compared between groups. RESULTS  There were 15 PTC HGF and 47 PDTC. PTC HGF was associated with a higher rate of pT4 disease (53% vs. 13%, p=0.0027) and lymph node metastases (73% vs. 38%, p=0.049). The disease-specific survival (DSS) was worse for patients with PTC HGF compared to those with PDTC using Kaplan-Meier estimation (p=&lt;0.001) and was worse in subgroup analysis evaluating patients with widely invasive PDTC (i.e. those with a similar rate of pT4 disease) and PTC HGF (p=0.040). PTC HGF had a higher BRAF V600E mutation rate (42% vs. 3%; p=0.003), a trend toward more gene fusions (25% vs. 3%; p=0.052), and a higher rate of relative gain of 1q (67% vs. 15%; p=0.002) than PDTC. CONCLUSIONS  Our results demonstrate that PTC HGF are important to recognize based on their aggressive behavior. The molecular differences between PTC HGF and PDTC suggest that PTC HGF should be considered as a distinct group from PDTC.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Coagulopathies,
 BACKGROUND  Detection of left atrial appendage thrombus (LAAt) in acute stroke patients can be improved by cardiac computed tomography using prospective electrocardiogram-gated volume acquisition, which was added to the acute stroke computed tomography protocol in our institution in 2018. AIMS  To evaluate the factors and clinical management associated with LAAt in patients with acute ischemic stroke. METHODS  We retrospectively included 324 consecutive patients with ischemic stroke from November 2018 to October 2019. Clinical data and post-stroke management were compared in LAAt and no-LAAt patients. RESULTS  Thirty-five patients (10.8%; 95%CI 7.4-14.2) had LAAt and 289 had no-LAAt. LAAt patients were significantly older (82 +/- 12 vs. 74 +/- 14 yo for no-LAAt, p = 0.002), predominantly female (71% vs. 45%, p = 0.004), and were more likely to have previous atrial fibrillation (63% vs. 15%, p &lt; 0.001) and previous stroke (32% vs. 14%, p = 0.005). There was no significant difference between groups in stroke localization or severity scales at admission or at hospital discharge. After multivariable analysis, female sex (odds ratio 2.51; 95%CI 1.09-5.77, p = 0.031), previous atrial fibrillation (odds ratio 4.87; 95%CI 2.11-11.22, p &lt; 0.001), and left atrial volume &gt;86 ml (odds ratio 5.33; 95%CI 1.70-16.69, p = 0.004) were independently associated with LAAt. More than a third of LAAt patients (37%) received acute heparin therapy compared to 13% of no-LAAt patients (p &lt; 0.001). Moreover, despite comparable stroke severity at admission, the mortality rate was markedly higher in the LAAt group than in the no-LAAt group (37% vs. 13%, p &lt; 0.001). CONCLUSIONS  Cardiac computed tomography for left atrial appendage thrombus evaluation in routine acute stroke imaging protocol could be beneficial for decision-making with regard to the initiation of early anticoagulation.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Coagulopathies,
 BACKGROUND  Detection of left atrial appendage thrombus (LAAt) in acute stroke patients can be improved by cardiac computed tomography using prospective electrocardiogram-gated volume acquisition, which was added to the acute stroke computed tomography protocol in our institution in 2018. AIMS  To evaluate the factors and clinical management associated with LAAt in patients with acute ischemic stroke. METHODS  We retrospectively included 324 consecutive patients with ischemic stroke from November 2018 to October 2019. Clinical data and post-stroke management were compared in LAAt and no-LAAt patients. RESULTS  Thirty-five patients (10.8%; 95%CI 7.4-14.2) had LAAt and 289 had no-LAAt. LAAt patients were significantly older (82 +/- 12 vs. 74 +/- 14 yo for no-LAAt, p = 0.002), predominantly female (71% vs. 45%, p = 0.004), and were more likely to have previous atrial fibrillation (63% vs. 15%, p &lt; 0.001) and previous stroke (32% vs. 14%, p = 0.005). There was no significant difference between groups in stroke localization or severity scales at admission or at hospital discharge. After multivariable analysis, female sex (odds ratio 2.51; 95%CI 1.09-5.77, p = 0.031), previous atrial fibrillation (odds ratio 4.87; 95%CI 2.11-11.22, p &lt; 0.001), and left atrial volume &gt;86 ml (odds ratio 5.33; 95%CI 1.70-16.69, p = 0.004) were independently associated with LAAt. More than a third of LAAt patients (37%) received acute heparin therapy compared to 13% of no-LAAt patients (p &lt; 0.001). Moreover, despite comparable stroke severity at admission, the mortality rate was markedly higher in the LAAt group than in the no-LAAt group (37% vs. 13%, p &lt; 0.001). CONCLUSIONS  Cardiac computed tomography for left atrial appendage thrombus evaluation in routine acute stroke imaging protocol could be beneficial for decision-making with regard to the initiation of early anticoagulation.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Ischemia,Heart failure,
 Chronic kidney disease is associated with increased cardiovascular morbidity and mortality. A well-functioning vascular access is associated with improved survival and among the available types of vascular access the arterio-venous (AV) fistula is the one associated with the best outcomes. However, AV access may affect heart function and, in some patients, could worsen the clinical status. This review article focuses on the specific cardiovascular hemodynamics of dialysis patients and how it is affected by the AV access; the effects of an excessive increase in AV access flow, leading to high-output heart failure; congestive heart failure in CKD patients and the contraindications to AV access; pulmonary hypertension. In severe heart failure, peritoneal dialysis (PD) might be the better choice for cardiac health, but if contraindicated suggestions for vascular access selection are provided based on the individual clinical presentation. Management of the AV access after kidney transplantation is also addressed, considering the cardiovascular benefit of AV access ligation compared to the advantage of having a functioning AVF as backup in case of allograft failure. In PD patients, who need to switch to hemodialysis, vascular access should be created timely. The influence of AV access in patients undergoing cardiac surgery for valvular or ischemic heart disease is also addressed. Cardiovascular implantable electronic devices are increasingly implanted in dialysis patients, but when doing so, the type and location of vascular access should be considered.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">tricuspid</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocardit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocard</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">cardit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,
 BACKGROUND  The incidence of infective endocarditis (IE) in chronic hemodialysis (CHD) patients remains high, despite the preventive measures implemented by nephrologists, especially the rigorous respect of hygiene, the use of antibiotic locks for catheters and the use of tunneled catheters instead of non-tunneled. OBJECTIVE  The objective of this study was to determine the clinical, biological, and echocardiographic characteristics, and the prognosis of IE in CHD. PATIENTS AND METHODS  It was a retrospective study, conducted from December 2010 to March 2020, at the Nephrology and Cardiology units of University Hospital in Oujda, Morocco. RESULTS  We compiled a series of 31 CHD patients having developed IE. Eleven cases (35.4%) were collected between 2010 and 2015, and 20 cases (64.6%) between 2016 and 2020. The mean age was 47 +/- 19 years, 58% were male, and 25.8% of patients had diabetes. Vascular access for hemodialysis was by arteriovenous fistula, non-tunneled catheter, and tunneled catheter in 22.5%, 32.2%, and 45.2%, of the cases, respectively. About 25.8% of patients had benefited from more than two catheters (tunneled or non-tunneled) during the 3 months preceding the occurrence of IE. The mitral, tricuspid, and aortic valves were the site of IE in 41.9%, 41.9%, and 13% of the cases, respectively. Right heart IE and left heart IE were observed in 42% (13 cases) and 58% (18 cases) of cases, respectively. Blood cultures were negative in 58.1% of the cases at the time of diagnosis of IE. Staphylococcus aureus was identified in 69.2% of the cases. Mortality occurred in 54.8% of the cases. CONCLUSION  IE remains a severe condition in CHD patients with an increasing incidence. Rigorous prevention and screening strategies should be implemented at the hemodialysis centers.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,Coagulopathies,
 BACKGROUND  Lipoprotein apheresis is an important therapeutic option in homozygous familial hypercholesterolemia, progressive atherosclerosis, or when depletion of lipoprotein(a) is indicated. It is generally regarded as safe, but drops in platelet counts as well as sporadic episodes of thrombocytopenia have been reported. We assessed the influence of platelet desialylation, which may be induced by endogenous or pathogen-derived neuraminidases, on platelet adhesion to polyacrylate-based adsorbents for whole blood lipoprotein apheresis. METHODS  Medical grade platelet concentrates were incubated with neuraminidase in vitro and were circulated over adsorbent columns downscaled from clinical application. RESULTS  Cleavage of terminal sialic residues resulted in platelet activation with significantly elevated expression of platelet factor 4 (PF4) and in enhanced platelet adhesion to the adsorbent, accompanied by a pronounced drop in platelet counts in the column flow-through. CONCLUSION  Alterations in endogenous neuraminidase activity or exogenous (pathogen-derived) neuraminidase may trigger enhanced platelet adhesion in whole blood lipoprotein apheresis.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Senile osteoporosis (OP) is often concomitant with decreased autophagic activity. OPTN (optineurin), a macroautophagy/autophagy (hereinafter referred to as autophagy) receptor, is found to play a pivotal role in selective autophagy, coupling autophagy with bone metabolism. However, its role in osteogenesis is still mysterious. Herein, we identified Optn as a critical molecule of cell fate decision for bone marrow mesenchymal stem cells (MSCs), whose expression decreased in aged mice. Aged mice revealed osteoporotic bone loss, elevated senescence of MSCs, decreased osteogenesis, and enhanced adipogenesis, as well as optn(-) (/ -) mice. Importantly, restoring Optn by transplanting wild-type MSCs to optn(-) (/ -) mice or infecting optn(-) (/ -) mice with Optn-containing lentivirus rescued bone loss. The introduction of a loss-of-function mutant of Optn(K193R) failed to reestablish a bone-fat balance. We further identified FABP3 (fatty acid binding protein 3, muscle and heart) as a novel selective autophagy substrate of OPTN. FABP3 promoted adipogenesis and inhibited osteogenesis of MSCs. Knockdown of FABP3 alleviated bone loss in optn(-) (/ -) mice and aged mice. Our study revealed that reduced OPTN expression during aging might lead to OP due to a lack of FABP3 degradation via selective autophagy. FABP3 accumulation impaired osteogenesis of MSCs, leading to the occurrence of OP. Thus, reactivating OPTN or inhibiting FABP3 would open a new avenue to treat senile OP. Abbreviations  ADIPOQ  adiponectin, C1Q and collagen domain containing; ALPL  alkaline phosphatase, liver/bone/kidney; BGLAP/OC/osteocalcin  bone gamma carboxyglutamate protein; BFR/BS  bone formation rate/bone surface; CALCOCO2/NDP52  calcium binding and coiled-coil domain 2; CDKN1A/p21  cyclin-dependent kinase inhibitor 1A; CDKN2A/p16  cyclin dependent kinase inhibitor 2A; CDKN2B/p15  cyclin dependent kinase inhibitor 2B; CEBPA  CCAAT/enhancer binding protein (C/EBP), alpha; COL1A1  collagen, type I, alpha 1; Ct. BV/TV  cortical bone volume fraction; Ct. Th  cortical thickness; Es. Pm  endocortical perimeter; FABP4/Ap2  fatty acid binding protein 4, adipocyte; H2AX  H2A.X variant histone; HE  hematoxylin and eosin; MAP1LC3B  microtubule-associated protein 1 light chain 3 beta; MAR  mineral apposition rate; MSCs  bone marrow mesenchymal stem cells; NBR1  NBR1, autophagy cargo receptor; OP  osteoporosis; OPTN  optineurin; PDB  Paget disease of bone; PPARG  peroxisome proliferator activated receptor gamma; Ps. Pm  periosteal perimeter; qRT-PCR  quantitative real-time PCR; gammaH2AX  Phosphorylation of the Serine residue of H2AX; ROS  reactive oxygen species; RUNX2  runt related transcription factor 2; SA-GLB1  senescence-associated (SA)-GLB1 (galactosidase, beta 1); SP7/Osx/Osterix  Sp7 transcription factor 7; SQSTM1/p62  sequestosome 1; TAX1BP1  Tax1 (human T cell leukemia virus type I) binding protein 1; Tb. BV/TV  trabecular bone volume fraction; Tb. N  trabecular number; Tb. Sp  trabecular separation; Tb. Th  trabecular thickness; muCT  micro computed tomography.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Objectives  To investigate the effect of cholecystectomy on the subsequent risk of acute myocardial infarction (AMI) in patients with gallbladder stones (GBS). Methods  We used the Taiwan National Health Insurance Research Database (NHIRD) for hospitalization to conduct a retrospective nationwide population-based cohort study. The study cohort consisted of a total of 122,421 patients aged &gt;/= 20 years with cholecystectomy for GBS between 2000 and 2010. The control cohort consisted of the GBS patients without cholecystectomy and they were randomly selected by propensity score matching with the study cohort at a 1 1 ratio according to age, sex, occupation category, urbanization level, comorbidities, and year of the index date for cholecystectomy. We measured the incidence of AMI for both cohorts. Results  The cumulative incidence of AMI was lower in GB patients with cholecystectomy than that in those without cholecystectomy (2.26 vs 3.28 per 1000 person-years, adjusted hazard ratio [aHR] = 0.65, 95% confidence interval [CI] = 0.61-0.69). Compared to those without cholecystectomy, the risk of developing AMI after cholecystectomy was 0.69 (95% CI = 0.63-0.76) for the first year, 0.69 (95% CI = 0.63-0.77) for 2-5 years, and 0.59 (95% CI = 0.53-0.66) for &gt;/= 5 years, respectively. Conclusions  Our findings indicate cholecystectomy ameliorates the risk of AMI in patients with GBS, and the protective effect tends to increase with incremental duration of follow-up. However, it needs more studies to ascertain the protective mechanisms of cholecystectomy against AMI.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 Idiopathic Intracranial Hypertension (IIH), also known as pseudotumor cerebri is a clinical syndrome of unknown etiology, which typically affects young, obese women of childbearing age and is characterized by increased intracranial pressure and bilateral papilledema. Unilateral and highly asymmetrical papilledema is a rare presentation in IIH occurring in less than 4% of patients with definite IIH and can poses a diagnostic challenge for the treating physician as it usually raises the suspicion of localized ocular pathology. As per current consensus, papilledema results in stasis of axoplasmic transport due to mechanical compression, leading to secondary vascular changes of venous dilation and hemorrhage. Given this mechanism, the underlying reasons for unilateral and asymmetrical papilledema remain unclear.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,Coagulopathies,
 Obesity and metabolic syndrome (MetS) are public health problems and are increasing globally. We assessed the differences in lipid profiles through lipid testing, thrombotic and inflammatory parameters, and oxidative stress indexes between overweight and obese patients with MetS in a Turkish adult population. We included 100 obese (body mass index [BMI] &gt;30 kg/m(2)) patients with MetS (66 women, 34 men, mean age 54.0 +/- 10.1 years) and 15 overweight (BMI 25-30 kg/m(2)) individuals (11 women, 4 men, mean age 50.2 +/- 14.5 years) as controls. The group with MetS had significantly higher levels of glycaemia, uric acid, high-sensitivity C-reactive protein, homocysteine, fibrinogen, total cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, small dense LDL, oxidized LDL, apolipoprotein B (Apo B), lipoprotein (a), small and intermediate high-density lipoprotein (HDL) particles, oxidative stress index, and significantly lower levels of HDL-cholesterol (HDL-C), Apo A, and large HDL particles. In conclusion, obesity with MetS increase atherogenic dyslipidemia and thrombotic, inflammatory and oxidative stress biomarkers. Furthermore, obesity with MetS decreases protective mechanisms of atherosclerosis. We should at least try to prevent overweight individuals from becoming obese with MetS.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  Sexual activity is an important element of quality of life for many individuals suffering from heart failure. AIMS  The study investigated the influence of disease acceptance on sexual function in a population of male patients with chronic heart failure. METHODS  The study included 80 patients with chronic heart failure (mean age 63.3+/-9.2 years) who filled in the Mell-Krat Scale questionnaire to evaluate sexual needs and reactions. We also used the International Index of Erection Function (IIEF-5) inventory and the Acceptance of Illness Scale (AIS). RESULTS  The study showed that the acceptance of the illness was positively associated with all of the Mell-Krat components such as sexual need, F = (3.27), frequency of intercourse, F = (2.46), position and technique, F = (1.88). Also, according to the IIEF-5 questionnaire, 84.42% of respondents had erectile dysfunction. Taken together these indicated that psychological adjustments such as acceptance of disease increase quality of all aspects of sexual functions in heart failure patients, including their erectile functions. CONCLUSIONS  Our findings suggest that psychological adjustments to feelings of loss associated with the onset of heart failure disease is the important determinant of quality of sexual life among male adults. Our research implicates that effects of AIS on sexual functioning give reasonable information to tailor sexual counselling for males suffering from heart failure.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 OBJECTIVE  To review data on efficacy and safety of osilodrostat (Isturisa), a novel oral steroidogenesis inhibitor for treatment of Cushing&#39;s disease (CD), a life-threatening endocrine disorder. DATA SOURCES  A PubMed/CINAHL search from inception to September 25, 2020, was performed using the following keywords  osilodrostat, 11-beta hydroxylase, pituitary, ACTH hypersecretion, and Cushing&#39;s disease. STUDY SELECTION AND DATA EXTRACTION  Phase 2 and 3 clinical trials and supplementary documents investigating osilodrostat were obtained from a primary literature search, the manufacturer&#39;s website, and the Food and Drug Administration website. These articles evaluated the clinical pharmacology, efficacy, safety, adverse events, warnings, and precautions for osilodrostat. DATA SYNTHESIS  Osilodrostat was efficacious and safe in the treatment of CD in mostly middle-aged Caucasian women. A pivotal phase 3 study revealed a significant difference in 24-hour mean urinary free cortisol (primary end point) between osilodrostat and placebo (86% vs 29%; P &lt; 0.001). RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE  Osilodrostat provides a potent and consistent effect in reducing life-threatening supraphysiological levels of cortisol in patients with CD. Hypocortisolism adverse effects can be mitigated by slowly increasing osilodrostat&#39;s dose at &gt;/=2-week intervals. QT interval prolongation was noted; therefore, the QT interval must be monitored by the electrocardiogram. Increased levels of cortisol precursors during treatment with osilodrostat may increase the risk of hypokalemia, edema, and hypertension. CONCLUSIONS  Osilodrostat was efficacious in decreasing cortisol levels and safe in treating patients who have failed or are ineligible for pituitary surgery. Although risks exist, a pivotal clinical trial revealed efficacy in 86% of participants.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">tricuspid</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Diseases of arteries,
 BACKGROUND  Levosimendan is an effective calcium sensitizer with complementary mechanisms of action  calcium sensitization and opening of adenosine triphosphate-dependent potassium channels, both on the sarcolemma of the smooth muscle cells in the vasculature and on the mitochondria of cardiomyocytes. Levosimendan has a long-acting metabolite with a half-life of approximately 80 h. There have been a few small studies on this drug regarding right ventricular function. In view of this, we investigated the effect of levosimendan on right ventricular function in patients with coronary artery disease. METHODS  This was a prospective, randomized, double-blind study on 50 patients with coronary artery disease and severe left ventricular dysfunction (left ventricular ejection fraction &lt;/=35%) undergoing elective off-pump coronary artery bypass. RESULTS  Levosimendan had an inotropic effect on right ventricular myocardium and a vasodilatory effect on blood vessels. It caused a decline in pulmonary vascular resistance (p &lt; 0.018), right ventricular systolic pressure (p &lt; 0.001), and pulmonary artery systolic pressure (p &lt; 0.001), and improved right ventricular diastolic function as shown by the decrease in right ventricular Tei index (p &lt; 0.001), right ventricular end-diastolic pressure, and the ratio of early diastolic tricuspid inflow to tricuspid lateral annular velocity (p &lt; 0.006). However, we found no beneficial effects on intensive care unit or hospital stay (p = 0.164, p = 0.349, respectively) nor a mortality benefit. CONCLUSIONS  Levosimendan has salutary effects on right ventricular function in patients with severe left ventricular dysfunction undergoing coronary artery bypass, in terms of improved hemodynamic parameters.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,
 The 2019 novel coronavirus [2019-nCoV], which started to spread from December 2019 onwards, caused a global pandemic. Besides being responsible for the severe acute respiratory syndrome 2 [SARS-CoV-2], the virus can affect other organs causing various symptoms. A close relationship between SARS-CoV-2 and the cardiovascular system has been shown, demonstrating an epidemiological linkage between SARS-CoV-2 and cardiac injury. There are emerging data regarding possible direct myocardial damage by 2019-nCoV. In this review, the most important available evidences will be discussed to clarify the precise mechanisms of cardiovascular injury in SARS-CoV-2 patients, even if further researches are needed.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 Melatonin (MT) and sirtuins (SIRT) are geroprotective molecules that hold back the aging process and the development of age-related diseases, including cardiovascular pathologies. Buccal epithelium (BE) sampling is a non-invasive procedure, yielding highly informative material for evaluating the expression of genes and proteins as well as the synthesis of molecules. Among these, MT and SIRTs are valuable markers of the aging process and age-related pathologies. The purpose of this study was to examine age-related expression patterns of these signaling molecules, in particular MT, SIRT1, SIRT3, and SIRT6 in BE of subjects of different ages with and without arterial hypertension (AH). We used real-time polymerase chain reaction (RT-PCR) and immunofluorescence analysis by confocal microscopy. We found that MT immunofluorescence intensity in BE decreases with aging, more evidently in AH patients. SIRT3 and SIRT6 genes expression and immunofluorescence intensity in BE was decreased in aging controls. In AH patients, SIRT1, SIRT3, and SIRT6 gene expression and immunofluorescence intensity in BE was decreased in relation to age and in comparison with age-matched controls. In conclusion, the evaluation of MT and sirtuins in BE could provide a non-invasive method for appraising the aging process, also when accompanied by AH.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 The concept of lysosomotropic agents significantly changed numerous aspects of cellular biochemistry, biochemical pharmacology, and clinical medicine. In the present review, we focused on numerous low-molecular and high-molecular lipophilic basic compounds and on the role of lipophagy and autophagy in experimental and clinical medicine. Attention was primarily focused on the most promising agents acting as autophagy inducers, which offer a new window for treatment and/or prophylaxis of various diseases, including type 2 diabetes mellitus, Parkinson&#39;s disease, and atherosclerosis. The present review summarizes current knowledge on the lysosomotropic features of medical drugs, as well as autophagy inducers, and their role in pathological processes.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">microvascul</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Diseases of arteries,
 Ischemic heart disease still represents a large burden on individuals and health care resources worldwide. By conventions, it is equated with atherosclerotic plaque due to flow-limiting obstruction in large-medium sized coronary arteries. However, clinical, angiographic and autoptic findings suggest a multifaceted pathophysiology for ischemic heart disease and just some cases are caused by severe or complicated atherosclerotic plaques. Currently there is no well-defined assessment of ischemic heart disease pathophysiology that satisfies all the observations and sometimes the underlying mechanism to everyday ischemic heart disease ward cases is misleading. In order to better examine this complicated disease and to provide future perspectives, it is important to know and analyze the pathophysiological mechanisms that underline it, because ischemic heart disease is not always determined by atherosclerotic plaque complication. Therefore, in order to have a more complete comprehension of ischemic heart disease we propose an overview of the available pathophysiological paradigms, from plaque activation to microvascular dysfunction.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">rhe</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Inflammatory diseases,
 The impaired ability to feed properly, evident in oncologic, elderly, and dysphagic patients, may result in malnutrition and sarcopenia. Increasing the consumption of dietary proteins by functional foods and enriching their composition by adding beneficial nutrients may represent an adjuvant therapy. We aimed to evaluate the safety and the positive effects of a standard diet (SD) supplemented with whey-derived protein puddings (WDPP), with appropriate rheological properties, and hemp seed oil (HSO), rich in polyphenols. Rats were assigned to SD, WDPP, WDPP plus hemp seed oil (HSOP), and HSO supplemented diets for eight weeks. &#34;Anthropometric&#34;, metabolic, and biochemical variables, oxidative stress, tissue injury, liver histology, and cardiac susceptibility to ischemia/reperfusion were analyzed. All the supplementations did not induce significant changes in biochemical and metabolic variables, also in relation to glucose tolerance, and livers did not undergo morphological alteration and injury. An improvement of cardiac post-ischemic function in the Langendorff perfused heart model and a reduction of infarct size were observed in WDPP and HSOP groups, thanks to their antioxidant effects and the activation of Akt- and AMPK-dependent protective pathways. Data suggest that (i) functional foods enriched with WDPP and HSOP may be used to approach malnutrition and sarcopenia successfully under disabling conditions, also conferring cardioprotection, and that (ii) adequate rheological properties could positively impact dysphagia-related problems.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Central nervous system (CNS) injury, including stroke, spinal cord injury, and traumatic brain injury, causes severe neurological symptoms such as sensory and motor deficits. Currently, there is no effective therapeutic method to restore neurological function because the adult CNS has limited capacity to regenerate after injury. Many efforts have been made to understand the molecular and cellular mechanisms underlying CNS regeneration and to establish novel therapeutic methods based on these mechanisms, with a variety of strategies including cell transplantation, modulation of cell intrinsic molecular mechanisms, and therapeutic targeting of the pathological nature of the extracellular environment in CNS injury. In this review, we will focus on the mechanisms that regulate CNS regeneration, highlighting the history, recent efforts, and questions left unanswered in this field.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 BACKGROUND  Fatigue is a common distressing symptom in patients with coronary artery disease (CAD). The Multidimensional Fatigue Inventory (MFI) is used for measuring fatigue in various clinical settings. Nevertheless, its multidimensional structure has not been consistent across studies. Thus, we aimed to psychometrically evaluate the MFI in patients with CAD. METHODS  In sum, 1162 CAD patients completed questionnaires assessing their subjective fatigue level (MFI-20), mental distress symptoms (HADS, STAI), and health-related quality of life (SF-36). Participants also completed exercise capacity (EC) testing. RESULTS  Confirmatory factor analysis of the four-factor model, showed acceptable fit (CFI = 0.905; GFI = 0.895; NFI = 0.893, RMSEA = 0.077). After eliminating four items, confirmatory factor analysis testing showed improvement in the four-factor model of the MFI-16 (CFI = 0.910; GFI = 0.909; NFI = 0.898, RMSEA = 0.077). Internal consistency values were adequate for the total score and four MFI-16 subscales  General fatigue, physical fatigue, reduced activity, and mental fatigue with Cronbach&#39;s alpha range  0.60-0.82. The inadequate value (Cronbach&#39;s alpha = 0.43) was received for the subscale of reduced motivation in both MFI-20 and MFI-16. Correlations between the MFI-16 and HADS, STAI, SF-36, and EC measures were statistically significant (all p&#39;s &lt; 0.001). CONCLUSIONS  The Lithuanian version of the modified MFI of 16 items showed good factorial structure and satisfactory psychometric characteristics, except for reduced motivation subscale.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 Dietary habits are a determining factor of the higher incidence and prevalence of chronic non-communicable diseases (NCDs). In the aim to find a possible preventive and intervention strategy, the Mediterranean diet (MedDiet) has been proposed as an effective approach. Within the MedDiet, moderate wine consumption with meals is a positive item in the MedDiet score; however, recent studies have reported a dose-response association between alcohol consumption and higher risk of a large number of NCDs. This review aimed to evaluate the association between NCDs and wine consumption in the framework of the MedDiet, with a simple review of 22 studies of the highest-level literature published over the last five years. We found that the information regarding the effects of wine in different health outcomes has not varied widely over the past five years, finding inconclusive results among the studies evaluated. Most of the literature agrees that light to moderate wine intake seems to have beneficial effects to some extent in NCDs, such as hypertension, cancer, dyslipidemia and dementia, but no definitive recommendations can be made on a specific dose intake that can benefit most diseases.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Inflammatory diseases,
 The aim of this case-control study was the evaluation of the association between biomarkers of early primary arterial hypertension (HA) and oral diseases among children and adolescents. Material and methods. Subjects suspected of primary HA (n = 180) underwent a complex evaluation of their vascular status  blood pressure, heart rate, vascular stiffness, sympathetic activity in a 24 h ambulatory examination, followed by measurement of serum uric acid (UA), cystatin C, and creatinine. This procedure allowed the identification of children with primary (n = 58) and secondary HA (n = 74), as well as of children with normal arterial blood pressure, who served as a control group (n = 48). All subjects with secondary HA were excluded from further investigation. Oral examination included the measurement of caries intensity (using the decayed, missing, filled index for permanent teeth DMFT /primary teeth dmft), bacterial plaque (by the plaque control record index, PCR%), and gingivitis (by the bleeding on probing index, BOP%). For statistical analysis, a linear regression model and Spearman rank correlation were used. Results. UA, cystatin C, and creatinine were not altered in the HA group. However, the number of decayed permanent teeth (DT) and the DMFT, PCR%, and BOP% indexes were significantly higher in the primary HA group compared to the control group (p = 0.0006; p = 0.02; p = 0.0009; p = 0.003). Our results are not sufficient to prove the important role of caries and gingival inflammation in the modulation of HA symptoms, although they prove the association of oral diseases with primary HA symptoms. This may indicate future strategies for preventive measures for hypertensive children and adolescents.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 The two main co-factors needed by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to enter human cells are angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2). Here, we focused on the study of microRNAs that specifically target TMPRSS2. Through a bioinformatic approach, we identified miR-98-5p as a suitable candidate. Since we and others have shown that endothelial cells play a pivotal role in the pathogenesis of the coronavirus disease 2019 (COVID-19), we mechanistically validated miR-98-5p as a regulator of TMPRSS2 transcription in two different human endothelial cell types, derived from the lung and from the umbilical vein. Taken together, our findings indicate that TMPRSS2 represents a valid target in COVID-19 treatment, which may be achieved by specific non-coding-RNA approaches.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">cerebrovascul</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 OBJECTIVE  The proportion of elderly individuals (&gt;/=65 years old) in Japan has markedly increased. However, the definition of senility in Japan is controversial. The aim of the present study was to investigate changes and variations in the number of deaths due to senility in Japan. METHODS  Information on the number of deaths due to senility between 1995 and 2018 as well as other major causes of death was obtained from the Statistics Bureau of Japan official website. Changes and variations in the number of deaths due to senility were compared with other major causes of death in Japan. The relationships between the number of deaths due to senility and socioeconomic factors were also examined in an ecological study. RESULTS  The number of deaths due to senility was 35.7 +/- 23.2/one hundred thousand people/year during the observation period and has continued to increase. A change point was identified in 2004 by a Jointpoint regression analysis. Variations in the number of deaths due to senility, which were evaluated by a coefficient of variation, were significantly greater than those due to other major causes of death, i.e., malignant neoplasm, heart diseases, cerebrovascular diseases, and pneumonia. The number of elderly individuals (&gt;/=65 years old) (%) and medical bills per elderly subject (&gt;/=75 years old) correlated with the number of deaths due to senility. CONCLUSION  The number of deaths due to senility has been increasing, particularly since 2004. However, variations in the number of deaths due to senility were observed among all prefectures in Japan.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Coagulopathies,
 Rivaroxaban (RIV) is commonly prescribed with carbamazepine or phenytoin (CBZ/PHT) in post-stroke seizure or post-stroke epilepsy patients. Although adverse events have been reported in several previous studies when they are coadministered, there are no studies of the interactions between these drugs. Therefore, our study was conducted to solve this lack of information. The potential effects of CBZ/PHT were investigated by comparing the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of RIV between the control group (RIV alone) and the test groups (RIV administered with CBZ/PHT) in rats using the noncompartmental analysis (NCA) and the compartmental model approach. The NCA results indicate that AUCt of RIV decreased by 57.9% or 89.7% and Cmax of RIV decreased by 43.3% or 70.0% after administration of CBZ/PHT, respectively. In addition, both CBZ and PHT generally reduced the effects of RIV on the prothrombin times of the blood samples. PK profiles of RIV were most properly described by a two-compartment disposition model with a mixed first- and zero-order absorption kinetics and a first-order elimination kinetics. The compartmental model approach showed that a 211% or 1030% increase in CL/F of RIV and a 33.9% or 43.4% increase in D2 of RIV were observed in the test groups by the effects of CBZ/PHT, respectively. In conclusion, CBZ and PHT significantly reduced RIV exposure and therefore reduced the therapeutic effects of RIV. Consequently, this might result in adverse events due to insufficient RIV concentration to attain its therapeutic effects. Further studies are needed to validate this finding.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 This commentary offers discussion on the pros and cons of universal healthcare in the United States. Disadvantages of universal healthcare include significant upfront costs and logistical challenges. On the other hand, universal healthcare may lead to a healthier populace, and thus, in the long-term, help to mitigate the economic costs of an unhealthy nation. In particular, substantial health disparities exist in the United States, with low socio-economic status segments of the population subject to decreased access to quality healthcare and increased risk of non-communicable chronic conditions such as obesity and type II diabetes, among other determinants of poor health. While the implementation of universal healthcare would be complicated and challenging, we argue that shifting from a market-based system to a universal healthcare system is necessary. Universal healthcare will better facilitate and encourage sustainable, preventive health practices and be more advantageous for the long-term public health and economy of the United States.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 This study aimed to identify the ideal timing and setting for measuring blood pressure (BP) and determine whether the left ventricular mass index (LVMI) is an independent risk factor associated with increased cardiovascular events in hemodialysis (HD) patients. BP and LVMI were measured at baseline and at 6 and 12 months after HD initiation. BP was monitored and recorded at nine different time points, including before and after HD over a one-week period (HDBP). The mean BP measurement was calculated as the weekly averaged BP (WABP). LVMI was significantly correlated with home BP, in-office BP, HDBP, and WABP. Receiver operating characteristic analysis indicated that the cutoff LVMI value for cardiovascular events was 156 g/m(2). LVMI and diabetes mellitus were significant influencing factors for cardiovascular events (hazards ratio (95% confidence interval)  diabetes mellitus, 2.84 (1.17,7.45); LVMI &gt; 156 g/m(2), 2.86 (1.22,6.99)). Pre-HDBP, post-HDBP, and WABP were independently associated with higher LVMI in the follow-up periods. Hemoglobin and human atrial natriuretic peptide (hANP) levels were associated with LVMI beyond 12 months after HD initiation. Treatment of hypertension, overhydration based on hANP, and anemia may reduce the progression of LVMI and help identify HD patients at high risk for cardiovascular events.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 Recreational hiking in the mountains is a common activity, whether for a single day or for several days in a row. We sought to measure blood pressure (BP) response during a 10-day trek at moderate-altitude elevation (6500-13,000 feet) and observe for uncontrolled hypertension and/or adverse cardiovascular outcomes. A total of 1279 adult participants completed an observational study of resting BP during a 10-day trek in the Sangre de Cristo mountains. Following initial recruitment, participants were issued a trail data card to record BP measurements at day 0 (basecamp), day 3, day 6 and day 9. BP was measured using a sphygmomanometer and auscultation. Demographic data, height, weight, home altitude, daily water and sports drink intake, existence of pre-arrival hypertension and BP medication class were also recorded. We observed a rise in mean blood pressure for the cohort during all exposures to moderate altitudes. The increases were greatest for individuals with pre-existing hypertension and/or obesity. There were no observed life-threatening cardiovascular events for participants. We conclude that for individuals with a modestly controlled blood pressure of 160/95 mmHg, hiking at a moderate altitude is a safe activity.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,Coagulopathies,
 COVID-19 symptoms, including hypokalemia, hypoalbuminemia, ageusia, neurological dysfunctions, D-dimer production, and multi-organ microthrombosis reach beyond effects attributed to impaired angiotensin-converting enzyme 2 (ACE2) signaling and elevated concentrations of angiotensin II (Ang II). Although both SARS-CoV (Severe Acute Respiratory Syndrome Coronavirus) and SARS-CoV-2 utilize ACE2 for host entry, distinct COVID-19 pathogenesis coincides with the acquisition of a new sequence, which is homologous to the furin cleavage site of the human epithelial Na(+) channel (ENaC). This review provides a comprehensive summary of the role of ACE2 in the assembly of Na(+)-dependent transporters of glucose, imino and neutral amino acids, as well as the functions of ENaC. Data support an osmotic adaptation mechanism in which osmotic and hemostatic instability induced by Ang II-activated ENaC is counterbalanced by an influx of organic osmolytes and Na(+) through the ACE2 complex. We propose a paradigm for the two-site attack of SARS-CoV-2 leading to ENaC hyperactivation and inactivation of the ACE2 complex, which collapses cell osmolality and leads to rupture and/or necrotic death of swollen pulmonary, endothelial, and cardiac cells, thrombosis in infected and non-infected tissues, and aberrant sensory and neurological perception in COVID-19 patients. This dual mechanism employed by SARS-CoV-2 calls for combinatorial treatment strategies to address and prevent severe complications of COVID-19.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Coagulopathies,
 Diabetes mellitus (DM) predicts ominous outcomes in acute pulmonary embolism (PE). The influence of gender on the prognostic impact of DM in PE is unknown. We did a retrospective analysis of a cohort of patients hospitalized with PE between 2006 and 2013. The exclusion criteria were age &lt;18, non-pulmonary veins thromboembolism, recurrent PE, chronic thromboembolic pulmonary hypertension, no radiologic confirmation of PE, and active neoplasia. The primary endpoint was all-cause mortality. The follow-up was from diagnosis until October 2017. We assessed the prognostic impact of DM using a multivariate Cox regression analysis. The analysis was stratified according to gender. The interaction between gender and DM in the outcome of patients with PE was tested. We studied 577 PE patients (median age 65 years, 36.9% men, 19.8% diabetic). The genders were similar regarding the prevalence of DM, the extension and location of PE, and the thrombolytic therapy or brain natriuretic peptide (BNP) value. Diabetics presented higher all-cause mortality (Hazard ratio (HR) = 2.33 (95% confidence Interval (CI) 1.513.61)) when compared with non-diabetics. However, when analysis was stratified according to gender, DM was independently associated with a worse prognosis only in women (HR = 2.31 (95% CI 1.453.65)), while in men the HR was 1.10 (95% CI 0.592.04). The interaction between gender and DM was significant (p = 0.04). Gender influences the prognostic impact of DM in acute PE. Diabetic women with PE have twice the long-term mortality risk, while DM is not mortality-associated in men.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Cardiovascular diseases, including peripheral arterial and venous disease, myocardial infarction, and stroke, are the number one cause of death worldwide annually. In the last 20 years, the role of necroptosis, a newly identified form of regulated necrotic cell death, in cardiovascular disease has come to light. Specifically, the damaging role of two kinase proteins pivotal in the necroptosis pathway, Receptor Interacting Protein Kinase 1 (RIPK1) and Receptor Interacting Protein Kinase 3 (RIPK3), in cardiovascular disease has become a subject of great interest and importance. In this review, we provide an overview of the current evidence supporting a pathologic role of RIPK1 and RIPK3 in cardiovascular disease. Moreover, we highlight the evidence behind the efficacy of targeted RIPK1 and RIPK3 inhibitors in the prevention and treatment of cardiovascular disease.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Heme released from red blood cells targets a number of cell components including the cytoskeleton. The purpose of the present study was to determine the impact of free heme (20-300 microM) on human skeletal muscle fibres made available during orthopedic surgery. Isometric force production and oxidative protein modifications were monitored in permeabilized skeletal muscle fibre segments. A single heme exposure (20 microM) to muscle fibres decreased Ca(2+)-activated maximal (active) force (Fo) by about 50% and evoked an approximately 3-fold increase in Ca(2+)-independent (passive) force (Fpassive). Oxidation of sulfhydryl (SH) groups was detected in structural proteins (e.g., nebulin, alpha-actinin, meromyosin 2) and in contractile proteins (e.g., myosin heavy chain and myosin-binding protein C) as well as in titin in the presence of 300 microM heme. This SH oxidation was not reversed by dithiothreitol (50 mM). Sulfenic acid (SOH) formation was also detected in the structural proteins (nebulin, alpha-actinin, meromyosin). Heme effects on SH oxidation and SOH formation were prevented by hemopexin (Hpx) and alpha1-microglobulin (A1M). These data suggest that free heme has a significant impact on human skeletal muscle fibres, whereby oxidative alterations in structural and contractile proteins limit contractile function. This may explain and or contribute to the weakness and increase of skeletal muscle stiffness in chronic heart failure, rhabdomyolysis, and other hemolytic diseases. Therefore, therapeutic use of Hpx and A1M supplementation might be effective in preventing heme-induced skeletal muscle alterations.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Inflammatory diseases,
 Obesity induces hemodynamic and humoral changes that are associated with functional and structural cardiac remodeling, which ultimately result in the development of heart failure (HF) with preserved ejection fraction (HFpEF). In recent years, pharmacological studies in patients with HFpEF were mostly unsatisfactory. In these conditions, alternative new therapeutic approaches are necessary. The aim of our study was (1) to assess the effects of obesity on heart function in an experimental model and (2) to evaluate the efficacy of an alpha-lipoic acid (ALA) antioxidant treatment. Sprague-Dawley rats (7 weeks old) were either included in the control group (n = 6) or subjected to abdominal aortic banding (AAB) and divided into three subgroups, depending on their diet  standard (AAB + SD, n = 8), hypecaloric (AAB + HD, n = 8) and hypercaloric with discontinuous ALA treatment (AAB + HD + ALA, n = 9). Body weight (BW), glycemia, echocardiography parameters and plasma hydroperoxides were monitored throughout the study. After 36 weeks, plasma adiposity (leptin and adiponectin) and inflammation (IL-6 and TNF-alpha) markers, together with B-type natriuretic peptide and oxidative stress markers (end-products of lipid peroxidation and endogenous antioxidant systems) were assessed. Moreover, cardiac fiber diameters were measured. In our experiment, diet-induced obesity generated cardiometabolic disturbances, and in association with pressure-overload induced by AAB, it precipitated the onset of heart failure, cardiac hypertrophy and diastolic dysfunction, while producing a pro-oxidant and pro-inflammatory plasmatic status. In relationship with its antioxidant effects, the chronic ALA-discontinuous treatment prevented BW gain and decreased metabolic and cardiac perturbations, confirming its protective effects on the cardiovascular system.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">microvascul</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coagulopathy</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,Coagulopathies,
 COVID-19 infection has protean systemic manifestations. Experience from previous coronavirus outbreaks, including the current SARS-CoV-2, has shown an augmented risk of thrombosis of both macrovasculature and microvasculature. The former involves both arterial and venous beds manifesting as stroke, acute coronary syndrome and venous thromboembolic events. The microvascular thrombosis is an underappreciated complication of SARS-CoV-2 infection with profound implications on the development of multisystem organ failure. The telltale signs of perpetual on-going coagulation and fibrinolytic cascades underscore the presence of diffuse endothelial damage in the patients with COVID-19. These parameters serve as strong predictors of mortality. While summarizing the alterations of various components of thrombosis in patients with COVID-19, this review points to the emerging evidence that implicates the prominent role of the extrinsic coagulation cascade in COVID-19-related coagulopathy. These mechanisms are triggered by widespread endothelial cell damage (endotheliopathy), the dominant driver of macro- and micro-vascular thrombosis in these patients. We also summarize other mediators of thrombosis, clinically relevant nuances such as the occurrence of thromboembolic events despite thromboprophylaxis (breakthrough thrombosis), current understanding of systemic anticoagulation therapy and its risk-benefit ratio. We conclude by emphasizing a need to probe COVID-19-specific mechanisms of thrombosis to develop better risk markers and safer therapeutic targets.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 Candesartan Cilexetil (CC) is a prodrug widely used in the treatment of hypertension and heart failure, but it has some limitations, such as very poor aqueous solubility, high affinity to P-glycoprotein efflux mechanism, and hepatic first-pass metabolism. Therefore, it has very low oral bioavailability. In this study, glyceryl monostearate (GMS) and Capryol 90 were selected as solid and liquid lipids, respectively, to develop CC-NLC (nanostructured lipid carrier). CC was successfully encapsulated into NLP (CC-NLC) to enhance its oral bioavailability. CC-NLC was formulated using a hot homogenization-ultrasonication technique, and the physicochemical properties were characterized. The developed CC-NLC formulation was showed in nanometric size (121.6 +/- 6.2 nm) with high encapsulation efficiency (96.23 +/- 3.14%). Furthermore, it appeared almost spherical in morphology under a transmission electron microscope. The surgical experiment of the designed CC-NLC for absorption from the gastrointestinal tract revealed that CC-NLC absorption in the stomach was only 15.26% of that in the intestine. Otherwise, cellular uptake study exhibit that CC-NLCs should be internalized through the enterocytes after that transported through the systemic circulation. The pharmacokinetic results indicated that the oral bioavailability of CC was remarkably improved above 2-fold after encapsulation into nanostructured lipid carriers. These results ensured that nanostructured lipid carriers have a highly beneficial effect on improving the oral bioavailability of poorly water-soluble drugs, such as CC.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 BACKGROUND  Relaxin (RLX)-2, produced by the corpus luteum and placenta, is known to be potentially effective in fibrotic diseases of the heart, lungs, kidneys, and bladder; however, its effectiveness in endometriosis has not yet been investigated. In the present study, we conducted a comprehensive study on the effect of RLX-2 on endometriosis. We checked the expressions of LGR-7, a primary receptor of RLX-2, in endometriomas using immunohistochemistry. Endometriotic stromal cells (ESCs) purified from surgical specimens were used in in vitro experiments. The effects of RLX-2 on ESCs were evaluated by quantitative-PCR, ELISA, and Western blotting. Gel contraction assay was used to assess the contraction suppressive effect of RLX-2. The effect of RLX-2 was also examined in the endometriosis mouse model. LGR-7 was expressed in endometriotic lesions. In ESCs, RLX-2 increased the production of cAMP and suppressed the secretion of interleukin-8, an inflammatory cytokine, by 15% and mRNA expression of fibrosis-related molecules, plasminogen activator inhibitor-1 (PAI-1), and collagen-I by approximately 50% (p &lt; 0.05). In the gel contraction assay, RLX-2 significantly suppressed the contraction of ESCs, which was cancelled by removing RLX-2 from the medium or by adding H89, a Protein Kinase A (PKA) inhibitor. In ESCs stimulated with RLX-2, p38 MAPK phosphorylation was significantly suppressed. In the endometriosis mouse model, administration of RLX-2 significantly decreased the area of the endometriotic-like lesion with decreasing fibrotic component compared to non-treated control (p = 0.01). RLX-2 may contribute to the control of endometriotic lesion by suppressing fibrosis, scar formation, and inflammation.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam diseas</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Diseases of arteries,
 Immune checkpoint molecules are the antigen-independent generator of secondary signals that aid in maintaining the homeostasis of the immune system. The programmed death ligand-1 (PD-L1)/PD-1 axis is one among the most extensively studied immune-inhibitory checkpoint molecules, which delivers a negative signal for T cell activation by binding to the PD-1 receptor. The general attributes of PD-L1&#39;s immune-suppressive qualities and novel mechanisms on the barrier functions of vascular endothelium to regulate blood vessel-related inflammatory diseases are concisely reviewed. Though targeting the PD-1/PD-L1 axis has received immense recognition-the Nobel Prize in clinical oncology was awarded in the year 2018 for this discovery-the use of therapeutic modulating strategies for the PD-L1/PD-1 pathway in chronic inflammatory blood vessel diseases is still limited to experimental models. However, studies using clinical specimens that support the role of PD-1 and PD-L1 in patients with underlying atherosclerosis are also detailed. Of note, delicate balances in the expression levels of PD-L1 that are needed to preserve T cell immunity and to curtail acute as well as chronic infections in underlying blood vessel diseases are discussed. A significant link exists between altered lipid and glucose metabolism in different cells and the expression of PD-1/PD-L1 molecules, and its possible implications on vascular inflammation are justified. This review summarizes the most recent insights concerning the role of the PD-L1/PD-1 axis in vascular inflammation and, in addition, provides an overview exploring the novel therapeutic approaches and challenges of manipulating these immune checkpoint proteins, PD-1 and PD-L1, for suppressing blood vessel inflammation.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 Dysbindin, a schizophrenia susceptibility marker and an essential constituent of BLOC-1 (biogenesis of lysosome-related organelles complex-1), has recently been associated with cardiomyocyte hypertrophy through the activation of Myozap-RhoA-mediated SRF signaling. We employed sandy mice (Dtnbp1_KO), which completely lack Dysbindin protein because of a spontaneous deletion of introns 5-7 of the Dtnbp1 gene, for pathophysiological characterization of the heart. Unlike in vitro, the loss-of-function of Dysbindin did not attenuate cardiac hypertrophy, either in response to transverse aortic constriction stress or upon phenylephrine treatment. Interestingly, however, the levels of hypertrophy-inducing interaction partner Myozap as well as the BLOC-1 partners of Dysbindin like Muted and Pallidin were dramatically reduced in Dtnbp1_KO mouse hearts. Taken together, our data suggest that Dysbindin&#39;s role in cardiomyocyte hypertrophy is redundant in vivo, yet essential to maintain the stability of its direct interaction partners like Myozap, Pallidin and Muted.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 BACKGROUND  Morbid obesity is a risk factor for pancreatic ductal adenocarcinoma (PDAC). However, the impact of obesity on postoperative outcomes and overall survival in patients with PDAC remains a controversial topic. METHODS  Patients who underwent pancreatic surgery for PDAC between 1997 and 2018 were included in this study. Matched pairs (1 1) were generated according to age, gender and American Society of Anesthesiologists status. Obesity was defined according to the WHO definition as BMI &gt;/= 30 kg/m(2). The primary endpoint was the difference in overall survival between patients with and without obesity. RESULTS  Out of 553 patients, a total of 76 fully matched pairs were generated. Obese patients had a mean BMI-level of 33 compared to 25 kg/m(2) in patients without obesity (p = 0.001). The frequency of arterial hypertension (p = 0.002), intraoperative blood loss (p = 0.039), and perineural invasion (p = 0.033) were also higher in obese patients. Clinically relevant postoperative complications (p = 0.163) and overall survival rates (p = 0.885) were comparable in both study groups. Grade II and III obesity resulted in an impaired overall survival, although this was not statistically significant. Subgroup survival analyses revealed no significant differences for completion of adjuvant chemotherapy and curative-intent surgery. CONCLUSIONS  Obesity did not affect overall survival and postoperative complications in these patients with PDAC. Therefore, pancreatic surgery should not be withheld from obese patients.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,
 Previously, we reported that inverse associations of high-density lipoprotein (HDL) with cardiovascular disease and diabetes were only observed for HDL that lacked the pro-inflammatory protein apolipoprotein C3 (apoC3). To provide further insight into the cardiometabolic properties of HDL subspecies defined by the presence or absence of apoC3, we aimed to examine these subspecies with liver fat content and non-alcoholic fatty liver disease (NAFLD). We investigated cross-sectional associations between ELISA-measured plasma levels of apoA1 in HDL that contained or lacked apoC3 and computed tomography-determined liver fat content and NAFLD (&lt;51 HU) at baseline (2000-2002) among 5007 participants in the Multi-Ethnic Study of Atherosclerosis (MESA) without heavy alcohol consumption (&gt;14 drinks/week in men and &gt;7 drinks/week in women). In multivariable-adjusted regression models, apoA1 in HDL that contained or lacked apoC3 was differentially associated with liver fat content (Pheterogeneity = 0.048). While apoA1 in HDL that lacked apoC3 was inversely associated with liver fat content (Ptrend &lt; 0.0001), apoA1 in HDL that contained apoC3 was not statistically significantly associated with liver fat content (Ptrend = 0.57). Higher apoA1 in HDL that lacked apoC3 was related to a lower prevalence of NAFLD (OR per SD  0.80; 95% CI  0.72, 0.89), whereas no association was found for apoA1 in HDL that contained apoC3 (OR per SD  0.95; 95% CI  0.85, 1.05; Pheterogeneity = 0.09). Higher apoA1 in HDL that lacked apoC3 was associated with less liver fat content and a lower prevalence of NAFLD. This finding extends the inverse association of HDL lacking apoC3 from cardiovascular disease to NAFLD. Lack of biopsy-proven hepatic steatosis and fibrosis data requires the replication of our study in further studies.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Diseases of arteries,
 Diabetes is a major risk factor for atherosclerosis and ischemic vascular diseases. Recently, regenerative medicine is expected to be a novel therapy for ischemic diseases. Our previous studies have reported that transplantation of stem cells promoted therapeutic angiogenesis for diabetic neuropathy and ischemic vascular disease in a paracrine manner, but the precise mechanism is unclear. Therefore, we examined whether secreted factors from stem cells had direct beneficial effects on endothelial cells to promote angiogenesis. The soluble factors were collected as conditioned medium (CM) 48 h after culturing stem cells from human exfoliated deciduous teeth (SHED) in serum-free DMEM. SHED-CM significantly increased cell viability of human umbilical vein endothelial cells (HUVECs) in MTT assays and accelerated HUVECs migration in wound healing and Boyden chamber assays. In a Matrigel plug assay of mice, the migrated number of primary endothelial cells was markedly increased in the plug containing SHED-CM or SHED suspension. SHED-CM induced complex tubular structures of HUVECs in a tube formation assay. Furthermore, SHED-CM significantly increased neovascularization from the primary rat aorta, indicating that SHED-CM stimulated primary endothelial cells to promote comprehensive angiogenesis processes. The angiogenic effects of SHED-CM were the same or greater than the effective concentration of VEGF. In conclusion, SHED-CM directly stimulates vascular endothelial cells to promote angiogenesis and is promising for future clinical application.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Diseases of arteries,Coagulopathies,
 Celecoxib, is a selective cyclooxygenase-2 (COX2) inhibitor with a 1,5-diaryl pyrazole scaffold. Celecoxib has a better safety profile compared to other COX2 inhibitors having side effects of systemic hypertension and thromboembolic complications. This may be partly attributed to an off-target activity involving phosphodiesterase 5 (PDE5) inhibition and the potentiation of NO/cGMP signalling allowing coronary vasodilation and aortic relaxation. Inspired by the structure of celecoxib, we synthesized a chemically diverse series of compounds containing a 1,3,5-trisubstituted pyrazoline scaffold to improve PDE5 inhibitory potency, while eliminating COX2 inhibitory activity. SAR studies for PDE5 inhibition revealed an essential role for a carboxylic acid functionality at the 1-phenyl and the importance of the non-planar pyrazoline core over the planar pyrazole with the 5-phenyl moiety tolerating a range of substituents. These modifications led to new PDE5 inhibitors with approximately 20-fold improved potency to inhibit PDE5 and no COX-2 inhibitory activity compared with celecoxib. PDE isozyme profiling of compound 11 revealed a favorable selectivity profile. These results suggest that trisubstituted pyrazolines provide a promising scaffold for further chemical optimization to identify novel PDE5 inhibitors with potential for less side effects compared with available PDE5 inhibitors used for the treatment of penile erectile dysfunction and pulmonary hypertension.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">stenos</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 Objective  To assess the impacts of incomplete revascularization following off-pump coronary artery bypass grafting (OPCABG) on perioperative outcomes in octogenarians. Methods  A retrospective analysis of 242 octogenarian patients with coronary artery disease (CAD) hospitalized in Beijing Anzhen Hospital from June 2008 to July 2016 was performed. These patients were divided into the complete revascularization group (n=181) and the incomplete revascularization group (n=61) depending on whether they underwent complete revascularization. The impacts of incomplete revascularization following OPCABG on perioperative outcomes were summarized and compared between the two groups. Results  Among the 242 patients over 80 years who received OPCABG, there were 198 males (81.8%). Compared to the complete revascularization group, those in the incomplete revascularization group were older [(83.2+/-1.5) vs (81.5+/-1.1) years old, P=0.03], with more carotid stenosis (44.3% vs 25.4%, P=0.01), more involved in the diagonal and circumflex branch of coronary artery (49.2% vs 17.1%, P=0.01; 83.6% vs 70.2%, P=0.03), shorter operative time [(4.1+/-1.7) h vs (4.7+/-1.2) h, P=0.03), longer preoperative [(7.1+/-2.3) d vs (5.2+/-2.0) d, P=0.01] and total hospitalization time [(16.3+/-6.8) d vs (12.5+/-4.2) d, P=0.01], however, the differences of the in-hospital mortality and incidence of other perioperative complications were not statistically significant between the two groups (all P&gt;0.05). Conclusion  Compared with complete revascularization, incomplete revascularization following OPCABG in CAD patients over 80 years old does not increase the perioperative mortality and the incidence of other complications, and it reduces the operative time. However, it increases the time of preoperative and total hospital stay.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">tricuspid</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocardit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocard</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">cardit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,
 Objective  To summarize the etiology and surgical treatment experience of tricuspid valve disease due to permanent pacemaker lead. Methods  The medical records of 22 patients who underwent tricuspid valve operation for tricuspid valve disease due to permanent cardiac pacemaker lead from January 2008 to December 2017 were retrospectively reviewed. There were 12 males and 10 females, with a mean age of (62.6+/-12.1) years old (45-82 years old). All patients underwent tricuspid valve surgery via open thoracotomy under general anesthesia, including 8 patients through median thoracotomy approach, 4 patients through right mini-thoracotomy approach, and 10 patients with endoscopy-assisted and totally endoscopic technique. Moreover, 8 patients underwent tricuspid valve replacement, and 14 patients received tricuspid valve repair. Results  During the operation, 10 cases of severe tricuspid regurgitation were detected due to valve and subvalvular structures dysfunction involved in the pacing electrode, 7 cases showed tricuspid annulus dilation, and pacing electrode-related infective endocarditis were involved in the tricuspid valve of 5 cases. Compared with conventional median thoracotomy surgery, the amount of postoperative drainage fluid and hospitalization time after minimally invasive surgery (including right mini-thoracotomy and endoscopic surgery) were significantly reduced [281(120, 489) ml vs 368(180, 560) ml, P=0.02; 9.2(4.8, 14.5) d vs 11.2(6.3, 16.9) d, P=0.03]. Postoperative echocardiographic data showed that the size of the right atrium and ventricle in these patients was significantly reduced compared with preoperative data, and their cardiac function were normal. There was no difference of pacing electrode parameters between pre-and postoperative period. All 22 patients were cured and discharged, with no valve-and pacemaker-related complications. Conclusions  Patients with tricuspid valve disease due to permanent cardiac pacemaker lead should actively undergo surgery including tricuspid replacement or repair according to different etiologies, which exhibit satisfactory outcomes. Minimally invasive endoscopic tricuspid surgery is a new technique for the treatment of isolated tricuspid valve disease, with less surgical trauma and faster recovery.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Diseases of arteries,
 Objective  To compare the effect of myotomy and coronary artery bypass grafting (CABG) to treat symptomatic myocardial bridges (MBs) of the left anterior descending artery (LAD). Methods  From January 2009 to December 2017, a total of 54 eligible patients [34 males, 20 females, with a median age of 60 (51, 64) years old] with symptomatic MBs of LAD who underwent myotomy (31 patients) or CABG (23 patients) at the Department of Cardiovascular Surgery of Zhongshan Hospital, Fudan University were included in the study. Surgical effect of the two groups were compared and multivariate logistic regression models were used to analyze the risk factors of major adverse cardiac events (MACE). Results  No significant differences between the two groups were observed with respect to age, gender, risk factors of coronary artery disease (CAD), symptoms, angiographic findings of MBs and preoperative cardiac status, and 0 surgery-associated death was observed. Among the 31 myotomy patients, 4 patients underwent off-pump myotomy (including one patient who underwent urgent conversion from off-pump to on-pump surgery due to massive hemorrhaging secondary to the right ventricular perforation), and the remaining 27 cases received myotomy under cardiopulmonary bypass with cardiac arrest. All 23 bypass surgery patients underwent off-pump CABG surgery with in situ left internal mammary artery (LIMA) grafting to the distal LAD. After LIMA grafting, the median graft flow was 14 (11, 20) ml/min. During a median follow-up of 26 months, 11 patients developed MACEs (7.4% for myotomy vs 40.9% for bypass surgery, P=0.007). Surgical strategy (CABG surgery vs myotomy) was an independent risk factor for MACE (OR=3.681, 95% CI  1.812-8.685, P=0.011). Compared with myotomy, CABG surgery had a significantly higher incidence of adverse angiographic results (3.7% of residual compression vs 40.9% of LIMA graft failure, P=0.003). Among 10 CABG surgery patients with LAD-MBs and proximal coronary obstruction, all LIMA grafts were patent, though one case reported recurrent angina pectoris 2 years after the surgery which was relieved after drug therapy. Conclusions  For patients with symtomatic LAD-MBs, myotomy may be associated with favorable mid-term outcomes and angiographic results. However, CABG surgery should be recommended for those with concomitant proximal obstruction of LAD.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Diseases of arteries,
 Objective  To compare the effect of myotomy and coronary artery bypass grafting (CABG) to treat symptomatic myocardial bridges (MBs) of the left anterior descending artery (LAD). Methods  From January 2009 to December 2017, a total of 54 eligible patients [34 males, 20 females, with a median age of 60 (51, 64) years old] with symptomatic MBs of LAD who underwent myotomy (31 patients) or CABG (23 patients) at the Department of Cardiovascular Surgery of Zhongshan Hospital, Fudan University were included in the study. Surgical effect of the two groups were compared and multivariate logistic regression models were used to analyze the risk factors of major adverse cardiac events (MACE). Results  No significant differences between the two groups were observed with respect to age, gender, risk factors of coronary artery disease (CAD), symptoms, angiographic findings of MBs and preoperative cardiac status, and 0 surgery-associated death was observed. Among the 31 myotomy patients, 4 patients underwent off-pump myotomy (including one patient who underwent urgent conversion from off-pump to on-pump surgery due to massive hemorrhaging secondary to the right ventricular perforation), and the remaining 27 cases received myotomy under cardiopulmonary bypass with cardiac arrest. All 23 bypass surgery patients underwent off-pump CABG surgery with in situ left internal mammary artery (LIMA) grafting to the distal LAD. After LIMA grafting, the median graft flow was 14 (11, 20) ml/min. During a median follow-up of 26 months, 11 patients developed MACEs (7.4% for myotomy vs 40.9% for bypass surgery, P=0.007). Surgical strategy (CABG surgery vs myotomy) was an independent risk factor for MACE (OR=3.681, 95% CI  1.812-8.685, P=0.011). Compared with myotomy, CABG surgery had a significantly higher incidence of adverse angiographic results (3.7% of residual compression vs 40.9% of LIMA graft failure, P=0.003). Among 10 CABG surgery patients with LAD-MBs and proximal coronary obstruction, all LIMA grafts were patent, though one case reported recurrent angina pectoris 2 years after the surgery which was relieved after drug therapy. Conclusions  For patients with symtomatic LAD-MBs, myotomy may be associated with favorable mid-term outcomes and angiographic results. However, CABG surgery should be recommended for those with concomitant proximal obstruction of LAD.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 The purpose of this review is to provide a framework for the cardiovascular evaluation and management of patients undergoing hematopoietic cell transplantation (HCT). To accomplish this, we have performed an extensive literature review, critically analyzed the available evidence, and developed a set of recommendations to guide best practice. Herein, we discuss the cardiovascular risk profile of patients undergoing HCT along with putative mechanisms of HCT-induced cardiovascular injury. We then present an algorithm for cardiovascular testing and risk mitigation of potential recipients. Last, we address the management of the most prevalent cardiovascular conditions associated with HCT recipients.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 OBJECTIVE  This study aimed to determine whether outcomes differed between infants enrolled in the PREMOD2 trial and those otherwise eligible but not enrolled, and whether the use of waiver effected these differences. STUDY DESIGN  The multicenter PREMOD2 (PREmature infants receiving Milking Or Delayed cord clamping) trial was approved for waiver of antenatal consent by six of the nine sites institutional review boards, while three sites exclusively used antenatal consent. Every randomized subject delivered at a site with a waiver of consent was approached for postnatal consent to allow for data collection. Four of those six sites&#39; IRBs required the study team to attempt antenatal consent when possible. Three sites exclusively used antenatal consent. RESULTS  Enrolled subjects had higher Apgar scores, less use of positive pressure ventilation, a lower rate of bronchopulmonary dysplasia, and a less frequent occurrence of the combined outcome of severe intraventricular hemorrhage or death. A significantly greater number of infants were enrolled at sites with an option of waiver of consent (66 vs. 26%, risk ratio = 2.54, p &lt; 0.001). At sites with an option of either approaching families before delivery or after delivery with a waiver of antenatal consent, those approached prior to delivery refused consent 40% (range 15-74% across six sites) of the time. CONCLUSION  PREMOD2 trial demonstrated analytical validity limitations because of the variable mix of antenatal consent and waiver of consent. A waiver of antenatal consent for minimal risk interventional trials conducted during the intrapartum period will be more successful in enrolling a representative sample of low and high-risk infants if investigators are able to enroll all eligible subjects. CLINICAL TRIAL REGISTRATION  ClinicalTrials.gov identifier  NCT03019367. KEY POINTS  . Waiver of consent is when informed consent cannot be obtained prior to delivery.. . Cord milking is a procedure in which blood is pushed (stripped) two to four times towards the newborn.. . Delayed clamping means the umbilical cord is not clamped immediately after birth..
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">cerebrovascul</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Diseases of arteries,
 INTRODUCTION  in Italy and Tuscany the resident population aged&amp;gt; 99 reached its all-time high in 2015. Respiratory diseases in men and ischemic heart diseases in women were the leading causes of death for Italian centenarians in 2015. The aim of this study is to describe the mortality of Tuscan centenarians by cause. MATERIALS AND METHODS  population-based observational study using current health data, extracted from the Tuscan Regional Mortality Register. Main outcome measures are  proportional mortality and annual mortality trend at age &amp;gt;99, age-specific mortality rates (85-89; 90-94; 95-99, &amp;gt;99). RESULTS  at age &amp;gt;99 ischemic heart diseases, cerebrovascular diseases and respiratory diseases are among the top 5 causes of death as in the less elderly age, the relative frequency of tumors decreases and that of the ill-defined causes increases. If ill-defined and ischemic heart diseases are separated, the first cause of death is cerebrovascular diseases in males and senility in females. In the period 2002-2015 at age &amp;gt;99 all-cause mortality fell on average every year by -0.15% for males and -0.14% for females, mortality due to arteriosclerosis decreases -10% (males) and -12% (females) every year, due to cardiac arrest and other non-specific cardiopathies -5% (males) and -7% (females) and due to cerebrovascular diseases -3% (females). Mortality due to senility increases +6% per year in women. CONCLUSIONS  in Tuscany the first cause of death is different by gender (cerebrovascular diseases in males and senility in females) and differs from what has been observed nationally. In the 2000s, mortality from cardiovascular diseases without diagnostic significance decreased in Tuscan centenarians and that from senility increased.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Inflammatory diseases,
 BACKGROUND  Fibrinogen is considered a marker of vascular pathology, indicating a weakened blood-brain barrier, and has a causative role in neuroinflammation and neurodegeneration. Little is known about the relationship between fibrinogen levels and cognitive function in patients with mild cognitive impairment (MCI). We aimed to investigate differences in cognitive profiles according to plasma fibrinogen levels in patients with MCI and the influence of plasma fibrinogen levels on cognitive decline. METHODS  This retrospective cohort study included 643 patients with MCI  323 patients in the high fibrinogen (high fib) group and 320 patients in the low fibrinogen (low fib) group. A multiple linear regression model was performed to compare cognitive test performance between groups. The Cox proportional hazard model was used to analyze the hazard ratio of fibrinogen level for disease progression. RESULTS  The high fib group demonstrated poorer performance in attention, executive function, and confrontation naming than the low fib group. After adjustment for APOE genotype, the high fib group was associated with poor attention and executive function. After adjustment for vascular risk factors including body mass index, hypertension, diabetes mellitus, dyslipidemia, and smoking history, the high fib group showed declined attention and confrontation naming ability. High fibrinogen levels did not predict disease progression to CDR 1. CONCLUSION  High plasma fibrinogen levels were associated with poor performance in attention in patients with MCI, regardless of APOE genotype or vascular risk factors.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-magenta-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">arrhythm</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Arrhythmia,Heart failure,Coagulopathies,
 BACKGROUND  Cancer and cardiovascular disease (CVD) are independently associated with adverse outcomes in patients with COVID-19. However, outcomes in patients with COVID-19 with both cancer and comorbid CVD are unknown. METHODS  This retrospective study included 2,476 patients who tested positive for SARS-CoV-2 at 4 Massachusetts hospitals between March 11 and May 21, 2020. Patients were stratified by a history of either cancer (n=195) or CVD (n=414) and subsequently by the presence of both cancer and CVD (n=82). We compared outcomes between patients with and without cancer and patients with both cancer and CVD compared with patients with either condition alone. The primary endpoint was COVID-19-associated severe disease, defined as a composite of the need for mechanical ventilation, shock, or death. Secondary endpoints included death, shock, need for mechanical ventilation, need for supplemental oxygen, arrhythmia, venous thromboembolism, encephalopathy, abnormal troponin level, and length of stay. RESULTS  Multivariable analysis identified cancer as an independent predictor of COVID-19-associated severe disease among all infected patients. Patients with cancer were more likely to develop COVID-19-associated severe disease than were those without cancer (hazard ratio [HR], 2.02; 95% CI, 1.53-2.68; P&lt;.001). Furthermore, patients with both cancer and CVD had a higher likelihood of COVID-19-associated severe disease compared with those with either cancer (HR, 1.86; 95% CI, 1.11-3.10; P=.02) or CVD (HR, 1.79; 95% CI, 1.21-2.66; P=.004) alone. Patients died more frequently if they had both cancer and CVD compared with either cancer (35% vs 17%; P=.004) or CVD (35% vs 21%; P=.009) alone. Arrhythmias and encephalopathy were also more frequent in patients with both cancer and CVD compared with those with cancer alone. CONCLUSIONS  Patients with a history of both cancer and CVD are at significantly higher risk of experiencing COVID-19-associated adverse outcomes. Aggressive public health measures are needed to mitigate the risks of COVID-19 infection in this vulnerable patient population.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 OBJECTIVE  To explore any apparent trends in maternal or neonatal outcomes during the Covid-19 pandemic by comparing the maternity outcomes before, during and after the pandemic. STUDY DESIGN  A retrospective review was performed of maternity statistics recorded on the hospital database of a large tertiary referral centre in Dublin with over 8000 deliveries per annum from 1st January to 31st July 2020. This time period represented the months prior to, during the peak and following the pandemic in Ireland. RESULTS  There was no correlation between the monthly number of Covid deaths and the monthly number of perinatal deaths (r=0.465, NS), preterm births (r=0.339, NS) or hypertensive pregnancies (r=0.48, NS). Compared to the combined numbers for the same month in 2018 and 2019, there were no significant changes in perinatal deaths or preterm births in the months when Covid deaths were at their height. The rate of preterm birth was significantly less common in January-July 2020 compared to January-July in 2018/2019 (7.4 % v 8.6 %, chi-sq 4.53, P=0.03). CONCLUSION  The was no evidence of a negative impact of the Covid-19 pandemic on maternity services, as demonstrated by maternal and neonatal outcomes.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlud</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 OBJECTIVES  Recent small subcortical infarcts (RSSI) are considered an acute manifestation of cerebral small vessel disease. Paramagnetic signals in perforating arteries supplying RSSI may be detected on T2*-relaxation derived sequences on MRI and is defined as susceptibility vessel sign (SVS). We aimed to study the prevalence of SVS in patients with RSSI, and explore whether its identification is related to cerebral small vessel disease markers. MATERIALS AND METHODS  We selected patients with RSSI identified on MRI during admission from a single-center stroke registry. The main demographic and clinical features, including vascular risk factors, were collected. Radiological features of RSSI and cerebral small vessel disease [white matter hyperintensities in deep and periventricular regions, enlarged perivascular spaces, lacunae, microbleeds, and brain atrophy] were described using validated qualitative scores. The presence of SVS was assessed on T2*gradient-echo or other susceptibility-weighted imaging. We compared the clinical and radiological features of patients with or without SVS in uni- and multivariate models. RESULTS  Out of 210 patients with an RSSI on an MRI, 35 (17%) showed SVS. The proportion of SVS+ patients was similar in different susceptibility imaging modalities (p=.64). Risk factor profiles and clinical course were similar in SVS+ and SVS- patients. SVS+ patients had a higher grade of deep white matter hyperintensities and brain atrophy, more lacunae (p=.001, p=.034, p=.022, respectively), and a similar degree of the rest of radiological variables, compared to SVS- patients. In the multivariate analysis, the grade of deep white matter hyperintensities was the only independent factor associated with SVS [OR 3.1 (95% CI, 1.5-6.4)]. CONCLUSIONS  SVS in patients with RSSI is uncommon and related to a higher grade of deep white matter hyperintensities. Pathophysiological mechanisms underlying the deposition of hemosiderin in the path of occluded perforating arteries are uncertain and might include endothelial dysfunction or embolic mechanisms.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Quercetin represents one of the most studied dietary flavonoids; it exerts a panel of pharmacological activities particularly on the cardiovascular system. Stimulation of vascular KCa1.1 channels contributes to its vasorelaxant activity, which is, however, counteracted in part by its concomitant stimulation of CaV1.2 channels. Therefore, several quercetin hybrid derivatives were designed and synthesized to produce a more selective KCa1.1 channel stimulator, then assessed both in silico and in vitro. All the derivatives interacted with the KCa1.1 channel with similar binding energy values. Among the selected derivatives, 1E was a weak vasodilator, though displaying an interesting CaV1.2 channel blocking activity. The lipoyl derivatives 1F and 3F, though showing pharmacological and electrophysiological features similar to those of quercetin, seemed to be more effective as KCa1.1 channel stimulators as compared to the parent compound. The strategy pursued demonstrated how different chemical substituents on the quercetin core can change/invert its effect on CaV1.2 channels or enhance its KCa1.1 channel stimulatory activity, thus opening new avenues for the synthesis of efficacious vasorelaxant quercetin hybrids.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-magenta-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">arrhythm</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Arrhythmia,Cardiomyopathy,
 BACKGROUND  Hypertrophic cardiomyopathy (HCM) is significantly associated with high risk of fatal ventricular arrhythmias (VAs). Increased frontal QRST angle (fQRSTa), Tpe interval, and Tp-e/QTc ratio are described as ventricular repolarization parameters which are related to arrhythmias. In this study, we aimed to investigate the predictive value of these repolarization parameters for fatal VAs in patients with HCM. METHODS  A total of 127 HCM patients (mean age  47.9+/-12.6years; male 79) were enrolled in this retrospective study. All patients underwent transthoracic echocardiography. Moreover, the last electrocardiograms within 3months prior to the fatal VA documentation were assessed. The primary outcome was the occurrence of fatal VAs including sustained ventricular tachycardia and ventricular fibrillation which were documented from implantable cardioverter defibrillator records. RESULTS  There were documented fatal VAs in 37 (29.1%) patients during a mean follow-up time of 70.1+/-22.6months. The prevalence of fatal VAs was significantly higher in patients with fQRSTa &gt;/=140 degrees (67.4 vs. 7.4%; p&lt;0.001) and in patients with Tp-e/QTc ratio&gt;/=0.19 (61.5 vs. 6.7%; p&lt;0.001) as compared to others. High Tp-e/QTc ratio (hazard ratio  1.564; 95% confidence interval  1.086-4.796; p=0.032) and high fQRSTa (hazard ratio  1.864; 95% confidence interval  1.106-8.745; p=0.002) were found to be independent predictors of fatal VAs in HCM patients. CONCLUSIONS  Wider fQRSTa, prolonged Tp-e interval, and increased Tp-e/QTc ratio may be associated with fatal VAs in HCM patients. In addition to traditional risk factors, these simple ECG parameters may provide valuable information during evaluation of sudden cardiac death risk in HCM patients.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 INTRODUCTION  Studies on the normal electrocardiogram limits in African populations are limited, especially in sub-Saharan Africa. There is no literature describing normal ECG limits in Angolans. OBJECTIVES  The aim of this study is to establish the normal ECG limits for adult Angolans, without established heart disease, stratified by gender and age. METHODS  A cross-sectional study was performed, involving 2179 participants from a population in northern Angola, without established heart disease, aged between 15 and 74 years. A 12lead ECG and a rhythm strip were recorded for all participants and analysed and processed by the University of Glasgow software and encoded by the Minnesota Code. The normal range of the electrocardiographic parameters were established as the 2nd and 98th percentiles of the measurement distribution per age group and gender. Mann-Whitney and Kruskal-Wallis tests were used for two independent groups and Bonferroni adjustments were used for multiple testing. GAMLSS models were used to obtain the continuous age-dependent percentile curves. RESULTS  The normal range of the ECG differed between men and women  heart rate 49 to 100bpm vs. 55 to 108bpm, P wave duration 81 to 130ms vs. 84 to 130ms, PR interval 119 to 210ms vs. 120 to 202ms, QRS duration 74 to 110ms vs. 70 to 104ms, QT interval 324 to 441ms vs. 314 and 438ms, P-wave axis-29 to 85(0) vs. -18 to 81(0), QRS-wave axis-13 to 85(0) vs. -18(0) and 82(0), T-wave axis 0 to 72(0) vs. -8 to 73(0), Sokolow-Lyon index 2.13 to 6.21mV vs. 1.60 to 4.87mV, Cornell index 0.17 to 6.24mV vs. 0.14mV to 4.35mV. CONCLUSIONS  The values described for the electrocardiographic measurements above can act as a reference framework for Angolan adults without established heart disease. Our study suggests that the normal range of most ECG parameters vary according to age and sex and the ECG diagnostic criteria must therefore be specific for these demographic measures.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Diseases of arteries,
 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the cause of a present pandemic, infects human lung alveolar type 2 (hAT2) cells. Characterizing pathogenesis is crucial for developing vaccines and therapeutics. However, the lack of models mirroring the cellular physiology and pathology of hAT2 cells limits the study. Here, we develop a feeder-free, long-term, three-dimensional (3D) culture technique for hAT2 cells derived from primary human lung tissue and investigate infection response to SARS-CoV-2. By imaging-based analysis and single-cell transcriptome profiling, we reveal rapid viral replication and the increased expression of interferon-associated genes and proinflammatory genes in infected hAT2 cells, indicating a robust endogenous innate immune response. Further tracing of viral mutations acquired during transmission identifies full infection of individual cells effectively from a single viral entry. Our study provides deep insights into the pathogenesis of SARS-CoV-2 and the application of defined 3D hAT2 cultures as models for respiratory diseases.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Cardiomyopathy,
 Gene therapy is an attractive approach being intensively studied to prevent muscle deterioration in patients with Duchenne muscular dystrophy. While clinical trials are only in early stages, initial reports are promising for its effects on ambulation. Cardiopulmonary failure, however, is the most common cause of mortality in Duchenne muscular dystrophy (DMD) patients, and little is known regarding the prospects for gene therapy on alleviating DMD-associated cardiomyopathy and respiratory failure. Here we review current knowledge regarding effects of gene therapy on DMD cardiomyopathy and discuss respiratory endpoints that should be considered as outcome measures in future clinical trials.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,Coagulopathies,
 BACKGROUND AND PURPOSE  Mechanical Thrombectomy (MT) using modern devices has proved to be efficacious in re-establishing intracranial circulation and reduced procedural times. We outline a number of endovascular techniques utilizing the distal access catheter, the circumstances where they are applicable, and the outcomes achieved. METHODS  In this review, we describe a variety of endovascular techniques with distal access catheter, deployed with and without the stent retriever device gained from our experience of performing over 700 procedures in 10 years of providing a 24/7 service within the national framework of a hyperacute stroke centre. RESULTS  We used distal access catheter techniques for intracranial support during a stent-retriever thrombectomy or thrombo-suction on its own. When used as a sole suction device, or combined with a stent-retriever, we have been able to provide a rapid route to successful reperfusion, with minimal complications related to our endovascular procedures. We can report distal access catheter techniques works well when access to thrombi involves navigation through tortuous vessel anatomy, notably when convoluted loops in the cervical internal carotid artery are encountered. We suggest use of the distal access catheter techniques in thrombectomy procedures for steep-angle Middle Cerebral Artery occlusions, M2/M3 occlusion, and for basilar occlusion, where thrombectomy via suction alone proved to be adequate. CONCLUSION  In this pictorial review, we have demonstrated techniques where distal access catheter when used as a sole suction device, or combined with a stent-retriever, has been able to provide a rapid route to successful reperfusion, with minimal complications related to our endovascular procedures.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 Only half of hypertensive patients respond to any given antihypertensive. Heterogeneity in pathophysiologic pathways underlying hypertension (HTN) is a major contributor. Personalizing antihypertensive therapy could improve blood pressure (BP) reduction. The objective of this study was to assess the effect of pragmatic implementation of a personalized plasma renin activity (PRA)-based smartphone app on improving BP reduction. Patients with untreated or treated but uncontrolled HTN were recruited. BP and PRA were measured at baseline with final BP measured at 6 months. Patient&#39;s information was entered into the app and treatment recommendations were returned. Clinicians were at liberty to follow or disregard the app recommendations. BP levels and percent BP control among patients whose clinicians did and did not follow the app recommendations were compared using independent t-test and Fisher&#39;s exact test, respectively. Twenty-nine European-American (EA) patients were included (38% women) with mean age of 52+/-9 years and median PRA of 1.3 ng/ml/hr (IQR 0.5-3.1 ng/ml/hr). Participants whose clinicians followed the app recommendations (n=16, 55%) as compared to those whose clinicians did not (n=13, 45%), had a greater reduction in 6-month systolic-BP (-15+/-21 vs. -3+/-21 mm Hg; adjusted-P=0.1) and diastolic-BP (-8+/-8 vs. -1+/-8 mm Hg; adjusted-P=0.04). BP control at 6 months tended to be greater among patients whose clinicians accepted the app recommendations versus those whose clinicians did not (63% vs. 23%, P=0.06). This pilot study demonstrates that acceptance of the app recommendations was associated with a greater BP reduction. Future studies to confirm these pilot findings are warranted.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 A high level of physical fitness, especially cardiorespiratory fitness, is associated with lower incidence of hypertension. However, the relationship between flexibility, which is a component of physical fitness, and the incidence of hypertension is unknown. The purpose of this study was to investigate the relationship between flexibility and the incidence of hypertension in a cohort study. A total of 22,972 (14,805 men and 8167 women; median age 49 years) normotensive participants were included in this study. Between April 2001 and March 2002, flexibility (standing forward bending) was measured using a standing trunk flexion meter. The participants were divided into quartiles of flexibility by sex and age group. Hypertension was defined as systolic blood pressure &gt;/=140 mmHg, diastolic blood pressure &gt;/=90 mm Hg, or a self-reported history of previously diagnosed hypertension or current medication for hypertension at a health examination between April, 2002 and March, 2008. Hazard ratios and 95% confidence intervals (95% CI) for the incidence of hypertension were estimated using Cox proportional hazards models after adjusting for age, sex, body mass index, exercise habits, smoking status, and drinking status. During 102,948 person years of follow-up (median 5.6 years), 4235 participants developed hypertension. Compared with the lowest flexibility (quartile 1), hazard ratios and 95% CI were 0.96 (0.88-1.04) for quartile 2, 0.94 (0.86-1.03) for quartile 3, and 0.83 (0.76-0.91) for quartile 4. A high level of flexibility was associated with lower incidence of hypertension, independent of other confounding factors.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocardit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">cardit</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">ischem cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Inflammatory diseases,Cardiomyopathy,
 BACKGROUND  Effects of cranioplasty (CP) and skullcap reimplantation after decompressive craniectomy (DC) for cerebral hemorrhage or malignant brain infarction in patients with left ventricular assist device support (LVAD) as bridge to transplantation has not been surveyed yet. The aim of this study was to evaluate outcome and management after CP when aiming for transplantation. METHODS  Data were collected from our prospective institutional database including all patients undergoing LVAD implantation between 2010 and 2019. Six patients needed CP-procedures and were included. Our analysis focused on post-operative outcome, survival and facilitation of heart transplantation. Study endpoints included also all-cause mortality. RESULTS  From a total of 1010 LVAD implantations during analysis period in our center, 6 bridge-to-transplantation LVAD patients [Median age at LVAD implantation  32.5 years (IQR  24.8-39.5 years); 4 male, HVAD, n=3; HM II, n=1; HM 3, n=2] underwent CP with imminent entrapment secondary to cerebral hemorrhage or malignant infarction. Primary HF etiology was myocarditis (n=2), dilated (n=2), or ischemic cardiomyopathy (n=2). Median INTERMACS class was 1.5 (IQR; 1.0-2.8). Median time on LVAD support to DC procedure was 33 months (IQR  16-48 months). The indication for DC was intraparenchymal hemorrhage (n=4), subdural hematoma (n=1), and malignant middle cerebral artery infarction (n=1). After a median time of 4 months (IQR  3.3-4.0 months, range; 2.0-10 months) after DC procedure, CP was subsequently performed without profound neurologic disabilities in all patients. After median time of 26 months (IQR  21-42 months) follow up, three patients successfully received heart transplantation, one patient could undergo LVAD explantation after myocardial recovery, and the remaining two patients are still on the list awaiting heart transplantation. CONCLUSION  CP procedure with skullcap reimplantation is feasible and can be safely performed in LVAD patients, which subsequently may even be eligible for heart transplantation with beneficial prognosis.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  During vascular surgery, restricted red-cell transfusion reduces frontal lobe oxygen (ScO2 ) saturation as determined by near-infrared spectroscopy. We evaluated whether inadequate increase in cardiac output (CO) following haemodilution explains reduction in ScO2 . METHODS  This is a post-hoc analysis of data from the Transfusion in Vascular surgery (TV) Trial where patients were randomised on haemoglobin drop below 9.7 g/dL to red-cell transfusion at haemoglobin below 8.0 (low-trigger) vs. 9.7 g/dL (high-trigger). Fluid administration was guided by optimising stroke volume. We compared mean intraoperative levels of CO, haemoglobin, oxygen delivery, and CO at nadir ScO2 with linear regression adjusted for age, operation type and baseline. Data for forty-six patients randomised before end of surgery were included for analysis. RESULTS  The low-trigger resulted in a 7.1% lower mean intraoperative haemoglobin level (mean difference, -0.74 g/dl; P&lt;0.001) and reduced volume of red-cell transfused (median [inter-quartile range], 0 [0-300] vs. 450 ml [300-675]; P&lt;0.001) compared with the high-trigger group. Mean CO during surgery was numerically 7.3% higher in the low-trigger compared with the high-trigger group (mean difference, 0.36 L/min; 95% confidence interval (CI.95), -0.05 to 0.78; P=0.092; n=42). At the nadir ScO2 -level, CO was 11.9% higher in the low-trigger group (mean difference, 0.58 L/min; CI.95, 0.10 to 1.07; P=0.024). No change in oxygen delivery was detected between trial groups (MD, 1.39 dLO2 /min; CI.95, -6.16 to 8.93; P=0.721). CONCLUSION  Vascular surgical patients exposed to restrictive RBC transfusion elicit the expected increase in CO making it unlikely that their potentially limited cardiac capacity explains the associated ScO2 decrease.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Sub-Saharan Africa is experiencing rapid urban growth. Cities enable greater access to health services and improved water and sanitation infrastructure, leading to some improvements in health. However, urban settings may also be associated with more sedentary, stressful lifestyles and consumption of less nutritious food. C-reactive protein (CRP) is a measure of chronic inflammation predictive of cardiovascular disease, and high body mass index (BMI), a ratio of weight to height, indicates overweight or obesity and is associated with an increased risk of many chronic diseases. To explore the association between urbanicity and these two markers, we overlaid data from the 2010 Tanzania Demographic and Health Survey (DHS) with a satellite-derived measure of built environment. Linear regression models were constructed for the outcomes of BMI and CRP, by 1) administratively defined urban/rural categorization from the DHS, 2) satellite derived built environment, and 3) built environment stratified by urban/rural. A total of 2,212 women were included; 23% had elevated CRP, 21% were overweight or obese. A third (33%) lived in a highly built up area and 29% lived in an area classified as urban. A strong positive association between both CRP and BMI and built environment was detected; log CRP increased 0.43 in the highest built up areas compared to not built up (p&lt;0.05); log BMI increased 0.02 in the most built up areas compared to not built up (p&lt;0.05). However, comparing urban to rural category was only significant in unadjusted models. Models stratified by urban/rural category highlight that the variation in CRP and BMI by built environment is mainly driven by rural areas; within urban areas there is less variation. Our findings highlight the potential negative effects of urbanicity on chronic disease markers, with potentially more change detected for those transitioning from rural to urban lifestyles. Satellite-derived urbanicity measures are reproducible and provide more nuanced understanding of effects of built environment on health.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">cerebrovascul</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Diseases of arteries,
 Recipients of Medical Aid, a government-funded social assistance program for the poor, have a shorter life expectancy than National Health Insurance beneficiaries in Korea. This study aims to explore the contributions of age and major causes of death to the life expectancy difference between the two groups. We used the National Health Information Database provided by the National Health Insurance Service individually linked to mortality registration data of Statistics Korea between 2008 and 2017. Annual abridged life tables were constructed and Arriaga&#39;s life expectancy decomposition method was employed to estimate age- and cause-specific contributions to the life expectancy gap between National Health Insurance beneficiaries and Medical Aid recipients. The life expectancy difference between National Health Insurance beneficiaries and Medical Aid recipients was 14.5 years during the period of 2008-2017. The age groups between 30 and 64 years accounted for 78.7% and 67.5% of the total life expectancy gap in men and women, respectively. Cancer was the leading cause of death contributing to excess mortality among Medical Aid recipients compared to National Health Insurance beneficiaries. More specifically, alcohol-attributable deaths (such as alcoholic liver disease, liver cancer, liver cirrhosis, and alcohol/substance abuse), suicide, and cardiometabolic risk factor-related deaths (such as cerebrovascular disease, ischemic heart disease, and diabetes) were the leading contributors to the life expectancy gap. To decrease excess deaths in Medical Aid recipients and reduce health inequalities, effective policies for tobacco and alcohol regulation, suicide prevention, and interventions to address cardiometabolic risk factors are needed.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 OBJECTIVES  The purpose is to assess the ability of low-dose CT (LDCT) to determine lung involvement in SARS-CoV-2 pneumonia and to describe a COVID19-LDCT severity score. MATERIALS AND METHODS  Patients with SARS-CoV-2 infection confirmed by RT-PCR were retrospectively analysed. Clinical data, the National Early Warning Score (NEWS) and imaging features were recorded. Lung features included ground-glass opacities (GGO), areas of consolidation and crazy paving patterns. The COVID19-LDCT score was calculated by summing the score of each segment from 0 (no involvement) to 10 (severe impairment). Univariate analysis was performed to explore predictive factor of high COVID19-LDCT score. The nonparametric Mann-Whitney test was used to compare groups and a Spearman correlation used with p&lt;0.05 for significance. RESULTS  Eighty patients with positive RT-PCR were analysed. The mean age was 55 years +/- 16, with 42 males (53%). The most frequent symptoms were fever (60/80, 75%) and cough (59/80, 74%), the mean NEWS was 1.7+/-2.3. All LDCT could be analysed and 23/80 (28%) were normal. The major imaging finding was GGOs in 56 cases (67%). The COVID19-LDCT score (mean value = 19+/-29) was correlated with NEWS (r = 0.48, p&lt;0.0001). No symptoms were risk factor to have pulmonary involvement. Univariate analysis shown that dyspnea, high respiratory rate, hypertension and diabetes are associated to a COVID19-LDCT score superior to 50. CONCLUSIONS  COVID19-LDCT score did correlate with NEWS. It was significantly different in the clinical low-risk and high-risk groups. Further work is needed to validate the COVID19-LDCT score against patient prognosis.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,
 BACKGROUND  Pro- and anti-inflammatory mediators are released during and after cardiac arrest, which may be unfavourable. Small case-series and observational studies suggested that unselective hemoadsorption may reduce inadequately high cytokine levels during sepsis or cardiac surgery. We aimed to assess the effect of cytokine adsorbtion on mortality in patients following out-of-hospital cardiac arrest by comparing a patient cohort with hemoadsorption after resuscitation for out-of-hospital cardiac arrest to a control cohort without adsorption within the HAnnover COling REgistry (HACORE). METHODS  We adopted an early routine use of hemoadsorption in patients after out-of-hospital cardiac arrest with increased vasopressor need and performed a 1 2 match according to age, gender, time to return of spontaneous circulation, initial left-ventricular ejection fraction, extracorporeal membrane-oxygenation or left-ventricular unloading by Impella, need for renal replacement therapy, admission lactate, pH, glomerular filtration rate to patients without an adsorber from HACORE. The primary endpoint was 30-day mortality. RESULTS  Twenty-four patients receiving hemoadsorption were matched to 48 patients without hemoadsorption (mean age 62+/-13 years, 83% male). While there was no significant difference in baseline parameters, 30-day mortality was higher in patients treated with hemoadsorption than in the matched control group (83% vs 65%, Log rank p = 0.011). CONCLUSIONS  Routine use of hemoadsorption did not reduce, but seems to be associated with higher 30-day mortality in patients after OHCA. Prior to routine adoption in daily practice, hemoadsorption should be evaluated in properly sized randomized controlled trials.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 OBJECTIVE  Risk factors for in-hospital mortality in confirmed COVID-19 patients have been summarized in numerous meta-analyses, but it is still unclear whether they vary according to the age, sex and health conditions of the studied populations. This study explored these variables as potential mortality predictors. METHODS  A systematic review was conducted by searching the MEDLINE, Scopus, and Web of Science databases of studies available through July 27, 2020. The pooled risk was estimated with the odds ratio (p-OR) or effect size (p-ES) obtained through random-effects meta-analyses. Subgroup analyses and meta-regression were applied to explore differences by age, sex and health conditions. The MOOSE guidelines were strictly followed. RESULTS  The meta-analysis included 60 studies, with a total of 51,225 patients (12,458 [24.3%] deaths) from hospitals in 13 countries. A higher in-hospital mortality risk was found for dyspnoea (p-OR = 2.5), smoking (p-OR = 1.6) and several comorbidities (p-OR range  1.8 to 4.7) and laboratory parameters (p-ES range  0.3 to -2.6). Age was the main source of heterogeneity, followed by sex and health condition. The following predictors were more markedly associated with mortality in studies with patients with a mean age &lt;/=60 years  dyspnoea (p-OR = 4.3), smoking (p-OR = 2.8), kidney disease (p-OR = 3.8), hypertension (p-OR = 3.7), malignancy (p-OR = 3.7), diabetes (p-OR = 3.2), pulmonary disease (p-OR = 3.1), decreased platelet count (p-ES = -1.7), decreased haemoglobin concentration (p-ES = -0.6), increased creatinine (p-ES = 2.4), increased interleukin-6 (p-ES = 2.4) and increased cardiac troponin I (p-ES = 0.7). On the other hand, in addition to comorbidities, the most important mortality predictors in studies with older patients were albumin (p-ES = -3.1), total bilirubin (p-ES = 0.7), AST (p-ES = 1.8), ALT (p-ES = 0.4), urea nitrogen (p-ES), C-reactive protein (p-ES = 2.7), LDH (p-ES = 2.4) and ferritin (p-ES = 1.7). Obesity was associated with increased mortality only in studies with fewer chronic or critical patients (p-OR = 1.8). CONCLUSION  The prognostic effect of clinical conditions on COVID-19 mortality vary substantially according to the mean age of patients. PROSPERO REGISTRATION NUMBER  CRD42020176595.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 Identification of individuals at risk for heart failure is needed to deliver targeted preventive strategies and maximize net benefit of interventions. To examine the clinical utility of the recently published heart failure-specific risk prediction model, the Pooled Cohort Equations to Prevent Heart Failure, we sought to demonstrate the range of risk values associated with diverse risk factor combinations in White and Black men and women. We varied individual risk factors while holding the other risk factors constant at age-adjusted national mean values for risk factors in each race-sex and age group. We also examined multiple combinations of risk factor levels and examined the range of predicted 10-year heart failure risk using the Pooled Cohort Equations to Prevent Heart Failure risk tool. Ten-year predicted heart failure risk varied widely for each race-sex group across a range of ages and risk factor scenarios. For example, predicted 10-year heart failure risk in a hypothetical 40 year old varied from 0.1% to 9.7% in a White man, 0.5% to 12.3% in a Black man, &lt;0.1% to 9.3% in a White woman, and 0.2% to 28.0% in a Black woman. Higher risk factor burden (e.g. diabetes and hypertension requiring treatment) consistently drove higher risk estimates in all race-sex groups and across all ages. Our analysis highlights the importance of a race and sex-specific multivariable risk prediction model for heart failure to personalize the clinician-patient discussion, inform future practice guidelines, and provide a framework for future risk-based prevention trials for heart failure.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">rhe</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,Coagulopathies,
 BACKGROUND  A concern about the susceptibility of immunocompromised patients to the worldwide pandemic of coronavirus disease 2019 (COVID-19) has been raised. We aimed at describing COVID-19 infections in the French cohort of lung transplant (LT) patients. METHODS  Multicenter nationwide cohort study of all LT recipients with COVID-19 diagnosed from March 1 to May 19, 2020. Recipient main characteristics and their management were retrieved. Hospitalization characteristics, occurrence of complications and survival were analyzed. RESULTS  Thirty-five LT patients with a COVID-19 infection were included. Median age was 50.4 [40.6-62.9] years, 16 (45.7%) were female, and 80% were double-LT recipients. Infection was community-acquired in 25 (71.4%). Thirty-one (88.6%) required hospitalization, including 13 (41.9%) in the intensive care unit. The main symptoms of COVID-19 were fever, cough, and diarrhea, present in 71.4%, 54.3%, and 31.4% of cases, respectively. Extension of pneumonia on chest CT was moderate to severe in 51.4% of cases. Among the 13 critically ill patients, 7 (53.9%) received invasive mechanical ventilation. Thrombotic events occurred in 4 patients. Overall survival rate was 85.7% after a median follow-up of 50 days [41.0-56.5]. Four of 5 nonsurvivors had had bronchial complications or intensification of immunosuppression in the previous weeks. On univariate analysis, overweight was significantly associated with risk of death (odds ratio 16.0 [95% confidence interval1.5-170.6], p=0.02). CONCLUSION  For the 35 LT recipients with COVID-19, the presentation was severe, requiring hospitalization in most cases, with a survival rate of 85.7%.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-magenta-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">arrhythm</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">effus</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">tamponad</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">pericard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">deep vein thrombosis</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Arrhythmia,Heart failure,Inflammatory diseases,Diseases of arteries,Coagulopathies,
 OBJECTIVE  The objective of this review is to synthesize the best available evidence to determine the prevalence and incidence of adverse events in patients with Wolff-Parkinson-White syndrome who have undergone catheter ablation. INTRODUCTION  Wolff-Parkinson-White syndrome is a rare congenital heart disease affecting the normal cardiac conduction system that predisposes an individual to tachyarrhythmias. Patients with Wolf-Parkinson-White syndrome can experience a wide range of life-threatening symptoms and frequently undergo catheter ablation procedures to treat this disease. These patients are at risk of developing a variety of adverse events, including pericardial effusion, cardiac tamponade, atrial fibrillation, stroke, cerebral hemorrhage, major bleeding or hematoma, deep vein thrombosis, atrioventricular-block, cardiac perforation, coronary artery injury, pulmonary emboli, and death. INCLUSION CRITERIA  This review will include adults aged 18 or older with a diagnosis of Wolff-Parkinson-White syndrome who have undergone catheter ablation, including radiofrequency ablation and cryoablation. METHODS  MEDLINE, CINAHL, Scopus, Embase, and Web of Science databases will be searched from 1980 to the present for English-language studies only. Prevalence and incidence data, experimental, quasi-experimental, observational, and descriptive studies will be included and critically appraised by two independent reviewers. Data will be extracted using the standardized data extraction tool for prevalence data. If sufficient data is available, a meta-analysis will be conducted; otherwise, the findings will be presented in narrative form including tables and figures to aid in data presentation where appropriate. SYSTEMATIC REVIEW REGISTRATION NUMBER  PROSPERO CRD42020180391.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">stenos</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Diseases of arteries,
 Oligodendrocytes express low-density lipoprotein receptor (LDLR) to endocytose cholesterol for the maintenance of adulthood myelination. However, the potential role of LDLR in chronic cerebral ischemia-related demyelination remains unclear. We used bilateral carotid artery stenosis (BCAS) to induce sustained cerebral ischemia in mice. This hypoxic-ischemic injury caused a remarkable decline of oligodendroglial LDLR with impaired oligodendroglial differentiation and survival. Oligodendroglial cholesterol levels, however, remained unchanged. Mice miR-344e-3p and human homolog miR-410-3p, two miRNAs directly targeting Ldlr, were identified in experimental and clinical leukoaraiosis, thus leading to LDLR reduction. Lentiviral delivery of LDLR ameliorated the demyelination following chronic cerebral ischemia. By contrast, Ldlr-/- mice displayed inadequate myelination in the corpus callosum. Ldlr-/- oligodendrocyte progenitor cells (OPCs) exhibited defective ability to differentiate and myelinate axons in vitro. Transplantation with Ldlr-/- OPCs could not rescue the BCAS-induced demyelination. Such LDLR-dependent myelin restoration might involve a physical interaction of the Asn-Pro-Val-Tyr (NPVY) motif with phosphotyrosine binding domain of Shc, which subsequently activated MEK/ERK pathway. Together, our findings demonstrate that the aberrant oligodendroglial LDLR in chronic cerebral ischemia impairs myelination through intracellular signal transduction. Preservation of oligodendroglial LDLR may provide a promising approach to treat ischemic demyelination.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Origami has inspired novel solutions across myriad fields from DNA synthesis to robotics. Even wider impact can be achieved by active origami, which can move and change shape independently. However, current active origami and the materials that power it are both limited in terms of strength, speed, and strain. Here, we introduce an electrostatic active origami concept, electro-origami, that overcomes these limitations and allows for simple, inexpensive, lightweight, efficient, powerful, and scalable electronic actuators and lightweight and thin robots. The simplest embodiment of electro-origami, electro-ribbon actuators, can be easily fabricated from any combination of conducting and insulating material. We present electro-ribbon actuators that can lift 1000 times their own weight, contract by 99.8% of their length, and deliver specific energy and specific power equivalent to muscle. We demonstrate their versatility in high-stroke and high-force morphologies, multiactuator lattices, 3D-printed and paper actuators, self-twisting spirals, and tensile elements inspired by spider silk. More complex electro-origami devices include solenoids, adaptive grippers, robotic cilia, locomoting robots, self-packing deployable structures, origami artificial muscles, and dynamic origami art.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">cerebrovascul</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Inflammatory diseases,Diseases of arteries,Coagulopathies,
 Dual antiplatelet therapy (DAPT) score emerged as a tool for quantification of ischemia and bleeding risks. However, there was discrepancy of the prediction ability of DAPT score in previous studies. We aimed to assess the utility of DAPT score in a large-scale cohort of consecutive percutaneous coronary intervention (PCI) patients. This study enrolled 9,114 patients who had undergone PCI at Fuwai Hospital in 2013, adhered to DAPT and were event-free within the first 12 months following PCI. The endpoints included primary ischemic endpoints (major adverse cardiovascular and cerebrovascular events, and myocardial infarction and/or stent thrombosis), and bleeding endpoint from 12 through 24 months after PCI. Patients were classified into low (score &lt;2, n = 3,989) and high (score &gt;/=2, n = 5,125) DAPT score groups. The incidence rates of primary ischemic endpoints and bleeding endpoint were similar between the two groups. Multivariable analysis demonstrated DAPT score not to be an independent predictor of primary ischemic endpoints or bleeding endpoint. Based on receiver operating characteristic curves analysis, the C-statistic of DAPT score for primary ischemic endpoints or bleeding endpoint did not achieve a significant extent. In this large-scale cohort of PCI patients, DAPT score did not discriminate the risks of ischemic and bleeding events.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Mitochondria are responsible for ATP production but are also known as regulators of cell death, and mitochondrial matrix Ca(2+) is a key modulator of both ATP production and cell death. Although mitochondrial Ca(2+) uptake and efflux have been studied for over 50 years, it is only in the past decade that the proteins responsible for mitochondrial Ca(2+) uptake and efflux have been identified. The identification of the mitochondrial Ca(2+) uniporter (MCU) led to an explosion of studies identifying regulators of the MCU. The levels of these regulators vary in a tissue- and disease-specific manner, providing new insight into how mitochondrial Ca(2+) is regulated. This review focuses on the proteins responsible for mitochondrial transport and what we have learned from mouse studies with genetic alterations in these proteins. Expected final online publication date for the Annual Review of Physiology, Volume 83 is February 10, 2021. Please see http //www.annualreviews.org/page/journal/pubdates for revised estimates.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Diseases of arteries,
 Background - In the Women&#39;s Health Initiative hormone therapy (WHI-HT) trials, treatment with oral conjugated equine estrogens and medroxyprogesterone acetate (CEE+MPA) resulted in increased risk of coronary heart disease (CHD), while oral conjugated equine estrogens alone (CEE) did not. Methods - 481 metabolites were measured at baseline and at 1-year in 503 and 431 participants in the WHI CEE and CEE+MPA trials, respectively. The effects of randomized HT on the change in metabolite profiles at 1-year was evaluated in linear models adjusting for age, BMI, race, incident CHD, prevalent hypertension and diabetes. Metabolites with discordant effects by HT type were evaluated for association with incident CHD in 944 participants (472 CHD cases) in the WHI Observational Study (WHI-OS), with replication in an independent cohort of 980 men and women at high risk for cardiovascular disease. Results - HT effects on the metabolome were profound; 62% of metabolites significantly changed with randomized CEE and 52% with CEE+MPA (FDR adjusted p value &lt; 0.05) in multivariable models. Concerted increases in abundance were seen within various metabolite classes including triacylglycerols (TAG), phosphatidylethanolamines and phosphatidylcholines (PC); decreases in abundance was observed for acylcarnitines, lysophosphatidylcholines, quaternary amines and cholesteryl/cholesteryl esters. Twelve metabolites had discordant effects by HT type and were associated with incident CHD in the WHI-OS; a metabolite score estimated in a LASSO regression was associated with CHD risk with an odds ratio of 1.47 per SD increase (95% CI  1.27-1.70, p&lt;10(-6)). The findings of a subset of four metabolites including C58 11 TAG, C54 9 TAG, C36 1 PC and sucrose replicated in an independent dataset of 980 participants. Conclusions - Randomized treatment with oral HT resulted in large metabolome shifts. Discordant metabolite effects between HT regimens may partially mediate the differences in CHD risk between the two WHI-HT trials.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">deep vein thrombosis</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Coagulopathies,
 Two of the more common potential complications after arthroplasty are venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolus (PE), and excess bleeding. Appropriate chemoprophylaxis choices are essential to prevent some of these adverse events and from exacerbating others. Risk stratification to prescribe safe and effective medications in the prevention of postoperative VTE has shown benefit in this regard. The Department of Orthopaedic Surgery at Syosset Hospital/Northwell Health, which performs over 1200 arthroplasties annually, has validated and is using the 2013 version of the Caprini Risk Assessment Model (RAM) to stratify each patient for risk of postoperative VTE. This tool results in a culling of information, past and present, personal and familial, that provides a truly thorough evaluation of the patient&#39;s risk for postoperative VTE. The Caprini score then guides the medication choices for thromboprophylaxis. The Caprini score is only valuable if the data is properly collected, and we have learned numerous lessons after applying it for 18 months. Risk stratification requires practice and experience to achieve expertise in perioperative patient evaluation. Having access to pertinent patient information, while gaining proficiency in completing the Caprini RAM, is vital to its efficacy. Ongoing, real time analyses of patient outcomes, with subsequent change in process, is key to improving patient care.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Introduction  In individuals with type 2 diabetes mellitus, sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and serious adverse renal events, both in randomized controlled trials and observational studies. Areas covered  In this paper, the authors critically discuss the rationale, results and implications of the recent placebo-controlled EMPEROR-Reduced trial [NCT03057977], which evaluated empagliflozin in subjects with chronic heart failure and a reduced ejection fraction (HFrEF), with or without diabetes. A parallel with the DAPA-HF trial, investigating dapagliflozin in a similar albeit not fully overlapping population, is also provided. The authors finally provide the reader with their expert perspectives. Expert opinion  EMPEROR-Reduced confirmed and extended the findings from DAPA-HF, especially on renal outcomes, thus strengthening the rationale for considering SGLT2 inhibitors among established treatments in HFrEF. Forthcoming guidelines supported by knowledge of the clinical pharmacology of SGLT2 inhibitors will hopefully assist cardiologists, nephrologists and general practitioners in selecting the target population and promoting safe prescribing.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Introduction  In individuals with type 2 diabetes mellitus, sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and serious adverse renal events, both in randomized controlled trials and observational studies. Areas covered  In this paper, the authors critically discuss the rationale, results and implications of the recent placebo-controlled EMPEROR-Reduced trial [NCT03057977], which evaluated empagliflozin in subjects with chronic heart failure and a reduced ejection fraction (HFrEF), with or without diabetes. A parallel with the DAPA-HF trial, investigating dapagliflozin in a similar albeit not fully overlapping population, is also provided. The authors finally provide the reader with their expert perspectives. Expert opinion  EMPEROR-Reduced confirmed and extended the findings from DAPA-HF, especially on renal outcomes, thus strengthening the rationale for considering SGLT2 inhibitors among established treatments in HFrEF. Forthcoming guidelines supported by knowledge of the clinical pharmacology of SGLT2 inhibitors will hopefully assist cardiologists, nephrologists and general practitioners in selecting the target population and promoting safe prescribing.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Wild-type transthyretin-associated (ATTRwt) amyloidosis is an age-related disease that causes heart failure in older adults. This disease frequently features cardiac amyloid fibril deposits that originate from dissociation of the tetrameric protein, transthyretin (TTR). Unlike hereditary TTR (ATTRm) amyloidosis, where amino acid replacements destabilize the native protein, in ATTRwt amyloidosis, amyloid-forming TTR lacks protein sequence alterations. The initiating cause of fibril formation in ATTRwt amyloidosis is unclear, and thus, it seems plausible that other factors are involved in TTR misfolding and unregulated accumulation of wild-type TTR fibrils. We believe that clusterin (CLU, UniProtKB P10909), a plasma circulating glycoprotein, plays a role in the pathobiology of ATTRwt amyloidosis. Previously, we have suggested a role for CLU in ATTRwt amyloidosis based on our studies showing that (1) CLU codeposits with non-native TTR in amyloid fibrils from ATTRwt cardiac tissue, (2) CLU interacts only with non-native (monomeric and aggregated) forms of TTR, and (3) CLU serum levels in patients with ATTRwt are significantly lower compared to healthy controls. In the present study, we provide comprehensive detail of compositional findings from mass spectrometry analyses of amino acid and glycan content of CLU purified from ATTRwt and control sera. The characterization of oligosaccharide content in serum CLU derived from patients with ATTRwt amyloidosis is novel data. Moreover, results comparing CLU oligosaccharide variations between patient and healthy controls are original and provide further evidence for the role of CLU in ATTRwt pathobiology, possibly linked to disease-specific structural features that limit the chaperoning capacity of CLU.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocardit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">cardit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,
 Osteoglycin (Ogn), a class III SLRP member with multiple glycosylation sites, has been proposed to be engaged in cardiac dysfunction and adverse remodeling in human heart failure following myocardial infarction. However, the underlying mechanism remains to be elucidated. Thus, we sought to define the role of Ogn in regulation of the Wnt pathway on myocardial fibrosis and epithelial/endothelial-mesenchymal transformation (EMT/EndMT) in mice with myocarditis. The pathological changes are observed, while hematoxylin-eosin staining and picric acid Sirius red staining were conducted in successfully constructed myocarditis mouse models. Immunohistochemistry and enzyme-linked immunosorbent assay were adopted to determine Ogn and beta-catenin levels and serum procollagen propeptide concentrations in the mouse myocardial tissues, respectively. Expression of Ogn and Wnt signaling pathway-related factors were measured by reverse transcription quantitative polymerase chain reaction and western blot assay, cell viability by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, and cell cycle distribution and apoptosis by flow cytometry. We saw indicative pathological changes accompanied by many Ogn and beta-catenin positive cells and increased serum procollagen propeptide, in the mouse myocardial tissues. Loss function assays showed reduced levels of Ogn, beta-catenin, LRP6, TGF-beta1, Twist, FSP-1, alpha-SMA and higher levels of E-cadherin and VE-cadherin, together with decreased proliferation rate, as well as increased apoptosis rate, indicating that the Wnt signaling pathway, proliferation were inhibited while apoptosis was enhanced with upon gene silencing. Coherently, depletion of Ogn inhibits myocardial fibroblasts proliferation and EMT/EndMT while facilitating myocardial fibroblasts apoptosis in myocarditis through the Wnt signaling pathway, thus serving as an intervention target for the molecular treatment of myocarditis.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 Clinicians and researchers need valid and reliable instruments to evaluate heart failure (HF) self-care. The Self-Care of Heart Failure Index (SCHFI) is a theoretically driven instrument developed for this purpose. The SCHFI measures self-care with three scales  self-care maintenance, measuring behaviors to maintain HF stability; symptom perception, measuring monitoring behaviors; and self-care management, assessing the response to symptoms. After the theory underpinning the SCHFI was updated, the instrument was updated to version 7.2 but it was only tested in the United States. In this study we tested the psychometric characteristics (structural and construct validity, internal consistency, and test-retest reliability) of the SCHFI v.7.2 in an Italian population of HF patients. We used a cross-sectional design to study 280 HF patients with additional data collected after 2 weeks for test-retest reliability. Adults with HF (mean age 75.6 (+/-10.8); 70.8% in New York Heart Association [NYHA] classes II and III) were enrolled from six centers across Italy. Confirmatory factor analysis showed supportive structural validity in the three SCHFI v.7.2 scales (CFI from 0.94 to 0.95; RMSEA from 0.05 to 0.07). Internal consistency reliability estimated with Cronbach&#39;s alpha and composite reliability ranged between .73 and .88; test-retest reliability ranged between 0.73 and 0.92. Construct validity was supported with significant correlations between the SCHFI v.7.2 scale scores and quality of life, brain natriuretic peptide levels and NYHA class. This study further supports the psychometric characteristics of the SCHFI v.7.2, illustrating that it can be used in clinical practice and research also in an Italian population.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlud</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Diseases of arteries,Coagulopathies,
 BACKGROUND  The data on long-term outcome after basilar artery occlusion (BAO) are scarce. Only a little is known about BAO survivors outcome over decades. AIM  We set out to investigate long-term survival and causes of death in BAO patients with up to two-decade follow-up. We also evaluated differences in outcome trends. METHODS  207 BAO patients treated with intravenous thrombolysis (IVT) at the Department of Neurology, Helsinki University Hospital, between 1995-2016 were analyzed. Short-term outcome was assessed with modified Rankin Scale (mRS) at three months. Long-term cumulative survival rate was analyzed using Kaplan-Meier analysis. Factors associated with mortality were analyzed with Cox regression. RESULTS  Moderate outcome (mRS 0-3) was achieved in 41.1% and good outcome (mRS 0-2) in 30.4% of patients at three months. Three-month mortality was 39.6%, of which 89% died within first month. The median follow-up time in 3-month survivors was 8.9 years (max. 21.8 years). Total mortality during the follow-up was 52.2%. Cumulative mortality rate was 25.7%. Older age, coronary artery disease and more extensive ischemic changes on admission brain imaging were independently associated with long-term mortality. After the acute phase, the rate of other vascular causes of death increased in relation to stroke. CONCLUSIONS  The described evolution of a large single-center BAO cohort shows a trend towards higher rate of good and/or moderate outcome during later years in IVT-treated patients. Survivors showed relative longevity and the rate of cardiac and other vascular causes of death increased in relation to stroke sequelae over long term.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 AIMS AND OBJECTIVES  This study aimed to describe nurses&#39; experiences of continuity of care for patients with heart failure. BACKGROUND  Heart failure is a life-influencing condition that causes varying care needs over time with risks of fragmentation. Nurses play an important role in caring for patients with heart failure. However, nurses&#39; experiences of continuity of care seems to be less explored in this context. DESIGN  A qualitative study with a descriptive design. METHODS  Four focus groups were chosen to collect the data, and the analysis was made by using a method for thematic analysis. A purposeful sampling of nurses (n=14) with experiences from hospital-connected heart failure clinics, primary healthcare centres and municipal home healthcare settings was recruited. The COREQ checklist was used in this study. RESULTS  The nurses&#39; experiences of continuity of care for patients with heart failure was described in four themes  access and flexibility, responsibility and transparency, trustful and caring relationships and communication and collaboration. CONCLUSIONS  The results indicate that nurses have an excellent position to act as the &#34;hub&#34; in caring for patients with heart failure, but they need to have the possibility of networking and establishing trusting relationships with their colleagues. From the nurses&#39; point of view, mutual trust between the nurse, the patient and the patient&#39;s next of kin is crucial for promoting and maintaining continuity of care in patients with heart failure. RELEVANCE TO CLINICAL PRACTICE  To promote continuity of care for patients with heart failure, nurses expressed the necessity of establishing trusting relationships in a continuity-promoting organisation with seamless coordination. Nurses can be the &#34;hub&#34; supporting a person-centred care approach based on the patients&#39; needs. There seems to be a need for better collaboration with common guidelines across and within primary healthcare centres, hospital-connected heart failure clinics and municipal home healthcare settings.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Inflammatory diseases,
 OBJECTIVE  To estimate the baseline rates of vascular events among people with migraine. BACKGROUND  Several novel medications that target the calcitonin gene-related peptide (CGRP) pathway are approved to treat people with migraine. Given that the CGRP pathway also plays a role in maintaining cardiovascular homeostasis, determining the baseline rates of vascular events among people with migraine will help inform the safety of these novel medications. METHODS  In this retrospective cohort study, patients 18- to 64-year-old patients with migraine were identified from the MarketScan((R)) database (January 2013-December 2017) and were categorized into 4 vascular risk categories  migraine with aura; and high, medium, and low vascular risk. Event rates (per 1000 person-years [PY]) for 19 vascular events were estimated overall, by risk category, and by baseline characteristics. RESULTS  Among 1,195,696 patients with migraine, 4.8% (57,853/1,195,696) had migraine with aura, and 2.8% (33,949/1,195,696), 15.5% (184,782/1,195,696), and 77.9% (931,059/1,195,696) were at high, medium, and low risk of vascular events, respectively. Rates of ischemic stroke (per 1000 PY) were 5.1 (95% confidence interval [CI]  5.0, 5.2) overall, 8.6 (95% CI  8.1, 9.1) for patients with migraine aura, 47.2 (95% CI  45.3, 49.0) in the high-risk group, 9.4 (95% CI  9.1, 9.7) in the medium-risk group, and 2.9 (95% CI  2.9, 3.0) in the low-risk group. Rates of acute myocardial infarction (per 1000 PY) were 1.8 (95% CI  1.8, 1.9) overall, 1.9 (95% CI  1.7, 2.2) for patients with migraine aura, 14.0 (95% CI  13.0, 14.9) in the high-risk group, 3.9 (95% CI  3.7, 4.1) in the medium-risk group, and 1.1 (95% CI  1.0, 1.1) in the low-risk group. High-risk patients had the highest rates of each of 19 evaluated vascular events, and rates were higher for men, older age groups, and those with higher comorbidity scores, medication usage, and medical utilization. CONCLUSION  Our findings provide recent rates of vascular disease in patients with migraine. In the future, this information will be useful to help inform clinical risk benefit decision making when assessing the use of therapies such as CGRP antagonists for migraine.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  Chronic venous insufficiency (CVI) is a condition in which veins are unable to transport blood unidirectionally towards the heart. CVI usually occurs in the lower limbs. It might result in considerable discomfort, with symptoms such as pain, itchiness and tiredness in the legs. Patients with CVI may also experience swelling and ulcers. Phlebotonics are a class of drugs often used to treat CVI. This is the second update of a review first published in 2005. OBJECTIVES  To assess the efficacy and safety of phlebotonics administered orally or topically for treatment of signs and symptoms of lower extremity CVI. SEARCH METHODS  The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase, and CINAHL databases and the World Health Organization International Clinical Trials Registry Platform and Clinicaltrials.gov trials register up to 12 November 2019. We searched the reference lists of the articles retrieved by electronic searches for additional citations. We also contacted authors of unpublished studies. SELECTION CRITERIA  We included randomised, double-blind, placebo-controlled trials (RCTs) assessing the efficacy of phlebotonics (rutosides, hidrosmine, diosmine, calcium dobesilate, chromocarbe, Centella asiatica, disodium flavodate, French maritime pine bark extract, grape seed extract and aminaftone) in patients with CVI at any stage of the disease. DATA COLLECTION AND ANALYSIS  Two review authors independently extracted data and assessed the quality of included RCTs. We estimated the effects of treatment by using risk ratios (RRs), mean differences (MDs) and standardized mean differences (SMDs), according to the outcome assessed. We calculated 95% confidence intervals (CIs) and percentage of heterogeneity (I(2)). Outcomes of interest were oedema, quality of life (QoL), assessment of CVI and adverse events. We used GRADE criteria to assess the certainty of the evidence. MAIN RESULTS  We identified three new studies for this update. In total, 69 RCTs of oral phlebotonics were included, but only 56 studies (7690 participants, mean age 50 years) provided quantifiable data for the efficacy analysis. These studies used different phlebotonics (28 on rutosides, 11 on hidrosmine and diosmine, 10 on calcium dobesilate, two on Centella asiatica, two on aminaftone, two on French maritime pine bark extract and one on grape seed extract). No studies evaluating topical phlebotonics, chromocarbe, naftazone or disodium flavodate fulfilled the inclusion criteria. Moderate-certainty evidence suggests that phlebotonics probably reduce oedema slightly in the lower legs, compared with placebo (RR 0.70, 95% CI 0.63 to 0.78; 13 studies; 1245 participants); and probably reduce ankle circumference (MD -4.27 mm, 95% CI -5.61 to -2.93 mm; 15 studies; 2010 participants). Moderate-certainty evidence shows that phlebotonics probably make little or no difference in QoL compared with placebo (SMD -0.06, 95% CI -0.22 to 0.10; five studies; 1639 participants); and similarly, may have little or no effect on ulcer healing (RR 0.94, 95% CI 0.79 to 1.13; six studies; 461 participants; low-certainty evidence). Thirty-seven studies reported on adverse events. Pooled data suggest that phlebotonics probably increase adverse events slightly, compared to placebo (RR 1.14, 95% CI 1.02 to 1.27; 37 studies; 5789 participants; moderate-certainty evidence). Gastrointestinal disorders were the most frequently reported adverse events. We downgraded our certainty in the evidence from &#39;high&#39; to &#39;moderate&#39; because of risk of bias concerns, and further to &#39;low&#39; because of imprecision. AUTHORS&#39; CONCLUSIONS  There is moderate-certainty evidence that phlebotonics probably reduce oedema slightly, compared to placebo; moderate-certainty evidence of little or no difference in QoL; and low-certainty evidence that these drugs do not influence ulcer healing. Moderate-certainty evidence suggests that phlebotonics are probably associated with a higher risk of adverse events than placebo. Studies included in this systematic review provided only short-term safety data; therefore, the medium- and long-term safety of phlebotonics could not be estimated. Findings for specific groups of phlebotonics are limited due to small study numbers and heterogeneous results. Additional high-quality RCTs focusing on clinically important outcomes are needed to improve the evidence base.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Inflammatory diseases,Diseases of arteries,
 Eicosanoids play important roles in the cardiovascular system. The metabolic disorders involving some eicosanoids in the pathophysiologic process include myocardial infarction and myocardial ischemia-reperfusion injury. Percutaneous coronary intervention (PCI) is often the first-choice strategy for acute ST segment elevation myocardial infarction (STEMI) according to current guidelines. This study aimed to investigate the dynamic eicosanoid metabolic profile in STEMI patients after PCI. The eicosanoid profiles in plasma of 20 patients at seven times (30 min before surgery; 6, 12, 24, and 72 hr after surgery; 1 day before discharge; and 28 days after surgery) were studied by using metabolomics. Levels of PGE2, PGD2, and TXA2 were decreased significantly and EETs contents were increased significantly at 6 hr after PCI. EETs were hydrolysed to DHETs within a short time time after surgery (12-72 hr). 20-HETE content was significantly increased. In samples taken at the time of discharge and at follow-up after discharge, LTB4 level continued to increase. This work suggests that change in content of some functional eicosanoids may be involved in cardiac injury and repair after PCI in a synergistic manner.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 INTRODUCTION  Although cardiac resynchronization therapy (CRT) has the potential to improve cardiac function in patients with heart failure (HF), a considerable portion of patients do not respond to therapy. This study assessed the economic burden among patients with and without HF worsening after receiving CRT in real-world practice. METHODS  In this retrospective claims-based study using Optum&#39;s de-identified Clinformatics((R)) Data Mart Database (January 2007-December 2018), adults who received CRT were stratified into two cohorts based on whether they showed evidence of HF worsening within 180 days post-CRT implantation. Inverse probability of treatment weighting (IPTW) was used to adjust for confounding, accounting for demographics (e.g., age, sex), the Quan-Charlson Comorbidity Index, other clinical characteristics, healthcare resource utilization (HRU), and healthcare costs during the 180 days pre-CRT (baseline period). Annualized all-cause and congestive HF-related HRU and healthcare costs from payer and patient perspectives were assessed from day 181 post-CRT (follow-up period), and compared between cohorts using incidence rate ratios (IRRs) and cost ratios (CRs). RESULTS  This study included 12,753 patients (n = 4785 with HF worsening; n = 7968 without). Mean age was 72 years and roughly two-thirds were male. Baseline characteristics were balanced between cohorts post-IPTW. During follow-up, patients with HF worsening had significantly greater annual all-cause inpatient [adjusted IRR (95% confidence interval) = 1.55 (1.44, 1.66), p &lt; 0.001], outpatient [adjusted IRR = 1.46 (1.32, 1.61), p &lt; 0.001], and emergency department [adjusted IRR = 1.31 (1.22, 1.41), p &lt; 0.001] visits. Mean annual total per patient payer-paid amounts were significantly higher for patients with HF worsening versus without HF worsening [adjusted CR = 1.68 (1.56, 1.80), p &lt; 0.001]. Annual patient-paid medical costs were also higher for patients with HF worsening [adjusted CR = 1.31 (1.25, 1.38), p &lt; 0.001]. Results were similar for congestive HF-related HRU and costs. CONCLUSIONS  The incremental economic burden among patients with HF worsening following CRT is substantial. Efforts aimed at CRT optimization may help reduce this burden.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Diseases of arteries,
 Several environmental and genetic factors have been found to influence the development and progression of coronary artery disease (CAD). Although the effects of the environmental hazards on CAD pathophysiology are well documented, the genetic architecture of the disease remains quite unclear. A number of single-nucleotide polymorphisms have been identified based on the results of the genome-wide association studies. However, there is a lack of strong evidence regarding molecular causality. The minority of the reported predisposing variants can be related to the conventional risk factors of CAD, while most of the polymorphisms occur in non-protein-coding regions of the DNA. However, independently of the specific underlying mechanisms, genetic information could lead to the identification of a population at higher genetic risk for the long-term development of CAD. Myocardial single-photon emission computed tomography (SPECT) and positron emission tomography (PET) are functional imaging techniques that can evaluate directly myocardial perfusion, and detect vascular and/or endothelial dysfunction. Therefore, these techniques could have a role in the investigation of the underlying mechanisms associated with the identified predisposing variants, advancing our understanding regarding molecular causality. In the population at higher genetic risk, myocardial SPECT or PET could provide important evidence through the early depiction of sub-clinical dysfunctions, well before any atherosclerosis marker could be identified. Notably, SPECT and PET techniques have been already used for the investigation of the functional consequences of several CAD-related polymorphisms, as well as the response to certain treatments (statins). Furthermore, therefore, in the clinical setting, the combination of genetic evidence with the findings of myocardial SPECT, or PET, functional imaging techniques could lead to more efficient screening methods and may improve decision making with regard to the diagnostic investigation and patients&#39; management.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,
 Risk stratification endeavors to categorize patients into groups based on the level of risk for each group. Improved perioperative screening tests using more sensitive cardiac biomarkers have revealed that about 68% of perioperative myocardial infarctions (MI) are asymptomatic and may only be detected by routine postoperative screening with troponin measurements. This is important since myocardial injury not meeting criteria for myocardial infarction is associated with increased risk of 30-day mortality (Botto et al. in Anesthesiology 120 564-578, 2014). Traditional risk indices including the revised cardiac risk index (RCRI) and the myocardial infarction cardiac arrest (MICA) index were developed based on overt clinical signs of myocardial infarction and significantly underestimate adverse cardiac events. Recently, brain type natriuretic peptides (BNP) and its precursor n- terminal pro-brain type natriuretic peptide (nt-proBNP) have been shown to be powerful prognostic markers. Incorporating serum biomarkers into updated clinical risk indices is likely to improve their performance. Further studies are needed to determine appropriate clinical interventions to treat isolated elevations in cardiac troponin levels and further mitigate the increased risk of morbidity and mortality. The objective of this review is to summarize the current literature on the clinical diagnoses of perioperative myocardial injury in the setting of noncardiac surgery.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,
 STUDY OBJECTIVES  To examine (1) the impact of adherence to continuous positive airway pressure (CPAP) therapy on risk for cardiovascular (CVD) events among a nationally representative sample of older adults with obstructive sleep apnea (OSA), and (2) the heterogeneity of this effect across subgroups defined by race, sex, and socioeconomic status. METHODS  We conducted a retrospective cohort study among Medicare beneficiaries aged &gt;/= 65 years with OSA (2009-2013). Monthly indicators of CPAP adherence (charges for machines, masks, or supplies) were summed over 25 months to create a CPAP adherence variable. New CVD events (ischemic heart disease, cardiac and peripheral procedures) were modeled as a function of CPAP adherence using generalized estimating equations. Heterogeneity of the effect of CPAP on new CVD events was evaluated based on race, sex, and socioeconomic status. RESULTS  Among 5024 beneficiaries diagnosed with OSA who initiated CPAP, 1678 (33%) demonstrated new CVD events. Following adjustment for demographic and clinical characteristics, CPAP adherence was associated with reduced risk of new CVD events (hazard ratio 0.95; 95% confidence interval 0.94, 0.96) over 25 months. When analyses were stratified by time since the first CPAP charge, the protective effect remained significant for the 12- and 6-month, but not 3-month, outcome models. No significant differences were observed in the protective effect of CPAP based on race, sex, or socioeconomic status. CONCLUSIONS  In this national study of older adult Medicare beneficiaries with OSA, CPAP adherence was associated with greatly reduced risk for CVD events. This risk reduction was consistent across race, sex, and socioeconomic subgroups.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 The aim of our study was to observe the temporal distribution of serum N-terminal pro-brain natriuretic peptide (NT-proBNP) in premature infants of &lt;/= 31 weeks of gestational age (GA) during the first weeks of life. NT-proBNP values of 118 preterm infants born &lt;/= 31 weeks GA were determined during the first week of life, after 4 +/- 1 weeks of life, and at a corrected GA of 36 +/- 2 weeks. Infants were divided into two groups  those without relevant complications and those with complications related to prematurity. NT-proBNP values of infants without complications define our exploratory reference values. The Median NT-proBNP level of these infants was 1896 ng/l (n = 27, interquartile range (IQR)  1277-5200) during the first week of life, 463 ng/l (n = 26, IQR  364-704) at 4 +/- 1 weeks of life, and 824 ng/l (n = 33, IQR  714-1233) at a corrected GA of 36 +/- 2 weeks. Infants born &lt; 28 + 0 weeks GA had significantly higher NT-proBNP values (n = 9, median  5200, IQR  1750-8972) than infants born &gt;/= 28 + 0-31 weeks GA (n = 18, median  1528, IQR  838-3052; p = 0.017). Growth restriction or PDA status could not account for the difference in NT-proBNP values between GA groups.Conclusions  The results of our observational and cross-sectional study describe exploratory reference values for NT-proBNP levels in preterm infants of &lt;/= 31 weeks GA according to postnatal age. NT-proBNP levels during the first week of life are high and widely distributed in preterm infants and decrease subsequently to reach a distinctly lower and stable plateau at around 1 month of life. Our results suggest an influence of GA on NT-proBNP values in the first week of life. What is Known  * Several complications related to prematurity, e.g., hemodynamically significant PDA, pulmonary hypertension, bronchopulmonary dysplasia, and retinopathy of prematurity, have been associated with a temporary rise in NT-proBNP values in preterm infants during their first weeks of life. What is New  * This observational study provides reference values for NT-proBNP levels of very and extremely preterm infants during their first weeks of life. * In premature infants without complications, NT-proBNP values during their first week of life depend on gestational age at birth.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 PURPOSE  Children born preterm have impaired lung function and altered lung structure. However, there are conflicting reports on how preterm birth impacts aerobic exercise capacity in childhood. We aimed to investigate how neonatal history and a diagnosis of bronchopulmonary dysplasia (BPD) impact the relationship between function and structure of the lung, and aerobic capacity in school-aged children born very preterm. METHODS  Preterm children (&lt;/= 32 w completed gestation) aged 9-12 years with (n = 38) and without (n = 35) BPD, and term-born controls (n = 31), underwent spirometry, lung volume measurements, gas transfer capacity, a high-resolution computer tomography (CT) scan of the chest, and an incremental treadmill exercise test. RESULTS  Children born preterm with BPD had an elevated breathing frequency to tidal volume ratio compared to term controls (76% vs 63%, p = 0.002). The majority (88%) of preterm children had structural changes on CT scan. There were no differences in peak VO2 (47.1 vs 47.7 mL/kg/min, p = 0.407) or oxygen uptake efficiency slope when corrected for body weight (67.6 vs 67.3, p = 0.5) between preterm children with BPD and term controls. There were no differences in any other exercise outcomes. The severity of structural lung disease was not associated with exercise outcomes in this preterm population. CONCLUSION  Children born preterm have impaired lung function, and a high prevalence of structural lung abnormalities. However, abnormal lung function and structure do not appear to impact on the aerobic exercise capacity of preterm children at school age.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 BACKGROUND  Pulmonary embolism (PE) has been described in coronavirus disease 2019 (COVID-19) critically ill patients, but the evidence from more heterogeneous cohorts is limited. METHODS  Data were retrospectively obtained from consecutive COVID-19 patients admitted to 13 Cardiology Units in Italy, from March 1st to April 9th, 2020, and followed until in-hospital death, discharge, or April 23rd, 2020. The association of baseline variables with computed tomography-confirmed PE was investigated by Cox hazards regression analysis. The relationship between D-dimer levels and PE incidence was evaluated using restricted cubic splines models. RESULTS  The study included 689 patients (67.3 +/- 13.2 year-old, 69.4% males), of whom 43.6% were non-invasively ventilated and 15.8% invasively. 52 (7.5%) had PE over 15 (9-24) days of follow-up. Compared with those without PE, these subjects had younger age, higher BMI, less often heart failure and chronic kidney disease, more severe cardio-pulmonary involvement, and higher admission D-dimer [4344 (1099-15,118) vs. 818.5 (417-1460) ng/mL, p &lt; 0.001]. They also received more frequently darunavir/ritonavir, tocilizumab and ventilation support. Furthermore, they faced more bleeding episodes requiring transfusion (15.6% vs. 5.1%, p &lt; 0.001) and non-significantly higher in-hospital mortality (34.6% vs. 22.9%, p = 0.06). In multivariate regression, only D-dimer was associated with PE (HR 1.72, 95% CI 1.13-2.62; p = 0.01). The relation between D-dimer concentrations and PE incidence was linear, without inflection point. Only two subjects had a baseline D-dimer &lt; 500 ng/mL. CONCLUSIONS  PE occurs in a sizable proportion of hospitalized COVID-19 patients. The implications of bleeding events and the role of D-dimer in this population need to be clarified.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 OBJECTIVES  The aim of study was to evaluate peripheral blood perfusion and the proximal-distal gradient (PDG) of the hands as biomarkers of SSc major vascular complications (digital ulcers, pulmonary arterial hypertension, scleroderma renal crisis) and mortality by laser speckle contrast analysis. METHODS  In this retrospective observational study, 176 SSc patients [158 female, median age 53 (51-57) years] and 142 healthy controls [115 female, median age 53 (48-55) years] were enrolled. Clinical data were collected at baseline and annually through 5 years of follow-up. Hand dorsum perfusion images were divided into three regions of interest (ROI)  ROI1 included the second, third, and fourth fingers distal to the proximal interphalangeal finger joint; ROI2 included the area between the proximal interphalangeal finger joint and the metacarpophalangeal joint; ROI3 included the hand dorsum. PDG was identified when the perfusion mean difference between ROI1 and ROI2 was &gt;30 perfusion units. RESULTS  Median peripheral blood perfusion was significantly lower for SSc patients than healthy controls. PDG was present in 51.5% of SSc patients and in 98.6% of healthy controls. Using the final multivariate model, nailfold videocapillaroscopy (NVC) pattern [hazard ratio (HR) 0.065 (0.015-0.283), P &lt;0.0001] and PDG [HR 0.376 (0.194-0.727), P &lt;0.01] were found to be risk factors for major vascular complications. By multivariate analysis, age [HR 1.051 (1.014-1.088), P &lt;0.01), NVC pattern [HR 0.001 (0.000-3.111), P &gt;0.05], and PDG [HR 0.207 (0.073-0.589), P &lt;0.01] were found to be risk factors for 5-year SSc mortality. CONCLUSION  PDG predicts major vascular complication and 5-year mortality of SSc patients.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 The worldwide burden of kidney disease is rising, but public awareness remains limited, underscoring the need for more effective communication by stakeholders in the kidney health community. Despite this need for clarity, the nomenclature for describing kidney function and disease lacks uniformity. In June 2019, Kidney Disease  Improving Global Outcomes (KDIGO) convened a consensus conference with the goal of standardizing and refining the nomenclature used in the English language to describe kidney function and disease, and of developing a glossary that could be used by journals in scientific publications. Guiding principles of the conference were that the revised nomenclature should be patient-centred, precise, and consistent with nomenclature used in the KDIGO guidelines. Conference attendees reached general consensus on the following recommendations  (i) to use &#39;kidney&#39; rather than &#39;renal&#39; or &#39;nephro&#39; when referring to kidney disease and kidney function; (ii) to use &#39;kidney failure&#39; with appropriate descriptions of the presence or absence of symptoms, signs, and treatment rather than &#39;end-stage&#39; kidney disease; (iii) to use the KDIGO definition and classification of acute kidney diseases and disorders (AKD) and acute kidney injury (AKI) rather than alternative descriptions to define and classify the severity of AKD and AKI; (iv) to use the KDIGO definition and classification of chronic kidney disease (CKD) rather than alternative descriptions to define and classify the severity of CKD; and (v) to use specific kidney measures, such as albuminuria or decreased glomerular filtration rate, rather than &#39;abnormal or reduced kidney function&#39; to describe alterations in kidney structure and function. A proposed five-part glossary contains specific items for which there was general agreement. Conference attendees acknowledged limitations of the recommendations and glossary but considered that standardizing scientific nomenclature is essential for improving communication.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlud</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 OBJECTIVES  Our aim was to evaluate clinical and neurological effects of common carotid artery (CCA) true lumen flow impairment or occlusion in patients with type A aortic dissection. METHODS  Characteristics and imaging data of patients with dissected CCA secondary to acute type A aortic dissection from 3 institutions were analysed. We defined true lumen blood flow as unimpaired when the maximum true lumen diameter exceeded 50% of the complete CCA diameter, as impaired when the true lumen was compressed to &gt;50% of the complete lumen, or as occluded. RESULTS  Out of 440 patients, 207 presented unimpaired CCA flow, 172 impaired CCA flow and CCA occlusion was present in 61 patients. Preoperative shock (P = 0.045) or a neurological deficit (P &lt; 0.001) were least common in patients with unimpaired CCA flow and most common in those with CCA occlusion. Non-cerebral, other-organ malperfusion was common in 37% of all patients, but the incidence was similar (P = 0.69). In patients with CCA occlusion, postoperative stroke (P &lt; 0.001) and in-hospital mortality (0.011) were significantly higher, while the incidences were similar between patients with unimpaired and impaired CCA flow. Mixed-effects logistic regression models showed that CCA flow impairment (P = 0.23) or occlusion (P = 0.55) was not predictive for in-hospital mortality, but CCA occlusion was predictive for in-hospital stroke (odds ratio 2.166, P = 0.023). CONCLUSIONS  Shock and non-cerebral, other-organ malperfusion are common in patients with CCA dissection. While there is a high risk for stroke in patients with CCA occlusion, CCA flow impairment and occlusion were not predictive for in-hospital mortality. Surgery should not be denied to patients with CCA flow impairment or occlusion.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 OBJECTIVES  We sought to evaluate the outcome after modified subcoronary Ross/Ross-Konno operation in children and young adults. METHODS  Between January 2013 and January 2019, a total of 50 patients with median age of 6.3 years (range 0.02-36.5 years, 58% males), including 10 infants (20%), received modified subcoronary Ross/Ross-Konno operation at our institution. Survival, morbidity, reinterventions, aortic valve function and aortic root dimensions were analysed. RESULTS  At a median follow-up of 31.2 months (range 14.4-51 months), there were 1 early death and 1 late death, both in the infant group. The overall survival at 5 years after the operation was 95%. Two patients needed aortic valve replacement, 11 and 15 months after their Ross operation. At 5 years, freedoms from reoperation on the autograft and on the right ventricle to pulmonary artery conduit were 94% and 97%, respectively. Freedom from aortic valve regurgitation greater than mild was 97% at 5 years. Median dimensions of the aortic root at all levels remained in normal range at last visit. Forty-four patients (95%) were in New York Heart Association class I with normal left ventricular function. CONCLUSIONS  The initial experience with the subcoronary Ross/Ross-Konno operation in children and young adults showed excellent outcome. The mortality and morbidity among infants remain significant. The described technique is reproducible and might be advantageous in situations when prosthetic supporting techniques interfere with somatic growth.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 Importance  Online programs may help with weight loss but have not been widely implemented in routine primary care. Objective  To compare the effectiveness of a combined intervention, including an online weight management program plus population health management, with the online program only and with usual care. Design, Setting, and Participants  Cluster randomized trial with enrollment from July 19, 2016, through August 10, 2017, at 15 primary care practices in the US. Eligible participants had a scheduled primary care visit and were aged 20 to 70 years, had a body mass index between 27 and less than 40, and had a diagnosis of hypertension or type 2 diabetes. Follow-up ended on May 8, 2019. Interventions  Participants in the usual care group (n = 326) were mailed general information about weight management. Participants in the online program only group (n = 216) and the combined intervention group (n = 298) were registered for the online program. The participants in the combined intervention group also received weight-related population health management, which included additional support from nonclinical staff who monitored their progress in the online program and conducted periodic outreach. Main Outcomes and Measures  The primary outcome was weight change at 12 months based on measured weights recorded in the electronic health record. Weight change at 18 months was a secondary outcome. Results  Among the 840 participants who enrolled (mean age, 59.3 years [SD, 8.6 years]; 60% female; 76.8% White), 732 (87.1%) had a recorded weight at 12 months and the missing weights for the remaining participants were imputed. There was a significant difference in weight change at 12 months by group with a mean weight change of -1.2 kg (95% CI, -2.1 to -0.3 kg) in the usual care group, -1.9 kg (95% CI, -2.6 to -1.1 kg) in the online program only group, and -3.1 kg (95% CI, -3.7 to -2.5 kg) in the combined intervention group (P &lt; .001). The difference in weight change between the combined intervention group and the usual care group was -1.9 kg (97.5% CI, -2.9 to -0.9 kg; P &lt; .001) and the difference between the combined intervention group and the online program only group was -1.2 kg (95% CI, -2.2 to -0.3 kg; P = .01). At 18 months, the mean weight change was -1.9 kg (95% CI, -2.8 to -1.0 kg) in the usual care group, -1.1 kg (95% CI, -2.0 to -0.3 kg) in the online program only group, and -2.8 kg (95% CI, -3.5 to -2.0 kg) in the combined intervention group (P &lt; .001). Conclusions and Relevance  Among primary care patients with overweight or obesity and hypertension or type 2 diabetes, combining population health management with an online program resulted in a small but statistically significant greater weight loss at 12 months compared with usual care or the online program only. Further research is needed to understand the generalizability, scalability, and durability of these findings. Trial Registration  ClinicalTrials.gov Identifier  NCT02656693.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 Importance  Online programs may help with weight loss but have not been widely implemented in routine primary care. Objective  To compare the effectiveness of a combined intervention, including an online weight management program plus population health management, with the online program only and with usual care. Design, Setting, and Participants  Cluster randomized trial with enrollment from July 19, 2016, through August 10, 2017, at 15 primary care practices in the US. Eligible participants had a scheduled primary care visit and were aged 20 to 70 years, had a body mass index between 27 and less than 40, and had a diagnosis of hypertension or type 2 diabetes. Follow-up ended on May 8, 2019. Interventions  Participants in the usual care group (n = 326) were mailed general information about weight management. Participants in the online program only group (n = 216) and the combined intervention group (n = 298) were registered for the online program. The participants in the combined intervention group also received weight-related population health management, which included additional support from nonclinical staff who monitored their progress in the online program and conducted periodic outreach. Main Outcomes and Measures  The primary outcome was weight change at 12 months based on measured weights recorded in the electronic health record. Weight change at 18 months was a secondary outcome. Results  Among the 840 participants who enrolled (mean age, 59.3 years [SD, 8.6 years]; 60% female; 76.8% White), 732 (87.1%) had a recorded weight at 12 months and the missing weights for the remaining participants were imputed. There was a significant difference in weight change at 12 months by group with a mean weight change of -1.2 kg (95% CI, -2.1 to -0.3 kg) in the usual care group, -1.9 kg (95% CI, -2.6 to -1.1 kg) in the online program only group, and -3.1 kg (95% CI, -3.7 to -2.5 kg) in the combined intervention group (P &lt; .001). The difference in weight change between the combined intervention group and the usual care group was -1.9 kg (97.5% CI, -2.9 to -0.9 kg; P &lt; .001) and the difference between the combined intervention group and the online program only group was -1.2 kg (95% CI, -2.2 to -0.3 kg; P = .01). At 18 months, the mean weight change was -1.9 kg (95% CI, -2.8 to -1.0 kg) in the usual care group, -1.1 kg (95% CI, -2.0 to -0.3 kg) in the online program only group, and -2.8 kg (95% CI, -3.5 to -2.0 kg) in the combined intervention group (P &lt; .001). Conclusions and Relevance  Among primary care patients with overweight or obesity and hypertension or type 2 diabetes, combining population health management with an online program resulted in a small but statistically significant greater weight loss at 12 months compared with usual care or the online program only. Further research is needed to understand the generalizability, scalability, and durability of these findings. Trial Registration  ClinicalTrials.gov Identifier  NCT02656693.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 Importance  Online programs may help with weight loss but have not been widely implemented in routine primary care. Objective  To compare the effectiveness of a combined intervention, including an online weight management program plus population health management, with the online program only and with usual care. Design, Setting, and Participants  Cluster randomized trial with enrollment from July 19, 2016, through August 10, 2017, at 15 primary care practices in the US. Eligible participants had a scheduled primary care visit and were aged 20 to 70 years, had a body mass index between 27 and less than 40, and had a diagnosis of hypertension or type 2 diabetes. Follow-up ended on May 8, 2019. Interventions  Participants in the usual care group (n = 326) were mailed general information about weight management. Participants in the online program only group (n = 216) and the combined intervention group (n = 298) were registered for the online program. The participants in the combined intervention group also received weight-related population health management, which included additional support from nonclinical staff who monitored their progress in the online program and conducted periodic outreach. Main Outcomes and Measures  The primary outcome was weight change at 12 months based on measured weights recorded in the electronic health record. Weight change at 18 months was a secondary outcome. Results  Among the 840 participants who enrolled (mean age, 59.3 years [SD, 8.6 years]; 60% female; 76.8% White), 732 (87.1%) had a recorded weight at 12 months and the missing weights for the remaining participants were imputed. There was a significant difference in weight change at 12 months by group with a mean weight change of -1.2 kg (95% CI, -2.1 to -0.3 kg) in the usual care group, -1.9 kg (95% CI, -2.6 to -1.1 kg) in the online program only group, and -3.1 kg (95% CI, -3.7 to -2.5 kg) in the combined intervention group (P &lt; .001). The difference in weight change between the combined intervention group and the usual care group was -1.9 kg (97.5% CI, -2.9 to -0.9 kg; P &lt; .001) and the difference between the combined intervention group and the online program only group was -1.2 kg (95% CI, -2.2 to -0.3 kg; P = .01). At 18 months, the mean weight change was -1.9 kg (95% CI, -2.8 to -1.0 kg) in the usual care group, -1.1 kg (95% CI, -2.0 to -0.3 kg) in the online program only group, and -2.8 kg (95% CI, -3.5 to -2.0 kg) in the combined intervention group (P &lt; .001). Conclusions and Relevance  Among primary care patients with overweight or obesity and hypertension or type 2 diabetes, combining population health management with an online program resulted in a small but statistically significant greater weight loss at 12 months compared with usual care or the online program only. Further research is needed to understand the generalizability, scalability, and durability of these findings. Trial Registration  ClinicalTrials.gov Identifier  NCT02656693.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocardit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocard</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">cardit</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Coagulopathies,
 OBJECTIVES  Long-term durability of bioprosthetic valves is predominantly limited by structural valve deterioration. RESILIA tissue has exhibited reduced calcification in pre-clinical and early clinical studies. This study evaluated the 5-year clinical and haemodynamic outcomes of an aortic valve with this tissue. METHODS  This was a prospective, non-randomized, single-arm study of 133 patients implanted with a RESILIA aortic bioprosthesis between July 2011 and February 2013 at 2 sites in Poland. Clinical outcomes and haemodynamic performance were assessed annually for 5 years post-implant. Safety events were adjudicated by a Clinical Events Committee and echocardiographic data were assessed by an independent core laboratory. RESULTS  Mean patient age was 65.3 +/- 13.5 years, with 34 patients (25.6%) &lt;/=60. The mean follow-up was 4.2 +/- 1.5 years. Early (&lt;/=30 days) and late (&gt;30 days) all-cause mortality were 2.3% (N = 3) and 3.2%/late patients-years (N = 18) respectively. Early events included thromboembolism in 3 patients (2.3%). Late valve-related events included endocarditis in 1 patient, which led to explant, and valve thrombosis in another patient. There were no events of structural valve deterioration throughout the study. At 5 years, mean gradient was 14.8 +/- 7.6 mmHg and effective orifice area was 1.4 +/- 0.5 cm2, a marked improvement over baseline values. All New York Heart Association class III patients and most class II patients at baseline had improved classifications at 5 years. CONCLUSIONS  The bioprosthesis with RESILIA tissue demonstrated a good safety profile with excellent haemodynamic performance over 5 years of follow-up. These encouraging outcomes warrant additional investigation of this novel tissue. CLINICAL TRIAL REGISTRATION NUMBER  NCT01651052.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocardit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocard</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">cardit</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Coagulopathies,
 OBJECTIVES  Long-term durability of bioprosthetic valves is predominantly limited by structural valve deterioration. RESILIA tissue has exhibited reduced calcification in pre-clinical and early clinical studies. This study evaluated the 5-year clinical and haemodynamic outcomes of an aortic valve with this tissue. METHODS  This was a prospective, non-randomized, single-arm study of 133 patients implanted with a RESILIA aortic bioprosthesis between July 2011 and February 2013 at 2 sites in Poland. Clinical outcomes and haemodynamic performance were assessed annually for 5 years post-implant. Safety events were adjudicated by a Clinical Events Committee and echocardiographic data were assessed by an independent core laboratory. RESULTS  Mean patient age was 65.3 +/- 13.5 years, with 34 patients (25.6%) &lt;/=60. The mean follow-up was 4.2 +/- 1.5 years. Early (&lt;/=30 days) and late (&gt;30 days) all-cause mortality were 2.3% (N = 3) and 3.2%/late patients-years (N = 18) respectively. Early events included thromboembolism in 3 patients (2.3%). Late valve-related events included endocarditis in 1 patient, which led to explant, and valve thrombosis in another patient. There were no events of structural valve deterioration throughout the study. At 5 years, mean gradient was 14.8 +/- 7.6 mmHg and effective orifice area was 1.4 +/- 0.5 cm2, a marked improvement over baseline values. All New York Heart Association class III patients and most class II patients at baseline had improved classifications at 5 years. CONCLUSIONS  The bioprosthesis with RESILIA tissue demonstrated a good safety profile with excellent haemodynamic performance over 5 years of follow-up. These encouraging outcomes warrant additional investigation of this novel tissue. CLINICAL TRIAL REGISTRATION NUMBER  NCT01651052.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischaem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,
 Impaired oxygen and cellular metabolism is a hallmark of ischaemic injury in acute stroke. Magnetic resonance spectroscopic imaging (MRSI) has long been recognized as a potentially powerful tool for non-invasive metabolic imaging. Nonetheless, long acquisition time, poor spatial resolution, and narrow coverage have limited its clinical application. Here we investigated the feasibility and potential clinical utility of rapid, high spatial resolution, near whole-brain 3D metabolic imaging based on a novel MRSI technology. In an 8-min scan, we simultaneously obtained 3D maps of N-acetylaspartate and lactate at a nominal spatial resolution of 2.0 x 3.0 x 3.0 mm3 with near whole-brain coverage from a cohort of 18 patients with acute ischaemic stroke. Serial structural and perfusion MRI was used to define detailed spatial maps of tissue-level outcomes against which high-resolution metabolic changes were evaluated. Within hypoperfused tissue, the lactate signal was higher in areas that ultimately infarcted compared with those that recovered (P &lt; 0.0001). Both lactate (P &lt; 0.0001) and N-acetylaspartate (P &lt; 0.001) differed between infarcted and other regions. Within the areas of diffusion-weighted abnormality, lactate was lower where recovery was observed compared with elsewhere (P &lt; 0.001). This feasibility study supports further investigation of fast high-resolution MRSI in acute stroke.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Objectives Cardiovascular diseases are major causes of non-infectious diseases globally. The use of pesticides has been linked with the high global burden of non-communicable diseases. Despite the indiscriminate exposure to dichlorvos (DDVP) by inhalation, no report exists on its possible cardiotoxic effect. This study investigated the cardiotoxicity of DDVP exposure by inhalation and the possible role of Moringa oleifera seed oil. Methods Twenty-one male rats were randomly assigned into 3 groups. Group A (control) received only standard rat diet and water ad&#39; libitum, group B (DDVP) was exposed to DDVP via inhalation for 15 min daily in addition to rat diet and water, and group C (DDVP + M. oleifera seed oil) received treatment as group B as well as 300 mg/kg of M. oleifera seed oil p.o for 28 days. Results Significant reductions in body weight gain and cardiac weight were observed in DDVP-exposed animals (p&lt;0.05). Similarly, 28 days of exposure to DDVP led to a significant increase in lactate dehydrogenase, creatinine kinase and troponin (p&lt;0.05). DDVP-exposed rats also showed a significant increase in malondialdehyde, and a significant decline in superoxide dismutase and glutathione peroxidase (p&lt;0.05). However, catalase was comparable in DDVP-exposed and control rats. Histopathological observations of the cardiac tissue revealed that DDVP caused marked fat degeneration and necrosis of the myocardial layer. The changes in DDVP-exposed rats were significantly, though not completely, restored by M. oleifera seed oil administration. Conclusions This study provides novel mechanistic information on the cardiotoxicity of DDVP inhalation, and the antioxidant potential of M. oleifera seed oil.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 BACKGROUND  Most adults are not achieving recommended levels of physical activity (150 minutes/week, moderate-to-vigorous intensity). Inadequate activity levels are associated with numerous poor health outcomes, and clinical recommendations endorse physical activity in the front-line treatment of obesity, diabetes, dyslipidemia, and hypertension. A framework for physical activity prescription and referral has been developed, but has not been widely implemented. This may be due, in part, to the lack of feasible and effective physical activity intervention programs designed to coordinate with clinical care delivery. OBJECTIVE  This manuscript describes the protocol for a pilot randomized controlled trial (RCT) that tests the efficacy of a 13-week online intervention for increasing physical activity in adult primary care patients (aged 21-70 years) reporting inadequate activity levels. The feasibility of implementing specific components of a physical activity clinical referral program, including screening for low activity levels and reporting patient program success to referring physicians, will also be examined. Analyses will include participant perspectives on maintaining physical activity. METHODS  This pilot study includes a 3-month wait-listed control RCT (1 1 ratio within age strata 21-54 and 55-70 years). After the RCT primary end point at 3 months, wait-listed participants are offered the full intervention and all participants are followed to 6 months after starting the intervention program. Primary RCT outcomes include differences across randomized groups in average step count, moderate-to-vigorous physical activity, and sedentary behavior (minutes/day) derived from accelerometers. Maintenance of physical activity changes will be examined for all participants at 6 months after the intervention start. RESULTS  Recruitment took place between October 2018 and May 2019 (79 participants were randomized). Data collection was completed in February 2020. Primary data analyses are ongoing. CONCLUSIONS  The results of this study will inform the development of a clinical referral program for physical activity improvement that combines an online intervention with clinical screening for low activity levels, support for postintervention behavior maintenance, and feedback to the referring physician. TRIAL REGISTRATION  ClinicalTrials.gov NCT03695016; https //clinicaltrials.gov/ct2/show/NCT03695016. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)  DERR1-10.2196/18891.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">rhe</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,
 BACKGROUND  Systemic lupus erythematosus is a systemic autoimmune disease, which is associated with high cardiovascular risk, a predisposition to metabolic disorders, muscle wasting, and fatigue. Exercise therapy has become an important part of the long-term treatment of comorbidities in systemic lupus erythematosus. Exercise can lead to various benefits in patients with systemic lupus erythematosus such as increased aerobic capacity and exercise tolerance, resulting in an increased quality of life, decreased depression, and decreased fatigue. At the moment, no evidence-based treatment guidelines that recommend exercise for patients with systemic lupus erythematosus exist. Also, the efficacy of different training programs requires further investigation. OBJECTIVE  This study focuses on the feasibility, efficacy, and safety of an internet-based exercise program in patients with systemic lupus erythematosus. Furthermore, we investigate the feasibility and efficiency of anaerobic training compared to aerobic training. METHODS  Overall, patients with systemic lupus erythematosus from the Division of Nephrology, Rheumatology, and Immunology outpatient clinic of the University Medical Center Mainz who are clinically stable status are included and randomized in an aerobic exercise group (n=10), anaerobic exercise group (n=10), or treatment as usual group (n=10). After completing initial clinical testing and physical fitness tests, patients undergo supervised 12-week online exercise programs, receiving weekly individualized training plans adapted to their physical performance. The primary outcome is change in physical fitness (VO2 peak) after 12 weeks compared to baseline. Secondary outcomes are disease activity measured via laboratory results (complement, autoantibodies) and questionnaires, as well as changes in muscle mass (anaerobic exercise group), results of the Chair-Stand test, and measurements of circulating cell-free DNA and extracellular vesicles. RESULTS  The study was registered in May 2019. Enrollment began in May 2019. Of 40 patients who were initially screened, 30 patients fulfilled the inclusion criteria and were included in the study; 1 participant withdrew prior to the start of the exercise program. Among the 25 patients who completed the study, no serious adverse events have been reported; 3 participants withdrew during the program (due to frequent colds, n=1; Crohn relapse, n=1; physical strain, n=1), and 1 participant has not yet completed the program. Data analysis is ongoing, and results are expected to be submitted for publication in January 2021. CONCLUSIONS  We expect the online exercise intervention to be a feasible and efficient tool to provide regular individualized exercise for patients with systemic lupus erythematosus. TRIAL REGISTRATION  ClinicalTrials.gov NCT03942718; http //clinicaltrials.gov/ct2/show/NCT03942718. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)  DERR1-10.2196/18291.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  To improve health outcomes in patients with heart failure, guideline-directed medical therapy (GDMT) should be optimized to target doses. However, GDMT remains underutilized, with less than25% of patients receiving target doses in clinical practice. Telemonitoring could provide reliable and real-time physiological data for clinical decision support to facilitate remote GDMT titration. OBJECTIVE  This paper aims to present findings from an internal pilot study regarding the effectiveness of remote titration facilitated by telemonitoring. METHODS  A 2-arm randomized controlled pilot trial comparing remote titration versus standard care in a heart function clinic was conducted. Patients were randomized to undergo remote medication titration facilitated by data from a smartphone-based telemonitoring system or standard titration performed during clinic visits. RESULTS  A total of 42 patients with new-onset (10/42, 24%) and existing (32/42, 76%) heart failure and a mean age of 55.29 (SD 11.28) years were randomized between January and June 2019. Within 6 months of enrollment, 86% (18/21) of patients in the intervention group achieved optimal doses versus 48% (10/21) of patients in the control group. The median time to dose optimization was 11.0 weeks for the intervention group versus 18.8 weeks for the control group. The number of in-person visits in the intervention group was 54.5% lower than in the control group. CONCLUSIONS  The results of this pilot study suggest that remote titration facilitated by telemonitoring has the potential to increase the proportion of patients who achieve optimal GDMT doses, decrease time to dose optimization, and reduce the number of clinic visits. Remote titration may facilitate optimal and efficient titration of patients with heart failure while reducing the burden for patients to attend in-person clinic visits. TRIAL REGISTRATION  ClinicalTrials.gov NCT04205513; https //clinicaltrials.gov/ct2/show/NCT04205513. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)  RR2-10.2196/preprints.19705.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  Cardiac rehabilitation participants are encouraged to meet physical activity guidelines to reduce the risk of repeat cardiac events. However, previous studies have found that physical activity levels are low and sedentary behavior is high, both during and after cardiac rehabilitation. There is potential for smartphone apps to be effective in reducing sedentary behavior, although among the few studies that have investigated smartphone apps in cardiac rehabilitation, none targeted sedentary behavior. OBJECTIVE  This study aims to evaluate the feasibility of a behavioral smartphone app (Vire) and a web-based behavior change program (ToDo-CR) to decrease sedentary behavior in cardiac rehabilitation participants. METHODS  Using a single-center, pre-post design, participants were recruited by nursing staff on admission to cardiac rehabilitation. All eligible participants installed the Vire app, were given a Fitbit Flex, and received the 6-week ToDo-CR program while attending cardiac rehabilitation. The ToDo-CR program uses personalized analytics to interpret important behavioral aspects (physical activity, variety, and social opportunity) and real-time information for generating and suggesting context-specific actionable microbehavioral alternatives (Do&#39;s). Do&#39;s were delivered via the app, with participants receiving 14 to 19 Do&#39;s during the 6-week intervention period. Outcome measures were collected at 0, 6, and 16 weeks. The assessors were not blinded. Feasibility outcomes included recruitment and follow-up rates, resource requirements, app usability (Unified Theory of Acceptance and Use of Technology 2 [UTAUT2] questionnaire), and objectively measured daily minutes of sedentary behavior (ActiGraph) for sample size estimation. Secondary outcomes included functional aerobic capacity (6-min walk test), quality of life (MacNew Heart Disease Health-Related Quality of Life Questionnaire), anxiety and depression (Hospital Anxiety and Depression Scale questionnaire), BMI, waist circumference, waist-to-hip ratio, and blood pressure. RESULTS  Between January and May 2019, 20 participants were recruited consecutively. One-third of people who commenced cardiac rehabilitation were eligible to participate. Other than declining to take part in the study (15/40, 38%), not having a smartphone was a major reason for exclusion (11/40, 28%). Those excluded without a smartphone were significantly older than participants with a smartphone (mean difference 20 [SD 5] years; P&lt;.001). Participants were, on average, aged 54 (SD 13) years, mostly male (17/20, 85%), and working (12/20, 67%). At 6 weeks, 95% (19/20) of participants were assessed, and 60% (12/20) of participants were assessed at 16 weeks. Participants were relatively satisfied with the usability of the app (UTAUT2 questionnaire). Overall, participants spent 11 to 12 hours per day sitting. There was a medium effect size (Cohen d=0.54) for the reduction in sedentary behavior (minutes per day) over 16 weeks. CONCLUSIONS  The use of a behavioral smartphone app to decrease sitting time appears to be feasible in cardiac rehabilitation. A larger randomized controlled trial is warranted to determine the effectiveness of the app.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">rhe</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Human activities in the areas of high altitude have increased significantly recently. Brain is highly sensitive to changing of oxygen pressure due to high altitude, and this physiological response may lead to serious brain injury, such as learning and memory disabilities. Puerarin is a phytoestrogen with many pharmacological activities, such as treatment of neurological disorders. However, most of current drugs can not easily enter brain through the blood-brain barrier (BBB). The nose-to-brain route can bypass BBB for brain-targeting. Here, thermosensitive in situ hydrogels (TISGs) of puerarin were prepared with poloxamers 407, poloxamers 188 and propylene glycol to improve bioavailability and brain targeting. In vitro drug release in simulated nasal fluids, rheological properties and cilia toxicity of puerarin TISGs were explored. The pharmacodynamics and pharmacokinetics of puerarin by intranasal (i.n.) and oral (p.o.) administrations were also evaluated. The viscosity of puerarin TISGs tended to increase obviously with increased temperature. The puerarin release profile and transmucosal process of puerarin TISGs could be described with the first-order kinetics equation, depending on drug diffusion. The cilia toxicity of puerarin TISGs was not obvious. Rat models of hypobarism/hypoxia-induced brain injury were established with a hypobaric simulation chamber. Morris water maze and open filed tests indicated that puerarin TISGs improved the spatial memory and spontaneous exploratory behavior of the rats suffering from hypoxia-induced brain injury. Furthermore, puerarin TISGs decreased the level of oxidative stress cytokines (malondialdehyde (MDA) and glutathione (GSH)) in the peripheral circulation, alleviated the cerebral histological lesions, and relieved the expression of hypoxia-inducible factor-1alpha (HIF-1alpha). Intranasal puerarin TISGs were absorbed quickly with a shorter Tmax (10.0 +/- 5.7 min) compared to that of oral puerarin (36 +/- 13.4 min). In addition, the relative bioavailability of i.n. puerarin TISGs was high to 300% compared to oral administration of puerarin. The area under the curve (AUC) of brain after i.n. administration of puerarin TISGs was 954.5 +/- 335.1 h.ng/mL, while no puerarin was detected in the brain after oral administration. Therefore, i.n. puerarin TISGs led to excellent brain targeting effect. Puerarin TISGs are an effective neuroprotector formulation for prevention of brain injury induced by acute high-altitude hypoxia.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,
 Ischemic preconditioning (IP) reduces brain damage after subsequent ischemic strokes by activating endogenous protective mechanisms in rodents. Transient ischemic attack (TIA) induces tolerance in the human brain after ischemic strokes; defining mechanisms of IP effects may provide therapeutic targets to improve recovery of patients with ischemic strokes. Iron transported across the blood-brain barrier (BBB) is required for brain functions, including myelination, and its levels should be finely regulated to avoid harmful effects. This study aimed to determine whether IP enhances repair processes by modulating iron metabolism during the post-stroke chronic phase. Male mice were divided into sham and IP groups, and IP was induced 24 h before a transient focal ischemic stroke. Sensorimotor recovery was observed over 8 weeks after the stroke, and brain volumes and levels of proteins related to repair processes and iron metabolism in the ischemic brains were examined 8 weeks after the stroke. There was significantly less ischemic brain atrophy in the IP group than in the sham group, with no differences in sensorimotor recovery between the groups. Levels of tight junction proteins of BBB, neurites outgrowth markers, and myelin sheath proteins and markers for mature oligodendrocytes were significantly increased in the IP group. Iron import proteins, transferrin receptor 1 and DMT1, were also increased in the IP group. These results indicate that IP increases brain repair processes and iron uptake during the chronic phase after an ischemic stroke, and provide new insights to understand the molecular mechanisms of TIA effects on post-stroke recovery.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 The progression of cardiovascular research is often impeded by the lack of reliable disease models that fully recapitulate the pathogenesis in humans. These limitations apply to both in vitro models such as cell-based cultures and in vivo animal models which invariably are limited to simulate the complexity of cardiovascular disease in humans. Implementing human heart tissue in cardiovascular research complements our research strategy using preclinical models. We established the Human Explanted Heart Program (HELP) which integrates clinical, tissue and molecular phenotyping thereby providing a comprehensive evaluation into human heart disease. Our collection and storage of biospecimens allow them to retain key pathogenic findings while providing novel insights into human heart failure. The use of human non-failing control explanted hearts provides a valuable comparison group for the diseased explanted hearts. Using HELP we have been able to create a tissue repository which have been used for genetic, molecular, cellular, and histological studies. This review describes the process of collection and use of explanted human heart specimens encompassing a spectrum of pediatric and adult heart diseases, while highlighting the role of these invaluable specimens in translational research. Furthermore, we highlight the efficient procurement and bio-preservation approaches ensuring analytical quality of heart specimens acquired in the context of heart donation and transplantation.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlud</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Diseases of arteries,
 AIM  We previously reported the protective effects of biscoumarin derivatives against oxidative stress, but effects of the derivative on mitochondrial oxidative damage induced apoptosis in ischemic stroke remains unknown. METHODS  Primary neurons were subjected to oxygen and glucose deprivation (OGD) for the in vitro simulation of ischemic stroke, and an ischemic stroke model was established in mice by operation of middle cerebral artery occlusion (MCAO). RESULTS  The results indicated that the nontoxic concentration range of biscoumarin derivative Comp. B in neurons was from 0 to 30 mug/ml and the optimal protective concentration was 20 mug/ml. Treatment with Comp. B increased the cell survival rate and alleviated mitochondrial oxidative damage and apoptosis in OGD-treated neurons. Comp. B reduced the ratio of Bax/Bcl-2, inhibited the phosphorylation of ERK, and thus alleviated apoptosis in OGD-treated neurons. Further research demonstrated that the dephosphorylation effect on ERK of Comp. B is a key factor in alleviating apoptosis in neurons induced by OGD injury. Furthermore, Comp. B reduced the infarct volume, improved neurobehavioural score, and alleviated morphological changes and brain apoptosis in MCAO mice. CONCLUSION  The novel biscoumarin derivative Comp. B alleviates mitochondrial oxidative damage and apoptosis in ischemic stroke mice. These findings might provide new insights that will aid in elucidating the effect of biscoumarin derivative against cerebral ischemic reperfusion injury and support the new development of Comp. B as a potential treatment for ischemic stroke.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Inflammatory diseases,
 AIMS  Obesity represents a global health problem. Excessive caloric intake promotes the release of inflammatory mediators by hypertrophic adipocytes and obesity-induced inflammation is now recognized as a risk factor for the development of several diseases, such as cardiovascular diseases, insulin resistance, type-II diabetes, liver steatosis and cancer. Since obesity causes inflammation, we tested the ability of acetylsalicylic acid (ASA), a potent anti-inflammatory drug, in counteracting this inflammatory process and in mitigating obesity-associated health complications. MAIN METHODS  Mice were fed with standard (SD) or high fat diet (HFD) for 3 months and then treated with acetylsalicylic acid for the subsequent two months. We then analyzed the metabolic and inflammatory status of their adipose and liver tissue by histological, molecular and biochemical analysis. KEY FINDINGS  Although ASA did not exert any effect on body weight, quantification of adipocyte size revealed that the drug slightly reduced adipocyte hypertrophy, however not sufficient so as to induce weight loss. Most importantly, ASA was able to improve insulin resistance. Gene expression profiles of pro- and anti-inflammatory cytokines as well as the expression of macrophage and lymphocyte markers revealed that HFD led to a marked macrophage accumulation in the adipose tissue and an increase of several pro-inflammatory cytokines, a situation almost completely reverted after ASA administration. In addition, liver steatosis caused by HFD was completely abrogated by ASA treatment. SIGNIFICANCE  ASA can efficiently ameliorate pathological conditions usually associated with obesity by inhibiting the inflammatory process occurring in the adipose tissue.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,
 Circular RNAs (circRNAs) are a novel class of endogenous non-coding RNAs characterized by a covalently closed-loop structure generated through a special type of alternative splicing termed back-splicing. Currently, an increasing body of evidence has demonstrated that 1) majority of circRNAs are evolutionarily conserved across species, stable, and resistant to RNase R degradation, and often exhibit cell-specific, and tissue-specific/developmental-stage-specific expression and can be largely independent of the expression levels of the linear host gene-encoded linear RNAs; 2) the biogenesis of circRNAs via back-splicing is different from the canonical splicing of linear RNAs; 3) circRNA biogenesis is regulated by specific cis-acting elements and trans-acting factors; 4) circRNAs regulate biological and pathological processes by sponging miRNAs, binding to RNA-binding protein (RBP), regulators of splicing and transcription, modifiers of parental gene expression, and regulators of protein translation or being translated into peptides in various diseases; 5) circRNAs have been identified for their enrichment and stability in exosomes and detected in body fluids such as human blood, saliva, and cerebrospinal fluids, suggesting that these exo-circRNAs have potential applications as disease biomarkers and novel therapeutic targets; 6) several circRNAs are regulated by oxidative stress and mediate reactive oxygen species (ROS) production as well as promote ROS-induced cellular death, cell apoptosis, and inflammation; 7) circRNAs have also emerged as important regulators in atherosclerotic cardiovascular disease, metabolic disease, and cancers; 8) the potential mechanisms of several circRNAs have been described in diseases, hinting at their potential applications as novel therapeutic targets. In this highlight, we summarized the current understandings of the biogenesis and functions of circRNAs and their roles in ROS regulation and vascular inflammation-associated with cardiovascular and metabolic disease. (Word count  272).
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,
 Circular RNAs (circRNAs) are a novel class of endogenous non-coding RNAs characterized by a covalently closed-loop structure generated through a special type of alternative splicing termed back-splicing. Currently, an increasing body of evidence has demonstrated that 1) majority of circRNAs are evolutionarily conserved across species, stable, and resistant to RNase R degradation, and often exhibit cell-specific, and tissue-specific/developmental-stage-specific expression and can be largely independent of the expression levels of the linear host gene-encoded linear RNAs; 2) the biogenesis of circRNAs via back-splicing is different from the canonical splicing of linear RNAs; 3) circRNA biogenesis is regulated by specific cis-acting elements and trans-acting factors; 4) circRNAs regulate biological and pathological processes by sponging miRNAs, binding to RNA-binding protein (RBP), regulators of splicing and transcription, modifiers of parental gene expression, and regulators of protein translation or being translated into peptides in various diseases; 5) circRNAs have been identified for their enrichment and stability in exosomes and detected in body fluids such as human blood, saliva, and cerebrospinal fluids, suggesting that these exo-circRNAs have potential applications as disease biomarkers and novel therapeutic targets; 6) several circRNAs are regulated by oxidative stress and mediate reactive oxygen species (ROS) production as well as promote ROS-induced cellular death, cell apoptosis, and inflammation; 7) circRNAs have also emerged as important regulators in atherosclerotic cardiovascular disease, metabolic disease, and cancers; 8) the potential mechanisms of several circRNAs have been described in diseases, hinting at their potential applications as novel therapeutic targets. In this highlight, we summarized the current understandings of the biogenesis and functions of circRNAs and their roles in ROS regulation and vascular inflammation-associated with cardiovascular and metabolic disease. (Word count  272).
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Coagulopathies,
 This article describes a clinical case of exacerbation of chronic right-sided epimesotimpanitis, complicated by secondary otogenic purulent meningoencephalitis, an abscess of the right hemisphere of the cerebellum and septic thrombosis of the sigmoid sinus. This is a rare complication of chronic epimesotimpanitis. The article describes the dynamics of treatment and diagnostic justifies the optimal choice of personalized tactics of treatment measures in the hospital, as well as further observation of the patient in the conditions of outpatient health care.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,
 Doxorubicin is a commonly used anthracycline chemotherapeutic drug. Its application for treatment has been impeded by its cardiotoxicity as it is detrimental and fatal. DNA damage, cardiac inflammation, oxidative stress and cell death are the critical links in DOX-induced myocardial injury. Previous studies found that TLR9-related signalling pathways are associated with the inflammatory response of cardiac myocytes, mitochondrial dysfunction and cardiomyocyte death, but it remains unclear whether TLR9 could influence DOX-induced heart injury. Our current data imply that DOX-induced cardiotoxicity is ameliorated by TLR9 deficiency both in vivo and in vitro, manifested as improved cardiac function and reduced cardiomyocyte apoptosis and oxidative stress. Furthermore, the deletion of TLR9 rescued DOX-induced abnormal autophagy flux in vivo and in vitro. However, the inhibition of autophagy by 3-MA abolished the protective effects of TLR9 deletion on DOX-induced cardiotoxicity. Moreover, TLR9 ablation suppressed the activation of p38 MAPK during DOX administration and may promote autophagy via the TLR9-p38 MAPK signalling pathway. Our study suggests that the deletion of TLR9 exhibits a protective effect on doxorubicin-induced cardiotoxicity by enhancing p38-dependent autophagy. This finding could be used as a basis for the development of a prospective therapy against DOX-induced cardiotoxicity.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">microvascul</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Diseases of arteries,
 BACKGROUND  There are limited data available regarding the use of diastolic deceleration time (DDT) of three major arteries measured by transthoracic echocardiography (TTE) for assessing coronary microvascular damage after acute myocardial infarction (AMI). Therefore, we aimed to compare the DDT of three major arteries using TTE with the transmural extent of infarction (TEI) and infarct size, which were classified using contrast-enhanced magnetic resonance imaging (CE-MRI), in patients with AMI. METHODS  The DDT of the culprit coronary artery was measured in 74 patients using TTE and CE-MRI 1 week after the onset of AMI. The TEI was graded based on the transmural extent of the hyper-enhanced tissue (grades 1-4). RESULTS  The assessable rate for the DDT was 95%; individual rates were 100% for the left anterior descending coronary artery, 90% for the left circumflex artery, and 93% for the right coronary artery. The DDT decreased gradually as the TEI grade progressed (P = .021). Infarct size was significantly correlated with the DDT (r = -0.51, P &lt; .0001). Univariate analysis revealed that the left ventricular (LV) end-systolic volume, LV ejection fraction, and DDT were significantly associated with TEI grade 4. After adjustment via multiple logistic regression analysis, the DDT was independently remained. With a cutoff value of 950ms, as determined by the ROC curve, DDT could detect TEI grade 4 with 81.1% sensitivity and 80.1% specificity. CONCLUSION  The DDT of three major coronary arteries measured by TTE 1 week after the onset of AMI can assess the extent of myocardial damage, which is determined by CE-MRI.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 The physiological response to high-level endurance exercise, such as running a marathon, poses several beneficial but also potentially harmful metabolic changes. The objective of this study was to determine the impact of marathon (M) and ultra-marathon (UM) on inflammation and iron homeostasis in paired samples. Fifteen well-trained, non-professional endurance athletes (14 males, 1 female) performed both a 130 km ultra-marathon and a traditional 42.195 km marathon. We determined markers of inflammation and iron homeostasis before, immediately after, and within five days after finishing each run, respectively. Biomarkers of inflammation (leucocytes, neutrophil granulocytes, monocytes and c-reactive protein [CRP]) increased significantly after both marathon and ultra-marathon with higher levels of CRP after ultra-marathon compared to marathon both immediately after the race (18.15 +/- 12.41 vs 5.58 +/-9.65 mg/L, p &lt; 0.001) and at follow-up (15.67 +/- 16.97 vs 7.19 +/- 7.75 mg/L, p = 0.045) Concentrations of ferritin also increased significantly after both races and remained high at follow-up. Higher levels of ferritin immediately after the race (111.5 +/- 103.2 vs 84.8 +/- 86.3, p = 0.001) and at follow-up (102.7+/- 79.5 vs 74.6 +/- 65.6, p = 0.001) were found in ultra-marathon finishers. The observed increase of serum iron and transferrin saturation (TSAT) after marathon and the decrease of serum iron and TSAT after ultra-marathon resulted in a significant absolute difference between the two races. The present data suggest a higher degree of inflammation after ultra-marathon compared to marathon. Markers of iron homeostasis also showed different response patterns with regards to running distance.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,Coagulopathies,
 AIM  This meta-analysis was carried out to explore if a personalized antiplatelet strategy based on genotyping is superior to conventional therapy. METHODS  PubMed, Web of Science, EMBASE, and the Cochrane Library were searched from the inception of each database to May 5, 2020. Studies reporting endpoints in genotype-guided treatment group and conventional treatment group were included. The endpoint results were presented as the risk ratio (RR), with 95 % confidence interval (CI). RESULTS  A total of 10,561 patients from 16 studies (8 randomized controlled trials [RCT] and 8 cohort studies) were included in the meta-analysis. The rates of major adverse cardiovascular events (MACE), stent thrombosis, and myocardial infarction (MI) were significantly lower in the genotype-guided group than in the conventional treatment group (RR  0.56, 95 % CI  0.44-0.73, p &lt; 0.0001; RR  0.40, 95 % CI  0.24-0.67, p = 0.0005; RR  0.45, 95 % CI  0.35-0.58, p &lt; 0.00001, respectively). A significant difference was found between the two groups in major bleeding (RR  0.73, 95 % CI  0.55-0.98, p = 0.04), which was not robust after sensitivity analysis. CONCLUSION  Genotype-guided antiplatelet treatment could decrease the risk of MACE, stent thrombosis, and MI in patients with coronary artery disease or undergoing PCI, without increasing the risk of bleeding over a long follow-up period. The decreased risk of efficacy outcomes was more obvious in cohort studies. Well-organized RCTs and clinical trials are required to verify the benefit of genotype-guided therapy.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">microvascul</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlud</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Diseases of arteries,
 BACKGROUND AND PURPOSE  Pulmonary veno-occlusive disease (PVOD) is a rare disease characterized by the obstruction of small pulmonary veins leading to pulmonary hypertension. However, the mechanisms underlying pulmonary vessel occlusion remain largely unclear. EXPERIMENTAL APPROACH  A mitomycin C (MMC)-induced PVOD rat model was used as in vivo animal model; and primarily cultured rat pulmonary microvascular endothelial cells (PMVECs) were used as in vitro cell model. RESULTS  Our data suggested an endothelial-to-mesenchymal transition (EndoMT) may be present in the pulmonary microvessels isolated from either PVOD patients or MMC-induced PVOD rats. In compare to the control vessels, vessels from both PVOD patients and PVOD rats represented co-localized staining of specific endothelial marker von Willebrand factor (vWF) and mesenchymal marker alpha-smooth muscle actin (alpha-SMA), suggesting the presence of cells that co-express endothelial and mesenchymal markers. Then, in both the lung tissues of MMC-induced PVOD rats and MMC-treated rat PMVECs, decreased levels of endothelial markers (e.g. VE-cadherin, CD31) and increased mesenchymal markers (e.g. Vimentin, Fibronectin, alpha-SMA) were detected, also indicating EndoMT. Moreover, MMC induced activation of the TGFbeta/Smad3/Snail axis, while blockage of this pathway with either specific Smad3 inhibitor (SIS3) or small interfering RNA (siRNA) against Smad3, both dramatically abolished the MMC-induced EndoMT. Notably, treatment with SIS3 remarkably prevented the pathogenesis of MMC-induced PVOD in rats. CONCLUSIONS  Our data indicated that targeted inhibition of Smad3 leads to a potential, novel strategy for PVOD therapy, likely by inhibiting the EndoMT in pulmonary microvasculature.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Coagulopathies,
 New oral anticoagulants (NOACs) is the preferred treatment in secondary prophylaxis of venous thromboembolic events (VTE). The aim of this study was to investigate possible risk factors associated with major bleeding in VTE-patients treated with NOACs. In this retrospective register-based study we screened the Swedish anticoagulation register Auricula (during 2012.01.01-2017.12.31) to find patients and used other national registers for outcomes. Primary endpoint was major bleeding defined as bleeding leading to hospital care. Multivariate Cox-regression analysis was used to reveal risk factors. 18 219 patients with NOAC due to VTE were included. 85.6% had their first VTE, mean age was 69.4 years and median follow-up time was 183 days. The most common NOAC was rivaroxaban (54.8%), followed by apixaban (42.0%), dabigatran (3.2%) and edoxaban (0.1%). The rate of major bleeding was 6.62 (95% CI 6.19-7.06) per 100 treatment years in all patients and 11.27 (CI 9.96-12.57) in patients above 80 years of age. Statistically independent risk factors associated with major bleeding were age (normalized HR 1.38, CI 1.27-1.50), earlier major bleeding (HR 1.58, Cl 1.09-2.30), COPD (HR 1.28, CI 1.04-1.60) and previous stroke (HR 1.28, Cl 1.03-1.58) or transient ischemic attack (TIA) (HR 1.33, Cl 1.01-1.76). Prior warfarin treatment was protective (HR 0.67, CI 0.58-0.78). This real world cohort shows a high bleeding rate especially among the elderly and in patients with previous major bleeding, COPD and previous stroke or TIA. This should be considered when deciding on treatment duration and NOAC dose in these patients.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">cerebrovascul</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 BACKGROUND  This study was to assess the prognostic value of Fasting Blood Glucose to HDL-C Ratio (GHR) in non-diabetic patients with CAD undergoing PCI. Methods and Results  6645 non-diabetic patients from two independent cohort the CORFCHD-PCI study (n=4282) and the CORFCHD-ZZ (n=2363) study were enrolled in Clinical Outcomes and Risk Factors of Patients with Coronary Heart Disease after PCI, Patients were divided into two groups according to the GHR value. The primary outcome included all-cause mortality (ACM) and cardiac mortality (CM). The average follow-up time was 36.51+/-22.50 months. We found that there were significant differences between the two groups in the incidences of ACM (P =0.013) and CM (P=0.038). Multivariate Cox regression analysis revealed GHR as an independent prognostic factor for ACM. The incidence of ACM increased 1.284 times in patients in the higher GHR group (hazard ratio [HR] 1.284 [95% confidence interval [CI] 1.010-1.631], P &lt;0.05). Kaplan-Meier survival analysis suggested that patients with high GHR value tended to have an increased accumulated risk of ACM. However, we did not found significant differences in the incidence of major adverse cardiac events, main adverse cardiovascular and cerebrovascular events (MACCE), stroke, recurrent MI, bleeding events. CONCLUSIONS  This study indicates that GHR index is an independent and novel predictor of ACM in non-diabetic CAD patients who underwent PCI.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  Loss of arm function is common after stroke. Robot-assisted training may improve arm outcomes. OBJECTIVE  The objectives were to determine the clinical effectiveness and cost-effectiveness of robot-assisted training, compared with an enhanced upper limb therapy programme and with usual care. DESIGN  This was a pragmatic, observer-blind, multicentre randomised controlled trial with embedded health economic and process evaluations. SETTING  The trial was set in four NHS trial centres. PARTICIPANTS  Patients with moderate or severe upper limb functional limitation, between 1 week and 5 years following first stroke, were recruited. INTERVENTIONS  Robot-assisted training using the Massachusetts Institute of Technology-Manus robotic gym system (InMotion commercial version, Interactive Motion Technologies, Inc., Watertown, MA, USA), an enhanced upper limb therapy programme comprising repetitive functional task practice, and usual care. MAIN OUTCOME MEASURES  The primary outcome was upper limb functional recovery &#39;success&#39; (assessed using the Action Research Arm Test) at 3 months. Secondary outcomes at 3 and 6 months were the Action Research Arm Test results, upper limb impairment (measured using the Fugl-Meyer Assessment), activities of daily living (measured using the Barthel Activities of Daily Living Index), quality of life (measured using the Stroke Impact Scale), resource use costs and quality-adjusted life-years. RESULTS  A total of 770 participants were randomised (robot-assisted training, n = 257; enhanced upper limb therapy, n = 259; usual care, n = 254). Upper limb functional recovery &#39;success&#39; was achieved in the robot-assisted training [103/232 (44%)], enhanced upper limb therapy [118/234 (50%)] and usual care groups [85/203 (42%)]. These differences were not statistically significant; the adjusted odds ratios were as follows  robot-assisted training versus usual care, 1.2 (98.33% confidence interval 0.7 to 2.0); enhanced upper limb therapy versus usual care, 1.5 (98.33% confidence interval 0.9 to 2.5); and robot-assisted training versus enhanced upper limb therapy, 0.8 (98.33% confidence interval 0.5 to 1.3). The robot-assisted training group had less upper limb impairment (as measured by the Fugl-Meyer Assessment motor subscale) than the usual care group at 3 and 6 months. The enhanced upper limb therapy group had less upper limb impairment (as measured by the Fugl-Meyer Assessment motor subscale), better mobility (as measured by the Stroke Impact Scale mobility domain) and better performance in activities of daily living (as measured by the Stroke Impact Scale activities of daily living domain) than the usual care group, at 3 months. The robot-assisted training group performed less well in activities of daily living (as measured by the Stroke Impact Scale activities of daily living domain) than the enhanced upper limb therapy group at 3 months. No other differences were clinically important and statistically significant. Participants found the robot-assisted training and the enhanced upper limb therapy group programmes acceptable. Neither intervention, as provided in this trial, was cost-effective at current National Institute for Health and Care Excellence willingness-to-pay thresholds for a quality-adjusted life-year. CONCLUSIONS  Robot-assisted training did not improve upper limb function compared with usual care. Although robot-assisted training improved upper limb impairment, this did not translate into improvements in other outcomes. Enhanced upper limb therapy resulted in potentially important improvements on upper limb impairment, in performance of activities of daily living, and in mobility. Neither intervention was cost-effective. FUTURE WORK  Further research is needed to find ways to translate the improvements in upper limb impairment seen with robot-assisted training into improvements in upper limb function and activities of daily living. Innovations to make rehabilitation programmes more cost-effective are required. LIMITATIONS  Pragmatic inclusion criteria led to the recruitment of some participants with little prospect of recovery. The attrition rate was higher in the usual care group than in the robot-assisted training or enhanced upper limb therapy groups, and differential attrition is a potential source of bias. Obtaining accurate information about the usual care that participants were receiving was a challenge. TRIAL REGISTRATION  Current Controlled Trials ISRCTN69371850. FUNDING  This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 54. See the NIHR Journals Library website for further project information.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">effus</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">pericard</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">restrict cardiomyopathy</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Cardiomyopathy,
 BACKGROUND  Percutaneous balloon pericardiotomy is a percutaneous procedure that creates a window in the parietal pericardium by balloon dilation. The use of percutaneous balloon pericardiotomy has not been reported well in children. OBJECTIVES  The objective of this study was to describe the single centre experience of percutaneous balloon pericardiotomy in children. METHODS  This was a retrospective study to describe all the children aged &lt;20 years undergoing percutaneous balloon pericardiotomy during an 18-year period (2001-2019). Patient characteristics, technical and ultimate procedural success, and repeat interventions were collected. RESULTS  A total of 13 percutaneous balloon pericardiotomy&#39;s were performed in 11 children at the median age of 12 years (range 1.8-19). The etiologies of pericardial effusion were post-pericardiotomy syndrome (n = 4), restrictive cardiomyopathy (n = 1), autoimmune diseases (n = 3), malignancy (n = 2), and idiopathic (n = 1). Two patients received two percutaneous balloon pericardiotomy. The technical success of percutaneous balloon pericardiotomy was 100% with no acute adverse events (balloon rupture or local bleeding). Five (45%) required re-intervention and ultimately three required a surgical pericardial window 6 to 35 days after the percutaneous balloon pericardiotomy. As a result, ultimate procedural success rate was 73% (8/11). CONCLUSION  Percutaneous balloon pericardiotomy was performed safely with high technical success in children. Percutaneous balloon pericardiotomy may be considered for recurrent and persistent pericardial effusion, before considering a surgical pericardial window.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 The COVID-19 pandemic is currently ravaging the globe and the African continent is not left out. While the direct effects of the pandemic in regard to morbidity and mortality appear to be more significant in the developed world, the indirect harmful effects on already insufficient healthcare infrastructure on the African continent would in the long term be more detrimental to the populace. Women and children form a significant vulnerable population in underserved areas such as the sub-Saharan region, and expectedly will experience the disadvantages of limited healthcare coverage which is a major fall out of the pandemic. Paediatric cardiac services that are already sparse in various sub-Saharan countries are not left out of this downsizing. Restrictions on international travel for patients out of the continent to seek medical care and for international experts into the continent for regular mission programmes leave few options for children with cardiac defects to get the much-needed care.There is a need for a region-adapted guideline to scale-up services to cater for more children with congenital heart disease (CHD) while providing a safe environment for healthcare workers, patients, and their caregivers. This article outlines measures adapted to maintain paediatric cardiac care in a sub-Saharan tertiary centre in Nigeria during the COVID-19 pandemic and will serve as a guide for other institutions in the region who will inadvertently need to provide these services as the demand increases.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Total anomalous pulmonary venous connection is a rare congenital heart defect. We report an infant with a mixed form of supracardiac TAPVC, in whom all pulmonary veins, except the right upper, entered a pulmonary venous confluence that is connected to a vertical vein and drained into the superior vena caval-right atrial junction. Several segmental right upper pulmonary veins entered the superior vena cava, superior to the entry of the vertical vein. Surgical repair consisted of the Warden procedure combined with direct anastomosis of the vertical vein to the left atrium. Separate pulmonary venous drainage pathways decreased the risk of post-operative pulmonary venous obstruction. Our patient had an uneventful post-operative course and encouraging 2-month follow-up echocardiography. Careful follow-up is warranted to detect post-operative complications, including obstruction of the pulmonary venous and cavoatrial anastomoses.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 INTRODUCTION  Prostaglandin E1 is used to maintain ductal patency in critical congenital heart disease (CHD). The standard starting dose of prostaglandin E1 is 0.05 microg/kg/minute. Lower doses are frequently used, but the efficacy and safety of a low-dose regimen of prostaglandin E1 has not been established. METHODS  We investigated neonates with critical CHD who were started on prostaglandin E1 at 0.01 microg/kg/minute. We reviewed 154 consecutive patients who were separated into three anatomical groups  obstruction to systemic circulation, obstruction to pulmonary circulation, and inadequate mixing (d-transposition of the great arteries). Treatment failure rates and two commonly reported side effects, respiratory depression and seizure, were studied. RESULTS  A total of 26 patients (17%) required a dose increase in prostaglandin E1. Patients with pulmonary obstruction were more likely to require higher doses than patients with systemic obstruction (15/49, 31% versus 9/88, 10%, p = 0.003). Twenty-eight per cent of patients developed respiratory depression and 8% of patients needed mechanical ventilation. Prematurity (&lt;37 week gestation) was the primary risk factor for respiratory depression. No patient required dose escalation or tracheal intubation while on transport. No patient had a seizure attributed to prostaglandin E1. CONCLUSIONS  Prostaglandin E1 at an initial and maintenance dose of 0.01 microg/kg/minute was sufficient to maintain ductal patency in 83% of our cohort. The incidence of respiratory depression requiring mechanical ventilation was low and was mostly seen in premature infants. Starting low-dose prostaglandin E1 at 0.01 microg/kg/minute is a safe and effective therapy for critical CHD.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  Acute Kidney Injury is a complication in children with heart disease undergoing cardiac surgery with cardiopulmonary bypass. The aim of this study is to describe the behavior of KIM-1 (Kidney Injury Molecule) and NGAL (Neutrophil Gelatinase Associated Lipocalin) as early predictors of renal damage, comparing them with serum creatinine and creatinine clearance, in neonates undergoing cardiac surgery. METHODS  Twenty-one (21) neonates, under 4 kg, with complex congenital heart diseases, RACHS-1 &gt; 3, without preoperative renal failure, were studied. Serum creatinine and creatinine clearance were measured preoperatively and at 24, 48, 72, 96 hours postoperatively. Urinary samples of KIM-1(pg/ml) and NGAL (ng/ml) were collected after induction of anesthesia at 24 and 48 hours post-operatively. RESULTS  nRIFLE criteria were used to divide cohorts in &#34;NO AKI&#34; (12 patients) and &#34;AKI&#34; (nine patients). In the AKI group, serum creatinine increased significantly and creatinine clearance decreased significantly at 24, 48, and 72 hours compared with their respective baseline values. There was no difference in KIM-1 and NGAL values between patients who developed AKI and those who did not at any measured time. CONCLUSIONS  The deterioration of renal function continues to be one of the most frequent complications in this population. In our study, biomarkers did not show any correlation with the appearance of AKI. It remains to be seen whether this behavior of the biomarkers is linked with the non-consistent release of these types of molecules in immature kidneys. It is likely that a larger panel of biomarkers together with other glomerular filtration rate assessment methods will provide more information about AKI diagnosis.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">stenos</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 Background The clinical significance of conduction disturbances after transcatheter aortic valve implantation has been described; however, little is known about the influence of baseline ECGs in the prognosis of these patients. Our aim was to study the influence of baseline ECG parameters, including interatrial block (IAB), in the prognosis of patients treated with transcatheter aortic valve implantation. Methods and Results The BIT (Baseline Interatrial Block and Transcatheter Aortic Valve Implantation) registry included 2527 patients with aortic stenosis treated with transcatheter aortic valve implantation. A centralized analysis of baseline ECGs was performed. Patients were divided into 4 groups  normal P wave duration (&lt;120 ms); partial IAB (P wave duration &gt;/=120 ms, positive in the inferior leads); advanced IAB (P wave duration &gt;/=120 ms, biphasic [+/-] morphology in the inferior leads); and nonsinus rhythm (atrial fibrillation/flutter and paced rhythm). The mean age of patients was 82.6+/-9.8 years and 1397 (55.3%) were women. A total of 960 patients (38.0%) had a normal P wave, 582 (23.0%) had partial IAB, 300 (11.9%) had advanced IAB, and 685 (27.1%) presented with nonsinus rhythm. Mean follow-up duration was 465+/-171 days. Advanced IAB was the only independent predictor of all-cause mortality (hazard ratio [HR], 1.48; 95% CI, 1.10-1.98 [P=0.010]) and of the composite end point (death/stroke/new atrial fibrillation) (HR, 1.51; 95% CI, 1.17-1.94 [P=0.001]). Conclusions Baseline ECG characteristics influence the prognosis of patients with aortic stenosis treated with transcatheter aortic valve implantation. Advanced IAB is present in about an eighth of patients and is associated with all-cause death and the composite end point of death, stroke, and new atrial fibrillation during follow-up.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 Adults with intellectual or developmental disabilities often have hypertension and mental illness, and are prescribed medications for treatment. This study examined psychotropic medication adherence as a mediator between the association of residence type and antihypertensive medication adherence for adults with intellectual or developmental disabilities. We used Medicaid data of adults with intellectual or developmental disabilities who had hypertension and prescribed antihypertensive medication (N = 1,201) to measure the direct effect, indirect effect, and total effect of residence type (home vs. supervised setting) and antihypertensive medication adherence, with a mediator of psychotropic medication adherence. The indirect effect of psychotropic medication adherence on antihypertensive medication adherence was 1.26 (OR = 1.26, CI  1.08-1.52), holding residency constant. The direct effect of residential type on antihypertensive medication adherence was 3.75 (OR = 3.75, CI  1.61-8.75). This association may be due to some features of having a mental illness or maybe the result of being prescribed more than one medication.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocardit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocard</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">cardit</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Coagulopathies,
 Antiphospholipid syndrome (APS) can occur as a primary disease or secondary to an underlying disease, such as systemic lupus erythematosus, or other systemic autoimmune diseases. Catastrophic APS refers to a rapid progression of the disease with the development of thrombotic events that affect three or more organs. This is the case of a 22-year-old woman without history of pregnancy. She developed a catastrophic APS associated with systemic lupus erythematosus, with kidney damage (focal lupus nephritis III), pulmonary embolism, and Libman-Sacks mitral valve endocarditis. Accurate diagnosis and optimal medical treatment (anticoagulants, corticosteroids, antimalarials, diuretics) improved her disease, and the patient was discharged in good clinical condition and continues her multidisciplinary follow-up in the outpatient clinic of our institution.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">deep vein thrombosis</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Coagulopathies,
 BACKGROUND  Venous thromboembolism (VTE) concomitant to acute limb ischemia (ALI) is rarely reported. The purposes of the study were to investigate characteristics and identify clinical indicators of VTE in patients with ALI. METHODS  Electronic medical record was used to identify patients diagnosed with ALI from January 2013 to June 2019. Eligible patients were categorized as VTE or non-VTE based on the presence or absence of concomitant VTE. Univariate analysis and multivariate analysis for indicators of VTE were performed. RESULTS  A total of 153 patients with 161 ischemic limbs were enrolled. Venous duplex ultrasound (DUS) for 149 patients (157 ischemic limbs) revealed deep vein thrombosis (DVT) in 38 (24.2%) ischemic limbs of 37 (24.8%) patients. Five femoral DVTs were found intraoperatively. Six patients had pulmonary embolism (PE) and three of them died. In all, 43 (28.1%) ALI patients were diagnosed with VTE. They were treated with trans-arterial catheter-directed thrombolysis (n=22), embolectomy (n=9), primary amputation (n=4) and anticoagulation alone (n=8). The univariate analysis indicated that symptoms &gt;/= 2 days [odds ratio (OR)  3.42, 95%CI 1.54-7.62], Rutherford classification b- (OR  9.17, 95%CI  2.10-40.12), leg swelling (OR  4.44, 95%CI  2.07-9.53), neutrophil ratio &gt;/= 0.80 (OR  3.92, 95%CI  1.72-8.93) and positive D-dimer (OR  8.44, 95%CI  3.65-19.53) were indicators of VTE concomitant to ALI. In the multivariate analysis, leg swelling and positive D-dimer appeared to be independent indicators. CONCLUSIONS  VTE commonly occurs to ALI. Venous DUS for DVT screening should be considered for ALI patients who present one or more of these indicators.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Diseases of arteries,Coagulopathies,
 BACKGROUND  The CHA(2)DS(2)-VASc (congestive heart failure, hypertension, age &gt;/=75 years, diabetes mellitus, previous stroke, vascular disease, age 65-74 years, female gender) score is used to estimate thromboembolic risk in atrial fibrillation (AF). Current studies have shown that CHA(2)DS(2)-VASc score can predict adverse clinical outcomes in coronary artery disease, stroke, and many diseases irrespective of the presence of AF. The usefulness of CHA(2)DS(2)-VASc score in predicting mortality of peripheral arterial disease (PAD) patients is unknown. In this study, we aimed to evaluate the predictive value of the CHA(2)DS(2)-VASc score for mortality of PAD patients. METHODS  A total of 396 patients diagnosed with PAD for the first time in our clinic between January 2010-July 2016 were included in this study. Patients were divided into two groups as deceased (group 1, n  153) and living (group 2, n  243). A ROC analysis was performed to determine if CHA(2)DS(2)VASc score could predict the death events among PAD patients. Kaplan-Meier analysis was used to evaluate the timing of death events in the two groups. RESULTS  The mean ages of group-1 and group-2 were 76.6 +/- 0.81 and 66.5 +/- 0.83 (p=0.007), respectively. The CHA(2)DS(2)VASc scores of group-1 (4.37+/-0.1) and group-2 (2.96+/-0.9) were significantly different (p&lt;0.001). A significant correlation between CHA(2)DS(2)VASc score and death was determined in Spearman correlation (R 0.454, p&lt;0.001). According to multivariate cox regression analysis, CHA(2)DS(2)-VASc score [odds ratio (OR)  1.81 (95% CI  1.42-2.30); p&lt;0.001], Stroke [OR  0.43 (95% CI  0.21-0.85); p=0.016] and CRP [OR  1.04 (95% CI  1.01-1.06); p=0.002] were independent predictors of death. CONCLUSIONS  The CHA(2)DS(2)VASc score is directly related with mortality in PAD patients. The CHA(2)DS(2)VASc score may be a useful and practical scoring method to identify high-risk patients, and further future studies are needed to assess the role of CHA(2)DS(2)VASc score in PAD.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlud</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Diseases of arteries,Coagulopathies,
 Portal hypertension is a clinical syndrome characterized by an increase in the portal pressure gradient, defined as the gradient between the portal vein at the site downstream of the site of obstruction and the inferior vena cava. The most frequent cause of portal hypertension is cirrhosis. In patients with cirrhosis, portal hypertension is the main driver of cirrhosis progression and development of hepatic decompensation (ascites, variceal hemorrhage, and hepatic encephalopathy), which defines the transition from compensated to decompensated stage. In decompensated patients, treatments aim at lowering the risk of death by preventing further decompensation and/or development of acute-on-chronic liver failure. Decompensated patients often pose a complex challenge which typically requires a multidisciplinary approach. The aims of the present review are to discuss the current knowledge regarding interventional treatments for patients with portal hypertension complications as well as to highlight useful information to aid hepatologists in their clinical practice. Specifically, we discuss indications and contraindications of transjugular intra-hepatic portosystemic shunt (TIPS) and balloon-occluded transvenous retrograde obliteration (BRTO) for the treatment of gastro-esophageal variceal hemorrhage in patients with decompensated cirrhosis (first section), we review the use of interventional treatments in patients with hepatic vein obstruction (Budd-Chiari syndrome) and in those with portal vein thrombosis (second section), and we briefly comment on the most frequent applications of selective splenic embolization in patients with and without underlying cirrhosis (third section).
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,
 BACKGROUND  The association of N-terminal pro-B type natriuretic peptide (NT-proBNP) and plasma renin activity (PRA) for the prognosis of the patients with acute heart failure (HF) has not been fully investigated. This study aimed to determine the association between NT-proBNP and PRA and to investigate the incremental value of PRA to NT-proBNP for predicting long term prognosis in patients with acute HF. METHODS  Three hundred and ninety-six patients (mean age, 64.7 +/- 15.9 years; 46.5% female) presenting with acute HF were enrolled between December 2004 and July 2013. Patients with newly diagnosed HF as well as patients with acute exacerbated chronic HF were included. The prognosis was assessed with the composite event of all-cause mortality and readmission for HF during a 2-year follow-up period. RESULTS  The etiology of HF was ischemic in 116 (29.3%) patients. In a Cox proportional hazards model, log-transformed PRA (hazard ratio [HR], 1.205; P = 0.007) was an independent predictor of the composite outcome of all-cause mortality and readmission for HF in addition to age (HR, 1.032; P = 0.001), white blood cell (WBC) count (HR, 1.103; P &lt; 0.001), and left ventricular ejection fraction (LVEF) (HR, 0.978; P = 0.013). Adding PRA to age, sex, LVEF, and NT-proBNP significantly improved the prediction for the composite outcome of all-cause mortality and readmission for HF, as shown by the net reclassification improvement (0.47; P &lt; 0.001) and integrated discrimination improvement (0.10; P &lt; 0.001). CONCLUSION  PRA could provide incremental predictive value to NT-proBNP for predicting long term prognosis in patients with acute HF.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">ischem cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">dil cardiomyopathy</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Cardiomyopathy,
 BACKGROUND  Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) might be considered a bridge therapy in patients who are expected to have short waiting times for heart transplantation. We investigated the clinical outcomes of patients who underwent VA-ECMO as a bridge to heart transplantation and whether the deployment of an early extubation ECMO strategy is beneficial. METHODS  Between November 2006 and December 2018, we studied 102 patients who received VA-ECMO as a bridge to heart transplantation. We classified these patients into an early extubation ECMO group (n = 24) and a deferred extubation ECMO group (n = 78) based on the length of the intubated period on VA-ECMO (&lt;/= 48 hours or &gt; 48 hours). The primary outcome was in-hospital mortality. RESULTS  The median duration of early extubation VA-ECMO was 10.0 (4.3-17.3) days. The most common cause for patients to be put on ECMO was dilated cardiomyopathy (65.7%) followed by ischemic cardiomyopathy (11.8%). In-hospital mortality rates for the deferred extubation and early extubation groups, respectively, were 24.4% and 8.3% (P = 0.147). During the study period, in the deferred extubation group, 60 (76.9%) underwent transplantation, while 22 (91.7%) underwent transplantation in the early extubation group. Delirium occurred in 83.3% and 33.3% of patients from the deferred extubation and early extubation groups (P &lt; 0.001) and microbiologically confirmed infection was identified in 64.1% and 41.7% of patients from the two groups (P = 0.051), respectively. CONCLUSION  VA-ECMO as a bridge therapy seems to be feasible for deployment in patients with a short waiting time for heart transplantation. Deployment of the early extubation ECMO strategy was associated with reductions in delirium and infection in this population.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">tricuspid</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 AIMS  Systemic metabolic impairment is the key pathophysiology of heart failure (HF) with preserved ejection fraction (HFpEF). Fatty acid-binding protein 4 (FABP4) is highly expressed in adipocytes and secreted in response to lipolytic signals. We hypothesized that circulating FABP4 levels would be elevated in patients with HFpEF, would correlate with cardiac structural and functional abnormalities, and could predict clinical outcomes. METHODS AND RESULTS  Serum FABP4 measurements and echocardiography were performed in patients with HFpEF (n = 92) and those with coronary artery disease free of HF (n = 20). Patients were prospectively followed-up for a composite endpoint of all-cause mortality or HF hospitalization. Compared with patients with coronary artery disease, those with HFpEF had higher FABP4 levels [12.5 (9.1-21.0) vs. 43.5 (24.6-77.4) ng/mL, P &lt; 0.0001]. FABP4 levels were associated with cardiac remodelling (left ventricular mass index  r = 0.29, P = 0.002; left atrial volume index  r = 0.40, P &lt; 0.0001), left ventricular systolic and diastolic dysfunction (global longitudinal strain  r = -0.24, P = 0.01; E/e&#39; ratio  r = 0.29, P = 0.002; and N-terminal pro-B-type natriuretic peptide  r = 0.62, P &lt; 0.0001), and right ventricular dysfunction (tricuspid annular plane systolic excursion  r = -0.43, P &lt; 0.0001). During a median follow-up of 9.1 months, there were 28 primary endpoints in the HFpEF cohort. Event-free survival was significantly decreased in patients with FABP4 levels &gt;/=43.5 ng/mL than in those with FABP4 levels &lt;43.5 ng/mL (P = 0.003). CONCLUSIONS  Serum FABP4 levels were increased in HFpEF and were associated with cardiac remodelling and dysfunction, and poor outcomes. Thus, FABP4 could be a potential biomarker in the complex pathophysiology of HFpEF.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 This research utilized the systematic biological and proteomics strategies to explore the regulatory mechanism of Danshen Yin Modified (DSYM) on atherosclerosis (AS) biological network. The traditional Chinese medicine database and HPLC was used to find the active compounds of DSYM, Pharmmapper database was used to predict potential targets, and OMIM database and GeneCards database were used to collect AS targets. String database was utilized to obtain the other protein of proteomics proteins and the protein-protein interaction (PPI) data of DSYM targets, AS genes, proteomics proteins and other proteins. The Cytoscape 3.7.1 software was utilized to construct and analyse the network. The DAVID database is used to discover the biological processes and signalling pathways that these proteins aggregate. Finally, animal experiments and proteomics analysis were used to further verify the prediction results. The results showed that 140 active compounds, 405 DSYM targets and 590 AS genes were obtained, and 51 differentially expressed proteins were identified in the DSYM-treated ApoE-/- mouse AS model. A total of 4 major networks and a number of their derivative networks were constructed and analysed. The prediction results showed that DSYM can regulate AS-related biological processes and signalling pathways. Animal experiments have also shown that DSYM has a therapeutic effect on ApoE-/-mouse AS model (P &lt; .05). Therefore, this study proposed a new method based on systems biology, proteomics, and experimental pharmacology, and analysed the pharmacological mechanism of DSYM. DSYM may achieve therapeutic effects by regulating AS-related signalling pathways and biological processes found in this research.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,
 OBJECTIVE  To explore whether poor sleep is associated with post-stroke anxiety (PSA) in Chinese patients with acute ischemic stroke (AIS) and to verify whether poor sleep is a predictor of PSA. METHODS  A total of 327 patients with AIS were enrolled and followed up for 1 month. Sleep quality within 1 month before stroke was evaluated using the Pittsburgh Sleep Quality Index (PSQI) at admission. The patients were divided into the poor sleep group (PSQI &gt; 7, n = 76) and good sleep group (PSQI &lt;/= 7, n = 251). One month after stroke, patients with obvious anxiety symptoms and a Hamilton Anxiety Scale score &gt;7 were diagnosed with PSA. RESULTS  Eighty-seven patients (26.6%) were diagnosed with PSA. Compared to the good sleep quality group, the incidence of PSA in patients with poor sleep quality was higher (42.1% vs. 21.9%, p = .001). Poor sleep quality is more common in patients with PSA (35.6% vs. 18.8%, p = .001). A logistic regression analysis indicated that poor sleep quality was significantly associated with PSA (OR  2.265, 95% CI  1.262-4.067, p = .003). After adjusting for conventional and identified risk factors, poor sleep quality was found to be independently associated with PSA (OR  2.676, 95% CI  1.451-4.936, p = .001). CONCLUSIONS  Poor sleep quality before stroke was associated with PSA and may be an independent risk factor of PSA 1 month after AIS onset.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Diseases of arteries,
 Macrophages are fundamental components of inflammation in post-myocardial infarction (MI) and contribute to adverse cardiac remodelling and heart failure. However, the regulatory mechanisms in macrophage activation have not been fully elucidated. Previous studies showed that myeloid-associated immunoglobulin-like receptor II (MAIR-II) is involved in inflammatory responses in macrophages. However, its role in MI is unknown. Thus, this study aimed to determine a novel role and mechanism of MAIR-II in MI. We first identified that MAIR-II-positive myeloid cells were abundant from post-MI days 3 to 5 in infarcted hearts of C57BL/6J (WT) mice induced by permanent left coronary artery ligation. Compared to WT, MAIR-II-deficient (Cd300c2(-/-) ) mice had longer survival, ameliorated cardiac remodelling, improved cardiac function and smaller infarct sizes. Moreover, we detected lower pro-inflammatory cytokine and fibrotic gene expressions in Cd300c2(-/-) -infarcted hearts. These mice also had less infiltrating pro-inflammatory macrophages following MI. To elucidate a novel molecular mechanism of MAIR-II, we considered macrophage activation by Toll-like receptor (TLR) 9-mediated inflammation. In vitro, we observed that Cd300c2(-/-) bone marrow-derived macrophages stimulated by a TLR9 agonist expressed less pro-inflammatory cytokines compared to WT. In conclusion, MAIR-II may enhance inflammation via TLR9-mediated macrophage activation in MI, leading to adverse cardiac remodelling and poor prognosis.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,
 Acute myocardial infarction (AMI) is one of the leading causes of death worldwide. Cardiac troponin I (cTn1) is a commonly used biomarker for the diagnosis of AMI. Although there are various detection methods for the rapid detection of cTn1 such as optical, electrochemical, and acoustic techniques, electrochemical aptasensing techniques are commonly used because of their ease of handling, portability, and compactness. In this study, an electrochemical cTn1 biosensor, MoS2 nanoflowers on screen-printed electrodes assisted by aptamer, was synthesized using hydrothermal technique. Field emission scanning electron microscopy revealed distinct 2D nanosheets and jagged flower-like 3D MoS2 nanoflower structure, with X-ray diffraction analysis revealing well-stacked MoS2 layers. Voltammetry aptasensing of cTn1 ranges from 10 fM to 1 nM, with a detection limit at 10 fM and a sensitivity of 0.10 nA microM(-1) cm(-2) . This is a approximately fivefold improvement in selectivity compared with the other proteins and human serum. This novel aptasensor retained 90% of its biosensing activity after 6 weeks with a 4.3% RSD and is a promising high-performance biosensor for detecting cTn1.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Cardiomyopathy,
 A 52-year-old gentleman with a subcutaneous implantable defibrillator (S-ICD) implanted in 2015 for primary prevention and a background of hypertrophic cardiomyopathy presented via remote monitoring alert (Boston Scientific Latitude NXT) with an aborted charge episode. The episode showed myopotential noise with baseline wander, and an urgent outpatient follow up was arranged. Upon investigation the S-ICD lead had retracted to the pocket of the generator via a reel mechanism, wrapping the lead around the can. This was likely to be caused by insufficient suturing of the lead collar at the base of xiphisternum. The device had automatically disabled the SmartPass filter, which does not currently have an alert mechanism. This case highlights the rare occurrence of S-ICD lead displacement and components of the SmartPass system which can provide an early warning to lead problems. This article is protected by copyright. All rights reserved.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  Recently published studies suggested that digoxin may increase mortality in heart failure with reduced ejection fraction (HFrEF). However, in the vast majority of former trials serum digoxin concentration (SDC) was not measured and therapy was not SDC-guided. AIM  To assess the impact of SDC-guided digoxin therapy on mortality in HFrEF patients. METHODS  Data of 580 HFrEF patients were retrospectively analyzed. In patients on digoxin, SDC was measured every 3 months and digoxin dosage was SDC-guided (target SDC  0.5-0.9 ng/mL). All-cause mortality of digoxin users and nonusers was compared after propensity score matching (PSM). RESULTS  After 7.1 +/- 4.7 years follow-up period (FUP) all-cause mortality of digoxin users (n = 180) was significantly higher than nonusers (n = 297) (propensity-adjusted HR = 1.430; 95% CI = 1.134-1.804; P = .003). Patients having SDC of 0.9 to 1.1 ng/mL (n = 60) or &gt; 1.1 ng/mL (n = 44) at any time during the FUP had an increased risk of all-cause mortality (HR = 1.750; 95% CI = 1.257-2.436, P = .001 and HR = 1.687; 95% CI = 1.153-2.466, P = .007), while patients having a maximal SDC &lt; 0.9 ng/mL (n = 76) had similar mortality risk (HR = 1.139; 95% CI = 0.827-1.570, P = .426), compared to digoxin nonusers. CONCLUSIONS  According to our propensity-matched analysis, SDC-guided digoxin therapy was associated with increased all-cause mortality in optimally treated HFrEF patients, especially with SDC &gt;/=0.9 ng/mL. These results reinforce the expert opinion that digoxin in HFrEF can only be used among carefully selected patients with close SDC monitoring.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">ischem cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Cardiomyopathy,Diseases of arteries,
 BACKGROUND  The hypoplastic coronary sinus is a rare anomaly of the cardiac venous system, wherein some of the tributaries fail to join the coronary sinus. These tributaries usually drain into atrial chambers through dilated thebesian channels. We report the first case where the tributaries are draining into the right superior vena cava (SVC). CASE SUMMARY  A case of ischemic cardiomyopathy with severe LV systolic dysfunction with NYHA class III symptoms was taken for CRTD implantation. Coronary sinus (CS) venogram after direct cannulation from left subclavian access revealed a hypoplastic coronary sinus. The part of coronary sinus beyond the attachment of the oblique vein of the left atrium to CS (distal to the posterolateral vein) formed a common channel and was draining into the right-sided SVC. The posterolateral vein was of sufficient caliber so that a LV lead could be implanted and the CRTD procedure could be completed. DISCUSSION  Hypoplastic coronary sinus though has no pathological significance in the normal population but for CRT it can become a significant limitation. Tributaries of coronary sinus draining into right SVC is the rarest of the finding, the channel draining most likely is a remnant of the splanchnic plexus around the embryonic foregut that usually has a temporary communication with cardinal veins during intrauterine growth. This communication somehow has persisted and resulted in a channel between coronary vein and the SVC, which may be referred to as coronary veno-cardinal vein. This article is protected by copyright. All rights reserved.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 BACKGROUND AND AIMS  Long-term antiviral therapy can effectively suppress viral replication and improve clinical outcomes in patients with chronic hepatitis B (CHB), but it cannot eliminate risk of hepatocellular carcinoma (HCC). We investigated the association of metabolic risk factors with the risks of cancer and all-cause mortality in CHB patients. APPROACH AND RESULTS  This nationwide population-based study from the Korean National Health Insurance Service database consisted of adults with CHB who underwent health examinations from 2007 through 2012. We collected baseline data on metabolic risk factors, including obesity, high blood pressure, hypercholesterolemia, and diabetes. The risks of developing HCC, non-HCC cancer, and overall death were analyzed according to the metabolic risk profile. The study population comprised of 317,856 patients (median age, 46 years [interquartile range, 37-54 years]; 219,418 men [69.0%]) had 2,609,523.8 person-years of follow-up. A total of 18,850 HCCs, 22,164 non-HCC cancers, and 15,768 deaths were observed during a median follow-up period of 8.5 years. The metabolic risk factor burden was positively associated with the risks of HCC, non-HCC cancer, and all-cause mortality (all P&lt;.0001 for trend). Patients with &gt;/=3 metabolic risk factors, compared to those without metabolic risk factors, showed adjusted hazard ratios of 1.23 (95% confidence interval [CI], 1.16-1.31) for HCC, 1.34 (95% CI, 1.27-1.41) for non-HCC cancer, and 1.31 (95% CI, 1.23-1.39) for all-cause mortality. Among patients receiving antiviral therapy for over 5 years, the risk-increasing association of the sum of metabolic risk factors with the risks of HCC and overall death was consistent. CONCLUSION  The metabolic risk factor burden was associated with increased risks of HCC, non-HCC cancer, and all-cause mortality in patients with CHB.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 INTRODUCTION  The potential effect of adipokines on the development of AF is yet to be established. The aim of this study was to investigate the association of baseline serum adipokines with 1) the presence of AF at baseline and 2) future risk of AF development. MATERIAL AND METHODS  The current study is a sub-analysis of the prospective, randomised AVOCADO (Aspirin Vs./Or Clopidogrel in Aspirin-resistant Diabetics inflammation Outcomes) trial. The AVOCADO study included patients with type 2 DM burdened with at least two additional cardiovascular risk factors and receiving acetylsalicylic acid. In patients included in the current analysis adipokines and inflammatory biomarker levels were measured. Information on the subsequent AF diagnosis was collected after a median of 5.4 years of follow-up. RESULTS  A total of 273 patients with type 2 DM (median age 68 years; 52% male) were included in the initial analysis comparing patients with and without AF at baseline. Patients with diagnosed AF (12%) had higher levels of serum resistin [8.5 (5.8-10.5) vs. 6.9 (5.6-8.7) ng/mL; p = 0.034], adiponectin [6.9 (5.6-8.7) vs. 2.7 (1.8-4.2) ng/mL; p = 0.032], and N-terminal pro-B-type natriuretic peptide [336 (148-473) vs. 108 [45-217]; p &lt; 0.001) than non-AF patients. There were no significant differences in serum leptin, IL-6, and TNF-alpha concentrations between the two groups. From subjects without known AF at study entry, 19% developed AF at follow-up. In logistic regression analysis, baseline adipokine levels did not predict AF development. CONCLUSION  In type 2 DM, patients with AF have higher resistin and adiponectin concentrations than patients with no AF. None of the studied adipokines proved a predictor of future AF development.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  There is a beneficial effect of adrenaline during adult cardiopulmonary resuscitation (CPR) from cardiac arrest but there is also uncertainty about its safety and effectiveness. The aim of this study was to evaluate the use of adrenaline versus non-adrenaline CPR. METHODS  PubMed, ScienceDirect, Embase, CENTRAL (Cochrane Central Register of Controlled Trials) and Google Scholar databases were searched from their inception up to 1st July 2020. Two reviewers independently assessed eligibility and risk of bias, with conflicts resolved by a third reviewer. Risk ratio (RR) or mean difference of groups were calculated using fixed or random-effect models. RESULTS  Nineteen trials were identified. The use of adrenaline during CPR was associated with a significantly higher percentage of return of spontaneous circulation (ROSC) compared to non-adrenaline treatment (20.9% vs. 5.9%; RR = 1.87; 95% confidence interval [CI] 1.37-2.55; p &lt; 0.001). The use of adrenaline in CPR was associated with ROSC at 19.4% and for non-adrenaline treatment -4.3% (RR = 3.23; 95% CI 1.89-5.53; p &lt; 0.001). Survival to discharge (or 30-day survival) when using adrenaline was 6.8% compared to non-adrenaline treatment (5.5%; RR = 0.99; 95% CI 0.76-1.30; p = 0.97). However, the use of adrenaline was associated with a worse neurological outcome (1.6% vs. 2.2%; RR = 0.57; 95% CI 0.42-0.78; p &lt; 0.001). CONCLUSIONS  This review suggests that resuscitation with adrenaline is associated with the return of spontaneous circulation and survival to hospital discharge, but no higher effectiveness was observed at discharge with favorable neurological outcome. The analysis showed higher effectiveness of ROSC and survival to hospital discharge in non-shockable rhythms. But more multicenter randomized controlled trials are needed in the future.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  Out-of-hospital cardiac arrest (OHCA) is a challenge for medical personnel, especially in the current COVID-19 pandemic, where medical personnel should perform resuscitation wearing full personal protective equipment. This study aims were to assess the characteristics and outcomes of adults who suffered an out-of-hospital cardiac arrest in the COVID-19 pandemic treated by emergency medical service (EMS) teams. METHODS  All EMS-attended OHCA adults over than 18 years in the Polish EMS registry were analyzed. The retrospective EMS database was conducted. EMS interventions performed between March 1, and April 30, 2020 were retrospectively screened. RESULTS  In the study period EMS operated 527 times for OHCA cases. The average age of patients with OHCA was 67.8 years. Statistically significantly more frequently men were involved (64.3%). 298 (56.6%) of all OHCA patients had resuscitation attempted by EMS providers. Among resuscitated patients, 73.8% were cardiac etiology. 9.4% of patients had return of spontaneous circulation, 27.2% of patients were admitted to hospital with ongoing chest compression. In the case of 63.4% cardiopulmonary resuscitation was ineffective and death was determined. CONCLUSIONS  The present study found that OHCA incidence rate in the Masovian population (central region of Poland) in March-April 2020 period was 12.2/100,000 adult inhabitants. Return of spontaneous circulation in EMS was observed only in 9.4% of resuscitated patients. The presence of shockable rhythms was associated with better prognosis. The prehospital mortality, even though it was high, did not differ from those reported by other studies.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  Out-of-hospital cardiac arrest (OHCA) is a challenge for medical personnel, especially in the current COVID-19 pandemic, where medical personnel should perform resuscitation wearing full personal protective equipment. This study aims were to assess the characteristics and outcomes of adults who suffered an out-of-hospital cardiac arrest in the COVID-19 pandemic treated by emergency medical service (EMS) teams. METHODS  All EMS-attended OHCA adults over than 18 years in the Polish EMS registry were analyzed. The retrospective EMS database was conducted. EMS interventions performed between March 1, and April 30, 2020 were retrospectively screened. RESULTS  In the study period EMS operated 527 times for OHCA cases. The average age of patients with OHCA was 67.8 years. Statistically significantly more frequently men were involved (64.3%). 298 (56.6%) of all OHCA patients had resuscitation attempted by EMS providers. Among resuscitated patients, 73.8% were cardiac etiology. 9.4% of patients had return of spontaneous circulation, 27.2% of patients were admitted to hospital with ongoing chest compression. In the case of 63.4% cardiopulmonary resuscitation was ineffective and death was determined. CONCLUSIONS  The present study found that OHCA incidence rate in the Masovian population (central region of Poland) in March-April 2020 period was 12.2/100,000 adult inhabitants. Return of spontaneous circulation in EMS was observed only in 9.4% of resuscitated patients. The presence of shockable rhythms was associated with better prognosis. The prehospital mortality, even though it was high, did not differ from those reported by other studies.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  Out-of-hospital cardiac arrest (OHCA) is a challenge for medical personnel, especially in the current COVID-19 pandemic, where medical personnel should perform resuscitation wearing full personal protective equipment. This study aims were to assess the characteristics and outcomes of adults who suffered an out-of-hospital cardiac arrest in the COVID-19 pandemic treated by emergency medical service (EMS) teams. METHODS  All EMS-attended OHCA adults over than 18 years in the Polish EMS registry were analyzed. The retrospective EMS database was conducted. EMS interventions performed between March 1, and April 30, 2020 were retrospectively screened. RESULTS  In the study period EMS operated 527 times for OHCA cases. The average age of patients with OHCA was 67.8 years. Statistically significantly more frequently men were involved (64.3%). 298 (56.6%) of all OHCA patients had resuscitation attempted by EMS providers. Among resuscitated patients, 73.8% were cardiac etiology. 9.4% of patients had return of spontaneous circulation, 27.2% of patients were admitted to hospital with ongoing chest compression. In the case of 63.4% cardiopulmonary resuscitation was ineffective and death was determined. CONCLUSIONS  The present study found that OHCA incidence rate in the Masovian population (central region of Poland) in March-April 2020 period was 12.2/100,000 adult inhabitants. Return of spontaneous circulation in EMS was observed only in 9.4% of resuscitated patients. The presence of shockable rhythms was associated with better prognosis. The prehospital mortality, even though it was high, did not differ from those reported by other studies.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  Metabolic derangements related to tissue energetics constitute an important pathophysiological feature of heart failure. We investigated whether iron deficiency and catabolic/anabolic imbalance contribute to decreased skeletal muscle performance in men with heart failure with reduced ejection fraction (HFrEF), and whether these pathologies are related to each other. METHODS  We comprehensively examined 23 men with stable HFrEF (median age [interquartile range]  63 [59-66] years; left ventricular ejection fraction  28 [25-35]%; New York Heart association class I/II/III  17/43/39%). We analyzed clinical characteristics, iron status, hormones, strength and fatigability of forearm flexors and quadriceps (surface electromyography), and exercise capacity (6-minute walking test). RESULTS  None of the patients had anemia whereas 8 were iron-deficient. Flexor carpi radialis fatigability correlated with lower reticulocyte hemoglobin content (CHR, p &lt; 0.05), and there was a trend towards greater fatigability in patients with higher body mass index and lower serum ferritin (both p &lt; 0.1). Flexor carpi ulnaris fatigability correlated with lower serum iron and CHR (both p &lt; 0.05). Vastus medialis fatigability was related to lower free and bioavailable testosterone (FT and BT, respectively, both p &lt; 0.05), and 6MWT distance was shorter in patients with higher cortisol/FT and cortisol/BT ratio (both p &lt; 0.05). Lower ferritin and transferrin saturation correlated with lower percentage of FT and BT. Men with HFrEF and ID had higher total testosterone, but lower percentage of FT and BT. CONCLUSIONS  Iron deficiency correlates with lower bioactive testosterone in men with HFrEF. These two pathologies can both contribute to decreased skeletal muscle performance in such patients.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlud</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">stenos</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Diseases of arteries,
 BACKGROUND  This pilot study revealed a relationship between the results of flow mediated skin fluorescence (FMSF) and of ECG-Holter-based estimated apnea/hypopnea index (eAHI) in asymptomatic individuals. The aim was to test whether the results of FMSF show a relationship with the eAHI in patients with coronary artery disease or aortic stenosis. METHODS  Twenty-one patients (12 coronary disease, 9 aortic stenosis) and 37 healthy volunteers were included in this study. FMSF was assessed before, during and after the pressure occlusion of the brachial artery, using a prototype device allowing the quantification of skin fluorescence. The values of FMSF expressed as baseline (BASE), maximum (MAX), and minimum (MIN) were analyzed. The percentages of ischemic response (IR) and hyperemic response (HR) were calculated. The eAHI was assessed from night ECG-Holter recordings. Differences between the groups and the relationships between the parameters were analyzed statistically. RESULTS  Mean +/- standard deviation of BASE, MAX, MIN and IR were not significantly different in both groups (p &gt; 0.05). HR was significantly lower in cardiac patients (14.7 +/- 7.5 vs. 11.8 +/- 5.1; p = 0.048), whose eAHI was significantly higher (11.0 +/- 7.4 vs. 36.3 +/- 16.5; p &lt; 0.01). Negative correlation for MAX and eAHI was found in volunteers and patients  r = -0.38, p = 0.02 and r = -0.47, p = 0.03, respectively. In volunteers, HR had a negative correlation with eAHI  r = -0.34, p = 0.04. CONCLUSIONS  This pioneer study confirms that FMSF can be used to detect the negative correlation between MAX fluorescence and eAHI not only among healthy volunteers, but also among cardiac patients with coronary artery disease or aortic stenosis.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,
 BACKGROUND  According to available research, there have been no head-to-head studies comparing the effect of glucagon-like peptide 1 (GLP-1) agonists and sodium-glucose cotransporter 2 (SGLT-2) inhibitors on cardiovascular outcomes among patients with type 2 diabetes not reaching glycemic goal with metformin. METHODS  Relevant studies were identified through electronic searches of PubMed and EMBASE published up to January 15, 2020. Efficacy outcomes of interest included the composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke, its individual components, all-cause death, and hospitalization for heart failure (HF). Safety outcomes included all suggested side effects of both agents previously reported. RESULTS  Eleven studies, including 94,727 patients were used for the analysis. The risk of composite end point was significantly lower in both groups compared to the control group (hazard ratio [HR], 0.88, 95% confidence interval [CI] 0.85-0.92, p &lt; 0.001). The risk of hospitalization for HF was significantly lower in both groups but the magnitude of the effect was more pronounced in the SGLT-2 inhibitors group (HR 0.68, 95% CI 0.60-0.76, p &lt; 0.001) than the GLP-1 agonists group (HR 0.92, 95% CI 0.84-0.99, p = 0.03). Patients treated with GLP-1 agonists discontinued trial medications more frequently compared to conventionally treated patients because of serious side effects. CONCLUSIONS  Both GLP-1 agonists and SGLT-2 inhibitors showed comparable cardiovascular outcomes in patients with type 2 diabetes. However, the SGLT-2 inhibitors were associated with more pronounced reduction of hospitalization for HF and lower risk of treatment discontinuation than GLP-1 agonists.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,
 BACKGROUND  Lymphopenia is associated with adverse prognosis in chronic disease states that are related to immune dysregulation. We aimed to determine the association between lymphopenia and mortality in patients presenting to coronary angiography and investigate whether elevated red blood cell distribution width (RDW), an established cardiovascular prognostic marker, further refines risk stratification. METHODS  Retrospective analysis of patients undergoing coronary angiography for evaluation or treatment of coronary artery disease between 2003 and 2018. Mortality risk associated with relative (1000-1500/muL) or severe (&lt; 1000/muL) lymphopenia was analyzed using adjusted Cox proportional hazards regression models. RESULTS  Overall, 15,179 patients aged 65 +/- 12 years underwent coronary angiography. During a median follow-up of 8 years, 4253 patients died. Compared to normal lymphocyte count, the adjusted hazard ratio (HR) for mortality was 1.31 (95% confidence interval [CI] 1.21-1.41) and 1.97 (95% CI 1.75-2.22) for relative and severe lymphopenia, respectively. The increase in mortality associated with severe lymphopenia was significant in patients presenting in the non-acute setting (HR 2.18, 95% CI 1.74-2.73), ST-segment elevation myocardial infarction (STEMI) (HR 1.59, 95% CI 1.15-2.21), or unstable angina/non-STEMI (HR 2.00, 95% CI 1.70-2.34); p-value for interaction 0.626. The association of lymphopenia with mortality remained significant after additional adjustment to RDW. High RDW (&gt; 14.5%) was associated with reduced survival, and it improved the predictive accuracy of lymphocytes count with an increase in Harrell&#39;s Concordance statistic from 0.634 (SE = 0.005) to 0.672 (SE = 0.005), p &lt; 0.001. CONCLUSIONS  lymphopenia is associated with increased risk of mortality during long-term follow-up in patients undergoing coronary angiography, regardless of the coronary presentation. High RDW may enhance the predictive ability of lymphopenia.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Diseases of arteries,Coagulopathies,
 BACKGROUND  Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has led to a paradigm shift in healthcare worldwide. Little is known about the impact on the cardiovascular system, and the incidence and consequences of new onset of atrial fibrillation (AF) in infected patients remain unclear. The aim of this study was to analyze the cardiovascular outcomes of patients with new-onset AF and coronavirus disease 2019 (COVID-19) infection. METHODS  This observational study analyzed a sample of 160 consecutive patients hospitalized due to COVID-19. A group with new-onset AF (n = 12) was compared with a control group (total  n = 148, sinus rhythm  n = 118, previous AF  n = 30). New-onset AF patients were significantly older and hypertensive, as well as presenting more frequently with a history of acute coronary syndrome and renal dysfunction. This group showed a higher incidence of thromboembolic events (41.7% vs. 4.1%; p &lt; 0.001), bleeding (33.3% vs. 4.7%, p = 0.005), a combined endpoint of thrombosis and death (58.3 vs. 19.6%, p = 0.006) and longer hospital stays (16.4 vs. 8.6 days, p &lt; 0.001), with no differences in all-cause mortality. RESULTS  In multivariate analysis, adjusted by potential confounding factors, new-onset AF demonstrated a 14.26 odds ratio for thromboembolism (95% confidence interval 2.86-71.10, p &lt; 0.001). CONCLUSIONS  New-onset AF in COVID-19 patients presumably has a notable impact on prognosis. The appearance of new-onset AF is related to worse cardiovascular outcomes, considering it as an independent predictor of embolic events. Further studies are needed to identify patients with COVID-19 at high risk of developing &#34;de novo&#34; AF, provide early anticoagulation and minimize the embolic risk of both entities.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Inflammatory diseases,Diseases of arteries,
 BACKGROUND  A definition of myocardial infarction with non-obstructive coronary arteries (MINOCA) was published by European Society of Cardiology in 2016. The aim of this study is to analyze the clinical profile and prognosis of these patients in a prospective single-center study and compare it with the literature data. METHODS  During a 3-year period, information from every consecutive MINOCA patient was gathered (n = 109). It was then compared with 412 contemporaneous patients with myocardial infarction and obstructive coronary arteries (MIOCA). Univariate and multivariate analyses were performed. Prognosis analysis was adjusted by age and cardiovascular risk factors (CVRF). RESULTS  MINOCA represented 16.9% of the total of patients admitted for myocardial infarction. Compared with MIOCA, they had more psychosocial disorders (22.9% vs. 10.7%; p &lt; 0.01) and more pro-inflammatory conditions (34.9% vs. 14.0%; p &lt; 0.01). Atrial fibrillation was twice as frequent in MINOCA (14.7% vs. 7.3%; p = 0.016). Predictors of MINOCA were as follows  female gender, absence of diabetes, absence of tobacco use, tachycardia, troponin above 10 times the 99th percentile, and pro-inflammatory conditions. Median follow-up was 17.3 +/- 9.3 months. Major adverse cardiovascular events (MACE; a composite of a recurrence of acute myocardial infarction, transient ischemic attack/stroke, or death from cardiovascular cause and death from any cause) occurred in 10.8% of the MINOCA group as compared with 10.7% in the MIOCA group (hazard ratio [HR] 1.19, 95% confidence interval [CI] 0.58-2.45; p = 0.645). Cardiovascular re-admission rates were higher in the MINOCA group  19.8% vs. 13.9% (HR 1.85; CI 1.06-3.21; p = 0.030). CONCLUSIONS  The frequency of MINOCA is high, with fewer CVRF, and it is linked to atrial fibrillation, psychosocial disorders, and pro-inflammatory conditions. Mid-term prognosis is worse than previously thought, with a similar proportion of MACE as compared to MIOCA, and even a higher rate of cardiovascular re-admissions.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Patients with severe heart failure (HF), who are not eligible for cardiac transplantation and receive optimal medical management, based mainly on the use of pharmacological treatment and devices such as resynchronization therapy (implantable cardioverter-defibrillator), achieve poor clinical outcomes and constitute a group with extremely poor prognosis. Currently, the technology used in the latest generation left ventricular assist devices (LVADs), such as the HeartMate3, makes it possible to achieve patient survival at the level obtained by patients after heart transplantation, and they can be used not only in patients eligible for heart transplantation as a bridge to transplant, but also in those with significantly worse prognosis, who are ineligible for heart transplantation as destination therapy. The objective of this publication is to present recommendations from experts in cardiology and cardiac surgery, supported by clinical trial results, on the use of LVADs as a destination therapy in HF patients who are not eligible for cardiac transplantation. The paper also presents the issue of cardiac transplantation and extracorporeal membrane oxygenation therapy in Poland, as well as current challenges faced by interventional cardiology and cardiac surgery in Poland.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Inflammatory diseases,
 We compared placental pathology, ultrasonographic findings, and obstetric outcomes, in gestations complicated by fetal growth restriction (FGR) with either a background of hypertensive disorder or heavy tobacco cigarette smoking. The medical records and placental pathology reports of pregnancies complicated with FGR (birthweight &lt; 10th percentile) between December 2008 and May 2018 from a single tertiary center were reviewed. Placental pathology, ultrasound findings, and pregnancy outcomes were compared between hypertensive patients (HTN) and heavy smokers (SMO). We included 213 pregnancies  129 (60.6%) in the SMO group and 84 (39.4%) in the HTN group. The HTN group was characterized by a higher BMI (p = 0.01), higher rates of Cesarean deliveries (p = 0.006), and a lower gestational age at delivery (35.6 +/- 3.8 vs. 37.5 +/- 2.9 weeks, p &lt; 0.001). The HTN group had higher rates of placental weights &lt; 10th percentile (p = 0.04) and maternal vascular malperfusion lesions (p &lt; 0.001), while the SMO group had higher rates of inflammatory lesions (p = 0.04). On ultrasound, the HTN group had a higher head/abdomen circumference ratio (p &lt; 0.001) and more abnormal Doppler studies (&lt; 0.001). Neonates in the HTN group had lower birthweights (p &lt; 0.001) and higher rates of NICU admissions (p = 0.002) and adverse neonatal outcome (p = 0.006). On multivariable analysis, gestational age at delivery (aOR = 0.65, 95%CI 0.55-0.87), hypertensive disorders (aOR = 1.8, 95%CI = 1.21-4.81), placental MVM lesions (aOR = 1.23, 95%CI = 1.08-5.02), and the combination of HTN+MVM (aOR = 2.63, 95%CI 1.78-7.30) were independently associated with adverse neonatal outcome. Hypertension and smoking may lead to FGR in different pathways as the two groups significantly differed in maternal characteristics, placental pathology, ultrasound findings, and neonatal outcomes. A hypertensive disorder probably represents a more hostile maternal environment than smoking and these pregnancies would probably benefit from closes monitoring.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam diseas</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,
 OBJECTIVES  Nigella sativa (NS) is a known medicinal herb with numerous therapeutic effects such as antidiabetic, anti-proliferative, anti-inflammatory, and anti-cancer activities. It has been indicated that NS can regulate cellular metabolism by adjusting transduction signaling pathways. Adenosine monophosphate-activated protein kinase (AMPK) is one of the main physiological processes, such as energy hemostasis, cellular metabolism, and autophagy regulators. Herb-derived medicines have always been considered as one of the main AMPK activators, and surprisingly recent data has demonstrated that it can be a target for NS and its derivatives. EVIDENCE ACQUISITION  The literature search was conducted in PubMed, SCOPUS, Embase, ProQuest, and Google Scholar electronic resources. Published articles up to September 2020 were considered, and those of which investigated Nigella sativa effects on the AMPK pathway after meeting the inclusion criteria were included. RESULTS  The search was performed on several online databases such as PubMed, Scopus, Embase, ProQuest, and Google Scholar from inception until January 2020. Among the initial search, 245 studies were found. After removing duplicated data and meeting the inclusion criteria, only 14 studies were selected. They included the effects of NS and its bioactive compounds as anti-hyperglycemic (n = 5), on liver function (n = 4), cancers (n = 3), and on Neuroinflammation and Atherosclerosis (n = 2). Most of the included studies are animals or in-vitro investigations. CONCLUSION  In this review, we discuss the latest findings on the molecular mechanism of NS effecting the AMPK signaling pathway. We also focus on the therapeutic effects of NS, including the prevention and treatment of metabolic and pro-inflammatory disease by targeting the AMPK pathway.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">cerebrovascul</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Ischemia,Heart failure,Diseases of arteries,Coagulopathies,
 BACKGROUND  Emerging evidence suggests that a subset of coronavirus disease 2019 (COVID-19) patients may present with or develop cerebrovascular disease during the course of hospitalization. Whereas ischemic stroke in COVID-19 patients has been well described, data on intracranial hemorrhage (ICH) in these patients is still limited. We, therefore, conducted a rapid systematic review of current scientific literature to identify and consolidate evidence of ICH in COVID-19 patients. METHODS  A systematic search of literature was conducted between November 1, 2019, and August 14, 2020, on PubMed and China National Knowledge Infrastructure (CNKI) to identify eligible studies. RESULTS  A total of 23 studies describing ICH in 148 COVID-19 patients were included. The pooled incidence of ICH in COVID-19 patients was 0.7% (95% CI 0.5-0.9), with low levels of inter-study heterogeneity observed (I(2) = 33.6%, Cochran&#39;s Q = 12.05, p = 0.149). Most of the patients were elderly male patients (65.8%) with comorbidities, the most common being systemic hypertension (54%). Hemorrhage involving multiple cranial compartments was reported in 9.5% of cases. Single compartments were involved in the rest, with intraparenchymal hemorrhage (IPH) being the most common variety (62.6%) and intraventricular hemorrhage (IVH) the least common (1.4%). Half of these patients were on some form of anticoagulation. Overall, the mortality rate in the COVID-19 patients with ICH was about 48.6%. CONCLUSION  Although relatively uncommon among COVID-19 patients, ICH is associated with a high mortality rate. Early identification of patients at risk of developing ICH, particularly with comorbid conditions and on anticoagulant therapy, may be important to improve outcomes.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 PURPOSE  Prostate cancer (PCa) is the commonest non-cutaneous malignancy worldwide and the second cause of cancer death among males in the USA. Approval of the new androgen receptor axis-targeted (ARAT) agents (abiraterone acetate, enzalutamide, apalutamide, and darolutamide) has altered the course of advanced PCa. We aimed to assess the endocrine and metabolic adverse events associated with treatment using ARAT compounds. METHODS  We searched the PubMed, Cochrane Library, and Scopus databases from database inception to August 2020. We included randomized controlled trials reporting the endocrine and metabolic side effects of ARAT agents compared to each other or to placebo. RESULTS  Although metastatic PCa remains incurable, ARAT medications combined with androgen deprivation therapy improve overall metastasis-free and progression-free survival in metastatic hormone-sensitive PCa, non-metastatic castration-resistant PCa, and metastatic castration-resistant PCa patients. This benefit comes at the cost of certain endocrine and metabolic consequences. Treatment with abiraterone acetate induces mineralocorticoid excess, hypokalemia, hypertension, elevated liver function tests, insulin resistance, and hyperglycemia. Enzalutamide may induce or worsen hypertension and increase the risk of falls and fractures in elderly patients, while common endocrine adverse events of apalutamide include hypothyroidism, hypertension, and skin rash. On the other hand, darolutamide seems to have a somewhat safer endocrine and metabolic profile. CONCLUSION  Treatment of advanced PCa should be personalized, with administration of a combination of androgen deprivation therapy, ARAT agents, and chemotherapy being based on the patient&#39;s safety profile and the risk of side effects.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Background Significant gaps exist between guidelines and practice in the management of heart failure, not only in Oman but the Arabian Gulf region in general. Currently, only limited research exists on the use of these guideline-based cardiovascular medications and their corresponding target doses in the region. Objective To evaluate the use of guideline-based cardiovascular medications and their corresponding target doses in heart failure patients with reduced (&lt; 40%) and mid-range (40-49%) ejection fraction in Oman. Setting Cardiology clinics at Sultan Qaboos University Hospital, Muscat, Oman. Methods The study included heart failure patients seen at the clinics between January 2016 and December 2019. The use of angiotensin-converting-enzyme inhibitors (captopril, lisinopril) or angiotensin II receptor blockers (irbesartan, valsartan), beta-blockers (bisoprolol, carvedilol) and spironolactone along with their respective target doses were evaluated as per the European, American, and Canadian heart failure guidelines. Analyses were performed using univariate statistics. Main outcome measure The proportion of patients that was prescribed guideline-based heart failure medications along with their target doses as per guidelines. Results The overall mean age of the cohort (N = 249) was 63 +/- 15 years and 61% (n = 151) were males. Seventy-one percent (n = 177) of the patients had heart failure with reduced ejection fraction while 29% (n = 72) had heart failure with mid-range ejection fraction. A total of 87% (n = 216), 62% (n = 154) and 39% (n = 96) of the patients were on beta-blockers, angiotensin-converting-enzyme inhibitors/angiotensin II receptor blockers and spironolactone, respectively. Only 33% (n = 81) of the patients were on the triple guideline-based cardiovascular medication classes concurrently. Patients with reduced ejection fraction were more likely to be prescribed the triple guideline-based cardiovascular medication classes concurrently than those that had heart failure with mid-range ejection fraction (37% vs 22%; p = 0.027). A total of 100% (96/96), 56% (121/216) and 42% (64/153) of the patients were prescribed &gt;/= 50% of target dose for spironolactone, beta-blockers and angiotensin-converting-enzyme inhibitors/angiotensin II receptor blockers, respectively. Conclusions The use of guideline-based cardiovascular medications in heart failure patients with reduced and mid-range ejection fraction is low in Oman. They were also largely not optimally dosed at target levels.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 BACKGROUND  Highly fragmented ambulatory care (i.e., care spread across many providers without a dominant provider) has been associated with excess tests, procedures, emergency department visits, and hospitalizations. Whether fragmented care is associated with worse health outcomes, or whether any association varies with health status, is unclear. OBJECTIVE  To determine whether fragmented care is associated with the risk of incident coronary heart disease (CHD) events, overall and stratified by self-rated general health. DESIGN AND PARTICIPANTS  We conducted a secondary analysis of the nationwide prospective Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study (2003-2016). We included participants who were &gt;/= 65 years old, had linked Medicare fee-for-service claims, and had no history of CHD (N = 10,556). MAIN MEASURES  We measured fragmentation with the reversed Bice-Boxerman Index. We used Cox proportional hazards models to determine the association between fragmentation as a time-varying exposure and adjudicated incident CHD events in the 3 months following each exposure period. KEY RESULTS  The mean age was 70 years; 57% were women, and 34% were African-American. Over 11.8 years of follow-up, 569 participants had CHD events. Overall, the adjusted hazard ratio (HR) for the association between high fragmentation and incident CHD events was 1.14 (95% confidence interval (CI) 0.92, 1.39). Among those with very good or good self-rated health, high fragmentation was associated with an increased hazard of CHD events (adjusted HR 1.35; 95% CI 1.06, 1.73; p = 0.01). Among those with fair or poor self-rated health, high fragmentation was associated with a trend toward a decreased hazard of CHD events (adjusted HR 0.54; 95% CI 0.29, 1.01; p = 0.052). There was no association among those with excellent self-rated health. CONCLUSION  High fragmentation was associated with an increased independent risk of incident CHD events among those with very good or good self-rated health.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  Small-animal single-photon emission computed tomography (SPECT) systems with multi-pinhole collimation and large stationary detectors have advantages compared to systems with moving small detectors. These systems benefit from less labour-intensive maintenance and quality control as fewer prone parts are moving, higher accuracy for focused scans and maintaining high resolution with increased sensitivity due to focused pinholes on the field of view. This study aims to investigate the performance of a novel ultra-high-resolution scanner with two-detector configuration (U-SPECT5-E) and to compare its image quality to a conventional micro-SPECT system with three stationary detectors (U-SPECT(+)). METHODS  The new U-SPECT5-E with two stationary detectors was used for acquiring data with (99m)Tc-filled point source, hot-rod and uniformity phantoms to analyse sensitivity, spatial resolution, uniformity and contrast-to-noise ratio (CNR). Three dedicated multi-pinhole mouse collimators with 75 pinholes each and 0.25-, 0.60- and 1.00-mm pinholes for extra ultra-high resolution (XUHR-M), general-purpose (GP-M) and ultra-high sensitivity (UHS-M) imaging were examined. For CNR analysis, four different activity ranges representing low- and high-count settings were investigated for all three collimators. The experiments for the performance assessment were repeated with the same GP-M collimator in the three-detector U-SPECT(+) for comparison. RESULTS  Peak sensitivity was 237 cps/MBq (XUHR-M), 847 cps/MBq (GP-M), 2054 cps/MBq (UHS-M) for U-SPECT5-E and 1710 cps/MBq (GP-M) for U-SPECT(+). In the visually analysed sections of the reconstructed mini Derenzo phantoms, rods as small as 0.35 mm (XUHR-M), 0.50 mm (GP-M) for the two-detector as well as the three-detector SPECT and 0.75 mm (UHS-M) were resolved. Uniformity for maximum resolution recorded 40.7% (XUHR-M), 29.1% (GP-M, U-SPECT5-E), 16.3% (GP-M, U-SPECT(+)) and 23.0% (UHS-M), respectively. UHS-M reached highest CNR values for low-count images; for rods smaller than 0.45 mm, acceptable CNR was only achieved by XUHR-M. GP-M was superior for imaging rods sized from 0.60 to 1.50 mm for intermediate activity concentrations. U-SPECT5-E and U-SPECT(+) both provided comparable CNR. CONCLUSIONS  While uniformity and sensitivity are negatively affected by the absence of a third detector, the investigated U-SPECT5-E system with two stationary detectors delivers excellent spatial resolution and CNR comparable to the performance of an established three-detector-setup.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Inflammatory diseases,
 Intravenous administration of tissue-type plasminogen activator (IV tPA) therapy has long been considered a mainstay in ischemic stroke management. However, patients respond to IV tPA therapy unequally with some subsets of patients having worsened outcomes after treatment. In particular, diabetes mellitus (DM) is recognized as a clinically important vascular comorbidity that leads to lower recanalization rates and increased risks of hemorrhagic transformation (HT). In this short-review, we summarize the recent advances in understanding of the underlying mechanisms involved in post-IV tPA worsening of outcome in diabetic stroke. Potential pathologic factors that are related to the suboptimal tPA recanalization in diabetic stroke include higher plasma plasminogen activator inhibitor (PAI)-1 level, diabetic atherogenic vascular damage, glycation of the tPA receptor annexin A2, and alterations in fibrin clot density. While factors contributing to the exacerbation of HT in diabetic stroke include hyperglycemia, vascular oxidative stress, and inflammation, tPA neurovascular toxicity and imbalance in extracellular proteolysis are discussed. Besides, impaired collaterals in DM also compromise the efficacy of IV tPA therapy. Additionally, several tPA combination approaches developed from experimental studies that may help to optimize IV tPA therapy are also briefly summarized. In summary, more research efforts are needed to improve the safety and efficacy of IV tPA therapy in ischemic stroke patients with DM/poststroke hyperglycemia.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Adjuvant systemic treatments in breast cancer are indicated to reduce the risk of relapse. Their systemic side effects have been well documented and include menopausal symptoms such as impaired libido and vaginal dryness, increased risk of endometrial cancer, stroke, musculoskeletal symptoms including arthralgia and myalgia, osteopenia and fractures, skin rashes, and hypercholesterolemia. However, few articles have focused on the oral mucosal reactions related to adjuvant endocrine therapies (AETs) which clearly differ from those reported with chemotherapies or other targeted therapies used for breast cancer. AETs primarily expose patient to a higher risk of worsened periodontal health, salivary flow modifications, taste disturbance, and global deterioration of oral health-related quality of life. Although the rate of permanent discontinuation of AETs because of oral mucosal changes remains low, an interdisciplinary approach to evaluate oral health and to optimize oral supportive care appears essential to ensure an appropriate management and limit dose adjustment in treated patients. In this respect and based on our clinical experience, we propose recommendations to allow oncologists, nurses, and attending practitioners to implement appropriate measures rapidly and/or refer patients to dentists.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">stenos</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Diseases of arteries,
 OBJECTIVES  To investigate long-term outcomes of Takayasu&#39;s arteritis (TA) and explore the predictive factors associated with poor prognosis. METHODS  We performed a retrospective study on consecutive TA patients admitted to the Nanjing Drum Tower Hospital during the period from July 2010 to March 2019. Potential factors contributing to adverse outcomes, including death, vascular complications, and vascular stenosis aggravation were assessed by Cox regression analysis. RESULTS  Seventy-one individuals were enrolled, in which 90.1% were female. The mean onset age was 29.44 +/- 11.75 years, and mean follow-up time was 3.42 +/- 2.38 years. Adverse outcomes were observed in twenty-five (35.2%) patients, and the 1-, 5-, and 8-year event-free survival was 94.2%, 61.8%, and 29.8% respectively. Univariable Cox regression revealed that pulmonary hypertension (PH) (HR 4.13), high total cholesterol levels (HR 4.49), high LDL cholesterol levels (HR 5.14), and low-dose cyclophosphamide (CTX) treatment (HR 0.53) were associated with adverse outcomes. Among them, only CTX treatment remained significant in multivariable Cox regression analysis (HR 0.62). Interestingly, compared to those ineffective to CTX, the responders had higher immunoglobulin A levels (p &lt; 0.05) but lower CRP levels (p &lt; 0.05). CONCLUSIONS  Even with vigorous therapy, a large proportion of TA patients may present adverse outcomes along with the development of disease. Low-dose CTX treatment is helpful for a better prognosis. Key Points * The prognosis of Takayasu&#39;s arteritis is still poor. * Application of low-dose cyclophosphamide in high-risk patients helps to improve the outcome. * Abnormal lipid profiles may contribute to the development of this disease, which also deserves attention.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Extracorporeal life support (ECLS) can support gas exchange in patients with the acute respiratory distress syndrome (ARDS). During ECLS, venous blood is drained from a central vein via a cannula, pumped through a semipermeable membrane that permits diffusion of oxygen and carbon dioxide, and returned via a cannula to a central vein. Two related forms of ECLS are used. Venovenous extracorporeal membrane oxygenation (ECMO), which uses high blood flow rates to both oxygenate the blood and remove carbon dioxide, may be considered in patients with severe ARDS whose oxygenation or ventilation cannot be maintained adequately with best practice conventional mechanical ventilation and adjunctive therapies, including prone positioning. Extracorporeal carbon dioxide removal (ECCO2R) uses lower blood flow rates through smaller cannulae and provides substantial CO2 elimination (~ 20-70% of total CO2 production), albeit with marginal improvement in oxygenation. The rationale for using ECCO2R in ARDS is to facilitate lung-protective ventilation by allowing a reduction of tidal volume, respiratory rate, plateau pressure, driving pressure and mechanical power delivered by the mechanical ventilator. This narrative review summarizes physiological concepts related to ECLS, as well as the rationale and evidence supporting ECMO and ECCO2R for the treatment of ARDS. It also reviews complications, limitations, and the ethical dilemmas that can arise in treating patients with ECLS. Finally, it discusses future key research questions and challenges for this technology.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 PURPOSE  The aim of this study was to compare chemical contents, expression of BMP-8a, and the presence of Mycoplasma and ExoS-ExoU exotoxins producing Pseudomonas aeruginosa in tympanosclerosis (TS) and atherosclerosis (AS) plaques. METHODS  Thirty-six cases with TS and AS plaques (18 each) were selected and examined for chemical, immunohistochemical, and microbial analysis. SPSS ver. 21 and t test analysis were used for comparing the findings, and the level of significance was considered as p &lt; 0.05. RESULTS  TS plaques showed lower carbon, higher calcium, and phosphorous contents compared to AS plaques (p value &lt; 0.05). Chlorine was detected in AS plaques (1.8 w%) which could probably be due to the presence of myeloperoxidase (MPO) in atherosclerotic artery. Contrary to spherical shape of the surface of TS plaques, AS plaques were needle shaped. BMP-8a expression in TS plaques (59.5%) was significantly higher (p value &lt; 0.0001) than AS plaques (20%). Of the 18 TS specimens, 12, 14, and 3 were positive for ExoS, ExoU Pseudomonas aeruginosa, and Mycoplasma genes, respectively, while of the 18 AS specimens, 2, 2, and 3 were positive for ExoS, ExoU Pseudomonas aeruginosa, and Mycoplasma genes, respectively. CONCLUSION  TS plaques are different from AS plaques in terms of elemental components, surface morphology, and BMP-8a expression. Therefore, different calcification process and pathogenesis may be responsible for these two diseases. The results of our study showed that both TS and AS plaques have genetic footprint of Mycoplasma, but the level of calcium concentration-dependent exotoxins genes was found only in TS plaques.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Coagulopathies,
 The optimization of antithrombotic therapy for acute stroke treatment and secondary prevention is an evolving process based on an increasing array of studies that provide an evidence-based approach. Options have increased dramatically with the release of the non-vitamin K oral anticoagulants and with the results of recent randomized clinical trials designed to assess potential benefits versus risks for patients in an individualized fashion. Recent studies have provided important information to guide choice and dosing of antiplatelet agents as well as the length of treatment. Anticoagulant use is particularly pertinent for stroke prevention in patients at higher risk of atrial fibrillation and may have a place in certain other stroke mechanisms. One important focus of study is the potential benefit of combined antiplatelet and anticoagulant therapy. Options for our patients, when the initial choice of therapy does not demonstrate benefit or is not well tolerated, clearly, are valuable. For example, short-term dual antiplatelet therapy for minor stroke and transient ischemic attack is being adopted, but with the recognition that longer-term combined therapy is not worth the increased risk of bleeding. Alternative antiplatelet choices, such as cilostazol and possibly ticagrelor, may be of benefit for refractory patients and this could affect the decision-making process. This review represents an effort to incorporate the information from more recent stroke prevention and treatment studies with information gleaned from prior studies.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 OBJECTIVES  Obesity and cardiovascular disease remain significant burdens on the overall provision of health care in the United States. Obesity has been shown to be a direct risk factor for heart failure (HF). We conducted a nationwide cohort study to assess the short-term impact of obesity in hospitalized patients with HF. METHODS  We identified 1,520,871 encounters with a primary diagnosis of HF in the 2013-2014 Nationwide Readmission Database. We excluded patients younger than 18 years (n = 2755), hospitalized patients discharged in December (n = 126,137), patients with missing mortality information (n = 477), missing length of stay (LOS; n = 91), patients who were transferred to another hospital (n = 38,489), and patients with conflicting body weight information (n = 7757). Multivariable logistic regression was used to evaluate the association between baseline characteristics (including the presence of obesity) and in-hospital mortality, as well as 30-day readmission rates. RESULTS  The overall in-patient mortality rate was 2.8% (n = 37,927). Obese patients had numerically a lower mortality (1.8%) compared with the nonobese patients (3.1%); however, the difference in risk was not significant on multivariable analysis (hazard ratio 0.97, 95% confidence interval 0.94-1.01). In the overall cohort, 20.6% (n = 269,988) were readmitted within 30 days. The risk of 30-day readmission was significantly lower in obese patients (19.4%) compared with nonobese patients (20.9%) (odds ratio 0.85, 95% confidence interval 0.84-0.86). Obese patients had longer LOSs (median of 5 days [3-7] vs 4 days [2-6], P &lt; 0.001) and higher costs of index admission (median of $27,206 [$16,027-$48,316] vs $23,339 [$13,698-$41,982], P &lt; 0.001) compared with nonobese patients. CONCLUSIONS  In this cross-sectional study of patients hospitalized for HF in the United States, obesity was not associated with a higher risk of inpatient mortality, but it was associated with a lower 30-day readmission rate. Obese patients with HF, however, had longer LOSs and higher costs of index admission. Our findings support the obesity paradox seen in patients with HF.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 OBJECTIVES  Obesity and cardiovascular disease remain significant burdens on the overall provision of health care in the United States. Obesity has been shown to be a direct risk factor for heart failure (HF). We conducted a nationwide cohort study to assess the short-term impact of obesity in hospitalized patients with HF. METHODS  We identified 1,520,871 encounters with a primary diagnosis of HF in the 2013-2014 Nationwide Readmission Database. We excluded patients younger than 18 years (n = 2755), hospitalized patients discharged in December (n = 126,137), patients with missing mortality information (n = 477), missing length of stay (LOS; n = 91), patients who were transferred to another hospital (n = 38,489), and patients with conflicting body weight information (n = 7757). Multivariable logistic regression was used to evaluate the association between baseline characteristics (including the presence of obesity) and in-hospital mortality, as well as 30-day readmission rates. RESULTS  The overall in-patient mortality rate was 2.8% (n = 37,927). Obese patients had numerically a lower mortality (1.8%) compared with the nonobese patients (3.1%); however, the difference in risk was not significant on multivariable analysis (hazard ratio 0.97, 95% confidence interval 0.94-1.01). In the overall cohort, 20.6% (n = 269,988) were readmitted within 30 days. The risk of 30-day readmission was significantly lower in obese patients (19.4%) compared with nonobese patients (20.9%) (odds ratio 0.85, 95% confidence interval 0.84-0.86). Obese patients had longer LOSs (median of 5 days [3-7] vs 4 days [2-6], P &lt; 0.001) and higher costs of index admission (median of $27,206 [$16,027-$48,316] vs $23,339 [$13,698-$41,982], P &lt; 0.001) compared with nonobese patients. CONCLUSIONS  In this cross-sectional study of patients hospitalized for HF in the United States, obesity was not associated with a higher risk of inpatient mortality, but it was associated with a lower 30-day readmission rate. Obese patients with HF, however, had longer LOSs and higher costs of index admission. Our findings support the obesity paradox seen in patients with HF.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-magenta-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">arrhythm</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,
<span class="ansi-bold">Embeded topics: </span>Arrhythmia,Heart failure,
 BACKGROUND  Central blood pressure becomes increasingly accepted as an important diagnostic and therapeutic parameter in the management of cardiovascular disease. This led to development of several non-invasive techniques most commonly based on peripheral pulse wave analysis. Accuracy of widespread applanation tonometry can be affected by calibration and operator training. To overcome this, we aimed to evaluate a novel device (VascAssist 2) using automated oscillometric radial pulse wave analysis and a refined multi-compartment model of the arterial tree. METHODS  225 patients were prospectively enrolled. Invasive aortic root measurements served as reference in MEASURE-cBP 1 (n=106) whereas an applanation tonometry device (SphygmoCor) was used in MEASURE-cBP 2 (n=119). RESULTS  In MEASURE-cBP 1, we found a mean overestimation for systolic values of 4+/-12 mmHg (3+/-10%) and 6+/-10 mmHg (9+/-14%) for diastolic values. Diabetes mellitus and low blood pressure were associated with larger variation. In MEASURE-cBP 2, mean overestimation of systolic values was 4+/-4 mmHg (4+/-4%) and 1+/-4 mmHg (1+/-7%) of diastolic values. Arrhythmia was significantly more frequent in invalid measurements (61 vs. 18%, p&lt;0.0001) which were most often due to a low quality index of SphygmoCor. Accuracy did not differ between patients with arrhythmia and sinus rhythm in MEASURE-cBP 1. CONCLUSIONS  Central blood pressure estimates using VascAssist 2 can be considered at least as accurate as available techniques, even including diabetic patients. In direct comparison, automated measurement considerably facilitates application not requiring operator training and can be reliably applied even in patients with arrhythmias.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 Background and study aims Assessment of endoscopic ultrasonography (EUS)-elastography of the liver and spleen may identify patients with portal hypertension secondary to chronic liver disease. We aimed to evaluate use of EUS-elastography of the liver and spleen in identification of portal hypertension in patients with chronic liver disease. Patients and methods This was a single-center, diagnostic cohort study. Consecutive patients with liver cirrhosis and portal hypertension underwent EUS-elastography of the liver and spleen. Patients without a history of liver disease were enrolled as controls. The primary outcome was diagnostic yield of liver and spleen stiffness measurement via EUS-elastography in prediction of portal hypertension secondary to chronic liver cirrhosis. Cutoff values were defined through Youden&#39;s index. Overall accuracy was calculated for parameters with an area under the receiver operating characteristic (AUROC) curve &gt;/= 80 %. Results Among the 61 patients included, 32 had cirrhosis of the liver. Liver and spleen stiffness was measured by the strain ratio and strain histogram, with sensitivity/(1 - specificity) AUROC values &gt;/= 80 %. For identification of patients with cirrhosis and portal hypertension, the liver strain ratio (SR) had a sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of 84.3 %, 82.8 %, 84.4 %, and 82.8 %, respectively; the liver strain histogram (SH) had values of 87.5 %, 69.0 %, 75.7 %, and 83.3 %, respectively. EUS elastography of the spleen via the SR reached a sensitivity, specificity, PPV, and NPV of 87.5 %, 69.0 %, 75.7 %, and 83.3 %, respectively, whereas the values of SH were 56.3 %, 89.7 %, 85.7 %, and 65.0 %, respectively. Conclusion Endoscopic ultrasonographic elastography of the liver and spleen is useful for diagnosis of portal hypertension in patients with cirrhosis.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocardit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">cardit</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Background  Myocardial strain analysis can provide diagnostic and prognostic information for myocarditis. The aim of the present study was to assess early and acute myocarditis in a rat model using cardiac magnetic resonance tissue tracking (CMR-TT) for myocardial strain analysis. We compared the strain&#39;s findings with the histological and immunohistochemical results. Methods  Experimental autoimmune myocarditis (EAM) was induced by footpad injections of porcine cardiac myosin. The rats were examined by 7.0T preclinical CMR at day 14 (n=15) and day 21 (n=16) after EAM induction and the two control groups (each n=15) were also examined at day 14 and day 21, respectively. Using CMR-TT, we found a global peak systolic radial strain (ErrSAX) and a circumferential strain (EccSAX) from the short-axis cine views and a radial strain (ErrLAX) and a longitudinal strain (EllLAX) from the long-axis cine views, which were calculated by dedicated TT software. Subsequently, histological and immunohistochemical evaluations were performed. Results  EllLAX significantly decreased in early myocarditis compared with the control (-23.40%+/-1.48% vs. -22.02%+/-0.81%, P&lt;0.05). ErrSAX, EccSAX, ErrLAX, and EllLAX values significantly reduced in acute myocarditis compared with the controls (ErrSAX  34.27%+/-9.80% vs. 49.76%+/-4.97%, EccSAX  -18.98%+/-3.69% vs. -24.13+/-1.23, ErrLAX  33.21%+/-10.24% vs. 49.59%+/-5.69%, and EllLAX  -17.75%+/-3.58% vs. -23.39%+/-1.48%; P&lt;0.001, respectively). The receiver operating characteristic curve showed that myocardial strain analysis had a good diagnostic performance in early and acute myocarditis. The pathological evaluation revealed that inflammatory lesions began to appear in early myocarditis and peaked in acute myocarditis. Conclusions  The CMR-TT strain analysis allowed accurate and reliable evaluation of early and acute myocarditis in a rat model, and has the potential to serve as a diagnostic indicator for the assessment of myocardial dysfunction in myocarditis.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocardit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">cardit</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Background  Myocarditis does not have typical clinical manifestations and thus is difficult to accurately diagnose by virtue of infection history, and electrocardiogram (EKG) and peripheral blood abnormalities. Endomyocardial biopsy is the gold standard for diagnosis of myocarditis, but is invasive, high risk, and has an observational blind area. Cardiac magnetic resonance imaging (CMRI) is multiparameter and multidirectional with high spatial resolution and high contrast of soft tissue. However, the optimal method of calculating left ventricular (LV) function in patients with apical-segment-injured myocarditis is unresolved. We compared and analyzed the differences between two different methods (Simpson and 4D B-spline surface model (known as the 4D method)) of measuring LV function by CMRI in patients with myocarditis in the 17th segment of the left ventricle. Methods  The basic clinical data of two groups (myocarditis and non-myocarditis) were statistically analyzed, and differences in the LV function parameters by the two imaging methods were compared in the myocarditis group. Receiver-operating characteristic curves of single parameters and combined parameters based on the Simpson and 4D methods were drawn and the area under the curve, diagnostic threshold, maximum sensitivity interval, and maximum specificity interval were calculated. Results  In the myocarditis and non-myocarditis groups the respective number of patients was 22 and 17, the percentage of males was 54.55% and 47.06%, and the average age was 32.20+/-11.59 and 43.06+/-11.62 years. The difference in LV ejection fraction (LVEF) (P=0.033) and LV end systolic volume (LVESV) (P=0.030) in the myocarditis group was statistically significant. The respective AUCs based on the Simpson and 4D methods were LVEF 0.602 vs. 0.778, LVESV 0.556 vs. 0.751, LVEF-and-LVESV 0.634 vs. 0.775. Based on the 4D method, the diagnostic thresholds of LVEF and LVESV were 34.965 (sensitivity 0.882, specificity 0.591) and 69.090 (sensitivity 0.727, specificity 0.706), the maximum sensitivity intervals of LVEF and LVESV were (24.610, 27.450) and (35.355, 37.200), and the maximum specificity intervals of LVEF and LVESV were (60.530, 65.625) and (91.625, 95.835), respectively. Conclusions  Compared with the Simpson method, the 4D method might be more effective for CMRI diagnosis of apical-segment-injured myocarditis. When the Simpson method is used, LVEF combined with LVESV is recommended for comprehensive evaluation to improve diagnostic efficiency. When the 4D method is used, LVEF might be the preferred parameter for evaluation of LV function.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Chronic low-grade white adipose tissue (WAT) inflammation is a hallmark of metabolic syndrome in obesity. Here, we demonstrate that a subpopulation of mouse WAT perivascular (PDGFRbeta(+)) cells, termed fibro-inflammatory progenitors (FIPs), activate proinflammatory signalling cascades shortly after the onset of high-fat diet feeding and regulate proinflammatory macrophage accumulation in WAT in a TLR4-dependent manner. FIPs activation in obesity is mediated by the downregulation of zinc-finger protein 423 (ZFP423), identified here as a transcriptional corepressor of NF-kappaB. ZFP423 suppresses the DNA-binding capacity of the p65 subunit of NF-kappaB by inducing a p300-to-NuRD coregulator switch. Doxycycline-inducible expression of Zfp423 in PDGFRbeta(+) cells suppresses inflammatory signalling in FIPs and attenuates metabolic inflammation of visceral WAT in obesity. Inducible inactivation of Zfp423 in PDGFRbeta(+) cells increases FIP activity, exacerbates adipose macrophage accrual and promotes WAT dysfunction. These studies implicate perivascular mesenchymal cells as important regulators of chronic adipose-tissue inflammation in obesity and identify ZFP423 as a transcriptional break on NF-kappaB signalling.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 OBJECTIVES  Neck adipose tissue (NAT) volume increases with general adiposity, with fat accumulating in different neck tissue compartments. In patients with certain malignant/benign tumours, the accumulation of NAT, and certain NAT distributions, have been associated with cardiometabolic risk (CMR). However, it is unknown whether the same relationships exist in healthy people, and whether NAT accumulation and distribution are related to the inflammatory status. METHODS  In this cross-sectional study, 139 young healthy adults (68% women) underwent a computed tomography scan to quantify the volume of compartmental (i.e., subcutaneous, intermuscular and perivertebral) and total NAT at the height of vertebra C5. Anthropometric indicators were measured, and body composition determined using dual energy X-ray absorptiometry. Information on CMR factors (i.e., blood glycaemic and lipid markers, blood pressure and physical fitness) was also gathered, and a CMR score calculated. Several plasma cytokines and serum components of the innate immune system were measured to determine the inflammatory status. RESULTS  Compartmental and total NAT volumes were directly related to body mass index (BMI), and lean, fat, and visceral adipose tissue (VAT) masses (all, P &lt;/= 0.05). Larger compartmental (especially intermuscular) and total NAT volumes were directly associated with the CMR score, several CMR factors (i.e., glycaemic and lipid markers and blood pressure), and the C3, C4 and leptin concentrations. They were, however, inversely correlated with the CMR factors high density lipoprotein-cholesterol (HDL-C) and physical fitness, and with the adiponectin concentration (all P &lt;/= 0.05). Several of these associations remained statistically significant (P &lt;/= 0.05) after adjustment for BMI, body fat percentage or VAT mass. Overall, results did not change after applying false discovery rate correction. CONCLUSIONS  NAT volume and its distribution among different tissue compartments is associated with the CMR and inflammatory profile of young healthy adults. Total NAT volume appears to be as valuable as VAT mass in terms of predicting CMR and inflammatory status.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 The last decade has witnessed the healthcare system going paperless with increased use of electronic healthcare records. Artificial intelligence tools including smartphones and smart watches have changed the landscape of day-to-day lives. Digitisation, decentralisation of healthcare and empowerment of allied healthcare providers and patients themselves have made shared clinical decision-making a reality. The year 2020 quickly turned into an unprecedented time in our lives with the entry of COVID-19. Amidst a pandemic, healthcare systems rapidly adapted and transformed, and changes that otherwise would have taken a decade, took a mere few weeks (Webster, Lancet 395 1180-1, 2020). This essay reviews evidence of transformation in the realm of hypertension management, namely diagnosis, lifestyle changes, therapeutics and prevention of hypertension at both individual and population levels, and presents an extrapolation of how this transformation might shape the next decade.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-magenta-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">arrhythm</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Arrhythmia,Inflammatory diseases,
 Myocardial infarction (MI) can result in sympathetic nerve loss in the infarct region. However, the contribution of hypo-innervation to electrophysiological remodeling, independent from MI-induced ischemia and fibrosis, has not been comprehensively investigated. We present a novel mouse model of regional cardiac sympathetic hypo-innervation utilizing a targeted-toxin (dopamine beta-hydroxylase antibody conjugated to saporin, DBH-Sap), and measure resulting electrophysiological and Ca(2+) handling dynamics. Five days post-surgery, sympathetic nerve density was reduced in the anterior left ventricular epicardium of DBH-Sap hearts compared to control. In Langendorff-perfused hearts, there were no differences in mean action potential duration (APD80) between groups; however, isoproterenol (ISO) significantly shortened APD80 in DBH-Sap but not control hearts, resulting in a significant increase in APD80 dispersion in the DBH-Sap group. ISO also produced spontaneous diastolic Ca(2+) elevation in DBH-Sap but not control hearts. In innervated hearts, sympathetic nerve stimulation (SNS) increased heart rate to a lesser degree in DBH-Sap hearts compared to control. Additionally, SNS produced APD80 prolongation in the apex of control but not DBH-Sap hearts. These results suggest that hypo-innervated hearts have regional super-sensitivity to circulating adrenergic stimulation (ISO), while having blunted responses to SNS, providing important insight into the mechanisms of arrhythmogenesis following sympathetic nerve loss.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 Smoking increases the risk of cardiovascular diseases. The present study was designed to determine the effects of 2-month exposure to cigarette smoke (CS) on proteins in the left ventricles of spontaneously hypertensive rats (SHR) and to identify the molecular targets associated with the pathogenesis/progression of CS-induced cardiac hypertrophy. SHR and Wistar Kyoto rats (WKY) were exposed to CS at low (2 puffs/min for 40 min) or high dose (2 puffs/min for 120 min), 5 days a week for 2 months. Using the two-dimensional fluorescence difference gel electrophoresis combined with MALDI-TOF/TOF tandem mass spectrometry, we compared differences in the expression levels of proteins in the whole left ventricles induced by long-term smoking. High-dose CS mainly caused cardiac hypertrophy in SHR, but not WKY, but no change in blood pressure. Proteomic analysis identified 30 protein spots with significant alterations, with 14 up-regulated and 16 down-regulated proteins in the left ventricles of CS-exposed SHR, compared with control SHR. Among these proteins, two members of the heat shock proteins (HSP70 and HSP20) showed significant up-regulation in the left ventricles of CS high-dose SHR, and the results were confirmed by western blot analysis. Our findings suggested that HSPs play an important role in regulation of CS-induced cardiac hypertrophy.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 The development of transcatheter mitral valve replacement therapies requires accurate post-processing analysis tools to provide D-shaped mitral annulus dimensions from 3-dimensional (3D) data. The agreement between two semi-automated, software packages to process 3D transesophageal echocardiography (TEE) data for the measurement of the mitral valve annulus dimensions was evaluated. 3DTEE data of patients with moderate-severe mitral regurgitation (MR) were postprocessed with semi-automated, vendor-independent (VI) software and vendor-specific (VS) software. Both post-processing software provided key measurements for the selection of transcatheter valve prosthesis size  annulus area, annulus circumference and the septal-to-lateral distance of the annulus. The intertrigonal distance was provided only by the VS software. The inter- and intra-observer agreements were assessed with Bland-Altman analysis. Of 105 patients (63.8 +/- 11 years, 66% male) with MR, 28 had secondary MR, 45 fibroelastic deficiency, and 32 Barlow&#39;s disease. Using VS software, the dimensions for the overall population were 16.1 +/- 4.6 cm(2) for annulus area, for circumference 14.4 +/- 1.9 cm, intertrigonal distance 3.4 +/- 0.5 cm and septal-to-lateral distance 3.8 +/- 0.6 cm. Similar dimensions were obtained using VI software  15.7 +/- 4.6 cm(2) for annulus area, 14.5 +/- 2.0 cm for circumference, and 4.1 +/- 0.6 cm for septal-to-lateral distance. The inter- and intra-observer agreement for both software programs was excellent. In conclusion, current post-processing software programs for 3DTEE data of the mitral valve annulus provide good reproducibility of key measurements to select the transcatheter prosthesis size.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 SGLT2 inhibitors (SGLT2i) slow the progression of chronic kidney disease; however, evidence for the underlying molecular mechanisms is scarce. We investigated SGLT2i-mediated effects on differential gene expression in two independent human proximal tubular cell (HPTC) lines (HK-2 and RPTEC/TERT1) at the mRNA and protein levels under normoglycemic conditions, utilizing IL-1beta as a pro-inflammatory mediator. Microarray hybridization identified 259 genes that were uniformly upregulated by IL-1beta (10 mg/mL) and downregulated by empagliflozin (Empa) (500 nM) after 24 h of stimulation in two independent HPTC lines (n = 2, each). The functional annotation of these genes identified eight pathway clusters. Among 12 genes annotated to the highest ranked cluster (enrichment score, 3.51), monocyte chemoattractant protein-1/CC-chemokine ligand 2 (MCP-1/CCL2) and endothelin-1 (ET-1) were selected for verification at mRNA and protein levels based on their established involvement in the early pathogenesis of chronic kidney disease  IL-1beta upregulated basal MCP-1/CCL2 (15- and 19-fold) and ET-1 (3- and 8-fold) mRNA expression, while Empa downregulated basal MCP-1/CCL2 (0.6- and 0.5-fold) and ET-1 (0.3- and 0.2-fold) mRNA expression as early as 1 h after stimulation and for at least 24 h in HK-2 and RPTEC/TERT1 cells, respectively. The co-administration of Empa inhibited IL-1beta-mediated MCP-1/CCL2 (0.2-fold, each) and ET-1 (0.2-fold, each) mRNA expression as early as 1 h after ligand stimulation and for at least 24 h in both HPTC lines, respectively. This inhibitory effect of Empa on basal and IL-1beta-mediated MCP-1/CCL2 and ET-1 mRNA expression was corroborated at the protein level. Our study presents novel evidence for the interference of SGLT2 inhibition with tubular inflammatory response mechanisms under normoglycemic conditions that might account for SGLT2i-mediated nephroprotection.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,
 Micronutrients such as vitamins and trace elements are crucial for maintaining the health of all organisms. Micronutrients are involved in every cellular/biochemical process. They play roles in proper heart and brain functioning, influence immunological responses, and antioxidant defense systems. Therefore, prolonged deficiency in one or more micronutrients leads to cardiovascular or neurodegenerative disorders. Keeping micronutrients at adequate levels is especially important for seniors. They are prone to deficiencies due to age-associated functional decline and often to a diet poor in nutrients. Moreover, lack of micronutrients has an indirect impact on the genome. Their low levels reduce the activity of antioxidant enzymes, and therefore inhibit the efficiency of defense against free radicals which can lead to the formation of DNA lesions. The more DNA damage in the genetic material, the faster aging at the cellular level and a higher risk of pathological processes (e.g., carcinogenesis). Supplementation of crucial antioxidative micronutrients such as selenium, zinc, vitamin C, and vitamin E seems to have the potential to positively influence the condition of an aging organism, including minimizing inflammation, enhancing antioxidative defense, and limiting the formation of DNA lesions. In consequence, it may lead to lowering the risk and incidence of age-related diseases such as cardiovascular diseases, neurodegenerative diseases, and malnutrition. In this article, we attempt to present the synergistic action of selected antioxidant micronutrients (vitamin C, vitamin E, selenium, and zinc) for inhibiting oxidative stress and DNA damage, which may impede the process of healthy aging.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Diet and lifestyle interventions are the recommended treatment for patients with non-alcoholic fatty liver disease (NAFLD), with the aim of achieving a 7-10% weight loss. Several dietary patterns have been suggested for this purpose, however, to date, the best one is represented by the Mediterranean diet (MD) as it is rich in macro- and micro- nutrients known for their effectiveness in health-promotion and cardio-vascular disease prevention. Moreover, MD is characterized by the inclusion of nuts. These foods have shown potential benefits in health-promotion as they are rich in fibers, which have lipid-lowering effects, rich in mono- and poly-unsaturated fatty acids, which help reduce insulin-resistance and serum cholesterol, and contain anti-oxidants which reduce oxidative stress and inflammation. Additionally, nuts are associated with a better control, or reduction, of Body Mass Index (BMI). All these effects are useful targets to achieve in NAFLD, so that nuts have been proposed as a suitable dietary treatment supplement for weight and metabolic control in these patients. In recent years, health authorities raised an alert on nuts consumption as these may be at high risk of aflatoxin (AF) contamination, for which controls and legislations are different among countries. AF is a well-known cancerogenic agent and a recognized risk factor for hepatocellular carcinoma. Patients with NAFLD have an overall, inherent sevenfold increased risk of developing hepatocellular carcinoma as compared with the general population. In this context, one could argue that recommending the inclusion of nuts in the diet of NAFLD patients has to be balanced with the risk of potential chronic exposure to AF, and every effort should be pursued to assure the safety of these nutrients. In this review, we aim to summarize the benefits of nuts consumption, the evidence for AF contamination of nuts and the consequent potential risks in patients with NAFLD.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Immersive virtual reality (IVR) is a technology that blurs the line between the physical world and a digital environment. Using appropriate pointing devices, it is possible to engage in physical activity (PA). The main aim of the study was to assess the attractiveness and intensity of physical exercise while playing active video games (AVGs) in IVR on an omnidirectional treadmill by obese children and to present the results compared to health recommendations (PA). It was also assessed whether the AVGs storyline can effectively motivate the participants to undertake locomotor activity by increasing the intensity of their effort (moving in a limited space vs. having to follow a set route). Eleven children aged 8 to 12 years with diagnosed obesity participated in the experiment. The attractiveness of PA was assessed with a questionnaire, while the intensity of exercise was estimated on the basis of heart rate. The answers show that AVGs are attractive and more enjoyable for the respondents than conventional video games. All participants declared their willingness to practice this form of PA. The intensity of PA of obese children during two games was high but during the game where the player was supposed to follow a set route, it was significantly higher (83.3 +/- 9.2% HRmax) than during the game whose storyline assumed moving in a limited space (77.4 +/- 9.8% HRmax). Due to the high intensity of PA while playing the AVGs studied, it can be assumed that obese children can benefit for their health if the games are used on a regular basis. However, further research is needed to verify this thesis.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Coagulopathies,
 Hyperphosphatemia has been proposed as a cardiovascular risk factor, contributing to long-term vascular calcification in hyperphosphatemic Chronic Kidney Disease (CKD) patients. However, more recent studies have also demonstrated acute effects of inorganic phosphate (Pi) on endothelial cells in vitro, especially generation of pro-coagulant endothelial microvesicles (MV). Hitherto, such direct effects of hyperphosphatemia have not been reported in vivo. Thirty-six male Sprague-Dawley rats were randomly allocated to three experimental groups  (1) CKD induced by partial nephrectomy receiving high (1.2%) dietary phosphorus; (2) CKD receiving low (0.2%) dietary phosphorus; and (3) sham-operated controls receiving 1.2% phosphorus. After 14 days the animals were sacrificed and plasma MVs counted by nanoparticle tracking analysis. MVs isolated by centrifugation were assayed for pro-coagulant activity by calibrated automated thrombography, and relative content of endothelium-derived MVs was assessed by anti-CD144 immunoblotting. When compared with sham controls, high phosphorus CKD rats were shown to be hyperphosphatemic (4.11 +/- 0.23 versus 2.41 +/- 0.22 mM Pi, p &lt; 0.0001) with elevated total plasma MVs (2.24 +/- 0.37 versus 1.31 +/- 0.24 x 10(8) per ml, p &lt; 0.01), showing increased CD144 expression (145 +/- 25% of control value, p &lt; 0.0001), and enhanced procoagulant activity (18.06 +/- 1.75 versus 4.99 +/- 1.77 nM peak thrombin, p &lt; 0.0001). These effects were abolished in the low phosphorus CKD group. In this rat model, hyperphosphatemia (or a Pi-dependent hormonal response derived from it) is sufficient to induce a marked increase in circulating pro-coagulant MVs, demonstrating an important link between hyperphosphatemia and thrombotic risk in CKD.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Common genetic variants interact with environmental factors to impact risk of heritable diseases. A notable example of this is a single-nucleotide variant in the Solute Carrier Family 39 Member 8 (SLC39A8) gene encoding the missense variant A391T, which is associated with a variety of traits ranging from Parkinson&#39;s disease and neuropsychiatric disease to cardiovascular and metabolic diseases and Crohn&#39;s disease. The remarkable extent of pleiotropy exhibited by SLC39A8 A391T raises key questions regarding how a single coding variant can contribute to this diversity of clinical outcomes and what is the mechanistic basis for this pleiotropy. Here, we generate a murine model for the Slc39a8 A391T allele and demonstrate that these mice exhibit Mn deficiency in the colon associated with impaired intestinal barrier function and epithelial glycocalyx disruption. Consequently, Slc39a8 A391T mice exhibit increased sensitivity to epithelial injury and pathological inflammation in the colon. Taken together, our results link a genetic variant with a dietary trace element to shed light on a tissue-specific mechanism of disease risk based on impaired intestinal barrier integrity.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Common genetic variants interact with environmental factors to impact risk of heritable diseases. A notable example of this is a single-nucleotide variant in the Solute Carrier Family 39 Member 8 (SLC39A8) gene encoding the missense variant A391T, which is associated with a variety of traits ranging from Parkinson&#39;s disease and neuropsychiatric disease to cardiovascular and metabolic diseases and Crohn&#39;s disease. The remarkable extent of pleiotropy exhibited by SLC39A8 A391T raises key questions regarding how a single coding variant can contribute to this diversity of clinical outcomes and what is the mechanistic basis for this pleiotropy. Here, we generate a murine model for the Slc39a8 A391T allele and demonstrate that these mice exhibit Mn deficiency in the colon associated with impaired intestinal barrier function and epithelial glycocalyx disruption. Consequently, Slc39a8 A391T mice exhibit increased sensitivity to epithelial injury and pathological inflammation in the colon. Taken together, our results link a genetic variant with a dietary trace element to shed light on a tissue-specific mechanism of disease risk based on impaired intestinal barrier integrity.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Common genetic variants interact with environmental factors to impact risk of heritable diseases. A notable example of this is a single-nucleotide variant in the Solute Carrier Family 39 Member 8 (SLC39A8) gene encoding the missense variant A391T, which is associated with a variety of traits ranging from Parkinson&#39;s disease and neuropsychiatric disease to cardiovascular and metabolic diseases and Crohn&#39;s disease. The remarkable extent of pleiotropy exhibited by SLC39A8 A391T raises key questions regarding how a single coding variant can contribute to this diversity of clinical outcomes and what is the mechanistic basis for this pleiotropy. Here, we generate a murine model for the Slc39a8 A391T allele and demonstrate that these mice exhibit Mn deficiency in the colon associated with impaired intestinal barrier function and epithelial glycocalyx disruption. Consequently, Slc39a8 A391T mice exhibit increased sensitivity to epithelial injury and pathological inflammation in the colon. Taken together, our results link a genetic variant with a dietary trace element to shed light on a tissue-specific mechanism of disease risk based on impaired intestinal barrier integrity.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlud</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,Coagulopathies,
 Patients with COVID-19 are at high risk for thrombotic arterial and venous occlusions. Lung histopathology often reveals fibrin-based occlusions in the small blood vessels of patients who succumb to the disease. Antiphospholipid syndrome is an acquired and potentially life-threatening thrombophilia in which patients develop pathogenic autoantibodies targeting phospholipids and phospholipid-binding proteins (aPL antibodies). Case series have recently detected aPL antibodies in patients with COVID-19. Here, we measured eight types of aPL antibodies in serum samples from 172 patients hospitalized with COVID-19. These aPL antibodies included anticardiolipin IgG, IgM and IgA; anti-beta2 glycoprotein I IgG, IgM, and IgA; and anti-phosphatidylserine/ prothrombin (aPS/PT) IgG and IgM. We detected aPS/PT IgG in 24% of serum samples, anticardiolipin IgM in 23% of samples, and aPS/PT IgM in 18% of samples. Antiphospholipid autoantibodies were present in 52% of serum samples using the manufacturer&#39;s threshold and in 30% using a more stringent cutoff (&gt;/=40 ELISA-specific units). Higher titers of aPL antibodies were associated with neutrophil hyperactivity including the release of neutrophil extracellular traps (NETs), higher platelet counts, more severe respiratory disease, and lower clinical estimated glomerular filtration rate. Similar to IgG from patients with antiphospholipid syndrome, IgG fractions isolated from COVID-19 patients promoted NET release from neutrophils isolated from healthy individuals. Furthermore, injection of IgG purified from COVID-19 patient serum into mice accelerated venous thrombosis in two mouse models. These findings suggest that half of patients hospitalized with COVID-19 become at least transiently positive for aPL antibodies and that these autoantibodies are potentially pathogenic.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,
 Perinatal arterial ischemic stroke (PAIS) is a common cause of seizures, encephalopathy, altered mental status, and focal neurologic deficits in the neonatal period. It is the leading known cause of cerebral palsy. Other long-term risks include the development of epilepsy and impairment in cognition, language, and behavior. This article will review the known risk factors for PAIS, as well as the evaluation, management, and prognosis. Long-term neurodevelopmental surveillance is recommended, along with intensive therapies to reduce morbidity.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Coagulopathies,
 Venovenous and venoarterial extracorporeal membrane oxygenation (ECMO) remains a crucial lifesaving therapy for critically ill neonates with severe cardiorespiratory failure. Both the roller pump as well as the centrifugal pump are safe and efficient systems, and some red blood cell breakdown and hemolysis occurs in all ECMO systems. The roller pump functions by gravity whereas the centrifugal pump promotes the flow of blood by a magnetically driven spinning rotor to generate negative pressure. Extracorporeal Life Support Organization data indicate a significant increase in intravascular hemolysis in neonatal and pediatric patients receiving ECMO when the centrifugal pump is used compared with its use in adults. Risk factors for developing hemolysis during ECMO are small cannula size, high negative inlet pressure in the pump head, and thrombosis in the pump head and oxygenator. Excessive red blood cell breakdown and release of plasma free hemoglobin (pfHb) saturate physiologic neutralizing mechanisms such as haptoglobin and hemopexin. The increase in pro-oxidant and proinflammatory pfHb levels causes endothelial dysfunction in a dose-dependent manner. Hemolysis also increases the risk of in-hospital morbidities such as renal injury, direct hyperbilirubinemia, and thrombosis without an increase in mortality in patients receiving ECMO. Hemolysis is an unavoidable side effect of current ECMO technology and there are no approved treatments or treatment guidelines for the neonatal population. Therefore, increased vigilance, recognition of the severity of the hemolytic process, and prompt management are essential to prevent severe endothelial injury leading to proinflammatory and prothrombotic events.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Diseases of arteries,
 BACKGROUND  First Nations people are more likely than the general population to experience long-term adverse health outcomes after coronary angiography. Our aim was to quantify the extent of coronary artery disease among First Nations and non-First Nations patients undergoing angiography to investigate differences in coronary artery disease and related health disparities. METHODS  We conducted a retrospective matched cohort study to compare health outcomes of First Nations and non-First Nations adult patients (&gt; 18 yr) who underwent index angiography between Apr. 1, 2008, and Mar. 31, 2012, in Manitoba, Canada. The SYNTAX Score was used to measure and compare severity of coronary artery disease between groups. Primary outcomes of all-cause and cardiovascular mortality were compared between groups using Cox proportional hazard models adjusted by SYNTAX Score results and weighted by the inverse probability of being First Nations. Secondary outcomes included all-cause and cardiovascular-related hospital admissions. RESULTS  The cohort consisted of 277 matched pairs of First Nations and non-First Nations patients undergoing angiography; the average age of patients was 56.0 (standard deviation 11.7) years. The median SYNTAX Score results and patient distributions across categories in the matched paired cohort groups were not significantly different. Although proportionally First Nations patients showed worse health outcomes, mortality risks were similar in the weighted sample, even after controlling for revascularization and SYNTAX Score results. Secondary outcomes showed that adjusted risks for hospital admission for acute myocardial infarction (adjusted hazard ratio [HR] 3.03, 95% confidence interval [CI] 1.40-6.55) and for congestive heart failure (adjusted HR 3.84, 95% CI 1.37-10.78) were significantly higher among First Nations patients in the weighted sample. INTERPRETATION  The extent of coronary artery disease among matched cohort groups of First Nations and non-First Nations patients appears similar, and controlling for baseline sociodemographic characteristics, coronary artery disease risk factors and SYNTAX Score results explained higher mortality risk and most hospital admissions among First Nations patients. Although there is a need to decrease risk factors for coronary artery disease among First Nations populations, addressing individuals&#39; behaviour without considering root causes underlying risk factors for coronary artery disease will fail to decrease health outcome disparities among First Nations patients undergoing angiography.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,Diseases of arteries,
 BACKGROUND  The ability to rule out or in a major adverse cardiac event (MACE) in patients with suspected acute coronary syndrome at emergency department (ED) presentation would be beneficial to patient care and the health care system. The clinical chemistry score (CCS) was evaluated in this context. METHODS  This diagnostic accuracy study evaluated 2 different ED cohorts with suspected acute coronary syndrome. For patients in cohort 1, who presented to the ED of 3 hospitals in Hamilton, Ontario, between May and August 2013, retrospective measurements were taken using the Ortho Clinical Diagnostics high-sensitivity cardiac troponin I (hs-cTnI) assay; for patients in cohort 2, who presented to the ED of the same 3 hospitals in Hamilton between November 2012 and February 2013, an ED cardiac presentation blood test panel was performed with the Abbott Diagnostics hs-cTnI assay. The sensitivity and specificity of the CCS (cut-offs of &gt;/= 1 and 5) and hs-cTnI alone (published cut-offs) were compared for MACE (composite of death, myocardial infarction, unstable angina, revascularization) at 30 days for both cohorts and at 90 days for cohort 2. RESULTS  The incidence of MACE at 30 days was higher in cohort 1 (n = 1058) (19.4%, 95% confidence interval [CI] 16.8%-22.2%) than in cohort 2 (n = 5974) (14.6%, 95% CI 13.6%-15.6%). In cohort 1, a CCS of 1 or above yielded a sensitivity of 99.5% (95% CI 97.3%-99.9%). The sensitivity with an Ortho hs-cTnI cut-off of 1 ng/L or above was 91.2% (95% CI 86.5%-95.7%). The specificity of a CCS of 5 (97.8%, 95% CI 96.5%-98.7%) was higher than when the overall 99th-percentile cut-off for the Ortho hs-cTnI assay (&gt; 11 ng/L; 90.1%, 95% CI 87.9%-92.0%) was used. A similar pattern was observed in cohort 2 at 30 days and persisted at 90 days with the Abbott hs-cTnI assay. INTERPRETATION  The CCS derived with 2 different hs-cTnI assays and ED populations yielded higher sensitivity and specificity estimates for MACE than hs-cTnI alone. An intervention study is needed to evaluate the impact of the CCS at both the patient and hospital levels. TRIAL REGISTRATION  ClinicalTrials.gov, no. NCT01994577.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Diseases of arteries,
 A 74-year-old man, with inflammatory arthritis, recently commenced on adalimumab, presented with a 4-week history of left-sided chest pain, malaise and shortness of breath. Admission ECG showed age-indeterminate left bundle branch block. Troponin T was 4444 ng/L (normal range &lt;15 ng/L) and acute coronary syndrome treatment was commenced. Catheter angiogram revealed mild-burden non-obstructive coronary disease. Cardiac magnetic resonance (CMR) was performed to refine the differential diagnosis and demonstrated no myocardial oedema or late gadolinium enhancement. Extracardiac review highlighted oedema and enhancement of the left shoulder girdle muscles consistent with acute myositis. Creatine kinase was subsequently measured and significantly elevated at 7386 IU/L (normal range 30-200 IU/L in men). Electrophoresis clarified that this was of predominantly skeletal muscle origin. Myositis protocol MRI revealed florid skeletal muscle oedema. The MR findings, together with positive anti-Scl-70 antibodies, suggested fulminant immune-mediated necrotising myopathy presenting as a rare mimic of myocardial infarction with non-obstructive coronary arteries, diagnosed by careful extracardiac CMR review.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">art thrombosis</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Coagulopathies,
 Popliteal venous aneurysm (PVA) and antiphospholipid syndrome (APS) are under-recognised as potential causes of pulmonary embolism (PE). A 66-year-old woman presented with progressive shortness of breath. A contrast-enhanced CT revealed bilateral PE, a small renal infarction and bilateral PVAs. Direct oral anticoagulant (DOAC) therapy was initiated immediately for venous thrombosis. Given the positivity for serum antiphospholipid antibody (aPL) in an initial blood test, low-dose aspirin was included to prevent further arterial thrombosis. Her symptoms resolved and she was discharged 1 week later. Twelve weeks later, she was diagnosed with APS because of persistent aPL. Surgical resection of the right PVA was performed 1 year later from her hospitalisation. To the best of our knowledge, this is the first case of PE caused by the combination of bilateral PVAs and APS. This report emphasises the importance of careful screening to identify PE causes, and its optimal management.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 BACKGROUND  About half of all people with heart failure have heart failure with preserved ejection fraction (HFpEF), in which the heart is stiff. This type of heart failure is more common in older people with a history of hypertension, obesity, and diabetes mellitus. Patients with HFpEF are often managed in primary care, sometimes in collaboration with specialists. Knowledge about how best to manage this growing population is limited, and there is a pressing need to improve care for these patients. AIM  To explore clinicians&#39; and patients&#39;/carers&#39; perspectives and experiences about the management of HFpEF to inform the development of an improved model of care. DESIGN AND SETTING  A multiperspective qualitative study involving primary and secondary care settings across the east of England, Greater Manchester, and the West Midlands. METHOD  Semi-structured interviews and focus groups were conducted. Transcribed data were analysed using framework analysis and informed by the normalisation process theory (NPT). RESULTS  In total, 50 patients, nine carers/relatives, and 73 clinicians were recruited. Difficulties with diagnosis, unclear illness perceptions, and management disparity were identified as important factors that may influence management of HFpEF. The NPT construct of coherence reflected what participants expressed about the need to improve the identification, understanding, and awareness of this condition in order to improve care. CONCLUSION  There is a pressing need to raise the public and clinical profile of HFpEF, develop a clear set of accepted practices concerning its management, and ensure that systems of care are accessible and attuned to the needs of patients with this condition.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">tricuspid</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 OBJECTIVES  Although the incidence of patients with isolated tricuspid regurgitation (TR) is increasing, data regarding the clinical outcomes of isolated TR surgery are limited. This study sought to investigate the prognostic implications according to procedural types, and to identify preoperative predictors of clinical outcomes after isolated TR surgery. METHODS  Among consecutive 2610 patients receiving tricuspid valve (TV) procedure, we analysed 238 patients (age, 59.6 years; 143 females) who underwent stand-alone TV surgery (repair, 132; replacement, 106) for severe TR. Primary outcome was the composite of all-cause mortality and heart transplantation. Clinical outcomes between the repair and the replacement groups were compared after adjusting with the inverse probability of treatment weighting (IPTW) method. RESULTS  During follow-up (median, 4.1 years), 53 patients died and 4 received heart transplantation. Multivariable analysis revealed that age (p=0.001), haemoglobin level (p=0.003), total bilirubin (p=0.040), TR jet area (p=0.005) and right atrial (RA) pressure (p=0.022) were independent predictors of the primary outcome. After IPTW adjustment, there were no significant intergroup differences in the risk of primary outcome (HR 1.01; 95% CI 0.55 to 1.87). In the subgroup analysis, tricuspid annular diameter was identified as a significant effect modifier (p=0.012) in the comparison between repair versus replacement, showing a trend favouring replacement in patients with annular diameter &gt;44 mm. CONCLUSIONS  The outcomes of stand-alone severe TR surgery were independently associated with the severity of TR and RA pressure. In selected patients with severe annular dilation &gt;44 mm, replacement may become a feasible option.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischaem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">dil cardiomyopathy</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Cardiomyopathy,
 OBJECTIVE  To explore the association between three-dimensional (3D) cardiac magnetic resonance (CMR) feature tracking (FT) right ventricular peak global longitudinal strain (RVpGLS) and major adverse cardiovascular events (MACEs) in patients with stage C or D heart failure (HF) with non-ischaemic dilated cardiomyopathy (NIDCM) but without atrial fibrillation (AF). METHODS  Patients with dilated cardiomyopathy were enrolled in this prospective cohort study. Comprehensive clinical and biochemical analysis and CMR imaging were performed. All patients were followed up for MACEs. RESULTS  A total of 192 patients (age 53+/-14 years) were eligible for this study. A combination of cardiovascular death and cardiac transplantation occurred in 18 subjects during the median follow-up of 567 (311, 920) days. Brain natriuretic peptide, creatinine, left ventricular (LV) end-diastolic volume, LV end-systolic volume, right ventricular (RV) end-diastolic volume and RVpGLS from CMR were associated with the outcomes. The multivariate Cox regression model adjusting for traditional risk factors and CMR variables detected a significant association between RVpGLS and MACEs in patients with stage C or D HF with NIDCM without AF. Kaplan-Meier analysis based on RVpGLS cut-off value revealed that patients with RVpGLS &lt;-8.5% showed more favourable clinical outcomes than those with RVpGLS &gt;/=-8.5% (p=0.0037). Subanalysis found that this association remained unchanged. CONCLUSIONS  RVpGLS-derived from 3D CMR FT is associated with a significant prognostic impact in patients with NIDCM with stage C or D HF and without AF.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischaem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">dil cardiomyopathy</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Cardiomyopathy,
 OBJECTIVE  To explore the association between three-dimensional (3D) cardiac magnetic resonance (CMR) feature tracking (FT) right ventricular peak global longitudinal strain (RVpGLS) and major adverse cardiovascular events (MACEs) in patients with stage C or D heart failure (HF) with non-ischaemic dilated cardiomyopathy (NIDCM) but without atrial fibrillation (AF). METHODS  Patients with dilated cardiomyopathy were enrolled in this prospective cohort study. Comprehensive clinical and biochemical analysis and CMR imaging were performed. All patients were followed up for MACEs. RESULTS  A total of 192 patients (age 53+/-14 years) were eligible for this study. A combination of cardiovascular death and cardiac transplantation occurred in 18 subjects during the median follow-up of 567 (311, 920) days. Brain natriuretic peptide, creatinine, left ventricular (LV) end-diastolic volume, LV end-systolic volume, right ventricular (RV) end-diastolic volume and RVpGLS from CMR were associated with the outcomes. The multivariate Cox regression model adjusting for traditional risk factors and CMR variables detected a significant association between RVpGLS and MACEs in patients with stage C or D HF with NIDCM without AF. Kaplan-Meier analysis based on RVpGLS cut-off value revealed that patients with RVpGLS &lt;-8.5% showed more favourable clinical outcomes than those with RVpGLS &gt;/=-8.5% (p=0.0037). Subanalysis found that this association remained unchanged. CONCLUSIONS  RVpGLS-derived from 3D CMR FT is associated with a significant prognostic impact in patients with NIDCM with stage C or D HF and without AF.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischaem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">dil cardiomyopathy</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Cardiomyopathy,
 OBJECTIVE  To explore the association between three-dimensional (3D) cardiac magnetic resonance (CMR) feature tracking (FT) right ventricular peak global longitudinal strain (RVpGLS) and major adverse cardiovascular events (MACEs) in patients with stage C or D heart failure (HF) with non-ischaemic dilated cardiomyopathy (NIDCM) but without atrial fibrillation (AF). METHODS  Patients with dilated cardiomyopathy were enrolled in this prospective cohort study. Comprehensive clinical and biochemical analysis and CMR imaging were performed. All patients were followed up for MACEs. RESULTS  A total of 192 patients (age 53+/-14 years) were eligible for this study. A combination of cardiovascular death and cardiac transplantation occurred in 18 subjects during the median follow-up of 567 (311, 920) days. Brain natriuretic peptide, creatinine, left ventricular (LV) end-diastolic volume, LV end-systolic volume, right ventricular (RV) end-diastolic volume and RVpGLS from CMR were associated with the outcomes. The multivariate Cox regression model adjusting for traditional risk factors and CMR variables detected a significant association between RVpGLS and MACEs in patients with stage C or D HF with NIDCM without AF. Kaplan-Meier analysis based on RVpGLS cut-off value revealed that patients with RVpGLS &lt;-8.5% showed more favourable clinical outcomes than those with RVpGLS &gt;/=-8.5% (p=0.0037). Subanalysis found that this association remained unchanged. CONCLUSIONS  RVpGLS-derived from 3D CMR FT is associated with a significant prognostic impact in patients with NIDCM with stage C or D HF and without AF.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">rhe</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Inflammatory diseases,
 On May 29, 2020, the FDA approved atezolizumab for use in combination with bevacizumab, for the treatment of adult patients with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC) with no prior systemic treatment. The approval was based on data from Study IMbrave150, which randomly allocated (2 1) patients to receive either atezolizumab plus bevacizumab (atezolizumab-bevacizumab) or sorafenib. Overall survival (OS) and independently-assessed progression free survival (PFS) in the intent-to-treat (ITT) population were the primary endpoints. At the time of the primary analysis, the estimated median OS could not be estimated in the atezolizumab-bevacizumab arm and was 13.2 months in the sorafenib arm (Hazard Ratio [HR]  0.58; 95% Confidence Interval [CI]  0.42, 0.79). The estimated median PFS was 6.8 months (95% CI  5.8, 8.3) and 4.3 months (95% CI  4.0, 5.6) in the atezolizumab-bevacizumab and sorafenib arms, respectively. Adverse reactions occurring in &gt;20% of patients receiving atezolizumab-bevacizumab were hypertension, fatigue/asthenia, and proteinuria. Adverse reactions occurring in &gt;20% of patients receiving sorafenib were palmar-plantar erythrodysesthesia, diarrhea, hypertension, and decreased appetite. Hemorrhage was reported more frequently in patients receiving atezolizumab-bevacizumab (25%) than in patients receiving sorafenib (17%). An evaluation for the presence of varices is recommended within 6 months of initiation of atezolizumab-bevacizumab in patients with HCC. Approval of atezolizumab-bevacizumab is likely to change the treatment paradigm for HCC given that treatment with atezolizumab-bevacizumab resulted in improved OS and PFS compared to sorafenib, an accepted standard of care for first-line treatment of patients with unresectable HCC.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">microvascul</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 BACKGROUND  Retinal imaging has been applied for detecting eye diseases and cardiovascular risks using deep learning-based methods. Furthermore, retinal microvascular and structural changes were found in renal function impairment. However, a deep learning-based method for detecting early renal function impairment from retinal images has not yet been well studied. OBJECTIVE  This study aimed to establish and evaluate a deep learning model for detecting early renal function impairment from retinal fundus images. METHODS  This retrospective study enrolled patients who underwent renal function tests with color fundus images at any time between January 1, 2001 and August 31, 2019. A deep learning model was constructed to detect impaired renal function from the images. Early renal function impairment was defined as estimated glomerular filtration rate &lt; 90 mL/min/1.73 m2. Model performance was evaluated with respect to receiver operating characteristic curve and area under the curve (AUC). RESULTS  In total, 25 706 retinal fundus images were obtained from 6212 patients for the study period. The images were divided at an 8 1 1 ratio. The training, validation, and testing data sets respectively, contained 20 787, 2189, and 2730 images from 4970, 621, and 621 patients. There were 10 686 and 15 020 images determined to indicate normal and impaired renal function, respectively. The AUC of the model was 0.81 in the overall population. In subgroups stratified by serum hemoglobin A1c (HbA1c) level, AUCs were 0.81, 0.84, 0.85, and 0.87 for the HbA1c levels of &lt;/=6.5%, &gt;6.5%, &gt;7.5%, and &gt;10%, respectively. CONCLUSIONS  This study&#39;s deep learning model allows for early renal function impairment to be detected using retinal fundus images. The model was more accurate for patients with elevated serum HbA1c levels. CLINICALTRIAL 
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Diseases of arteries,
 AIM  To assess the impact of liver function test (LFT) abnormalities on the prognosis of patients with coronavirus disease 2019 (COVID-19) in a French cohort of hospitalized patients. PATIENTS AND METHOD  From March 13 to April 22, 2020, we collected on a computerized and anonymized database, medical records, laboratory data and clinical outcomes of patients hospitalized for confirmed cases of COVID-19 infection (RT-PCR and/or CT-scan). Patients were followed up until April 22, 2020 or until death or discharge. We have considered for statistical analysis, LFT abnormalities with levels greater than two times the upper limit of normal. Composite endpoint included admission to ICU, mechanical ventilation, severe radiologic injury and death to define disease severity. RESULTS  Among 281 patients (median age 60 years) with COVID-19, 102 (36.3%) had abnormal LFT. Hypertension (45.6%) and diabetes (29.5%) were the main comorbidities. 20.2% were taken liver-toxic drugs at the admission and 27.4% were given drugs known to induce hepatic cytolysis during hospitalization. Patients with elevated levels of ALT or AST were significantly more severe with a higher rate of admission to ICU (40.0% vs 6.0%, p&lt; 0.0001), and global mortality (26.7% vs 12.1%, p= 0.03). In multivariate analysis, obesity and cytolytic profil were associated with the composite endpoint (respectively 2.37 [1.21; 4.64], p= 0.01 and OR 6.20, 95% confidence interval [1.84, 20.95], p-value 0.003) CONCLUSION  Most of liver injuries are mild and transient during COVID-19. LFT abnormalities are associated with a poorer prognosis and could be a relevant biomarker for early detection of severe infection.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Diseases of arteries,
 AIM  To assess the impact of liver function test (LFT) abnormalities on the prognosis of patients with coronavirus disease 2019 (COVID-19) in a French cohort of hospitalized patients. PATIENTS AND METHOD  From March 13 to April 22, 2020, we collected on a computerized and anonymized database, medical records, laboratory data and clinical outcomes of patients hospitalized for confirmed cases of COVID-19 infection (RT-PCR and/or CT-scan). Patients were followed up until April 22, 2020 or until death or discharge. We have considered for statistical analysis, LFT abnormalities with levels greater than two times the upper limit of normal. Composite endpoint included admission to ICU, mechanical ventilation, severe radiologic injury and death to define disease severity. RESULTS  Among 281 patients (median age 60 years) with COVID-19, 102 (36.3%) had abnormal LFT. Hypertension (45.6%) and diabetes (29.5%) were the main comorbidities. 20.2% were taken liver-toxic drugs at the admission and 27.4% were given drugs known to induce hepatic cytolysis during hospitalization. Patients with elevated levels of ALT or AST were significantly more severe with a higher rate of admission to ICU (40.0% vs 6.0%, p&lt; 0.0001), and global mortality (26.7% vs 12.1%, p= 0.03). In multivariate analysis, obesity and cytolytic profil were associated with the composite endpoint (respectively 2.37 [1.21; 4.64], p= 0.01 and OR 6.20, 95% confidence interval [1.84, 20.95], p-value 0.003) CONCLUSION  Most of liver injuries are mild and transient during COVID-19. LFT abnormalities are associated with a poorer prognosis and could be a relevant biomarker for early detection of severe infection.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,
 PURPOSE  To review outcomes of patients with critical limb ischemia (CLI) who underwent conventional percutaneous transluminal angioplasty (PTA) as first-line treatment for revascularization. MATERIALS AND METHODS  Retrospective review of 3,303 angioplasty procedures on 2,402 limbs in 1,968 patients with CLI was conducted. Mean patient age was 68 years +/- 11, and 1,057 patients (54%) were male. Diabetes mellitus (DM) was present in 1,736 patients (88%), and end-stage renal disease (ESRD) in 579 (29%). A majority of patients (90%) had tissue loss. Limb salvage rates were generated by Kaplan-Meier plot. Univariate and multivariate Cox regression analysis was conducted to investigate associations between clinical predictors and time-to-event outcome. RESULTS  Limb salvage rates at 1, 3, 5, and 10 years were 75%, 73%, 72%, and 62%, respectively, and overall survival rates were 79%, 64%, 56%, and 34%, respectively. In multivariable Cox regression analysis with the outcome of major amputation, significant predictors included age &lt; 69 years (P = .032), Malay race (P = .029), DM (P &lt; .001), history of cerebral vascular disease (P = .003), ESRD (P &lt; .001), Rutherford classification (P = .042), repeat intervention (P = .034), and number of straight-line flows (P &lt; .001) and plantar arch integrity (P &lt; .001) on completion angiography. Significant associations with mortality were age &lt; 69 years (P &lt; .001), male sex (P = .030), Malay race (P = .027), history of ischemic heart disease (P &lt; .001), ESRD (P &lt; .001), and repeat intervention (P &lt; .001). CONCLUSIONS  PTA as first-line revascularization for patients with CLI is safe and effective. Further studies are suggested to validate the outcome predictive model.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 OBJECTIVE  This paper reviewed clinical experiences to evaluate the feasibility of a surgical strategy for an entire shaggy aorta. METHODS  Fifty-two (52) surgeries (47 men, average age 72+/-7 years) were performed for an entire shaggy aorta at the current institution from 2002-2017. Open surgery was performed in 30 cases, including total arch replacement in 12, extended aortic arch replacement via L-shaped thoracotomy in 10 and median sternotomy combined with left thoracotomy in two, and thoracoabdominal aortic replacement in six. Hybrid procedures were performed in 22 cases  type I hybrid arch repair in six, type II hybrid arch repair in seven and type III hybrid arch repair in nine. RESULTS  Hospital mortality was significantly higher with a hybrid repair  surgical, one case (3%); hybrid, six cases (27%), (p=0.0125). Stroke occurred at relatively high rates in both groups  surgical, seven cases (23%); hybrid, six cases (27%) (p=0.75). Spinal cord injury was significantly higher in hybrid repair  surgical, one case (3%); hybrid, seven cases (32%), (p=0.004). Open surgery revealed a better long-term survival rate than the hybrid procedure at 5 and 10 years  surgical, 82%, 65.7%; hybrid, 53%, 35.1%, respectively (p=0.0452). The rate of freedom from aortic events was significantly better with open surgery than a hybrid procedure at 5 and 10 years  surgical, 96%, 85%; hybrid, 83%, 41.3%, respectively (p=0.0082). CONCLUSIONS  Surgery for an entire shaggy aorta was frequently associated with embolic complications such as stroke, paraplegia, renal failure, and bowel necrosis. However, open surgical repair may produce better early and late outcomes and freedom from aortic events compared with hybrid repair.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">stenos</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 INTRODUCTION  Compared to bare-metal stents (BMS), drug-eluting stents reduce stent restenosis and improve subsequent revascularization rates. The impact on patients&#39; survival has been the subject of debate. OBJECTIVE  To assess the long-term (10-year) survival of patients undergoing percutaneous coronary intervention (PCI) with first-generation sirolimus-eluting stents (SES) in comparison with BMS. METHODS  In a single-center registry, 600 consecutive patients who underwent successful PCI with SES between April 2002 and February 2003 were compared to 594 patients who underwent PCI with BMS between January 2002 and April 2002, just before the introduction of SES. Clinical and procedural data were collected at the time of intervention and 10-year survival status was assessed via the national life status database. RESULTS  All baseline characteristics were similar between groups except for smaller stent diameter (2.84+/-0.38 vs. 3.19+/-0.49 mm; p&lt;0.001), greater stent length (18.50+/-8.2 vs. 15.96+/-6.10 mm; p&lt;0.001) and higher number of stents per patient (1.95 vs. 1.46, p&lt;0.001) in the SES group. Overall five- and 10-year all-cause mortality was 9.6% (n=110) and 22.7% (n=272), respectively. The adjusted HR for 10-year mortality in patients undergoing PCI with SES was 0.74 (95% CI 0.58-0.94; p=0.013), corresponding to a relative risk reduction of 19.8%. Other than PCI with BMS, older age, chronic kidney disease, chronic obstructive pulmonary disease and lower ejection fraction were independent predictors of 10-year mortality. CONCLUSION  To date, this is the longest follow-up study ever showing a potential survival benefit of first-generation sirolimus-eluting stents versus bare-metal stents, supporting prior observations on their sustained efficacy and safety relative to contemporary BMS.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-magenta-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">arrhythm</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Arrhythmia,Heart failure,Inflammatory diseases,
 The maintenance of tissue, organ, and organism homeostasis relies on an intricate network of players and mechanisms that assist in the different forms of cell-cell communication. Myocardial infarction, following heart ischemia and reperfusion, is associated with profound changes in key processes of intercellular communication, involving gap junctions, extracellular vesicles, and tunneling nanotubes, some of which have been implicated in communication defects associated with cardiac injury, namely arrhythmogenesis and progression into heart failure. Therefore, intercellular communication players have emerged as attractive powerful therapeutic targets aimed at preserving a fine-tuned crosstalk between the different cardiac cells in order to prevent or repair some of harmful consequences of heart ischemia and reperfusion, re-establishing myocardial function.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Coagulopathies,
 Diagnosis and treatment of renal cell carcinoma with venous tumor thrombosis remains a challenge today, requiring multidisciplinary teams, mainly in tumor thrombus levels III-IV. Our objective is to present the various diagnostic techniques used and its controversies. A review of the most relevant related articles between January 2000 and August 2020 has been carried out in PubMed, EMBASE and Scielo. Continuous technological development has allowed progress in its detection, in the approximation of the histological subtype, and in the determination of tumor thrombus level. Regardless of the imaging technique used for its diagnosis (CT, MRI, TEE, ultrasound with contrast), the time elapsed until treatment is vitally important to reduce the risk of complications, some of them fatal, such as pulmonary thromboembolism.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">stenos</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 Transthyretin (TTR) cardiac amyloidosis is a severe, progressive, infiltrative disease caused by the deposition of TTR at cardiac level. It may be due to a genetic alteration in its hereditary form (ATTRv) or as a consequence of an age-related degenerative process (ATTRwt). Thanks to advances in imaging techniques and the possibility of achieving a non-invasive diagnosis, we now know that ATTR is more frequent than traditionally considered and that it is particularly relevant in patients over 65 years with heart failure or with aortic stenosis. With the appearance of several treatment options capable of modifying the natural history of ATTR, it is necessary for clinicians to be familiar with the diagnostic process and treatment of this disease. This review will cover the clinical spectrum of presentation of ATTR, its diagnosis and treatment.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,
 BACKGROUND  As of June 15, 2020, a cumulative total of 7,823,289 confirmed cases of COVID-19 have been reported across 216 countries and territories worldwide. However, there is little information on the clinical characteristics and outcomes of critically ill patients with severe COVID-19 who were admitted to intensive care units (ICUs) in Latin America. The present study evaluated the clinical characteristics and outcomes of critically ill patients with severe COVID-19 who were admitted to ICUs in Mexico. METHODS  This was a multicenter observational study that included 164 critically ill patients with laboratory-confirmed COVID-19 who were admitted to 10 ICUs in Mexico, from April 1 to April 30, 2020. Demographic data, comorbid conditions, clinical presentation, treatment, and outcomes were collected and analyzed. The date of final follow-up was June 4, 2020. RESULTS  A total of 164 patients with severe COVID-19 were included in this study. The mean age of patients was 57.3 years (SD 13.7), 114 (69.5%) were men, and 6.0% were healthcare workers. Comorbid conditions were common in patients with critical COVID-19  38.4% of patients had hypertension and 32.3% had diabetes. Compared to survivors, nonsurvivors were older and more likely to have diabetes, hypertension or other conditions. Patients presented to the hospital a median of 7 days (IQR 4.5-9) after symptom onset. The most common presenting symptoms were shortness of breath, fever, dry cough, and myalgias. One hundred percent of patients received invasive mechanical ventilation for a median time of 11 days (IQR 6-14). A total of 139 of 164 patients (89.4%) received vasopressors, and 24 patients (14.6%) received renal replacement therapy during hospitalization. Eighty-five (51.8%) patients died at or before 30 days, with a median survival of 25 days. Age (OR, 1.05; 95% CI, 1.02-1.08; p&lt;0.001) and C-reactive protein levels upon ICU admission (1.008; 95% CI, 1.003-1.012; p&lt;0.001) were associated with a higher risk of in-hospital death. ICU length of stay was associated with reduced in-hospital mortality risk (OR, 0.89; 95% CI, 0.84-0.94; p&lt;0.001). CONCLUSIONS  This observational study of critically ill patients with laboratory-confirmed COVID-19 who were admitted to the ICU in Mexico demonstrated that age and C-reactive protein level upon ICU admission were associated with in-hospital mortality, and the overall hospital mortality rate was high. TRIAL REGISTRATION  ClinicalTrials.gov, NCT04336345.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 OBJECTIVE  To determine predictors of in-hospital mortality related to COVID-19 in older patients. DESIGN  Retrospective cohort study. SETTING AND PARTICIPANTS  Patients aged 65 years and older hospitalized for a diagnosis of COVID-19. METHODS  Data from hospital admission were collected from the electronic medical records. Logistic regression and Cox proportional hazard models were used to predict mortality, our primary outcome. Variables at hospital admission were categorized according to the following domains  demographics, clinical history, comorbidities, previous treatment, clinical status, vital signs, clinical scales and scores, routine laboratory analysis, and imaging results. RESULTS  Of a total of 235 Caucasian patients, 43% were male, with a mean age of 86 +/- 6.5 years. Seventy-six patients (32%) died. Nonsurvivors had a shorter number of days from initial symptoms to hospitalization (P = .007) and the length of stay in acute wards than survivors (P &lt; .001). Similarly, they had a higher prevalence of heart failure (P = .044), peripheral artery disease (P = .009), crackles at clinical status (P &lt; .001), respiratory rate (P = .005), oxygen support needs (P &lt; .001), C-reactive protein (P &lt; .001), bilateral and peripheral infiltrates on chest radiographs (P = .001), and a lower prevalence of headache (P = .009). Furthermore, nonsurvivors were more often frail (P &lt; .001), with worse functional status (P &lt; .001), higher comorbidity burden (P &lt; .001), and delirium at admission (P = .007). A multivariable Cox model showed that male sex (HR 4.00, 95% CI 2.08-7.71, P &lt; .001), increased fraction of inspired oxygen (HR 1.06, 95% CI 1.03-1.09, P &lt; .001), and crackles (HR 2.42, 95% CI 1.15-6.06, P = .019) were the best predictors of mortality, while better functional status was protective (HR 0.98, 95% CI 0.97-0.99, P = .001). CONCLUSIONS AND IMPLICATIONS  In older patients hospitalized for COVID-19, male sex, crackles, a higher fraction of inspired oxygen, and functionality were independent risk factors of mortality. These routine parameters, and not differences in age, should be used to evaluate prognosis in older patients.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 Background  A multidisciplinary Heart Team (HT) is nowadays considered to be of great importance for a complete and accurate assessment of patients with stable coronary disease (CAD). This study evaluates the role of the HT approach in the selection of best therapeutic strategies for patients with stable CAD. Methods  The study included 200 patients with stable coronary artery disease. The weekly HT meetings consisted of open discussion taking into consideration the latest recommended therapies. HT outcome options included medical therapy (MT), percutaneous coronary intervention (PCI), or surgical intervention (CABG). Following HT implementation, the 1-, 3-, and 6-month outcomes in addition to the distribution of baseline characteristics were assessed. Results  The following HT strategies were implemented  PCI - 46%, CABG - 10% and MT - 44% of patients. Patients selected for surgical treatment were more likely to have multi-vessel coronary disease (p=0.011). The survival rates at 6 months according to HT strategy were 96.8% for PCI, 95% for CABG, and 94.2% for MT. Conclusions  The HT multidisciplinary decision is mandatory for optimal patient care and can prevent specialty biases. Tertiary care institutions should develop and implement interdisciplinary protocols for common CAD cases.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Cardiomyopathy,
 The goal of this study was to evaluate diastolic intraventricular pressure gradients (IVPG) and 2-dimensional tissue tracking(2DTT) patterns during diabetes and cardiomyopathy. Rats (n = 60) were induced to become diabetic (DM group, n = 15) by using streptozotocin, to become cardiomyopathic (CM group, n = 15) by using isoproterenol, and to become both diabetic and cardiomyopathic (DMCM group, n = 15); control rats (CT group, n = 15) were injected with saline. Two months after induction, all rats underwent conventional echocardiography, IVPG, and 2DTT and then were euthanized for microscopic examination of cardiac fibrosis. Compared with the controls, all 3 treated groups showed diastolic dysfunction and delayed cardiac relaxation. DMCM rats showed the most pronounced cardiac abnormalities. In addition, CM and DMCM groups had showed decreased middle IVPG, whereas DMCM rats had decreased midapical IVPG. Although the overall IVPG of the CM group was normal, the middle segment was significantly decreased. 2DTT results showed that the DMCM group had a delay in relaxation compared with other groups. IVPG and 2DTT can be used to overcome the limitation of conventional echocardiographic methods and reveal diastolic dysfunction. DM worsened diastolic function during cardiac disease.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  With the &#34;Artemis&#34;-mission mankind will return to the Moon by 2024. Prolonged periods in space will not only present physical and psychological challenges to the astronauts, but also pose risks concerning the medical treatment capabilities of the crew. So far, no guideline exists for the treatment of severe medical emergencies in microgravity. We, as a international group of researchers related to the field of aerospace medicine and critical care, took on the challenge and developed a an evidence-based guideline for the arguably most severe medical emergency - cardiac arrest. METHODS  After the creation of said international group, PICO questions regarding the topic cardiopulmonary resuscitation in microgravity were developed to guide the systematic literature research. Afterwards a precise search strategy was compiled which was then applied to &#34;MEDLINE&#34;. Four thousand one hundred sixty-five findings were retrieved and consecutively screened by at least 2 reviewers. This led to 88 original publications that were acquired in full-text version and then critically appraised using the GRADE methodology. Those studies formed to basis for the guideline recommendations that were designed by at least 2 experts on the given field. Afterwards those recommendations were subject to a consensus finding process according to the DELPHI-methodology. RESULTS  We recommend a differentiated approach to CPR in microgravity with a division into basic life support (BLS) and advanced life support (ALS) similar to the Earth-based guidelines. In immediate BLS, the chest compression method of choice is the Evetts-Russomano method (ER), whereas in an ALS scenario, with the patient being restrained on the Crew Medical Restraint System, the handstand method (HS) should be applied. Airway management should only be performed if at least two rescuers are present and the patient has been restrained. A supraglottic airway device should be used for airway management where crew members untrained in tracheal intubation (TI) are involved. DISCUSSION  CPR in microgravity is feasible and should be applied according to the Earth-based guidelines of the AHA/ERC in relation to fundamental statements, like urgent recognition and action, focus on high-quality chest compressions, compression depth and compression-ventilation ratio. However, the special circumstances presented by microgravity and spaceflight must be considered concerning central points such as rescuer position and methods for the performance of chest compressions, airway management and defibrillation.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 BACKGROUND  Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection spreaded rapidly worldwide, as far as it has become a global pandemic. Therefore, the introduction of serological tests for determination of IgM and IgG antibodies has become the main diagnostic tool, useful for tracking the spread of the virus and for consequently allowing its containment. In our study we compared point of care test (POCT) lateral flow immunoassay (FIA) vs automated chemiluminescent immunoassay (CLIA), in order to assess their specificity and sensibility for COVID-19 antibodies detection. RESULTS  We find that different specificities and sensitivities for IgM and IgG tests. Notably IgM POCT FIA method vs CLIA method (gold standard) has a low sensitivity (0.526), while IgG POCT FIA method vs CLIA method (gold standard) test has a much higher sensitivity (0.937); further, with respect of IgG, FIA and CLIA could arguably provide equivalent information. CONCLUSIONS  FIA method could be helpful in assessing in short time, the possible contagiousness of subjects that for work reasons cannot guarantee &#34;social distancing&#34;.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">valv</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">stenos</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Diseases of arteries,
 BACKGROUND  A history of previous cardiac disease increases the maternal mortality risk by as much as 100%. There is no consensus on the absolute contraindications to vaginal delivery in valvular heart disease, but central regional anesthesia is traditionally considered contraindicated in patients with severe aortic stenosis. CASE PRESENTATION  A 29-year-old primigravid woman with severe aortic stenosis was admitted to the obstetrics department for programmed labor induction. With epidural anesthesia and mini-invasive hemodynamic monitoring labor and operative vaginal delivery were well tolerated, and hemodynamic stability was always maintained. CONCLUSIONS  Epidural analgesia and oxytocin induction are possible for the labor management of parturients with severe aortic stenosis given that continuous non-invasive followed by invasive hemodynamic monitoring can be provided and given the absence of any obstetric or cardiologic contraindications and the strong will of the patient.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Coagulopathies,
 BACKGROUND  Portal vein thrombosis (PVT) is a rare presentation in dogs with protein-losing enteropathy (PLE). Rivaroxaban, an oral, selective, direct factor Xa inhibitor, has not been reported to be administrated for canine PVT and the effect is unclear in dogs with PLE. CASE PRESENTATION  An 11-year-old Yorkshire Terrier presented with moderate ascites. The dog had severe hypoalbuminemia (1.2 g/dL), and a portal vein thrombus was confirmed on computed tomographic angiography (CTA). On endoscopic examination, it became apparent that the hypoalbuminemia was caused by PLE, which was consequent of lymphatic dilation and lymphoplasmacytic enteritis. Therefore, the dog was initially treated with oral administrations of spironolactone and clopidogrel, with dietary fat restriction. However, a follow-up CTA showed no changes in the ascites, thrombus, and portal vein to aorta (PV/Ao) ratio. Therefore, the dog was additionally prescribed rivaroxaban and low-dose prednisolone for the portal vein thrombus and hypoalbuminemia due to lymphoplasmacytic enteritis, respectively. Following the treatment, the PV/Ao ratio decreased because of a decrease in the thrombus and the ascites disappeared completely with an elevation of albumin concentration (1.9 g/dL). CONCLUSIONS  This case report demonstrated that oral administration of rivaroxaban combined with low-dose glucocorticoid was effective management for PVT in a dog with PLE.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 BACKGROUND  The rising burden of premature mortality for Non-Communicable Diseases (NCDs) in developing countries necessitates the institutionalization of a comprehensive surveillance framework to track trends and provide evidence to design, implement, and evaluate preventive strategies. This study aims to conduct an organization-based prospective cohort study on the NCDs and NCD-related secondary outcomes in adult personnel of the Mashhad University of Medical Sciences (MUMS) as main target population. METHODS  This study was designed to recruit 12,000 adults aged between 30 and 70 years for 15 years. Baseline assessment includes a wide range of established NCD risk factors obtaining by face-to-face interview or examination. The questionnaires consist of demographic and socioeconomic characteristics, lifestyle pattern, fuel consumption and pesticide exposures, occupational history and hazards, personal and familial medical history, medication profile, oral hygiene, reproduction history, dietary intake, and psychological conditions. Examinations include body size and composition test, abdominopelvic and thyroid ultrasonography, orthopedic evaluation, pulse wave velocity test, electrocardiography, blood pressure measurement, smell-taste evaluation, spirometry, mammography, and preferred tea temperature assessment. Routine biochemical, cell count, and fecal occult blood tests are also performed, and the biological samples (i.e., blood, urine, hair, and nail) are stored in preserving temperature. Annual telephone interviews and repeated examinations at 5-year intervals are planned to update information on health status and its determinants. RESULTS  A total of 5287 individuals (mean age of 43.9 +/- 7.6 and 45.9% male) were included in the study thus far. About 18.5% were nurses and midwives and 44.2% had at least bachelor&#39;s degree. Fatty liver (15.4%), thyroid disorders (11.2%), hypertension (8.8%), and diabetes (4.9%) were the most prevalent NCDs. A large proportion of the population had some degree of anxiety (64.2%). Low physical activity (13 +/- 22.4 min per day), high calorie intake (3079 +/- 1252), and poor pulse-wave velocity (7.2 +/- 1.6 m/s) highlight the need for strategies to improve lifestyle behaviors. CONCLUSION  The PERSIAN Organizational Cohort study in Mashhad University of Medical Sciences is the first organizational cohort study in a metropolitan city of Iran aiming to provide a large data repository on the prevalence and risk factors of the NCDs in a developing country for future national and international research cooperation.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,
 Amongst the various diseases on global scale, the second leading cause of mortality and morbidity is ischemic stroke due to the unavailability of an effective therapy. With the growing occurrence and its related health risks along with the absence of effective therapeutics, the ischemic stroke demands the continued and intensive research to explore the effective and safe therapeutics. These therapies may positively affect the numerous pathways associated with neuroprotection thus, extending the advantages to a larger population of stroke patients. Several preclinical studies employing neuroprotectants have shown promising outcomes, but failed in clinical trials either because of the lack of safety or efficacy. The blood brain barrier (BBB) restricts delivery of various potent neuroprotectants to the specific areas of the brain. The application of nanovehicles for delivery of drugs in the brain however, could revolutionize the treatment of ischemic stroke. These nanovehicles loaded with the drug could readily traverse the BBB via carrier, receptor and adsorptive-mediated endocytosis into the brain without compromising the integrity of BBB. Recent advances in neuronanotherapeutics have resulted in the improved neuronal regeneration and recovery after the ischemic stroke. In this review, we have attempted to discuss unexploited neuronanotherapeutics potentials to treat and manage ischemic stroke.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">cerebrovascul</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,Coagulopathies,
 More than 70 years have passed since the first description of Klinefelter Syndrome (KS), the most frequent chromosome disorder causing male infertility and hypogonadism. KS is associated with increased cardiovascular (CV) mortality due to several comorbidities, including hypogonadism, as well as metabolic syndrome and type 2 diabetes, which are highly prevalent in these patients. Aside from metabolic disturbances, patients with KS suffer from both acquired and congenital CV abnormalities, cerebrovascular thromboembolic disease, subclinical atherosclerosis and endothelial dysfunction, which may all contribute to increased CV mortality. The mechanisms involved in this increased risk of CV morbidity and mortality are not entirely understood. More research is needed to better characterise the CV manifestations, elucidate the pathophysiological mechanisms and define the contribution of testosterone replacement in restoring CV health in KS patients. This review explores the complex association between KS, metabolic syndrome and CV risk in order to plan future studies and improve strategies to reduce mortality in this high-risk population.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">microvascul</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 MicroRNAs represent a class of small (19-25 nucleotides) single-strand pieces of RNA, that are non-coding ones. They are synthesized by RNA polymerase II from transcripts which fold back on themselves. They mostly act as gene regulatory agents, that pair with complementary sequences on mRNA and produce silencing complexes, which in turn suppress coding genes at a post-transcriptional level. There is now evidence that microRNAs may affect insulin secretion or insulin action, as they can alter pancreatic beta cells development, insulin production, as well as insulin signalling. Any molecular disorder that affects these pathways can deteriorate insulin resistance and lead to type 2 diabetes mellitus (T2DM) onset. Furthermore, the expression of several microRNAs is up- or down-regulated in the presence of diabetic microvascular complications (i.e. peripheral neuropathy, nephropathy, retinopathy, foot ulcers), as well as in patients with coronary heart disease, stroke, and peripheral artery disease. However, more evidence is needed, specifically regarding T2DM patients, to establish the use of such microRNAs as diagnostical biomarkers or therapeutic targets in daily practice.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Drug repositioning is a strategy to identify new uses for approved or investigational drugs that are used off-label outside the scope of the original medical indication. In this review we report the most relevant studies about drug repositioning in hematology, reporting the signalling pathways and molecular targets of these drugs, and describing the biological mechanisms which are responsible for anticancer effects. Although the majority of studies on drug repositioning in hematology concern acute myeloid leukemia and multiple myeloma, numerous studies are present in the literature on the possibility to use these drugs also in other hematological diseases, such as acute lymphoblastic leukemia, chronic myeloid leukemia, and lymphomas. Numerous anti-infectious drugs, chemical entities used for the therapy of neurological or endocrine diseases, oral antidiabetics, statins, medications used to treat high blood pressure and heart failure, bisphosphonate, natural substance such as artemisin and curcumin, have found a place in hematological diseases treatment. Moreover, seve.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlud</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">occlu</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">sten</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 Intravascular ultrasound (IVUS) has been used extensively in coronary applications. Its use in venous applications has increased as endovascular therapy has increasingly become the mainstay therapy for central venous diseases. IVUS has been used for both diagnostic and therapeutic purposes in managing venous stenotic disease, venous occlusive disease, and IVC filter placement and removal. IVUS has been proven to be effective in providing detailed measurement of the venous anatomy, which aid in determining the appropriate size and the approach for venous stent placement. In IVC filter placement, IVUS can provide detailed measurement and guide IVC filter placement in emergent and critical care settings. It also has certain utility in filter removal. At any rate, to date there are only a few studies examining its impact on patient outcomes. Prospective randomized controlled trials are warranted in the future.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  Stroke patients are often inactive outside of structured therapy sessions - an enduring international challenge despite large scale organizational changes, national guidelines and performance targets. We examined whether experienced-based co-design (EBCD) - an improvement methodology - could address inactivity in stroke units. AIMS  To evaluate the feasibility and impact of patients, carers, and staff co-designing and implementing improvements to increase supervised and independent therapeutic patient activity in stroke units and to compare use of full and accelerated EBCD cycles. METHODS  Mixed-methods case comparison in four stroke units in England. RESULTS  Interviews were held with 156 patients, staff, and carers in total; ethnographic observations for 364 hours, behavioral mapping of 68 patients, and self-report surveys from 179 patients, pre- and post-implementation of EBCD improvement cycles.Three priority areas emerged  (1) &#39;Space&#39; (environment); (2) &#39;Activity opportunities&#39; and (3) &#39;Communication&#39;. More than 40 improvements were co-designed and implemented to address these priorities across participating units. Post-implementation interview and ethnographic observational data confirmed use of new social spaces and increased activity opportunities. However, staff interactions remained largely task-driven with limited focus on enabling patient activity. Behavioral mapping indicated some increases in social, cognitive, and physical activity post-implementation, but was variable across sites. Survey responses rates were low at 12-38% and inconclusive. CONCLUSION  It was feasible to implement EBCD in stroke units. This resulted in multiple improvements in stroke unit environments and increased activity opportunities but minimal change in recorded activity levels. There was no discernible difference in experience or outcome between full and accelerated EBCD; this methodology could be used across hospital stroke units to assist staff and other stakeholders to co-design and implement improvement plans.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Exercise training has become one of the most fundamental components of cardiac rehabilitation. This systematic review with meta-analyses has the objective to determine the effectiveness of exercise on selected cardiac rehabilitation outcomes, i.e., peak oxygen consumption (VO2peak), hospitalization and quality of life (QOL) of patients with heart failure. PubMed, EMBASE, and Cochrane Library were searched up to May 2019 to identify randomized controlled trials comparing exercise training to usual care. Overall, 131 trials were included with a total of 9,761 patients, the majority of whom were males (74%), predominantly with reduced ejection fraction and NYHA class ranging from II to III. There was a significant improvement in VO2peak in the exercise group compared to non-exercise control group (mean difference  2.98 mL/kg/ min, 95% CI  2.52 to 3.43, p&lt;0.001; 84 RCTs, n=3,690 patients). Exercise training was also beneficial for the patients&#39; QOL. The QOL meta-analysis included 5,786 patients and showed a clinically significant improvement of QOL following exercise (-0.82, 95% CI  -1.02 to -0.62; p=0.00001; I(2)=91%). Hospitalization incidence of heart failure patients was also lower in the exercise compared to control group (fixed-effect Odds Ratio  0.56, 95% CI  0.42 to 0.75, p&lt;0.0001; 26 trials, 4,664 participants). Exercise-based rehabilitation improves V02peak and QOL and reduces the incidence of hospitalization of heart failure patients.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 BACKGROUND  Malnutrition in early life may permanently change the structure and function of the body, which lead to a number of diseases in adulthood. The effect of famine exposure during the early life on thyroid function and disorders remains unclear. This study investigated the association between exposure to the Great Chinese Famine (1959-1961) in early life and thyroid function and disorders in adulthood. METHODS  9881 subjects with appropriate birth dates derived from the Thyroid disorders, Iodine status and Diabetes Epidemiological survey were included. Thyroid function and disorders were defined by the test results of blood sample and ultrasonography of all participants. Associations between famine exposure in early life and thyroid function and disorders in adulthood were assessed with binary logistic regression and linear regression. RESULTS  Participants exposed to the Great Chinese Famine during the fetal stage was associated with a higher TSH level in adulthood (beta = 0.024; P = 0.038), compared with the non-exposed participants. The association was significant among rural participants (beta = 0.039; P = 0.02) but not in urban participants (beta = 0.005; P =0.77). Fetal-exposed group did not show a higher risk of thyroid disorders than the age-balanced control group, including overt hyperthyroidism, subclinical hyperthyroidism, overt hypothyroidism, subclinical hypothyroidism, autoimmune thyroiditis, and thyroid nodules (P &gt; 0.05). CONCLUSIONS  Famine exposure during the fetal stage was associated with a higher TSH level in adulthood. The fetal stage could be the critical period for programming the pituitary-thyroid axis.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Diseases of arteries,Coagulopathies,
 AIM  To investigate clinical characteristics and identify risk factors for severity of coronavirus disease 2019 (COVID-19) pneumonia outside of Wuhan, China. MATERIALS AND METHODS  We included 213 patients with confirmed COVID-19 who had been discharged or died by 15 March 2020. We retrospectively collected epidemiological, clinical, laboratory, computed tomography imaging and outcome data. Clinical characteristics were described and relative risk factors were compared. RESULTS  Most clinical characteristics of this study were similar to those from studies in Wuhan, but there were lower mortality rate and milder severity. The median time from onset of symptoms to confirmation and hospitalization was 4 and 5 days, respectively. The median virus clearance and shedding times were 10 and 15 days, respectively. When the severe/critical group was compared with the mild/moderate group, significant risk factors included  older age; dyspnea; hypertension; poor appetite; fatigue; higher white cell count, neutrophil count, prothrombin time, creatine kinase, creatine kinase-MB, D-dimer, alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH) and C-reactive protein; and lower lymphocyte count and albumin (p &lt; 0.05). In the intensive care unit (ICU) group compared with the non-ICU group, risk factors included  older age; chronic obstructive pulmonary disease (COPD); dyspnea; poor appetite; higher white cell count, D-dimer, ALT, AST and LDH; and lower lymphocyte count and albumin (p &lt; 0.05). Independent risk factors associated with the severe/critical group were dyspnea [odds ratio (OR) = 19.48], ALT (OR = 6.02) and albumin (OR = 3.36). Independent risk factors associated with the ICU group were dyspnea (OR = 8.88), COPD (OR = 31.80), D-dimer (OR = 8.37), ALT (OR = 28.76) and LDH (OR = 9.95) (p &lt; 0.05). CONCLUSION  The severity of COVID-19 outside Wuhan, China was milder than that within Wuhan. The clinical infective period was long, and the longest virus shedding time was 35 days. The most important risk factors were dyspnea, COPD, D-dimer, ALT, LDH and albumin.The reviews of this paper are available via the supplemental material section.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,
 Asymptomatic SARS-CoV-2-infected individuals are thought to play major roles in virus transmission. This study aimed to analyze the characteristics of asymptomatic carriers with COVID-19 to control the spread of the virus. We retrospectively investigated the clinical characteristics of 648 consecutive subjects who were enrolled in the study and were divided into asymptomatic carriers, mild cases, ordinary cases, severe or critical cases, and evaluated their impact on disease severity by means of Spearman correlation and multiple regression analyses. Receiver operating characteristic curve analysis was conducted to determine the optimum cutoff levels of laboratory findings for diagnostic predictors of asymptomatic carriers of COVID-19. In our study, a total of 648 subjects on admission with a mean age of 45.61 y including 345 males and 303 females were enrolled in our study. The leukocyte, lymphocyte, eosinophil, platelet, C-reactive protein, interleukin-6, CD3+, CD4+, and CD8 + T lymphocyte levels, and the erythrocyte sedimentation rate differed significantly among the groups (all p &lt;/= 0.05). Disease severity was negatively associated with the CD3+ (r = -0.340; p &lt; 0.001), CD4+ (r = -0.290; p = 0.001) and CD8+ (r = -0.322; p &lt; 0.001) T lymphocyte levels. The significant diagnostic predictors of asymptomatic carriers of COVID-19 included the blood cell, cytokine, and T lymphocyte subset levels. Inflammation and immune response may play important roles in disease progression. Hence, the laboratory parameters identified should be considered in clinical practice, which provide new insights into the identification of asymptomatic individuals and the prevention of virus transmission.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,
 BACKGROUND AND PURPOSE  Cerebral endothelial cells (CECs) and axons of neurons interact to maintain vascular and neuronal homeostasis and axonal remodeling in normal and ischemic brain, respectively. However, the role of exosomes in the interaction of CECs and axons in brain under normal conditions and after stroke is unknown. METHODS  Exosomes were isolated from CECs of nonischemic rats and is chemic rats (nCEC-exos and isCEC-exos), respectively. A multicompartmental cell culture system was used to separate axons from neuronal cell bodies. RESULTS  Axonal application of nCEC-exos promotes axonal growth of cortical neurons, whereas isCEC-exos further enhance axonal growth than nCEC-exos. Ultrastructural analysis revealed that CEC-exos applied into distal axons were internalized by axons and reached to their parent somata. Bioinformatic analysis revealed that both nCEC-exos and isCEC-exos contain abundant mature miRNAs; however, isCEC-exos exhibit more robust elevation of select miRNAs than nCEC-exos. Mechanistically, axonal application of nCEC-exos and isCEC-exos significantly elevated miRNAs and reduced proteins in distal axons and their parent somata that are involved in inhibiting axonal outgrowth. Blockage of axonal transport suppressed isCEC-exo-altered miRNAs and proteins in somata but not in distal axons. CONCLUSIONS  nCEC-exos and isCEC-exos facilitate axonal growth by altering miRNAs and their target protein profiles in recipient neurons.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Diseases of arteries,Coagulopathies,
 BACKGROUND AND PURPOSE  We aim to investigate whether histopathologic examination of thrombi retrieved from acute ischemic stroke patients undergoing endovascular treatment could distinguish cancer-related stroke from other etiologies. METHODS  Thrombi from patients undergoing endovascular treatment were analyzed. The etiology of stroke was divided into cardioembolism, large artery atherosclerosis, and active cancer groups. All selected thrombi were subjected to hematoxylin and eosin staining. The percentages of fibrin/platelets, red blood cells, and white blood cells within a thrombus were quantified. RESULTS  One-hundred fifty-two patients (active cancer, 19; cardioembolism, 107; large artery atherosclerosis, 26) were included. Thrombi from the active cancer group exhibited a higher fibrin/platelet composition than did those from the cardioembolism and large artery atherosclerosis groups (median, 85.7% versus 43.9% and 42.5%; P&lt;0.001). Fibrin/platelet composition was the only independent factor (odds ratio, 1.05 [95% CI, 1.02-1.08]) in differentiating cancer-related stroke from stroke caused by cardioembolism and large artery atherosclerosis. A fibrin/platelet proportion of &gt;/=65% accurately predicted cancer-related stroke (area under the curve, 0.84; P&lt;0.001). CONCLUSIONS  In thrombi retrieved from patients undergoing endovascular treatment, a high fibrin/platelet composition was a probable indicator of cancer-related stroke.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Coagulopathies,
 INTRODUCTION  There is limited efficacy and safety data for direct oral anticoagulants (DOACs) in patients with obesity, and it has been suggested to avoid DOACs in this patient population. OBJECTIVE  Describe the prescribing pattern of oral anticoagulants in obese patients in an urban university setting and assess efficacy, safety, and adherence. METHODS  Retrospective, cohort study in patients &gt;/=18 years with a history of VTE and/or atrial fibrillation. Patients with a BMI &gt;40 kg/m(2) and/or weight &gt;120 kilograms and a prescription for warfarin or a DOAC from August 25, 2014 until August 25, 2017 are included. The primary outcome is the number of warfarin or DOAC prescriptions. Secondary outcomes include thromboembolism and bleeding events. Patient adherence was evaluated using time in therapeutic range (TTR), adherence rate to clinic appointments, and medication possession ratio (MPR). RESULTS  Of the 276 patients who met eligibility criteria, 158 (57.2%) were prescribed warfarin and 118 (42.8%) were prescribed a DOAC. There was no difference in the rate of stroke or recurrent VTE between groups (3.2% vs. 3.4%, p = 0.944). There was also no difference in the rate of bleeding between groups (16.1% vs. 17.8%, p = 0.707). The TTR for the warfarin group was 44.8 +/- 23%, and appointment adherence was 78.6 +/- 20%. The MPR for the DOAC group was 0.93 +/- 0.24. CONCLUSIONS  Despite limited data in obese patients, DOACs are prescribed in this population. Results suggest no difference in safety and efficacy compared to warfarin, but barriers to quality anticoagulation may exist in this population.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  The COVID-19 pandemic caused by SARS-CoV-2 commenced in Wuhan China in 2019 and soon spread worldwide. SARS-CoV-2 enters the cell by binding to the ACE II receptor and begins viral replication. The effects and clinical findings of SARS-CoV-2 on the liver, kidney, heart, gastrointestinal (GI) system and especially lungs have been widely discussed. However, the effects on the pancreas-another organ that also expresses ACE II-have not been studied. METHODS  This work prospectively evaluated data from 316 patients who were admitted with a diagnosis of COVID-19 pneumonia. The patients were categorized into three according to the severity of pneumonia (mild, severe, critical). Demographic data, rate of pancreatitis, biochemical parameters, and radiological images from each group were analyzed. The patients were divided into two groups and outcomes were compared  COVID-19 patients with acute pancreatitis (Group P) and without acute pancreatitis (Group C). RESULTS  The median age was 54 (18-87), and the median age for patients with acute pancreatitis was 55 (26-84). As an expected finding, we found a positive correlation between advanced age and mortality (p = 0.0003). 12.6% of the patients had acute pancreatitis. While pancreatitis was not seen in patients on mild status, the rate of pancreatitis was 32.5% in critical patients. Hospitalization and mortality rates were higher in patients with COVID-19 accompanied by acute pancreatitis (p = 0.0038 and p &lt; 0.0001, respectively). C-Reactive Protein (CRP) and ferritin were significantly higher in those who had pancreatitis (p &lt; 0.0001). D-Dimer and procalcitonin levels had only a small difference (p = 0.1127 and p = 0.3403, respectively). CONCLUSION  Acute pancreatitis alone is a clinical condition that can lead to mortality and may be one of the reasons for the exaggerated immune response developing in the progression of COVID-19. Our results point out that the presence of pancreatic damage triggered by SARS-CoV-2 can deteriorate the clinical condition of patients and the mortality rate may increase in these patients.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocardit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocard</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">cardit</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">deep vein thrombosis</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">art thrombosis</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,Coagulopathies,
 Patients with malignancy may present with significant thromboembolic complications including deep vein thrombosis (DVT), pulmonary embolism, arterial thrombosis, nonbacterial thrombotic endocarditis, and stroke due to abnormal coagulation cascades. Although these events are typically recognized later in the disease process, complications of a hypercoagulable state can rarely present as the first manifestation of an occult malignancy. We report a case of a young male who was ultimately found to have an aggressive form of lung adenocarcinoma after the initial presentation of multiple thromboembolic events. DVT and stroke as an initial presentation of an active lung adenocarcinoma in a young patient is extremely rare as patients presenting in a hypercoagulable state usually are older. Though testing for a hypercoagulable state is not recommended for the first unprovoked DVT, clinicians should be prompted to screen for malignancy in the setting of cryptogenic strokes, especially in younger patients with no prior risk factors.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,Inflammatory diseases,
 Background  The VOYAGER PAD trial demonstrated superiority of rivaroxaban plus aspirin versus aspirin to reduce major cardiac and ischemic limb events following lower extremity revascularization (LER). Clopidogrel is commonly used as a short-term adjunct to aspirin after endovascular revascularization, whether clopidogrel modifies the efficacy and safety of rivaroxaban has not been described. Methods  VOYAGER PAD was a phase 3, international, double-blind, placebo-controlled trial in symptomatic PAD patients undergoing LER randomized to rivaroxaban 2.5 mg twice daily plus 100 mg aspirin daily or rivaroxaban placebo plus aspirin. The primary efficacy outcome was a composite of acute limb ischemia, major amputation of a vascular cause, myocardial infarction, ischemic stroke or cardiovascular death. The principal safety endpoint was TIMI major bleeding with ISTH major bleeding a secondary safety outcome. Clopidogrel use was allowed at the discretion of the investigator for up to six months following the qualifying revascularization. Results  3313 (50.6%) of the randomized patients received clopidogrel, median duration of 29.0 days. Over 3-years the hazard ratio (HR) for the primary outcome of rivaroxaban versus placebo was 0.85 (95% CI 0.71-1.01) with clopidogrel and 0.86 (95% CI 0.73-1.01) without, without statistical heterogeneity (p-interaction =0.92). Rivaroxaban resulted in an early apparent reduction in acute limb ischemia (ALI) within 30 days, HR 0.45 (95%CI 0.14-1.46) with and HR 0.48 (95% CI 0.22-1.01) without clopidogrel (p-interaction = 0.93). Compared with aspirin, rivaroxaban increased TIMI major bleeding similarly regardless of clopidogrel use (p-interaction 0.71). With clopidogrel use &gt;30 days, rivaroxaban was associated with more ISTH major bleeding within 365 days (HR 3.20, 95% CI 1.44-7.13) compared with shorter durations of clopidogrel (p-trend 0.06). Conclusions  In the VOYAGER PAD trial, rivaroxaban plus aspirin reduced the risk of adverse cardiovascular and limb events with an early benefit for ALI regardless of clopidogrel use. The safety of rivaroxaban was consistent regardless of clopidogrel use, but with a trend for more ISTH major bleeding with clopidogrel use &gt; 30 days than a shorter duration. These data support the addition of rivaroxaban to aspirin after LER regardless of concomitant clopidogrel with a short (course &lt;/= 30 days) associated with less bleeding. Clinical Trial Registration  URL  https //clinicaltrials.gov Unique Identifier  NCT02504216.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Inflammatory diseases,Diseases of arteries,
 BACKGROUND  The objective of the study was to evaluate changes in percutaneous coronary intervention (PCI) practice in England by analyzing procedural numbers, changes in the clinical presentation, and characteristics of patients and their clinical outcomes during the coronavirus disease 2019 (COVID-19) pandemic. METHODS  We conducted a retrospective cohort study of all patients who underwent PCI in England between January 2017 and April 2020 in the British Cardiovascular Intervention Society database. RESULTS  Forty-four hospitals reported PCI procedures for 126 491 patients. There were approximately 700 procedures performed each week before the lockdown. After the March 23, 2020 lockdown (11th/12th week in 2020), there was a 49% fall in the number of PCI procedures after the 12th week in 2020. The decrease was greatest in PCI procedures performed for stable angina (66%), followed by non-ST-segment-elevation myocardial infarction (45%), and ST-segment-elevation myocardial infarction (33%). Patients after the lockdown were younger (64.5 versus 65.5 years, P&lt;0.001) and less likely to have diabetes (20.4% versus 24.6%, P&lt;0.001), hypertension (52.0% versus 56.8%, P=0.001), previous myocardial infarction (23.5% versus 26.7%, P=0.008), previous PCI (24.3% versus 28.3%, P=0.001), or previous coronary artery bypass graft (4.6% versus 7.2%, P&lt;0.001) compared with before the lockdown. CONCLUSIONS  The lockdown in England has resulted in a significant decline in PCI procedures. Fewer patients underwent PCI for stable angina. This enabled greater capacity for urgent and emergency cases, and a reduced length of stay was seen for such patients. Significant changes in the characteristics of patients towards a lower risk phenotype were observed, particularly for non-ST-segment-elevation myocardial infarction, reflecting a more conservative approach to this cohort.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">deep vein thrombosis</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">coag</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Coagulopathies,
 In patients with suspected venous thromboembolism, the goal is to accurately and rapidly identify those with and without thrombosis. Failure to diagnose venous thromboembolism (VTE) can lead to fatal pulmonary embolism (PE), and unnecessary anticoagulation can cause avoidable bleeding. The adoption of a structured approach to VTE diagnosis, that includes clinical prediction rules, D-dimer testing and non-invasive imaging modalities, has enabled rapid, cost-effective and accurate VTE diagnosis, but problems still persist. First, with increased reliance on imaging and widespread use of sensitive multidetector computed tomography (CT) scanners, there is a potential for overdiagnosis of VTE. Second, the optimal strategy for diagnosing recurrent leg deep venous thrombosis remains unclear as is that for venous thrombosis at unusual sites. Third, the conventional diagnostic approach is inefficient in that it is unable to exclude VTE in high-risk patients. In this review, we outline pragmatic approaches for the clinician faced with difficult VTE diagnostic cases. In addition to discussing the principles of the current diagnostic framework, we explore the diagnostic approach to recurrent VTE, isolated distal deep-vein thrombosis (DVT), pregnancy associated VTE, subsegmental PE, and VTE diagnosis in complex medical patients (including those with impaired renal function).
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopathy</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">cardiomyopa</span>,<span class="ansi-cyan-intense-fg ansi-black-bg ansi-bold ansi-underline">dil cardiomyopathy</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Cardiomyopathy,
 Large cardiovascular outcome trials have reported favorable effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on heart failure. To study the potential mechanism of the SGLT2 inhibition in heart failure, we used the murine doxorubicin-induced cardiomyopathy model and identified the toll-like receptor 9 (TLR9), NAD-dependent deacetylase sirtuin-3 (SIRT3), and Beclin 1, acting in a complex together in response to empagliflozin treatment. The interactions and implications in mitochondrial function were evaluated with TLR9 deficient, SIRT3 deficient, Beclin 1 haplodeficient, and autophagy reporter mice and confirmed in a patient with SIRT3 point mutation and reduced enzymatic activity. The SGLT2 inhibitor, empagliflozin, protects the heart from doxorubicin cardiomyopathy in mice, by acting through a novel Beclin 1-toll-like receptor (TLR) 9-sirtuin-(SIRT) 3 axis. TLR9 and SIRT3 were both essential for the protective effects of empagliflozin. The dilated cardiomyopathy patient with SIRT3 point mutation and reduced enzymatic activity is associated with reduced TLR9 activation and the absence of mitochondrial responses in the heart after the SGLT2 inhibitor treatment. Our data indicate a dynamic communication between autophagy and Beclin 1-TLR9-SIRT3 complexes in the mitochondria in response to empagliflozin that may serve as a potential treatment strategy for heart failure.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">rhe</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Inflammatory diseases,
 This study determined the association between periodontal disease (PD) and major lifestyle-related comorbidities (LCs) using the database of the nationwide population-based National Health Insurance Service-Elderly Cohort 2002-2015. A nationwide representative sample comprising 558,147 participants, aged 60 years, was analyzed. Univariate and multivariate logistic regression analyses adjusted for sociodemographic and economic factors (sex, age, household income, insurance status, health status, and living area) and major LCs (hypertension, diabetes mellitus, rheumatoid arthritis, osteoporosis, cerebral infarction, angina pectoris, myocardial infarction, erectile dysfunction, lipoprotein disorder, and obesity) were used to determine the association between PD and major LCs. Elderly participants with PD had a higher risk of major LCs (hypertension  odds ratio (OR) = 1.40, diabetes mellitus  OR = 1.22, rheumatoid arthritis  OR = 1.16, osteoporosis  OR = 1.37, erectile dysfunction  OR = 1.73, lipoprotein disorder  OR = 1.50, and obesity  OR = 1.59). Our longitudinal cohort study provided evidence that PD was significantly associated with major LCs in elderly participants. In particular, the association between PD and erectile dysfunction had the highest OR in the multivariate analyses.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-green-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">ischem</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Ischemia,Heart failure,
 In 2015, stricter regulations to reduce sulfur dioxide emissions and particulate air pollution from shipping were implemented in the Baltic Sea. We investigated the effects on population exposure to particles &lt;2.5 microm (PM2.5) from shipping and estimated related morbidity and mortality in Sweden&#39;s 21 counties at different spatial resolutions. We used a regional model to estimate exposure in Sweden and a city-scale model for Gothenburg. Effects of PM2.5 exposure on total mortality, ischemic heart disease, and stroke were estimated using exposure-response functions from the literature and combining them into disability-adjusted life years (DALYS). PM2.5 exposure from shipping in Gothenburg decreased by 7% (1.6 to 1.5 microg/m(3)) using the city-scale model, and 35% (0.5 to 0.3 microg/m(3)) using the regional model. Different population resolutions had no effects on population exposures. In the city-scale model, annual premature deaths due to shipping PM2.5 dropped from 97 with the high-sulfur scenario to 90 in the low-sulfur scenario, and in the regional model from 32 to 21. In Sweden, DALYs lost due to PM2.5 from Baltic Sea shipping decreased from approximately 5700 to 4200. In conclusion, sulfur emission restrictions for shipping had positive effects on health, but the model resolution affects estimations.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocardit</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">endocard</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">cardit</span>,
<span class="ansi-bold">Embeded topics: </span>Inflammatory diseases,
 Bacteria are social organisms able to build complex structures, such as biofilms, that are highly organized surface-associated communities of microorganisms, encased within a self- produced extracellular matrix. Biofilm is commonly associated with many health problems since its formation increases resistance to antibiotics and antimicrobial agents, as in the case of Pseudomonas aeruginosa and Staphylococcus aureus, two human pathogens causing major concern. P. aeruginosa is responsible for severe nosocomial infections, the most frequent of which is ventilator-associated pneumonia, while S. aureus causes several problems, like skin infections, septic arthritis, and endocarditis, to name just a few. Literature data suggest that natural products from plants, bacteria, fungi, and marine organisms have proven to be effective as anti-biofilm agents, inhibiting the formation of the polymer matrix, suppressing cell adhesion and attachment, and decreasing the virulence factors&#39; production, thereby blocking the quorum sensing network. Here, we focus on plant derived chemicals, and provide an updated literature review on the anti-biofilm properties of terpenes, flavonoids, alkaloids, and phenolic compounds. Moreover, whenever information is available, we also report the mechanisms of action.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 Metabolic alterations have been documented in peripheral tissues in heart failure (HF). Outcomes might be improved by early identification of risk. However, the prognostic information offered is still far from enough. We hypothesized that plasma metabolic profiling potentially provides risk stratification for HF patients. Of 61 patients hospitalized due to acute decompensated HF, 31 developed HF-related events in one year after discharge (Event group), and the other 30 patients did not (Non-event group). The plasma collected during hospital admission was analyzed by an ultra-high performance liquid chromatography time-of-flight mass spectrometry (UPLC-TOFMS)-based metabolomic approach. The orthogonal projection to latent structure discriminant analysis (OPLS-DA) reveals that the metabolomics profile is able to distinguish between events in HF. Levels of 19 metabolites including acylcarnitines, lysophospholipids, dimethylxanthine, dimethyluric acid, tryptophan, phenylacetylglutamine, and hypoxanthine are significantly different between patients with and without event (p &lt; 0.05). Established risk prediction models of event patients by using receiver operating characteristics analysis reveal that the combination of tetradecenoylcarnitine, dimethylxanthine, phenylacetylglutamine, and hypoxanthine has better discrimination than B-type natriuretic peptide (BNP) (AUC 0.871 and 0.602, respectively). These findings suggest that metabolomics-derived metabolic profiling have the potential of identifying patients with high risk of HF-related events and provide insights related to HF outcome.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">heart fail</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">inflam</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,
 Indoxyl sulfate (IS), a uremic toxin, causes chronic kidney disease (CKD) progression via its tubulotoxicity. After cellular uptake, IS directly induces apoptotic and necrotic cell death of tubular cells. Additionally, IS increases oxidative stress and decreases antioxidant capacity, which are associated with tubulointerstitial injury. Injured tubular cells are a major source of transforming growth factor-beta1 (TGF-beta1), which induces myofibroblast transition from residual renal cells in damaged kidney, recruits inflammatory cells and thereby promotes extracellular matrix deposition in renal fibrosis. Moreover, IS upregulates signal transducers and activators of transcription 3 phosphorylation, followed by increases in TGF-beta1, monocyte chemotactic protein-1 and alpha-smooth muscle actin production, which participate in interstitial inflammation, renal fibrosis and, consequently, CKD progression. Clinically, higher serum IS levels are independently associated with renal function decline and predict all-cause mortality in CKD. The poor removal of serum IS in conventional hemodialysis is also significantly associated with all-cause mortality and heart failure incidence in end-stage renal disease patients. Scavenging the IS precursor by AST-120 can markedly reduce tubular IS staining that attenuates renal tubular injury, ameliorates IS-induced oxidative stress and rescues antioxidant glutathione activity in tubular epithelial cells, thereby providing a protective role against tubular injury and ultimately retarding renal function decline.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 Alzheimer&#39;s disease (AD) is the leading cause of dementia, which is a growing public health concern. Although there is no curative treatment for established AD, early recognition and modification of the known risk factors can reduce both severity and the rate of progression. Currently, an early diagnosis of AD is rarely achieved, as there is no screening for AD. The cognitive decline in AD is gradual and often goes unnoticed by patients and caregivers, resulting in patients presenting at later stages of the disease. Primary care physicians (general practitioners in the UK) can administer a battery of tests for patients presenting with memory problems and cognitive impairment, however final diagnosis of AD is usually made by specialised tertiary level clinics. Recent studies suggest that in AD, visuospatial difficulties develop prior to the development of memory problems and screening for visuospatial difficulties may offer a tool to screen for early stage AD. AD and cataracts share common risk and predisposing factors, and the stage of cataract presentation for intervention has shifted dramatically with early cataract referral and surgical intervention becoming the norm. This presentation offers an ideal opportunity to administer a screening test for AD, and visuospatial tools can be administered at post-operative visits by eye clinics. Abnormal findings can be communicated to primary care physicians for further follow up and assessment, or possible interventions which modify risk factors such as diabetes, hypertension and obesity can be undertaken. We propose that eye clinics and ophthalmology facilities have a role to play in the early diagnosis of AD and reducing the burdens arising from severe dementia.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">coron</span>,<span class="ansi-yellow-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">thromb</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,Heart failure,Diseases of arteries,Coagulopathies,
 The 1918 influenza killed approximately 50 million people in a few short years, and now, the world is facing another pandemic. In December 2019, a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused an international outbreak of a respiratory illness termed coronavirus disease 2019 (COVID-19) and rapidly spread to cause the worst pandemic since 1918. Recent clinical reports highlight an atypical presentation of acute respiratory distress syndrome (ARDS) in COVID-19 patients characterized by severe hypoxemia, an imbalance of the renin-angiotensin system, an increase in thrombogenic processes, and a cytokine release storm. These processes not only exacerbate lung injury but can also promote pulmonary vascular remodeling and vasoconstriction, which are hallmarks of pulmonary hypertension (PH). PH is a complication of ARDS that has received little attention; thus, we hypothesize that PH in COVID-19-induced ARDS represents an important target for disease amelioration. The mechanisms that can promote PH following SARS-CoV-2 infection are described. In this review article, we outline emerging mechanisms of pulmonary vascular dysfunction and outline potential treatment options that have been clinically tested.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">aort</span>,<span class="ansi-white-intense-fg ansi-black-bg ansi-bold ansi-underline">myocard</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,Inflammatory diseases,
 Pregnancy is associated with adaptation of the left ventricular (LV) function. Due to differences between breeds in baseline echocardiographic values and specific predispositions for myocardial diseases, breed-specific echocardiographic parameters may be helpful to evaluate whether the systolic function varies during pregnancy. This study enrolled nine healthy Great Dane bitches with uncomplicated pregnancy. Echocardiographic M-mode and B-mode data were collected before ovulation and within 7 days of the predicted parturition term. Evaluated parameters were  LV dimension in diastole (LVd) and systole (LVs), end-diastolic (EDVI) and end-systolic (ESVI) volumes indexed to body surface area (BSA), end-diastolic (EDV) and end-systolic (ESV), end-point-septal-separation (EPSS), left atrium to aortic root ratio (LA/Ao), sphericity index (SI), ejection fraction (EF), fractional shortening (FS), stroke volume (SV), heart rate (HR), and cardiac output (CO). The ANOVA showed a statistical effect of the age of gestation (p &lt; 0.01) on the increase of diastolic dimensions and functional parameters and on the decrease of systolic dimensions. The CO increase parallels the rise in SV and HR (p &lt; 0.01). No statistical differences were observed for EPSS, LA/Ao, and SI. The changes in cardiac chambers and function are likely to reflect maternal adaptation to allow the fetal development in uncomplicated pregnancy. The present study provides specific echocardiographic values in uncomplicated pregnancy of Great Danes, showing that the systolic function is enhanced and that the increase in preload, observed during gestation, is the likely mechanism.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypertend</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">hypert</span>,
<span class="ansi-bold">Embeded topics: </span>Hypertension,
 This study aims to investigate spousal concordance in dietary behaviors, spousal concordance in metabolic components (MCs), and their association. A cross-sectional survey was conducted in Taiwan from November 2014 to May 2015. Matched-pair analysis, McNemar&#39;s test, logistic regression analysis, and stratified analysis were performed. A total of 901 pairs of spouses (1802 participants) were analyzed. Husbands were less likely to report intakes of high-fiber food (ORMP (matched pairs odds ratio) = 0.30, p &lt; 0.0001), fish (ORMP = 0.74, p = 0.0128), biscuits or cakes (ORMP = 0.60, p &lt; 0.0001), and fast food (ORMP = 0.65, p = 0.01) compared with their wives. Husbands had significantly higher odds of being overweight (ORMP = 2.34, p &lt; 0.0001); and of having hypertension (ORMP = 2.14, p &lt; 0.0001), hypercholesterolemia (ORMP = 1.75, p = 0.0007), hyperlipidemia (ORMP = 2.96, p &lt; 0.0001), and one or more metabolic components (composite MCs) (ORMP = 2.50, p &lt; 0.0001) compared with their wives. After adjusting for age and education, the spousal concordance in high-fiber food intake was inversely associated with the spousal concordance in composite MCs (aOR = 0.62, 95% CI = 0.44-0.88, p = 0.0074), whereas the spousal concordance in processed food intake was positively associated with the concordance in composite MCs (aOR (adjusted odds ratio) = 1.56, 95% CI (Confidence Interval) = 1.03-2.36, p = 0.034). An intervention study for couples with intakes of different fiber foods and/or processed foods is critical for future study, in order to test what kinds of fiber foods/processed foods are associated with the development of the spousal concordance of metabolic components.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atheroscleros</span>,<span class="ansi-yellow-intense-fg ansi-black-bg ansi-bold ansi-underline">atherosclero</span>,
<span class="ansi-bold">Embeded topics: </span>Diseases of arteries,
 Atherosclerosis is a progressive chronic arterial disease characterised by atheromatous plaque formation in the intima of the arterial wall. Several invasive and non-invasive imaging techniques have been developed to detect and characterise atherosclerosis in the vessel wall  anatomic/structural imaging, functional imaging and molecular imaging. In molecular imaging, vascular cell adhesion molecule-1 (VCAM-1) is a promising target for the non-invasive detection of atherosclerosis and for the assessment of novel antiatherogenic treatments. VCAM-1 is an adhesion molecule expressed on the activated endothelial surface that binds leucocyte ligands and therefore promotes leucocyte adhesion and transendothelial migration. Hence, for several years, there has been an increase in molecular imaging methods for detecting VCAM-1 in MRI, PET, SPECT, optical imaging and ultrasound. The use of microparticles of iron oxide (MPIO), ultrasmall superparamagnetic iron oxide (USPIO), microbubbles, echogenic immunoliposomes, peptides, nanobodies and other nanoparticles has been described. However, these approaches have been tested in animal models, and the remaining challenge is bench-to-bedside development and clinical applicability.
-------------------
<span class="ansi-bold">Embeded keys: </span><span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">mit</span>,<span class="ansi-red-intense-fg ansi-white-intense-bg ansi-bold ansi-underline">pulmon</span>,
<span class="ansi-bold">Embeded topics: </span>Heart failure,
 BACKGROUND  Alternative cardiopulmonary resuscitation (CPR) algorithms, introduced to improve outcomes after cardiac arrest, have so far not been compared in randomized trials with established CPR guidelines. METHODS  286 physician teams were confronted with simulated cardiac arrests and randomly allocated to one of three versions of a CPR algorithm  (1) current International Liaison Committee on Resuscitation (ILCOR) guidelines (&#34;ILCOR&#34;), (2) the cardiocerebral resuscitation (&#34;CCR&#34;) protocol (3 cycles of 200 uninterrupted chest compressions with no ventilation), or (3) a local interpretation of the current guidelines (&#34;Arnsberg&#34;, immediate insertion of a supraglottic airway and cycles of 200 uninterrupted chest compressions). The primary endpoint was percentage of hands-on time. RESULTS  Median percentage of hands-on time was 88 (interquartile range (IQR) 6) in &#34;ILCOR&#34; teams, 90 (IQR 5) in &#34;CCR&#34; teams (p = 0.001 vs. &#34;ILCOR&#34;), and 89 (IQR 4) in &#34;Arnsberg&#34; teams (p = 0.032 vs. &#34;ILCOR&#34;; p = 0.10 vs. &#34;CCR&#34;). &#34;ILCOR&#34; teams delivered fewer chest compressions and deviated more from allocated targets than &#34;CCR&#34; and &#34;Arnsberg&#34; teams. &#34;CCR&#34; teams demonstrated the least within-team and between-team variance. CONCLUSIONS  Compared to current ILCOR guidelines, two alternative CPR algorithms advocating cycles of uninterrupted chest compressions resulted in very similar hands-on times, fewer deviations from targets, and less within-team and between-team variance in execution.
-------------------

</pre>
</div>
</div>

</div>

</div>

</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs jp-mod-noInput ">

</div>
</body>







</html>
